/*! For license information please see main.af6b048d.js.LICENSE.txt */
(()=>{var t={4(t,e,a){"use strict";var i=a(853),n=a(43),o=a(950);function s(t){var e="https://react.dev/errors/"+t;if(1<arguments.length){e+="?args[]="+encodeURIComponent(arguments[1]);for(var a=2;a<arguments.length;a++)e+="&args[]="+encodeURIComponent(arguments[a])}return"Minified React error #"+t+"; visit "+e+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function r(t){return!(!t||1!==t.nodeType&&9!==t.nodeType&&11!==t.nodeType)}function l(t){var e=t,a=t;if(t.alternate)for(;e.return;)e=e.return;else{t=e;do{0!==(4098&(e=t).flags)&&(a=e.return),t=e.return}while(t)}return 3===e.tag?a:null}function d(t){if(13===t.tag){var e=t.memoizedState;if(null===e&&(null!==(t=t.alternate)&&(e=t.memoizedState)),null!==e)return e.dehydrated}return null}function c(t){if(31===t.tag){var e=t.memoizedState;if(null===e&&(null!==(t=t.alternate)&&(e=t.memoizedState)),null!==e)return e.dehydrated}return null}function m(t){if(l(t)!==t)throw Error(s(188))}function u(t){var e=t.tag;if(5===e||26===e||27===e||6===e)return t;for(t=t.child;null!==t;){if(null!==(e=u(t)))return e;t=t.sibling}return null}var h=Object.assign,f=Symbol.for("react.element"),g=Symbol.for("react.transitional.element"),p=Symbol.for("react.portal"),y=Symbol.for("react.fragment"),b=Symbol.for("react.strict_mode"),v=Symbol.for("react.profiler"),w=Symbol.for("react.consumer"),x=Symbol.for("react.context"),k=Symbol.for("react.forward_ref"),I=Symbol.for("react.suspense"),C=Symbol.for("react.suspense_list"),S=Symbol.for("react.memo"),A=Symbol.for("react.lazy");Symbol.for("react.scope");var T=Symbol.for("react.activity");Symbol.for("react.legacy_hidden"),Symbol.for("react.tracing_marker");var P=Symbol.for("react.memo_cache_sentinel");Symbol.for("react.view_transition");var D=Symbol.iterator;function N(t){return null===t||"object"!==typeof t?null:"function"===typeof(t=D&&t[D]||t["@@iterator"])?t:null}var L=Symbol.for("react.client.reference");function E(t){if(null==t)return null;if("function"===typeof t)return t.$$typeof===L?null:t.displayName||t.name||null;if("string"===typeof t)return t;switch(t){case y:return"Fragment";case v:return"Profiler";case b:return"StrictMode";case I:return"Suspense";case C:return"SuspenseList";case T:return"Activity"}if("object"===typeof t)switch(t.$$typeof){case p:return"Portal";case x:return t.displayName||"Context";case w:return(t._context.displayName||"Context")+".Consumer";case k:var e=t.render;return(t=t.displayName)||(t=""!==(t=e.displayName||e.name||"")?"ForwardRef("+t+")":"ForwardRef"),t;case S:return null!==(e=t.displayName||null)?e:E(t.type)||"Memo";case A:e=t._payload,t=t._init;try{return E(t(e))}catch(a){}}return null}var j=Array.isArray,M=n.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,z=o.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,R={pending:!1,data:null,method:null,action:null},F=[],q=-1;function _(t){return{current:t}}function O(t){0>q||(t.current=F[q],F[q]=null,q--)}function U(t,e){q++,F[q]=t.current,t.current=e}var H,V,B=_(null),G=_(null),W=_(null),Q=_(null);function K(t,e){switch(U(W,e),U(G,t),U(B,null),e.nodeType){case 9:case 11:t=(t=e.documentElement)&&(t=t.namespaceURI)?ym(t):0;break;default:if(t=e.tagName,e=e.namespaceURI)t=bm(e=ym(e),t);else switch(t){case"svg":t=1;break;case"math":t=2;break;default:t=0}}O(B),U(B,t)}function Z(){O(B),O(G),O(W)}function $(t){null!==t.memoizedState&&U(Q,t);var e=B.current,a=bm(e,t.type);e!==a&&(U(G,t),U(B,a))}function X(t){G.current===t&&(O(B),O(G)),Q.current===t&&(O(Q),cu._currentValue=R)}function Y(t){if(void 0===H)try{throw Error()}catch(a){var e=a.stack.trim().match(/\n( *(at )?)/);H=e&&e[1]||"",V=-1<a.stack.indexOf("\n    at")?" (<anonymous>)":-1<a.stack.indexOf("@")?"@unknown:0:0":""}return"\n"+H+t+V}var J=!1;function tt(t,e){if(!t||J)return"";J=!0;var a=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var i={DetermineComponentFrameRoot:function(){try{if(e){var a=function(){throw Error()};if(Object.defineProperty(a.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(a,[])}catch(n){var i=n}Reflect.construct(t,[],a)}else{try{a.call()}catch(o){i=o}t.call(a.prototype)}}else{try{throw Error()}catch(s){i=s}(a=t())&&"function"===typeof a.catch&&a.catch(function(){})}}catch(r){if(r&&i&&"string"===typeof r.stack)return[r.stack,i.stack]}return[null,null]}};i.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var n=Object.getOwnPropertyDescriptor(i.DetermineComponentFrameRoot,"name");n&&n.configurable&&Object.defineProperty(i.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var o=i.DetermineComponentFrameRoot(),s=o[0],r=o[1];if(s&&r){var l=s.split("\n"),d=r.split("\n");for(n=i=0;i<l.length&&!l[i].includes("DetermineComponentFrameRoot");)i++;for(;n<d.length&&!d[n].includes("DetermineComponentFrameRoot");)n++;if(i===l.length||n===d.length)for(i=l.length-1,n=d.length-1;1<=i&&0<=n&&l[i]!==d[n];)n--;for(;1<=i&&0<=n;i--,n--)if(l[i]!==d[n]){if(1!==i||1!==n)do{if(i--,0>--n||l[i]!==d[n]){var c="\n"+l[i].replace(" at new "," at ");return t.displayName&&c.includes("<anonymous>")&&(c=c.replace("<anonymous>",t.displayName)),c}}while(1<=i&&0<=n);break}}}finally{J=!1,Error.prepareStackTrace=a}return(a=t?t.displayName||t.name:"")?Y(a):""}function et(t,e){switch(t.tag){case 26:case 27:case 5:return Y(t.type);case 16:return Y("Lazy");case 13:return t.child!==e&&null!==e?Y("Suspense Fallback"):Y("Suspense");case 19:return Y("SuspenseList");case 0:case 15:return tt(t.type,!1);case 11:return tt(t.type.render,!1);case 1:return tt(t.type,!0);case 31:return Y("Activity");default:return""}}function at(t){try{var e="",a=null;do{e+=et(t,a),a=t,t=t.return}while(t);return e}catch(i){return"\nError generating stack: "+i.message+"\n"+i.stack}}var it=Object.prototype.hasOwnProperty,nt=i.unstable_scheduleCallback,ot=i.unstable_cancelCallback,st=i.unstable_shouldYield,rt=i.unstable_requestPaint,lt=i.unstable_now,dt=i.unstable_getCurrentPriorityLevel,ct=i.unstable_ImmediatePriority,mt=i.unstable_UserBlockingPriority,ut=i.unstable_NormalPriority,ht=i.unstable_LowPriority,ft=i.unstable_IdlePriority,gt=i.log,pt=i.unstable_setDisableYieldValue,yt=null,bt=null;function vt(t){if("function"===typeof gt&&pt(t),bt&&"function"===typeof bt.setStrictMode)try{bt.setStrictMode(yt,t)}catch(e){}}var wt=Math.clz32?Math.clz32:function(t){return 0===(t>>>=0)?32:31-(xt(t)/kt|0)|0},xt=Math.log,kt=Math.LN2;var It=256,Ct=262144,St=4194304;function At(t){var e=42&t;if(0!==e)return e;switch(t&-t){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:return 261888&t;case 262144:case 524288:case 1048576:case 2097152:return 3932160&t;case 4194304:case 8388608:case 16777216:case 33554432:return 62914560&t;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return t}}function Tt(t,e,a){var i=t.pendingLanes;if(0===i)return 0;var n=0,o=t.suspendedLanes,s=t.pingedLanes;t=t.warmLanes;var r=134217727&i;return 0!==r?0!==(i=r&~o)?n=At(i):0!==(s&=r)?n=At(s):a||0!==(a=r&~t)&&(n=At(a)):0!==(r=i&~o)?n=At(r):0!==s?n=At(s):a||0!==(a=i&~t)&&(n=At(a)),0===n?0:0!==e&&e!==n&&0===(e&o)&&((o=n&-n)>=(a=e&-e)||32===o&&0!==(4194048&a))?e:n}function Pt(t,e){return 0===(t.pendingLanes&~(t.suspendedLanes&~t.pingedLanes)&e)}function Dt(t,e){switch(t){case 1:case 2:case 4:case 8:case 64:return e+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return e+5e3;default:return-1}}function Nt(){var t=St;return 0===(62914560&(St<<=1))&&(St=4194304),t}function Lt(t){for(var e=[],a=0;31>a;a++)e.push(t);return e}function Et(t,e){t.pendingLanes|=e,268435456!==e&&(t.suspendedLanes=0,t.pingedLanes=0,t.warmLanes=0)}function jt(t,e,a){t.pendingLanes|=e,t.suspendedLanes&=~e;var i=31-wt(e);t.entangledLanes|=e,t.entanglements[i]=1073741824|t.entanglements[i]|261930&a}function Mt(t,e){var a=t.entangledLanes|=e;for(t=t.entanglements;a;){var i=31-wt(a),n=1<<i;n&e|t[i]&e&&(t[i]|=e),a&=~n}}function zt(t,e){var a=e&-e;return 0!==((a=0!==(42&a)?1:Rt(a))&(t.suspendedLanes|e))?0:a}function Rt(t){switch(t){case 2:t=1;break;case 8:t=4;break;case 32:t=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:t=128;break;case 268435456:t=134217728;break;default:t=0}return t}function Ft(t){return 2<(t&=-t)?8<t?0!==(134217727&t)?32:268435456:8:2}function qt(){var t=z.p;return 0!==t?t:void 0===(t=window.event)?32:Au(t.type)}function _t(t,e){var a=z.p;try{return z.p=t,e()}finally{z.p=a}}var Ot=Math.random().toString(36).slice(2),Ut="__reactFiber$"+Ot,Ht="__reactProps$"+Ot,Vt="__reactContainer$"+Ot,Bt="__reactEvents$"+Ot,Gt="__reactListeners$"+Ot,Wt="__reactHandles$"+Ot,Qt="__reactResources$"+Ot,Kt="__reactMarker$"+Ot;function Zt(t){delete t[Ut],delete t[Ht],delete t[Bt],delete t[Gt],delete t[Wt]}function $t(t){var e=t[Ut];if(e)return e;for(var a=t.parentNode;a;){if(e=a[Vt]||a[Ut]){if(a=e.alternate,null!==e.child||null!==a&&null!==a.child)for(t=Rm(t);null!==t;){if(a=t[Ut])return a;t=Rm(t)}return e}a=(t=a).parentNode}return null}function Xt(t){if(t=t[Ut]||t[Vt]){var e=t.tag;if(5===e||6===e||13===e||31===e||26===e||27===e||3===e)return t}return null}function Yt(t){var e=t.tag;if(5===e||26===e||27===e||6===e)return t.stateNode;throw Error(s(33))}function Jt(t){var e=t[Qt];return e||(e=t[Qt]={hoistableStyles:new Map,hoistableScripts:new Map}),e}function te(t){t[Kt]=!0}var ee=new Set,ae={};function ie(t,e){ne(t,e),ne(t+"Capture",e)}function ne(t,e){for(ae[t]=e,t=0;t<e.length;t++)ee.add(e[t])}var oe=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),se={},re={};function le(t,e,a){if(n=e,it.call(re,n)||!it.call(se,n)&&(oe.test(n)?re[n]=!0:(se[n]=!0,0)))if(null===a)t.removeAttribute(e);else{switch(typeof a){case"undefined":case"function":case"symbol":return void t.removeAttribute(e);case"boolean":var i=e.toLowerCase().slice(0,5);if("data-"!==i&&"aria-"!==i)return void t.removeAttribute(e)}t.setAttribute(e,""+a)}var n}function de(t,e,a){if(null===a)t.removeAttribute(e);else{switch(typeof a){case"undefined":case"function":case"symbol":case"boolean":return void t.removeAttribute(e)}t.setAttribute(e,""+a)}}function ce(t,e,a,i){if(null===i)t.removeAttribute(a);else{switch(typeof i){case"undefined":case"function":case"symbol":case"boolean":return void t.removeAttribute(a)}t.setAttributeNS(e,a,""+i)}}function me(t){switch(typeof t){case"bigint":case"boolean":case"number":case"string":case"undefined":case"object":return t;default:return""}}function ue(t){var e=t.type;return(t=t.nodeName)&&"input"===t.toLowerCase()&&("checkbox"===e||"radio"===e)}function he(t){if(!t._valueTracker){var e=ue(t)?"checked":"value";t._valueTracker=function(t,e,a){var i=Object.getOwnPropertyDescriptor(t.constructor.prototype,e);if(!t.hasOwnProperty(e)&&"undefined"!==typeof i&&"function"===typeof i.get&&"function"===typeof i.set){var n=i.get,o=i.set;return Object.defineProperty(t,e,{configurable:!0,get:function(){return n.call(this)},set:function(t){a=""+t,o.call(this,t)}}),Object.defineProperty(t,e,{enumerable:i.enumerable}),{getValue:function(){return a},setValue:function(t){a=""+t},stopTracking:function(){t._valueTracker=null,delete t[e]}}}}(t,e,""+t[e])}}function fe(t){if(!t)return!1;var e=t._valueTracker;if(!e)return!0;var a=e.getValue(),i="";return t&&(i=ue(t)?t.checked?"true":"false":t.value),(t=i)!==a&&(e.setValue(t),!0)}function ge(t){if("undefined"===typeof(t=t||("undefined"!==typeof document?document:void 0)))return null;try{return t.activeElement||t.body}catch(e){return t.body}}var pe=/[\n"\\]/g;function ye(t){return t.replace(pe,function(t){return"\\"+t.charCodeAt(0).toString(16)+" "})}function be(t,e,a,i,n,o,s,r){t.name="",null!=s&&"function"!==typeof s&&"symbol"!==typeof s&&"boolean"!==typeof s?t.type=s:t.removeAttribute("type"),null!=e?"number"===s?(0===e&&""===t.value||t.value!=e)&&(t.value=""+me(e)):t.value!==""+me(e)&&(t.value=""+me(e)):"submit"!==s&&"reset"!==s||t.removeAttribute("value"),null!=e?we(t,s,me(e)):null!=a?we(t,s,me(a)):null!=i&&t.removeAttribute("value"),null==n&&null!=o&&(t.defaultChecked=!!o),null!=n&&(t.checked=n&&"function"!==typeof n&&"symbol"!==typeof n),null!=r&&"function"!==typeof r&&"symbol"!==typeof r&&"boolean"!==typeof r?t.name=""+me(r):t.removeAttribute("name")}function ve(t,e,a,i,n,o,s,r){if(null!=o&&"function"!==typeof o&&"symbol"!==typeof o&&"boolean"!==typeof o&&(t.type=o),null!=e||null!=a){if(!("submit"!==o&&"reset"!==o||void 0!==e&&null!==e))return void he(t);a=null!=a?""+me(a):"",e=null!=e?""+me(e):a,r||e===t.value||(t.value=e),t.defaultValue=e}i="function"!==typeof(i=null!=i?i:n)&&"symbol"!==typeof i&&!!i,t.checked=r?t.checked:!!i,t.defaultChecked=!!i,null!=s&&"function"!==typeof s&&"symbol"!==typeof s&&"boolean"!==typeof s&&(t.name=s),he(t)}function we(t,e,a){"number"===e&&ge(t.ownerDocument)===t||t.defaultValue===""+a||(t.defaultValue=""+a)}function xe(t,e,a,i){if(t=t.options,e){e={};for(var n=0;n<a.length;n++)e["$"+a[n]]=!0;for(a=0;a<t.length;a++)n=e.hasOwnProperty("$"+t[a].value),t[a].selected!==n&&(t[a].selected=n),n&&i&&(t[a].defaultSelected=!0)}else{for(a=""+me(a),e=null,n=0;n<t.length;n++){if(t[n].value===a)return t[n].selected=!0,void(i&&(t[n].defaultSelected=!0));null!==e||t[n].disabled||(e=t[n])}null!==e&&(e.selected=!0)}}function ke(t,e,a){null==e||((e=""+me(e))!==t.value&&(t.value=e),null!=a)?t.defaultValue=null!=a?""+me(a):"":t.defaultValue!==e&&(t.defaultValue=e)}function Ie(t,e,a,i){if(null==e){if(null!=i){if(null!=a)throw Error(s(92));if(j(i)){if(1<i.length)throw Error(s(93));i=i[0]}a=i}null==a&&(a=""),e=a}a=me(e),t.defaultValue=a,(i=t.textContent)===a&&""!==i&&null!==i&&(t.value=i),he(t)}function Ce(t,e){if(e){var a=t.firstChild;if(a&&a===t.lastChild&&3===a.nodeType)return void(a.nodeValue=e)}t.textContent=e}var Se=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function Ae(t,e,a){var i=0===e.indexOf("--");null==a||"boolean"===typeof a||""===a?i?t.setProperty(e,""):"float"===e?t.cssFloat="":t[e]="":i?t.setProperty(e,a):"number"!==typeof a||0===a||Se.has(e)?"float"===e?t.cssFloat=a:t[e]=(""+a).trim():t[e]=a+"px"}function Te(t,e,a){if(null!=e&&"object"!==typeof e)throw Error(s(62));if(t=t.style,null!=a){for(var i in a)!a.hasOwnProperty(i)||null!=e&&e.hasOwnProperty(i)||(0===i.indexOf("--")?t.setProperty(i,""):"float"===i?t.cssFloat="":t[i]="");for(var n in e)i=e[n],e.hasOwnProperty(n)&&a[n]!==i&&Ae(t,n,i)}else for(var o in e)e.hasOwnProperty(o)&&Ae(t,o,e[o])}function Pe(t){if(-1===t.indexOf("-"))return!1;switch(t){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var De=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),Ne=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function Le(t){return Ne.test(""+t)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":t}function Ee(){}var je=null;function Me(t){return(t=t.target||t.srcElement||window).correspondingUseElement&&(t=t.correspondingUseElement),3===t.nodeType?t.parentNode:t}var ze=null,Re=null;function Fe(t){var e=Xt(t);if(e&&(t=e.stateNode)){var a=t[Ht]||null;t:switch(t=e.stateNode,e.type){case"input":if(be(t,a.value,a.defaultValue,a.defaultValue,a.checked,a.defaultChecked,a.type,a.name),e=a.name,"radio"===a.type&&null!=e){for(a=t;a.parentNode;)a=a.parentNode;for(a=a.querySelectorAll('input[name="'+ye(""+e)+'"][type="radio"]'),e=0;e<a.length;e++){var i=a[e];if(i!==t&&i.form===t.form){var n=i[Ht]||null;if(!n)throw Error(s(90));be(i,n.value,n.defaultValue,n.defaultValue,n.checked,n.defaultChecked,n.type,n.name)}}for(e=0;e<a.length;e++)(i=a[e]).form===t.form&&fe(i)}break t;case"textarea":ke(t,a.value,a.defaultValue);break t;case"select":null!=(e=a.value)&&xe(t,!!a.multiple,e,!1)}}}var qe=!1;function _e(t,e,a){if(qe)return t(e,a);qe=!0;try{return t(e)}finally{if(qe=!1,(null!==ze||null!==Re)&&(Jd(),ze&&(e=ze,t=Re,Re=ze=null,Fe(e),t)))for(e=0;e<t.length;e++)Fe(t[e])}}function Oe(t,e){var a=t.stateNode;if(null===a)return null;var i=a[Ht]||null;if(null===i)return null;a=i[e];t:switch(e){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(i=!i.disabled)||(i=!("button"===(t=t.type)||"input"===t||"select"===t||"textarea"===t)),t=!i;break t;default:t=!1}if(t)return null;if(a&&"function"!==typeof a)throw Error(s(231,e,typeof a));return a}var Ue=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),He=!1;if(Ue)try{var Ve={};Object.defineProperty(Ve,"passive",{get:function(){He=!0}}),window.addEventListener("test",Ve,Ve),window.removeEventListener("test",Ve,Ve)}catch(Xu){He=!1}var Be=null,Ge=null,We=null;function Qe(){if(We)return We;var t,e,a=Ge,i=a.length,n="value"in Be?Be.value:Be.textContent,o=n.length;for(t=0;t<i&&a[t]===n[t];t++);var s=i-t;for(e=1;e<=s&&a[i-e]===n[o-e];e++);return We=n.slice(t,1<e?1-e:void 0)}function Ke(t){var e=t.keyCode;return"charCode"in t?0===(t=t.charCode)&&13===e&&(t=13):t=e,10===t&&(t=13),32<=t||13===t?t:0}function Ze(){return!0}function $e(){return!1}function Xe(t){function e(e,a,i,n,o){for(var s in this._reactName=e,this._targetInst=i,this.type=a,this.nativeEvent=n,this.target=o,this.currentTarget=null,t)t.hasOwnProperty(s)&&(e=t[s],this[s]=e?e(n):n[s]);return this.isDefaultPrevented=(null!=n.defaultPrevented?n.defaultPrevented:!1===n.returnValue)?Ze:$e,this.isPropagationStopped=$e,this}return h(e.prototype,{preventDefault:function(){this.defaultPrevented=!0;var t=this.nativeEvent;t&&(t.preventDefault?t.preventDefault():"unknown"!==typeof t.returnValue&&(t.returnValue=!1),this.isDefaultPrevented=Ze)},stopPropagation:function(){var t=this.nativeEvent;t&&(t.stopPropagation?t.stopPropagation():"unknown"!==typeof t.cancelBubble&&(t.cancelBubble=!0),this.isPropagationStopped=Ze)},persist:function(){},isPersistent:Ze}),e}var Ye,Je,ta,ea={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(t){return t.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},aa=Xe(ea),ia=h({},ea,{view:0,detail:0}),na=Xe(ia),oa=h({},ia,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:pa,button:0,buttons:0,relatedTarget:function(t){return void 0===t.relatedTarget?t.fromElement===t.srcElement?t.toElement:t.fromElement:t.relatedTarget},movementX:function(t){return"movementX"in t?t.movementX:(t!==ta&&(ta&&"mousemove"===t.type?(Ye=t.screenX-ta.screenX,Je=t.screenY-ta.screenY):Je=Ye=0,ta=t),Ye)},movementY:function(t){return"movementY"in t?t.movementY:Je}}),sa=Xe(oa),ra=Xe(h({},oa,{dataTransfer:0})),la=Xe(h({},ia,{relatedTarget:0})),da=Xe(h({},ea,{animationName:0,elapsedTime:0,pseudoElement:0})),ca=Xe(h({},ea,{clipboardData:function(t){return"clipboardData"in t?t.clipboardData:window.clipboardData}})),ma=Xe(h({},ea,{data:0})),ua={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},ha={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},fa={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function ga(t){var e=this.nativeEvent;return e.getModifierState?e.getModifierState(t):!!(t=fa[t])&&!!e[t]}function pa(){return ga}var ya=Xe(h({},ia,{key:function(t){if(t.key){var e=ua[t.key]||t.key;if("Unidentified"!==e)return e}return"keypress"===t.type?13===(t=Ke(t))?"Enter":String.fromCharCode(t):"keydown"===t.type||"keyup"===t.type?ha[t.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:pa,charCode:function(t){return"keypress"===t.type?Ke(t):0},keyCode:function(t){return"keydown"===t.type||"keyup"===t.type?t.keyCode:0},which:function(t){return"keypress"===t.type?Ke(t):"keydown"===t.type||"keyup"===t.type?t.keyCode:0}})),ba=Xe(h({},oa,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),va=Xe(h({},ia,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:pa})),wa=Xe(h({},ea,{propertyName:0,elapsedTime:0,pseudoElement:0})),xa=Xe(h({},oa,{deltaX:function(t){return"deltaX"in t?t.deltaX:"wheelDeltaX"in t?-t.wheelDeltaX:0},deltaY:function(t){return"deltaY"in t?t.deltaY:"wheelDeltaY"in t?-t.wheelDeltaY:"wheelDelta"in t?-t.wheelDelta:0},deltaZ:0,deltaMode:0})),ka=Xe(h({},ea,{newState:0,oldState:0})),Ia=[9,13,27,32],Ca=Ue&&"CompositionEvent"in window,Sa=null;Ue&&"documentMode"in document&&(Sa=document.documentMode);var Aa=Ue&&"TextEvent"in window&&!Sa,Ta=Ue&&(!Ca||Sa&&8<Sa&&11>=Sa),Pa=String.fromCharCode(32),Da=!1;function Na(t,e){switch(t){case"keyup":return-1!==Ia.indexOf(e.keyCode);case"keydown":return 229!==e.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function La(t){return"object"===typeof(t=t.detail)&&"data"in t?t.data:null}var Ea=!1;var ja={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Ma(t){var e=t&&t.nodeName&&t.nodeName.toLowerCase();return"input"===e?!!ja[t.type]:"textarea"===e}function za(t,e,a,i){ze?Re?Re.push(i):Re=[i]:ze=i,0<(e=im(e,"onChange")).length&&(a=new aa("onChange","change",null,a,i),t.push({event:a,listeners:e}))}var Ra=null,Fa=null;function qa(t){Zc(t,0)}function _a(t){if(fe(Yt(t)))return t}function Oa(t,e){if("change"===t)return e}var Ua=!1;if(Ue){var Ha;if(Ue){var Va="oninput"in document;if(!Va){var Ba=document.createElement("div");Ba.setAttribute("oninput","return;"),Va="function"===typeof Ba.oninput}Ha=Va}else Ha=!1;Ua=Ha&&(!document.documentMode||9<document.documentMode)}function Ga(){Ra&&(Ra.detachEvent("onpropertychange",Wa),Fa=Ra=null)}function Wa(t){if("value"===t.propertyName&&_a(Fa)){var e=[];za(e,Fa,t,Me(t)),_e(qa,e)}}function Qa(t,e,a){"focusin"===t?(Ga(),Fa=a,(Ra=e).attachEvent("onpropertychange",Wa)):"focusout"===t&&Ga()}function Ka(t){if("selectionchange"===t||"keyup"===t||"keydown"===t)return _a(Fa)}function Za(t,e){if("click"===t)return _a(e)}function $a(t,e){if("input"===t||"change"===t)return _a(e)}var Xa="function"===typeof Object.is?Object.is:function(t,e){return t===e&&(0!==t||1/t===1/e)||t!==t&&e!==e};function Ya(t,e){if(Xa(t,e))return!0;if("object"!==typeof t||null===t||"object"!==typeof e||null===e)return!1;var a=Object.keys(t),i=Object.keys(e);if(a.length!==i.length)return!1;for(i=0;i<a.length;i++){var n=a[i];if(!it.call(e,n)||!Xa(t[n],e[n]))return!1}return!0}function Ja(t){for(;t&&t.firstChild;)t=t.firstChild;return t}function ti(t,e){var a,i=Ja(t);for(t=0;i;){if(3===i.nodeType){if(a=t+i.textContent.length,t<=e&&a>=e)return{node:i,offset:e-t};t=a}t:{for(;i;){if(i.nextSibling){i=i.nextSibling;break t}i=i.parentNode}i=void 0}i=Ja(i)}}function ei(t,e){return!(!t||!e)&&(t===e||(!t||3!==t.nodeType)&&(e&&3===e.nodeType?ei(t,e.parentNode):"contains"in t?t.contains(e):!!t.compareDocumentPosition&&!!(16&t.compareDocumentPosition(e))))}function ai(t){for(var e=ge((t=null!=t&&null!=t.ownerDocument&&null!=t.ownerDocument.defaultView?t.ownerDocument.defaultView:window).document);e instanceof t.HTMLIFrameElement;){try{var a="string"===typeof e.contentWindow.location.href}catch(i){a=!1}if(!a)break;e=ge((t=e.contentWindow).document)}return e}function ii(t){var e=t&&t.nodeName&&t.nodeName.toLowerCase();return e&&("input"===e&&("text"===t.type||"search"===t.type||"tel"===t.type||"url"===t.type||"password"===t.type)||"textarea"===e||"true"===t.contentEditable)}var ni=Ue&&"documentMode"in document&&11>=document.documentMode,oi=null,si=null,ri=null,li=!1;function di(t,e,a){var i=a.window===a?a.document:9===a.nodeType?a:a.ownerDocument;li||null==oi||oi!==ge(i)||("selectionStart"in(i=oi)&&ii(i)?i={start:i.selectionStart,end:i.selectionEnd}:i={anchorNode:(i=(i.ownerDocument&&i.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:i.anchorOffset,focusNode:i.focusNode,focusOffset:i.focusOffset},ri&&Ya(ri,i)||(ri=i,0<(i=im(si,"onSelect")).length&&(e=new aa("onSelect","select",null,e,a),t.push({event:e,listeners:i}),e.target=oi)))}function ci(t,e){var a={};return a[t.toLowerCase()]=e.toLowerCase(),a["Webkit"+t]="webkit"+e,a["Moz"+t]="moz"+e,a}var mi={animationend:ci("Animation","AnimationEnd"),animationiteration:ci("Animation","AnimationIteration"),animationstart:ci("Animation","AnimationStart"),transitionrun:ci("Transition","TransitionRun"),transitionstart:ci("Transition","TransitionStart"),transitioncancel:ci("Transition","TransitionCancel"),transitionend:ci("Transition","TransitionEnd")},ui={},hi={};function fi(t){if(ui[t])return ui[t];if(!mi[t])return t;var e,a=mi[t];for(e in a)if(a.hasOwnProperty(e)&&e in hi)return ui[t]=a[e];return t}Ue&&(hi=document.createElement("div").style,"AnimationEvent"in window||(delete mi.animationend.animation,delete mi.animationiteration.animation,delete mi.animationstart.animation),"TransitionEvent"in window||delete mi.transitionend.transition);var gi=fi("animationend"),pi=fi("animationiteration"),yi=fi("animationstart"),bi=fi("transitionrun"),vi=fi("transitionstart"),wi=fi("transitioncancel"),xi=fi("transitionend"),ki=new Map,Ii="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Ci(t,e){ki.set(t,e),ie(e,[t])}Ii.push("scrollEnd");var Si="function"===typeof reportError?reportError:function(t){if("object"===typeof window&&"function"===typeof window.ErrorEvent){var e=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:"object"===typeof t&&null!==t&&"string"===typeof t.message?String(t.message):String(t),error:t});if(!window.dispatchEvent(e))return}else if("object"===typeof process&&"function"===typeof process.emit)return void process.emit("uncaughtException",t);console.error(t)},Ai=[],Ti=0,Pi=0;function Di(){for(var t=Ti,e=Pi=Ti=0;e<t;){var a=Ai[e];Ai[e++]=null;var i=Ai[e];Ai[e++]=null;var n=Ai[e];Ai[e++]=null;var o=Ai[e];if(Ai[e++]=null,null!==i&&null!==n){var s=i.pending;null===s?n.next=n:(n.next=s.next,s.next=n),i.pending=n}0!==o&&ji(a,n,o)}}function Ni(t,e,a,i){Ai[Ti++]=t,Ai[Ti++]=e,Ai[Ti++]=a,Ai[Ti++]=i,Pi|=i,t.lanes|=i,null!==(t=t.alternate)&&(t.lanes|=i)}function Li(t,e,a,i){return Ni(t,e,a,i),Mi(t)}function Ei(t,e){return Ni(t,null,null,e),Mi(t)}function ji(t,e,a){t.lanes|=a;var i=t.alternate;null!==i&&(i.lanes|=a);for(var n=!1,o=t.return;null!==o;)o.childLanes|=a,null!==(i=o.alternate)&&(i.childLanes|=a),22===o.tag&&(null===(t=o.stateNode)||1&t._visibility||(n=!0)),t=o,o=o.return;return 3===t.tag?(o=t.stateNode,n&&null!==e&&(n=31-wt(a),null===(i=(t=o.hiddenUpdates)[n])?t[n]=[e]:i.push(e),e.lane=536870912|a),o):null}function Mi(t){if(50<Bd)throw Bd=0,Gd=null,Error(s(185));for(var e=t.return;null!==e;)e=(t=e).return;return 3===t.tag?t.stateNode:null}var zi={};function Ri(t,e,a,i){this.tag=t,this.key=a,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=e,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=i,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Fi(t,e,a,i){return new Ri(t,e,a,i)}function qi(t){return!(!(t=t.prototype)||!t.isReactComponent)}function _i(t,e){var a=t.alternate;return null===a?((a=Fi(t.tag,e,t.key,t.mode)).elementType=t.elementType,a.type=t.type,a.stateNode=t.stateNode,a.alternate=t,t.alternate=a):(a.pendingProps=e,a.type=t.type,a.flags=0,a.subtreeFlags=0,a.deletions=null),a.flags=65011712&t.flags,a.childLanes=t.childLanes,a.lanes=t.lanes,a.child=t.child,a.memoizedProps=t.memoizedProps,a.memoizedState=t.memoizedState,a.updateQueue=t.updateQueue,e=t.dependencies,a.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext},a.sibling=t.sibling,a.index=t.index,a.ref=t.ref,a.refCleanup=t.refCleanup,a}function Oi(t,e){t.flags&=65011714;var a=t.alternate;return null===a?(t.childLanes=0,t.lanes=e,t.child=null,t.subtreeFlags=0,t.memoizedProps=null,t.memoizedState=null,t.updateQueue=null,t.dependencies=null,t.stateNode=null):(t.childLanes=a.childLanes,t.lanes=a.lanes,t.child=a.child,t.subtreeFlags=0,t.deletions=null,t.memoizedProps=a.memoizedProps,t.memoizedState=a.memoizedState,t.updateQueue=a.updateQueue,t.type=a.type,e=a.dependencies,t.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),t}function Ui(t,e,a,i,n,o){var r=0;if(i=t,"function"===typeof t)qi(t)&&(r=1);else if("string"===typeof t)r=function(t,e,a){if(1===a||null!=e.itemProp)return!1;switch(t){case"meta":case"title":return!0;case"style":if("string"!==typeof e.precedence||"string"!==typeof e.href||""===e.href)break;return!0;case"link":if("string"!==typeof e.rel||"string"!==typeof e.href||""===e.href||e.onLoad||e.onError)break;return"stylesheet"!==e.rel||(t=e.disabled,"string"===typeof e.precedence&&null==t);case"script":if(e.async&&"function"!==typeof e.async&&"symbol"!==typeof e.async&&!e.onLoad&&!e.onError&&e.src&&"string"===typeof e.src)return!0}return!1}(t,a,B.current)?26:"html"===t||"head"===t||"body"===t?27:5;else t:switch(t){case T:return(t=Fi(31,a,e,n)).elementType=T,t.lanes=o,t;case y:return Hi(a.children,n,o,e);case b:r=8,n|=24;break;case v:return(t=Fi(12,a,e,2|n)).elementType=v,t.lanes=o,t;case I:return(t=Fi(13,a,e,n)).elementType=I,t.lanes=o,t;case C:return(t=Fi(19,a,e,n)).elementType=C,t.lanes=o,t;default:if("object"===typeof t&&null!==t)switch(t.$$typeof){case x:r=10;break t;case w:r=9;break t;case k:r=11;break t;case S:r=14;break t;case A:r=16,i=null;break t}r=29,a=Error(s(130,null===t?"null":typeof t,"")),i=null}return(e=Fi(r,a,e,n)).elementType=t,e.type=i,e.lanes=o,e}function Hi(t,e,a,i){return(t=Fi(7,t,i,e)).lanes=a,t}function Vi(t,e,a){return(t=Fi(6,t,null,e)).lanes=a,t}function Bi(t){var e=Fi(18,null,null,0);return e.stateNode=t,e}function Gi(t,e,a){return(e=Fi(4,null!==t.children?t.children:[],t.key,e)).lanes=a,e.stateNode={containerInfo:t.containerInfo,pendingChildren:null,implementation:t.implementation},e}var Wi=new WeakMap;function Qi(t,e){if("object"===typeof t&&null!==t){var a=Wi.get(t);return void 0!==a?a:(e={value:t,source:e,stack:at(e)},Wi.set(t,e),e)}return{value:t,source:e,stack:at(e)}}var Ki=[],Zi=0,$i=null,Xi=0,Yi=[],Ji=0,tn=null,en=1,an="";function nn(t,e){Ki[Zi++]=Xi,Ki[Zi++]=$i,$i=t,Xi=e}function on(t,e,a){Yi[Ji++]=en,Yi[Ji++]=an,Yi[Ji++]=tn,tn=t;var i=en;t=an;var n=32-wt(i)-1;i&=~(1<<n),a+=1;var o=32-wt(e)+n;if(30<o){var s=n-n%5;o=(i&(1<<s)-1).toString(32),i>>=s,n-=s,en=1<<32-wt(e)+n|a<<n|i,an=o+t}else en=1<<o|a<<n|i,an=t}function sn(t){null!==t.return&&(nn(t,1),on(t,1,0))}function rn(t){for(;t===$i;)$i=Ki[--Zi],Ki[Zi]=null,Xi=Ki[--Zi],Ki[Zi]=null;for(;t===tn;)tn=Yi[--Ji],Yi[Ji]=null,an=Yi[--Ji],Yi[Ji]=null,en=Yi[--Ji],Yi[Ji]=null}function ln(t,e){Yi[Ji++]=en,Yi[Ji++]=an,Yi[Ji++]=tn,en=e.id,an=e.overflow,tn=t}var dn=null,cn=null,mn=!1,un=null,hn=!1,fn=Error(s(519));function gn(t){throw xn(Qi(Error(s(418,1<arguments.length&&void 0!==arguments[1]&&arguments[1]?"text":"HTML","")),t)),fn}function pn(t){var e=t.stateNode,a=t.type,i=t.memoizedProps;switch(e[Ut]=t,e[Ht]=i,a){case"dialog":$c("cancel",e),$c("close",e);break;case"iframe":case"object":case"embed":$c("load",e);break;case"video":case"audio":for(a=0;a<Qc.length;a++)$c(Qc[a],e);break;case"source":$c("error",e);break;case"img":case"image":case"link":$c("error",e),$c("load",e);break;case"details":$c("toggle",e);break;case"input":$c("invalid",e),ve(e,i.value,i.defaultValue,i.checked,i.defaultChecked,i.type,i.name,!0);break;case"select":$c("invalid",e);break;case"textarea":$c("invalid",e),Ie(e,i.value,i.defaultValue,i.children)}"string"!==typeof(a=i.children)&&"number"!==typeof a&&"bigint"!==typeof a||e.textContent===""+a||!0===i.suppressHydrationWarning||dm(e.textContent,a)?(null!=i.popover&&($c("beforetoggle",e),$c("toggle",e)),null!=i.onScroll&&$c("scroll",e),null!=i.onScrollEnd&&$c("scrollend",e),null!=i.onClick&&(e.onclick=Ee),e=!0):e=!1,e||gn(t,!0)}function yn(t){for(dn=t.return;dn;)switch(dn.tag){case 5:case 31:case 13:return void(hn=!1);case 27:case 3:return void(hn=!0);default:dn=dn.return}}function bn(t){if(t!==dn)return!1;if(!mn)return yn(t),mn=!0,!1;var e,a=t.tag;if((e=3!==a&&27!==a)&&((e=5===a)&&(e=!("form"!==(e=t.type)&&"button"!==e)||vm(t.type,t.memoizedProps)),e=!e),e&&cn&&gn(t),yn(t),13===a){if(!(t=null!==(t=t.memoizedState)?t.dehydrated:null))throw Error(s(317));cn=zm(t)}else if(31===a){if(!(t=null!==(t=t.memoizedState)?t.dehydrated:null))throw Error(s(317));cn=zm(t)}else 27===a?(a=cn,Am(t.type)?(t=Mm,Mm=null,cn=t):cn=a):cn=dn?jm(t.stateNode.nextSibling):null;return!0}function vn(){cn=dn=null,mn=!1}function wn(){var t=un;return null!==t&&(null===Nd?Nd=t:Nd.push.apply(Nd,t),un=null),t}function xn(t){null===un?un=[t]:un.push(t)}var kn=_(null),In=null,Cn=null;function Sn(t,e,a){U(kn,e._currentValue),e._currentValue=a}function An(t){t._currentValue=kn.current,O(kn)}function Tn(t,e,a){for(;null!==t;){var i=t.alternate;if((t.childLanes&e)!==e?(t.childLanes|=e,null!==i&&(i.childLanes|=e)):null!==i&&(i.childLanes&e)!==e&&(i.childLanes|=e),t===a)break;t=t.return}}function Pn(t,e,a,i){var n=t.child;for(null!==n&&(n.return=t);null!==n;){var o=n.dependencies;if(null!==o){var r=n.child;o=o.firstContext;t:for(;null!==o;){var l=o;o=n;for(var d=0;d<e.length;d++)if(l.context===e[d]){o.lanes|=a,null!==(l=o.alternate)&&(l.lanes|=a),Tn(o.return,a,t),i||(r=null);break t}o=l.next}}else if(18===n.tag){if(null===(r=n.return))throw Error(s(341));r.lanes|=a,null!==(o=r.alternate)&&(o.lanes|=a),Tn(r,a,t),r=null}else r=n.child;if(null!==r)r.return=n;else for(r=n;null!==r;){if(r===t){r=null;break}if(null!==(n=r.sibling)){n.return=r.return,r=n;break}r=r.return}n=r}}function Dn(t,e,a,i){t=null;for(var n=e,o=!1;null!==n;){if(!o)if(0!==(524288&n.flags))o=!0;else if(0!==(262144&n.flags))break;if(10===n.tag){var r=n.alternate;if(null===r)throw Error(s(387));if(null!==(r=r.memoizedProps)){var l=n.type;Xa(n.pendingProps.value,r.value)||(null!==t?t.push(l):t=[l])}}else if(n===Q.current){if(null===(r=n.alternate))throw Error(s(387));r.memoizedState.memoizedState!==n.memoizedState.memoizedState&&(null!==t?t.push(cu):t=[cu])}n=n.return}null!==t&&Pn(e,t,a,i),e.flags|=262144}function Nn(t){for(t=t.firstContext;null!==t;){if(!Xa(t.context._currentValue,t.memoizedValue))return!0;t=t.next}return!1}function Ln(t){In=t,Cn=null,null!==(t=t.dependencies)&&(t.firstContext=null)}function En(t){return Mn(In,t)}function jn(t,e){return null===In&&Ln(t),Mn(t,e)}function Mn(t,e){var a=e._currentValue;if(e={context:e,memoizedValue:a,next:null},null===Cn){if(null===t)throw Error(s(308));Cn=e,t.dependencies={lanes:0,firstContext:e},t.flags|=524288}else Cn=Cn.next=e;return a}var zn="undefined"!==typeof AbortController?AbortController:function(){var t=[],e=this.signal={aborted:!1,addEventListener:function(e,a){t.push(a)}};this.abort=function(){e.aborted=!0,t.forEach(function(t){return t()})}},Rn=i.unstable_scheduleCallback,Fn=i.unstable_NormalPriority,qn={$$typeof:x,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function _n(){return{controller:new zn,data:new Map,refCount:0}}function On(t){t.refCount--,0===t.refCount&&Rn(Fn,function(){t.controller.abort()})}var Un=null,Hn=0,Vn=0,Bn=null;function Gn(){if(0===--Hn&&null!==Un){null!==Bn&&(Bn.status="fulfilled");var t=Un;Un=null,Vn=0,Bn=null;for(var e=0;e<t.length;e++)(0,t[e])()}}var Wn=M.S;M.S=function(t,e){jd=lt(),"object"===typeof e&&null!==e&&"function"===typeof e.then&&function(t,e){if(null===Un){var a=Un=[];Hn=0,Vn=Hc(),Bn={status:"pending",value:void 0,then:function(t){a.push(t)}}}Hn++,e.then(Gn,Gn)}(0,e),null!==Wn&&Wn(t,e)};var Qn=_(null);function Kn(){var t=Qn.current;return null!==t?t:fd.pooledCache}function Zn(t,e){U(Qn,null===e?Qn.current:e.pool)}function $n(){var t=Kn();return null===t?null:{parent:qn._currentValue,pool:t}}var Xn=Error(s(460)),Yn=Error(s(474)),Jn=Error(s(542)),to={then:function(){}};function eo(t){return"fulfilled"===(t=t.status)||"rejected"===t}function ao(t,e,a){switch(void 0===(a=t[a])?t.push(e):a!==e&&(e.then(Ee,Ee),e=a),e.status){case"fulfilled":return e.value;case"rejected":throw so(t=e.reason),t;default:if("string"===typeof e.status)e.then(Ee,Ee);else{if(null!==(t=fd)&&100<t.shellSuspendCounter)throw Error(s(482));(t=e).status="pending",t.then(function(t){if("pending"===e.status){var a=e;a.status="fulfilled",a.value=t}},function(t){if("pending"===e.status){var a=e;a.status="rejected",a.reason=t}})}switch(e.status){case"fulfilled":return e.value;case"rejected":throw so(t=e.reason),t}throw no=e,Xn}}function io(t){try{return(0,t._init)(t._payload)}catch(e){if(null!==e&&"object"===typeof e&&"function"===typeof e.then)throw no=e,Xn;throw e}}var no=null;function oo(){if(null===no)throw Error(s(459));var t=no;return no=null,t}function so(t){if(t===Xn||t===Jn)throw Error(s(483))}var ro=null,lo=0;function co(t){var e=lo;return lo+=1,null===ro&&(ro=[]),ao(ro,t,e)}function mo(t,e){e=e.props.ref,t.ref=void 0!==e?e:null}function uo(t,e){if(e.$$typeof===f)throw Error(s(525));throw t=Object.prototype.toString.call(e),Error(s(31,"[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t))}function ho(t){function e(e,a){if(t){var i=e.deletions;null===i?(e.deletions=[a],e.flags|=16):i.push(a)}}function a(a,i){if(!t)return null;for(;null!==i;)e(a,i),i=i.sibling;return null}function i(t){for(var e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function n(t,e){return(t=_i(t,e)).index=0,t.sibling=null,t}function o(e,a,i){return e.index=i,t?null!==(i=e.alternate)?(i=i.index)<a?(e.flags|=67108866,a):i:(e.flags|=67108866,a):(e.flags|=1048576,a)}function r(e){return t&&null===e.alternate&&(e.flags|=67108866),e}function l(t,e,a,i){return null===e||6!==e.tag?((e=Vi(a,t.mode,i)).return=t,e):((e=n(e,a)).return=t,e)}function d(t,e,a,i){var o=a.type;return o===y?m(t,e,a.props.children,i,a.key):null!==e&&(e.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===A&&io(o)===e.type)?(mo(e=n(e,a.props),a),e.return=t,e):(mo(e=Ui(a.type,a.key,a.props,null,t.mode,i),a),e.return=t,e)}function c(t,e,a,i){return null===e||4!==e.tag||e.stateNode.containerInfo!==a.containerInfo||e.stateNode.implementation!==a.implementation?((e=Gi(a,t.mode,i)).return=t,e):((e=n(e,a.children||[])).return=t,e)}function m(t,e,a,i,o){return null===e||7!==e.tag?((e=Hi(a,t.mode,i,o)).return=t,e):((e=n(e,a)).return=t,e)}function u(t,e,a){if("string"===typeof e&&""!==e||"number"===typeof e||"bigint"===typeof e)return(e=Vi(""+e,t.mode,a)).return=t,e;if("object"===typeof e&&null!==e){switch(e.$$typeof){case g:return mo(a=Ui(e.type,e.key,e.props,null,t.mode,a),e),a.return=t,a;case p:return(e=Gi(e,t.mode,a)).return=t,e;case A:return u(t,e=io(e),a)}if(j(e)||N(e))return(e=Hi(e,t.mode,a,null)).return=t,e;if("function"===typeof e.then)return u(t,co(e),a);if(e.$$typeof===x)return u(t,jn(t,e),a);uo(t,e)}return null}function h(t,e,a,i){var n=null!==e?e.key:null;if("string"===typeof a&&""!==a||"number"===typeof a||"bigint"===typeof a)return null!==n?null:l(t,e,""+a,i);if("object"===typeof a&&null!==a){switch(a.$$typeof){case g:return a.key===n?d(t,e,a,i):null;case p:return a.key===n?c(t,e,a,i):null;case A:return h(t,e,a=io(a),i)}if(j(a)||N(a))return null!==n?null:m(t,e,a,i,null);if("function"===typeof a.then)return h(t,e,co(a),i);if(a.$$typeof===x)return h(t,e,jn(t,a),i);uo(t,a)}return null}function f(t,e,a,i,n){if("string"===typeof i&&""!==i||"number"===typeof i||"bigint"===typeof i)return l(e,t=t.get(a)||null,""+i,n);if("object"===typeof i&&null!==i){switch(i.$$typeof){case g:return d(e,t=t.get(null===i.key?a:i.key)||null,i,n);case p:return c(e,t=t.get(null===i.key?a:i.key)||null,i,n);case A:return f(t,e,a,i=io(i),n)}if(j(i)||N(i))return m(e,t=t.get(a)||null,i,n,null);if("function"===typeof i.then)return f(t,e,a,co(i),n);if(i.$$typeof===x)return f(t,e,a,jn(e,i),n);uo(e,i)}return null}function b(l,d,c,m){if("object"===typeof c&&null!==c&&c.type===y&&null===c.key&&(c=c.props.children),"object"===typeof c&&null!==c){switch(c.$$typeof){case g:t:{for(var v=c.key;null!==d;){if(d.key===v){if((v=c.type)===y){if(7===d.tag){a(l,d.sibling),(m=n(d,c.props.children)).return=l,l=m;break t}}else if(d.elementType===v||"object"===typeof v&&null!==v&&v.$$typeof===A&&io(v)===d.type){a(l,d.sibling),mo(m=n(d,c.props),c),m.return=l,l=m;break t}a(l,d);break}e(l,d),d=d.sibling}c.type===y?((m=Hi(c.props.children,l.mode,m,c.key)).return=l,l=m):(mo(m=Ui(c.type,c.key,c.props,null,l.mode,m),c),m.return=l,l=m)}return r(l);case p:t:{for(v=c.key;null!==d;){if(d.key===v){if(4===d.tag&&d.stateNode.containerInfo===c.containerInfo&&d.stateNode.implementation===c.implementation){a(l,d.sibling),(m=n(d,c.children||[])).return=l,l=m;break t}a(l,d);break}e(l,d),d=d.sibling}(m=Gi(c,l.mode,m)).return=l,l=m}return r(l);case A:return b(l,d,c=io(c),m)}if(j(c))return function(n,s,r,l){for(var d=null,c=null,m=s,g=s=0,p=null;null!==m&&g<r.length;g++){m.index>g?(p=m,m=null):p=m.sibling;var y=h(n,m,r[g],l);if(null===y){null===m&&(m=p);break}t&&m&&null===y.alternate&&e(n,m),s=o(y,s,g),null===c?d=y:c.sibling=y,c=y,m=p}if(g===r.length)return a(n,m),mn&&nn(n,g),d;if(null===m){for(;g<r.length;g++)null!==(m=u(n,r[g],l))&&(s=o(m,s,g),null===c?d=m:c.sibling=m,c=m);return mn&&nn(n,g),d}for(m=i(m);g<r.length;g++)null!==(p=f(m,n,g,r[g],l))&&(t&&null!==p.alternate&&m.delete(null===p.key?g:p.key),s=o(p,s,g),null===c?d=p:c.sibling=p,c=p);return t&&m.forEach(function(t){return e(n,t)}),mn&&nn(n,g),d}(l,d,c,m);if(N(c)){if("function"!==typeof(v=N(c)))throw Error(s(150));return function(n,r,l,d){if(null==l)throw Error(s(151));for(var c=null,m=null,g=r,p=r=0,y=null,b=l.next();null!==g&&!b.done;p++,b=l.next()){g.index>p?(y=g,g=null):y=g.sibling;var v=h(n,g,b.value,d);if(null===v){null===g&&(g=y);break}t&&g&&null===v.alternate&&e(n,g),r=o(v,r,p),null===m?c=v:m.sibling=v,m=v,g=y}if(b.done)return a(n,g),mn&&nn(n,p),c;if(null===g){for(;!b.done;p++,b=l.next())null!==(b=u(n,b.value,d))&&(r=o(b,r,p),null===m?c=b:m.sibling=b,m=b);return mn&&nn(n,p),c}for(g=i(g);!b.done;p++,b=l.next())null!==(b=f(g,n,p,b.value,d))&&(t&&null!==b.alternate&&g.delete(null===b.key?p:b.key),r=o(b,r,p),null===m?c=b:m.sibling=b,m=b);return t&&g.forEach(function(t){return e(n,t)}),mn&&nn(n,p),c}(l,d,c=v.call(c),m)}if("function"===typeof c.then)return b(l,d,co(c),m);if(c.$$typeof===x)return b(l,d,jn(l,c),m);uo(l,c)}return"string"===typeof c&&""!==c||"number"===typeof c||"bigint"===typeof c?(c=""+c,null!==d&&6===d.tag?(a(l,d.sibling),(m=n(d,c)).return=l,l=m):(a(l,d),(m=Vi(c,l.mode,m)).return=l,l=m),r(l)):a(l,d)}return function(t,e,a,i){try{lo=0;var n=b(t,e,a,i);return ro=null,n}catch(s){if(s===Xn||s===Jn)throw s;var o=Fi(29,s,null,t.mode);return o.lanes=i,o.return=t,o}}}var fo=ho(!0),go=ho(!1),po=!1;function yo(t){t.updateQueue={baseState:t.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function bo(t,e){t=t.updateQueue,e.updateQueue===t&&(e.updateQueue={baseState:t.baseState,firstBaseUpdate:t.firstBaseUpdate,lastBaseUpdate:t.lastBaseUpdate,shared:t.shared,callbacks:null})}function vo(t){return{lane:t,tag:0,payload:null,callback:null,next:null}}function wo(t,e,a){var i=t.updateQueue;if(null===i)return null;if(i=i.shared,0!==(2&hd)){var n=i.pending;return null===n?e.next=e:(e.next=n.next,n.next=e),i.pending=e,e=Mi(t),ji(t,null,a),e}return Ni(t,i,e,a),Mi(t)}function xo(t,e,a){if(null!==(e=e.updateQueue)&&(e=e.shared,0!==(4194048&a))){var i=e.lanes;a|=i&=t.pendingLanes,e.lanes=a,Mt(t,a)}}function ko(t,e){var a=t.updateQueue,i=t.alternate;if(null!==i&&a===(i=i.updateQueue)){var n=null,o=null;if(null!==(a=a.firstBaseUpdate)){do{var s={lane:a.lane,tag:a.tag,payload:a.payload,callback:null,next:null};null===o?n=o=s:o=o.next=s,a=a.next}while(null!==a);null===o?n=o=e:o=o.next=e}else n=o=e;return a={baseState:i.baseState,firstBaseUpdate:n,lastBaseUpdate:o,shared:i.shared,callbacks:i.callbacks},void(t.updateQueue=a)}null===(t=a.lastBaseUpdate)?a.firstBaseUpdate=e:t.next=e,a.lastBaseUpdate=e}var Io=!1;function Co(){if(Io){if(null!==Bn)throw Bn}}function So(t,e,a,i){Io=!1;var n=t.updateQueue;po=!1;var o=n.firstBaseUpdate,s=n.lastBaseUpdate,r=n.shared.pending;if(null!==r){n.shared.pending=null;var l=r,d=l.next;l.next=null,null===s?o=d:s.next=d,s=l;var c=t.alternate;null!==c&&((r=(c=c.updateQueue).lastBaseUpdate)!==s&&(null===r?c.firstBaseUpdate=d:r.next=d,c.lastBaseUpdate=l))}if(null!==o){var m=n.baseState;for(s=0,c=d=l=null,r=o;;){var u=-536870913&r.lane,f=u!==r.lane;if(f?(pd&u)===u:(i&u)===u){0!==u&&u===Vn&&(Io=!0),null!==c&&(c=c.next={lane:0,tag:r.tag,payload:r.payload,callback:null,next:null});t:{var g=t,p=r;u=e;var y=a;switch(p.tag){case 1:if("function"===typeof(g=p.payload)){m=g.call(y,m,u);break t}m=g;break t;case 3:g.flags=-65537&g.flags|128;case 0:if(null===(u="function"===typeof(g=p.payload)?g.call(y,m,u):g)||void 0===u)break t;m=h({},m,u);break t;case 2:po=!0}}null!==(u=r.callback)&&(t.flags|=64,f&&(t.flags|=8192),null===(f=n.callbacks)?n.callbacks=[u]:f.push(u))}else f={lane:u,tag:r.tag,payload:r.payload,callback:r.callback,next:null},null===c?(d=c=f,l=m):c=c.next=f,s|=u;if(null===(r=r.next)){if(null===(r=n.shared.pending))break;r=(f=r).next,f.next=null,n.lastBaseUpdate=f,n.shared.pending=null}}null===c&&(l=m),n.baseState=l,n.firstBaseUpdate=d,n.lastBaseUpdate=c,null===o&&(n.shared.lanes=0),Cd|=s,t.lanes=s,t.memoizedState=m}}function Ao(t,e){if("function"!==typeof t)throw Error(s(191,t));t.call(e)}function To(t,e){var a=t.callbacks;if(null!==a)for(t.callbacks=null,t=0;t<a.length;t++)Ao(a[t],e)}var Po=_(null),Do=_(0);function No(t,e){U(Do,t=kd),U(Po,e),kd=t|e.baseLanes}function Lo(){U(Do,kd),U(Po,Po.current)}function Eo(){kd=Do.current,O(Po),O(Do)}var jo=_(null),Mo=null;function zo(t){var e=t.alternate;U(Oo,1&Oo.current),U(jo,t),null===Mo&&(null===e||null!==Po.current||null!==e.memoizedState)&&(Mo=t)}function Ro(t){U(Oo,Oo.current),U(jo,t),null===Mo&&(Mo=t)}function Fo(t){22===t.tag?(U(Oo,Oo.current),U(jo,t),null===Mo&&(Mo=t)):qo()}function qo(){U(Oo,Oo.current),U(jo,jo.current)}function _o(t){O(jo),Mo===t&&(Mo=null),O(Oo)}var Oo=_(0);function Uo(t){for(var e=t;null!==e;){if(13===e.tag){var a=e.memoizedState;if(null!==a&&(null===(a=a.dehydrated)||Lm(a)||Em(a)))return e}else if(19!==e.tag||"forwards"!==e.memoizedProps.revealOrder&&"backwards"!==e.memoizedProps.revealOrder&&"unstable_legacy-backwards"!==e.memoizedProps.revealOrder&&"together"!==e.memoizedProps.revealOrder){if(null!==e.child){e.child.return=e,e=e.child;continue}}else if(0!==(128&e.flags))return e;if(e===t)break;for(;null===e.sibling;){if(null===e.return||e.return===t)return null;e=e.return}e.sibling.return=e.return,e=e.sibling}return null}var Ho=0,Vo=null,Bo=null,Go=null,Wo=!1,Qo=!1,Ko=!1,Zo=0,$o=0,Xo=null,Yo=0;function Jo(){throw Error(s(321))}function ts(t,e){if(null===e)return!1;for(var a=0;a<e.length&&a<t.length;a++)if(!Xa(t[a],e[a]))return!1;return!0}function es(t,e,a,i,n,o){return Ho=o,Vo=e,e.memoizedState=null,e.updateQueue=null,e.lanes=0,M.H=null===t||null===t.memoizedState?pr:yr,Ko=!1,o=a(i,n),Ko=!1,Qo&&(o=is(e,a,i,n)),as(t),o}function as(t){M.H=gr;var e=null!==Bo&&null!==Bo.next;if(Ho=0,Go=Bo=Vo=null,Wo=!1,$o=0,Xo=null,e)throw Error(s(300));null===t||jr||null!==(t=t.dependencies)&&Nn(t)&&(jr=!0)}function is(t,e,a,i){Vo=t;var n=0;do{if(Qo&&(Xo=null),$o=0,Qo=!1,25<=n)throw Error(s(301));if(n+=1,Go=Bo=null,null!=t.updateQueue){var o=t.updateQueue;o.lastEffect=null,o.events=null,o.stores=null,null!=o.memoCache&&(o.memoCache.index=0)}M.H=br,o=e(a,i)}while(Qo);return o}function ns(){var t=M.H,e=t.useState()[0];return e="function"===typeof e.then?cs(e):e,t=t.useState()[0],(null!==Bo?Bo.memoizedState:null)!==t&&(Vo.flags|=1024),e}function os(){var t=0!==Zo;return Zo=0,t}function ss(t,e,a){e.updateQueue=t.updateQueue,e.flags&=-2053,t.lanes&=~a}function rs(t){if(Wo){for(t=t.memoizedState;null!==t;){var e=t.queue;null!==e&&(e.pending=null),t=t.next}Wo=!1}Ho=0,Go=Bo=Vo=null,Qo=!1,$o=Zo=0,Xo=null}function ls(){var t={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===Go?Vo.memoizedState=Go=t:Go=Go.next=t,Go}function ds(){if(null===Bo){var t=Vo.alternate;t=null!==t?t.memoizedState:null}else t=Bo.next;var e=null===Go?Vo.memoizedState:Go.next;if(null!==e)Go=e,Bo=t;else{if(null===t){if(null===Vo.alternate)throw Error(s(467));throw Error(s(310))}t={memoizedState:(Bo=t).memoizedState,baseState:Bo.baseState,baseQueue:Bo.baseQueue,queue:Bo.queue,next:null},null===Go?Vo.memoizedState=Go=t:Go=Go.next=t}return Go}function cs(t){var e=$o;return $o+=1,null===Xo&&(Xo=[]),t=ao(Xo,t,e),e=Vo,null===(null===Go?e.memoizedState:Go.next)&&(e=e.alternate,M.H=null===e||null===e.memoizedState?pr:yr),t}function ms(t){if(null!==t&&"object"===typeof t){if("function"===typeof t.then)return cs(t);if(t.$$typeof===x)return En(t)}throw Error(s(438,String(t)))}function us(t){var e=null,a=Vo.updateQueue;if(null!==a&&(e=a.memoCache),null==e){var i=Vo.alternate;null!==i&&(null!==(i=i.updateQueue)&&(null!=(i=i.memoCache)&&(e={data:i.data.map(function(t){return t.slice()}),index:0})))}if(null==e&&(e={data:[],index:0}),null===a&&(a={lastEffect:null,events:null,stores:null,memoCache:null},Vo.updateQueue=a),a.memoCache=e,void 0===(a=e.data[e.index]))for(a=e.data[e.index]=Array(t),i=0;i<t;i++)a[i]=P;return e.index++,a}function hs(t,e){return"function"===typeof e?e(t):e}function fs(t){return gs(ds(),Bo,t)}function gs(t,e,a){var i=t.queue;if(null===i)throw Error(s(311));i.lastRenderedReducer=a;var n=t.baseQueue,o=i.pending;if(null!==o){if(null!==n){var r=n.next;n.next=o.next,o.next=r}e.baseQueue=n=o,i.pending=null}if(o=t.baseState,null===n)t.memoizedState=o;else{var l=r=null,d=null,c=e=n.next,m=!1;do{var u=-536870913&c.lane;if(u!==c.lane?(pd&u)===u:(Ho&u)===u){var h=c.revertLane;if(0===h)null!==d&&(d=d.next={lane:0,revertLane:0,gesture:null,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),u===Vn&&(m=!0);else{if((Ho&h)===h){c=c.next,h===Vn&&(m=!0);continue}u={lane:0,revertLane:c.revertLane,gesture:null,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null},null===d?(l=d=u,r=o):d=d.next=u,Vo.lanes|=h,Cd|=h}u=c.action,Ko&&a(o,u),o=c.hasEagerState?c.eagerState:a(o,u)}else h={lane:u,revertLane:c.revertLane,gesture:c.gesture,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null},null===d?(l=d=h,r=o):d=d.next=h,Vo.lanes|=u,Cd|=u;c=c.next}while(null!==c&&c!==e);if(null===d?r=o:d.next=l,!Xa(o,t.memoizedState)&&(jr=!0,m&&null!==(a=Bn)))throw a;t.memoizedState=o,t.baseState=r,t.baseQueue=d,i.lastRenderedState=o}return null===n&&(i.lanes=0),[t.memoizedState,i.dispatch]}function ps(t){var e=ds(),a=e.queue;if(null===a)throw Error(s(311));a.lastRenderedReducer=t;var i=a.dispatch,n=a.pending,o=e.memoizedState;if(null!==n){a.pending=null;var r=n=n.next;do{o=t(o,r.action),r=r.next}while(r!==n);Xa(o,e.memoizedState)||(jr=!0),e.memoizedState=o,null===e.baseQueue&&(e.baseState=o),a.lastRenderedState=o}return[o,i]}function ys(t,e,a){var i=Vo,n=ds(),o=mn;if(o){if(void 0===a)throw Error(s(407));a=a()}else a=e();var r=!Xa((Bo||n).memoizedState,a);if(r&&(n.memoizedState=a,jr=!0),n=n.queue,Hs(ws.bind(null,i,n,t),[t]),n.getSnapshot!==e||r||null!==Go&&1&Go.memoizedState.tag){if(i.flags|=2048,Fs(9,{destroy:void 0},vs.bind(null,i,n,a,e),null),null===fd)throw Error(s(349));o||0!==(127&Ho)||bs(i,e,a)}return a}function bs(t,e,a){t.flags|=16384,t={getSnapshot:e,value:a},null===(e=Vo.updateQueue)?(e={lastEffect:null,events:null,stores:null,memoCache:null},Vo.updateQueue=e,e.stores=[t]):null===(a=e.stores)?e.stores=[t]:a.push(t)}function vs(t,e,a,i){e.value=a,e.getSnapshot=i,xs(e)&&ks(t)}function ws(t,e,a){return a(function(){xs(e)&&ks(t)})}function xs(t){var e=t.getSnapshot;t=t.value;try{var a=e();return!Xa(t,a)}catch(i){return!0}}function ks(t){var e=Ei(t,2);null!==e&&Kd(e,t,2)}function Is(t){var e=ls();if("function"===typeof t){var a=t;if(t=a(),Ko){vt(!0);try{a()}finally{vt(!1)}}}return e.memoizedState=e.baseState=t,e.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:hs,lastRenderedState:t},e}function Cs(t,e,a,i){return t.baseState=a,gs(t,Bo,"function"===typeof i?i:hs)}function Ss(t,e,a,i,n){if(ur(t))throw Error(s(485));if(null!==(t=e.action)){var o={payload:n,action:t,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(t){o.listeners.push(t)}};null!==M.T?a(!0):o.isTransition=!1,i(o),null===(a=e.pending)?(o.next=e.pending=o,As(e,o)):(o.next=a.next,e.pending=a.next=o)}}function As(t,e){var a=e.action,i=e.payload,n=t.state;if(e.isTransition){var o=M.T,s={};M.T=s;try{var r=a(n,i),l=M.S;null!==l&&l(s,r),Ts(t,e,r)}catch(d){Ds(t,e,d)}finally{null!==o&&null!==s.types&&(o.types=s.types),M.T=o}}else try{Ts(t,e,o=a(n,i))}catch(c){Ds(t,e,c)}}function Ts(t,e,a){null!==a&&"object"===typeof a&&"function"===typeof a.then?a.then(function(a){Ps(t,e,a)},function(a){return Ds(t,e,a)}):Ps(t,e,a)}function Ps(t,e,a){e.status="fulfilled",e.value=a,Ns(e),t.state=a,null!==(e=t.pending)&&((a=e.next)===e?t.pending=null:(a=a.next,e.next=a,As(t,a)))}function Ds(t,e,a){var i=t.pending;if(t.pending=null,null!==i){i=i.next;do{e.status="rejected",e.reason=a,Ns(e),e=e.next}while(e!==i)}t.action=null}function Ns(t){t=t.listeners;for(var e=0;e<t.length;e++)(0,t[e])()}function Ls(t,e){return e}function Es(t,e){if(mn){var a=fd.formState;if(null!==a){t:{var i=Vo;if(mn){if(cn){e:{for(var n=cn,o=hn;8!==n.nodeType;){if(!o){n=null;break e}if(null===(n=jm(n.nextSibling))){n=null;break e}}n="F!"===(o=n.data)||"F"===o?n:null}if(n){cn=jm(n.nextSibling),i="F!"===n.data;break t}}gn(i)}i=!1}i&&(e=a[0])}}return(a=ls()).memoizedState=a.baseState=e,i={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Ls,lastRenderedState:e},a.queue=i,a=dr.bind(null,Vo,i),i.dispatch=a,i=Is(!1),o=mr.bind(null,Vo,!1,i.queue),n={state:e,dispatch:null,action:t,pending:null},(i=ls()).queue=n,a=Ss.bind(null,Vo,n,o,a),n.dispatch=a,i.memoizedState=t,[e,a,!1]}function js(t){return Ms(ds(),Bo,t)}function Ms(t,e,a){if(e=gs(t,e,Ls)[0],t=fs(hs)[0],"object"===typeof e&&null!==e&&"function"===typeof e.then)try{var i=cs(e)}catch(s){if(s===Xn)throw Jn;throw s}else i=e;var n=(e=ds()).queue,o=n.dispatch;return a!==e.memoizedState&&(Vo.flags|=2048,Fs(9,{destroy:void 0},zs.bind(null,n,a),null)),[i,o,t]}function zs(t,e){t.action=e}function Rs(t){var e=ds(),a=Bo;if(null!==a)return Ms(e,a,t);ds(),e=e.memoizedState;var i=(a=ds()).queue.dispatch;return a.memoizedState=t,[e,i,!1]}function Fs(t,e,a,i){return t={tag:t,create:a,deps:i,inst:e,next:null},null===(e=Vo.updateQueue)&&(e={lastEffect:null,events:null,stores:null,memoCache:null},Vo.updateQueue=e),null===(a=e.lastEffect)?e.lastEffect=t.next=t:(i=a.next,a.next=t,t.next=i,e.lastEffect=t),t}function qs(){return ds().memoizedState}function _s(t,e,a,i){var n=ls();Vo.flags|=t,n.memoizedState=Fs(1|e,{destroy:void 0},a,void 0===i?null:i)}function Os(t,e,a,i){var n=ds();i=void 0===i?null:i;var o=n.memoizedState.inst;null!==Bo&&null!==i&&ts(i,Bo.memoizedState.deps)?n.memoizedState=Fs(e,o,a,i):(Vo.flags|=t,n.memoizedState=Fs(1|e,o,a,i))}function Us(t,e){_s(8390656,8,t,e)}function Hs(t,e){Os(2048,8,t,e)}function Vs(t){var e=ds().memoizedState;return function(t){Vo.flags|=4;var e=Vo.updateQueue;if(null===e)e={lastEffect:null,events:null,stores:null,memoCache:null},Vo.updateQueue=e,e.events=[t];else{var a=e.events;null===a?e.events=[t]:a.push(t)}}({ref:e,nextImpl:t}),function(){if(0!==(2&hd))throw Error(s(440));return e.impl.apply(void 0,arguments)}}function Bs(t,e){return Os(4,2,t,e)}function Gs(t,e){return Os(4,4,t,e)}function Ws(t,e){if("function"===typeof e){t=t();var a=e(t);return function(){"function"===typeof a?a():e(null)}}if(null!==e&&void 0!==e)return t=t(),e.current=t,function(){e.current=null}}function Qs(t,e,a){a=null!==a&&void 0!==a?a.concat([t]):null,Os(4,4,Ws.bind(null,e,t),a)}function Ks(){}function Zs(t,e){var a=ds();e=void 0===e?null:e;var i=a.memoizedState;return null!==e&&ts(e,i[1])?i[0]:(a.memoizedState=[t,e],t)}function $s(t,e){var a=ds();e=void 0===e?null:e;var i=a.memoizedState;if(null!==e&&ts(e,i[1]))return i[0];if(i=t(),Ko){vt(!0);try{t()}finally{vt(!1)}}return a.memoizedState=[i,e],i}function Xs(t,e,a){return void 0===a||0!==(1073741824&Ho)&&0===(261930&pd)?t.memoizedState=e:(t.memoizedState=a,t=Qd(),Vo.lanes|=t,Cd|=t,a)}function Ys(t,e,a,i){return Xa(a,e)?a:null!==Po.current?(t=Xs(t,a,i),Xa(t,e)||(jr=!0),t):0===(42&Ho)||0!==(1073741824&Ho)&&0===(261930&pd)?(jr=!0,t.memoizedState=a):(t=Qd(),Vo.lanes|=t,Cd|=t,e)}function Js(t,e,a,i,n){var o=z.p;z.p=0!==o&&8>o?o:8;var s=M.T,r={};M.T=r,mr(t,!1,e,a);try{var l=n(),d=M.S;if(null!==d&&d(r,l),null!==l&&"object"===typeof l&&"function"===typeof l.then)cr(t,e,function(t,e){var a=[],i={status:"pending",value:null,reason:null,then:function(t){a.push(t)}};return t.then(function(){i.status="fulfilled",i.value=e;for(var t=0;t<a.length;t++)(0,a[t])(e)},function(t){for(i.status="rejected",i.reason=t,t=0;t<a.length;t++)(0,a[t])(void 0)}),i}(l,i),Wd());else cr(t,e,i,Wd())}catch(c){cr(t,e,{then:function(){},status:"rejected",reason:c},Wd())}finally{z.p=o,null!==s&&null!==r.types&&(s.types=r.types),M.T=s}}function tr(){}function er(t,e,a,i){if(5!==t.tag)throw Error(s(476));var n=ar(t).queue;Js(t,n,e,R,null===a?tr:function(){return ir(t),a(i)})}function ar(t){var e=t.memoizedState;if(null!==e)return e;var a={};return(e={memoizedState:R,baseState:R,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:hs,lastRenderedState:R},next:null}).next={memoizedState:a,baseState:a,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:hs,lastRenderedState:a},next:null},t.memoizedState=e,null!==(t=t.alternate)&&(t.memoizedState=e),e}function ir(t){var e=ar(t);null===e.next&&(e=t.alternate.memoizedState),cr(t,e.next.queue,{},Wd())}function nr(){return En(cu)}function or(){return ds().memoizedState}function sr(){return ds().memoizedState}function rr(t){for(var e=t.return;null!==e;){switch(e.tag){case 24:case 3:var a=Wd(),i=wo(e,t=vo(a),a);return null!==i&&(Kd(i,e,a),xo(i,e,a)),e={cache:_n()},void(t.payload=e)}e=e.return}}function lr(t,e,a){var i=Wd();a={lane:i,revertLane:0,gesture:null,action:a,hasEagerState:!1,eagerState:null,next:null},ur(t)?hr(e,a):null!==(a=Li(t,e,a,i))&&(Kd(a,t,i),fr(a,e,i))}function dr(t,e,a){cr(t,e,a,Wd())}function cr(t,e,a,i){var n={lane:i,revertLane:0,gesture:null,action:a,hasEagerState:!1,eagerState:null,next:null};if(ur(t))hr(e,n);else{var o=t.alternate;if(0===t.lanes&&(null===o||0===o.lanes)&&null!==(o=e.lastRenderedReducer))try{var s=e.lastRenderedState,r=o(s,a);if(n.hasEagerState=!0,n.eagerState=r,Xa(r,s))return Ni(t,e,n,0),null===fd&&Di(),!1}catch(l){}if(null!==(a=Li(t,e,n,i)))return Kd(a,t,i),fr(a,e,i),!0}return!1}function mr(t,e,a,i){if(i={lane:2,revertLane:Hc(),gesture:null,action:i,hasEagerState:!1,eagerState:null,next:null},ur(t)){if(e)throw Error(s(479))}else null!==(e=Li(t,a,i,2))&&Kd(e,t,2)}function ur(t){var e=t.alternate;return t===Vo||null!==e&&e===Vo}function hr(t,e){Qo=Wo=!0;var a=t.pending;null===a?e.next=e:(e.next=a.next,a.next=e),t.pending=e}function fr(t,e,a){if(0!==(4194048&a)){var i=e.lanes;a|=i&=t.pendingLanes,e.lanes=a,Mt(t,a)}}var gr={readContext:En,use:ms,useCallback:Jo,useContext:Jo,useEffect:Jo,useImperativeHandle:Jo,useLayoutEffect:Jo,useInsertionEffect:Jo,useMemo:Jo,useReducer:Jo,useRef:Jo,useState:Jo,useDebugValue:Jo,useDeferredValue:Jo,useTransition:Jo,useSyncExternalStore:Jo,useId:Jo,useHostTransitionStatus:Jo,useFormState:Jo,useActionState:Jo,useOptimistic:Jo,useMemoCache:Jo,useCacheRefresh:Jo};gr.useEffectEvent=Jo;var pr={readContext:En,use:ms,useCallback:function(t,e){return ls().memoizedState=[t,void 0===e?null:e],t},useContext:En,useEffect:Us,useImperativeHandle:function(t,e,a){a=null!==a&&void 0!==a?a.concat([t]):null,_s(4194308,4,Ws.bind(null,e,t),a)},useLayoutEffect:function(t,e){return _s(4194308,4,t,e)},useInsertionEffect:function(t,e){_s(4,2,t,e)},useMemo:function(t,e){var a=ls();e=void 0===e?null:e;var i=t();if(Ko){vt(!0);try{t()}finally{vt(!1)}}return a.memoizedState=[i,e],i},useReducer:function(t,e,a){var i=ls();if(void 0!==a){var n=a(e);if(Ko){vt(!0);try{a(e)}finally{vt(!1)}}}else n=e;return i.memoizedState=i.baseState=n,t={pending:null,lanes:0,dispatch:null,lastRenderedReducer:t,lastRenderedState:n},i.queue=t,t=t.dispatch=lr.bind(null,Vo,t),[i.memoizedState,t]},useRef:function(t){return t={current:t},ls().memoizedState=t},useState:function(t){var e=(t=Is(t)).queue,a=dr.bind(null,Vo,e);return e.dispatch=a,[t.memoizedState,a]},useDebugValue:Ks,useDeferredValue:function(t,e){return Xs(ls(),t,e)},useTransition:function(){var t=Is(!1);return t=Js.bind(null,Vo,t.queue,!0,!1),ls().memoizedState=t,[!1,t]},useSyncExternalStore:function(t,e,a){var i=Vo,n=ls();if(mn){if(void 0===a)throw Error(s(407));a=a()}else{if(a=e(),null===fd)throw Error(s(349));0!==(127&pd)||bs(i,e,a)}n.memoizedState=a;var o={value:a,getSnapshot:e};return n.queue=o,Us(ws.bind(null,i,o,t),[t]),i.flags|=2048,Fs(9,{destroy:void 0},vs.bind(null,i,o,a,e),null),a},useId:function(){var t=ls(),e=fd.identifierPrefix;if(mn){var a=an;e="_"+e+"R_"+(a=(en&~(1<<32-wt(en)-1)).toString(32)+a),0<(a=Zo++)&&(e+="H"+a.toString(32)),e+="_"}else e="_"+e+"r_"+(a=Yo++).toString(32)+"_";return t.memoizedState=e},useHostTransitionStatus:nr,useFormState:Es,useActionState:Es,useOptimistic:function(t){var e=ls();e.memoizedState=e.baseState=t;var a={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return e.queue=a,e=mr.bind(null,Vo,!0,a),a.dispatch=e,[t,e]},useMemoCache:us,useCacheRefresh:function(){return ls().memoizedState=rr.bind(null,Vo)},useEffectEvent:function(t){var e=ls(),a={impl:t};return e.memoizedState=a,function(){if(0!==(2&hd))throw Error(s(440));return a.impl.apply(void 0,arguments)}}},yr={readContext:En,use:ms,useCallback:Zs,useContext:En,useEffect:Hs,useImperativeHandle:Qs,useInsertionEffect:Bs,useLayoutEffect:Gs,useMemo:$s,useReducer:fs,useRef:qs,useState:function(){return fs(hs)},useDebugValue:Ks,useDeferredValue:function(t,e){return Ys(ds(),Bo.memoizedState,t,e)},useTransition:function(){var t=fs(hs)[0],e=ds().memoizedState;return["boolean"===typeof t?t:cs(t),e]},useSyncExternalStore:ys,useId:or,useHostTransitionStatus:nr,useFormState:js,useActionState:js,useOptimistic:function(t,e){return Cs(ds(),0,t,e)},useMemoCache:us,useCacheRefresh:sr};yr.useEffectEvent=Vs;var br={readContext:En,use:ms,useCallback:Zs,useContext:En,useEffect:Hs,useImperativeHandle:Qs,useInsertionEffect:Bs,useLayoutEffect:Gs,useMemo:$s,useReducer:ps,useRef:qs,useState:function(){return ps(hs)},useDebugValue:Ks,useDeferredValue:function(t,e){var a=ds();return null===Bo?Xs(a,t,e):Ys(a,Bo.memoizedState,t,e)},useTransition:function(){var t=ps(hs)[0],e=ds().memoizedState;return["boolean"===typeof t?t:cs(t),e]},useSyncExternalStore:ys,useId:or,useHostTransitionStatus:nr,useFormState:Rs,useActionState:Rs,useOptimistic:function(t,e){var a=ds();return null!==Bo?Cs(a,0,t,e):(a.baseState=t,[t,a.queue.dispatch])},useMemoCache:us,useCacheRefresh:sr};function vr(t,e,a,i){a=null===(a=a(i,e=t.memoizedState))||void 0===a?e:h({},e,a),t.memoizedState=a,0===t.lanes&&(t.updateQueue.baseState=a)}br.useEffectEvent=Vs;var wr={enqueueSetState:function(t,e,a){t=t._reactInternals;var i=Wd(),n=vo(i);n.payload=e,void 0!==a&&null!==a&&(n.callback=a),null!==(e=wo(t,n,i))&&(Kd(e,t,i),xo(e,t,i))},enqueueReplaceState:function(t,e,a){t=t._reactInternals;var i=Wd(),n=vo(i);n.tag=1,n.payload=e,void 0!==a&&null!==a&&(n.callback=a),null!==(e=wo(t,n,i))&&(Kd(e,t,i),xo(e,t,i))},enqueueForceUpdate:function(t,e){t=t._reactInternals;var a=Wd(),i=vo(a);i.tag=2,void 0!==e&&null!==e&&(i.callback=e),null!==(e=wo(t,i,a))&&(Kd(e,t,a),xo(e,t,a))}};function xr(t,e,a,i,n,o,s){return"function"===typeof(t=t.stateNode).shouldComponentUpdate?t.shouldComponentUpdate(i,o,s):!e.prototype||!e.prototype.isPureReactComponent||(!Ya(a,i)||!Ya(n,o))}function kr(t,e,a,i){t=e.state,"function"===typeof e.componentWillReceiveProps&&e.componentWillReceiveProps(a,i),"function"===typeof e.UNSAFE_componentWillReceiveProps&&e.UNSAFE_componentWillReceiveProps(a,i),e.state!==t&&wr.enqueueReplaceState(e,e.state,null)}function Ir(t,e){var a=e;if("ref"in e)for(var i in a={},e)"ref"!==i&&(a[i]=e[i]);if(t=t.defaultProps)for(var n in a===e&&(a=h({},a)),t)void 0===a[n]&&(a[n]=t[n]);return a}function Cr(t){Si(t)}function Sr(t){console.error(t)}function Ar(t){Si(t)}function Tr(t,e){try{(0,t.onUncaughtError)(e.value,{componentStack:e.stack})}catch(a){setTimeout(function(){throw a})}}function Pr(t,e,a){try{(0,t.onCaughtError)(a.value,{componentStack:a.stack,errorBoundary:1===e.tag?e.stateNode:null})}catch(i){setTimeout(function(){throw i})}}function Dr(t,e,a){return(a=vo(a)).tag=3,a.payload={element:null},a.callback=function(){Tr(t,e)},a}function Nr(t){return(t=vo(t)).tag=3,t}function Lr(t,e,a,i){var n=a.type.getDerivedStateFromError;if("function"===typeof n){var o=i.value;t.payload=function(){return n(o)},t.callback=function(){Pr(e,a,i)}}var s=a.stateNode;null!==s&&"function"===typeof s.componentDidCatch&&(t.callback=function(){Pr(e,a,i),"function"!==typeof n&&(null===Rd?Rd=new Set([this]):Rd.add(this));var t=i.stack;this.componentDidCatch(i.value,{componentStack:null!==t?t:""})})}var Er=Error(s(461)),jr=!1;function Mr(t,e,a,i){e.child=null===t?go(e,null,a,i):fo(e,t.child,a,i)}function zr(t,e,a,i,n){a=a.render;var o=e.ref;if("ref"in i){var s={};for(var r in i)"ref"!==r&&(s[r]=i[r])}else s=i;return Ln(e),i=es(t,e,a,s,o,n),r=os(),null===t||jr?(mn&&r&&sn(e),e.flags|=1,Mr(t,e,i,n),e.child):(ss(t,e,n),nl(t,e,n))}function Rr(t,e,a,i,n){if(null===t){var o=a.type;return"function"!==typeof o||qi(o)||void 0!==o.defaultProps||null!==a.compare?((t=Ui(a.type,null,i,e,e.mode,n)).ref=e.ref,t.return=e,e.child=t):(e.tag=15,e.type=o,Fr(t,e,o,i,n))}if(o=t.child,!ol(t,n)){var s=o.memoizedProps;if((a=null!==(a=a.compare)?a:Ya)(s,i)&&t.ref===e.ref)return nl(t,e,n)}return e.flags|=1,(t=_i(o,i)).ref=e.ref,t.return=e,e.child=t}function Fr(t,e,a,i,n){if(null!==t){var o=t.memoizedProps;if(Ya(o,i)&&t.ref===e.ref){if(jr=!1,e.pendingProps=i=o,!ol(t,n))return e.lanes=t.lanes,nl(t,e,n);0!==(131072&t.flags)&&(jr=!0)}}return Br(t,e,a,i,n)}function qr(t,e,a,i){var n=i.children,o=null!==t?t.memoizedState:null;if(null===t&&null===e.stateNode&&(e.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),"hidden"===i.mode){if(0!==(128&e.flags)){if(o=null!==o?o.baseLanes|a:a,null!==t){for(i=e.child=t.child,n=0;null!==i;)n=n|i.lanes|i.childLanes,i=i.sibling;i=n&~o}else i=0,e.child=null;return Or(t,e,o,a,i)}if(0===(536870912&a))return i=e.lanes=536870912,Or(t,e,null!==o?o.baseLanes|a:a,a,i);e.memoizedState={baseLanes:0,cachePool:null},null!==t&&Zn(0,null!==o?o.cachePool:null),null!==o?No(e,o):Lo(),Fo(e)}else null!==o?(Zn(0,o.cachePool),No(e,o),qo(),e.memoizedState=null):(null!==t&&Zn(0,null),Lo(),qo());return Mr(t,e,n,a),e.child}function _r(t,e){return null!==t&&22===t.tag||null!==e.stateNode||(e.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),e.sibling}function Or(t,e,a,i,n){var o=Kn();return o=null===o?null:{parent:qn._currentValue,pool:o},e.memoizedState={baseLanes:a,cachePool:o},null!==t&&Zn(0,null),Lo(),Fo(e),null!==t&&Dn(t,e,i,!0),e.childLanes=n,null}function Ur(t,e){return(e=Jr({mode:e.mode,children:e.children},t.mode)).ref=t.ref,t.child=e,e.return=t,e}function Hr(t,e,a){return fo(e,t.child,null,a),(t=Ur(e,e.pendingProps)).flags|=2,_o(e),e.memoizedState=null,t}function Vr(t,e){var a=e.ref;if(null===a)null!==t&&null!==t.ref&&(e.flags|=4194816);else{if("function"!==typeof a&&"object"!==typeof a)throw Error(s(284));null!==t&&t.ref===a||(e.flags|=4194816)}}function Br(t,e,a,i,n){return Ln(e),a=es(t,e,a,i,void 0,n),i=os(),null===t||jr?(mn&&i&&sn(e),e.flags|=1,Mr(t,e,a,n),e.child):(ss(t,e,n),nl(t,e,n))}function Gr(t,e,a,i,n,o){return Ln(e),e.updateQueue=null,a=is(e,i,a,n),as(t),i=os(),null===t||jr?(mn&&i&&sn(e),e.flags|=1,Mr(t,e,a,o),e.child):(ss(t,e,o),nl(t,e,o))}function Wr(t,e,a,i,n){if(Ln(e),null===e.stateNode){var o=zi,s=a.contextType;"object"===typeof s&&null!==s&&(o=En(s)),o=new a(i,o),e.memoizedState=null!==o.state&&void 0!==o.state?o.state:null,o.updater=wr,e.stateNode=o,o._reactInternals=e,(o=e.stateNode).props=i,o.state=e.memoizedState,o.refs={},yo(e),s=a.contextType,o.context="object"===typeof s&&null!==s?En(s):zi,o.state=e.memoizedState,"function"===typeof(s=a.getDerivedStateFromProps)&&(vr(e,a,s,i),o.state=e.memoizedState),"function"===typeof a.getDerivedStateFromProps||"function"===typeof o.getSnapshotBeforeUpdate||"function"!==typeof o.UNSAFE_componentWillMount&&"function"!==typeof o.componentWillMount||(s=o.state,"function"===typeof o.componentWillMount&&o.componentWillMount(),"function"===typeof o.UNSAFE_componentWillMount&&o.UNSAFE_componentWillMount(),s!==o.state&&wr.enqueueReplaceState(o,o.state,null),So(e,i,o,n),Co(),o.state=e.memoizedState),"function"===typeof o.componentDidMount&&(e.flags|=4194308),i=!0}else if(null===t){o=e.stateNode;var r=e.memoizedProps,l=Ir(a,r);o.props=l;var d=o.context,c=a.contextType;s=zi,"object"===typeof c&&null!==c&&(s=En(c));var m=a.getDerivedStateFromProps;c="function"===typeof m||"function"===typeof o.getSnapshotBeforeUpdate,r=e.pendingProps!==r,c||"function"!==typeof o.UNSAFE_componentWillReceiveProps&&"function"!==typeof o.componentWillReceiveProps||(r||d!==s)&&kr(e,o,i,s),po=!1;var u=e.memoizedState;o.state=u,So(e,i,o,n),Co(),d=e.memoizedState,r||u!==d||po?("function"===typeof m&&(vr(e,a,m,i),d=e.memoizedState),(l=po||xr(e,a,l,i,u,d,s))?(c||"function"!==typeof o.UNSAFE_componentWillMount&&"function"!==typeof o.componentWillMount||("function"===typeof o.componentWillMount&&o.componentWillMount(),"function"===typeof o.UNSAFE_componentWillMount&&o.UNSAFE_componentWillMount()),"function"===typeof o.componentDidMount&&(e.flags|=4194308)):("function"===typeof o.componentDidMount&&(e.flags|=4194308),e.memoizedProps=i,e.memoizedState=d),o.props=i,o.state=d,o.context=s,i=l):("function"===typeof o.componentDidMount&&(e.flags|=4194308),i=!1)}else{o=e.stateNode,bo(t,e),c=Ir(a,s=e.memoizedProps),o.props=c,m=e.pendingProps,u=o.context,d=a.contextType,l=zi,"object"===typeof d&&null!==d&&(l=En(d)),(d="function"===typeof(r=a.getDerivedStateFromProps)||"function"===typeof o.getSnapshotBeforeUpdate)||"function"!==typeof o.UNSAFE_componentWillReceiveProps&&"function"!==typeof o.componentWillReceiveProps||(s!==m||u!==l)&&kr(e,o,i,l),po=!1,u=e.memoizedState,o.state=u,So(e,i,o,n),Co();var h=e.memoizedState;s!==m||u!==h||po||null!==t&&null!==t.dependencies&&Nn(t.dependencies)?("function"===typeof r&&(vr(e,a,r,i),h=e.memoizedState),(c=po||xr(e,a,c,i,u,h,l)||null!==t&&null!==t.dependencies&&Nn(t.dependencies))?(d||"function"!==typeof o.UNSAFE_componentWillUpdate&&"function"!==typeof o.componentWillUpdate||("function"===typeof o.componentWillUpdate&&o.componentWillUpdate(i,h,l),"function"===typeof o.UNSAFE_componentWillUpdate&&o.UNSAFE_componentWillUpdate(i,h,l)),"function"===typeof o.componentDidUpdate&&(e.flags|=4),"function"===typeof o.getSnapshotBeforeUpdate&&(e.flags|=1024)):("function"!==typeof o.componentDidUpdate||s===t.memoizedProps&&u===t.memoizedState||(e.flags|=4),"function"!==typeof o.getSnapshotBeforeUpdate||s===t.memoizedProps&&u===t.memoizedState||(e.flags|=1024),e.memoizedProps=i,e.memoizedState=h),o.props=i,o.state=h,o.context=l,i=c):("function"!==typeof o.componentDidUpdate||s===t.memoizedProps&&u===t.memoizedState||(e.flags|=4),"function"!==typeof o.getSnapshotBeforeUpdate||s===t.memoizedProps&&u===t.memoizedState||(e.flags|=1024),i=!1)}return o=i,Vr(t,e),i=0!==(128&e.flags),o||i?(o=e.stateNode,a=i&&"function"!==typeof a.getDerivedStateFromError?null:o.render(),e.flags|=1,null!==t&&i?(e.child=fo(e,t.child,null,n),e.child=fo(e,null,a,n)):Mr(t,e,a,n),e.memoizedState=o.state,t=e.child):t=nl(t,e,n),t}function Qr(t,e,a,i){return vn(),e.flags|=256,Mr(t,e,a,i),e.child}var Kr={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function Zr(t){return{baseLanes:t,cachePool:$n()}}function $r(t,e,a){return t=null!==t?t.childLanes&~a:0,e&&(t|=Td),t}function Xr(t,e,a){var i,n=e.pendingProps,o=!1,r=0!==(128&e.flags);if((i=r)||(i=(null===t||null!==t.memoizedState)&&0!==(2&Oo.current)),i&&(o=!0,e.flags&=-129),i=0!==(32&e.flags),e.flags&=-33,null===t){if(mn){if(o?zo(e):qo(),(t=cn)?null!==(t=null!==(t=Nm(t,hn))&&"&"!==t.data?t:null)&&(e.memoizedState={dehydrated:t,treeContext:null!==tn?{id:en,overflow:an}:null,retryLane:536870912,hydrationErrors:null},(a=Bi(t)).return=e,e.child=a,dn=e,cn=null):t=null,null===t)throw gn(e);return Em(t)?e.lanes=32:e.lanes=536870912,null}var l=n.children;return n=n.fallback,o?(qo(),l=Jr({mode:"hidden",children:l},o=e.mode),n=Hi(n,o,a,null),l.return=e,n.return=e,l.sibling=n,e.child=l,(n=e.child).memoizedState=Zr(a),n.childLanes=$r(t,i,a),e.memoizedState=Kr,_r(null,n)):(zo(e),Yr(e,l))}var d=t.memoizedState;if(null!==d&&null!==(l=d.dehydrated)){if(r)256&e.flags?(zo(e),e.flags&=-257,e=tl(t,e,a)):null!==e.memoizedState?(qo(),e.child=t.child,e.flags|=128,e=null):(qo(),l=n.fallback,o=e.mode,n=Jr({mode:"visible",children:n.children},o),(l=Hi(l,o,a,null)).flags|=2,n.return=e,l.return=e,n.sibling=l,e.child=n,fo(e,t.child,null,a),(n=e.child).memoizedState=Zr(a),n.childLanes=$r(t,i,a),e.memoizedState=Kr,e=_r(null,n));else if(zo(e),Em(l)){if(i=l.nextSibling&&l.nextSibling.dataset)var c=i.dgst;i=c,(n=Error(s(419))).stack="",n.digest=i,xn({value:n,source:null,stack:null}),e=tl(t,e,a)}else if(jr||Dn(t,e,a,!1),i=0!==(a&t.childLanes),jr||i){if(null!==(i=fd)&&(0!==(n=zt(i,a))&&n!==d.retryLane))throw d.retryLane=n,Ei(t,n),Kd(i,t,n),Er;Lm(l)||sc(),e=tl(t,e,a)}else Lm(l)?(e.flags|=192,e.child=t.child,e=null):(t=d.treeContext,cn=jm(l.nextSibling),dn=e,mn=!0,un=null,hn=!1,null!==t&&ln(e,t),(e=Yr(e,n.children)).flags|=4096);return e}return o?(qo(),l=n.fallback,o=e.mode,c=(d=t.child).sibling,(n=_i(d,{mode:"hidden",children:n.children})).subtreeFlags=65011712&d.subtreeFlags,null!==c?l=_i(c,l):(l=Hi(l,o,a,null)).flags|=2,l.return=e,n.return=e,n.sibling=l,e.child=n,_r(null,n),n=e.child,null===(l=t.child.memoizedState)?l=Zr(a):(null!==(o=l.cachePool)?(d=qn._currentValue,o=o.parent!==d?{parent:d,pool:d}:o):o=$n(),l={baseLanes:l.baseLanes|a,cachePool:o}),n.memoizedState=l,n.childLanes=$r(t,i,a),e.memoizedState=Kr,_r(t.child,n)):(zo(e),t=(a=t.child).sibling,(a=_i(a,{mode:"visible",children:n.children})).return=e,a.sibling=null,null!==t&&(null===(i=e.deletions)?(e.deletions=[t],e.flags|=16):i.push(t)),e.child=a,e.memoizedState=null,a)}function Yr(t,e){return(e=Jr({mode:"visible",children:e},t.mode)).return=t,t.child=e}function Jr(t,e){return(t=Fi(22,t,null,e)).lanes=0,t}function tl(t,e,a){return fo(e,t.child,null,a),(t=Yr(e,e.pendingProps.children)).flags|=2,e.memoizedState=null,t}function el(t,e,a){t.lanes|=e;var i=t.alternate;null!==i&&(i.lanes|=e),Tn(t.return,e,a)}function al(t,e,a,i,n,o){var s=t.memoizedState;null===s?t.memoizedState={isBackwards:e,rendering:null,renderingStartTime:0,last:i,tail:a,tailMode:n,treeForkCount:o}:(s.isBackwards=e,s.rendering=null,s.renderingStartTime=0,s.last=i,s.tail=a,s.tailMode=n,s.treeForkCount=o)}function il(t,e,a){var i=e.pendingProps,n=i.revealOrder,o=i.tail;i=i.children;var s=Oo.current,r=0!==(2&s);if(r?(s=1&s|2,e.flags|=128):s&=1,U(Oo,s),Mr(t,e,i,a),i=mn?Xi:0,!r&&null!==t&&0!==(128&t.flags))t:for(t=e.child;null!==t;){if(13===t.tag)null!==t.memoizedState&&el(t,a,e);else if(19===t.tag)el(t,a,e);else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break t;for(;null===t.sibling;){if(null===t.return||t.return===e)break t;t=t.return}t.sibling.return=t.return,t=t.sibling}switch(n){case"forwards":for(a=e.child,n=null;null!==a;)null!==(t=a.alternate)&&null===Uo(t)&&(n=a),a=a.sibling;null===(a=n)?(n=e.child,e.child=null):(n=a.sibling,a.sibling=null),al(e,!1,n,a,o,i);break;case"backwards":case"unstable_legacy-backwards":for(a=null,n=e.child,e.child=null;null!==n;){if(null!==(t=n.alternate)&&null===Uo(t)){e.child=n;break}t=n.sibling,n.sibling=a,a=n,n=t}al(e,!0,a,null,o,i);break;case"together":al(e,!1,null,null,void 0,i);break;default:e.memoizedState=null}return e.child}function nl(t,e,a){if(null!==t&&(e.dependencies=t.dependencies),Cd|=e.lanes,0===(a&e.childLanes)){if(null===t)return null;if(Dn(t,e,a,!1),0===(a&e.childLanes))return null}if(null!==t&&e.child!==t.child)throw Error(s(153));if(null!==e.child){for(a=_i(t=e.child,t.pendingProps),e.child=a,a.return=e;null!==t.sibling;)t=t.sibling,(a=a.sibling=_i(t,t.pendingProps)).return=e;a.sibling=null}return e.child}function ol(t,e){return 0!==(t.lanes&e)||!(null===(t=t.dependencies)||!Nn(t))}function sl(t,e,a){if(null!==t)if(t.memoizedProps!==e.pendingProps)jr=!0;else{if(!ol(t,a)&&0===(128&e.flags))return jr=!1,function(t,e,a){switch(e.tag){case 3:K(e,e.stateNode.containerInfo),Sn(0,qn,t.memoizedState.cache),vn();break;case 27:case 5:$(e);break;case 4:K(e,e.stateNode.containerInfo);break;case 10:Sn(0,e.type,e.memoizedProps.value);break;case 31:if(null!==e.memoizedState)return e.flags|=128,Ro(e),null;break;case 13:var i=e.memoizedState;if(null!==i)return null!==i.dehydrated?(zo(e),e.flags|=128,null):0!==(a&e.child.childLanes)?Xr(t,e,a):(zo(e),null!==(t=nl(t,e,a))?t.sibling:null);zo(e);break;case 19:var n=0!==(128&t.flags);if((i=0!==(a&e.childLanes))||(Dn(t,e,a,!1),i=0!==(a&e.childLanes)),n){if(i)return il(t,e,a);e.flags|=128}if(null!==(n=e.memoizedState)&&(n.rendering=null,n.tail=null,n.lastEffect=null),U(Oo,Oo.current),i)break;return null;case 22:return e.lanes=0,qr(t,e,a,e.pendingProps);case 24:Sn(0,qn,t.memoizedState.cache)}return nl(t,e,a)}(t,e,a);jr=0!==(131072&t.flags)}else jr=!1,mn&&0!==(1048576&e.flags)&&on(e,Xi,e.index);switch(e.lanes=0,e.tag){case 16:t:{var i=e.pendingProps;if(t=io(e.elementType),e.type=t,"function"!==typeof t){if(void 0!==t&&null!==t){var n=t.$$typeof;if(n===k){e.tag=11,e=zr(null,e,t,i,a);break t}if(n===S){e.tag=14,e=Rr(null,e,t,i,a);break t}}throw e=E(t)||t,Error(s(306,e,""))}qi(t)?(i=Ir(t,i),e.tag=1,e=Wr(null,e,t,i,a)):(e.tag=0,e=Br(null,e,t,i,a))}return e;case 0:return Br(t,e,e.type,e.pendingProps,a);case 1:return Wr(t,e,i=e.type,n=Ir(i,e.pendingProps),a);case 3:t:{if(K(e,e.stateNode.containerInfo),null===t)throw Error(s(387));i=e.pendingProps;var o=e.memoizedState;n=o.element,bo(t,e),So(e,i,null,a);var r=e.memoizedState;if(i=r.cache,Sn(0,qn,i),i!==o.cache&&Pn(e,[qn],a,!0),Co(),i=r.element,o.isDehydrated){if(o={element:i,isDehydrated:!1,cache:r.cache},e.updateQueue.baseState=o,e.memoizedState=o,256&e.flags){e=Qr(t,e,i,a);break t}if(i!==n){xn(n=Qi(Error(s(424)),e)),e=Qr(t,e,i,a);break t}if(9===(t=e.stateNode.containerInfo).nodeType)t=t.body;else t="HTML"===t.nodeName?t.ownerDocument.body:t;for(cn=jm(t.firstChild),dn=e,mn=!0,un=null,hn=!0,a=go(e,null,i,a),e.child=a;a;)a.flags=-3&a.flags|4096,a=a.sibling}else{if(vn(),i===n){e=nl(t,e,a);break t}Mr(t,e,i,a)}e=e.child}return e;case 26:return Vr(t,e),null===t?(a=Gm(e.type,null,e.pendingProps,null))?e.memoizedState=a:mn||(a=e.type,t=e.pendingProps,(i=pm(W.current).createElement(a))[Ut]=e,i[Ht]=t,um(i,a,t),te(i),e.stateNode=i):e.memoizedState=Gm(e.type,t.memoizedProps,e.pendingProps,t.memoizedState),null;case 27:return $(e),null===t&&mn&&(i=e.stateNode=Fm(e.type,e.pendingProps,W.current),dn=e,hn=!0,n=cn,Am(e.type)?(Mm=n,cn=jm(i.firstChild)):cn=n),Mr(t,e,e.pendingProps.children,a),Vr(t,e),null===t&&(e.flags|=4194304),e.child;case 5:return null===t&&mn&&((n=i=cn)&&(null!==(i=function(t,e,a,i){for(;1===t.nodeType;){var n=a;if(t.nodeName.toLowerCase()!==e.toLowerCase()){if(!i&&("INPUT"!==t.nodeName||"hidden"!==t.type))break}else if(i){if(!t[Kt])switch(e){case"meta":if(!t.hasAttribute("itemprop"))break;return t;case"link":if("stylesheet"===(o=t.getAttribute("rel"))&&t.hasAttribute("data-precedence"))break;if(o!==n.rel||t.getAttribute("href")!==(null==n.href||""===n.href?null:n.href)||t.getAttribute("crossorigin")!==(null==n.crossOrigin?null:n.crossOrigin)||t.getAttribute("title")!==(null==n.title?null:n.title))break;return t;case"style":if(t.hasAttribute("data-precedence"))break;return t;case"script":if(((o=t.getAttribute("src"))!==(null==n.src?null:n.src)||t.getAttribute("type")!==(null==n.type?null:n.type)||t.getAttribute("crossorigin")!==(null==n.crossOrigin?null:n.crossOrigin))&&o&&t.hasAttribute("async")&&!t.hasAttribute("itemprop"))break;return t;default:return t}}else{if("input"!==e||"hidden"!==t.type)return t;var o=null==n.name?null:""+n.name;if("hidden"===n.type&&t.getAttribute("name")===o)return t}if(null===(t=jm(t.nextSibling)))break}return null}(i,e.type,e.pendingProps,hn))?(e.stateNode=i,dn=e,cn=jm(i.firstChild),hn=!1,n=!0):n=!1),n||gn(e)),$(e),n=e.type,o=e.pendingProps,r=null!==t?t.memoizedProps:null,i=o.children,vm(n,o)?i=null:null!==r&&vm(n,r)&&(e.flags|=32),null!==e.memoizedState&&(n=es(t,e,ns,null,null,a),cu._currentValue=n),Vr(t,e),Mr(t,e,i,a),e.child;case 6:return null===t&&mn&&((t=a=cn)&&(null!==(a=function(t,e,a){if(""===e)return null;for(;3!==t.nodeType;){if((1!==t.nodeType||"INPUT"!==t.nodeName||"hidden"!==t.type)&&!a)return null;if(null===(t=jm(t.nextSibling)))return null}return t}(a,e.pendingProps,hn))?(e.stateNode=a,dn=e,cn=null,t=!0):t=!1),t||gn(e)),null;case 13:return Xr(t,e,a);case 4:return K(e,e.stateNode.containerInfo),i=e.pendingProps,null===t?e.child=fo(e,null,i,a):Mr(t,e,i,a),e.child;case 11:return zr(t,e,e.type,e.pendingProps,a);case 7:return Mr(t,e,e.pendingProps,a),e.child;case 8:case 12:return Mr(t,e,e.pendingProps.children,a),e.child;case 10:return i=e.pendingProps,Sn(0,e.type,i.value),Mr(t,e,i.children,a),e.child;case 9:return n=e.type._context,i=e.pendingProps.children,Ln(e),i=i(n=En(n)),e.flags|=1,Mr(t,e,i,a),e.child;case 14:return Rr(t,e,e.type,e.pendingProps,a);case 15:return Fr(t,e,e.type,e.pendingProps,a);case 19:return il(t,e,a);case 31:return function(t,e,a){var i=e.pendingProps,n=0!==(128&e.flags);if(e.flags&=-129,null===t){if(mn){if("hidden"===i.mode)return t=Ur(e,i),e.lanes=536870912,_r(null,t);if(Ro(e),(t=cn)?null!==(t=null!==(t=Nm(t,hn))&&"&"===t.data?t:null)&&(e.memoizedState={dehydrated:t,treeContext:null!==tn?{id:en,overflow:an}:null,retryLane:536870912,hydrationErrors:null},(a=Bi(t)).return=e,e.child=a,dn=e,cn=null):t=null,null===t)throw gn(e);return e.lanes=536870912,null}return Ur(e,i)}var o=t.memoizedState;if(null!==o){var r=o.dehydrated;if(Ro(e),n)if(256&e.flags)e.flags&=-257,e=Hr(t,e,a);else{if(null===e.memoizedState)throw Error(s(558));e.child=t.child,e.flags|=128,e=null}else if(jr||Dn(t,e,a,!1),n=0!==(a&t.childLanes),jr||n){if(null!==(i=fd)&&0!==(r=zt(i,a))&&r!==o.retryLane)throw o.retryLane=r,Ei(t,r),Kd(i,t,r),Er;sc(),e=Hr(t,e,a)}else t=o.treeContext,cn=jm(r.nextSibling),dn=e,mn=!0,un=null,hn=!1,null!==t&&ln(e,t),(e=Ur(e,i)).flags|=4096;return e}return(t=_i(t.child,{mode:i.mode,children:i.children})).ref=e.ref,e.child=t,t.return=e,t}(t,e,a);case 22:return qr(t,e,a,e.pendingProps);case 24:return Ln(e),i=En(qn),null===t?(null===(n=Kn())&&(n=fd,o=_n(),n.pooledCache=o,o.refCount++,null!==o&&(n.pooledCacheLanes|=a),n=o),e.memoizedState={parent:i,cache:n},yo(e),Sn(0,qn,n)):(0!==(t.lanes&a)&&(bo(t,e),So(e,null,null,a),Co()),n=t.memoizedState,o=e.memoizedState,n.parent!==i?(n={parent:i,cache:i},e.memoizedState=n,0===e.lanes&&(e.memoizedState=e.updateQueue.baseState=n),Sn(0,qn,i)):(i=o.cache,Sn(0,qn,i),i!==n.cache&&Pn(e,[qn],a,!0))),Mr(t,e,e.pendingProps.children,a),e.child;case 29:throw e.pendingProps}throw Error(s(156,e.tag))}function rl(t){t.flags|=4}function ll(t,e,a,i,n){if((e=0!==(32&t.mode))&&(e=!1),e){if(t.flags|=16777216,(335544128&n)===n)if(t.stateNode.complete)t.flags|=8192;else{if(!ic())throw no=to,Yn;t.flags|=8192}}else t.flags&=-16777217}function dl(t,e){if("stylesheet"!==e.type||0!==(4&e.state.loading))t.flags&=-16777217;else if(t.flags|=16777216,!nu(e)){if(!ic())throw no=to,Yn;t.flags|=8192}}function cl(t,e){null!==e&&(t.flags|=4),16384&t.flags&&(e=22!==t.tag?Nt():536870912,t.lanes|=e,Pd|=e)}function ml(t,e){if(!mn)switch(t.tailMode){case"hidden":e=t.tail;for(var a=null;null!==e;)null!==e.alternate&&(a=e),e=e.sibling;null===a?t.tail=null:a.sibling=null;break;case"collapsed":a=t.tail;for(var i=null;null!==a;)null!==a.alternate&&(i=a),a=a.sibling;null===i?e||null===t.tail?t.tail=null:t.tail.sibling=null:i.sibling=null}}function ul(t){var e=null!==t.alternate&&t.alternate.child===t.child,a=0,i=0;if(e)for(var n=t.child;null!==n;)a|=n.lanes|n.childLanes,i|=65011712&n.subtreeFlags,i|=65011712&n.flags,n.return=t,n=n.sibling;else for(n=t.child;null!==n;)a|=n.lanes|n.childLanes,i|=n.subtreeFlags,i|=n.flags,n.return=t,n=n.sibling;return t.subtreeFlags|=i,t.childLanes=a,e}function hl(t,e,a){var i=e.pendingProps;switch(rn(e),e.tag){case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:case 1:return ul(e),null;case 3:return a=e.stateNode,i=null,null!==t&&(i=t.memoizedState.cache),e.memoizedState.cache!==i&&(e.flags|=2048),An(qn),Z(),a.pendingContext&&(a.context=a.pendingContext,a.pendingContext=null),null!==t&&null!==t.child||(bn(e)?rl(e):null===t||t.memoizedState.isDehydrated&&0===(256&e.flags)||(e.flags|=1024,wn())),ul(e),null;case 26:var n=e.type,o=e.memoizedState;return null===t?(rl(e),null!==o?(ul(e),dl(e,o)):(ul(e),ll(e,n,0,0,a))):o?o!==t.memoizedState?(rl(e),ul(e),dl(e,o)):(ul(e),e.flags&=-16777217):((t=t.memoizedProps)!==i&&rl(e),ul(e),ll(e,n,0,0,a)),null;case 27:if(X(e),a=W.current,n=e.type,null!==t&&null!=e.stateNode)t.memoizedProps!==i&&rl(e);else{if(!i){if(null===e.stateNode)throw Error(s(166));return ul(e),null}t=B.current,bn(e)?pn(e):(t=Fm(n,i,a),e.stateNode=t,rl(e))}return ul(e),null;case 5:if(X(e),n=e.type,null!==t&&null!=e.stateNode)t.memoizedProps!==i&&rl(e);else{if(!i){if(null===e.stateNode)throw Error(s(166));return ul(e),null}if(o=B.current,bn(e))pn(e);else{var r=pm(W.current);switch(o){case 1:o=r.createElementNS("http://www.w3.org/2000/svg",n);break;case 2:o=r.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;default:switch(n){case"svg":o=r.createElementNS("http://www.w3.org/2000/svg",n);break;case"math":o=r.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;case"script":(o=r.createElement("div")).innerHTML="<script><\/script>",o=o.removeChild(o.firstChild);break;case"select":o="string"===typeof i.is?r.createElement("select",{is:i.is}):r.createElement("select"),i.multiple?o.multiple=!0:i.size&&(o.size=i.size);break;default:o="string"===typeof i.is?r.createElement(n,{is:i.is}):r.createElement(n)}}o[Ut]=e,o[Ht]=i;t:for(r=e.child;null!==r;){if(5===r.tag||6===r.tag)o.appendChild(r.stateNode);else if(4!==r.tag&&27!==r.tag&&null!==r.child){r.child.return=r,r=r.child;continue}if(r===e)break t;for(;null===r.sibling;){if(null===r.return||r.return===e)break t;r=r.return}r.sibling.return=r.return,r=r.sibling}e.stateNode=o;t:switch(um(o,n,i),n){case"button":case"input":case"select":case"textarea":i=!!i.autoFocus;break t;case"img":i=!0;break t;default:i=!1}i&&rl(e)}}return ul(e),ll(e,e.type,null===t||t.memoizedProps,e.pendingProps,a),null;case 6:if(t&&null!=e.stateNode)t.memoizedProps!==i&&rl(e);else{if("string"!==typeof i&&null===e.stateNode)throw Error(s(166));if(t=W.current,bn(e)){if(t=e.stateNode,a=e.memoizedProps,i=null,null!==(n=dn))switch(n.tag){case 27:case 5:i=n.memoizedProps}t[Ut]=e,(t=!!(t.nodeValue===a||null!==i&&!0===i.suppressHydrationWarning||dm(t.nodeValue,a)))||gn(e,!0)}else(t=pm(t).createTextNode(i))[Ut]=e,e.stateNode=t}return ul(e),null;case 31:if(a=e.memoizedState,null===t||null!==t.memoizedState){if(i=bn(e),null!==a){if(null===t){if(!i)throw Error(s(318));if(!(t=null!==(t=e.memoizedState)?t.dehydrated:null))throw Error(s(557));t[Ut]=e}else vn(),0===(128&e.flags)&&(e.memoizedState=null),e.flags|=4;ul(e),t=!1}else a=wn(),null!==t&&null!==t.memoizedState&&(t.memoizedState.hydrationErrors=a),t=!0;if(!t)return 256&e.flags?(_o(e),e):(_o(e),null);if(0!==(128&e.flags))throw Error(s(558))}return ul(e),null;case 13:if(i=e.memoizedState,null===t||null!==t.memoizedState&&null!==t.memoizedState.dehydrated){if(n=bn(e),null!==i&&null!==i.dehydrated){if(null===t){if(!n)throw Error(s(318));if(!(n=null!==(n=e.memoizedState)?n.dehydrated:null))throw Error(s(317));n[Ut]=e}else vn(),0===(128&e.flags)&&(e.memoizedState=null),e.flags|=4;ul(e),n=!1}else n=wn(),null!==t&&null!==t.memoizedState&&(t.memoizedState.hydrationErrors=n),n=!0;if(!n)return 256&e.flags?(_o(e),e):(_o(e),null)}return _o(e),0!==(128&e.flags)?(e.lanes=a,e):(a=null!==i,t=null!==t&&null!==t.memoizedState,a&&(n=null,null!==(i=e.child).alternate&&null!==i.alternate.memoizedState&&null!==i.alternate.memoizedState.cachePool&&(n=i.alternate.memoizedState.cachePool.pool),o=null,null!==i.memoizedState&&null!==i.memoizedState.cachePool&&(o=i.memoizedState.cachePool.pool),o!==n&&(i.flags|=2048)),a!==t&&a&&(e.child.flags|=8192),cl(e,e.updateQueue),ul(e),null);case 4:return Z(),null===t&&Jc(e.stateNode.containerInfo),ul(e),null;case 10:return An(e.type),ul(e),null;case 19:if(O(Oo),null===(i=e.memoizedState))return ul(e),null;if(n=0!==(128&e.flags),null===(o=i.rendering))if(n)ml(i,!1);else{if(0!==Id||null!==t&&0!==(128&t.flags))for(t=e.child;null!==t;){if(null!==(o=Uo(t))){for(e.flags|=128,ml(i,!1),t=o.updateQueue,e.updateQueue=t,cl(e,t),e.subtreeFlags=0,t=a,a=e.child;null!==a;)Oi(a,t),a=a.sibling;return U(Oo,1&Oo.current|2),mn&&nn(e,i.treeForkCount),e.child}t=t.sibling}null!==i.tail&&lt()>Md&&(e.flags|=128,n=!0,ml(i,!1),e.lanes=4194304)}else{if(!n)if(null!==(t=Uo(o))){if(e.flags|=128,n=!0,t=t.updateQueue,e.updateQueue=t,cl(e,t),ml(i,!0),null===i.tail&&"hidden"===i.tailMode&&!o.alternate&&!mn)return ul(e),null}else 2*lt()-i.renderingStartTime>Md&&536870912!==a&&(e.flags|=128,n=!0,ml(i,!1),e.lanes=4194304);i.isBackwards?(o.sibling=e.child,e.child=o):(null!==(t=i.last)?t.sibling=o:e.child=o,i.last=o)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=lt(),t.sibling=null,a=Oo.current,U(Oo,n?1&a|2:1&a),mn&&nn(e,i.treeForkCount),t):(ul(e),null);case 22:case 23:return _o(e),Eo(),i=null!==e.memoizedState,null!==t?null!==t.memoizedState!==i&&(e.flags|=8192):i&&(e.flags|=8192),i?0!==(536870912&a)&&0===(128&e.flags)&&(ul(e),6&e.subtreeFlags&&(e.flags|=8192)):ul(e),null!==(a=e.updateQueue)&&cl(e,a.retryQueue),a=null,null!==t&&null!==t.memoizedState&&null!==t.memoizedState.cachePool&&(a=t.memoizedState.cachePool.pool),i=null,null!==e.memoizedState&&null!==e.memoizedState.cachePool&&(i=e.memoizedState.cachePool.pool),i!==a&&(e.flags|=2048),null!==t&&O(Qn),null;case 24:return a=null,null!==t&&(a=t.memoizedState.cache),e.memoizedState.cache!==a&&(e.flags|=2048),An(qn),ul(e),null;case 25:case 30:return null}throw Error(s(156,e.tag))}function fl(t,e){switch(rn(e),e.tag){case 1:return 65536&(t=e.flags)?(e.flags=-65537&t|128,e):null;case 3:return An(qn),Z(),0!==(65536&(t=e.flags))&&0===(128&t)?(e.flags=-65537&t|128,e):null;case 26:case 27:case 5:return X(e),null;case 31:if(null!==e.memoizedState){if(_o(e),null===e.alternate)throw Error(s(340));vn()}return 65536&(t=e.flags)?(e.flags=-65537&t|128,e):null;case 13:if(_o(e),null!==(t=e.memoizedState)&&null!==t.dehydrated){if(null===e.alternate)throw Error(s(340));vn()}return 65536&(t=e.flags)?(e.flags=-65537&t|128,e):null;case 19:return O(Oo),null;case 4:return Z(),null;case 10:return An(e.type),null;case 22:case 23:return _o(e),Eo(),null!==t&&O(Qn),65536&(t=e.flags)?(e.flags=-65537&t|128,e):null;case 24:return An(qn),null;default:return null}}function gl(t,e){switch(rn(e),e.tag){case 3:An(qn),Z();break;case 26:case 27:case 5:X(e);break;case 4:Z();break;case 31:null!==e.memoizedState&&_o(e);break;case 13:_o(e);break;case 19:O(Oo);break;case 10:An(e.type);break;case 22:case 23:_o(e),Eo(),null!==t&&O(Qn);break;case 24:An(qn)}}function pl(t,e){try{var a=e.updateQueue,i=null!==a?a.lastEffect:null;if(null!==i){var n=i.next;a=n;do{if((a.tag&t)===t){i=void 0;var o=a.create,s=a.inst;i=o(),s.destroy=i}a=a.next}while(a!==n)}}catch(r){Ic(e,e.return,r)}}function yl(t,e,a){try{var i=e.updateQueue,n=null!==i?i.lastEffect:null;if(null!==n){var o=n.next;i=o;do{if((i.tag&t)===t){var s=i.inst,r=s.destroy;if(void 0!==r){s.destroy=void 0,n=e;var l=a,d=r;try{d()}catch(c){Ic(n,l,c)}}}i=i.next}while(i!==o)}}catch(c){Ic(e,e.return,c)}}function bl(t){var e=t.updateQueue;if(null!==e){var a=t.stateNode;try{To(e,a)}catch(i){Ic(t,t.return,i)}}}function vl(t,e,a){a.props=Ir(t.type,t.memoizedProps),a.state=t.memoizedState;try{a.componentWillUnmount()}catch(i){Ic(t,e,i)}}function wl(t,e){try{var a=t.ref;if(null!==a){switch(t.tag){case 26:case 27:case 5:var i=t.stateNode;break;default:i=t.stateNode}"function"===typeof a?t.refCleanup=a(i):a.current=i}}catch(n){Ic(t,e,n)}}function xl(t,e){var a=t.ref,i=t.refCleanup;if(null!==a)if("function"===typeof i)try{i()}catch(n){Ic(t,e,n)}finally{t.refCleanup=null,null!=(t=t.alternate)&&(t.refCleanup=null)}else if("function"===typeof a)try{a(null)}catch(o){Ic(t,e,o)}else a.current=null}function kl(t){var e=t.type,a=t.memoizedProps,i=t.stateNode;try{t:switch(e){case"button":case"input":case"select":case"textarea":a.autoFocus&&i.focus();break t;case"img":a.src?i.src=a.src:a.srcSet&&(i.srcset=a.srcSet)}}catch(n){Ic(t,t.return,n)}}function Il(t,e,a){try{var i=t.stateNode;!function(t,e,a,i){switch(e){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var n=null,o=null,r=null,l=null,d=null,c=null,m=null;for(f in a){var u=a[f];if(a.hasOwnProperty(f)&&null!=u)switch(f){case"checked":case"value":break;case"defaultValue":d=u;default:i.hasOwnProperty(f)||cm(t,e,f,null,i,u)}}for(var h in i){var f=i[h];if(u=a[h],i.hasOwnProperty(h)&&(null!=f||null!=u))switch(h){case"type":o=f;break;case"name":n=f;break;case"checked":c=f;break;case"defaultChecked":m=f;break;case"value":r=f;break;case"defaultValue":l=f;break;case"children":case"dangerouslySetInnerHTML":if(null!=f)throw Error(s(137,e));break;default:f!==u&&cm(t,e,h,f,i,u)}}return void be(t,r,l,d,c,m,o,n);case"select":for(o in f=r=l=h=null,a)if(d=a[o],a.hasOwnProperty(o)&&null!=d)switch(o){case"value":break;case"multiple":f=d;default:i.hasOwnProperty(o)||cm(t,e,o,null,i,d)}for(n in i)if(o=i[n],d=a[n],i.hasOwnProperty(n)&&(null!=o||null!=d))switch(n){case"value":h=o;break;case"defaultValue":l=o;break;case"multiple":r=o;default:o!==d&&cm(t,e,n,o,i,d)}return e=l,a=r,i=f,void(null!=h?xe(t,!!a,h,!1):!!i!==!!a&&(null!=e?xe(t,!!a,e,!0):xe(t,!!a,a?[]:"",!1)));case"textarea":for(l in f=h=null,a)if(n=a[l],a.hasOwnProperty(l)&&null!=n&&!i.hasOwnProperty(l))switch(l){case"value":case"children":break;default:cm(t,e,l,null,i,n)}for(r in i)if(n=i[r],o=a[r],i.hasOwnProperty(r)&&(null!=n||null!=o))switch(r){case"value":h=n;break;case"defaultValue":f=n;break;case"children":break;case"dangerouslySetInnerHTML":if(null!=n)throw Error(s(91));break;default:n!==o&&cm(t,e,r,n,i,o)}return void ke(t,h,f);case"option":for(var g in a)if(h=a[g],a.hasOwnProperty(g)&&null!=h&&!i.hasOwnProperty(g))if("selected"===g)t.selected=!1;else cm(t,e,g,null,i,h);for(d in i)if(h=i[d],f=a[d],i.hasOwnProperty(d)&&h!==f&&(null!=h||null!=f))if("selected"===d)t.selected=h&&"function"!==typeof h&&"symbol"!==typeof h;else cm(t,e,d,h,i,f);return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var p in a)h=a[p],a.hasOwnProperty(p)&&null!=h&&!i.hasOwnProperty(p)&&cm(t,e,p,null,i,h);for(c in i)if(h=i[c],f=a[c],i.hasOwnProperty(c)&&h!==f&&(null!=h||null!=f))switch(c){case"children":case"dangerouslySetInnerHTML":if(null!=h)throw Error(s(137,e));break;default:cm(t,e,c,h,i,f)}return;default:if(Pe(e)){for(var y in a)h=a[y],a.hasOwnProperty(y)&&void 0!==h&&!i.hasOwnProperty(y)&&mm(t,e,y,void 0,i,h);for(m in i)h=i[m],f=a[m],!i.hasOwnProperty(m)||h===f||void 0===h&&void 0===f||mm(t,e,m,h,i,f);return}}for(var b in a)h=a[b],a.hasOwnProperty(b)&&null!=h&&!i.hasOwnProperty(b)&&cm(t,e,b,null,i,h);for(u in i)h=i[u],f=a[u],!i.hasOwnProperty(u)||h===f||null==h&&null==f||cm(t,e,u,h,i,f)}(i,t.type,a,e),i[Ht]=e}catch(n){Ic(t,t.return,n)}}function Cl(t){return 5===t.tag||3===t.tag||26===t.tag||27===t.tag&&Am(t.type)||4===t.tag}function Sl(t){t:for(;;){for(;null===t.sibling;){if(null===t.return||Cl(t.return))return null;t=t.return}for(t.sibling.return=t.return,t=t.sibling;5!==t.tag&&6!==t.tag&&18!==t.tag;){if(27===t.tag&&Am(t.type))continue t;if(2&t.flags)continue t;if(null===t.child||4===t.tag)continue t;t.child.return=t,t=t.child}if(!(2&t.flags))return t.stateNode}}function Al(t,e,a){var i=t.tag;if(5===i||6===i)t=t.stateNode,e?(9===a.nodeType?a.body:"HTML"===a.nodeName?a.ownerDocument.body:a).insertBefore(t,e):((e=9===a.nodeType?a.body:"HTML"===a.nodeName?a.ownerDocument.body:a).appendChild(t),null!==(a=a._reactRootContainer)&&void 0!==a||null!==e.onclick||(e.onclick=Ee));else if(4!==i&&(27===i&&Am(t.type)&&(a=t.stateNode,e=null),null!==(t=t.child)))for(Al(t,e,a),t=t.sibling;null!==t;)Al(t,e,a),t=t.sibling}function Tl(t,e,a){var i=t.tag;if(5===i||6===i)t=t.stateNode,e?a.insertBefore(t,e):a.appendChild(t);else if(4!==i&&(27===i&&Am(t.type)&&(a=t.stateNode),null!==(t=t.child)))for(Tl(t,e,a),t=t.sibling;null!==t;)Tl(t,e,a),t=t.sibling}function Pl(t){var e=t.stateNode,a=t.memoizedProps;try{for(var i=t.type,n=e.attributes;n.length;)e.removeAttributeNode(n[0]);um(e,i,a),e[Ut]=t,e[Ht]=a}catch(o){Ic(t,t.return,o)}}var Dl=!1,Nl=!1,Ll=!1,El="function"===typeof WeakSet?WeakSet:Set,jl=null;function Ml(t,e,a){var i=a.flags;switch(a.tag){case 0:case 11:case 15:Kl(t,a),4&i&&pl(5,a);break;case 1:if(Kl(t,a),4&i)if(t=a.stateNode,null===e)try{t.componentDidMount()}catch(s){Ic(a,a.return,s)}else{var n=Ir(a.type,e.memoizedProps);e=e.memoizedState;try{t.componentDidUpdate(n,e,t.__reactInternalSnapshotBeforeUpdate)}catch(r){Ic(a,a.return,r)}}64&i&&bl(a),512&i&&wl(a,a.return);break;case 3:if(Kl(t,a),64&i&&null!==(t=a.updateQueue)){if(e=null,null!==a.child)switch(a.child.tag){case 27:case 5:case 1:e=a.child.stateNode}try{To(t,e)}catch(s){Ic(a,a.return,s)}}break;case 27:null===e&&4&i&&Pl(a);case 26:case 5:Kl(t,a),null===e&&4&i&&kl(a),512&i&&wl(a,a.return);break;case 12:Kl(t,a);break;case 31:Kl(t,a),4&i&&Ol(t,a);break;case 13:Kl(t,a),4&i&&Ul(t,a),64&i&&(null!==(t=a.memoizedState)&&(null!==(t=t.dehydrated)&&function(t,e){var a=t.ownerDocument;if("$~"===t.data)t._reactRetry=e;else if("$?"!==t.data||"loading"!==a.readyState)e();else{var i=function(){e(),a.removeEventListener("DOMContentLoaded",i)};a.addEventListener("DOMContentLoaded",i),t._reactRetry=i}}(t,a=Tc.bind(null,a))));break;case 22:if(!(i=null!==a.memoizedState||Dl)){e=null!==e&&null!==e.memoizedState||Nl,n=Dl;var o=Nl;Dl=i,(Nl=e)&&!o?$l(t,a,0!==(8772&a.subtreeFlags)):Kl(t,a),Dl=n,Nl=o}break;case 30:break;default:Kl(t,a)}}function zl(t){var e=t.alternate;null!==e&&(t.alternate=null,zl(e)),t.child=null,t.deletions=null,t.sibling=null,5===t.tag&&(null!==(e=t.stateNode)&&Zt(e)),t.stateNode=null,t.return=null,t.dependencies=null,t.memoizedProps=null,t.memoizedState=null,t.pendingProps=null,t.stateNode=null,t.updateQueue=null}var Rl=null,Fl=!1;function ql(t,e,a){for(a=a.child;null!==a;)_l(t,e,a),a=a.sibling}function _l(t,e,a){if(bt&&"function"===typeof bt.onCommitFiberUnmount)try{bt.onCommitFiberUnmount(yt,a)}catch(o){}switch(a.tag){case 26:Nl||xl(a,e),ql(t,e,a),a.memoizedState?a.memoizedState.count--:a.stateNode&&(a=a.stateNode).parentNode.removeChild(a);break;case 27:Nl||xl(a,e);var i=Rl,n=Fl;Am(a.type)&&(Rl=a.stateNode,Fl=!1),ql(t,e,a),qm(a.stateNode),Rl=i,Fl=n;break;case 5:Nl||xl(a,e);case 6:if(i=Rl,n=Fl,Rl=null,ql(t,e,a),Fl=n,null!==(Rl=i))if(Fl)try{(9===Rl.nodeType?Rl.body:"HTML"===Rl.nodeName?Rl.ownerDocument.body:Rl).removeChild(a.stateNode)}catch(s){Ic(a,e,s)}else try{Rl.removeChild(a.stateNode)}catch(s){Ic(a,e,s)}break;case 18:null!==Rl&&(Fl?(Tm(9===(t=Rl).nodeType?t.body:"HTML"===t.nodeName?t.ownerDocument.body:t,a.stateNode),Bu(t)):Tm(Rl,a.stateNode));break;case 4:i=Rl,n=Fl,Rl=a.stateNode.containerInfo,Fl=!0,ql(t,e,a),Rl=i,Fl=n;break;case 0:case 11:case 14:case 15:yl(2,a,e),Nl||yl(4,a,e),ql(t,e,a);break;case 1:Nl||(xl(a,e),"function"===typeof(i=a.stateNode).componentWillUnmount&&vl(a,e,i)),ql(t,e,a);break;case 21:ql(t,e,a);break;case 22:Nl=(i=Nl)||null!==a.memoizedState,ql(t,e,a),Nl=i;break;default:ql(t,e,a)}}function Ol(t,e){if(null===e.memoizedState&&(null!==(t=e.alternate)&&null!==(t=t.memoizedState))){t=t.dehydrated;try{Bu(t)}catch(a){Ic(e,e.return,a)}}}function Ul(t,e){if(null===e.memoizedState&&(null!==(t=e.alternate)&&(null!==(t=t.memoizedState)&&null!==(t=t.dehydrated))))try{Bu(t)}catch(a){Ic(e,e.return,a)}}function Hl(t,e){var a=function(t){switch(t.tag){case 31:case 13:case 19:var e=t.stateNode;return null===e&&(e=t.stateNode=new El),e;case 22:return null===(e=(t=t.stateNode)._retryCache)&&(e=t._retryCache=new El),e;default:throw Error(s(435,t.tag))}}(t);e.forEach(function(e){if(!a.has(e)){a.add(e);var i=Pc.bind(null,t,e);e.then(i,i)}})}function Vl(t,e){var a=e.deletions;if(null!==a)for(var i=0;i<a.length;i++){var n=a[i],o=t,r=e,l=r;t:for(;null!==l;){switch(l.tag){case 27:if(Am(l.type)){Rl=l.stateNode,Fl=!1;break t}break;case 5:Rl=l.stateNode,Fl=!1;break t;case 3:case 4:Rl=l.stateNode.containerInfo,Fl=!0;break t}l=l.return}if(null===Rl)throw Error(s(160));_l(o,r,n),Rl=null,Fl=!1,null!==(o=n.alternate)&&(o.return=null),n.return=null}if(13886&e.subtreeFlags)for(e=e.child;null!==e;)Gl(e,t),e=e.sibling}var Bl=null;function Gl(t,e){var a=t.alternate,i=t.flags;switch(t.tag){case 0:case 11:case 14:case 15:Vl(e,t),Wl(t),4&i&&(yl(3,t,t.return),pl(3,t),yl(5,t,t.return));break;case 1:Vl(e,t),Wl(t),512&i&&(Nl||null===a||xl(a,a.return)),64&i&&Dl&&(null!==(t=t.updateQueue)&&(null!==(i=t.callbacks)&&(a=t.shared.hiddenCallbacks,t.shared.hiddenCallbacks=null===a?i:a.concat(i))));break;case 26:var n=Bl;if(Vl(e,t),Wl(t),512&i&&(Nl||null===a||xl(a,a.return)),4&i){var o=null!==a?a.memoizedState:null;if(i=t.memoizedState,null===a)if(null===i)if(null===t.stateNode){t:{i=t.type,a=t.memoizedProps,n=n.ownerDocument||n;e:switch(i){case"title":(!(o=n.getElementsByTagName("title")[0])||o[Kt]||o[Ut]||"http://www.w3.org/2000/svg"===o.namespaceURI||o.hasAttribute("itemprop"))&&(o=n.createElement(i),n.head.insertBefore(o,n.querySelector("head > title"))),um(o,i,a),o[Ut]=t,te(o),i=o;break t;case"link":var r=au("link","href",n).get(i+(a.href||""));if(r)for(var l=0;l<r.length;l++)if((o=r[l]).getAttribute("href")===(null==a.href||""===a.href?null:a.href)&&o.getAttribute("rel")===(null==a.rel?null:a.rel)&&o.getAttribute("title")===(null==a.title?null:a.title)&&o.getAttribute("crossorigin")===(null==a.crossOrigin?null:a.crossOrigin)){r.splice(l,1);break e}um(o=n.createElement(i),i,a),n.head.appendChild(o);break;case"meta":if(r=au("meta","content",n).get(i+(a.content||"")))for(l=0;l<r.length;l++)if((o=r[l]).getAttribute("content")===(null==a.content?null:""+a.content)&&o.getAttribute("name")===(null==a.name?null:a.name)&&o.getAttribute("property")===(null==a.property?null:a.property)&&o.getAttribute("http-equiv")===(null==a.httpEquiv?null:a.httpEquiv)&&o.getAttribute("charset")===(null==a.charSet?null:a.charSet)){r.splice(l,1);break e}um(o=n.createElement(i),i,a),n.head.appendChild(o);break;default:throw Error(s(468,i))}o[Ut]=t,te(o),i=o}t.stateNode=i}else iu(n,t.type,t.stateNode);else t.stateNode=Xm(n,i,t.memoizedProps);else o!==i?(null===o?null!==a.stateNode&&(a=a.stateNode).parentNode.removeChild(a):o.count--,null===i?iu(n,t.type,t.stateNode):Xm(n,i,t.memoizedProps)):null===i&&null!==t.stateNode&&Il(t,t.memoizedProps,a.memoizedProps)}break;case 27:Vl(e,t),Wl(t),512&i&&(Nl||null===a||xl(a,a.return)),null!==a&&4&i&&Il(t,t.memoizedProps,a.memoizedProps);break;case 5:if(Vl(e,t),Wl(t),512&i&&(Nl||null===a||xl(a,a.return)),32&t.flags){n=t.stateNode;try{Ce(n,"")}catch(g){Ic(t,t.return,g)}}4&i&&null!=t.stateNode&&Il(t,n=t.memoizedProps,null!==a?a.memoizedProps:n),1024&i&&(Ll=!0);break;case 6:if(Vl(e,t),Wl(t),4&i){if(null===t.stateNode)throw Error(s(162));i=t.memoizedProps,a=t.stateNode;try{a.nodeValue=i}catch(g){Ic(t,t.return,g)}}break;case 3:if(eu=null,n=Bl,Bl=Um(e.containerInfo),Vl(e,t),Bl=n,Wl(t),4&i&&null!==a&&a.memoizedState.isDehydrated)try{Bu(e.containerInfo)}catch(g){Ic(t,t.return,g)}Ll&&(Ll=!1,Ql(t));break;case 4:i=Bl,Bl=Um(t.stateNode.containerInfo),Vl(e,t),Wl(t),Bl=i;break;case 12:default:Vl(e,t),Wl(t);break;case 31:case 19:Vl(e,t),Wl(t),4&i&&(null!==(i=t.updateQueue)&&(t.updateQueue=null,Hl(t,i)));break;case 13:Vl(e,t),Wl(t),8192&t.child.flags&&null!==t.memoizedState!==(null!==a&&null!==a.memoizedState)&&(Ed=lt()),4&i&&(null!==(i=t.updateQueue)&&(t.updateQueue=null,Hl(t,i)));break;case 22:n=null!==t.memoizedState;var d=null!==a&&null!==a.memoizedState,c=Dl,m=Nl;if(Dl=c||n,Nl=m||d,Vl(e,t),Nl=m,Dl=c,Wl(t),8192&i)t:for(e=t.stateNode,e._visibility=n?-2&e._visibility:1|e._visibility,n&&(null===a||d||Dl||Nl||Zl(t)),a=null,e=t;;){if(5===e.tag||26===e.tag){if(null===a){d=a=e;try{if(o=d.stateNode,n)"function"===typeof(r=o.style).setProperty?r.setProperty("display","none","important"):r.display="none";else{l=d.stateNode;var u=d.memoizedProps.style,h=void 0!==u&&null!==u&&u.hasOwnProperty("display")?u.display:null;l.style.display=null==h||"boolean"===typeof h?"":(""+h).trim()}}catch(g){Ic(d,d.return,g)}}}else if(6===e.tag){if(null===a){d=e;try{d.stateNode.nodeValue=n?"":d.memoizedProps}catch(g){Ic(d,d.return,g)}}}else if(18===e.tag){if(null===a){d=e;try{var f=d.stateNode;n?Pm(f,!0):Pm(d.stateNode,!1)}catch(g){Ic(d,d.return,g)}}}else if((22!==e.tag&&23!==e.tag||null===e.memoizedState||e===t)&&null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break t;for(;null===e.sibling;){if(null===e.return||e.return===t)break t;a===e&&(a=null),e=e.return}a===e&&(a=null),e.sibling.return=e.return,e=e.sibling}4&i&&(null!==(i=t.updateQueue)&&(null!==(a=i.retryQueue)&&(i.retryQueue=null,Hl(t,a))));case 30:case 21:}}function Wl(t){var e=t.flags;if(2&e){try{for(var a,i=t.return;null!==i;){if(Cl(i)){a=i;break}i=i.return}if(null==a)throw Error(s(160));switch(a.tag){case 27:var n=a.stateNode;Tl(t,Sl(t),n);break;case 5:var o=a.stateNode;32&a.flags&&(Ce(o,""),a.flags&=-33),Tl(t,Sl(t),o);break;case 3:case 4:var r=a.stateNode.containerInfo;Al(t,Sl(t),r);break;default:throw Error(s(161))}}catch(l){Ic(t,t.return,l)}t.flags&=-3}4096&e&&(t.flags&=-4097)}function Ql(t){if(1024&t.subtreeFlags)for(t=t.child;null!==t;){var e=t;Ql(e),5===e.tag&&1024&e.flags&&e.stateNode.reset(),t=t.sibling}}function Kl(t,e){if(8772&e.subtreeFlags)for(e=e.child;null!==e;)Ml(t,e.alternate,e),e=e.sibling}function Zl(t){for(t=t.child;null!==t;){var e=t;switch(e.tag){case 0:case 11:case 14:case 15:yl(4,e,e.return),Zl(e);break;case 1:xl(e,e.return);var a=e.stateNode;"function"===typeof a.componentWillUnmount&&vl(e,e.return,a),Zl(e);break;case 27:qm(e.stateNode);case 26:case 5:xl(e,e.return),Zl(e);break;case 22:null===e.memoizedState&&Zl(e);break;default:Zl(e)}t=t.sibling}}function $l(t,e,a){for(a=a&&0!==(8772&e.subtreeFlags),e=e.child;null!==e;){var i=e.alternate,n=t,o=e,s=o.flags;switch(o.tag){case 0:case 11:case 15:$l(n,o,a),pl(4,o);break;case 1:if($l(n,o,a),"function"===typeof(n=(i=o).stateNode).componentDidMount)try{n.componentDidMount()}catch(d){Ic(i,i.return,d)}if(null!==(n=(i=o).updateQueue)){var r=i.stateNode;try{var l=n.shared.hiddenCallbacks;if(null!==l)for(n.shared.hiddenCallbacks=null,n=0;n<l.length;n++)Ao(l[n],r)}catch(d){Ic(i,i.return,d)}}a&&64&s&&bl(o),wl(o,o.return);break;case 27:Pl(o);case 26:case 5:$l(n,o,a),a&&null===i&&4&s&&kl(o),wl(o,o.return);break;case 12:$l(n,o,a);break;case 31:$l(n,o,a),a&&4&s&&Ol(n,o);break;case 13:$l(n,o,a),a&&4&s&&Ul(n,o);break;case 22:null===o.memoizedState&&$l(n,o,a),wl(o,o.return);break;case 30:break;default:$l(n,o,a)}e=e.sibling}}function Xl(t,e){var a=null;null!==t&&null!==t.memoizedState&&null!==t.memoizedState.cachePool&&(a=t.memoizedState.cachePool.pool),t=null,null!==e.memoizedState&&null!==e.memoizedState.cachePool&&(t=e.memoizedState.cachePool.pool),t!==a&&(null!=t&&t.refCount++,null!=a&&On(a))}function Yl(t,e){t=null,null!==e.alternate&&(t=e.alternate.memoizedState.cache),(e=e.memoizedState.cache)!==t&&(e.refCount++,null!=t&&On(t))}function Jl(t,e,a,i){if(10256&e.subtreeFlags)for(e=e.child;null!==e;)td(t,e,a,i),e=e.sibling}function td(t,e,a,i){var n=e.flags;switch(e.tag){case 0:case 11:case 15:Jl(t,e,a,i),2048&n&&pl(9,e);break;case 1:case 31:case 13:default:Jl(t,e,a,i);break;case 3:Jl(t,e,a,i),2048&n&&(t=null,null!==e.alternate&&(t=e.alternate.memoizedState.cache),(e=e.memoizedState.cache)!==t&&(e.refCount++,null!=t&&On(t)));break;case 12:if(2048&n){Jl(t,e,a,i),t=e.stateNode;try{var o=e.memoizedProps,s=o.id,r=o.onPostCommit;"function"===typeof r&&r(s,null===e.alternate?"mount":"update",t.passiveEffectDuration,-0)}catch(l){Ic(e,e.return,l)}}else Jl(t,e,a,i);break;case 23:break;case 22:o=e.stateNode,s=e.alternate,null!==e.memoizedState?2&o._visibility?Jl(t,e,a,i):ad(t,e):2&o._visibility?Jl(t,e,a,i):(o._visibility|=2,ed(t,e,a,i,0!==(10256&e.subtreeFlags)||!1)),2048&n&&Xl(s,e);break;case 24:Jl(t,e,a,i),2048&n&&Yl(e.alternate,e)}}function ed(t,e,a,i,n){for(n=n&&(0!==(10256&e.subtreeFlags)||!1),e=e.child;null!==e;){var o=t,s=e,r=a,l=i,d=s.flags;switch(s.tag){case 0:case 11:case 15:ed(o,s,r,l,n),pl(8,s);break;case 23:break;case 22:var c=s.stateNode;null!==s.memoizedState?2&c._visibility?ed(o,s,r,l,n):ad(o,s):(c._visibility|=2,ed(o,s,r,l,n)),n&&2048&d&&Xl(s.alternate,s);break;case 24:ed(o,s,r,l,n),n&&2048&d&&Yl(s.alternate,s);break;default:ed(o,s,r,l,n)}e=e.sibling}}function ad(t,e){if(10256&e.subtreeFlags)for(e=e.child;null!==e;){var a=t,i=e,n=i.flags;switch(i.tag){case 22:ad(a,i),2048&n&&Xl(i.alternate,i);break;case 24:ad(a,i),2048&n&&Yl(i.alternate,i);break;default:ad(a,i)}e=e.sibling}}var id=8192;function nd(t,e,a){if(t.subtreeFlags&id)for(t=t.child;null!==t;)od(t,e,a),t=t.sibling}function od(t,e,a){switch(t.tag){case 26:nd(t,e,a),t.flags&id&&null!==t.memoizedState&&function(t,e,a,i){if("stylesheet"===a.type&&("string"!==typeof i.media||!1!==matchMedia(i.media).matches)&&0===(4&a.state.loading)){if(null===a.instance){var n=Wm(i.href),o=e.querySelector(Qm(n));if(o)return null!==(e=o._p)&&"object"===typeof e&&"function"===typeof e.then&&(t.count++,t=su.bind(t),e.then(t,t)),a.state.loading|=4,a.instance=o,void te(o);o=e.ownerDocument||e,i=Km(i),(n=_m.get(n))&&Jm(i,n),te(o=o.createElement("link"));var s=o;s._p=new Promise(function(t,e){s.onload=t,s.onerror=e}),um(o,"link",i),a.instance=o}null===t.stylesheets&&(t.stylesheets=new Map),t.stylesheets.set(a,e),(e=a.state.preload)&&0===(3&a.state.loading)&&(t.count++,a=su.bind(t),e.addEventListener("load",a),e.addEventListener("error",a))}}(a,Bl,t.memoizedState,t.memoizedProps);break;case 5:default:nd(t,e,a);break;case 3:case 4:var i=Bl;Bl=Um(t.stateNode.containerInfo),nd(t,e,a),Bl=i;break;case 22:null===t.memoizedState&&(null!==(i=t.alternate)&&null!==i.memoizedState?(i=id,id=16777216,nd(t,e,a),id=i):nd(t,e,a))}}function sd(t){var e=t.alternate;if(null!==e&&null!==(t=e.child)){e.child=null;do{e=t.sibling,t.sibling=null,t=e}while(null!==t)}}function rd(t){var e=t.deletions;if(0!==(16&t.flags)){if(null!==e)for(var a=0;a<e.length;a++){var i=e[a];jl=i,cd(i,t)}sd(t)}if(10256&t.subtreeFlags)for(t=t.child;null!==t;)ld(t),t=t.sibling}function ld(t){switch(t.tag){case 0:case 11:case 15:rd(t),2048&t.flags&&yl(9,t,t.return);break;case 3:case 12:default:rd(t);break;case 22:var e=t.stateNode;null!==t.memoizedState&&2&e._visibility&&(null===t.return||13!==t.return.tag)?(e._visibility&=-3,dd(t)):rd(t)}}function dd(t){var e=t.deletions;if(0!==(16&t.flags)){if(null!==e)for(var a=0;a<e.length;a++){var i=e[a];jl=i,cd(i,t)}sd(t)}for(t=t.child;null!==t;){switch((e=t).tag){case 0:case 11:case 15:yl(8,e,e.return),dd(e);break;case 22:2&(a=e.stateNode)._visibility&&(a._visibility&=-3,dd(e));break;default:dd(e)}t=t.sibling}}function cd(t,e){for(;null!==jl;){var a=jl;switch(a.tag){case 0:case 11:case 15:yl(8,a,e);break;case 23:case 22:if(null!==a.memoizedState&&null!==a.memoizedState.cachePool){var i=a.memoizedState.cachePool.pool;null!=i&&i.refCount++}break;case 24:On(a.memoizedState.cache)}if(null!==(i=a.child))i.return=a,jl=i;else t:for(a=t;null!==jl;){var n=(i=jl).sibling,o=i.return;if(zl(i),i===a){jl=null;break t}if(null!==n){n.return=o,jl=n;break t}jl=o}}}var md={getCacheForType:function(t){var e=En(qn),a=e.data.get(t);return void 0===a&&(a=t(),e.data.set(t,a)),a},cacheSignal:function(){return En(qn).controller.signal}},ud="function"===typeof WeakMap?WeakMap:Map,hd=0,fd=null,gd=null,pd=0,yd=0,bd=null,vd=!1,wd=!1,xd=!1,kd=0,Id=0,Cd=0,Sd=0,Ad=0,Td=0,Pd=0,Dd=null,Nd=null,Ld=!1,Ed=0,jd=0,Md=1/0,zd=null,Rd=null,Fd=0,qd=null,_d=null,Od=0,Ud=0,Hd=null,Vd=null,Bd=0,Gd=null;function Wd(){return 0!==(2&hd)&&0!==pd?pd&-pd:null!==M.T?Hc():qt()}function Qd(){if(0===Td)if(0===(536870912&pd)||mn){var t=Ct;0===(3932160&(Ct<<=1))&&(Ct=262144),Td=t}else Td=536870912;return null!==(t=jo.current)&&(t.flags|=32),Td}function Kd(t,e,a){(t!==fd||2!==yd&&9!==yd)&&null===t.cancelPendingCommit||(ec(t,0),Yd(t,pd,Td,!1)),Et(t,a),0!==(2&hd)&&t===fd||(t===fd&&(0===(2&hd)&&(Sd|=a),4===Id&&Yd(t,pd,Td,!1)),zc(t))}function Zd(t,e,a){if(0!==(6&hd))throw Error(s(327));for(var i=!a&&0===(127&e)&&0===(e&t.expiredLanes)||Pt(t,e),n=i?function(t,e){var a=hd;hd|=2;var i=nc(),n=oc();fd!==t||pd!==e?(zd=null,Md=lt()+500,ec(t,e)):wd=Pt(t,e);t:for(;;)try{if(0!==yd&&null!==gd){e=gd;var o=bd;e:switch(yd){case 1:yd=0,bd=null,uc(t,e,o,1);break;case 2:case 9:if(eo(o)){yd=0,bd=null,mc(e);break}e=function(){2!==yd&&9!==yd||fd!==t||(yd=7),zc(t)},o.then(e,e);break t;case 3:yd=7;break t;case 4:yd=5;break t;case 7:eo(o)?(yd=0,bd=null,mc(e)):(yd=0,bd=null,uc(t,e,o,7));break;case 5:var r=null;switch(gd.tag){case 26:r=gd.memoizedState;case 5:case 27:var l=gd;if(r?nu(r):l.stateNode.complete){yd=0,bd=null;var d=l.sibling;if(null!==d)gd=d;else{var c=l.return;null!==c?(gd=c,hc(c)):gd=null}break e}}yd=0,bd=null,uc(t,e,o,5);break;case 6:yd=0,bd=null,uc(t,e,o,6);break;case 8:tc(),Id=6;break t;default:throw Error(s(462))}}dc();break}catch(m){ac(t,m)}return Cn=In=null,M.H=i,M.A=n,hd=a,null!==gd?0:(fd=null,pd=0,Di(),Id)}(t,e):rc(t,e,!0),o=i;;){if(0===n){wd&&!i&&Yd(t,e,0,!1);break}if(a=t.current.alternate,!o||Xd(a)){if(2===n){if(o=e,t.errorRecoveryDisabledLanes&o)var r=0;else r=0!==(r=-536870913&t.pendingLanes)?r:536870912&r?536870912:0;if(0!==r){e=r;t:{var l=t;n=Dd;var d=l.current.memoizedState.isDehydrated;if(d&&(ec(l,r).flags|=256),2!==(r=rc(l,r,!1))){if(xd&&!d){l.errorRecoveryDisabledLanes|=o,Sd|=o,n=4;break t}o=Nd,Nd=n,null!==o&&(null===Nd?Nd=o:Nd.push.apply(Nd,o))}n=r}if(o=!1,2!==n)continue}}if(1===n){ec(t,0),Yd(t,e,0,!0);break}t:{switch(i=t,o=n){case 0:case 1:throw Error(s(345));case 4:if((4194048&e)!==e)break;case 6:Yd(i,e,Td,!vd);break t;case 2:Nd=null;break;case 3:case 5:break;default:throw Error(s(329))}if((62914560&e)===e&&10<(n=Ed+300-lt())){if(Yd(i,e,Td,!vd),0!==Tt(i,0,!0))break t;Od=e,i.timeoutHandle=xm($d.bind(null,i,a,Nd,zd,Ld,e,Td,Sd,Pd,vd,o,"Throttled",-0,0),n)}else $d(i,a,Nd,zd,Ld,e,Td,Sd,Pd,vd,o,null,-0,0)}break}n=rc(t,e,!1),o=!1}zc(t)}function $d(t,e,a,i,n,o,s,r,l,d,c,m,u,h){if(t.timeoutHandle=-1,8192&(m=e.subtreeFlags)||16785408===(16785408&m)){od(e,o,m={stylesheets:null,count:0,imgCount:0,imgBytes:0,suspenseyImages:[],waitingForImages:!0,waitingForViewTransition:!1,unsuspend:Ee});var f=(62914560&o)===o?Ed-lt():(4194048&o)===o?jd-lt():0;if(null!==(f=function(t,e){return t.stylesheets&&0===t.count&&lu(t,t.stylesheets),0<t.count||0<t.imgCount?function(a){var i=setTimeout(function(){if(t.stylesheets&&lu(t,t.stylesheets),t.unsuspend){var e=t.unsuspend;t.unsuspend=null,e()}},6e4+e);0<t.imgBytes&&0===ou&&(ou=62500*function(){if("function"===typeof performance.getEntriesByType){for(var t=0,e=0,a=performance.getEntriesByType("resource"),i=0;i<a.length;i++){var n=a[i],o=n.transferSize,s=n.initiatorType,r=n.duration;if(o&&r&&hm(s)){for(s=0,r=n.responseEnd,i+=1;i<a.length;i++){var l=a[i],d=l.startTime;if(d>r)break;var c=l.transferSize,m=l.initiatorType;c&&hm(m)&&(s+=c*((l=l.responseEnd)<r?1:(r-d)/(l-d)))}if(--i,e+=8*(o+s)/(n.duration/1e3),10<++t)break}}if(0<t)return e/t/1e6}return navigator.connection&&"number"===typeof(t=navigator.connection.downlink)?t:5}());var n=setTimeout(function(){if(t.waitingForImages=!1,0===t.count&&(t.stylesheets&&lu(t,t.stylesheets),t.unsuspend)){var e=t.unsuspend;t.unsuspend=null,e()}},(t.imgBytes>ou?50:800)+e);return t.unsuspend=a,function(){t.unsuspend=null,clearTimeout(i),clearTimeout(n)}}:null}(m,f)))return Od=o,t.cancelPendingCommit=f(gc.bind(null,t,e,o,a,i,n,s,r,l,c,m,null,u,h)),void Yd(t,o,s,!d)}gc(t,e,o,a,i,n,s,r,l)}function Xd(t){for(var e=t;;){var a=e.tag;if((0===a||11===a||15===a)&&16384&e.flags&&(null!==(a=e.updateQueue)&&null!==(a=a.stores)))for(var i=0;i<a.length;i++){var n=a[i],o=n.getSnapshot;n=n.value;try{if(!Xa(o(),n))return!1}catch(s){return!1}}if(a=e.child,16384&e.subtreeFlags&&null!==a)a.return=e,e=a;else{if(e===t)break;for(;null===e.sibling;){if(null===e.return||e.return===t)return!0;e=e.return}e.sibling.return=e.return,e=e.sibling}}return!0}function Yd(t,e,a,i){e&=~Ad,e&=~Sd,t.suspendedLanes|=e,t.pingedLanes&=~e,i&&(t.warmLanes|=e),i=t.expirationTimes;for(var n=e;0<n;){var o=31-wt(n),s=1<<o;i[o]=-1,n&=~s}0!==a&&jt(t,a,e)}function Jd(){return 0!==(6&hd)||(Rc(0,!1),!1)}function tc(){if(null!==gd){if(0===yd)var t=gd.return;else Cn=In=null,rs(t=gd),ro=null,lo=0,t=gd;for(;null!==t;)gl(t.alternate,t),t=t.return;gd=null}}function ec(t,e){var a=t.timeoutHandle;-1!==a&&(t.timeoutHandle=-1,km(a)),null!==(a=t.cancelPendingCommit)&&(t.cancelPendingCommit=null,a()),Od=0,tc(),fd=t,gd=a=_i(t.current,null),pd=e,yd=0,bd=null,vd=!1,wd=Pt(t,e),xd=!1,Pd=Td=Ad=Sd=Cd=Id=0,Nd=Dd=null,Ld=!1,0!==(8&e)&&(e|=32&e);var i=t.entangledLanes;if(0!==i)for(t=t.entanglements,i&=e;0<i;){var n=31-wt(i),o=1<<n;e|=t[n],i&=~o}return kd=e,Di(),a}function ac(t,e){Vo=null,M.H=gr,e===Xn||e===Jn?(e=oo(),yd=3):e===Yn?(e=oo(),yd=4):yd=e===Er?8:null!==e&&"object"===typeof e&&"function"===typeof e.then?6:1,bd=e,null===gd&&(Id=1,Tr(t,Qi(e,t.current)))}function ic(){var t=jo.current;return null===t||((4194048&pd)===pd?null===Mo:((62914560&pd)===pd||0!==(536870912&pd))&&t===Mo)}function nc(){var t=M.H;return M.H=gr,null===t?gr:t}function oc(){var t=M.A;return M.A=md,t}function sc(){Id=4,vd||(4194048&pd)!==pd&&null!==jo.current||(wd=!0),0===(134217727&Cd)&&0===(134217727&Sd)||null===fd||Yd(fd,pd,Td,!1)}function rc(t,e,a){var i=hd;hd|=2;var n=nc(),o=oc();fd===t&&pd===e||(zd=null,ec(t,e)),e=!1;var s=Id;t:for(;;)try{if(0!==yd&&null!==gd){var r=gd,l=bd;switch(yd){case 8:tc(),s=6;break t;case 3:case 2:case 9:case 6:null===jo.current&&(e=!0);var d=yd;if(yd=0,bd=null,uc(t,r,l,d),a&&wd){s=0;break t}break;default:d=yd,yd=0,bd=null,uc(t,r,l,d)}}lc(),s=Id;break}catch(c){ac(t,c)}return e&&t.shellSuspendCounter++,Cn=In=null,hd=i,M.H=n,M.A=o,null===gd&&(fd=null,pd=0,Di()),s}function lc(){for(;null!==gd;)cc(gd)}function dc(){for(;null!==gd&&!st();)cc(gd)}function cc(t){var e=sl(t.alternate,t,kd);t.memoizedProps=t.pendingProps,null===e?hc(t):gd=e}function mc(t){var e=t,a=e.alternate;switch(e.tag){case 15:case 0:e=Gr(a,e,e.pendingProps,e.type,void 0,pd);break;case 11:e=Gr(a,e,e.pendingProps,e.type.render,e.ref,pd);break;case 5:rs(e);default:gl(a,e),e=sl(a,e=gd=Oi(e,kd),kd)}t.memoizedProps=t.pendingProps,null===e?hc(t):gd=e}function uc(t,e,a,i){Cn=In=null,rs(e),ro=null,lo=0;var n=e.return;try{if(function(t,e,a,i,n){if(a.flags|=32768,null!==i&&"object"===typeof i&&"function"===typeof i.then){if(null!==(e=a.alternate)&&Dn(e,a,n,!0),null!==(a=jo.current)){switch(a.tag){case 31:case 13:return null===Mo?sc():null===a.alternate&&0===Id&&(Id=3),a.flags&=-257,a.flags|=65536,a.lanes=n,i===to?a.flags|=16384:(null===(e=a.updateQueue)?a.updateQueue=new Set([i]):e.add(i),Cc(t,i,n)),!1;case 22:return a.flags|=65536,i===to?a.flags|=16384:(null===(e=a.updateQueue)?(e={transitions:null,markerInstances:null,retryQueue:new Set([i])},a.updateQueue=e):null===(a=e.retryQueue)?e.retryQueue=new Set([i]):a.add(i),Cc(t,i,n)),!1}throw Error(s(435,a.tag))}return Cc(t,i,n),sc(),!1}if(mn)return null!==(e=jo.current)?(0===(65536&e.flags)&&(e.flags|=256),e.flags|=65536,e.lanes=n,i!==fn&&xn(Qi(t=Error(s(422),{cause:i}),a))):(i!==fn&&xn(Qi(e=Error(s(423),{cause:i}),a)),(t=t.current.alternate).flags|=65536,n&=-n,t.lanes|=n,i=Qi(i,a),ko(t,n=Dr(t.stateNode,i,n)),4!==Id&&(Id=2)),!1;var o=Error(s(520),{cause:i});if(o=Qi(o,a),null===Dd?Dd=[o]:Dd.push(o),4!==Id&&(Id=2),null===e)return!0;i=Qi(i,a),a=e;do{switch(a.tag){case 3:return a.flags|=65536,t=n&-n,a.lanes|=t,ko(a,t=Dr(a.stateNode,i,t)),!1;case 1:if(e=a.type,o=a.stateNode,0===(128&a.flags)&&("function"===typeof e.getDerivedStateFromError||null!==o&&"function"===typeof o.componentDidCatch&&(null===Rd||!Rd.has(o))))return a.flags|=65536,n&=-n,a.lanes|=n,Lr(n=Nr(n),t,a,i),ko(a,n),!1}a=a.return}while(null!==a);return!1}(t,n,e,a,pd))return Id=1,Tr(t,Qi(a,t.current)),void(gd=null)}catch(o){if(null!==n)throw gd=n,o;return Id=1,Tr(t,Qi(a,t.current)),void(gd=null)}32768&e.flags?(mn||1===i?t=!0:wd||0!==(536870912&pd)?t=!1:(vd=t=!0,(2===i||9===i||3===i||6===i)&&(null!==(i=jo.current)&&13===i.tag&&(i.flags|=16384))),fc(e,t)):hc(e)}function hc(t){var e=t;do{if(0!==(32768&e.flags))return void fc(e,vd);t=e.return;var a=hl(e.alternate,e,kd);if(null!==a)return void(gd=a);if(null!==(e=e.sibling))return void(gd=e);gd=e=t}while(null!==e);0===Id&&(Id=5)}function fc(t,e){do{var a=fl(t.alternate,t);if(null!==a)return a.flags&=32767,void(gd=a);if(null!==(a=t.return)&&(a.flags|=32768,a.subtreeFlags=0,a.deletions=null),!e&&null!==(t=t.sibling))return void(gd=t);gd=t=a}while(null!==t);Id=6,gd=null}function gc(t,e,a,i,n,o,r,l,d){t.cancelPendingCommit=null;do{wc()}while(0!==Fd);if(0!==(6&hd))throw Error(s(327));if(null!==e){if(e===t.current)throw Error(s(177));if(o=e.lanes|e.childLanes,function(t,e,a,i,n,o){var s=t.pendingLanes;t.pendingLanes=a,t.suspendedLanes=0,t.pingedLanes=0,t.warmLanes=0,t.expiredLanes&=a,t.entangledLanes&=a,t.errorRecoveryDisabledLanes&=a,t.shellSuspendCounter=0;var r=t.entanglements,l=t.expirationTimes,d=t.hiddenUpdates;for(a=s&~a;0<a;){var c=31-wt(a),m=1<<c;r[c]=0,l[c]=-1;var u=d[c];if(null!==u)for(d[c]=null,c=0;c<u.length;c++){var h=u[c];null!==h&&(h.lane&=-536870913)}a&=~m}0!==i&&jt(t,i,0),0!==o&&0===n&&0!==t.tag&&(t.suspendedLanes|=o&~(s&~e))}(t,a,o|=Pi,r,l,d),t===fd&&(gd=fd=null,pd=0),_d=e,qd=t,Od=a,Ud=o,Hd=n,Vd=i,0!==(10256&e.subtreeFlags)||0!==(10256&e.flags)?(t.callbackNode=null,t.callbackPriority=0,nt(ut,function(){return xc(),null})):(t.callbackNode=null,t.callbackPriority=0),i=0!==(13878&e.flags),0!==(13878&e.subtreeFlags)||i){i=M.T,M.T=null,n=z.p,z.p=2,r=hd,hd|=4;try{!function(t,e){if(t=t.containerInfo,fm=vu,ii(t=ai(t))){if("selectionStart"in t)var a={start:t.selectionStart,end:t.selectionEnd};else t:{var i=(a=(a=t.ownerDocument)&&a.defaultView||window).getSelection&&a.getSelection();if(i&&0!==i.rangeCount){a=i.anchorNode;var n=i.anchorOffset,o=i.focusNode;i=i.focusOffset;try{a.nodeType,o.nodeType}catch(p){a=null;break t}var r=0,l=-1,d=-1,c=0,m=0,u=t,h=null;e:for(;;){for(var f;u!==a||0!==n&&3!==u.nodeType||(l=r+n),u!==o||0!==i&&3!==u.nodeType||(d=r+i),3===u.nodeType&&(r+=u.nodeValue.length),null!==(f=u.firstChild);)h=u,u=f;for(;;){if(u===t)break e;if(h===a&&++c===n&&(l=r),h===o&&++m===i&&(d=r),null!==(f=u.nextSibling))break;h=(u=h).parentNode}u=f}a=-1===l||-1===d?null:{start:l,end:d}}else a=null}a=a||{start:0,end:0}}else a=null;for(gm={focusedElem:t,selectionRange:a},vu=!1,jl=e;null!==jl;)if(t=(e=jl).child,0!==(1028&e.subtreeFlags)&&null!==t)t.return=e,jl=t;else for(;null!==jl;){switch(o=(e=jl).alternate,t=e.flags,e.tag){case 0:if(0!==(4&t)&&null!==(t=null!==(t=e.updateQueue)?t.events:null))for(a=0;a<t.length;a++)(n=t[a]).ref.impl=n.nextImpl;break;case 11:case 15:case 5:case 26:case 27:case 6:case 4:case 17:break;case 1:if(0!==(1024&t)&&null!==o){t=void 0,a=e,n=o.memoizedProps,o=o.memoizedState,i=a.stateNode;try{var g=Ir(a.type,n);t=i.getSnapshotBeforeUpdate(g,o),i.__reactInternalSnapshotBeforeUpdate=t}catch(y){Ic(a,a.return,y)}}break;case 3:if(0!==(1024&t))if(9===(a=(t=e.stateNode.containerInfo).nodeType))Dm(t);else if(1===a)switch(t.nodeName){case"HEAD":case"HTML":case"BODY":Dm(t);break;default:t.textContent=""}break;default:if(0!==(1024&t))throw Error(s(163))}if(null!==(t=e.sibling)){t.return=e.return,jl=t;break}jl=e.return}}(t,e)}finally{hd=r,z.p=n,M.T=i}}Fd=1,pc(),yc(),bc()}}function pc(){if(1===Fd){Fd=0;var t=qd,e=_d,a=0!==(13878&e.flags);if(0!==(13878&e.subtreeFlags)||a){a=M.T,M.T=null;var i=z.p;z.p=2;var n=hd;hd|=4;try{Gl(e,t);var o=gm,s=ai(t.containerInfo),r=o.focusedElem,l=o.selectionRange;if(s!==r&&r&&r.ownerDocument&&ei(r.ownerDocument.documentElement,r)){if(null!==l&&ii(r)){var d=l.start,c=l.end;if(void 0===c&&(c=d),"selectionStart"in r)r.selectionStart=d,r.selectionEnd=Math.min(c,r.value.length);else{var m=r.ownerDocument||document,u=m&&m.defaultView||window;if(u.getSelection){var h=u.getSelection(),f=r.textContent.length,g=Math.min(l.start,f),p=void 0===l.end?g:Math.min(l.end,f);!h.extend&&g>p&&(s=p,p=g,g=s);var y=ti(r,g),b=ti(r,p);if(y&&b&&(1!==h.rangeCount||h.anchorNode!==y.node||h.anchorOffset!==y.offset||h.focusNode!==b.node||h.focusOffset!==b.offset)){var v=m.createRange();v.setStart(y.node,y.offset),h.removeAllRanges(),g>p?(h.addRange(v),h.extend(b.node,b.offset)):(v.setEnd(b.node,b.offset),h.addRange(v))}}}}for(m=[],h=r;h=h.parentNode;)1===h.nodeType&&m.push({element:h,left:h.scrollLeft,top:h.scrollTop});for("function"===typeof r.focus&&r.focus(),r=0;r<m.length;r++){var w=m[r];w.element.scrollLeft=w.left,w.element.scrollTop=w.top}}vu=!!fm,gm=fm=null}finally{hd=n,z.p=i,M.T=a}}t.current=e,Fd=2}}function yc(){if(2===Fd){Fd=0;var t=qd,e=_d,a=0!==(8772&e.flags);if(0!==(8772&e.subtreeFlags)||a){a=M.T,M.T=null;var i=z.p;z.p=2;var n=hd;hd|=4;try{Ml(t,e.alternate,e)}finally{hd=n,z.p=i,M.T=a}}Fd=3}}function bc(){if(4===Fd||3===Fd){Fd=0,rt();var t=qd,e=_d,a=Od,i=Vd;0!==(10256&e.subtreeFlags)||0!==(10256&e.flags)?Fd=5:(Fd=0,_d=qd=null,vc(t,t.pendingLanes));var n=t.pendingLanes;if(0===n&&(Rd=null),Ft(a),e=e.stateNode,bt&&"function"===typeof bt.onCommitFiberRoot)try{bt.onCommitFiberRoot(yt,e,void 0,128===(128&e.current.flags))}catch(l){}if(null!==i){e=M.T,n=z.p,z.p=2,M.T=null;try{for(var o=t.onRecoverableError,s=0;s<i.length;s++){var r=i[s];o(r.value,{componentStack:r.stack})}}finally{M.T=e,z.p=n}}0!==(3&Od)&&wc(),zc(t),n=t.pendingLanes,0!==(261930&a)&&0!==(42&n)?t===Gd?Bd++:(Bd=0,Gd=t):Bd=0,Rc(0,!1)}}function vc(t,e){0===(t.pooledCacheLanes&=e)&&(null!=(e=t.pooledCache)&&(t.pooledCache=null,On(e)))}function wc(){return pc(),yc(),bc(),xc()}function xc(){if(5!==Fd)return!1;var t=qd,e=Ud;Ud=0;var a=Ft(Od),i=M.T,n=z.p;try{z.p=32>a?32:a,M.T=null,a=Hd,Hd=null;var o=qd,r=Od;if(Fd=0,_d=qd=null,Od=0,0!==(6&hd))throw Error(s(331));var l=hd;if(hd|=4,ld(o.current),td(o,o.current,r,a),hd=l,Rc(0,!1),bt&&"function"===typeof bt.onPostCommitFiberRoot)try{bt.onPostCommitFiberRoot(yt,o)}catch(d){}return!0}finally{z.p=n,M.T=i,vc(t,e)}}function kc(t,e,a){e=Qi(a,e),null!==(t=wo(t,e=Dr(t.stateNode,e,2),2))&&(Et(t,2),zc(t))}function Ic(t,e,a){if(3===t.tag)kc(t,t,a);else for(;null!==e;){if(3===e.tag){kc(e,t,a);break}if(1===e.tag){var i=e.stateNode;if("function"===typeof e.type.getDerivedStateFromError||"function"===typeof i.componentDidCatch&&(null===Rd||!Rd.has(i))){t=Qi(a,t),null!==(i=wo(e,a=Nr(2),2))&&(Lr(a,i,e,t),Et(i,2),zc(i));break}}e=e.return}}function Cc(t,e,a){var i=t.pingCache;if(null===i){i=t.pingCache=new ud;var n=new Set;i.set(e,n)}else void 0===(n=i.get(e))&&(n=new Set,i.set(e,n));n.has(a)||(xd=!0,n.add(a),t=Sc.bind(null,t,e,a),e.then(t,t))}function Sc(t,e,a){var i=t.pingCache;null!==i&&i.delete(e),t.pingedLanes|=t.suspendedLanes&a,t.warmLanes&=~a,fd===t&&(pd&a)===a&&(4===Id||3===Id&&(62914560&pd)===pd&&300>lt()-Ed?0===(2&hd)&&ec(t,0):Ad|=a,Pd===pd&&(Pd=0)),zc(t)}function Ac(t,e){0===e&&(e=Nt()),null!==(t=Ei(t,e))&&(Et(t,e),zc(t))}function Tc(t){var e=t.memoizedState,a=0;null!==e&&(a=e.retryLane),Ac(t,a)}function Pc(t,e){var a=0;switch(t.tag){case 31:case 13:var i=t.stateNode,n=t.memoizedState;null!==n&&(a=n.retryLane);break;case 19:i=t.stateNode;break;case 22:i=t.stateNode._retryCache;break;default:throw Error(s(314))}null!==i&&i.delete(e),Ac(t,a)}var Dc=null,Nc=null,Lc=!1,Ec=!1,jc=!1,Mc=0;function zc(t){t!==Nc&&null===t.next&&(null===Nc?Dc=Nc=t:Nc=Nc.next=t),Ec=!0,Lc||(Lc=!0,Cm(function(){0!==(6&hd)?nt(ct,Fc):qc()}))}function Rc(t,e){if(!jc&&Ec){jc=!0;do{for(var a=!1,i=Dc;null!==i;){if(!e)if(0!==t){var n=i.pendingLanes;if(0===n)var o=0;else{var s=i.suspendedLanes,r=i.pingedLanes;o=(1<<31-wt(42|t)+1)-1,o=201326741&(o&=n&~(s&~r))?201326741&o|1:o?2|o:0}0!==o&&(a=!0,Uc(i,o))}else o=pd,0===(3&(o=Tt(i,i===fd?o:0,null!==i.cancelPendingCommit||-1!==i.timeoutHandle)))||Pt(i,o)||(a=!0,Uc(i,o));i=i.next}}while(a);jc=!1}}function Fc(){qc()}function qc(){Ec=Lc=!1;var t=0;0!==Mc&&function(){var t=window.event;if(t&&"popstate"===t.type)return t!==wm&&(wm=t,!0);return wm=null,!1}()&&(t=Mc);for(var e=lt(),a=null,i=Dc;null!==i;){var n=i.next,o=_c(i,e);0===o?(i.next=null,null===a?Dc=n:a.next=n,null===n&&(Nc=a)):(a=i,(0!==t||0!==(3&o))&&(Ec=!0)),i=n}0!==Fd&&5!==Fd||Rc(t,!1),0!==Mc&&(Mc=0)}function _c(t,e){for(var a=t.suspendedLanes,i=t.pingedLanes,n=t.expirationTimes,o=-62914561&t.pendingLanes;0<o;){var s=31-wt(o),r=1<<s,l=n[s];-1===l?0!==(r&a)&&0===(r&i)||(n[s]=Dt(r,e)):l<=e&&(t.expiredLanes|=r),o&=~r}if(a=pd,a=Tt(t,t===(e=fd)?a:0,null!==t.cancelPendingCommit||-1!==t.timeoutHandle),i=t.callbackNode,0===a||t===e&&(2===yd||9===yd)||null!==t.cancelPendingCommit)return null!==i&&null!==i&&ot(i),t.callbackNode=null,t.callbackPriority=0;if(0===(3&a)||Pt(t,a)){if((e=a&-a)===t.callbackPriority)return e;switch(null!==i&&ot(i),Ft(a)){case 2:case 8:a=mt;break;case 32:default:a=ut;break;case 268435456:a=ft}return i=Oc.bind(null,t),a=nt(a,i),t.callbackPriority=e,t.callbackNode=a,e}return null!==i&&null!==i&&ot(i),t.callbackPriority=2,t.callbackNode=null,2}function Oc(t,e){if(0!==Fd&&5!==Fd)return t.callbackNode=null,t.callbackPriority=0,null;var a=t.callbackNode;if(wc()&&t.callbackNode!==a)return null;var i=pd;return 0===(i=Tt(t,t===fd?i:0,null!==t.cancelPendingCommit||-1!==t.timeoutHandle))?null:(Zd(t,i,e),_c(t,lt()),null!=t.callbackNode&&t.callbackNode===a?Oc.bind(null,t):null)}function Uc(t,e){if(wc())return null;Zd(t,e,!0)}function Hc(){if(0===Mc){var t=Vn;0===t&&(t=It,0===(261888&(It<<=1))&&(It=256)),Mc=t}return Mc}function Vc(t){return null==t||"symbol"===typeof t||"boolean"===typeof t?null:"function"===typeof t?t:Le(""+t)}function Bc(t,e){var a=e.ownerDocument.createElement("input");return a.name=e.name,a.value=e.value,t.id&&a.setAttribute("form",t.id),e.parentNode.insertBefore(a,e),t=new FormData(t),a.parentNode.removeChild(a),t}for(var Gc=0;Gc<Ii.length;Gc++){var Wc=Ii[Gc];Ci(Wc.toLowerCase(),"on"+(Wc[0].toUpperCase()+Wc.slice(1)))}Ci(gi,"onAnimationEnd"),Ci(pi,"onAnimationIteration"),Ci(yi,"onAnimationStart"),Ci("dblclick","onDoubleClick"),Ci("focusin","onFocus"),Ci("focusout","onBlur"),Ci(bi,"onTransitionRun"),Ci(vi,"onTransitionStart"),Ci(wi,"onTransitionCancel"),Ci(xi,"onTransitionEnd"),ne("onMouseEnter",["mouseout","mouseover"]),ne("onMouseLeave",["mouseout","mouseover"]),ne("onPointerEnter",["pointerout","pointerover"]),ne("onPointerLeave",["pointerout","pointerover"]),ie("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),ie("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),ie("onBeforeInput",["compositionend","keypress","textInput","paste"]),ie("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),ie("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),ie("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Qc="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Kc=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(Qc));function Zc(t,e){e=0!==(4&e);for(var a=0;a<t.length;a++){var i=t[a],n=i.event;i=i.listeners;t:{var o=void 0;if(e)for(var s=i.length-1;0<=s;s--){var r=i[s],l=r.instance,d=r.currentTarget;if(r=r.listener,l!==o&&n.isPropagationStopped())break t;o=r,n.currentTarget=d;try{o(n)}catch(c){Si(c)}n.currentTarget=null,o=l}else for(s=0;s<i.length;s++){if(l=(r=i[s]).instance,d=r.currentTarget,r=r.listener,l!==o&&n.isPropagationStopped())break t;o=r,n.currentTarget=d;try{o(n)}catch(c){Si(c)}n.currentTarget=null,o=l}}}}function $c(t,e){var a=e[Bt];void 0===a&&(a=e[Bt]=new Set);var i=t+"__bubble";a.has(i)||(tm(e,t,2,!1),a.add(i))}function Xc(t,e,a){var i=0;e&&(i|=4),tm(a,t,i,e)}var Yc="_reactListening"+Math.random().toString(36).slice(2);function Jc(t){if(!t[Yc]){t[Yc]=!0,ee.forEach(function(e){"selectionchange"!==e&&(Kc.has(e)||Xc(e,!1,t),Xc(e,!0,t))});var e=9===t.nodeType?t:t.ownerDocument;null===e||e[Yc]||(e[Yc]=!0,Xc("selectionchange",!1,e))}}function tm(t,e,a,i){switch(Au(e)){case 2:var n=wu;break;case 8:n=xu;break;default:n=ku}a=n.bind(null,e,a,t),n=void 0,!He||"touchstart"!==e&&"touchmove"!==e&&"wheel"!==e||(n=!0),i?void 0!==n?t.addEventListener(e,a,{capture:!0,passive:n}):t.addEventListener(e,a,!0):void 0!==n?t.addEventListener(e,a,{passive:n}):t.addEventListener(e,a,!1)}function em(t,e,a,i,n){var o=i;if(0===(1&e)&&0===(2&e)&&null!==i)t:for(;;){if(null===i)return;var s=i.tag;if(3===s||4===s){var r=i.stateNode.containerInfo;if(r===n)break;if(4===s)for(s=i.return;null!==s;){var d=s.tag;if((3===d||4===d)&&s.stateNode.containerInfo===n)return;s=s.return}for(;null!==r;){if(null===(s=$t(r)))return;if(5===(d=s.tag)||6===d||26===d||27===d){i=o=s;continue t}r=r.parentNode}}i=i.return}_e(function(){var i=o,n=Me(a),s=[];t:{var r=ki.get(t);if(void 0!==r){var d=aa,c=t;switch(t){case"keypress":if(0===Ke(a))break t;case"keydown":case"keyup":d=ya;break;case"focusin":c="focus",d=la;break;case"focusout":c="blur",d=la;break;case"beforeblur":case"afterblur":d=la;break;case"click":if(2===a.button)break t;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":d=sa;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":d=ra;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":d=va;break;case gi:case pi:case yi:d=da;break;case xi:d=wa;break;case"scroll":case"scrollend":d=na;break;case"wheel":d=xa;break;case"copy":case"cut":case"paste":d=ca;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":d=ba;break;case"toggle":case"beforetoggle":d=ka}var m=0!==(4&e),u=!m&&("scroll"===t||"scrollend"===t),h=m?null!==r?r+"Capture":null:r;m=[];for(var f,g=i;null!==g;){var p=g;if(f=p.stateNode,5!==(p=p.tag)&&26!==p&&27!==p||null===f||null===h||null!=(p=Oe(g,h))&&m.push(am(g,p,f)),u)break;g=g.return}0<m.length&&(r=new d(r,c,null,a,n),s.push({event:r,listeners:m}))}}if(0===(7&e)){if(d="mouseout"===t||"pointerout"===t,(!(r="mouseover"===t||"pointerover"===t)||a===je||!(c=a.relatedTarget||a.fromElement)||!$t(c)&&!c[Vt])&&(d||r)&&(r=n.window===n?n:(r=n.ownerDocument)?r.defaultView||r.parentWindow:window,d?(d=i,null!==(c=(c=a.relatedTarget||a.toElement)?$t(c):null)&&(u=l(c),m=c.tag,c!==u||5!==m&&27!==m&&6!==m)&&(c=null)):(d=null,c=i),d!==c)){if(m=sa,p="onMouseLeave",h="onMouseEnter",g="mouse","pointerout"!==t&&"pointerover"!==t||(m=ba,p="onPointerLeave",h="onPointerEnter",g="pointer"),u=null==d?r:Yt(d),f=null==c?r:Yt(c),(r=new m(p,g+"leave",d,a,n)).target=u,r.relatedTarget=f,p=null,$t(n)===i&&((m=new m(h,g+"enter",c,a,n)).target=f,m.relatedTarget=u,p=m),u=p,d&&c)t:{for(m=nm,g=c,f=0,p=h=d;p;p=m(p))f++;p=0;for(var y=g;y;y=m(y))p++;for(;0<f-p;)h=m(h),f--;for(;0<p-f;)g=m(g),p--;for(;f--;){if(h===g||null!==g&&h===g.alternate){m=h;break t}h=m(h),g=m(g)}m=null}else m=null;null!==d&&om(s,r,d,m,!1),null!==c&&null!==u&&om(s,u,c,m,!0)}if("select"===(d=(r=i?Yt(i):window).nodeName&&r.nodeName.toLowerCase())||"input"===d&&"file"===r.type)var b=Oa;else if(Ma(r))if(Ua)b=$a;else{b=Ka;var v=Qa}else!(d=r.nodeName)||"input"!==d.toLowerCase()||"checkbox"!==r.type&&"radio"!==r.type?i&&Pe(i.elementType)&&(b=Oa):b=Za;switch(b&&(b=b(t,i))?za(s,b,a,n):(v&&v(t,r,i),"focusout"===t&&i&&"number"===r.type&&null!=i.memoizedProps.value&&we(r,"number",r.value)),v=i?Yt(i):window,t){case"focusin":(Ma(v)||"true"===v.contentEditable)&&(oi=v,si=i,ri=null);break;case"focusout":ri=si=oi=null;break;case"mousedown":li=!0;break;case"contextmenu":case"mouseup":case"dragend":li=!1,di(s,a,n);break;case"selectionchange":if(ni)break;case"keydown":case"keyup":di(s,a,n)}var w;if(Ca)t:{switch(t){case"compositionstart":var x="onCompositionStart";break t;case"compositionend":x="onCompositionEnd";break t;case"compositionupdate":x="onCompositionUpdate";break t}x=void 0}else Ea?Na(t,a)&&(x="onCompositionEnd"):"keydown"===t&&229===a.keyCode&&(x="onCompositionStart");x&&(Ta&&"ko"!==a.locale&&(Ea||"onCompositionStart"!==x?"onCompositionEnd"===x&&Ea&&(w=Qe()):(Ge="value"in(Be=n)?Be.value:Be.textContent,Ea=!0)),0<(v=im(i,x)).length&&(x=new ma(x,t,null,a,n),s.push({event:x,listeners:v}),w?x.data=w:null!==(w=La(a))&&(x.data=w))),(w=Aa?function(t,e){switch(t){case"compositionend":return La(e);case"keypress":return 32!==e.which?null:(Da=!0,Pa);case"textInput":return(t=e.data)===Pa&&Da?null:t;default:return null}}(t,a):function(t,e){if(Ea)return"compositionend"===t||!Ca&&Na(t,e)?(t=Qe(),We=Ge=Be=null,Ea=!1,t):null;switch(t){case"paste":default:return null;case"keypress":if(!(e.ctrlKey||e.altKey||e.metaKey)||e.ctrlKey&&e.altKey){if(e.char&&1<e.char.length)return e.char;if(e.which)return String.fromCharCode(e.which)}return null;case"compositionend":return Ta&&"ko"!==e.locale?null:e.data}}(t,a))&&(0<(x=im(i,"onBeforeInput")).length&&(v=new ma("onBeforeInput","beforeinput",null,a,n),s.push({event:v,listeners:x}),v.data=w)),function(t,e,a,i,n){if("submit"===e&&a&&a.stateNode===n){var o=Vc((n[Ht]||null).action),s=i.submitter;s&&null!==(e=(e=s[Ht]||null)?Vc(e.formAction):s.getAttribute("formAction"))&&(o=e,s=null);var r=new aa("action","action",null,i,n);t.push({event:r,listeners:[{instance:null,listener:function(){if(i.defaultPrevented){if(0!==Mc){var t=s?Bc(n,s):new FormData(n);er(a,{pending:!0,data:t,method:n.method,action:o},null,t)}}else"function"===typeof o&&(r.preventDefault(),t=s?Bc(n,s):new FormData(n),er(a,{pending:!0,data:t,method:n.method,action:o},o,t))},currentTarget:n}]})}}(s,t,i,a,n)}Zc(s,e)})}function am(t,e,a){return{instance:t,listener:e,currentTarget:a}}function im(t,e){for(var a=e+"Capture",i=[];null!==t;){var n=t,o=n.stateNode;if(5!==(n=n.tag)&&26!==n&&27!==n||null===o||(null!=(n=Oe(t,a))&&i.unshift(am(t,n,o)),null!=(n=Oe(t,e))&&i.push(am(t,n,o))),3===t.tag)return i;t=t.return}return[]}function nm(t){if(null===t)return null;do{t=t.return}while(t&&5!==t.tag&&27!==t.tag);return t||null}function om(t,e,a,i,n){for(var o=e._reactName,s=[];null!==a&&a!==i;){var r=a,l=r.alternate,d=r.stateNode;if(r=r.tag,null!==l&&l===i)break;5!==r&&26!==r&&27!==r||null===d||(l=d,n?null!=(d=Oe(a,o))&&s.unshift(am(a,d,l)):n||null!=(d=Oe(a,o))&&s.push(am(a,d,l))),a=a.return}0!==s.length&&t.push({event:e,listeners:s})}var sm=/\r\n?/g,rm=/\u0000|\uFFFD/g;function lm(t){return("string"===typeof t?t:""+t).replace(sm,"\n").replace(rm,"")}function dm(t,e){return e=lm(e),lm(t)===e}function cm(t,e,a,i,n,o){switch(a){case"children":"string"===typeof i?"body"===e||"textarea"===e&&""===i||Ce(t,i):("number"===typeof i||"bigint"===typeof i)&&"body"!==e&&Ce(t,""+i);break;case"className":de(t,"class",i);break;case"tabIndex":de(t,"tabindex",i);break;case"dir":case"role":case"viewBox":case"width":case"height":de(t,a,i);break;case"style":Te(t,i,o);break;case"data":if("object"!==e){de(t,"data",i);break}case"src":case"href":if(""===i&&("a"!==e||"href"!==a)){t.removeAttribute(a);break}if(null==i||"function"===typeof i||"symbol"===typeof i||"boolean"===typeof i){t.removeAttribute(a);break}i=Le(""+i),t.setAttribute(a,i);break;case"action":case"formAction":if("function"===typeof i){t.setAttribute(a,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}if("function"===typeof o&&("formAction"===a?("input"!==e&&cm(t,e,"name",n.name,n,null),cm(t,e,"formEncType",n.formEncType,n,null),cm(t,e,"formMethod",n.formMethod,n,null),cm(t,e,"formTarget",n.formTarget,n,null)):(cm(t,e,"encType",n.encType,n,null),cm(t,e,"method",n.method,n,null),cm(t,e,"target",n.target,n,null))),null==i||"symbol"===typeof i||"boolean"===typeof i){t.removeAttribute(a);break}i=Le(""+i),t.setAttribute(a,i);break;case"onClick":null!=i&&(t.onclick=Ee);break;case"onScroll":null!=i&&$c("scroll",t);break;case"onScrollEnd":null!=i&&$c("scrollend",t);break;case"dangerouslySetInnerHTML":if(null!=i){if("object"!==typeof i||!("__html"in i))throw Error(s(61));if(null!=(a=i.__html)){if(null!=n.children)throw Error(s(60));t.innerHTML=a}}break;case"multiple":t.multiple=i&&"function"!==typeof i&&"symbol"!==typeof i;break;case"muted":t.muted=i&&"function"!==typeof i&&"symbol"!==typeof i;break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":case"autoFocus":break;case"xlinkHref":if(null==i||"function"===typeof i||"boolean"===typeof i||"symbol"===typeof i){t.removeAttribute("xlink:href");break}a=Le(""+i),t.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",a);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":null!=i&&"function"!==typeof i&&"symbol"!==typeof i?t.setAttribute(a,""+i):t.removeAttribute(a);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":i&&"function"!==typeof i&&"symbol"!==typeof i?t.setAttribute(a,""):t.removeAttribute(a);break;case"capture":case"download":!0===i?t.setAttribute(a,""):!1!==i&&null!=i&&"function"!==typeof i&&"symbol"!==typeof i?t.setAttribute(a,i):t.removeAttribute(a);break;case"cols":case"rows":case"size":case"span":null!=i&&"function"!==typeof i&&"symbol"!==typeof i&&!isNaN(i)&&1<=i?t.setAttribute(a,i):t.removeAttribute(a);break;case"rowSpan":case"start":null==i||"function"===typeof i||"symbol"===typeof i||isNaN(i)?t.removeAttribute(a):t.setAttribute(a,i);break;case"popover":$c("beforetoggle",t),$c("toggle",t),le(t,"popover",i);break;case"xlinkActuate":ce(t,"http://www.w3.org/1999/xlink","xlink:actuate",i);break;case"xlinkArcrole":ce(t,"http://www.w3.org/1999/xlink","xlink:arcrole",i);break;case"xlinkRole":ce(t,"http://www.w3.org/1999/xlink","xlink:role",i);break;case"xlinkShow":ce(t,"http://www.w3.org/1999/xlink","xlink:show",i);break;case"xlinkTitle":ce(t,"http://www.w3.org/1999/xlink","xlink:title",i);break;case"xlinkType":ce(t,"http://www.w3.org/1999/xlink","xlink:type",i);break;case"xmlBase":ce(t,"http://www.w3.org/XML/1998/namespace","xml:base",i);break;case"xmlLang":ce(t,"http://www.w3.org/XML/1998/namespace","xml:lang",i);break;case"xmlSpace":ce(t,"http://www.w3.org/XML/1998/namespace","xml:space",i);break;case"is":le(t,"is",i);break;case"innerText":case"textContent":break;default:(!(2<a.length)||"o"!==a[0]&&"O"!==a[0]||"n"!==a[1]&&"N"!==a[1])&&le(t,a=De.get(a)||a,i)}}function mm(t,e,a,i,n,o){switch(a){case"style":Te(t,i,o);break;case"dangerouslySetInnerHTML":if(null!=i){if("object"!==typeof i||!("__html"in i))throw Error(s(61));if(null!=(a=i.__html)){if(null!=n.children)throw Error(s(60));t.innerHTML=a}}break;case"children":"string"===typeof i?Ce(t,i):("number"===typeof i||"bigint"===typeof i)&&Ce(t,""+i);break;case"onScroll":null!=i&&$c("scroll",t);break;case"onScrollEnd":null!=i&&$c("scrollend",t);break;case"onClick":null!=i&&(t.onclick=Ee);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":case"innerText":case"textContent":break;default:ae.hasOwnProperty(a)||("o"!==a[0]||"n"!==a[1]||(n=a.endsWith("Capture"),e=a.slice(2,n?a.length-7:void 0),"function"===typeof(o=null!=(o=t[Ht]||null)?o[a]:null)&&t.removeEventListener(e,o,n),"function"!==typeof i)?a in t?t[a]=i:!0===i?t.setAttribute(a,""):le(t,a,i):("function"!==typeof o&&null!==o&&(a in t?t[a]=null:t.hasAttribute(a)&&t.removeAttribute(a)),t.addEventListener(e,i,n)))}}function um(t,e,a){switch(e){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":$c("error",t),$c("load",t);var i,n=!1,o=!1;for(i in a)if(a.hasOwnProperty(i)){var r=a[i];if(null!=r)switch(i){case"src":n=!0;break;case"srcSet":o=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(s(137,e));default:cm(t,e,i,r,a,null)}}return o&&cm(t,e,"srcSet",a.srcSet,a,null),void(n&&cm(t,e,"src",a.src,a,null));case"input":$c("invalid",t);var l=i=r=o=null,d=null,c=null;for(n in a)if(a.hasOwnProperty(n)){var m=a[n];if(null!=m)switch(n){case"name":o=m;break;case"type":r=m;break;case"checked":d=m;break;case"defaultChecked":c=m;break;case"value":i=m;break;case"defaultValue":l=m;break;case"children":case"dangerouslySetInnerHTML":if(null!=m)throw Error(s(137,e));break;default:cm(t,e,n,m,a,null)}}return void ve(t,i,l,d,c,r,o,!1);case"select":for(o in $c("invalid",t),n=r=i=null,a)if(a.hasOwnProperty(o)&&null!=(l=a[o]))switch(o){case"value":i=l;break;case"defaultValue":r=l;break;case"multiple":n=l;default:cm(t,e,o,l,a,null)}return e=i,a=r,t.multiple=!!n,void(null!=e?xe(t,!!n,e,!1):null!=a&&xe(t,!!n,a,!0));case"textarea":for(r in $c("invalid",t),i=o=n=null,a)if(a.hasOwnProperty(r)&&null!=(l=a[r]))switch(r){case"value":n=l;break;case"defaultValue":o=l;break;case"children":i=l;break;case"dangerouslySetInnerHTML":if(null!=l)throw Error(s(91));break;default:cm(t,e,r,l,a,null)}return void Ie(t,n,o,i);case"option":for(d in a)if(a.hasOwnProperty(d)&&null!=(n=a[d]))if("selected"===d)t.selected=n&&"function"!==typeof n&&"symbol"!==typeof n;else cm(t,e,d,n,a,null);return;case"dialog":$c("beforetoggle",t),$c("toggle",t),$c("cancel",t),$c("close",t);break;case"iframe":case"object":$c("load",t);break;case"video":case"audio":for(n=0;n<Qc.length;n++)$c(Qc[n],t);break;case"image":$c("error",t),$c("load",t);break;case"details":$c("toggle",t);break;case"embed":case"source":case"link":$c("error",t),$c("load",t);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(c in a)if(a.hasOwnProperty(c)&&null!=(n=a[c]))switch(c){case"children":case"dangerouslySetInnerHTML":throw Error(s(137,e));default:cm(t,e,c,n,a,null)}return;default:if(Pe(e)){for(m in a)a.hasOwnProperty(m)&&(void 0!==(n=a[m])&&mm(t,e,m,n,a,void 0));return}}for(l in a)a.hasOwnProperty(l)&&(null!=(n=a[l])&&cm(t,e,l,n,a,null))}function hm(t){switch(t){case"css":case"script":case"font":case"img":case"image":case"input":case"link":return!0;default:return!1}}var fm=null,gm=null;function pm(t){return 9===t.nodeType?t:t.ownerDocument}function ym(t){switch(t){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function bm(t,e){if(0===t)switch(e){case"svg":return 1;case"math":return 2;default:return 0}return 1===t&&"foreignObject"===e?0:t}function vm(t,e){return"textarea"===t||"noscript"===t||"string"===typeof e.children||"number"===typeof e.children||"bigint"===typeof e.children||"object"===typeof e.dangerouslySetInnerHTML&&null!==e.dangerouslySetInnerHTML&&null!=e.dangerouslySetInnerHTML.__html}var wm=null;var xm="function"===typeof setTimeout?setTimeout:void 0,km="function"===typeof clearTimeout?clearTimeout:void 0,Im="function"===typeof Promise?Promise:void 0,Cm="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof Im?function(t){return Im.resolve(null).then(t).catch(Sm)}:xm;function Sm(t){setTimeout(function(){throw t})}function Am(t){return"head"===t}function Tm(t,e){var a=e,i=0;do{var n=a.nextSibling;if(t.removeChild(a),n&&8===n.nodeType)if("/$"===(a=n.data)||"/&"===a){if(0===i)return t.removeChild(n),void Bu(e);i--}else if("$"===a||"$?"===a||"$~"===a||"$!"===a||"&"===a)i++;else if("html"===a)qm(t.ownerDocument.documentElement);else if("head"===a){qm(a=t.ownerDocument.head);for(var o=a.firstChild;o;){var s=o.nextSibling,r=o.nodeName;o[Kt]||"SCRIPT"===r||"STYLE"===r||"LINK"===r&&"stylesheet"===o.rel.toLowerCase()||a.removeChild(o),o=s}}else"body"===a&&qm(t.ownerDocument.body);a=n}while(a);Bu(e)}function Pm(t,e){var a=t;t=0;do{var i=a.nextSibling;if(1===a.nodeType?e?(a._stashedDisplay=a.style.display,a.style.display="none"):(a.style.display=a._stashedDisplay||"",""===a.getAttribute("style")&&a.removeAttribute("style")):3===a.nodeType&&(e?(a._stashedText=a.nodeValue,a.nodeValue=""):a.nodeValue=a._stashedText||""),i&&8===i.nodeType)if("/$"===(a=i.data)){if(0===t)break;t--}else"$"!==a&&"$?"!==a&&"$~"!==a&&"$!"!==a||t++;a=i}while(a)}function Dm(t){var e=t.firstChild;for(e&&10===e.nodeType&&(e=e.nextSibling);e;){var a=e;switch(e=e.nextSibling,a.nodeName){case"HTML":case"HEAD":case"BODY":Dm(a),Zt(a);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if("stylesheet"===a.rel.toLowerCase())continue}t.removeChild(a)}}function Nm(t,e){for(;8!==t.nodeType;){if((1!==t.nodeType||"INPUT"!==t.nodeName||"hidden"!==t.type)&&!e)return null;if(null===(t=jm(t.nextSibling)))return null}return t}function Lm(t){return"$?"===t.data||"$~"===t.data}function Em(t){return"$!"===t.data||"$?"===t.data&&"loading"!==t.ownerDocument.readyState}function jm(t){for(;null!=t;t=t.nextSibling){var e=t.nodeType;if(1===e||3===e)break;if(8===e){if("$"===(e=t.data)||"$!"===e||"$?"===e||"$~"===e||"&"===e||"F!"===e||"F"===e)break;if("/$"===e||"/&"===e)return null}}return t}var Mm=null;function zm(t){t=t.nextSibling;for(var e=0;t;){if(8===t.nodeType){var a=t.data;if("/$"===a||"/&"===a){if(0===e)return jm(t.nextSibling);e--}else"$"!==a&&"$!"!==a&&"$?"!==a&&"$~"!==a&&"&"!==a||e++}t=t.nextSibling}return null}function Rm(t){t=t.previousSibling;for(var e=0;t;){if(8===t.nodeType){var a=t.data;if("$"===a||"$!"===a||"$?"===a||"$~"===a||"&"===a){if(0===e)return t;e--}else"/$"!==a&&"/&"!==a||e++}t=t.previousSibling}return null}function Fm(t,e,a){switch(e=pm(a),t){case"html":if(!(t=e.documentElement))throw Error(s(452));return t;case"head":if(!(t=e.head))throw Error(s(453));return t;case"body":if(!(t=e.body))throw Error(s(454));return t;default:throw Error(s(451))}}function qm(t){for(var e=t.attributes;e.length;)t.removeAttributeNode(e[0]);Zt(t)}var _m=new Map,Om=new Set;function Um(t){return"function"===typeof t.getRootNode?t.getRootNode():9===t.nodeType?t:t.ownerDocument}var Hm=z.d;z.d={f:function(){var t=Hm.f(),e=Jd();return t||e},r:function(t){var e=Xt(t);null!==e&&5===e.tag&&"form"===e.type?ir(e):Hm.r(t)},D:function(t){Hm.D(t),Bm("dns-prefetch",t,null)},C:function(t,e){Hm.C(t,e),Bm("preconnect",t,e)},L:function(t,e,a){Hm.L(t,e,a);var i=Vm;if(i&&t&&e){var n='link[rel="preload"][as="'+ye(e)+'"]';"image"===e&&a&&a.imageSrcSet?(n+='[imagesrcset="'+ye(a.imageSrcSet)+'"]',"string"===typeof a.imageSizes&&(n+='[imagesizes="'+ye(a.imageSizes)+'"]')):n+='[href="'+ye(t)+'"]';var o=n;switch(e){case"style":o=Wm(t);break;case"script":o=Zm(t)}_m.has(o)||(t=h({rel:"preload",href:"image"===e&&a&&a.imageSrcSet?void 0:t,as:e},a),_m.set(o,t),null!==i.querySelector(n)||"style"===e&&i.querySelector(Qm(o))||"script"===e&&i.querySelector($m(o))||(um(e=i.createElement("link"),"link",t),te(e),i.head.appendChild(e)))}},m:function(t,e){Hm.m(t,e);var a=Vm;if(a&&t){var i=e&&"string"===typeof e.as?e.as:"script",n='link[rel="modulepreload"][as="'+ye(i)+'"][href="'+ye(t)+'"]',o=n;switch(i){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":o=Zm(t)}if(!_m.has(o)&&(t=h({rel:"modulepreload",href:t},e),_m.set(o,t),null===a.querySelector(n))){switch(i){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(a.querySelector($m(o)))return}um(i=a.createElement("link"),"link",t),te(i),a.head.appendChild(i)}}},X:function(t,e){Hm.X(t,e);var a=Vm;if(a&&t){var i=Jt(a).hoistableScripts,n=Zm(t),o=i.get(n);o||((o=a.querySelector($m(n)))||(t=h({src:t,async:!0},e),(e=_m.get(n))&&tu(t,e),te(o=a.createElement("script")),um(o,"link",t),a.head.appendChild(o)),o={type:"script",instance:o,count:1,state:null},i.set(n,o))}},S:function(t,e,a){Hm.S(t,e,a);var i=Vm;if(i&&t){var n=Jt(i).hoistableStyles,o=Wm(t);e=e||"default";var s=n.get(o);if(!s){var r={loading:0,preload:null};if(s=i.querySelector(Qm(o)))r.loading=5;else{t=h({rel:"stylesheet",href:t,"data-precedence":e},a),(a=_m.get(o))&&Jm(t,a);var l=s=i.createElement("link");te(l),um(l,"link",t),l._p=new Promise(function(t,e){l.onload=t,l.onerror=e}),l.addEventListener("load",function(){r.loading|=1}),l.addEventListener("error",function(){r.loading|=2}),r.loading|=4,Ym(s,e,i)}s={type:"stylesheet",instance:s,count:1,state:r},n.set(o,s)}}},M:function(t,e){Hm.M(t,e);var a=Vm;if(a&&t){var i=Jt(a).hoistableScripts,n=Zm(t),o=i.get(n);o||((o=a.querySelector($m(n)))||(t=h({src:t,async:!0,type:"module"},e),(e=_m.get(n))&&tu(t,e),te(o=a.createElement("script")),um(o,"link",t),a.head.appendChild(o)),o={type:"script",instance:o,count:1,state:null},i.set(n,o))}}};var Vm="undefined"===typeof document?null:document;function Bm(t,e,a){var i=Vm;if(i&&"string"===typeof e&&e){var n=ye(e);n='link[rel="'+t+'"][href="'+n+'"]',"string"===typeof a&&(n+='[crossorigin="'+a+'"]'),Om.has(n)||(Om.add(n),t={rel:t,crossOrigin:a,href:e},null===i.querySelector(n)&&(um(e=i.createElement("link"),"link",t),te(e),i.head.appendChild(e)))}}function Gm(t,e,a,i){var n,o,r,l,d=(d=W.current)?Um(d):null;if(!d)throw Error(s(446));switch(t){case"meta":case"title":return null;case"style":return"string"===typeof a.precedence&&"string"===typeof a.href?(e=Wm(a.href),(i=(a=Jt(d).hoistableStyles).get(e))||(i={type:"style",instance:null,count:0,state:null},a.set(e,i)),i):{type:"void",instance:null,count:0,state:null};case"link":if("stylesheet"===a.rel&&"string"===typeof a.href&&"string"===typeof a.precedence){t=Wm(a.href);var c=Jt(d).hoistableStyles,m=c.get(t);if(m||(d=d.ownerDocument||d,m={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},c.set(t,m),(c=d.querySelector(Qm(t)))&&!c._p&&(m.instance=c,m.state.loading=5),_m.has(t)||(a={rel:"preload",as:"style",href:a.href,crossOrigin:a.crossOrigin,integrity:a.integrity,media:a.media,hrefLang:a.hrefLang,referrerPolicy:a.referrerPolicy},_m.set(t,a),c||(n=d,o=t,r=a,l=m.state,n.querySelector('link[rel="preload"][as="style"]['+o+"]")?l.loading=1:(o=n.createElement("link"),l.preload=o,o.addEventListener("load",function(){return l.loading|=1}),o.addEventListener("error",function(){return l.loading|=2}),um(o,"link",r),te(o),n.head.appendChild(o))))),e&&null===i)throw Error(s(528,""));return m}if(e&&null!==i)throw Error(s(529,""));return null;case"script":return e=a.async,"string"===typeof(a=a.src)&&e&&"function"!==typeof e&&"symbol"!==typeof e?(e=Zm(a),(i=(a=Jt(d).hoistableScripts).get(e))||(i={type:"script",instance:null,count:0,state:null},a.set(e,i)),i):{type:"void",instance:null,count:0,state:null};default:throw Error(s(444,t))}}function Wm(t){return'href="'+ye(t)+'"'}function Qm(t){return'link[rel="stylesheet"]['+t+"]"}function Km(t){return h({},t,{"data-precedence":t.precedence,precedence:null})}function Zm(t){return'[src="'+ye(t)+'"]'}function $m(t){return"script[async]"+t}function Xm(t,e,a){if(e.count++,null===e.instance)switch(e.type){case"style":var i=t.querySelector('style[data-href~="'+ye(a.href)+'"]');if(i)return e.instance=i,te(i),i;var n=h({},a,{"data-href":a.href,"data-precedence":a.precedence,href:null,precedence:null});return te(i=(t.ownerDocument||t).createElement("style")),um(i,"style",n),Ym(i,a.precedence,t),e.instance=i;case"stylesheet":n=Wm(a.href);var o=t.querySelector(Qm(n));if(o)return e.state.loading|=4,e.instance=o,te(o),o;i=Km(a),(n=_m.get(n))&&Jm(i,n),te(o=(t.ownerDocument||t).createElement("link"));var r=o;return r._p=new Promise(function(t,e){r.onload=t,r.onerror=e}),um(o,"link",i),e.state.loading|=4,Ym(o,a.precedence,t),e.instance=o;case"script":return o=Zm(a.src),(n=t.querySelector($m(o)))?(e.instance=n,te(n),n):(i=a,(n=_m.get(o))&&tu(i=h({},a),n),te(n=(t=t.ownerDocument||t).createElement("script")),um(n,"link",i),t.head.appendChild(n),e.instance=n);case"void":return null;default:throw Error(s(443,e.type))}else"stylesheet"===e.type&&0===(4&e.state.loading)&&(i=e.instance,e.state.loading|=4,Ym(i,a.precedence,t));return e.instance}function Ym(t,e,a){for(var i=a.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),n=i.length?i[i.length-1]:null,o=n,s=0;s<i.length;s++){var r=i[s];if(r.dataset.precedence===e)o=r;else if(o!==n)break}o?o.parentNode.insertBefore(t,o.nextSibling):(e=9===a.nodeType?a.head:a).insertBefore(t,e.firstChild)}function Jm(t,e){null==t.crossOrigin&&(t.crossOrigin=e.crossOrigin),null==t.referrerPolicy&&(t.referrerPolicy=e.referrerPolicy),null==t.title&&(t.title=e.title)}function tu(t,e){null==t.crossOrigin&&(t.crossOrigin=e.crossOrigin),null==t.referrerPolicy&&(t.referrerPolicy=e.referrerPolicy),null==t.integrity&&(t.integrity=e.integrity)}var eu=null;function au(t,e,a){if(null===eu){var i=new Map,n=eu=new Map;n.set(a,i)}else(i=(n=eu).get(a))||(i=new Map,n.set(a,i));if(i.has(t))return i;for(i.set(t,null),a=a.getElementsByTagName(t),n=0;n<a.length;n++){var o=a[n];if(!(o[Kt]||o[Ut]||"link"===t&&"stylesheet"===o.getAttribute("rel"))&&"http://www.w3.org/2000/svg"!==o.namespaceURI){var s=o.getAttribute(e)||"";s=t+s;var r=i.get(s);r?r.push(o):i.set(s,[o])}}return i}function iu(t,e,a){(t=t.ownerDocument||t).head.insertBefore(a,"title"===e?t.querySelector("head > title"):null)}function nu(t){return"stylesheet"!==t.type||0!==(3&t.state.loading)}var ou=0;function su(){if(this.count--,0===this.count&&(0===this.imgCount||!this.waitingForImages))if(this.stylesheets)lu(this,this.stylesheets);else if(this.unsuspend){var t=this.unsuspend;this.unsuspend=null,t()}}var ru=null;function lu(t,e){t.stylesheets=null,null!==t.unsuspend&&(t.count++,ru=new Map,e.forEach(du,t),ru=null,su.call(t))}function du(t,e){if(!(4&e.state.loading)){var a=ru.get(t);if(a)var i=a.get(null);else{a=new Map,ru.set(t,a);for(var n=t.querySelectorAll("link[data-precedence],style[data-precedence]"),o=0;o<n.length;o++){var s=n[o];"LINK"!==s.nodeName&&"not all"===s.getAttribute("media")||(a.set(s.dataset.precedence,s),i=s)}i&&a.set(null,i)}s=(n=e.instance).getAttribute("data-precedence"),(o=a.get(s)||i)===i&&a.set(null,n),a.set(s,n),this.count++,i=su.bind(this),n.addEventListener("load",i),n.addEventListener("error",i),o?o.parentNode.insertBefore(n,o.nextSibling):(t=9===t.nodeType?t.head:t).insertBefore(n,t.firstChild),e.state.loading|=4}}var cu={$$typeof:x,Provider:null,Consumer:null,_currentValue:R,_currentValue2:R,_threadCount:0};function mu(t,e,a,i,n,o,s,r,l){this.tag=1,this.containerInfo=t,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=Lt(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=Lt(0),this.hiddenUpdates=Lt(null),this.identifierPrefix=i,this.onUncaughtError=n,this.onCaughtError=o,this.onRecoverableError=s,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=l,this.incompleteTransitions=new Map}function uu(t,e,a,i,n,o,s,r,l,d,c,m){return t=new mu(t,e,a,s,l,d,c,m,r),e=1,!0===o&&(e|=24),o=Fi(3,null,null,e),t.current=o,o.stateNode=t,(e=_n()).refCount++,t.pooledCache=e,e.refCount++,o.memoizedState={element:i,isDehydrated:a,cache:e},yo(o),t}function hu(t){return t?t=zi:zi}function fu(t,e,a,i,n,o){n=hu(n),null===i.context?i.context=n:i.pendingContext=n,(i=vo(e)).payload={element:a},null!==(o=void 0===o?null:o)&&(i.callback=o),null!==(a=wo(t,i,e))&&(Kd(a,0,e),xo(a,t,e))}function gu(t,e){if(null!==(t=t.memoizedState)&&null!==t.dehydrated){var a=t.retryLane;t.retryLane=0!==a&&a<e?a:e}}function pu(t,e){gu(t,e),(t=t.alternate)&&gu(t,e)}function yu(t){if(13===t.tag||31===t.tag){var e=Ei(t,67108864);null!==e&&Kd(e,0,67108864),pu(t,67108864)}}function bu(t){if(13===t.tag||31===t.tag){var e=Wd(),a=Ei(t,e=Rt(e));null!==a&&Kd(a,0,e),pu(t,e)}}var vu=!0;function wu(t,e,a,i){var n=M.T;M.T=null;var o=z.p;try{z.p=2,ku(t,e,a,i)}finally{z.p=o,M.T=n}}function xu(t,e,a,i){var n=M.T;M.T=null;var o=z.p;try{z.p=8,ku(t,e,a,i)}finally{z.p=o,M.T=n}}function ku(t,e,a,i){if(vu){var n=Iu(i);if(null===n)em(t,e,i,Cu,a),zu(t,i);else if(function(t,e,a,i,n){switch(e){case"focusin":return Pu=Ru(Pu,t,e,a,i,n),!0;case"dragenter":return Du=Ru(Du,t,e,a,i,n),!0;case"mouseover":return Nu=Ru(Nu,t,e,a,i,n),!0;case"pointerover":var o=n.pointerId;return Lu.set(o,Ru(Lu.get(o)||null,t,e,a,i,n)),!0;case"gotpointercapture":return o=n.pointerId,Eu.set(o,Ru(Eu.get(o)||null,t,e,a,i,n)),!0}return!1}(n,t,e,a,i))i.stopPropagation();else if(zu(t,i),4&e&&-1<Mu.indexOf(t)){for(;null!==n;){var o=Xt(n);if(null!==o)switch(o.tag){case 3:if((o=o.stateNode).current.memoizedState.isDehydrated){var s=At(o.pendingLanes);if(0!==s){var r=o;for(r.pendingLanes|=2,r.entangledLanes|=2;s;){var l=1<<31-wt(s);r.entanglements[1]|=l,s&=~l}zc(o),0===(6&hd)&&(Md=lt()+500,Rc(0,!1))}}break;case 31:case 13:null!==(r=Ei(o,2))&&Kd(r,0,2),Jd(),pu(o,2)}if(null===(o=Iu(i))&&em(t,e,i,Cu,a),o===n)break;n=o}null!==n&&i.stopPropagation()}else em(t,e,i,null,a)}}function Iu(t){return Su(t=Me(t))}var Cu=null;function Su(t){if(Cu=null,null!==(t=$t(t))){var e=l(t);if(null===e)t=null;else{var a=e.tag;if(13===a){if(null!==(t=d(e)))return t;t=null}else if(31===a){if(null!==(t=c(e)))return t;t=null}else if(3===a){if(e.stateNode.current.memoizedState.isDehydrated)return 3===e.tag?e.stateNode.containerInfo:null;t=null}else e!==t&&(t=null)}}return Cu=t,null}function Au(t){switch(t){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(dt()){case ct:return 2;case mt:return 8;case ut:case ht:return 32;case ft:return 268435456;default:return 32}default:return 32}}var Tu=!1,Pu=null,Du=null,Nu=null,Lu=new Map,Eu=new Map,ju=[],Mu="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function zu(t,e){switch(t){case"focusin":case"focusout":Pu=null;break;case"dragenter":case"dragleave":Du=null;break;case"mouseover":case"mouseout":Nu=null;break;case"pointerover":case"pointerout":Lu.delete(e.pointerId);break;case"gotpointercapture":case"lostpointercapture":Eu.delete(e.pointerId)}}function Ru(t,e,a,i,n,o){return null===t||t.nativeEvent!==o?(t={blockedOn:e,domEventName:a,eventSystemFlags:i,nativeEvent:o,targetContainers:[n]},null!==e&&(null!==(e=Xt(e))&&yu(e)),t):(t.eventSystemFlags|=i,e=t.targetContainers,null!==n&&-1===e.indexOf(n)&&e.push(n),t)}function Fu(t){var e=$t(t.target);if(null!==e){var a=l(e);if(null!==a)if(13===(e=a.tag)){if(null!==(e=d(a)))return t.blockedOn=e,void _t(t.priority,function(){bu(a)})}else if(31===e){if(null!==(e=c(a)))return t.blockedOn=e,void _t(t.priority,function(){bu(a)})}else if(3===e&&a.stateNode.current.memoizedState.isDehydrated)return void(t.blockedOn=3===a.tag?a.stateNode.containerInfo:null)}t.blockedOn=null}function qu(t){if(null!==t.blockedOn)return!1;for(var e=t.targetContainers;0<e.length;){var a=Iu(t.nativeEvent);if(null!==a)return null!==(e=Xt(a))&&yu(e),t.blockedOn=a,!1;var i=new(a=t.nativeEvent).constructor(a.type,a);je=i,a.target.dispatchEvent(i),je=null,e.shift()}return!0}function _u(t,e,a){qu(t)&&a.delete(e)}function Ou(){Tu=!1,null!==Pu&&qu(Pu)&&(Pu=null),null!==Du&&qu(Du)&&(Du=null),null!==Nu&&qu(Nu)&&(Nu=null),Lu.forEach(_u),Eu.forEach(_u)}function Uu(t,e){t.blockedOn===e&&(t.blockedOn=null,Tu||(Tu=!0,i.unstable_scheduleCallback(i.unstable_NormalPriority,Ou)))}var Hu=null;function Vu(t){Hu!==t&&(Hu=t,i.unstable_scheduleCallback(i.unstable_NormalPriority,function(){Hu===t&&(Hu=null);for(var e=0;e<t.length;e+=3){var a=t[e],i=t[e+1],n=t[e+2];if("function"!==typeof i){if(null===Su(i||a))continue;break}var o=Xt(a);null!==o&&(t.splice(e,3),e-=3,er(o,{pending:!0,data:n,method:a.method,action:i},i,n))}}))}function Bu(t){function e(e){return Uu(e,t)}null!==Pu&&Uu(Pu,t),null!==Du&&Uu(Du,t),null!==Nu&&Uu(Nu,t),Lu.forEach(e),Eu.forEach(e);for(var a=0;a<ju.length;a++){var i=ju[a];i.blockedOn===t&&(i.blockedOn=null)}for(;0<ju.length&&null===(a=ju[0]).blockedOn;)Fu(a),null===a.blockedOn&&ju.shift();if(null!=(a=(t.ownerDocument||t).$$reactFormReplay))for(i=0;i<a.length;i+=3){var n=a[i],o=a[i+1],s=n[Ht]||null;if("function"===typeof o)s||Vu(a);else if(s){var r=null;if(o&&o.hasAttribute("formAction")){if(n=o,s=o[Ht]||null)r=s.formAction;else if(null!==Su(n))continue}else r=s.action;"function"===typeof r?a[i+1]=r:(a.splice(i,3),i-=3),Vu(a)}}}function Gu(){function t(t){t.canIntercept&&"react-transition"===t.info&&t.intercept({handler:function(){return new Promise(function(t){return n=t})},focusReset:"manual",scroll:"manual"})}function e(){null!==n&&(n(),n=null),i||setTimeout(a,20)}function a(){if(!i&&!navigation.transition){var t=navigation.currentEntry;t&&null!=t.url&&navigation.navigate(t.url,{state:t.getState(),info:"react-transition",history:"replace"})}}if("object"===typeof navigation){var i=!1,n=null;return navigation.addEventListener("navigate",t),navigation.addEventListener("navigatesuccess",e),navigation.addEventListener("navigateerror",e),setTimeout(a,100),function(){i=!0,navigation.removeEventListener("navigate",t),navigation.removeEventListener("navigatesuccess",e),navigation.removeEventListener("navigateerror",e),null!==n&&(n(),n=null)}}}function Wu(t){this._internalRoot=t}function Qu(t){this._internalRoot=t}Qu.prototype.render=Wu.prototype.render=function(t){var e=this._internalRoot;if(null===e)throw Error(s(409));fu(e.current,Wd(),t,e,null,null)},Qu.prototype.unmount=Wu.prototype.unmount=function(){var t=this._internalRoot;if(null!==t){this._internalRoot=null;var e=t.containerInfo;fu(t.current,2,null,t,null,null),Jd(),e[Vt]=null}},Qu.prototype.unstable_scheduleHydration=function(t){if(t){var e=qt();t={blockedOn:null,target:t,priority:e};for(var a=0;a<ju.length&&0!==e&&e<ju[a].priority;a++);ju.splice(a,0,t),0===a&&Fu(t)}};var Ku=n.version;if("19.2.3"!==Ku)throw Error(s(527,Ku,"19.2.3"));z.findDOMNode=function(t){var e=t._reactInternals;if(void 0===e){if("function"===typeof t.render)throw Error(s(188));throw t=Object.keys(t).join(","),Error(s(268,t))}return t=function(t){var e=t.alternate;if(!e){if(null===(e=l(t)))throw Error(s(188));return e!==t?null:t}for(var a=t,i=e;;){var n=a.return;if(null===n)break;var o=n.alternate;if(null===o){if(null!==(i=n.return)){a=i;continue}break}if(n.child===o.child){for(o=n.child;o;){if(o===a)return m(n),t;if(o===i)return m(n),e;o=o.sibling}throw Error(s(188))}if(a.return!==i.return)a=n,i=o;else{for(var r=!1,d=n.child;d;){if(d===a){r=!0,a=n,i=o;break}if(d===i){r=!0,i=n,a=o;break}d=d.sibling}if(!r){for(d=o.child;d;){if(d===a){r=!0,a=o,i=n;break}if(d===i){r=!0,i=o,a=n;break}d=d.sibling}if(!r)throw Error(s(189))}}if(a.alternate!==i)throw Error(s(190))}if(3!==a.tag)throw Error(s(188));return a.stateNode.current===a?t:e}(e),t=null===(t=null!==t?u(t):null)?null:t.stateNode};var Zu={bundleType:0,version:"19.2.3",rendererPackageName:"react-dom",currentDispatcherRef:M,reconcilerVersion:"19.2.3"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var $u=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!$u.isDisabled&&$u.supportsFiber)try{yt=$u.inject(Zu),bt=$u}catch(Yu){}}e.createRoot=function(t,e){if(!r(t))throw Error(s(299));var a=!1,i="",n=Cr,o=Sr,l=Ar;return null!==e&&void 0!==e&&(!0===e.unstable_strictMode&&(a=!0),void 0!==e.identifierPrefix&&(i=e.identifierPrefix),void 0!==e.onUncaughtError&&(n=e.onUncaughtError),void 0!==e.onCaughtError&&(o=e.onCaughtError),void 0!==e.onRecoverableError&&(l=e.onRecoverableError)),e=uu(t,1,!1,null,0,a,i,null,n,o,l,Gu),t[Vt]=e.current,Jc(t),new Wu(e)},e.hydrateRoot=function(t,e,a){if(!r(t))throw Error(s(299));var i=!1,n="",o=Cr,l=Sr,d=Ar,c=null;return null!==a&&void 0!==a&&(!0===a.unstable_strictMode&&(i=!0),void 0!==a.identifierPrefix&&(n=a.identifierPrefix),void 0!==a.onUncaughtError&&(o=a.onUncaughtError),void 0!==a.onCaughtError&&(l=a.onCaughtError),void 0!==a.onRecoverableError&&(d=a.onRecoverableError),void 0!==a.formState&&(c=a.formState)),(e=uu(t,1,!0,e,0,i,n,c,o,l,d,Gu)).context=hu(null),a=e.current,(n=vo(i=Rt(i=Wd()))).callback=null,wo(a,n,i),a=i,e.current.lanes=a,Et(e,a),zc(e),t[Vt]=e.current,Jc(t),new Qu(e)},e.version="19.2.3"},43(t,e,a){"use strict";t.exports=a(288)},67(t,e,a){t=a.nmd(t);var i="__lodash_hash_undefined__",n=9007199254740991,o="[object Arguments]",s="[object Array]",r="[object Boolean]",l="[object Date]",d="[object Error]",c="[object Function]",m="[object Map]",u="[object Number]",h="[object Object]",f="[object Promise]",g="[object RegExp]",p="[object Set]",y="[object String]",b="[object Symbol]",v="[object WeakMap]",w="[object ArrayBuffer]",x="[object DataView]",k=/^\[object .+?Constructor\]$/,I=/^(?:0|[1-9]\d*)$/,C={};C["[object Float32Array]"]=C["[object Float64Array]"]=C["[object Int8Array]"]=C["[object Int16Array]"]=C["[object Int32Array]"]=C["[object Uint8Array]"]=C["[object Uint8ClampedArray]"]=C["[object Uint16Array]"]=C["[object Uint32Array]"]=!0,C[o]=C[s]=C[w]=C[r]=C[x]=C[l]=C[d]=C[c]=C[m]=C[u]=C[h]=C[g]=C[p]=C[y]=C[v]=!1;var S="object"==typeof a.g&&a.g&&a.g.Object===Object&&a.g,A="object"==typeof self&&self&&self.Object===Object&&self,T=S||A||Function("return this")(),P=e&&!e.nodeType&&e,D=P&&t&&!t.nodeType&&t,N=D&&D.exports===P,L=N&&S.process,E=function(){try{return L&&L.binding&&L.binding("util")}catch(t){}}(),j=E&&E.isTypedArray;function M(t,e){for(var a=-1,i=null==t?0:t.length;++a<i;)if(e(t[a],a,t))return!0;return!1}function z(t){var e=-1,a=Array(t.size);return t.forEach(function(t,i){a[++e]=[i,t]}),a}function R(t){var e=-1,a=Array(t.size);return t.forEach(function(t){a[++e]=t}),a}var F,q,_=Array.prototype,O=Function.prototype,U=Object.prototype,H=T["__core-js_shared__"],V=O.toString,B=U.hasOwnProperty,G=function(){var t=/[^.]+$/.exec(H&&H.keys&&H.keys.IE_PROTO||"");return t?"Symbol(src)_1."+t:""}(),W=U.toString,Q=RegExp("^"+V.call(B).replace(/[\\^$.*+?()[\]{}|]/g,"\\$&").replace(/hasOwnProperty|(function).*?(?=\\\()| for .+?(?=\\\])/g,"$1.*?")+"$"),K=N?T.Buffer:void 0,Z=T.Symbol,$=T.Uint8Array,X=U.propertyIsEnumerable,Y=_.splice,J=Z?Z.toStringTag:void 0,tt=Object.getOwnPropertySymbols,et=K?K.isBuffer:void 0,at=(F=Object.keys,q=Object,function(t){return F(q(t))}),it=Lt(T,"DataView"),nt=Lt(T,"Map"),ot=Lt(T,"Promise"),st=Lt(T,"Set"),rt=Lt(T,"WeakMap"),lt=Lt(Object,"create"),dt=zt(it),ct=zt(nt),mt=zt(ot),ut=zt(st),ht=zt(rt),ft=Z?Z.prototype:void 0,gt=ft?ft.valueOf:void 0;function pt(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function yt(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function bt(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function vt(t){var e=-1,a=null==t?0:t.length;for(this.__data__=new bt;++e<a;)this.add(t[e])}function wt(t){var e=this.__data__=new yt(t);this.size=e.size}function xt(t,e){var a=qt(t),i=!a&&Ft(t),n=!a&&!i&&_t(t),o=!a&&!i&&!n&&Bt(t),s=a||i||n||o,r=s?function(t,e){for(var a=-1,i=Array(t);++a<t;)i[a]=e(a);return i}(t.length,String):[],l=r.length;for(var d in t)!e&&!B.call(t,d)||s&&("length"==d||n&&("offset"==d||"parent"==d)||o&&("buffer"==d||"byteLength"==d||"byteOffset"==d)||Mt(d,l))||r.push(d);return r}function kt(t,e){for(var a=t.length;a--;)if(Rt(t[a][0],e))return a;return-1}function It(t){return null==t?void 0===t?"[object Undefined]":"[object Null]":J&&J in Object(t)?function(t){var e=B.call(t,J),a=t[J];try{t[J]=void 0;var i=!0}catch(o){}var n=W.call(t);i&&(e?t[J]=a:delete t[J]);return n}(t):function(t){return W.call(t)}(t)}function Ct(t){return Vt(t)&&It(t)==o}function St(t,e,a,i,n){return t===e||(null==t||null==e||!Vt(t)&&!Vt(e)?t!==t&&e!==e:function(t,e,a,i,n,c){var f=qt(t),v=qt(e),k=f?s:jt(t),I=v?s:jt(e),C=(k=k==o?h:k)==h,S=(I=I==o?h:I)==h,A=k==I;if(A&&_t(t)){if(!_t(e))return!1;f=!0,C=!1}if(A&&!C)return c||(c=new wt),f||Bt(t)?Pt(t,e,a,i,n,c):function(t,e,a,i,n,o,s){switch(a){case x:if(t.byteLength!=e.byteLength||t.byteOffset!=e.byteOffset)return!1;t=t.buffer,e=e.buffer;case w:return!(t.byteLength!=e.byteLength||!o(new $(t),new $(e)));case r:case l:case u:return Rt(+t,+e);case d:return t.name==e.name&&t.message==e.message;case g:case y:return t==e+"";case m:var c=z;case p:var h=1&i;if(c||(c=R),t.size!=e.size&&!h)return!1;var f=s.get(t);if(f)return f==e;i|=2,s.set(t,e);var v=Pt(c(t),c(e),i,n,o,s);return s.delete(t),v;case b:if(gt)return gt.call(t)==gt.call(e)}return!1}(t,e,k,a,i,n,c);if(!(1&a)){var T=C&&B.call(t,"__wrapped__"),P=S&&B.call(e,"__wrapped__");if(T||P){var D=T?t.value():t,N=P?e.value():e;return c||(c=new wt),n(D,N,a,i,c)}}if(!A)return!1;return c||(c=new wt),function(t,e,a,i,n,o){var s=1&a,r=Dt(t),l=r.length,d=Dt(e),c=d.length;if(l!=c&&!s)return!1;var m=l;for(;m--;){var u=r[m];if(!(s?u in e:B.call(e,u)))return!1}var h=o.get(t);if(h&&o.get(e))return h==e;var f=!0;o.set(t,e),o.set(e,t);var g=s;for(;++m<l;){var p=t[u=r[m]],y=e[u];if(i)var b=s?i(y,p,u,e,t,o):i(p,y,u,t,e,o);if(!(void 0===b?p===y||n(p,y,a,i,o):b)){f=!1;break}g||(g="constructor"==u)}if(f&&!g){var v=t.constructor,w=e.constructor;v==w||!("constructor"in t)||!("constructor"in e)||"function"==typeof v&&v instanceof v&&"function"==typeof w&&w instanceof w||(f=!1)}return o.delete(t),o.delete(e),f}(t,e,a,i,n,c)}(t,e,a,i,St,n))}function At(t){return!(!Ht(t)||function(t){return!!G&&G in t}(t))&&(Ot(t)?Q:k).test(zt(t))}function Tt(t){if(!function(t){var e=t&&t.constructor,a="function"==typeof e&&e.prototype||U;return t===a}(t))return at(t);var e=[];for(var a in Object(t))B.call(t,a)&&"constructor"!=a&&e.push(a);return e}function Pt(t,e,a,i,n,o){var s=1&a,r=t.length,l=e.length;if(r!=l&&!(s&&l>r))return!1;var d=o.get(t);if(d&&o.get(e))return d==e;var c=-1,m=!0,u=2&a?new vt:void 0;for(o.set(t,e),o.set(e,t);++c<r;){var h=t[c],f=e[c];if(i)var g=s?i(f,h,c,e,t,o):i(h,f,c,t,e,o);if(void 0!==g){if(g)continue;m=!1;break}if(u){if(!M(e,function(t,e){if(s=e,!u.has(s)&&(h===t||n(h,t,a,i,o)))return u.push(e);var s})){m=!1;break}}else if(h!==f&&!n(h,f,a,i,o)){m=!1;break}}return o.delete(t),o.delete(e),m}function Dt(t){return function(t,e,a){var i=e(t);return qt(t)?i:function(t,e){for(var a=-1,i=e.length,n=t.length;++a<i;)t[n+a]=e[a];return t}(i,a(t))}(t,Gt,Et)}function Nt(t,e){var a=t.__data__;return function(t){var e=typeof t;return"string"==e||"number"==e||"symbol"==e||"boolean"==e?"__proto__"!==t:null===t}(e)?a["string"==typeof e?"string":"hash"]:a.map}function Lt(t,e){var a=function(t,e){return null==t?void 0:t[e]}(t,e);return At(a)?a:void 0}pt.prototype.clear=function(){this.__data__=lt?lt(null):{},this.size=0},pt.prototype.delete=function(t){var e=this.has(t)&&delete this.__data__[t];return this.size-=e?1:0,e},pt.prototype.get=function(t){var e=this.__data__;if(lt){var a=e[t];return a===i?void 0:a}return B.call(e,t)?e[t]:void 0},pt.prototype.has=function(t){var e=this.__data__;return lt?void 0!==e[t]:B.call(e,t)},pt.prototype.set=function(t,e){var a=this.__data__;return this.size+=this.has(t)?0:1,a[t]=lt&&void 0===e?i:e,this},yt.prototype.clear=function(){this.__data__=[],this.size=0},yt.prototype.delete=function(t){var e=this.__data__,a=kt(e,t);return!(a<0)&&(a==e.length-1?e.pop():Y.call(e,a,1),--this.size,!0)},yt.prototype.get=function(t){var e=this.__data__,a=kt(e,t);return a<0?void 0:e[a][1]},yt.prototype.has=function(t){return kt(this.__data__,t)>-1},yt.prototype.set=function(t,e){var a=this.__data__,i=kt(a,t);return i<0?(++this.size,a.push([t,e])):a[i][1]=e,this},bt.prototype.clear=function(){this.size=0,this.__data__={hash:new pt,map:new(nt||yt),string:new pt}},bt.prototype.delete=function(t){var e=Nt(this,t).delete(t);return this.size-=e?1:0,e},bt.prototype.get=function(t){return Nt(this,t).get(t)},bt.prototype.has=function(t){return Nt(this,t).has(t)},bt.prototype.set=function(t,e){var a=Nt(this,t),i=a.size;return a.set(t,e),this.size+=a.size==i?0:1,this},vt.prototype.add=vt.prototype.push=function(t){return this.__data__.set(t,i),this},vt.prototype.has=function(t){return this.__data__.has(t)},wt.prototype.clear=function(){this.__data__=new yt,this.size=0},wt.prototype.delete=function(t){var e=this.__data__,a=e.delete(t);return this.size=e.size,a},wt.prototype.get=function(t){return this.__data__.get(t)},wt.prototype.has=function(t){return this.__data__.has(t)},wt.prototype.set=function(t,e){var a=this.__data__;if(a instanceof yt){var i=a.__data__;if(!nt||i.length<199)return i.push([t,e]),this.size=++a.size,this;a=this.__data__=new bt(i)}return a.set(t,e),this.size=a.size,this};var Et=tt?function(t){return null==t?[]:(t=Object(t),function(t,e){for(var a=-1,i=null==t?0:t.length,n=0,o=[];++a<i;){var s=t[a];e(s,a,t)&&(o[n++]=s)}return o}(tt(t),function(e){return X.call(t,e)}))}:function(){return[]},jt=It;function Mt(t,e){return!!(e=null==e?n:e)&&("number"==typeof t||I.test(t))&&t>-1&&t%1==0&&t<e}function zt(t){if(null!=t){try{return V.call(t)}catch(e){}try{return t+""}catch(e){}}return""}function Rt(t,e){return t===e||t!==t&&e!==e}(it&&jt(new it(new ArrayBuffer(1)))!=x||nt&&jt(new nt)!=m||ot&&jt(ot.resolve())!=f||st&&jt(new st)!=p||rt&&jt(new rt)!=v)&&(jt=function(t){var e=It(t),a=e==h?t.constructor:void 0,i=a?zt(a):"";if(i)switch(i){case dt:return x;case ct:return m;case mt:return f;case ut:return p;case ht:return v}return e});var Ft=Ct(function(){return arguments}())?Ct:function(t){return Vt(t)&&B.call(t,"callee")&&!X.call(t,"callee")},qt=Array.isArray;var _t=et||function(){return!1};function Ot(t){if(!Ht(t))return!1;var e=It(t);return e==c||"[object GeneratorFunction]"==e||"[object AsyncFunction]"==e||"[object Proxy]"==e}function Ut(t){return"number"==typeof t&&t>-1&&t%1==0&&t<=n}function Ht(t){var e=typeof t;return null!=t&&("object"==e||"function"==e)}function Vt(t){return null!=t&&"object"==typeof t}var Bt=j?function(t){return function(e){return t(e)}}(j):function(t){return Vt(t)&&Ut(t.length)&&!!C[It(t)]};function Gt(t){return null!=(e=t)&&Ut(e.length)&&!Ot(e)?xt(t):Tt(t);var e}t.exports=function(t,e){return St(t,e)}},100(t,e){"use strict";var a;Object.defineProperty(e,"__esModule",{value:!0}),function(t){t.length=function(t){return"number"===typeof t.delete?t.delete:"number"===typeof t.retain?t.retain:"object"===typeof t.retain&&null!==t.retain?1:"string"===typeof t.insert?t.insert.length:1}}(a||(a={})),e.default=a},249(t,e,a){"use strict";Object.defineProperty(e,"__esModule",{value:!0}),e.AttributeMap=e.OpIterator=e.Op=void 0;const i=a(551),n=a(992),o=a(67),s=a(785);e.AttributeMap=s.default;const r=a(100);e.Op=r.default;const l=a(646);e.OpIterator=l.default;const d=String.fromCharCode(0),c=(t,e)=>{if("object"!==typeof t||null===t)throw new Error("cannot retain a ".concat(typeof t));if("object"!==typeof e||null===e)throw new Error("cannot retain a ".concat(typeof e));const a=Object.keys(t)[0];if(!a||a!==Object.keys(e)[0])throw new Error("embed types not matched: ".concat(a," != ").concat(Object.keys(e)[0]));return[a,t[a],e[a]]};class m{constructor(t){Array.isArray(t)?this.ops=t:null!=t&&Array.isArray(t.ops)?this.ops=t.ops:this.ops=[]}static registerEmbed(t,e){this.handlers[t]=e}static unregisterEmbed(t){delete this.handlers[t]}static getHandler(t){const e=this.handlers[t];if(!e)throw new Error('no handlers for embed type "'.concat(t,'"'));return e}insert(t,e){const a={};return"string"===typeof t&&0===t.length?this:(a.insert=t,null!=e&&"object"===typeof e&&Object.keys(e).length>0&&(a.attributes=e),this.push(a))}delete(t){return t<=0?this:this.push({delete:t})}retain(t,e){if("number"===typeof t&&t<=0)return this;const a={retain:t};return null!=e&&"object"===typeof e&&Object.keys(e).length>0&&(a.attributes=e),this.push(a)}push(t){let e=this.ops.length,a=this.ops[e-1];if(t=n(t),"object"===typeof a){if("number"===typeof t.delete&&"number"===typeof a.delete)return this.ops[e-1]={delete:a.delete+t.delete},this;if("number"===typeof a.delete&&null!=t.insert&&(e-=1,a=this.ops[e-1],"object"!==typeof a))return this.ops.unshift(t),this;if(o(t.attributes,a.attributes)){if("string"===typeof t.insert&&"string"===typeof a.insert)return this.ops[e-1]={insert:a.insert+t.insert},"object"===typeof t.attributes&&(this.ops[e-1].attributes=t.attributes),this;if("number"===typeof t.retain&&"number"===typeof a.retain)return this.ops[e-1]={retain:a.retain+t.retain},"object"===typeof t.attributes&&(this.ops[e-1].attributes=t.attributes),this}}return e===this.ops.length?this.ops.push(t):this.ops.splice(e,0,t),this}chop(){const t=this.ops[this.ops.length-1];return t&&"number"===typeof t.retain&&!t.attributes&&this.ops.pop(),this}filter(t){return this.ops.filter(t)}forEach(t){this.ops.forEach(t)}map(t){return this.ops.map(t)}partition(t){const e=[],a=[];return this.forEach(i=>{(t(i)?e:a).push(i)}),[e,a]}reduce(t,e){return this.ops.reduce(t,e)}changeLength(){return this.reduce((t,e)=>e.insert?t+r.default.length(e):e.delete?t-e.delete:t,0)}length(){return this.reduce((t,e)=>t+r.default.length(e),0)}slice(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:1/0;const a=[],i=new l.default(this.ops);let n=0;for(;n<e&&i.hasNext();){let o;n<t?o=i.next(t-n):(o=i.next(e-n),a.push(o)),n+=r.default.length(o)}return new m(a)}compose(t){const e=new l.default(this.ops),a=new l.default(t.ops),i=[],n=a.peek();if(null!=n&&"number"===typeof n.retain&&null==n.attributes){let t=n.retain;for(;"insert"===e.peekType()&&e.peekLength()<=t;)t-=e.peekLength(),i.push(e.next());n.retain-t>0&&a.next(n.retain-t)}const r=new m(i);for(;e.hasNext()||a.hasNext();)if("insert"===a.peekType())r.push(a.next());else if("delete"===e.peekType())r.push(e.next());else{const t=Math.min(e.peekLength(),a.peekLength()),i=e.next(t),n=a.next(t);if(n.retain){const l={};if("number"===typeof i.retain)l.retain="number"===typeof n.retain?t:n.retain;else if("number"===typeof n.retain)null==i.retain?l.insert=i.insert:l.retain=i.retain;else{const t=null==i.retain?"insert":"retain",[e,a,o]=c(i[t],n.retain),s=m.getHandler(e);l[t]={[e]:s.compose(a,o,"retain"===t)}}const d=s.default.compose(i.attributes,n.attributes,"number"===typeof i.retain);if(d&&(l.attributes=d),r.push(l),!a.hasNext()&&o(r.ops[r.ops.length-1],l)){const t=new m(e.rest());return r.concat(t).chop()}}else"number"===typeof n.delete&&("number"===typeof i.retain||"object"===typeof i.retain&&null!==i.retain)&&r.push(n)}return r.chop()}concat(t){const e=new m(this.ops.slice());return t.ops.length>0&&(e.push(t.ops[0]),e.ops=e.ops.concat(t.ops.slice(1))),e}diff(t,e){if(this.ops===t.ops)return new m;const a=[this,t].map(e=>e.map(a=>{if(null!=a.insert)return"string"===typeof a.insert?a.insert:d;throw new Error("diff() called "+(e===t?"on":"with")+" non-document")}).join("")),n=new m,r=i(a[0],a[1],e,!0),c=new l.default(this.ops),u=new l.default(t.ops);return r.forEach(t=>{let e=t[1].length;for(;e>0;){let a=0;switch(t[0]){case i.INSERT:a=Math.min(u.peekLength(),e),n.push(u.next(a));break;case i.DELETE:a=Math.min(e,c.peekLength()),c.next(a),n.delete(a);break;case i.EQUAL:a=Math.min(c.peekLength(),u.peekLength(),e);const t=c.next(a),r=u.next(a);o(t.insert,r.insert)?n.retain(a,s.default.diff(t.attributes,r.attributes)):n.push(r).delete(a)}e-=a}}),n.chop()}eachLine(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"\n";const a=new l.default(this.ops);let i=new m,n=0;for(;a.hasNext();){if("insert"!==a.peekType())return;const o=a.peek(),s=r.default.length(o)-a.peekLength(),l="string"===typeof o.insert?o.insert.indexOf(e,s)-s:-1;if(l<0)i.push(a.next());else if(l>0)i.push(a.next(l));else{if(!1===t(i,a.next(1).attributes||{},n))return;n+=1,i=new m}}i.length()>0&&t(i,{},n)}invert(t){const e=new m;return this.reduce((a,i)=>{if(i.insert)e.delete(r.default.length(i));else{if("number"===typeof i.retain&&null==i.attributes)return e.retain(i.retain),a+i.retain;if(i.delete||"number"===typeof i.retain){const n=i.delete||i.retain;return t.slice(a,a+n).forEach(t=>{i.delete?e.push(t):i.retain&&i.attributes&&e.retain(r.default.length(t),s.default.invert(i.attributes,t.attributes))}),a+n}if("object"===typeof i.retain&&null!==i.retain){const n=t.slice(a,a+1),o=new l.default(n.ops).next(),[r,d,u]=c(i.retain,o.insert),h=m.getHandler(r);return e.retain({[r]:h.invert(d,u)},s.default.invert(i.attributes,o.attributes)),a+1}}return a},0),e.chop()}transform(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(e=!!e,"number"===typeof t)return this.transformPosition(t,e);const a=t,i=new l.default(this.ops),n=new l.default(a.ops),o=new m;for(;i.hasNext()||n.hasNext();)if("insert"!==i.peekType()||!e&&"insert"===n.peekType())if("insert"===n.peekType())o.push(n.next());else{const t=Math.min(i.peekLength(),n.peekLength()),a=i.next(t),r=n.next(t);if(a.delete)continue;if(r.delete)o.push(r);else{const i=a.retain,n=r.retain;let l="object"===typeof n&&null!==n?n:t;if("object"===typeof i&&null!==i&&"object"===typeof n&&null!==n){const t=Object.keys(i)[0];if(t===Object.keys(n)[0]){const a=m.getHandler(t);a&&(l={[t]:a.transform(i[t],n[t],e)})}}o.retain(l,s.default.transform(a.attributes,r.attributes,e))}}else o.retain(r.default.length(i.next()));return o.chop()}transformPosition(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];e=!!e;const a=new l.default(this.ops);let i=0;for(;a.hasNext()&&i<=t;){const n=a.peekLength(),o=a.peekType();a.next(),"delete"!==o?("insert"===o&&(i<t||!e)&&(t+=n),i+=n):t-=Math.min(n,t-i)}return t}}m.Op=r.default,m.OpIterator=l.default,m.AttributeMap=s.default,m.handlers={},e.default=m,t.exports=m,t.exports.default=m},288(t,e){"use strict";var a=Symbol.for("react.transitional.element"),i=Symbol.for("react.portal"),n=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),s=Symbol.for("react.profiler"),r=Symbol.for("react.consumer"),l=Symbol.for("react.context"),d=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),m=Symbol.for("react.memo"),u=Symbol.for("react.lazy"),h=Symbol.for("react.activity"),f=Symbol.iterator;var g={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},p=Object.assign,y={};function b(t,e,a){this.props=t,this.context=e,this.refs=y,this.updater=a||g}function v(){}function w(t,e,a){this.props=t,this.context=e,this.refs=y,this.updater=a||g}b.prototype.isReactComponent={},b.prototype.setState=function(t,e){if("object"!==typeof t&&"function"!==typeof t&&null!=t)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,t,e,"setState")},b.prototype.forceUpdate=function(t){this.updater.enqueueForceUpdate(this,t,"forceUpdate")},v.prototype=b.prototype;var x=w.prototype=new v;x.constructor=w,p(x,b.prototype),x.isPureReactComponent=!0;var k=Array.isArray;function I(){}var C={H:null,A:null,T:null,S:null},S=Object.prototype.hasOwnProperty;function A(t,e,i){var n=i.ref;return{$$typeof:a,type:t,key:e,ref:void 0!==n?n:null,props:i}}function T(t){return"object"===typeof t&&null!==t&&t.$$typeof===a}var P=/\/+/g;function D(t,e){return"object"===typeof t&&null!==t&&null!=t.key?function(t){var e={"=":"=0",":":"=2"};return"$"+t.replace(/[=:]/g,function(t){return e[t]})}(""+t.key):e.toString(36)}function N(t,e,n,o,s){var r=typeof t;"undefined"!==r&&"boolean"!==r||(t=null);var l,d,c=!1;if(null===t)c=!0;else switch(r){case"bigint":case"string":case"number":c=!0;break;case"object":switch(t.$$typeof){case a:case i:c=!0;break;case u:return N((c=t._init)(t._payload),e,n,o,s)}}if(c)return s=s(t),c=""===o?"."+D(t,0):o,k(s)?(n="",null!=c&&(n=c.replace(P,"$&/")+"/"),N(s,e,n,"",function(t){return t})):null!=s&&(T(s)&&(l=s,d=n+(null==s.key||t&&t.key===s.key?"":(""+s.key).replace(P,"$&/")+"/")+c,s=A(l.type,d,l.props)),e.push(s)),1;c=0;var m,h=""===o?".":o+":";if(k(t))for(var g=0;g<t.length;g++)c+=N(o=t[g],e,n,r=h+D(o,g),s);else if("function"===typeof(g=null===(m=t)||"object"!==typeof m?null:"function"===typeof(m=f&&m[f]||m["@@iterator"])?m:null))for(t=g.call(t),g=0;!(o=t.next()).done;)c+=N(o=o.value,e,n,r=h+D(o,g++),s);else if("object"===r){if("function"===typeof t.then)return N(function(t){switch(t.status){case"fulfilled":return t.value;case"rejected":throw t.reason;default:switch("string"===typeof t.status?t.then(I,I):(t.status="pending",t.then(function(e){"pending"===t.status&&(t.status="fulfilled",t.value=e)},function(e){"pending"===t.status&&(t.status="rejected",t.reason=e)})),t.status){case"fulfilled":return t.value;case"rejected":throw t.reason}}throw t}(t),e,n,o,s);throw e=String(t),Error("Objects are not valid as a React child (found: "+("[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e)+"). If you meant to render a collection of children, use an array instead.")}return c}function L(t,e,a){if(null==t)return t;var i=[],n=0;return N(t,i,"","",function(t){return e.call(a,t,n++)}),i}function E(t){if(-1===t._status){var e=t._result;(e=e()).then(function(e){0!==t._status&&-1!==t._status||(t._status=1,t._result=e)},function(e){0!==t._status&&-1!==t._status||(t._status=2,t._result=e)}),-1===t._status&&(t._status=0,t._result=e)}if(1===t._status)return t._result.default;throw t._result}var j="function"===typeof reportError?reportError:function(t){if("object"===typeof window&&"function"===typeof window.ErrorEvent){var e=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:"object"===typeof t&&null!==t&&"string"===typeof t.message?String(t.message):String(t),error:t});if(!window.dispatchEvent(e))return}else if("object"===typeof process&&"function"===typeof process.emit)return void process.emit("uncaughtException",t);console.error(t)},M={map:L,forEach:function(t,e,a){L(t,function(){e.apply(this,arguments)},a)},count:function(t){var e=0;return L(t,function(){e++}),e},toArray:function(t){return L(t,function(t){return t})||[]},only:function(t){if(!T(t))throw Error("React.Children.only expected to receive a single React element child.");return t}};e.Activity=h,e.Children=M,e.Component=b,e.Fragment=n,e.Profiler=s,e.PureComponent=w,e.StrictMode=o,e.Suspense=c,e.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=C,e.__COMPILER_RUNTIME={__proto__:null,c:function(t){return C.H.useMemoCache(t)}},e.cache=function(t){return function(){return t.apply(null,arguments)}},e.cacheSignal=function(){return null},e.cloneElement=function(t,e,a){if(null===t||void 0===t)throw Error("The argument must be a React element, but you passed "+t+".");var i=p({},t.props),n=t.key;if(null!=e)for(o in void 0!==e.key&&(n=""+e.key),e)!S.call(e,o)||"key"===o||"__self"===o||"__source"===o||"ref"===o&&void 0===e.ref||(i[o]=e[o]);var o=arguments.length-2;if(1===o)i.children=a;else if(1<o){for(var s=Array(o),r=0;r<o;r++)s[r]=arguments[r+2];i.children=s}return A(t.type,n,i)},e.createContext=function(t){return(t={$$typeof:l,_currentValue:t,_currentValue2:t,_threadCount:0,Provider:null,Consumer:null}).Provider=t,t.Consumer={$$typeof:r,_context:t},t},e.createElement=function(t,e,a){var i,n={},o=null;if(null!=e)for(i in void 0!==e.key&&(o=""+e.key),e)S.call(e,i)&&"key"!==i&&"__self"!==i&&"__source"!==i&&(n[i]=e[i]);var s=arguments.length-2;if(1===s)n.children=a;else if(1<s){for(var r=Array(s),l=0;l<s;l++)r[l]=arguments[l+2];n.children=r}if(t&&t.defaultProps)for(i in s=t.defaultProps)void 0===n[i]&&(n[i]=s[i]);return A(t,o,n)},e.createRef=function(){return{current:null}},e.forwardRef=function(t){return{$$typeof:d,render:t}},e.isValidElement=T,e.lazy=function(t){return{$$typeof:u,_payload:{_status:-1,_result:t},_init:E}},e.memo=function(t,e){return{$$typeof:m,type:t,compare:void 0===e?null:e}},e.startTransition=function(t){var e=C.T,a={};C.T=a;try{var i=t(),n=C.S;null!==n&&n(a,i),"object"===typeof i&&null!==i&&"function"===typeof i.then&&i.then(I,j)}catch(o){j(o)}finally{null!==e&&null!==a.types&&(e.types=a.types),C.T=e}},e.unstable_useCacheRefresh=function(){return C.H.useCacheRefresh()},e.use=function(t){return C.H.use(t)},e.useActionState=function(t,e,a){return C.H.useActionState(t,e,a)},e.useCallback=function(t,e){return C.H.useCallback(t,e)},e.useContext=function(t){return C.H.useContext(t)},e.useDebugValue=function(){},e.useDeferredValue=function(t,e){return C.H.useDeferredValue(t,e)},e.useEffect=function(t,e){return C.H.useEffect(t,e)},e.useEffectEvent=function(t){return C.H.useEffectEvent(t)},e.useId=function(){return C.H.useId()},e.useImperativeHandle=function(t,e,a){return C.H.useImperativeHandle(t,e,a)},e.useInsertionEffect=function(t,e){return C.H.useInsertionEffect(t,e)},e.useLayoutEffect=function(t,e){return C.H.useLayoutEffect(t,e)},e.useMemo=function(t,e){return C.H.useMemo(t,e)},e.useOptimistic=function(t,e){return C.H.useOptimistic(t,e)},e.useReducer=function(t,e,a){return C.H.useReducer(t,e,a)},e.useRef=function(t){return C.H.useRef(t)},e.useState=function(t){return C.H.useState(t)},e.useSyncExternalStore=function(t,e,a){return C.H.useSyncExternalStore(t,e,a)},e.useTransition=function(){return C.H.useTransition()},e.version="19.2.3"},391(t,e,a){"use strict";!function t(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(t)}catch(e){console.error(e)}}(),t.exports=a(4)},551(t){var e=-1;function a(t,h,f,g,p){if(t===h)return t?[[0,t]]:[];if(null!=f){var b=function(t,e,a){var i="number"===typeof a?{index:a,length:0}:a.oldRange,n="number"===typeof a?null:a.newRange,o=t.length,s=e.length;if(0===i.length&&(null===n||0===n.length)){var r=i.index,l=t.slice(0,r),d=t.slice(r),c=n?n.index:null,m=r+s-o;if((null===c||c===m)&&!(m<0||m>s)){var u=e.slice(0,m);if((g=e.slice(m))===d){var h=Math.min(r,m);if((b=l.slice(0,h))===(w=u.slice(0,h)))return y(b,l.slice(h),u.slice(h),d)}}if(null===c||c===r){var f=r,g=(u=e.slice(0,f),e.slice(f));if(u===l){var p=Math.min(o-f,s-f);if((v=d.slice(d.length-p))===(x=g.slice(g.length-p)))return y(l,d.slice(0,d.length-p),g.slice(0,g.length-p),v)}}}if(i.length>0&&n&&0===n.length){var b=t.slice(0,i.index),v=t.slice(i.index+i.length);if(!(s<(h=b.length)+(p=v.length))){var w=e.slice(0,h),x=e.slice(s-p);if(b===w&&v===x)return y(b,t.slice(h,o-p),e.slice(h,s-p),v)}}return null}(t,h,f);if(b)return b}var v=n(t,h),w=t.substring(0,v);v=s(t=t.substring(v),h=h.substring(v));var x=t.substring(t.length-v),k=function(t,o){var r;if(!t)return[[1,o]];if(!o)return[[e,t]];var l=t.length>o.length?t:o,d=t.length>o.length?o:t,c=l.indexOf(d);if(-1!==c)return r=[[1,l.substring(0,c)],[0,d],[1,l.substring(c+d.length)]],t.length>o.length&&(r[0][0]=r[2][0]=e),r;if(1===d.length)return[[e,t],[1,o]];var m=function(t,e){var a=t.length>e.length?t:e,i=t.length>e.length?e:t;if(a.length<4||2*i.length<a.length)return null;function o(t,e,a){for(var i,o,r,l,d=t.substring(a,a+Math.floor(t.length/4)),c=-1,m="";-1!==(c=e.indexOf(d,c+1));){var u=n(t.substring(a),e.substring(c)),h=s(t.substring(0,a),e.substring(0,c));m.length<h+u&&(m=e.substring(c-h,c)+e.substring(c,c+u),i=t.substring(0,a-h),o=t.substring(a+u),r=e.substring(0,c-h),l=e.substring(c+u))}return 2*m.length>=t.length?[i,o,r,l,m]:null}var r,l,d,c,m,u=o(a,i,Math.ceil(a.length/4)),h=o(a,i,Math.ceil(a.length/2));if(!u&&!h)return null;r=h?u&&u[4].length>h[4].length?u:h:u;t.length>e.length?(l=r[0],d=r[1],c=r[2],m=r[3]):(c=r[0],m=r[1],l=r[2],d=r[3]);var f=r[4];return[l,d,c,m,f]}(t,o);if(m){var u=m[0],h=m[1],f=m[2],g=m[3],p=m[4],y=a(u,f),b=a(h,g);return y.concat([[0,p]],b)}return function(t,a){for(var n=t.length,o=a.length,s=Math.ceil((n+o)/2),r=s,l=2*s,d=new Array(l),c=new Array(l),m=0;m<l;m++)d[m]=-1,c[m]=-1;d[r+1]=0,c[r+1]=0;for(var u=n-o,h=u%2!==0,f=0,g=0,p=0,y=0,b=0;b<s;b++){for(var v=-b+f;v<=b-g;v+=2){for(var w=r+v,x=(A=v===-b||v!==b&&d[w-1]<d[w+1]?d[w+1]:d[w-1]+1)-v;A<n&&x<o&&t.charAt(A)===a.charAt(x);)A++,x++;if(d[w]=A,A>n)g+=2;else if(x>o)f+=2;else if(h){if((C=r+u-v)>=0&&C<l&&-1!==c[C])if(A>=(I=n-c[C]))return i(t,a,A,x)}}for(var k=-b+p;k<=b-y;k+=2){for(var I,C=r+k,S=(I=k===-b||k!==b&&c[C-1]<c[C+1]?c[C+1]:c[C-1]+1)-k;I<n&&S<o&&t.charAt(n-I-1)===a.charAt(o-S-1);)I++,S++;if(c[C]=I,I>n)y+=2;else if(S>o)p+=2;else if(!h){if((w=r+u-k)>=0&&w<l&&-1!==d[w]){var A;x=r+(A=d[w])-w;if(A>=(I=n-I))return i(t,a,A,x)}}}}return[[e,t],[1,a]]}(t,o)}(t=t.substring(0,t.length-v),h=h.substring(0,h.length-v));return w&&k.unshift([0,w]),x&&k.push([0,x]),u(k,p),g&&function(t){var a=!1,i=[],n=0,h=null,f=0,g=0,p=0,y=0,b=0;for(;f<t.length;)0==t[f][0]?(i[n++]=f,g=y,p=b,y=0,b=0,h=t[f][1]):(1==t[f][0]?y+=t[f][1].length:b+=t[f][1].length,h&&h.length<=Math.max(g,p)&&h.length<=Math.max(y,b)&&(t.splice(i[n-1],0,[e,h]),t[i[n-1]+1][0]=1,n--,f=--n>0?i[n-1]:-1,g=0,p=0,y=0,b=0,h=null,a=!0)),f++;a&&u(t);(function(t){function e(t,e){if(!t||!e)return 6;var a=t.charAt(t.length-1),i=e.charAt(0),n=a.match(r),o=i.match(r),s=n&&a.match(l),u=o&&i.match(l),h=s&&a.match(d),f=u&&i.match(d),g=h&&t.match(c),p=f&&e.match(m);return g||p?5:h||f?4:n&&!s&&u?3:s||u?2:n||o?1:0}var a=1;for(;a<t.length-1;){if(0==t[a-1][0]&&0==t[a+1][0]){var i=t[a-1][1],n=t[a][1],o=t[a+1][1],u=s(i,n);if(u){var h=n.substring(n.length-u);i=i.substring(0,i.length-u),n=h+n.substring(0,n.length-u),o=h+o}for(var f=i,g=n,p=o,y=e(i,n)+e(n,o);n.charAt(0)===o.charAt(0);){i+=n.charAt(0),n=n.substring(1)+o.charAt(0),o=o.substring(1);var b=e(i,n)+e(n,o);b>=y&&(y=b,f=i,g=n,p=o)}t[a-1][1]!=f&&(f?t[a-1][1]=f:(t.splice(a-1,1),a--),t[a][1]=g,p?t[a+1][1]=p:(t.splice(a+1,1),a--))}a++}})(t),f=1;for(;f<t.length;){if(t[f-1][0]==e&&1==t[f][0]){var v=t[f-1][1],w=t[f][1],x=o(v,w),k=o(w,v);x>=k?(x>=v.length/2||x>=w.length/2)&&(t.splice(f,0,[0,w.substring(0,x)]),t[f-1][1]=v.substring(0,v.length-x),t[f+1][1]=w.substring(x),f++):(k>=v.length/2||k>=w.length/2)&&(t.splice(f,0,[0,v.substring(0,k)]),t[f-1][0]=1,t[f-1][1]=w.substring(0,w.length-k),t[f+1][0]=e,t[f+1][1]=v.substring(k),f++),f++}f++}}(k),k}function i(t,e,i,n){var o=t.substring(0,i),s=e.substring(0,n),r=t.substring(i),l=e.substring(n),d=a(o,s),c=a(r,l);return d.concat(c)}function n(t,e){if(!t||!e||t.charAt(0)!==e.charAt(0))return 0;for(var a=0,i=Math.min(t.length,e.length),n=i,o=0;a<n;)t.substring(o,n)==e.substring(o,n)?o=a=n:i=n,n=Math.floor((i-a)/2+a);return h(t.charCodeAt(n-1))&&n--,n}function o(t,e){var a=t.length,i=e.length;if(0==a||0==i)return 0;a>i?t=t.substring(a-i):a<i&&(e=e.substring(0,a));var n=Math.min(a,i);if(t==e)return n;for(var o=0,s=1;;){var r=t.substring(n-s),l=e.indexOf(r);if(-1==l)return o;s+=l,0!=l&&t.substring(n-s)!=e.substring(0,s)||(o=s,s++)}}function s(t,e){if(!t||!e||t.slice(-1)!==e.slice(-1))return 0;for(var a=0,i=Math.min(t.length,e.length),n=i,o=0;a<n;)t.substring(t.length-n,t.length-o)==e.substring(e.length-n,e.length-o)?o=a=n:i=n,n=Math.floor((i-a)/2+a);return f(t.charCodeAt(t.length-n))&&n--,n}var r=/[^a-zA-Z0-9]/,l=/\s/,d=/[\r\n]/,c=/\n\r?\n$/,m=/^\r?\n\r?\n/;function u(t,a){t.push([0,""]);for(var i,o=0,r=0,l=0,d="",c="";o<t.length;)if(o<t.length-1&&!t[o][1])t.splice(o,1);else switch(t[o][0]){case 1:l++,c+=t[o][1],o++;break;case e:r++,d+=t[o][1],o++;break;case 0:var m=o-l-r-1;if(a){if(m>=0&&p(t[m][1])){var h=t[m][1].slice(-1);if(t[m][1]=t[m][1].slice(0,-1),d=h+d,c=h+c,!t[m][1]){t.splice(m,1),o--;var f=m-1;t[f]&&1===t[f][0]&&(l++,c=t[f][1]+c,f--),t[f]&&t[f][0]===e&&(r++,d=t[f][1]+d,f--),m=f}}if(g(t[o][1])){h=t[o][1].charAt(0);t[o][1]=t[o][1].slice(1),d+=h,c+=h}}if(o<t.length-1&&!t[o][1]){t.splice(o,1);break}if(d.length>0||c.length>0){d.length>0&&c.length>0&&(0!==(i=n(c,d))&&(m>=0?t[m][1]+=c.substring(0,i):(t.splice(0,0,[0,c.substring(0,i)]),o++),c=c.substring(i),d=d.substring(i)),0!==(i=s(c,d))&&(t[o][1]=c.substring(c.length-i)+t[o][1],c=c.substring(0,c.length-i),d=d.substring(0,d.length-i)));var y=l+r;0===d.length&&0===c.length?(t.splice(o-y,y),o-=y):0===d.length?(t.splice(o-y,y,[1,c]),o=o-y+1):0===c.length?(t.splice(o-y,y,[e,d]),o=o-y+1):(t.splice(o-y,y,[e,d],[1,c]),o=o-y+2)}0!==o&&0===t[o-1][0]?(t[o-1][1]+=t[o][1],t.splice(o,1)):o++,l=0,r=0,d="",c=""}""===t[t.length-1][1]&&t.pop();var b=!1;for(o=1;o<t.length-1;)0===t[o-1][0]&&0===t[o+1][0]&&(t[o][1].substring(t[o][1].length-t[o-1][1].length)===t[o-1][1]?(t[o][1]=t[o-1][1]+t[o][1].substring(0,t[o][1].length-t[o-1][1].length),t[o+1][1]=t[o-1][1]+t[o+1][1],t.splice(o-1,1),b=!0):t[o][1].substring(0,t[o+1][1].length)==t[o+1][1]&&(t[o-1][1]+=t[o+1][1],t[o][1]=t[o][1].substring(t[o+1][1].length)+t[o+1][1],t.splice(o+1,1),b=!0)),o++;b&&u(t,a)}function h(t){return t>=55296&&t<=56319}function f(t){return t>=56320&&t<=57343}function g(t){return f(t.charCodeAt(0))}function p(t){return h(t.charCodeAt(t.length-1))}function y(t,a,i,n){return p(t)||g(n)?null:function(t){for(var e=[],a=0;a<t.length;a++)t[a][1].length>0&&e.push(t[a]);return e}([[0,t],[e,a],[1,i],[0,n]])}function b(t,e,i,n){return a(t,e,i,n,!0)}b.INSERT=1,b.DELETE=e,b.EQUAL=0,t.exports=b},579(t,e,a){"use strict";t.exports=a(799)},646(t,e,a){"use strict";Object.defineProperty(e,"__esModule",{value:!0});const i=a(100);e.default=class{constructor(t){this.ops=t,this.index=0,this.offset=0}hasNext(){return this.peekLength()<1/0}next(t){t||(t=1/0);const e=this.ops[this.index];if(e){const a=this.offset,n=i.default.length(e);if(t>=n-a?(t=n-a,this.index+=1,this.offset=0):this.offset+=t,"number"===typeof e.delete)return{delete:t};{const i={};return e.attributes&&(i.attributes=e.attributes),"number"===typeof e.retain?i.retain=t:"object"===typeof e.retain&&null!==e.retain?i.retain=e.retain:"string"===typeof e.insert?i.insert=e.insert.substr(a,t):i.insert=e.insert,i}}return{retain:1/0}}peek(){return this.ops[this.index]}peekLength(){return this.ops[this.index]?i.default.length(this.ops[this.index])-this.offset:1/0}peekType(){const t=this.ops[this.index];return t?"number"===typeof t.delete?"delete":"number"===typeof t.retain||"object"===typeof t.retain&&null!==t.retain?"retain":"insert":"retain"}rest(){if(this.hasNext()){if(0===this.offset)return this.ops.slice(this.index);{const t=this.offset,e=this.index,a=this.next(),i=this.ops.slice(this.index);return this.offset=t,this.index=e,[a].concat(i)}}return[]}}},672(t,e,a){"use strict";var i=a(43);function n(t){var e="https://react.dev/errors/"+t;if(1<arguments.length){e+="?args[]="+encodeURIComponent(arguments[1]);for(var a=2;a<arguments.length;a++)e+="&args[]="+encodeURIComponent(arguments[a])}return"Minified React error #"+t+"; visit "+e+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function o(){}var s={d:{f:o,r:function(){throw Error(n(522))},D:o,C:o,L:o,m:o,X:o,S:o,M:o},p:0,findDOMNode:null},r=Symbol.for("react.portal");var l=i.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function d(t,e){return"font"===t?"":"string"===typeof e?"use-credentials"===e?e:"":void 0}e.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=s,e.createPortal=function(t,e){var a=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)throw Error(n(299));return function(t,e,a){var i=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:r,key:null==i?null:""+i,children:t,containerInfo:e,implementation:a}}(t,e,null,a)},e.flushSync=function(t){var e=l.T,a=s.p;try{if(l.T=null,s.p=2,t)return t()}finally{l.T=e,s.p=a,s.d.f()}},e.preconnect=function(t,e){"string"===typeof t&&(e?e="string"===typeof(e=e.crossOrigin)?"use-credentials"===e?e:"":void 0:e=null,s.d.C(t,e))},e.prefetchDNS=function(t){"string"===typeof t&&s.d.D(t)},e.preinit=function(t,e){if("string"===typeof t&&e&&"string"===typeof e.as){var a=e.as,i=d(a,e.crossOrigin),n="string"===typeof e.integrity?e.integrity:void 0,o="string"===typeof e.fetchPriority?e.fetchPriority:void 0;"style"===a?s.d.S(t,"string"===typeof e.precedence?e.precedence:void 0,{crossOrigin:i,integrity:n,fetchPriority:o}):"script"===a&&s.d.X(t,{crossOrigin:i,integrity:n,fetchPriority:o,nonce:"string"===typeof e.nonce?e.nonce:void 0})}},e.preinitModule=function(t,e){if("string"===typeof t)if("object"===typeof e&&null!==e){if(null==e.as||"script"===e.as){var a=d(e.as,e.crossOrigin);s.d.M(t,{crossOrigin:a,integrity:"string"===typeof e.integrity?e.integrity:void 0,nonce:"string"===typeof e.nonce?e.nonce:void 0})}}else null==e&&s.d.M(t)},e.preload=function(t,e){if("string"===typeof t&&"object"===typeof e&&null!==e&&"string"===typeof e.as){var a=e.as,i=d(a,e.crossOrigin);s.d.L(t,a,{crossOrigin:i,integrity:"string"===typeof e.integrity?e.integrity:void 0,nonce:"string"===typeof e.nonce?e.nonce:void 0,type:"string"===typeof e.type?e.type:void 0,fetchPriority:"string"===typeof e.fetchPriority?e.fetchPriority:void 0,referrerPolicy:"string"===typeof e.referrerPolicy?e.referrerPolicy:void 0,imageSrcSet:"string"===typeof e.imageSrcSet?e.imageSrcSet:void 0,imageSizes:"string"===typeof e.imageSizes?e.imageSizes:void 0,media:"string"===typeof e.media?e.media:void 0})}},e.preloadModule=function(t,e){if("string"===typeof t)if(e){var a=d(e.as,e.crossOrigin);s.d.m(t,{as:"string"===typeof e.as&&"script"!==e.as?e.as:void 0,crossOrigin:a,integrity:"string"===typeof e.integrity?e.integrity:void 0})}else s.d.m(t)},e.requestFormReset=function(t){s.d.r(t)},e.unstable_batchedUpdates=function(t,e){return t(e)},e.useFormState=function(t,e,a){return l.H.useFormState(t,e,a)},e.useFormStatus=function(){return l.H.useHostTransitionStatus()},e.version="19.2.3"},752(t){"use strict";var e=Object.prototype.hasOwnProperty,a="~";function i(){}function n(t,e,a){this.fn=t,this.context=e,this.once=a||!1}function o(t,e,i,o,s){if("function"!==typeof i)throw new TypeError("The listener must be a function");var r=new n(i,o||t,s),l=a?a+e:e;return t._events[l]?t._events[l].fn?t._events[l]=[t._events[l],r]:t._events[l].push(r):(t._events[l]=r,t._eventsCount++),t}function s(t,e){0===--t._eventsCount?t._events=new i:delete t._events[e]}function r(){this._events=new i,this._eventsCount=0}Object.create&&(i.prototype=Object.create(null),(new i).__proto__||(a=!1)),r.prototype.eventNames=function(){var t,i,n=[];if(0===this._eventsCount)return n;for(i in t=this._events)e.call(t,i)&&n.push(a?i.slice(1):i);return Object.getOwnPropertySymbols?n.concat(Object.getOwnPropertySymbols(t)):n},r.prototype.listeners=function(t){var e=a?a+t:t,i=this._events[e];if(!i)return[];if(i.fn)return[i.fn];for(var n=0,o=i.length,s=new Array(o);n<o;n++)s[n]=i[n].fn;return s},r.prototype.listenerCount=function(t){var e=a?a+t:t,i=this._events[e];return i?i.fn?1:i.length:0},r.prototype.emit=function(t,e,i,n,o,s){var r=a?a+t:t;if(!this._events[r])return!1;var l,d,c=this._events[r],m=arguments.length;if(c.fn){switch(c.once&&this.removeListener(t,c.fn,void 0,!0),m){case 1:return c.fn.call(c.context),!0;case 2:return c.fn.call(c.context,e),!0;case 3:return c.fn.call(c.context,e,i),!0;case 4:return c.fn.call(c.context,e,i,n),!0;case 5:return c.fn.call(c.context,e,i,n,o),!0;case 6:return c.fn.call(c.context,e,i,n,o,s),!0}for(d=1,l=new Array(m-1);d<m;d++)l[d-1]=arguments[d];c.fn.apply(c.context,l)}else{var u,h=c.length;for(d=0;d<h;d++)switch(c[d].once&&this.removeListener(t,c[d].fn,void 0,!0),m){case 1:c[d].fn.call(c[d].context);break;case 2:c[d].fn.call(c[d].context,e);break;case 3:c[d].fn.call(c[d].context,e,i);break;case 4:c[d].fn.call(c[d].context,e,i,n);break;default:if(!l)for(u=1,l=new Array(m-1);u<m;u++)l[u-1]=arguments[u];c[d].fn.apply(c[d].context,l)}}return!0},r.prototype.on=function(t,e,a){return o(this,t,e,a,!1)},r.prototype.once=function(t,e,a){return o(this,t,e,a,!0)},r.prototype.removeListener=function(t,e,i,n){var o=a?a+t:t;if(!this._events[o])return this;if(!e)return s(this,o),this;var r=this._events[o];if(r.fn)r.fn!==e||n&&!r.once||i&&r.context!==i||s(this,o);else{for(var l=0,d=[],c=r.length;l<c;l++)(r[l].fn!==e||n&&!r[l].once||i&&r[l].context!==i)&&d.push(r[l]);d.length?this._events[o]=1===d.length?d[0]:d:s(this,o)}return this},r.prototype.removeAllListeners=function(t){var e;return t?(e=a?a+t:t,this._events[e]&&s(this,e)):(this._events=new i,this._eventsCount=0),this},r.prototype.off=r.prototype.removeListener,r.prototype.addListener=r.prototype.on,r.prefixed=a,r.EventEmitter=r,t.exports=r},785(t,e,a){"use strict";Object.defineProperty(e,"__esModule",{value:!0});const i=a(992),n=a(67);var o;!function(t){t.compose=function(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},a=arguments.length>2&&void 0!==arguments[2]&&arguments[2];"object"!==typeof t&&(t={}),"object"!==typeof e&&(e={});let n=i(e);a||(n=Object.keys(n).reduce((t,e)=>(null!=n[e]&&(t[e]=n[e]),t),{}));for(const i in t)void 0!==t[i]&&void 0===e[i]&&(n[i]=t[i]);return Object.keys(n).length>0?n:void 0},t.diff=function(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};"object"!==typeof t&&(t={}),"object"!==typeof e&&(e={});const a=Object.keys(t).concat(Object.keys(e)).reduce((a,i)=>(n(t[i],e[i])||(a[i]=void 0===e[i]?null:e[i]),a),{});return Object.keys(a).length>0?a:void 0},t.invert=function(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};t=t||{};const a=Object.keys(e).reduce((a,i)=>(e[i]!==t[i]&&void 0!==t[i]&&(a[i]=e[i]),a),{});return Object.keys(t).reduce((a,i)=>(t[i]!==e[i]&&void 0===e[i]&&(a[i]=null),a),a)},t.transform=function(t,e){if("object"!==typeof t)return e;if("object"!==typeof e)return;if(!(arguments.length>2&&void 0!==arguments[2]&&arguments[2]))return e;const a=Object.keys(e).reduce((a,i)=>(void 0===t[i]&&(a[i]=e[i]),a),{});return Object.keys(a).length>0?a:void 0}}(o||(o={})),e.default=o},799(t,e){"use strict";var a=Symbol.for("react.transitional.element"),i=Symbol.for("react.fragment");function n(t,e,i){var n=null;if(void 0!==i&&(n=""+i),void 0!==e.key&&(n=""+e.key),"key"in e)for(var o in i={},e)"key"!==o&&(i[o]=e[o]);else i=e;return e=i.ref,{$$typeof:a,type:t,key:n,ref:void 0!==e?e:null,props:i}}e.Fragment=i,e.jsx=n,e.jsxs=n},853(t,e,a){"use strict";t.exports=a(896)},896(t,e){"use strict";function a(t,e){var a=t.length;t.push(e);t:for(;0<a;){var i=a-1>>>1,n=t[i];if(!(0<o(n,e)))break t;t[i]=e,t[a]=n,a=i}}function i(t){return 0===t.length?null:t[0]}function n(t){if(0===t.length)return null;var e=t[0],a=t.pop();if(a!==e){t[0]=a;t:for(var i=0,n=t.length,s=n>>>1;i<s;){var r=2*(i+1)-1,l=t[r],d=r+1,c=t[d];if(0>o(l,a))d<n&&0>o(c,l)?(t[i]=c,t[d]=a,i=d):(t[i]=l,t[r]=a,i=r);else{if(!(d<n&&0>o(c,a)))break t;t[i]=c,t[d]=a,i=d}}}return e}function o(t,e){var a=t.sortIndex-e.sortIndex;return 0!==a?a:t.id-e.id}if(e.unstable_now=void 0,"object"===typeof performance&&"function"===typeof performance.now){var s=performance;e.unstable_now=function(){return s.now()}}else{var r=Date,l=r.now();e.unstable_now=function(){return r.now()-l}}var d=[],c=[],m=1,u=null,h=3,f=!1,g=!1,p=!1,y=!1,b="function"===typeof setTimeout?setTimeout:null,v="function"===typeof clearTimeout?clearTimeout:null,w="undefined"!==typeof setImmediate?setImmediate:null;function x(t){for(var e=i(c);null!==e;){if(null===e.callback)n(c);else{if(!(e.startTime<=t))break;n(c),e.sortIndex=e.expirationTime,a(d,e)}e=i(c)}}function k(t){if(p=!1,x(t),!g)if(null!==i(d))g=!0,C||(C=!0,I());else{var e=i(c);null!==e&&E(k,e.startTime-t)}}var I,C=!1,S=-1,A=5,T=-1;function P(){return!!y||!(e.unstable_now()-T<A)}function D(){if(y=!1,C){var t=e.unstable_now();T=t;var a=!0;try{t:{g=!1,p&&(p=!1,v(S),S=-1),f=!0;var o=h;try{e:{for(x(t),u=i(d);null!==u&&!(u.expirationTime>t&&P());){var s=u.callback;if("function"===typeof s){u.callback=null,h=u.priorityLevel;var r=s(u.expirationTime<=t);if(t=e.unstable_now(),"function"===typeof r){u.callback=r,x(t),a=!0;break e}u===i(d)&&n(d),x(t)}else n(d);u=i(d)}if(null!==u)a=!0;else{var l=i(c);null!==l&&E(k,l.startTime-t),a=!1}}break t}finally{u=null,h=o,f=!1}a=void 0}}finally{a?I():C=!1}}}if("function"===typeof w)I=function(){w(D)};else if("undefined"!==typeof MessageChannel){var N=new MessageChannel,L=N.port2;N.port1.onmessage=D,I=function(){L.postMessage(null)}}else I=function(){b(D,0)};function E(t,a){S=b(function(){t(e.unstable_now())},a)}e.unstable_IdlePriority=5,e.unstable_ImmediatePriority=1,e.unstable_LowPriority=4,e.unstable_NormalPriority=3,e.unstable_Profiling=null,e.unstable_UserBlockingPriority=2,e.unstable_cancelCallback=function(t){t.callback=null},e.unstable_forceFrameRate=function(t){0>t||125<t?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):A=0<t?Math.floor(1e3/t):5},e.unstable_getCurrentPriorityLevel=function(){return h},e.unstable_next=function(t){switch(h){case 1:case 2:case 3:var e=3;break;default:e=h}var a=h;h=e;try{return t()}finally{h=a}},e.unstable_requestPaint=function(){y=!0},e.unstable_runWithPriority=function(t,e){switch(t){case 1:case 2:case 3:case 4:case 5:break;default:t=3}var a=h;h=t;try{return e()}finally{h=a}},e.unstable_scheduleCallback=function(t,n,o){var s=e.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?s+o:s:o=s,t){case 1:var r=-1;break;case 2:r=250;break;case 5:r=1073741823;break;case 4:r=1e4;break;default:r=5e3}return t={id:m++,callback:n,priorityLevel:t,startTime:o,expirationTime:r=o+r,sortIndex:-1},o>s?(t.sortIndex=o,a(c,t),null===i(d)&&t===i(c)&&(p?(v(S),S=-1):p=!0,E(k,o-s))):(t.sortIndex=r,a(d,t),g||f||(g=!0,C||(C=!0,I()))),t},e.unstable_shouldYield=P,e.unstable_wrapCallback=function(t){var e=h;return function(){var a=h;h=e;try{return t.apply(this,arguments)}finally{h=a}}}},950(t,e,a){"use strict";!function t(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(t)}catch(e){console.error(e)}}(),t.exports=a(672)},992(t,e,a){t=a.nmd(t);var i="__lodash_hash_undefined__",n=9007199254740991,o="[object Arguments]",s="[object Boolean]",r="[object Date]",l="[object Function]",d="[object GeneratorFunction]",c="[object Map]",m="[object Number]",u="[object Object]",h="[object Promise]",f="[object RegExp]",g="[object Set]",p="[object String]",y="[object Symbol]",b="[object WeakMap]",v="[object ArrayBuffer]",w="[object DataView]",x="[object Float32Array]",k="[object Float64Array]",I="[object Int8Array]",C="[object Int16Array]",S="[object Int32Array]",A="[object Uint8Array]",T="[object Uint8ClampedArray]",P="[object Uint16Array]",D="[object Uint32Array]",N=/\w*$/,L=/^\[object .+?Constructor\]$/,E=/^(?:0|[1-9]\d*)$/,j={};j[o]=j["[object Array]"]=j[v]=j[w]=j[s]=j[r]=j[x]=j[k]=j[I]=j[C]=j[S]=j[c]=j[m]=j[u]=j[f]=j[g]=j[p]=j[y]=j[A]=j[T]=j[P]=j[D]=!0,j["[object Error]"]=j[l]=j[b]=!1;var M="object"==typeof a.g&&a.g&&a.g.Object===Object&&a.g,z="object"==typeof self&&self&&self.Object===Object&&self,R=M||z||Function("return this")(),F=e&&!e.nodeType&&e,q=F&&t&&!t.nodeType&&t,_=q&&q.exports===F;function O(t,e){return t.set(e[0],e[1]),t}function U(t,e){return t.add(e),t}function H(t,e,a,i){var n=-1,o=t?t.length:0;for(i&&o&&(a=t[++n]);++n<o;)a=e(a,t[n],n,t);return a}function V(t){var e=!1;if(null!=t&&"function"!=typeof t.toString)try{e=!!(t+"")}catch(a){}return e}function B(t){var e=-1,a=Array(t.size);return t.forEach(function(t,i){a[++e]=[i,t]}),a}function G(t,e){return function(a){return t(e(a))}}function W(t){var e=-1,a=Array(t.size);return t.forEach(function(t){a[++e]=t}),a}var Q=Array.prototype,K=Function.prototype,Z=Object.prototype,$=R["__core-js_shared__"],X=function(){var t=/[^.]+$/.exec($&&$.keys&&$.keys.IE_PROTO||"");return t?"Symbol(src)_1."+t:""}(),Y=K.toString,J=Z.hasOwnProperty,tt=Z.toString,et=RegExp("^"+Y.call(J).replace(/[\\^$.*+?()[\]{}|]/g,"\\$&").replace(/hasOwnProperty|(function).*?(?=\\\()| for .+?(?=\\\])/g,"$1.*?")+"$"),at=_?R.Buffer:void 0,it=R.Symbol,nt=R.Uint8Array,ot=G(Object.getPrototypeOf,Object),st=Object.create,rt=Z.propertyIsEnumerable,lt=Q.splice,dt=Object.getOwnPropertySymbols,ct=at?at.isBuffer:void 0,mt=G(Object.keys,Object),ut=Ft(R,"DataView"),ht=Ft(R,"Map"),ft=Ft(R,"Promise"),gt=Ft(R,"Set"),pt=Ft(R,"WeakMap"),yt=Ft(Object,"create"),bt=Ht(ut),vt=Ht(ht),wt=Ht(ft),xt=Ht(gt),kt=Ht(pt),It=it?it.prototype:void 0,Ct=It?It.valueOf:void 0;function St(t){var e=-1,a=t?t.length:0;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function At(t){var e=-1,a=t?t.length:0;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function Tt(t){var e=-1,a=t?t.length:0;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}function Pt(t){this.__data__=new At(t)}function Dt(t,e){var a=Bt(t)||function(t){return function(t){return function(t){return!!t&&"object"==typeof t}(t)&&Gt(t)}(t)&&J.call(t,"callee")&&(!rt.call(t,"callee")||tt.call(t)==o)}(t)?function(t,e){for(var a=-1,i=Array(t);++a<t;)i[a]=e(a);return i}(t.length,String):[],i=a.length,n=!!i;for(var s in t)!e&&!J.call(t,s)||n&&("length"==s||Ot(s,i))||a.push(s);return a}function Nt(t,e,a){var i=t[e];J.call(t,e)&&Vt(i,a)&&(void 0!==a||e in t)||(t[e]=a)}function Lt(t,e){for(var a=t.length;a--;)if(Vt(t[a][0],e))return a;return-1}function Et(t,e,a,i,n,h,b){var L;if(i&&(L=h?i(t,n,h,b):i(t)),void 0!==L)return L;if(!Kt(t))return t;var E=Bt(t);if(E){if(L=function(t){var e=t.length,a=t.constructor(e);e&&"string"==typeof t[0]&&J.call(t,"index")&&(a.index=t.index,a.input=t.input);return a}(t),!e)return function(t,e){var a=-1,i=t.length;e||(e=Array(i));for(;++a<i;)e[a]=t[a];return e}(t,L)}else{var M=_t(t),z=M==l||M==d;if(Wt(t))return function(t,e){if(e)return t.slice();var a=new t.constructor(t.length);return t.copy(a),a}(t,e);if(M==u||M==o||z&&!h){if(V(t))return h?t:{};if(L=function(t){return"function"!=typeof t.constructor||Ut(t)?{}:(e=ot(t),Kt(e)?st(e):{});var e}(z?{}:t),!e)return function(t,e){return zt(t,qt(t),e)}(t,function(t,e){return t&&zt(e,Zt(e),t)}(L,t))}else{if(!j[M])return h?t:{};L=function(t,e,a,i){var n=t.constructor;switch(e){case v:return Mt(t);case s:case r:return new n(+t);case w:return function(t,e){var a=e?Mt(t.buffer):t.buffer;return new t.constructor(a,t.byteOffset,t.byteLength)}(t,i);case x:case k:case I:case C:case S:case A:case T:case P:case D:return function(t,e){var a=e?Mt(t.buffer):t.buffer;return new t.constructor(a,t.byteOffset,t.length)}(t,i);case c:return function(t,e,a){var i=e?a(B(t),!0):B(t);return H(i,O,new t.constructor)}(t,i,a);case m:case p:return new n(t);case f:return function(t){var e=new t.constructor(t.source,N.exec(t));return e.lastIndex=t.lastIndex,e}(t);case g:return function(t,e,a){var i=e?a(W(t),!0):W(t);return H(i,U,new t.constructor)}(t,i,a);case y:return o=t,Ct?Object(Ct.call(o)):{}}var o}(t,M,Et,e)}}b||(b=new Pt);var R=b.get(t);if(R)return R;if(b.set(t,L),!E)var F=a?function(t){return function(t,e,a){var i=e(t);return Bt(t)?i:function(t,e){for(var a=-1,i=e.length,n=t.length;++a<i;)t[n+a]=e[a];return t}(i,a(t))}(t,Zt,qt)}(t):Zt(t);return function(t,e){for(var a=-1,i=t?t.length:0;++a<i&&!1!==e(t[a],a,t););}(F||t,function(n,o){F&&(n=t[o=n]),Nt(L,o,Et(n,e,a,i,o,t,b))}),L}function jt(t){return!(!Kt(t)||(e=t,X&&X in e))&&(Qt(t)||V(t)?et:L).test(Ht(t));var e}function Mt(t){var e=new t.constructor(t.byteLength);return new nt(e).set(new nt(t)),e}function zt(t,e,a,i){a||(a={});for(var n=-1,o=e.length;++n<o;){var s=e[n],r=i?i(a[s],t[s],s,a,t):void 0;Nt(a,s,void 0===r?t[s]:r)}return a}function Rt(t,e){var a=t.__data__;return function(t){var e=typeof t;return"string"==e||"number"==e||"symbol"==e||"boolean"==e?"__proto__"!==t:null===t}(e)?a["string"==typeof e?"string":"hash"]:a.map}function Ft(t,e){var a=function(t,e){return null==t?void 0:t[e]}(t,e);return jt(a)?a:void 0}St.prototype.clear=function(){this.__data__=yt?yt(null):{}},St.prototype.delete=function(t){return this.has(t)&&delete this.__data__[t]},St.prototype.get=function(t){var e=this.__data__;if(yt){var a=e[t];return a===i?void 0:a}return J.call(e,t)?e[t]:void 0},St.prototype.has=function(t){var e=this.__data__;return yt?void 0!==e[t]:J.call(e,t)},St.prototype.set=function(t,e){return this.__data__[t]=yt&&void 0===e?i:e,this},At.prototype.clear=function(){this.__data__=[]},At.prototype.delete=function(t){var e=this.__data__,a=Lt(e,t);return!(a<0)&&(a==e.length-1?e.pop():lt.call(e,a,1),!0)},At.prototype.get=function(t){var e=this.__data__,a=Lt(e,t);return a<0?void 0:e[a][1]},At.prototype.has=function(t){return Lt(this.__data__,t)>-1},At.prototype.set=function(t,e){var a=this.__data__,i=Lt(a,t);return i<0?a.push([t,e]):a[i][1]=e,this},Tt.prototype.clear=function(){this.__data__={hash:new St,map:new(ht||At),string:new St}},Tt.prototype.delete=function(t){return Rt(this,t).delete(t)},Tt.prototype.get=function(t){return Rt(this,t).get(t)},Tt.prototype.has=function(t){return Rt(this,t).has(t)},Tt.prototype.set=function(t,e){return Rt(this,t).set(t,e),this},Pt.prototype.clear=function(){this.__data__=new At},Pt.prototype.delete=function(t){return this.__data__.delete(t)},Pt.prototype.get=function(t){return this.__data__.get(t)},Pt.prototype.has=function(t){return this.__data__.has(t)},Pt.prototype.set=function(t,e){var a=this.__data__;if(a instanceof At){var i=a.__data__;if(!ht||i.length<199)return i.push([t,e]),this;a=this.__data__=new Tt(i)}return a.set(t,e),this};var qt=dt?G(dt,Object):function(){return[]},_t=function(t){return tt.call(t)};function Ot(t,e){return!!(e=null==e?n:e)&&("number"==typeof t||E.test(t))&&t>-1&&t%1==0&&t<e}function Ut(t){var e=t&&t.constructor;return t===("function"==typeof e&&e.prototype||Z)}function Ht(t){if(null!=t){try{return Y.call(t)}catch(e){}try{return t+""}catch(e){}}return""}function Vt(t,e){return t===e||t!==t&&e!==e}(ut&&_t(new ut(new ArrayBuffer(1)))!=w||ht&&_t(new ht)!=c||ft&&_t(ft.resolve())!=h||gt&&_t(new gt)!=g||pt&&_t(new pt)!=b)&&(_t=function(t){var e=tt.call(t),a=e==u?t.constructor:void 0,i=a?Ht(a):void 0;if(i)switch(i){case bt:return w;case vt:return c;case wt:return h;case xt:return g;case kt:return b}return e});var Bt=Array.isArray;function Gt(t){return null!=t&&function(t){return"number"==typeof t&&t>-1&&t%1==0&&t<=n}(t.length)&&!Qt(t)}var Wt=ct||function(){return!1};function Qt(t){var e=Kt(t)?tt.call(t):"";return e==l||e==d}function Kt(t){var e=typeof t;return!!t&&("object"==e||"function"==e)}function Zt(t){return Gt(t)?Dt(t):function(t){if(!Ut(t))return mt(t);var e=[];for(var a in Object(t))J.call(t,a)&&"constructor"!=a&&e.push(a);return e}(t)}t.exports=function(t){return Et(t,!0,!0)}},998(t){"use strict";const e=function(){};e.prototype=Object.create(null);const a=/; *([!#-'\*\+\x2D\.0-9A-Z\^-z\|~]+)=("(?:[\x0B !#-\[\]-~\x80-\xFF]|\\[\x0B -\xFF])*"|[!#-'\*\+\x2D\.0-9A-Z\^-z\|~]+) */g,i=/\\([\x0B -\xFF])/g,n=/^[!#-'\*\+\x2D\.0-9A-Z\^_a-z\|~]+\/[!#-'\*\+\x2D\.0-9A-Z\^_a-z\|~]+$/,o={type:"",parameters:new e};function s(t){if("string"!==typeof t)throw new TypeError("argument header is required and must be a string");let o=t.indexOf(";");const s=-1!==o?t.slice(0,o).trim():t.trim();if(!1===n.test(s))throw new TypeError("invalid media type");const r={type:s.toLowerCase(),parameters:new e};if(-1===o)return r;let l,d,c;for(a.lastIndex=o;d=a.exec(t);){if(d.index!==o)throw new TypeError("invalid parameter format");o+=d[0].length,l=d[1].toLowerCase(),c=d[2],'"'===c[0]&&(c=c.slice(1,c.length-1),i.test(c)&&(c=c.replace(i,"$1"))),r.parameters[l]=c}if(o!==t.length)throw new TypeError("invalid parameter format");return r}function r(t){if("string"!==typeof t)return o;let s=t.indexOf(";");const r=-1!==s?t.slice(0,s).trim():t.trim();if(!1===n.test(r))return o;const l={type:r.toLowerCase(),parameters:new e};if(-1===s)return l;let d,c,m;for(a.lastIndex=s;c=a.exec(t);){if(c.index!==s)return o;s+=c[0].length,d=c[1].toLowerCase(),m=c[2],'"'===m[0]&&(m=m.slice(1,m.length-1),i.test(m)&&(m=m.replace(i,"$1"))),l.parameters[d]=m}return s!==t.length?o:l}Object.freeze(o.parameters),Object.freeze(o),t.exports.xL=r}},e={};function a(i){var n=e[i];if(void 0!==n)return n.exports;var o=e[i]={id:i,loaded:!1,exports:{}};return t[i](o,o.exports,a),o.loaded=!0,o.exports}a.m=t,(()=>{var t,e=Object.getPrototypeOf?t=>Object.getPrototypeOf(t):t=>t.__proto__;a.t=function(i,n){if(1&n&&(i=this(i)),8&n)return i;if("object"===typeof i&&i){if(4&n&&i.__esModule)return i;if(16&n&&"function"===typeof i.then)return i}var o=Object.create(null);a.r(o);var s={};t=t||[null,e({}),e([]),e(e)];for(var r=2&n&&i;("object"==typeof r||"function"==typeof r)&&!~t.indexOf(r);r=e(r))Object.getOwnPropertyNames(r).forEach(t=>s[t]=()=>i[t]);return s.default=()=>i,a.d(o,s),o}})(),a.d=(t,e)=>{for(var i in e)a.o(e,i)&&!a.o(t,i)&&Object.defineProperty(t,i,{enumerable:!0,get:e[i]})},a.f={},a.e=t=>Promise.all(Object.keys(a.f).reduce((e,i)=>(a.f[i](t,e),e),[])),a.u=t=>"static/js/"+t+".3c99cd73.chunk.js",a.miniCssF=t=>{},a.g=function(){if("object"===typeof globalThis)return globalThis;try{return this||new Function("return this")()}catch(t){if("object"===typeof window)return window}}(),a.o=(t,e)=>Object.prototype.hasOwnProperty.call(t,e),(()=>{var t={},e="myvetcorner:";a.l=(i,n,o,s)=>{if(t[i])t[i].push(n);else{var r,l;if(void 0!==o)for(var d=document.getElementsByTagName("script"),c=0;c<d.length;c++){var m=d[c];if(m.getAttribute("src")==i||m.getAttribute("data-webpack")==e+o){r=m;break}}r||(l=!0,(r=document.createElement("script")).charset="utf-8",a.nc&&r.setAttribute("nonce",a.nc),r.setAttribute("data-webpack",e+o),r.src=i),t[i]=[n];var u=(e,a)=>{r.onerror=r.onload=null,clearTimeout(h);var n=t[i];if(delete t[i],r.parentNode&&r.parentNode.removeChild(r),n&&n.forEach(t=>t(a)),e)return e(a)},h=setTimeout(u.bind(null,void 0,{type:"timeout",target:r}),12e4);r.onerror=u.bind(null,r.onerror),r.onload=u.bind(null,r.onload),l&&document.head.appendChild(r)}}})(),a.r=t=>{"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(t,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(t,"__esModule",{value:!0})},a.nmd=t=>(t.paths=[],t.children||(t.children=[]),t),a.p="/",(()=>{var t={792:0};a.f.j=(e,i)=>{var n=a.o(t,e)?t[e]:void 0;if(0!==n)if(n)i.push(n[2]);else{var o=new Promise((a,i)=>n=t[e]=[a,i]);i.push(n[2]=o);var s=a.p+a.u(e),r=new Error;a.l(s,i=>{if(a.o(t,e)&&(0!==(n=t[e])&&(t[e]=void 0),n)){var o=i&&("load"===i.type?"missing":i.type),s=i&&i.target&&i.target.src;r.message="Loading chunk "+e+" failed.\n("+o+": "+s+")",r.name="ChunkLoadError",r.type=o,r.request=s,n[1](r)}},"chunk-"+e,e)}};var e=(e,i)=>{var n,o,[s,r,l]=i,d=0;if(s.some(e=>0!==t[e])){for(n in r)a.o(r,n)&&(a.m[n]=r[n]);if(l)l(a)}for(e&&e(i);d<s.length;d++)o=s[d],a.o(t,o)&&t[o]&&t[o][0](),t[o]=0},i=self.webpackChunkmyvetcorner=self.webpackChunkmyvetcorner||[];i.forEach(e.bind(null,0)),i.push=e.bind(null,i.push.bind(i))})(),(()=>{"use strict";var t={};a.r(t),a.d(t,{Attributor:()=>Zn,AttributorStore:()=>io,BlockBlot:()=>po,ClassAttributor:()=>to,ContainerBlot:()=>bo,EmbedBlot:()=>vo,InlineBlot:()=>fo,LeafBlot:()=>ro,ParentBlot:()=>uo,Registry:()=>Yn,Scope:()=>Kn,ScrollBlot:()=>ko,StyleAttributor:()=>ao,TextBlot:()=>Co});var e,i=a(43),n=a.t(i,2),o=a(950),s=a.t(o,2);function r(){return r=Object.assign?Object.assign.bind():function(t){for(var e=1;e<arguments.length;e++){var a=arguments[e];for(var i in a)Object.prototype.hasOwnProperty.call(a,i)&&(t[i]=a[i])}return t},r.apply(this,arguments)}!function(t){t.Pop="POP",t.Push="PUSH",t.Replace="REPLACE"}(e||(e={}));const l="popstate";function d(t,e){if(!1===t||null===t||"undefined"===typeof t)throw new Error(e)}function c(t,e){if(!t){"undefined"!==typeof console&&console.warn(e);try{throw new Error(e)}catch(a){}}}function m(t,e){return{usr:t.state,key:t.key,idx:e}}function u(t,e,a,i){return void 0===a&&(a=null),r({pathname:"string"===typeof t?t:t.pathname,search:"",hash:""},"string"===typeof e?f(e):e,{state:a,key:e&&e.key||i||Math.random().toString(36).substr(2,8)})}function h(t){let{pathname:e="/",search:a="",hash:i=""}=t;return a&&"?"!==a&&(e+="?"===a.charAt(0)?a:"?"+a),i&&"#"!==i&&(e+="#"===i.charAt(0)?i:"#"+i),e}function f(t){let e={};if(t){let a=t.indexOf("#");a>=0&&(e.hash=t.substr(a),t=t.substr(0,a));let i=t.indexOf("?");i>=0&&(e.search=t.substr(i),t=t.substr(0,i)),t&&(e.pathname=t)}return e}function g(t,a,i,n){void 0===n&&(n={});let{window:o=document.defaultView,v5Compat:s=!1}=n,c=o.history,f=e.Pop,g=null,p=y();function y(){return(c.state||{idx:null}).idx}function b(){f=e.Pop;let t=y(),a=null==t?null:t-p;p=t,g&&g({action:f,location:w.location,delta:a})}function v(t){let e="null"!==o.location.origin?o.location.origin:o.location.href,a="string"===typeof t?t:h(t);return a=a.replace(/ $/,"%20"),d(e,"No window.location.(origin|href) available to create URL for href: "+a),new URL(a,e)}null==p&&(p=0,c.replaceState(r({},c.state,{idx:p}),""));let w={get action(){return f},get location(){return t(o,c)},listen(t){if(g)throw new Error("A history only accepts one active listener");return o.addEventListener(l,b),g=t,()=>{o.removeEventListener(l,b),g=null}},createHref:t=>a(o,t),createURL:v,encodeLocation(t){let e=v(t);return{pathname:e.pathname,search:e.search,hash:e.hash}},push:function(t,a){f=e.Push;let n=u(w.location,t,a);i&&i(n,t),p=y()+1;let r=m(n,p),l=w.createHref(n);try{c.pushState(r,"",l)}catch(d){if(d instanceof DOMException&&"DataCloneError"===d.name)throw d;o.location.assign(l)}s&&g&&g({action:f,location:w.location,delta:1})},replace:function(t,a){f=e.Replace;let n=u(w.location,t,a);i&&i(n,t),p=y();let o=m(n,p),r=w.createHref(n);c.replaceState(o,"",r),s&&g&&g({action:f,location:w.location,delta:0})},go:t=>c.go(t)};return w}var p;!function(t){t.data="data",t.deferred="deferred",t.redirect="redirect",t.error="error"}(p||(p={}));new Set(["lazy","caseSensitive","path","id","index","children"]);function y(t,e,a){return void 0===a&&(a="/"),b(t,e,a,!1)}function b(t,e,a,i){let n=E(("string"===typeof e?f(e):e).pathname||"/",a);if(null==n)return null;let o=v(t);!function(t){t.sort((t,e)=>t.score!==e.score?e.score-t.score:function(t,e){let a=t.length===e.length&&t.slice(0,-1).every((t,a)=>t===e[a]);return a?t[t.length-1]-e[e.length-1]:0}(t.routesMeta.map(t=>t.childrenIndex),e.routesMeta.map(t=>t.childrenIndex)))}(o);let s=null;for(let r=0;null==s&&r<o.length;++r){let t=L(n);s=D(o[r],t,i)}return s}function v(t,e,a,i){void 0===e&&(e=[]),void 0===a&&(a=[]),void 0===i&&(i="");let n=(t,n,o)=>{let s={relativePath:void 0===o?t.path||"":o,caseSensitive:!0===t.caseSensitive,childrenIndex:n,route:t};s.relativePath.startsWith("/")&&(d(s.relativePath.startsWith(i),'Absolute route path "'+s.relativePath+'" nested under path "'+i+'" is not valid. An absolute child route path must start with the combined path of all its parent routes.'),s.relativePath=s.relativePath.slice(i.length));let r=O([i,s.relativePath]),l=a.concat(s);t.children&&t.children.length>0&&(d(!0!==t.index,'Index routes must not have child routes. Please remove all child routes from route path "'+r+'".'),v(t.children,e,l,r)),(null!=t.path||t.index)&&e.push({path:r,score:P(r,t.index),routesMeta:l})};return t.forEach((t,e)=>{var a;if(""!==t.path&&null!=(a=t.path)&&a.includes("?"))for(let i of w(t.path))n(t,e,i);else n(t,e)}),e}function w(t){let e=t.split("/");if(0===e.length)return[];let[a,...i]=e,n=a.endsWith("?"),o=a.replace(/\?$/,"");if(0===i.length)return n?[o,""]:[o];let s=w(i.join("/")),r=[];return r.push(...s.map(t=>""===t?o:[o,t].join("/"))),n&&r.push(...s),r.map(e=>t.startsWith("/")&&""===e?"/":e)}const x=/^:[\w-]+$/,k=3,I=2,C=1,S=10,A=-2,T=t=>"*"===t;function P(t,e){let a=t.split("/"),i=a.length;return a.some(T)&&(i+=A),e&&(i+=I),a.filter(t=>!T(t)).reduce((t,e)=>t+(x.test(e)?k:""===e?C:S),i)}function D(t,e,a){void 0===a&&(a=!1);let{routesMeta:i}=t,n={},o="/",s=[];for(let r=0;r<i.length;++r){let t=i[r],l=r===i.length-1,d="/"===o?e:e.slice(o.length)||"/",c=N({path:t.relativePath,caseSensitive:t.caseSensitive,end:l},d),m=t.route;if(!c&&l&&a&&!i[i.length-1].route.index&&(c=N({path:t.relativePath,caseSensitive:t.caseSensitive,end:!1},d)),!c)return null;Object.assign(n,c.params),s.push({params:n,pathname:O([o,c.pathname]),pathnameBase:U(O([o,c.pathnameBase])),route:m}),"/"!==c.pathnameBase&&(o=O([o,c.pathnameBase]))}return s}function N(t,e){"string"===typeof t&&(t={path:t,caseSensitive:!1,end:!0});let[a,i]=function(t,e,a){void 0===e&&(e=!1);void 0===a&&(a=!0);c("*"===t||!t.endsWith("*")||t.endsWith("/*"),'Route path "'+t+'" will be treated as if it were "'+t.replace(/\*$/,"/*")+'" because the `*` character must always follow a `/` in the pattern. To get rid of this warning, please change the route path to "'+t.replace(/\*$/,"/*")+'".');let i=[],n="^"+t.replace(/\/*\*?$/,"").replace(/^\/*/,"/").replace(/[\\.*+^${}|()[\]]/g,"\\$&").replace(/\/:([\w-]+)(\?)?/g,(t,e,a)=>(i.push({paramName:e,isOptional:null!=a}),a?"/?([^\\/]+)?":"/([^\\/]+)"));t.endsWith("*")?(i.push({paramName:"*"}),n+="*"===t||"/*"===t?"(.*)$":"(?:\\/(.+)|\\/*)$"):a?n+="\\/*$":""!==t&&"/"!==t&&(n+="(?:(?=\\/|$))");let o=new RegExp(n,e?void 0:"i");return[o,i]}(t.path,t.caseSensitive,t.end),n=e.match(a);if(!n)return null;let o=n[0],s=o.replace(/(.)\/+$/,"$1"),r=n.slice(1);return{params:i.reduce((t,e,a)=>{let{paramName:i,isOptional:n}=e;if("*"===i){let t=r[a]||"";s=o.slice(0,o.length-t.length).replace(/(.)\/+$/,"$1")}const l=r[a];return t[i]=n&&!l?void 0:(l||"").replace(/%2F/g,"/"),t},{}),pathname:o,pathnameBase:s,pattern:t}}function L(t){try{return t.split("/").map(t=>decodeURIComponent(t).replace(/\//g,"%2F")).join("/")}catch(e){return c(!1,'The URL path "'+t+'" could not be decoded because it is is a malformed URL segment. This is probably due to a bad percent encoding ('+e+")."),t}}function E(t,e){if("/"===e)return t;if(!t.toLowerCase().startsWith(e.toLowerCase()))return null;let a=e.endsWith("/")?e.length-1:e.length,i=t.charAt(a);return i&&"/"!==i?null:t.slice(a)||"/"}const j=/^(?:[a-z][a-z0-9+.-]*:|\/\/)/i;function M(t,e){void 0===e&&(e="/");let a,{pathname:i,search:n="",hash:o=""}="string"===typeof t?f(t):t;if(i)if(s=i,j.test(s))a=i;else{if(i.includes("//")){let t=i;i=i.replace(/\/\/+/g,"/"),c(!1,"Pathnames cannot have embedded double slashes - normalizing "+t+" -> "+i)}a=i.startsWith("/")?z(i.substring(1),"/"):z(i,e)}else a=e;var s;return{pathname:a,search:H(n),hash:V(o)}}function z(t,e){let a=e.replace(/\/+$/,"").split("/");return t.split("/").forEach(t=>{".."===t?a.length>1&&a.pop():"."!==t&&a.push(t)}),a.length>1?a.join("/"):"/"}function R(t,e,a,i){return"Cannot include a '"+t+"' character in a manually specified `to."+e+"` field ["+JSON.stringify(i)+"].  Please separate it out to the `to."+a+'` field. Alternatively you may provide the full path as a string in <Link to="..."> and the router will parse it for you.'}function F(t){return t.filter((t,e)=>0===e||t.route.path&&t.route.path.length>0)}function q(t,e){let a=F(t);return e?a.map((t,e)=>e===a.length-1?t.pathname:t.pathnameBase):a.map(t=>t.pathnameBase)}function _(t,e,a,i){let n;void 0===i&&(i=!1),"string"===typeof t?n=f(t):(n=r({},t),d(!n.pathname||!n.pathname.includes("?"),R("?","pathname","search",n)),d(!n.pathname||!n.pathname.includes("#"),R("#","pathname","hash",n)),d(!n.search||!n.search.includes("#"),R("#","search","hash",n)));let o,s=""===t||""===n.pathname,l=s?"/":n.pathname;if(null==l)o=a;else{let t=e.length-1;if(!i&&l.startsWith("..")){let e=l.split("/");for(;".."===e[0];)e.shift(),t-=1;n.pathname=e.join("/")}o=t>=0?e[t]:"/"}let c=M(n,o),m=l&&"/"!==l&&l.endsWith("/"),u=(s||"."===l)&&a.endsWith("/");return c.pathname.endsWith("/")||!m&&!u||(c.pathname+="/"),c}const O=t=>t.join("/").replace(/\/\/+/g,"/"),U=t=>t.replace(/\/+$/,"").replace(/^\/*/,"/"),H=t=>t&&"?"!==t?t.startsWith("?")?t:"?"+t:"",V=t=>t&&"#"!==t?t.startsWith("#")?t:"#"+t:"";Error;function B(t){return null!=t&&"number"===typeof t.status&&"string"===typeof t.statusText&&"boolean"===typeof t.internal&&"data"in t}const G=["post","put","patch","delete"],W=(new Set(G),["get",...G]);new Set(W),new Set([301,302,303,307,308]),new Set([307,308]);Symbol("deferred");function Q(){return Q=Object.assign?Object.assign.bind():function(t){for(var e=1;e<arguments.length;e++){var a=arguments[e];for(var i in a)Object.prototype.hasOwnProperty.call(a,i)&&(t[i]=a[i])}return t},Q.apply(this,arguments)}const K=i.createContext(null);const Z=i.createContext(null);const $=i.createContext(null);const X=i.createContext(null);const Y=i.createContext({outlet:null,matches:[],isDataRoute:!1});const J=i.createContext(null);function tt(){return null!=i.useContext(X)}function et(){return tt()||d(!1),i.useContext(X).location}function at(t){i.useContext($).static||i.useLayoutEffect(t)}function it(){let{isDataRoute:t}=i.useContext(Y);return t?function(){let{router:t}=ht(mt.UseNavigateStable),e=gt(ut.UseNavigateStable),a=i.useRef(!1);return at(()=>{a.current=!0}),i.useCallback(function(i,n){void 0===n&&(n={}),a.current&&("number"===typeof i?t.navigate(i):t.navigate(i,Q({fromRouteId:e},n)))},[t,e])}():function(){tt()||d(!1);let t=i.useContext(K),{basename:e,future:a,navigator:n}=i.useContext($),{matches:o}=i.useContext(Y),{pathname:s}=et(),r=JSON.stringify(q(o,a.v7_relativeSplatPath)),l=i.useRef(!1);return at(()=>{l.current=!0}),i.useCallback(function(a,i){if(void 0===i&&(i={}),!l.current)return;if("number"===typeof a)return void n.go(a);let o=_(a,JSON.parse(r),s,"path"===i.relative);null==t&&"/"!==e&&(o.pathname="/"===o.pathname?e:O([e,o.pathname])),(i.replace?n.replace:n.push)(o,i.state,i)},[e,n,r,s,t])}()}function nt(t,e){let{relative:a}=void 0===e?{}:e,{future:n}=i.useContext($),{matches:o}=i.useContext(Y),{pathname:s}=et(),r=JSON.stringify(q(o,n.v7_relativeSplatPath));return i.useMemo(()=>_(t,JSON.parse(r),s,"path"===a),[t,r,s,a])}function ot(t,a,n,o){tt()||d(!1);let{navigator:s}=i.useContext($),{matches:r}=i.useContext(Y),l=r[r.length-1],c=l?l.params:{},m=(l&&l.pathname,l?l.pathnameBase:"/");l&&l.route;let u,h=et();if(a){var g;let t="string"===typeof a?f(a):a;"/"===m||(null==(g=t.pathname)?void 0:g.startsWith(m))||d(!1),u=t}else u=h;let p=u.pathname||"/",b=p;if("/"!==m){let t=m.replace(/^\//,"").split("/");b="/"+p.replace(/^\//,"").split("/").slice(t.length).join("/")}let v=y(t,{pathname:b});let w=ct(v&&v.map(t=>Object.assign({},t,{params:Object.assign({},c,t.params),pathname:O([m,s.encodeLocation?s.encodeLocation(t.pathname).pathname:t.pathname]),pathnameBase:"/"===t.pathnameBase?m:O([m,s.encodeLocation?s.encodeLocation(t.pathnameBase).pathname:t.pathnameBase])})),r,n,o);return a&&w?i.createElement(X.Provider,{value:{location:Q({pathname:"/",search:"",hash:"",state:null,key:"default"},u),navigationType:e.Pop}},w):w}function st(){let t=function(){var t;let e=i.useContext(J),a=ft(ut.UseRouteError),n=gt(ut.UseRouteError);if(void 0!==e)return e;return null==(t=a.errors)?void 0:t[n]}(),e=B(t)?t.status+" "+t.statusText:t instanceof Error?t.message:JSON.stringify(t),a=t instanceof Error?t.stack:null,n="rgba(200,200,200, 0.5)",o={padding:"0.5rem",backgroundColor:n};return i.createElement(i.Fragment,null,i.createElement("h2",null,"Unexpected Application Error!"),i.createElement("h3",{style:{fontStyle:"italic"}},e),a?i.createElement("pre",{style:o},a):null,null)}const rt=i.createElement(st,null);class lt extends i.Component{constructor(t){super(t),this.state={location:t.location,revalidation:t.revalidation,error:t.error}}static getDerivedStateFromError(t){return{error:t}}static getDerivedStateFromProps(t,e){return e.location!==t.location||"idle"!==e.revalidation&&"idle"===t.revalidation?{error:t.error,location:t.location,revalidation:t.revalidation}:{error:void 0!==t.error?t.error:e.error,location:e.location,revalidation:t.revalidation||e.revalidation}}componentDidCatch(t,e){console.error("React Router caught the following error during render",t,e)}render(){return void 0!==this.state.error?i.createElement(Y.Provider,{value:this.props.routeContext},i.createElement(J.Provider,{value:this.state.error,children:this.props.component})):this.props.children}}function dt(t){let{routeContext:e,match:a,children:n}=t,o=i.useContext(K);return o&&o.static&&o.staticContext&&(a.route.errorElement||a.route.ErrorBoundary)&&(o.staticContext._deepestRenderedBoundaryId=a.route.id),i.createElement(Y.Provider,{value:e},n)}function ct(t,e,a,n){var o;if(void 0===e&&(e=[]),void 0===a&&(a=null),void 0===n&&(n=null),null==t){var s;if(!a)return null;if(a.errors)t=a.matches;else{if(!(null!=(s=n)&&s.v7_partialHydration&&0===e.length&&!a.initialized&&a.matches.length>0))return null;t=a.matches}}let r=t,l=null==(o=a)?void 0:o.errors;if(null!=l){let t=r.findIndex(t=>t.route.id&&void 0!==(null==l?void 0:l[t.route.id]));t>=0||d(!1),r=r.slice(0,Math.min(r.length,t+1))}let c=!1,m=-1;if(a&&n&&n.v7_partialHydration)for(let i=0;i<r.length;i++){let t=r[i];if((t.route.HydrateFallback||t.route.hydrateFallbackElement)&&(m=i),t.route.id){let{loaderData:e,errors:i}=a,n=t.route.loader&&void 0===e[t.route.id]&&(!i||void 0===i[t.route.id]);if(t.route.lazy||n){c=!0,r=m>=0?r.slice(0,m+1):[r[0]];break}}}return r.reduceRight((t,n,o)=>{let s,d=!1,u=null,h=null;var f;a&&(s=l&&n.route.id?l[n.route.id]:void 0,u=n.route.errorElement||rt,c&&(m<0&&0===o?(f="route-fallback",!1||pt[f]||(pt[f]=!0),d=!0,h=null):m===o&&(d=!0,h=n.route.hydrateFallbackElement||null)));let g=e.concat(r.slice(0,o+1)),p=()=>{let e;return e=s?u:d?h:n.route.Component?i.createElement(n.route.Component,null):n.route.element?n.route.element:t,i.createElement(dt,{match:n,routeContext:{outlet:t,matches:g,isDataRoute:null!=a},children:e})};return a&&(n.route.ErrorBoundary||n.route.errorElement||0===o)?i.createElement(lt,{location:a.location,revalidation:a.revalidation,component:u,error:s,children:p(),routeContext:{outlet:null,matches:g,isDataRoute:!0}}):p()},null)}var mt=function(t){return t.UseBlocker="useBlocker",t.UseRevalidator="useRevalidator",t.UseNavigateStable="useNavigate",t}(mt||{}),ut=function(t){return t.UseBlocker="useBlocker",t.UseLoaderData="useLoaderData",t.UseActionData="useActionData",t.UseRouteError="useRouteError",t.UseNavigation="useNavigation",t.UseRouteLoaderData="useRouteLoaderData",t.UseMatches="useMatches",t.UseRevalidator="useRevalidator",t.UseNavigateStable="useNavigate",t.UseRouteId="useRouteId",t}(ut||{});function ht(t){let e=i.useContext(K);return e||d(!1),e}function ft(t){let e=i.useContext(Z);return e||d(!1),e}function gt(t){let e=function(){let t=i.useContext(Y);return t||d(!1),t}(),a=e.matches[e.matches.length-1];return a.route.id||d(!1),a.route.id}const pt={};function yt(t,e){null==t||t.v7_startTransition,void 0===(null==t?void 0:t.v7_relativeSplatPath)&&(!e||e.v7_relativeSplatPath),e&&(e.v7_fetcherPersist,e.v7_normalizeFormMethod,e.v7_partialHydration,e.v7_skipActionErrorRevalidation)}n.startTransition;function bt(t){let{to:e,replace:a,state:n,relative:o}=t;tt()||d(!1);let{future:s,static:r}=i.useContext($),{matches:l}=i.useContext(Y),{pathname:c}=et(),m=it(),u=_(e,q(l,s.v7_relativeSplatPath),c,"path"===o),h=JSON.stringify(u);return i.useEffect(()=>m(JSON.parse(h),{replace:a,state:n,relative:o}),[m,h,o,a,n]),null}function vt(t){d(!1)}function wt(t){let{basename:a="/",children:n=null,location:o,navigationType:s=e.Pop,navigator:r,static:l=!1,future:c}=t;tt()&&d(!1);let m=a.replace(/^\/*/,"/"),u=i.useMemo(()=>({basename:m,navigator:r,static:l,future:Q({v7_relativeSplatPath:!1},c)}),[m,c,r,l]);"string"===typeof o&&(o=f(o));let{pathname:h="/",search:g="",hash:p="",state:y=null,key:b="default"}=o,v=i.useMemo(()=>{let t=E(h,m);return null==t?null:{location:{pathname:t,search:g,hash:p,state:y,key:b},navigationType:s}},[m,h,g,p,y,b,s]);return null==v?null:i.createElement($.Provider,{value:u},i.createElement(X.Provider,{children:n,value:v}))}function xt(t){let{children:e,location:a}=t;return ot(kt(e),a)}new Promise(()=>{});i.Component;function kt(t,e){void 0===e&&(e=[]);let a=[];return i.Children.forEach(t,(t,n)=>{if(!i.isValidElement(t))return;let o=[...e,n];if(t.type===i.Fragment)return void a.push.apply(a,kt(t.props.children,o));t.type!==vt&&d(!1),t.props.index&&t.props.children&&d(!1);let s={id:t.props.id||o.join("-"),caseSensitive:t.props.caseSensitive,element:t.props.element,Component:t.props.Component,index:t.props.index,path:t.props.path,loader:t.props.loader,action:t.props.action,errorElement:t.props.errorElement,ErrorBoundary:t.props.ErrorBoundary,hasErrorBoundary:null!=t.props.ErrorBoundary||null!=t.props.errorElement,shouldRevalidate:t.props.shouldRevalidate,handle:t.props.handle,lazy:t.props.lazy};t.props.children&&(s.children=kt(t.props.children,o)),a.push(s)}),a}function It(){return It=Object.assign?Object.assign.bind():function(t){for(var e=1;e<arguments.length;e++){var a=arguments[e];for(var i in a)Object.prototype.hasOwnProperty.call(a,i)&&(t[i]=a[i])}return t},It.apply(this,arguments)}function Ct(t,e){if(null==t)return{};var a,i,n={},o=Object.keys(t);for(i=0;i<o.length;i++)a=o[i],e.indexOf(a)>=0||(n[a]=t[a]);return n}new Set(["application/x-www-form-urlencoded","multipart/form-data","text/plain"]);const St=["onClick","relative","reloadDocument","replace","state","target","to","preventScrollReset","viewTransition"],At=["aria-current","caseSensitive","className","end","style","to","viewTransition","children"];try{window.__reactRouterVersion="6"}catch(cu){}const Tt=i.createContext({isTransitioning:!1});new Map;const Pt=n.startTransition;s.flushSync,n.useId;function Dt(t){let{basename:e,children:a,future:n,window:o}=t,s=i.useRef();var r;null==s.current&&(s.current=(void 0===(r={window:o,v5Compat:!0})&&(r={}),g(function(t,e){let{pathname:a,search:i,hash:n}=t.location;return u("",{pathname:a,search:i,hash:n},e.state&&e.state.usr||null,e.state&&e.state.key||"default")},function(t,e){return"string"===typeof e?e:h(e)},null,r)));let l=s.current,[d,c]=i.useState({action:l.action,location:l.location}),{v7_startTransition:m}=n||{},f=i.useCallback(t=>{m&&Pt?Pt(()=>c(t)):c(t)},[c,m]);return i.useLayoutEffect(()=>l.listen(f),[l,f]),i.useEffect(()=>yt(n),[n]),i.createElement(wt,{basename:e,children:a,location:d.location,navigationType:d.action,navigator:l,future:n})}const Nt="undefined"!==typeof window&&"undefined"!==typeof window.document&&"undefined"!==typeof window.document.createElement,Lt=/^(?:[a-z][a-z0-9+.-]*:|\/\/)/i,Et=i.forwardRef(function(t,e){let a,{onClick:n,relative:o,reloadDocument:s,replace:r,state:l,target:c,to:m,preventScrollReset:u,viewTransition:f}=t,g=Ct(t,St),{basename:p}=i.useContext($),y=!1;if("string"===typeof m&&Lt.test(m)&&(a=m,Nt))try{let t=new URL(window.location.href),e=m.startsWith("//")?new URL(t.protocol+m):new URL(m),a=E(e.pathname,p);e.origin===t.origin&&null!=a?m=a+e.search+e.hash:y=!0}catch(cu){}let b=function(t,e){let{relative:a}=void 0===e?{}:e;tt()||d(!1);let{basename:n,navigator:o}=i.useContext($),{hash:s,pathname:r,search:l}=nt(t,{relative:a}),c=r;return"/"!==n&&(c="/"===r?n:O([n,r])),o.createHref({pathname:c,search:l,hash:s})}(m,{relative:o}),v=function(t,e){let{target:a,replace:n,state:o,preventScrollReset:s,relative:r,viewTransition:l}=void 0===e?{}:e,d=it(),c=et(),m=nt(t,{relative:r});return i.useCallback(e=>{if(function(t,e){return 0===t.button&&(!e||"_self"===e)&&!function(t){return!!(t.metaKey||t.altKey||t.ctrlKey||t.shiftKey)}(t)}(e,a)){e.preventDefault();let a=void 0!==n?n:h(c)===h(m);d(t,{replace:a,state:o,preventScrollReset:s,relative:r,viewTransition:l})}},[c,d,m,n,o,a,t,s,r,l])}(m,{replace:r,state:l,target:c,preventScrollReset:u,relative:o,viewTransition:f});return i.createElement("a",It({},g,{href:a||b,onClick:y||s?n:function(t){n&&n(t),t.defaultPrevented||v(t)},ref:e,target:c}))});const jt=i.forwardRef(function(t,e){let{"aria-current":a="page",caseSensitive:n=!1,className:o="",end:s=!1,style:r,to:l,viewTransition:c,children:m}=t,u=Ct(t,At),h=nt(l,{relative:u.relative}),f=et(),g=i.useContext(Z),{navigator:p,basename:y}=i.useContext($),b=null!=g&&function(t,e){void 0===e&&(e={});let a=i.useContext(Tt);null==a&&d(!1);let{basename:n}=Rt(Mt.useViewTransitionState),o=nt(t,{relative:e.relative});if(!a.isTransitioning)return!1;let s=E(a.currentLocation.pathname,n)||a.currentLocation.pathname,r=E(a.nextLocation.pathname,n)||a.nextLocation.pathname;return null!=N(o.pathname,r)||null!=N(o.pathname,s)}(h)&&!0===c,v=p.encodeLocation?p.encodeLocation(h).pathname:h.pathname,w=f.pathname,x=g&&g.navigation&&g.navigation.location?g.navigation.location.pathname:null;n||(w=w.toLowerCase(),x=x?x.toLowerCase():null,v=v.toLowerCase()),x&&y&&(x=E(x,y)||x);const k="/"!==v&&v.endsWith("/")?v.length-1:v.length;let I,C=w===v||!s&&w.startsWith(v)&&"/"===w.charAt(k),S=null!=x&&(x===v||!s&&x.startsWith(v)&&"/"===x.charAt(v.length)),A={isActive:C,isPending:S,isTransitioning:b},T=C?a:void 0;I="function"===typeof o?o(A):[o,C?"active":null,S?"pending":null,b?"transitioning":null].filter(Boolean).join(" ");let P="function"===typeof r?r(A):r;return i.createElement(Et,It({},u,{"aria-current":T,className:I,ref:e,style:P,to:l,viewTransition:c}),"function"===typeof m?m(A):m)});var Mt,zt;function Rt(t){let e=i.useContext(K);return e||d(!1),e}(function(t){t.UseScrollRestoration="useScrollRestoration",t.UseSubmit="useSubmit",t.UseSubmitFetcher="useSubmitFetcher",t.UseFetcher="useFetcher",t.useViewTransitionState="useViewTransitionState"})(Mt||(Mt={})),function(t){t.UseFetcher="useFetcher",t.UseFetchers="useFetchers",t.UseScrollRestoration="useScrollRestoration"}(zt||(zt={}));var Ft=a(391);function qt(t){return qt="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t},qt(t)}function _t(t){var e=function(t,e){if("object"!=qt(t)||!t)return t;var a=t[Symbol.toPrimitive];if(void 0!==a){var i=a.call(t,e||"default");if("object"!=qt(i))return i;throw new TypeError("@@toPrimitive must return a primitive value.")}return("string"===e?String:Number)(t)}(t,"string");return"symbol"==qt(e)?e:e+""}function Ot(t,e,a){return(e=_t(e))in t?Object.defineProperty(t,e,{value:a,enumerable:!0,configurable:!0,writable:!0}):t[e]=a,t}function Ut(t,e){var a=Object.keys(t);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(t);e&&(i=i.filter(function(e){return Object.getOwnPropertyDescriptor(t,e).enumerable})),a.push.apply(a,i)}return a}function Ht(t){for(var e=1;e<arguments.length;e++){var a=null!=arguments[e]?arguments[e]:{};e%2?Ut(Object(a),!0).forEach(function(e){Ot(t,e,a[e])}):Object.getOwnPropertyDescriptors?Object.defineProperties(t,Object.getOwnPropertyDescriptors(a)):Ut(Object(a)).forEach(function(e){Object.defineProperty(t,e,Object.getOwnPropertyDescriptor(a,e))})}return t}function Vt(t){const e={Dogs:"/dogs",Cats:"/cats","Small Mammals":"/small-mammals",Chickens:"/chickens",Ducks:"/ducks",Turkeys:"/turkeys","Disease Management":"/disease-management","Pet Nutrition":"/pet-nutrition","Poultry Nutrition":"/poultry-nutrition","Research & Journals":"/research-journals","Pet Health":"/pet-health","Poultry Health":"/poultry-health",Nutrition:"/nutrition",Resources:"/resources","Vet Finder":"/vet-finder","Drug Index":"/drug-index","Dog Health":"/dogs","Cat Care":"/cats","Backyard Poultry":"/backyard-poultry","Research Archive":"/research-journals","Editorial Policy":"/editorial-policy","Medical Review Board":"/medical-review-board",Careers:"/careers"}[t];return e||"/"+t.toLowerCase().replace(/&/g,"and").replace(/[^a-z0-9]+/g,"-").replace(/(^-|-$)/g,"")}const Bt={site:{name:"My Vet Corner",tagline:"Expert Pet & Poultry Health Resources",description:"Your trusted source for expert veterinary information on pets and poultry."},adminPassword:"Master@47",slides:[{tag:"Featured Article",title:"The Ultimate Guide to Chicken Coop Hygiene",excerpt:"Learn essential biosecurity practices and cleaning protocols to keep your flock healthy and productive year-round.",image:"https://images.unsplash.com/photo-1548550023-2bdb3c5beed7?w=800&h=500&fit=crop",readTime:"5 min read"},{tag:"Latest Research",title:"Latest Research on Canine Parvovirus Prevention",excerpt:"New studies reveal breakthrough vaccination protocols that could significantly reduce parvovirus cases in puppies.",image:"https://images.unsplash.com/photo-1587300003388-59208cc962cb?w=800&h=500&fit=crop",readTime:"7 min read"},{tag:"Pet Nutrition",title:"Understanding Your Cat's Nutritional Needs",excerpt:"Expert veterinarians share insights on optimal feline nutrition for every life stage.",image:"https://images.unsplash.com/photo-1514888286974-6c03e2ca1dba?w=800&h=500&fit=crop",readTime:"6 min read"}],stats:[{value:"500+",label:"Vet-Reviewed Articles",icon:"shield"},{value:"Latest",label:"Poultry Research",icon:"book"},{value:"50,000+",label:"Trusted Owners",icon:"users"},{value:"Expert",label:"Medical Board",icon:"lab"}],articles:[{image:"https://images.unsplash.com/photo-1587300003388-59208cc962cb?w=600&h=400&fit=crop",category:"Dog Health",categoryColor:"blue",title:"Latest Research on Canine Parvovirus Prevention",excerpt:"New studies reveal breakthrough vaccination protocols that could significantly reduce parvovirus cases in puppies.",date:"Dec 15, 2024",readTime:"7 min read",published:!0},{image:"https://images.unsplash.com/photo-1569396116180-210c182bedb8?w=600&h=400&fit=crop",category:"Poultry Nutrition",categoryColor:"green",title:"Optimal Layer Feed Formulations for Maximum Egg Production",excerpt:"Expert nutritionists share their recommended calcium and protein ratios for healthy laying hens.",date:"Dec 14, 2024",readTime:"5 min read",published:!0},{image:"https://images.unsplash.com/photo-1514888286974-6c03e2ca1dba?w=600&h=400&fit=crop",category:"Cat Care",categoryColor:"purple",title:"Understanding Feline Kidney Disease: Early Detection Signs",excerpt:"Recognize the subtle symptoms of CKD in cats and learn preventive care strategies from veterinary experts.",date:"Dec 13, 2024",readTime:"6 min read",published:!0}],experts:[{name:"Dr. Sarah Mitchell",title:"DVM, DACVIM",specialty:"Small Animal Internal Medicine",image:"https://images.unsplash.com/photo-1559839734-2b71ea197ec2?w=200&h=200&fit=crop&crop=face"},{name:"Dr. James Chen",title:"PhD, Poultry Science",specialty:"Avian Health & Nutrition",image:"https://images.unsplash.com/photo-1612349317150-e413f6a5b16d?w=200&h=200&fit=crop&crop=face"},{name:"Dr. Emily Rodriguez",title:"DVM, MS",specialty:"Veterinary Nutrition",image:"https://images.unsplash.com/photo-1594824476967-48c8b964273f?w=200&h=200&fit=crop&crop=face"}],categories:[{name:"Dogs",count:"",image:"https://images.unsplash.com/photo-1543466835-00a7907e9de1?auto=format&fit=crop&w=800&q=80"},{name:"Cats",count:"",image:"https://images.unsplash.com/photo-1514888286974-6c03e2ca1dba?auto=format&fit=crop&w=800&q=80"},{name:"Small Mammals",count:"",image:"https://images.unsplash.com/photo-1585110396063-7a9a0427d2c0?auto=format&fit=crop&w=800&q=80"},{name:"Chickens",count:"",image:"https://images.unsplash.com/photo-1548550023-2bdb3c5beed7?auto=format&fit=crop&w=800&q=80"},{name:"Ducks",count:"",image:"https://images.unsplash.com/photo-1555852095-64e7428df0fa?auto=format&fit=crop&w=800&q=80"},{name:"Turkeys",count:"",image:"https://images.unsplash.com/photo-1560709409-d7790b53d4c5?auto=format&fit=crop&w=800&q=80"},{name:"Disease Management",count:"",image:"https://images.unsplash.com/photo-1576086213369-97a306d36557?auto=format&fit=crop&w=800&q=80"},{name:"Pet Nutrition",count:"",image:"https://images.unsplash.com/photo-1589924691195-41432c84c161?auto=format&fit=crop&w=800&q=80"},{name:"Poultry Nutrition",count:"",image:"https://images.unsplash.com/photo-1563514227147-6d22fc0293ec?auto=format&fit=crop&w=800&q=80"},{name:"Research & Journals",count:"",image:"https://images.unsplash.com/photo-1532094349884-543bc11b234d?auto=format&fit=crop&w=800&q=80"},{name:"Vet Finder",count:"",image:"https://images.unsplash.com/photo-1559839734-2b71ea197ec2?auto=format&fit=crop&w=800&q=80"},{name:"Drug Index",count:"",image:"https://images.unsplash.com/photo-1587854692152-cbe660dbde88?auto=format&fit=crop&w=800&q=80"}],research:[{type:"Peer Reviewed",typeColor:"blue",year:"2024",title:"Efficacy of Novel Vaccination Protocols in Preventing Marek's Disease in Commercial Layer Flocks",authors:"Chen, J., Thompson, M., et al.",journal:"Journal of Avian Medicine and Surgery, Vol. 38(2)",abstract:"This study evaluates protocols against Marek's disease in commercial layer operations..."},{type:"Clinical Study",typeColor:"green",year:"2024",title:"Gut Microbiome Diversity and Its Impact on Canine Digestive Health",authors:"Mitchell, S., Rodriguez, E., et al.",journal:"Veterinary Internal Medicine Journal, Vol. 42(4)",abstract:"This longitudinal study examines microbiome composition and digestive health outcomes..."}],newsletter:{title:"Stay Updated",subtitle:"Get the latest vet-reviewed pet and poultry health articles delivered to your inbox weekly.",buttonText:"Subscribe Now",footerText:"Join 50,000+ pet and poultry owners. Unsubscribe anytime."},footer:{description:"Your trusted source for expert veterinary information on pets and poultry.",socialLinks:[{platform:"Twitter",url:"#"},{platform:"Facebook",url:"#"},{platform:"Instagram",url:"#"}],quickLinks:["Pet Health","Poultry Health","Nutrition Guides","Research & Journals","Vet Finder"],companyLinks:["About Us","Editorial Policy","Medical Review Board","Contact Us","Careers"],legalLinks:["Privacy Policy","Terms of Service","Cookie Policy","Disclaimer"],copyright:"\xa9 2024 My Vet Corner. All rights reserved.",disclaimerText:"Content is for informational purposes only and does not replace professional veterinary advice."},navigation:[{label:"Pet Health",dropdown:["Dogs","Cats","Small Mammals"]},{label:"Poultry Health",dropdown:["Chickens","Ducks","Turkeys","Disease Management"]},{label:"Nutrition",dropdown:["Pet Nutrition","Poultry Nutrition"]},{label:"Research & Journals",dropdown:[]},{label:"Resources",dropdown:["Vet Finder","Drug Index"]}],tags:["health","nutrition","research"],media:[],comments:[{author:"Guest",text:"Great article!",at:"2024-12-01",status:"pending"}],users:[{name:"Admin",email:"admin@example.com",role:"admin",twoFA:!1}],versions:[],settings:{injectScript:""},homeLayout:["hero","stats","articles","experts","categories","research","newsletter","footer"],theme:{primary:"#1e40af",secondary:"#374151",radius:12},integrations:{gaId:"",fbPixel:""},locales:["en"],defaultLocale:"en",translations:{},security:{twoFARequired:!1},performance:{lazyImages:!0,prefetchRoutes:!1},logs:[]};var Gt=a(579);const Wt=(0,i.createContext)();function Qt(t){let{children:e}=t;const[a,n]=(0,i.useState)(()=>{const t=localStorage.getItem("vetCornerData");return t?JSON.parse(t):Bt}),[o,s]=(0,i.useState)(!0);return(0,i.useEffect)(()=>{(async function(){try{const[t,e,a,i,n,o,s,r,l]=await Promise.all([fetch("/content/articles.json").then(t=>t.json()).catch(()=>[]),fetch("/content/research.json").then(t=>t.json()).catch(()=>[]),fetch("/content/experts.json").then(t=>t.json()).catch(()=>[]),fetch("/content/categories.json").then(t=>t.json()).catch(()=>[]),fetch("/content/media.json").then(t=>t.json()).catch(()=>[]),fetch("/content/slides.json").then(t=>t.json()).catch(()=>[]),fetch("/content/users.json").then(t=>t.json()).catch(()=>[]),fetch("/content/comments.json").then(t=>t.json()).catch(()=>[]),fetch("/content/site-config.json").then(t=>t.json()).catch(()=>({}))]);return Ht(Ht({},l),{},{articles:t,research:e,experts:a,categories:i,media:n,slides:o,users:s,comments:r})}catch(t){return console.error("Failed to load content from JSON:",t),Bt}})().then(t=>{const e=localStorage.getItem("vetCornerData");if(e){const a=JSON.parse(e);n(Ht(Ht({},t),a))}else n(t);s(!1)})},[]),(0,i.useEffect)(()=>{o||localStorage.setItem("vetCornerData",JSON.stringify(a))},[a,o]),o?(0,Gt.jsx)("div",{style:{display:"flex",justifyContent:"center",alignItems:"center",minHeight:"100vh",fontSize:"1.2rem",color:"#666"},children:"Loading..."}):(0,Gt.jsx)(Wt.Provider,{value:{siteData:a,setSiteData:n},children:e})}function Kt(){return(0,i.useContext)(Wt)}const Zt=(0,i.createContext)(),$t=()=>(0,i.useContext)(Zt),Xt=t=>{let{children:e}=t;const[a,n]=(0,i.useState)(()=>{const t=localStorage.getItem("theme");return t?"dark"===t:"undefined"!==typeof window&&window.matchMedia("(prefers-color-scheme: dark)").matches});(0,i.useEffect)(()=>{const t=window.matchMedia("(prefers-color-scheme: dark)"),e=t=>{localStorage.getItem("theme")||n(t.matches)};return t.addEventListener("change",e),()=>t.removeEventListener("change",e)},[]),(0,i.useEffect)(()=>{a?(document.body.classList.add("dark-mode"),document.body.classList.add("dark"),document.body.classList.remove("light-mode"),document.body.classList.remove("light")):(document.body.classList.add("light-mode"),document.body.classList.add("light"),document.body.classList.remove("dark-mode"),document.body.classList.remove("dark"))},[a]);return(0,Gt.jsx)(Zt.Provider,{value:{darkMode:a,toggleTheme:()=>{n(t=>{const e=!t;return localStorage.setItem("theme",e?"dark":"light"),e})}},children:e})};function Yt(t){let{siteName:e,navigation:a}=t;const n=et(),o=it(),[s,r]=(0,i.useState)(!1),[l,d]=(0,i.useState)(""),{siteData:c}=Kt()||{},{darkMode:m,toggleTheme:u}=$t();function h(t){const e=Vt(t);return n.pathname===e||"/"===n.pathname&&"/"===e}function f(t){return Vt(t)}function g(t){return t.some(t=>f(t)===n.pathname||Vt(t)===n.pathname)}function p(t){t.preventDefault(),l.trim()&&(o("/articles?q=".concat(encodeURIComponent(l))),r(!1))}const y=a&&a.length>0?a:[];return(0,Gt.jsxs)("header",{className:"bg-white shadow-sm sticky top-0 z-40",children:[(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsxs)("div",{className:"flex items-center justify-between h-16 lg:h-20",children:[(0,Gt.jsxs)(Et,{to:"/",className:"flex items-center space-x-2",children:[(0,Gt.jsx)("img",{src:"/logo1.png",alt:e,className:"w-8 h-8 -ml-1 rounded"}),(0,Gt.jsxs)("span",{className:"text-xl lg:text-2xl font-bold",children:[(0,Gt.jsx)("span",{className:"text-green-600",children:"My"}),(0,Gt.jsx)("span",{className:"text-blue-800",children:"VetCorner"})]})]}),(0,Gt.jsxs)("div",{className:"hidden lg:flex items-center gap-4 whitespace-nowrap",children:[(0,Gt.jsx)("nav",{className:"flex items-center gap-4 xl:gap-6",children:y.map((t,e)=>t.dropdown&&t.dropdown.length>0?(0,Gt.jsxs)("div",{className:"dropdown relative group",children:[(0,Gt.jsxs)(Et,{to:Vt(t.label),className:"flex items-center space-x-1 py-6 font-medium transition ".concat(h(t.label)||g(t.dropdown)?"text-blue-800 border-b-2 border-blue-800":"text-gray-700 hover:text-blue-800"),children:[(0,Gt.jsx)("span",{children:t.label}),(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M19 9l-7 7-7-7"})})]}),(0,Gt.jsx)("div",{className:"dropdown-menu hidden group-hover:block absolute left-0 mt-0 w-48 bg-white rounded-lg shadow-lg py-2 border border-gray-100 z-50",children:t.dropdown.map(t=>{const e=f(t),a=e===n.pathname;return(0,Gt.jsx)(Et,{to:e,className:"block px-4 py-2 ".concat(a?"bg-blue-50 text-blue-800 font-medium":"text-gray-700 hover:bg-blue-50 hover:text-blue-800"),children:t},t)})})]},e):(0,Gt.jsx)(Et,{to:Vt(t.label),className:"font-medium transition ".concat(h(t.label)?"text-blue-800 border-b-2 border-blue-800 py-6":"text-gray-700 hover:text-blue-800"),children:t.label},e))}),(0,Gt.jsxs)("form",{onSubmit:p,className:"flex items-center",children:[(0,Gt.jsx)("input",{type:"text",className:"border border-gray-300 rounded-l-lg px-3 py-2 text-sm focus:outline-none focus:ring-2 focus:ring-blue-500 w-40 xl:w-48",placeholder:"Search...",value:l,onChange:t=>d(t.target.value)}),(0,Gt.jsx)("button",{type:"submit",className:"bg-blue-800 text-white px-3 py-2 rounded-r-lg text-sm hover:bg-blue-900 transition",children:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})})]})]}),(0,Gt.jsx)("button",{onClick:u,className:"hidden lg:block ml-4 p-2 rounded-full hover:bg-gray-100 text-gray-700 transition","aria-label":"Toggle Theme",children:m?(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M12 3v1m0 16v1m9-9h-1M4 12H3m15.364 6.364l-.707-.707M6.343 6.343l-.707-.707m12.728 0l-.707.707M6.343 17.657l-.707.707M16 12a4 4 0 11-8 0 4 4 0 018 0z"})}):(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M20.354 15.354A9 9 0 018.646 3.646 9.003 9.003 0 0012 21a9.003 9.003 0 008.354-5.646z"})})}),(0,Gt.jsx)("div",{className:"flex items-center space-x-4 lg:hidden",children:(0,Gt.jsx)("button",{className:"p-2",onClick:()=>r(t=>!t),children:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M4 6h16M4 12h16M4 18h16"})})})})]})}),(0,Gt.jsx)("div",{className:"".concat(s?"":"hidden"," lg:hidden bg-white border-t"),children:(0,Gt.jsxs)("div",{className:"px-4 py-4 space-y-3",children:[(0,Gt.jsxs)("form",{onSubmit:p,className:"flex items-center mb-4",children:[(0,Gt.jsx)("input",{type:"text",className:"border border-gray-300 rounded-l-lg px-3 py-2 text-sm focus:outline-none focus:ring-2 focus:ring-blue-500 w-full",placeholder:"Search...",value:l,onChange:t=>d(t.target.value)}),(0,Gt.jsx)("button",{type:"submit",className:"bg-blue-800 text-white px-3 py-2 rounded-r-lg text-sm hover:bg-blue-900 transition",children:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})})]}),(0,Gt.jsxs)("div",{className:"flex items-center justify-between px-1 pb-4",children:[(0,Gt.jsx)("span",{className:"text-sm font-medium text-gray-700",children:"Appearance"}),(0,Gt.jsx)("button",{onClick:u,className:"p-2 rounded-full hover:bg-gray-100 text-gray-700 transition","aria-label":"Toggle Theme",children:m?(0,Gt.jsxs)("div",{className:"flex items-center space-x-2",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M12 3v1m0 16v1m9-9h-1M4 12H3m15.364 6.364l-.707-.707M6.343 6.343l-.707-.707m12.728 0l-.707.707M6.343 17.657l-.707.707M16 12a4 4 0 11-8 0 4 4 0 018 0z"})}),(0,Gt.jsx)("span",{children:"Light"})]}):(0,Gt.jsxs)("div",{className:"flex items-center space-x-2",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M20.354 15.354A9 9 0 018.646 3.646 9.003 9.003 0 0012 21a9.003 9.003 0 008.354-5.646z"})}),(0,Gt.jsx)("span",{children:"Dark"})]})})]}),y.map(t=>t.dropdown&&t.dropdown.length>0?(0,Gt.jsxs)("div",{className:"pb-2",children:[(0,Gt.jsx)(Et,{to:Vt(t.label),className:"font-medium block pb-1 transition ".concat(h(t.label)||g(t.dropdown)?"text-blue-800":"text-gray-700 hover:text-blue-800"),children:t.label}),t.dropdown.map(t=>{const e=f(t),a=e===n.pathname;return(0,Gt.jsx)(Et,{to:e,className:"block py-2 pl-4 transition ".concat(a?"text-blue-800 font-medium":"text-gray-700 hover:text-blue-800"),children:t},t)})]},t.label):(0,Gt.jsx)(Et,{to:Vt(t.label),className:"block py-2 font-medium transition ".concat(h(t.label)?"text-blue-800":"text-gray-700 hover:text-blue-800"),children:t.label},t.label))]})})]})}function Jt(t){var e,a;let{siteName:i,footer:n}=t;const{siteData:o}=Kt()||{},{darkMode:s}=$t(),r=(null===o||void 0===o?void 0:o.pages)||[];function l(t){const e=r.find(e=>((null===e||void 0===e?void 0:e.title)||"")===t);return null!==e&&void 0!==e&&e.slug?"/pages/".concat(e.slug):function(t){return{"Pet Health":"/pet-health","Poultry Health":"/poultry-health","Nutrition Guides":"/nutrition-guides","Research & Journals":"/research-journals","Vet Finder":"/vet-finder","Drug Index":"/drug-index","About Us":"/about-us","Editorial Policy":"/editorial-policy","Medical Review Board":"/medical-review-board","Contact Us":"/contact-us",Careers:"/careers","Privacy Policy":"/privacy-policy","Terms of Service":"/terms-of-service","Cookie Policy":"/cookie-policy",Disclaimer:"/disclaimer"}[t]||"/"}(t)}const d=Array.isArray(null===o||void 0===o||null===(e=o.footer)||void 0===e?void 0:e.socialLinks)?o.footer.socialLinks:Array.isArray(null===n||void 0===n?void 0:n.socialLinks)?n.socialLinks:[],c=t=>{switch(t.toLowerCase()){case"twitter":return(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M24 4.557c-.883.392-1.832.656-2.828.775 1.017-.609 1.798-1.574 2.165-2.724-.951.564-2.005.974-3.127 1.195-.897-.957-2.178-1.555-3.594-1.555-3.179 0-5.515 2.966-4.797 6.045-4.091-.205-7.719-2.165-10.148-5.144-1.29 2.213-.669 5.108 1.523 6.574-.806-.026-1.566-.247-2.229-.616-.054 2.281 1.581 4.415 3.949 4.89-.693.188-1.452.232-2.224.084.626 1.956 2.444 3.379 4.6 3.419-2.07 1.623-4.678 2.348-7.29 2.04 2.179 1.397 4.768 2.212 7.548 2.212 9.142 0 14.307-7.721 13.995-14.646.962-.695 1.797-1.562 2.457-2.549z"})});case"facebook":return(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M22.675 0h-21.35c-.732 0-1.325.593-1.325 1.325v21.351c0 .731.593 1.324 1.324 1.324h11.495v-9.294h-3.128v-3.622h3.128v-2.671c0-3.1 1.893-4.788 4.659-4.788 1.325 0 2.463.099 2.795.143v3.24l-1.918.001c-1.504 0-1.795.715-1.795 1.763v2.313h3.587l-.467 3.622h-3.12v9.293h6.116c.73 0 1.323-.593 1.323-1.325v-21.35c0-.732-.593-1.325-1.325-1.325z"})});case"instagram":return(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M12 2.163c3.204 0 3.584.012 4.85.07 3.252.148 4.771 1.691 4.919 4.919.058 1.265.069 1.645.069 4.849 0 3.205-.012 3.584-.069 4.849-.149 3.225-1.664 4.771-4.919 4.919-1.266.058-1.644.07-4.85.07-3.204 0-3.584-.012-4.849-.07-3.26-.149-4.771-1.699-4.919-4.92-.058-1.265-.07-1.644-.07-4.849 0-3.204.013-3.583.07-4.849.149-3.227 1.664-4.771 4.919-4.919 1.266-.057 1.645-.069 4.849-.069z"})});case"linkedin":return(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M19 0h-14c-2.761 0-5 2.239-5 5v14c0 2.761 2.239 5 5 5h14c2.762 0 5-2.239 5-5v-14c0-2.761-2.238-5-5-5zm-11 19h-3v-11h3v11zm-1.5-12.268c-.966 0-1.75-.79-1.75-1.764s.784-1.764 1.75-1.764 1.75.79 1.75 1.764-.783 1.764-1.75 1.764zm13.5 12.268h-3v-5.604c0-3.368-4-3.113-4 0v5.604h-3v-11h3v1.765c1.396-2.586 7-2.777 7 2.476v6.759z"})});case"youtube":return(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M23.498 6.186a3.016 3.016 0 0 0-2.122-2.136C19.505 3.545 12 3.545 12 3.545s-7.505 0-9.377.505A3.017 3.017 0 0 0 .502 6.186C0 8.07 0 12 0 12s0 3.93 0 5.814a3.016 3.016 0 0 0 2.122 2.136c1.871.505 9.376.505 9.376.505s7.505 0 9.377-.505a3.015 3.015 0 0 0 2.122-2.136C24 15.93 24 12 24 12s0-3.93-.502-5.814zM9.545 15.568V8.432L15.818 12l-6.273 3.568z"})});default:return(0,Gt.jsx)("span",{className:"font-bold text-xs",children:null===t||void 0===t?void 0:t[0]})}},m=s?"bg-gray-900":"bg-blue-50 border-t border-gray-200",u=s?"text-gray-400":"text-gray-600",h=s?"text-white":"text-gray-900",f=s?"hover:text-white":"hover:text-blue-800",g=s?"border-gray-800":"border-gray-200";return(0,Gt.jsx)("footer",{className:"".concat(m," ").concat(u," py-12 transition-colors duration-300"),children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsxs)("div",{className:"grid md:grid-cols-4 gap-8 mb-8",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"flex items-center space-x-2 mb-4",children:(0,Gt.jsxs)("span",{className:"text-xl font-bold",children:[(0,Gt.jsx)("span",{className:"text-green-500",children:"My"}),(0,Gt.jsx)("span",{className:"text-blue-400",children:"VetCorner"})]})}),(0,Gt.jsx)("p",{className:"text-sm mb-4",children:(null===o||void 0===o||null===(a=o.footer)||void 0===a?void 0:a.description)||n.description}),(0,Gt.jsx)("div",{className:"flex space-x-4",children:d.map((t,e)=>t.url&&(0,Gt.jsx)("a",{href:t.url,target:"_blank",rel:"noopener noreferrer",className:"".concat(f," transition"),"aria-label":t.platform,children:c(t.platform)},e))})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"".concat(h," font-semibold mb-3"),children:"Quick Links"}),(0,Gt.jsx)("ul",{className:"space-y-2",children:n.quickLinks.map(t=>(0,Gt.jsx)("li",{children:(0,Gt.jsx)(Et,{className:"".concat(f," transition"),to:l(t),children:t})},t))})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"".concat(h," font-semibold mb-3"),children:"Company"}),(0,Gt.jsx)("ul",{className:"space-y-2",children:n.companyLinks.map(t=>(0,Gt.jsx)("li",{children:(0,Gt.jsx)(Et,{className:"".concat(f," transition"),to:l(t),children:t})},t))})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"".concat(h," font-semibold mb-3"),children:"Legal"}),(0,Gt.jsx)("ul",{className:"space-y-2",children:n.legalLinks.map(t=>(0,Gt.jsx)("li",{children:(0,Gt.jsx)(Et,{className:"".concat(f," transition"),to:l(t),children:t})},t))})]})]}),(0,Gt.jsx)("div",{className:"border-t ".concat(g," pt-6 text-sm"),children:(0,Gt.jsxs)("div",{className:"flex flex-col md:flex-row md:items-center md:justify-between gap-2",children:[(0,Gt.jsxs)("p",{className:u,children:["\xa9 ",(new Date).getFullYear()," ",(0,Gt.jsx)("span",{className:"text-green-500",children:"My"}),(0,Gt.jsx)("span",{className:"text-blue-400",children:"VetCorner"}),". All rights reserved."]}),(0,Gt.jsx)("p",{className:"".concat(u," md:text-right"),children:n.disclaimerText})]})})]})})}const te={shield:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M9 12l2 2 4-4m5.618-4.016A11.955 11.955 0 0112 2.944a11.955 11.955 0 01-8.618 3.04A12.02 12.02 0 003 9c0 5.591 3.824 10.29 9 11.622 5.176-1.332 9-6.03 9-11.622 0-1.042-.133-2.052-.382-3.016z"})}),book:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M12 6.253v13m0-13C10.832 5.477 9.246 5 7.5 5S4.168 5.477 3 6.253v13C4.168 18.477 5.754 18 7.5 18s3.332.477 4.5 1.253m0-13C13.168 5.477 14.754 5 16.5 5c1.747 0 3.332.477 4.5 1.253v13C19.832 18.477 18.247 18 16.5 18c-1.746 0-3.332.477-4.5 1.253"})}),users:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M17 20h5v-2a3 3 0 00-5.356-1.857M17 20H7m10 0v-2c0-.656-.126-1.283-.356-1.857M7 20H2v-2a3 3 0 015.356-1.857M7 20v-2c0-.656.126-1.283.356-1.857m0 0a5.002 5.002 0 019.288 0M15 7a3 3 0 11-6 0 3 3 0 016 0z"})}),lab:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})})};const ee=function(){var t,e,a,n,o,s,r,l,d,c,m,u,h,f;const{siteData:g,setSiteData:p}=Kt()||{},{darkMode:y}=$t(),[b,v]=(0,i.useState)(0),[w,x]=(0,i.useState)(!1),[k,I]=(0,i.useState)(!1),[C,S]=(0,i.useState)("articles"),[A,T]=(0,i.useState)("newest"),[P,D]=(0,i.useState)("original"),[N,L]=(0,i.useState)("newest"),[E,j]=(0,i.useState)(null),[M,z]=(0,i.useState)(null),[R,F]=(0,i.useState)(null),[q,_]=(0,i.useState)(null),[O,U]=(0,i.useState)(null),[H,V]=(0,i.useState)(""),[B,G]=(0,i.useState)(""),[W,Q]=(0,i.useState)(""),[K,Z]=(0,i.useState)(""),$=(0,i.useRef)(null),X=(0,i.useRef)(null);function Y(t,e,a){p(i=>Ht(Ht({},i),{},{articles:i.articles.map((i,n)=>{if(n!==t)return i;const o=Ht(Ht({},i),{},{[e]:a});if("excerpt"===e||"content"===e){const t=(("content"===e?a:o.content||a||"")||"").trim().split(/\s+/).filter(Boolean).length,i=Math.max(1,Math.ceil(t/200));o.readTime="".concat(i," min read")}return o})}))}function J(t,e){p(a=>{const i=[...a.articles],n="up"===e?t-1:t+1;if(n<0||n>=i.length)return a;const o=i[t];return i[t]=i[n],i[n]=o,Ht(Ht({},a),{},{articles:i})})}function tt(t,e,a){p(i=>Ht(Ht({},i),{},{articles:i.articles.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}function et(t,e,a){p(i=>Ht(Ht({},i),{},{slides:i.slides.map((i,n)=>{if(n!==t)return i;const o=Ht(Ht({},i),{},{[e]:a});if("excerpt"===e){const t=(a||"").trim().split(/\s+/).filter(Boolean).length,e=Math.max(1,Math.ceil(t/200));o.readTime="".concat(e," min read")}return o})}))}function at(t,e){p(a=>{const i=[...a.slides],n="up"===e?t-1:t+1;if(n<0||n>=i.length)return a;const o=i[t];return i[t]=i[n],i[n]=o,Ht(Ht({},a),{},{slides:i})})}function it(t,e,a){p(i=>Ht(Ht({},i),{},{experts:i.experts.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}function nt(t,e,a){p(i=>Ht(Ht({},i),{},{categories:i.categories.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}(0,i.useEffect)(()=>{null!==g&&void 0!==g&&g.site&&(document.title="".concat(g.site.name," - ").concat(g.site.tagline))},[null===g||void 0===g?void 0:g.site]),(0,i.useEffect)(()=>{const t=setInterval(()=>{var t;const e=(null===g||void 0===g||null===(t=g.slides)||void 0===t?void 0:t.length)||0;e>0&&v(t=>(t+1)%e)},6e3);return()=>clearInterval(t)},[null===g||void 0===g?void 0:g.slides]),(0,i.useEffect)(()=>{const t=document.body.style.overflow;return document.body.style.overflow=w?"hidden":"",()=>{document.body.style.overflow=t}},[w]);const[ot,st]=(0,i.useState)(0);function rt(t,e,a){p(i=>Ht(Ht({},i),{},{research:i.research.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}return(0,Gt.jsxs)("div",{className:"bg-white text-gray-800 min-h-screen",children:[w&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50 admin-panel",style:{background:"rgba(0,0,0,0.5)",overflowY:"auto"},children:k?(0,Gt.jsxs)("div",{className:"flex items-stretch min-h-screen",style:{maxHeight:"100vh",overflowY:"auto"},children:[(0,Gt.jsxs)("div",{className:"bg-gray-900 text-gray-300 w-72 p-6 admin-sidebar overflow-y-auto",children:[(0,Gt.jsxs)("div",{className:"mb-6",children:[(0,Gt.jsx)("h3",{className:"text-lg font-bold text-white",children:"Admin Panel"}),(0,Gt.jsx)("p",{className:"text-gray-400 text-sm",children:"Manage site content and settings"})]}),(0,Gt.jsxs)("div",{className:"space-y-2",children:[[{key:"hero",label:"Hero Slides"},{key:"stats",label:"Trust Statistics"},{key:"articles",label:"Articles"},{key:"experts",label:"Experts"},{key:"categories",label:"Categories"},{key:"research",label:"Research"},{key:"security",label:"Security Settings"}].map(t=>(0,Gt.jsx)("button",{"data-tab":t.key,className:"admin-tab w-full text-left px-4 py-3 rounded-lg ".concat(C===t.key?"tab-active":"hover:bg-gray-800"),onClick:()=>S(t.key),children:t.label},t.key)),(0,Gt.jsx)("button",{className:"w-full text-left px-4 py-3 rounded-lg hover:bg-gray-800 transition text-red-400",onClick:()=>{I(!1)},children:"Logout"})]})]}),(0,Gt.jsx)("div",{className:"flex-1",style:{maxHeight:"100vh",overflowY:"auto"},children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-8 w-full max-w-4xl mx-4 shadow-2xl relative",children:[(0,Gt.jsx)("button",{className:"absolute top-4 right-4 text-gray-500 hover:text-gray-700",onClick:()=>{I(!1),x(!1)},children:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M6 18L18 6M6 6l12 12"})})}),(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-gray-900 mb-6 text-center",children:"Admin Panel"}),"articles"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-4",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900",children:"Manage Articles"}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:function(){const t=function(){const t=new Date,e=t.toLocaleString("en-US",{month:"short"}),a=t.getDate(),i=t.getFullYear();return"".concat(e," ").concat(a,", ").concat(i)}();p(e=>Ht(Ht({},e),{},{articles:[{image:"",category:"",categoryColor:"blue",title:"",excerpt:"",date:t,readTime:""},...e.articles]}))},children:"Add Article"}),(0,Gt.jsxs)("select",{className:"px-3 py-2 border border-gray-300 rounded-lg",value:A,onChange:t=>T(t.target.value),children:[(0,Gt.jsx)("option",{value:"newest",children:"Newest first"}),(0,Gt.jsx)("option",{value:"oldest",children:"Oldest first"}),(0,Gt.jsx)("option",{value:"title-az",children:"Title A\u2013Z"}),(0,Gt.jsx)("option",{value:"title-za",children:"Title Z\u2013A"}),(0,Gt.jsx)("option",{value:"published",children:"Published first"}),(0,Gt.jsx)("option",{value:"draft",children:"Drafts first"})]})]})]}),(0,Gt.jsx)("div",{className:"space-y-6",children:g.articles.map((t,e)=>({a:t,i:e})).sort((t,e)=>"newest"===A?t.i-e.i:"oldest"===A?e.i-t.i:"title-az"===A?(t.a.title||"").localeCompare(e.a.title||""):"title-za"===A?(e.a.title||"").localeCompare(t.a.title||""):"published"===A?Number(Boolean(e.a.published))-Number(Boolean(t.a.published)):"draft"===A?Number(Boolean(t.a.published))-Number(Boolean(e.a.published)):0).map(t=>{let{a:e,i:a}=t;return(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4 editable-item",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Title",value:e.title,onChange:t=>Y(a,"title",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Slug",value:e.slug||"",onChange:t=>Y(a,"slug",t.target.value)}),(0,Gt.jsxs)("div",{className:"px-4 py-3 border border-gray-300 rounded-lg flex flex-col",children:[(0,Gt.jsx)("label",{className:"text-sm text-gray-600 mb-2",children:"Category"}),(0,Gt.jsx)("select",{className:"px-3 py-2 border border-gray-300 rounded-lg",value:e.category||"",onChange:t=>Y(a,"category",t.target.value),children:[...new Set(["Dogs","Cats","Small Mammals","Chickens","Ducks","Turkeys","Disease Management","Pet Nutrition","Poultry Nutrition","Research & Journals","Vet Finder","Drug Index",...(g.categories||[]).map(t=>t.name)])].map((t,e)=>(0,Gt.jsx)("option",{value:t,children:t},e))})]}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Category Color (e.g., blue, green)",value:e.categoryColor,onChange:t=>Y(a,"categoryColor",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Date",value:e.date,onChange:t=>Y(a,"date",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Read Time",value:e.readTime,onChange:t=>Y(a,"readTime",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Image URL",value:e.image,onChange:t=>Y(a,"image",t.target.value)})]}),(0,Gt.jsx)("textarea",{rows:3,className:"mt-4 w-full px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Excerpt",value:e.excerpt,onChange:t=>Y(a,"excerpt",t.target.value)}),(0,Gt.jsxs)("div",{className:"mt-3 flex items-center justify-between",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"px-3 py-2 bg-gray-100 rounded-lg text-sm",onClick:()=>Y(a,"slug",(e.title||"").toLowerCase().replace(/&/g,"and").replace(/[^a-z0-9]+/g,"-").replace(/(^-|-$)/g,"")),children:"Generate Slug"}),(0,Gt.jsxs)("label",{className:"flex items-center gap-2 text-sm",children:[(0,Gt.jsx)("input",{type:"checkbox",checked:!!e.published,onChange:t=>tt(a,"published",t.target.checked)})," Published"]}),(0,Gt.jsxs)("label",{className:"flex items-center gap-2 text-sm",children:[(0,Gt.jsx)("input",{type:"checkbox",checked:!!e.featured,onChange:t=>tt(a,"featured",t.target.checked)})," Featured"]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("button",{className:"px-3 py-2 border rounded text-sm",onClick:()=>tt(a,"published",!0),children:"Publish"}),(0,Gt.jsx)("button",{className:"px-3 py-2 border rounded text-sm",onClick:()=>tt(a,"published",!1),children:"Save to Draft"}),(0,Gt.jsx)("span",{className:"text-xs text-gray-500",children:e.published?"Published":"Draft"})]})]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"text-gray-700 hover:text-gray-900 text-sm font-semibold",onClick:()=>J(a,"up"),children:"Move Up"}),(0,Gt.jsx)("button",{className:"text-gray-700 hover:text-gray-900 text-sm font-semibold",onClick:()=>J(a,"down"),children:"Move Down"}),(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>j(a),children:"Delete"})]})]})]},a)})}),null!==E&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50",style:{background:"rgba(0,0,0,0.5)"},children:(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen p-4",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-6 w-full max-w-md shadow-2xl",children:[(0,Gt.jsx)("h4",{className:"text-lg font-bold text-gray-900 mb-2",children:"Delete Article?"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 mb-4",children:['Are you sure you want to delete "',(null===(t=g.articles[E])||void 0===t?void 0:t.title)||"Untitled",'"?']}),(0,Gt.jsxs)("div",{className:"flex items-center justify-end gap-3",children:[(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg border",onClick:()=>j(null),children:"Cancel"}),(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg bg-red-600 text-white",onClick:()=>{var t;t=E,p(e=>Ht(Ht({},e),{},{articles:e.articles.filter((e,a)=>a!==t)})),j(null)},children:"Delete"})]})]})})})]}),"hero"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-4",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900",children:"Manage Slides"}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:function(){p(t=>Ht(Ht({},t),{},{slides:[...t.slides,{tag:"",title:"",excerpt:"",image:"",readTime:""}]}))},children:"Add Slide"}),(0,Gt.jsxs)("select",{className:"px-3 py-2 border border-gray-300 rounded-lg",value:P,onChange:t=>D(t.target.value),children:[(0,Gt.jsx)("option",{value:"original",children:"Original order"}),(0,Gt.jsx)("option",{value:"title-az",children:"Title A\u2013Z"}),(0,Gt.jsx)("option",{value:"title-za",children:"Title Z\u2013A"}),(0,Gt.jsx)("option",{value:"tag-az",children:"Tag A\u2013Z"}),(0,Gt.jsx)("option",{value:"tag-za",children:"Tag Z\u2013A"})]})]})]}),(0,Gt.jsx)("div",{className:"space-y-6",children:g.slides.map((t,e)=>({a:t,i:e})).sort((t,e)=>"original"===P?t.i-e.i:"title-az"===P?(t.a.title||"").localeCompare(e.a.title||""):"title-za"===P?(e.a.title||"").localeCompare(t.a.title||""):"tag-az"===P?(t.a.tag||"").localeCompare(e.a.tag||""):"tag-za"===P?(e.a.tag||"").localeCompare(t.a.tag||""):0).map(t=>{let{a:e,i:a}=t;return(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4 editable-item",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Tag",value:e.tag,onChange:t=>et(a,"tag",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Title",value:e.title,onChange:t=>et(a,"title",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Read Time",value:e.readTime,onChange:t=>et(a,"readTime",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Image URL",value:e.image,onChange:t=>et(a,"image",t.target.value)})]}),(0,Gt.jsx)("textarea",{rows:3,className:"mt-4 w-full px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Excerpt",value:e.excerpt,onChange:t=>et(a,"excerpt",t.target.value)}),(0,Gt.jsxs)("div",{className:"mt-3 flex items-center justify-between",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"text-gray-700 hover:text-gray-900 text-sm font-semibold",onClick:()=>at(a,"up"),children:"Move Up"}),(0,Gt.jsx)("button",{className:"text-gray-700 hover:text-gray-900 text-sm font-semibold",onClick:()=>at(a,"down"),children:"Move Down"})]}),(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>z(a),children:"Delete"})]})]},a)})}),null!==M&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50",style:{background:"rgba(0,0,0,0.5)"},children:(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen p-4",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-6 w-full max-w-md shadow-2xl",children:[(0,Gt.jsx)("h4",{className:"text-lg font-bold text-gray-900 mb-2",children:"Delete Slide?"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 mb-4",children:['Are you sure you want to delete "',(null===(e=g.slides[M])||void 0===e?void 0:e.title)||"Untitled",'"?']}),(0,Gt.jsxs)("div",{className:"flex items-center justify-end gap-3",children:[(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg border",onClick:()=>z(null),children:"Cancel"}),(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg bg-red-600 text-white",onClick:()=>{var t;t=M,p(e=>Ht(Ht({},e),{},{slides:e.slides.filter((e,a)=>a!==t)})),z(null)},children:"Delete"})]})]})})})]}),"experts"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-4",children:"Manage Experts"}),(0,Gt.jsx)("div",{className:"space-y-6",children:g.experts.map((t,e)=>(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4 editable-item",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Name",value:t.name,onChange:t=>it(e,"name",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Title",value:t.title,onChange:t=>it(e,"title",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Specialty",value:t.specialty,onChange:t=>it(e,"specialty",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Image URL",value:t.image,onChange:t=>it(e,"image",t.target.value)})]}),(0,Gt.jsx)("div",{className:"mt-3 flex items-center justify-end",children:(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>F(e),children:"Delete"})})]},e))}),(0,Gt.jsx)("div",{className:"mt-4 flex items-center justify-between",children:(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:function(){p(t=>Ht(Ht({},t),{},{experts:[...t.experts,{name:"",title:"",specialty:"",image:""}]}))},children:"Add Expert"})}),null!==R&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50",style:{background:"rgba(0,0,0,0.5)"},children:(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen p-4",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-6 w-full max-w-md shadow-2xl",children:[(0,Gt.jsx)("h4",{className:"text-lg font-bold text-gray-900 mb-2",children:"Delete Expert?"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 mb-4",children:['Are you sure you want to delete "',(null===(a=g.experts[R])||void 0===a?void 0:a.name)||"Unnamed Expert",'"?']}),(0,Gt.jsxs)("div",{className:"flex items-center justify-end gap-3",children:[(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg border",onClick:()=>F(null),children:"Cancel"}),(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg bg-red-600 text-white",onClick:()=>{var t;t=R,p(e=>Ht(Ht({},e),{},{experts:e.experts.filter((e,a)=>a!==t)})),F(null)},children:"Delete"})]})]})})})]}),"categories"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-4",children:"Manage Categories"}),(0,Gt.jsxs)("div",{className:"mb-4 bg-white rounded shadow p-4",children:[(0,Gt.jsx)("div",{className:"font-semibold mb-2",children:"Select Category"}),(0,Gt.jsx)("input",{type:"range",min:0,max:((null===(n=g.categories)||void 0===n?void 0:n.length)||1)-1,value:ot,onChange:t=>st(Number(t.target.value))}),(0,Gt.jsx)("div",{className:"text-sm text-gray-600 mt-2",children:(null===(o=g.categories)||void 0===o||null===(s=o[ot])||void 0===s?void 0:s.name)||""})]}),(0,Gt.jsx)("div",{className:"space-y-6",children:(g.categories||[]).map((t,e)=>e===ot?(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4 editable-item",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Name",value:t.name,onChange:t=>nt(e,"name",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Count",value:t.count,onChange:t=>nt(e,"count",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Image URL",value:t.image,onChange:t=>nt(e,"image",t.target.value)})]}),(0,Gt.jsxs)("div",{className:"mt-3 flex items-center justify-between",children:[(0,Gt.jsxs)("div",{className:"text-sm text-gray-600",children:["Path: ",Vt(t.name||"")]}),(0,Gt.jsx)(Et,{to:Vt(t.name||""),className:"text-blue-800 hover:underline text-sm font-semibold",children:"Open Page"})]}),(0,Gt.jsx)("div",{className:"mt-3 flex items-center justify-end",children:(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>_(e),children:"Delete"})})]},e):null)}),(0,Gt.jsx)("div",{className:"mt-4 flex items-center justify-between",children:(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:function(){p(t=>Ht(Ht({},t),{},{categories:[...t.categories,{name:"",count:"",image:""}]}))},children:"Add Category"})}),null!==q&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50",style:{background:"rgba(0,0,0,0.5)"},children:(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen p-4",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-6 w-full max-w-md shadow-2xl",children:[(0,Gt.jsx)("h4",{className:"text-lg font-bold text-gray-900 mb-2",children:"Delete Category?"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 mb-4",children:['Are you sure you want to delete "',(null===(r=g.categories[q])||void 0===r?void 0:r.name)||"Unnamed Category",'"?']}),(0,Gt.jsxs)("div",{className:"flex items-center justify-end gap-3",children:[(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg border",onClick:()=>_(null),children:"Cancel"}),(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg bg-red-600 text-white",onClick:()=>{var t;t=q,p(e=>Ht(Ht({},e),{},{categories:e.categories.filter((e,a)=>a!==t)})),_(null)},children:"Delete"})]})]})})})]}),"research"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-4",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900",children:"Manage Research"}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:function(){p(t=>Ht(Ht({},t),{},{research:[...t.research,{type:"",typeColor:"blue",year:"",title:"",authors:"",journal:"",abstract:""}]}))},children:"Add Research"}),(0,Gt.jsxs)("select",{className:"px-3 py-2 border border-gray-300 rounded-lg",value:N,onChange:t=>L(t.target.value),children:[(0,Gt.jsx)("option",{value:"newest",children:"Newest year first"}),(0,Gt.jsx)("option",{value:"oldest",children:"Oldest year first"}),(0,Gt.jsx)("option",{value:"title-az",children:"Title A\u2013Z"}),(0,Gt.jsx)("option",{value:"title-za",children:"Title Z\u2013A"}),(0,Gt.jsx)("option",{value:"type-az",children:"Type A\u2013Z"}),(0,Gt.jsx)("option",{value:"type-za",children:"Type Z\u2013A"})]})]})]}),(0,Gt.jsx)("div",{className:"space-y-6",children:g.research.map((t,e)=>({a:t,i:e})).sort((t,e)=>"newest"===N?(parseInt(e.a.year)||0)-(parseInt(t.a.year)||0):"oldest"===N?(parseInt(t.a.year)||0)-(parseInt(e.a.year)||0):"title-az"===N?(t.a.title||"").localeCompare(e.a.title||""):"title-za"===N?(e.a.title||"").localeCompare(t.a.title||""):"type-az"===N?(t.a.type||"").localeCompare(e.a.type||""):"type-za"===N?(e.a.type||"").localeCompare(t.a.type||""):t.i-e.i).map(t=>{let{a:e,i:a}=t;return(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4 editable-item",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Type",value:e.type,onChange:t=>rt(a,"type",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Type Color",value:e.typeColor,onChange:t=>rt(a,"typeColor",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Year",value:e.year,onChange:t=>rt(a,"year",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Title",value:e.title,onChange:t=>rt(a,"title",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Authors",value:e.authors,onChange:t=>rt(a,"authors",t.target.value)}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Journal",value:e.journal,onChange:t=>rt(a,"journal",t.target.value)})]}),(0,Gt.jsx)("textarea",{rows:3,className:"mt-4 w-full px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Abstract",value:e.abstract,onChange:t=>rt(a,"abstract",t.target.value)}),(0,Gt.jsx)("div",{className:"mt-3 flex items-center justify-end",children:(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>U(a),children:"Delete"})})]},a)})}),null!==O&&(0,Gt.jsx)("div",{className:"fixed inset-0 z-50",style:{background:"rgba(0,0,0,0.5)"},children:(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen p-4",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-6 w-full max-w-md shadow-2xl",children:[(0,Gt.jsx)("h4",{className:"text-lg font-bold text-gray-900 mb-2",children:"Delete Research?"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 mb-4",children:['Are you sure you want to delete "',(null===(l=g.research[O])||void 0===l?void 0:l.title)||"Untitled",'"?']}),(0,Gt.jsxs)("div",{className:"flex items-center justify-end gap-3",children:[(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg border",onClick:()=>U(null),children:"Cancel"}),(0,Gt.jsx)("button",{className:"px-4 py-2 rounded-lg bg-red-600 text-white",onClick:()=>{var t;t=O,p(e=>Ht(Ht({},e),{},{research:e.research.filter((e,a)=>a!==t)})),U(null)},children:"Delete"})]})]})})})]}),(0,Gt.jsxs)("div",{children:["stats"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-4",children:"Manage Trust Statistics"}),(0,Gt.jsx)("div",{className:"space-y-6",children:g.stats.map((t,e)=>(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-lg p-4",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Value",value:t.value,onChange:t=>p(a=>Ht(Ht({},a),{},{stats:a.stats.map((a,i)=>i===e?Ht(Ht({},a),{},{value:t.target.value}):a)}))}),(0,Gt.jsx)("input",{className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Label",value:t.label,onChange:t=>p(a=>Ht(Ht({},a),{},{stats:a.stats.map((a,i)=>i===e?Ht(Ht({},a),{},{label:t.target.value}):a)}))}),(0,Gt.jsxs)("select",{className:"px-4 py-3 border border-gray-300 rounded-lg",value:t.icon,onChange:t=>p(a=>Ht(Ht({},a),{},{stats:a.stats.map((a,i)=>i===e?Ht(Ht({},a),{},{icon:t.target.value}):a)})),children:[(0,Gt.jsx)("option",{value:"shield",children:"shield"}),(0,Gt.jsx)("option",{value:"book",children:"book"}),(0,Gt.jsx)("option",{value:"users",children:"users"}),(0,Gt.jsx)("option",{value:"lab",children:"lab"})]})]}),(0,Gt.jsx)("div",{className:"mt-3 flex items-center justify-end",children:(0,Gt.jsx)("button",{className:"text-red-600 hover:text-red-700 text-sm font-semibold",onClick:()=>p(t=>Ht(Ht({},t),{},{stats:t.stats.filter((t,a)=>a!==e)})),children:"Delete"})})]},e))}),(0,Gt.jsx)("div",{className:"mt-4 flex items-center justify-between",children:(0,Gt.jsx)("button",{className:"bg-green-600 hover:bg-green-700 text-white px-4 py-2 rounded-lg font-semibold",onClick:()=>p(t=>Ht(Ht({},t),{},{stats:[...t.stats,{value:"",label:"",icon:"shield"}]})),children:"Add Stat"})})]}),"security"===C&&(0,Gt.jsxs)("div",{className:"mt-8",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-4",children:"Security Settings"}),(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-3",children:[(0,Gt.jsx)("input",{type:"password",className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Old password",value:H,onChange:t=>V(t.target.value)}),(0,Gt.jsx)("input",{type:"password",className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"New password",value:B,onChange:t=>G(t.target.value)}),(0,Gt.jsx)("input",{type:"password",className:"px-4 py-3 border border-gray-300 rounded-lg",placeholder:"Confirm new password",value:W,onChange:t=>Q(t.target.value)})]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{className:"bg-blue-800 text-white px-4 py-2 rounded-lg",onClick:()=>{H===g.adminPassword?B&&B===W?(p(t=>Ht(Ht({},t),{},{adminPassword:B})),Z("Password updated"),V(""),G(""),Q("")):Z("Passwords do not match"):Z("Old password incorrect")},children:"Change Password"}),K&&(0,Gt.jsx)("span",{className:"text-sm text-gray-600",children:K})]})]})]})]})]})})]}):(0,Gt.jsx)("div",{className:"flex items-center justify-center min-h-screen",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-8 w-full max-w-md mx-4 shadow-2xl relative",children:[(0,Gt.jsx)("button",{className:"absolute top-4 right-4 text-gray-500 hover:text-gray-700",onClick:()=>x(!1),children:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M6 18L18 6M6 6l12 12"})})}),(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-gray-900 mb-6 text-center",children:"Admin Login"}),(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsx)("input",{type:"password",placeholder:"Enter admin password",className:"w-full px-4 py-3 border border-gray-300 rounded-lg focus:ring-2 focus:ring-blue-500 outline-none",onKeyDown:t=>{"Enter"===t.key&&t.currentTarget.value===g.adminPassword&&I(!0)}}),(0,Gt.jsx)("button",{className:"w-full bg-blue-800 text-white py-3 rounded-lg font-semibold hover:bg-blue-900 transition",onClick:t=>{var e;const a=null===(e=t.currentTarget.parentElement)||void 0===e?void 0:e.querySelector("input");a&&a.value===g.adminPassword&&I(!0)},children:"Login"})]})]})})}),(0,Gt.jsx)(Yt,{siteName:g.site.name,navigation:g.navigation}),(0,Gt.jsx)("section",{className:"relative bg-gradient-to-br from-blue-50 to-white",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4 py-12 lg:py-20",children:[(0,Gt.jsx)("div",{className:"relative hero-slider",children:(0,Gt.jsxs)("div",{className:"hero-slide flex flex-col lg:flex-row items-center gap-8 lg:gap-12",children:[(0,Gt.jsxs)("div",{className:"lg:w-1/2 space-y-6",children:[(0,Gt.jsx)("span",{className:"inline-block bg-orange-100 text-orange-600 text-sm font-semibold px-3 py-1 rounded-full",children:null===(d=g.slides[b])||void 0===d?void 0:d.tag}),(0,Gt.jsx)("h1",{className:"text-3xl lg:text-5xl font-bold text-gray-900 leading-tight",children:null===(c=g.slides[b])||void 0===c?void 0:c.title}),(0,Gt.jsx)("p",{className:"text-lg text-gray-600 leading-relaxed",children:null===(m=g.slides[b])||void 0===m?void 0:m.excerpt}),(0,Gt.jsxs)("div",{className:"flex items-center space-x-4",children:[(0,Gt.jsxs)(Et,{to:"/articles",className:"inline-flex items-center bg-blue-800 text-white px-6 py-3 rounded-full font-medium hover:bg-blue-900 transition",children:["Read Article",(0,Gt.jsx)("svg",{className:"w-5 h-5 ml-2",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M17 8l4 4m0 0l-4 4m4-4H3"})})]}),(0,Gt.jsxs)("span",{className:"text-sm text-gray-500",children:[null===(u=g.slides[b])||void 0===u?void 0:u.readTime," \u2022 Vet Reviewed"]})]})]}),(0,Gt.jsx)("div",{className:"lg:w-1/2",children:(0,Gt.jsx)("img",{src:null===(h=g.slides[b])||void 0===h?void 0:h.image,alt:null===(f=g.slides[b])||void 0===f?void 0:f.title,className:"rounded-2xl shadow-2xl w-full object-cover"})})]})}),(0,Gt.jsx)("div",{className:"flex justify-center mt-8 space-x-2",children:g.slides.map((t,e)=>(0,Gt.jsx)("button",{className:"w-3 h-3 rounded-full ".concat(e===b?"bg-blue-800":"bg-gray-300"),onClick:()=>v(e)},e))})]})}),(0,Gt.jsx)("section",{className:"bg-blue-800 py-6",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsx)("div",{className:"grid grid-cols-2 lg:grid-cols-4 gap-6",children:g.stats.map((t,e)=>(0,Gt.jsxs)("div",{className:"flex items-center justify-center space-x-3 text-white",children:[(0,Gt.jsx)("div",{className:"bg-blue-700 p-3 rounded-full",children:te[t.icon]||te.shield}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"font-bold text-lg",children:t.value}),(0,Gt.jsx)("div",{className:"text-blue-200 text-sm",children:t.label})]})]},e))})})}),(0,Gt.jsx)("section",{className:"bg-gray-50 py-3 border-b",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsxs)("nav",{className:"text-sm text-gray-500",children:[(0,Gt.jsx)(Et,{to:"/",className:"hover:text-blue-800",children:"Home"}),(0,Gt.jsx)("span",{className:"mx-2",children:"\u203a"}),(0,Gt.jsx)("span",{className:"text-gray-700",children:"Latest Articles"})]})})}),(0,Gt.jsx)("section",{className:"py-16 bg-gray-50",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsxs)("div",{className:"flex flex-col md:flex-row md:items-center md:justify-between mb-10",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold text-gray-900",children:"Recent Articles"}),(0,Gt.jsx)("p",{className:"text-gray-600 mt-2",children:"Stay updated with the latest pet and poultry health insights"})]}),(0,Gt.jsxs)(Et,{to:"/articles",className:"mt-4 md:mt-0 text-blue-800 font-medium hover:underline flex items-center",children:["View All Articles",(0,Gt.jsx)("svg",{className:"w-4 h-4 ml-1",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M9 5l7 7-7 7"})})]})]}),(0,Gt.jsx)("div",{className:"grid md:grid-cols-2 lg:grid-cols-3 gap-8",children:g.articles.slice(0,6).map((t,e)=>(0,Gt.jsxs)("article",{className:"article-card bg-white rounded-xl overflow-hidden shadow-sm transition duration-300",children:[(0,Gt.jsx)("img",{src:t.image,alt:t.title,className:"w-full h-48 object-cover"}),(0,Gt.jsxs)("div",{className:"p-6",children:[(0,Gt.jsx)("span",{className:"inline-block bg-".concat(t.categoryColor||"blue","-100 text-").concat(t.categoryColor||"blue","-800 text-xs font-semibold px-3 py-1 rounded-full mb-3"),children:t.subCategory||t.category}),(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-2 hover:text-blue-800 transition",children:t.title}),(0,Gt.jsx)("p",{className:"text-gray-600 text-sm mb-4",children:t.excerpt}),(0,Gt.jsxs)("div",{className:"flex items-center justify-between",children:[(0,Gt.jsxs)("span",{className:"text-xs text-gray-500",children:[t.date," \u2022 ",t.readTime]}),(0,Gt.jsxs)(Et,{to:"/articles",className:"text-blue-800 font-medium text-sm flex items-center hover:underline",children:["Read More",(0,Gt.jsx)("svg",{className:"w-4 h-4 ml-1",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M17 8l4 4m0 0l-4 4m4-4H3"})})]})]})]})]},e))})]})}),(0,Gt.jsx)("section",{className:"py-16 bg-white",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsxs)("div",{className:"text-center mb-12",children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold text-gray-900",children:"Meet Our Experts"}),(0,Gt.jsx)("p",{className:"text-gray-600 mt-2",children:"Our Medical Review Board ensures every article meets the highest standards"})]}),(0,Gt.jsxs)("div",{className:"relative",children:[(0,Gt.jsx)("div",{ref:$,className:"expert-carousel flex overflow-x-auto gap-6 pb-4 snap-x snap-mandatory",style:{scrollbarWidth:"none",msOverflowStyle:"none"},children:g.experts.map((t,e)=>(0,Gt.jsxs)("div",{className:"flex-shrink-0 w-64 bg-gray-50 rounded-xl p-6 text-center snap-start",children:[(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-24 h-24 rounded-full mx-auto mb-4 object-cover border-4 border-white shadow-lg"}),(0,Gt.jsx)("h3",{className:"font-bold text-gray-900",children:t.name}),(0,Gt.jsx)("p",{className:"text-blue-800 text-sm font-medium",children:t.title}),(0,Gt.jsx)("p",{className:"text-gray-500 text-sm mt-2",children:t.specialty})]},e))}),(0,Gt.jsx)("button",{className:"absolute left-0 top-1/2 -translate-y-1/2 -translate-x-4 bg-white shadow-lg rounded-full p-2 hover:bg-gray-50 hidden lg:block",onClick:()=>{var t;return null===(t=$.current)||void 0===t?void 0:t.scrollBy({left:-280,behavior:"smooth"})},children:(0,Gt.jsx)("svg",{className:"w-6 h-6 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M15 19l-7-7 7-7"})})}),(0,Gt.jsx)("button",{className:"absolute right-0 top-1/2 -translate-y-1/2 translate-x-4 bg-white shadow-lg rounded-full p-2 hover:bg-gray-50 hidden lg:block",onClick:()=>{var t;return null===(t=$.current)||void 0===t?void 0:t.scrollBy({left:280,behavior:"smooth"})},children:(0,Gt.jsx)("svg",{className:"w-6 h-6 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M9 5l7 7-7 7"})})})]})]})}),(0,Gt.jsx)("section",{className:"py-16 bg-gradient-to-b from-white to-gray-50",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsxs)("div",{className:"text-center mb-12",children:[(0,Gt.jsx)("h2",{className:"text-3l font-bold text-gray-900",children:"Explore by Category"}),(0,Gt.jsx)("p",{className:"text-gray-600 mt-2",children:"Quick access to our most popular topics"})]}),(0,Gt.jsxs)("div",{className:"relative",children:[(0,Gt.jsx)("div",{ref:X,className:"category-carousel flex overflow-x-auto gap-6 pb-4 snap-x snap-mandatory",style:{scrollbarWidth:"none",msOverflowStyle:"none"},children:g.categories.map((t,e)=>{return(0,Gt.jsxs)(Et,{to:(a=t.name,Vt(a)),className:"category-card group relative rounded-2xl overflow-hidden aspect-square flex-shrink-0 w-56 md:w-64 snap-start transition duration-300",children:[(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-full h-full object-cover group-hover:scale-105 transition duration-500"}),(0,Gt.jsx)("div",{className:"absolute inset-0 bg-gradient-to-t from-black/70 via-black/20 to-transparent"}),(0,Gt.jsxs)("div",{className:"absolute bottom-4 left-4 right-4",children:[(0,Gt.jsx)("h3",{className:"text-white font-bold text-xl",children:t.name}),(0,Gt.jsx)("p",{className:"text-white/80 text-sm",children:t.count})]})]},e);var a})}),(0,Gt.jsx)("button",{className:"absolute left-0 top-1/2 -translate-y-1/2 -translate-x-4 bg-white shadow-lg rounded-full p-2 hover:bg-gray-50 hidden lg:block",onClick:()=>{var t;return null===(t=X.current)||void 0===t?void 0:t.scrollBy({left:-280,behavior:"smooth"})},children:(0,Gt.jsx)("svg",{className:"w-6 h-6 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M15 19l-7-7 7-7"})})}),(0,Gt.jsx)("button",{className:"absolute right-0 top-1/2 -translate-y-1/2 translate-x-4 bg-white shadow-lg rounded-full p-2 hover:bg-gray-50 hidden lg:block",onClick:()=>{var t;return null===(t=X.current)||void 0===t?void 0:t.scrollBy({left:280,behavior:"smooth"})},children:(0,Gt.jsx)("svg",{className:"w-6 h-6 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M9 5l7 7-7 7"})})})]})]})}),(0,Gt.jsx)("section",{id:"research",className:"py-16 bg-gray-100",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsxs)("div",{className:"flex flex-col md:flex-row md:items-center md:justify-between mb-10",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold text-gray-900",children:"Research & Journals"}),(0,Gt.jsx)("p",{className:"text-gray-600 mt-2",children:"Peer-reviewed studies and academic resources"})]}),(0,Gt.jsxs)(Et,{to:"/research-journals",className:"mt-4 md:mt-0 text-blue-800 font-medium hover:underline flex items-center",children:["Browse Full Archive",(0,Gt.jsx)("svg",{className:"w-4 h-4 ml-1",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M9 5l7 7-7 7"})})]})]}),(0,Gt.jsx)("div",{className:"grid lg:grid-cols-2 gap-6",children:g.research.slice(0,2).map((t,e)=>(0,Gt.jsxs)("div",{className:"bg-white rounded-xl p-6 shadow-sm border-l-4 border-".concat(t.typeColor,"-600"),children:[(0,Gt.jsxs)("div",{className:"flex items-start justify-between mb-4",children:[(0,Gt.jsx)("span",{className:"bg-".concat(t.typeColor,"-100 text-").concat(t.typeColor,"-800 text-xs font-semibold px-3 py-1 rounded-full"),children:t.type}),(0,Gt.jsx)("span",{className:"text-gray-400 text-sm",children:t.year})]}),(0,Gt.jsx)("h3",{className:"font-bold text-lg text-gray-900 mb-2",children:t.title}),(0,Gt.jsxs)("p",{className:"text-gray-600 text-sm mb-4",children:[t.authors," \u2014 ",t.journal]}),(0,Gt.jsxs)("p",{className:"text-gray-500 text-sm mb-4",children:[(0,Gt.jsx)("strong",{children:"Abstract:"})," ",t.abstract]}),(0,Gt.jsx)("div",{className:"flex items-center space-x-4",children:(0,Gt.jsxs)("button",{className:"inline-flex items-center text-blue-800 font-medium text-sm",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4 mr-1",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M12 10v6m0 0l-3-3m3 3l3-3m2 8H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),"Download PDF"]})})]},e))})]})}),(0,Gt.jsx)("section",{className:"py-16 ".concat(y?"bg-gray-900":""),style:{backgroundColor:y?void 0:"#3F9AAE"},children:(0,Gt.jsxs)("div",{className:"max-w-4xl mx-auto px-4 text-center",children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold text-white mb-4",children:g.newsletter.title}),(0,Gt.jsx)("p",{className:"".concat(y?"text-gray-400":"text-blue-100"," mb-8"),children:g.newsletter.subtitle}),(0,Gt.jsxs)("form",{className:"flex flex-col sm:flex-row gap-4 max-w-xl mx-auto",onSubmit:t=>t.preventDefault(),children:[(0,Gt.jsx)("input",{type:"email",placeholder:"Enter your email address",className:"flex-1 px-6 py-4 rounded-full outline-none text-gray-800 focus:ring-4 focus:ring-blue-300"}),(0,Gt.jsx)("button",{type:"submit",className:"bg-orange-500 hover:bg-orange-600 text-white font-bold px-8 py-4 rounded-full transition",children:g.newsletter.buttonText})]}),(0,Gt.jsx)("p",{className:"".concat(y?"text-gray-500":"text-blue-100"," text-sm mt-4"),children:g.newsletter.footerText})]})}),(0,Gt.jsx)(Jt,{siteName:g.site.name,footer:g.footer})]})};function ae(t){var e,a;let{title:n}=t;const{siteData:o}=Kt()||{},s=et(),{slug:r}=function(){let{matches:t}=i.useContext(Y),e=t[t.length-1];return e?e.params:{}}(),l=(null===o||void 0===o||null===(e=o.site)||void 0===e?void 0:e.name)||"My Vet Corner",d=(null===o||void 0===o?void 0:o.navigation)||[],c=(null===o||void 0===o?void 0:o.footer)||{description:"",quickLinks:[],companyLinks:[],legalLinks:[],disclaimerText:"",copyright:""},m=new URLSearchParams(s.search).get("q"),u=(null===o||void 0===o?void 0:o.articles)||[];let h=[...u];const f=s.pathname,g=((null===o||void 0===o?void 0:o.categories)||[]).some(t=>Vt(t.name)===f)||n||m?null:u.find(t=>t.slug===r||("/"+(t.slug||"")).replace("//","/")===f);let p=null;if(g);else if(m){const t=m.toLowerCase();h=h.filter(e=>e.title&&e.title.toLowerCase().includes(t)||e.excerpt&&e.excerpt.toLowerCase().includes(t)||e.content&&e.content.toLowerCase().includes(t))}else n||(p=((null===o||void 0===o?void 0:o.categories)||[]).find(t=>Vt(t.name||"")===f),h=h.filter(t=>Vt(t.category||"")===f));return g?(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:l,navigation:d}),(0,Gt.jsxs)("article",{className:"max-w-4xl mx-auto px-4 py-12",children:[(0,Gt.jsxs)("div",{className:"mb-8 text-center",children:[(0,Gt.jsx)("span",{className:"inline-block bg-".concat(g.categoryColor||"blue","-100 text-").concat(g.categoryColor||"blue","-800 text-sm font-bold px-3 py-1 rounded-full mb-4"),children:g.category||"Article"}),(0,Gt.jsx)("h1",{className:"text-3xl md:text-5xl font-bold text-gray-900 mb-4",children:g.title}),(0,Gt.jsxs)("div",{className:"text-gray-500 text-sm flex justify-center items-center space-x-4",children:[(0,Gt.jsx)("span",{children:g.date}),(0,Gt.jsx)("span",{children:"\u2022"}),(0,Gt.jsx)("span",{children:g.readTime}),g.author&&(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)("span",{children:"\u2022"}),(0,Gt.jsxs)("span",{children:["By ",g.author]})]})]})]}),g.image&&(0,Gt.jsx)("div",{className:"mb-10 rounded-2xl overflow-hidden shadow-lg h-[400px] w-full",children:(0,Gt.jsx)("img",{src:g.image,alt:g.title,className:"w-full h-full object-cover"})}),(0,Gt.jsx)("div",{className:"prose prose-lg prose-blue max-w-none text-gray-700",dangerouslySetInnerHTML:{__html:g.content||""}})]}),(0,Gt.jsx)(Jt,{siteName:l,footer:c})]}):(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800",children:[(0,Gt.jsx)(Yt,{siteName:l,navigation:d}),(0,Gt.jsx)("section",{className:"bg-gray-50 py-3 border-b",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsxs)("nav",{className:"text-sm text-gray-500",children:[(0,Gt.jsx)(Et,{to:"/",className:"hover:text-blue-800",children:"Home"}),(0,Gt.jsx)("span",{className:"mx-2",children:"\u203a"}),(0,Gt.jsx)("span",{className:"text-gray-700",children:n||(null===(a=p)||void 0===a?void 0:a.name)||"Archives"})]})})}),(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4 py-16",children:[p?(0,Gt.jsxs)("div",{className:"relative rounded-2xl overflow-hidden mb-8",children:[(0,Gt.jsx)("img",{src:p.image,alt:p.name,className:"w-full h-56 md:h-72 object-cover"}),(0,Gt.jsx)("div",{className:"absolute inset-0 bg-gradient-to-t from-black/60 via-black/20 to-transparent"}),(0,Gt.jsxs)("div",{className:"absolute bottom-4 left-4 right-4",children:[(0,Gt.jsx)("h1",{className:"text-2xl md:text-3xl font-bold text-white",children:p.name}),p.count?(0,Gt.jsx)("p",{className:"text-white/80 text-sm",children:p.count}):null]})]}):(0,Gt.jsx)("h1",{className:"text-3xl font-bold text-gray-900 mb-6",children:n||"Articles"}),0===h.length?(0,Gt.jsx)("p",{className:"text-gray-600",children:"No articles found."}):(0,Gt.jsx)("div",{className:"grid md:grid-cols-2 lg:grid-cols-3 gap-8",children:h.map((t,e)=>(0,Gt.jsx)(Et,{to:t.slug?"/".concat(t.slug):"#",className:"group block h-full",children:(0,Gt.jsxs)("article",{className:"bg-white rounded-xl overflow-hidden shadow-sm hover:shadow-lg transition duration-300 h-full flex flex-col border border-gray-100",children:[(0,Gt.jsx)("div",{className:"h-48 overflow-hidden",children:(0,Gt.jsx)("img",{src:t.image,alt:t.title,className:"w-full h-full object-cover transform group-hover:scale-105 transition duration-500"})}),(0,Gt.jsxs)("div",{className:"p-6 flex-1 flex flex-col",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("span",{className:"inline-block bg-".concat(t.categoryColor,"-100 text-").concat(t.categoryColor,"-800 text-xs font-semibold px-3 py-1 rounded-full mb-3"),children:t.category}),(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-2 group-hover:text-blue-700 transition",children:t.title}),(0,Gt.jsx)("p",{className:"text-gray-600 text-sm mb-4 line-clamp-3",children:t.excerpt})]}),(0,Gt.jsxs)("div",{className:"mt-auto text-xs text-gray-500 border-t pt-4 flex justify-between",children:[(0,Gt.jsx)("span",{children:t.date}),(0,Gt.jsx)("span",{children:t.readTime})]})]})]})},e))})]}),(0,Gt.jsx)(Jt,{siteName:l,footer:c})]})}function ie(t){var e;let{title:a,subCategoryNames:i=[]}=t;const{siteData:n}=Kt()||{},o=(null===n||void 0===n||null===(e=n.site)||void 0===e?void 0:e.name)||"My Vet Corner",s=(null===n||void 0===n?void 0:n.navigation)||[],r=(null===n||void 0===n?void 0:n.footer)||{description:"",quickLinks:[],companyLinks:[],legalLinks:[]},l=((null===n||void 0===n?void 0:n.categories)||[]).filter(t=>i.includes(t.name));return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:o,navigation:s}),(0,Gt.jsx)("section",{className:"bg-gray-50 py-12 border-b",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4 text-center",children:[(0,Gt.jsx)("h1",{className:"text-4xl font-bold text-gray-900 mb-4",children:a}),(0,Gt.jsxs)("nav",{className:"text-sm text-gray-500 flex justify-center items-center",children:[(0,Gt.jsx)(Et,{to:"/",className:"hover:text-blue-800 transition",children:"Home"}),(0,Gt.jsx)("span",{className:"mx-2",children:"\u203a"}),(0,Gt.jsx)("span",{className:"text-gray-700",children:a})]})]})}),(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4 py-16",children:0===l.length?(0,Gt.jsx)("p",{className:"text-center text-gray-600",children:"No categories found for this section."}):(0,Gt.jsx)("div",{className:"grid md:grid-cols-2 lg:grid-cols-3 gap-8",children:l.map((t,e)=>(0,Gt.jsxs)(Et,{to:Vt(t.name),className:"group relative rounded-2xl overflow-hidden aspect-video shadow-md hover:shadow-xl transition duration-300 block",children:[(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-full h-full object-cover group-hover:scale-105 transition duration-500"}),(0,Gt.jsx)("div",{className:"absolute inset-0 bg-gradient-to-t from-black/80 via-black/20 to-transparent"}),(0,Gt.jsxs)("div",{className:"absolute bottom-6 left-6 right-6",children:[(0,Gt.jsx)("h3",{className:"text-white font-bold text-2xl mb-1",children:t.name}),t.count&&(0,Gt.jsx)("p",{className:"text-white/80 text-sm",children:t.count})]})]},e))})}),(0,Gt.jsx)(Jt,{siteName:o,footer:r})]})}const ne=(0,i.createContext)();function oe(t){let{children:e}=t;const[a,n]=(0,i.useState)([]),o=(0,i.useCallback)(function(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"info",a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:3e3;const i=Date.now();n(n=>[...n,{id:i,message:t,type:e,duration:a}]),a>0&&setTimeout(()=>{n(t=>t.filter(t=>t.id!==i))},a)},[]),s=(0,i.useCallback)(t=>{n(e=>e.filter(e=>e.id!==t))},[]),r={success:(t,e)=>o(t,"success",e),error:(t,e)=>o(t,"error",e),info:(t,e)=>o(t,"info",e),warning:(t,e)=>o(t,"warning",e)};return(0,Gt.jsxs)(ne.Provider,{value:r,children:[e,(0,Gt.jsx)(re,{toasts:a,onRemove:s})]})}function se(){const t=(0,i.useContext)(ne);if(!t)throw new Error("useToast must be used within ToastProvider");return t}function re(t){let{toasts:e,onRemove:a}=t;return(0,Gt.jsx)("div",{className:"fixed bottom-4 right-4 z-50 flex flex-col gap-2 max-w-sm",children:e.map(t=>(0,Gt.jsx)(le,Ht(Ht({},t),{},{onClose:()=>a(t.id)}),t.id))})}function le(t){let{message:e,type:a,onClose:i}=t;const n={success:{bg:"bg-green-50 dark:bg-green-900/20",border:"border-green-500",text:"text-green-800 dark:text-green-200",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})})},error:{bg:"bg-red-50 dark:bg-red-900/20",border:"border-red-500",text:"text-red-800 dark:text-red-200",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})},warning:{bg:"bg-yellow-50 dark:bg-yellow-900/20",border:"border-yellow-500",text:"text-yellow-800 dark:text-yellow-200",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"})})},info:{bg:"bg-blue-50 dark:bg-blue-900/20",border:"border-blue-500",text:"text-blue-800 dark:text-blue-200",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}},o=n[a]||n.info;return(0,Gt.jsxs)("div",{className:"".concat(o.bg," ").concat(o.text," border-l-4 ").concat(o.border," p-4 rounded-lg shadow-lg animate-slide-in-right flex items-start gap-3"),children:[(0,Gt.jsx)("div",{className:"flex-shrink-0",children:o.icon}),(0,Gt.jsx)("p",{className:"flex-1 text-sm font-medium",children:e}),(0,Gt.jsx)("button",{onClick:i,className:"flex-shrink-0 hover:opacity-70 transition",children:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]})}function de(){const t=et().pathname.split("/").filter(t=>t).filter(t=>"admin"!==t),e={editor:"Articles",categories:"Categories",users:"Experts",homepage:"Homepage",research:"Research","category-heroes":"Category Images",media:"Media Library",theme:"Settings",settings:"Settings"};return 0===t.length?(0,Gt.jsxs)("div",{className:"flex items-center gap-2 text-sm",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4 text-gray-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 12l2-2m0 0l7-7 7 7M5 10v10a1 1 0 001 1h3m10-11l2 2m-2-2v10a1 1 0 01-1 1h-3m-6 0a1 1 0 001-1v-4a1 1 0 011-1h2a1 1 0 011 1v4a1 1 0 001 1m-6 0h6"})}),(0,Gt.jsx)("span",{className:"text-gray-600 dark:text-gray-300 font-medium",children:"Dashboard"})]}):(0,Gt.jsxs)("nav",{className:"flex items-center gap-2 text-sm",children:[(0,Gt.jsxs)(Et,{to:"/admin",className:"text-gray-500 dark:text-gray-400 hover:text-blue-600 dark:hover:text-blue-400 transition flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 12l2-2m0 0l7-7 7 7M5 10v10a1 1 0 001 1h3m10-11l2 2m-2-2v10a1 1 0 01-1 1h-3m-6 0a1 1 0 001-1v-4a1 1 0 011-1h2a1 1 0 011 1v4a1 1 0 001 1m-6 0h6"})}),"Dashboard"]}),t.map((a,i)=>{const n="/admin/".concat(t.slice(0,i+1).join("/")),o=i===t.length-1,s=e[a]||a.charAt(0).toUpperCase()+a.slice(1);return(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4 text-gray-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5l7 7-7 7"})}),o?(0,Gt.jsx)("span",{className:"text-gray-600 dark:text-gray-300 font-medium",children:s}):(0,Gt.jsx)(Et,{to:n,className:"text-gray-500 dark:text-gray-400 hover:text-blue-600 dark:hover:text-blue-400 transition",children:s})]},a)})]})}function ce(t){let{children:e,className:a="",padding:i="p-6",hover:n=!1,onClick:o}=t;const s=n?"hover:shadow-md transition-shadow duration-200 cursor-pointer":"",r=o?"cursor-pointer":"";return(0,Gt.jsx)("div",{className:"".concat("bg-white dark:bg-gray-800 rounded-xl shadow-sm border border-gray-100 dark:border-gray-700"," ").concat(i," ").concat(s," ").concat(r," ").concat(a),onClick:o,children:e})}function me(t){let{title:e,subtitle:a,action:i}=t;return(0,Gt.jsxs)("div",{className:"flex justify-between items-start mb-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-xl font-bold text-gray-900 dark:text-white",children:e}),a&&(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400 mt-1",children:a})]}),i&&(0,Gt.jsx)("div",{children:i})]})}function ue(t){let{children:e,className:a=""}=t;return(0,Gt.jsx)("div",{className:a,children:e})}function he(t,e){if(null==t)return{};var a,i,n=function(t,e){if(null==t)return{};var a={};for(var i in t)if({}.hasOwnProperty.call(t,i)){if(-1!==e.indexOf(i))continue;a[i]=t[i]}return a}(t,e);if(Object.getOwnPropertySymbols){var o=Object.getOwnPropertySymbols(t);for(i=0;i<o.length;i++)a=o[i],-1===e.indexOf(a)&&{}.propertyIsEnumerable.call(t,a)&&(n[a]=t[a])}return n}const fe=["children","variant","size","icon","iconPosition","disabled","loading","className"];function ge(t){let{children:e,variant:a="primary",size:i="md",icon:n,iconPosition:o="left",disabled:s=!1,loading:r=!1,className:l=""}=t,d=he(t,fe);const c=s||r?"opacity-50 cursor-not-allowed pointer-events-none":"";return(0,Gt.jsx)("button",Ht(Ht({className:"".concat("inline-flex items-center justify-center font-medium rounded-lg transition-all duration-200 focus:outline-none focus:ring-2 focus:ring-offset-2"," ").concat({primary:"bg-blue-600 text-white hover:bg-blue-700 focus:ring-blue-500 disabled:bg-blue-300",secondary:"bg-gray-200 text-gray-900 hover:bg-gray-300 focus:ring-gray-500 dark:bg-gray-700 dark:text-white dark:hover:bg-gray-600",danger:"bg-red-600 text-white hover:bg-red-700 focus:ring-red-500 disabled:bg-red-300",success:"bg-green-600 text-white hover:bg-green-700 focus:ring-green-500 disabled:bg-green-300",ghost:"bg-transparent text-gray-700 hover:bg-gray-100 focus:ring-gray-500 dark:text-gray-300 dark:hover:bg-gray-800",outline:"border-2 border-blue-600 text-blue-600 hover:bg-blue-50 focus:ring-blue-500 dark:border-blue-500 dark:text-blue-400 dark:hover:bg-blue-900/20"}[a]," ").concat({sm:"px-3 py-1.5 text-sm gap-1.5",md:"px-4 py-2 text-base gap-2",lg:"px-6 py-3 text-lg gap-2.5"}[i]," ").concat(c," ").concat(l),disabled:s||r},d),{},{children:r?(0,Gt.jsxs)("svg",{className:"animate-spin h-4 w-4",fill:"none",viewBox:"0 0 24 24",children:[(0,Gt.jsx)("circle",{className:"opacity-25",cx:"12",cy:"12",r:"10",stroke:"currentColor",strokeWidth:"4"}),(0,Gt.jsx)("path",{className:"opacity-75",fill:"currentColor",d:"M4 12a8 8 0 018-8V0C5.373 0 0 5.373 0 12h4zm2 5.291A7.962 7.962 0 014 12H0c0 3.042 1.135 5.824 3 7.938l3-2.647z"})]}):(0,Gt.jsxs)(Gt.Fragment,{children:[n&&"left"===o&&(0,Gt.jsx)("span",{children:n}),e,n&&"right"===o&&(0,Gt.jsx)("span",{children:n})]})}))}function pe(){const{siteData:t}=Kt()||{},e=[{label:"Total Articles",value:((null===t||void 0===t?void 0:t.articles)||[]).length,icon:(0,Gt.jsx)("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),color:"bg-blue-500",change:"+12%"},{label:"Categories",value:((null===t||void 0===t?void 0:t.categories)||[]).length,icon:(0,Gt.jsx)("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})}),color:"bg-green-500",change:"+3"},{label:"Experts",value:((null===t||void 0===t?void 0:t.experts)||[]).length,icon:(0,Gt.jsx)("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4.354a4 4 0 110 5.292M15 21H3v-1a6 6 0 0112 0v1zm0 0h6v-1a6 6 0 00-9-5.197M13 7a4 4 0 11-8 0 4 4 0 018 0z"})}),color:"bg-purple-500",change:"+2"},{label:"Research Papers",value:((null===t||void 0===t?void 0:t.research)||[]).length,icon:(0,Gt.jsx)("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.384-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})}),color:"bg-orange-500",change:"+5"}],a=((null===t||void 0===t?void 0:t.articles)||[]).slice(0,5);return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)("div",{className:"bg-white dark:bg-gray-800 rounded-xl p-8 border border-gray-200 dark:border-gray-700 shadow-sm",children:[(0,Gt.jsx)("h1",{className:"text-3xl font-bold mb-2 text-gray-900 dark:text-white",children:"Welcome to My Vet Corner Admin"}),(0,Gt.jsx)("p",{className:"text-gray-600 dark:text-gray-400",children:"Manage your veterinary knowledge platform with ease"})]}),(0,Gt.jsx)("div",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-4 gap-6",children:e.map((t,e)=>(0,Gt.jsx)(ce,{padding:"p-6",hover:!0,children:(0,Gt.jsxs)("div",{className:"flex items-center justify-between",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("p",{className:"text-sm font-medium text-gray-500 dark:text-gray-400",children:t.label}),(0,Gt.jsx)("p",{className:"text-3xl font-bold text-gray-900 dark:text-white mt-2",children:t.value}),(0,Gt.jsx)("p",{className:"text-sm text-green-600 dark:text-green-400 mt-1",children:t.change})]}),(0,Gt.jsx)("div",{className:"".concat(t.color," p-3 rounded-lg text-white"),children:t.icon})]})},e))}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-6",children:[(0,Gt.jsxs)(ce,{className:"lg:col-span-1",children:[(0,Gt.jsx)(me,{title:"Quick Actions"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"grid grid-cols-2 gap-3",children:[{label:"New Article",to:"/admin/editor",icon:"\ud83d\udcdd",color:"blue"},{label:"Add Category",to:"/admin/categories",icon:"\ud83d\udcc1",color:"green"},{label:"Add Expert",to:"/admin/users",icon:"\ud83d\udc64",color:"purple"},{label:"Homepage",to:"/admin/homepage",icon:"\ud83c\udfe0",color:"orange"}].map((t,e)=>(0,Gt.jsx)(Et,{to:t.to,children:(0,Gt.jsxs)("button",{className:"w-full p-4 bg-gray-50 dark:bg-gray-700 hover:bg-gray-100 dark:hover:bg-gray-600 rounded-lg transition text-center",children:[(0,Gt.jsx)("div",{className:"text-2xl mb-2",children:t.icon}),(0,Gt.jsx)("div",{className:"text-sm font-medium text-gray-900 dark:text-white",children:t.label})]})},e))})})]}),(0,Gt.jsxs)(ce,{className:"lg:col-span-2",children:[(0,Gt.jsx)(me,{title:"Recent Articles",subtitle:"".concat(a.length," most recent"),action:(0,Gt.jsx)(Et,{to:"/admin/editor",children:(0,Gt.jsx)(ge,{size:"sm",variant:"ghost",children:"View All"})})}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"space-y-3",children:0===a.length?(0,Gt.jsx)("p",{className:"text-center py-8 text-gray-500 dark:text-gray-400",children:"No articles yet. Create your first one!"}):a.map((t,e)=>(0,Gt.jsxs)("div",{className:"flex items-center justify-between p-3 bg-gray-50 dark:bg-gray-700 rounded-lg hover:bg-gray-100 dark:hover:bg-gray-600 transition",children:[(0,Gt.jsxs)("div",{className:"flex-1",children:[(0,Gt.jsx)("h4",{className:"font-medium text-gray-900 dark:text-white",children:t.title||"Untitled"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-500 dark:text-gray-400 mt-1",children:[t.category||"Uncategorized"," \u2022 ",t.date||"No date"]})]}),(0,Gt.jsx)("div",{className:"flex items-center gap-2",children:t.published?(0,Gt.jsx)("span",{className:"px-2 py-1 bg-green-100 text-green-800 dark:bg-green-900 dark:text-green-200 text-xs rounded-full",children:"Published"}):(0,Gt.jsx)("span",{className:"px-2 py-1 bg-yellow-100 text-yellow-800 dark:bg-yellow-900 dark:text-yellow-200 text-xs rounded-full",children:"Draft"})})]},e))})})]})]}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Site Health",subtitle:"System status and recommendations"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[(0,Gt.jsxs)("div",{className:"p-4 bg-green-50 dark:bg-green-900/20 rounded-lg border border-green-200 dark:border-green-800",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-2",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5 text-green-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}),(0,Gt.jsx)("h5",{className:"font-semibold text-green-800 dark:text-green-200",children:"All Systems Operational"})]}),(0,Gt.jsx)("p",{className:"text-sm text-green-600 dark:text-green-300",children:"Backend and frontend running smoothly"})]}),(0,Gt.jsxs)("div",{className:"p-4 bg-blue-50 dark:bg-blue-900/20 rounded-lg border border-blue-200 dark:border-blue-800",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-2",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5 text-blue-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})}),(0,Gt.jsx)("h5",{className:"font-semibold text-blue-800 dark:text-blue-200",children:"Content Quality"})]}),(0,Gt.jsx)("p",{className:"text-sm text-blue-600 dark:text-blue-300",children:"SEO optimization recommended"})]}),(0,Gt.jsxs)("div",{className:"p-4 bg-purple-50 dark:bg-purple-900/20 rounded-lg border border-purple-200 dark:border-purple-800",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-2",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5 text-purple-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 8h10M7 12h4m1 8l-4-4H5a2 2 0 01-2-2V6a2 2 0 012-2h14a2 2 0 012 2v8a2 2 0 01-2 2h-3l-4 4z"})}),(0,Gt.jsx)("h5",{className:"font-semibold text-purple-800 dark:text-purple-200",children:"Expert Network"})]}),(0,Gt.jsxs)("p",{className:"text-sm text-purple-600 dark:text-purple-300",children:[((null===t||void 0===t?void 0:t.experts)||[]).length," medical professionals"]})]})]})})]})]})}const ye=function(){this.__data__=[],this.size=0};const be=function(t,e){return t===e||t!==t&&e!==e};const ve=function(t,e){for(var a=t.length;a--;)if(be(t[a][0],e))return a;return-1};var we=Array.prototype.splice;const xe=function(t){var e=this.__data__,a=ve(e,t);return!(a<0)&&(a==e.length-1?e.pop():we.call(e,a,1),--this.size,!0)};const ke=function(t){var e=this.__data__,a=ve(e,t);return a<0?void 0:e[a][1]};const Ie=function(t){return ve(this.__data__,t)>-1};const Ce=function(t,e){var a=this.__data__,i=ve(a,t);return i<0?(++this.size,a.push([t,e])):a[i][1]=e,this};function Se(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}Se.prototype.clear=ye,Se.prototype.delete=xe,Se.prototype.get=ke,Se.prototype.has=Ie,Se.prototype.set=Ce;const Ae=Se;const Te=function(){this.__data__=new Ae,this.size=0};const Pe=function(t){var e=this.__data__,a=e.delete(t);return this.size=e.size,a};const De=function(t){return this.__data__.get(t)};const Ne=function(t){return this.__data__.has(t)};const Le="object"==typeof a.g&&a.g&&a.g.Object===Object&&a.g;var Ee="object"==typeof self&&self&&self.Object===Object&&self;const je=Le||Ee||Function("return this")();const Me=je.Symbol;var ze=Object.prototype,Re=ze.hasOwnProperty,Fe=ze.toString,qe=Me?Me.toStringTag:void 0;const _e=function(t){var e=Re.call(t,qe),a=t[qe];try{t[qe]=void 0;var i=!0}catch(cu){}var n=Fe.call(t);return i&&(e?t[qe]=a:delete t[qe]),n};var Oe=Object.prototype.toString;const Ue=function(t){return Oe.call(t)};var He=Me?Me.toStringTag:void 0;const Ve=function(t){return null==t?void 0===t?"[object Undefined]":"[object Null]":He&&He in Object(t)?_e(t):Ue(t)};const Be=function(t){var e=typeof t;return null!=t&&("object"==e||"function"==e)};const Ge=function(t){if(!Be(t))return!1;var e=Ve(t);return"[object Function]"==e||"[object GeneratorFunction]"==e||"[object AsyncFunction]"==e||"[object Proxy]"==e};const We=je["__core-js_shared__"];var Qe=function(){var t=/[^.]+$/.exec(We&&We.keys&&We.keys.IE_PROTO||"");return t?"Symbol(src)_1."+t:""}();const Ke=function(t){return!!Qe&&Qe in t};var Ze=Function.prototype.toString;const $e=function(t){if(null!=t){try{return Ze.call(t)}catch(cu){}try{return t+""}catch(cu){}}return""};var Xe=/^\[object .+?Constructor\]$/,Ye=Function.prototype,Je=Object.prototype,ta=Ye.toString,ea=Je.hasOwnProperty,aa=RegExp("^"+ta.call(ea).replace(/[\\^$.*+?()[\]{}|]/g,"\\$&").replace(/hasOwnProperty|(function).*?(?=\\\()| for .+?(?=\\\])/g,"$1.*?")+"$");const ia=function(t){return!(!Be(t)||Ke(t))&&(Ge(t)?aa:Xe).test($e(t))};const na=function(t,e){return null==t?void 0:t[e]};const oa=function(t,e){var a=na(t,e);return ia(a)?a:void 0};const sa=oa(je,"Map");const ra=oa(Object,"create");const la=function(){this.__data__=ra?ra(null):{},this.size=0};const da=function(t){var e=this.has(t)&&delete this.__data__[t];return this.size-=e?1:0,e};var ca=Object.prototype.hasOwnProperty;const ma=function(t){var e=this.__data__;if(ra){var a=e[t];return"__lodash_hash_undefined__"===a?void 0:a}return ca.call(e,t)?e[t]:void 0};var ua=Object.prototype.hasOwnProperty;const ha=function(t){var e=this.__data__;return ra?void 0!==e[t]:ua.call(e,t)};const fa=function(t,e){var a=this.__data__;return this.size+=this.has(t)?0:1,a[t]=ra&&void 0===e?"__lodash_hash_undefined__":e,this};function ga(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}ga.prototype.clear=la,ga.prototype.delete=da,ga.prototype.get=ma,ga.prototype.has=ha,ga.prototype.set=fa;const pa=ga;const ya=function(){this.size=0,this.__data__={hash:new pa,map:new(sa||Ae),string:new pa}};const ba=function(t){var e=typeof t;return"string"==e||"number"==e||"symbol"==e||"boolean"==e?"__proto__"!==t:null===t};const va=function(t,e){var a=t.__data__;return ba(e)?a["string"==typeof e?"string":"hash"]:a.map};const wa=function(t){var e=va(this,t).delete(t);return this.size-=e?1:0,e};const xa=function(t){return va(this,t).get(t)};const ka=function(t){return va(this,t).has(t)};const Ia=function(t,e){var a=va(this,t),i=a.size;return a.set(t,e),this.size+=a.size==i?0:1,this};function Ca(t){var e=-1,a=null==t?0:t.length;for(this.clear();++e<a;){var i=t[e];this.set(i[0],i[1])}}Ca.prototype.clear=ya,Ca.prototype.delete=wa,Ca.prototype.get=xa,Ca.prototype.has=ka,Ca.prototype.set=Ia;const Sa=Ca;const Aa=function(t,e){var a=this.__data__;if(a instanceof Ae){var i=a.__data__;if(!sa||i.length<199)return i.push([t,e]),this.size=++a.size,this;a=this.__data__=new Sa(i)}return a.set(t,e),this.size=a.size,this};function Ta(t){var e=this.__data__=new Ae(t);this.size=e.size}Ta.prototype.clear=Te,Ta.prototype.delete=Pe,Ta.prototype.get=De,Ta.prototype.has=Ne,Ta.prototype.set=Aa;const Pa=Ta;const Da=function(t){return this.__data__.set(t,"__lodash_hash_undefined__"),this};const Na=function(t){return this.__data__.has(t)};function La(t){var e=-1,a=null==t?0:t.length;for(this.__data__=new Sa;++e<a;)this.add(t[e])}La.prototype.add=La.prototype.push=Da,La.prototype.has=Na;const Ea=La;const ja=function(t,e){for(var a=-1,i=null==t?0:t.length;++a<i;)if(e(t[a],a,t))return!0;return!1};const Ma=function(t,e){return t.has(e)};const za=function(t,e,a,i,n,o){var s=1&a,r=t.length,l=e.length;if(r!=l&&!(s&&l>r))return!1;var d=o.get(t),c=o.get(e);if(d&&c)return d==e&&c==t;var m=-1,u=!0,h=2&a?new Ea:void 0;for(o.set(t,e),o.set(e,t);++m<r;){var f=t[m],g=e[m];if(i)var p=s?i(g,f,m,e,t,o):i(f,g,m,t,e,o);if(void 0!==p){if(p)continue;u=!1;break}if(h){if(!ja(e,function(t,e){if(!Ma(h,e)&&(f===t||n(f,t,a,i,o)))return h.push(e)})){u=!1;break}}else if(f!==g&&!n(f,g,a,i,o)){u=!1;break}}return o.delete(t),o.delete(e),u};const Ra=je.Uint8Array;const Fa=function(t){var e=-1,a=Array(t.size);return t.forEach(function(t,i){a[++e]=[i,t]}),a};const qa=function(t){var e=-1,a=Array(t.size);return t.forEach(function(t){a[++e]=t}),a};var _a=Me?Me.prototype:void 0,Oa=_a?_a.valueOf:void 0;const Ua=function(t,e,a,i,n,o,s){switch(a){case"[object DataView]":if(t.byteLength!=e.byteLength||t.byteOffset!=e.byteOffset)return!1;t=t.buffer,e=e.buffer;case"[object ArrayBuffer]":return!(t.byteLength!=e.byteLength||!o(new Ra(t),new Ra(e)));case"[object Boolean]":case"[object Date]":case"[object Number]":return be(+t,+e);case"[object Error]":return t.name==e.name&&t.message==e.message;case"[object RegExp]":case"[object String]":return t==e+"";case"[object Map]":var r=Fa;case"[object Set]":var l=1&i;if(r||(r=qa),t.size!=e.size&&!l)return!1;var d=s.get(t);if(d)return d==e;i|=2,s.set(t,e);var c=za(r(t),r(e),i,n,o,s);return s.delete(t),c;case"[object Symbol]":if(Oa)return Oa.call(t)==Oa.call(e)}return!1};const Ha=function(t,e){for(var a=-1,i=e.length,n=t.length;++a<i;)t[n+a]=e[a];return t};const Va=Array.isArray;const Ba=function(t,e,a){var i=e(t);return Va(t)?i:Ha(i,a(t))};const Ga=function(t,e){for(var a=-1,i=null==t?0:t.length,n=0,o=[];++a<i;){var s=t[a];e(s,a,t)&&(o[n++]=s)}return o};const Wa=function(){return[]};var Qa=Object.prototype.propertyIsEnumerable,Ka=Object.getOwnPropertySymbols;const Za=Ka?function(t){return null==t?[]:(t=Object(t),Ga(Ka(t),function(e){return Qa.call(t,e)}))}:Wa;const $a=function(t,e){for(var a=-1,i=Array(t);++a<t;)i[a]=e(a);return i};const Xa=function(t){return null!=t&&"object"==typeof t};const Ya=function(t){return Xa(t)&&"[object Arguments]"==Ve(t)};var Ja=Object.prototype,ti=Ja.hasOwnProperty,ei=Ja.propertyIsEnumerable;const ai=Ya(function(){return arguments}())?Ya:function(t){return Xa(t)&&ti.call(t,"callee")&&!ei.call(t,"callee")};const ii=function(){return!1};var ni="object"==typeof exports&&exports&&!exports.nodeType&&exports,oi=ni&&"object"==typeof module&&module&&!module.nodeType&&module,si=oi&&oi.exports===ni?je.Buffer:void 0;const ri=(si?si.isBuffer:void 0)||ii;var li=/^(?:0|[1-9]\d*)$/;const di=function(t,e){var a=typeof t;return!!(e=null==e?9007199254740991:e)&&("number"==a||"symbol"!=a&&li.test(t))&&t>-1&&t%1==0&&t<e};const ci=function(t){return"number"==typeof t&&t>-1&&t%1==0&&t<=9007199254740991};var mi={};mi["[object Float32Array]"]=mi["[object Float64Array]"]=mi["[object Int8Array]"]=mi["[object Int16Array]"]=mi["[object Int32Array]"]=mi["[object Uint8Array]"]=mi["[object Uint8ClampedArray]"]=mi["[object Uint16Array]"]=mi["[object Uint32Array]"]=!0,mi["[object Arguments]"]=mi["[object Array]"]=mi["[object ArrayBuffer]"]=mi["[object Boolean]"]=mi["[object DataView]"]=mi["[object Date]"]=mi["[object Error]"]=mi["[object Function]"]=mi["[object Map]"]=mi["[object Number]"]=mi["[object Object]"]=mi["[object RegExp]"]=mi["[object Set]"]=mi["[object String]"]=mi["[object WeakMap]"]=!1;const ui=function(t){return Xa(t)&&ci(t.length)&&!!mi[Ve(t)]};const hi=function(t){return function(e){return t(e)}};var fi="object"==typeof exports&&exports&&!exports.nodeType&&exports,gi=fi&&"object"==typeof module&&module&&!module.nodeType&&module,pi=gi&&gi.exports===fi&&Le.process;const yi=function(){try{var t=gi&&gi.require&&gi.require("util").types;return t||pi&&pi.binding&&pi.binding("util")}catch(cu){}}();var bi=yi&&yi.isTypedArray;const vi=bi?hi(bi):ui;var wi=Object.prototype.hasOwnProperty;const xi=function(t,e){var a=Va(t),i=!a&&ai(t),n=!a&&!i&&ri(t),o=!a&&!i&&!n&&vi(t),s=a||i||n||o,r=s?$a(t.length,String):[],l=r.length;for(var d in t)!e&&!wi.call(t,d)||s&&("length"==d||n&&("offset"==d||"parent"==d)||o&&("buffer"==d||"byteLength"==d||"byteOffset"==d)||di(d,l))||r.push(d);return r};var ki=Object.prototype;const Ii=function(t){var e=t&&t.constructor;return t===("function"==typeof e&&e.prototype||ki)};const Ci=function(t,e){return function(a){return t(e(a))}};const Si=Ci(Object.keys,Object);var Ai=Object.prototype.hasOwnProperty;const Ti=function(t){if(!Ii(t))return Si(t);var e=[];for(var a in Object(t))Ai.call(t,a)&&"constructor"!=a&&e.push(a);return e};const Pi=function(t){return null!=t&&ci(t.length)&&!Ge(t)};const Di=function(t){return Pi(t)?xi(t):Ti(t)};const Ni=function(t){return Ba(t,Di,Za)};var Li=Object.prototype.hasOwnProperty;const Ei=function(t,e,a,i,n,o){var s=1&a,r=Ni(t),l=r.length;if(l!=Ni(e).length&&!s)return!1;for(var d=l;d--;){var c=r[d];if(!(s?c in e:Li.call(e,c)))return!1}var m=o.get(t),u=o.get(e);if(m&&u)return m==e&&u==t;var h=!0;o.set(t,e),o.set(e,t);for(var f=s;++d<l;){var g=t[c=r[d]],p=e[c];if(i)var y=s?i(p,g,c,e,t,o):i(g,p,c,t,e,o);if(!(void 0===y?g===p||n(g,p,a,i,o):y)){h=!1;break}f||(f="constructor"==c)}if(h&&!f){var b=t.constructor,v=e.constructor;b==v||!("constructor"in t)||!("constructor"in e)||"function"==typeof b&&b instanceof b&&"function"==typeof v&&v instanceof v||(h=!1)}return o.delete(t),o.delete(e),h};const ji=oa(je,"DataView");const Mi=oa(je,"Promise");const zi=oa(je,"Set");const Ri=oa(je,"WeakMap");var Fi="[object Map]",qi="[object Promise]",_i="[object Set]",Oi="[object WeakMap]",Ui="[object DataView]",Hi=$e(ji),Vi=$e(sa),Bi=$e(Mi),Gi=$e(zi),Wi=$e(Ri),Qi=Ve;(ji&&Qi(new ji(new ArrayBuffer(1)))!=Ui||sa&&Qi(new sa)!=Fi||Mi&&Qi(Mi.resolve())!=qi||zi&&Qi(new zi)!=_i||Ri&&Qi(new Ri)!=Oi)&&(Qi=function(t){var e=Ve(t),a="[object Object]"==e?t.constructor:void 0,i=a?$e(a):"";if(i)switch(i){case Hi:return Ui;case Vi:return Fi;case Bi:return qi;case Gi:return _i;case Wi:return Oi}return e});const Ki=Qi;var Zi="[object Arguments]",$i="[object Array]",Xi="[object Object]",Yi=Object.prototype.hasOwnProperty;const Ji=function(t,e,a,i,n,o){var s=Va(t),r=Va(e),l=s?$i:Ki(t),d=r?$i:Ki(e),c=(l=l==Zi?Xi:l)==Xi,m=(d=d==Zi?Xi:d)==Xi,u=l==d;if(u&&ri(t)){if(!ri(e))return!1;s=!0,c=!1}if(u&&!c)return o||(o=new Pa),s||vi(t)?za(t,e,a,i,n,o):Ua(t,e,l,a,i,n,o);if(!(1&a)){var h=c&&Yi.call(t,"__wrapped__"),f=m&&Yi.call(e,"__wrapped__");if(h||f){var g=h?t.value():t,p=f?e.value():e;return o||(o=new Pa),n(g,p,a,i,o)}}return!!u&&(o||(o=new Pa),Ei(t,e,a,i,n,o))};const tn=function t(e,a,i,n,o){return e===a||(null==e||null==a||!Xa(e)&&!Xa(a)?e!==e&&a!==a:Ji(e,a,i,n,t,o))};const en=function(t,e){return tn(t,e)};const an=function(){try{var t=oa(Object,"defineProperty");return t({},"",{}),t}catch(cu){}}();const nn=function(t,e,a){"__proto__"==e&&an?an(t,e,{configurable:!0,enumerable:!0,value:a,writable:!0}):t[e]=a};const on=function(t,e,a){(void 0!==a&&!be(t[e],a)||void 0===a&&!(e in t))&&nn(t,e,a)};const sn=function(t){return function(e,a,i){for(var n=-1,o=Object(e),s=i(e),r=s.length;r--;){var l=s[t?r:++n];if(!1===a(o[l],l,o))break}return e}}();var rn="object"==typeof exports&&exports&&!exports.nodeType&&exports,ln=rn&&"object"==typeof module&&module&&!module.nodeType&&module,dn=ln&&ln.exports===rn?je.Buffer:void 0,cn=dn?dn.allocUnsafe:void 0;const mn=function(t,e){if(e)return t.slice();var a=t.length,i=cn?cn(a):new t.constructor(a);return t.copy(i),i};const un=function(t){var e=new t.constructor(t.byteLength);return new Ra(e).set(new Ra(t)),e};const hn=function(t,e){var a=e?un(t.buffer):t.buffer;return new t.constructor(a,t.byteOffset,t.length)};const fn=function(t,e){var a=-1,i=t.length;for(e||(e=Array(i));++a<i;)e[a]=t[a];return e};var gn=Object.create;const pn=function(){function t(){}return function(e){if(!Be(e))return{};if(gn)return gn(e);t.prototype=e;var a=new t;return t.prototype=void 0,a}}();const yn=Ci(Object.getPrototypeOf,Object);const bn=function(t){return"function"!=typeof t.constructor||Ii(t)?{}:pn(yn(t))};const vn=function(t){return Xa(t)&&Pi(t)};var wn=Function.prototype,xn=Object.prototype,kn=wn.toString,In=xn.hasOwnProperty,Cn=kn.call(Object);const Sn=function(t){if(!Xa(t)||"[object Object]"!=Ve(t))return!1;var e=yn(t);if(null===e)return!0;var a=In.call(e,"constructor")&&e.constructor;return"function"==typeof a&&a instanceof a&&kn.call(a)==Cn};const An=function(t,e){if(("constructor"!==e||"function"!==typeof t[e])&&"__proto__"!=e)return t[e]};var Tn=Object.prototype.hasOwnProperty;const Pn=function(t,e,a){var i=t[e];Tn.call(t,e)&&be(i,a)&&(void 0!==a||e in t)||nn(t,e,a)};const Dn=function(t,e,a,i){var n=!a;a||(a={});for(var o=-1,s=e.length;++o<s;){var r=e[o],l=i?i(a[r],t[r],r,a,t):void 0;void 0===l&&(l=t[r]),n?nn(a,r,l):Pn(a,r,l)}return a};const Nn=function(t){var e=[];if(null!=t)for(var a in Object(t))e.push(a);return e};var Ln=Object.prototype.hasOwnProperty;const En=function(t){if(!Be(t))return Nn(t);var e=Ii(t),a=[];for(var i in t)("constructor"!=i||!e&&Ln.call(t,i))&&a.push(i);return a};const jn=function(t){return Pi(t)?xi(t,!0):En(t)};const Mn=function(t){return Dn(t,jn(t))};const zn=function(t,e,a,i,n,o,s){var r=An(t,a),l=An(e,a),d=s.get(l);if(d)on(t,a,d);else{var c=o?o(r,l,a+"",t,e,s):void 0,m=void 0===c;if(m){var u=Va(l),h=!u&&ri(l),f=!u&&!h&&vi(l);c=l,u||h||f?Va(r)?c=r:vn(r)?c=fn(r):h?(m=!1,c=mn(l,!0)):f?(m=!1,c=hn(l,!0)):c=[]:Sn(l)||ai(l)?(c=r,ai(r)?c=Mn(r):Be(r)&&!Ge(r)||(c=bn(l))):m=!1}m&&(s.set(l,c),n(c,l,i,o,s),s.delete(l)),on(t,a,c)}};const Rn=function t(e,a,i,n,o){e!==a&&sn(a,function(s,r){if(o||(o=new Pa),Be(s))zn(e,a,r,i,t,n,o);else{var l=n?n(An(e,r),s,r+"",e,a,o):void 0;void 0===l&&(l=s),on(e,r,l)}},jn)};const Fn=function(t){return t};const qn=function(t,e,a){switch(a.length){case 0:return t.call(e);case 1:return t.call(e,a[0]);case 2:return t.call(e,a[0],a[1]);case 3:return t.call(e,a[0],a[1],a[2])}return t.apply(e,a)};var _n=Math.max;const On=function(t,e,a){return e=_n(void 0===e?t.length-1:e,0),function(){for(var i=arguments,n=-1,o=_n(i.length-e,0),s=Array(o);++n<o;)s[n]=i[e+n];n=-1;for(var r=Array(e+1);++n<e;)r[n]=i[n];return r[e]=a(s),qn(t,this,r)}};const Un=function(t){return function(){return t}};const Hn=an?function(t,e){return an(t,"toString",{configurable:!0,enumerable:!1,value:Un(e),writable:!0})}:Fn;var Vn=Date.now;const Bn=function(t){var e=0,a=0;return function(){var i=Vn(),n=16-(i-a);if(a=i,n>0){if(++e>=800)return arguments[0]}else e=0;return t.apply(void 0,arguments)}}(Hn);const Gn=function(t,e){return Bn(On(t,e,Fn),t+"")};const Wn=function(t,e,a){if(!Be(a))return!1;var i=typeof e;return!!("number"==i?Pi(a)&&di(e,a.length):"string"==i&&e in a)&&be(a[e],t)};const Qn=function(t){return Gn(function(e,a){var i=-1,n=a.length,o=n>1?a[n-1]:void 0,s=n>2?a[2]:void 0;for(o=t.length>3&&"function"==typeof o?(n--,o):void 0,s&&Wn(a[0],a[1],s)&&(o=n<3?void 0:o,n=1),e=Object(e);++i<n;){var r=a[i];r&&t(e,r,i,o)}return e})}(function(t,e,a){Rn(t,e,a)});var Kn=(t=>(t[t.TYPE=3]="TYPE",t[t.LEVEL=12]="LEVEL",t[t.ATTRIBUTE=13]="ATTRIBUTE",t[t.BLOT=14]="BLOT",t[t.INLINE=7]="INLINE",t[t.BLOCK=11]="BLOCK",t[t.BLOCK_BLOT=10]="BLOCK_BLOT",t[t.INLINE_BLOT=6]="INLINE_BLOT",t[t.BLOCK_ATTRIBUTE=9]="BLOCK_ATTRIBUTE",t[t.INLINE_ATTRIBUTE=5]="INLINE_ATTRIBUTE",t[t.ANY=15]="ANY",t))(Kn||{});class Zn{constructor(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};this.attrName=t,this.keyName=e;const i=Kn.TYPE&Kn.ATTRIBUTE;this.scope=null!=a.scope?a.scope&Kn.LEVEL|i:Kn.ATTRIBUTE,null!=a.whitelist&&(this.whitelist=a.whitelist)}static keys(t){return Array.from(t.attributes).map(t=>t.name)}add(t,e){return!!this.canAdd(t,e)&&(t.setAttribute(this.keyName,e),!0)}canAdd(t,e){return null==this.whitelist||("string"==typeof e?this.whitelist.indexOf(e.replace(/["']/g,""))>-1:this.whitelist.indexOf(e)>-1)}remove(t){t.removeAttribute(this.keyName)}value(t){const e=t.getAttribute(this.keyName);return this.canAdd(t,e)&&e?e:""}}class $n extends Error{constructor(t){super(t="[Parchment] "+t),this.message=t,this.name=this.constructor.name}}const Xn=class t{constructor(){this.attributes={},this.classes={},this.tags={},this.types={}}static find(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(null==t)return null;if(this.blots.has(t))return this.blots.get(t)||null;if(e){let i=null;try{i=t.parentNode}catch(a){return null}return this.find(i,e)}return null}create(e,a,i){const n=this.query(a);if(null==n)throw new $n("Unable to create ".concat(a," blot"));const o=n,s=a instanceof Node||a.nodeType===Node.TEXT_NODE?a:o.create(i),r=new o(e,s,i);return t.blots.set(r.domNode,r),r}find(e){let a=arguments.length>1&&void 0!==arguments[1]&&arguments[1];return t.find(e,a)}query(t){let e,a=arguments.length>1&&void 0!==arguments[1]?arguments[1]:Kn.ANY;return"string"==typeof t?e=this.types[t]||this.attributes[t]:t instanceof Text||t.nodeType===Node.TEXT_NODE?e=this.types.text:"number"==typeof t?t&Kn.LEVEL&Kn.BLOCK?e=this.types.block:t&Kn.LEVEL&Kn.INLINE&&(e=this.types.inline):t instanceof Element&&((t.getAttribute("class")||"").split(/\s+/).some(t=>(e=this.classes[t],!!e)),e=e||this.tags[t.tagName]),null==e?null:"scope"in e&&a&Kn.LEVEL&e.scope&&a&Kn.TYPE&e.scope?e:null}register(){for(var t=arguments.length,e=new Array(t),a=0;a<t;a++)e[a]=arguments[a];return e.map(t=>{const e="blotName"in t,a="attrName"in t;if(!e&&!a)throw new $n("Invalid definition");if(e&&"abstract"===t.blotName)throw new $n("Cannot register abstract class");const i=e?t.blotName:a?t.attrName:void 0;return this.types[i]=t,a?"string"==typeof t.keyName&&(this.attributes[t.keyName]=t):e&&(t.className&&(this.classes[t.className]=t),t.tagName&&(Array.isArray(t.tagName)?t.tagName=t.tagName.map(t=>t.toUpperCase()):t.tagName=t.tagName.toUpperCase(),(Array.isArray(t.tagName)?t.tagName:[t.tagName]).forEach(e=>{(null==this.tags[e]||null==t.className)&&(this.tags[e]=t)}))),t})}};Xn.blots=new WeakMap;let Yn=Xn;function Jn(t,e){return(t.getAttribute("class")||"").split(/\s+/).filter(t=>0===t.indexOf("".concat(e,"-")))}const to=class extends Zn{static keys(t){return(t.getAttribute("class")||"").split(/\s+/).map(t=>t.split("-").slice(0,-1).join("-"))}add(t,e){return!!this.canAdd(t,e)&&(this.remove(t),t.classList.add("".concat(this.keyName,"-").concat(e)),!0)}remove(t){Jn(t,this.keyName).forEach(e=>{t.classList.remove(e)}),0===t.classList.length&&t.removeAttribute("class")}value(t){const e=(Jn(t,this.keyName)[0]||"").slice(this.keyName.length+1);return this.canAdd(t,e)?e:""}};function eo(t){const e=t.split("-"),a=e.slice(1).map(t=>t[0].toUpperCase()+t.slice(1)).join("");return e[0]+a}const ao=class extends Zn{static keys(t){return(t.getAttribute("style")||"").split(";").map(t=>t.split(":")[0].trim())}add(t,e){return!!this.canAdd(t,e)&&(t.style[eo(this.keyName)]=e,!0)}remove(t){t.style[eo(this.keyName)]="",t.getAttribute("style")||t.removeAttribute("style")}value(t){const e=t.style[eo(this.keyName)];return this.canAdd(t,e)?e:""}};const io=class{constructor(t){this.attributes={},this.domNode=t,this.build()}attribute(t,e){e?t.add(this.domNode,e)&&(null!=t.value(this.domNode)?this.attributes[t.attrName]=t:delete this.attributes[t.attrName]):(t.remove(this.domNode),delete this.attributes[t.attrName])}build(){this.attributes={};const t=Yn.find(this.domNode);if(null==t)return;const e=Zn.keys(this.domNode),a=to.keys(this.domNode),i=ao.keys(this.domNode);e.concat(a).concat(i).forEach(e=>{const a=t.scroll.query(e,Kn.ATTRIBUTE);a instanceof Zn&&(this.attributes[a.attrName]=a)})}copy(t){Object.keys(this.attributes).forEach(e=>{const a=this.attributes[e].value(this.domNode);t.format(e,a)})}move(t){this.copy(t),Object.keys(this.attributes).forEach(t=>{this.attributes[t].remove(this.domNode)}),this.attributes={}}values(){return Object.keys(this.attributes).reduce((t,e)=>(t[e]=this.attributes[e].value(this.domNode),t),{})}},no=class{constructor(t,e){this.scroll=t,this.domNode=e,Yn.blots.set(e,this),this.prev=null,this.next=null}static create(t){if(null==this.tagName)throw new $n("Blot definition missing tagName");let e,a;return Array.isArray(this.tagName)?("string"==typeof t?(a=t.toUpperCase(),parseInt(a,10).toString()===a&&(a=parseInt(a,10))):"number"==typeof t&&(a=t),e="number"==typeof a?document.createElement(this.tagName[a-1]):a&&this.tagName.indexOf(a)>-1?document.createElement(a):document.createElement(this.tagName[0])):e=document.createElement(this.tagName),this.className&&e.classList.add(this.className),e}get statics(){return this.constructor}attach(){}clone(){const t=this.domNode.cloneNode(!1);return this.scroll.create(t)}detach(){null!=this.parent&&this.parent.removeChild(this),Yn.blots.delete(this.domNode)}deleteAt(t,e){this.isolate(t,e).remove()}formatAt(t,e,a,i){const n=this.isolate(t,e);if(null!=this.scroll.query(a,Kn.BLOT)&&i)n.wrap(a,i);else if(null!=this.scroll.query(a,Kn.ATTRIBUTE)){const t=this.scroll.create(this.statics.scope);n.wrap(t),t.format(a,i)}}insertAt(t,e,a){const i=null==a?this.scroll.create("text",e):this.scroll.create(e,a),n=this.split(t);this.parent.insertBefore(i,n||void 0)}isolate(t,e){const a=this.split(t);if(null==a)throw new Error("Attempt to isolate at end");return a.split(e),a}length(){return 1}offset(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.parent;return null==this.parent||this===t?0:this.parent.children.offset(this)+this.parent.offset(t)}optimize(t){this.statics.requiredContainer&&!(this.parent instanceof this.statics.requiredContainer)&&this.wrap(this.statics.requiredContainer.blotName)}remove(){null!=this.domNode.parentNode&&this.domNode.parentNode.removeChild(this.domNode),this.detach()}replaceWith(t,e){const a="string"==typeof t?this.scroll.create(t,e):t;return null!=this.parent&&(this.parent.insertBefore(a,this.next||void 0),this.remove()),a}split(t,e){return 0===t?this:this.next}update(t,e){}wrap(t,e){const a="string"==typeof t?this.scroll.create(t,e):t;if(null!=this.parent&&this.parent.insertBefore(a,this.next||void 0),"function"!=typeof a.appendChild)throw new $n("Cannot wrap ".concat(t));return a.appendChild(this),a}};no.blotName="abstract";let oo=no;const so=class extends oo{static value(t){return!0}index(t,e){return this.domNode===t||this.domNode.compareDocumentPosition(t)&Node.DOCUMENT_POSITION_CONTAINED_BY?Math.min(e,1):-1}position(t,e){let a=Array.from(this.parent.domNode.childNodes).indexOf(this.domNode);return t>0&&(a+=1),[this.parent.domNode,a]}value(){return{[this.statics.blotName]:this.statics.value(this.domNode)||!0}}};so.scope=Kn.INLINE_BLOT;const ro=so;class lo{constructor(){this.head=null,this.tail=null,this.length=0}append(){for(var t=arguments.length,e=new Array(t),a=0;a<t;a++)e[a]=arguments[a];if(this.insertBefore(e[0],null),e.length>1){const t=e.slice(1);this.append(...t)}}at(t){const e=this.iterator();let a=e();for(;a&&t>0;)t-=1,a=e();return a}contains(t){const e=this.iterator();let a=e();for(;a;){if(a===t)return!0;a=e()}return!1}indexOf(t){const e=this.iterator();let a=e(),i=0;for(;a;){if(a===t)return i;i+=1,a=e()}return-1}insertBefore(t,e){null!=t&&(this.remove(t),t.next=e,null!=e?(t.prev=e.prev,null!=e.prev&&(e.prev.next=t),e.prev=t,e===this.head&&(this.head=t)):null!=this.tail?(this.tail.next=t,t.prev=this.tail,this.tail=t):(t.prev=null,this.head=this.tail=t),this.length+=1)}offset(t){let e=0,a=this.head;for(;null!=a;){if(a===t)return e;e+=a.length(),a=a.next}return-1}remove(t){this.contains(t)&&(null!=t.prev&&(t.prev.next=t.next),null!=t.next&&(t.next.prev=t.prev),t===this.head&&(this.head=t.next),t===this.tail&&(this.tail=t.prev),this.length-=1)}iterator(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.head;return()=>{const e=t;return null!=t&&(t=t.next),e}}find(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];const a=this.iterator();let i=a();for(;i;){const n=i.length();if(t<n||e&&t===n&&(null==i.next||0!==i.next.length()))return[i,t];t-=n,i=a()}return[null,0]}forEach(t){const e=this.iterator();let a=e();for(;a;)t(a),a=e()}forEachAt(t,e,a){if(e<=0)return;const[i,n]=this.find(t);let o=t-n;const s=this.iterator(i);let r=s();for(;r&&o<t+e;){const i=r.length();t>o?a(r,t-o,Math.min(e,o+i-t)):a(r,0,Math.min(i,t+e-o)),o+=i,r=s()}}map(t){return this.reduce((e,a)=>(e.push(t(a)),e),[])}reduce(t,e){const a=this.iterator();let i=a();for(;i;)e=t(e,i),i=a();return e}}function co(t,e){const a=e.find(t);if(a)return a;try{return e.create(t)}catch(i){const a=e.create(Kn.INLINE);return Array.from(t.childNodes).forEach(t=>{a.domNode.appendChild(t)}),t.parentNode&&t.parentNode.replaceChild(a.domNode,t),a.attach(),a}}const mo=class t extends oo{constructor(t,e){super(t,e),this.uiNode=null,this.build()}appendChild(t){this.insertBefore(t)}attach(){super.attach(),this.children.forEach(t=>{t.attach()})}attachUI(e){null!=this.uiNode&&this.uiNode.remove(),this.uiNode=e,t.uiClass&&this.uiNode.classList.add(t.uiClass),this.uiNode.setAttribute("contenteditable","false"),this.domNode.insertBefore(this.uiNode,this.domNode.firstChild)}build(){this.children=new lo,Array.from(this.domNode.childNodes).filter(t=>t!==this.uiNode).reverse().forEach(t=>{try{const e=co(t,this.scroll);this.insertBefore(e,this.children.head||void 0)}catch(e){if(e instanceof $n)return;throw e}})}deleteAt(t,e){if(0===t&&e===this.length())return this.remove();this.children.forEachAt(t,e,(t,e,a)=>{t.deleteAt(e,a)})}descendant(e){let a=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0;const[i,n]=this.children.find(a);return null==e.blotName&&e(i)||null!=e.blotName&&i instanceof e?[i,n]:i instanceof t?i.descendant(e,n):[null,-1]}descendants(e){let a=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:Number.MAX_VALUE,n=[],o=i;return this.children.forEachAt(a,i,(a,i,s)=>{(null==e.blotName&&e(a)||null!=e.blotName&&a instanceof e)&&n.push(a),a instanceof t&&(n=n.concat(a.descendants(e,i,o))),o-=s}),n}detach(){this.children.forEach(t=>{t.detach()}),super.detach()}enforceAllowedChildren(){let e=!1;this.children.forEach(a=>{e||this.statics.allowedChildren.some(t=>a instanceof t)||(a.statics.scope===Kn.BLOCK_BLOT?(null!=a.next&&this.splitAfter(a),null!=a.prev&&this.splitAfter(a.prev),a.parent.unwrap(),e=!0):a instanceof t?a.unwrap():a.remove())})}formatAt(t,e,a,i){this.children.forEachAt(t,e,(t,e,n)=>{t.formatAt(e,n,a,i)})}insertAt(t,e,a){const[i,n]=this.children.find(t);if(i)i.insertAt(n,e,a);else{const t=null==a?this.scroll.create("text",e):this.scroll.create(e,a);this.appendChild(t)}}insertBefore(t,e){null!=t.parent&&t.parent.children.remove(t);let a=null;this.children.insertBefore(t,e||null),t.parent=this,null!=e&&(a=e.domNode),(this.domNode.parentNode!==t.domNode||this.domNode.nextSibling!==a)&&this.domNode.insertBefore(t.domNode,a),t.attach()}length(){return this.children.reduce((t,e)=>t+e.length(),0)}moveChildren(t,e){this.children.forEach(a=>{t.insertBefore(a,e)})}optimize(t){if(super.optimize(t),this.enforceAllowedChildren(),null!=this.uiNode&&this.uiNode!==this.domNode.firstChild&&this.domNode.insertBefore(this.uiNode,this.domNode.firstChild),0===this.children.length)if(null!=this.statics.defaultChild){const t=this.scroll.create(this.statics.defaultChild.blotName);this.appendChild(t)}else this.remove()}path(e){let a=arguments.length>1&&void 0!==arguments[1]&&arguments[1];const[i,n]=this.children.find(e,a),o=[[this,e]];return i instanceof t?o.concat(i.path(n,a)):(null!=i&&o.push([i,n]),o)}removeChild(t){this.children.remove(t)}replaceWith(e,a){const i="string"==typeof e?this.scroll.create(e,a):e;return i instanceof t&&this.moveChildren(i),super.replaceWith(i)}split(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(!e){if(0===t)return this;if(t===this.length())return this.next}const a=this.clone();return this.parent&&this.parent.insertBefore(a,this.next||void 0),this.children.forEachAt(t,this.length(),(t,i,n)=>{const o=t.split(i,e);null!=o&&a.appendChild(o)}),a}splitAfter(t){const e=this.clone();for(;null!=t.next;)e.appendChild(t.next);return this.parent&&this.parent.insertBefore(e,this.next||void 0),e}unwrap(){this.parent&&this.moveChildren(this.parent,this.next||void 0),this.remove()}update(t,e){const a=[],i=[];t.forEach(t=>{t.target===this.domNode&&"childList"===t.type&&(a.push(...t.addedNodes),i.push(...t.removedNodes))}),i.forEach(t=>{if(null!=t.parentNode&&"IFRAME"!==t.tagName&&document.body.compareDocumentPosition(t)&Node.DOCUMENT_POSITION_CONTAINED_BY)return;const e=this.scroll.find(t);null!=e&&(null==e.domNode.parentNode||e.domNode.parentNode===this.domNode)&&e.detach()}),a.filter(t=>t.parentNode===this.domNode&&t!==this.uiNode).sort((t,e)=>t===e?0:t.compareDocumentPosition(e)&Node.DOCUMENT_POSITION_FOLLOWING?1:-1).forEach(t=>{let e=null;null!=t.nextSibling&&(e=this.scroll.find(t.nextSibling));const a=co(t,this.scroll);(a.next!==e||null==a.next)&&(null!=a.parent&&a.parent.removeChild(this),this.insertBefore(a,e||void 0))}),this.enforceAllowedChildren()}};mo.uiClass="";const uo=mo;const ho=class t extends uo{static create(t){return super.create(t)}static formats(e,a){const i=a.query(t.blotName);if(null==i||e.tagName!==i.tagName){if("string"==typeof this.tagName)return!0;if(Array.isArray(this.tagName))return e.tagName.toLowerCase()}}constructor(t,e){super(t,e),this.attributes=new io(this.domNode)}format(e,a){if(e!==this.statics.blotName||a){const t=this.scroll.query(e,Kn.INLINE);if(null==t)return;t instanceof Zn?this.attributes.attribute(t,a):a&&(e!==this.statics.blotName||this.formats()[e]!==a)&&this.replaceWith(e,a)}else this.children.forEach(e=>{e instanceof t||(e=e.wrap(t.blotName,!0)),this.attributes.copy(e)}),this.unwrap()}formats(){const t=this.attributes.values(),e=this.statics.formats(this.domNode,this.scroll);return null!=e&&(t[this.statics.blotName]=e),t}formatAt(t,e,a,i){null!=this.formats()[a]||this.scroll.query(a,Kn.ATTRIBUTE)?this.isolate(t,e).format(a,i):super.formatAt(t,e,a,i)}optimize(e){super.optimize(e);const a=this.formats();if(0===Object.keys(a).length)return this.unwrap();const i=this.next;i instanceof t&&i.prev===this&&function(t,e){if(Object.keys(t).length!==Object.keys(e).length)return!1;for(const a in t)if(t[a]!==e[a])return!1;return!0}(a,i.formats())&&(i.moveChildren(this),i.remove())}replaceWith(t,e){const a=super.replaceWith(t,e);return this.attributes.copy(a),a}update(t,e){super.update(t,e),t.some(t=>t.target===this.domNode&&"attributes"===t.type)&&this.attributes.build()}wrap(e,a){const i=super.wrap(e,a);return i instanceof t&&this.attributes.move(i),i}};ho.allowedChildren=[ho,ro],ho.blotName="inline",ho.scope=Kn.INLINE_BLOT,ho.tagName="SPAN";const fo=ho,go=class t extends uo{static create(t){return super.create(t)}static formats(e,a){const i=a.query(t.blotName);if(null==i||e.tagName!==i.tagName){if("string"==typeof this.tagName)return!0;if(Array.isArray(this.tagName))return e.tagName.toLowerCase()}}constructor(t,e){super(t,e),this.attributes=new io(this.domNode)}format(e,a){const i=this.scroll.query(e,Kn.BLOCK);null!=i&&(i instanceof Zn?this.attributes.attribute(i,a):e!==this.statics.blotName||a?a&&(e!==this.statics.blotName||this.formats()[e]!==a)&&this.replaceWith(e,a):this.replaceWith(t.blotName))}formats(){const t=this.attributes.values(),e=this.statics.formats(this.domNode,this.scroll);return null!=e&&(t[this.statics.blotName]=e),t}formatAt(t,e,a,i){null!=this.scroll.query(a,Kn.BLOCK)?this.format(a,i):super.formatAt(t,e,a,i)}insertAt(t,e,a){if(null==a||null!=this.scroll.query(e,Kn.INLINE))super.insertAt(t,e,a);else{const i=this.split(t);if(null==i)throw new Error("Attempt to insertAt after block boundaries");{const t=this.scroll.create(e,a);i.parent.insertBefore(t,i)}}}replaceWith(t,e){const a=super.replaceWith(t,e);return this.attributes.copy(a),a}update(t,e){super.update(t,e),t.some(t=>t.target===this.domNode&&"attributes"===t.type)&&this.attributes.build()}};go.blotName="block",go.scope=Kn.BLOCK_BLOT,go.tagName="P",go.allowedChildren=[fo,go,ro];const po=go,yo=class extends uo{checkMerge(){return null!==this.next&&this.next.statics.blotName===this.statics.blotName}deleteAt(t,e){super.deleteAt(t,e),this.enforceAllowedChildren()}formatAt(t,e,a,i){super.formatAt(t,e,a,i),this.enforceAllowedChildren()}insertAt(t,e,a){super.insertAt(t,e,a),this.enforceAllowedChildren()}optimize(t){super.optimize(t),this.children.length>0&&null!=this.next&&this.checkMerge()&&(this.next.moveChildren(this),this.next.remove())}};yo.blotName="container",yo.scope=Kn.BLOCK_BLOT;const bo=yo;const vo=class extends ro{static formats(t,e){}format(t,e){super.formatAt(0,this.length(),t,e)}formatAt(t,e,a,i){0===t&&e===this.length()?this.format(a,i):super.formatAt(t,e,a,i)}formats(){return this.statics.formats(this.domNode,this.scroll)}},wo={attributes:!0,characterData:!0,characterDataOldValue:!0,childList:!0,subtree:!0},xo=class extends uo{constructor(t,e){super(null,e),this.registry=t,this.scroll=this,this.build(),this.observer=new MutationObserver(t=>{this.update(t)}),this.observer.observe(this.domNode,wo),this.attach()}create(t,e){return this.registry.create(this,t,e)}find(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];const a=this.registry.find(t,e);return a?a.scroll===this?a:e?this.find(a.scroll.domNode.parentNode,!0):null:null}query(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:Kn.ANY;return this.registry.query(t,e)}register(){return this.registry.register(...arguments)}build(){null!=this.scroll&&super.build()}detach(){super.detach(),this.observer.disconnect()}deleteAt(t,e){this.update(),0===t&&e===this.length()?this.children.forEach(t=>{t.remove()}):super.deleteAt(t,e)}formatAt(t,e,a,i){this.update(),super.formatAt(t,e,a,i)}insertAt(t,e,a){this.update(),super.insertAt(t,e,a)}optimize(){var t=this;let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:[],a=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};super.optimize(a);const i=a.mutationsMap||new WeakMap;let n=Array.from(this.observer.takeRecords());for(;n.length>0;)e.push(n.pop());const o=function(e){let a=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];null==e||e===t||null!=e.domNode.parentNode&&(i.has(e.domNode)||i.set(e.domNode,[]),a&&o(e.parent))},s=t=>{i.has(t.domNode)&&(t instanceof uo&&t.children.forEach(s),i.delete(t.domNode),t.optimize(a))};let r=e;for(let l=0;r.length>0;l+=1){if(l>=100)throw new Error("[Parchment] Maximum optimize iterations reached");for(r.forEach(t=>{const e=this.find(t.target,!0);null!=e&&(e.domNode===t.target&&("childList"===t.type?(o(this.find(t.previousSibling,!1)),Array.from(t.addedNodes).forEach(t=>{const e=this.find(t,!1);o(e,!1),e instanceof uo&&e.children.forEach(t=>{o(t,!1)})})):"attributes"===t.type&&o(e.prev)),o(e))}),this.children.forEach(s),r=Array.from(this.observer.takeRecords()),n=r.slice();n.length>0;)e.push(n.pop())}}update(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};t=t||this.observer.takeRecords();const a=new WeakMap;t.map(t=>{const e=this.find(t.target,!0);return null==e?null:a.has(e.domNode)?(a.get(e.domNode).push(t),null):(a.set(e.domNode,[t]),e)}).forEach(t=>{null!=t&&t!==this&&a.has(t.domNode)&&t.update(a.get(t.domNode)||[],e)}),e.mutationsMap=a,a.has(this.domNode)&&super.update(a.get(this.domNode),e),this.optimize(t,e)}};xo.blotName="scroll",xo.defaultChild=po,xo.allowedChildren=[po,bo],xo.scope=Kn.BLOCK_BLOT,xo.tagName="DIV";const ko=xo,Io=class t extends ro{static create(t){return document.createTextNode(t)}static value(t){return t.data}constructor(t,e){super(t,e),this.text=this.statics.value(this.domNode)}deleteAt(t,e){this.domNode.data=this.text=this.text.slice(0,t)+this.text.slice(t+e)}index(t,e){return this.domNode===t?e:-1}insertAt(t,e,a){null==a?(this.text=this.text.slice(0,t)+e+this.text.slice(t),this.domNode.data=this.text):super.insertAt(t,e,a)}length(){return this.text.length}optimize(e){super.optimize(e),this.text=this.statics.value(this.domNode),0===this.text.length?this.remove():this.next instanceof t&&this.next.prev===this&&(this.insertAt(this.length(),this.next.value()),this.next.remove())}position(t){return[this.domNode,t]}split(t){if(!(arguments.length>1&&void 0!==arguments[1]&&arguments[1])){if(0===t)return this;if(t===this.length())return this.next}const e=this.scroll.create(this.domNode.splitText(t));return this.parent.insertBefore(e,this.next||void 0),this.text=this.statics.value(this.domNode),e}update(t,e){t.some(t=>"characterData"===t.type&&t.target===this.domNode)&&(this.text=this.statics.value(this.domNode))}value(){return this.text}};Io.blotName="text",Io.scope=Kn.INLINE_BLOT;const Co=Io;var So=a(249);const Ao=function(t,e){for(var a=-1,i=null==t?0:t.length;++a<i&&!1!==e(t[a],a,t););return t};const To=function(t,e){return t&&Dn(e,Di(e),t)};const Po=function(t,e){return t&&Dn(e,jn(e),t)};const Do=function(t,e){return Dn(t,Za(t),e)};const No=Object.getOwnPropertySymbols?function(t){for(var e=[];t;)Ha(e,Za(t)),t=yn(t);return e}:Wa;const Lo=function(t,e){return Dn(t,No(t),e)};const Eo=function(t){return Ba(t,jn,No)};var jo=Object.prototype.hasOwnProperty;const Mo=function(t){var e=t.length,a=new t.constructor(e);return e&&"string"==typeof t[0]&&jo.call(t,"index")&&(a.index=t.index,a.input=t.input),a};const zo=function(t,e){var a=e?un(t.buffer):t.buffer;return new t.constructor(a,t.byteOffset,t.byteLength)};var Ro=/\w*$/;const Fo=function(t){var e=new t.constructor(t.source,Ro.exec(t));return e.lastIndex=t.lastIndex,e};var qo=Me?Me.prototype:void 0,_o=qo?qo.valueOf:void 0;const Oo=function(t){return _o?Object(_o.call(t)):{}};const Uo=function(t,e,a){var i=t.constructor;switch(e){case"[object ArrayBuffer]":return un(t);case"[object Boolean]":case"[object Date]":return new i(+t);case"[object DataView]":return zo(t,a);case"[object Float32Array]":case"[object Float64Array]":case"[object Int8Array]":case"[object Int16Array]":case"[object Int32Array]":case"[object Uint8Array]":case"[object Uint8ClampedArray]":case"[object Uint16Array]":case"[object Uint32Array]":return hn(t,a);case"[object Map]":case"[object Set]":return new i;case"[object Number]":case"[object String]":return new i(t);case"[object RegExp]":return Fo(t);case"[object Symbol]":return Oo(t)}};const Ho=function(t){return Xa(t)&&"[object Map]"==Ki(t)};var Vo=yi&&yi.isMap;const Bo=Vo?hi(Vo):Ho;const Go=function(t){return Xa(t)&&"[object Set]"==Ki(t)};var Wo=yi&&yi.isSet;const Qo=Wo?hi(Wo):Go;var Ko="[object Arguments]",Zo="[object Function]",$o="[object Object]",Xo={};Xo[Ko]=Xo["[object Array]"]=Xo["[object ArrayBuffer]"]=Xo["[object DataView]"]=Xo["[object Boolean]"]=Xo["[object Date]"]=Xo["[object Float32Array]"]=Xo["[object Float64Array]"]=Xo["[object Int8Array]"]=Xo["[object Int16Array]"]=Xo["[object Int32Array]"]=Xo["[object Map]"]=Xo["[object Number]"]=Xo[$o]=Xo["[object RegExp]"]=Xo["[object Set]"]=Xo["[object String]"]=Xo["[object Symbol]"]=Xo["[object Uint8Array]"]=Xo["[object Uint8ClampedArray]"]=Xo["[object Uint16Array]"]=Xo["[object Uint32Array]"]=!0,Xo["[object Error]"]=Xo[Zo]=Xo["[object WeakMap]"]=!1;const Yo=function t(e,a,i,n,o,s){var r,l=1&a,d=2&a,c=4&a;if(i&&(r=o?i(e,n,o,s):i(e)),void 0!==r)return r;if(!Be(e))return e;var m=Va(e);if(m){if(r=Mo(e),!l)return fn(e,r)}else{var u=Ki(e),h=u==Zo||"[object GeneratorFunction]"==u;if(ri(e))return mn(e,l);if(u==$o||u==Ko||h&&!o){if(r=d||h?{}:bn(e),!l)return d?Lo(e,Po(r,e)):Do(e,To(r,e))}else{if(!Xo[u])return o?e:{};r=Uo(e,u,l)}}s||(s=new Pa);var f=s.get(e);if(f)return f;s.set(e,r),Qo(e)?e.forEach(function(n){r.add(t(n,a,i,n,e,s))}):Bo(e)&&e.forEach(function(n,o){r.set(o,t(n,a,i,o,e,s))});var g=m?void 0:(c?d?Eo:Ni:d?jn:Di)(e);return Ao(g||e,function(n,o){g&&(n=e[o=n]),Pn(r,o,t(n,a,i,o,e,s))}),r};const Jo=function(t){return Yo(t,5)};class ts extends vo{static value(){}optimize(){(this.prev||this.next)&&this.remove()}length(){return 0}value(){return""}}ts.blotName="break",ts.tagName="BR";const es=ts;class as extends Co{}const is={"&":"&amp;","<":"&lt;",">":"&gt;",'"':"&quot;","'":"&#39;"};function ns(t){return t.replace(/[&<>"']/g,t=>is[t])}class os extends fo{static compare(t,e){const a=os.order.indexOf(t),i=os.order.indexOf(e);return a>=0||i>=0?a-i:t===e?0:t<e?-1:1}formatAt(t,e,a,i){if(os.compare(this.statics.blotName,a)<0&&this.scroll.query(a,Kn.BLOT)){const n=this.isolate(t,e);i&&n.wrap(a,i)}else super.formatAt(t,e,a,i)}optimize(t){if(super.optimize(t),this.parent instanceof os&&os.compare(this.statics.blotName,this.parent.statics.blotName)>0){const t=this.parent.isolate(this.offset(),this.length());this.moveChildren(t),t.wrap(this)}}}Ot(os,"allowedChildren",[os,es,vo,as]),Ot(os,"order",["cursor","inline","link","underline","strike","italic","bold","script","code"]);const ss=os;class rs extends po{constructor(){super(...arguments),Ot(this,"cache",{})}delta(){return null==this.cache.delta&&(this.cache.delta=ds(this)),this.cache.delta}deleteAt(t,e){super.deleteAt(t,e),this.cache={}}formatAt(t,e,a,i){e<=0||(this.scroll.query(a,Kn.BLOCK)?t+e===this.length()&&this.format(a,i):super.formatAt(t,Math.min(e,this.length()-t-1),a,i),this.cache={})}insertAt(t,e,a){if(null!=a)return super.insertAt(t,e,a),void(this.cache={});if(0===e.length)return;const i=e.split("\n"),n=i.shift();n.length>0&&(t<this.length()-1||null==this.children.tail?super.insertAt(Math.min(t,this.length()-1),n):this.children.tail.insertAt(this.children.tail.length(),n),this.cache={});let o=this;i.reduce((t,e)=>(o=o.split(t,!0),o.insertAt(0,e),e.length),t+n.length)}insertBefore(t,e){const{head:a}=this.children;super.insertBefore(t,e),a instanceof es&&a.remove(),this.cache={}}length(){return null==this.cache.length&&(this.cache.length=super.length()+1),this.cache.length}moveChildren(t,e){super.moveChildren(t,e),this.cache={}}optimize(t){super.optimize(t),this.cache={}}path(t){return super.path(t,!0)}removeChild(t){super.removeChild(t),this.cache={}}split(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(e&&(0===t||t>=this.length()-1)){const e=this.clone();return 0===t?(this.parent.insertBefore(e,this),this):(this.parent.insertBefore(e,this.next),e)}const a=super.split(t,e);return this.cache={},a}}rs.blotName="block",rs.tagName="P",rs.defaultChild=es,rs.allowedChildren=[es,ss,vo,as];class ls extends vo{attach(){super.attach(),this.attributes=new io(this.domNode)}delta(){return(new So).insert(this.value(),Ht(Ht({},this.formats()),this.attributes.values()))}format(t,e){const a=this.scroll.query(t,Kn.BLOCK_ATTRIBUTE);null!=a&&this.attributes.attribute(a,e)}formatAt(t,e,a,i){this.format(a,i)}insertAt(t,e,a){if(null!=a)return void super.insertAt(t,e,a);const i=e.split("\n"),n=i.pop(),o=i.map(t=>{const e=this.scroll.create(rs.blotName);return e.insertAt(0,t),e}),s=this.split(t);o.forEach(t=>{this.parent.insertBefore(t,s)}),n&&this.parent.insertBefore(this.scroll.create("text",n),s)}}function ds(t){let e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];return t.descendants(ro).reduce((t,a)=>0===a.length()?t:t.insert(a.value(),cs(a,{},e)),new So).insert("\n",cs(t))}function cs(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},a=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];return null==t?e:("formats"in t&&"function"===typeof t.formats&&(e=Ht(Ht({},e),t.formats()),a&&delete e["code-token"]),null==t.parent||"scroll"===t.parent.statics.blotName||t.parent.statics.scope!==t.statics.scope?e:cs(t.parent,e,a))}ls.scope=Kn.BLOCK_BLOT;class ms extends vo{static value(){}constructor(t,e,a){super(t,e),this.selection=a,this.textNode=document.createTextNode(ms.CONTENTS),this.domNode.appendChild(this.textNode),this.savedLength=0}detach(){null!=this.parent&&this.parent.removeChild(this)}format(t,e){if(0!==this.savedLength)return void super.format(t,e);let a=this,i=0;for(;null!=a&&a.statics.scope!==Kn.BLOCK_BLOT;)i+=a.offset(a.parent),a=a.parent;null!=a&&(this.savedLength=ms.CONTENTS.length,a.optimize(),a.formatAt(i,ms.CONTENTS.length,t,e),this.savedLength=0)}index(t,e){return t===this.textNode?0:super.index(t,e)}length(){return this.savedLength}position(){return[this.textNode,this.textNode.data.length]}remove(){super.remove(),this.parent=null}restore(){if(this.selection.composing||null==this.parent)return null;const t=this.selection.getNativeRange();for(;null!=this.domNode.lastChild&&this.domNode.lastChild!==this.textNode;)this.domNode.parentNode.insertBefore(this.domNode.lastChild,this.domNode);const e=this.prev instanceof as?this.prev:null,a=e?e.length():0,i=this.next instanceof as?this.next:null,n=i?i.text:"",{textNode:o}=this,s=o.data.split(ms.CONTENTS).join("");let r;if(o.data=ms.CONTENTS,e)r=e,(s||i)&&(e.insertAt(e.length(),s+n),i&&i.remove());else if(i)r=i,i.insertAt(0,s);else{const t=document.createTextNode(s);r=this.scroll.create(t),this.parent.insertBefore(r,this)}if(this.remove(),t){const n=(t,n)=>e&&t===e.domNode?n:t===o?a+n-1:i&&t===i.domNode?a+s.length+n:null,l=n(t.start.node,t.start.offset),d=n(t.end.node,t.end.offset);if(null!==l&&null!==d)return{startNode:r.domNode,startOffset:l,endNode:r.domNode,endOffset:d}}return null}update(t,e){if(t.some(t=>"characterData"===t.type&&t.target===this.textNode)){const t=this.restore();t&&(e.range=t)}}optimize(t){super.optimize(t);let{parent:e}=this;for(;e;){if("A"===e.domNode.tagName){this.savedLength=ms.CONTENTS.length,e.isolate(this.offset(e),this.length()).unwrap(),this.savedLength=0;break}e=e.parent}}value(){return""}}Ot(ms,"blotName","cursor"),Ot(ms,"className","ql-cursor"),Ot(ms,"tagName","span"),Ot(ms,"CONTENTS","\ufeff");const us=ms;var hs=a(752);const fs=new WeakMap,gs=["error","warn","log","info"];let ps="warn";function ys(t){if(ps&&gs.indexOf(t)<=gs.indexOf(ps)){for(var e=arguments.length,a=new Array(e>1?e-1:0),i=1;i<e;i++)a[i-1]=arguments[i];console[t](...a)}}function bs(t){return gs.reduce((e,a)=>(e[a]=ys.bind(console,a,t),e),{})}bs.level=t=>{ps=t},ys.level=bs.level;const vs=bs,ws=vs("quill:events");["selectionchange","mousedown","mouseup","click"].forEach(t=>{document.addEventListener(t,function(){for(var t=arguments.length,e=new Array(t),a=0;a<t;a++)e[a]=arguments[a];Array.from(document.querySelectorAll(".ql-container")).forEach(t=>{const a=fs.get(t);a&&a.emitter&&a.emitter.handleDOM(...e)})})});class xs extends hs{constructor(){super(),this.domListeners={},this.on("error",ws.error)}emit(){for(var t=arguments.length,e=new Array(t),a=0;a<t;a++)e[a]=arguments[a];return ws.log.call(ws,...e),super.emit(...e)}handleDOM(t){for(var e=arguments.length,a=new Array(e>1?e-1:0),i=1;i<e;i++)a[i-1]=arguments[i];(this.domListeners[t.type]||[]).forEach(e=>{let{node:i,handler:n}=e;(t.target===i||i.contains(t.target))&&n(t,...a)})}listenDOM(t,e,a){this.domListeners[t]||(this.domListeners[t]=[]),this.domListeners[t].push({node:e,handler:a})}}Ot(xs,"events",{EDITOR_CHANGE:"editor-change",SCROLL_BEFORE_UPDATE:"scroll-before-update",SCROLL_BLOT_MOUNT:"scroll-blot-mount",SCROLL_BLOT_UNMOUNT:"scroll-blot-unmount",SCROLL_OPTIMIZE:"scroll-optimize",SCROLL_UPDATE:"scroll-update",SCROLL_EMBED_UPDATE:"scroll-embed-update",SELECTION_CHANGE:"selection-change",TEXT_CHANGE:"text-change",COMPOSITION_BEFORE_START:"composition-before-start",COMPOSITION_START:"composition-start",COMPOSITION_BEFORE_END:"composition-before-end",COMPOSITION_END:"composition-end"}),Ot(xs,"sources",{API:"api",SILENT:"silent",USER:"user"});const ks=xs,Is=vs("quill:selection");class Cs{constructor(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0;this.index=t,this.length=e}}function Ss(t,e){try{e.parentNode}catch(cu){return!1}return t.contains(e)}const As=class{constructor(t,e){this.emitter=e,this.scroll=t,this.composing=!1,this.mouseDown=!1,this.root=this.scroll.domNode,this.cursor=this.scroll.create("cursor",this),this.savedRange=new Cs(0,0),this.lastRange=this.savedRange,this.lastNative=null,this.handleComposition(),this.handleDragging(),this.emitter.listenDOM("selectionchange",document,()=>{this.mouseDown||this.composing||setTimeout(this.update.bind(this,ks.sources.USER),1)}),this.emitter.on(ks.events.SCROLL_BEFORE_UPDATE,()=>{if(!this.hasFocus())return;const t=this.getNativeRange();null!=t&&t.start.node!==this.cursor.textNode&&this.emitter.once(ks.events.SCROLL_UPDATE,(e,a)=>{try{this.root.contains(t.start.node)&&this.root.contains(t.end.node)&&this.setNativeRange(t.start.node,t.start.offset,t.end.node,t.end.offset);const i=a.some(t=>"characterData"===t.type||"childList"===t.type||"attributes"===t.type&&t.target===this.root);this.update(i?ks.sources.SILENT:e)}catch(i){}})}),this.emitter.on(ks.events.SCROLL_OPTIMIZE,(t,e)=>{if(e.range){const{startNode:t,startOffset:a,endNode:i,endOffset:n}=e.range;this.setNativeRange(t,a,i,n),this.update(ks.sources.SILENT)}}),this.update(ks.sources.SILENT)}handleComposition(){this.emitter.on(ks.events.COMPOSITION_BEFORE_START,()=>{this.composing=!0}),this.emitter.on(ks.events.COMPOSITION_END,()=>{if(this.composing=!1,this.cursor.parent){const t=this.cursor.restore();if(!t)return;setTimeout(()=>{this.setNativeRange(t.startNode,t.startOffset,t.endNode,t.endOffset)},1)}})}handleDragging(){this.emitter.listenDOM("mousedown",document.body,()=>{this.mouseDown=!0}),this.emitter.listenDOM("mouseup",document.body,()=>{this.mouseDown=!1,this.update(ks.sources.USER)})}focus(){this.hasFocus()||(this.root.focus({preventScroll:!0}),this.setRange(this.savedRange))}format(t,e){this.scroll.update();const a=this.getNativeRange();if(null!=a&&a.native.collapsed&&!this.scroll.query(t,Kn.BLOCK)){if(a.start.node!==this.cursor.textNode){const t=this.scroll.find(a.start.node,!1);if(null==t)return;if(t instanceof ro){const e=t.split(a.start.offset);t.parent.insertBefore(this.cursor,e)}else t.insertBefore(this.cursor,a.start.node);this.cursor.attach()}this.cursor.format(t,e),this.scroll.optimize(),this.setNativeRange(this.cursor.textNode,this.cursor.textNode.data.length),this.update()}}getBounds(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0;const a=this.scroll.length();let i;t=Math.min(t,a-1),e=Math.min(t+e,a-1)-t;let[n,o]=this.scroll.leaf(t);if(null==n)return null;if(e>0&&o===n.length()){const[e]=this.scroll.leaf(t+1);if(e){const[a]=this.scroll.line(t),[i]=this.scroll.line(t+1);a===i&&(n=e,o=0)}}[i,o]=n.position(o,!0);const s=document.createRange();if(e>0)return s.setStart(i,o),[n,o]=this.scroll.leaf(t+e),null==n?null:([i,o]=n.position(o,!0),s.setEnd(i,o),s.getBoundingClientRect());let r,l="left";if(i instanceof Text){if(!i.data.length)return null;o<i.data.length?(s.setStart(i,o),s.setEnd(i,o+1)):(s.setStart(i,o-1),s.setEnd(i,o),l="right"),r=s.getBoundingClientRect()}else{if(!(n.domNode instanceof Element))return null;r=n.domNode.getBoundingClientRect(),o>0&&(l="right")}return{bottom:r.top+r.height,height:r.height,left:r[l],right:r[l],top:r.top,width:0}}getNativeRange(){const t=document.getSelection();if(null==t||t.rangeCount<=0)return null;const e=t.getRangeAt(0);if(null==e)return null;const a=this.normalizeNative(e);return Is.info("getNativeRange",a),a}getRange(){const t=this.scroll.domNode;if("isConnected"in t&&!t.isConnected)return[null,null];const e=this.getNativeRange();if(null==e)return[null,null];return[this.normalizedToRange(e),e]}hasFocus(){return document.activeElement===this.root||null!=document.activeElement&&Ss(this.root,document.activeElement)}normalizedToRange(t){const e=[[t.start.node,t.start.offset]];t.native.collapsed||e.push([t.end.node,t.end.offset]);const a=e.map(t=>{const[e,a]=t,i=this.scroll.find(e,!0),n=i.offset(this.scroll);return 0===a?n:i instanceof ro?n+i.index(e,a):n+i.length()}),i=Math.min(Math.max(...a),this.scroll.length()-1),n=Math.min(i,...a);return new Cs(n,i-n)}normalizeNative(t){if(!Ss(this.root,t.startContainer)||!t.collapsed&&!Ss(this.root,t.endContainer))return null;const e={start:{node:t.startContainer,offset:t.startOffset},end:{node:t.endContainer,offset:t.endOffset},native:t};return[e.start,e.end].forEach(t=>{let{node:e,offset:a}=t;for(;!(e instanceof Text)&&e.childNodes.length>0;)if(e.childNodes.length>a)e=e.childNodes[a],a=0;else{if(e.childNodes.length!==a)break;e=e.lastChild,a=e instanceof Text?e.data.length:e.childNodes.length>0?e.childNodes.length:e.childNodes.length+1}t.node=e,t.offset=a}),e}rangeToNative(t){const e=this.scroll.length(),a=(t,a)=>{t=Math.min(e-1,t);const[i,n]=this.scroll.leaf(t);return i?i.position(n,a):[null,-1]};return[...a(t.index,!1),...a(t.index+t.length,!0)]}setNativeRange(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:t,i=arguments.length>3&&void 0!==arguments[3]?arguments[3]:e,n=arguments.length>4&&void 0!==arguments[4]&&arguments[4];if(Is.info("setNativeRange",t,e,a,i),null!=t&&(null==this.root.parentNode||null==t.parentNode||null==a.parentNode))return;const o=document.getSelection();if(null!=o)if(null!=t){this.hasFocus()||this.root.focus({preventScroll:!0});const{native:s}=this.getNativeRange()||{};if(null==s||n||t!==s.startContainer||e!==s.startOffset||a!==s.endContainer||i!==s.endOffset){t instanceof Element&&"BR"===t.tagName&&(e=Array.from(t.parentNode.childNodes).indexOf(t),t=t.parentNode),a instanceof Element&&"BR"===a.tagName&&(i=Array.from(a.parentNode.childNodes).indexOf(a),a=a.parentNode);const n=document.createRange();n.setStart(t,e),n.setEnd(a,i),o.removeAllRanges(),o.addRange(n)}}else o.removeAllRanges(),this.root.blur()}setRange(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1],a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:ks.sources.API;if("string"===typeof e&&(a=e,e=!1),Is.info("setRange",t),null!=t){const a=this.rangeToNative(t);this.setNativeRange(...a,e)}else this.setNativeRange(null);this.update(a)}update(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ks.sources.USER;const e=this.lastRange,[a,i]=this.getRange();if(this.lastRange=a,this.lastNative=i,null!=this.lastRange&&(this.savedRange=this.lastRange),!en(e,this.lastRange)){if(!this.composing&&null!=i&&i.native.collapsed&&i.start.node!==this.cursor.textNode){const t=this.cursor.restore();t&&this.setNativeRange(t.startNode,t.startOffset,t.endNode,t.endOffset)}const a=[ks.events.SELECTION_CHANGE,Jo(this.lastRange),Jo(e),t];this.emitter.emit(ks.events.EDITOR_CHANGE,...a),t!==ks.sources.SILENT&&this.emitter.emit(...a)}}},Ts=/^[ -~]*$/;function Ps(t,e,a){if(0===t.length){const[t]=Ls(a.pop());return e<=0?"</li></".concat(t,">"):"</li></".concat(t,">").concat(Ps([],e-1,a))}const[{child:i,offset:n,length:o,indent:s,type:r},...l]=t,[d,c]=Ls(r);if(s>e)return a.push(r),s===e+1?"<".concat(d,"><li").concat(c,">").concat(Ds(i,n,o)).concat(Ps(l,s,a)):"<".concat(d,"><li>").concat(Ps(t,e+1,a));const m=a[a.length-1];if(s===e&&r===m)return"</li><li".concat(c,">").concat(Ds(i,n,o)).concat(Ps(l,s,a));const[u]=Ls(a.pop());return"</li></".concat(u,">").concat(Ps(t,e-1,a))}function Ds(t,e,a){let i=arguments.length>3&&void 0!==arguments[3]&&arguments[3];if("html"in t&&"function"===typeof t.html)return t.html(e,a);if(t instanceof as){return ns(t.value().slice(e,e+a)).replaceAll(" ","&nbsp;")}if(t instanceof uo){if("list-container"===t.statics.blotName){const i=[];return t.children.forEachAt(e,a,(t,e,a)=>{const n="formats"in t&&"function"===typeof t.formats?t.formats():{};i.push({child:t,offset:e,length:a,indent:n.indent||0,type:n.list})}),Ps(i,-1,[])}const n=[];if(t.children.forEachAt(e,a,(t,e,a)=>{n.push(Ds(t,e,a))}),i||"list"===t.statics.blotName)return n.join("");const{outerHTML:o,innerHTML:s}=t.domNode,[r,l]=o.split(">".concat(s,"<"));return"<table"===r?'<table style="border: 1px solid #000;">'.concat(n.join(""),"<").concat(l):"".concat(r,">").concat(n.join(""),"<").concat(l)}return t.domNode instanceof Element?t.domNode.outerHTML:""}function Ns(t,e){return Object.keys(e).reduce((a,i)=>{if(null==t[i])return a;const n=e[i];return n===t[i]?a[i]=n:Array.isArray(n)?n.indexOf(t[i])<0?a[i]=n.concat([t[i]]):a[i]=n:a[i]=[n,t[i]],a},{})}function Ls(t){const e="ordered"===t?"ol":"ul";switch(t){case"checked":return[e,' data-list="checked"'];case"unchecked":return[e,' data-list="unchecked"'];default:return[e,""]}}function Es(t){return t.reduce((t,e)=>{if("string"===typeof e.insert){const a=e.insert.replace(/\r\n/g,"\n").replace(/\r/g,"\n");return t.insert(a,e.attributes)}return t.push(e)},new So)}function js(t,e){let{index:a,length:i}=t;return new Cs(a+e,i)}const Ms=class{constructor(t){this.scroll=t,this.delta=this.getDelta()}applyDelta(t){this.scroll.update();let e=this.scroll.length();this.scroll.batchStart();const a=Es(t),i=new So;return function(t){const e=[];return t.forEach(t=>{if("string"===typeof t.insert){t.insert.split("\n").forEach((a,i)=>{i&&e.push({insert:"\n",attributes:t.attributes}),a&&e.push({insert:a,attributes:t.attributes})})}else e.push(t)}),e}(a.ops.slice()).reduce((t,a)=>{const n=So.Op.length(a);let o=a.attributes||{},s=!1,r=!1;if(null!=a.insert){if(i.retain(n),"string"===typeof a.insert){const i=a.insert;r=!i.endsWith("\n")&&(e<=t||!!this.scroll.descendant(ls,t)[0]),this.scroll.insertAt(t,i);const[n,s]=this.scroll.line(t);let l=Qn({},cs(n));if(n instanceof rs){const[t]=n.descendant(ro,s);t&&(l=Qn(l,cs(t)))}o=So.AttributeMap.diff(l,o)||{}}else if("object"===typeof a.insert){const i=Object.keys(a.insert)[0];if(null==i)return t;const n=null!=this.scroll.query(i,Kn.INLINE);if(n)(e<=t||this.scroll.descendant(ls,t)[0])&&(r=!0);else if(t>0){const[e,a]=this.scroll.descendant(ro,t-1);if(e instanceof as){"\n"!==e.value()[a]&&(s=!0)}else e instanceof vo&&e.statics.scope===Kn.INLINE_BLOT&&(s=!0)}if(this.scroll.insertAt(t,i,a.insert[i]),n){const[e]=this.scroll.descendant(ro,t);if(e){const t=Qn({},cs(e));o=So.AttributeMap.diff(t,o)||{}}}}e+=n}else if(i.push(a),null!==a.retain&&"object"===typeof a.retain){const e=Object.keys(a.retain)[0];if(null==e)return t;this.scroll.updateEmbedAt(t,e,a.retain[e])}Object.keys(o).forEach(e=>{this.scroll.formatAt(t,n,e,o[e])});const l=s?1:0,d=r?1:0;return e+=l+d,i.retain(l),i.delete(d),t+n+l+d},0),i.reduce((t,e)=>"number"===typeof e.delete?(this.scroll.deleteAt(t,e.delete),t):t+So.Op.length(e),0),this.scroll.batchEnd(),this.scroll.optimize(),this.update(a)}deleteText(t,e){return this.scroll.deleteAt(t,e),this.update((new So).retain(t).delete(e))}formatLine(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};this.scroll.update(),Object.keys(a).forEach(i=>{this.scroll.lines(t,Math.max(e,1)).forEach(t=>{t.format(i,a[i])})}),this.scroll.optimize();const i=(new So).retain(t).retain(e,Jo(a));return this.update(i)}formatText(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};Object.keys(a).forEach(i=>{this.scroll.formatAt(t,e,i,a[i])});const i=(new So).retain(t).retain(e,Jo(a));return this.update(i)}getContents(t,e){return this.delta.slice(t,t+e)}getDelta(){return this.scroll.lines().reduce((t,e)=>t.concat(e.delta()),new So)}getFormat(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,a=[],i=[];0===e?this.scroll.path(t).forEach(t=>{const[e]=t;e instanceof rs?a.push(e):e instanceof ro&&i.push(e)}):(a=this.scroll.lines(t,e),i=this.scroll.descendants(ro,t,e));const[n,o]=[a,i].map(t=>{const e=t.shift();if(null==e)return{};let a=cs(e);for(;Object.keys(a).length>0;){const e=t.shift();if(null==e)return a;a=Ns(cs(e),a)}return a});return Ht(Ht({},n),o)}getHTML(t,e){const[a,i]=this.scroll.line(t);if(a){const n=a.length();return!(a.length()>=i+e)||0===i&&e===n?Ds(this.scroll,t,e,!0):Ds(a,i,e,!0)}return""}getText(t,e){return this.getContents(t,e).filter(t=>"string"===typeof t.insert).map(t=>t.insert).join("")}insertContents(t,e){const a=Es(e),i=(new So).retain(t).concat(a);return this.scroll.insertContents(t,a),this.update(i)}insertEmbed(t,e,a){return this.scroll.insertAt(t,e,a),this.update((new So).retain(t).insert({[e]:a}))}insertText(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};return e=e.replace(/\r\n/g,"\n").replace(/\r/g,"\n"),this.scroll.insertAt(t,e),Object.keys(a).forEach(i=>{this.scroll.formatAt(t,e.length,i,a[i])}),this.update((new So).retain(t).insert(e,Jo(a)))}isBlank(){if(0===this.scroll.children.length)return!0;if(this.scroll.children.length>1)return!1;const t=this.scroll.children.head;if((null===t||void 0===t?void 0:t.statics.blotName)!==rs.blotName)return!1;const e=t;return!(e.children.length>1)&&e.children.head instanceof es}removeFormat(t,e){const a=this.getText(t,e),[i,n]=this.scroll.line(t+e);let o=0,s=new So;null!=i&&(o=i.length()-n,s=i.delta().slice(n,n+o-1).insert("\n"));const r=this.getContents(t,e+o).diff((new So).insert(a).concat(s)),l=(new So).retain(t).concat(r);return this.applyDelta(l)}update(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[],a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:void 0;const i=this.delta;if(1===e.length&&"characterData"===e[0].type&&e[0].target.data.match(Ts)&&this.scroll.find(e[0].target)){const n=this.scroll.find(e[0].target),o=cs(n),s=n.offset(this.scroll),r=e[0].oldValue.replace(us.CONTENTS,""),l=(new So).insert(r),d=(new So).insert(n.value()),c=a&&{oldRange:js(a.oldRange,-s),newRange:js(a.newRange,-s)};t=(new So).retain(s).concat(l.diff(d,c)).reduce((t,e)=>e.insert?t.insert(e.insert,o):t.push(e),new So),this.delta=i.compose(t)}else this.delta=this.getDelta(),t&&en(i.compose(t),this.delta)||(t=i.diff(this.delta,a));return t}};class zs{constructor(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};this.quill=t,this.options=e}}Ot(zs,"DEFAULTS",{});const Rs=zs,Fs="\ufeff";const qs=class extends vo{constructor(t,e){super(t,e),this.contentNode=document.createElement("span"),this.contentNode.setAttribute("contenteditable","false"),Array.from(this.domNode.childNodes).forEach(t=>{this.contentNode.appendChild(t)}),this.leftGuard=document.createTextNode(Fs),this.rightGuard=document.createTextNode(Fs),this.domNode.appendChild(this.leftGuard),this.domNode.appendChild(this.contentNode),this.domNode.appendChild(this.rightGuard)}index(t,e){return t===this.leftGuard?0:t===this.rightGuard?1:super.index(t,e)}restore(t){let e,a=null;const i=t.data.split(Fs).join("");if(t===this.leftGuard)if(this.prev instanceof as){const t=this.prev.length();this.prev.insertAt(t,i),a={startNode:this.prev.domNode,startOffset:t+i.length}}else e=document.createTextNode(i),this.parent.insertBefore(this.scroll.create(e),this),a={startNode:e,startOffset:i.length};else t===this.rightGuard&&(this.next instanceof as?(this.next.insertAt(0,i),a={startNode:this.next.domNode,startOffset:i.length}):(e=document.createTextNode(i),this.parent.insertBefore(this.scroll.create(e),this.next),a={startNode:e,startOffset:i.length}));return t.data=Fs,a}update(t,e){t.forEach(t=>{if("characterData"===t.type&&(t.target===this.leftGuard||t.target===this.rightGuard)){const a=this.restore(t.target);a&&(e.range=a)}})}};const _s=class{constructor(t,e){Ot(this,"isComposing",!1),this.scroll=t,this.emitter=e,this.setupListeners()}setupListeners(){this.scroll.domNode.addEventListener("compositionstart",t=>{this.isComposing||this.handleCompositionStart(t)}),this.scroll.domNode.addEventListener("compositionend",t=>{this.isComposing&&queueMicrotask(()=>{this.handleCompositionEnd(t)})})}handleCompositionStart(t){const e=t.target instanceof Node?this.scroll.find(t.target,!0):null;!e||e instanceof qs||(this.emitter.emit(ks.events.COMPOSITION_BEFORE_START,t),this.scroll.batchStart(),this.emitter.emit(ks.events.COMPOSITION_START,t),this.isComposing=!0)}handleCompositionEnd(t){this.emitter.emit(ks.events.COMPOSITION_BEFORE_END,t),this.scroll.batchEnd(),this.emitter.emit(ks.events.COMPOSITION_END,t),this.isComposing=!1}};var Os;class Us{constructor(t,e){Ot(this,"modules",{}),this.quill=t,this.options=e}init(){Object.keys(this.options.modules).forEach(t=>{null==this.modules[t]&&this.addModule(t)})}addModule(t){const e=this.quill.constructor.import("modules/".concat(t));return this.modules[t]=new e(this.quill,this.options.modules[t]||{}),this.modules[t]}}Os=Us,Ot(Us,"DEFAULTS",{modules:{}}),Ot(Us,"themes",{default:Os});const Hs=Us,Vs=t=>t.parentElement||t.getRootNode().host||null,Bs=t=>{const e=t.getBoundingClientRect(),a="offsetWidth"in t&&Math.abs(e.width)/t.offsetWidth||1,i="offsetHeight"in t&&Math.abs(e.height)/t.offsetHeight||1;return{top:e.top,right:e.left+t.clientWidth*a,bottom:e.top+t.clientHeight*i,left:e.left}},Gs=t=>{const e=parseInt(t,10);return Number.isNaN(e)?0:e},Ws=(t,e,a,i,n,o)=>t<a&&e>i?0:t<a?-(a-t+n):e>i?e-t>i-a?t+n-a:e-i+o:0,Qs=(t,e)=>{const a=t.ownerDocument;let i=e,n=t;for(;n;){var o,s,r,l;const t=n===a.body,e=t?{top:0,right:null!==(o=null===(s=window.visualViewport)||void 0===s?void 0:s.width)&&void 0!==o?o:a.documentElement.clientWidth,bottom:null!==(r=null===(l=window.visualViewport)||void 0===l?void 0:l.height)&&void 0!==r?r:a.documentElement.clientHeight,left:0}:Bs(n),c=getComputedStyle(n),m=Ws(i.left,i.right,e.left,e.right,Gs(c.scrollPaddingLeft),Gs(c.scrollPaddingRight)),u=Ws(i.top,i.bottom,e.top,e.bottom,Gs(c.scrollPaddingTop),Gs(c.scrollPaddingBottom));if(m||u)if(t){var d;null===(d=a.defaultView)||void 0===d||d.scrollBy(m,u)}else{const{scrollLeft:t,scrollTop:e}=n;u&&(n.scrollTop+=u),m&&(n.scrollLeft+=m);const a=n.scrollLeft-t,o=n.scrollTop-e;i={left:i.left-a,top:i.top-o,right:i.right-a,bottom:i.bottom-o}}n=t||"fixed"===c.position?null:Vs(n)}},Ks=["block","break","cursor","inline","scroll","text"],Zs=(t,e,a)=>{const i=new Yn;return Ks.forEach(t=>{const a=e.query(t);a&&i.register(a)}),t.forEach(t=>{let n=e.query(t);n||a.error('Cannot register "'.concat(t,'" specified in "formats" config. Are you sure it was registered?'));let o=0;for(;n;){var s;if(i.register(n),n="blotName"in n&&null!==(s=n.requiredContainer)&&void 0!==s?s:null,o+=1,o>100){a.error('Cycle detected in registering blot requiredContainer: "'.concat(t,'"'));break}}}),i},$s=["modules"],Xs=["modules"],Ys=vs("quill"),Js=new Yn;uo.uiClass="ql-ui";class tr{static debug(t){!0===t&&(t="log"),vs.level(t)}static find(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];return fs.get(t)||Js.find(t,e)}static import(t){return null==this.imports[t]&&Ys.error("Cannot import ".concat(t,". Are you sure it was registered?")),this.imports[t]}static register(){if("string"!==typeof(arguments.length<=0?void 0:arguments[0])){const t=arguments.length<=0?void 0:arguments[0],e=!!(arguments.length<=1?void 0:arguments[1]),a="attrName"in t?t.attrName:t.blotName;"string"===typeof a?this.register("formats/".concat(a),t,e):Object.keys(t).forEach(a=>{this.register(a,t[a],e)})}else{const t=arguments.length<=0?void 0:arguments[0],e=arguments.length<=1?void 0:arguments[1],a=!!(arguments.length<=2?void 0:arguments[2]);null==this.imports[t]||a||Ys.warn("Overwriting ".concat(t," with"),e),this.imports[t]=e,(t.startsWith("blots/")||t.startsWith("formats/"))&&e&&"boolean"!==typeof e&&"abstract"!==e.blotName&&Js.register(e),"function"===typeof e.register&&e.register(Js)}}constructor(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(this.options=function(t,e){const a=er(t);if(!a)throw new Error("Invalid Quill container");const i=!e.theme||e.theme===tr.DEFAULTS.theme,n=i?Hs:tr.import("themes/".concat(e.theme));if(!n)throw new Error("Invalid theme ".concat(e.theme,". Did you register it?"));const o=tr.DEFAULTS,{modules:s}=o,r=he(o,$s),l=n.DEFAULTS,{modules:d}=l,c=he(l,Xs);let m=ar(e.modules);null!=m&&m.toolbar&&m.toolbar.constructor!==Object&&(m=Ht(Ht({},m),{},{toolbar:{container:m.toolbar}}));const u=Qn({},ar(s),ar(d),m),h=Ht(Ht(Ht({},r),ir(c)),ir(e));let f=e.registry;f?e.formats&&Ys.warn('Ignoring "formats" option because "registry" is specified'):f=e.formats?Zs(e.formats,h.registry,Ys):h.registry;return Ht(Ht({},h),{},{registry:f,container:a,theme:n,modules:Object.entries(u).reduce((t,e)=>{let[a,i]=e;if(!i)return t;const n=tr.import("modules/".concat(a));return null==n?(Ys.error("Cannot load ".concat(a," module. Are you sure you registered it?")),t):Ht(Ht({},t),{},{[a]:Qn({},n.DEFAULTS||{},i)})},{}),bounds:er(h.bounds)})}(t,e),this.container=this.options.container,null==this.container)return void Ys.error("Invalid Quill container",t);this.options.debug&&tr.debug(this.options.debug);const a=this.container.innerHTML.trim();this.container.classList.add("ql-container"),this.container.innerHTML="",fs.set(this.container,this),this.root=this.addContainer("ql-editor"),this.root.classList.add("ql-blank"),this.emitter=new ks;const i=ko.blotName,n=this.options.registry.query(i);if(!n||!("blotName"in n))throw new Error('Cannot initialize Quill without "'.concat(i,'" blot'));if(this.scroll=new n(this.options.registry,this.root,{emitter:this.emitter}),this.editor=new Ms(this.scroll),this.selection=new As(this.scroll,this.emitter),this.composition=new _s(this.scroll,this.emitter),this.theme=new this.options.theme(this,this.options),this.keyboard=this.theme.addModule("keyboard"),this.clipboard=this.theme.addModule("clipboard"),this.history=this.theme.addModule("history"),this.uploader=this.theme.addModule("uploader"),this.theme.addModule("input"),this.theme.addModule("uiNode"),this.theme.init(),this.emitter.on(ks.events.EDITOR_CHANGE,t=>{t===ks.events.TEXT_CHANGE&&this.root.classList.toggle("ql-blank",this.editor.isBlank())}),this.emitter.on(ks.events.SCROLL_UPDATE,(t,e)=>{const a=this.selection.lastRange,[i]=this.selection.getRange(),n=a&&i?{oldRange:a,newRange:i}:void 0;nr.call(this,()=>this.editor.update(null,e,n),t)}),this.emitter.on(ks.events.SCROLL_EMBED_UPDATE,(t,e)=>{const a=this.selection.lastRange,[i]=this.selection.getRange(),n=a&&i?{oldRange:a,newRange:i}:void 0;nr.call(this,()=>{const a=(new So).retain(t.offset(this)).retain({[t.statics.blotName]:e});return this.editor.update(a,[],n)},tr.sources.USER)}),a){const t=this.clipboard.convert({html:"".concat(a,"<p><br></p>"),text:"\n"});this.setContents(t)}this.history.clear(),this.options.placeholder&&this.root.setAttribute("data-placeholder",this.options.placeholder),this.options.readOnly&&this.disable(),this.allowReadOnlyEdits=!1}addContainer(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:null;if("string"===typeof t){const e=t;(t=document.createElement("div")).classList.add(e)}return this.container.insertBefore(t,e),t}blur(){this.selection.setRange(null)}deleteText(t,e,a){return[t,e,,a]=or(t,e,a),nr.call(this,()=>this.editor.deleteText(t,e),a,t,-1*e)}disable(){this.enable(!1)}editReadOnly(t){this.allowReadOnlyEdits=!0;const e=t();return this.allowReadOnlyEdits=!1,e}enable(){let t=!(arguments.length>0&&void 0!==arguments[0])||arguments[0];this.scroll.enable(t),this.container.classList.toggle("ql-disabled",!t)}focus(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};this.selection.focus(),t.preventScroll||this.scrollSelectionIntoView()}format(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:ks.sources.API;return nr.call(this,()=>{const a=this.getSelection(!0);let i=new So;if(null==a)return i;if(this.scroll.query(t,Kn.BLOCK))i=this.editor.formatLine(a.index,a.length,{[t]:e});else{if(0===a.length)return this.selection.format(t,e),i;i=this.editor.formatText(a.index,a.length,{[t]:e})}return this.setSelection(a,ks.sources.SILENT),i},a)}formatLine(t,e,a,i,n){let o;return[t,e,o,n]=or(t,e,a,i,n),nr.call(this,()=>this.editor.formatLine(t,e,o),n,t,0)}formatText(t,e,a,i,n){let o;return[t,e,o,n]=or(t,e,a,i,n),nr.call(this,()=>this.editor.formatText(t,e,o),n,t,0)}getBounds(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,a=null;if(a="number"===typeof t?this.selection.getBounds(t,e):this.selection.getBounds(t.index,t.length),!a)return null;const i=this.container.getBoundingClientRect();return{bottom:a.bottom-i.top,height:a.height,left:a.left-i.left,right:a.right-i.left,top:a.top-i.top,width:a.width}}getContents(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.getLength()-t;return[t,e]=or(t,e),this.editor.getContents(t,e)}getFormat(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.getSelection(!0),e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0;return"number"===typeof t?this.editor.getFormat(t,e):this.editor.getFormat(t.index,t.length)}getIndex(t){return t.offset(this.scroll)}getLength(){return this.scroll.length()}getLeaf(t){return this.scroll.leaf(t)}getLine(t){return this.scroll.line(t)}getLines(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:Number.MAX_VALUE;return"number"!==typeof t?this.scroll.lines(t.index,t.length):this.scroll.lines(t,e)}getModule(t){return this.theme.modules[t]}getSelection(){return arguments.length>0&&void 0!==arguments[0]&&arguments[0]&&this.focus(),this.update(),this.selection.getRange()[0]}getSemanticHTML(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1?arguments[1]:void 0;return"number"===typeof t&&(e=null!==e&&void 0!==e?e:this.getLength()-t),[t,e]=or(t,e),this.editor.getHTML(t,e)}getText(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1?arguments[1]:void 0;return"number"===typeof t&&(e=null!==e&&void 0!==e?e:this.getLength()-t),[t,e]=or(t,e),this.editor.getText(t,e)}hasFocus(){return this.selection.hasFocus()}insertEmbed(t,e,a){let i=arguments.length>3&&void 0!==arguments[3]?arguments[3]:tr.sources.API;return nr.call(this,()=>this.editor.insertEmbed(t,e,a),i,t)}insertText(t,e,a,i,n){let o;return[t,,o,n]=or(t,0,a,i,n),nr.call(this,()=>this.editor.insertText(t,e,o),n,t,e.length)}isEnabled(){return this.scroll.isEnabled()}off(){return this.emitter.off(...arguments)}on(){return this.emitter.on(...arguments)}once(){return this.emitter.once(...arguments)}removeFormat(t,e,a){return[t,e,,a]=or(t,e,a),nr.call(this,()=>this.editor.removeFormat(t,e),a,t)}scrollRectIntoView(t){Qs(this.root,t)}scrollIntoView(){console.warn("Quill#scrollIntoView() has been deprecated and will be removed in the near future. Please use Quill#scrollSelectionIntoView() instead."),this.scrollSelectionIntoView()}scrollSelectionIntoView(){const t=this.selection.lastRange,e=t&&this.selection.getBounds(t.index,t.length);e&&this.scrollRectIntoView(e)}setContents(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:ks.sources.API;return nr.call(this,()=>{t=new So(t);const e=this.getLength(),a=this.editor.deleteText(0,e),i=this.editor.insertContents(0,t),n=this.editor.deleteText(this.getLength()-1,1);return a.compose(i).compose(n)},e)}setSelection(t,e,a){null==t?this.selection.setRange(null,e||tr.sources.API):([t,e,,a]=or(t,e,a),this.selection.setRange(new Cs(Math.max(0,t),e),a),a!==ks.sources.SILENT&&this.scrollSelectionIntoView())}setText(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:ks.sources.API;const a=(new So).insert(t);return this.setContents(a,e)}update(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ks.sources.USER;const e=this.scroll.update(t);return this.selection.update(t),e}updateContents(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:ks.sources.API;return nr.call(this,()=>(t=new So(t),this.editor.applyDelta(t)),e,!0)}}function er(t){return"string"===typeof t?document.querySelector(t):t}function ar(t){return Object.entries(null!==t&&void 0!==t?t:{}).reduce((t,e)=>{let[a,i]=e;return Ht(Ht({},t),{},{[a]:!0===i?{}:i})},{})}function ir(t){return Object.fromEntries(Object.entries(t).filter(t=>void 0!==t[1]))}function nr(t,e,a,i){if(!this.isEnabled()&&e===ks.sources.USER&&!this.allowReadOnlyEdits)return new So;let n=null==a?null:this.getSelection();const o=this.editor.delta,s=t();if(null!=n&&(!0===a&&(a=n.index),null==i?n=sr(n,s,e):0!==i&&(n=sr(n,a,i,e)),this.setSelection(n,ks.sources.SILENT)),s.length()>0){const t=[ks.events.TEXT_CHANGE,s,o,e];this.emitter.emit(ks.events.EDITOR_CHANGE,...t),e!==ks.sources.SILENT&&this.emitter.emit(...t)}return s}function or(t,e,a,i,n){let o={};return"number"===typeof t.index&&"number"===typeof t.length?"number"!==typeof e?(n=i,i=a,a=e,e=t.length,t=t.index):(e=t.length,t=t.index):"number"!==typeof e&&(n=i,i=a,a=e,e=0),"object"===typeof a?(o=a,n=i):"string"===typeof a&&(null!=i?o[a]=i:n=a),[t,e,o,n=n||ks.sources.API]}function sr(t,e,a,i){const n="number"===typeof a?a:0;if(null==t)return null;let o,s;return e&&"function"===typeof e.transformPosition?[o,s]=[t.index,t.index+t.length].map(t=>e.transformPosition(t,i!==ks.sources.USER)):[o,s]=[t.index,t.index+t.length].map(t=>t<e||t===e&&i===ks.sources.USER?t:n>=0?t+n:Math.max(e,t+n)),new Cs(o,s-o)}Ot(tr,"DEFAULTS",{bounds:null,modules:{clipboard:!0,keyboard:!0,history:!0,uploader:!0},placeholder:"",readOnly:!1,registry:Js,theme:"default"}),Ot(tr,"events",ks.events),Ot(tr,"sources",ks.sources),Ot(tr,"version","2.0.3"),Ot(tr,"imports",{delta:So,parchment:t,"core/module":Rs,"core/theme":Hs});const rr=class extends bo{};function lr(t){return t instanceof rs||t instanceof ls}function dr(t){return"function"===typeof t.updateContent}class cr extends ko{constructor(t,e,a){let{emitter:i}=a;super(t,e),this.emitter=i,this.batch=!1,this.optimize(),this.enable(),this.domNode.addEventListener("dragstart",t=>this.handleDragStart(t))}batchStart(){Array.isArray(this.batch)||(this.batch=[])}batchEnd(){if(!this.batch)return;const t=this.batch;this.batch=!1,this.update(t)}emitMount(t){this.emitter.emit(ks.events.SCROLL_BLOT_MOUNT,t)}emitUnmount(t){this.emitter.emit(ks.events.SCROLL_BLOT_UNMOUNT,t)}emitEmbedUpdate(t,e){this.emitter.emit(ks.events.SCROLL_EMBED_UPDATE,t,e)}deleteAt(t,e){const[a,i]=this.line(t),[n]=this.line(t+e);if(super.deleteAt(t,e),null!=n&&a!==n&&i>0){if(a instanceof ls||n instanceof ls)return void this.optimize();const t=n.children.head instanceof es?null:n.children.head;a.moveChildren(n,t),a.remove()}this.optimize()}enable(){let t=!(arguments.length>0&&void 0!==arguments[0])||arguments[0];this.domNode.setAttribute("contenteditable",t?"true":"false")}formatAt(t,e,a,i){super.formatAt(t,e,a,i),this.optimize()}insertAt(t,e,a){if(t>=this.length())if(null==a||null==this.scroll.query(e,Kn.BLOCK)){const t=this.scroll.create(this.statics.defaultChild.blotName);this.appendChild(t),null==a&&e.endsWith("\n")?t.insertAt(0,e.slice(0,-1),a):t.insertAt(0,e,a)}else{const t=this.scroll.create(e,a);this.appendChild(t)}else super.insertAt(t,e,a);this.optimize()}insertBefore(t,e){if(t.statics.scope===Kn.INLINE_BLOT){const a=this.scroll.create(this.statics.defaultChild.blotName);a.appendChild(t),super.insertBefore(a,e)}else super.insertBefore(t,e)}insertContents(t,e){const a=this.deltaToRenderBlocks(e.concat((new So).insert("\n"))),i=a.pop();if(null==i)return;this.batchStart();const n=a.shift();if(n){const e="block"===n.type&&(0===n.delta.length()||!this.descendant(ls,t)[0]&&t<this.length()),a="block"===n.type?n.delta:(new So).insert({[n.key]:n.value});mr(this,t,a);const i="block"===n.type?1:0,o=t+a.length()+i;e&&this.insertAt(o-1,"\n");const s=cs(this.line(t)[0]),r=So.AttributeMap.diff(s,n.attributes)||{};Object.keys(r).forEach(t=>{this.formatAt(o-1,1,t,r[t])}),t=o}let[o,s]=this.children.find(t);if(a.length&&(o&&(o=o.split(s),s=0),a.forEach(t=>{if("block"===t.type){mr(this.createBlock(t.attributes,o||void 0),0,t.delta)}else{const e=this.create(t.key,t.value);this.insertBefore(e,o||void 0),Object.keys(t.attributes).forEach(a=>{e.format(a,t.attributes[a])})}})),"block"===i.type&&i.delta.length()){mr(this,o?o.offset(o.scroll)+s:this.length(),i.delta)}this.batchEnd(),this.optimize()}isEnabled(){return"true"===this.domNode.getAttribute("contenteditable")}leaf(t){const e=this.path(t).pop();if(!e)return[null,-1];const[a,i]=e;return a instanceof ro?[a,i]:[null,-1]}line(t){return t===this.length()?this.line(t-1):this.descendant(lr,t)}lines(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:0,e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:Number.MAX_VALUE;const a=(t,e,i)=>{let n=[],o=i;return t.children.forEachAt(e,i,(t,e,i)=>{lr(t)?n.push(t):t instanceof bo&&(n=n.concat(a(t,e,o))),o-=i}),n};return a(this,t,e)}optimize(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:[],e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};this.batch||(super.optimize(t,e),t.length>0&&this.emitter.emit(ks.events.SCROLL_OPTIMIZE,t,e))}path(t){return super.path(t).slice(1)}remove(){}update(t){if(this.batch)return void(Array.isArray(t)&&(this.batch=this.batch.concat(t)));let e=ks.sources.USER;"string"===typeof t&&(e=t),Array.isArray(t)||(t=this.observer.takeRecords()),(t=t.filter(t=>{let{target:e}=t;const a=this.find(e,!0);return a&&!dr(a)})).length>0&&this.emitter.emit(ks.events.SCROLL_BEFORE_UPDATE,e,t),super.update(t.concat([])),t.length>0&&this.emitter.emit(ks.events.SCROLL_UPDATE,e,t)}updateEmbedAt(t,e,a){const[i]=this.descendant(t=>t instanceof ls,t);i&&i.statics.blotName===e&&dr(i)&&i.updateContent(a)}handleDragStart(t){t.preventDefault()}deltaToRenderBlocks(t){const e=[];let a=new So;return t.forEach(t=>{const i=null===t||void 0===t?void 0:t.insert;if(i)if("string"===typeof i){const n=i.split("\n");n.slice(0,-1).forEach(i=>{var n;a.insert(i,t.attributes),e.push({type:"block",delta:a,attributes:null!==(n=t.attributes)&&void 0!==n?n:{}}),a=new So});const o=n[n.length-1];o&&a.insert(o,t.attributes)}else{const o=Object.keys(i)[0];if(!o)return;var n;if(this.query(o,Kn.INLINE))a.push(t);else a.length()&&e.push({type:"block",delta:a,attributes:{}}),a=new So,e.push({type:"blockEmbed",key:o,value:i[o],attributes:null!==(n=t.attributes)&&void 0!==n?n:{}})}}),a.length()&&e.push({type:"block",delta:a,attributes:{}}),e}createBlock(t,e){let a;const i={};Object.entries(t).forEach(t=>{let[e,n]=t;null!=this.query(e,Kn.BLOCK&Kn.BLOT)?a=e:i[e]=n});const n=this.create(a||this.statics.defaultChild.blotName,a?t[a]:void 0);this.insertBefore(n,e||void 0);const o=n.length();return Object.entries(i).forEach(t=>{let[e,a]=t;n.formatAt(0,o,e,a)}),n}}function mr(t,e,a){a.reduce((e,a)=>{const i=So.Op.length(a);let n=a.attributes||{};if(null!=a.insert)if("string"===typeof a.insert){const i=a.insert;t.insertAt(e,i);const[o]=t.descendant(ro,e),s=cs(o);n=So.AttributeMap.diff(s,n)||{}}else if("object"===typeof a.insert){const i=Object.keys(a.insert)[0];if(null==i)return e;t.insertAt(e,i,a.insert[i]);if(null!=t.scroll.query(i,Kn.INLINE)){const[a]=t.descendant(ro,e),i=cs(a);n=So.AttributeMap.diff(i,n)||{}}}return Object.keys(n).forEach(a=>{t.formatAt(e,i,a,n[a])}),e+i},e)}Ot(cr,"blotName","scroll"),Ot(cr,"className","ql-editor"),Ot(cr,"tagName","DIV"),Ot(cr,"defaultChild",rs),Ot(cr,"allowedChildren",[rs,ls,rr]);const ur=cr,hr={scope:Kn.BLOCK,whitelist:["right","center","justify"]},fr=new Zn("align","align",hr),gr=new to("align","ql-align",hr),pr=new ao("align","text-align",hr);class yr extends ao{value(t){let e=super.value(t);if(!e.startsWith("rgb("))return e;e=e.replace(/^[^\d]+/,"").replace(/[^\d]+$/,"");const a=e.split(",").map(t=>"00".concat(parseInt(t,10).toString(16)).slice(-2)).join("");return"#".concat(a)}}const br=new to("color","ql-color",{scope:Kn.INLINE}),vr=new yr("color","color",{scope:Kn.INLINE}),wr=new to("background","ql-bg",{scope:Kn.INLINE}),xr=new yr("background","background-color",{scope:Kn.INLINE});class kr extends rr{static create(t){const e=super.create(t);return e.setAttribute("spellcheck","false"),e}code(t,e){return this.children.map(t=>t.length()<=1?"":t.domNode.innerText).join("\n").slice(t,t+e)}html(t,e){return"<pre>\n".concat(ns(this.code(t,e)),"\n</pre>")}}class Ir extends rs{static register(){tr.register(kr)}}Ot(Ir,"TAB","  ");class Cr extends ss{}Cr.blotName="code",Cr.tagName="CODE",Ir.blotName="code-block",Ir.className="ql-code-block",Ir.tagName="DIV",kr.blotName="code-block-container",kr.className="ql-code-block-container",kr.tagName="DIV",kr.allowedChildren=[Ir],Ir.allowedChildren=[as,es,us],Ir.requiredContainer=kr;const Sr={scope:Kn.BLOCK,whitelist:["rtl"]},Ar=new Zn("direction","dir",Sr),Tr=new to("direction","ql-direction",Sr),Pr=new ao("direction","direction",Sr),Dr={scope:Kn.INLINE,whitelist:["serif","monospace"]},Nr=new to("font","ql-font",Dr);const Lr=new class extends ao{value(t){return super.value(t).replace(/["']/g,"")}}("font","font-family",Dr),Er=new to("size","ql-size",{scope:Kn.INLINE,whitelist:["small","large","huge"]}),jr=new ao("size","font-size",{scope:Kn.INLINE,whitelist:["10px","18px","32px"]}),Mr=vs("quill:keyboard"),zr=/Mac/i.test(navigator.platform)?"metaKey":"ctrlKey";class Rr extends Rs{static match(t,e){return!["altKey","ctrlKey","metaKey","shiftKey"].some(a=>!!e[a]!==t[a]&&null!==e[a])&&(e.key===t.key||e.key===t.which)}constructor(t,e){super(t,e),this.bindings={},Object.keys(this.options.bindings).forEach(t=>{this.options.bindings[t]&&this.addBinding(this.options.bindings[t])}),this.addBinding({key:"Enter",shiftKey:null},this.handleEnter),this.addBinding({key:"Enter",metaKey:null,ctrlKey:null,altKey:null},()=>{}),/Firefox/i.test(navigator.userAgent)?(this.addBinding({key:"Backspace"},{collapsed:!0},this.handleBackspace),this.addBinding({key:"Delete"},{collapsed:!0},this.handleDelete)):(this.addBinding({key:"Backspace"},{collapsed:!0,prefix:/^.?$/},this.handleBackspace),this.addBinding({key:"Delete"},{collapsed:!0,suffix:/^.?$/},this.handleDelete)),this.addBinding({key:"Backspace"},{collapsed:!1},this.handleDeleteRange),this.addBinding({key:"Delete"},{collapsed:!1},this.handleDeleteRange),this.addBinding({key:"Backspace",altKey:null,ctrlKey:null,metaKey:null,shiftKey:null},{collapsed:!0,offset:0},this.handleBackspace),this.listen()}addBinding(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};const i=function(t){if("string"===typeof t||"number"===typeof t)t={key:t};else{if("object"!==typeof t)return null;t=Jo(t)}t.shortKey&&(t[zr]=t.shortKey,delete t.shortKey);return t}(t);if(null==i)return void Mr.warn("Attempted to add invalid keyboard binding",i);"function"===typeof e&&(e={handler:e}),"function"===typeof a&&(a={handler:a});(Array.isArray(i.key)?i.key:[i.key]).forEach(t=>{const n=Ht(Ht(Ht({},i),{},{key:t},e),a);this.bindings[n.key]=this.bindings[n.key]||[],this.bindings[n.key].push(n)})}listen(){this.quill.root.addEventListener("keydown",t=>{if(t.defaultPrevented||t.isComposing)return;if(229===t.keyCode&&("Enter"===t.key||"Backspace"===t.key))return;const e=(this.bindings[t.key]||[]).concat(this.bindings[t.which]||[]).filter(e=>Rr.match(t,e));if(0===e.length)return;const a=tr.find(t.target,!0);if(a&&a.scroll!==this.quill.scroll)return;const i=this.quill.getSelection();if(null==i||!this.quill.hasFocus())return;const[n,o]=this.quill.getLine(i.index),[s,r]=this.quill.getLeaf(i.index),[l,d]=0===i.length?[s,r]:this.quill.getLeaf(i.index+i.length),c=s instanceof Co?s.value().slice(0,r):"",m=l instanceof Co?l.value().slice(d):"",u={collapsed:0===i.length,empty:0===i.length&&n.length()<=1,format:this.quill.getFormat(i),line:n,offset:o,prefix:c,suffix:m,event:t};e.some(t=>{if(null!=t.collapsed&&t.collapsed!==u.collapsed)return!1;if(null!=t.empty&&t.empty!==u.empty)return!1;if(null!=t.offset&&t.offset!==u.offset)return!1;if(Array.isArray(t.format)){if(t.format.every(t=>null==u.format[t]))return!1}else if("object"===typeof t.format&&!Object.keys(t.format).every(e=>!0===t.format[e]?null!=u.format[e]:!1===t.format[e]?null==u.format[e]:en(t.format[e],u.format[e])))return!1;return!(null!=t.prefix&&!t.prefix.test(u.prefix))&&(!(null!=t.suffix&&!t.suffix.test(u.suffix))&&!0!==t.handler.call(this,i,u,t))})&&t.preventDefault()})}handleBackspace(t,e){const a=/[\uD800-\uDBFF][\uDC00-\uDFFF]$/.test(e.prefix)?2:1;if(0===t.index||this.quill.getLength()<=1)return;let i={};const[n]=this.quill.getLine(t.index);let o=(new So).retain(t.index-a).delete(a);if(0===e.offset){const[e]=this.quill.getLine(t.index-1);if(e){if(!("block"===e.statics.blotName&&e.length()<=1)){const e=n.formats(),a=this.quill.getFormat(t.index-1,1);if(i=So.AttributeMap.diff(e,a)||{},Object.keys(i).length>0){const e=(new So).retain(t.index+n.length()-2).retain(1,i);o=o.compose(e)}}}}this.quill.updateContents(o,tr.sources.USER),this.quill.focus()}handleDelete(t,e){const a=/^[\uD800-\uDBFF][\uDC00-\uDFFF]/.test(e.suffix)?2:1;if(t.index>=this.quill.getLength()-a)return;let i={};const[n]=this.quill.getLine(t.index);let o=(new So).retain(t.index).delete(a);if(e.offset>=n.length()-1){const[e]=this.quill.getLine(t.index+1);if(e){const a=n.formats(),s=this.quill.getFormat(t.index,1);i=So.AttributeMap.diff(a,s)||{},Object.keys(i).length>0&&(o=o.retain(e.length()-1).retain(1,i))}}this.quill.updateContents(o,tr.sources.USER),this.quill.focus()}handleDeleteRange(t){Hr({range:t,quill:this.quill}),this.quill.focus()}handleEnter(t,e){const a=Object.keys(e.format).reduce((t,a)=>(this.quill.scroll.query(a,Kn.BLOCK)&&!Array.isArray(e.format[a])&&(t[a]=e.format[a]),t),{}),i=(new So).retain(t.index).delete(t.length).insert("\n",a);this.quill.updateContents(i,tr.sources.USER),this.quill.setSelection(t.index+1,tr.sources.SILENT),this.quill.focus()}}const Fr={bindings:{bold:Or("bold"),italic:Or("italic"),underline:Or("underline"),indent:{key:"Tab",format:["blockquote","indent","list"],handler(t,e){return!(!e.collapsed||0===e.offset)||(this.quill.format("indent","+1",tr.sources.USER),!1)}},outdent:{key:"Tab",shiftKey:!0,format:["blockquote","indent","list"],handler(t,e){return!(!e.collapsed||0===e.offset)||(this.quill.format("indent","-1",tr.sources.USER),!1)}},"outdent backspace":{key:"Backspace",collapsed:!0,shiftKey:null,metaKey:null,ctrlKey:null,altKey:null,format:["indent","list"],offset:0,handler(t,e){null!=e.format.indent?this.quill.format("indent","-1",tr.sources.USER):null!=e.format.list&&this.quill.format("list",!1,tr.sources.USER)}},"indent code-block":qr(!0),"outdent code-block":qr(!1),"remove tab":{key:"Tab",shiftKey:!0,collapsed:!0,prefix:/\t$/,handler(t){this.quill.deleteText(t.index-1,1,tr.sources.USER)}},tab:{key:"Tab",handler(t,e){if(e.format.table)return!0;this.quill.history.cutoff();const a=(new So).retain(t.index).delete(t.length).insert("\t");return this.quill.updateContents(a,tr.sources.USER),this.quill.history.cutoff(),this.quill.setSelection(t.index+1,tr.sources.SILENT),!1}},"blockquote empty enter":{key:"Enter",collapsed:!0,format:["blockquote"],empty:!0,handler(){this.quill.format("blockquote",!1,tr.sources.USER)}},"list empty enter":{key:"Enter",collapsed:!0,format:["list"],empty:!0,handler(t,e){const a={list:!1};e.format.indent&&(a.indent=!1),this.quill.formatLine(t.index,t.length,a,tr.sources.USER)}},"checklist enter":{key:"Enter",collapsed:!0,format:{list:"checked"},handler(t){const[e,a]=this.quill.getLine(t.index),i=Ht(Ht({},e.formats()),{},{list:"checked"}),n=(new So).retain(t.index).insert("\n",i).retain(e.length()-a-1).retain(1,{list:"unchecked"});this.quill.updateContents(n,tr.sources.USER),this.quill.setSelection(t.index+1,tr.sources.SILENT),this.quill.scrollSelectionIntoView()}},"header enter":{key:"Enter",collapsed:!0,format:["header"],suffix:/^$/,handler(t,e){const[a,i]=this.quill.getLine(t.index),n=(new So).retain(t.index).insert("\n",e.format).retain(a.length()-i-1).retain(1,{header:null});this.quill.updateContents(n,tr.sources.USER),this.quill.setSelection(t.index+1,tr.sources.SILENT),this.quill.scrollSelectionIntoView()}},"table backspace":{key:"Backspace",format:["table"],collapsed:!0,offset:0,handler(){}},"table delete":{key:"Delete",format:["table"],collapsed:!0,suffix:/^$/,handler(){}},"table enter":{key:"Enter",shiftKey:null,format:["table"],handler(t){const e=this.quill.getModule("table");if(e){const[a,i,n,o]=e.getTable(t),s=function(t,e,a,i){if(null==e.prev&&null==e.next)return null==a.prev&&null==a.next?0===i?-1:1:null==a.prev?-1:1;if(null==e.prev)return-1;if(null==e.next)return 1;return null}(0,i,n,o);if(null==s)return;let r=a.offset();if(s<0){const e=(new So).retain(r).insert("\n");this.quill.updateContents(e,tr.sources.USER),this.quill.setSelection(t.index+1,t.length,tr.sources.SILENT)}else if(s>0){r+=a.length();const t=(new So).retain(r).insert("\n");this.quill.updateContents(t,tr.sources.USER),this.quill.setSelection(r,tr.sources.USER)}}}},"table tab":{key:"Tab",shiftKey:null,format:["table"],handler(t,e){const{event:a,line:i}=e,n=i.offset(this.quill.scroll);a.shiftKey?this.quill.setSelection(n-1,tr.sources.USER):this.quill.setSelection(n+i.length(),tr.sources.USER)}},"list autofill":{key:" ",shiftKey:null,collapsed:!0,format:{"code-block":!1,blockquote:!1,table:!1},prefix:/^\s*?(\d+\.|-|\*|\[ ?\]|\[x\])$/,handler(t,e){if(null==this.quill.scroll.query("list"))return!0;const{length:a}=e.prefix,[i,n]=this.quill.getLine(t.index);if(n>a)return!0;let o;switch(e.prefix.trim()){case"[]":case"[ ]":o="unchecked";break;case"[x]":o="checked";break;case"-":case"*":o="bullet";break;default:o="ordered"}this.quill.insertText(t.index," ",tr.sources.USER),this.quill.history.cutoff();const s=(new So).retain(t.index-n).delete(a+1).retain(i.length()-2-n).retain(1,{list:o});return this.quill.updateContents(s,tr.sources.USER),this.quill.history.cutoff(),this.quill.setSelection(t.index-a,tr.sources.SILENT),!1}},"code exit":{key:"Enter",collapsed:!0,format:["code-block"],prefix:/^$/,suffix:/^\s*$/,handler(t){const[e,a]=this.quill.getLine(t.index);let i=2,n=e;for(;null!=n&&n.length()<=1&&n.formats()["code-block"];)if(n=n.prev,i-=1,i<=0){const i=(new So).retain(t.index+e.length()-a-2).retain(1,{"code-block":null}).delete(1);return this.quill.updateContents(i,tr.sources.USER),this.quill.setSelection(t.index-1,tr.sources.SILENT),!1}return!0}},"embed left":_r("ArrowLeft",!1),"embed left shift":_r("ArrowLeft",!0),"embed right":_r("ArrowRight",!1),"embed right shift":_r("ArrowRight",!0),"table down":Ur(!1),"table up":Ur(!0)}};function qr(t){return{key:"Tab",shiftKey:!t,format:{"code-block":!0},handler(e,a){let{event:i}=a;const n=this.quill.scroll.query("code-block"),{TAB:o}=n;if(0===e.length&&!i.shiftKey)return this.quill.insertText(e.index,o,tr.sources.USER),void this.quill.setSelection(e.index+o.length,tr.sources.SILENT);const s=0===e.length?this.quill.getLines(e.index,1):this.quill.getLines(e);let{index:r,length:l}=e;s.forEach((e,a)=>{t?(e.insertAt(0,o),0===a?r+=o.length:l+=o.length):e.domNode.textContent.startsWith(o)&&(e.deleteAt(0,o.length),0===a?r-=o.length:l-=o.length)}),this.quill.update(tr.sources.USER),this.quill.setSelection(r,l,tr.sources.SILENT)}}}function _r(t,e){const a="ArrowLeft"===t?"prefix":"suffix";return{key:t,shiftKey:e,altKey:null,[a]:/^$/,handler(a){let{index:i}=a;"ArrowRight"===t&&(i+=a.length+1);const[n]=this.quill.getLeaf(i);return!(n instanceof vo)||("ArrowLeft"===t?e?this.quill.setSelection(a.index-1,a.length+1,tr.sources.USER):this.quill.setSelection(a.index-1,tr.sources.USER):e?this.quill.setSelection(a.index,a.length+1,tr.sources.USER):this.quill.setSelection(a.index+a.length+1,tr.sources.USER),!1)}}}function Or(t){return{key:t[0],shortKey:!0,handler(e,a){this.quill.format(t,!a.format[t],tr.sources.USER)}}}function Ur(t){return{key:t?"ArrowUp":"ArrowDown",collapsed:!0,format:["table"],handler(e,a){const i=t?"prev":"next",n=a.line,o=n.parent[i];if(null!=o){if("table-row"===o.statics.blotName){let t=o.children.head,e=n;for(;null!=e.prev;)e=e.prev,t=t.next;const i=t.offset(this.quill.scroll)+Math.min(a.offset,t.length()-1);this.quill.setSelection(i,0,tr.sources.USER)}}else{const e=n.table()[i];null!=e&&(t?this.quill.setSelection(e.offset(this.quill.scroll)+e.length()-1,0,tr.sources.USER):this.quill.setSelection(e.offset(this.quill.scroll),0,tr.sources.USER))}return!1}}}function Hr(t){let{quill:e,range:a}=t;const i=e.getLines(a);let n={};if(i.length>1){const t=i[0].formats(),e=i[i.length-1].formats();n=So.AttributeMap.diff(e,t)||{}}e.deleteText(a,tr.sources.USER),Object.keys(n).length>0&&e.formatLine(a.index,1,n,tr.sources.USER),e.setSelection(a.index,tr.sources.SILENT)}Rr.DEFAULTS=Fr;const Vr=/font-weight:\s*normal/,Br=["P","OL","UL"],Gr=t=>t&&Br.includes(t.tagName);const Wr=/\bmso-list:[^;]*ignore/i,Qr=/\bmso-list:[^;]*\bl(\d+)/i,Kr=/\bmso-list:[^;]*\blevel(\d+)/i,Zr=t=>{const e=Array.from(t.querySelectorAll("[style*=mso-list]")),a=[],i=[];e.forEach(t=>{(t.getAttribute("style")||"").match(Wr)?a.push(t):i.push(t)}),a.forEach(t=>{var e;return null===(e=t.parentNode)||void 0===e?void 0:e.removeChild(t)});const n=t.documentElement.innerHTML,o=i.map(t=>((t,e)=>{const a=t.getAttribute("style"),i=null===a||void 0===a?void 0:a.match(Qr);if(!i)return null;const n=Number(i[1]),o=null===a||void 0===a?void 0:a.match(Kr),s=o?Number(o[1]):1,r=new RegExp("@list l".concat(n,":level").concat(s,"\\s*\\{[^\\}]*mso-level-number-format:\\s*([\\w-]+)"),"i"),l=e.match(r);return{id:n,indent:s,type:l&&"bullet"===l[1]?"bullet":"ordered",element:t}})(t,n)).filter(t=>t);for(;o.length;){var s;const t=[];let e=o.shift();for(;e;){var r;t.push(e),e=o.length&&(null===(r=o[0])||void 0===r?void 0:r.element)===e.element.nextElementSibling&&o[0].id===e.id?o.shift():null}const a=document.createElement("ul");t.forEach(t=>{const e=document.createElement("li");e.setAttribute("data-list",t.type),t.indent>1&&e.setAttribute("class","ql-indent-".concat(t.indent-1)),e.innerHTML=t.element.innerHTML,a.appendChild(e)});const i=null===(s=t[0])||void 0===s?void 0:s.element,{parentNode:n}=null!==i&&void 0!==i?i:{};i&&(null===n||void 0===n||n.replaceChild(a,i)),t.slice(1).forEach(t=>{let{element:e}=t;null===n||void 0===n||n.removeChild(e)})}};const $r=[function(t){"urn:schemas-microsoft-com:office:word"===t.documentElement.getAttribute("xmlns:w")&&Zr(t)},function(t){t.querySelector('[id^="docs-internal-guid-"]')&&((t=>{Array.from(t.querySelectorAll('b[style*="font-weight"]')).filter(t=>{var e;return null===(e=t.getAttribute("style"))||void 0===e?void 0:e.match(Vr)}).forEach(e=>{var a;const i=t.createDocumentFragment();i.append(...e.childNodes),null===(a=e.parentNode)||void 0===a||a.replaceChild(i,e)})})(t),(t=>{Array.from(t.querySelectorAll("br")).filter(t=>Gr(t.previousElementSibling)&&Gr(t.nextElementSibling)).forEach(t=>{var e;null===(e=t.parentNode)||void 0===e||e.removeChild(t)})})(t))}],Xr=t=>{t.documentElement&&$r.forEach(e=>{e(t)})},Yr=vs("quill:clipboard"),Jr=[[Node.TEXT_NODE,function(t,e,a){var i;let n=t.data;if("O:P"===(null===(i=t.parentElement)||void 0===i?void 0:i.tagName))return e.insert(n.trim());if(!rl(t)){if(0===n.trim().length&&n.includes("\n")&&!function(t,e){return t.previousElementSibling&&t.nextElementSibling&&!ol(t.previousElementSibling,e)&&!ol(t.nextElementSibling,e)}(t,a))return e;n=n.replace(/[^\S\u00a0]/g," "),n=n.replace(/ {2,}/g," "),(null==t.previousSibling&&null!=t.parentElement&&ol(t.parentElement,a)||t.previousSibling instanceof Element&&ol(t.previousSibling,a))&&(n=n.replace(/^ /,"")),(null==t.nextSibling&&null!=t.parentElement&&ol(t.parentElement,a)||t.nextSibling instanceof Element&&ol(t.nextSibling,a))&&(n=n.replace(/ $/,"")),n=n.replaceAll("\xa0"," ")}return e.insert(n)}],[Node.TEXT_NODE,cl],["br",function(t,e){nl(e,"\n")||e.insert("\n");return e}],[Node.ELEMENT_NODE,cl],[Node.ELEMENT_NODE,function(t,e,a){const i=a.query(t);if(null==i)return e;if(i.prototype instanceof vo){const e={},n=i.value(t);if(null!=n)return e[i.blotName]=n,(new So).insert(e,i.formats(t,a))}else if(i.prototype instanceof po&&!nl(e,"\n")&&e.insert("\n"),"blotName"in i&&"formats"in i&&"function"===typeof i.formats)return il(e,i.blotName,i.formats(t,a),a);return e}],[Node.ELEMENT_NODE,function(t,e,a){const i=Zn.keys(t),n=to.keys(t),o=ao.keys(t),s={};return i.concat(n).concat(o).forEach(e=>{let i=a.query(e,Kn.ATTRIBUTE);null!=i&&(s[i.attrName]=i.value(t),s[i.attrName])||(i=tl[e],null==i||i.attrName!==e&&i.keyName!==e||(s[i.attrName]=i.value(t)||void 0),i=el[e],null==i||i.attrName!==e&&i.keyName!==e||(i=el[e],s[i.attrName]=i.value(t)||void 0))}),Object.entries(s).reduce((t,e)=>{let[i,n]=e;return il(t,i,n,a)},e)}],[Node.ELEMENT_NODE,function(t,e,a){var i;const n={},o=t.style||{};"italic"===o.fontStyle&&(n.italic=!0);"underline"===o.textDecoration&&(n.underline=!0);"line-through"===o.textDecoration&&(n.strike=!0);(null!==(i=o.fontWeight)&&void 0!==i&&i.startsWith("bold")||parseInt(o.fontWeight,10)>=700)&&(n.bold=!0);if(e=Object.entries(n).reduce((t,e)=>{let[i,n]=e;return il(t,i,n,a)},e),parseFloat(o.textIndent||0)>0)return(new So).insert("\t").concat(e);return e}],["li",function(t,e,a){const i=a.query(t);if(null==i||"list"!==i.blotName||!nl(e,"\n"))return e;let n=-1,o=t.parentNode;for(;null!=o;)["OL","UL"].includes(o.tagName)&&(n+=1),o=o.parentNode;return n<=0?e:e.reduce((t,e)=>e.insert?e.attributes&&"number"===typeof e.attributes.indent?t.push(e):t.insert(e.insert,Ht({indent:n},e.attributes||{})):t,new So)}],["ol, ul",function(t,e,a){const i=t;let n="OL"===i.tagName?"ordered":"bullet";const o=i.getAttribute("data-checked");o&&(n="true"===o?"checked":"unchecked");return il(e,"list",n,a)}],["pre",function(t,e,a){const i=a.query("code-block"),n=!i||!("formats"in i)||"function"!==typeof i.formats||i.formats(t,a);return il(e,"code-block",n,a)}],["tr",function(t,e,a){var i,n;const o="TABLE"===(null===(i=t.parentElement)||void 0===i?void 0:i.tagName)?t.parentElement:null===(n=t.parentElement)||void 0===n?void 0:n.parentElement;if(null!=o){return il(e,"table",Array.from(o.querySelectorAll("tr")).indexOf(t)+1,a)}return e}],["b",dl("bold")],["i",dl("italic")],["strike",dl("strike")],["style",function(){return new So}]],tl=[fr,Ar].reduce((t,e)=>(t[e.keyName]=e,t),{}),el=[pr,xr,vr,Pr,Lr,jr].reduce((t,e)=>(t[e.keyName]=e,t),{});class al extends Rs{constructor(t,e){var a;super(t,e),this.quill.root.addEventListener("copy",t=>this.onCaptureCopy(t,!1)),this.quill.root.addEventListener("cut",t=>this.onCaptureCopy(t,!0)),this.quill.root.addEventListener("paste",this.onCapturePaste.bind(this)),this.matchers=[],Jr.concat(null!==(a=this.options.matchers)&&void 0!==a?a:[]).forEach(t=>{let[e,a]=t;this.addMatcher(e,a)})}addMatcher(t,e){this.matchers.push([t,e])}convert(t){let{html:e,text:a}=t,i=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(i[Ir.blotName])return(new So).insert(a||"",{[Ir.blotName]:i[Ir.blotName]});if(!e)return(new So).insert(a||"",i);const n=this.convertHTML(e);return nl(n,"\n")&&(null==n.ops[n.ops.length-1].attributes||i.table)?n.compose((new So).retain(n.length()-1).delete(1)):n}normalizeHTML(t){Xr(t)}convertHTML(t){const e=(new DOMParser).parseFromString(t,"text/html");this.normalizeHTML(e);const a=e.body,i=new WeakMap,[n,o]=this.prepareMatching(a,i);return ll(this.quill.scroll,a,n,o,i)}dangerouslyPasteHTML(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:tr.sources.API;if("string"===typeof t){const a=this.convert({html:t,text:""});this.quill.setContents(a,e),this.quill.setSelection(0,tr.sources.SILENT)}else{const i=this.convert({html:e,text:""});this.quill.updateContents((new So).retain(t).concat(i),a),this.quill.setSelection(t+i.length(),tr.sources.SILENT)}}onCaptureCopy(t){var e,a;let i=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(t.defaultPrevented)return;t.preventDefault();const[n]=this.quill.selection.getRange();if(null==n)return;const{html:o,text:s}=this.onCopy(n,i);null===(e=t.clipboardData)||void 0===e||e.setData("text/plain",s),null===(a=t.clipboardData)||void 0===a||a.setData("text/html",o),i&&Hr({range:n,quill:this.quill})}normalizeURIList(t){return t.split(/\r?\n/).filter(t=>"#"!==t[0]).join("\n")}onCapturePaste(t){var e,a,i;if(t.defaultPrevented||!this.quill.isEnabled())return;t.preventDefault();const n=this.quill.getSelection(!0);if(null==n)return;const o=null===(e=t.clipboardData)||void 0===e?void 0:e.getData("text/html");let s=null===(a=t.clipboardData)||void 0===a?void 0:a.getData("text/plain");if(!o&&!s){var r;const e=null===(r=t.clipboardData)||void 0===r?void 0:r.getData("text/uri-list");e&&(s=this.normalizeURIList(e))}const l=Array.from((null===(i=t.clipboardData)||void 0===i?void 0:i.files)||[]);if(!o&&l.length>0)this.quill.uploader.upload(n,l);else{if(o&&l.length>0){var d;const t=(new DOMParser).parseFromString(o,"text/html");if(1===t.body.childElementCount&&"IMG"===(null===(d=t.body.firstElementChild)||void 0===d?void 0:d.tagName))return void this.quill.uploader.upload(n,l)}this.onPaste(n,{html:o,text:s})}}onCopy(t){const e=this.quill.getText(t);return{html:this.quill.getSemanticHTML(t),text:e}}onPaste(t,e){let{text:a,html:i}=e;const n=this.quill.getFormat(t.index),o=this.convert({text:a,html:i},n);Yr.log("onPaste",o,{text:a,html:i});const s=(new So).retain(t.index).delete(t.length).concat(o);this.quill.updateContents(s,tr.sources.USER),this.quill.setSelection(s.length()-t.length,tr.sources.SILENT),this.quill.scrollSelectionIntoView()}prepareMatching(t,e){const a=[],i=[];return this.matchers.forEach(n=>{const[o,s]=n;switch(o){case Node.TEXT_NODE:i.push(s);break;case Node.ELEMENT_NODE:a.push(s);break;default:Array.from(t.querySelectorAll(o)).forEach(t=>{if(e.has(t)){const a=e.get(t);null===a||void 0===a||a.push(s)}else e.set(t,[s])})}}),[a,i]}}function il(t,e,a,i){return i.query(e)?t.reduce((t,i)=>{if(!i.insert)return t;if(i.attributes&&i.attributes[e])return t.push(i);const n=a?{[e]:a}:{};return t.insert(i.insert,Ht(Ht({},n),i.attributes))},new So):t}function nl(t,e){let a="";for(let i=t.ops.length-1;i>=0&&a.length<e.length;--i){const e=t.ops[i];if("string"!==typeof e.insert)break;a=e.insert+a}return a.slice(-1*e.length)===e}function ol(t,e){if(!(t instanceof Element))return!1;const a=e.query(t);return!(a&&a.prototype instanceof vo)&&["address","article","blockquote","canvas","dd","div","dl","dt","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","header","iframe","li","main","nav","ol","output","p","pre","section","table","td","tr","ul","video"].includes(t.tagName.toLowerCase())}Ot(al,"DEFAULTS",{matchers:[]});const sl=new WeakMap;function rl(t){return null!=t&&(sl.has(t)||("PRE"===t.tagName?sl.set(t,!0):sl.set(t,rl(t.parentNode))),sl.get(t))}function ll(t,e,a,i,n){return e.nodeType===e.TEXT_NODE?i.reduce((a,i)=>i(e,a,t),new So):e.nodeType===e.ELEMENT_NODE?Array.from(e.childNodes||[]).reduce((o,s)=>{let r=ll(t,s,a,i,n);return s.nodeType===e.ELEMENT_NODE&&(r=a.reduce((e,a)=>a(s,e,t),r),r=(n.get(s)||[]).reduce((e,a)=>a(s,e,t),r)),o.concat(r)},new So):new So}function dl(t){return(e,a,i)=>il(a,t,!0,i)}function cl(t,e,a){if(!nl(e,"\n")){if(ol(t,a)&&(t.childNodes.length>0||t instanceof HTMLParagraphElement))return e.insert("\n");if(e.length()>0&&t.nextSibling){let i=t.nextSibling;for(;null!=i;){if(ol(i,a))return e.insert("\n");const t=a.query(i);if(t&&t.prototype instanceof ls)return e.insert("\n");i=i.firstChild}}}return e}class ml extends Rs{constructor(t,e){super(t,e),Ot(this,"lastRecorded",0),Ot(this,"ignoreChange",!1),Ot(this,"stack",{undo:[],redo:[]}),Ot(this,"currentRange",null),this.quill.on(tr.events.EDITOR_CHANGE,(t,e,a,i)=>{t===tr.events.SELECTION_CHANGE?e&&i!==tr.sources.SILENT&&(this.currentRange=e):t===tr.events.TEXT_CHANGE&&(this.ignoreChange||(this.options.userOnly&&i!==tr.sources.USER?this.transform(e):this.record(e,a)),this.currentRange=hl(this.currentRange,e))}),this.quill.keyboard.addBinding({key:"z",shortKey:!0},this.undo.bind(this)),this.quill.keyboard.addBinding({key:["z","Z"],shortKey:!0,shiftKey:!0},this.redo.bind(this)),/Win/i.test(navigator.platform)&&this.quill.keyboard.addBinding({key:"y",shortKey:!0},this.redo.bind(this)),this.quill.root.addEventListener("beforeinput",t=>{"historyUndo"===t.inputType?(this.undo(),t.preventDefault()):"historyRedo"===t.inputType&&(this.redo(),t.preventDefault())})}change(t,e){if(0===this.stack[t].length)return;const a=this.stack[t].pop();if(!a)return;const i=this.quill.getContents(),n=a.delta.invert(i);this.stack[e].push({delta:n,range:hl(a.range,n)}),this.lastRecorded=0,this.ignoreChange=!0,this.quill.updateContents(a.delta,tr.sources.USER),this.ignoreChange=!1,this.restoreSelection(a)}clear(){this.stack={undo:[],redo:[]}}cutoff(){this.lastRecorded=0}record(t,e){if(0===t.ops.length)return;this.stack.redo=[];let a=t.invert(e),i=this.currentRange;const n=Date.now();if(this.lastRecorded+this.options.delay>n&&this.stack.undo.length>0){const t=this.stack.undo.pop();t&&(a=a.compose(t.delta),i=t.range)}else this.lastRecorded=n;0!==a.length()&&(this.stack.undo.push({delta:a,range:i}),this.stack.undo.length>this.options.maxStack&&this.stack.undo.shift())}redo(){this.change("redo","undo")}transform(t){ul(this.stack.undo,t),ul(this.stack.redo,t)}undo(){this.change("undo","redo")}restoreSelection(t){if(t.range)this.quill.setSelection(t.range,tr.sources.USER);else{const e=function(t,e){const a=e.reduce((t,e)=>t+(e.delete||0),0);let i=e.length()-a;(function(t,e){const a=e.ops[e.ops.length-1];if(null==a)return!1;if(null!=a.insert)return"string"===typeof a.insert&&a.insert.endsWith("\n");if(null!=a.attributes)return Object.keys(a.attributes).some(e=>null!=t.query(e,Kn.BLOCK));return!1})(t,e)&&(i-=1);return i}(this.quill.scroll,t.delta);this.quill.setSelection(e,tr.sources.USER)}}}function ul(t,e){let a=e;for(let i=t.length-1;i>=0;i-=1){const e=t[i];t[i]={delta:a.transform(e.delta,!0),range:e.range&&hl(e.range,a)},a=e.delta.transform(a),0===t[i].delta.length()&&t.splice(i,1)}}function hl(t,e){if(!t)return t;const a=e.transformPosition(t.index);return{index:a,length:e.transformPosition(t.index+t.length)-a}}Ot(ml,"DEFAULTS",{delay:1e3,maxStack:100,userOnly:!1});class fl extends Rs{constructor(t,e){super(t,e),t.root.addEventListener("drop",e=>{e.preventDefault();let a=null;if(document.caretRangeFromPoint)a=document.caretRangeFromPoint(e.clientX,e.clientY);else if(document.caretPositionFromPoint){const t=document.caretPositionFromPoint(e.clientX,e.clientY);a=document.createRange(),a.setStart(t.offsetNode,t.offset),a.setEnd(t.offsetNode,t.offset)}const i=a&&t.selection.normalizeNative(a);if(i){var n;const a=t.selection.normalizedToRange(i);null!==(n=e.dataTransfer)&&void 0!==n&&n.files&&this.upload(a,e.dataTransfer.files)}})}upload(t,e){const a=[];Array.from(e).forEach(t=>{var e;t&&null!==(e=this.options.mimetypes)&&void 0!==e&&e.includes(t.type)&&a.push(t)}),a.length>0&&this.options.handler.call(this,t,a)}}fl.DEFAULTS={mimetypes:["image/png","image/jpeg"],handler(t,e){if(!this.quill.scroll.query("image"))return;const a=e.map(t=>new Promise(e=>{const a=new FileReader;a.onload=()=>{e(a.result)},a.readAsDataURL(t)}));Promise.all(a).then(e=>{const a=e.reduce((t,e)=>t.insert({image:e}),(new So).retain(t.index).delete(t.length));this.quill.updateContents(a,ks.sources.USER),this.quill.setSelection(t.index+e.length,ks.sources.SILENT)})}};const gl=fl,pl=["insertText","insertReplacementText"];const yl=class extends Rs{constructor(t,e){super(t,e),t.root.addEventListener("beforeinput",t=>{this.handleBeforeInput(t)}),/Android/i.test(navigator.userAgent)||t.on(tr.events.COMPOSITION_BEFORE_START,()=>{this.handleCompositionStart()})}deleteRange(t){Hr({range:t,quill:this.quill})}replaceText(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"";if(0===t.length)return!1;if(e){const a=this.quill.getFormat(t.index,1);this.deleteRange(t),this.quill.updateContents((new So).retain(t.index).insert(e,a),tr.sources.USER)}else this.deleteRange(t);return this.quill.setSelection(t.index+e.length,0,tr.sources.SILENT),!0}handleBeforeInput(t){if(this.quill.composition.isComposing||t.defaultPrevented||!pl.includes(t.inputType))return;const e=t.getTargetRanges?t.getTargetRanges()[0]:null;if(!e||!0===e.collapsed)return;const a=function(t){var e;if("string"===typeof t.data)return t.data;if(null!==(e=t.dataTransfer)&&void 0!==e&&e.types.includes("text/plain"))return t.dataTransfer.getData("text/plain");return null}(t);if(null==a)return;const i=this.quill.selection.normalizeNative(e),n=i?this.quill.selection.normalizedToRange(i):null;n&&this.replaceText(n,a)&&t.preventDefault()}handleCompositionStart(){const t=this.quill.getSelection();t&&this.replaceText(t)}},bl=/Mac/i.test(navigator.platform);const vl=class extends Rs{constructor(t,e){super(t,e),Ot(this,"isListening",!1),Ot(this,"selectionChangeDeadline",0),this.handleArrowKeys(),this.handleNavigationShortcuts()}handleArrowKeys(){this.quill.keyboard.addBinding({key:["ArrowLeft","ArrowRight"],offset:0,shiftKey:null,handler(t,e){let{line:a,event:i}=e;if(!(a instanceof uo)||!a.uiNode)return!0;const n="rtl"===getComputedStyle(a.domNode).direction;return!!(n&&"ArrowRight"!==i.key||!n&&"ArrowLeft"!==i.key)||(this.quill.setSelection(t.index-1,t.length+(i.shiftKey?1:0),tr.sources.USER),!1)}})}handleNavigationShortcuts(){this.quill.root.addEventListener("keydown",t=>{!t.defaultPrevented&&(t=>"ArrowLeft"===t.key||"ArrowRight"===t.key||"ArrowUp"===t.key||"ArrowDown"===t.key||"Home"===t.key||!(!bl||"a"!==t.key||!0!==t.ctrlKey))(t)&&this.ensureListeningToSelectionChange()})}ensureListeningToSelectionChange(){if(this.selectionChangeDeadline=Date.now()+100,this.isListening)return;this.isListening=!0;document.addEventListener("selectionchange",()=>{this.isListening=!1,Date.now()<=this.selectionChangeDeadline&&this.handleSelectionChange()},{once:!0})}handleSelectionChange(){const t=document.getSelection();if(!t)return;const e=t.getRangeAt(0);if(!0!==e.collapsed||0!==e.startOffset)return;const a=this.quill.scroll.find(e.startContainer);if(!(a instanceof uo)||!a.uiNode)return;const i=document.createRange();i.setStartAfter(a.uiNode),i.setEndAfter(a.uiNode),t.removeAllRanges(),t.addRange(i)}};tr.register({"blots/block":rs,"blots/block/embed":ls,"blots/break":es,"blots/container":rr,"blots/cursor":us,"blots/embed":qs,"blots/inline":ss,"blots/scroll":ur,"blots/text":as,"modules/clipboard":al,"modules/history":ml,"modules/keyboard":Rr,"modules/uploader":gl,"modules/input":yl,"modules/uiNode":vl});const wl=tr;const xl=new class extends to{add(t,e){let a=0;if("+1"===e||"-1"===e){const i=this.value(t)||0;a="+1"===e?i+1:i-1}else"number"===typeof e&&(a=e);return 0===a?(this.remove(t),!0):super.add(t,a.toString())}canAdd(t,e){return super.canAdd(t,e)||super.canAdd(t,parseInt(e,10))}value(t){return parseInt(super.value(t),10)||void 0}}("indent","ql-indent",{scope:Kn.BLOCK,whitelist:[1,2,3,4,5,6,7,8]}),kl=xl;class Il extends rs{}Ot(Il,"blotName","blockquote"),Ot(Il,"tagName","blockquote");const Cl=Il;class Sl extends rs{static formats(t){return this.tagName.indexOf(t.tagName)+1}}Ot(Sl,"blotName","header"),Ot(Sl,"tagName",["H1","H2","H3","H4","H5","H6"]);const Al=Sl;class Tl extends rr{}Tl.blotName="list-container",Tl.tagName="OL";class Pl extends rs{static create(t){const e=super.create();return e.setAttribute("data-list",t),e}static formats(t){return t.getAttribute("data-list")||void 0}static register(){tr.register(Tl)}constructor(t,e){super(t,e);const a=e.ownerDocument.createElement("span"),i=a=>{if(!t.isEnabled())return;const i=this.statics.formats(e,t);"checked"===i?(this.format("list","unchecked"),a.preventDefault()):"unchecked"===i&&(this.format("list","checked"),a.preventDefault())};a.addEventListener("mousedown",i),a.addEventListener("touchstart",i),this.attachUI(a)}format(t,e){t===this.statics.blotName&&e?this.domNode.setAttribute("data-list",e):super.format(t,e)}}Pl.blotName="list",Pl.tagName="LI",Tl.allowedChildren=[Pl],Pl.requiredContainer=Tl;class Dl extends ss{static create(){return super.create()}static formats(){return!0}optimize(t){super.optimize(t),this.domNode.tagName!==this.statics.tagName[0]&&this.replaceWith(this.statics.blotName)}}Ot(Dl,"blotName","bold"),Ot(Dl,"tagName",["STRONG","B"]);const Nl=Dl;class Ll extends Nl{}Ot(Ll,"blotName","italic"),Ot(Ll,"tagName",["EM","I"]);const El=Ll;class jl extends ss{static create(t){const e=super.create(t);return e.setAttribute("href",this.sanitize(t)),e.setAttribute("rel","noopener noreferrer"),e.setAttribute("target","_blank"),e}static formats(t){return t.getAttribute("href")}static sanitize(t){return Ml(t,this.PROTOCOL_WHITELIST)?t:this.SANITIZED_URL}format(t,e){t===this.statics.blotName&&e?this.domNode.setAttribute("href",this.constructor.sanitize(e)):super.format(t,e)}}function Ml(t,e){const a=document.createElement("a");a.href=t;const i=a.href.slice(0,a.href.indexOf(":"));return e.indexOf(i)>-1}Ot(jl,"blotName","link"),Ot(jl,"tagName","A"),Ot(jl,"SANITIZED_URL","about:blank"),Ot(jl,"PROTOCOL_WHITELIST",["http","https","mailto","tel","sms"]);class zl extends ss{static create(t){return"super"===t?document.createElement("sup"):"sub"===t?document.createElement("sub"):super.create(t)}static formats(t){return"SUB"===t.tagName?"sub":"SUP"===t.tagName?"super":void 0}}Ot(zl,"blotName","script"),Ot(zl,"tagName",["SUB","SUP"]);const Rl=zl;class Fl extends Nl{}Ot(Fl,"blotName","strike"),Ot(Fl,"tagName",["S","STRIKE"]);const ql=Fl;class _l extends ss{}Ot(_l,"blotName","underline"),Ot(_l,"tagName","U");const Ol=_l;class Ul extends qs{static create(t){if(null==window.katex)throw new Error("Formula module requires KaTeX.");const e=super.create(t);return"string"===typeof t&&(window.katex.render(t,e,{throwOnError:!1,errorColor:"#f00"}),e.setAttribute("data-value",t)),e}static value(t){return t.getAttribute("data-value")}html(){const{formula:t}=this.value();return"<span>".concat(t,"</span>")}}Ot(Ul,"blotName","formula"),Ot(Ul,"className","ql-formula"),Ot(Ul,"tagName","SPAN");const Hl=Ul,Vl=["alt","height","width"];class Bl extends vo{static create(t){const e=super.create(t);return"string"===typeof t&&e.setAttribute("src",this.sanitize(t)),e}static formats(t){return Vl.reduce((e,a)=>(t.hasAttribute(a)&&(e[a]=t.getAttribute(a)),e),{})}static match(t){return/\.(jpe?g|gif|png)$/.test(t)||/^data:image\/.+;base64/.test(t)}static sanitize(t){return Ml(t,["http","https","data"])?t:"//:0"}static value(t){return t.getAttribute("src")}format(t,e){Vl.indexOf(t)>-1?e?this.domNode.setAttribute(t,e):this.domNode.removeAttribute(t):super.format(t,e)}}Ot(Bl,"blotName","image"),Ot(Bl,"tagName","IMG");const Gl=Bl,Wl=["height","width"];class Ql extends ls{static create(t){const e=super.create(t);return e.setAttribute("frameborder","0"),e.setAttribute("allowfullscreen","true"),e.setAttribute("src",this.sanitize(t)),e}static formats(t){return Wl.reduce((e,a)=>(t.hasAttribute(a)&&(e[a]=t.getAttribute(a)),e),{})}static sanitize(t){return jl.sanitize(t)}static value(t){return t.getAttribute("src")}format(t,e){Wl.indexOf(t)>-1?e?this.domNode.setAttribute(t,e):this.domNode.removeAttribute(t):super.format(t,e)}html(){const{video:t}=this.value();return'<a href="'.concat(t,'">').concat(t,"</a>")}}Ot(Ql,"blotName","video"),Ot(Ql,"className","ql-video"),Ot(Ql,"tagName","IFRAME");const Kl=Ql,Zl=new to("code-token","hljs",{scope:Kn.INLINE});class $l extends ss{static formats(t,e){for(;null!=t&&t!==e.domNode;){if(t.classList&&t.classList.contains(Ir.className))return super.formats(t,e);t=t.parentNode}}constructor(t,e,a){super(t,e,a),Zl.add(this.domNode,a)}format(t,e){t!==$l.blotName?super.format(t,e):e?Zl.add(this.domNode,e):(Zl.remove(this.domNode),this.domNode.classList.remove(this.statics.className))}optimize(){super.optimize(...arguments),Zl.value(this.domNode)||this.unwrap()}}$l.blotName="code-token",$l.className="ql-token";class Xl extends Ir{static create(t){const e=super.create(t);return"string"===typeof t&&e.setAttribute("data-language",t),e}static formats(t){return t.getAttribute("data-language")||"plain"}static register(){}format(t,e){t===this.statics.blotName&&e?this.domNode.setAttribute("data-language",e):super.format(t,e)}replaceWith(t,e){return this.formatAt(0,this.length(),$l.blotName,!1),super.replaceWith(t,e)}}class Yl extends kr{attach(){super.attach(),this.forceNext=!1,this.scroll.emitMount(this)}format(t,e){t===Xl.blotName&&(this.forceNext=!0,this.children.forEach(a=>{a.format(t,e)}))}formatAt(t,e,a,i){a===Xl.blotName&&(this.forceNext=!0),super.formatAt(t,e,a,i)}highlight(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(null==this.children.head)return;const a=Array.from(this.domNode.childNodes).filter(t=>t!==this.uiNode),i="".concat(a.map(t=>t.textContent).join("\n"),"\n"),n=Xl.formats(this.children.head.domNode);if(e||this.forceNext||this.cachedText!==i){if(i.trim().length>0||null==this.cachedText){const e=this.children.reduce((t,e)=>t.concat(ds(e,!1)),new So),a=t(i,n);e.diff(a).reduce((t,e)=>{let{retain:a,attributes:i}=e;return a?(i&&Object.keys(i).forEach(e=>{[Xl.blotName,$l.blotName].includes(e)&&this.formatAt(t,a,e,i[e])}),t+a):t},0)}this.cachedText=i,this.forceNext=!1}}html(t,e){const[a]=this.children.find(t),i=a?Xl.formats(a.domNode):"plain";return'<pre data-language="'.concat(i,'">\n').concat(ns(this.code(t,e)),"\n</pre>")}optimize(t){if(super.optimize(t),null!=this.parent&&null!=this.children.head&&null!=this.uiNode){const t=Xl.formats(this.children.head.domNode);t!==this.uiNode.value&&(this.uiNode.value=t)}}}Yl.allowedChildren=[Xl],Xl.requiredContainer=Yl,Xl.allowedChildren=[$l,us,as,es];class Jl extends Rs{static register(){tr.register($l,!0),tr.register(Xl,!0),tr.register(Yl,!0)}constructor(t,e){if(super(t,e),null==this.options.hljs)throw new Error("Syntax module requires highlight.js. Please include the library on the page before Quill.");this.languages=this.options.languages.reduce((t,e)=>{let{key:a}=e;return t[a]=!0,t},{}),this.highlightBlot=this.highlightBlot.bind(this),this.initListener(),this.initTimer()}initListener(){this.quill.on(tr.events.SCROLL_BLOT_MOUNT,t=>{if(!(t instanceof Yl))return;const e=this.quill.root.ownerDocument.createElement("select");this.options.languages.forEach(t=>{let{key:a,label:i}=t;const n=e.ownerDocument.createElement("option");n.textContent=i,n.setAttribute("value",a),e.appendChild(n)}),e.addEventListener("change",()=>{t.format(Xl.blotName,e.value),this.quill.root.focus(),this.highlight(t,!0)}),null==t.uiNode&&(t.attachUI(e),t.children.head&&(e.value=Xl.formats(t.children.head.domNode)))})}initTimer(){let t=null;this.quill.on(tr.events.SCROLL_OPTIMIZE,()=>{t&&clearTimeout(t),t=setTimeout(()=>{this.highlight(),t=null},this.options.interval)})}highlight(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(this.quill.selection.composing)return;this.quill.update(tr.sources.USER);const a=this.quill.getSelection();(null==t?this.quill.scroll.descendants(Yl):[t]).forEach(t=>{t.highlight(this.highlightBlot,e)}),this.quill.update(tr.sources.SILENT),null!=a&&this.quill.setSelection(a,tr.sources.SILENT)}highlightBlot(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"plain";if(e=this.languages[e]?e:"plain","plain"===e)return ns(t).split("\n").reduce((t,a,i)=>(0!==i&&t.insert("\n",{[Ir.blotName]:e}),t.insert(a)),new So);const a=this.quill.root.ownerDocument.createElement("div");return a.classList.add(Ir.className),a.innerHTML=((t,e,a)=>{if("string"===typeof t.versionString){const i=t.versionString.split(".")[0];if(parseInt(i,10)>=11)return t.highlight(a,{language:e}).value}return t.highlight(e,a).value})(this.options.hljs,e,t),ll(this.quill.scroll,a,[(t,e)=>{const a=Zl.value(t);return a?e.compose((new So).retain(e.length(),{[$l.blotName]:a})):e}],[(t,a)=>t.data.split("\n").reduce((t,a,i)=>(0!==i&&t.insert("\n",{[Ir.blotName]:e}),t.insert(a)),a)],new WeakMap)}}Jl.DEFAULTS={hljs:window.hljs,interval:1e3,languages:[{key:"plain",label:"Plain"},{key:"bash",label:"Bash"},{key:"cpp",label:"C++"},{key:"cs",label:"C#"},{key:"css",label:"CSS"},{key:"diff",label:"Diff"},{key:"xml",label:"HTML/XML"},{key:"java",label:"Java"},{key:"javascript",label:"JavaScript"},{key:"markdown",label:"Markdown"},{key:"php",label:"PHP"},{key:"python",label:"Python"},{key:"ruby",label:"Ruby"},{key:"sql",label:"SQL"}]};class td extends rs{static create(t){const e=super.create();return t?e.setAttribute("data-row",t):e.setAttribute("data-row",nd()),e}static formats(t){if(t.hasAttribute("data-row"))return t.getAttribute("data-row")}cellOffset(){return this.parent?this.parent.children.indexOf(this):-1}format(t,e){t===td.blotName&&e?this.domNode.setAttribute("data-row",e):super.format(t,e)}row(){return this.parent}rowOffset(){return this.row()?this.row().rowOffset():-1}table(){return this.row()&&this.row().table()}}Ot(td,"blotName","table"),Ot(td,"tagName","TD");class ed extends rr{checkMerge(){if(super.checkMerge()&&null!=this.next.children.head){const t=this.children.head.formats(),e=this.children.tail.formats(),a=this.next.children.head.formats(),i=this.next.children.tail.formats();return t.table===e.table&&t.table===a.table&&t.table===i.table}return!1}optimize(t){super.optimize(t),this.children.forEach(t=>{if(null==t.next)return;const e=t.formats(),a=t.next.formats();if(e.table!==a.table){const e=this.splitAfter(t);e&&e.optimize(),this.prev&&this.prev.optimize()}})}rowOffset(){return this.parent?this.parent.children.indexOf(this):-1}table(){return this.parent&&this.parent.parent}}Ot(ed,"blotName","table-row"),Ot(ed,"tagName","TR");class ad extends rr{}Ot(ad,"blotName","table-body"),Ot(ad,"tagName","TBODY");class id extends rr{balanceCells(){const t=this.descendants(ed),e=t.reduce((t,e)=>Math.max(e.children.length,t),0);t.forEach(t=>{new Array(e-t.children.length).fill(0).forEach(()=>{let e;null!=t.children.head&&(e=td.formats(t.children.head.domNode));const a=this.scroll.create(td.blotName,e);t.appendChild(a),a.optimize()})})}cells(t){return this.rows().map(e=>e.children.at(t))}deleteColumn(t){const[e]=this.descendant(ad);null!=e&&null!=e.children.head&&e.children.forEach(e=>{const a=e.children.at(t);null!=a&&a.remove()})}insertColumn(t){const[e]=this.descendant(ad);null!=e&&null!=e.children.head&&e.children.forEach(e=>{const a=e.children.at(t),i=td.formats(e.children.head.domNode),n=this.scroll.create(td.blotName,i);e.insertBefore(n,a)})}insertRow(t){const[e]=this.descendant(ad);if(null==e||null==e.children.head)return;const a=nd(),i=this.scroll.create(ed.blotName);e.children.head.children.forEach(()=>{const t=this.scroll.create(td.blotName,a);i.appendChild(t)});const n=e.children.at(t);e.insertBefore(i,n)}rows(){const t=this.children.head;return null==t?[]:t.children.map(t=>t)}}function nd(){const t=Math.random().toString(36).slice(2,6);return"row-".concat(t)}Ot(id,"blotName","table-container"),Ot(id,"tagName","TABLE"),id.allowedChildren=[ad],ad.requiredContainer=id,ad.allowedChildren=[ed],ed.requiredContainer=ad,ed.allowedChildren=[td],td.requiredContainer=ed;const od=class extends Rs{static register(){tr.register(td),tr.register(ed),tr.register(ad),tr.register(id)}constructor(){super(...arguments),this.listenBalanceCells()}balanceTables(){this.quill.scroll.descendants(id).forEach(t=>{t.balanceCells()})}deleteColumn(){const[t,,e]=this.getTable();null!=e&&(t.deleteColumn(e.cellOffset()),this.quill.update(tr.sources.USER))}deleteRow(){const[,t]=this.getTable();null!=t&&(t.remove(),this.quill.update(tr.sources.USER))}deleteTable(){const[t]=this.getTable();if(null==t)return;const e=t.offset();t.remove(),this.quill.update(tr.sources.USER),this.quill.setSelection(e,tr.sources.SILENT)}getTable(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.quill.getSelection();if(null==t)return[null,null,null,-1];const[e,a]=this.quill.getLine(t.index);if(null==e||e.statics.blotName!==td.blotName)return[null,null,null,-1];const i=e.parent;return[i.parent.parent,i,e,a]}insertColumn(t){const e=this.quill.getSelection();if(!e)return;const[a,i,n]=this.getTable(e);if(null==n)return;const o=n.cellOffset();a.insertColumn(o+t),this.quill.update(tr.sources.USER);let s=i.rowOffset();0===t&&(s+=1),this.quill.setSelection(e.index+s,e.length,tr.sources.SILENT)}insertColumnLeft(){this.insertColumn(0)}insertColumnRight(){this.insertColumn(1)}insertRow(t){const e=this.quill.getSelection();if(!e)return;const[a,i,n]=this.getTable(e);if(null==n)return;const o=i.rowOffset();a.insertRow(o+t),this.quill.update(tr.sources.USER),t>0?this.quill.setSelection(e,tr.sources.SILENT):this.quill.setSelection(e.index+i.children.length,e.length,tr.sources.SILENT)}insertRowAbove(){this.insertRow(0)}insertRowBelow(){this.insertRow(1)}insertTable(t,e){const a=this.quill.getSelection();if(null==a)return;const i=new Array(t).fill(0).reduce(t=>{const a=new Array(e).fill("\n").join("");return t.insert(a,{table:nd()})},(new So).retain(a.index));this.quill.updateContents(i,tr.sources.USER),this.quill.setSelection(a.index,tr.sources.SILENT),this.balanceTables()}listenBalanceCells(){this.quill.on(tr.events.SCROLL_OPTIMIZE,t=>{t.some(t=>!!["TD","TR","TBODY","TABLE"].includes(t.target.tagName)&&(this.quill.once(tr.events.TEXT_CHANGE,(t,e,a)=>{a===tr.sources.USER&&this.balanceTables()}),!0))})}},sd=vs("quill:toolbar");class rd extends Rs{constructor(t,e){if(super(t,e),Array.isArray(this.options.container)){var a;const e=document.createElement("div");e.setAttribute("role","toolbar"),function(t,e){Array.isArray(e[0])||(e=[e]);e.forEach(e=>{const a=document.createElement("span");a.classList.add("ql-formats"),e.forEach(t=>{if("string"===typeof t)ld(a,t);else{const e=Object.keys(t)[0],i=t[e];Array.isArray(i)?function(t,e,a){const i=document.createElement("select");i.classList.add("ql-".concat(e)),a.forEach(t=>{const e=document.createElement("option");!1!==t?e.setAttribute("value",String(t)):e.setAttribute("selected","selected"),i.appendChild(e)}),t.appendChild(i)}(a,e,i):ld(a,e,i)}}),t.appendChild(a)})}(e,this.options.container),null===(a=t.container)||void 0===a||null===(a=a.parentNode)||void 0===a||a.insertBefore(e,t.container),this.container=e}else"string"===typeof this.options.container?this.container=document.querySelector(this.options.container):this.container=this.options.container;this.container instanceof HTMLElement?(this.container.classList.add("ql-toolbar"),this.controls=[],this.handlers={},this.options.handlers&&Object.keys(this.options.handlers).forEach(t=>{var e;const a=null===(e=this.options.handlers)||void 0===e?void 0:e[t];a&&this.addHandler(t,a)}),Array.from(this.container.querySelectorAll("button, select")).forEach(t=>{this.attach(t)}),this.quill.on(tr.events.EDITOR_CHANGE,()=>{const[t]=this.quill.selection.getRange();this.update(t)})):sd.error("Container required for toolbar",this.options)}addHandler(t,e){this.handlers[t]=e}attach(t){let e=Array.from(t.classList).find(t=>0===t.indexOf("ql-"));if(!e)return;if(e=e.slice(3),"BUTTON"===t.tagName&&t.setAttribute("type","button"),null==this.handlers[e]&&null==this.quill.scroll.query(e))return void sd.warn("ignoring attaching to nonexistent format",e,t);const a="SELECT"===t.tagName?"change":"click";t.addEventListener(a,a=>{let i;if("SELECT"===t.tagName){if(t.selectedIndex<0)return;const e=t.options[t.selectedIndex];i=!e.hasAttribute("selected")&&(e.value||!1)}else i=!t.classList.contains("ql-active")&&(t.value||!t.hasAttribute("value")),a.preventDefault();this.quill.focus();const[n]=this.quill.selection.getRange();if(null!=this.handlers[e])this.handlers[e].call(this,i);else if(this.quill.scroll.query(e).prototype instanceof vo){if(i=prompt("Enter ".concat(e)),!i)return;this.quill.updateContents((new So).retain(n.index).delete(n.length).insert({[e]:i}),tr.sources.USER)}else this.quill.format(e,i,tr.sources.USER);this.update(n)}),this.controls.push([e,t])}update(t){const e=null==t?{}:this.quill.getFormat(t);this.controls.forEach(a=>{const[i,n]=a;if("SELECT"===n.tagName){let a=null;if(null==t)a=null;else if(null==e[i])a=n.querySelector("option[selected]");else if(!Array.isArray(e[i])){let t=e[i];"string"===typeof t&&(t=t.replace(/"/g,'\\"')),a=n.querySelector('option[value="'.concat(t,'"]'))}null==a?(n.value="",n.selectedIndex=-1):a.selected=!0}else if(null==t)n.classList.remove("ql-active"),n.setAttribute("aria-pressed","false");else if(n.hasAttribute("value")){const t=e[i],a=t===n.getAttribute("value")||null!=t&&t.toString()===n.getAttribute("value")||null==t&&!n.getAttribute("value");n.classList.toggle("ql-active",a),n.setAttribute("aria-pressed",a.toString())}else{const t=null!=e[i];n.classList.toggle("ql-active",t),n.setAttribute("aria-pressed",t.toString())}})}}function ld(t,e,a){const i=document.createElement("button");i.setAttribute("type","button"),i.classList.add("ql-".concat(e)),i.setAttribute("aria-pressed","false"),null!=a?(i.value=a,i.setAttribute("aria-label","".concat(e,": ").concat(a))):i.setAttribute("aria-label",e),t.appendChild(i)}rd.DEFAULTS={},rd.DEFAULTS={container:null,handlers:{clean(){const t=this.quill.getSelection();if(null!=t)if(0===t.length){const t=this.quill.getFormat();Object.keys(t).forEach(t=>{null!=this.quill.scroll.query(t,Kn.INLINE)&&this.quill.format(t,!1,tr.sources.USER)})}else this.quill.removeFormat(t.index,t.length,tr.sources.USER)},direction(t){const{align:e}=this.quill.getFormat();"rtl"===t&&null==e?this.quill.format("align","right",tr.sources.USER):t||"right"!==e||this.quill.format("align",!1,tr.sources.USER),this.quill.format("direction",t,tr.sources.USER)},indent(t){const e=this.quill.getSelection(),a=this.quill.getFormat(e),i=parseInt(a.indent||0,10);if("+1"===t||"-1"===t){let e="+1"===t?1:-1;"rtl"===a.direction&&(e*=-1),this.quill.format("indent",i+e,tr.sources.USER)}},link(t){!0===t&&(t=prompt("Enter link URL:")),this.quill.format("link",t,tr.sources.USER)},list(t){const e=this.quill.getSelection(),a=this.quill.getFormat(e);"check"===t?"checked"===a.list||"unchecked"===a.list?this.quill.format("list",!1,tr.sources.USER):this.quill.format("list","unchecked",tr.sources.USER):this.quill.format("list",t,tr.sources.USER)}}};const dd='<svg viewbox="0 0 18 18"><polyline class="ql-even ql-stroke" points="5 7 3 9 5 11"/><polyline class="ql-even ql-stroke" points="13 7 15 9 13 11"/><line class="ql-stroke" x1="10" x2="8" y1="5" y2="13"/></svg>',cd={align:{"":'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="3" x2="15" y1="9" y2="9"/><line class="ql-stroke" x1="3" x2="13" y1="14" y2="14"/><line class="ql-stroke" x1="3" x2="9" y1="4" y2="4"/></svg>',center:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="15" x2="3" y1="9" y2="9"/><line class="ql-stroke" x1="14" x2="4" y1="14" y2="14"/><line class="ql-stroke" x1="12" x2="6" y1="4" y2="4"/></svg>',right:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="15" x2="3" y1="9" y2="9"/><line class="ql-stroke" x1="15" x2="5" y1="14" y2="14"/><line class="ql-stroke" x1="15" x2="9" y1="4" y2="4"/></svg>',justify:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="15" x2="3" y1="9" y2="9"/><line class="ql-stroke" x1="15" x2="3" y1="14" y2="14"/><line class="ql-stroke" x1="15" x2="3" y1="4" y2="4"/></svg>'},background:'<svg viewbox="0 0 18 18"><g class="ql-fill ql-color-label"><polygon points="6 6.868 6 6 5 6 5 7 5.942 7 6 6.868"/><rect height="1" width="1" x="4" y="4"/><polygon points="6.817 5 6 5 6 6 6.38 6 6.817 5"/><rect height="1" width="1" x="2" y="6"/><rect height="1" width="1" x="3" y="5"/><rect height="1" width="1" x="4" y="7"/><polygon points="4 11.439 4 11 3 11 3 12 3.755 12 4 11.439"/><rect height="1" width="1" x="2" y="12"/><rect height="1" width="1" x="2" y="9"/><rect height="1" width="1" x="2" y="15"/><polygon points="4.63 10 4 10 4 11 4.192 11 4.63 10"/><rect height="1" width="1" x="3" y="8"/><path d="M10.832,4.2L11,4.582V4H10.708A1.948,1.948,0,0,1,10.832,4.2Z"/><path d="M7,4.582L7.168,4.2A1.929,1.929,0,0,1,7.292,4H7V4.582Z"/><path d="M8,13H7.683l-0.351.8a1.933,1.933,0,0,1-.124.2H8V13Z"/><rect height="1" width="1" x="12" y="2"/><rect height="1" width="1" x="11" y="3"/><path d="M9,3H8V3.282A1.985,1.985,0,0,1,9,3Z"/><rect height="1" width="1" x="2" y="3"/><rect height="1" width="1" x="6" y="2"/><rect height="1" width="1" x="3" y="2"/><rect height="1" width="1" x="5" y="3"/><rect height="1" width="1" x="9" y="2"/><rect height="1" width="1" x="15" y="14"/><polygon points="13.447 10.174 13.469 10.225 13.472 10.232 13.808 11 14 11 14 10 13.37 10 13.447 10.174"/><rect height="1" width="1" x="13" y="7"/><rect height="1" width="1" x="15" y="5"/><rect height="1" width="1" x="14" y="6"/><rect height="1" width="1" x="15" y="8"/><rect height="1" width="1" x="14" y="9"/><path d="M3.775,14H3v1H4V14.314A1.97,1.97,0,0,1,3.775,14Z"/><rect height="1" width="1" x="14" y="3"/><polygon points="12 6.868 12 6 11.62 6 12 6.868"/><rect height="1" width="1" x="15" y="2"/><rect height="1" width="1" x="12" y="5"/><rect height="1" width="1" x="13" y="4"/><polygon points="12.933 9 13 9 13 8 12.495 8 12.933 9"/><rect height="1" width="1" x="9" y="14"/><rect height="1" width="1" x="8" y="15"/><path d="M6,14.926V15H7V14.316A1.993,1.993,0,0,1,6,14.926Z"/><rect height="1" width="1" x="5" y="15"/><path d="M10.668,13.8L10.317,13H10v1h0.792A1.947,1.947,0,0,1,10.668,13.8Z"/><rect height="1" width="1" x="11" y="15"/><path d="M14.332,12.2a1.99,1.99,0,0,1,.166.8H15V12H14.245Z"/><rect height="1" width="1" x="14" y="15"/><rect height="1" width="1" x="15" y="11"/></g><polyline class="ql-stroke" points="5.5 13 9 5 12.5 13"/><line class="ql-stroke" x1="11.63" x2="6.38" y1="11" y2="11"/></svg>',blockquote:'<svg viewbox="0 0 18 18"><rect class="ql-fill ql-stroke" height="3" width="3" x="4" y="5"/><rect class="ql-fill ql-stroke" height="3" width="3" x="11" y="5"/><path class="ql-even ql-fill ql-stroke" d="M7,8c0,4.031-3,5-3,5"/><path class="ql-even ql-fill ql-stroke" d="M14,8c0,4.031-3,5-3,5"/></svg>',bold:'<svg viewbox="0 0 18 18"><path class="ql-stroke" d="M5,4H9.5A2.5,2.5,0,0,1,12,6.5v0A2.5,2.5,0,0,1,9.5,9H5A0,0,0,0,1,5,9V4A0,0,0,0,1,5,4Z"/><path class="ql-stroke" d="M5,9h5.5A2.5,2.5,0,0,1,13,11.5v0A2.5,2.5,0,0,1,10.5,14H5a0,0,0,0,1,0,0V9A0,0,0,0,1,5,9Z"/></svg>',clean:'<svg class="" viewbox="0 0 18 18"><line class="ql-stroke" x1="5" x2="13" y1="3" y2="3"/><line class="ql-stroke" x1="6" x2="9.35" y1="12" y2="3"/><line class="ql-stroke" x1="11" x2="15" y1="11" y2="15"/><line class="ql-stroke" x1="15" x2="11" y1="11" y2="15"/><rect class="ql-fill" height="1" rx="0.5" ry="0.5" width="7" x="2" y="14"/></svg>',code:dd,"code-block":dd,color:'<svg viewbox="0 0 18 18"><line class="ql-color-label ql-stroke ql-transparent" x1="3" x2="15" y1="15" y2="15"/><polyline class="ql-stroke" points="5.5 11 9 3 12.5 11"/><line class="ql-stroke" x1="11.63" x2="6.38" y1="9" y2="9"/></svg>',direction:{"":'<svg viewbox="0 0 18 18"><polygon class="ql-stroke ql-fill" points="3 11 5 9 3 7 3 11"/><line class="ql-stroke ql-fill" x1="15" x2="11" y1="4" y2="4"/><path class="ql-fill" d="M11,3a3,3,0,0,0,0,6h1V3H11Z"/><rect class="ql-fill" height="11" width="1" x="11" y="4"/><rect class="ql-fill" height="11" width="1" x="13" y="4"/></svg>',rtl:'<svg viewbox="0 0 18 18"><polygon class="ql-stroke ql-fill" points="15 12 13 10 15 8 15 12"/><line class="ql-stroke ql-fill" x1="9" x2="5" y1="4" y2="4"/><path class="ql-fill" d="M5,3A3,3,0,0,0,5,9H6V3H5Z"/><rect class="ql-fill" height="11" width="1" x="5" y="4"/><rect class="ql-fill" height="11" width="1" x="7" y="4"/></svg>'},formula:'<svg viewbox="0 0 18 18"><path class="ql-fill" d="M11.759,2.482a2.561,2.561,0,0,0-3.53.607A7.656,7.656,0,0,0,6.8,6.2C6.109,9.188,5.275,14.677,4.15,14.927a1.545,1.545,0,0,0-1.3-.933A0.922,0.922,0,0,0,2,15.036S1.954,16,4.119,16s3.091-2.691,3.7-5.553c0.177-.826.36-1.726,0.554-2.6L8.775,6.2c0.381-1.421.807-2.521,1.306-2.676a1.014,1.014,0,0,0,1.02.56A0.966,0.966,0,0,0,11.759,2.482Z"/><rect class="ql-fill" height="1.6" rx="0.8" ry="0.8" width="5" x="5.15" y="6.2"/><path class="ql-fill" d="M13.663,12.027a1.662,1.662,0,0,1,.266-0.276q0.193,0.069.456,0.138a2.1,2.1,0,0,0,.535.069,1.075,1.075,0,0,0,.767-0.3,1.044,1.044,0,0,0,.314-0.8,0.84,0.84,0,0,0-.238-0.619,0.8,0.8,0,0,0-.594-0.239,1.154,1.154,0,0,0-.781.3,4.607,4.607,0,0,0-.781,1q-0.091.15-.218,0.346l-0.246.38c-0.068-.288-0.137-0.582-0.212-0.885-0.459-1.847-2.494-.984-2.941-0.8-0.482.2-.353,0.647-0.094,0.529a0.869,0.869,0,0,1,1.281.585c0.217,0.751.377,1.436,0.527,2.038a5.688,5.688,0,0,1-.362.467,2.69,2.69,0,0,1-.264.271q-0.221-.08-0.471-0.147a2.029,2.029,0,0,0-.522-0.066,1.079,1.079,0,0,0-.768.3A1.058,1.058,0,0,0,9,15.131a0.82,0.82,0,0,0,.832.852,1.134,1.134,0,0,0,.787-0.3,5.11,5.11,0,0,0,.776-0.993q0.141-.219.215-0.34c0.046-.076.122-0.194,0.223-0.346a2.786,2.786,0,0,0,.918,1.726,2.582,2.582,0,0,0,2.376-.185c0.317-.181.212-0.565,0-0.494A0.807,0.807,0,0,1,14.176,15a5.159,5.159,0,0,1-.913-2.446l0,0Q13.487,12.24,13.663,12.027Z"/></svg>',header:{1:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M10,4V14a1,1,0,0,1-2,0V10H3v4a1,1,0,0,1-2,0V4A1,1,0,0,1,3,4V8H8V4a1,1,0,0,1,2,0Zm6.06787,9.209H14.98975V7.59863a.54085.54085,0,0,0-.605-.60547h-.62744a1.01119,1.01119,0,0,0-.748.29688L11.645,8.56641a.5435.5435,0,0,0-.022.8584l.28613.30762a.53861.53861,0,0,0,.84717.0332l.09912-.08789a1.2137,1.2137,0,0,0,.2417-.35254h.02246s-.01123.30859-.01123.60547V13.209H12.041a.54085.54085,0,0,0-.605.60547v.43945a.54085.54085,0,0,0,.605.60547h4.02686a.54085.54085,0,0,0,.605-.60547v-.43945A.54085.54085,0,0,0,16.06787,13.209Z"/></svg>',2:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M16.73975,13.81445v.43945a.54085.54085,0,0,1-.605.60547H11.855a.58392.58392,0,0,1-.64893-.60547V14.0127c0-2.90527,3.39941-3.42187,3.39941-4.55469a.77675.77675,0,0,0-.84717-.78125,1.17684,1.17684,0,0,0-.83594.38477c-.2749.26367-.561.374-.85791.13184l-.4292-.34082c-.30811-.24219-.38525-.51758-.1543-.81445a2.97155,2.97155,0,0,1,2.45361-1.17676,2.45393,2.45393,0,0,1,2.68408,2.40918c0,2.45312-3.1792,2.92676-3.27832,3.93848h2.79443A.54085.54085,0,0,1,16.73975,13.81445ZM9,3A.99974.99974,0,0,0,8,4V8H3V4A1,1,0,0,0,1,4V14a1,1,0,0,0,2,0V10H8v4a1,1,0,0,0,2,0V4A.99974.99974,0,0,0,9,3Z"/></svg>',3:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M16.65186,12.30664a2.6742,2.6742,0,0,1-2.915,2.68457,3.96592,3.96592,0,0,1-2.25537-.6709.56007.56007,0,0,1-.13232-.83594L11.64648,13c.209-.34082.48389-.36328.82471-.1543a2.32654,2.32654,0,0,0,1.12256.33008c.71484,0,1.12207-.35156,1.12207-.78125,0-.61523-.61621-.86816-1.46338-.86816H13.2085a.65159.65159,0,0,1-.68213-.41895l-.05518-.10937a.67114.67114,0,0,1,.14307-.78125l.71533-.86914a8.55289,8.55289,0,0,1,.68213-.7373V8.58887a3.93913,3.93913,0,0,1-.748.05469H11.9873a.54085.54085,0,0,1-.605-.60547V7.59863a.54085.54085,0,0,1,.605-.60547h3.75146a.53773.53773,0,0,1,.60547.59375v.17676a1.03723,1.03723,0,0,1-.27539.748L14.74854,10.0293A2.31132,2.31132,0,0,1,16.65186,12.30664ZM9,3A.99974.99974,0,0,0,8,4V8H3V4A1,1,0,0,0,1,4V14a1,1,0,0,0,2,0V10H8v4a1,1,0,0,0,2,0V4A.99974.99974,0,0,0,9,3Z"/></svg>',4:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M10,4V14a1,1,0,0,1-2,0V10H3v4a1,1,0,0,1-2,0V4A1,1,0,0,1,3,4V8H8V4a1,1,0,0,1,2,0Zm7.05371,7.96582v.38477c0,.39648-.165.60547-.46191.60547h-.47314v1.29785a.54085.54085,0,0,1-.605.60547h-.69336a.54085.54085,0,0,1-.605-.60547V12.95605H11.333a.5412.5412,0,0,1-.60547-.60547v-.15332a1.199,1.199,0,0,1,.22021-.748l2.56348-4.05957a.7819.7819,0,0,1,.72607-.39648h1.27637a.54085.54085,0,0,1,.605.60547v3.7627h.33008A.54055.54055,0,0,1,17.05371,11.96582ZM14.28125,8.7207h-.022a4.18969,4.18969,0,0,1-.38525.81348l-1.188,1.80469v.02246h1.5293V9.60059A7.04058,7.04058,0,0,1,14.28125,8.7207Z"/></svg>',5:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M16.74023,12.18555a2.75131,2.75131,0,0,1-2.91553,2.80566,3.908,3.908,0,0,1-2.25537-.68164.54809.54809,0,0,1-.13184-.8252L11.73438,13c.209-.34082.48389-.36328.8252-.1543a2.23757,2.23757,0,0,0,1.1001.33008,1.01827,1.01827,0,0,0,1.1001-.96777c0-.61621-.53906-.97949-1.25439-.97949a2.15554,2.15554,0,0,0-.64893.09961,1.15209,1.15209,0,0,1-.814.01074l-.12109-.04395a.64116.64116,0,0,1-.45117-.71484l.231-3.00391a.56666.56666,0,0,1,.62744-.583H15.541a.54085.54085,0,0,1,.605.60547v.43945a.54085.54085,0,0,1-.605.60547H13.41748l-.04395.72559a1.29306,1.29306,0,0,1-.04395.30859h.022a2.39776,2.39776,0,0,1,.57227-.07715A2.53266,2.53266,0,0,1,16.74023,12.18555ZM9,3A.99974.99974,0,0,0,8,4V8H3V4A1,1,0,0,0,1,4V14a1,1,0,0,0,2,0V10H8v4a1,1,0,0,0,2,0V4A.99974.99974,0,0,0,9,3Z"/></svg>',6:'<svg viewBox="0 0 18 18"><path class="ql-fill" d="M14.51758,9.64453a1.85627,1.85627,0,0,0-1.24316.38477H13.252a1.73532,1.73532,0,0,1,1.72754-1.4082,2.66491,2.66491,0,0,1,.5498.06641c.35254.05469.57227.01074.70508-.40723l.16406-.5166a.53393.53393,0,0,0-.373-.75977,4.83723,4.83723,0,0,0-1.17773-.14258c-2.43164,0-3.7627,2.17773-3.7627,4.43359,0,2.47559,1.60645,3.69629,3.19043,3.69629A2.70585,2.70585,0,0,0,16.96,12.19727,2.43861,2.43861,0,0,0,14.51758,9.64453Zm-.23047,3.58691c-.67187,0-1.22168-.81445-1.22168-1.45215,0-.47363.30762-.583.72559-.583.96875,0,1.27734.59375,1.27734,1.12207A.82182.82182,0,0,1,14.28711,13.23145ZM10,4V14a1,1,0,0,1-2,0V10H3v4a1,1,0,0,1-2,0V4A1,1,0,0,1,3,4V8H8V4a1,1,0,0,1,2,0Z"/></svg>'},italic:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="7" x2="13" y1="4" y2="4"/><line class="ql-stroke" x1="5" x2="11" y1="14" y2="14"/><line class="ql-stroke" x1="8" x2="10" y1="14" y2="4"/></svg>',image:'<svg viewbox="0 0 18 18"><rect class="ql-stroke" height="10" width="12" x="3" y="4"/><circle class="ql-fill" cx="6" cy="7" r="1"/><polyline class="ql-even ql-fill" points="5 12 5 11 7 9 8 10 11 7 13 9 13 12 5 12"/></svg>',indent:{"+1":'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="3" x2="15" y1="14" y2="14"/><line class="ql-stroke" x1="3" x2="15" y1="4" y2="4"/><line class="ql-stroke" x1="9" x2="15" y1="9" y2="9"/><polyline class="ql-fill ql-stroke" points="3 7 3 11 5 9 3 7"/></svg>',"-1":'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="3" x2="15" y1="14" y2="14"/><line class="ql-stroke" x1="3" x2="15" y1="4" y2="4"/><line class="ql-stroke" x1="9" x2="15" y1="9" y2="9"/><polyline class="ql-stroke" points="5 7 5 11 3 9 5 7"/></svg>'},link:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="7" x2="11" y1="7" y2="11"/><path class="ql-even ql-stroke" d="M8.9,4.577a3.476,3.476,0,0,1,.36,4.679A3.476,3.476,0,0,1,4.577,8.9C3.185,7.5,2.035,6.4,4.217,4.217S7.5,3.185,8.9,4.577Z"/><path class="ql-even ql-stroke" d="M13.423,9.1a3.476,3.476,0,0,0-4.679-.36,3.476,3.476,0,0,0,.36,4.679c1.392,1.392,2.5,2.542,4.679.36S14.815,10.5,13.423,9.1Z"/></svg>',list:{bullet:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="6" x2="15" y1="4" y2="4"/><line class="ql-stroke" x1="6" x2="15" y1="9" y2="9"/><line class="ql-stroke" x1="6" x2="15" y1="14" y2="14"/><line class="ql-stroke" x1="3" x2="3" y1="4" y2="4"/><line class="ql-stroke" x1="3" x2="3" y1="9" y2="9"/><line class="ql-stroke" x1="3" x2="3" y1="14" y2="14"/></svg>',check:'<svg class="" viewbox="0 0 18 18"><line class="ql-stroke" x1="9" x2="15" y1="4" y2="4"/><polyline class="ql-stroke" points="3 4 4 5 6 3"/><line class="ql-stroke" x1="9" x2="15" y1="14" y2="14"/><polyline class="ql-stroke" points="3 14 4 15 6 13"/><line class="ql-stroke" x1="9" x2="15" y1="9" y2="9"/><polyline class="ql-stroke" points="3 9 4 10 6 8"/></svg>',ordered:'<svg viewbox="0 0 18 18"><line class="ql-stroke" x1="7" x2="15" y1="4" y2="4"/><line class="ql-stroke" x1="7" x2="15" y1="9" y2="9"/><line class="ql-stroke" x1="7" x2="15" y1="14" y2="14"/><line class="ql-stroke ql-thin" x1="2.5" x2="4.5" y1="5.5" y2="5.5"/><path class="ql-fill" d="M3.5,6A0.5,0.5,0,0,1,3,5.5V3.085l-0.276.138A0.5,0.5,0,0,1,2.053,3c-0.124-.247-0.023-0.324.224-0.447l1-.5A0.5,0.5,0,0,1,4,2.5v3A0.5,0.5,0,0,1,3.5,6Z"/><path class="ql-stroke ql-thin" d="M4.5,10.5h-2c0-.234,1.85-1.076,1.85-2.234A0.959,0.959,0,0,0,2.5,8.156"/><path class="ql-stroke ql-thin" d="M2.5,14.846a0.959,0.959,0,0,0,1.85-.109A0.7,0.7,0,0,0,3.75,14a0.688,0.688,0,0,0,.6-0.736,0.959,0.959,0,0,0-1.85-.109"/></svg>'},script:{sub:'<svg viewbox="0 0 18 18"><path class="ql-fill" d="M15.5,15H13.861a3.858,3.858,0,0,0,1.914-2.975,1.8,1.8,0,0,0-1.6-1.751A1.921,1.921,0,0,0,12.021,11.7a0.50013,0.50013,0,1,0,.957.291h0a0.914,0.914,0,0,1,1.053-.725,0.81,0.81,0,0,1,.744.762c0,1.076-1.16971,1.86982-1.93971,2.43082A1.45639,1.45639,0,0,0,12,15.5a0.5,0.5,0,0,0,.5.5h3A0.5,0.5,0,0,0,15.5,15Z"/><path class="ql-fill" d="M9.65,5.241a1,1,0,0,0-1.409.108L6,7.964,3.759,5.349A1,1,0,0,0,2.192,6.59178Q2.21541,6.6213,2.241,6.649L4.684,9.5,2.241,12.35A1,1,0,0,0,3.71,13.70722q0.02557-.02768.049-0.05722L6,11.036,8.241,13.65a1,1,0,1,0,1.567-1.24277Q9.78459,12.3777,9.759,12.35L7.316,9.5,9.759,6.651A1,1,0,0,0,9.65,5.241Z"/></svg>',super:'<svg viewbox="0 0 18 18"><path class="ql-fill" d="M15.5,7H13.861a4.015,4.015,0,0,0,1.914-2.975,1.8,1.8,0,0,0-1.6-1.751A1.922,1.922,0,0,0,12.021,3.7a0.5,0.5,0,1,0,.957.291,0.917,0.917,0,0,1,1.053-.725,0.81,0.81,0,0,1,.744.762c0,1.077-1.164,1.925-1.934,2.486A1.423,1.423,0,0,0,12,7.5a0.5,0.5,0,0,0,.5.5h3A0.5,0.5,0,0,0,15.5,7Z"/><path class="ql-fill" d="M9.651,5.241a1,1,0,0,0-1.41.108L6,7.964,3.759,5.349a1,1,0,1,0-1.519,1.3L4.683,9.5,2.241,12.35a1,1,0,1,0,1.519,1.3L6,11.036,8.241,13.65a1,1,0,0,0,1.519-1.3L7.317,9.5,9.759,6.651A1,1,0,0,0,9.651,5.241Z"/></svg>'},strike:'<svg viewbox="0 0 18 18"><line class="ql-stroke ql-thin" x1="15.5" x2="2.5" y1="8.5" y2="9.5"/><path class="ql-fill" d="M9.007,8C6.542,7.791,6,7.519,6,6.5,6,5.792,7.283,5,9,5c1.571,0,2.765.679,2.969,1.309a1,1,0,0,0,1.9-.617C13.356,4.106,11.354,3,9,3,6.2,3,4,4.538,4,6.5a3.2,3.2,0,0,0,.5,1.843Z"/><path class="ql-fill" d="M8.984,10C11.457,10.208,12,10.479,12,11.5c0,0.708-1.283,1.5-3,1.5-1.571,0-2.765-.679-2.969-1.309a1,1,0,1,0-1.9.617C4.644,13.894,6.646,15,9,15c2.8,0,5-1.538,5-3.5a3.2,3.2,0,0,0-.5-1.843Z"/></svg>',table:'<svg viewbox="0 0 18 18"><rect class="ql-stroke" height="12" width="12" x="3" y="3"/><rect class="ql-fill" height="2" width="3" x="5" y="5"/><rect class="ql-fill" height="2" width="4" x="9" y="5"/><g class="ql-fill ql-transparent"><rect height="2" width="3" x="5" y="8"/><rect height="2" width="4" x="9" y="8"/><rect height="2" width="3" x="5" y="11"/><rect height="2" width="4" x="9" y="11"/></g></svg>',underline:'<svg viewbox="0 0 18 18"><path class="ql-stroke" d="M5,3V9a4.012,4.012,0,0,0,4,4H9a4.012,4.012,0,0,0,4-4V3"/><rect class="ql-fill" height="1" rx="0.5" ry="0.5" width="12" x="3" y="15"/></svg>',video:'<svg viewbox="0 0 18 18"><rect class="ql-stroke" height="12" width="12" x="3" y="3"/><rect class="ql-fill" height="12" width="1" x="5" y="3"/><rect class="ql-fill" height="12" width="1" x="12" y="3"/><rect class="ql-fill" height="2" width="8" x="5" y="8"/><rect class="ql-fill" height="1" width="3" x="3" y="5"/><rect class="ql-fill" height="1" width="3" x="3" y="7"/><rect class="ql-fill" height="1" width="3" x="3" y="10"/><rect class="ql-fill" height="1" width="3" x="3" y="12"/><rect class="ql-fill" height="1" width="3" x="12" y="5"/><rect class="ql-fill" height="1" width="3" x="12" y="7"/><rect class="ql-fill" height="1" width="3" x="12" y="10"/><rect class="ql-fill" height="1" width="3" x="12" y="12"/></svg>'};let md=0;function ud(t,e){t.setAttribute(e,"".concat(!("true"===t.getAttribute(e))))}const hd=class{constructor(t){this.select=t,this.container=document.createElement("span"),this.buildPicker(),this.select.style.display="none",this.select.parentNode.insertBefore(this.container,this.select),this.label.addEventListener("mousedown",()=>{this.togglePicker()}),this.label.addEventListener("keydown",t=>{switch(t.key){case"Enter":this.togglePicker();break;case"Escape":this.escape(),t.preventDefault()}}),this.select.addEventListener("change",this.update.bind(this))}togglePicker(){this.container.classList.toggle("ql-expanded"),ud(this.label,"aria-expanded"),ud(this.options,"aria-hidden")}buildItem(t){const e=document.createElement("span");e.tabIndex="0",e.setAttribute("role","button"),e.classList.add("ql-picker-item");const a=t.getAttribute("value");return a&&e.setAttribute("data-value",a),t.textContent&&e.setAttribute("data-label",t.textContent),e.addEventListener("click",()=>{this.selectItem(e,!0)}),e.addEventListener("keydown",t=>{switch(t.key){case"Enter":this.selectItem(e,!0),t.preventDefault();break;case"Escape":this.escape(),t.preventDefault()}}),e}buildLabel(){const t=document.createElement("span");return t.classList.add("ql-picker-label"),t.innerHTML='<svg viewbox="0 0 18 18"><polygon class="ql-stroke" points="7 11 9 13 11 11 7 11"/><polygon class="ql-stroke" points="7 7 9 5 11 7 7 7"/></svg>',t.tabIndex="0",t.setAttribute("role","button"),t.setAttribute("aria-expanded","false"),this.container.appendChild(t),t}buildOptions(){const t=document.createElement("span");t.classList.add("ql-picker-options"),t.setAttribute("aria-hidden","true"),t.tabIndex="-1",t.id="ql-picker-options-".concat(md),md+=1,this.label.setAttribute("aria-controls",t.id),this.options=t,Array.from(this.select.options).forEach(e=>{const a=this.buildItem(e);t.appendChild(a),!0===e.selected&&this.selectItem(a)}),this.container.appendChild(t)}buildPicker(){Array.from(this.select.attributes).forEach(t=>{this.container.setAttribute(t.name,t.value)}),this.container.classList.add("ql-picker"),this.label=this.buildLabel(),this.buildOptions()}escape(){this.close(),setTimeout(()=>this.label.focus(),1)}close(){this.container.classList.remove("ql-expanded"),this.label.setAttribute("aria-expanded","false"),this.options.setAttribute("aria-hidden","true")}selectItem(t){let e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];const a=this.container.querySelector(".ql-selected");t!==a&&(null!=a&&a.classList.remove("ql-selected"),null!=t&&(t.classList.add("ql-selected"),this.select.selectedIndex=Array.from(t.parentNode.children).indexOf(t),t.hasAttribute("data-value")?this.label.setAttribute("data-value",t.getAttribute("data-value")):this.label.removeAttribute("data-value"),t.hasAttribute("data-label")?this.label.setAttribute("data-label",t.getAttribute("data-label")):this.label.removeAttribute("data-label"),e&&(this.select.dispatchEvent(new Event("change")),this.close())))}update(){let t;if(this.select.selectedIndex>-1){const e=this.container.querySelector(".ql-picker-options").children[this.select.selectedIndex];t=this.select.options[this.select.selectedIndex],this.selectItem(e)}else this.selectItem(null);const e=null!=t&&t!==this.select.querySelector("option[selected]");this.label.classList.toggle("ql-active",e)}};const fd=class extends hd{constructor(t,e){super(t),this.label.innerHTML=e,this.container.classList.add("ql-color-picker"),Array.from(this.container.querySelectorAll(".ql-picker-item")).slice(0,7).forEach(t=>{t.classList.add("ql-primary")})}buildItem(t){const e=super.buildItem(t);return e.style.backgroundColor=t.getAttribute("value")||"",e}selectItem(t,e){super.selectItem(t,e);const a=this.label.querySelector(".ql-color-label"),i=t&&t.getAttribute("data-value")||"";a&&("line"===a.tagName?a.style.stroke=i:a.style.fill=i)}};const gd=class extends hd{constructor(t,e){super(t),this.container.classList.add("ql-icon-picker"),Array.from(this.container.querySelectorAll(".ql-picker-item")).forEach(t=>{t.innerHTML=e[t.getAttribute("data-value")||""]}),this.defaultItem=this.container.querySelector(".ql-selected"),this.selectItem(this.defaultItem)}selectItem(t,e){super.selectItem(t,e);const a=t||this.defaultItem;if(null!=a){if(this.label.innerHTML===a.innerHTML)return;this.label.innerHTML=a.innerHTML}}};const pd=class{constructor(t,e){this.quill=t,this.boundsContainer=e||document.body,this.root=t.addContainer("ql-tooltip"),this.root.innerHTML=this.constructor.TEMPLATE,(t=>{const{overflowY:e}=getComputedStyle(t,null);return"visible"!==e&&"clip"!==e})(this.quill.root)&&this.quill.root.addEventListener("scroll",()=>{this.root.style.marginTop="".concat(-1*this.quill.root.scrollTop,"px")}),this.hide()}hide(){this.root.classList.add("ql-hidden")}position(t){const e=t.left+t.width/2-this.root.offsetWidth/2,a=t.bottom+this.quill.root.scrollTop;this.root.style.left="".concat(e,"px"),this.root.style.top="".concat(a,"px"),this.root.classList.remove("ql-flip");const i=this.boundsContainer.getBoundingClientRect(),n=this.root.getBoundingClientRect();let o=0;if(n.right>i.right&&(o=i.right-n.right,this.root.style.left="".concat(e+o,"px")),n.left<i.left&&(o=i.left-n.left,this.root.style.left="".concat(e+o,"px")),n.bottom>i.bottom){const e=n.bottom-n.top,i=t.bottom-t.top+e;this.root.style.top="".concat(a-i,"px"),this.root.classList.add("ql-flip")}return o}show(){this.root.classList.remove("ql-editing"),this.root.classList.remove("ql-hidden")}},yd=[!1,"center","right","justify"],bd=["#000000","#e60000","#ff9900","#ffff00","#008a00","#0066cc","#9933ff","#ffffff","#facccc","#ffebcc","#ffffcc","#cce8cc","#cce0f5","#ebd6ff","#bbbbbb","#f06666","#ffc266","#ffff66","#66b966","#66a3e0","#c285ff","#888888","#a10000","#b26b00","#b2b200","#006100","#0047b2","#6b24b2","#444444","#5c0000","#663d00","#666600","#003700","#002966","#3d1466"],vd=[!1,"serif","monospace"],wd=["1","2","3",!1],xd=["small",!1,"large","huge"];class kd extends Hs{constructor(t,e){super(t,e);const a=e=>{document.body.contains(t.root)?(null==this.tooltip||this.tooltip.root.contains(e.target)||document.activeElement===this.tooltip.textbox||this.quill.hasFocus()||this.tooltip.hide(),null!=this.pickers&&this.pickers.forEach(t=>{t.container.contains(e.target)||t.close()})):document.body.removeEventListener("click",a)};t.emitter.listenDOM("click",document.body,a)}addModule(t){const e=super.addModule(t);return"toolbar"===t&&this.extendToolbar(e),e}buildButtons(t,e){Array.from(t).forEach(t=>{(t.getAttribute("class")||"").split(/\s+/).forEach(a=>{if(a.startsWith("ql-")&&(a=a.slice(3),null!=e[a]))if("direction"===a)t.innerHTML=e[a][""]+e[a].rtl;else if("string"===typeof e[a])t.innerHTML=e[a];else{const i=t.value||"";null!=i&&e[a][i]&&(t.innerHTML=e[a][i])}})})}buildPickers(t,e){this.pickers=Array.from(t).map(t=>{if(t.classList.contains("ql-align")&&(null==t.querySelector("option")&&Cd(t,yd),"object"===typeof e.align))return new gd(t,e.align);if(t.classList.contains("ql-background")||t.classList.contains("ql-color")){const a=t.classList.contains("ql-background")?"background":"color";return null==t.querySelector("option")&&Cd(t,bd,"background"===a?"#ffffff":"#000000"),new fd(t,e[a])}return null==t.querySelector("option")&&(t.classList.contains("ql-font")?Cd(t,vd):t.classList.contains("ql-header")?Cd(t,wd):t.classList.contains("ql-size")&&Cd(t,xd)),new hd(t)});this.quill.on(ks.events.EDITOR_CHANGE,()=>{this.pickers.forEach(t=>{t.update()})})}}kd.DEFAULTS=Qn({},Hs.DEFAULTS,{modules:{toolbar:{handlers:{formula(){this.quill.theme.tooltip.edit("formula")},image(){let t=this.container.querySelector("input.ql-image[type=file]");null==t&&(t=document.createElement("input"),t.setAttribute("type","file"),t.setAttribute("accept",this.quill.uploader.options.mimetypes.join(", ")),t.classList.add("ql-image"),t.addEventListener("change",()=>{const e=this.quill.getSelection(!0);this.quill.uploader.upload(e,t.files),t.value=""}),this.container.appendChild(t)),t.click()},video(){this.quill.theme.tooltip.edit("video")}}}}});class Id extends pd{constructor(t,e){super(t,e),this.textbox=this.root.querySelector('input[type="text"]'),this.listen()}listen(){this.textbox.addEventListener("keydown",t=>{"Enter"===t.key?(this.save(),t.preventDefault()):"Escape"===t.key&&(this.cancel(),t.preventDefault())})}cancel(){this.hide(),this.restoreFocus()}edit(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"link",e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:null;if(this.root.classList.remove("ql-hidden"),this.root.classList.add("ql-editing"),null==this.textbox)return;null!=e?this.textbox.value=e:t!==this.root.getAttribute("data-mode")&&(this.textbox.value="");const a=this.quill.getBounds(this.quill.selection.savedRange);null!=a&&this.position(a),this.textbox.select(),this.textbox.setAttribute("placeholder",this.textbox.getAttribute("data-".concat(t))||""),this.root.setAttribute("data-mode",t)}restoreFocus(){this.quill.focus({preventScroll:!0})}save(){let{value:t}=this.textbox;switch(this.root.getAttribute("data-mode")){case"link":{const{scrollTop:e}=this.quill.root;this.linkRange?(this.quill.formatText(this.linkRange,"link",t,ks.sources.USER),delete this.linkRange):(this.restoreFocus(),this.quill.format("link",t,ks.sources.USER)),this.quill.root.scrollTop=e;break}case"video":t=function(t){let e=t.match(/^(?:(https?):\/\/)?(?:(?:www|m)\.)?youtube\.com\/watch.*v=([a-zA-Z0-9_-]+)/)||t.match(/^(?:(https?):\/\/)?(?:(?:www|m)\.)?youtu\.be\/([a-zA-Z0-9_-]+)/);if(e)return"".concat(e[1]||"https","://www.youtube.com/embed/").concat(e[2],"?showinfo=0");if(e=t.match(/^(?:(https?):\/\/)?(?:www\.)?vimeo\.com\/(\d+)/))return"".concat(e[1]||"https","://player.vimeo.com/video/").concat(e[2],"/");return t}(t);case"formula":{if(!t)break;const e=this.quill.getSelection(!0);if(null!=e){const a=e.index+e.length;this.quill.insertEmbed(a,this.root.getAttribute("data-mode"),t,ks.sources.USER),"formula"===this.root.getAttribute("data-mode")&&this.quill.insertText(a+1," ",ks.sources.USER),this.quill.setSelection(a+2,ks.sources.USER)}break}}this.textbox.value="",this.hide()}}function Cd(t,e){let a=arguments.length>2&&void 0!==arguments[2]&&arguments[2];e.forEach(e=>{const i=document.createElement("option");e===a?i.setAttribute("selected","selected"):i.setAttribute("value",String(e)),t.appendChild(i)})}const Sd=[["bold","italic","link"],[{header:1},{header:2},"blockquote"]];class Ad extends Id{constructor(t,e){super(t,e),this.quill.on(ks.events.EDITOR_CHANGE,(t,e,a,i)=>{if(t===ks.events.SELECTION_CHANGE)if(null!=e&&e.length>0&&i===ks.sources.USER){this.show(),this.root.style.left="0px",this.root.style.width="",this.root.style.width="".concat(this.root.offsetWidth,"px");const t=this.quill.getLines(e.index,e.length);if(1===t.length){const t=this.quill.getBounds(e);null!=t&&this.position(t)}else{const a=t[t.length-1],i=this.quill.getIndex(a),n=Math.min(a.length()-1,e.index+e.length-i),o=this.quill.getBounds(new Cs(i,n));null!=o&&this.position(o)}}else document.activeElement!==this.textbox&&this.quill.hasFocus()&&this.hide()})}listen(){super.listen(),this.root.querySelector(".ql-close").addEventListener("click",()=>{this.root.classList.remove("ql-editing")}),this.quill.on(ks.events.SCROLL_OPTIMIZE,()=>{setTimeout(()=>{if(this.root.classList.contains("ql-hidden"))return;const t=this.quill.getSelection();if(null!=t){const e=this.quill.getBounds(t);null!=e&&this.position(e)}},1)})}cancel(){this.show()}position(t){const e=super.position(t),a=this.root.querySelector(".ql-tooltip-arrow");return a.style.marginLeft="",0!==e&&(a.style.marginLeft="".concat(-1*e-a.offsetWidth/2,"px")),e}}Ot(Ad,"TEMPLATE",['<span class="ql-tooltip-arrow"></span>','<div class="ql-tooltip-editor">','<input type="text" data-formula="e=mc^2" data-link="https://quilljs.com" data-video="Embed URL">','<a class="ql-close"></a>',"</div>"].join(""));class Td extends kd{constructor(t,e){null!=e.modules.toolbar&&null==e.modules.toolbar.container&&(e.modules.toolbar.container=Sd),super(t,e),this.quill.container.classList.add("ql-bubble")}extendToolbar(t){this.tooltip=new Ad(this.quill,this.options.bounds),null!=t.container&&(this.tooltip.root.appendChild(t.container),this.buildButtons(t.container.querySelectorAll("button"),cd),this.buildPickers(t.container.querySelectorAll("select"),cd))}}Td.DEFAULTS=Qn({},kd.DEFAULTS,{modules:{toolbar:{handlers:{link(t){t?this.quill.theme.tooltip.edit():this.quill.format("link",!1,tr.sources.USER)}}}}});const Pd=[[{header:["1","2","3",!1]}],["bold","italic","underline","link"],[{list:"ordered"},{list:"bullet"}],["clean"]];class Dd extends Id{constructor(){super(...arguments),Ot(this,"preview",this.root.querySelector("a.ql-preview"))}listen(){super.listen(),this.root.querySelector("a.ql-action").addEventListener("click",t=>{this.root.classList.contains("ql-editing")?this.save():this.edit("link",this.preview.textContent),t.preventDefault()}),this.root.querySelector("a.ql-remove").addEventListener("click",t=>{if(null!=this.linkRange){const t=this.linkRange;this.restoreFocus(),this.quill.formatText(t,"link",!1,ks.sources.USER),delete this.linkRange}t.preventDefault(),this.hide()}),this.quill.on(ks.events.SELECTION_CHANGE,(t,e,a)=>{if(null!=t){if(0===t.length&&a===ks.sources.USER){const[e,a]=this.quill.scroll.descendant(jl,t.index);if(null!=e){this.linkRange=new Cs(t.index-a,e.length());const i=jl.formats(e.domNode);this.preview.textContent=i,this.preview.setAttribute("href",i),this.show();const n=this.quill.getBounds(this.linkRange);return void(null!=n&&this.position(n))}}else delete this.linkRange;this.hide()}})}show(){super.show(),this.root.removeAttribute("data-mode")}}Ot(Dd,"TEMPLATE",['<a class="ql-preview" rel="noopener noreferrer" target="_blank" href="about:blank"></a>','<input type="text" data-formula="e=mc^2" data-link="https://quilljs.com" data-video="Embed URL">','<a class="ql-action"></a>','<a class="ql-remove"></a>'].join(""));class Nd extends kd{constructor(t,e){null!=e.modules.toolbar&&null==e.modules.toolbar.container&&(e.modules.toolbar.container=Pd),super(t,e),this.quill.container.classList.add("ql-snow")}extendToolbar(t){null!=t.container&&(t.container.classList.add("ql-snow"),this.buildButtons(t.container.querySelectorAll("button"),cd),this.buildPickers(t.container.querySelectorAll("select"),cd),this.tooltip=new Dd(this.quill,this.options.bounds),t.container.querySelector(".ql-link")&&this.quill.keyboard.addBinding({key:"k",shortKey:!0},(e,a)=>{t.handlers.link.call(t,!a.format.link)}))}}Nd.DEFAULTS=Qn({},kd.DEFAULTS,{modules:{toolbar:{handlers:{link(t){if(t){const t=this.quill.getSelection();if(null==t||0===t.length)return;let e=this.quill.getText(t);/^\S+@\S+\.\S+$/.test(e)&&0!==e.indexOf("mailto:")&&(e="mailto:".concat(e));const{tooltip:a}=this.quill.theme;a.edit("link",e)}else this.quill.format("link",!1,tr.sources.USER)}}}}});const Ld=Nd;wl.register({"attributors/attribute/direction":Ar,"attributors/class/align":gr,"attributors/class/background":wr,"attributors/class/color":br,"attributors/class/direction":Tr,"attributors/class/font":Nr,"attributors/class/size":Er,"attributors/style/align":pr,"attributors/style/background":xr,"attributors/style/color":vr,"attributors/style/direction":Pr,"attributors/style/font":Lr,"attributors/style/size":jr},!0),wl.register({"formats/align":gr,"formats/direction":Tr,"formats/indent":kl,"formats/background":xr,"formats/color":vr,"formats/font":Nr,"formats/size":Er,"formats/blockquote":Cl,"formats/code-block":Ir,"formats/header":Al,"formats/list":Pl,"formats/bold":Nl,"formats/code":Cr,"formats/italic":El,"formats/link":jl,"formats/script":Rl,"formats/strike":ql,"formats/underline":Ol,"formats/formula":Hl,"formats/image":Gl,"formats/video":Kl,"modules/syntax":Jl,"modules/table":od,"modules/toolbar":rd,"themes/bubble":Td,"themes/snow":Ld,"ui/icons":cd,"ui/picker":hd,"ui/icon-picker":gd,"ui/color-picker":fd,"ui/tooltip":pd},!0);const Ed=wl;class jd extends i.Component{constructor(t){super(t),this.editingAreaRef=(0,i.createRef)(),this.containerRef=(0,i.createRef)(),this.dirtyProps=["modules","formats","bounds","theme","children"],this.cleanProps=["id","className","style","placeholder","tabIndex","onChange","onChangeSelection","onFocus","onBlur","onKeyPress","onKeyDown","onKeyUp"],this.state={generation:0},this.selection=null,this.onEditorChange=(t,e,a,i)=>{var n;if("text-change"===t)null===(n=this.onEditorChangeText)||void 0===n||n.call(this,this.editor.getSemanticHTML(),e,i,this.unprivilegedEditor);else if("selection-change"===t){var o;null===(o=this.onEditorChangeSelection)||void 0===o||o.call(this,e,i,this.unprivilegedEditor)}};const e=this.isControlled()?t.value:t.defaultValue;this.value=null!==e&&void 0!==e?e:""}validateProps(t){if(i.Children.count(t.children)>1)throw new Error("The Quill editing area can only be composed of a single React element.");if(i.Children.count(t.children)){const e=i.Children.only(t.children);if("textarea"===(null===e||void 0===e?void 0:e.type))throw new Error("Quill does not support editing on a <textarea>. Use a <div> instead.")}if(this.lastDeltaChangeSet&&t.value===this.lastDeltaChangeSet)throw new Error("You are passing the `delta` object from the `onChange` event back as `value`. You most probably want `editor.getContents()` instead. See: https://github.com/zenoamaro/react-quill#using-deltas")}shouldComponentUpdate(t,e){if(this.validateProps(t),!this.editor||this.state.generation!==e.generation)return!0;if("value"in t){var a;const e=this.getEditorContents(),i=null!==(a=t.value)&&void 0!==a?a:"";this.isEqualValue(i,e)||this.setEditorContents(this.editor,i)}return t.readOnly!==this.props.readOnly&&this.setEditorReadOnly(this.editor,t.readOnly),[...this.cleanProps,...this.dirtyProps].some(e=>!en(t[e],this.props[e]))}shouldComponentRegenerate(t){return this.dirtyProps.some(e=>!en(t[e],this.props[e]))}componentDidMount(){this.instantiateEditor(),this.setEditorContents(this.editor,this.getEditorContents())}componentWillUnmount(){this.destroyEditor()}componentDidUpdate(t,e){if(this.editor&&this.shouldComponentRegenerate(t)){const t=this.editor.getContents(),e=this.editor.getSelection();this.regenerationSnapshot={delta:t,selection:e},this.setState({generation:this.state.generation+1}),this.destroyEditor()}if(this.editor&&t.placeholder!==this.props.placeholder&&(this.editor.root.dataset.placeholder=this.props.placeholder||""),this.state.generation!==e.generation){const{delta:t,selection:e}=this.regenerationSnapshot;delete this.regenerationSnapshot,this.instantiateEditor();const a=this.editor;a.setContents(t),Md(()=>this.setEditorSelection(a,e))}}instantiateEditor(){this.editor?this.hookEditor(this.editor):this.editor=this.createEditor(this.getEditingArea(),this.getEditorConfig())}destroyEditor(){var t;if(!this.editor)return;this.unhookEditor(this.editor);const e=null===(t=this.props.modules)||void 0===t?void 0:t.toolbar;if(!("object"===typeof e&&e&&"container"in e&&"string"===typeof e.container||"string"===typeof e)){var a;const t=null===(a=this.containerRef.current)||void 0===a?void 0:a.querySelector(".ql-toolbar");t&&t.remove()}delete this.editor}isControlled(){return"value"in this.props}getEditorConfig(){return{bounds:this.props.bounds,formats:this.props.formats,modules:this.props.modules,placeholder:this.props.placeholder,readOnly:this.props.readOnly,tabIndex:this.props.tabIndex,theme:this.props.theme}}getEditor(){if(!this.editor)throw new Error("Accessing non-instantiated editor");return this.editor}createEditor(t,e){const a=new Ed(t,e);return null!=e.tabIndex&&this.setEditorTabIndex(a,e.tabIndex),this.hookEditor(a),a}hookEditor(t){this.unprivilegedEditor=this.makeUnprivilegedEditor(t),t.on("editor-change",this.onEditorChange)}unhookEditor(t){t.off("editor-change",this.onEditorChange)}getEditorContents(){return this.value}getEditorSelection(){return this.selection}isDelta(t){return t&&t.ops}isEqualValue(t,e){return this.isDelta(t)&&this.isDelta(e)?en(t.ops,e.ops):en(t,e)}setEditorContents(t,e){this.value=e;const a=this.getEditorSelection();"string"===typeof e?t.setContents(t.clipboard.convert({html:e})):t.setContents(e),Md(()=>this.setEditorSelection(t,a))}setEditorSelection(t,e){if(this.selection=e,e){const a=t.getLength();e.index=Math.max(0,Math.min(e.index,a-1)),e.length=Math.max(0,Math.min(e.length,a-1-e.index)),t.setSelection(e)}}setEditorTabIndex(t,e){var a;null!==t&&void 0!==t&&null!==(a=t.scroll)&&void 0!==a&&a.domNode&&(t.scroll.domNode.tabIndex=e)}setEditorReadOnly(t,e){e?t.disable():t.enable()}makeUnprivilegedEditor(t){const e=t;return{getHTML:()=>e.root.innerHTML,getSemanticHTML:e.getSemanticHTML.bind(e),getLength:e.getLength.bind(e),getText:e.getText.bind(e),getContents:e.getContents.bind(e),getSelection:e.getSelection.bind(e),getBounds:e.getBounds.bind(e)}}getEditingArea(){const t=this.editingAreaRef.current;if(!t)throw new Error("Cannot find element for editing area");if(3===t.nodeType)throw new Error("Editing area cannot be a text node");return t}renderEditingArea(){const{children:t,preserveWhitespace:e}=this.props,{generation:a}=this.state,n={key:a,ref:this.editingAreaRef};return i.Children.count(t)?i.cloneElement(i.Children.only(t),n):e?i.createElement("pre",Ht({},n)):i.createElement("div",Ht({},n))}render(){var t;return i.createElement("div",{ref:this.containerRef,id:this.props.id,style:this.props.style,key:this.state.generation,className:"quill ".concat(null!==(t=this.props.className)&&void 0!==t?t:""),onKeyPress:this.props.onKeyPress,onKeyDown:this.props.onKeyDown,onKeyUp:this.props.onKeyUp},this.renderEditingArea())}onEditorChangeText(t,e,a,i){if(!this.editor)return;const n=this.isDelta(this.value)?i.getContents():i.getSemanticHTML();var o,s;n!==this.getEditorContents()&&(this.lastDeltaChangeSet=e,this.value=n,null===(o=(s=this.props).onChange)||void 0===o||o.call(s,t,e,a,i))}onEditorChangeSelection(t,e,a){var i,n;if(!this.editor)return;const o=this.getEditorSelection(),s=!o&&t,r=o&&!t;var l,d;if(!en(t,o))if(this.selection=t,null===(i=(n=this.props).onChangeSelection)||void 0===i||i.call(n,t,e,a),s)null===(l=(d=this.props).onFocus)||void 0===l||l.call(d,t,e,a);else if(r){var c,m;null===(c=(m=this.props).onBlur)||void 0===c||c.call(m,o,e,a)}}focus(){this.editor&&this.editor.focus()}blur(){this.editor&&(this.selection=null,this.editor.blur())}}function Md(t){Promise.resolve().then(t)}jd.displayName="React Quill",jd.Quill=Ed,jd.defaultProps={theme:"snow",modules:{},readOnly:!1};const zd=jd;function Rd(t){let{isOpen:e,onClose:a,title:n,children:o,footer:s,size:r="md",closeOnOverlay:l=!0}=t;if((0,i.useEffect)(()=>(document.body.style.overflow=e?"hidden":"unset",()=>{document.body.style.overflow="unset"}),[e]),!e)return null;return(0,Gt.jsx)("div",{className:"fixed inset-0 z-50 overflow-y-auto",children:(0,Gt.jsxs)("div",{className:"flex min-h-screen items-center justify-center p-4",children:[(0,Gt.jsx)("div",{className:"fixed inset-0 bg-black bg-opacity-50 transition-opacity backdrop-blur-sm",onClick:l?a:void 0}),(0,Gt.jsxs)("div",{className:"relative bg-white dark:bg-gray-800 rounded-xl shadow-2xl ".concat({sm:"max-w-md",md:"max-w-2xl",lg:"max-w-4xl",xl:"max-w-6xl"}[r]," w-full max-h-[90vh] flex flex-col"),children:[n&&(0,Gt.jsxs)("div",{className:"flex justify-between items-center px-6 py-4 border-b border-gray-200 dark:border-gray-700",children:[(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 dark:text-white",children:n}),(0,Gt.jsx)("button",{onClick:a,className:"text-gray-400 hover:text-gray-600 dark:hover:text-gray-200 transition",children:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),(0,Gt.jsx)("div",{className:"px-6 py-4 overflow-y-auto flex-1",children:o}),s&&(0,Gt.jsx)("div",{className:"px-6 py-4 border-t border-gray-200 dark:border-gray-700 flex justify-end gap-3",children:s})]})]})})}function Fd(t){let{isOpen:e,onClose:a,onConfirm:i,title:n,message:o,confirmText:s="Confirm",cancelText:r="Cancel",variant:l="danger"}=t;return(0,Gt.jsx)(Rd,{isOpen:e,onClose:a,title:n,size:"sm",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:a,children:r}),(0,Gt.jsx)(ge,{variant:l,onClick:i,children:s})]}),children:(0,Gt.jsx)("p",{className:"text-gray-600 dark:text-gray-300",children:o})})}function qd(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),[n,o]=(0,i.useState)(0),[s,r]=(0,i.useState)(""),[l,d]=(0,i.useState)("all"),[c,m]=(0,i.useState)(!1),u=(0,i.useMemo)(()=>Array.isArray(null===t||void 0===t?void 0:t.articles)?t.articles:[],[t]),h=(0,i.useMemo)(()=>Array.isArray(null===t||void 0===t?void 0:t.categories)?t.categories:[],[t]),f=u[n]||{},g=(0,i.useMemo)(()=>{let t=[...u];if(s){const e=s.toLowerCase();t=t.filter(t=>(t.title||"").toLowerCase().includes(e)||(t.excerpt||"").toLowerCase().includes(e)||(t.category||"").toLowerCase().includes(e))}return"published"===l?t=t.filter(t=>t.published):"draft"===l&&(t=t.filter(t=>!t.published)),t},[u,s,l]);function p(t,a){e(e=>Ht(Ht({},e),{},{articles:e.articles.map((e,i)=>{if(i!==n)return e;const o=Ht(Ht({},e),{},{[t]:a});if("content"===t){const t=(a||"").replace(/<[^>]*>/g,"").trim().split(/\s+/).filter(Boolean).length;o.readTime="".concat(Math.max(1,Math.ceil(t/200))," min read")}return o})}))}function y(){const t=Date.now(),i={_id:String(t),title:"New Article ".concat(t),slug:"article-".concat(t),category:"",categoryColor:"blue",content:"",excerpt:"",image:"",readTime:"1 min read",date:(new Date).toLocaleDateString("en-US",{month:"short",day:"numeric",year:"numeric"}),featured:!1,published:!1};e(t=>Ht(Ht({},t),{},{articles:[i,...t.articles||[]]})),o(0),a.success("Article created successfully!")}function b(){const t=(new Date).toLocaleDateString("en-US",{month:"short",day:"numeric",year:"numeric"});e(e=>Ht(Ht({},e),{},{articles:e.articles.map((e,a)=>a===n?Ht(Ht({},e),{},{date:t}):e)})),a.success("Article saved!")}return(0,Gt.jsxs)("div",{className:"grid grid-cols-12 gap-6",children:[(0,Gt.jsx)("div",{className:"col-span-12 lg:col-span-4",children:(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Articles",subtitle:"".concat(g.length," total"),action:(0,Gt.jsx)(ge,{size:"sm",onClick:y,icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4v16m8-8H4"})}),children:"New"})}),(0,Gt.jsxs)(ue,{className:"space-y-4",children:[(0,Gt.jsxs)("div",{className:"space-y-2",children:[(0,Gt.jsx)("input",{type:"text",placeholder:"Search articles...",value:s,onChange:t=>r(t.target.value),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white focus:ring-2 focus:ring-blue-500 outline-none"}),(0,Gt.jsxs)("div",{className:"flex gap-2",children:[(0,Gt.jsx)("button",{onClick:()=>d("all"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("all"===l?"bg-blue-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:"All"}),(0,Gt.jsx)("button",{onClick:()=>d("published"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("published"===l?"bg-green-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:"Published"}),(0,Gt.jsx)("button",{onClick:()=>d("draft"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("draft"===l?"bg-yellow-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:"Drafts"})]})]}),(0,Gt.jsx)("div",{className:"space-y-2 max-h-[600px] overflow-y-auto",children:0===g.length?(0,Gt.jsx)("p",{className:"text-center py-8 text-gray-500 dark:text-gray-400",children:"No articles found"}):g.map((t,e)=>{const a=u.indexOf(t);return(0,Gt.jsxs)("button",{onClick:()=>o(a),className:"w-full text-left p-3 rounded-lg transition ".concat(a===n?"bg-blue-50 dark:bg-blue-900/20 border-2 border-blue-500":"bg-gray-50 dark:bg-gray-700 hover:bg-gray-100 dark:hover:bg-gray-600"),children:[(0,Gt.jsx)("h4",{className:"font-medium text-gray-900 dark:text-white truncate",children:t.title||"Untitled"}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mt-1",children:[(0,Gt.jsx)("span",{className:"text-xs text-gray-500 dark:text-gray-400",children:t.category||"No category"}),(0,Gt.jsx)("span",{className:"text-xs",children:"\u2022"}),t.published?(0,Gt.jsx)("span",{className:"text-xs text-green-600 dark:text-green-400",children:"Published"}):(0,Gt.jsx)("span",{className:"text-xs text-yellow-600 dark:text-yellow-400",children:"Draft"})]})]},t._id||e)})})]})]})}),(0,Gt.jsx)("div",{className:"col-span-12 lg:col-span-8 space-y-4",children:0===u.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No articles yet"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Create your first article to get started"}),(0,Gt.jsx)(ge,{onClick:y,children:"Create Article"})]})}):(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"flex justify-between items-start",children:[(0,Gt.jsxs)("div",{className:"flex-1",children:[(0,Gt.jsx)("input",{type:"text",placeholder:"Article Title",value:f.title||"",onChange:t=>p("title",t.target.value),className:"text-2xl font-bold w-full bg-transparent border-none outline-none text-gray-900 dark:text-white"}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mt-2",children:[f.published?(0,Gt.jsx)("span",{className:"px-2 py-1 bg-green-100 text-green-800 dark:bg-green-900 dark:text-green-200 text-xs rounded-full font-medium",children:"Published"}):(0,Gt.jsx)("span",{className:"px-2 py-1 bg-yellow-100 text-yellow-800 dark:bg-yellow-900 dark:text-yellow-200 text-xs rounded-full font-medium",children:"Draft"}),(0,Gt.jsx)("span",{className:"text-sm text-gray-500 dark:text-gray-400",children:f.date||"No date"})]})]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>m(!0),icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]})}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Article Details"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Category"}),(0,Gt.jsxs)("select",{value:f.category||"",onChange:t=>p("category",t.target.value),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white",children:[(0,Gt.jsx)("option",{value:"",children:"Select category"}),h.map(t=>(0,Gt.jsx)("option",{value:t.name,children:t.name},t._id||t.name))]})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Category Color"}),(0,Gt.jsx)("select",{value:f.categoryColor||"blue",onChange:t=>p("categoryColor",t.target.value),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white",children:["blue","green","red","yellow","purple","pink","indigo","gray"].map(t=>(0,Gt.jsx)("option",{value:t,children:t.charAt(0).toUpperCase()+t.slice(1)},t))})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Date"}),(0,Gt.jsx)("input",{type:"text",value:f.date||"",onChange:t=>p("date",t.target.value),placeholder:"Dec 15, 2024",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Read Time"}),(0,Gt.jsx)("input",{type:"text",value:f.readTime||"",onChange:t=>p("readTime",t.target.value),placeholder:"5 min read",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{className:"md:col-span-2",children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Featured Image URL"}),(0,Gt.jsx)("input",{type:"text",value:f.image||"",onChange:t=>p("image",t.target.value),placeholder:"https://...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),f.image&&(0,Gt.jsx)("img",{src:f.image,alt:"Preview",className:"mt-2 w-full h-40 object-cover rounded-lg"})]}),(0,Gt.jsxs)("div",{className:"md:col-span-2",children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Excerpt"}),(0,Gt.jsx)("textarea",{value:f.excerpt||"",onChange:t=>p("excerpt",t.target.value),rows:3,placeholder:"Brief article summary...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]})]})})]}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Content"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"h-96",children:(0,Gt.jsx)(zd,{theme:"snow",value:f.content||"",onChange:t=>p("content",t),className:"h-full bg-white dark:bg-gray-700",modules:{toolbar:[[{header:[1,2,3,4,5,6,!1]}],["bold","italic","underline","strike"],[{list:"ordered"},{list:"bullet"}],[{indent:"-1"},{indent:"+1"}],[{color:[]},{background:[]}],[{align:[]}],["link","image","video"],["clean"]]}})})})]}),(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"flex justify-between items-center",children:[(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:function(){const t={_id:String(Date.now()),tag:f.category||"Featured",title:f.title,excerpt:f.excerpt,image:f.image,readTime:f.readTime};e(e=>Ht(Ht({},e),{},{slides:[...e.slides||[],t]})),a.success("Promoted to hero slides!")},children:"\u2b50 Promote to Hero"}),(0,Gt.jsxs)("div",{className:"flex gap-2",children:[(0,Gt.jsx)(ge,{variant:"secondary",onClick:b,children:"Save Draft"}),(0,Gt.jsx)(ge,{onClick:function(){p("published",!0),setTimeout(()=>{b(),a.success("Article published!")},100)},children:"Publish"})]})]})})})]})}),(0,Gt.jsx)(Fd,{isOpen:c,onClose:()=>m(!1),onConfirm:function(){e(t=>Ht(Ht({},t),{},{articles:t.articles.filter((t,e)=>e!==n)})),o(0),m(!1),a.success("Article deleted")},title:"Delete Article",message:'Are you sure you want to delete "'.concat(f.title,'"? This action cannot be undone.'),confirmText:"Delete",variant:"danger"})]})}function _d(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),[n,o]=(0,i.useState)(!1),[s,r]=(0,i.useState)(!1),[l,d]=(0,i.useState)(null),c=(null===t||void 0===t?void 0:t.categories)||[];function m(){d((arguments.length>0&&void 0!==arguments[0]?arguments[0]:null)||{_id:String(Date.now()),name:"",image:"",count:"",slug:""}),o(!0)}return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Categories",subtitle:"".concat(c.length," total categories"),action:(0,Gt.jsx)(ge,{onClick:()=>m(),icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4v16m8-8H4"})}),children:"Add Category"})})}),0===c.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No categories yet"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Create your first category to organize articles"}),(0,Gt.jsx)(ge,{onClick:()=>m(),children:"Create Category"})]})}):(0,Gt.jsx)("div",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6",children:c.map((t,e)=>(0,Gt.jsxs)(ce,{hover:!0,className:"group",children:[(0,Gt.jsxs)("div",{className:"aspect-video relative rounded-lg overflow-hidden mb-4",children:[t.image?(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-full h-full object-cover"}):(0,Gt.jsx)("div",{className:"w-full h-full bg-gradient-to-br from-blue-400 to-purple-500 flex items-center justify-center",children:(0,Gt.jsx)("svg",{className:"w-12 h-12 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})})}),(0,Gt.jsxs)("div",{className:"absolute inset-0 bg-black bg-opacity-0 group-hover:bg-opacity-40 transition flex items-center justify-center gap-2 opacity-0 group-hover:opacity-100",children:[(0,Gt.jsx)("button",{onClick:()=>m(t),className:"p-2 bg-white rounded-lg hover:bg-gray-100 transition",children:(0,Gt.jsx)("svg",{className:"w-5 h-5 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M11 5H6a2 2 0 00-2 2v11a2 2 0 002 2h11a2 2 0 002-2v-5m-1.414-9.414a2 2 0 112.828 2.828L11.828 15H9v-2.828l8.586-8.586z"})})}),(0,Gt.jsx)("button",{onClick:()=>(d(t),void r(!0)),className:"p-2 bg-white rounded-lg hover:bg-red-50 transition",children:(0,Gt.jsx)("svg",{className:"w-5 h-5 text-red-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]})]}),(0,Gt.jsx)("h3",{className:"font-bold text-lg text-gray-900 dark:text-white mb-1",children:t.name}),t.count&&(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400",children:t.count})]},t._id||t.id||e))}),(0,Gt.jsx)(Rd,{isOpen:n,onClose:()=>o(!1),title:null!==l&&void 0!==l&&l._id||null!==l&&void 0!==l&&l.id?"Edit Category":"New Category",size:"md",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>o(!1),children:"Cancel"}),(0,Gt.jsx)(ge,{onClick:function(){if(l._id||l.id)e(t=>Ht(Ht({},t),{},{categories:t.categories.map(t=>(t._id||t.id)===(l._id||l.id)?l:t)})),a.success("Category updated!");else{const t=Ht(Ht({},l),{},{_id:String(Date.now())});e(e=>Ht(Ht({},e),{},{categories:[t,...e.categories||[]]})),a.success("Category created!")}o(!1)},children:"Save"})]}),children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Name"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.name)||"",onChange:t=>d(Ht(Ht({},l),{},{name:t.target.value})),placeholder:"e.g., Dog Health",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Image URL"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.image)||"",onChange:t=>d(Ht(Ht({},l),{},{image:t.target.value})),placeholder:"https://...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(null===l||void 0===l?void 0:l.image)&&(0,Gt.jsx)("img",{src:l.image,alt:"Preview",className:"mt-2 w-full h-40 object-cover rounded-lg"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Description (optional)"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.count)||"",onChange:t=>d(Ht(Ht({},l),{},{count:t.target.value})),placeholder:"e.g., Expert guides on canine health",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})}),(0,Gt.jsx)(Fd,{isOpen:s,onClose:()=>r(!1),onConfirm:function(){const t=l._id||l.id;e(e=>Ht(Ht({},e),{},{categories:e.categories.filter(e=>(e._id||e.id)!==t)})),a.success("Category deleted"),r(!1)},title:"Delete Category",message:'Are you sure you want to delete "'.concat(null===l||void 0===l?void 0:l.name,'"? This action cannot be undone.'),confirmText:"Delete",variant:"danger"})]})}function Od(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),[n,o]=(0,i.useState)(!1),[s,r]=(0,i.useState)(!1),[l,d]=(0,i.useState)(null),c=(null===t||void 0===t?void 0:t.experts)||[];function m(){d((arguments.length>0&&void 0!==arguments[0]?arguments[0]:null)||{name:"",title:"",specialty:"",image:"",bio:""}),o(!0)}return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Medical Experts",subtitle:"".concat(c.length," expert profiles"),action:(0,Gt.jsx)(ge,{onClick:()=>m(),icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4v16m8-8H4"})}),children:"Add Expert"})})}),0===c.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4.354a4 4 0 110 5.292M15 21H3v-1a6 6 0 0112 0v1zm0 0h6v-1a6 6 0 00-9-5.197M13 7a4 4 0 11-8 0 4 4 0 018 0z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No experts yet"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Add medical professionals to build credibility"}),(0,Gt.jsx)(ge,{onClick:()=>m(),children:"Add Expert"})]})}):(0,Gt.jsx)("div",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6",children:c.map((t,e)=>{var a;return(0,Gt.jsx)(ce,{hover:!0,className:"group",children:(0,Gt.jsxs)("div",{className:"flex flex-col items-center text-center",children:[(0,Gt.jsxs)("div",{className:"relative mb-4",children:[(0,Gt.jsx)("div",{className:"w-24 h-24 rounded-full overflow-hidden bg-gradient-to-br from-blue-400 to-purple-500",children:t.image?(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-full h-full object-cover"}):(0,Gt.jsx)("div",{className:"w-full h-full flex items-center justify-center text-white text-3xl font-bold",children:(null===(a=t.name)||void 0===a?void 0:a.charAt(0))||"?"})}),(0,Gt.jsxs)("div",{className:"absolute -bottom-2 -right-2 flex gap-1 opacity-0 group-hover:opacity-100 transition",children:[(0,Gt.jsx)("button",{onClick:()=>m(t),className:"p-2 bg-white dark:bg-gray-700 rounded-full shadow-lg hover:bg-gray-100 dark:hover:bg-gray-600 transition",children:(0,Gt.jsx)("svg",{className:"w-4 h-4 text-gray-700 dark:text-gray-300",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M11 5H6a2 2 0 00-2 2v11a2 2 0 002 2h11a2 2 0 002-2v-5m-1.414-9.414a2 2 0 112.828 2.828L11.828 15H9v-2.828l8.586-8.586z"})})}),(0,Gt.jsx)("button",{onClick:()=>function(t){d(t),r(!0)}(t),className:"p-2 bg-white dark:bg-gray-700 rounded-full shadow-lg hover:bg-red-50 dark:hover:bg-red-900/20 transition",children:(0,Gt.jsx)("svg",{className:"w-4 h-4 text-red-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]})]}),(0,Gt.jsx)("h3",{className:"font-bold text-lg text-gray-900 dark:text-white mb-1",children:t.name}),(0,Gt.jsx)("p",{className:"text-sm font-medium text-blue-600 dark:text-blue-400 mb-1",children:t.title}),(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400",children:t.specialty}),t.bio&&(0,Gt.jsx)("p",{className:"text-sm text-gray-600 dark:text-gray-300 mt-3 line-clamp-2",children:t.bio})]})},t._id||e)})}),(0,Gt.jsx)(Rd,{isOpen:n,onClose:()=>o(!1),title:null!==l&&void 0!==l&&l._id?"Edit Expert":"New Expert",size:"md",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>o(!1),children:"Cancel"}),(0,Gt.jsx)(ge,{onClick:function(){if(l._id)e(t=>Ht(Ht({},t),{},{experts:t.experts.map(t=>t._id===l._id?l:t)})),a.success("Expert updated!");else{const t=Ht(Ht({},l),{},{_id:String(Date.now())});e(e=>Ht(Ht({},e),{},{experts:[t,...e.experts||[]]})),a.success("Expert added!")}o(!1)},children:"Save"})]}),children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Name"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.name)||"",onChange:t=>d(Ht(Ht({},l),{},{name:t.target.value})),placeholder:"Dr. Jane Smith",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Title/Credentials"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.title)||"",onChange:t=>d(Ht(Ht({},l),{},{title:t.target.value})),placeholder:"DVM, DACVIM",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Specialty"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.specialty)||"",onChange:t=>d(Ht(Ht({},l),{},{specialty:t.target.value})),placeholder:"Small Animal Internal Medicine",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Photo URL"}),(0,Gt.jsx)("input",{type:"text",value:(null===l||void 0===l?void 0:l.image)||"",onChange:t=>d(Ht(Ht({},l),{},{image:t.target.value})),placeholder:"https://...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(null===l||void 0===l?void 0:l.image)&&(0,Gt.jsx)("img",{src:l.image,alt:"Preview",className:"mt-2 w-24 h-24 rounded-full object-cover mx-auto"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Bio (optional)"}),(0,Gt.jsx)("textarea",{rows:3,value:(null===l||void 0===l?void 0:l.bio)||"",onChange:t=>d(Ht(Ht({},l),{},{bio:t.target.value})),placeholder:"Brief professional background...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})}),(0,Gt.jsx)(Fd,{isOpen:s,onClose:()=>r(!1),onConfirm:function(){e(t=>Ht(Ht({},t),{},{experts:t.experts.filter(t=>t._id!==l._id)})),a.success("Expert  removed"),r(!1)},title:"Remove Expert",message:'Are you sure you want to remove "'.concat(null===l||void 0===l?void 0:l.name,'"? This action cannot be undone.'),confirmText:"Remove",variant:"danger"})]})}function Ud(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),n=(0,i.useRef)(null),[o,s]=(0,i.useState)(!1),[r,l]=(0,i.useState)(!1),[d,c]=(0,i.useState)(null),[m,u]=(0,i.useState)(null),[h,f]=(0,i.useState)("all"),g=(null===t||void 0===t?void 0:t.media)||[];function p(t){navigator.clipboard.writeText(t),a.success("URL copied to clipboard")}const y=g.filter(t=>"all"===h||("images"===h?t.type.startsWith("image"):"videos"===h?t.type.startsWith("video"):"documents"!==h||!t.type.startsWith("image")&&!t.type.startsWith("video")));function b(t){if(0===t)return"0 Bytes";const e=Math.floor(Math.log(t)/Math.log(1024));return Math.round(t/Math.pow(1024,e)*100)/100+" "+["Bytes","KB","MB","GB"][e]}function v(t){return t.startsWith("image")?"\ud83d\uddbc\ufe0f":t.startsWith("video")?"\ud83c\udfa5":t.includes("pdf")?"\ud83d\udcc4":"\ud83d\udcce"}return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Media Library",subtitle:"".concat(y.length," of ").concat(g.length," items"),action:(0,Gt.jsx)(ge,{onClick:()=>{var t;return null===(t=n.current)||void 0===t?void 0:t.click()},icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 16a4 4 0 01-.88-7.903A5 5 0 1115.9 6L16 6a5 5 0 011 9.9M15 13l-3-3m0 0l-3 3m3-3v12"})}),children:"Upload Files"})}),(0,Gt.jsxs)(ue,{children:[(0,Gt.jsx)("input",{ref:n,type:"file",multiple:!0,accept:"image/*,video/*,.pdf,.doc,.docx",onChange:t=>function(t){const i=Array.from(t).map(t=>({name:t.name,type:t.type,size:t.size,url:URL.createObjectURL(t),uploadedAt:(new Date).toISOString(),_id:String(Date.now()+Math.random())}));e(t=>Ht(Ht({},t),{},{media:[...i,...t.media||[]]})),a.success("".concat(i.length," file(s) uploaded"))}(t.target.files),className:"hidden"}),(0,Gt.jsxs)("div",{className:"flex gap-2 mb-4",children:[(0,Gt.jsxs)("button",{onClick:()=>f("all"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("all"===h?"bg-blue-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:["All (",g.length,")"]}),(0,Gt.jsxs)("button",{onClick:()=>f("images"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("images"===h?"bg-blue-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:["Images (",g.filter(t=>t.type.startsWith("image")).length,")"]}),(0,Gt.jsxs)("button",{onClick:()=>f("videos"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("videos"===h?"bg-blue-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:["Videos (",g.filter(t=>t.type.startsWith("video")).length,")"]}),(0,Gt.jsxs)("button",{onClick:()=>f("documents"),className:"px-3 py-1 rounded-lg text-sm font-medium transition ".concat("documents"===h?"bg-blue-600 text-white":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300"),children:["Documents (",g.filter(t=>!t.type.startsWith("image")&&!t.type.startsWith("video")).length,")"]})]})]})]}),0===y.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 16l4.586-4.586a2 2 0 012.828 0L16 16m-2-2l1.586-1.586a2 2 0 012.828 0L20 14m-6-6h.01M6 20h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No media files"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Upload images, videos, or documents"}),(0,Gt.jsx)(ge,{onClick:()=>{var t;return null===(t=n.current)||void 0===t?void 0:t.click()},children:"Upload Files"})]})}):(0,Gt.jsx)("div",{className:"grid grid-cols-2 md:grid-cols-3 lg:grid-cols-4 gap-4",children:y.map((t,e)=>{const a=g.indexOf(t);return(0,Gt.jsxs)(ce,{padding:"p-0",className:"group overflow-hidden",children:[(0,Gt.jsxs)("div",{className:"relative aspect-square bg-gray-100 dark:bg-gray-700",children:[t.type.startsWith("image")?(0,Gt.jsx)("img",{src:t.url,alt:t.name,className:"w-full h-full object-cover"}):t.type.startsWith("video")?(0,Gt.jsx)("video",{src:t.url,className:"w-full h-full object-cover"}):(0,Gt.jsx)("div",{className:"w-full h-full flex items-center justify-center text-4xl",children:v(t.type)}),(0,Gt.jsxs)("div",{className:"absolute inset-0 bg-black bg-opacity-0 group-hover:bg-opacity-60 transition flex items-center justify-center gap-2 opacity-0 group-hover:opacity-100",children:[(0,Gt.jsx)("button",{onClick:()=>function(t,e){c(t),u(e),s(!0)}(t,a),className:"p-2 bg-white rounded-lg hover:bg-gray-100 transition",title:"View",children:(0,Gt.jsxs)("svg",{className:"w-5 h-5 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:[(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M15 12a3 3 0 11-6 0 3 3 0 016 0z"}),(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M2.458 12C3.732 7.943 7.523 5 12 5c4.478 0 8.268 2.943 9.542 7-1.274 4.057-5.064 7-9.542 7-4.477 0-8.268-2.943-9.542-7z"})]})}),(0,Gt.jsx)("button",{onClick:()=>p(t.url),className:"p-2 bg-white rounded-lg hover:bg-gray-100 transition",title:"Copy URL",children:(0,Gt.jsx)("svg",{className:"w-5 h-5 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})})}),(0,Gt.jsx)("button",{onClick:()=>function(t,e){c(t),u(e),l(!0)}(t,a),className:"p-2 bg-white rounded-lg hover:bg-red-50 transition",title:"Delete",children:(0,Gt.jsx)("svg",{className:"w-5 h-5 text-red-600",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]})]}),(0,Gt.jsxs)("div",{className:"p-3",children:[(0,Gt.jsx)("p",{className:"text-sm font-medium text-gray-900 dark:text-white truncate",title:t.name,children:t.name}),(0,Gt.jsx)("p",{className:"text-xs text-gray-500 dark:text-gray-400 mt-1",children:b(t.size)})]})]},t._id||e)})}),(0,Gt.jsx)(Rd,{isOpen:o,onClose:()=>s(!1),title:null===d||void 0===d?void 0:d.name,size:"lg",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>s(!1),children:"Close"}),(0,Gt.jsx)(ge,{onClick:()=>p(null===d||void 0===d?void 0:d.url),children:"Copy URL"}),(0,Gt.jsx)("a",{href:null===d||void 0===d?void 0:d.url,download:null===d||void 0===d?void 0:d.name,children:(0,Gt.jsx)(ge,{variant:"secondary",children:"Download"})})]}),children:d&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[d.type.startsWith("image")?(0,Gt.jsx)("img",{src:d.url,alt:d.name,className:"w-full rounded-lg"}):d.type.startsWith("video")?(0,Gt.jsx)("video",{src:d.url,controls:!0,className:"w-full rounded-lg"}):(0,Gt.jsxs)("div",{className:"text-center py-8",children:[(0,Gt.jsx)("div",{className:"text-6xl mb-4",children:v(d.type)}),(0,Gt.jsx)("p",{className:"text-gray-600 dark:text-gray-400",children:d.type})]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-2 gap-4 text-sm",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400",children:"File Size"}),(0,Gt.jsx)("p",{className:"font-medium text-gray-900 dark:text-white",children:b(d.size)})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400",children:"Type"}),(0,Gt.jsx)("p",{className:"font-medium text-gray-900 dark:text-white",children:d.type})]}),(0,Gt.jsxs)("div",{className:"col-span-2",children:[(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400",children:"URL"}),(0,Gt.jsx)("p",{className:"font-medium text-gray-900 dark:text-white text-xs break-all",children:d.url})]})]})]})}),(0,Gt.jsx)(Fd,{isOpen:r,onClose:()=>l(!1),onConfirm:function(){e(t=>Ht(Ht({},t),{},{media:t.media.filter((t,e)=>e!==m)})),a.success("Media deleted"),l(!1)},title:"Delete Media",message:'Are you sure you want to delete "'.concat(null===d||void 0===d?void 0:d.name,'"? This action cannot be undone.'),confirmText:"Delete",variant:"danger"})]})}function Hd(){var t,e,a,n,o,s,r,l;const{siteData:d,setSiteData:c}=Kt()||{},m=se(),[u,h]=(0,i.useState)("hero"),[f,g]=(0,i.useState)(!1),[p,y]=(0,i.useState)({type:"",index:null});function b(){c(t=>Ht(Ht({},t),{},{slides:[{tag:"Featured",title:"New Slide",excerpt:"",image:"",readTime:"5 min read"},...t.slides||[]]})),m.success("Slide added")}function v(t,e,a){c(i=>Ht(Ht({},i),{},{slides:i.slides.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}function w(t,e,a){c(i=>Ht(Ht({},i),{},{stats:i.stats.map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}function x(t,e){c(a=>Ht(Ht({},a),{},{newsletter:Ht(Ht({},a.newsletter||{}),{},{[t]:e})}))}function k(t,e){c(a=>Ht(Ht({},a),{},{footer:Ht(Ht({},a.footer||{}),{},{[t]:e})}))}function I(t,e,a){c(i=>{var n;return Ht(Ht({},i),{},{footer:Ht(Ht({},i.footer),{},{socialLinks:((null===(n=i.footer)||void 0===n?void 0:n.socialLinks)||[]).map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)})})})}const C=["shield","book","users","lab"];return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Homepage Builder",subtitle:"Customize your homepage sections"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"flex gap-2 overflow-x-auto pb-2",children:[{id:"hero",label:"Hero Slides",icon:"\ud83c\udfa8"},{id:"stats",label:"Statistics",icon:"\ud83d\udcca"},{id:"newsletter",label:"Newsletter",icon:"\ud83d\udce7"},{id:"footer",label:"Footer",icon:"\ud83d\udd17"}].map(t=>(0,Gt.jsxs)("button",{onClick:()=>h(t.id),className:"px-4 py-2 rounded-lg font-medium whitespace-nowrap transition ".concat(u===t.id?"bg-blue-600 text-white shadow-lg":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-600"),children:[(0,Gt.jsx)("span",{className:"mr-2",children:t.icon}),t.label]},t.id))})})]}),"hero"===u&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Hero Slides",subtitle:"".concat(((null===d||void 0===d?void 0:d.slides)||[]).length," active slides"),action:(0,Gt.jsx)(ge,{size:"sm",onClick:b,children:"+ Add Slide"})})}),0===((null===d||void 0===d?void 0:d.slides)||[]).length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"No slides yet"}),(0,Gt.jsx)(ge,{onClick:b,children:"Create First Slide"})]})}):((null===d||void 0===d?void 0:d.slides)||[]).map((t,e)=>(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)(ue,{children:[(0,Gt.jsxs)("div",{className:"flex justify-between items-start mb-4",children:[(0,Gt.jsxs)("h3",{className:"font-semibold text-lg",children:["Slide ",e+1]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){y({type:"slide",index:t}),g(!0)}(e),children:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]}),(0,Gt.jsxs)("div",{className:"space-y-3",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-2 gap-3",children:[(0,Gt.jsx)("input",{type:"text",value:t.tag||"",onChange:t=>v(e,"tag",t.target.value),placeholder:"Tag (e.g., Featured)",className:"px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(0,Gt.jsx)("input",{type:"text",value:t.readTime||"",onChange:t=>v(e,"readTime",t.target.value),placeholder:"Read time",className:"px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsx)("input",{type:"text",value:t.title||"",onChange:t=>v(e,"title",t.target.value),placeholder:"Slide title",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 font-semibold"}),(0,Gt.jsx)("input",{type:"text",value:t.image||"",onChange:t=>v(e,"image",t.target.value),placeholder:"Image URL",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),t.image&&(0,Gt.jsx)("img",{src:t.image,alt:"Preview",className:"w-full h-40 object-cover rounded-lg"}),(0,Gt.jsx)("textarea",{value:t.excerpt||"",onChange:t=>v(e,"excerpt",t.target.value),placeholder:"Slide description",rows:3,className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})},e))]}),"stats"===u&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Statistics",subtitle:"Homepage stat counters",action:(0,Gt.jsx)(ge,{size:"sm",onClick:function(){c(t=>Ht(Ht({},t),{},{stats:[{value:"100+",label:"New Stat",icon:"shield"},...t.stats||[]]})),m.success("Stat added")},children:"+ Add Stat"})})}),(0,Gt.jsx)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:((null===d||void 0===d?void 0:d.stats)||[]).map((t,e)=>(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)(ue,{children:[(0,Gt.jsxs)("div",{className:"flex justify-between items-start mb-3",children:[(0,Gt.jsxs)("h3",{className:"font-semibold",children:["Stat ",e+1]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){y({type:"stat",index:t}),g(!0)}(e),children:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),(0,Gt.jsxs)("div",{className:"space-y-2",children:[(0,Gt.jsx)("input",{type:"text",value:t.value||"",onChange:t=>w(e,"value",t.target.value),placeholder:"Value (e.g., 500+)",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 font-bold text-lg"}),(0,Gt.jsx)("input",{type:"text",value:t.label||"",onChange:t=>w(e,"label",t.target.value),placeholder:"Label",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(0,Gt.jsx)("select",{value:t.icon||"shield",onChange:t=>w(e,"icon",t.target.value),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700",children:C.map(t=>(0,Gt.jsx)("option",{value:t,children:t.charAt(0).toUpperCase()+t.slice(1)},t))})]})]})},e))})]}),"newsletter"===u&&(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Newsletter Section",subtitle:"Subscription call-to-action"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Title"}),(0,Gt.jsx)("input",{type:"text",value:(null===d||void 0===d||null===(t=d.newsletter)||void 0===t?void 0:t.title)||"",onChange:t=>x("title",t.target.value),placeholder:"Stay Updated",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Subtitle"}),(0,Gt.jsx)("textarea",{value:(null===d||void 0===d||null===(e=d.newsletter)||void 0===e?void 0:e.subtitle)||"",onChange:t=>x("subtitle",t.target.value),placeholder:"Get the latest vet-reviewed articles...",rows:2,className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Button Text"}),(0,Gt.jsx)("input",{type:"text",value:(null===d||void 0===d||null===(a=d.newsletter)||void 0===a?void 0:a.buttonText)||"",onChange:t=>x("buttonText",t.target.value),placeholder:"Subscribe Now",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Footer Text"}),(0,Gt.jsx)("input",{type:"text",value:(null===d||void 0===d||null===(n=d.newsletter)||void 0===n?void 0:n.footerText)||"",onChange:t=>x("footerText",t.target.value),placeholder:"Join 50,000+ subscribers...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})})]}),"footer"===u&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Footer Content"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Description"}),(0,Gt.jsx)("textarea",{value:(null===d||void 0===d||null===(o=d.footer)||void 0===o?void 0:o.description)||"",onChange:t=>k("description",t.target.value),rows:2,className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Copyright Text"}),(0,Gt.jsx)("input",{type:"text",value:(null===d||void 0===d||null===(s=d.footer)||void 0===s?void 0:s.copyright)||"",onChange:t=>k("copyright",t.target.value),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Disclaimer"}),(0,Gt.jsx)("textarea",{value:(null===d||void 0===d||null===(r=d.footer)||void 0===r?void 0:r.disclaimerText)||"",onChange:t=>k("disclaimerText",t.target.value),rows:2,className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})})]}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Social Media Links",action:(0,Gt.jsx)(ge,{size:"sm",onClick:function(){c(t=>{var e;return Ht(Ht({},t),{},{footer:Ht(Ht({},t.footer),{},{socialLinks:[...(null===(e=t.footer)||void 0===e?void 0:e.socialLinks)||[],{platform:"New Platform",url:"#"}]})})})},children:"+ Add Link"})}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"space-y-3",children:((null===d||void 0===d||null===(l=d.footer)||void 0===l?void 0:l.socialLinks)||[]).map((t,e)=>(0,Gt.jsxs)("div",{className:"flex gap-2",children:[(0,Gt.jsx)("input",{type:"text",value:t.platform||"",onChange:t=>I(e,"platform",t.target.value),placeholder:"Platform",className:"flex-1 px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(0,Gt.jsx)("input",{type:"text",value:t.url||"",onChange:t=>I(e,"url",t.target.value),placeholder:"URL",className:"flex-1 px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){c(e=>{var a;return Ht(Ht({},e),{},{footer:Ht(Ht({},e.footer),{},{socialLinks:((null===(a=e.footer)||void 0===a?void 0:a.socialLinks)||[]).filter((e,a)=>a!==t)})})})}(e),children:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]},e))})})]})]}),(0,Gt.jsx)(Fd,{isOpen:f,onClose:()=>g(!1),onConfirm:"slide"===p.type?function(){c(t=>Ht(Ht({},t),{},{slides:t.slides.filter((t,e)=>e!==p.index)})),m.success("Slide removed"),g(!1)}:function(){c(t=>Ht(Ht({},t),{},{stats:t.stats.filter((t,e)=>e!==p.index)})),m.success("Stat removed"),g(!1)},title:"Delete ".concat("slide"===p.type?"Slide":"Stat"),message:"Are you sure you want to delete this ".concat(p.type,"?"),confirmText:"Delete",variant:"danger"})]})}function Vd(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),[n,o]=(0,i.useState)(!1),[s,r]=(0,i.useState)(null),[l,d]=(0,i.useState)({}),c=(null===t||void 0===t?void 0:t.research)||[];function m(){e(t=>Ht(Ht({},t),{},{research:[{title:"New Study",type:"Peer Reviewed",typeColor:"blue",year:(new Date).getFullYear().toString(),authors:"",journal:"",abstract:"",content:"",pdfUrl:"",_id:String(Date.now())},...t.research||[]]})),a.success("Research paper added")}function u(t,a,i){e(e=>Ht(Ht({},e),{},{research:e.research.map((e,n)=>n===t?Ht(Ht({},e),{},{[a]:i}):e)}))}const h=["Peer Reviewed","Clinical Study","Case Report","Meta-Analysis","Review"],f=["blue","green","purple","red","orange"];return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Research & Journals",subtitle:"".concat(c.length," publications"),action:(0,Gt.jsx)(ge,{onClick:m,icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4v16m8-8H4"})}),children:"Add Paper"})})}),0===c.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.384-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No research papers yet"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Add published research to establish credibility"}),(0,Gt.jsx)(ge,{onClick:m,children:"Add Research"})]})}):(0,Gt.jsx)("div",{className:"space-y-4",children:c.map((t,e)=>(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)(ue,{children:[(0,Gt.jsxs)("div",{className:"flex justify-between items-start mb-4",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 flex-wrap",children:[(0,Gt.jsx)("select",{value:t.type||"Peer Reviewed",onChange:t=>u(e,"type",t.target.value),className:"px-2 py-1 text-sm border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white",children:h.map(t=>(0,Gt.jsx)("option",{value:t,children:t},t))}),(0,Gt.jsx)("select",{value:t.typeColor||"blue",onChange:t=>u(e,"typeColor",t.target.value),className:"px-2 py-1 text-sm border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white",children:f.map(t=>(0,Gt.jsx)("option",{value:t,children:t},t))}),(0,Gt.jsx)("input",{type:"text",value:t.year||"",onChange:t=>u(e,"year",t.target.value),placeholder:"Year",className:"w-20 px-2 py-1 text-sm border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),t.pdfUrl&&(0,Gt.jsxs)("span",{className:"px-2 py-1 bg-green-100 dark:bg-green-900 text-green-800 dark:text-green-200 text-xs rounded-full flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-3 h-3",fill:"currentColor",viewBox:"0 0 20 20",children:(0,Gt.jsx)("path",{d:"M4 4a2 2 0 012-2h4.586A2 2 0 0112 2.586L15.414 6A2 2 0 0116 7.414V16a2 2 0 01-2 2H6a2 2 0 01-2-2V4z"})}),"PDF Linked"]})]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){r(t),o(!0)}(e),icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]}),(0,Gt.jsxs)("div",{className:"space-y-3",children:[(0,Gt.jsx)("input",{type:"text",value:t.title||"",onChange:t=>u(e,"title",t.target.value),placeholder:"Research Title",className:"w-full text-lg font-semibold px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-3",children:[(0,Gt.jsx)("input",{type:"text",value:t.authors||"",onChange:t=>u(e,"authors",t.target.value),placeholder:"Authors (e.g., Smith, J., Doe, M.)",className:"px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),(0,Gt.jsx)("input",{type:"text",value:t.journal||"",onChange:t=>u(e,"journal",t.target.value),placeholder:"Journal Name, Vol(Issue)",className:"px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Abstract (Summary)"}),(0,Gt.jsx)("textarea",{value:t.abstract||"",onChange:t=>u(e,"abstract",t.target.value),rows:3,placeholder:"Brief abstract summary for preview...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{className:"border-t border-gray-200 dark:border-gray-700 pt-4",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-2",children:[(0,Gt.jsx)("label",{className:"text-sm font-medium text-gray-700 dark:text-gray-300",children:"Full Content"}),(0,Gt.jsxs)("button",{onClick:()=>function(t){d(e=>Ht(Ht({},e),{},{[t]:!e[t]}))}(e),className:"text-sm text-blue-600 dark:text-blue-400 hover:underline",children:[l[e]?"Collapse":"Expand"," Editor"]})]}),l[e]&&(0,Gt.jsx)("div",{className:"h-96",children:(0,Gt.jsx)(zd,{theme:"snow",value:t.content||"",onChange:t=>u(e,"content",t),className:"h-full bg-white dark:bg-gray-700",modules:{toolbar:[[{header:[1,2,3,4,5,6,!1]}],["bold","italic","underline","strike"],[{list:"ordered"},{list:"bullet"}],[{indent:"-1"},{indent:"+1"}],[{color:[]},{background:[]}],[{align:[]}],["link","image"],["clean"]]}})})]}),(0,Gt.jsxs)("div",{className:"border-t border-gray-200 dark:border-gray-700 pt-4",children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-2",children:"\ud83d\udcc4 Research Paper PDF URL"}),(0,Gt.jsx)("input",{type:"text",value:t.pdfUrl||"",onChange:t=>u(e,"pdfUrl",t.target.value),placeholder:"https://... (link to PDF hosted elsewhere)",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),t.pdfUrl&&(0,Gt.jsxs)("div",{className:"mt-2 flex items-center gap-2 p-2 bg-green-50 dark:bg-green-900/20 rounded-lg",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5 text-green-600 dark:text-green-400",fill:"currentColor",viewBox:"0 0 20 20",children:(0,Gt.jsx)("path",{d:"M4 4a2 2 0 012-2h4.586A2 2 0 0112 2.586L15.414 6A2 2 0 0116 7.414V16a2 2 0 01-2 2H6a2 2 0 01-2-2V4z"})}),(0,Gt.jsx)("a",{href:t.pdfUrl,target:"_blank",rel:"noopener noreferrer",className:"flex-1 text-sm text-blue-600 dark:text-blue-400 hover:underline truncate",children:t.pdfUrl})]}),(0,Gt.jsx)("p",{className:"mt-1 text-xs text-gray-500 dark:text-gray-400",children:"Enter URL to PDF hosted on GitHub, cloud storage, or other service"})]})]})]})},t._id||e))}),(0,Gt.jsx)(Fd,{isOpen:n,onClose:()=>o(!1),onConfirm:function(){e(t=>Ht(Ht({},t),{},{research:t.research.filter((t,e)=>e!==s)})),a.success("Research paper removed"),o(!1)},title:"Delete Research",message:"Are you sure you want to delete this research paper?",confirmText:"Delete",variant:"danger"})]})}function Bd(){const{siteData:t,setSiteData:e}=Kt()||{},a=se(),[n,o]=(0,i.useState)(!1),[s,r]=(0,i.useState)(null),[l,d]=(0,i.useState)(""),c=(null===t||void 0===t?void 0:t.categories)||[];return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Category Hero Images",subtitle:"Customize banner images for category pages"})}),0===c.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No categories found"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400",children:"Create categories first to add hero images"})]})}):(0,Gt.jsx)("div",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6",children:c.map(t=>(0,Gt.jsx)(ce,{padding:"p-0",hover:!0,onClick:()=>{return r(e=t),d(e.image||""),void o(!0);var e},className:"cursor-pointer group overflow-hidden",children:(0,Gt.jsxs)("div",{className:"relative aspect-video bg-gradient-to-br from-blue-400 to-purple-500",children:[t.image?(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-full h-full object-cover"}):(0,Gt.jsx)("div",{className:"w-full h-full flex items-center justify-center text-white",children:(0,Gt.jsx)("svg",{className:"w-16 h-16 opacity-50",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 16l4.586-4.586a2 2 0 012.828 0L16 16m-2-2l1.586-1.586a2 2 0 012.828 0L20 14m-6-6h.01M6 20h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"})})}),(0,Gt.jsx)("div",{className:"absolute inset-0 bg-black bg-opacity-0 group-hover:bg-opacity-40 transition flex items-center justify-center opacity-0 group-hover:opacity-100",children:(0,Gt.jsx)("svg",{className:"w-12 h-12 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M11 5H6a2 2 0 00-2 2v11a2 2 0 002 2h11a2 2 0 002-2v-5m-1.414-9.414a2 2 0 112.828 2.828L11.828 15H9v-2.828l8.586-8.586z"})})}),(0,Gt.jsxs)("div",{className:"absolute bottom-0 left-0 right-0 bg-gradient-to-t from-black via-black/70 to-transparent p-4",children:[(0,Gt.jsx)("h3",{className:"text-white font-bold text-lg",children:t.name}),t.image?(0,Gt.jsxs)("span",{className:"text-green-400 text-sm flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}),"Image set"]}):(0,Gt.jsx)("span",{className:"text-gray-300 text-sm",children:"No image"})]})]})},t._id||t.id))}),(0,Gt.jsx)(Rd,{isOpen:n,onClose:()=>o(!1),title:"Edit Hero Image - ".concat(null===s||void 0===s?void 0:s.name),size:"lg",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>o(!1),children:"Cancel"}),l&&(0,Gt.jsx)(ge,{variant:"danger",onClick:function(){d(""),a.info("Image URL cleared")},children:"Clear Image"}),(0,Gt.jsx)(ge,{onClick:function(){s&&(e(t=>Ht(Ht({},t),{},{categories:(t.categories||[]).map(t=>(t._id||t.id)===(s._id||s.id)?Ht(Ht({},t),{},{image:l}):t)})),a.success("Hero image updated!"),o(!1))},children:"Save Changes"})]}),children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Category"}),(0,Gt.jsx)("input",{type:"text",value:(null===s||void 0===s?void 0:s.name)||"",readOnly:!0,className:"w-full px-3 py-2 bg-gray-100 dark:bg-gray-700 border border-gray-300 dark:border-gray-600 rounded-lg cursor-not-allowed"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Hero Image URL"}),(0,Gt.jsx)("input",{type:"text",value:l,onChange:t=>d(t.target.value),placeholder:"https://example.com/image.jpg",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 focus:ring-2 focus:ring-blue-500 outline-none"}),(0,Gt.jsx)("p",{className:"text-xs text-gray-500 dark:text-gray-400 mt-1",children:"Enter a direct URL to an image (recommended: 1200x400px)"})]}),l&&(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-2",children:"Preview"}),(0,Gt.jsx)("div",{className:"rounded-lg overflow-hidden bg-gray-100 dark:bg-gray-900",children:(0,Gt.jsx)("img",{src:l,alt:"Preview",className:"w-full h-64 object-cover",onError:t=>{t.target.style.display="none",a.error("Invalid image URL")}})})]})]})})]})}function Gd(){const{siteData:t,setSiteData:e}=Kt()||{},a=(null===t||void 0===t?void 0:t.theme)||{primary:"#1e40af",secondary:"#374151",radius:12},n=(null===t||void 0===t?void 0:t.integrations)||{gaId:"",fbPixel:""};function o(t,a){e(e=>Ht(Ht({},e),{},{theme:Ht(Ht({},e.theme||{}),{},{[t]:a})}))}function s(t,a){e(e=>Ht(Ht({},e),{},{integrations:Ht(Ht({},e.integrations||{}),{},{[t]:a})}))}return(0,i.useEffect)(()=>{const t=document.documentElement;t.style.setProperty("--primary",a.primary),t.style.setProperty("--secondary",a.secondary),t.style.setProperty("--radius","".concat(a.radius,"px"))},[a.primary,a.secondary,a.radius]),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h1",{className:"text-2xl font-semibold mb-4",children:"Theme & Integrations"}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[(0,Gt.jsxs)("div",{className:"bg-white rounded shadow p-4 space-y-3",children:[(0,Gt.jsx)("div",{className:"font-semibold",children:"Theme"}),(0,Gt.jsx)("input",{type:"color",className:"border rounded px-3 py-2",value:a.primary,onChange:t=>o("primary",t.target.value)}),(0,Gt.jsx)("input",{type:"color",className:"border rounded px-3 py-2",value:a.secondary,onChange:t=>o("secondary",t.target.value)}),(0,Gt.jsx)("input",{type:"number",className:"border rounded px-3 py-2",value:a.radius,onChange:t=>o("radius",Number(t.target.value))})]}),(0,Gt.jsxs)("div",{className:"bg-white rounded shadow p-4 space-y-3",children:[(0,Gt.jsx)("div",{className:"font-semibold",children:"Integrations"}),(0,Gt.jsx)("input",{className:"border rounded px-3 py-2 w-full",placeholder:"Google Analytics ID",value:n.gaId||"",onChange:t=>s("gaId",t.target.value)}),(0,Gt.jsx)("input",{className:"border rounded px-3 py-2 w-full",placeholder:"Facebook Pixel ID",value:n.fbPixel||"",onChange:t=>s("fbPixel",t.target.value)})]})]})]})}function Wd(){var t,e,a,n,o,s,r,l,d,c;const{siteData:m,setSiteData:u}=Kt()||{},h=se(),[f,g]=(0,i.useState)("general");function p(t,e){u(a=>Ht(Ht({},a),{},{site:Ht(Ht({},a.site||{}),{},{[t]:e})}))}function y(t,e){u(a=>Ht(Ht({},a),{},{integrations:Ht(Ht({},a.integrations||{}),{},{[t]:e})}))}function b(t,e){u(a=>Ht(Ht({},a),{},{performance:Ht(Ht({},a.performance||{}),{},{[t]:e})}))}function v(t,e,a){u(i=>Ht(Ht({},i),{},{navigation:(i.navigation||[]).map((i,n)=>n===t?Ht(Ht({},i),{},{[e]:a}):i)}))}return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Site Settings",subtitle:"Configure your website"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"flex gap-2 overflow-x-auto pb-2",children:[{id:"general",label:"General",icon:"\u2699\ufe0f"},{id:"navigation",label:"Navigation",icon:"\ud83e\udded"},{id:"integrations",label:"Integrations",icon:"\ud83d\udd0c"},{id:"security",label:"Security",icon:"\ud83d\udd12"},{id:"advanced",label:"Advanced",icon:"\u26a1"}].map(t=>(0,Gt.jsxs)("button",{onClick:()=>g(t.id),className:"px-4 py-2 rounded-lg font-medium whitespace-nowrap transition ".concat(f===t.id?"bg-blue-600 text-white shadow-lg":"bg-gray-100 dark:bg-gray-700 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-600"),children:[(0,Gt.jsx)("span",{className:"mr-2",children:t.icon}),t.label]},t.id))})})]}),"general"===f&&(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"General Information"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Site Name"}),(0,Gt.jsx)("input",{type:"text",value:(null===m||void 0===m||null===(t=m.site)||void 0===t?void 0:t.name)||"",onChange:t=>p("name",t.target.value),placeholder:"My Vet Corner",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-lg font-semibold"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Tagline"}),(0,Gt.jsx)("input",{type:"text",value:(null===m||void 0===m||null===(e=m.site)||void 0===e?void 0:e.tagline)||"",onChange:t=>p("tagline",t.target.value),placeholder:"Expert Pet & Poultry Health Resources",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Description"}),(0,Gt.jsx)("textarea",{value:(null===m||void 0===m||null===(a=m.site)||void 0===a?void 0:a.description)||"",onChange:t=>p("description",t.target.value),rows:3,placeholder:"Your trusted source for veterinary information...",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Admin Password"}),(0,Gt.jsx)("input",{type:"text",value:(null===m||void 0===m?void 0:m.adminPassword)||"",onChange:t=>u(e=>Ht(Ht({},e),{},{adminPassword:t.target.value})),placeholder:"Change admin password",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"}),(0,Gt.jsx)("p",{className:"text-xs text-gray-500 dark:text-gray-400 mt-1",children:"Update this to secure your admin panel"})]})]})})]}),"navigation"===f&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Navigation Menu",subtitle:"Customize your site's main menu",action:(0,Gt.jsx)(ge,{size:"sm",onClick:function(){u(t=>Ht(Ht({},t),{},{navigation:[...t.navigation||[],{label:"New Menu",dropdown:[]}]})),h.success("Menu item added")},children:"+ Add Item"})})}),((null===m||void 0===m?void 0:m.navigation)||[]).map((t,e)=>(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)(ue,{children:[(0,Gt.jsxs)("div",{className:"flex justify-between items-start mb-3",children:[(0,Gt.jsxs)("h3",{className:"font-semibold",children:["Menu Item ",e+1]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){u(e=>Ht(Ht({},e),{},{navigation:(e.navigation||[]).filter((e,a)=>a!==t)})),h.success("Menu item removed")}(e),children:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})})})]}),(0,Gt.jsxs)("div",{className:"space-y-3",children:[(0,Gt.jsx)("input",{type:"text",value:t.label||"",onChange:t=>v(e,"label",t.target.value),placeholder:"Menu Label",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 font-medium"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-xs text-gray-500 dark:text-gray-400 mb-1",children:"Dropdown Items (comma-separated)"}),(0,Gt.jsx)("input",{type:"text",value:(t.dropdown||[]).join(", "),onChange:t=>v(e,"dropdown",t.target.value.split(",").map(t=>t.trim()).filter(Boolean)),placeholder:"Item 1, Item 2, Item 3",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})]})},e))]}),"integrations"===f&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Analytics & Tracking"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Google Analytics ID"}),(0,Gt.jsx)("input",{type:"text",value:(null===m||void 0===m||null===(n=m.integrations)||void 0===n?void 0:n.gaId)||"",onChange:t=>y("gaId",t.target.value),placeholder:"UA-XXXXX-Y or G-XXXXXXXXXX",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Facebook Pixel ID"}),(0,Gt.jsx)("input",{type:"text",value:(null===m||void 0===m||null===(o=m.integrations)||void 0===o?void 0:o.fbPixel)||"",onChange:t=>y("fbPixel",t.target.value),placeholder:"1234567890",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700"})]})]})})]}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Custom Scripts"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Script Injection (Advanced)"}),(0,Gt.jsx)("textarea",{value:(null===m||void 0===m||null===(s=m.settings)||void 0===s?void 0:s.injectScript)||"",onChange:t=>{return e="injectScript",a=t.target.value,void u(t=>Ht(Ht({},t),{},{settings:Ht(Ht({},t.settings||{}),{},{[e]:a})}));var e,a},rows:6,placeholder:"<script>...<\/script>",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 font-mono text-sm"}),(0,Gt.jsx)("p",{className:"text-xs text-gray-500 dark:text-gray-400 mt-1",children:"Scripts will be injected in the page header. Use with caution."})]})})]})]}),"security"===f&&(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Security Settings"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsx)("div",{className:"space-y-4",children:(0,Gt.jsxs)("div",{className:"flex items-center justify-between p-4 bg-gray-50 dark:bg-gray-700 rounded-lg",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-medium text-gray-900 dark:text-white",children:"Two-Factor Authentication"}),(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400",children:"Require 2FA for admin access (Mock)"})]}),(0,Gt.jsxs)("label",{className:"relative inline-flex items-center cursor-pointer",children:[(0,Gt.jsx)("input",{type:"checkbox",checked:(null===m||void 0===m||null===(r=m.security)||void 0===r?void 0:r.twoFARequired)||!1,onChange:t=>{return e="twoFARequired",a=t.target.checked,void u(t=>Ht(Ht({},t),{},{security:Ht(Ht({},t.security||{}),{},{[e]:a})}));var e,a},className:"sr-only peer"}),(0,Gt.jsx)("div",{className:"w-11 h-6 bg-gray-200 peer-focus:outline-none peer-focus:ring-4 peer-focus:ring-blue-300 dark:peer-focus:ring-blue-800 rounded-full peer dark:bg-gray-600 peer-checked:after:translate-x-full peer-checked:after:border-white after:content-[''] after:absolute after:top-[2px] after:left-[2px] after:bg-white after:border-gray-300 after:border after:rounded-full after:h-5 after:w-5 after:transition-all dark:border-gray-600 peer-checked:bg-blue-600"})]})]})})})]}),"advanced"===f&&(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Performance"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between p-4 bg-gray-50 dark:bg-gray-700 rounded-lg",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-medium text-gray-900 dark:text-white",children:"Lazy Load Images"}),(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400",children:"Improve page load speed"})]}),(0,Gt.jsxs)("label",{className:"relative inline-flex items-center cursor-pointer",children:[(0,Gt.jsx)("input",{type:"checkbox",checked:null===(l=null===m||void 0===m||null===(d=m.performance)||void 0===d?void 0:d.lazyImages)||void 0===l||l,onChange:t=>b("lazyImages",t.target.checked),className:"sr-only peer"}),(0,Gt.jsx)("div",{className:"w-11 h-6 bg-gray-200 peer-focus:outline-none peer-focus:ring-4 peer-focus:ring-blue-300 dark:peer-focus:ring-blue-800 rounded-full peer dark:bg-gray-600 peer-checked:after:translate-x-full peer-checked:after:border-white after:content-[''] after:absolute after:top-[2px] after:left-[2px] after:bg-white after:border-gray-300 after:border after:rounded-full after:h-5 after:w-5 after:transition-all dark:border-gray-600 peer-checked:bg-blue-600"})]})]}),(0,Gt.jsxs)("div",{className:"flex items-center justify-between p-4 bg-gray-50 dark:bg-gray-700 rounded-lg",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-medium text-gray-900 dark:text-white",children:"Prefetch Routes"}),(0,Gt.jsx)("p",{className:"text-sm text-gray-500 dark:text-gray-400",children:"Pre-load pages for faster navigation"})]}),(0,Gt.jsxs)("label",{className:"relative inline-flex items-center cursor-pointer",children:[(0,Gt.jsx)("input",{type:"checkbox",checked:(null===m||void 0===m||null===(c=m.performance)||void 0===c?void 0:c.prefetchRoutes)||!1,onChange:t=>b("prefetchRoutes",t.target.checked),className:"sr-only peer"}),(0,Gt.jsx)("div",{className:"w-11 h-6 bg-gray-200 peer-focus:outline-none peer-focus:ring-4 peer-focus:ring-blue-300 dark:peer-focus:ring-blue-800 rounded-full peer dark:bg-gray-600 peer-checked:after:translate-x-full peer-checked:after:border-white after:content-[''] after:absolute after:top-[2px] after:left-[2px] after:bg-white after:border-gray-300 after:border after:rounded-full after:h-5 after:w-5 after:transition-all dark:border-gray-600 peer-checked:bg-blue-600"})]})]})]})})]}),(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Localization"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Default Locale"}),(0,Gt.jsxs)("select",{value:(null===m||void 0===m?void 0:m.defaultLocale)||"en",onChange:t=>u(e=>Ht(Ht({},e),{},{defaultLocale:t.target.value})),className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700",children:[(0,Gt.jsx)("option",{value:"en",children:"English"}),(0,Gt.jsx)("option",{value:"es",children:"Spanish"}),(0,Gt.jsx)("option",{value:"fr",children:"French"}),(0,Gt.jsx)("option",{value:"de",children:"German"})]})]}),(0,Gt.jsx)("div",{children:(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 dark:text-gray-400",children:["Active Locales: ",((null===m||void 0===m?void 0:m.locales)||["en"]).join(", ")]})})]})})]})]})]})}function Qd(){const t=se(),[e,a]=(0,i.useState)([]),[n,o]=(0,i.useState)(!1),[s,r]=(0,i.useState)(null),[l,d]=(0,i.useState)({username:"",password:"",email:"",fullName:""}),[c,m]=(0,i.useState)(!1),[u,h]=(0,i.useState)({currentPassword:"",newUsername:"",newPassword:"",confirmPassword:""});function f(){d({username:"",password:"",email:"",fullName:""}),o(!0)}return(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"Admin Account",subtitle:"Manage administrator credentials"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"flex items-center justify-between p-4 bg-blue-50 dark:bg-blue-900/20 rounded-lg",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h3",{className:"font-semibold text-gray-900 dark:text-white",children:"Administrator Account"}),(0,Gt.jsxs)("p",{className:"text-sm text-gray-600 dark:text-gray-400 mt-1",children:["Current username: ",(0,Gt.jsx)("span",{className:"font-medium",children:localStorage.getItem("adminUsername")||"admin"})]})]}),(0,Gt.jsx)(ge,{onClick:function(){h({currentPassword:"",newUsername:"",newPassword:"",confirmPassword:""}),m(!0)},variant:"outline",icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M15 7a2 2 0 012 2m4 0a6 6 0 01-7.743 5.743L11 17H9v2H7v2H4a1 1 0 01-1-1v-2.586a1 1 0 01.293-.707l5.964-5.964A6 6 0 1121 9z"})}),children:"Change Credentials"})]})})]}),(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(me,{title:"Moderators",subtitle:"".concat(e.length," moderator accounts"),action:(0,Gt.jsx)(ge,{onClick:f,icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M18 9v3m0 0v3m0-3h3m-3 0h-3m-2-5a4 4 0 11-8 0 4 4 0 018 0zM3 20a6 6 0 0112 0v1H3v-1z"})}),children:"Add Moderator"})})}),0===e.length?(0,Gt.jsx)(ce,{children:(0,Gt.jsxs)("div",{className:"text-center py-12",children:[(0,Gt.jsx)("svg",{className:"w-16 h-16 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M17 20h5v-2a3 3 0 00-5.356-1.857M17 20H7m10 0v-2c0-.656-.126-1.283-.356-1.857M7 20H2v-2a3 3 0 015.356-1.857M7 20v-2c0-.656.126-1.283.356-1.857m0 0a5.002 5.002 0 019.288 0M15 7a3 3 0 11-6 0 3 3 0 016 0zm6 3a2 2 0 11-4 0 2 2 0 014 0zM7 10a2 2 0 11-4 0 2 2 0 014 0z"})}),(0,Gt.jsx)("h3",{className:"text-lg font-semibold text-gray-900 dark:text-white mb-2",children:"No moderators yet"}),(0,Gt.jsx)("p",{className:"text-gray-500 dark:text-gray-400 mb-4",children:"Add moderators to help manage content"}),(0,Gt.jsx)(ge,{onClick:f,children:"Add First Moderator"})]})}):(0,Gt.jsx)("div",{className:"space-y-4",children:e.map(t=>{var e,a;return(0,Gt.jsx)(ce,{hover:!0,children:(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"flex items-center justify-between",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-4",children:[(0,Gt.jsx)("div",{className:"w-12 h-12 rounded-full bg-gradient-to-br from-green-400 to-blue-500 flex items-center justify-center text-white font-bold text-lg",children:(null===(e=t.fullName)||void 0===e?void 0:e.charAt(0))||(null===(a=t.username)||void 0===a?void 0:a.charAt(0))||"M"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-semibold text-gray-900 dark:text-white",children:t.fullName||t.username}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3 text-sm text-gray-600 dark:text-gray-400",children:[(0,Gt.jsxs)("span",{className:"flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M16 7a4 4 0 11-8 0 4 4 0 018 0zM12 14a7 7 0 00-7 7h14a7 7 0 00-7-7z"})}),t.username]}),t.email&&(0,Gt.jsxs)("span",{className:"flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 8l7.89 5.26a2 2 0 002.22 0L21 8M5 19h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v10a2 2 0 002 2z"})}),t.email]})]}),(0,Gt.jsx)("span",{className:"inline-block mt-1 px-2 py-0.5 bg-green-100 dark:bg-green-900 text-green-800 dark:text-green-200 text-xs font-semibold rounded-full",children:"Moderator"})]})]}),(0,Gt.jsx)(ge,{variant:"ghost",size:"sm",onClick:()=>function(t){r(t)}(t),icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 7l-.867 12.142A2 2 0 0116.138 21H7.862a2 2 0 01-1.995-1.858L5 7m5 4v6m4-6v6m1-10V4a1 1 0 00-1-1h-4a1 1 0 00-1 1v3M4 7h16"})}),children:"Remove"})]})})},t._id)})}),(0,Gt.jsx)(Rd,{isOpen:n,onClose:()=>o(!1),title:"Add Moderator",size:"md",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>o(!1),children:"Cancel"}),(0,Gt.jsx)(ge,{onClick:function(){if(!l.username||!l.password)return void t.error("Username and password are required");const e={_id:String(Date.now()),username:l.username,email:l.email,fullName:l.fullName,role:"moderator",createdAt:(new Date).toISOString()};a(t=>[e,...t]),t.success("Moderator added successfully!"),o(!1)},children:"Add Moderator"})]}),children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsxs)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:["Username ",(0,Gt.jsx)("span",{className:"text-red-500",children:"*"})]}),(0,Gt.jsx)("input",{type:"text",value:l.username,onChange:t=>d(Ht(Ht({},l),{},{username:t.target.value})),placeholder:"moderator1",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsxs)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:["Password ",(0,Gt.jsx)("span",{className:"text-red-500",children:"*"})]}),(0,Gt.jsx)("input",{type:"password",value:l.password,onChange:t=>d(Ht(Ht({},l),{},{password:t.target.value})),placeholder:"\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"}),(0,Gt.jsx)("p",{className:"text-xs text-gray-500 dark:text-gray-400 mt-1",children:"Minimum 6 characters"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Full Name"}),(0,Gt.jsx)("input",{type:"text",value:l.fullName,onChange:t=>d(Ht(Ht({},l),{},{fullName:t.target.value})),placeholder:"John Doe",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Email"}),(0,Gt.jsx)("input",{type:"email",value:l.email,onChange:t=>d(Ht(Ht({},l),{},{email:t.target.value})),placeholder:"moderator@example.com",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]})]})}),(0,Gt.jsx)(Rd,{isOpen:c,onClose:()=>m(!1),title:"Change Admin Credentials",size:"md",footer:(0,Gt.jsxs)(Gt.Fragment,{children:[(0,Gt.jsx)(ge,{variant:"ghost",onClick:()=>m(!1),children:"Cancel"}),(0,Gt.jsx)(ge,{onClick:function(){if(!u.currentPassword)return void t.error("Current password is required");const e=localStorage.getItem("adminPassword")||"admin";if(u.currentPassword===e){if(u.newUsername&&localStorage.setItem("adminUsername",u.newUsername),u.newPassword){if(u.newPassword!==u.confirmPassword)return void t.error("New passwords do not match");if(u.newPassword.length<6)return void t.error("Password must be at least 6 characters");localStorage.setItem("adminPassword",u.newPassword)}t.success("Admin credentials updated successfully!"),m(!1)}else t.error("Current password is incorrect")},children:"Save Changes"})]}),children:(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsx)("div",{className:"p-3 bg-yellow-50 dark:bg-yellow-900/20 border border-yellow-200 dark:border-yellow-700 rounded-lg",children:(0,Gt.jsxs)("p",{className:"text-sm text-yellow-800 dark:text-yellow-200",children:[(0,Gt.jsx)("strong",{children:"Important:"})," Changing your credentials will affect your login access. Make sure to remember your new credentials."]})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsxs)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:["Current Password ",(0,Gt.jsx)("span",{className:"text-red-500",children:"*"})]}),(0,Gt.jsx)("input",{type:"password",value:u.currentPassword,onChange:t=>h(Ht(Ht({},u),{},{currentPassword:t.target.value})),placeholder:"\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsx)("hr",{className:"border-gray-200 dark:border-gray-700"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"New Username (optional)"}),(0,Gt.jsx)("input",{type:"text",value:u.newUsername,onChange:t=>h(Ht(Ht({},u),{},{newUsername:t.target.value})),placeholder:localStorage.getItem("adminUsername")||"admin",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"New Password (optional)"}),(0,Gt.jsx)("input",{type:"password",value:u.newPassword,onChange:t=>h(Ht(Ht({},u),{},{newPassword:t.target.value})),placeholder:"\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-1",children:"Confirm New Password"}),(0,Gt.jsx)("input",{type:"password",value:u.confirmPassword,onChange:t=>h(Ht(Ht({},u),{},{confirmPassword:t.target.value})),placeholder:"\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022",className:"w-full px-3 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white"})]})]})}),(0,Gt.jsx)(Fd,{isOpen:null!==s,onClose:()=>r(null),onConfirm:function(){a(t=>t.filter(t=>t._id!==s._id)),t.success("Moderator removed"),r(null)},title:"Remove Moderator",message:'Are you sure you want to remove "'.concat((null===s||void 0===s?void 0:s.fullName)||(null===s||void 0===s?void 0:s.username),'"? This action cannot be undone.'),confirmText:"Remove",variant:"danger"})]})}function Kd(){return"object"===typeof navigator&&"userAgent"in navigator?navigator.userAgent:"object"===typeof process&&void 0!==process.version?"Node.js/".concat(process.version.substr(1)," (").concat(process.platform,"; ").concat(process.arch,")"):"<environment undetectable>"}function Zd(t,e,a,i){if("function"!==typeof a)throw new Error("method for before hook must be a function");return i||(i={}),Array.isArray(e)?e.reverse().reduce((e,a)=>Zd.bind(null,t,a,e,i),a)():Promise.resolve().then(()=>t.registry[e]?t.registry[e].reduce((t,e)=>e.hook.bind(null,t,i),a)():a(i))}function $d(t,e,a,i){const n=i;t.registry[a]||(t.registry[a]=[]),"before"===e&&(i=(t,e)=>Promise.resolve().then(n.bind(null,e)).then(t.bind(null,e))),"after"===e&&(i=(t,e)=>{let a;return Promise.resolve().then(t.bind(null,e)).then(t=>(a=t,n(a,e))).then(()=>a)}),"error"===e&&(i=(t,e)=>Promise.resolve().then(t.bind(null,e)).catch(t=>n(t,e))),t.registry[a].push({hook:i,orig:n})}function Xd(t,e,a){if(!t.registry[e])return;const i=t.registry[e].map(t=>t.orig).indexOf(a);-1!==i&&t.registry[e].splice(i,1)}const Yd=Function.bind,Jd=Yd.bind(Yd);function tc(t,e,a){const i=Jd(Xd,null).apply(null,a?[e,a]:[e]);t.api={remove:i},t.remove=i,["before","error","after","wrap"].forEach(i=>{const n=a?[e,i,a]:[e,i];t[i]=t.api[i]=Jd($d,null).apply(null,n)})}const ec={Singular:function(){const t=Symbol("Singular"),e={registry:{}},a=Zd.bind(null,e,t);return tc(a,e,t),a},Collection:function(){const t={registry:{}},e=Zd.bind(null,t);return tc(e,t),e}};var ac="octokit-endpoint.js/".concat("0.0.0-development"," ").concat(Kd());function ic(t,e){const a=Object.assign({},t);return Object.keys(e).forEach(i=>{!function(t){if("object"!==typeof t||null===t)return!1;if("[object Object]"!==Object.prototype.toString.call(t))return!1;const e=Object.getPrototypeOf(t);if(null===e)return!0;const a=Object.prototype.hasOwnProperty.call(e,"constructor")&&e.constructor;return"function"===typeof a&&a instanceof a&&Function.prototype.call(a)===Function.prototype.call(t)}(e[i])?Object.assign(a,{[i]:e[i]}):i in t?a[i]=ic(t[i],e[i]):Object.assign(a,{[i]:e[i]})}),a}function nc(t){for(const e in t)void 0===t[e]&&delete t[e];return t}function oc(t,e,a){if("string"===typeof e){let[t,i]=e.split(" ");a=Object.assign(i?{method:t,url:i}:{url:t},a)}else a=Object.assign({},e);var i;a.headers=(i=a.headers)?Object.keys(i).reduce((t,e)=>(t[e.toLowerCase()]=i[e],t),{}):{},nc(a),nc(a.headers);const n=ic(t||{},a);var o;"/graphql"===a.url&&(t&&null!==(o=t.mediaType.previews)&&void 0!==o&&o.length&&(n.mediaType.previews=t.mediaType.previews.filter(t=>!n.mediaType.previews.includes(t)).concat(n.mediaType.previews)),n.mediaType.previews=(n.mediaType.previews||[]).map(t=>t.replace(/-preview/,"")));return n}var sc=/\{[^{}}]+\}/g;function rc(t){return t.replace(/(?:^\W+)|(?:(?<!\W)\W+$)/g,"").split(/,/)}function lc(t,e){const a={__proto__:null};for(const i of Object.keys(t))-1===e.indexOf(i)&&(a[i]=t[i]);return a}function dc(t){return t.split(/(%[0-9A-Fa-f]{2})/g).map(function(t){return/%[0-9A-Fa-f]/.test(t)||(t=encodeURI(t).replace(/%5B/g,"[").replace(/%5D/g,"]")),t}).join("")}function cc(t){return encodeURIComponent(t).replace(/[!'()*]/g,function(t){return"%"+t.charCodeAt(0).toString(16).toUpperCase()})}function mc(t,e,a){return e="+"===t||"#"===t?dc(e):cc(e),a?cc(a)+"="+e:e}function uc(t){return void 0!==t&&null!==t}function hc(t){return";"===t||"&"===t||"?"===t}function fc(t,e){var a=["+","#",".","/",";","?","&"];return t=t.replace(/\{([^\{\}]+)\}|([^\{\}]+)/g,function(t,i,n){if(i){let t="";const n=[];if(-1!==a.indexOf(i.charAt(0))&&(t=i.charAt(0),i=i.substr(1)),i.split(/,/g).forEach(function(a){var i=/([^:\*]*)(?::(\d+)|(\*))?/.exec(a);n.push(function(t,e,a,i){var n=t[a],o=[];if(uc(n)&&""!==n)if("string"===typeof n||"number"===typeof n||"boolean"===typeof n)n=n.toString(),i&&"*"!==i&&(n=n.substring(0,parseInt(i,10))),o.push(mc(e,n,hc(e)?a:""));else if("*"===i)Array.isArray(n)?n.filter(uc).forEach(function(t){o.push(mc(e,t,hc(e)?a:""))}):Object.keys(n).forEach(function(t){uc(n[t])&&o.push(mc(e,n[t],t))});else{const t=[];Array.isArray(n)?n.filter(uc).forEach(function(a){t.push(mc(e,a))}):Object.keys(n).forEach(function(a){uc(n[a])&&(t.push(cc(a)),t.push(mc(e,n[a].toString())))}),hc(e)?o.push(cc(a)+"="+t.join(",")):0!==t.length&&o.push(t.join(","))}else";"===e?uc(n)&&o.push(cc(a)):""!==n||"&"!==e&&"?"!==e?""===n&&o.push(""):o.push(cc(a)+"=");return o}(e,t,i[1],i[2]||i[3]))}),t&&"+"!==t){var o=",";return"?"===t?o="&":"#"!==t&&(o=t),(0!==n.length?t:"")+n.join(o)}return n.join(",")}return dc(n)}),"/"===t?t:t.replace(/\/$/,"")}function gc(t){let e,a=t.method.toUpperCase(),i=(t.url||"/").replace(/:([a-z]\w+)/g,"{$1}"),n=Object.assign({},t.headers),o=lc(t,["method","baseUrl","url","headers","request","mediaType"]);const s=function(t){const e=t.match(sc);return e?e.map(rc).reduce((t,e)=>t.concat(e),[]):[]}(i);var r;i=(r=i,{expand:fc.bind(null,r)}).expand(o),/^http/.test(i)||(i=t.baseUrl+i);const l=lc(o,Object.keys(t).filter(t=>s.includes(t)).concat("baseUrl"));var d;if(!/application\/octet-stream/i.test(n.accept)&&(t.mediaType.format&&(n.accept=n.accept.split(/,/).map(e=>e.replace(/application\/vnd(\.\w+)(\.v3)?(\.\w+)?(\+json)?$/,"application/vnd$1$2.".concat(t.mediaType.format))).join(",")),i.endsWith("/graphql")&&null!==(d=t.mediaType.previews)&&void 0!==d&&d.length)){const e=n.accept.match(/(?<![\w-])[\w-]+(?=-preview)/g)||[];n.accept=e.concat(t.mediaType.previews).map(e=>{const a=t.mediaType.format?".".concat(t.mediaType.format):"+json";return"application/vnd.github.".concat(e,"-preview").concat(a)}).join(",")}return["GET","HEAD"].includes(a)?i=function(t,e){const a=/\?/.test(t)?"&":"?",i=Object.keys(e);return 0===i.length?t:t+a+i.map(t=>"q"===t?"q="+e.q.split("+").map(encodeURIComponent).join("+"):"".concat(t,"=").concat(encodeURIComponent(e[t]))).join("&")}(i,l):"data"in l?e=l.data:Object.keys(l).length&&(e=l),n["content-type"]||"undefined"===typeof e||(n["content-type"]="application/json; charset=utf-8"),["PATCH","PUT"].includes(a)&&"undefined"===typeof e&&(e=""),Object.assign({method:a,url:i,headers:n},"undefined"!==typeof e?{body:e}:null,t.request?{request:t.request}:null)}function pc(t,e,a){return gc(oc(t,e,a))}var yc=function t(e,a){const i=oc(e,a),n=pc.bind(null,i);return Object.assign(n,{DEFAULTS:i,defaults:t.bind(null,i),merge:oc.bind(null,i),parse:gc})}(null,{method:"GET",baseUrl:"https://api.github.com",headers:{accept:"application/vnd.github.v3+json","user-agent":ac},mediaType:{format:""}}),bc=a(998);class vc extends Error{constructor(t,e,a){super(t,{cause:a.cause}),Ot(this,"name",void 0),Ot(this,"status",void 0),Ot(this,"request",void 0),Ot(this,"response",void 0),this.name="HttpError",this.status=Number.parseInt(e),Number.isNaN(this.status)&&(this.status=0),"response"in a&&(this.response=a.response);const i=Object.assign({},a.request);a.request.headers.authorization&&(i.headers=Object.assign({},a.request.headers,{authorization:a.request.headers.authorization.replace(/(?<! ) .*$/," [REDACTED]")})),i.url=i.url.replace(/\bclient_secret=\w+/g,"client_secret=[REDACTED]").replace(/\baccess_token=\w+/g,"access_token=[REDACTED]"),this.request=i}}var wc={headers:{"user-agent":"octokit-request.js/".concat("10.0.7"," ").concat(Kd())}};var xc=()=>"";async function kc(t){var e,a,i;const n=(null===(e=t.request)||void 0===e?void 0:e.fetch)||globalThis.fetch;if(!n)throw new Error("fetch is not set. Please pass a fetch implementation as new Octokit({ request: { fetch }}). Learn more at https://github.com/octokit/octokit.js/#fetch-missing");const o=(null===(a=t.request)||void 0===a?void 0:a.log)||console,s=!1!==(null===(i=t.request)||void 0===i?void 0:i.parseSuccessResponseBody),r=function(t){if("object"!==typeof t||null===t)return!1;if("[object Object]"!==Object.prototype.toString.call(t))return!1;const e=Object.getPrototypeOf(t);if(null===e)return!0;const a=Object.prototype.hasOwnProperty.call(e,"constructor")&&e.constructor;return"function"===typeof a&&a instanceof a&&Function.prototype.call(a)===Function.prototype.call(t)}(t.body)||Array.isArray(t.body)?JSON.stringify(t.body):t.body,l=Object.fromEntries(Object.entries(t.headers).map(t=>{let[e,a]=t;return[e,String(a)]}));let d;try{var c,m;d=await n(t.url,Ht({method:t.method,body:r,redirect:null===(c=t.request)||void 0===c?void 0:c.redirect,headers:l,signal:null===(m=t.request)||void 0===m?void 0:m.signal},t.body&&{duplex:"half"}))}catch(p){let e="Unknown Error";if(p instanceof Error){if("AbortError"===p.name)throw p.status=500,p;e=p.message,"TypeError"===p.name&&"cause"in p&&(p.cause instanceof Error?e=p.cause.message:"string"===typeof p.cause&&(e=p.cause))}const a=new vc(e,500,{request:t});throw a.cause=p,a}const u=d.status,h=d.url,f={};for(const[y,b]of d.headers)f[y]=b;const g={url:h,status:u,headers:f,data:""};if("deprecation"in f){const e=f.link&&f.link.match(/<([^<>]+)>; rel="deprecation"/),a=e&&e.pop();o.warn('[@octokit/request] "'.concat(t.method," ").concat(t.url,'" is deprecated. It is scheduled to be removed on ').concat(f.sunset).concat(a?". See ".concat(a):""))}if(204===u||205===u)return g;if("HEAD"===t.method){if(u<400)return g;throw new vc(d.statusText,u,{response:g,request:t})}if(304===u)throw g.data=await Ic(d),new vc("Not modified",u,{response:g,request:t});if(u>=400)throw g.data=await Ic(d),new vc(function(t){if("string"===typeof t)return t;if(t instanceof ArrayBuffer)return"Unknown error";if("message"in t){const e="documentation_url"in t?" - ".concat(t.documentation_url):"";return Array.isArray(t.errors)?"".concat(t.message,": ").concat(t.errors.map(t=>JSON.stringify(t)).join(", ")).concat(e):"".concat(t.message).concat(e)}return"Unknown error: ".concat(JSON.stringify(t))}(g.data),u,{response:g,request:t});return g.data=s?await Ic(d):d.body,g}async function Ic(t){var e;const a=t.headers.get("content-type");if(!a)return t.text().catch(xc);const i=(0,bc.xL)(a);if(!function(t){return"application/json"===t.type||"application/scim+json"===t.type}(i))return i.type.startsWith("text/")||"utf-8"===(null===(e=i.parameters.charset)||void 0===e?void 0:e.toLowerCase())?t.text().catch(xc):t.arrayBuffer().catch(()=>new ArrayBuffer(0));{let e="";try{return e=await t.text(),JSON.parse(e)}catch(n){return e}}}var Cc=function t(e,a){const i=e.defaults(a);return Object.assign(function(e,a){const n=i.merge(e,a);if(!n.request||!n.request.hook)return kc(i.parse(n));const o=(t,e)=>kc(i.parse(i.merge(t,e)));return Object.assign(o,{endpoint:i,defaults:t.bind(null,i)}),n.request.hook(o,n)},{endpoint:i,defaults:t.bind(null,i)})}(yc,wc);var Sc=class extends Error{constructor(t,e,a){super(function(t){return"Request failed due to following response errors:\n"+t.errors.map(t=>" - ".concat(t.message)).join("\n")}(a)),Ot(this,"name","GraphqlResponseError"),Ot(this,"errors",void 0),Ot(this,"data",void 0),this.request=t,this.headers=e,this.response=a,this.errors=a.errors,this.data=a.data,Error.captureStackTrace&&Error.captureStackTrace(this,this.constructor)}},Ac=["method","baseUrl","url","headers","request","query","mediaType","operationName"],Tc=["query","method","url"],Pc=/\/api\/v3\/?$/;function Dc(t,e){const a=t.defaults(e);return Object.assign((t,e)=>function(t,e,a){if(a){if("string"===typeof e&&"query"in a)return Promise.reject(new Error('[@octokit/graphql] "query" cannot be used as variable name'));for(const t in a)if(Tc.includes(t))return Promise.reject(new Error('[@octokit/graphql] "'.concat(t,'" cannot be used as variable name')))}const i="string"===typeof e?Object.assign({query:e},a):e,n=Object.keys(i).reduce((t,e)=>Ac.includes(e)?(t[e]=i[e],t):(t.variables||(t.variables={}),t.variables[e]=i[e],t),{}),o=i.baseUrl||t.endpoint.DEFAULTS.baseUrl;return Pc.test(o)&&(n.url=o.replace(Pc,"/api/graphql")),t(n).then(t=>{if(t.data.errors){const e={};for(const a of Object.keys(t.headers))e[a]=t.headers[a];throw new Sc(n,e,t.data)}return t.data.data})}(a,t,e),{defaults:Dc.bind(null,a),endpoint:a.endpoint})}Dc(Cc,{headers:{"user-agent":"octokit-graphql.js/".concat("0.0.0-development"," ").concat(Kd())},method:"POST",url:"/graphql"});var Nc="(?:[a-zA-Z0-9_-]+)",Lc=new RegExp("^".concat(Nc).concat("\\.").concat(Nc).concat("\\.").concat(Nc,"$")),Ec=Lc.test.bind(Lc);async function jc(t){const e=Ec(t),a=t.startsWith("v1.")||t.startsWith("ghs_"),i=t.startsWith("ghu_");return{type:"token",token:t,tokenType:e?"app":a?"installation":i?"user-to-server":"oauth"}}async function Mc(t,e,a,i){const n=e.endpoint.merge(a,i);return n.headers.authorization=function(t){return 3===t.split(/\./).length?"bearer ".concat(t):"token ".concat(t)}(t),e(n)}var zc=function(t){if(!t)throw new Error("[@octokit/auth-token] No token passed to createTokenAuth");if("string"!==typeof t)throw new Error("[@octokit/auth-token] Token passed to createTokenAuth is not a string");return t=t.replace(/^(token|bearer) +/i,""),Object.assign(jc.bind(null,t),{hook:Mc.bind(null,t)})};const Rc="7.0.6",Fc=["authStrategy"],qc=()=>{},_c=console.warn.bind(console),Oc=console.error.bind(console);const Uc="octokit-core.js/".concat(Rc," ").concat(Kd());class Hc{static defaults(t){return class extends(this){constructor(){const e=(arguments.length<=0?void 0:arguments[0])||{};super("function"!==typeof t?Object.assign({},t,e,e.userAgent&&t.userAgent?{userAgent:"".concat(e.userAgent," ").concat(t.userAgent)}:null):t(e))}}}static plugin(){var t;const e=this.plugins;for(var a=arguments.length,i=new Array(a),n=0;n<a;n++)i[n]=arguments[n];return Ot(t=class extends(this){},"plugins",e.concat(i.filter(t=>!e.includes(t)))),t}constructor(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};Ot(this,"request",void 0),Ot(this,"graphql",void 0),Ot(this,"log",void 0),Ot(this,"hook",void 0),Ot(this,"auth",void 0);const e=new ec.Collection,a={baseUrl:Cc.endpoint.DEFAULTS.baseUrl,headers:{},request:Object.assign({},t.request,{hook:e.bind(null,"request")}),mediaType:{previews:[],format:""}};var i;if(a.headers["user-agent"]=t.userAgent?"".concat(t.userAgent," ").concat(Uc):Uc,t.baseUrl&&(a.baseUrl=t.baseUrl),t.previews&&(a.mediaType.previews=t.previews),t.timeZone&&(a.headers["time-zone"]=t.timeZone),this.request=Cc.defaults(a),this.graphql=(i=this.request,Dc(i,{method:"POST",url:"/graphql"})).defaults(a),this.log=function(){let t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};return"function"!==typeof t.debug&&(t.debug=qc),"function"!==typeof t.info&&(t.info=qc),"function"!==typeof t.warn&&(t.warn=_c),"function"!==typeof t.error&&(t.error=Oc),t}(t.log),this.hook=e,t.authStrategy){const{authStrategy:a}=t,i=he(t,Fc),n=a(Object.assign({request:this.request,log:this.log,octokit:this,octokitOptions:i},t.auth));e.wrap("request",n.hook),this.auth=n}else if(t.auth){const a=zc(t.auth);e.wrap("request",a.hook),this.auth=a}else this.auth=async()=>({type:"unauthenticated"});const n=this.constructor;for(let o=0;o<n.plugins.length;++o)Object.assign(this,n.plugins[o](this,t))}}Ot(Hc,"VERSION",Rc),Ot(Hc,"plugins",[]);function Vc(t){t.hook.wrap("request",(e,a)=>{t.log.debug("request",a);const i=Date.now(),n=t.request.endpoint.parse(a),o=n.url.replace(a.baseUrl,"");return e(a).then(e=>{const a=e.headers["x-github-request-id"];return t.log.info("".concat(n.method," ").concat(o," - ").concat(e.status," with id ").concat(a," in ").concat(Date.now()-i,"ms")),e}).catch(e=>{var a;const s=(null===(a=e.response)||void 0===a?void 0:a.headers["x-github-request-id"])||"UNKNOWN";throw t.log.error("".concat(n.method," ").concat(o," - ").concat(e.status," with id ").concat(s," in ").concat(Date.now()-i,"ms")),e})})}Vc.VERSION="6.0.0";function Bc(t,e,a){const i="function"===typeof e?e.endpoint(a):t.request.endpoint(e,a),n="function"===typeof e?e:t.request,o=i.method,s=i.headers;let r=i.url;return{[Symbol.asyncIterator]:()=>({async next(){if(!r)return{done:!0};try{const t=function(t){if(!t.data)return Ht(Ht({},t),{},{data:[]});if(!("total_count"in t.data)&&!("total_commits"in t.data)||"url"in t.data)return t;const e=t.data.incomplete_results,a=t.data.repository_selection,i=t.data.total_count,n=t.data.total_commits;delete t.data.incomplete_results,delete t.data.repository_selection,delete t.data.total_count,delete t.data.total_commits;const o=Object.keys(t.data)[0],s=t.data[o];return t.data=s,"undefined"!==typeof e&&(t.data.incomplete_results=e),"undefined"!==typeof a&&(t.data.repository_selection=a),t.data.total_count=i,t.data.total_commits=n,t}(await n({method:o,url:r,headers:s}));if(r=((t.headers.link||"").match(/<([^<>]+)>;\s*rel="next"/)||[])[1],!r&&"total_commits"in t.data){const e=new URL(t.url),a=e.searchParams,i=parseInt(a.get("page")||"1",10);i*parseInt(a.get("per_page")||"250",10)<t.data.total_commits&&(a.set("page",String(i+1)),r=e.toString())}return{value:t}}catch(t){if(409!==t.status)throw t;return r="",{value:{status:200,headers:{},data:[]}}}}})}}function Gc(t,e,a,i){return"function"===typeof a&&(i=a,a=void 0),Wc(t,[],Bc(t,e,a)[Symbol.asyncIterator](),i)}function Wc(t,e,a,i){return a.next().then(n=>{if(n.done)return e;let o=!1;return e=e.concat(i?i(n.value,function(){o=!0}):n.value.data),o?e:Wc(t,e,a,i)})}Object.assign(Gc,{iterator:Bc});function Qc(t){return{paginate:Object.assign(Gc.bind(null,t),{iterator:Bc.bind(null,t)})}}Qc.VERSION="0.0.0-development";const Kc="17.0.0";var Zc={actions:{addCustomLabelsToSelfHostedRunnerForOrg:["POST /orgs/{org}/actions/runners/{runner_id}/labels"],addCustomLabelsToSelfHostedRunnerForRepo:["POST /repos/{owner}/{repo}/actions/runners/{runner_id}/labels"],addRepoAccessToSelfHostedRunnerGroupInOrg:["PUT /orgs/{org}/actions/runner-groups/{runner_group_id}/repositories/{repository_id}"],addSelectedRepoToOrgSecret:["PUT /orgs/{org}/actions/secrets/{secret_name}/repositories/{repository_id}"],addSelectedRepoToOrgVariable:["PUT /orgs/{org}/actions/variables/{name}/repositories/{repository_id}"],approveWorkflowRun:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/approve"],cancelWorkflowRun:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/cancel"],createEnvironmentVariable:["POST /repos/{owner}/{repo}/environments/{environment_name}/variables"],createHostedRunnerForOrg:["POST /orgs/{org}/actions/hosted-runners"],createOrUpdateEnvironmentSecret:["PUT /repos/{owner}/{repo}/environments/{environment_name}/secrets/{secret_name}"],createOrUpdateOrgSecret:["PUT /orgs/{org}/actions/secrets/{secret_name}"],createOrUpdateRepoSecret:["PUT /repos/{owner}/{repo}/actions/secrets/{secret_name}"],createOrgVariable:["POST /orgs/{org}/actions/variables"],createRegistrationTokenForOrg:["POST /orgs/{org}/actions/runners/registration-token"],createRegistrationTokenForRepo:["POST /repos/{owner}/{repo}/actions/runners/registration-token"],createRemoveTokenForOrg:["POST /orgs/{org}/actions/runners/remove-token"],createRemoveTokenForRepo:["POST /repos/{owner}/{repo}/actions/runners/remove-token"],createRepoVariable:["POST /repos/{owner}/{repo}/actions/variables"],createWorkflowDispatch:["POST /repos/{owner}/{repo}/actions/workflows/{workflow_id}/dispatches"],deleteActionsCacheById:["DELETE /repos/{owner}/{repo}/actions/caches/{cache_id}"],deleteActionsCacheByKey:["DELETE /repos/{owner}/{repo}/actions/caches{?key,ref}"],deleteArtifact:["DELETE /repos/{owner}/{repo}/actions/artifacts/{artifact_id}"],deleteCustomImageFromOrg:["DELETE /orgs/{org}/actions/hosted-runners/images/custom/{image_definition_id}"],deleteCustomImageVersionFromOrg:["DELETE /orgs/{org}/actions/hosted-runners/images/custom/{image_definition_id}/versions/{version}"],deleteEnvironmentSecret:["DELETE /repos/{owner}/{repo}/environments/{environment_name}/secrets/{secret_name}"],deleteEnvironmentVariable:["DELETE /repos/{owner}/{repo}/environments/{environment_name}/variables/{name}"],deleteHostedRunnerForOrg:["DELETE /orgs/{org}/actions/hosted-runners/{hosted_runner_id}"],deleteOrgSecret:["DELETE /orgs/{org}/actions/secrets/{secret_name}"],deleteOrgVariable:["DELETE /orgs/{org}/actions/variables/{name}"],deleteRepoSecret:["DELETE /repos/{owner}/{repo}/actions/secrets/{secret_name}"],deleteRepoVariable:["DELETE /repos/{owner}/{repo}/actions/variables/{name}"],deleteSelfHostedRunnerFromOrg:["DELETE /orgs/{org}/actions/runners/{runner_id}"],deleteSelfHostedRunnerFromRepo:["DELETE /repos/{owner}/{repo}/actions/runners/{runner_id}"],deleteWorkflowRun:["DELETE /repos/{owner}/{repo}/actions/runs/{run_id}"],deleteWorkflowRunLogs:["DELETE /repos/{owner}/{repo}/actions/runs/{run_id}/logs"],disableSelectedRepositoryGithubActionsOrganization:["DELETE /orgs/{org}/actions/permissions/repositories/{repository_id}"],disableWorkflow:["PUT /repos/{owner}/{repo}/actions/workflows/{workflow_id}/disable"],downloadArtifact:["GET /repos/{owner}/{repo}/actions/artifacts/{artifact_id}/{archive_format}"],downloadJobLogsForWorkflowRun:["GET /repos/{owner}/{repo}/actions/jobs/{job_id}/logs"],downloadWorkflowRunAttemptLogs:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/attempts/{attempt_number}/logs"],downloadWorkflowRunLogs:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/logs"],enableSelectedRepositoryGithubActionsOrganization:["PUT /orgs/{org}/actions/permissions/repositories/{repository_id}"],enableWorkflow:["PUT /repos/{owner}/{repo}/actions/workflows/{workflow_id}/enable"],forceCancelWorkflowRun:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/force-cancel"],generateRunnerJitconfigForOrg:["POST /orgs/{org}/actions/runners/generate-jitconfig"],generateRunnerJitconfigForRepo:["POST /repos/{owner}/{repo}/actions/runners/generate-jitconfig"],getActionsCacheList:["GET /repos/{owner}/{repo}/actions/caches"],getActionsCacheUsage:["GET /repos/{owner}/{repo}/actions/cache/usage"],getActionsCacheUsageByRepoForOrg:["GET /orgs/{org}/actions/cache/usage-by-repository"],getActionsCacheUsageForOrg:["GET /orgs/{org}/actions/cache/usage"],getAllowedActionsOrganization:["GET /orgs/{org}/actions/permissions/selected-actions"],getAllowedActionsRepository:["GET /repos/{owner}/{repo}/actions/permissions/selected-actions"],getArtifact:["GET /repos/{owner}/{repo}/actions/artifacts/{artifact_id}"],getCustomImageForOrg:["GET /orgs/{org}/actions/hosted-runners/images/custom/{image_definition_id}"],getCustomImageVersionForOrg:["GET /orgs/{org}/actions/hosted-runners/images/custom/{image_definition_id}/versions/{version}"],getCustomOidcSubClaimForRepo:["GET /repos/{owner}/{repo}/actions/oidc/customization/sub"],getEnvironmentPublicKey:["GET /repos/{owner}/{repo}/environments/{environment_name}/secrets/public-key"],getEnvironmentSecret:["GET /repos/{owner}/{repo}/environments/{environment_name}/secrets/{secret_name}"],getEnvironmentVariable:["GET /repos/{owner}/{repo}/environments/{environment_name}/variables/{name}"],getGithubActionsDefaultWorkflowPermissionsOrganization:["GET /orgs/{org}/actions/permissions/workflow"],getGithubActionsDefaultWorkflowPermissionsRepository:["GET /repos/{owner}/{repo}/actions/permissions/workflow"],getGithubActionsPermissionsOrganization:["GET /orgs/{org}/actions/permissions"],getGithubActionsPermissionsRepository:["GET /repos/{owner}/{repo}/actions/permissions"],getHostedRunnerForOrg:["GET /orgs/{org}/actions/hosted-runners/{hosted_runner_id}"],getHostedRunnersGithubOwnedImagesForOrg:["GET /orgs/{org}/actions/hosted-runners/images/github-owned"],getHostedRunnersLimitsForOrg:["GET /orgs/{org}/actions/hosted-runners/limits"],getHostedRunnersMachineSpecsForOrg:["GET /orgs/{org}/actions/hosted-runners/machine-sizes"],getHostedRunnersPartnerImagesForOrg:["GET /orgs/{org}/actions/hosted-runners/images/partner"],getHostedRunnersPlatformsForOrg:["GET /orgs/{org}/actions/hosted-runners/platforms"],getJobForWorkflowRun:["GET /repos/{owner}/{repo}/actions/jobs/{job_id}"],getOrgPublicKey:["GET /orgs/{org}/actions/secrets/public-key"],getOrgSecret:["GET /orgs/{org}/actions/secrets/{secret_name}"],getOrgVariable:["GET /orgs/{org}/actions/variables/{name}"],getPendingDeploymentsForRun:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/pending_deployments"],getRepoPermissions:["GET /repos/{owner}/{repo}/actions/permissions",{},{renamed:["actions","getGithubActionsPermissionsRepository"]}],getRepoPublicKey:["GET /repos/{owner}/{repo}/actions/secrets/public-key"],getRepoSecret:["GET /repos/{owner}/{repo}/actions/secrets/{secret_name}"],getRepoVariable:["GET /repos/{owner}/{repo}/actions/variables/{name}"],getReviewsForRun:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/approvals"],getSelfHostedRunnerForOrg:["GET /orgs/{org}/actions/runners/{runner_id}"],getSelfHostedRunnerForRepo:["GET /repos/{owner}/{repo}/actions/runners/{runner_id}"],getWorkflow:["GET /repos/{owner}/{repo}/actions/workflows/{workflow_id}"],getWorkflowAccessToRepository:["GET /repos/{owner}/{repo}/actions/permissions/access"],getWorkflowRun:["GET /repos/{owner}/{repo}/actions/runs/{run_id}"],getWorkflowRunAttempt:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/attempts/{attempt_number}"],getWorkflowRunUsage:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/timing"],getWorkflowUsage:["GET /repos/{owner}/{repo}/actions/workflows/{workflow_id}/timing"],listArtifactsForRepo:["GET /repos/{owner}/{repo}/actions/artifacts"],listCustomImageVersionsForOrg:["GET /orgs/{org}/actions/hosted-runners/images/custom/{image_definition_id}/versions"],listCustomImagesForOrg:["GET /orgs/{org}/actions/hosted-runners/images/custom"],listEnvironmentSecrets:["GET /repos/{owner}/{repo}/environments/{environment_name}/secrets"],listEnvironmentVariables:["GET /repos/{owner}/{repo}/environments/{environment_name}/variables"],listGithubHostedRunnersInGroupForOrg:["GET /orgs/{org}/actions/runner-groups/{runner_group_id}/hosted-runners"],listHostedRunnersForOrg:["GET /orgs/{org}/actions/hosted-runners"],listJobsForWorkflowRun:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/jobs"],listJobsForWorkflowRunAttempt:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/attempts/{attempt_number}/jobs"],listLabelsForSelfHostedRunnerForOrg:["GET /orgs/{org}/actions/runners/{runner_id}/labels"],listLabelsForSelfHostedRunnerForRepo:["GET /repos/{owner}/{repo}/actions/runners/{runner_id}/labels"],listOrgSecrets:["GET /orgs/{org}/actions/secrets"],listOrgVariables:["GET /orgs/{org}/actions/variables"],listRepoOrganizationSecrets:["GET /repos/{owner}/{repo}/actions/organization-secrets"],listRepoOrganizationVariables:["GET /repos/{owner}/{repo}/actions/organization-variables"],listRepoSecrets:["GET /repos/{owner}/{repo}/actions/secrets"],listRepoVariables:["GET /repos/{owner}/{repo}/actions/variables"],listRepoWorkflows:["GET /repos/{owner}/{repo}/actions/workflows"],listRunnerApplicationsForOrg:["GET /orgs/{org}/actions/runners/downloads"],listRunnerApplicationsForRepo:["GET /repos/{owner}/{repo}/actions/runners/downloads"],listSelectedReposForOrgSecret:["GET /orgs/{org}/actions/secrets/{secret_name}/repositories"],listSelectedReposForOrgVariable:["GET /orgs/{org}/actions/variables/{name}/repositories"],listSelectedRepositoriesEnabledGithubActionsOrganization:["GET /orgs/{org}/actions/permissions/repositories"],listSelfHostedRunnersForOrg:["GET /orgs/{org}/actions/runners"],listSelfHostedRunnersForRepo:["GET /repos/{owner}/{repo}/actions/runners"],listWorkflowRunArtifacts:["GET /repos/{owner}/{repo}/actions/runs/{run_id}/artifacts"],listWorkflowRuns:["GET /repos/{owner}/{repo}/actions/workflows/{workflow_id}/runs"],listWorkflowRunsForRepo:["GET /repos/{owner}/{repo}/actions/runs"],reRunJobForWorkflowRun:["POST /repos/{owner}/{repo}/actions/jobs/{job_id}/rerun"],reRunWorkflow:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/rerun"],reRunWorkflowFailedJobs:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/rerun-failed-jobs"],removeAllCustomLabelsFromSelfHostedRunnerForOrg:["DELETE /orgs/{org}/actions/runners/{runner_id}/labels"],removeAllCustomLabelsFromSelfHostedRunnerForRepo:["DELETE /repos/{owner}/{repo}/actions/runners/{runner_id}/labels"],removeCustomLabelFromSelfHostedRunnerForOrg:["DELETE /orgs/{org}/actions/runners/{runner_id}/labels/{name}"],removeCustomLabelFromSelfHostedRunnerForRepo:["DELETE /repos/{owner}/{repo}/actions/runners/{runner_id}/labels/{name}"],removeSelectedRepoFromOrgSecret:["DELETE /orgs/{org}/actions/secrets/{secret_name}/repositories/{repository_id}"],removeSelectedRepoFromOrgVariable:["DELETE /orgs/{org}/actions/variables/{name}/repositories/{repository_id}"],reviewCustomGatesForRun:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/deployment_protection_rule"],reviewPendingDeploymentsForRun:["POST /repos/{owner}/{repo}/actions/runs/{run_id}/pending_deployments"],setAllowedActionsOrganization:["PUT /orgs/{org}/actions/permissions/selected-actions"],setAllowedActionsRepository:["PUT /repos/{owner}/{repo}/actions/permissions/selected-actions"],setCustomLabelsForSelfHostedRunnerForOrg:["PUT /orgs/{org}/actions/runners/{runner_id}/labels"],setCustomLabelsForSelfHostedRunnerForRepo:["PUT /repos/{owner}/{repo}/actions/runners/{runner_id}/labels"],setCustomOidcSubClaimForRepo:["PUT /repos/{owner}/{repo}/actions/oidc/customization/sub"],setGithubActionsDefaultWorkflowPermissionsOrganization:["PUT /orgs/{org}/actions/permissions/workflow"],setGithubActionsDefaultWorkflowPermissionsRepository:["PUT /repos/{owner}/{repo}/actions/permissions/workflow"],setGithubActionsPermissionsOrganization:["PUT /orgs/{org}/actions/permissions"],setGithubActionsPermissionsRepository:["PUT /repos/{owner}/{repo}/actions/permissions"],setSelectedReposForOrgSecret:["PUT /orgs/{org}/actions/secrets/{secret_name}/repositories"],setSelectedReposForOrgVariable:["PUT /orgs/{org}/actions/variables/{name}/repositories"],setSelectedRepositoriesEnabledGithubActionsOrganization:["PUT /orgs/{org}/actions/permissions/repositories"],setWorkflowAccessToRepository:["PUT /repos/{owner}/{repo}/actions/permissions/access"],updateEnvironmentVariable:["PATCH /repos/{owner}/{repo}/environments/{environment_name}/variables/{name}"],updateHostedRunnerForOrg:["PATCH /orgs/{org}/actions/hosted-runners/{hosted_runner_id}"],updateOrgVariable:["PATCH /orgs/{org}/actions/variables/{name}"],updateRepoVariable:["PATCH /repos/{owner}/{repo}/actions/variables/{name}"]},activity:{checkRepoIsStarredByAuthenticatedUser:["GET /user/starred/{owner}/{repo}"],deleteRepoSubscription:["DELETE /repos/{owner}/{repo}/subscription"],deleteThreadSubscription:["DELETE /notifications/threads/{thread_id}/subscription"],getFeeds:["GET /feeds"],getRepoSubscription:["GET /repos/{owner}/{repo}/subscription"],getThread:["GET /notifications/threads/{thread_id}"],getThreadSubscriptionForAuthenticatedUser:["GET /notifications/threads/{thread_id}/subscription"],listEventsForAuthenticatedUser:["GET /users/{username}/events"],listNotificationsForAuthenticatedUser:["GET /notifications"],listOrgEventsForAuthenticatedUser:["GET /users/{username}/events/orgs/{org}"],listPublicEvents:["GET /events"],listPublicEventsForRepoNetwork:["GET /networks/{owner}/{repo}/events"],listPublicEventsForUser:["GET /users/{username}/events/public"],listPublicOrgEvents:["GET /orgs/{org}/events"],listReceivedEventsForUser:["GET /users/{username}/received_events"],listReceivedPublicEventsForUser:["GET /users/{username}/received_events/public"],listRepoEvents:["GET /repos/{owner}/{repo}/events"],listRepoNotificationsForAuthenticatedUser:["GET /repos/{owner}/{repo}/notifications"],listReposStarredByAuthenticatedUser:["GET /user/starred"],listReposStarredByUser:["GET /users/{username}/starred"],listReposWatchedByUser:["GET /users/{username}/subscriptions"],listStargazersForRepo:["GET /repos/{owner}/{repo}/stargazers"],listWatchedReposForAuthenticatedUser:["GET /user/subscriptions"],listWatchersForRepo:["GET /repos/{owner}/{repo}/subscribers"],markNotificationsAsRead:["PUT /notifications"],markRepoNotificationsAsRead:["PUT /repos/{owner}/{repo}/notifications"],markThreadAsDone:["DELETE /notifications/threads/{thread_id}"],markThreadAsRead:["PATCH /notifications/threads/{thread_id}"],setRepoSubscription:["PUT /repos/{owner}/{repo}/subscription"],setThreadSubscription:["PUT /notifications/threads/{thread_id}/subscription"],starRepoForAuthenticatedUser:["PUT /user/starred/{owner}/{repo}"],unstarRepoForAuthenticatedUser:["DELETE /user/starred/{owner}/{repo}"]},apps:{addRepoToInstallation:["PUT /user/installations/{installation_id}/repositories/{repository_id}",{},{renamed:["apps","addRepoToInstallationForAuthenticatedUser"]}],addRepoToInstallationForAuthenticatedUser:["PUT /user/installations/{installation_id}/repositories/{repository_id}"],checkToken:["POST /applications/{client_id}/token"],createFromManifest:["POST /app-manifests/{code}/conversions"],createInstallationAccessToken:["POST /app/installations/{installation_id}/access_tokens"],deleteAuthorization:["DELETE /applications/{client_id}/grant"],deleteInstallation:["DELETE /app/installations/{installation_id}"],deleteToken:["DELETE /applications/{client_id}/token"],getAuthenticated:["GET /app"],getBySlug:["GET /apps/{app_slug}"],getInstallation:["GET /app/installations/{installation_id}"],getOrgInstallation:["GET /orgs/{org}/installation"],getRepoInstallation:["GET /repos/{owner}/{repo}/installation"],getSubscriptionPlanForAccount:["GET /marketplace_listing/accounts/{account_id}"],getSubscriptionPlanForAccountStubbed:["GET /marketplace_listing/stubbed/accounts/{account_id}"],getUserInstallation:["GET /users/{username}/installation"],getWebhookConfigForApp:["GET /app/hook/config"],getWebhookDelivery:["GET /app/hook/deliveries/{delivery_id}"],listAccountsForPlan:["GET /marketplace_listing/plans/{plan_id}/accounts"],listAccountsForPlanStubbed:["GET /marketplace_listing/stubbed/plans/{plan_id}/accounts"],listInstallationReposForAuthenticatedUser:["GET /user/installations/{installation_id}/repositories"],listInstallationRequestsForAuthenticatedApp:["GET /app/installation-requests"],listInstallations:["GET /app/installations"],listInstallationsForAuthenticatedUser:["GET /user/installations"],listPlans:["GET /marketplace_listing/plans"],listPlansStubbed:["GET /marketplace_listing/stubbed/plans"],listReposAccessibleToInstallation:["GET /installation/repositories"],listSubscriptionsForAuthenticatedUser:["GET /user/marketplace_purchases"],listSubscriptionsForAuthenticatedUserStubbed:["GET /user/marketplace_purchases/stubbed"],listWebhookDeliveries:["GET /app/hook/deliveries"],redeliverWebhookDelivery:["POST /app/hook/deliveries/{delivery_id}/attempts"],removeRepoFromInstallation:["DELETE /user/installations/{installation_id}/repositories/{repository_id}",{},{renamed:["apps","removeRepoFromInstallationForAuthenticatedUser"]}],removeRepoFromInstallationForAuthenticatedUser:["DELETE /user/installations/{installation_id}/repositories/{repository_id}"],resetToken:["PATCH /applications/{client_id}/token"],revokeInstallationAccessToken:["DELETE /installation/token"],scopeToken:["POST /applications/{client_id}/token/scoped"],suspendInstallation:["PUT /app/installations/{installation_id}/suspended"],unsuspendInstallation:["DELETE /app/installations/{installation_id}/suspended"],updateWebhookConfigForApp:["PATCH /app/hook/config"]},billing:{getGithubActionsBillingOrg:["GET /orgs/{org}/settings/billing/actions"],getGithubActionsBillingUser:["GET /users/{username}/settings/billing/actions"],getGithubBillingPremiumRequestUsageReportOrg:["GET /organizations/{org}/settings/billing/premium_request/usage"],getGithubBillingPremiumRequestUsageReportUser:["GET /users/{username}/settings/billing/premium_request/usage"],getGithubBillingUsageReportOrg:["GET /organizations/{org}/settings/billing/usage"],getGithubBillingUsageReportUser:["GET /users/{username}/settings/billing/usage"],getGithubPackagesBillingOrg:["GET /orgs/{org}/settings/billing/packages"],getGithubPackagesBillingUser:["GET /users/{username}/settings/billing/packages"],getSharedStorageBillingOrg:["GET /orgs/{org}/settings/billing/shared-storage"],getSharedStorageBillingUser:["GET /users/{username}/settings/billing/shared-storage"]},campaigns:{createCampaign:["POST /orgs/{org}/campaigns"],deleteCampaign:["DELETE /orgs/{org}/campaigns/{campaign_number}"],getCampaignSummary:["GET /orgs/{org}/campaigns/{campaign_number}"],listOrgCampaigns:["GET /orgs/{org}/campaigns"],updateCampaign:["PATCH /orgs/{org}/campaigns/{campaign_number}"]},checks:{create:["POST /repos/{owner}/{repo}/check-runs"],createSuite:["POST /repos/{owner}/{repo}/check-suites"],get:["GET /repos/{owner}/{repo}/check-runs/{check_run_id}"],getSuite:["GET /repos/{owner}/{repo}/check-suites/{check_suite_id}"],listAnnotations:["GET /repos/{owner}/{repo}/check-runs/{check_run_id}/annotations"],listForRef:["GET /repos/{owner}/{repo}/commits/{ref}/check-runs"],listForSuite:["GET /repos/{owner}/{repo}/check-suites/{check_suite_id}/check-runs"],listSuitesForRef:["GET /repos/{owner}/{repo}/commits/{ref}/check-suites"],rerequestRun:["POST /repos/{owner}/{repo}/check-runs/{check_run_id}/rerequest"],rerequestSuite:["POST /repos/{owner}/{repo}/check-suites/{check_suite_id}/rerequest"],setSuitesPreferences:["PATCH /repos/{owner}/{repo}/check-suites/preferences"],update:["PATCH /repos/{owner}/{repo}/check-runs/{check_run_id}"]},codeScanning:{commitAutofix:["POST /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}/autofix/commits"],createAutofix:["POST /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}/autofix"],createVariantAnalysis:["POST /repos/{owner}/{repo}/code-scanning/codeql/variant-analyses"],deleteAnalysis:["DELETE /repos/{owner}/{repo}/code-scanning/analyses/{analysis_id}{?confirm_delete}"],deleteCodeqlDatabase:["DELETE /repos/{owner}/{repo}/code-scanning/codeql/databases/{language}"],getAlert:["GET /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}",{},{renamedParameters:{alert_id:"alert_number"}}],getAnalysis:["GET /repos/{owner}/{repo}/code-scanning/analyses/{analysis_id}"],getAutofix:["GET /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}/autofix"],getCodeqlDatabase:["GET /repos/{owner}/{repo}/code-scanning/codeql/databases/{language}"],getDefaultSetup:["GET /repos/{owner}/{repo}/code-scanning/default-setup"],getSarif:["GET /repos/{owner}/{repo}/code-scanning/sarifs/{sarif_id}"],getVariantAnalysis:["GET /repos/{owner}/{repo}/code-scanning/codeql/variant-analyses/{codeql_variant_analysis_id}"],getVariantAnalysisRepoTask:["GET /repos/{owner}/{repo}/code-scanning/codeql/variant-analyses/{codeql_variant_analysis_id}/repos/{repo_owner}/{repo_name}"],listAlertInstances:["GET /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}/instances"],listAlertsForOrg:["GET /orgs/{org}/code-scanning/alerts"],listAlertsForRepo:["GET /repos/{owner}/{repo}/code-scanning/alerts"],listAlertsInstances:["GET /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}/instances",{},{renamed:["codeScanning","listAlertInstances"]}],listCodeqlDatabases:["GET /repos/{owner}/{repo}/code-scanning/codeql/databases"],listRecentAnalyses:["GET /repos/{owner}/{repo}/code-scanning/analyses"],updateAlert:["PATCH /repos/{owner}/{repo}/code-scanning/alerts/{alert_number}"],updateDefaultSetup:["PATCH /repos/{owner}/{repo}/code-scanning/default-setup"],uploadSarif:["POST /repos/{owner}/{repo}/code-scanning/sarifs"]},codeSecurity:{attachConfiguration:["POST /orgs/{org}/code-security/configurations/{configuration_id}/attach"],attachEnterpriseConfiguration:["POST /enterprises/{enterprise}/code-security/configurations/{configuration_id}/attach"],createConfiguration:["POST /orgs/{org}/code-security/configurations"],createConfigurationForEnterprise:["POST /enterprises/{enterprise}/code-security/configurations"],deleteConfiguration:["DELETE /orgs/{org}/code-security/configurations/{configuration_id}"],deleteConfigurationForEnterprise:["DELETE /enterprises/{enterprise}/code-security/configurations/{configuration_id}"],detachConfiguration:["DELETE /orgs/{org}/code-security/configurations/detach"],getConfiguration:["GET /orgs/{org}/code-security/configurations/{configuration_id}"],getConfigurationForRepository:["GET /repos/{owner}/{repo}/code-security-configuration"],getConfigurationsForEnterprise:["GET /enterprises/{enterprise}/code-security/configurations"],getConfigurationsForOrg:["GET /orgs/{org}/code-security/configurations"],getDefaultConfigurations:["GET /orgs/{org}/code-security/configurations/defaults"],getDefaultConfigurationsForEnterprise:["GET /enterprises/{enterprise}/code-security/configurations/defaults"],getRepositoriesForConfiguration:["GET /orgs/{org}/code-security/configurations/{configuration_id}/repositories"],getRepositoriesForEnterpriseConfiguration:["GET /enterprises/{enterprise}/code-security/configurations/{configuration_id}/repositories"],getSingleConfigurationForEnterprise:["GET /enterprises/{enterprise}/code-security/configurations/{configuration_id}"],setConfigurationAsDefault:["PUT /orgs/{org}/code-security/configurations/{configuration_id}/defaults"],setConfigurationAsDefaultForEnterprise:["PUT /enterprises/{enterprise}/code-security/configurations/{configuration_id}/defaults"],updateConfiguration:["PATCH /orgs/{org}/code-security/configurations/{configuration_id}"],updateEnterpriseConfiguration:["PATCH /enterprises/{enterprise}/code-security/configurations/{configuration_id}"]},codesOfConduct:{getAllCodesOfConduct:["GET /codes_of_conduct"],getConductCode:["GET /codes_of_conduct/{key}"]},codespaces:{addRepositoryForSecretForAuthenticatedUser:["PUT /user/codespaces/secrets/{secret_name}/repositories/{repository_id}"],addSelectedRepoToOrgSecret:["PUT /orgs/{org}/codespaces/secrets/{secret_name}/repositories/{repository_id}"],checkPermissionsForDevcontainer:["GET /repos/{owner}/{repo}/codespaces/permissions_check"],codespaceMachinesForAuthenticatedUser:["GET /user/codespaces/{codespace_name}/machines"],createForAuthenticatedUser:["POST /user/codespaces"],createOrUpdateOrgSecret:["PUT /orgs/{org}/codespaces/secrets/{secret_name}"],createOrUpdateRepoSecret:["PUT /repos/{owner}/{repo}/codespaces/secrets/{secret_name}"],createOrUpdateSecretForAuthenticatedUser:["PUT /user/codespaces/secrets/{secret_name}"],createWithPrForAuthenticatedUser:["POST /repos/{owner}/{repo}/pulls/{pull_number}/codespaces"],createWithRepoForAuthenticatedUser:["POST /repos/{owner}/{repo}/codespaces"],deleteForAuthenticatedUser:["DELETE /user/codespaces/{codespace_name}"],deleteFromOrganization:["DELETE /orgs/{org}/members/{username}/codespaces/{codespace_name}"],deleteOrgSecret:["DELETE /orgs/{org}/codespaces/secrets/{secret_name}"],deleteRepoSecret:["DELETE /repos/{owner}/{repo}/codespaces/secrets/{secret_name}"],deleteSecretForAuthenticatedUser:["DELETE /user/codespaces/secrets/{secret_name}"],exportForAuthenticatedUser:["POST /user/codespaces/{codespace_name}/exports"],getCodespacesForUserInOrg:["GET /orgs/{org}/members/{username}/codespaces"],getExportDetailsForAuthenticatedUser:["GET /user/codespaces/{codespace_name}/exports/{export_id}"],getForAuthenticatedUser:["GET /user/codespaces/{codespace_name}"],getOrgPublicKey:["GET /orgs/{org}/codespaces/secrets/public-key"],getOrgSecret:["GET /orgs/{org}/codespaces/secrets/{secret_name}"],getPublicKeyForAuthenticatedUser:["GET /user/codespaces/secrets/public-key"],getRepoPublicKey:["GET /repos/{owner}/{repo}/codespaces/secrets/public-key"],getRepoSecret:["GET /repos/{owner}/{repo}/codespaces/secrets/{secret_name}"],getSecretForAuthenticatedUser:["GET /user/codespaces/secrets/{secret_name}"],listDevcontainersInRepositoryForAuthenticatedUser:["GET /repos/{owner}/{repo}/codespaces/devcontainers"],listForAuthenticatedUser:["GET /user/codespaces"],listInOrganization:["GET /orgs/{org}/codespaces",{},{renamedParameters:{org_id:"org"}}],listInRepositoryForAuthenticatedUser:["GET /repos/{owner}/{repo}/codespaces"],listOrgSecrets:["GET /orgs/{org}/codespaces/secrets"],listRepoSecrets:["GET /repos/{owner}/{repo}/codespaces/secrets"],listRepositoriesForSecretForAuthenticatedUser:["GET /user/codespaces/secrets/{secret_name}/repositories"],listSecretsForAuthenticatedUser:["GET /user/codespaces/secrets"],listSelectedReposForOrgSecret:["GET /orgs/{org}/codespaces/secrets/{secret_name}/repositories"],preFlightWithRepoForAuthenticatedUser:["GET /repos/{owner}/{repo}/codespaces/new"],publishForAuthenticatedUser:["POST /user/codespaces/{codespace_name}/publish"],removeRepositoryForSecretForAuthenticatedUser:["DELETE /user/codespaces/secrets/{secret_name}/repositories/{repository_id}"],removeSelectedRepoFromOrgSecret:["DELETE /orgs/{org}/codespaces/secrets/{secret_name}/repositories/{repository_id}"],repoMachinesForAuthenticatedUser:["GET /repos/{owner}/{repo}/codespaces/machines"],setRepositoriesForSecretForAuthenticatedUser:["PUT /user/codespaces/secrets/{secret_name}/repositories"],setSelectedReposForOrgSecret:["PUT /orgs/{org}/codespaces/secrets/{secret_name}/repositories"],startForAuthenticatedUser:["POST /user/codespaces/{codespace_name}/start"],stopForAuthenticatedUser:["POST /user/codespaces/{codespace_name}/stop"],stopInOrganization:["POST /orgs/{org}/members/{username}/codespaces/{codespace_name}/stop"],updateForAuthenticatedUser:["PATCH /user/codespaces/{codespace_name}"]},copilot:{addCopilotSeatsForTeams:["POST /orgs/{org}/copilot/billing/selected_teams"],addCopilotSeatsForUsers:["POST /orgs/{org}/copilot/billing/selected_users"],cancelCopilotSeatAssignmentForTeams:["DELETE /orgs/{org}/copilot/billing/selected_teams"],cancelCopilotSeatAssignmentForUsers:["DELETE /orgs/{org}/copilot/billing/selected_users"],copilotMetricsForOrganization:["GET /orgs/{org}/copilot/metrics"],copilotMetricsForTeam:["GET /orgs/{org}/team/{team_slug}/copilot/metrics"],getCopilotOrganizationDetails:["GET /orgs/{org}/copilot/billing"],getCopilotSeatDetailsForUser:["GET /orgs/{org}/members/{username}/copilot"],listCopilotSeats:["GET /orgs/{org}/copilot/billing/seats"]},credentials:{revoke:["POST /credentials/revoke"]},dependabot:{addSelectedRepoToOrgSecret:["PUT /orgs/{org}/dependabot/secrets/{secret_name}/repositories/{repository_id}"],createOrUpdateOrgSecret:["PUT /orgs/{org}/dependabot/secrets/{secret_name}"],createOrUpdateRepoSecret:["PUT /repos/{owner}/{repo}/dependabot/secrets/{secret_name}"],deleteOrgSecret:["DELETE /orgs/{org}/dependabot/secrets/{secret_name}"],deleteRepoSecret:["DELETE /repos/{owner}/{repo}/dependabot/secrets/{secret_name}"],getAlert:["GET /repos/{owner}/{repo}/dependabot/alerts/{alert_number}"],getOrgPublicKey:["GET /orgs/{org}/dependabot/secrets/public-key"],getOrgSecret:["GET /orgs/{org}/dependabot/secrets/{secret_name}"],getRepoPublicKey:["GET /repos/{owner}/{repo}/dependabot/secrets/public-key"],getRepoSecret:["GET /repos/{owner}/{repo}/dependabot/secrets/{secret_name}"],listAlertsForEnterprise:["GET /enterprises/{enterprise}/dependabot/alerts"],listAlertsForOrg:["GET /orgs/{org}/dependabot/alerts"],listAlertsForRepo:["GET /repos/{owner}/{repo}/dependabot/alerts"],listOrgSecrets:["GET /orgs/{org}/dependabot/secrets"],listRepoSecrets:["GET /repos/{owner}/{repo}/dependabot/secrets"],listSelectedReposForOrgSecret:["GET /orgs/{org}/dependabot/secrets/{secret_name}/repositories"],removeSelectedRepoFromOrgSecret:["DELETE /orgs/{org}/dependabot/secrets/{secret_name}/repositories/{repository_id}"],repositoryAccessForOrg:["GET /organizations/{org}/dependabot/repository-access"],setRepositoryAccessDefaultLevel:["PUT /organizations/{org}/dependabot/repository-access/default-level"],setSelectedReposForOrgSecret:["PUT /orgs/{org}/dependabot/secrets/{secret_name}/repositories"],updateAlert:["PATCH /repos/{owner}/{repo}/dependabot/alerts/{alert_number}"],updateRepositoryAccessForOrg:["PATCH /organizations/{org}/dependabot/repository-access"]},dependencyGraph:{createRepositorySnapshot:["POST /repos/{owner}/{repo}/dependency-graph/snapshots"],diffRange:["GET /repos/{owner}/{repo}/dependency-graph/compare/{basehead}"],exportSbom:["GET /repos/{owner}/{repo}/dependency-graph/sbom"]},emojis:{get:["GET /emojis"]},enterpriseTeamMemberships:{add:["PUT /enterprises/{enterprise}/teams/{enterprise-team}/memberships/{username}"],bulkAdd:["POST /enterprises/{enterprise}/teams/{enterprise-team}/memberships/add"],bulkRemove:["POST /enterprises/{enterprise}/teams/{enterprise-team}/memberships/remove"],get:["GET /enterprises/{enterprise}/teams/{enterprise-team}/memberships/{username}"],list:["GET /enterprises/{enterprise}/teams/{enterprise-team}/memberships"],remove:["DELETE /enterprises/{enterprise}/teams/{enterprise-team}/memberships/{username}"]},enterpriseTeamOrganizations:{add:["PUT /enterprises/{enterprise}/teams/{enterprise-team}/organizations/{org}"],bulkAdd:["POST /enterprises/{enterprise}/teams/{enterprise-team}/organizations/add"],bulkRemove:["POST /enterprises/{enterprise}/teams/{enterprise-team}/organizations/remove"],delete:["DELETE /enterprises/{enterprise}/teams/{enterprise-team}/organizations/{org}"],getAssignment:["GET /enterprises/{enterprise}/teams/{enterprise-team}/organizations/{org}"],getAssignments:["GET /enterprises/{enterprise}/teams/{enterprise-team}/organizations"]},enterpriseTeams:{create:["POST /enterprises/{enterprise}/teams"],delete:["DELETE /enterprises/{enterprise}/teams/{team_slug}"],get:["GET /enterprises/{enterprise}/teams/{team_slug}"],list:["GET /enterprises/{enterprise}/teams"],update:["PATCH /enterprises/{enterprise}/teams/{team_slug}"]},gists:{checkIsStarred:["GET /gists/{gist_id}/star"],create:["POST /gists"],createComment:["POST /gists/{gist_id}/comments"],delete:["DELETE /gists/{gist_id}"],deleteComment:["DELETE /gists/{gist_id}/comments/{comment_id}"],fork:["POST /gists/{gist_id}/forks"],get:["GET /gists/{gist_id}"],getComment:["GET /gists/{gist_id}/comments/{comment_id}"],getRevision:["GET /gists/{gist_id}/{sha}"],list:["GET /gists"],listComments:["GET /gists/{gist_id}/comments"],listCommits:["GET /gists/{gist_id}/commits"],listForUser:["GET /users/{username}/gists"],listForks:["GET /gists/{gist_id}/forks"],listPublic:["GET /gists/public"],listStarred:["GET /gists/starred"],star:["PUT /gists/{gist_id}/star"],unstar:["DELETE /gists/{gist_id}/star"],update:["PATCH /gists/{gist_id}"],updateComment:["PATCH /gists/{gist_id}/comments/{comment_id}"]},git:{createBlob:["POST /repos/{owner}/{repo}/git/blobs"],createCommit:["POST /repos/{owner}/{repo}/git/commits"],createRef:["POST /repos/{owner}/{repo}/git/refs"],createTag:["POST /repos/{owner}/{repo}/git/tags"],createTree:["POST /repos/{owner}/{repo}/git/trees"],deleteRef:["DELETE /repos/{owner}/{repo}/git/refs/{ref}"],getBlob:["GET /repos/{owner}/{repo}/git/blobs/{file_sha}"],getCommit:["GET /repos/{owner}/{repo}/git/commits/{commit_sha}"],getRef:["GET /repos/{owner}/{repo}/git/ref/{ref}"],getTag:["GET /repos/{owner}/{repo}/git/tags/{tag_sha}"],getTree:["GET /repos/{owner}/{repo}/git/trees/{tree_sha}"],listMatchingRefs:["GET /repos/{owner}/{repo}/git/matching-refs/{ref}"],updateRef:["PATCH /repos/{owner}/{repo}/git/refs/{ref}"]},gitignore:{getAllTemplates:["GET /gitignore/templates"],getTemplate:["GET /gitignore/templates/{name}"]},hostedCompute:{createNetworkConfigurationForOrg:["POST /orgs/{org}/settings/network-configurations"],deleteNetworkConfigurationFromOrg:["DELETE /orgs/{org}/settings/network-configurations/{network_configuration_id}"],getNetworkConfigurationForOrg:["GET /orgs/{org}/settings/network-configurations/{network_configuration_id}"],getNetworkSettingsForOrg:["GET /orgs/{org}/settings/network-settings/{network_settings_id}"],listNetworkConfigurationsForOrg:["GET /orgs/{org}/settings/network-configurations"],updateNetworkConfigurationForOrg:["PATCH /orgs/{org}/settings/network-configurations/{network_configuration_id}"]},interactions:{getRestrictionsForAuthenticatedUser:["GET /user/interaction-limits"],getRestrictionsForOrg:["GET /orgs/{org}/interaction-limits"],getRestrictionsForRepo:["GET /repos/{owner}/{repo}/interaction-limits"],getRestrictionsForYourPublicRepos:["GET /user/interaction-limits",{},{renamed:["interactions","getRestrictionsForAuthenticatedUser"]}],removeRestrictionsForAuthenticatedUser:["DELETE /user/interaction-limits"],removeRestrictionsForOrg:["DELETE /orgs/{org}/interaction-limits"],removeRestrictionsForRepo:["DELETE /repos/{owner}/{repo}/interaction-limits"],removeRestrictionsForYourPublicRepos:["DELETE /user/interaction-limits",{},{renamed:["interactions","removeRestrictionsForAuthenticatedUser"]}],setRestrictionsForAuthenticatedUser:["PUT /user/interaction-limits"],setRestrictionsForOrg:["PUT /orgs/{org}/interaction-limits"],setRestrictionsForRepo:["PUT /repos/{owner}/{repo}/interaction-limits"],setRestrictionsForYourPublicRepos:["PUT /user/interaction-limits",{},{renamed:["interactions","setRestrictionsForAuthenticatedUser"]}]},issues:{addAssignees:["POST /repos/{owner}/{repo}/issues/{issue_number}/assignees"],addBlockedByDependency:["POST /repos/{owner}/{repo}/issues/{issue_number}/dependencies/blocked_by"],addLabels:["POST /repos/{owner}/{repo}/issues/{issue_number}/labels"],addSubIssue:["POST /repos/{owner}/{repo}/issues/{issue_number}/sub_issues"],checkUserCanBeAssigned:["GET /repos/{owner}/{repo}/assignees/{assignee}"],checkUserCanBeAssignedToIssue:["GET /repos/{owner}/{repo}/issues/{issue_number}/assignees/{assignee}"],create:["POST /repos/{owner}/{repo}/issues"],createComment:["POST /repos/{owner}/{repo}/issues/{issue_number}/comments"],createLabel:["POST /repos/{owner}/{repo}/labels"],createMilestone:["POST /repos/{owner}/{repo}/milestones"],deleteComment:["DELETE /repos/{owner}/{repo}/issues/comments/{comment_id}"],deleteLabel:["DELETE /repos/{owner}/{repo}/labels/{name}"],deleteMilestone:["DELETE /repos/{owner}/{repo}/milestones/{milestone_number}"],get:["GET /repos/{owner}/{repo}/issues/{issue_number}"],getComment:["GET /repos/{owner}/{repo}/issues/comments/{comment_id}"],getEvent:["GET /repos/{owner}/{repo}/issues/events/{event_id}"],getLabel:["GET /repos/{owner}/{repo}/labels/{name}"],getMilestone:["GET /repos/{owner}/{repo}/milestones/{milestone_number}"],getParent:["GET /repos/{owner}/{repo}/issues/{issue_number}/parent"],list:["GET /issues"],listAssignees:["GET /repos/{owner}/{repo}/assignees"],listComments:["GET /repos/{owner}/{repo}/issues/{issue_number}/comments"],listCommentsForRepo:["GET /repos/{owner}/{repo}/issues/comments"],listDependenciesBlockedBy:["GET /repos/{owner}/{repo}/issues/{issue_number}/dependencies/blocked_by"],listDependenciesBlocking:["GET /repos/{owner}/{repo}/issues/{issue_number}/dependencies/blocking"],listEvents:["GET /repos/{owner}/{repo}/issues/{issue_number}/events"],listEventsForRepo:["GET /repos/{owner}/{repo}/issues/events"],listEventsForTimeline:["GET /repos/{owner}/{repo}/issues/{issue_number}/timeline"],listForAuthenticatedUser:["GET /user/issues"],listForOrg:["GET /orgs/{org}/issues"],listForRepo:["GET /repos/{owner}/{repo}/issues"],listLabelsForMilestone:["GET /repos/{owner}/{repo}/milestones/{milestone_number}/labels"],listLabelsForRepo:["GET /repos/{owner}/{repo}/labels"],listLabelsOnIssue:["GET /repos/{owner}/{repo}/issues/{issue_number}/labels"],listMilestones:["GET /repos/{owner}/{repo}/milestones"],listSubIssues:["GET /repos/{owner}/{repo}/issues/{issue_number}/sub_issues"],lock:["PUT /repos/{owner}/{repo}/issues/{issue_number}/lock"],removeAllLabels:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/labels"],removeAssignees:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/assignees"],removeDependencyBlockedBy:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/dependencies/blocked_by/{issue_id}"],removeLabel:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/labels/{name}"],removeSubIssue:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/sub_issue"],reprioritizeSubIssue:["PATCH /repos/{owner}/{repo}/issues/{issue_number}/sub_issues/priority"],setLabels:["PUT /repos/{owner}/{repo}/issues/{issue_number}/labels"],unlock:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/lock"],update:["PATCH /repos/{owner}/{repo}/issues/{issue_number}"],updateComment:["PATCH /repos/{owner}/{repo}/issues/comments/{comment_id}"],updateLabel:["PATCH /repos/{owner}/{repo}/labels/{name}"],updateMilestone:["PATCH /repos/{owner}/{repo}/milestones/{milestone_number}"]},licenses:{get:["GET /licenses/{license}"],getAllCommonlyUsed:["GET /licenses"],getForRepo:["GET /repos/{owner}/{repo}/license"]},markdown:{render:["POST /markdown"],renderRaw:["POST /markdown/raw",{headers:{"content-type":"text/plain; charset=utf-8"}}]},meta:{get:["GET /meta"],getAllVersions:["GET /versions"],getOctocat:["GET /octocat"],getZen:["GET /zen"],root:["GET /"]},migrations:{deleteArchiveForAuthenticatedUser:["DELETE /user/migrations/{migration_id}/archive"],deleteArchiveForOrg:["DELETE /orgs/{org}/migrations/{migration_id}/archive"],downloadArchiveForOrg:["GET /orgs/{org}/migrations/{migration_id}/archive"],getArchiveForAuthenticatedUser:["GET /user/migrations/{migration_id}/archive"],getStatusForAuthenticatedUser:["GET /user/migrations/{migration_id}"],getStatusForOrg:["GET /orgs/{org}/migrations/{migration_id}"],listForAuthenticatedUser:["GET /user/migrations"],listForOrg:["GET /orgs/{org}/migrations"],listReposForAuthenticatedUser:["GET /user/migrations/{migration_id}/repositories"],listReposForOrg:["GET /orgs/{org}/migrations/{migration_id}/repositories"],listReposForUser:["GET /user/migrations/{migration_id}/repositories",{},{renamed:["migrations","listReposForAuthenticatedUser"]}],startForAuthenticatedUser:["POST /user/migrations"],startForOrg:["POST /orgs/{org}/migrations"],unlockRepoForAuthenticatedUser:["DELETE /user/migrations/{migration_id}/repos/{repo_name}/lock"],unlockRepoForOrg:["DELETE /orgs/{org}/migrations/{migration_id}/repos/{repo_name}/lock"]},oidc:{getOidcCustomSubTemplateForOrg:["GET /orgs/{org}/actions/oidc/customization/sub"],updateOidcCustomSubTemplateForOrg:["PUT /orgs/{org}/actions/oidc/customization/sub"]},orgs:{addSecurityManagerTeam:["PUT /orgs/{org}/security-managers/teams/{team_slug}",{},{deprecated:"octokit.rest.orgs.addSecurityManagerTeam() is deprecated, see https://docs.github.com/rest/orgs/security-managers#add-a-security-manager-team"}],assignTeamToOrgRole:["PUT /orgs/{org}/organization-roles/teams/{team_slug}/{role_id}"],assignUserToOrgRole:["PUT /orgs/{org}/organization-roles/users/{username}/{role_id}"],blockUser:["PUT /orgs/{org}/blocks/{username}"],cancelInvitation:["DELETE /orgs/{org}/invitations/{invitation_id}"],checkBlockedUser:["GET /orgs/{org}/blocks/{username}"],checkMembershipForUser:["GET /orgs/{org}/members/{username}"],checkPublicMembershipForUser:["GET /orgs/{org}/public_members/{username}"],convertMemberToOutsideCollaborator:["PUT /orgs/{org}/outside_collaborators/{username}"],createArtifactStorageRecord:["POST /orgs/{org}/artifacts/metadata/storage-record"],createInvitation:["POST /orgs/{org}/invitations"],createIssueType:["POST /orgs/{org}/issue-types"],createWebhook:["POST /orgs/{org}/hooks"],customPropertiesForOrgsCreateOrUpdateOrganizationValues:["PATCH /organizations/{org}/org-properties/values"],customPropertiesForOrgsGetOrganizationValues:["GET /organizations/{org}/org-properties/values"],customPropertiesForReposCreateOrUpdateOrganizationDefinition:["PUT /orgs/{org}/properties/schema/{custom_property_name}"],customPropertiesForReposCreateOrUpdateOrganizationDefinitions:["PATCH /orgs/{org}/properties/schema"],customPropertiesForReposCreateOrUpdateOrganizationValues:["PATCH /orgs/{org}/properties/values"],customPropertiesForReposDeleteOrganizationDefinition:["DELETE /orgs/{org}/properties/schema/{custom_property_name}"],customPropertiesForReposGetOrganizationDefinition:["GET /orgs/{org}/properties/schema/{custom_property_name}"],customPropertiesForReposGetOrganizationDefinitions:["GET /orgs/{org}/properties/schema"],customPropertiesForReposGetOrganizationValues:["GET /orgs/{org}/properties/values"],delete:["DELETE /orgs/{org}"],deleteAttestationsBulk:["POST /orgs/{org}/attestations/delete-request"],deleteAttestationsById:["DELETE /orgs/{org}/attestations/{attestation_id}"],deleteAttestationsBySubjectDigest:["DELETE /orgs/{org}/attestations/digest/{subject_digest}"],deleteIssueType:["DELETE /orgs/{org}/issue-types/{issue_type_id}"],deleteWebhook:["DELETE /orgs/{org}/hooks/{hook_id}"],disableSelectedRepositoryImmutableReleasesOrganization:["DELETE /orgs/{org}/settings/immutable-releases/repositories/{repository_id}"],enableSelectedRepositoryImmutableReleasesOrganization:["PUT /orgs/{org}/settings/immutable-releases/repositories/{repository_id}"],get:["GET /orgs/{org}"],getImmutableReleasesSettings:["GET /orgs/{org}/settings/immutable-releases"],getImmutableReleasesSettingsRepositories:["GET /orgs/{org}/settings/immutable-releases/repositories"],getMembershipForAuthenticatedUser:["GET /user/memberships/orgs/{org}"],getMembershipForUser:["GET /orgs/{org}/memberships/{username}"],getOrgRole:["GET /orgs/{org}/organization-roles/{role_id}"],getOrgRulesetHistory:["GET /orgs/{org}/rulesets/{ruleset_id}/history"],getOrgRulesetVersion:["GET /orgs/{org}/rulesets/{ruleset_id}/history/{version_id}"],getWebhook:["GET /orgs/{org}/hooks/{hook_id}"],getWebhookConfigForOrg:["GET /orgs/{org}/hooks/{hook_id}/config"],getWebhookDelivery:["GET /orgs/{org}/hooks/{hook_id}/deliveries/{delivery_id}"],list:["GET /organizations"],listAppInstallations:["GET /orgs/{org}/installations"],listArtifactStorageRecords:["GET /orgs/{org}/artifacts/{subject_digest}/metadata/storage-records"],listAttestationRepositories:["GET /orgs/{org}/attestations/repositories"],listAttestations:["GET /orgs/{org}/attestations/{subject_digest}"],listAttestationsBulk:["POST /orgs/{org}/attestations/bulk-list{?per_page,before,after}"],listBlockedUsers:["GET /orgs/{org}/blocks"],listFailedInvitations:["GET /orgs/{org}/failed_invitations"],listForAuthenticatedUser:["GET /user/orgs"],listForUser:["GET /users/{username}/orgs"],listInvitationTeams:["GET /orgs/{org}/invitations/{invitation_id}/teams"],listIssueTypes:["GET /orgs/{org}/issue-types"],listMembers:["GET /orgs/{org}/members"],listMembershipsForAuthenticatedUser:["GET /user/memberships/orgs"],listOrgRoleTeams:["GET /orgs/{org}/organization-roles/{role_id}/teams"],listOrgRoleUsers:["GET /orgs/{org}/organization-roles/{role_id}/users"],listOrgRoles:["GET /orgs/{org}/organization-roles"],listOrganizationFineGrainedPermissions:["GET /orgs/{org}/organization-fine-grained-permissions"],listOutsideCollaborators:["GET /orgs/{org}/outside_collaborators"],listPatGrantRepositories:["GET /orgs/{org}/personal-access-tokens/{pat_id}/repositories"],listPatGrantRequestRepositories:["GET /orgs/{org}/personal-access-token-requests/{pat_request_id}/repositories"],listPatGrantRequests:["GET /orgs/{org}/personal-access-token-requests"],listPatGrants:["GET /orgs/{org}/personal-access-tokens"],listPendingInvitations:["GET /orgs/{org}/invitations"],listPublicMembers:["GET /orgs/{org}/public_members"],listSecurityManagerTeams:["GET /orgs/{org}/security-managers",{},{deprecated:"octokit.rest.orgs.listSecurityManagerTeams() is deprecated, see https://docs.github.com/rest/orgs/security-managers#list-security-manager-teams"}],listWebhookDeliveries:["GET /orgs/{org}/hooks/{hook_id}/deliveries"],listWebhooks:["GET /orgs/{org}/hooks"],pingWebhook:["POST /orgs/{org}/hooks/{hook_id}/pings"],redeliverWebhookDelivery:["POST /orgs/{org}/hooks/{hook_id}/deliveries/{delivery_id}/attempts"],removeMember:["DELETE /orgs/{org}/members/{username}"],removeMembershipForUser:["DELETE /orgs/{org}/memberships/{username}"],removeOutsideCollaborator:["DELETE /orgs/{org}/outside_collaborators/{username}"],removePublicMembershipForAuthenticatedUser:["DELETE /orgs/{org}/public_members/{username}"],removeSecurityManagerTeam:["DELETE /orgs/{org}/security-managers/teams/{team_slug}",{},{deprecated:"octokit.rest.orgs.removeSecurityManagerTeam() is deprecated, see https://docs.github.com/rest/orgs/security-managers#remove-a-security-manager-team"}],reviewPatGrantRequest:["POST /orgs/{org}/personal-access-token-requests/{pat_request_id}"],reviewPatGrantRequestsInBulk:["POST /orgs/{org}/personal-access-token-requests"],revokeAllOrgRolesTeam:["DELETE /orgs/{org}/organization-roles/teams/{team_slug}"],revokeAllOrgRolesUser:["DELETE /orgs/{org}/organization-roles/users/{username}"],revokeOrgRoleTeam:["DELETE /orgs/{org}/organization-roles/teams/{team_slug}/{role_id}"],revokeOrgRoleUser:["DELETE /orgs/{org}/organization-roles/users/{username}/{role_id}"],setImmutableReleasesSettings:["PUT /orgs/{org}/settings/immutable-releases"],setImmutableReleasesSettingsRepositories:["PUT /orgs/{org}/settings/immutable-releases/repositories"],setMembershipForUser:["PUT /orgs/{org}/memberships/{username}"],setPublicMembershipForAuthenticatedUser:["PUT /orgs/{org}/public_members/{username}"],unblockUser:["DELETE /orgs/{org}/blocks/{username}"],update:["PATCH /orgs/{org}"],updateIssueType:["PUT /orgs/{org}/issue-types/{issue_type_id}"],updateMembershipForAuthenticatedUser:["PATCH /user/memberships/orgs/{org}"],updatePatAccess:["POST /orgs/{org}/personal-access-tokens/{pat_id}"],updatePatAccesses:["POST /orgs/{org}/personal-access-tokens"],updateWebhook:["PATCH /orgs/{org}/hooks/{hook_id}"],updateWebhookConfigForOrg:["PATCH /orgs/{org}/hooks/{hook_id}/config"]},packages:{deletePackageForAuthenticatedUser:["DELETE /user/packages/{package_type}/{package_name}"],deletePackageForOrg:["DELETE /orgs/{org}/packages/{package_type}/{package_name}"],deletePackageForUser:["DELETE /users/{username}/packages/{package_type}/{package_name}"],deletePackageVersionForAuthenticatedUser:["DELETE /user/packages/{package_type}/{package_name}/versions/{package_version_id}"],deletePackageVersionForOrg:["DELETE /orgs/{org}/packages/{package_type}/{package_name}/versions/{package_version_id}"],deletePackageVersionForUser:["DELETE /users/{username}/packages/{package_type}/{package_name}/versions/{package_version_id}"],getAllPackageVersionsForAPackageOwnedByAnOrg:["GET /orgs/{org}/packages/{package_type}/{package_name}/versions",{},{renamed:["packages","getAllPackageVersionsForPackageOwnedByOrg"]}],getAllPackageVersionsForAPackageOwnedByTheAuthenticatedUser:["GET /user/packages/{package_type}/{package_name}/versions",{},{renamed:["packages","getAllPackageVersionsForPackageOwnedByAuthenticatedUser"]}],getAllPackageVersionsForPackageOwnedByAuthenticatedUser:["GET /user/packages/{package_type}/{package_name}/versions"],getAllPackageVersionsForPackageOwnedByOrg:["GET /orgs/{org}/packages/{package_type}/{package_name}/versions"],getAllPackageVersionsForPackageOwnedByUser:["GET /users/{username}/packages/{package_type}/{package_name}/versions"],getPackageForAuthenticatedUser:["GET /user/packages/{package_type}/{package_name}"],getPackageForOrganization:["GET /orgs/{org}/packages/{package_type}/{package_name}"],getPackageForUser:["GET /users/{username}/packages/{package_type}/{package_name}"],getPackageVersionForAuthenticatedUser:["GET /user/packages/{package_type}/{package_name}/versions/{package_version_id}"],getPackageVersionForOrganization:["GET /orgs/{org}/packages/{package_type}/{package_name}/versions/{package_version_id}"],getPackageVersionForUser:["GET /users/{username}/packages/{package_type}/{package_name}/versions/{package_version_id}"],listDockerMigrationConflictingPackagesForAuthenticatedUser:["GET /user/docker/conflicts"],listDockerMigrationConflictingPackagesForOrganization:["GET /orgs/{org}/docker/conflicts"],listDockerMigrationConflictingPackagesForUser:["GET /users/{username}/docker/conflicts"],listPackagesForAuthenticatedUser:["GET /user/packages"],listPackagesForOrganization:["GET /orgs/{org}/packages"],listPackagesForUser:["GET /users/{username}/packages"],restorePackageForAuthenticatedUser:["POST /user/packages/{package_type}/{package_name}/restore{?token}"],restorePackageForOrg:["POST /orgs/{org}/packages/{package_type}/{package_name}/restore{?token}"],restorePackageForUser:["POST /users/{username}/packages/{package_type}/{package_name}/restore{?token}"],restorePackageVersionForAuthenticatedUser:["POST /user/packages/{package_type}/{package_name}/versions/{package_version_id}/restore"],restorePackageVersionForOrg:["POST /orgs/{org}/packages/{package_type}/{package_name}/versions/{package_version_id}/restore"],restorePackageVersionForUser:["POST /users/{username}/packages/{package_type}/{package_name}/versions/{package_version_id}/restore"]},privateRegistries:{createOrgPrivateRegistry:["POST /orgs/{org}/private-registries"],deleteOrgPrivateRegistry:["DELETE /orgs/{org}/private-registries/{secret_name}"],getOrgPrivateRegistry:["GET /orgs/{org}/private-registries/{secret_name}"],getOrgPublicKey:["GET /orgs/{org}/private-registries/public-key"],listOrgPrivateRegistries:["GET /orgs/{org}/private-registries"],updateOrgPrivateRegistry:["PATCH /orgs/{org}/private-registries/{secret_name}"]},projects:{addItemForOrg:["POST /orgs/{org}/projectsV2/{project_number}/items"],addItemForUser:["POST /users/{username}/projectsV2/{project_number}/items"],deleteItemForOrg:["DELETE /orgs/{org}/projectsV2/{project_number}/items/{item_id}"],deleteItemForUser:["DELETE /users/{username}/projectsV2/{project_number}/items/{item_id}"],getFieldForOrg:["GET /orgs/{org}/projectsV2/{project_number}/fields/{field_id}"],getFieldForUser:["GET /users/{username}/projectsV2/{project_number}/fields/{field_id}"],getForOrg:["GET /orgs/{org}/projectsV2/{project_number}"],getForUser:["GET /users/{username}/projectsV2/{project_number}"],getOrgItem:["GET /orgs/{org}/projectsV2/{project_number}/items/{item_id}"],getUserItem:["GET /users/{username}/projectsV2/{project_number}/items/{item_id}"],listFieldsForOrg:["GET /orgs/{org}/projectsV2/{project_number}/fields"],listFieldsForUser:["GET /users/{username}/projectsV2/{project_number}/fields"],listForOrg:["GET /orgs/{org}/projectsV2"],listForUser:["GET /users/{username}/projectsV2"],listItemsForOrg:["GET /orgs/{org}/projectsV2/{project_number}/items"],listItemsForUser:["GET /users/{username}/projectsV2/{project_number}/items"],updateItemForOrg:["PATCH /orgs/{org}/projectsV2/{project_number}/items/{item_id}"],updateItemForUser:["PATCH /users/{username}/projectsV2/{project_number}/items/{item_id}"]},pulls:{checkIfMerged:["GET /repos/{owner}/{repo}/pulls/{pull_number}/merge"],create:["POST /repos/{owner}/{repo}/pulls"],createReplyForReviewComment:["POST /repos/{owner}/{repo}/pulls/{pull_number}/comments/{comment_id}/replies"],createReview:["POST /repos/{owner}/{repo}/pulls/{pull_number}/reviews"],createReviewComment:["POST /repos/{owner}/{repo}/pulls/{pull_number}/comments"],deletePendingReview:["DELETE /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}"],deleteReviewComment:["DELETE /repos/{owner}/{repo}/pulls/comments/{comment_id}"],dismissReview:["PUT /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}/dismissals"],get:["GET /repos/{owner}/{repo}/pulls/{pull_number}"],getReview:["GET /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}"],getReviewComment:["GET /repos/{owner}/{repo}/pulls/comments/{comment_id}"],list:["GET /repos/{owner}/{repo}/pulls"],listCommentsForReview:["GET /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}/comments"],listCommits:["GET /repos/{owner}/{repo}/pulls/{pull_number}/commits"],listFiles:["GET /repos/{owner}/{repo}/pulls/{pull_number}/files"],listRequestedReviewers:["GET /repos/{owner}/{repo}/pulls/{pull_number}/requested_reviewers"],listReviewComments:["GET /repos/{owner}/{repo}/pulls/{pull_number}/comments"],listReviewCommentsForRepo:["GET /repos/{owner}/{repo}/pulls/comments"],listReviews:["GET /repos/{owner}/{repo}/pulls/{pull_number}/reviews"],merge:["PUT /repos/{owner}/{repo}/pulls/{pull_number}/merge"],removeRequestedReviewers:["DELETE /repos/{owner}/{repo}/pulls/{pull_number}/requested_reviewers"],requestReviewers:["POST /repos/{owner}/{repo}/pulls/{pull_number}/requested_reviewers"],submitReview:["POST /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}/events"],update:["PATCH /repos/{owner}/{repo}/pulls/{pull_number}"],updateBranch:["PUT /repos/{owner}/{repo}/pulls/{pull_number}/update-branch"],updateReview:["PUT /repos/{owner}/{repo}/pulls/{pull_number}/reviews/{review_id}"],updateReviewComment:["PATCH /repos/{owner}/{repo}/pulls/comments/{comment_id}"]},rateLimit:{get:["GET /rate_limit"]},reactions:{createForCommitComment:["POST /repos/{owner}/{repo}/comments/{comment_id}/reactions"],createForIssue:["POST /repos/{owner}/{repo}/issues/{issue_number}/reactions"],createForIssueComment:["POST /repos/{owner}/{repo}/issues/comments/{comment_id}/reactions"],createForPullRequestReviewComment:["POST /repos/{owner}/{repo}/pulls/comments/{comment_id}/reactions"],createForRelease:["POST /repos/{owner}/{repo}/releases/{release_id}/reactions"],createForTeamDiscussionCommentInOrg:["POST /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}/reactions"],createForTeamDiscussionInOrg:["POST /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/reactions"],deleteForCommitComment:["DELETE /repos/{owner}/{repo}/comments/{comment_id}/reactions/{reaction_id}"],deleteForIssue:["DELETE /repos/{owner}/{repo}/issues/{issue_number}/reactions/{reaction_id}"],deleteForIssueComment:["DELETE /repos/{owner}/{repo}/issues/comments/{comment_id}/reactions/{reaction_id}"],deleteForPullRequestComment:["DELETE /repos/{owner}/{repo}/pulls/comments/{comment_id}/reactions/{reaction_id}"],deleteForRelease:["DELETE /repos/{owner}/{repo}/releases/{release_id}/reactions/{reaction_id}"],deleteForTeamDiscussion:["DELETE /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/reactions/{reaction_id}"],deleteForTeamDiscussionComment:["DELETE /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}/reactions/{reaction_id}"],listForCommitComment:["GET /repos/{owner}/{repo}/comments/{comment_id}/reactions"],listForIssue:["GET /repos/{owner}/{repo}/issues/{issue_number}/reactions"],listForIssueComment:["GET /repos/{owner}/{repo}/issues/comments/{comment_id}/reactions"],listForPullRequestReviewComment:["GET /repos/{owner}/{repo}/pulls/comments/{comment_id}/reactions"],listForRelease:["GET /repos/{owner}/{repo}/releases/{release_id}/reactions"],listForTeamDiscussionCommentInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}/reactions"],listForTeamDiscussionInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/reactions"]},repos:{acceptInvitation:["PATCH /user/repository_invitations/{invitation_id}",{},{renamed:["repos","acceptInvitationForAuthenticatedUser"]}],acceptInvitationForAuthenticatedUser:["PATCH /user/repository_invitations/{invitation_id}"],addAppAccessRestrictions:["POST /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/apps",{},{mapToData:"apps"}],addCollaborator:["PUT /repos/{owner}/{repo}/collaborators/{username}"],addStatusCheckContexts:["POST /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks/contexts",{},{mapToData:"contexts"}],addTeamAccessRestrictions:["POST /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/teams",{},{mapToData:"teams"}],addUserAccessRestrictions:["POST /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/users",{},{mapToData:"users"}],cancelPagesDeployment:["POST /repos/{owner}/{repo}/pages/deployments/{pages_deployment_id}/cancel"],checkAutomatedSecurityFixes:["GET /repos/{owner}/{repo}/automated-security-fixes"],checkCollaborator:["GET /repos/{owner}/{repo}/collaborators/{username}"],checkImmutableReleases:["GET /repos/{owner}/{repo}/immutable-releases"],checkPrivateVulnerabilityReporting:["GET /repos/{owner}/{repo}/private-vulnerability-reporting"],checkVulnerabilityAlerts:["GET /repos/{owner}/{repo}/vulnerability-alerts"],codeownersErrors:["GET /repos/{owner}/{repo}/codeowners/errors"],compareCommits:["GET /repos/{owner}/{repo}/compare/{base}...{head}"],compareCommitsWithBasehead:["GET /repos/{owner}/{repo}/compare/{basehead}"],createAttestation:["POST /repos/{owner}/{repo}/attestations"],createAutolink:["POST /repos/{owner}/{repo}/autolinks"],createCommitComment:["POST /repos/{owner}/{repo}/commits/{commit_sha}/comments"],createCommitSignatureProtection:["POST /repos/{owner}/{repo}/branches/{branch}/protection/required_signatures"],createCommitStatus:["POST /repos/{owner}/{repo}/statuses/{sha}"],createDeployKey:["POST /repos/{owner}/{repo}/keys"],createDeployment:["POST /repos/{owner}/{repo}/deployments"],createDeploymentBranchPolicy:["POST /repos/{owner}/{repo}/environments/{environment_name}/deployment-branch-policies"],createDeploymentProtectionRule:["POST /repos/{owner}/{repo}/environments/{environment_name}/deployment_protection_rules"],createDeploymentStatus:["POST /repos/{owner}/{repo}/deployments/{deployment_id}/statuses"],createDispatchEvent:["POST /repos/{owner}/{repo}/dispatches"],createForAuthenticatedUser:["POST /user/repos"],createFork:["POST /repos/{owner}/{repo}/forks"],createInOrg:["POST /orgs/{org}/repos"],createOrUpdateEnvironment:["PUT /repos/{owner}/{repo}/environments/{environment_name}"],createOrUpdateFileContents:["PUT /repos/{owner}/{repo}/contents/{path}"],createOrgRuleset:["POST /orgs/{org}/rulesets"],createPagesDeployment:["POST /repos/{owner}/{repo}/pages/deployments"],createPagesSite:["POST /repos/{owner}/{repo}/pages"],createRelease:["POST /repos/{owner}/{repo}/releases"],createRepoRuleset:["POST /repos/{owner}/{repo}/rulesets"],createUsingTemplate:["POST /repos/{template_owner}/{template_repo}/generate"],createWebhook:["POST /repos/{owner}/{repo}/hooks"],customPropertiesForReposCreateOrUpdateRepositoryValues:["PATCH /repos/{owner}/{repo}/properties/values"],customPropertiesForReposGetRepositoryValues:["GET /repos/{owner}/{repo}/properties/values"],declineInvitation:["DELETE /user/repository_invitations/{invitation_id}",{},{renamed:["repos","declineInvitationForAuthenticatedUser"]}],declineInvitationForAuthenticatedUser:["DELETE /user/repository_invitations/{invitation_id}"],delete:["DELETE /repos/{owner}/{repo}"],deleteAccessRestrictions:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/restrictions"],deleteAdminBranchProtection:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/enforce_admins"],deleteAnEnvironment:["DELETE /repos/{owner}/{repo}/environments/{environment_name}"],deleteAutolink:["DELETE /repos/{owner}/{repo}/autolinks/{autolink_id}"],deleteBranchProtection:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection"],deleteCommitComment:["DELETE /repos/{owner}/{repo}/comments/{comment_id}"],deleteCommitSignatureProtection:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/required_signatures"],deleteDeployKey:["DELETE /repos/{owner}/{repo}/keys/{key_id}"],deleteDeployment:["DELETE /repos/{owner}/{repo}/deployments/{deployment_id}"],deleteDeploymentBranchPolicy:["DELETE /repos/{owner}/{repo}/environments/{environment_name}/deployment-branch-policies/{branch_policy_id}"],deleteFile:["DELETE /repos/{owner}/{repo}/contents/{path}"],deleteInvitation:["DELETE /repos/{owner}/{repo}/invitations/{invitation_id}"],deleteOrgRuleset:["DELETE /orgs/{org}/rulesets/{ruleset_id}"],deletePagesSite:["DELETE /repos/{owner}/{repo}/pages"],deletePullRequestReviewProtection:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/required_pull_request_reviews"],deleteRelease:["DELETE /repos/{owner}/{repo}/releases/{release_id}"],deleteReleaseAsset:["DELETE /repos/{owner}/{repo}/releases/assets/{asset_id}"],deleteRepoRuleset:["DELETE /repos/{owner}/{repo}/rulesets/{ruleset_id}"],deleteWebhook:["DELETE /repos/{owner}/{repo}/hooks/{hook_id}"],disableAutomatedSecurityFixes:["DELETE /repos/{owner}/{repo}/automated-security-fixes"],disableDeploymentProtectionRule:["DELETE /repos/{owner}/{repo}/environments/{environment_name}/deployment_protection_rules/{protection_rule_id}"],disableImmutableReleases:["DELETE /repos/{owner}/{repo}/immutable-releases"],disablePrivateVulnerabilityReporting:["DELETE /repos/{owner}/{repo}/private-vulnerability-reporting"],disableVulnerabilityAlerts:["DELETE /repos/{owner}/{repo}/vulnerability-alerts"],downloadArchive:["GET /repos/{owner}/{repo}/zipball/{ref}",{},{renamed:["repos","downloadZipballArchive"]}],downloadTarballArchive:["GET /repos/{owner}/{repo}/tarball/{ref}"],downloadZipballArchive:["GET /repos/{owner}/{repo}/zipball/{ref}"],enableAutomatedSecurityFixes:["PUT /repos/{owner}/{repo}/automated-security-fixes"],enableImmutableReleases:["PUT /repos/{owner}/{repo}/immutable-releases"],enablePrivateVulnerabilityReporting:["PUT /repos/{owner}/{repo}/private-vulnerability-reporting"],enableVulnerabilityAlerts:["PUT /repos/{owner}/{repo}/vulnerability-alerts"],generateReleaseNotes:["POST /repos/{owner}/{repo}/releases/generate-notes"],get:["GET /repos/{owner}/{repo}"],getAccessRestrictions:["GET /repos/{owner}/{repo}/branches/{branch}/protection/restrictions"],getAdminBranchProtection:["GET /repos/{owner}/{repo}/branches/{branch}/protection/enforce_admins"],getAllDeploymentProtectionRules:["GET /repos/{owner}/{repo}/environments/{environment_name}/deployment_protection_rules"],getAllEnvironments:["GET /repos/{owner}/{repo}/environments"],getAllStatusCheckContexts:["GET /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks/contexts"],getAllTopics:["GET /repos/{owner}/{repo}/topics"],getAppsWithAccessToProtectedBranch:["GET /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/apps"],getAutolink:["GET /repos/{owner}/{repo}/autolinks/{autolink_id}"],getBranch:["GET /repos/{owner}/{repo}/branches/{branch}"],getBranchProtection:["GET /repos/{owner}/{repo}/branches/{branch}/protection"],getBranchRules:["GET /repos/{owner}/{repo}/rules/branches/{branch}"],getClones:["GET /repos/{owner}/{repo}/traffic/clones"],getCodeFrequencyStats:["GET /repos/{owner}/{repo}/stats/code_frequency"],getCollaboratorPermissionLevel:["GET /repos/{owner}/{repo}/collaborators/{username}/permission"],getCombinedStatusForRef:["GET /repos/{owner}/{repo}/commits/{ref}/status"],getCommit:["GET /repos/{owner}/{repo}/commits/{ref}"],getCommitActivityStats:["GET /repos/{owner}/{repo}/stats/commit_activity"],getCommitComment:["GET /repos/{owner}/{repo}/comments/{comment_id}"],getCommitSignatureProtection:["GET /repos/{owner}/{repo}/branches/{branch}/protection/required_signatures"],getCommunityProfileMetrics:["GET /repos/{owner}/{repo}/community/profile"],getContent:["GET /repos/{owner}/{repo}/contents/{path}"],getContributorsStats:["GET /repos/{owner}/{repo}/stats/contributors"],getCustomDeploymentProtectionRule:["GET /repos/{owner}/{repo}/environments/{environment_name}/deployment_protection_rules/{protection_rule_id}"],getDeployKey:["GET /repos/{owner}/{repo}/keys/{key_id}"],getDeployment:["GET /repos/{owner}/{repo}/deployments/{deployment_id}"],getDeploymentBranchPolicy:["GET /repos/{owner}/{repo}/environments/{environment_name}/deployment-branch-policies/{branch_policy_id}"],getDeploymentStatus:["GET /repos/{owner}/{repo}/deployments/{deployment_id}/statuses/{status_id}"],getEnvironment:["GET /repos/{owner}/{repo}/environments/{environment_name}"],getLatestPagesBuild:["GET /repos/{owner}/{repo}/pages/builds/latest"],getLatestRelease:["GET /repos/{owner}/{repo}/releases/latest"],getOrgRuleSuite:["GET /orgs/{org}/rulesets/rule-suites/{rule_suite_id}"],getOrgRuleSuites:["GET /orgs/{org}/rulesets/rule-suites"],getOrgRuleset:["GET /orgs/{org}/rulesets/{ruleset_id}"],getOrgRulesets:["GET /orgs/{org}/rulesets"],getPages:["GET /repos/{owner}/{repo}/pages"],getPagesBuild:["GET /repos/{owner}/{repo}/pages/builds/{build_id}"],getPagesDeployment:["GET /repos/{owner}/{repo}/pages/deployments/{pages_deployment_id}"],getPagesHealthCheck:["GET /repos/{owner}/{repo}/pages/health"],getParticipationStats:["GET /repos/{owner}/{repo}/stats/participation"],getPullRequestReviewProtection:["GET /repos/{owner}/{repo}/branches/{branch}/protection/required_pull_request_reviews"],getPunchCardStats:["GET /repos/{owner}/{repo}/stats/punch_card"],getReadme:["GET /repos/{owner}/{repo}/readme"],getReadmeInDirectory:["GET /repos/{owner}/{repo}/readme/{dir}"],getRelease:["GET /repos/{owner}/{repo}/releases/{release_id}"],getReleaseAsset:["GET /repos/{owner}/{repo}/releases/assets/{asset_id}"],getReleaseByTag:["GET /repos/{owner}/{repo}/releases/tags/{tag}"],getRepoRuleSuite:["GET /repos/{owner}/{repo}/rulesets/rule-suites/{rule_suite_id}"],getRepoRuleSuites:["GET /repos/{owner}/{repo}/rulesets/rule-suites"],getRepoRuleset:["GET /repos/{owner}/{repo}/rulesets/{ruleset_id}"],getRepoRulesetHistory:["GET /repos/{owner}/{repo}/rulesets/{ruleset_id}/history"],getRepoRulesetVersion:["GET /repos/{owner}/{repo}/rulesets/{ruleset_id}/history/{version_id}"],getRepoRulesets:["GET /repos/{owner}/{repo}/rulesets"],getStatusChecksProtection:["GET /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks"],getTeamsWithAccessToProtectedBranch:["GET /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/teams"],getTopPaths:["GET /repos/{owner}/{repo}/traffic/popular/paths"],getTopReferrers:["GET /repos/{owner}/{repo}/traffic/popular/referrers"],getUsersWithAccessToProtectedBranch:["GET /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/users"],getViews:["GET /repos/{owner}/{repo}/traffic/views"],getWebhook:["GET /repos/{owner}/{repo}/hooks/{hook_id}"],getWebhookConfigForRepo:["GET /repos/{owner}/{repo}/hooks/{hook_id}/config"],getWebhookDelivery:["GET /repos/{owner}/{repo}/hooks/{hook_id}/deliveries/{delivery_id}"],listActivities:["GET /repos/{owner}/{repo}/activity"],listAttestations:["GET /repos/{owner}/{repo}/attestations/{subject_digest}"],listAutolinks:["GET /repos/{owner}/{repo}/autolinks"],listBranches:["GET /repos/{owner}/{repo}/branches"],listBranchesForHeadCommit:["GET /repos/{owner}/{repo}/commits/{commit_sha}/branches-where-head"],listCollaborators:["GET /repos/{owner}/{repo}/collaborators"],listCommentsForCommit:["GET /repos/{owner}/{repo}/commits/{commit_sha}/comments"],listCommitCommentsForRepo:["GET /repos/{owner}/{repo}/comments"],listCommitStatusesForRef:["GET /repos/{owner}/{repo}/commits/{ref}/statuses"],listCommits:["GET /repos/{owner}/{repo}/commits"],listContributors:["GET /repos/{owner}/{repo}/contributors"],listCustomDeploymentRuleIntegrations:["GET /repos/{owner}/{repo}/environments/{environment_name}/deployment_protection_rules/apps"],listDeployKeys:["GET /repos/{owner}/{repo}/keys"],listDeploymentBranchPolicies:["GET /repos/{owner}/{repo}/environments/{environment_name}/deployment-branch-policies"],listDeploymentStatuses:["GET /repos/{owner}/{repo}/deployments/{deployment_id}/statuses"],listDeployments:["GET /repos/{owner}/{repo}/deployments"],listForAuthenticatedUser:["GET /user/repos"],listForOrg:["GET /orgs/{org}/repos"],listForUser:["GET /users/{username}/repos"],listForks:["GET /repos/{owner}/{repo}/forks"],listInvitations:["GET /repos/{owner}/{repo}/invitations"],listInvitationsForAuthenticatedUser:["GET /user/repository_invitations"],listLanguages:["GET /repos/{owner}/{repo}/languages"],listPagesBuilds:["GET /repos/{owner}/{repo}/pages/builds"],listPublic:["GET /repositories"],listPullRequestsAssociatedWithCommit:["GET /repos/{owner}/{repo}/commits/{commit_sha}/pulls"],listReleaseAssets:["GET /repos/{owner}/{repo}/releases/{release_id}/assets"],listReleases:["GET /repos/{owner}/{repo}/releases"],listTags:["GET /repos/{owner}/{repo}/tags"],listTeams:["GET /repos/{owner}/{repo}/teams"],listWebhookDeliveries:["GET /repos/{owner}/{repo}/hooks/{hook_id}/deliveries"],listWebhooks:["GET /repos/{owner}/{repo}/hooks"],merge:["POST /repos/{owner}/{repo}/merges"],mergeUpstream:["POST /repos/{owner}/{repo}/merge-upstream"],pingWebhook:["POST /repos/{owner}/{repo}/hooks/{hook_id}/pings"],redeliverWebhookDelivery:["POST /repos/{owner}/{repo}/hooks/{hook_id}/deliveries/{delivery_id}/attempts"],removeAppAccessRestrictions:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/apps",{},{mapToData:"apps"}],removeCollaborator:["DELETE /repos/{owner}/{repo}/collaborators/{username}"],removeStatusCheckContexts:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks/contexts",{},{mapToData:"contexts"}],removeStatusCheckProtection:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks"],removeTeamAccessRestrictions:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/teams",{},{mapToData:"teams"}],removeUserAccessRestrictions:["DELETE /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/users",{},{mapToData:"users"}],renameBranch:["POST /repos/{owner}/{repo}/branches/{branch}/rename"],replaceAllTopics:["PUT /repos/{owner}/{repo}/topics"],requestPagesBuild:["POST /repos/{owner}/{repo}/pages/builds"],setAdminBranchProtection:["POST /repos/{owner}/{repo}/branches/{branch}/protection/enforce_admins"],setAppAccessRestrictions:["PUT /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/apps",{},{mapToData:"apps"}],setStatusCheckContexts:["PUT /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks/contexts",{},{mapToData:"contexts"}],setTeamAccessRestrictions:["PUT /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/teams",{},{mapToData:"teams"}],setUserAccessRestrictions:["PUT /repos/{owner}/{repo}/branches/{branch}/protection/restrictions/users",{},{mapToData:"users"}],testPushWebhook:["POST /repos/{owner}/{repo}/hooks/{hook_id}/tests"],transfer:["POST /repos/{owner}/{repo}/transfer"],update:["PATCH /repos/{owner}/{repo}"],updateBranchProtection:["PUT /repos/{owner}/{repo}/branches/{branch}/protection"],updateCommitComment:["PATCH /repos/{owner}/{repo}/comments/{comment_id}"],updateDeploymentBranchPolicy:["PUT /repos/{owner}/{repo}/environments/{environment_name}/deployment-branch-policies/{branch_policy_id}"],updateInformationAboutPagesSite:["PUT /repos/{owner}/{repo}/pages"],updateInvitation:["PATCH /repos/{owner}/{repo}/invitations/{invitation_id}"],updateOrgRuleset:["PUT /orgs/{org}/rulesets/{ruleset_id}"],updatePullRequestReviewProtection:["PATCH /repos/{owner}/{repo}/branches/{branch}/protection/required_pull_request_reviews"],updateRelease:["PATCH /repos/{owner}/{repo}/releases/{release_id}"],updateReleaseAsset:["PATCH /repos/{owner}/{repo}/releases/assets/{asset_id}"],updateRepoRuleset:["PUT /repos/{owner}/{repo}/rulesets/{ruleset_id}"],updateStatusCheckPotection:["PATCH /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks",{},{renamed:["repos","updateStatusCheckProtection"]}],updateStatusCheckProtection:["PATCH /repos/{owner}/{repo}/branches/{branch}/protection/required_status_checks"],updateWebhook:["PATCH /repos/{owner}/{repo}/hooks/{hook_id}"],updateWebhookConfigForRepo:["PATCH /repos/{owner}/{repo}/hooks/{hook_id}/config"],uploadReleaseAsset:["POST /repos/{owner}/{repo}/releases/{release_id}/assets{?name,label}",{baseUrl:"https://uploads.github.com"}]},search:{code:["GET /search/code"],commits:["GET /search/commits"],issuesAndPullRequests:["GET /search/issues"],labels:["GET /search/labels"],repos:["GET /search/repositories"],topics:["GET /search/topics"],users:["GET /search/users"]},secretScanning:{createPushProtectionBypass:["POST /repos/{owner}/{repo}/secret-scanning/push-protection-bypasses"],getAlert:["GET /repos/{owner}/{repo}/secret-scanning/alerts/{alert_number}"],getScanHistory:["GET /repos/{owner}/{repo}/secret-scanning/scan-history"],listAlertsForOrg:["GET /orgs/{org}/secret-scanning/alerts"],listAlertsForRepo:["GET /repos/{owner}/{repo}/secret-scanning/alerts"],listLocationsForAlert:["GET /repos/{owner}/{repo}/secret-scanning/alerts/{alert_number}/locations"],listOrgPatternConfigs:["GET /orgs/{org}/secret-scanning/pattern-configurations"],updateAlert:["PATCH /repos/{owner}/{repo}/secret-scanning/alerts/{alert_number}"],updateOrgPatternConfigs:["PATCH /orgs/{org}/secret-scanning/pattern-configurations"]},securityAdvisories:{createFork:["POST /repos/{owner}/{repo}/security-advisories/{ghsa_id}/forks"],createPrivateVulnerabilityReport:["POST /repos/{owner}/{repo}/security-advisories/reports"],createRepositoryAdvisory:["POST /repos/{owner}/{repo}/security-advisories"],createRepositoryAdvisoryCveRequest:["POST /repos/{owner}/{repo}/security-advisories/{ghsa_id}/cve"],getGlobalAdvisory:["GET /advisories/{ghsa_id}"],getRepositoryAdvisory:["GET /repos/{owner}/{repo}/security-advisories/{ghsa_id}"],listGlobalAdvisories:["GET /advisories"],listOrgRepositoryAdvisories:["GET /orgs/{org}/security-advisories"],listRepositoryAdvisories:["GET /repos/{owner}/{repo}/security-advisories"],updateRepositoryAdvisory:["PATCH /repos/{owner}/{repo}/security-advisories/{ghsa_id}"]},teams:{addOrUpdateMembershipForUserInOrg:["PUT /orgs/{org}/teams/{team_slug}/memberships/{username}"],addOrUpdateRepoPermissionsInOrg:["PUT /orgs/{org}/teams/{team_slug}/repos/{owner}/{repo}"],checkPermissionsForRepoInOrg:["GET /orgs/{org}/teams/{team_slug}/repos/{owner}/{repo}"],create:["POST /orgs/{org}/teams"],createDiscussionCommentInOrg:["POST /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments"],createDiscussionInOrg:["POST /orgs/{org}/teams/{team_slug}/discussions"],deleteDiscussionCommentInOrg:["DELETE /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}"],deleteDiscussionInOrg:["DELETE /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}"],deleteInOrg:["DELETE /orgs/{org}/teams/{team_slug}"],getByName:["GET /orgs/{org}/teams/{team_slug}"],getDiscussionCommentInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}"],getDiscussionInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}"],getMembershipForUserInOrg:["GET /orgs/{org}/teams/{team_slug}/memberships/{username}"],list:["GET /orgs/{org}/teams"],listChildInOrg:["GET /orgs/{org}/teams/{team_slug}/teams"],listDiscussionCommentsInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments"],listDiscussionsInOrg:["GET /orgs/{org}/teams/{team_slug}/discussions"],listForAuthenticatedUser:["GET /user/teams"],listMembersInOrg:["GET /orgs/{org}/teams/{team_slug}/members"],listPendingInvitationsInOrg:["GET /orgs/{org}/teams/{team_slug}/invitations"],listReposInOrg:["GET /orgs/{org}/teams/{team_slug}/repos"],removeMembershipForUserInOrg:["DELETE /orgs/{org}/teams/{team_slug}/memberships/{username}"],removeRepoInOrg:["DELETE /orgs/{org}/teams/{team_slug}/repos/{owner}/{repo}"],updateDiscussionCommentInOrg:["PATCH /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}/comments/{comment_number}"],updateDiscussionInOrg:["PATCH /orgs/{org}/teams/{team_slug}/discussions/{discussion_number}"],updateInOrg:["PATCH /orgs/{org}/teams/{team_slug}"]},users:{addEmailForAuthenticated:["POST /user/emails",{},{renamed:["users","addEmailForAuthenticatedUser"]}],addEmailForAuthenticatedUser:["POST /user/emails"],addSocialAccountForAuthenticatedUser:["POST /user/social_accounts"],block:["PUT /user/blocks/{username}"],checkBlocked:["GET /user/blocks/{username}"],checkFollowingForUser:["GET /users/{username}/following/{target_user}"],checkPersonIsFollowedByAuthenticated:["GET /user/following/{username}"],createGpgKeyForAuthenticated:["POST /user/gpg_keys",{},{renamed:["users","createGpgKeyForAuthenticatedUser"]}],createGpgKeyForAuthenticatedUser:["POST /user/gpg_keys"],createPublicSshKeyForAuthenticated:["POST /user/keys",{},{renamed:["users","createPublicSshKeyForAuthenticatedUser"]}],createPublicSshKeyForAuthenticatedUser:["POST /user/keys"],createSshSigningKeyForAuthenticatedUser:["POST /user/ssh_signing_keys"],deleteAttestationsBulk:["POST /users/{username}/attestations/delete-request"],deleteAttestationsById:["DELETE /users/{username}/attestations/{attestation_id}"],deleteAttestationsBySubjectDigest:["DELETE /users/{username}/attestations/digest/{subject_digest}"],deleteEmailForAuthenticated:["DELETE /user/emails",{},{renamed:["users","deleteEmailForAuthenticatedUser"]}],deleteEmailForAuthenticatedUser:["DELETE /user/emails"],deleteGpgKeyForAuthenticated:["DELETE /user/gpg_keys/{gpg_key_id}",{},{renamed:["users","deleteGpgKeyForAuthenticatedUser"]}],deleteGpgKeyForAuthenticatedUser:["DELETE /user/gpg_keys/{gpg_key_id}"],deletePublicSshKeyForAuthenticated:["DELETE /user/keys/{key_id}",{},{renamed:["users","deletePublicSshKeyForAuthenticatedUser"]}],deletePublicSshKeyForAuthenticatedUser:["DELETE /user/keys/{key_id}"],deleteSocialAccountForAuthenticatedUser:["DELETE /user/social_accounts"],deleteSshSigningKeyForAuthenticatedUser:["DELETE /user/ssh_signing_keys/{ssh_signing_key_id}"],follow:["PUT /user/following/{username}"],getAuthenticated:["GET /user"],getById:["GET /user/{account_id}"],getByUsername:["GET /users/{username}"],getContextForUser:["GET /users/{username}/hovercard"],getGpgKeyForAuthenticated:["GET /user/gpg_keys/{gpg_key_id}",{},{renamed:["users","getGpgKeyForAuthenticatedUser"]}],getGpgKeyForAuthenticatedUser:["GET /user/gpg_keys/{gpg_key_id}"],getPublicSshKeyForAuthenticated:["GET /user/keys/{key_id}",{},{renamed:["users","getPublicSshKeyForAuthenticatedUser"]}],getPublicSshKeyForAuthenticatedUser:["GET /user/keys/{key_id}"],getSshSigningKeyForAuthenticatedUser:["GET /user/ssh_signing_keys/{ssh_signing_key_id}"],list:["GET /users"],listAttestations:["GET /users/{username}/attestations/{subject_digest}"],listAttestationsBulk:["POST /users/{username}/attestations/bulk-list{?per_page,before,after}"],listBlockedByAuthenticated:["GET /user/blocks",{},{renamed:["users","listBlockedByAuthenticatedUser"]}],listBlockedByAuthenticatedUser:["GET /user/blocks"],listEmailsForAuthenticated:["GET /user/emails",{},{renamed:["users","listEmailsForAuthenticatedUser"]}],listEmailsForAuthenticatedUser:["GET /user/emails"],listFollowedByAuthenticated:["GET /user/following",{},{renamed:["users","listFollowedByAuthenticatedUser"]}],listFollowedByAuthenticatedUser:["GET /user/following"],listFollowersForAuthenticatedUser:["GET /user/followers"],listFollowersForUser:["GET /users/{username}/followers"],listFollowingForUser:["GET /users/{username}/following"],listGpgKeysForAuthenticated:["GET /user/gpg_keys",{},{renamed:["users","listGpgKeysForAuthenticatedUser"]}],listGpgKeysForAuthenticatedUser:["GET /user/gpg_keys"],listGpgKeysForUser:["GET /users/{username}/gpg_keys"],listPublicEmailsForAuthenticated:["GET /user/public_emails",{},{renamed:["users","listPublicEmailsForAuthenticatedUser"]}],listPublicEmailsForAuthenticatedUser:["GET /user/public_emails"],listPublicKeysForUser:["GET /users/{username}/keys"],listPublicSshKeysForAuthenticated:["GET /user/keys",{},{renamed:["users","listPublicSshKeysForAuthenticatedUser"]}],listPublicSshKeysForAuthenticatedUser:["GET /user/keys"],listSocialAccountsForAuthenticatedUser:["GET /user/social_accounts"],listSocialAccountsForUser:["GET /users/{username}/social_accounts"],listSshSigningKeysForAuthenticatedUser:["GET /user/ssh_signing_keys"],listSshSigningKeysForUser:["GET /users/{username}/ssh_signing_keys"],setPrimaryEmailVisibilityForAuthenticated:["PATCH /user/email/visibility",{},{renamed:["users","setPrimaryEmailVisibilityForAuthenticatedUser"]}],setPrimaryEmailVisibilityForAuthenticatedUser:["PATCH /user/email/visibility"],unblock:["DELETE /user/blocks/{username}"],unfollow:["DELETE /user/following/{username}"],updateAuthenticated:["PATCH /user"]}};const $c=new Map;for(const[a,mu]of Object.entries(Zc))for(const[t,e]of Object.entries(mu)){const[i,n,o]=e,[s,r]=i.split(/ /),l=Object.assign({method:s,url:r},n);$c.has(a)||$c.set(a,new Map),$c.get(a).set(t,{scope:a,methodName:t,endpointDefaults:l,decorations:o})}const Xc={has(t,e){let{scope:a}=t;return $c.get(a).has(e)},getOwnPropertyDescriptor(t,e){return{value:this.get(t,e),configurable:!0,writable:!0,enumerable:!0}},defineProperty:(t,e,a)=>(Object.defineProperty(t.cache,e,a),!0),deleteProperty:(t,e)=>(delete t.cache[e],!0),ownKeys(t){let{scope:e}=t;return[...$c.get(e).keys()]},set:(t,e,a)=>t.cache[e]=a,get(t,e){let{octokit:a,scope:i,cache:n}=t;if(n[e])return n[e];const o=$c.get(i).get(e);if(!o)return;const{endpointDefaults:s,decorations:r}=o;return n[e]=r?function(t,e,a,i,n){const o=t.request.defaults(i);function s(){let i=o.endpoint.merge(...arguments);if(n.mapToData)return i=Object.assign({},i,{data:i[n.mapToData],[n.mapToData]:void 0}),o(i);if(n.renamed){const[i,o]=n.renamed;t.log.warn("octokit.".concat(e,".").concat(a,"() has been renamed to octokit.").concat(i,".").concat(o,"()"))}if(n.deprecated&&t.log.warn(n.deprecated),n.renamedParameters){const i=o.endpoint.merge(...arguments);for(const[o,s]of Object.entries(n.renamedParameters))o in i&&(t.log.warn('"'.concat(o,'" parameter is deprecated for "octokit.').concat(e,".").concat(a,'()". Use "').concat(s,'" instead')),s in i||(i[s]=i[o]),delete i[o]);return o(i)}return o(...arguments)}return Object.assign(s,o)}(a,i,e,s,r):a.request.defaults(s),n[e]}};function Yc(t){const e={};for(const a of $c.keys())e[a]=new Proxy({octokit:t,scope:a,cache:{}},Xc);return e}function Jc(t){const e=Yc(t);return Ht(Ht({},e),{},{rest:e})}Jc.VERSION=Kc;const tm=Hc.plugin(Vc,Jc,Qc).defaults({userAgent:"octokit-rest.js/".concat("22.0.1")});const em=class{constructor(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:null,a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:null;if(!t)throw new Error("GitHub token is required");this.octokit=new tm({auth:t}),this.owner=e||localStorage.getItem("github_owner")||"",this.repo=a||localStorage.getItem("github_repo")||"myvetcorner",this.branch="main"}async updateContent(t,e){let a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:null;const i="public/content/".concat(t),n=JSON.stringify(e,null,2),o=a||"Update ".concat(t," via admin panel");try{let e=null;try{const{data:t}=await this.octokit.repos.getContent({owner:this.owner,repo:this.repo,path:i,ref:this.branch});e=t.sha}catch(s){if(404!==s.status)throw s}const a={owner:this.owner,repo:this.repo,path:i,message:o,content:Buffer.from(n).toString("base64"),branch:this.branch};e&&(a.sha=e);return{success:!0,commit:(await this.octokit.repos.createOrUpdateFileContents(a)).data.commit,message:"Successfully committed ".concat(t)}}catch(s){console.error("GitHub API Error:",s);let e="Failed to update ".concat(t);throw 401===s.status?e="Invalid GitHub token. Please check your token in Settings.":404===s.status?e="Repository not found. Please check owner/repo in Settings.":s.message&&(e+=": ".concat(s.message)),new Error(e)}}async getContent(t){const e="public/content/".concat(t);try{const{data:t}=await this.octokit.repos.getContent({owner:this.owner,repo:this.repo,path:e,ref:this.branch}),a=Buffer.from(t.content,"base64").toString("utf8");return JSON.parse(a)}catch(a){throw console.error("Error fetching ".concat(t,":"),a),new Error("Failed to fetch ".concat(t," from GitHub"))}}async updateArticles(t){return this.updateContent("articles.json",t,"Update articles")}async updateResearch(t){return this.updateContent("research.json",t,"Update research papers")}async updateExperts(t){return this.updateContent("experts.json",t,"Update medical board")}async updateCategories(t){return this.updateContent("categories.json",t,"Update categories")}async updateMedia(t){return this.updateContent("media.json",t,"Update media library")}async updateSlides(t){return this.updateContent("slides.json",t,"Update hero slides")}async updateSiteConfig(t){return this.updateContent("site-config.json",t,"Update site configuration")}async updateUsers(t){return this.updateContent("users.json",t,"Update users")}async uploadFile(t){let e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"uploads";return new Promise((a,i)=>{const n=new FileReader;n.onload=async()=>{try{const i=n.result.split(",")[1],o=Date.now(),s="".concat(o,"-").concat(t.name),r="public/".concat(e,"/").concat(s);await this.octokit.repos.createOrUpdateFileContents({owner:this.owner,repo:this.repo,path:r,message:"Upload ".concat(t.name),content:i,branch:this.branch});const l="/".concat(e,"/").concat(s);a({success:!0,url:l,filename:s,originalName:t.name})}catch(o){console.error("Upload error:",o),i(new Error("Failed to upload ".concat(t.name,": ").concat(o.message)))}},n.onerror=()=>{i(new Error("Failed to read file"))},n.readAsDataURL(t)})}async testConnection(){try{const{data:t}=await this.octokit.repos.get({owner:this.owner,repo:this.repo});return{success:!0,repoName:t.full_name,private:t.private}}catch(t){throw new Error("Connection test failed: ".concat(t.message))}}};function am(){const t=se(),[e,a]=(0,i.useState)(""),[n,o]=(0,i.useState)(""),[s,r]=(0,i.useState)("myvetcorner"),[l,d]=(0,i.useState)(!1),[c,m]=(0,i.useState)(null);return(0,i.useEffect)(()=>{a(localStorage.getItem("github_token")||""),o(localStorage.getItem("github_owner")||""),r(localStorage.getItem("github_repo")||"myvetcorner")},[]),(0,Gt.jsxs)("div",{className:"space-y-6",children:[(0,Gt.jsxs)(ce,{children:[(0,Gt.jsx)(me,{title:"GitHub Configuration",subtitle:"Configure GitHub repository for content management"}),(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"space-y-5",children:[(0,Gt.jsxs)("div",{className:"bg-blue-50 dark:bg-blue-900/20 border border-blue-200 dark:border-blue-800 rounded-lg p-4",children:[(0,Gt.jsx)("h3",{className:"font-semibold text-blue-900 dark:text-blue-200 mb-2",children:"\ud83d\udcda Setup Instructions"}),(0,Gt.jsxs)("ol",{className:"text-sm text-blue-800 dark:text-blue-300 space-y-1 list-decimal list-inside",children:[(0,Gt.jsxs)("li",{children:["Go to ",(0,Gt.jsx)("a",{href:"https://github.com/settings/tokens",target:"_blank",rel:"noopener noreferrer",className:"underline font-medium",children:"GitHub Settings \u2192 Developer settings \u2192 Personal access tokens"})]}),(0,Gt.jsx)("li",{children:'Click "Generate new token (classic)"'}),(0,Gt.jsx)("li",{children:'Give it a name (e.g., "My Vet Corner Admin")'}),(0,Gt.jsxs)("li",{children:["Select scope: ",(0,Gt.jsx)("code",{className:"bg-blue-100 dark:bg-blue-900 px-1 rounded",children:"repo"})," (full repository access)"]}),(0,Gt.jsx)("li",{children:'Click "Generate token" and copy it'}),(0,Gt.jsx)("li",{children:"Paste the token below and save"})]})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-2",children:"GitHub Username or Organization"}),(0,Gt.jsx)("input",{type:"text",value:n,onChange:t=>o(t.target.value),placeholder:"your-github-username",className:"w-full px-4 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white focus:ring-2 focus:ring-blue-500"}),(0,Gt.jsx)("p",{className:"mt-1 text-xs text-gray-500 dark:text-gray-400",children:'Your GitHub username or organization name (e.g., "octocat")'})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-2",children:"Repository Name"}),(0,Gt.jsx)("input",{type:"text",value:s,onChange:t=>r(t.target.value),placeholder:"myvetcorner",className:"w-full px-4 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white focus:ring-2 focus:ring-blue-500"}),(0,Gt.jsx)("p",{className:"mt-1 text-xs text-gray-500 dark:text-gray-400",children:'The repository name (without username, e.g., "myvetcorner")'})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 dark:text-gray-300 mb-2",children:"Personal Access Token"}),(0,Gt.jsx)("input",{type:"password",value:e,onChange:t=>a(t.target.value),placeholder:"ghp_xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx",className:"w-full px-4 py-2 border border-gray-300 dark:border-gray-600 rounded-lg bg-white dark:bg-gray-700 text-gray-900 dark:text-white focus:ring-2 focus:ring-blue-500 font-mono text-sm"}),(0,Gt.jsxs)("p",{className:"mt-1 text-xs text-gray-500 dark:text-gray-400",children:["Required scope: ",(0,Gt.jsx)("code",{className:"bg-gray-100 dark:bg-gray-800 px-1 rounded",children:"repo"})]})]}),c&&(0,Gt.jsxs)("div",{className:"p-4 rounded-lg border ".concat(c.success?"bg-green-50 dark:bg-green-900/20 border-green-200 dark:border-green-800":"bg-red-50 dark:bg-red-900/20 border-red-200 dark:border-red-800"),children:[(0,Gt.jsx)("p",{className:"font-medium ".concat(c.success?"text-green-900 dark:text-green-200":"text-red-900 dark:text-red-200"),children:c.message}),(0,Gt.jsx)("p",{className:"text-sm mt-1 ".concat(c.success?"text-green-700 dark:text-green-300":"text-red-700 dark:text-red-300"),children:c.details})]}),(0,Gt.jsxs)("div",{className:"flex gap-3 pt-4 border-t border-gray-200 dark:border-gray-700",children:[(0,Gt.jsx)(ge,{onClick:function(){e?n?s?(localStorage.setItem("github_token",e),localStorage.setItem("github_owner",n),localStorage.setItem("github_repo",s),t.success("\u2705 GitHub settings saved!"),m(null)):t.error("Please enter your repository name"):t.error("Please enter your GitHub username/organization"):t.error("Please enter a GitHub token")},variant:"primary",icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}),children:"Save Settings"}),(0,Gt.jsx)(ge,{onClick:async function(){if(e&&n&&s){d(!0),m(null);try{const a=new em(e,n,s),i=await a.testConnection();m({success:!0,message:"\u2705 Connected to ".concat(i.repoName),details:i.private?"\ud83d\udd12 Private repository":"\ud83c\udf0d Public repository"}),t.success("Connection successful!")}catch(a){m({success:!1,message:"\u274c Connection failed",details:a.message}),t.error("Connection failed: "+a.message)}finally{d(!1)}}else t.error("Please fill in all fields and save first")},disabled:l,variant:"secondary",icon:(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 10V3L4 14h7v7l9-11h-7z"})}),children:l?"Testing...":"Test Connection"})]})]})})]}),(0,Gt.jsx)(ce,{children:(0,Gt.jsx)(ue,{children:(0,Gt.jsxs)("div",{className:"flex items-start gap-3",children:[(0,Gt.jsx)("svg",{className:"w-6 h-6 text-yellow-600 dark:text-yellow-400 flex-shrink-0",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h3",{className:"font-semibold text-gray-900 dark:text-white mb-1",children:"\ud83d\udd10 Security Notice"}),(0,Gt.jsx)("p",{className:"text-sm text-gray-600 dark:text-gray-400",children:"Your GitHub token is stored locally in your browser's localStorage. Never share your token with anyone. Only use this admin panel on trusted devices. If you suspect your token has been compromised, revoke it immediately on GitHub and generate a new one."})]})]})})})]})}function im(){var t;const{siteData:e,setSiteData:a}=Kt()||{},{darkMode:n,toggleTheme:o}=$t(),[s,r]=(0,i.useState)(!1),[l,d]=(0,i.useState)(!1),c=et();function m(){alert("\u2705 All changes are automatically saved to your browser!\n\nNote: Changes are stored in localStorage and will persist on this browser. To make changes permanent across all users, you need to export the data and commit it to your repository.")}(0,i.useEffect)(()=>{localStorage.getItem("adminToken")||localStorage.setItem("adminToken","static-admin-token")},[]),(0,i.useEffect)(()=>{d(!1)},[c]);const u=[{to:"/admin",label:"Dashboard",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 12l2-2m0 0l7-7 7 7M5 10v10a1 1 0 001 1h3m10-11l2 2m-2-2v10a1 1 0 01-1 1h-3m-6 0a1 1 0 001-1v-4a1 1 0 011-1h2a1 1 0 011 1v4a1 1 0 001 1m-6 0h6"})}),exact:!0},{to:"/admin/editor",label:"Articles",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})})},{to:"/admin/categories",label:"Categories",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})})},{to:"/admin/users",label:"Experts",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4.354a4 4 0 110 5.292M15 21H3v-1a6 6 0 0112 0v1zm0 0h6v-1a6 6 0 00-9-5.197M13 7a4 4 0 11-8 0 4 4 0 018 0z"})})},{to:"/admin/research",label:"Research",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.384-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})})},{to:"/admin/homepage",label:"Homepage",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 5a1 1 0 011-1h14a1 1 0 011 1v2a1 1 0 01-1 1H5a1 1 0 01-1-1V5zM4 13a1 1 0 011-1h6a1 1 0 011 1v6a1 1 0 01-1 1H5a1 1 0 01-1-1v-6zM16 13a1 1 0 011-1h2a1 1 0 011 1v6a1 1 0 01-1 1h-2a1 1 0 01-1-1v-6z"})})},{to:"/admin/category-heroes",label:"Category Images",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 16l4.586-4.586a2 2 0 012.828 0L16 16m-2-2l1.586-1.586a2 2 0 012.828 0L20 14m-6-6h.01M6 20h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"})})},{to:"/admin/media",label:"Media",icon:(0,Gt.jsxs)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:[(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 9a2 2 0 012-2h.93a2 2 0 001.664-.89l.812-1.22A2 2 0 0110.07 4h3.86a2 2 0 011.664.89l.812 1.22A2 2 0 0018.07 7H19a2 2 0 012 2v9a2 2 0 01-2 2H5a2 2 0 01-2-2V9z"}),(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M15 13a3 3 0 11-6 0 3 3 0 016 0z"})]})},{to:"/admin/system-users",label:"System Users",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 4.354a4 4 0 110 5.292M15 21H3v-1a6 6 0 0112 0v1zm0 0h6v-1a6 6 0 00-9-5.197M13 7a4 4 0 11-8 0 4 4 0 018 0z"})})},{to:"/admin/github",label:"GitHub",icon:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{d:"M 12 2c-5.523 0-10 4.477-10 10 0 4.418 2.865 8.166 6.839 9.489.5.092.682-.217.682-.482 0-.237-.008-.866-.013-1.7-2.782.604-3.369-1.34-3.369-1.34-.454-1.156-1.11-1.464-1.11-1.464-.908-.62.069-.608.069-.608 1.003.07 1.531 1.03 1.531 1.03.892 1.529 2.341 1.087 2.91.831.092-.646.35-1.086.636-1.336-2.22-.253-4.555-1.11-4.555-4.943 0-1.091.39-1.984 1.029-2.683-.103-.253-.446-1.27.098-2.647 0 0 .84-.269 2.75 1.025A9.578 9.578 0 0112 6.836c.85.004 1.705.114 2.504.336 1.909-1.294 2.747-1.025 2.747-1.025.546 1.377.203 2.394.1 2.647.64.699 1.028 1.592 1.028 2.683 0 3.842-2.339 4.687-4.566 4.935.359.309.678.919.678 1.852 0 1.336-.012 2.415-.012 2.743 0 .267.18.578.688.48C19.138 20.163 22 16.418 22 12c0-5.523-4.477-10-10-10z"})})},{to:"/admin/theme",label:"Settings",icon:(0,Gt.jsxs)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:[(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M10.325 4.317c.426-1.756 2.924-1.756 3.35 0a1.724 1.724 0 002.573 1.066c1.543-.94 3.31.826 2.37 2.37a1.724 1.724 0 001.065 2.572c1.756.426 1.756 2.924 0 3.35a1.724 1.724 0 00-1.066 2.573c.94 1.543-.826 3.31-2.37 2.37a1.724 1.724 0 00-2.572 1.065c-.426 1.756-2.924 1.756-3.35 0a1.724 1.724 0 00-2.573-1.066c-1.543.94-3.31-.826-2.37-2.37a1.724 1.724 0 00-1.065-2.572c-1.756-.426-1.756-2.924 0-3.35a1.724 1.724 0 001.066-2.573c-.94-1.543.826-3.31 2.37-2.37.996.608 2.296.07 2.572-1.065z"}),(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M15 12a3 3 0 11-6 0 3 3 0 016 0z"})]})}];return(0,Gt.jsx)(oe,{children:(0,Gt.jsxs)("div",{className:"flex h-screen bg-gray-50 dark:bg-gray-900 overflow-hidden",children:[(0,Gt.jsxs)("aside",{className:"".concat(s?"w-20":"w-64"," bg-white dark:bg-gray-800 border-r border-gray-200 dark:border-gray-700 transition-all duration-300 flex-shrink-0 hidden lg:flex flex-col"),children:[(0,Gt.jsxs)("div",{className:"h-16 flex items-center justify-between px-4 border-b border-gray-200 dark:border-gray-700 bg-white dark:bg-gray-900",children:[s?(0,Gt.jsxs)("h1",{className:"text-lg font-bold text-gray-900 dark:text-white",children:[(0,Gt.jsx)("span",{className:"text-green-600",children:"A"}),(0,Gt.jsx)("span",{className:"text-blue-600",children:"P"})]}):(0,Gt.jsxs)("h1",{className:"text-xl font-bold text-gray-900 dark:text-white",children:[(0,Gt.jsx)("span",{className:"text-green-600",children:"Admin"}),(0,Gt.jsx)("br",{}),(0,Gt.jsx)("span",{className:"text-blue-600",children:"Panel"})]}),(0,Gt.jsx)("button",{onClick:()=>r(!s),className:"p-2 rounded-lg hover:bg-gray-100 dark:hover:bg-gray-800 text-gray-700 dark:text-gray-300 transition",children:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:s?"M13 5l7 7-7 7M5 5l7 7-7 7":"M11 19l-7-7 7-7m8 14l-7-7 7-7"})})})]}),(0,Gt.jsx)("nav",{className:"flex-1 overflow-y-auto p-4",children:(0,Gt.jsx)("div",{className:"space-y-1",children:u.map(t=>(0,Gt.jsxs)(jt,{to:t.to,end:t.exact,className:t=>{let{isActive:e}=t;return"flex items-center gap-3 px-3 py-2.5 rounded-lg transition-all duration-200 ".concat(e?"bg-blue-600 text-white shadow-lg shadow-blue-500/50":"text-gray-700 dark:text-gray-300 hover:bg-gray-100 dark:hover:bg-gray-700")},title:s?t.label:"",children:[t.icon,!s&&(0,Gt.jsx)("span",{className:"font-medium",children:t.label})]},t.to))})}),(0,Gt.jsx)("div",{className:"p-4 border-t border-gray-200 dark:border-gray-700 bg-white dark:bg-gray-900",children:(0,Gt.jsxs)("button",{onClick:m,className:"w-full bg-gradient-to-r from-green-600 to-blue-600 hover:from-green-700 hover:to-blue-700 text-white font-semibold py-3 px-4 rounded-lg shadow-lg hover:shadow-xl transition-all duration-200 flex items-center justify-center gap-2",children:[!s&&"View Save Info",s&&(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})]})})]}),l&&(0,Gt.jsxs)("div",{className:"fixed inset-0 z-50 lg:hidden",children:[(0,Gt.jsx)("div",{className:"absolute inset-0 bg-black bg-opacity-50",onClick:()=>d(!1)}),(0,Gt.jsxs)("aside",{className:"absolute left-0 top-0 bottom-0 w-64 bg-white dark:bg-gray-800 shadow-xl flex flex-col",children:[(0,Gt.jsxs)("div",{className:"h-16 flex items-center justify-between px-4 border-b border-gray-200 dark:border-gray-700",children:[(0,Gt.jsx)("h1",{className:"text-xl font-bold bg-gradient-to-r from-green-600 to-blue-600 bg-clip-text text-transparent",children:"Admin Panel"}),(0,Gt.jsx)("button",{onClick:()=>d(!1),className:"p-2 rounded-lg hover:bg-gray-100 dark:hover:bg-gray-700",children:(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),(0,Gt.jsx)("nav",{className:"flex-1 overflow-y-auto p-4",children:(0,Gt.jsx)("div",{className:"space-y-1",children:u.map(t=>(0,Gt.jsxs)(jt,{to:t.to,end:t.exact,className:t=>{let{isActive:e}=t;return"flex items-center gap-3 px-3 py-2.5 rounded-lg transition ".concat(e?"bg-blue-600 text-white":"text-gray-700 dark:text-gray-300 hover:bg-gray-100 dark:hover:bg-gray-700")},children:[t.icon,(0,Gt.jsx)("span",{className:"font-medium",children:t.label})]},t.to))})}),(0,Gt.jsx)("div",{className:"p-4 border-t border-gray-200 dark:border-gray-700",children:(0,Gt.jsx)("button",{onClick:m,className:"w-full bg-green-600 text-white py-2.5 rounded-lg font-medium hover:bg-green-700 transition",children:"Save Info"})})]})]}),(0,Gt.jsxs)("div",{className:"flex-1 flex flex-col overflow-hidden",children:[(0,Gt.jsxs)("header",{className:"h-16 bg-white dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700 flex items-center justify-between px-6",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-4",children:[(0,Gt.jsx)("button",{onClick:()=>d(!0),className:"lg:hidden p-2 rounded-lg hover:bg-gray-100 dark:hover:bg-gray-700",children:(0,Gt.jsx)("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 6h16M4 12h16M4 18h16"})})}),(0,Gt.jsx)("h2",{className:"text-lg font-semibold text-gray-800 dark:text-white",children:(null===e||void 0===e||null===(t=e.site)||void 0===t?void 0:t.name)||"My Vet Corner"})]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-3",children:[(0,Gt.jsx)("button",{onClick:o,className:"p-2 rounded-lg hover:bg-gray-100 dark:hover:bg-gray-700 transition",title:"Toggle theme",children:n?(0,Gt.jsx)("svg",{className:"w-5 h-5 text-yellow-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 3v1m0 16v1m9-9h-1M4 12H3m15.364 6.364l-.707-.707M6.343 6.343l-.707-.707m12.728 0l-.707.707M6.343 17.657l-.707.707M16 12a4 4 0 11-8 0 4 4 0 018 0z"})}):(0,Gt.jsx)("svg",{className:"w-5 h-5 text-gray-700",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M20.354 15.354A9 9 0 018.646 3.646 9.003 9.003 0 0012 21a9.003 9.003 0 008.354-5.646z"})})}),(0,Gt.jsxs)("a",{href:"/",target:"_blank",rel:"noopener noreferrer",className:"px-4 py-2 bg-blue-600 text-white rounded-lg font-medium hover:bg-blue-700 transition flex items-center gap-2",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"})}),(0,Gt.jsx)("span",{className:"hidden sm:inline",children:"View Site"})]})]})]}),(0,Gt.jsxs)("main",{className:"flex-1 overflow-y-auto p-6",children:[(0,Gt.jsx)("div",{className:"mb-6",children:(0,Gt.jsx)(de,{})}),(0,Gt.jsxs)(xt,{children:[(0,Gt.jsx)(vt,{path:"/",element:(0,Gt.jsx)(pe,{})}),(0,Gt.jsx)(vt,{path:"editor",element:(0,Gt.jsx)(qd,{})}),(0,Gt.jsx)(vt,{path:"categories",element:(0,Gt.jsx)(_d,{})}),(0,Gt.jsx)(vt,{path:"users",element:(0,Gt.jsx)(Od,{})}),(0,Gt.jsx)(vt,{path:"homepage",element:(0,Gt.jsx)(Hd,{})}),(0,Gt.jsx)(vt,{path:"research",element:(0,Gt.jsx)(Vd,{})}),(0,Gt.jsx)(vt,{path:"category-heroes",element:(0,Gt.jsx)(Bd,{})}),(0,Gt.jsx)(vt,{path:"media",element:(0,Gt.jsx)(Ud,{})}),(0,Gt.jsx)(vt,{path:"system-users",element:(0,Gt.jsx)(Qd,{})}),(0,Gt.jsx)(vt,{path:"github",element:(0,Gt.jsx)(am,{})}),(0,Gt.jsx)(vt,{path:"theme",element:(0,Gt.jsx)(Gd,{})}),(0,Gt.jsx)(vt,{path:"settings",element:(0,Gt.jsx)(Wd,{})}),(0,Gt.jsx)(vt,{path:"*",element:(0,Gt.jsx)(bt,{to:"/admin",replace:!0})})]})]})]})]})})}function nm(){const[t,e]=(0,i.useState)(""),[a,n]=(0,i.useState)(""),[o,s]=(0,i.useState)("Master@47"),r=it();function l(){t===o?(localStorage.setItem("adminToken","static-admin-token"),localStorage.setItem("adminLoggedIn","true"),n(""),r("/admin",{replace:!0})):n("Invalid credentials")}return(0,i.useEffect)(()=>{fetch("/content/site-config.json").then(t=>t.json()).then(t=>{t.adminPassword&&s(t.adminPassword)}).catch(t=>console.error("Failed to load config:",t))},[]),(0,Gt.jsx)("div",{className:"min-h-screen flex items-center justify-center bg-gray-100",children:(0,Gt.jsxs)("div",{className:"bg-white rounded-xl p-6 w-full max-w-md",children:[(0,Gt.jsx)("h2",{className:"text-xl font-semibold mb-4",children:"Admin Login"}),a&&(0,Gt.jsx)("div",{className:"bg-red-100 text-red-700 rounded p-2 mb-3",children:a}),(0,Gt.jsx)("input",{type:"password",className:"w-full border rounded px-3 py-2 mb-3",placeholder:"Password",value:t,onChange:t=>e(t.target.value),onKeyDown:t=>{"Enter"===t.key&&l()}}),(0,Gt.jsx)("button",{className:"w-full bg-blue-700 text-white rounded px-3 py-2",onClick:l,children:"Login"})]})})}function om(){var t;const{siteData:e}=Kt()||{},a=(null===e||void 0===e||null===(t=e.site)||void 0===t?void 0:t.name)||"My Vet Corner";return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:a,navigation:null===e||void 0===e?void 0:e.navigation}),(0,Gt.jsxs)("section",{className:"relative bg-gray-900 text-white py-24 px-4 overflow-hidden",children:[(0,Gt.jsx)("div",{className:"absolute inset-0 bg-blue-900 opacity-50"}),(0,Gt.jsxs)("div",{className:"relative max-w-5xl mx-auto text-center z-10",children:[(0,Gt.jsx)("h1",{className:"text-5xl font-bold mb-6",children:"Empowering Pet Owners"}),(0,Gt.jsx)("p",{className:"text-xl text-blue-100 max-w-2xl mx-auto",children:"We bridge the gap between complex veterinary science and loving pet care, providing you with trusted knowledge to keep your companions healthy."})]})]}),(0,Gt.jsx)("section",{className:"py-20 px-4",children:(0,Gt.jsxs)("div",{className:"max-w-4xl mx-auto flex flex-col md:flex-row items-center gap-12",children:[(0,Gt.jsx)("div",{className:"md:w-1/2",children:(0,Gt.jsx)("img",{src:"https://images.unsplash.com/photo-1554692996-43e950af06fc?auto=format&fit=crop&q=80&w=800",alt:"Veterinarian with dog",className:"rounded-2xl shadow-2xl"})}),(0,Gt.jsxs)("div",{className:"md:w-1/2",children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold mb-6 text-gray-900",children:"Our Story"}),(0,Gt.jsxs)("p",{className:"text-gray-600 mb-4 leading-relaxed",children:["Founded in 2024, ",(0,Gt.jsx)("span",{className:"text-green-600 font-semibold",children:"My"}),(0,Gt.jsx)("span",{className:"text-blue-800 font-semibold",children:"VetCorner"}),' started with a simple question: "Why is accurate veterinary advice so hard to find online?"']}),(0,Gt.jsx)("p",{className:"text-gray-600 leading-relaxed",children:"We gathered a team of passionate veterinarians, researchers, and animal lovers to create a platform that respects the intelligence of pet owners while ensuring absolute medical accuracy."})]})]})}),(0,Gt.jsx)("section",{className:"bg-blue-50 py-16",children:(0,Gt.jsxs)("div",{className:"max-w-6xl mx-auto px-4 grid grid-cols-2 md:grid-cols-4 gap-8 text-center",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-4xl font-bold text-blue-600 mb-2",children:"500+"}),(0,Gt.jsx)("div",{className:"text-gray-600",children:"Articles Published"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-4xl font-bold text-blue-600 mb-2",children:"50k+"}),(0,Gt.jsx)("div",{className:"text-gray-600",children:"Monthly Readers"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-4xl font-bold text-blue-600 mb-2",children:"20+"}),(0,Gt.jsx)("div",{className:"text-gray-600",children:"Vet Experts"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-4xl font-bold text-blue-600 mb-2",children:"100%"}),(0,Gt.jsx)("div",{className:"text-gray-600",children:"Fact Checked"})]})]})}),(0,Gt.jsx)(Jt,{siteName:a,footer:null===e||void 0===e?void 0:e.footer})]})}function sm(){var t;const{siteData:e}=Kt()||{},a=(null===e||void 0===e||null===(t=e.site)||void 0===t?void 0:t.name)||"My Vet Corner";return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:a,navigation:null===e||void 0===e?void 0:e.navigation}),(0,Gt.jsx)("section",{className:"bg-gray-50 py-20 px-4",children:(0,Gt.jsxs)("div",{className:"max-w-4xl mx-auto bg-white rounded-2xl shadow-xl overflow-hidden flex flex-col md:flex-row",children:[(0,Gt.jsxs)("div",{className:"md:w-5/12 bg-blue-900 p-10 text-white flex flex-col justify-between",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-3xl font-bold mb-4",children:"Get in Touch"}),(0,Gt.jsx)("p",{className:"text-blue-100 mb-8",children:"Have a question? We'd love to hear from you. Send us a message and we'll respond as soon as possible."})]}),(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{className:"flex items-center space-x-3",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M3 8l7.89 5.26a2 2 0 002.22 0L21 8M5 19h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v10a2 2 0 002 2z"})}),(0,Gt.jsx)("span",{children:"support@myvetcorner.com"})]}),(0,Gt.jsxs)("div",{className:"flex items-center space-x-3",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:"2",d:"M3 5a2 2 0 012-2h3.28a1 1 0 01.948.684l1.498 4.493a1 1 0 01-.502 1.21l-2.257 1.13a11.042 11.042 0 005.516 5.516l1.13-2.257a1 1 0 011.21-.502l4.493 1.498a1 1 0 01.684.949V19a2 2 0 01-2 2h-1C9.716 21 3 14.284 3 6V5z"})}),(0,Gt.jsx)("span",{children:"+1 (555) 123-4567"})]})]})]}),(0,Gt.jsx)("div",{className:"md:w-7/12 p-10",children:(0,Gt.jsxs)("form",{className:"space-y-6",onSubmit:t=>{t.preventDefault(),alert("Message Sent!")},children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 mb-1",children:"Name"}),(0,Gt.jsx)("input",{type:"text",className:"w-full border-gray-300 border rounded-lg px-4 py-3 focus:ring-2 focus:ring-blue-500 outline-none",placeholder:"Your Name"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 mb-1",children:"Email"}),(0,Gt.jsx)("input",{type:"email",className:"w-full border-gray-300 border rounded-lg px-4 py-3 focus:ring-2 focus:ring-blue-500 outline-none",placeholder:"you@example.com"})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-medium text-gray-700 mb-1",children:"Message"}),(0,Gt.jsx)("textarea",{className:"w-full border-gray-300 border rounded-lg px-4 py-3 focus:ring-2 focus:ring-blue-500 outline-none h-32",placeholder:"How can we help?"})]}),(0,Gt.jsx)("button",{type:"submit",className:"w-full bg-blue-600 hover:bg-blue-700 text-white font-bold py-3 rounded-lg transition",children:"Send Message"})]})})]})}),(0,Gt.jsx)(Jt,{siteName:a,footer:null===e||void 0===e?void 0:e.footer})]})}function rm(){var t;const{siteData:e}=Kt()||{},a=(null===e||void 0===e||null===(t=e.site)||void 0===t?void 0:t.name)||"My Vet Corner";return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:a,navigation:null===e||void 0===e?void 0:e.navigation}),(0,Gt.jsxs)("section",{className:"bg-blue-900 text-white py-20 px-4 text-center",children:[(0,Gt.jsx)("h1",{className:"text-4xl md:text-5xl font-bold mb-4",children:"Medical Review Board"}),(0,Gt.jsx)("p",{className:"max-w-2xl mx-auto text-blue-100 text-lg",children:"Our team of veterinary professionals ensures every article is accurate, up-to-date, and safe for your pets."})]}),(0,Gt.jsx)("section",{className:"max-w-5xl mx-auto px-4 py-16 text-center",children:(0,Gt.jsxs)("p",{className:"text-xl text-gray-600 leading-relaxed",children:["At ",(0,Gt.jsx)("span",{className:"text-green-600 font-semibold",children:"My"}),(0,Gt.jsx)("span",{className:"text-blue-800 font-semibold",children:"VetCorner"}),", we believe in accurate, science-backed information. Our Medical Review Board consists of board-certified veterinarians and veterinary experts who rigorously review our content to maintain the highest standards of veterinary care."]})}),(0,Gt.jsx)("section",{className:"bg-gray-50 py-16",children:(0,Gt.jsxs)("div",{className:"max-w-7xl mx-auto px-4",children:[(0,Gt.jsx)("div",{className:"grid md:grid-cols-2 lg:grid-cols-3 gap-8",children:((null===e||void 0===e?void 0:e.experts)||[]).map((t,e)=>(0,Gt.jsxs)("div",{className:"bg-white rounded-2xl p-8 shadow-sm hover:shadow-xl transition duration-300 text-center border border-gray-100",children:[(0,Gt.jsx)("img",{src:t.image,alt:t.name,className:"w-32 h-32 rounded-full mx-auto mb-6 object-cover border-4 border-blue-50"}),(0,Gt.jsx)("h3",{className:"text-2xl font-bold text-gray-900 mb-2",children:t.name}),(0,Gt.jsx)("p",{className:"text-blue-600 font-semibold mb-2",children:t.title}),(0,Gt.jsx)("p",{className:"text-gray-500",children:t.specialty})]},e))}),0===((null===e||void 0===e?void 0:e.experts)||[]).length&&(0,Gt.jsx)("p",{className:"text-center text-gray-500",children:"No experts listed yet."})]})}),(0,Gt.jsx)(Jt,{siteName:a,footer:null===e||void 0===e?void 0:e.footer})]})}function lm(){var t,e;const{siteData:a}=Kt()||{};return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:null===a||void 0===a||null===(t=a.site)||void 0===t?void 0:t.name,navigation:null===a||void 0===a?void 0:a.navigation}),(0,Gt.jsxs)("section",{className:"py-20 px-4 max-w-4xl mx-auto text-center",children:[(0,Gt.jsx)("h1",{className:"text-4xl font-bold mb-4",children:"Join Our Team"}),(0,Gt.jsx)("p",{className:"text-gray-600 mb-12",children:"Help us build the most trusted resource for pet health."}),(0,Gt.jsx)("div",{className:"text-left space-y-4",children:[{title:"Veterinary Content Writer",type:"Remote",dept:"Editorial"},{title:"Senior Veterinary Reviewer",type:"Part-time",dept:"Medical Board"},{title:"Community Manager",type:"Remote",dept:"Marketing"}].map((t,e)=>(0,Gt.jsxs)("div",{className:"border border-gray-200 rounded-xl p-6 flex justify-between items-center hover:shadow-md transition bg-white",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h3",{className:"font-bold text-lg text-gray-900",children:t.title}),(0,Gt.jsxs)("div",{className:"text-sm text-gray-500 space-x-2",children:[(0,Gt.jsx)("span",{children:t.dept}),(0,Gt.jsx)("span",{children:"\u2022"}),(0,Gt.jsx)("span",{children:t.type})]})]}),(0,Gt.jsx)("button",{className:"bg-blue-600 text-white px-4 py-2 rounded-lg text-sm font-semibold hover:bg-blue-700",children:"Apply"})]},e))})]}),(0,Gt.jsx)(Jt,{siteName:null===a||void 0===a||null===(e=a.site)||void 0===e?void 0:e.name,footer:null===a||void 0===a?void 0:a.footer})]})}function dm(t){var e,a;let{title:i,children:n}=t;const{siteData:o}=Kt()||{};return(0,Gt.jsxs)("div",{className:"bg-white min-h-screen text-gray-800 font-sans",children:[(0,Gt.jsx)(Yt,{siteName:null===o||void 0===o||null===(e=o.site)||void 0===e?void 0:e.name,navigation:null===o||void 0===o?void 0:o.navigation}),(0,Gt.jsx)("div",{className:"bg-gray-50 border-b py-12",children:(0,Gt.jsx)("div",{className:"max-w-4xl mx-auto px-4",children:(0,Gt.jsx)("h1",{className:"text-4xl font-bold text-gray-900",children:i})})}),(0,Gt.jsx)("div",{className:"max-w-4xl mx-auto px-4 py-12 prose md:prose-lg text-gray-600",children:n||(0,Gt.jsxs)("div",{children:[(0,Gt.jsxs)("h2",{className:"text-2xl font-bold text-gray-900 mb-4",children:["Last Updated: ",(new Date).toLocaleDateString()]}),(0,Gt.jsxs)("p",{className:"mb-6",children:["This is a placeholder for the ",(0,Gt.jsx)("strong",{children:i}),". In a real application, this content would be managed via the admin panel or loaded from specific markdown files."]}),(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-3",children:"1. Introduction"}),(0,Gt.jsx)("p",{className:"mb-4",children:"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat."}),(0,Gt.jsx)("h3",{className:"text-xl font-bold text-gray-900 mb-3",children:"2. Terms"}),(0,Gt.jsx)("p",{className:"mb-4",children:"Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident."})]})}),(0,Gt.jsx)(Jt,{siteName:null===o||void 0===o||null===(a=o.site)||void 0===a?void 0:a.name,footer:null===o||void 0===o?void 0:o.footer})]})}function cm(){var t,e;const{siteData:a}=Kt()||{},i=(null===a||void 0===a?void 0:a.research)||[];return(0,Gt.jsxs)("div",{className:"min-h-screen bg-gray-50 dark:bg-gray-900",children:[(0,Gt.jsx)(Yt,{siteName:null===(t=a.site)||void 0===t?void 0:t.name,navigation:a.navigation}),(0,Gt.jsx)("section",{className:"bg-gradient-to-br from-blue-600 to-blue-800 py-16",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsxs)("div",{className:"text-center text-white",children:[(0,Gt.jsx)("h1",{className:"text-4xl lg:text-5xl font-bold mb-4",children:"Research & Journals"}),(0,Gt.jsx)("p",{className:"text-xl text-blue-100 max-w-3xl mx-auto",children:"Peer-reviewed studies, case reports, and academic resources to advance veterinary medicine"})]})})}),(0,Gt.jsx)("section",{className:"bg-white dark:bg-gray-800 py-3 border-b dark:border-gray-700",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:(0,Gt.jsxs)("nav",{className:"text-sm text-gray-500 dark:text-gray-400",children:[(0,Gt.jsx)(Et,{to:"/",className:"hover:text-blue-600 dark:hover:text-blue-400",children:"Home"}),(0,Gt.jsx)("span",{className:"mx-2",children:"\u203a"}),(0,Gt.jsx)("span",{className:"text-gray-700 dark:text-gray-300",children:"Research & Journals"})]})})}),(0,Gt.jsx)("section",{className:"py-12",children:(0,Gt.jsx)("div",{className:"max-w-7xl mx-auto px-4",children:0===i.length?(0,Gt.jsxs)("div",{className:"text-center py-16",children:[(0,Gt.jsx)("svg",{className:"w-20 h-20 mx-auto text-gray-400 mb-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.384-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})}),(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-gray-900 dark:text-white mb-2",children:"No research papers yet"}),(0,Gt.jsx)("p",{className:"text-gray-600 dark:text-gray-400",children:"Check back soon for peer-reviewed studies and research articles"})]}):(0,Gt.jsx)("div",{className:"space-y-8",children:i.map((t,e)=>{const a=t.typeColor||"blue",i=t.content&&(t=>{const e=document.createElement("DIV");return e.innerHTML=t,e.textContent||e.innerText||""})(t.content).trim().length>0,n=t.pdfUrl&&t.pdfUrl.trim().length>0;return(0,Gt.jsxs)("article",{className:"bg-white dark:bg-gray-800 rounded-xl p-8 shadow-sm border-l-4 border-".concat(a,"-600 hover:shadow-md transition-shadow"),children:[(0,Gt.jsxs)("div",{className:"flex items-start justify-between mb-4 flex-wrap gap-2",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-3 flex-wrap",children:[(0,Gt.jsx)("span",{className:"bg-".concat(a,"-100 dark:bg-").concat(a,"-900 text-").concat(a,"-800 dark:text-").concat(a,"-200 text-sm font-semibold px-4 py-1.5 rounded-full"),children:t.type||"Research"}),n&&(0,Gt.jsxs)("span",{className:"bg-green-100 dark:bg-green-900 text-green-800 dark:text-green-200 text-xs font-semibold px-3 py-1 rounded-full flex items-center gap-1",children:[(0,Gt.jsx)("svg",{className:"w-3 h-3",fill:"currentColor",viewBox:"0 0 20 20",children:(0,Gt.jsx)("path",{d:"M4 4a2 2 0 012-2h4.586A2 2 0 0112 2.586L15.414 6A2 2 0 0116 7.414V16a2 2 0 01-2 2H6a2 2 0 01-2-2V4z"})}),"PDF Available"]})]}),(0,Gt.jsx)("span",{className:"text-gray-500 dark:text-gray-400 text-sm font-medium",children:t.year})]}),(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-gray-900 dark:text-white mb-3",children:t.title}),(0,Gt.jsxs)("div",{className:"text-gray-600 dark:text-gray-300 text-sm mb-4 space-y-1",children:[t.authors&&(0,Gt.jsxs)("p",{children:[(0,Gt.jsx)("strong",{className:"font-semibold",children:"Authors:"})," ",t.authors]}),t.journal&&(0,Gt.jsxs)("p",{children:[(0,Gt.jsx)("strong",{className:"font-semibold",children:"Published in:"})," ",t.journal]})]}),t.abstract&&(0,Gt.jsxs)("div",{className:"mb-6",children:[(0,Gt.jsx)("h3",{className:"font-semibold text-gray-900 dark:text-white mb-2",children:"Abstract"}),(0,Gt.jsx)("p",{className:"text-gray-600 dark:text-gray-300 leading-relaxed",children:t.abstract})]}),i&&(0,Gt.jsxs)("div",{className:"mb-6 pb-6 border-b dark:border-gray-700",children:[(0,Gt.jsx)("h3",{className:"font-semibold text-gray-900 dark:text-white mb-3",children:"Full Content"}),(0,Gt.jsx)("div",{className:"prose dark:prose-invert max-w-none text-gray-600 dark:text-gray-300",dangerouslySetInnerHTML:{__html:t.content}})]}),n&&(0,Gt.jsxs)("div",{className:"flex items-center gap-4",children:[(0,Gt.jsxs)("a",{href:"http://localhost:5000".concat(t.pdfUrl),download:!0,className:"inline-flex items-center gap-2 bg-blue-600 hover:bg-blue-700 text-white font-semibold px-6 py-3 rounded-lg transition-colors shadow-sm",children:[(0,Gt.jsx)("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:(0,Gt.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 10v6m0 0l-3-3m3 3l3-3m2 8H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),"Download Full Paper (PDF)"]}),(0,Gt.jsx)("span",{className:"text-sm text-gray-500 dark:text-gray-400",children:t.pdfFileName||"Research paper"})]}),!n&&i&&(0,Gt.jsxs)("div",{className:"flex items-center gap-2 text-sm text-gray-500 dark:text-gray-400",children:[(0,Gt.jsx)("svg",{className:"w-4 h-4",fill:"currentColor",viewBox:"0 0 20 20",children:(0,Gt.jsx)("path",{fillRule:"evenodd",d:"M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z",clipRule:"evenodd"})}),"Full content available online only"]})]},t._id||e)})})})}),(0,Gt.jsx)(Jt,{siteName:null===(e=a.site)||void 0===e?void 0:e.name,footer:a.footer})]})}const mm=t=>{const e=(t=>t.replace(/^([A-Z])|[\s-_]+(\w)/g,(t,e,a)=>a?a.toUpperCase():e.toLowerCase()))(t);return e.charAt(0).toUpperCase()+e.slice(1)},um=function(){for(var t=arguments.length,e=new Array(t),a=0;a<t;a++)e[a]=arguments[a];return e.filter((t,e,a)=>Boolean(t)&&""!==t.trim()&&a.indexOf(t)===e).join(" ").trim()};var hm={xmlns:"http://www.w3.org/2000/svg",width:24,height:24,viewBox:"0 0 24 24",fill:"none",stroke:"currentColor",strokeWidth:2,strokeLinecap:"round",strokeLinejoin:"round"};const fm=["color","size","strokeWidth","absoluteStrokeWidth","className","children","iconNode"],gm=(0,i.forwardRef)((t,e)=>{let{color:a="currentColor",size:n=24,strokeWidth:o=2,absoluteStrokeWidth:s,className:r="",children:l,iconNode:d}=t,c=he(t,fm);return(0,i.createElement)("svg",Ht(Ht(Ht({ref:e},hm),{},{width:n,height:n,stroke:a,strokeWidth:s?24*Number(o)/Number(n):o,className:um("lucide",r)},!l&&!(t=>{for(const e in t)if(e.startsWith("aria-")||"role"===e||"title"===e)return!0})(c)&&{"aria-hidden":"true"}),c),[...d.map(t=>{let[e,a]=t;return(0,i.createElement)(e,a)}),...Array.isArray(l)?l:[l]])}),pm=["className"],ym=(t,e)=>{const a=(0,i.forwardRef)((a,n)=>{let{className:o}=a,s=he(a,pm);return(0,i.createElement)(gm,Ht({ref:n,iconNode:e,className:um("lucide-".concat((r=mm(t),r.replace(/([a-z0-9])([A-Z])/g,"$1-$2").toLowerCase())),"lucide-".concat(t),o)},s));var r});return a.displayName=mm(t),a},bm=ym("book-open",[["path",{d:"M12 7v14",key:"1akyts"}],["path",{d:"M3 18a1 1 0 0 1-1-1V4a1 1 0 0 1 1-1h5a4 4 0 0 1 4 4 4 4 0 0 1 4-4h5a1 1 0 0 1 1 1v13a1 1 0 0 1-1 1h-6a3 3 0 0 0-3 3 3 3 0 0 0-3-3z",key:"ruj8y"}]]),vm=ym("calculator",[["rect",{width:"16",height:"20",x:"4",y:"2",rx:"2",key:"1nb95v"}],["line",{x1:"8",x2:"16",y1:"6",y2:"6",key:"x4nwl0"}],["line",{x1:"16",x2:"16",y1:"14",y2:"18",key:"wjye3r"}],["path",{d:"M16 10h.01",key:"1m94wz"}],["path",{d:"M12 10h.01",key:"1nrarc"}],["path",{d:"M8 10h.01",key:"19clt8"}],["path",{d:"M12 14h.01",key:"1etili"}],["path",{d:"M8 14h.01",key:"6423bh"}],["path",{d:"M12 18h.01",key:"mhygvu"}],["path",{d:"M8 18h.01",key:"lrp35t"}]]),wm=ym("stethoscope",[["path",{d:"M11 2v2",key:"1539x4"}],["path",{d:"M5 2v2",key:"1yf1q8"}],["path",{d:"M5 3H4a2 2 0 0 0-2 2v4a6 6 0 0 0 12 0V5a2 2 0 0 0-2-2h-1",key:"rb5t3r"}],["path",{d:"M8 15a6 6 0 0 0 12 0v-3",key:"x18d4x"}],["circle",{cx:"20",cy:"10",r:"2",key:"ts1r5v"}]]),xm=ym("pill",[["path",{d:"m10.5 20.5 10-10a4.95 4.95 0 1 0-7-7l-10 10a4.95 4.95 0 1 0 7 7Z",key:"wa1lgi"}],["path",{d:"m8.5 8.5 7 7",key:"rvfmvr"}]]),km=ym("chevron-right",[["path",{d:"m9 18 6-6-6-6",key:"mthhwq"}]]),Im=ym("search",[["path",{d:"m21 21-4.34-4.34",key:"14j7rj"}],["circle",{cx:"11",cy:"11",r:"8",key:"4ej97u"}]]);function Cm(t){let{value:e,onChange:a,placeholder:i,className:n=""}=t;return(0,Gt.jsxs)("div",{className:"group flex items-center gap-3 rounded-2xl border border-clinical-gray dark:border-slate-700 bg-white dark:bg-slate-800 px-4 py-3 shadow-sm transition-all focus-within:border-clinical-blue focus-within:ring-4 focus-within:ring-clinical-blue/10 ".concat(n),children:[(0,Gt.jsx)(Im,{className:"h-5 w-5 text-clinical-slate dark:text-slate-400 group-focus-within:text-clinical-blue transition-colors"}),(0,Gt.jsx)("input",{className:"w-full bg-transparent text-base outline-none placeholder:text-clinical-slate/50 dark:placeholder:text-slate-500 text-clinical-navy dark:text-white",value:e,onChange:t=>a(t.target.value),placeholder:null!==i&&void 0!==i?i:"Search..."})]})}const Sm=ym("bug",[["path",{d:"M12 20v-9",key:"1qisl0"}],["path",{d:"M14 7a4 4 0 0 1 4 4v3a6 6 0 0 1-12 0v-3a4 4 0 0 1 4-4z",key:"uouzyp"}],["path",{d:"M14.12 3.88 16 2",key:"qol33r"}],["path",{d:"M21 21a4 4 0 0 0-3.81-4",key:"1b0z45"}],["path",{d:"M21 5a4 4 0 0 1-3.55 3.97",key:"5cxbf6"}],["path",{d:"M22 13h-4",key:"1jl80f"}],["path",{d:"M3 21a4 4 0 0 1 3.81-4",key:"1fjd4g"}],["path",{d:"M3 5a4 4 0 0 0 3.55 3.97",key:"1d7oge"}],["path",{d:"M6 13H2",key:"82j7cp"}],["path",{d:"m8 2 1.88 1.88",key:"fmnt4t"}],["path",{d:"M9 7.13V6a3 3 0 1 1 6 0v1.13",key:"1vgav8"}]]),Am=ym("activity",[["path",{d:"M22 12h-2.48a2 2 0 0 0-1.93 1.46l-2.35 8.36a.25.25 0 0 1-.48 0L9.24 2.18a.25.25 0 0 0-.48 0l-2.35 8.36A2 2 0 0 1 4.49 12H2",key:"169zse"}]]),Tm=ym("heart",[["path",{d:"M2 9.5a5.5 5.5 0 0 1 9.591-3.676.56.56 0 0 0 .818 0A5.49 5.49 0 0 1 22 9.5c0 2.29-1.5 4-3 5.5l-5.492 5.313a2 2 0 0 1-3 .019L5 15c-1.5-1.5-3-3.2-3-5.5",key:"mvr1a0"}]]),Pm=ym("brain",[["path",{d:"M12 18V5",key:"adv99a"}],["path",{d:"M15 13a4.17 4.17 0 0 1-3-4 4.17 4.17 0 0 1-3 4",key:"1e3is1"}],["path",{d:"M17.598 6.5A3 3 0 1 0 12 5a3 3 0 1 0-5.598 1.5",key:"1gqd8o"}],["path",{d:"M17.997 5.125a4 4 0 0 1 2.526 5.77",key:"iwvgf7"}],["path",{d:"M18 18a4 4 0 0 0 2-7.464",key:"efp6ie"}],["path",{d:"M19.967 17.483A4 4 0 1 1 12 18a4 4 0 1 1-7.967-.517",key:"1gq6am"}],["path",{d:"M6 18a4 4 0 0 1-2-7.464",key:"k1g0md"}],["path",{d:"M6.003 5.125a4 4 0 0 0-2.526 5.77",key:"q97ue3"}]]),Dm=ym("shield",[["path",{d:"M20 13c0 5-3.5 7.5-7.66 8.95a1 1 0 0 1-.67-.01C7.5 20.5 4 18 4 13V6a1 1 0 0 1 1-1c2 0 4.5-1.2 6.24-2.72a1.17 1.17 0 0 1 1.52 0C14.51 3.81 17 5 19 5a1 1 0 0 1 1 1z",key:"oel41y"}]]),Nm=ym("wind",[["path",{d:"M12.8 19.6A2 2 0 1 0 14 16H2",key:"148xed"}],["path",{d:"M17.5 8a2.5 2.5 0 1 1 2 4H2",key:"1u4tom"}],["path",{d:"M9.8 4.4A2 2 0 1 1 11 8H2",key:"75valh"}]]),Lm=ym("droplets",[["path",{d:"M7 16.3c2.2 0 4-1.83 4-4.05 0-1.16-.57-2.26-1.71-3.19S7.29 6.75 7 5.3c-.29 1.45-1.14 2.84-2.29 3.76S3 11.1 3 12.25c0 2.22 1.8 4.05 4 4.05z",key:"1ptgy4"}],["path",{d:"M12.56 6.6A10.97 10.97 0 0 0 14 3.02c.5 2.5 2 4.9 4 6.5s3 3.5 3 5.5a6.98 6.98 0 0 1-11.91 4.97",key:"1sl1rz"}]]),Em=ym("bone",[["path",{d:"M17 10c.7-.7 1.69 0 2.5 0a2.5 2.5 0 1 0 0-5 .5.5 0 0 1-.5-.5 2.5 2.5 0 1 0-5 0c0 .81.7 1.8 0 2.5l-7 7c-.7.7-1.69 0-2.5 0a2.5 2.5 0 0 0 0 5c.28 0 .5.22.5.5a2.5 2.5 0 1 0 5 0c0-.81-.7-1.8 0-2.5Z",key:"w610uw"}]]),jm=ym("zap",[["path",{d:"M4 14a1 1 0 0 1-.78-1.63l9.9-10.2a.5.5 0 0 1 .86.46l-1.92 6.02A1 1 0 0 0 13 10h7a1 1 0 0 1 .78 1.63l-9.9 10.2a.5.5 0 0 1-.86-.46l1.92-6.02A1 1 0 0 0 11 14z",key:"1xq2db"}]]),Mm=ym("syringe",[["path",{d:"m18 2 4 4",key:"22kx64"}],["path",{d:"m17 7 3-3",key:"1w1zoj"}],["path",{d:"M19 9 8.7 19.3c-1 1-2.5 1-3.4 0l-.6-.6c-1-1-1-2.5 0-3.4L15 5",key:"1exhtz"}],["path",{d:"m9 11 4 4",key:"rovt3i"}],["path",{d:"m5 19-3 3",key:"59f2uf"}],["path",{d:"m14 4 6 6",key:"yqp9t2"}]]),zm=ym("arrow-right",[["path",{d:"M5 12h14",key:"1ays0h"}],["path",{d:"m12 5 7 7-7 7",key:"xquz4c"}]]);function Rm(t){let{title:e,count:a,onClick:i}=t;const n=(t=>{const e=t.toLowerCase();return e.includes("antibiotic")||e.includes("bacterial")?Sm:e.includes("analgesic")||e.includes("pain")||e.includes("opioid")?Am:e.includes("cardio")||e.includes("heart")?Tm:e.includes("neuro")||e.includes("convulsant")||e.includes("sedative")||e.includes("anesthetic")?Pm:e.includes("inflam")?Dm:e.includes("parasit")?Sm:e.includes("respiratory")||e.includes("lung")?Nm:e.includes("fluid")||e.includes("renal")||e.includes("diuretic")?Lm:e.includes("ortho")||e.includes("bone")?Em:e.includes("emergency")||e.includes("critical")?jm:e.includes("vaccine")||e.includes("immune")?Mm:xm})(e);return(0,Gt.jsxs)("button",{onClick:i,className:"group relative flex flex-col justify-between rounded-3xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-6 text-left shadow-sm transition-all duration-300 hover:-translate-y-1 hover:border-teal-500/30 hover:shadow-xl hover:shadow-teal-900/5 dark:hover:border-teal-500/50",children:[(0,Gt.jsx)("div",{className:"mb-4 flex h-14 w-14 items-center justify-center rounded-2xl bg-slate-50 dark:bg-slate-700 text-teal-600 dark:text-teal-400 group-hover:bg-teal-500 group-hover:text-white transition-colors duration-300",children:(0,Gt.jsx)(n,{className:"h-7 w-7"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h3",{className:"text-lg font-bold text-slate-800 dark:text-white group-hover:text-teal-700 dark:group-hover:text-teal-400 transition-colors",children:e}),(0,Gt.jsxs)("p",{className:"mt-1 text-sm font-medium text-slate-400 group-hover:text-slate-500 dark:group-hover:text-slate-300 transition-colors",children:[a," formulations"]})]}),(0,Gt.jsx)("div",{className:"absolute top-6 right-6 opacity-0 -translate-x-2 group-hover:opacity-100 group-hover:translate-x-0 transition-all duration-300",children:(0,Gt.jsx)(zm,{className:"h-5 w-5 text-teal-500"})})]})}const Fm=ym("x",[["path",{d:"M18 6 6 18",key:"1bl5f8"}],["path",{d:"m6 6 12 12",key:"d8bk6v"}]]),qm=ym("circle-check",[["circle",{cx:"12",cy:"12",r:"10",key:"1mglay"}],["path",{d:"m9 12 2 2 4-4",key:"dzmm74"}]]),_m=ym("file-text",[["path",{d:"M6 22a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h8a2.4 2.4 0 0 1 1.704.706l3.588 3.588A2.4 2.4 0 0 1 20 8v12a2 2 0 0 1-2 2z",key:"1oefj6"}],["path",{d:"M14 2v5a1 1 0 0 0 1 1h5",key:"wfsgrz"}],["path",{d:"M10 9H8",key:"b1mrlr"}],["path",{d:"M16 13H8",key:"t4e002"}],["path",{d:"M16 17H8",key:"z1uh3a"}]]),Om=ym("copy",[["rect",{width:"14",height:"14",x:"8",y:"8",rx:"2",ry:"2",key:"17jyea"}],["path",{d:"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2",key:"zix9uf"}]]),Um=ym("circle-alert",[["circle",{cx:"12",cy:"12",r:"10",key:"1mglay"}],["line",{x1:"12",x2:"12",y1:"8",y2:"12",key:"1pkeuh"}],["line",{x1:"12",x2:"12.01",y1:"16",y2:"16",key:"4dfq90"}]]),Hm=ym("star",[["path",{d:"M11.525 2.295a.53.53 0 0 1 .95 0l2.31 4.679a2.123 2.123 0 0 0 1.595 1.16l5.166.756a.53.53 0 0 1 .294.904l-3.736 3.638a2.123 2.123 0 0 0-.611 1.878l.882 5.14a.53.53 0 0 1-.771.56l-4.618-2.428a2.122 2.122 0 0 0-1.973 0L6.396 21.01a.53.53 0 0 1-.77-.56l.881-5.139a2.122 2.122 0 0 0-.611-1.879L2.16 9.795a.53.53 0 0 1 .294-.906l5.165-.755a2.122 2.122 0 0 0 1.597-1.16z",key:"r04s7s"}]]),Vm=t=>{if(!t||"Not specified in source"===t)return[];let e=t.replace(/^Indications and Clinical Uses\s*/i,"").replace(/^Dosage\s*/i,"").replace(/^Contraindications and Precautions\s*/i,"").trim();return e.includes("\u2022")?e.split("\u2022").map(t=>t.trim()).filter(t=>t.length>0):e.split(/\.\s+/).map(t=>t.trim()).filter(t=>t.length>0).map(t=>t.endsWith(".")||t.endsWith(":")?t:t+".")};function Bm(t){let{drug:e,onClose:a,onOpenCalculator:n}=t;const[o,s]=(0,i.useState)(""),[r,l]=(0,i.useState)("All"),[d,c]=(0,i.useState)(null),[m,u]=(0,i.useState)(""),[h,f]=(0,i.useState)("kg"),[g,p]=(0,i.useState)(""),[y,b]=(0,i.useState)("mg/mL"),[v,w]=(0,i.useState)(null);(0,i.useEffect)(()=>{if(e){const t=localStorage.getItem("note-".concat(e.name));s(t||"")}},[e]);const x=()=>{if(null===v||void 0===v||!v.dose)return null;const t=(t=>{if(!t)return null;const e=t.match(/^(\d+(?:\.\d+)?)\s*\u2013\s*(\d+(?:\.\d+)?)\s*(mcg|mg)\/(kg|m2)$/i),a=t.match(/^(\d+(?:\.\d+)?)\s*(mcg|mg)\/(kg|m2)$/i);if(e)return{min:parseFloat(e[1]),max:parseFloat(e[2]),unit:e[3].toLowerCase(),basis:e[4].toLowerCase()};if(a){const t=parseFloat(a[1]);return{min:t,max:t,unit:a[2].toLowerCase(),basis:a[3].toLowerCase()}}return null})(v.dose);if(!t)return null;const e=parseFloat(m);if(isNaN(e)||e<=0)return null;const a="lb"===h?e/2.20462:e;if("kg"!==t.basis)return{weightKg:a,minTotal:null,maxTotal:null,minVol:null,maxVol:null,unit:t.unit};const i=(t,e)=>"mg"===e?t:t/1e3,n=a*t.min,o=a*t.max,s=parseFloat(g);let r=null,l=null;if(!isNaN(s)&&s>0){const e=i(n,t.unit),a=i(o,t.unit),d="mg/mL"===y?s:s/1e3;r=e/d,l=a/d}return{weightKg:a,minTotal:n,maxTotal:o,minVol:r,maxVol:l,unit:t.unit}};if(!e)return null;const k=Vm("Not specified in source"!==e.indications?e.indications:e.notes||""),I=(t=>{if(!t||"Not specified in source"===t)return[];const e=t.replace(/^Dosage\s*/i,"").trim().split("\u2022").map(t=>t.trim()),a=[];let i="General";const n=["Dogs and Cats","Dogs","Cats","Horses","Cattle","Calves","Ruminants","Sheep","Goats","Pigs","Swine","Birds","Poultry","Rabbits","Ferrets","Exotics","Wildlife"];for(let o=0;o<e.length;o++){let t=e[o];if(!t)continue;if(0===o&&1===e.length)for(const e of n)if(t.toLowerCase().startsWith(e.toLowerCase()+" ")){i=e,t=t.substring(e.length).trim();break}let s=null;if(o<e.length-1)for(const e of n){const a=e.replace(" ","\\s"),i=new RegExp("(?:^|[\\.\\s])".concat(a,"\\s*$"),"i");if(t.match(i)){s=e,t=t.replace(new RegExp("".concat(a,"\\s*$"),"i"),"").trim();break}}if(n.some(e=>e.toLowerCase()===t.toLowerCase()||e.toLowerCase()===t.replace(/\.$/,"").toLowerCase())){const e=n.find(e=>e.toLowerCase()===t.replace(/\.$/,"").toLowerCase());i=e||t.replace(/\.$/,"");continue}if(t=t.replace(/\t/g," ").replace(/\s+/g," ").trim(),t){let e=a.find(t=>t.species===i);e||(e={species:i,points:[]},a.push(e)),e.points.push(t)}s&&(i=s)}return a})(e.dosage),C=Vm("Not specified in source"!==e.contraindications?e.contraindications:""),S=Vm("Not specified in source"!==e.side_effects?e.side_effects:"");return(0,Gt.jsx)("div",{className:"fixed inset-0 z-50 flex items-center justify-center bg-black/50 p-4 backdrop-blur-sm animate-in fade-in duration-200",children:(0,Gt.jsxs)("div",{className:"w-full max-w-2xl max-h-[90vh] overflow-y-auto rounded-3xl bg-white dark:bg-slate-900 shadow-2xl flex flex-col border border-white/20 dark:border-slate-700",children:[(0,Gt.jsxs)("div",{className:"sticky top-0 z-10 flex items-center justify-between bg-clinical-lightTeal px-6 py-5 border-b border-clinical-teal/10 bg-[#f0fdfa] dark:bg-slate-800 dark:border-slate-700",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-clinical-textTeal text-[#115e59] dark:text-teal-400 capitalize",children:e.name}),(0,Gt.jsx)("div",{className:"text-sm text-clinical-slate font-medium mt-1 dark:text-slate-400",children:e.original_category||"Uncategorized"})]}),(0,Gt.jsx)("button",{onClick:a,className:"p-2 hover:bg-black/5 dark:hover:bg-white/10 rounded-full transition text-slate-400 hover:text-slate-600 dark:hover:text-slate-200",children:(0,Gt.jsx)(Fm,{className:"w-6 h-6"})})]}),(0,Gt.jsxs)("div",{className:"p-6 space-y-8 flex-1 overflow-y-auto bg-white dark:bg-slate-900",children:[(0,Gt.jsx)("div",{className:"flex items-center justify-between",children:(0,Gt.jsx)("div",{className:"text-xs text-slate-500 dark:text-slate-400",children:"Source: Papich Handbook of Veterinary Drugs \u2022 5th Edition"})}),(0,Gt.jsxs)("section",{className:"bg-blue-50/50 dark:bg-blue-900/20 rounded-2xl p-5 border border-blue-100 dark:border-blue-900/30",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-3",children:[(0,Gt.jsx)(qm,{className:"w-5 h-5 text-blue-600"}),(0,Gt.jsx)("h3",{className:"text-sm font-bold tracking-wide text-blue-900 dark:text-blue-300 uppercase",children:"INDICATIONS"})]}),k.length>0?(0,Gt.jsx)("ul",{className:"space-y-2",children:k.map((t,e)=>(0,Gt.jsxs)("li",{className:"flex items-start gap-2 text-slate-700 dark:text-slate-300 text-sm leading-relaxed",children:[(0,Gt.jsx)("span",{className:"mt-1.5 h-1.5 w-1.5 flex-shrink-0 rounded-full bg-blue-400"}),(0,Gt.jsx)("span",{children:t})]},e))}):(0,Gt.jsx)("p",{className:"text-slate-500 italic text-sm",children:"No specific indications listed."})]}),(0,Gt.jsxs)("section",{className:"bg-teal-50/50 dark:bg-teal-900/20 rounded-2xl p-5 border border-teal-100 dark:border-teal-900/30",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-3",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)(_m,{className:"w-5 h-5 text-teal-600 dark:text-teal-400"}),(0,Gt.jsx)("h3",{className:"text-sm font-bold tracking-wide text-teal-900 dark:text-teal-300 uppercase",children:"DOSAGE & ADMINISTRATION"})]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[n&&(0,Gt.jsxs)("button",{onClick:()=>{a(),n()},className:"flex items-center gap-1.5 text-xs font-medium text-teal-700 hover:text-teal-900 bg-teal-100/50 hover:bg-teal-100 px-3 py-1.5 rounded-full transition",children:[(0,Gt.jsx)(vm,{className:"w-3.5 h-3.5"}),"Calculate"]}),(0,Gt.jsxs)("button",{onClick:()=>{null!==e&&void 0!==e&&e.dosage&&(navigator.clipboard.writeText(e.dosage),alert("Dosage copied to clipboard!"))},className:"flex items-center gap-1.5 text-xs font-medium text-teal-700 hover:text-teal-900 bg-teal-100/50 hover:bg-teal-100 px-3 py-1.5 rounded-full transition",children:[(0,Gt.jsx)(Om,{className:"w-3.5 h-3.5"}),"Copy"]})]})]}),I.length>1&&(0,Gt.jsxs)("div",{className:"mb-4 flex flex-wrap gap-2",children:[(0,Gt.jsx)("button",{onClick:()=>l("All"),className:"px-3 py-1.5 rounded-full text-xs font-medium border ".concat("All"===r?"bg-teal-600 text-white border-teal-600":"bg-white dark:bg-slate-800 text-teal-700 dark:text-teal-400 border-teal-200 dark:border-slate-700"),children:"All"}),I.map(t=>(0,Gt.jsx)("button",{onClick:()=>l(t.species),className:"px-3 py-1.5 rounded-full text-xs font-medium border ".concat(r===t.species?"bg-teal-600 text-white border-teal-600":"bg-white dark:bg-slate-800 text-teal-700 dark:text-teal-400 border-teal-200 dark:border-slate-700"),children:t.species},t.species))]}),I.length>0?(0,Gt.jsx)("div",{className:"space-y-4",children:I.filter(t=>"All"===r||t.species===r).map((t,e)=>(0,Gt.jsxs)("div",{children:["General"!==t.species&&(0,Gt.jsxs)("h4",{className:"font-bold text-teal-800 text-sm mb-2 flex items-center gap-2 uppercase",children:[(0,Gt.jsx)("span",{className:"w-1.5 h-1.5 rounded-full bg-teal-600"}),t.species]}),(0,Gt.jsx)("ul",{className:"space-y-2",children:t.points.map((t,a)=>{const i=(t=>{if(!t)return null;const e=t.replace(/\s+/g," ").trim();let a;const i=e.match(/\b(IV|IM|SC|SQ|PO|PR|IO|Topical|Transdermal)\b/i);let n;i&&(a=i[1].toUpperCase());const o=e.match(/\b(SID|BID|TID|QID)\b/i)||e.match(/\bq\s*(\d+)\s*h\b/i)||e.match(/\bevery\s+(\d+)\s*(?:hours?|h)\b/i);let s;o&&(n="SID"===o[0].toUpperCase()||"BID"===o[0].toUpperCase()||"TID"===o[0].toUpperCase()||"QID"===o[0].toUpperCase()?o[0].toUpperCase():o[1]?"q".concat(o[1],"h"):o[0].replace(/every\s+/i,"q").replace(/\s*hours?/i,"h"));const r=e.match(/\bfor\s+(\d+)\s*(days?|d|weeks?)\b/i);let l;r&&(s="".concat(r[1]," ").concat(r[2].toLowerCase().startsWith("d")?"days":"weeks"));const d=e.match(/(\d+(?:\.\d+)?)\s*(?:\u2013|-|to)\s*(\d+(?:\.\d+)?)\s*(mg|mcg|ug)\s*\/\s*(kg|m2)\b/i),c=e.match(/(\d+(?:\.\d+)?)\s*(mg|mcg|ug)\s*\/\s*(kg|m2)(?:\s*bw)?\b/i);if(d){const t="ug"===d[3].toLowerCase()?"mcg":d[3].toLowerCase();l="".concat(d[1],"\u2013").concat(d[2]," ").concat(t,"/").concat(d[4].toLowerCase())}else if(c){const t="ug"===c[2].toLowerCase()?"mcg":c[2].toLowerCase();l="".concat(c[1]," ").concat(t,"/").concat(c[3].toLowerCase())}return l||a||n||s?{dose:l,route:a,frequency:n,duration:s}:null})(t);return(0,Gt.jsxs)("li",{className:"flex flex-col gap-2 text-slate-700 dark:text-slate-300 text-sm leading-relaxed bg-white/60 dark:bg-slate-800/80 p-2 rounded-lg border border-teal-50 dark:border-teal-900/10",children:[(0,Gt.jsxs)("div",{className:"flex flex-wrap items-center gap-2",children:[(null===i||void 0===i?void 0:i.dose)&&(0,Gt.jsx)("span",{className:"inline-flex items-center rounded-full bg-teal-100 px-2.5 py-1 text-xs font-semibold text-teal-800 ring-1 ring-inset ring-teal-600/20",children:i.dose}),(null===i||void 0===i?void 0:i.route)&&(0,Gt.jsx)("span",{className:"inline-flex items-center rounded-full bg-slate-100 px-2.5 py-1 text-xs font-semibold text-slate-700 ring-1 ring-inset ring-slate-600/10",children:i.route}),(null===i||void 0===i?void 0:i.frequency)&&(0,Gt.jsx)("span",{className:"inline-flex items-center rounded-full bg-indigo-100 px-2.5 py-1 text-xs font-semibold text-indigo-800 ring-1 ring-inset ring-indigo-600/20",children:i.frequency}),(null===i||void 0===i?void 0:i.duration)&&(0,Gt.jsx)("span",{className:"inline-flex items-center rounded-full bg-amber-100 px-2.5 py-1 text-xs font-semibold text-amber-800 ring-1 ring-inset ring-amber-600/20",children:i.duration}),(0,Gt.jsxs)("button",{onClick:()=>navigator.clipboard.writeText(t),className:"ml-auto inline-flex items-center gap-1.5 text-xs font-medium text-teal-700 hover:text-teal-900 bg-teal-100/50 hover:bg-teal-100 px-2.5 py-1 rounded-full transition",children:[(0,Gt.jsx)(Om,{className:"w-3.5 h-3.5"}),"Copy line"]}),(null===i||void 0===i?void 0:i.dose)&&(0,Gt.jsxs)("button",{onClick:()=>{c("".concat(e,"-").concat(a)),w(i)},className:"inline-flex items-center gap-1.5 text-xs font-medium text-indigo-700 hover:text-indigo-900 bg-indigo-100/50 hover:bg-indigo-100 px-2.5 py-1 rounded-full transition",children:[(0,Gt.jsx)(vm,{className:"w-3.5 h-3.5"}),"Mini calc"]})]}),(0,Gt.jsx)("div",{className:"text-slate-700 dark:text-slate-300",children:(0,Gt.jsx)("span",{className:"font-medium text-teal-900/80 dark:text-teal-200/90",children:t})}),d==="".concat(e,"-").concat(a)&&(null===v||void 0===v?void 0:v.dose)&&(0,Gt.jsxs)("div",{className:"mt-2 rounded-lg border border-slate-200 bg-slate-50 p-3",children:[(0,Gt.jsxs)("div",{className:"grid grid-cols-1 gap-3 sm:grid-cols-3",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("input",{value:m,onChange:t=>u(t.target.value),placeholder:"Weight",className:"w-full rounded-md border border-slate-300 bg-white px-2 py-1 text-xs"}),(0,Gt.jsxs)("div",{className:"flex gap-1",children:[(0,Gt.jsx)("button",{onClick:()=>f("kg"),className:"px-2 py-1 rounded-md text-xs border ".concat("kg"===h?"bg-teal-600 text-white border-teal-600":"bg-white text-slate-700 border-slate-300"),children:"kg"}),(0,Gt.jsx)("button",{onClick:()=>f("lb"),className:"px-2 py-1 rounded-md text-xs border ".concat("lb"===h?"bg-teal-600 text-white border-teal-600":"bg-white text-slate-700 border-slate-300"),children:"lb"})]})]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("input",{value:g,onChange:t=>p(t.target.value),placeholder:"Concentration",className:"w-full rounded-md border border-slate-300 bg-white px-2 py-1 text-xs"}),(0,Gt.jsxs)("select",{value:y,onChange:t=>b(t.target.value),className:"rounded-md border border-slate-300 bg-white px-2 py-1 text-xs",children:[(0,Gt.jsx)("option",{value:"mg/mL",children:"mg/mL"}),(0,Gt.jsx)("option",{value:"mcg/mL",children:"mcg/mL"})]})]}),(0,Gt.jsxs)("div",{className:"text-xs text-slate-600",children:[(0,Gt.jsx)("div",{className:"font-bold text-slate-800",children:"Dose"}),(0,Gt.jsx)("div",{children:v.dose}),v.route&&(0,Gt.jsx)("div",{children:v.route}),v.frequency&&(0,Gt.jsx)("div",{children:v.frequency})]})]}),(0,Gt.jsx)("div",{className:"mt-3 text-xs",children:(t=>{const e=x();if(!e)return(0,Gt.jsx)("div",{className:"text-slate-500",children:"Enter weight to compute."});const a=e.unit.toUpperCase();return(0,Gt.jsxs)("div",{className:"grid grid-cols-1 gap-2 sm:grid-cols-2",children:[(0,Gt.jsxs)("div",{className:"rounded-md bg-white p-2 border border-slate-200",children:[(0,Gt.jsxs)("div",{className:"font-bold text-slate-800",children:["Total ",a]}),null!==e.minTotal&&null!==e.maxTotal&&e.minTotal!==e.maxTotal?(0,Gt.jsxs)("div",{children:[e.minTotal.toFixed(2),"\u2013",e.maxTotal.toFixed(2)," ",a]}):(0,Gt.jsxs)("div",{children:[(null!==(t=e.minTotal)&&void 0!==t?t:0).toFixed(2)," ",a]})]}),(0,Gt.jsxs)("div",{className:"rounded-md bg-white p-2 border border-slate-200",children:[(0,Gt.jsx)("div",{className:"font-bold text-slate-800",children:"Volume mL"}),null!==e.minVol&&null!==e.maxVol&&e.minVol!==e.maxVol?(0,Gt.jsxs)("div",{children:[e.minVol.toFixed(2),"\u2013",e.maxVol.toFixed(2)," mL"]}):(0,Gt.jsxs)("div",{children:[null!==e.minVol?e.minVol.toFixed(2):"-"," mL"]})]})]})})()}),(0,Gt.jsxs)("div",{className:"mt-2 flex items-center gap-2",children:[(0,Gt.jsx)("button",{onClick:()=>c(null),className:"px-2.5 py-1.5 rounded-md bg-slate-200 text-slate-700 text-xs font-medium hover:bg-slate-300 transition",children:"Close"}),(0,Gt.jsx)("button",{onClick:()=>{var t;const e=x();if(!e)return;const a=e.unit.toUpperCase(),i=null!==e.minTotal&&null!==e.maxTotal&&e.minTotal!==e.maxTotal?"".concat(e.minTotal.toFixed(2),"\u2013").concat(e.maxTotal.toFixed(2)," ").concat(a):"".concat((null!==(t=e.minTotal)&&void 0!==t?t:0).toFixed(2)," ").concat(a),n=null!==e.minVol&&null!==e.maxVol&&e.minVol!==e.maxVol?"".concat(e.minVol.toFixed(2),"\u2013").concat(e.maxVol.toFixed(2)," mL"):null!==e.minVol?"".concat(e.minVol.toFixed(2)," mL"):"-",o="Weight: ".concat(e.weightKg.toFixed(2)," kg; Total: ").concat(i,"; Volume: ").concat(n,"; Dose: ").concat(null===v||void 0===v?void 0:v.dose).concat(null!==v&&void 0!==v&&v.route?" ".concat(v.route):"").concat(null!==v&&void 0!==v&&v.frequency?" ".concat(v.frequency):"");navigator.clipboard.writeText(o)},className:"px-2.5 py-1.5 rounded-md bg-teal-600 text-white text-xs font-medium hover:bg-teal-700 transition",children:"Copy result"})]})]})]},a)})})]},e))}):(0,Gt.jsx)("p",{className:"text-slate-500 italic text-sm",children:"No dosage information available."})]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,Gt.jsxs)("section",{className:"p-4 rounded-2xl border border-red-100 dark:border-red-900/30 bg-red-50/30 dark:bg-red-900/20",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-2",children:[(0,Gt.jsx)(Um,{className:"w-4 h-4 text-red-500"}),(0,Gt.jsx)("h3",{className:"text-xs font-bold tracking-wide text-red-800 dark:text-red-300 uppercase",children:"CONTRAINDICATIONS"})]}),C.length>0?(0,Gt.jsx)("ul",{className:"space-y-2",children:C.map((t,e)=>(0,Gt.jsxs)("li",{className:"flex items-start gap-2 text-slate-700 dark:text-slate-300 text-sm leading-relaxed",children:[(0,Gt.jsx)("span",{className:"mt-1.5 h-1.5 w-1.5 flex-shrink-0 rounded-full bg-red-400"}),(0,Gt.jsx)("span",{children:t})]},e))}):(0,Gt.jsx)("p",{className:"text-slate-500 italic text-sm",children:"None listed"})]}),(0,Gt.jsxs)("section",{className:"p-4 rounded-2xl border border-orange-100 dark:border-orange-900/30 bg-orange-50/30 dark:bg-orange-900/10",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2 mb-2",children:[(0,Gt.jsx)(Um,{className:"w-4 h-4 text-orange-500"}),(0,Gt.jsx)("h3",{className:"text-xs font-bold tracking-wide text-orange-800 dark:text-orange-300 uppercase",children:"SIDE EFFECTS"})]}),S.length>0?(0,Gt.jsx)("ul",{className:"space-y-2",children:S.map((t,e)=>(0,Gt.jsxs)("li",{className:"flex items-start gap-2 text-slate-700 dark:text-slate-300 text-sm leading-relaxed",children:[(0,Gt.jsx)("span",{className:"mt-1.5 h-1.5 w-1.5 flex-shrink-0 rounded-full bg-orange-400"}),(0,Gt.jsx)("span",{children:t})]},e))}):(0,Gt.jsx)("p",{className:"text-slate-500 italic text-sm",children:"None listed"})]})]}),(0,Gt.jsxs)("section",{children:[(0,Gt.jsx)("h3",{className:"text-sm font-bold tracking-wide text-clinical-teal text-[#0d9488] dark:text-teal-400 uppercase mb-2",children:"SUMMARY"}),(0,Gt.jsxs)("p",{className:"text-gray-700 dark:text-slate-300",children:[e.active_ingredient," is used for ",(e.species||[]).join(", "),". ",e.original_category||"Uncategorized","."]})]}),(0,Gt.jsxs)("section",{className:"pt-6 border-t border-gray-100",children:[(0,Gt.jsxs)("div",{className:"flex items-center justify-between mb-4",children:[(0,Gt.jsxs)("h3",{className:"flex items-center gap-2 text-sm font-bold tracking-wide text-clinical-teal text-[#0d9488] dark:text-teal-400 uppercase",children:[(0,Gt.jsx)(_m,{className:"w-4 h-4"}),"CLINICAL NOTES"]}),(0,Gt.jsxs)("button",{className:"flex items-center gap-2 bg-[#0d9488] text-white px-3 py-1.5 rounded-lg text-xs font-medium hover:bg-[#115e59] transition shadow-sm",children:[(0,Gt.jsx)(Hm,{className:"w-3 h-3"}),"Add to Favorites"]})]}),(0,Gt.jsx)("textarea",{value:o,onChange:t=>{return a=t.target.value,s(a),void(e&&localStorage.setItem("note-".concat(e.name),a));var a},placeholder:"Add your personal clinical notes here... (Auto-saved)",className:"w-full h-32 p-4 rounded-lg border border-gray-200 dark:border-slate-700 focus:border-[#0d9488] focus:ring-1 focus:ring-[#0d9488] outline-none resize-none text-sm bg-gray-50 dark:bg-slate-800 text-gray-700 dark:text-slate-200 placeholder:text-gray-400"})]})]})]})})}function Gm(t){let{categories:e,onSelectCategory:a,onSelectDrug:n,selectedDrug:o,onCloseDrug:s,onOpenCalculator:r,onOpenFormulary:l,onOpenProtocols:d}=t;const[c,m]=(0,i.useState)(""),u=(0,i.useMemo)(()=>e.flatMap(t=>t.drugs.map(e=>Ht(Ht({},e),{},{_category:t.category}))),[e]),h=(0,i.useMemo)(()=>{const t=c.trim().toLowerCase();return t?u.filter(e=>e.name.toLowerCase().includes(t)||e._category.toLowerCase().includes(t)||e.active_ingredient&&e.active_ingredient.toLowerCase().includes(t)||e.indications&&e.indications.toLowerCase().includes(t)):[]},[c,u]);return(0,Gt.jsxs)("div",{className:"min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)("div",{className:"bg-white dark:bg-slate-800 border-b border-slate-200 dark:border-slate-700",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 py-3 sm:px-6 lg:px-8 flex justify-center sm:justify-end gap-3",children:[(0,Gt.jsxs)("button",{onClick:l,className:"inline-flex items-center gap-1.5 px-3 py-1.5 rounded-full bg-slate-100 dark:bg-slate-700 text-slate-600 dark:text-slate-300 text-sm font-medium hover:bg-teal-50 dark:hover:bg-teal-900/30 hover:text-teal-700 dark:hover:text-teal-400 transition-colors",children:[(0,Gt.jsx)(bm,{className:"w-4 h-4"}),"Formulary"]}),(0,Gt.jsxs)("button",{onClick:r,className:"inline-flex items-center gap-1.5 px-3 py-1.5 rounded-full bg-slate-100 dark:bg-slate-700 text-slate-600 dark:text-slate-300 text-sm font-medium hover:bg-teal-50 dark:hover:bg-teal-900/30 hover:text-teal-700 dark:hover:text-teal-400 transition-colors",children:[(0,Gt.jsx)(vm,{className:"w-4 h-4"}),"Calculators"]}),(0,Gt.jsxs)("button",{onClick:d,className:"inline-flex items-center gap-1.5 px-3 py-1.5 rounded-full bg-slate-100 dark:bg-slate-700 text-slate-600 dark:text-slate-300 text-sm font-medium hover:bg-teal-50 dark:hover:bg-teal-900/30 hover:text-teal-700 dark:hover:text-teal-400 transition-colors",children:[(0,Gt.jsx)(wm,{className:"w-4 h-4"}),"Protocols"]})]})}),(0,Gt.jsxs)("div",{className:"relative overflow-hidden bg-slate-900 pb-32 pt-16 lg:pt-24",children:[(0,Gt.jsxs)("div",{className:"absolute inset-0 z-0",children:[(0,Gt.jsx)("div",{className:"absolute inset-0 bg-gradient-to-br from-slate-900 via-slate-800 to-teal-900/40"}),(0,Gt.jsx)("div",{className:"absolute -top-24 -right-24 h-96 w-96 rounded-full bg-teal-500 blur-3xl opacity-10"}),(0,Gt.jsx)("div",{className:"absolute top-1/2 -left-24 h-72 w-72 rounded-full bg-blue-600 blur-3xl opacity-10"}),(0,Gt.jsx)("div",{className:"absolute inset-0 bg-[url('data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjAiIGhlaWdodD0iMjAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PGNpcmNsZSBjeD0iMSIgY3k9IjEiIHI9IjEiIGZpbGw9InJnYmEoMjU1LDI1NSwyNTUsMC4wNSkiLz48L3N2Zz4=')] [mask-image:linear-gradient(to_bottom,white,transparent)]"})]}),(0,Gt.jsxs)("div",{className:"relative z-10 mx-auto max-w-7xl px-4 sm:px-6 lg:px-8 text-center",children:[(0,Gt.jsxs)("h1",{className:"text-4xl font-bold tracking-tight text-white sm:text-6xl mb-6",children:["Precision Medicine for ",(0,Gt.jsx)("br",{}),(0,Gt.jsx)("span",{className:"text-transparent bg-clip-text bg-gradient-to-r from-teal-400 to-emerald-400",children:"Veterinary Professionals"})]}),(0,Gt.jsx)("p",{className:"mx-auto mt-6 max-w-2xl text-lg leading-8 text-slate-300",children:"Instant access to verified drug dosages, interactions, and clinical protocols for canine, feline, equine, and bovine patients."}),(0,Gt.jsxs)("div",{className:"mx-auto mt-10 max-w-xl",children:[(0,Gt.jsx)(Cm,{value:c,onChange:m,placeholder:"Search by drug, indication (e.g. 'pain'), or active ingredient...",className:"h-14 text-lg shadow-2xl shadow-teal-900/20 border-0 ring-4 ring-white/10 focus:ring-teal-500/50"}),(0,Gt.jsxs)("div",{className:"mt-4 flex flex-wrap justify-center gap-2",children:[(0,Gt.jsx)("span",{className:"text-xs text-slate-400 font-medium mr-1",children:"Quick Access:"}),["Antibiotics","Analgesics","Anesthesia","Emergency"].map(t=>(0,Gt.jsx)("button",{onClick:()=>{const i=e.find(e=>e.category.includes(t)||"Emergency"===t&&e.category.includes("Cardio"));i?a(i.category):m(t)},className:"rounded-full bg-white/5 px-2.5 py-1 text-xs font-medium text-slate-300 hover:bg-white/10 hover:text-white transition-colors border border-white/10",children:t},t))]})]})]}),(0,Gt.jsx)("div",{className:"absolute bottom-0 w-full border-t border-white/10 bg-white/5 backdrop-blur-sm py-4",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 flex justify-center gap-8 sm:gap-16 text-slate-300 text-sm font-medium",children:[(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsxs)("span",{className:"font-bold text-white",children:[u.length,"+"]})," Formulations"]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("span",{className:"font-bold text-white",children:e.length})," Therapeutic Classes"]}),(0,Gt.jsxs)("div",{className:"flex items-center gap-2",children:[(0,Gt.jsx)("span",{className:"font-bold text-white",children:"4+"})," Species"]})]})})]}),(0,Gt.jsx)("main",{className:"relative mx-auto max-w-7xl px-4 sm:px-6 lg:px-8 py-16",children:c?(0,Gt.jsxs)("div",{className:"animate-in fade-in slide-in-from-bottom-4 duration-500",children:[(0,Gt.jsxs)("div",{className:"mb-6 flex items-center justify-between",children:[(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-slate-900 dark:text-white",children:"Search Results"}),(0,Gt.jsxs)("span",{className:"text-sm text-slate-500 dark:text-slate-400",children:[h.length," results found"]})]}),h.length>0?(0,Gt.jsx)("div",{className:"grid grid-cols-1 gap-4 sm:grid-cols-2 lg:grid-cols-3",children:h.map(t=>(0,Gt.jsxs)("button",{onClick:()=>n(t),className:"group flex flex-col items-start rounded-2xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-5 text-left shadow-sm transition-all hover:border-teal-500/50 hover:shadow-md hover:ring-1 hover:ring-teal-500/50",children:[(0,Gt.jsx)("div",{className:"mb-2 flex h-10 w-10 items-center justify-center rounded-full bg-teal-50 text-teal-600 group-hover:bg-teal-600 group-hover:text-white transition-colors",children:(0,Gt.jsx)(xm,{className:"h-5 w-5"})}),(0,Gt.jsx)("div",{className:"text-lg font-bold text-slate-900 dark:text-white group-hover:text-teal-700 dark:group-hover:text-teal-400 transition-colors capitalize",children:t.name}),(0,Gt.jsx)("div",{className:"text-sm font-medium text-slate-500 dark:text-slate-400 mt-1",children:t.active_ingredient||"Active ingredient not listed"}),(0,Gt.jsxs)("div",{className:"mt-4 flex w-full items-center justify-between border-t border-slate-100 dark:border-slate-700 pt-3",children:[(0,Gt.jsx)("span",{className:"text-xs font-medium text-slate-400 dark:text-slate-500 uppercase tracking-wider",children:t._category}),(0,Gt.jsx)(km,{className:"h-4 w-4 text-slate-300 dark:text-slate-600 group-hover:text-teal-600 dark:group-hover:text-teal-400 transition-colors"})]})]},"".concat(t.name,"-").concat(t.active_ingredient)))}):(0,Gt.jsxs)("div",{className:"rounded-3xl border border-dashed border-slate-300 dark:border-slate-700 bg-slate-50 dark:bg-slate-800/50 p-12 text-center",children:[(0,Gt.jsx)("div",{className:"mx-auto flex h-16 w-16 items-center justify-center rounded-full bg-white dark:bg-slate-700 shadow-sm",children:(0,Gt.jsx)(Im,{className:"h-8 w-8 text-slate-400 dark:text-slate-500"})}),(0,Gt.jsx)("h3",{className:"mt-4 text-lg font-semibold text-slate-900 dark:text-white",children:"No drugs found"}),(0,Gt.jsxs)("p",{className:"mt-2 text-slate-500 dark:text-slate-400",children:["We couldn't find any drugs matching \"",c,'". Try checking for typos or using a broader term.']})]})]}):(0,Gt.jsx)("div",{className:"space-y-12",children:(0,Gt.jsxs)("section",{children:[(0,Gt.jsx)("div",{className:"mb-8 flex items-end justify-between border-b border-slate-200 dark:border-slate-700 pb-4",children:(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h2",{className:"text-2xl font-bold text-slate-900 dark:text-white",children:"Therapeutic Classes"}),(0,Gt.jsx)("p",{className:"mt-1 text-slate-500 dark:text-slate-400",children:"Browse drugs by their pharmacological classification"})]})}),(0,Gt.jsx)("div",{className:"grid grid-cols-1 gap-6 sm:grid-cols-2 lg:grid-cols-3 xl:grid-cols-4",children:e.map((t,e)=>(0,Gt.jsx)("div",{className:"animate-in fade-in zoom-in duration-500",style:{animationDelay:"".concat(50*e,"ms")},children:(0,Gt.jsx)(Rm,{title:t.category,count:t.drugs.length,onClick:()=>a(t.category)})},t.category))})]})})}),(0,Gt.jsx)(Bm,{drug:o,onClose:s,onOpenCalculator:r})]})}const Wm=ym("arrow-left",[["path",{d:"m12 19-7-7 7-7",key:"1l729n"}],["path",{d:"M19 12H5",key:"x3x0zl"}]]);function Qm(t){let{category:e,drugs:a,onBack:i,onSelectDrug:n,selectedDrug:o,onCloseDrug:s,onOpenCalculator:r}=t;return(0,Gt.jsxs)("div",{className:"min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)("header",{className:"border-b border-slate-200 dark:border-slate-700 bg-white/80 dark:bg-slate-800/80 backdrop-blur-md",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 py-4 flex items-center gap-4",children:[(0,Gt.jsx)("button",{onClick:i,className:"group flex items-center justify-center h-10 w-10 rounded-full border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 text-slate-500 dark:text-slate-400 hover:border-teal-500 hover:text-teal-600 dark:hover:text-teal-400 transition-all",children:(0,Gt.jsx)(Wm,{className:"h-5 w-5"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h1",{className:"text-xl font-bold text-slate-900 dark:text-white",children:e}),(0,Gt.jsxs)("p",{className:"text-xs text-slate-500 dark:text-slate-400",children:[a.length," drugs found"]})]})]})}),(0,Gt.jsx)("main",{className:"mx-auto max-w-7xl px-4 py-8 animate-in fade-in slide-in-from-bottom-4 duration-500",children:(0,Gt.jsx)("div",{className:"grid grid-cols-1 gap-4 sm:grid-cols-2 lg:grid-cols-3",children:a.map((t,e)=>{var a;return(0,Gt.jsxs)("button",{onClick:()=>n(t),className:"group flex flex-col items-start rounded-2xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-5 text-left shadow-sm transition-all hover:border-teal-500/50 hover:shadow-md hover:ring-1 hover:ring-teal-500/50",style:{animationDelay:"".concat(30*e,"ms")},children:[(0,Gt.jsx)("div",{className:"mb-2 flex h-10 w-10 items-center justify-center rounded-full bg-teal-50 dark:bg-slate-700 text-teal-600 dark:text-teal-400 group-hover:bg-teal-600 group-hover:text-white transition-colors",children:(0,Gt.jsx)(xm,{className:"h-5 w-5"})}),(0,Gt.jsx)("div",{className:"text-lg font-bold text-slate-900 dark:text-white group-hover:text-teal-700 dark:group-hover:text-teal-400 transition-colors capitalize",children:t.name}),(0,Gt.jsx)("div",{className:"text-sm font-medium text-slate-500 dark:text-slate-400 mt-1",children:t.active_ingredient||"Active ingredient not listed"}),(0,Gt.jsxs)("div",{className:"mt-4 flex w-full items-center justify-between border-t border-slate-100 dark:border-slate-700 pt-3",children:[(0,Gt.jsxs)("div",{className:"flex flex-wrap gap-1",children:[null===(a=t.species)||void 0===a?void 0:a.slice(0,2).map(t=>(0,Gt.jsx)("span",{className:"inline-flex items-center rounded-md bg-slate-100 dark:bg-slate-700 px-2 py-1 text-xs font-medium text-slate-600 dark:text-slate-300 ring-1 ring-inset ring-slate-500/10",children:t},t)),t.species&&t.species.length>2&&(0,Gt.jsxs)("span",{className:"inline-flex items-center rounded-md bg-slate-100 dark:bg-slate-700 px-2 py-1 text-xs font-medium text-slate-600 dark:text-slate-300 ring-1 ring-inset ring-slate-500/10",children:["+",t.species.length-2]})]}),(0,Gt.jsx)(km,{className:"h-4 w-4 text-slate-300 dark:text-slate-600 group-hover:text-teal-600 transition-colors"})]})]},"".concat(t.name,"-").concat(t.active_ingredient))})})}),(0,Gt.jsx)(Bm,{drug:o,onClose:s,onOpenCalculator:r})]})}const Km=ym("scale",[["path",{d:"M12 3v18",key:"108xh3"}],["path",{d:"m19 8 3 8a5 5 0 0 1-6 0zV7",key:"zcdpyk"}],["path",{d:"M3 7h1a17 17 0 0 0 8-2 17 17 0 0 0 8 2h1",key:"1yorad"}],["path",{d:"m5 8 3 8a5 5 0 0 1-6 0zV7",key:"eua70x"}],["path",{d:"M7 21h10",key:"1b0cd5"}]]),Zm=ym("flask-conical",[["path",{d:"M14 2v6a2 2 0 0 0 .245.96l5.51 10.08A2 2 0 0 1 18 22H6a2 2 0 0 1-1.755-2.96l5.51-10.08A2 2 0 0 0 10 8V2",key:"18mbvz"}],["path",{d:"M6.453 15h11.094",key:"3shlmq"}],["path",{d:"M8.5 2h7",key:"csnxdl"}]]);function $m(t){let{onBack:e}=t;const[a,n]=(0,i.useState)("basic");return(0,Gt.jsxs)("div",{className:"min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)("header",{className:"border-b border-slate-200 dark:border-slate-700 bg-white/80 dark:bg-slate-800/80 backdrop-blur-md",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 py-4 flex items-center gap-4",children:[(0,Gt.jsx)("button",{onClick:e,className:"group flex items-center justify-center h-10 w-10 rounded-full border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 text-slate-500 dark:text-slate-400 hover:border-teal-500 hover:text-teal-600 transition-all",children:(0,Gt.jsx)(Wm,{className:"h-5 w-5"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h1",{className:"text-xl font-bold text-slate-900 dark:text-white",children:"Dose Calculator"}),(0,Gt.jsx)("p",{className:"text-xs text-slate-500 dark:text-slate-400",children:"Accurate dosage calculations"})]})]})}),(0,Gt.jsxs)("main",{className:"mx-auto max-w-3xl px-4 py-8 animate-in fade-in slide-in-from-bottom-4 duration-500",children:[(0,Gt.jsxs)("div",{className:"mb-8 flex p-1 bg-slate-200 dark:bg-slate-800 rounded-xl",children:[(0,Gt.jsxs)("button",{onClick:()=>n("basic"),className:"flex-1 flex items-center justify-center gap-2 py-3 rounded-lg text-sm font-bold transition-all ".concat("basic"===a?"bg-white dark:bg-slate-600 text-teal-700 dark:text-teal-400 shadow-sm":"text-slate-500 dark:text-slate-400 hover:text-slate-700"),children:[(0,Gt.jsx)(vm,{className:"w-4 h-4"}),"Basic Dose"]}),(0,Gt.jsxs)("button",{onClick:()=>n("liquid"),className:"flex-1 flex items-center justify-center gap-2 py-3 rounded-lg text-sm font-bold transition-all ".concat("liquid"===a?"bg-white dark:bg-slate-600 text-teal-700 dark:text-teal-400 shadow-sm":"text-slate-500 dark:text-slate-400 hover:text-slate-700"),children:[(0,Gt.jsx)(Mm,{className:"w-4 h-4"}),"Liquid/Injectable"]})]}),"basic"===a?(0,Gt.jsx)(Xm,{}):(0,Gt.jsx)(Ym,{})]})]})}function Xm(){const[t,e]=(0,i.useState)(""),[a,n]=(0,i.useState)("kg"),[o,s]=(0,i.useState)(""),[r,l]=(0,i.useState)(""),d=(()=>{const e=parseFloat(t),i=parseFloat(o),n=parseFloat(r);if(isNaN(e)||isNaN(i))return null;const s="lb"===a?e/2.20462:e,l=s*i;let d=null;return!isNaN(n)&&n>0&&(d=l/n),{total:l,weightKg:s,tablets:d}})();return(0,Gt.jsxs)("div",{className:"bg-white dark:bg-slate-800 rounded-2xl shadow-sm border border-slate-200 dark:border-slate-700 overflow-hidden",children:[(0,Gt.jsxs)("div",{className:"p-6 space-y-6",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-semibold text-slate-700 dark:text-slate-300 mb-2",children:"Patient Weight"}),(0,Gt.jsxs)("div",{className:"flex rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 dark:ring-slate-600 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("input",{type:"number",value:t,onChange:t=>e(t.target.value),className:"block flex-1 border-0 bg-transparent py-3 pl-4 text-slate-900 dark:text-white placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsxs)("div",{className:"flex bg-slate-50 dark:bg-slate-700 border-l border-slate-200 dark:border-slate-600 rounded-r-xl",children:[(0,Gt.jsx)("button",{onClick:()=>n("kg"),className:"px-4 text-sm font-bold transition-colors ".concat("kg"===a?"text-teal-700 dark:text-teal-400 bg-teal-50 dark:bg-slate-600":"text-slate-500 dark:text-slate-400 hover:bg-slate-100 dark:hover:bg-slate-600"),children:"kg"}),(0,Gt.jsx)("button",{onClick:()=>n("lb"),className:"px-4 text-sm font-bold transition-colors rounded-r-xl ".concat("lb"===a?"text-teal-700 dark:text-teal-400 bg-teal-50 dark:bg-slate-600":"text-slate-500 dark:text-slate-400 hover:bg-slate-100 dark:hover:bg-slate-600"),children:"lb"})]})]})]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 sm:grid-cols-2 gap-6",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-semibold text-slate-700 mb-2",children:"Target Dosage"}),(0,Gt.jsxs)("div",{className:"relative rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 left-0 flex items-center pl-3",children:(0,Gt.jsx)(Km,{className:"h-5 w-5 text-slate-400"})}),(0,Gt.jsx)("input",{type:"number",value:o,onChange:t=>s(t.target.value),className:"block w-full border-0 bg-transparent py-3 pl-10 pr-12 text-slate-900 placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 right-0 flex items-center pr-3",children:(0,Gt.jsx)("span",{className:"text-slate-500 sm:text-sm font-medium",children:"mg/kg"})})]})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsxs)("label",{className:"block text-sm font-semibold text-slate-700 dark:text-slate-300 mb-2",children:["Tablet/Bolus Strength ",(0,Gt.jsx)("span",{className:"text-slate-400 font-normal",children:"(Optional)"})]}),(0,Gt.jsxs)("div",{className:"relative rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 dark:ring-slate-600 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 left-0 flex items-center pl-3",children:(0,Gt.jsx)(xm,{className:"h-5 w-5 text-slate-400"})}),(0,Gt.jsx)("input",{type:"number",value:r,onChange:t=>l(t.target.value),className:"block w-full border-0 bg-transparent py-3 pl-10 pr-12 text-slate-900 dark:text-white placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 right-0 flex items-center pr-3",children:(0,Gt.jsx)("span",{className:"text-slate-500 sm:text-sm font-medium",children:"mg"})})]})]})]})]}),(0,Gt.jsx)("div",{className:"bg-teal-50/50 dark:bg-teal-900/10 border-t border-teal-100 dark:border-teal-900/30 p-6",children:d?(0,Gt.jsxs)("div",{className:"space-y-6 animate-in slide-in-from-bottom-2",children:[(0,Gt.jsx)("div",{className:"flex items-start justify-between",children:(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-sm font-medium text-teal-800 dark:text-teal-300",children:"Total Dose Required"}),(0,Gt.jsxs)("div",{className:"flex items-baseline gap-2",children:[(0,Gt.jsx)("span",{className:"text-4xl font-bold text-teal-700 dark:text-teal-400",children:d.total.toLocaleString(void 0,{maximumFractionDigits:2})}),(0,Gt.jsx)("span",{className:"text-lg font-semibold text-teal-600 dark:text-teal-500",children:"mg"})]}),"lb"===a&&(0,Gt.jsxs)("div",{className:"text-xs text-teal-600/70 mt-1",children:["(Based on ",d.weightKg.toFixed(2)," kg body weight)"]})]})}),null!==d.tablets&&(0,Gt.jsxs)("div",{className:"bg-white/60 dark:bg-slate-700/60 rounded-xl p-4 border border-teal-100 dark:border-slate-600",children:[(0,Gt.jsx)("div",{className:"text-sm font-medium text-teal-800 dark:text-teal-300 mb-1",children:"Tablets/Bolus to Administer"}),(0,Gt.jsxs)("div",{className:"flex items-baseline gap-2",children:[(0,Gt.jsx)("span",{className:"text-3xl font-bold text-teal-700 dark:text-teal-400",children:d.tablets.toLocaleString(void 0,{maximumFractionDigits:2})}),(0,Gt.jsx)("span",{className:"text-base font-medium text-teal-600 dark:text-teal-500",children:"tablets"})]}),(0,Gt.jsxs)("div",{className:"text-xs text-teal-600/70 mt-1",children:["(",d.tablets.toFixed(1)," tablets of ",parseFloat(r)," mg)"]})]})]}):(0,Gt.jsx)("div",{className:"text-center py-4 text-slate-400 text-sm",children:"Enter weight and dosage to calculate"})})]})}function Ym(){const[t,e]=(0,i.useState)(""),[a,n]=(0,i.useState)("kg"),[o,s]=(0,i.useState)(""),[r,l]=(0,i.useState)(""),d=(()=>{const e=parseFloat(t),i=parseFloat(o),n=parseFloat(r);if(isNaN(e)||isNaN(i)||isNaN(n)||0===n)return null;const s="lb"===a?e/2.20462:e,l=s*i;return{totalMg:l,volume:l/n,weightKg:s}})();return(0,Gt.jsxs)("div",{className:"bg-white dark:bg-slate-800 rounded-2xl shadow-sm border border-slate-200 dark:border-slate-700 overflow-hidden",children:[(0,Gt.jsxs)("div",{className:"p-6 space-y-6",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-semibold text-slate-700 dark:text-slate-300 mb-2",children:"Patient Weight"}),(0,Gt.jsxs)("div",{className:"flex rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 dark:ring-slate-600 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("input",{type:"number",value:t,onChange:t=>e(t.target.value),className:"block flex-1 border-0 bg-transparent py-3 pl-4 text-slate-900 dark:text-white placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsxs)("div",{className:"flex bg-slate-50 dark:bg-slate-700 border-l border-slate-200 dark:border-slate-600 rounded-r-xl",children:[(0,Gt.jsx)("button",{onClick:()=>n("kg"),className:"px-4 text-sm font-bold transition-colors ".concat("kg"===a?"text-teal-700 dark:text-teal-400 bg-teal-50 dark:bg-slate-600":"text-slate-500 dark:text-slate-400 hover:bg-slate-100 dark:hover:bg-slate-600"),children:"kg"}),(0,Gt.jsx)("button",{onClick:()=>n("lb"),className:"px-4 text-sm font-bold transition-colors rounded-r-xl ".concat("lb"===a?"text-teal-700 dark:text-teal-400 bg-teal-50 dark:bg-slate-600":"text-slate-500 dark:text-slate-400 hover:bg-slate-100 dark:hover:bg-slate-600"),children:"lb"})]})]})]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 sm:grid-cols-2 gap-6",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-semibold text-slate-700 mb-2",children:"Target Dosage"}),(0,Gt.jsxs)("div",{className:"relative rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 left-0 flex items-center pl-3",children:(0,Gt.jsx)(Km,{className:"h-5 w-5 text-slate-400"})}),(0,Gt.jsx)("input",{type:"number",value:o,onChange:t=>s(t.target.value),className:"block w-full border-0 bg-transparent py-3 pl-10 pr-12 text-slate-900 placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 right-0 flex items-center pr-3",children:(0,Gt.jsx)("span",{className:"text-slate-500 sm:text-sm font-medium",children:"mg/kg"})})]})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("label",{className:"block text-sm font-semibold text-slate-700 dark:text-slate-300 mb-2",children:"Concentration"}),(0,Gt.jsxs)("div",{className:"relative rounded-xl shadow-sm ring-1 ring-inset ring-slate-300 dark:ring-slate-600 focus-within:ring-2 focus-within:ring-inset focus-within:ring-teal-500",children:[(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 left-0 flex items-center pl-3",children:(0,Gt.jsx)(Zm,{className:"h-5 w-5 text-slate-400"})}),(0,Gt.jsx)("input",{type:"number",value:r,onChange:t=>l(t.target.value),className:"block w-full border-0 bg-transparent py-3 pl-10 pr-12 text-slate-900 dark:text-white placeholder:text-slate-400 focus:ring-0 sm:text-lg font-medium",placeholder:"0.0"}),(0,Gt.jsx)("div",{className:"pointer-events-none absolute inset-y-0 right-0 flex items-center pr-3",children:(0,Gt.jsx)("span",{className:"text-slate-500 sm:text-sm font-medium",children:"mg/ml"})})]})]})]})]}),(0,Gt.jsx)("div",{className:"bg-teal-50/50 dark:bg-teal-900/10 border-t border-teal-100 dark:border-teal-900/30 p-6",children:d?(0,Gt.jsxs)("div",{className:"grid grid-cols-2 gap-4 animate-in slide-in-from-bottom-2",children:[(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-sm font-medium text-teal-800 dark:text-teal-300",children:"Volume to Administer"}),(0,Gt.jsxs)("div",{className:"flex items-baseline gap-2",children:[(0,Gt.jsx)("span",{className:"text-4xl font-bold text-teal-700 dark:text-teal-400",children:d.volume.toLocaleString(void 0,{maximumFractionDigits:2})}),(0,Gt.jsx)("span",{className:"text-lg font-semibold text-teal-600 dark:text-teal-500",children:"ml"})]})]}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("div",{className:"text-sm font-medium text-teal-800 dark:text-teal-300",children:"Total Dose"}),(0,Gt.jsxs)("div",{className:"flex items-baseline gap-2",children:[(0,Gt.jsx)("span",{className:"text-2xl font-bold text-teal-700/80 dark:text-teal-400/80",children:d.totalMg.toLocaleString(void 0,{maximumFractionDigits:1})}),(0,Gt.jsx)("span",{className:"text-sm font-semibold text-teal-600/80 dark:text-teal-500/80",children:"mg"})]})]})]}):(0,Gt.jsx)("div",{className:"text-center py-4 text-slate-400 text-sm",children:"Enter all fields to calculate"})})]})}const Jm=ym("book-open-check",[["path",{d:"M12 21V7",key:"gj6g52"}],["path",{d:"m16 12 2 2 4-4",key:"mdajum"}],["path",{d:"M22 6V4a1 1 0 0 0-1-1h-5a4 4 0 0 0-4 4 4 4 0 0 0-4-4H3a1 1 0 0 0-1 1v13a1 1 0 0 0 1 1h6a3 3 0 0 1 3 3 3 3 0 0 1 3-3h6a1 1 0 0 0 1-1v-1.3",key:"8arnkb"}]]);function tu(t){let{onBack:e}=t;const a=[{title:"Analgesics Used in Animals",href:"https://www.msdvetmanual.com/therapeutics/pain-assessment-and-management/analgesics-used-in-animals",icon:Am,description:"Overview of analgesic drug classes and dosing considerations"},{title:"NSAIDs: Pain Management Table (Dogs & Cats)",href:"https://www.msdvetmanual.com/multimedia/table/nsaids-used-for-pain-management-in-dogs-and-cats",icon:Dm,description:"Quick-reference table of NSAID options and cautions"},{title:"Nonsteroidal Anti-inflammatory Drugs",href:"https://www.msdvetmanual.com/pharmacology/inflammation/nonsteroidal-anti-inflammatory-drugs-in-animals",icon:Dm,description:"Pharmacology and indications of NSAIDs in veterinary medicine"},{title:"Beta-Lactam Antimicrobial Use",href:"https://www.msdvetmanual.com/pharmacology/antibacterial-agents/beta-lactam-antimicrobial-use-in-animals",icon:Mm,description:"Penicillins, cephalosporins, cephamycins \u2014 spectrum and use"},{title:"Antimicrobial Drug Factors",href:"https://www.msdvetmanual.com/pharmacology/antimicrobials/antimicrobial-drug-factors-for-animals",icon:Mm,description:"Mechanisms, PK/PD, resistance, and regimen design"},{title:"Routes & Dosage Forms",href:"https://www.msdvetmanual.com/pharmacology/pharmacology-introduction/routes-of-administration-and-dosage-forms-of-drugs?autoredirectid=21721&ruleredirectid=458",icon:Jm,description:"Veterinary-specific dosage forms and administration routes"},{title:"Veterinary Topics Index",href:"https://www.msdvetmanual.com/veterinary-topics",icon:xm,description:"Browse MSD Veterinary Manual topics and use built-in search"}];return(0,Gt.jsxs)("div",{className:"min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)("header",{className:"border-b border-slate-200 dark:border-slate-700 bg-white/80 dark:bg-slate-800/80 backdrop-blur-md",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 py-4 flex items-center gap-4",children:[(0,Gt.jsx)("button",{onClick:e,className:"group flex items-center justify-center h-10 w-10 rounded-full border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 text-slate-500 dark:text-slate-400 hover:border-teal-500 hover:text-teal-600 dark:hover:text-teal-400 transition-all",children:(0,Gt.jsx)(Wm,{className:"h-5 w-5"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h1",{className:"text-xl font-bold text-slate-900 dark:text-white",children:"Formulary"}),(0,Gt.jsx)("p",{className:"text-xs text-slate-500 dark:text-slate-400",children:"Links reference exclusively MSD Veterinary Manual"})]})]})}),(0,Gt.jsxs)("main",{className:"mx-auto max-w-7xl px-4 py-8 animate-in fade-in slide-in-from-bottom-4 duration-500",children:[(0,Gt.jsxs)("section",{className:"mb-12",children:[(0,Gt.jsxs)("h2",{className:"text-xl font-bold text-slate-900 dark:text-white mb-6 flex items-center gap-2",children:[(0,Gt.jsx)(Jm,{className:"h-5 w-5 text-teal-600"}),"Quick Reference Dosages (MSD)"]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 gap-6 lg:grid-cols-2",children:[(0,Gt.jsxs)("div",{className:"rounded-xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-6 shadow-sm",children:[(0,Gt.jsxs)("h3",{className:"text-lg font-bold text-slate-800 dark:text-slate-200 mb-4 flex items-center gap-2",children:[(0,Gt.jsx)(Am,{className:"h-4 w-4 text-red-500"}),"Emergency Drugs (Dogs & Cats)"]}),(0,Gt.jsx)("div",{className:"overflow-x-auto",children:(0,Gt.jsxs)("table",{className:"w-full text-sm text-left",children:[(0,Gt.jsx)("thead",{className:"bg-slate-50 dark:bg-slate-700 text-slate-500 dark:text-slate-400",children:(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("th",{className:"px-3 py-2 rounded-l-lg",children:"Drug"}),(0,Gt.jsx)("th",{className:"px-3 py-2 rounded-r-lg",children:"Dosage / Notes"})]})}),(0,Gt.jsxs)("tbody",{className:"divide-y divide-slate-100 dark:divide-slate-700",children:[(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Lidocaine (Dogs)"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"2 mg/kg IV bolus over ~1 min (to effect). Max cumulative 8 mg/kg over 30 min."})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Lidocaine (Cats)"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"0.1\u20130.4 mg/kg IV bolus over ~1 min. Use caution (sensitive)."})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Epinephrine"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"High dose no longer recommended. Administer every second CPR cycle."})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Atropine"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"Give early and once if bradycardia or high vagal tone suspected."})]})]})]})})]}),(0,Gt.jsxs)("div",{className:"rounded-xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-6 shadow-sm",children:[(0,Gt.jsxs)("h3",{className:"text-lg font-bold text-slate-800 dark:text-slate-200 mb-4 flex items-center gap-2",children:[(0,Gt.jsx)(Mm,{className:"h-4 w-4 text-blue-500"}),"Common Antibiotics (Antistaphylococcal)"]}),(0,Gt.jsx)("div",{className:"overflow-x-auto",children:(0,Gt.jsxs)("table",{className:"w-full text-sm text-left",children:[(0,Gt.jsx)("thead",{className:"bg-slate-50 dark:bg-slate-700 text-slate-500 dark:text-slate-400",children:(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("th",{className:"px-3 py-2 rounded-l-lg",children:"Drug"}),(0,Gt.jsx)("th",{className:"px-3 py-2 rounded-r-lg",children:"Dosage (PO)"})]})}),(0,Gt.jsxs)("tbody",{className:"divide-y divide-slate-100 dark:divide-slate-700",children:[(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Cephalexin"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"20\u201330 mg/kg q 12 h"})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Amoxicillin-clavulanate"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"13.75 mg/kg q 12 h"})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Enrofloxacin"}),(0,Gt.jsx)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:"5 mg/kg q 24 h"})]}),(0,Gt.jsxs)("tr",{children:[(0,Gt.jsx)("td",{className:"px-3 py-3 font-medium text-slate-900 dark:text-white",children:"Clindamycin"}),(0,Gt.jsxs)("td",{className:"px-3 py-3 text-slate-600 dark:text-slate-300",children:["Dogs: 10\u201320 mg/kg q 12 h",(0,Gt.jsx)("br",{}),"Cats: 12.5\u201325 mg/kg q 12 h"]})]})]})]})})]})]})]}),(0,Gt.jsxs)("div",{className:"mb-6",children:[(0,Gt.jsx)("h2",{className:"text-xl font-bold text-slate-900 dark:text-white mb-4",children:"MSD Veterinary Manual Resources"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-400",children:"Use these authoritative resources for full details. All links open the MSD Veterinary Manual in a new tab."})]}),(0,Gt.jsx)("div",{className:"grid grid-cols-1 gap-4 sm:grid-cols-2 lg:grid-cols-3",children:a.map((t,e)=>{const a=t.icon;return(0,Gt.jsxs)("a",{href:t.href,target:"_blank",rel:"noopener noreferrer",className:"group flex flex-col rounded-2xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-5 text-left shadow-sm transition-all hover:border-teal-500/50 hover:shadow-md hover:ring-1 hover:ring-teal-500/50",style:{animationDelay:"".concat(30*e,"ms")},children:[(0,Gt.jsx)("div",{className:"mb-2 flex h-10 w-10 items-center justify-center rounded-full bg-teal-50 dark:bg-slate-700 text-teal-600 dark:text-teal-400 group-hover:bg-teal-600 group-hover:text-white transition-colors",children:(0,Gt.jsx)(a,{className:"h-5 w-5"})}),(0,Gt.jsx)("div",{className:"text-lg font-bold text-slate-900 dark:text-white group-hover:text-teal-700 dark:group-hover:text-teal-400 transition-colors",children:t.title}),(0,Gt.jsx)("div",{className:"text-sm font-medium text-slate-500 dark:text-slate-400 mt-1",children:t.description})]},t.href)})})]})]})}const eu=ym("ambulance",[["path",{d:"M10 10H6",key:"1bsnug"}],["path",{d:"M14 18V6a2 2 0 0 0-2-2H4a2 2 0 0 0-2 2v11a1 1 0 0 0 1 1h2",key:"wrbu53"}],["path",{d:"M19 18h2a1 1 0 0 0 1-1v-3.28a1 1 0 0 0-.684-.948l-1.923-.641a1 1 0 0 1-.578-.502l-1.539-3.076A1 1 0 0 0 16.382 8H14",key:"lrkjwd"}],["path",{d:"M8 8v4",key:"1fwk8c"}],["path",{d:"M9 18h6",key:"x1upvd"}],["circle",{cx:"17",cy:"18",r:"2",key:"332jqn"}],["circle",{cx:"7",cy:"18",r:"2",key:"19iecd"}]]),au=ym("square-activity",[["rect",{width:"18",height:"18",x:"3",y:"3",rx:"2",key:"afitv7"}],["path",{d:"M17 12h-2l-2 5-2-10-2 5H7",key:"15hlnc"}]]),iu=ym("heart-pulse",[["path",{d:"M2 9.5a5.5 5.5 0 0 1 9.591-3.676.56.56 0 0 0 .818 0A5.49 5.49 0 0 1 22 9.5c0 2.29-1.5 4-3 5.5l-5.492 5.313a2 2 0 0 1-3 .019L5 15c-1.5-1.5-3-3.2-3-5.5",key:"mvr1a0"}],["path",{d:"M3.22 13H9.5l.5-1 2 4.5 2-7 1.5 3.5h5.27",key:"auskq0"}]]),nu=ym("file-check-corner",[["path",{d:"M10.5 22H6a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h8a2.4 2.4 0 0 1 1.706.706l3.588 3.588A2.4 2.4 0 0 1 20 8v6",key:"g5mvt7"}],["path",{d:"M14 2v5a1 1 0 0 0 1 1h5",key:"wfsgrz"}],["path",{d:"m14 20 2 2 4-4",key:"15kota"}]]);function ou(t){let{onBack:e}=t;const a=[{title:"Emergency Medicine in Animals",href:"https://www.msdvetmanual.com/emergency-medicine-and-critical-care/emergency-medicine-introduction/emergency-medicine-in-animals",icon:eu,description:"Principles, readiness, and approach to veterinary emergencies"},{title:"Initial Triage & Resuscitation (Small Animals)",href:"https://www.msdvetmanual.com/emergency-medicine-and-critical-care/evaluation-and-initial-treatment-of-small-animal-emergency-patients/initial-triage-and-resuscitation-of-small-animal-emergency-patients",icon:au,description:"Primary survey, stabilization steps, and rapid interventions"},{title:"CPR in Small Animals",href:"https://www.msdvetmanual.com/emergency-medicine-and-critical-care/specific-diagnostics-and-therapy/cardiopulmonary-resuscitation-of-small-animals",icon:iu,description:"Algorithms, drug charts, and post\u2013cardiac arrest care"},{title:"Trauma in Small Animal Emergency Medicine",href:"https://www.msdvetmanual.com/emergency-medicine-and-critical-care/specific-diagnostics-and-therapy/trauma-in-emergency-medicine-in-small-animals",icon:nu,description:"Assessment, diagnostics, and surgical decision criteria"},{title:"Veterinary Topics Index",href:"https://www.msdvetmanual.com/veterinary-topics",icon:eu,description:"Browse MSD Veterinary Manual topics and use built-in search"}];return(0,Gt.jsxs)("div",{className:"min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)("header",{className:"border-b border-slate-200 dark:border-slate-700 bg-white/80 dark:bg-slate-800/80 backdrop-blur-md",children:(0,Gt.jsxs)("div",{className:"mx-auto max-w-7xl px-4 py-4 flex items-center gap-4",children:[(0,Gt.jsx)("button",{onClick:e,className:"group flex items-center justify-center h-10 w-10 rounded-full border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 text-slate-500 dark:text-slate-400 hover:border-teal-500 hover:text-teal-600 transition-all",children:(0,Gt.jsx)(Wm,{className:"h-5 w-5"})}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h1",{className:"text-xl font-bold text-slate-900 dark:text-white",children:"Protocols"}),(0,Gt.jsx)("p",{className:"text-xs text-slate-500 dark:text-slate-400",children:"Emergency and critical care references from MSD Veterinary Manual"})]})]})}),(0,Gt.jsxs)("main",{className:"mx-auto max-w-7xl px-4 py-8 animate-in fade-in slide-in-from-bottom-4 duration-500",children:[(0,Gt.jsxs)("section",{className:"mb-12",children:[(0,Gt.jsxs)("h2",{className:"text-xl font-bold text-slate-900 dark:text-white mb-6 flex items-center gap-2",children:[(0,Gt.jsx)(iu,{className:"h-5 w-5 text-red-600"}),"Emergency Algorithms (MSD/RECOVER)"]}),(0,Gt.jsxs)("div",{className:"grid grid-cols-1 gap-6 lg:grid-cols-2",children:[(0,Gt.jsxs)("div",{className:"rounded-xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-6 shadow-sm",children:[(0,Gt.jsx)("h3",{className:"text-lg font-bold text-slate-800 dark:text-slate-200 mb-4",children:"CPR Basic Life Support (BLS)"}),(0,Gt.jsxs)("div",{className:"space-y-4",children:[(0,Gt.jsxs)("div",{className:"flex gap-3",children:[(0,Gt.jsx)("div",{className:"flex-none flex items-center justify-center w-8 h-8 rounded-full bg-red-100 dark:bg-red-900/30 text-red-600 dark:text-red-400 font-bold text-sm",children:"1"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-bold text-slate-900 dark:text-white",children:"Compression Rate"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"100\u2013120 compressions/minute (Dogs & Cats)"})]})]}),(0,Gt.jsxs)("div",{className:"flex gap-3",children:[(0,Gt.jsx)("div",{className:"flex-none flex items-center justify-center w-8 h-8 rounded-full bg-red-100 dark:bg-red-900/30 text-red-600 dark:text-red-400 font-bold text-sm",children:"2"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-bold text-slate-900 dark:text-white",children:"Ratio (Single Rescuer)"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"30 compressions : 2 breaths"})]})]}),(0,Gt.jsxs)("div",{className:"flex gap-3",children:[(0,Gt.jsx)("div",{className:"flex-none flex items-center justify-center w-8 h-8 rounded-full bg-red-100 dark:bg-red-900/30 text-red-600 dark:text-red-400 font-bold text-sm",children:"3"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-bold text-slate-900 dark:text-white",children:"Position"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"Lateral recumbency (most patients). Lock elbows, compress 1/3\u20131/2 chest width."})]})]}),(0,Gt.jsxs)("div",{className:"flex gap-3",children:[(0,Gt.jsx)("div",{className:"flex-none flex items-center justify-center w-8 h-8 rounded-full bg-red-100 dark:bg-red-900/30 text-red-600 dark:text-red-400 font-bold text-sm",children:"4"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("h4",{className:"font-bold text-slate-900 dark:text-white",children:"Ventilation"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"10 breaths/min (1 breath every 6 sec). Volume ~10 mL/kg."})]})]})]})]}),(0,Gt.jsxs)("div",{className:"rounded-xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-6 shadow-sm",children:[(0,Gt.jsx)("h3",{className:"text-lg font-bold text-slate-800 dark:text-slate-200 mb-4",children:"Primary Survey (Triage ABCs)"}),(0,Gt.jsxs)("ul",{className:"space-y-3",children:[(0,Gt.jsxs)("li",{className:"flex items-start gap-3 p-3 rounded-lg bg-slate-50 dark:bg-slate-700",children:[(0,Gt.jsx)("span",{className:"font-bold text-teal-600 dark:text-teal-400 text-lg",children:"A"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("span",{className:"font-bold text-slate-900 dark:text-white",children:"Airway"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"Clear obstruction? Patent airway? Intubate if unconscious."})]})]}),(0,Gt.jsxs)("li",{className:"flex items-start gap-3 p-3 rounded-lg bg-slate-50 dark:bg-slate-700",children:[(0,Gt.jsx)("span",{className:"font-bold text-teal-600 dark:text-teal-400 text-lg",children:"B"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("span",{className:"font-bold text-slate-900 dark:text-white",children:"Breathing"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"Respiratory rate & effort. Auscultate lungs. Check SpO2."})]})]}),(0,Gt.jsxs)("li",{className:"flex items-start gap-3 p-3 rounded-lg bg-slate-50 dark:bg-slate-700",children:[(0,Gt.jsx)("span",{className:"font-bold text-teal-600 dark:text-teal-400 text-lg",children:"C"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("span",{className:"font-bold text-slate-900 dark:text-white",children:"Circulation"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"Heart rate, pulse quality, MM color, CRT, blood pressure."})]})]}),(0,Gt.jsxs)("li",{className:"flex items-start gap-3 p-3 rounded-lg bg-slate-50 dark:bg-slate-700",children:[(0,Gt.jsx)("span",{className:"font-bold text-teal-600 dark:text-teal-400 text-lg",children:"D"}),(0,Gt.jsxs)("div",{children:[(0,Gt.jsx)("span",{className:"font-bold text-slate-900 dark:text-white",children:"Disability (Neuro)"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-300",children:"Level of consciousness, spinal reflexes, pupil size/PLR."})]})]})]})]})]})]}),(0,Gt.jsxs)("div",{className:"mb-6",children:[(0,Gt.jsx)("h2",{className:"text-xl font-bold text-slate-900 dark:text-white mb-4",children:"MSD Veterinary Manual Resources"}),(0,Gt.jsx)("p",{className:"text-sm text-slate-600 dark:text-slate-400",children:"Reference protocols for triage, CPR, trauma, and general emergency medicine. All links open MSD Veterinary Manual in a new tab."})]}),(0,Gt.jsx)("div",{className:"grid grid-cols-1 gap-4 sm:grid-cols-2 lg:grid-cols-3",children:a.map((t,e)=>{const a=t.icon;return(0,Gt.jsxs)("a",{href:t.href,target:"_blank",rel:"noopener noreferrer",className:"group flex flex-col rounded-2xl border border-slate-200 dark:border-slate-700 bg-white dark:bg-slate-800 p-5 text-left shadow-sm transition-all hover:border-teal-500/50 hover:shadow-md hover:ring-1 hover:ring-teal-500/50",style:{animationDelay:"".concat(30*e,"ms")},children:[(0,Gt.jsx)("div",{className:"mb-2 flex h-10 w-10 items-center justify-center rounded-full bg-teal-50 dark:bg-slate-700 text-teal-600 dark:text-teal-400 group-hover:bg-teal-600 group-hover:text-white transition-colors",children:(0,Gt.jsx)(a,{className:"h-5 w-5"})}),(0,Gt.jsx)("div",{className:"text-lg font-bold text-slate-900 dark:text-white group-hover:text-teal-700 dark:group-hover:text-teal-400 transition-colors",children:t.title}),(0,Gt.jsx)("div",{className:"text-sm font-medium text-slate-500 dark:text-slate-400 mt-1",children:t.description})]},t.href)})})]})]})}const su=JSON.parse('[{"category":"Analgesics","drugs":[{"name":"Acetaminophen","active_ingredient":"Acetaminophen","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t15\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\tContraindicated.  Horses \u2022\\t\\t20\\tmg/kg\\tPO\\tper\\tday. Calves \u2022\\t\\t50\\tmg/kg\\tPO\\tfollowed\\tby\\t30\\tmg/kg\\tPO\\tq6h. \u2022\\t\\tNo\\tother\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank\\t(FARAD)\\tat www.FARAD.org. RCI\\tClassification:\\t4 ah- seet- ah- mee \u0301noe- fen  +  koe \u0301deen Trade and other names: Tylenol with codeine and many generic brands","contraindications":"Contraindications and Precautions Do not administer to cats. In people, toxic episodes are more likely when administered with drugs that alter the activity of hepatic drug enzymes. Such a reaction also is possible in animals. In cats, treatment of intoxication requires prompt treatment with acetylcysteine (see Acetylcysteine), supportive care, and monitoring. Drug Interactions In people, other drugs (especially alcohol) will increase the risk of hepatotoxicosis. It is not known if other drugs increase this risk in animals.","indications":"Indications and Clinical Uses Acetaminophen is used as an analgesic and for pain control in dogs. Do not use in cats. It is considered relatively weak as an analgesic. It is often used in combination with an opiate (e.g., codeine), but the contribution of codeine for treatment in animals is undetermined. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Acetaminophen is well tolerated in dogs at doses listed; however, high doses have caused liver toxicity. It causes severe toxicosis in cats because of their inability to excrete metabolites. Acetaminophen relies on conjugation with glutathione for excretion, and deficiencies in glutathione can lead to toxicity. Treatment of a toxic overdose consists of administration of acetylcysteine (see Acetylcysteine for more details). Clinical signs of toxicity include methemoglobinemia, acute hepatic toxicosis, swelling of paws, and Heinz body anemia.","notes":"Instructions for Use Many nonprescription (over- the- counter) formulations are available. Acetaminophen with codeine also is available, but it is undetermined if this formulation has better analgesic efficacy in animals than acetaminophen alone. See other entries for formulations that contain codeine. A Patient Monitoring and Laboratory Tests Monitor liver enzyme levels periodically to look for evidence of hepatotoxicity. In cats that have received acetaminophen, there is a high risk of toxicity, and careful monitoring of liver enzymes and blood cell parameters is needed. Many human hospitals and some diagnostic laboratories can measure acetaminophen concentrations in plasma. In people, treatment is initiated if plasma/serum concentrations are above 200 mcg/mL 4 hours after ingestion. Formulations \u2022\\t\\tAcetaminophen\\tis\\tavailable\\tin\\t120-\\t,\\t160-\\t   ,\\t325-\\t   ,\\tand\\t500-\\tmg\\ttablets. Stability and Storage Acetaminophen is stable in aqueous solutions. Maximum stability is at pH of 5\u20137.","original_category":"Analgesic"},{"name":"Acetaminophen + Codeine","active_ingredient":"Acetaminophen + Codeine","species":["Canine","Feline"],"dosage":"Dogs Follow\\tdosing\\trecommendations\\tfor\\tcodeine.\\tAdminister\\tdosages\\tof\\tcodeine equivalent to 0.5\u20131.0 mg/kg q4\u20136h PO. Cats \u2022\\t\\tContraindicated.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. A Acetazolamide 7 Regulatory Information Acetaminophen + codeine is a Schedule III drug controlled by the Drug Enforcement Agency (DEA). Do not administer to animals intended for food. Acetazolamide ah- seet- ah- zole \u0301a- mide Trade and other names: Diamox, Vetamox (veterinary formulation)","contraindications":"Contraindications and Precautions Do not administer to cats because acetaminophen is known to be toxic to cats. Codeine is a Schedule II controlled substance. Drug Interactions In people, other drugs (especially alcohol) increase the risk of hepatotoxicity. It is not known if other drugs increase this risk in animals but consider this possibility when administering other drugs that may affect hepatic metabolism.","indications":"Indications and Clinical Uses Acetaminophen codeine combinations are used for analgesia in dogs (e.g., postoperative use), but the effectiveness of this combination has not been established. Codeine formulations have also been used as an antitussive. Despite the widespread use of codeine in humans, the efficacy in animals for its antitussive use or analgesic use has not been established. Oral absorption of codeine in dogs is low. Because codeine is converted to morphine (10% of dose) for its activity and the duration of morphine is short in dogs, the clinical effectiveness of codeine in dogs may be questionable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Acetaminophen and codeine formulations are well tolerated in dogs at doses listed because these doses are eliminated quickly. However, high doses can produce liver toxicity.","notes":"Instructions for Use Many generic preparations are available. Consider that other ingredients may be present in some combination tablets (e.g., ibuprofen or caffeine). Patient Monitoring and Laboratory Tests Monitor liver enzyme levels periodically to look for evidence of hepatotoxicity caused by acetaminophen. Formulations \u2022\\t\\tAcetaminophen\\tand\\tcodeine\\tcombinations\\tare\\tavailable\\tin\\toral\\tsolution\\tand\\ttablets. A variety of formulations are available (e.g., 300- mg acetaminophen plus 15- , 30- , or 60- mg codeine). Stability and Storage Acetaminophen is stable in aqueous solutions. Maximum stability is at pH of 5\u20137.","original_category":"Analgesic, opioid"},{"name":"Buprenorphine Hydrochloride","active_ingredient":"Buprenorphine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tConventional\\tformulation\\t(0.3\\tmg/mL):\\t0.006\u20130.02\\tmg/kg\\tq4\u20138h\\tIV,\\tIM,\\tor SQ. For analgesia, higher doses are used in the range of 0.03\u20130.04 mg/kg, IV, IM, or SQ (30\u201340 mcg/kg). \u2022\\t\\tConcentrated\\tsolution\\t(1.8\\tmg/mL):\\t20\\tmcg/kg,\\tIM\\tor\\tSQ,\\tadministered\\tfor relief of surgical pain. \u2022\\t\\tConstant\\trate\\tinfusion\\t(CRI):\\t20\\tmcg/kg\\tIV\\tfollowed\\tby\\t5\\tmcg/kg/h\\tinfusion. \u2022\\t\\tEpidural:\\t0.003\u20130.006\\tmg/kg\\t(3\u20136\\tmcg/kg). \u2022\\t\\tBuprenorphine\\tSR:\\t120\u2013270\\tmcg/kg\\t(0.12\u20130.27\\tmg/kg)\\tSQ\\t(duration\\tof\\t72 hours). Cats \u2022\\t\\tFor\\tanalgesia,\\ta\\tdose\\tof\\t0.01\u20130.02\\tmg/kg\\t(10\u201320\\tmcg/kg)\\tIV\\tor\\t0.02\\tmg/kg\\t(20 mcg/kg) IM. Duration is 4\u20136 hours typically. Additional doses of 0.02 mg/kg may be administered. \u2022\\t\\tFor\\tsedation,\\toften\\twith\\tother\\tsedative\\tagents,\\tthe\\tdose\\tof\\t0.02\u20130.04\\tmg/kg\\tIV\\tor IM is used. It is not as effective for sedation as other combinations of agents. \u2022\\t\\tCRI:\\t20\\tmcg/kg\\tIV\\tfollowed\\tby\\t12\\tmcg/kg/h\\tinfusion. \u2022\\t\\tSubcutaneous\\tadministration:\\tThe\\tconcentrated\\tformulation\\t(Simbadol)\\tcan\\tbe administered SQ once daily for up to 3 days at a dose of 0.24 mg/kg (240 mcg/ kg). This formulation may be administered prior to surgery. \u2022\\t\\tBuccal\\t(transmucosal)\\tadministration:\\t0.02\u20130.04\\tmg/kg\\t(20\u201340\\tmcg/kg)\\tq8h. 0.02\\tmg/kg\\t(20\\tmcg/kg)\\tis\\tequivalent\\tto\\t0.066\\tmL/kg.\\tThis\\tmay\\tbe\\tapplied\\tto the\\tcat\u2019s\\tgingival\\tor\\toral\\tmucosa\\t(i.e.,\\tsublingual). \u2022\\t\\tEpidural:\\t12.5\\tmcg/kg\\tdiluted\\twith\\tsaline\\tto\\ta\\tvolume\\tof\\t0.3\\tmL/kg. \u2022\\t\\tBuprenorphine\\tSR:\\t120\u2013270\\tmcg/kg\\t(0.12\u20130.27\\tmg/kg)\\tSQ\\t(duration\\tof 72 hours).  Horses \u2022\\t\\t0.005\u20130.01\\tmg/kg\\t(5\u201310\\tmcg/kg\\tIM);\\tshort\\tacting\\tin\\thorses. Sheep \u2022\\t\\t0.01\\tmg/kg\\t(10\\tmcg/kg)\\tIM\\tq6h. Regulatory Information The drug is controlled by the Drug Enforcement Administration. Do not administer to animals intended for food. Schedule III controlled drug. RCI\\tClassification:\\t2 Buspirone Hydrochloride byoo- speer\u2032own  hye- droe- klor\u2032ide Trade and other names: BuSpar","contraindications":"Contraindications and Precautions Patients\\treceiving\\tbuprenorphine\\tmay\\trequire\\thigher\\tdoses\\tof\\tnaloxone\\tfor reversal. IV dose in horses may cause behavior reactions (excitement, pacing). There\\tare\\tformulations\\tthat\\tvary\\tgreatly\\tin\\tconcentration\\tfrom\\t0.3\\tmg/mL\\tto 1.8\\tmg/mL\\t(Simbadol);\\ttherefore,\\tpay\\tclose\\tattention\\tto\\tthe\\tconcentration\\tof\\tthe formulation to avoid overdoses. Drug Interactions As a partial agonist, buprenorphine may reverse or antagonize some of the mu- receptor effects of other opiates, such as morphine or fentanyl. It may be used with other analgesic agents and NSAIDs.","indications":"Indications and Clinical Uses Buprenorphine is an opiate analgesic that is used for pain control in dogs, cats, horses, and some exotic and zoo species. It has high binding affinity but lower efficacy (lower ceiling) than pure mu- receptor agonists such as morphine. Buprenorphine has been shown to be effective in animal studies for treating postoperative pain. Duration of analgesia based on plasma values in animals is 3\u20134 hours, but it may be longer clinically because of slow dissociation from binding sites and higher affinity for the mu- receptor or longer half- life in the CNS. Duration of effect has not been established for all indications in well- controlled studies and has been variable. After injection, it may have a longer time to the onset of effect than other opiates. In cats, the low doses (0.01\u20130.02 mg/kg, or 10\u201320 mcg/kg) given by the IM or IV route are more effective than the SQ route. Studies using the SQ route in cats used higher doses. Higher doses in cats may produce a longer duration of action. For example, a dose of 0.02 mg/kg has a duration of 6\u201312 hours, but higher doses of 0.12 or 0.24 mg/kg have a duration of 24 hours. In cats, it has been administered for transmucosal absorption (buccal administration) at a dose of 20 mcg/kg (0.02 mg/kg) and reported to be effective in some studies. However, other studies have shown lower absorption of 23%\u201332% from transmucosal delivery in cats and lower efficacy; therefore, higher doses of 0.04 mg/ kg\\t(40\\tmcg/kg)\\ttransmucosal\\tdelivery\\tmay\\tbe\\tneeded\\tq8h\\tto\\tcontrol\\tpain\\tin\\tmany cats. In dogs, absorption from transmucosal (gingival) administration is low (47%), B and high doses must be administered to achieve analgesic effects. In dogs, 120 mcg/ kg\\tadministered\\ttransmucosally\\t(to\\tthe\\tgingiva)\\tis\\tequivalent\\tto\\t20\\tmcg/kg\\tIV.\\tAt these doses for dogs, the high volume increases the risk of drug loss from the mouth or from swallowing. Buprenorphine patches for transdermal administration (Butrans) have been used in\\tdogs\\tat\\ta\\tdose\\tof\\t70\\tmcg/h,\\twhich\\twas\\tequivalent\\tto\\ta\\tSQ\\tdose\\tof\\t20\\tmcg/kg. The patch has a slow onset (17 hours of lag time) but a duration of 7 days. However, a 35- mcg/h patch in cats did not produce antinociceptive effects, and plasma drug levels were not detected until 36 hours after placement of the patch. Buprenorphine buccal film (Belbuca) is available in various sizes (see the Formulation section) for application to the buccal membrane in people for relief of pain. However, these film strips have not been evaluated in animals. The oral transmucosal tablets have been administered to cats after first dissolving in water or simple syrup. The bioavailability of this preparation in cats was 57%. A\\tconcentrated\\tsolution\\t(1.8\\tmg/mL)\\tis\\tavailable\\tfor\\tadministration\\tSQ\\tto\\tcats\\tat a dosage of 0.24 mg/kg (240 mcg/kg) once per day. This concentrated formulation has\\talso\\tbeen\\tevaluated\\tin\\tdogs\\tfor\\tpost-\\tsurgical\\tpain\\tand\\twas\\tequivalent\\tto\\tthe conventional\\tformulation\\tof\\t0.3\\tmg/mL\\tfor\\tpain\\trelief\\twhen\\tadministered\\tat\\ta\\tdose of 20 mcg/kg IM. Buprenorphine SR is available as an unapproved sustained- release biodegradable polymer designed to produce effective concentrations for 72 hours. Injection\\tof\\tBuprenorphine\\tSR\\tin\\tdogs\\tproduced\\tconcentrations\\tover\\t1\\tng/mL\\tfor over 72 hours at a dose of 270 mcg/kg SQ. In horses, the doses that are analgesic are likely to produce adverse effects (excitement and locomotor activity), which limits the use in horses unless it is administered with sedatives and other analgesics. The adverse effects in horses persist longer than the analgesic effects. In people, buprenorphine analgesia has been enhanced with the addition of small doses of naloxone (0.001\u20130.1 mcg/kg), but this effect has not been investigated in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are similar to other opiate agonists, but there may be less respiratory depression. Sedation is common. Dependency from chronic use of buprenorphine may be less than with pure agonists. The lethal dose in dogs (80 mg/kg) is much higher than the therapeutic dose. In horses, restlessness, excitatory reactions, head shaking, pawing, shifting leg movements, decreased intestinal motility, and increased locomotor activity are likely and may persist for several hours.","notes":"Instructions for Use Buprenorphine is used for analgesia, often in combination with other analgesics or in conjunction with general anesthesia. It has been used safely with acepromazine and alpha 2 agonists as a pre- anesthetic. It has been safely used for pain relief in animals in conjunction with NSAIDs. It is longer acting than morphine and only partially reversed by naloxone. When administration is intended to be buccal (transmucosal), it is important that the entire dose be applied to the oral mucosa and not swallowed. Ingested drug will not be effective (only 3%\u20136% oral absorption). Therefore, as the dose increases, the volume also increases, and there is a higher likelihood that some of the drug will be lost from the mouth or swallowed (e.g., at a dose of 0.03 mg/kg to cats, the volume necessary for administration is 0.45\\tmL\\tper\\taverage\\tcat). The oral mucosal tablets prepared for people have been used in cats. To prepare these tablets for administration, dissolve a 2- mg tablet in water or simple syrup to\\ta\\tconcentration\\tof\\t0.3\\tmg/mL.\\tThis\\tformulation\\tis\\tstable\\tfor\\t21\\tdays\\tat\\troom temperature. This may be administered to the oral mucosa in cats at a dose of 0.03\u20130.04 mg/kg. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\theart\\trate\\tand\\trespiration.\\tAlthough\\tbradycardia\\trarely\\tneeds\\tto\\tbe treated when it is caused by an opioid, if necessary, atropine can be administered. If serious respiratory depression occurs, the opioid can be reversed with naloxone, but animals\\treceiving\\tbuprenorphine\\tmay\\trequire\\thigher\\tdoses\\tof\\tnaloxone\\tfor\\treversal. Although plasma or serum concentrations are not typically measured, levels of 4\u201310 ng/mL\\thave\\tbeen\\tassociated\\twith\\tanalgesic\\tefficacy. Formulations \u2022\\t\\tBuprenorphine\\tis\\tavailable\\tin\\t0.3-\\tmg/mL\\tinjection\\tsolution\\tin\\ta\\t1-\\tmL\\tvial. Simbadol\\tis\\ta\\tveterinary\\tformulation\\tconcentrated\\tin\\t1.8\\tmg/mL\\tfor\\tuse\\tin\\tcats\\tbut has also been used in dogs. \u2022\\t\\tTablets:\\t2-\\t\\tor\\t8-\\tmg\\tsublingual\\ttablets\\t(Subutex\\tand\\tSuboxone\\twith\\tnaloxone), which has been used in people to treat substance abuse. Suboxone (with naloxone) is also available in a transmucosal/sublingual film. \u2022\\t\\tButrans\\tis\\ta\\t7-\\tday\\ttransdermal\\tsystem\\t(Butrans)\\tthat\\tdelivers\\t5-\\t,\\t10-\\t  ,\\tand\\t20- mcg/h to human patients. \u2022\\t\\tBuprenorphine\\tSR\\tis\\tavailable\\tas\\tan\\tunapproved\\tinjectable\\tsustained-\\trelease polymer\\tthat\\tis\\tdesigned\\tfor\\t72-\\thour\\tdelivery\\tin\\ta\\t10-or\\t3-\\tmg/mL\\tformulation. \u2022\\t\\tBuprenorphine\\tbuccal\\tfilm\\t(Belbuca):\\tavailable\\tin\\tsizes\\tof\\t75-\\t,\\t150-\\t   ,\\t300-\\t   ,\\t450-\\t   , 600-\\t  ,\\t750-\\t   ,\\tand\\t900-\\tmcg\\tbuccal\\tfilm.\\tThese\\thave\\tnot\\tbeen\\tevaluated\\tin\\tanimals.\\tIn people,\\tthey\\tare\\tapplied\\tq12\u201324h\\tfor\\tpain\\trelief\\tat\\ta\\tmaximum\\tdose\\tof\\t13\\tmcg/kg. \u2022\\t\\tBuprenorphine\\t3\\tmg/mL\\toral\\tgel\\t(buccal\\tsolution):\\tThis\\tformulation\\thas\\tbeen compounded into a transdermal gel for cats. The formulation that has been tested\\tfor\\tstability\\tand\\tpotency\\tis\\tas\\tfollows:\\tbuprenorphine\\thydrochloride\\t30\\tmg, dextrose 500 mg, sodium citrate 20 mg, citric acid monohydrate 25 mg, purified water\\tin\\ta\\tsufficient\\tquantity\\tto\\tmake\\ta\\ttotal\\tof\\t10\\tmL.\\tThese\\tingredients\\tare\\tall combined together and mixed well. The pH of the formulation is 3.5\u20134.2. This product\\tis\\tstable\\tfor\\t90\\tdays\\tafter\\tpreparation\\twhen\\tstored\\tin\\tthe\\trefrigerator\\tor room temperature in an amber glass dropper bottle. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Mix with sodium chloride for intravenous infusions. Compounded forms, if prepared as\\tdescribed\\tin\\tthe\\tFormulation\\tsection,\\tare\\tstable\\tfor\\t90\\tdays. B Buspirone Hydrochloride 103","original_category":"Analgesic, opioid"},{"name":"Butorphanol Tartrate","active_ingredient":"Butorphanol Tartrate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t \\tAntitussive:\\t0.055\\tmg/kg\\tq6\u201312h\\tSQ,\\t0.011\\tmg/kg\\tIM,\\tor\\t0.5\u20131\\tmg/kg q6\u201312h\\tPO. \u2022\\t\\tPre-\\t  anesthetic\\tor\\tsedative\\tuse:\\t0.2\u20130.4\\tmg/kg\\tIV,\\tIM,\\tor\\tSQ.\\tMay\\tbe\\tused\\twith other sedatives such as acepromazine. \u2022\\t\\tAnalgesic:\\t0.2\u20130.4\\tmg/kg\\tq2\u20134h\\tIV,\\tIM,\\tor\\tSQ\\tor\\t1\u20134\\tmg/kg\\tq6h\\tPO. \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t0.2\u20130.4\\tmg/kg\\tIV\\tfollowed\\tby\\t0.1\u20130.2\\tmg/kg/h. Cats \u2022\\t\\tAnalgesic:\\t0.2\u20130.8\\tmg/kg\\tq2\u20136h\\tIV\\tor\\tSQ\\tor\\t1.5\\tmg/kg\\tq4\u20138h\\tPO. \u2022\\t\\tSedation:\\t0.2\u20130.5\\tmg/kg\\tIV\\tor\\tIM.\\tOften\\tadministered\\twith\\tother\\tsedative\\tagents. When combined with other agents for short- term use, use the lower dose of 0.2 mg/kg. \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t0.2\u20130.4\\tmg/kg\\tIV,\\tfollowed\\tby\\t0.1\u20130.2\\tmg/kg/h.  Horses \u2022\\t\\tPain:\\t0.2\u20130.4\\tmg/kg\\tq3\u20134h\\tIV.\\tIn\\tsome\\tinstances,\\tlower\\tdoses\\tof\\t0.02\u20130.1\\tmg/kg IV\\tor\\t0.04\u20130.2\\tmg/kg\\tIM\\thave\\tbeen\\tused.\\tLow\\tdoses\\tof\\t0.1\\tmg/kg\\tIV\\thave\\tbeen used to minimize the decrease in intestinal motility. \u2022\\t\\tSedation:\\t0.01\u20130.06\\tmg/kg\\tIV. \u2022\\t\\tCRI:\\t13\u201324\\tmcg/kg/h\\t(0.013\u20130.024\\tmg/kg)\\tIV. Ruminants \u2022\\t\\t0.05\u20130.2\\tmg/kg\\tIV. Cattle \u2022\\t\\tIn\\tcombination\\twith\\txylazine,\\t0.01\u20130.02\\tmg/kg\\tIV. Regulatory Information Drug controlled by DEA, Schedule IV. Do not administer to animals intended for food. RCI\\tClassification:\\t2 108    N-    Butylscopolammonium Bromide (Butylscopolamine Bromide) N-    Butylscopolammonium Bromide (Butylscopolamine Bromide) en- byoo- til- skoe- pahl\u2019ah- moe- nee- um  broe\u2019mide Trade and other names: Buscopan","contraindications":"Contraindications and Precautions Schedule\\tIV\\tcontrolled\\tsubstance.\\tButorphanol\\tuse\\tin\\tbirds\\trequires\\tmuch\\thigher doses than in mammals because of shorter half- life and rapid clearance (e.g., 2\u20134 mg/kg\\tq2\u20134h). Drug Interactions Butorphanol is compatible with many other analgesics and is used in combination treatment for analgesia. Because butorphanol is an agonist/antagonist, it may antagonize some effects of drugs that are pure agonists (e.g., fentanyl, morphine, hydromorphone, and oxymorphone). However, the clinical significance of this antagonism has been debated among experts. Do not mix with sodium barbiturates. B","indications":"Indications and Clinical Uses Butorphanol is used for perioperative analgesia, for chronic pain, and as an antitussive agent. It is considered a weak analgesic compared with drugs that are pure mu- receptor agonists, and some of the observed effects may be caused by sedation rather than analgesia. It can be used, often with other agents, for sedation in patients with anxiety or when sedation is needed. In dogs, at doses of 0.4 mg/kg, butorphanol produces analgesia for a duration of 1 hour or less. As an antitussive, it is more potent than morphine (4\xd7) and codeine (100\xd7). Duration of the antitussive effect is\\tapproximately\\t90\\tminutes,\\tbut\\tthe\\teffect\\tmay\\tpersist\\tfor\\tas\\tlong\\tas\\t4\\thours.\\tIn horses, it may be administered IV, IM, and as a CRI. CRI has been shown effective in controlled studies for relief of abdominal pain in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are similar to other opioid analgesic drugs, but without significant mu- receptor effects. Sedation is common at analgesic doses. Respiratory depression\\tcan\\toccur\\twith\\thigh\\tdoses.\\tLethal\\tdose\\tin\\tdogs\\t(LD 50 ) is 20 mg/kg, which is much higher than clinical doses. Although bradycardia rarely needs to be treated when it is caused by an opioid, if necessary, atropine can be administered. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Dysphoric effects have been observed with agonist/antagonist drugs; this effect has been observed in cats. Decreased intestinal peristalsis and constipation may occur in some animals. A decrease in intestinal motility may be a particular concern in some horses.","notes":"Instructions for Use Butorphanol is often used in combination with anesthetic agents or in conjunction with other analgesic drugs. For most indications, a dose of 0.4 mg/kg is considered optimum, and there is little justification to increase the dose above 0.8 mg/kg because this is considered the ceiling dose. Butorphanol has a short duration of effect of less than 2 hours and usually only 1 hour. In horses, because butorphanol may cause increased locomotor activity and excitement, xylazine may be administered prior to buprenorphine. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\theart\\trate\\tand\\trespiration. Formulations \u2022\\t\\tButorphanol\\tis\\tavailable\\tin\\t1-\\t,\\t5-\\t ,\\tand\\t10-\\tmg\\ttablets\\tand\\t0.5-\\t\\tand\\t1-\\tmg/mL injection.\\tTorbugesic\\tis\\tavailable\\tas\\ta\\t10\\tmg/mL\\tinjection;\\tButorphine\\tfor\\tcats\\tis available\\tas\\ta\\t2-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Analgesic, opioid"},{"name":"Codeine","active_ingredient":"Codeine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tAnalgesia:\\t0.5\u20131\\tmg/kg\\tq4\u20136h\\tPO. \u2022\\t\\tAntitussive:\\t0.1\u20130.3\\tmg/kg\\tq4\u20136h\\tPO. Cats \u2022\\t\\tAnalgesia:\\t0.5\\tmg/kg\\tq6h\\tPO.\\tIncrease\\tdose\\tas\\tneeded\\tto\\tcontrol\\tpain. \u2022\\t\\tAntitussive:\\t0.1\\tmg/kg\\tq6h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Drug controlled by the Drug Enforcement Administration. Schedule II; some antitussive forms are Schedule V. RCI\\tClassification:\\t1 Colchicine kol\u2032chih- seen Trade and other names: Colcrys and generic brands","contraindications":"Contraindications and Precautions Codeine is a Schedule II controlled substance. Tolerance and dependence occur with chronic administration. High doses (60- mg tablet with acetaminophen) can cause sedation in dogs. Cats are more susceptible to excitement than other species. Some codeine formulations may contain other ingredients (e.g., acetaminophen) that should not be administered to cats. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tit\\tpotentiates\\teffects\\tfrom other\\tsedatives\\tand\\tCNS\\tdepressants.","indications":"Indications and Clinical Uses Codeine, or codeine with acetaminophen, has been used for treatment of moderate pain. It also has been used as an antitussive. Despite the widespread use of codeine in humans, the efficacy in animals for its antitussive or analgesic use has not been established. The limited experience shows that for joint pain in dogs, it is not as\\teffective\\tas\\toral\\tNSAIDs.\\tCodeine,\\tmorphine,\\tand\\tother\\topiates\\tin\\tdogs\\thave rapid clearance and short half- lives. Therefore, even if absorption is adequate, the duration of action is short, and clinical effectiveness in dogs may be questionable. There is little evidence available for the use in cats. Oral codeine (\u22482 mg/kg) did not produce antinociceptive effects in research cats. There is some evidence that horses are capable of conversion of codeine to morphine, which may be useful for treating pain in horses. However, the clinical effectiveness in horses has not been examined. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like all opiates, side effects from codeine are predictable. Side effects include sedation, constipation, and bradycardia. Respiratory depression occurs with high doses.","notes":"Instructions for Use Available as codeine phosphate and codeine sulfate oral tablets. Doses listed for analgesia are considered initial doses; individual patients may need higher doses depending on degree of tolerance or pain threshold. When administering acetaminophen\u2013codeine combinations, the high- dose tablet (containing 60 mg codeine) tends to cause sedation in dogs (body weight 20\u201330 kg), and the lower dose (containing 30 mg) is recommended. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, if necessary, atropine can be administered. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations \u2022\\t\\tCodeine\\tis\\tavailable\\tin\\t15-\\t,\\t30-\\t  ,\\tand\\t60-\\tmg\\ttablets;\\t5-\\tmg/mL\\tsyrup;\\tand\\t3-\\tmg/ mL\\toral\\tsolution.\\tIt\\tis\\talso\\tavailable\\tin\\tformulations\\twith\\tacetaminophen.\\tNote\\tthat many of the syrups have other ingredients that may not be appropriate for pets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. 210    Colchicine","original_category":"Analgesic, opioid, antitussive"},{"name":"Dexmedetomidine Hydrochloride","active_ingredient":"Dexmedetomidine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t125\\tmcg/m 2 IM for preanesthetic, minor sedation, short- term procedures, and analgesia\\t(range,\\t9\\tmcg/kg\\tfor\\tsmall\\tdogs\\tto\\t3\\tmcg/kg\\tfor\\tlarge\\tdogs). \u2022\\t \\t375\\tmcg/m 2 IV\\tor\\t500\\tmcg/m 2 IM for deeper sedation, analgesia, and minor surgical procedures.\\tFor\\tcomparison,\\ta\\tdose\\tof\\t375\\tmcg/m 2 is\\tequivalent\\tto\\t176\\tmcg/kg\\tfor\\ta 10-kg\\tdog\\tand\\tto\\t36.75\\tmcg/kg\\tfor\\ta\\t30-kg\\tdog. \u2022\\t\\tWhen\\tcalculating\\tdoses,\\tthe\\tlower\\tdoses\\tare\\tused\\tfor\\tshort-\\tterm\\tsedation\\tand analgesia or when combined with other analgesic or anesthetic agents. \u2022\\t\\tCombination\\tanesthetics:\\tKetamine\\t(3\\tmg/kg),\\tdexmedetomidine\\t(15\\tmcg/kg), and\\tbuprenorphine\\t(40\\tmcg/kg)\\tcan\\tbe\\tcombined\\tfor\\tone\\tsingle\\tIM\\tinjection\\tin dogs for short- term surgical procedure or intubation for surgery. \u2022\\t\\tOromucosal\\tgel:\\t125\\tmg/m 2 applied to the gingiva between the cheek and gum. If swallowed, it will not be effective. Cats \u2022\\t\\tIM\\tdose:\\t40\\tmcg/kg\\t(0.04\\tmg/kg)\\tIM\\t(0.35\\tmL\\tfor\\t4-\\tkg\\tcat).\\tLower\\tdoses\\t(e.g., 10\u201325\\tmcg/kg)\\thave\\tbeen\\tused\\tfor\\tshort-\\tterm\\tsedation\\tand\\tanalgesia\\tor\\twhen combined with other agents. \u2022\\t\\tInjectable\\tsolution\\tapplied\\tto\\tthe\\toral\\tmucosa:\\t20\u201340\\t\u03bcg/kg\\tsprayed\\tinto\\tthe\\tcat\u2019s mouth for sedation. (It can be mixed with buprenorphine.) \u2022\\t\\tIV\\tdose:\\t5\u201320\\tmcg/kg,\\twith\\tdegree\\tof\\tsedation\\tincreasing\\twith\\tthe\\tdose.\\t(This may\\tbe\\tused\\twith\\tother\\tagents,\\tsuch\\tas\\tketamine\\t5\\tmg/kg.) D Dextran 255 \u2022\\t\\tOral\\tmucosal\\tgel\\t(Sileo):\\t5\\tmcg/kg\\tapplied\\tto\\tthe\\tgingiva\\tof\\tcats\\tbetween\\tcheek and\\tgum\\t(0.25\\tmL,\\tor\\t\u201cone\\tdot\u201d\\tfrom\\tthe\\tdosing\\tsyringe\\tper\\tcat). \u2022\\t\\tCombinations:\\tDexmedetomidine\\tcan\\tbe\\tcombined\\twith\\tother\\tagents\\tand administered for short- term procedures. In these protocols, the dose of dexmedetomidine\\tgenerally\\tranges\\tfrom\\t10\\tto\\t20\\tmcg/kg\\tadministered\\tIM with\\tother\\tagents.\\tExamples\\tinclude\\t3\u20135\\tmg/kg\\tketamine\\t+\\t20\\tmcg/kg dexmedetomidine,\\tbutorphanol\\t0.2\\tmg/kg\\t+\\t10\\tmcg/kg\\tdexmedetomidine, or\\talfaxalone\\t2\\tmg/kg\\t+\\tdexmedetomidine\\t20\\tmcg/kg)\\tin\\tone\\tsyringe\\tand administered\\tIM\\t10\\tminutes\\tprior\\tto\\ta\\tminor\\tprocedure.\\tOther\\tcombinations\\thave included\\tdexmedetomidine\\t(10\\tmcg/kg),\\tketamine\\t(5\\tmg/kg),\\tand\\tbutorphanol (0.2\u20130.4\\tmg/kg),\\tor\\tbuprenorphine\\t(0.03\\tmg/kg)\\tinjected\\tIM\\tto\\tproduce\\tlateral recumbency. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\tAdminister\\tinitial\\tdose\\tof\\t3\u201310\\tmcg/kg\\tIM\\tfollowed by\\t1\\tmcg/kg/h\\tCRI. \u2022\\t\\tReversal:\\tatipamezole\\t0.2\\tmg/kg\\tIM. \u2022\\t\\tInduction\\tof\\tvomiting:\\t10\\tmcg/kg,\\tIM.\\tLower\\tdoses\\tIV\\talso\\tare\\teffective.  Horses \u2022\\t\\tSurgery:\\t5\\tmcg/kg\\tIV\\tbolus.\\tCRI:\\t8\\tmcg/kg/h\\tIV. \u2022\\t\\tPerioperative\\tanalgesia:\\t1.75\u20132\\tmcg/kg/h\\tIV. Regulatory Information Withdrawal times are not established for animals that produce food. The withdrawals time\\tfor\\txylazine\\tin\\tfood\\tanimals\\tare\\t4\\tdays\\tfor\\tmeat\\tand\\t24\\thours\\tfor\\tmilk.\\tA minimum of these withdrawal periods should be used for dexmedetomidine. For additional extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Dextran deks \u0301tran Trade and other names: Dextran 70 and Gentran- 70","contraindications":"Contraindications and Precautions Use cautiously in animals with heart disease. Use may be contraindicated in older animals with preexisting cardiac disease, hypotension, hypoxia, or bradycardia. Use cautiously in animals with respiratory, liver, or kidney disease. Do not use in animals with signs of shock. Use cautiously in animals that are pregnant because alpha 2 agonists have been reported to induce labor. In addition, it may decrease oxygen delivery to fetus in late gestation. Dexmedetomidine can be absorbed through intact human skin; therefore avoid human exposure. Drug Interactions Do not use with other drugs that may cause cardiac depression. Use with opioid analgesic drugs will greatly enhance the CNS depression. Consider lowering doses if administered with opioids. Anticholinergic drugs (e.g., atropine) may be given in moderate doses prior to drug administration to prevent bradycardia induced by alpha 2 agonists, but it is not routinely needed and may prolong initial hypertension.\\tHowever,\\tadministration\\tsimultaneously with alpha 2 agonists is not recommended. Administration of atropine to dogs with dexmedetomidine resulted in adverse cardiovascular effects. lower\\tdoses\\t(as\\tmuch\\tas\\t40%\u201360%)\\tof\\tother\\tdrugs\\tare\\tanticipated\\twhen\\tused\\twith dexmedetomidine. It has also been safe and effective in cats as a preanesthetic at a dose of\\t40\\tmcg/kg\\tcombined\\twith\\t5\\tmg/kg\\tof\\tketamine.\\tIn\\tdogs\\tand\\tcats,\\tafter\\tprocedures in which dexmedetomidine has been used, it can be reversed with atipamezole at a dose of\\t25\u2013300\\tmcg/kg\\t(equal\\tto\\tvolume\\tof\\tdexmedetomidine\\tused)\\tIM. Dexmedetomidine oromucosal gel for treatment of noise aversion should be applied 30\u201360\\tminutes\\tprior\\tto\\tthe\\tnoise\\tevent\\tthat\\ttriggers\\tanxiety\\tbehavior\\tor\\tat\\tthe\\tfirst\\tsign of\\tanxiety\\trelated\\tto\\tloud\\tnoise.\\tIt\\tmay\\tbe\\tredosed\\tif\\tnecessary\\tafter\\t2\u20133\\thours,\\tbut\\tno more than 5 doses should be administered.","indications":"Indications and Clinical Uses Dexmedetomidine, like other alpha 2 agonists,\\tis\\tused\\tas\\ta\\tsedative,\\tanesthetic\\tadjunct, and analgesia. It is approved for use in both dogs and cats. It can be administered to facilitate examinations, diagnostic procedures, treatments, ear and teeth cleaning, and minor surgery. It has been used to sedate animals for intradermal skin testing without affecting results. The oral mucosal gel (oromucosal gel) formulation (Sileo) is approved for the treatment of noise aversion (noise phobia) in dogs. The dose of transmucosal dexmedetomidine needed to produce sedation is higher than the noise-aversion dose. The canine oromucosal gel has also been administered to cats to anxiolytic\\tuses\\tat\\ta\\tdose\\tof\\t5\\tmcg/kg\\t(0.25\\tmL/cat\\tof\\tdosing\\tsyringe). Dexmedetomidine\\tinjection\\tis\\tcommonly\\tused\\tin\\tcats.\\tIn\\tcats,\\tthe\\tpeak\\teffects\\tare observed\\tin\\t15\u201360\\tminutes,\\tand\\tthe\\trecovery\\toccurs\\tby\\t180\\tminutes.\\tIt\\thas\\tsimilar\\tclinical effects as medetomidine and can be used for similar indications. It can be administered in combination with ketamine, butorphanol, or opiate agonists for sedation and short- term surgical procedures (see Instructions for Use). In the dosing section, note that many doses listed\\tare\\tlower\\tthan\\tthe\\tmanufacturer\u2019s\\tapproved\\tlabel\\tdose. Dexmedetomidine (and xylazine) can be used to induce vomiting in cats that have ingested\\ta\\tpoison\\tat\\ta\\tdose\\tof\\t10\\tmcg/kg\\tIM. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In small animals, vomiting is the most common acute effect. Vomiting is more common in cats than dogs. Alpha 2 agonists decrease sympathetic output. D","notes":"Instructions for Use Dexmedetomidine, medetomidine, and detomidine are more specific for the alpha 2 receptor than xylazine. They may be used for sedation, analgesia, and minor surgical procedures. It is recommended to withhold food for several hours prior to administration of alpha 2 agonists to minimize vomiting. Lower\\tdoses\\tare\\toften\\tadministered\\tfor\\tcases\\twhen\\tless\\tsedation\\tis\\tneeded or\\twhen\\tcombined\\twith\\tother\\tdrugs.\\tFor\\texample,\\ta\\tdose\\tof\\t10\\tmcg/kg\\tIM\\tof dexmedetomidine\\tin\\tcombination\\twith\\tketamine\\tand/or\\tbutorphanol\\thas\\tbeen\\tused for short- term procedures in cats. These combinations induce more sedation and achieved with dexmedetomidine alone, without significant cardiovascular effects. Recommended\\tcanine\\tdoses\\tfor\\tinjection\\tare\\tshown\\tin\\tthe\\tdosing\\tsection. Dexmedetomidine can also be used with other anesthetics such as propofol, ketamine,\\tthiopental,\\topiates,\\tbenzodiazepines,\\tand\\tinhalant\\tgas\\tanesthetics.\\tHowever, Cardiovascular\\tdepression\\tmay\\toccur.\\tLike\\tmedetomidine,\\tdexmedetomidine can produce an initial bradycardia and hypertension. Although bradycardia is common,\\tit\\trarely\\trequires\\ttreatment\\twith\\tantimuscarinic\\tagents\\t(e.g.,\\tatropine). An initial increase in blood pressure may be followed by a decrease in blood pressure\\tcaused\\tby\\tdecreased\\tsympathetic\\ttone.\\tLower\\trespiratory\\trate\\tand\\tbody temperature occur in animals during dexmedetomidine sedation. Transient arrhythmias may occur in some animals. Paradoxical excitement may occur in some animals, and animals with high anxiety levels may not respond predictably to alpha 2 agonists. If adverse reactions are observed, reverse with atipamezole (Antisedan)\\twith\\ta\\tdose\\tof\\t25\u2013300\\tmcg/kg\\tIM.\\t(See\\tAtipamezole\\tdosing section.) It is not recommended to administer atropine to animals to modify cardiovascular effects. Administration of atropine to dogs with dexmedetomidine resulted in increases in blood pressure and heart rate and deleterious cardiac arrhythmias. In\\thorses,\\tthere\\tare\\tprominent\\tsedative\\teffects,\\tespecially\\tin\\tthe\\tfirst\\t20\u201330 minutes\\tand\\tdecreased\\tintestinal\\tmotility\\tthat\\tlasted\\t60\\tminutes. Patient Monitoring and Laboratory Tests Monitor\\tvital\\tsigns\\tduring\\tanesthesia.\\tMonitor\\theart\\trate,\\tblood\\tpressure,\\tand\\tECG during anesthesia. Alpha 2 agonists will increase blood glucose because of effects on insulin secretion. Formulations \u2022\\t\\tDexmedetomidine\\tis\\tavailable\\tin\\tvials\\tcontaining\\t0.5-\\tmg/mL\\tinjection,\\tand\\ta\\tlower concentration\\tof\\t0.1\\tmg/mL\\tin\\tsterile\\tvials.\\tHuman\\tformulation\\tis\\tPrecedex. \u2022\\t\\tDexmedetomidine\\toromucosal\\tgel\\t(Sileo)\\tcontains\\t0.9\\tmg/mL\\tdexmedetomidine supplied\\tin\\ta\\t3-mL\\tsyringe\\twith\\ta\\tmarked\\tplunger\\tto\\tallow\\tfor\\tadministration\\tof\\tan accurate dose. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability\\tof\\tspecific\\tcompounded\\tformulations\\thas\\tnot\\tbeen\\tevaluated.\\tHowever, dexmedetomidine has been combined in the same syringe with ketamine, opioids, and\\tother\\twater-\\tsoluble\\tagents\\tand\\tinjected\\twithout\\tsigns\\tof\\tincompatibility. Dexmedetomidine\\toromucosal\\tgel\\tis\\tavailable\\tin\\ta\\tpreloaded\\tsyringe.\\tOnce\\topened,\\tit should be used within 4 weeks.","original_category":"Analgesic, alpha"},{"name":"Dipyrone","active_ingredient":"Dipyrone","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tDogs:\\t50\\tmg/kg\\tIV,\\tIM,\\tSQ\\tq12h. \u2022\\t\\tCats:\\tsafe\\tdoses\\tare\\tnot\\testablished  \u2022\\t \\tHorses,\\tantipyrexia\\tuse:\\t30\\tmg/kg\\tIV,\\ttwice-daily\\t(every\\t12\\thours),\\tfor\\tup\\tto\\t3\\tdays. Regulatory Information Do not administer to food- producing animals. Precautionary Information","contraindications":"Contraindications and Precautions Do not use concurrently with other NSAIDs, corticosteroids, or drugs that are ulcerogenic. Do not use in animals in which other NSAIDs are contraindicated. Humans\\tshould\\thandle\\tthis\\tdrug\\tcarefully.\\tHuman\\tcontact\\tshould\\tbe\\tavoided.\\tIn 1977,\\tdipyrone-containing\\tdrugs\\twere\\tremoved\\tfrom\\tthe\\thuman\\tmarket\\tbecause of concern of agranulocytosis. Dipyrone is prohibited for use in humans in several countries.\\tHowever,\\tthis\\teffect\\thas\\tnot\\tbeen\\tobserve\\tin\\thorses. Drug Interactions NSAIDs such as dipyrone can interact with multiple other drugs, but there are no specific instances identified for dipyrone. D Disopyramide 293 Dirlotapide dir- loe\u2019ta- pyed Trade and other names: Slentrol","indications":"Indications and Clinical Uses The most common use for dipyrone has been in horses. The use had diminished because the availability is limited, and there are other NSAIDs used for pain and inflammation\\tin\\thorses.\\tDipyrone\\twas\\tremoved\\tfrom\\tthe\\tUS\\tmarket\\tin\\t1995\\tbut was\\tapproved\\tby\\tthe\\tFDA\\tfor\\thorses\\tin\\tNovember\\t2019\\t(Zimeta).\\tIn\\tthe\\tUnited States, it has not been used in small animals, but it has been in other countries. In horses, the approved use is as an antipyretic agent, but it has also been administered as an analgesic and antispasmodic agent for some forms of colic in horses. The antispasmodic effect has not been shown through well-controlled studies in horses; however, controlled studies and the FDA approval have demonstrated the antipyretic effectiveness.","side_effects":"Adverse Reactions and Side Effects Intramuscular\\tand\\tSQ\\tinjections\\tcan\\tbe\\tirritating.\\tDipyrone\\tshould\\tbe\\tadministered IV.\\tIn\\tfield\\ttrials\\tin\\thorses,\\tit\\twas\\tgenerally\\tsafe\\twith\\t2\\thorses\\tout\\tof\\t107\\tdeveloping gastric\\tulcers,\\tand\\t1\\thorse\\tout\\tof\\t107\\twith\\tright\\tdorsal\\tcolitis.\\tThere\\tis\\ta\\trisk\\tof dipyrone-induced agranulocytosis, but this has not been reported from use in horses. Other\\teffects\\tfrom\\tNSAIDs\\tmay\\tbe\\tpossible,\\tthrough\\tdecreased\\tPG\\tsynthesis. When administered to dogs, it has inhibited platelet function for as long as 3 hours and also may prolong bleeding in horses.","notes":"Instructions for Use Dipyrone is approved for horses in the United States but is used in small companion animals in other countries. Administer to horses according to the label instructions, IV. Avoid human contact. Patient Monitoring and Laboratory Tests As with use of any NSAID, monitor for NSAID- related adverse effects, such as bleeding,\\tGI\\tproblems,\\tand\\tprotein\\tloss. Formulations \u2022\\t\\tDipyrone\\tis\\tavailable\\tin\\tthe\\tUnited\\tStates\\tas\\ta\\t500\\tmg/mL\\tIV\\tinjection (Zimeta).\\tThere\\thas\\tbeen\\ta\\t50%\\tinjection\\tavailable\\tin\\tCanada\\t(500\\tmg/mL). Some compounding pharmacies have prepared it for horses, but these are not recommended because of the availability of an FDA-approved form. It may be available in other countries as metamizole. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded oral formulations have not been evaluated and should be avoided.","original_category":"Analgesic, Antipyretic, nonsteroidal anti- inflammatory drug"},{"name":"Fentanyl, Transdermal","active_ingredient":"Fentanyl, Transdermal","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tPatches:\\t10\u201320\\tkg:\\t50-\\tmcg/h\\tpatch\\tq72h.\\tHigher\\tsize\\tpatch\\t(75-\\t\\tor\\t100-\\tmcg patch) may be used in large dogs, but there is no evidence showing a relationship between size of the patch and dog size. Cats \u2022\\t\\t25-\\t mcg\\tpatch\\tper\\tcat\\tq120h.\\tFor\\tsmall\\tcats,\\thalf\\tof\\tthe\\tpatch\\tsurface\\tcan\\tbe covered to reduce surface area and decrease amount absorbed.  Horses \u2022\\t\\tPatches:\\tIn\\tadult\\thorses,\\ttwo\\tor\\tthree\\ttransdermal\\tpatches\\tof\\t100\\tmcg/h\\teach\\t(10 mg of fentanyl, equivalent to 35\u2013110 mcg/kg delivered transdermally). \u2022\\t\\tPatches:\\tIn\\tfoals,\\tone\\ttransdermal\\tpatch\\tof\\t100\\tmcg/h. Sheep and Goats \u2022\\t\\t100-\\t  mcg/h\\tpatch,\\tor\\tapproximately\\t2.5\\tmcg/kg/h,\\tdepending\\ton\\tgoat\\tsize. (Absorption has been inconsistent.) Regulatory Information Schedule II controlled drug by the DEA. Fentanyl should not be administered to animals that produce food. Withdrawal times are not established. Ferrous Sulfate fare\u2032us sul\u2032fate Trade and other names: Ferospace and generic brands (over- the- counter)","contraindications":"Contraindications and Precautions Transdermal fentanyl is a Schedule II controlled substance. Use cautiously in animals of small body weight (e.g., small toy dogs and young or debilitated cats). Fentanyl has high potency and abuse potential in people. The patches have been abused in people and have caused deaths. Animal owners should be advised of the high risks to humans if transdermal patches is applied to humans. Fentanyl is absorbed through intact human skin. Drug Interactions There are no specific drug interactions, but transdermal fentanyl decreases other anesthetic requirements. Transdermal fentanyl potentiates other opiates and CNS depressants.","indications":"Indications and Clinical Uses Transdermal absorption from fentanyl patches has been demonstrated for cats, dogs, horses, and goats. In dogs, fentanyl transdermal patches (50 mcg/h) are appropriate for most average- size dogs. Transdermal fentanyl patches have been shown in clinical studies to be effective to relieve postoperative pain in dogs. The patches have been well tolerated in cats, except for some mild opioid- related effects when the full patch (25 mcg/h) is applied. Fentanyl patches (25 mcg/h) were effective and safe to relieve pain from onychectomy surgery in cats. Cats that have received fentanyl patches have had improvement in temperament, attitude, and appetite. Transdermal fentanyl has been used alone or combined with NSAIDs for treating severe pain in horses and may provide pain relief that is superior to NSAIDs alone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Severe adverse effects have not been reported. Typical opiate effects can be anticipated. The patch may cause slight skin irritation at the site of application. If patch delivery of fentanyl is high, some signs of opiate overdose may occur (e.g., excitement in cats or sedation in dogs); however, these reactions are rare. Adverse effects have not been reported from the use in horses. If adverse effects are observed in animals (e.g., respiratory depression, excess sedation, or excitement in cats), remove the patch and, if necessary, administer naloxone hydrochloride (0.4- mg/mL solution at a dose of 0.04 mg/kg).","notes":"Instructions for Use Transdermal fentanyl incorporates fentanyl into adhesive patches applied to the skin of dogs and cats. Studies have determined that patches release sustained levels of fentanyl for 72\u2013108 hours in dogs and cats. One 100- mcg/h patch is equivalent to 10 mg/kg of morphine q4h IM. Studies have determined that 25- mcg/h patches are appropriate for most cats, but if the rate of delivery is too high for cats and adverse reactions are suspected, covering half the adhesive surface area reduces the rate of delivery. A single 50- mcg/h patch is appropriate for dogs weighing 10\u201320 kg. In horses, two or three 100- mcg/h patches achieved rapid plasma concentrations within effective ranges in adults, but it was highly variable. Duration of effect in horses is less than in dogs or cats at only 48 hours. Follow the manufacturer\u2019s recommendations carefully when applying patches and disposing of used patches. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, atropine can be administered if necessary. If F Ferrous Sulfate 365 serious respiratory depression occurs, the opioid can be reversed with naloxone (0.04 mg/kg). Monitor for signs of excitement in cats. Formulations \u2022\\t\\tTransdermal\\tfentanyl\\tpatches\\tare\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\t75-\\t  ,\\tand\\t100-\\tmcg/h patches. In May 2009, the formulation was switched to a matrix vehicle instead of a reservoir system. These have been bioequivalent to previous formulations in people. \u2022\\t\\tFentanyl\\ttransdermal\\tsolution\\t(Recuvyra)\\thas\\tbeen\\twithdrawn\\tby\\tthe\\tmanufacturer and is no longer available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not open the fentanyl patch membrane.","original_category":"Analgesic, opioid"},{"name":"Gabapentin","active_ingredient":"Gabapentin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnticonvulsant\\tdosage:\\t10\u201320\\tmg/kg\\tq8h\\tPO.\\tThe\\thigher\\tdose\\tmay\\tbe\\tneeded\\tin some dogs to control seizures. \u2022\\t\\tNeuropathic\\tpain:\\tStart\\twith\\t5\u201315\\tmg/kg\\tq12h\\tPO\\tand\\tincrease\\tdosage\\tgradually to\\tas\\thigh\\tas\\t40\\tmg/kg\\tq8\u201312h\\tPO\\tif\\tnecessary. \u2022\\t\\tTreatment\\tof\\tbehavior\\tdisorders:\\t(often\\tused\\tconcurrently\\twith\\tSSRI\\tor\\tTCA drugs) 5\u201330 mg/kg up to three times daily. Start at the low end and titrate up to achieve the desired event but avoid adverse effects. Dose changes should occur about 7 days apart. For short-term treatment to achieve anxiolysis, doses have been as high as 30\u201360 mg/kg 1\u20132 hours before an event that is anticipated to trigger anxiety in a dog. Cats \u2022\\t\\tAnticonvulsant\\tdosage:\\t5\u201310\\tmg/kg\\tq12h\\tPO.\\tThe\\tdosage\\thas\\tbeen\\tincreased\\tto 20 mg/kg q8\u201312h in some cats to control seizures. \u2022\\t\\tNeuropathic\\tpain:\\t5\u201310\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tTreatment\\tof\\tanxiety:\\t100\\tmg\\tper\\tcat\\tPO\\t(20\u201330\\tmg/kg).\\tAdminister\\t90\\tminutes prior to a stressful event (such as a veterinary visit) with a peak effect at 2\u20133 hours.  Horses \u2022\\t\\tNeuropathic\\tpain:\\t2.5\\tmg/kg\\tq12h\\tPO,\\tincreased\\tto\\thigher\\tdoses\\tif\\tneeded\\t(see laminitis dose). \u2022\\t\\tLaminitis:\\t2.5\\tmg/kg\\tq8h,\\tq12h,\\tor\\tq24h,\\tincreased\\tto\\thigher\\tdoses\\tas\\tneeded. Doses of 10 mg/kg and higher administered q8\u201312h reached concentrations that are effective in other animals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 Gamithromycin gam- ith- roe- mye\u2032sin Trade and other names: Zactran","contraindications":"Contraindications and Precautions No known contraindications in animals. However, because this is only licensed as a human drug, the full extent of adverse effects and precautions in animals is not known. Any discontinuation of this medication should be done with a gradual taper, rather than a sudden withdrawal. Drug Interactions Antacids decrease oral absorption. If antacids are administered, there should be 2 hours between dosing of each drug. Other drug interactions are possible based on experience in people, but these have not been documented in animals. If an animal is scheduled for an anesthetic procedure, consider lower doses of the anesthetic or sedative used for anesthesia.","indications":"Indications and Clinical Uses Gabapentin is used as an anticonvulsant, sedative, anxiolytic, and to treat chronic pain syndromes, including neuropathic pain. It is used to treat neuropathic pain that does not respond to nonsteroidal anti- inflammatory drugs (NSAIDs) or opioids. However, studies demonstrating efficacy for pain treatment in dogs and cats are currently lacking. It was not effective for postoperative pain in dogs and was not effective in a thermal nociceptive study in experimental cats at doses up to 30 mg/kg. However, it has been effective in one study in dogs with syringomyelia. In cats, it has also been used to reduce anxiety in cats prior to traveling, visits to the veterinarian, or other stressful events with evidence from clinical studies that it may be helpful for this indication. For this use, administer 100 mg per cat (\u224820\u201330 mg/kg) 90 minutes prior to a stressful event (e.g., visit to a veterinary office). The peak effect occurs in 2\u20133 hours. This use may decrease stress- related behavior and aggression and improve compliance of cats. In dogs, gabapentin has gained attention, as adjunctive treatment, for treating anxiety, phobias, panic disorders, and compulsive disorders. It is used when other agents (selective serotonin reuptake inhibitors [SSRIs] or tricyclic antidepressants [TCAs]) have not been effective and has been used concurrently with SSRIs or TCAs). In horses, gabapentin has been used to treat laminitis and other pain syndromes, but efficacy has not been shown in well- controlled studies. The use is based on anecdotal or small observational case studies. It has low and variable oral absorption in horses, and the doses have varied widely (5\u201320 mg/kg two or three times daily). In calves, it has a long half- life but is not effective for analgesia in dehorning procedures. G G When used to treat epilepsy, gabapentin (or pregabalin) is rarely used as a single agent but is considered when the seizures have become refractory to other drugs. Neurologists consider gabapentin an \u201cadd- on\u201d for treating seizures in animals, but it is not very effective when used alone. When included in a regimen as an add- on, it is not as effective as zonisamide or levetiracetam. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation and ataxia are reported adverse effects. As dose increases in dogs (see the dosing section), sedation is more likely. In people, a withdrawal syndrome from abrupt discontinuation has been described, but it is not reported in animals. However, based on this concern in people, gradual withdrawal should be considered. When high doses are administered (see the dosing section), adverse effects include ataxia, decreased appetite, vomiting, and diarrhea. Some of these effects are transient, but if they persist, lower the dose by one-half or consider another alternative. The oral solution contains xylitol, which is an artificial sweetener that can be toxic to dogs and produces hypoglycemia and liver injury with high doses exceeding 0.1 g/kg. With standard doses of gabapentin oral solution, the toxic level of xylitol is not likely to be exceeded, but one should be cautious about adding other drugs that also contain xylitol.","notes":"Instructions for Use Gabapentin has been used in some animals as an anticonvulsant when they are refractory to other drugs. It can be used with other drugs such as phenobarbital and bromide. It also has been used to treat neuropathic pain syndromes and can be used with NSAIDs and opioids. Efficacy for each of these indications is anecdotal or based on small uncontrolled observational studies; there are no controlled studies published to show efficacy for treating pain syndromes in animals. Gabapentin has been administered to cats to reduce anxiety and fear associated with stressful events. For this use, administer gabapentin orally 2\u20133 hours prior to the anticipated stressful event. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. If plasma/serum drug concentrations are monitored, the targeted trough concentration is 2 mcg/mL in dogs. Formulations \u2022\\t\\tGabapentin\\tis\\tavailable\\tin\\t100-\\t,\\t300-\\t   ,\\tand\\t400-\\tmg\\tcapsules;\\t100-\\t,\\t300-\\t   ,\\t400-\\t   , 600- , and 800- mg scored tablets; and 50- mg/mL oral solution. A gastroretentive tablet is available (Gralise) that releases for 10 hours in people and is used once daily but has not been evaluated in dogs or cats. \u2022\\t\\tTransdermal\\tformulations\\thave\\tbeen\\texamined\\tin\\tcats\\tbut\\tare\\tnot\\tabsorbed sufficiently to produce efficacy. 400    Gamithromycin Stability and Storage If stored at high temperatures and high humidity, there may be degradation within 9 weeks. Split tablets and intact tablets are stable after storage at room temperature for 9 weeks. Stability of compounded formulations has not been evaluated.","original_category":"Anticonvulsant, analgesic"},{"name":"Hydrocodone Bitartrate","active_ingredient":"Hydrocodone Bitartrate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAntitussive\\tdose:\\t0.5\\tmg/kg\\tq8\\th\\tPO.\\tIncrease\\tthe\\tdose\\tif\\tneeded\\tfor\\ttracheal collapse in dogs but not above the dose of 1.5 mg/kg. \u2022\\t\\tAnalgesic\\tdose:\\t0.5\\tmg/kg\\tq8\u201312\\th\\tPO.\\t(Analgesic\\tproperties\\thave\\tnot\\tbeen established in dogs.) Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished.\\tOral\\tdoses\\tmay\\tbe\\teffective\\tin\\tcats,\\tbut\\tcaution should be used because many formulations contain acetaminophen.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Hydrocodone is a Schedule II drug controlled by the Drug Enforcement Administration (DEA). Hydrocodone is not recommended for food- producing animals. If administered to a food animal, consult FARAD for extralabel use withdrawal interval estimates (www.FARAD.org). RCI\\tClassification:\\t1.\\tDo\\tnot\\tadminister\\tto\\tracing\\thorses. Hydrocortisone hye- droe- kor\u2032tih- sone Trade and other names: Hydrocortisone, Cortef and generic brands, hydrocortisone sodium succinate, Solu- Cortef","contraindications":"Contraindications and Precautions Do not use in patients that may be sensitive to opioid effects or experience dysphoria. Because preparations for oral use contain atropine, do not use in animals in which atropine may be contraindicated. Many formulations for treating pain in people contain hydrocodone and acetaminophen or hydrocodone and aspirin. Do not administer to animals sensitive to these other ingredients. Acetaminophen- containing products should never be administered to cats. Hydrocodone is combined with atropine in the product Hycodan. Atropine can decrease respiratory secretions but probably does not exert significant clinical effects at doses in this preparation (1.5 mg homatropine per 5-mg tablet). Drug Interactions No specific drug interactions are reported for animals. However, other typical drug interactions that affect opioids should be considered.","indications":"Indications and Clinical Uses Hydrocodone is an opiate agonist that has antitussive, analgesic, and sedative properties. In people, the combinations of hydrocodone and acetaminophen (e.g., Vicodin)\\tand\\thydrocodone\\tand\\taspirin\\tare\\toften\\tprescribed\\tas\\toral\\ttreatments\\tfor pain. However, in animals, the efficacy of these medications for treating pain has not been established. The most common use of hydrocodone in dogs has been as an antitussive for symptomatic treatment of airway diseases, and many clinicians believe (anecdotally) that it is an effective antitussive. There are no antitussive preparations marketed for use in the United States that do not contain atropine. (Canadian preparations H may contain only hydrocodone.) It may also contain other ingredients for treating cough. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like all opiates, side effects from opioids are predictable and unavoidable. Side effects include sedation, constipation, and bradycardia. Respiratory depression occurs with high doses but is not documented from the use in animals. Paradoxical excitement may occur in some animals.","notes":"Instructions for Use Hydrocodone use in animals (primarily dogs) is derived from anecdotal experience and opinions from experts. It is most often used as an antitussive in dogs. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t \\tThere\\tare\\tmany\\toral\\tformulations\\tfor\\thumans\\tto\\ttreat\\tpain\\tthat\\tcontain hydrocodone\\tand\\tother\\tanalgesics\\tsuch\\tas\\tacetaminophen\\t(e.g.,\\tVicodin). Typically, these preparations contain 5 mg of hydrocodone and 500 mg of acetaminophen. \u2022\\t\\tHydrocodone\\tis\\talso\\tavailable\\tas\\tan\\tantitussive\\t(Hycodan) in 5- mg tablets and 1-   mg/mL syrup combined with homatropine in a concentration of 1.5 mg in tablets and 0.3 mg/mL in syrup, respectively. Formulations in Canada do not contain homatropine. \u2022\\t \\tThe\\textended-\\trelease\\tformulations\\tfor\\tpeople\\tcontain\\t10-\\t,\\t15-\\t  ,\\t20-\\t  ,\\t30-\\t  ,\\t40-\\t  , 50- , 60-,  80- , 100- , and 120- mg tablets) approved for use in people for treating pain. These extended- release formulations provide extended duration for once-  or twice- daily administration but have not been evaluated for animals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. 436    Hydrocortisone","original_category":"Antitussive, analgesic"},{"name":"Hydromorphone","active_ingredient":"Hydromorphone","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.22\\tmg/kg\\tIM\\tor\\tSQ.\\tRepeat\\tq4\u20136h\\tor\\tas\\tneeded\\tfor\\tpain\\ttreatment. \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tIV,\\trepeated\\tq2h\\tor\\tas\\tnecessary.\\tA\\tdose\\tof\\t0.1\\tmg/kg\\tmay\\tbe\\tused with acepromazine as a preoperative sedative. \u2022\\t\\tCRI:\\t0.01\\tmg/kg/h\\tIV. Cats \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tSQ\\tor\\tIM\\tor\\t0.05\u20130.1\\tmg/kg\\tIV\\tq2\u20136h\\t(as\\tneeded). \u2022\\t\\tEpidural\\tdose:\\t0.05\\tmg/kg,\\tdiluted\\tin\\tsaline\\tto\\t0.2\\tmL/kg\\t(1\\tmL\\tper\\tcat). \u2022\\t\\tDose\\tto\\tproduce\\temesis\\t(for\\tpoisoning):\\t0.1\\tmg/kg\\tSQ\\tonce.  Horses \u2022\\t\\tEpidural:\\t0.04\\tmg/kg\\tdiluted\\tin\\t0.9%\\tsaline\\tto\\t20\\tmL. \u2022\\t\\tNo\\tsystemic\\tdoses\\thave\\tbeen\\treported. Regulatory Information Hydromorphone is a Schedule II drug controlled by the DEA. Withdrawal times have not been established for food animals, but the elimination rate is rapid, and a brief withdrawal time is suggested. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t1 Hydroxyethyl Starch Trade and other names: HES, hetastarch, Hespan, tetrastarch, and VetStarch (veterinary product)","contraindications":"Contraindications and Precautions Cats and horses are more sensitive to excitement than other species. Monitor the body temperature in cats because hyperthermia may occur. Hydromorphone may cause bradycardia and atrioventricular block in some patients. Drug Interactions There are no specific drug interactions, but hydromorphone potentiates the effects of other anesthetics and sedatives. Hydromorphone may be used with other anesthetics, but doses should be adjusted because of potentiation of the other drugs. If butorphanol is used concurrently, it may diminish the effects of hydromorphone by antagonizing mu- opiate receptors.","indications":"Indications and Clinical Uses Hydromorphone is used in animals for analgesia and sedation and as an adjunct for anesthesia. In dogs and cats, it is used as a single agent or in combination with other agents. Hydromorphone is similar in action to morphine; however, it is more potent\\tthan\\tmorphine\\t(6\u20137\xd7)\\tand\\tshould\\tbe\\tused\\tat\\tlower\\tdoses.\\tHydromorphone is approximately half as potent as oxymorphone. Studies in dogs indicate that hydromorphone at equivalent doses is equal to oxymorphone for producing sedation in\\tdogs.\\tIn\\tcats,\\tduration\\tof\\teffect\\t(0.1\\tmg/kg)\\thas\\tbeen\\t6\u20137.5\\thours\\tdespite\\ta relatively\\tshort\\tplasma\\thalf-\\tlife\\tof\\t1\u20131.5\\thours. H Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like all opioids, side effects from hydromorphone are predictable and unavoidable. Side effects from administration include sedation, panting, constipation,\\turinary\\tretention,\\tand\\tbradycardia.\\tVomiting\\tis\\tcommon\\tafter\\tinitial administration but is a predicted event and does not require treatment. In dogs, hydromorphone produces less histamine release than morphine administration and therefore may produce fewer histamine- related side effects. In cats, the most common adverse effects are dysphoria, hypersalivation, and vomiting. Hyperthermia also has been observed in cats, but the mechanism is not known. In horses, undesirable and even dangerous behavior actions can follow rapid IV\\topioid\\tadministration.\\tHorses\\tshould\\treceive\\ta\\tpreanesthetic\\tof\\tacepromazine or an alpha 2 agonist. Respiratory depression occurs with high doses. As with other opiates, a slight decrease in heart rate is expected. In most cases, this decrease does not have to be treated with anticholinergic drugs (e.g., atropine) but should be monitored. Tolerance and dependence occur with chronic administration.","notes":"Instructions for Use Hydromorphone may be used interchangeably with morphine or oxymorphone, provided that doses are adjusted for potency differences. Administration to cats has been more effective when injected intravenously, rather than intramuscularly or subcutaneously, and resulted in faster onset with fewer adverse effects. Oral tablets and solution are available for human use, but use has not been reported for animals. It is uncertain if oral forms are absorbed sufficiently for clinical use in animals. In addition to sedative and analgesic uses, hydromorphone also has been used to induce vomiting by stimulating the chemoreceptor trigger zone. This has been used for the purpose of treating an animal that has ingested a toxin. It is more effective as an emetic in dogs and cats when injected subcutaneously or intramuscularly rather than intravenously. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, atropine or glycopyrrolate can be administered if needed. If serious respiratory depression occurs, the opioid can be reversed with naloxone (0.04 mg/kg). Monitor body temperature in cats. Hyperthermia has been observed in patients after anesthesia. 440    Hydroxyethyl Starch Formulations \u2022\\t\\tHydromorphone\\tis\\tavailable\\tin\\t1-\\tmg/mL\\toral\\tsolution;\\t2-\\t,\\t4-\\t ,\\tand\\t8-\\t    mg\\ttablets; and 1- , 2- , 4- , and 10- mg/mL injection. \u2022\\t\\tExalgo\\tis\\tan\\textended-\\trelease\\tformulation\\tfor\\tpeople\\tin\\t8-\\t,\\t12-\\t  ,\\tand\\t16-\\tmg\\ttablets that allows for once- daily treatment. This formulation has not been evaluated in animals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Hydromorphone is soluble in water. Compounded solutions in fluids have been stable for 30 days. It is a Schedule II drug and should be stored in a locked compartment.","original_category":"Analgesic, opiate"},{"name":"Loperamide Hydrochloride","active_ingredient":"Loperamide Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"DogsCats \u2022\\t\\t0.12\\tmg/kg\\tq8\u201312h\\tPO. \\t\u2022\\t\\t0.08\u20130.16\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported.\\tIf\\tadministered\\tto\\thorses\\tor\\truminants, it may induce problems associated with decreased intestinal motility. Regulatory Information Withdrawal times are not established for animals that produce food. If administered to food animals, consult FARAD for extralabel use withdrawal interval estimates, at www.FARAD.org. RCI\\tClassification:\\t4 Lorazepam lor- ay\u2032zeh- pam Trade and other names: Ativan and generic brands","contraindications":"Contraindications and Precautions Small dogs and collie- type dogs may be at higher risk of adverse effects. Drug Interactions Do not administer with drugs that may act as MDR1 (p- glycoprotein) membrane inhibitors,\\tsuch\\tas\\tketoconazole.\\t(Other\\tinhibitors\\tare\\tlisted\\tin\\tAppendix\\tJ.)\\tThese inhibitors may increase blood\u2013brain barrier penetration and cause depression. 532    Lorazepam","indications":"Indications and Clinical Uses Loperamide is used for symptomatic treatment of acute nonspecific diarrhea. It has been administered orally to dogs and cats. There are no clinical studies in animals, and the use is based on extrapolation from the human uses or anecdotal evidence in animals. Long- term use is discouraged because it may lead to constipation. It has been administered to large animals, but this is generally not recommended. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Loperamide can cause severe constipation with repeated use. In some dogs that have a mutation in the ABCB1 gene (previously known as the MDR gene), they may lack P- glycoprotein in the blood\u2013brain barrier. In these susceptible animals, loperamide crosses the blood\u2013brain barrier and causes profound sedation. Such cases may be reversed with naloxone. Dogs most susceptible include collie breeds, Australian\\tshepherds,\\tOld\\tEnglish\\tsheepdogs,\\tlonghaired\\twhippets,\\tand\\tShetland sheepdogs.","notes":"Instructions for Use Doses are based primarily on empiricism or extrapolation of human doses. Clinical studies have not been performed in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tLoperamide\\tis\\tavailable\\tin\\t2-\\tmg\\ttablets,\\t2-\\tmg\\tcapsules,\\tand\\t0.2-\\tmg/mL\\toral\\tliquid (over the counter). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Loperamide is slightly soluble in water but only at low pH. Stability of compounded formulations has not been evaluated.","original_category":"Analgesic, opioid"},{"name":"Medetomidine Hydrochloride","active_ingredient":"Medetomidine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t \\t750\\tmcg/m 2 IV\\tor\\t1000\\tmcg/m 2 IM.\\tThe\\tIV\\tdose\\tis\\tequivalent\\tto\\t18\u201371\\tmcg/kg\\tIV. \u2022\\t\\tLower\\tdoses\\tare\\toften\\tused\\tfor\\tshort-\\tterm\\tsedation\\tand\\tanalgesia\\tof\\t5\u201315\\tmcg/kg (0.005\u20130.015\\tmg/kg)\\tIV,\\tIM,\\tor\\tSQ.\\tThese\\tdoses\\tmay\\tbe\\tincreased\\tup\\tto 560    Medroxyprogesterone Acetate 60\\tmcg/kg\\twhen\\tsevere\\tpain\\tis\\tinvolved.\\t20\\tmcg/kg\\thas\\tbeen\\tused\\tin\\tcombination with\\tbutorphanol\\t(0.2\\tmg/kg),\\thydromorphone\\t(0.1\\tmg/kg),\\tor\\tketamine\\tfor short-\\t   term\\tprocedures. \u2022\\t \\tCRI:\\tLoading\\tdose\\tof\\t1\\tmcg/kg\\tIV\\tfollowed\\tby\\t0.0015\\tmg/kg/h\\t(1.5\\tmcg/kg/h). CRI\\tmay\\tproduce\\tadverse\\tcardiovascular\\teffects\\tand\\tshould\\tbe\\tmonitored\\tclosely. Cats \u2022\\t\\t750\\tmcg/m 2 IV\\tor\\t1000\\tmcg/m 2 IM.\\tThe\\tIV\\tdose\\tis\\tequivalent\\tto\\t18\u201371\\tmcg/ kg\\tIV.\\tDoses\\tin\\tthe\\tlower\\trange\\tare\\tused\\tfor\\tshort-\\tterm\\tsedation\\tand\\tanalgesia (e.g.,\\t10\u201320\\tmcg/kg),\\tbut\\thigher\\tdoses\\t(up\\tto\\t80\\tmcg/kg)\\thave\\tbeen\\tused\\tfor more severe pain. Medetomidine may be administered IM or IV. \u2022\\t\\tCombination\\twith\\tketamine:\\t5\\tmg/kg\\tketamine\\t+\\t5\\tmcg/kg\\tmedetomidine\\tmixed in one syringe and administered IM.  Lambs \u2022\\t\\t30\\tmcg/kg\\t(0.03\\tmg/kg)\\tIV. Horses \u2022\\t\\t10\\tmcg/kg\\tIM\\tas\\ta\\tsedative\\tprior\\tto\\tinduction\\tfor\\tanesthesia.\\tSome\\thorses\\tmay need\\tan\\tadditional\\tdose\\tof\\t4\\tmcg/kg\\tIV.\\tIn\\thorses,\\tguaifenesin\\t(5%\\tsolution)\\tand ketamine\\t(2.2\\tmg/kg)\\thave\\tbeen\\tused\\tin\\tcombination. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t3 Medroxyprogesterone Acetate meh- droks\u2032ee- proe- jess\u2032teh- rone  ass\u2032ih- tate Trade and other names: Depo- Provera (injection), Provera (tablets), and Cycrin (tablets)","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\theart\\tdisease.\\tThe\\tuse\\tmay\\tbe\\tcontraindicated in\\tolder\\tanimals\\twith\\tpre-\\texisting\\tcardiac\\tdisease.\\tXylazine\\tcauses\\tproblems\\tin pregnant animals, and this also should be considered for other alpha 2 agonists. Use\\tcautiously\\tin\\tanimals\\tthat\\tare\\tpregnant\\tbecause\\tit\\tmay\\tinduce\\tlabor.\\tIn addition, it may decrease oxygen delivery to the fetus in late gestation. Drug Interactions Do not use with other drugs that may cause cardiac depression. Do not mix in a vial or syringe\\twith\\tother\\tanesthetics,\\texcept\\tas\\tlisted\\tunder\\tthe\\tdosing\\tsection.\\tReverse\\twith atipamezole\\tat\\ta\\tdose\\tof\\t25\u2013300\\tmcg/kg\\tIM.\\tUse\\twith\\topioid\\tanalgesic\\tdrugs\\tgreatly enhances the CNS depression, so consider lowering doses if administered with opioids.","indications":"Indications and Clinical Uses Because of potency and availability, dexmedetomidine has replaced medetomidine for most indications in small animals. Medetomidine, like other alpha 2 agonists, is used\\tas\\ta\\tsedative,\\tanesthetic\\tadjunct,\\tand\\tanalgesic.\\tDuration\\tof\\teffect\\tis\\t0.5\u20131.5 hours at the low dose and up to 3 hours for the high dose. Compared with xylazine, medetomidine has produced better sedation and analgesia than xylazine in dogs. Medetomidine has been used with combinations of ketamine, butorphanol, or opioids in\\tdogs\\tfor\\tsedation\\tand\\tshort-\\tterm\\tprocedures.\\tMedetomidine\\tcombined\\twith\\tan opiate (butorphanol or hydromorphone) has produced a longer duration of sedation and more desirable degree of sedation than medetomidine used alone. It has been used to sedate animals for intradermal skin testing without affecting results. M Precautionary Information","side_effects":"Adverse Reactions and Side Effects In small animals, vomiting is the most common initial effect. Alpha 2 agonists decrease\\tsympathetic\\toutput.\\tCardiovascular\\tdepression\\tmay\\toccur.\\tA\\tCRI\\tof\\t1.5 mcg/kg/h\\thas\\tcaused\\tdecreased\\theart\\trate\\tand\\tsinus\\tarrhythmia\\tin\\tdogs.\\tDoses as\\tlow\\tas\\t1\\tmcg/kg\\tIV\\tcan\\treduce\\tcardiac\\toutput\\tto\\tless\\tthan\\t40%\\tof\\tresting value. Although medetomidine causes initial bradycardia and hypertension, the bradycardia usually does not require intervention with anticholinergic drugs (e.g., atropine). If adverse reactions are observed, reverse with atipamezole. If atipamezole is not available, yohimbine also can reverse medetomidine.","notes":"Instructions for Use Medetomidine, dexmedetomidine, and detomidine are more specific for the alpha 2 receptor than xylazine. Dexmedetomidine has twice the potency of medetomidine. Therefore\\tthese\\tdrugs\\tshould\\tnot\\tbe\\tused\\tinterchangeably\\twithout\\tconsulting\\tthe dose\\trecommendations.\\tThe\\talpha 2 agonists may be used for sedation, analgesia, and minor surgical procedures. Many veterinarians use doses that are much less than the doses\\tlisted\\ton\\tthe\\tsponsor\u2019s\\tlabel.\\tFor\\texample,\\tlower\\tdoses\\tare\\tsometimes\\tused\\tfor short-\\t   term\\tsedation\\tand\\tanalgesia,\\tparticularly\\twhen\\tcombined\\twith\\tother\\tdrugs\\tsuch as\\topioids.\\tReverse\\twith\\tatipamezole\\tat\\ta\\tdose\\tof\\t25\u2013300\\tmcg/kg\\t(equal\\tto\\tvolume of medetomidine used) IM. Patient Monitoring and Laboratory Tests Monitor\\tvital\\tsigns\\tduring\\tanesthesia.\\tMonitor\\theart\\trate,\\tblood\\tpressure,\\tand\\tECG\\tif possible during anesthesia. Formulations \u2022\\t \\tMedetomidine\\thas\\tbeen\\tavailable\\tin\\ta\\t1.0-\\tmg/mL\\tinjection,\\tbut\\tthe commercial form has been discontinued in many countries and replaced by dexmedetomidine. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Analgesic, alpha"},{"name":"Meperidine Hydrochloride","active_ingredient":"Meperidine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5\u201310\\tmg/kg\\tIV\\tor\\tIM\\tas\\toften\\tas\\tevery\\t2\u20133\\thours\\t(or\\tas\\tneeded). Cats \u2022\\t\\t3\u20135\\tmg/kg\\tIV\\tor\\tIM\\tevery\\t2\u20134\\thours\\t(or\\tas\\tneeded). 572    Mepivacaine  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Schedule II controlled drug. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t1 Mepivacaine meh- piv\u2032ah- kane Trade and other names:  Carbocaine- V","contraindications":"Contraindications and Precautions Meperidine is a Schedule II controlled substance. Cats are more sensitive to excitement than other species, although they have tolerated meperidine relatively well. Avoid repeated doses because accumulation of metabolites may be toxic. Drug Interactions Meperidine should not be administered with monoamine oxidase inhibitors (MAOIs), such as selegiline. Meperidine and metabolites may inhibit reuptake of serotonin and cause excess serotonin effect, especially if combined with other drugs that produce similar action, such as selective serotonin reuptake inhibitors (SSRIs;\\te.g.,\\tfluoxetine),\\ttricyclic\\tantidepressants\\t(e.g.,\\tclomipramine),\\tor\\tother analgesics such as tramadol.","indications":"Indications and Clinical Uses Meperidine\\thas\\tbeen\\tused\\tfor\\tshort-\\tterm\\tsedative\\teffects,\\toften\\tused\\twith\\tother sedatives\\tor\\tanesthetics.\\tFor\\tanalgesic\\tuse,\\tit\\tis\\tshort\\tacting,\\tusually\\tless\\tthan\\t2\\thours and\\toften\\tmuch\\tshorter.\\tTherefore,\\tits\\tuse\\tfor\\ttreating\\tpain\\thas\\tnot\\tbeen\\tpopular\\tand has\\tbeen\\treplaced\\tby\\tother\\topioid\\tdrugs.\\tMeperidine\\tmay\\tproduce\\tfewer\\tGI\\tmotility problems compared with other opioids, but this has not been enough of an advantage M to\\tjustify\\tcommon\\tuse.\\tThe\\tuse\\tof\\tmeperidine\\tin\\thuman\\tmedicine\\thas\\tdeclined because toxic effects have been observed from accumulation of metabolites. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like\\tall\\topiates,\\tsome\\tside\\teffects\\tare\\tpredictable\\tand\\tunavoidable.\\tSide\\teffects include\\tsedation,\\turine\\tretention,\\tconstipation,\\tand\\tbradycardia.\\tRespiratory depression\\toccurs\\twith\\thigh\\tdoses.\\tTolerance\\tand\\tdependence\\toccur\\twith\\tchronic administration.\\tRepeated\\tdoses\\tin\\thumans\\tmay\\tcause\\ttoxicity\\tfrom\\taccumulation of metabolite. One of the metabolites, normeperidine, accumulates with repeated administration\\tbecause\\tit\\thas\\ta\\thalf-\\tlife\\tmuch\\tlonger\\tthan\\tmeperidine.\\tThe accumulation of the metabolite causes excitatory effects that may be related to serotonergic properties. Similar reactions have not been reported from clinical use in animals (see Drug Interactions for other precautions), but the use has been infrequent in animals, and these reactions may not have been reported.","notes":"Instructions for Use Although comparative clinical studies have not been conducted in animals, meperidine\\tmay\\tbe\\teffective\\tfor\\tshort\\tduration\\tbut\\thas\\tnot\\tbeen\\tused\\tfor\\tlong-\\tterm pain management. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\theart\\trate\\tand\\trespiration.\\tAlthough\\tbradycardia\\trarely\\tneeds\\tto\\tbe treated when it is caused by an opioid, atropine can be administered if necessary. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations \u2022\\t\\tMeperidine\\tis\\tavailable\\tin\\t50-\\t\\tand\\t100-\\tmg\\ttablets;\\t10-\\tmg/mL\\tsyrup;\\tand\\t25-\\t,\\t50-\\t  , 75-\\t ,\\tand\\t100-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It\\tis\\tsoluble\\tin\\twater.\\tIt\\tmay\\tbe\\tmixed\\twith\\t0.9%\\tsaline\\tor\\t5%\\tdextrose\\tfor\\t28\\tdays without loss of potency or stability. It is stable in syrup formulation. Protect from freezing.","original_category":"Analgesic, opioid"},{"name":"Methadone Hydrochloride","active_ingredient":"Methadone Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.5\\tmg/kg\\tIV\\tor\\t0.5\u20132.2\\tmg/kg\\tq3\u20134h\\tSQ\\tor\\tIM. Cats \u2022\\t\\t0.3\u20130.6\\tmg/kg\\tq3\u20134h\\tIV,\\tSQ,\\tor\\tIM.\\tCats\\thave\\ttolerated\\tdoses\\tup\\tto\\t0.6\\tmg/kg IM,\\twith\\ta\\t4-\\thour\\tduration\\tof\\tactivity. \u2022\\t\\tOral\\tmucosal\\tadministration\\tis\\tapproximately\\ttwo\\ttimes\\tthe\\tIV\\tdose\\tbecause\\tof\\tless than\\t50%\\tabsorption.  Horses \u2022\\t\\t0.15\\tmg/kg\\tIV\\tor\\tIM\\tq6\u20138h.\\tOral\\tadministration\\talso\\thas\\tbeen\\tused,\\twith\\tsome evidence of adequate oral absorption. Regulatory Information Do not administer to animals intended for food. Methadone is a Schedule II controlled drug. RCI\\tClassification:\\t1 Methazolamide meth- ah- zole\u2032ah- mide Trade and other names: Neptazane","contraindications":"Contraindications and Precautions Methadone is a Schedule II controlled substance. Cats may be more sensitive to excitement than other species, but this has not been examined for methadone. Availability of methadone in some regions may be difficult because it is used in people to treat opioid use disorder. Drug Interactions Chloramphenicol, and possibly other drugs such as antifungal agents, decrease clearance and increase plasma concentrations of methadone in dogs.","indications":"Indications and Clinical Uses Most of the use in veterinary medicine to document the efficacy and safety of methadone is based on anecdotal experience, small observational efficacy studies, and pharmacokinetic\\tstudies.\\tHowever,\\tthere\\tis\\tan\\tapproved\\tformulation\\tin\\tEurope\\twith controlled studies to support efficacy. Methadone\\tis\\tindicated\\tfor\\tshort-\\tterm\\tanalgesia,\\tfor\\tsedation,\\tand\\tas\\tan\\tadjunct to anesthesia. It is compatible with most anesthetics and can be used as part of a multimodal approach to analgesia and anesthesia. Administration of methadone may lower dose requirements for other anesthetics and analgesics used. Methadone IM\\t(0.6\\tmg/kg)\\tprovides\\tantinociceptive\\teffects\\tfor\\tup\\tto\\t4\\thours.\\tIt\\thas\\talso been\\tadministered\\tto\\tcats\\t(0.5\\tmg/kg)\\tin\\tcombination\\twith\\talpha 2 agonists and administered\\tIM\\tfor\\tanalgesia\\teffects\\tfor\\t4\u20136\\thours. Oral doses to dogs are not absorbed systemically, and this route is not recommended. Oral mucosal (buccal) administration to dogs is not practical, but oral mucosal\\tadministration\\tto\\tcats\\tmay\\tbe\\tconsidered\\t(absorption,\\t44%).\\tDuration\\tof analgesia\\tin\\tcats\\tis\\t2\u20134\\thours\\tand\\tas\\tlong\\tas\\t6\u20138\\thours. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like\\tall\\topiates,\\tside\\teffects\\tfrom\\tmethadone\\tare\\tpredictable\\tand\\tunavoidable. However, some side effects such as excitement and dysphoria seen with other opiates have not been as common with methadone in dogs and cats. Side effects from methadone administration may include sedation, vomiting, constipation, urinary retention, and bradycardia. Panting may occur in dogs as a result of changes\\tin\\tthermoregulation.\\tEffects\\tsuch\\tas\\texcitement\\tand\\tdysphoria\\thave\\tnot been observed with administration of methadone as much as some of the other opiates. In dogs, IV administration produced less dysphoria and excitement compared with other opiates. In horses, IV administration did not produce behavior changes, sedation, increased locomotion, or decreased intestinal motility that\\tis\\ttypical\\twith\\tadministration\\tof\\topioid\\tmu-\\tagonists\\tin\\thorses.\\tOral\\tdoses\\tup to\\t0.4\\tmg/kg\\tin\\thorses\\tdid\\tnot\\tproduce\\tadverse\\treactions.","notes":"Instructions for Use The\\tdose\\tin\\tdogs\\tis\\tbased\\ton\\tsmall\\tclinical\\tstudies\\tand\\tpharmacokinetic\\tresults. Effective\\tdose\\thas\\tnot\\tbeen\\testablished\\tfor\\thorses,\\tbut\\toral\\tadministration\\tof 0.1\u20130.4\\tmg/kg\\thas\\tbeen\\tadministered\\twithout\\tadverse\\teffects\\tand\\tproduces drug concentrations in the effective range. Doses used in cats are based on pharmacokinetics and small research studies. Patient Monitoring and Laboratory Tests Monitor\\tthe\\tpatient\u2019s\\theart\\trate\\tand\\trespiration.\\tAlthough\\tbradycardia\\trarely needs to be treated when it is caused by an opioid, atropine can be administered if necessary. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Although plasma concentrations are not typically monitored, the range of concentrations\\tconsidered\\ttherapeutic\\tin\\tpeople\\tis\\t33\u201360\\tng/mL. Formulations \u2022\\t\\tMethadone\\tis\\tavailable\\tin\\t1-\\t\\tand\\t2-\\tmg/mL\\toral\\tsolution;\\t5-\\t,\\t10-\\t  ,\\tand\\t40-\\tmg tablets;\\tand\\t10-\\tmg/mL\\tinjectable\\tsolution.\\tThere\\tis\\ta\\tlicensed\\tformulation\\tof methadone\\tfor\\tcats\\tavailable\\tin\\tsome\\tEuropean\\tcountries. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It\\tis\\tsoluble\\tin\\twater\\tand\\tethanol.\\tIt\\tis\\ta\\tweak\\tbase,\\twith\\ta\\tpKa\\tof\\t8.9,\\tand may precipitate\\tfrom\\ta\\tsolution\\tif\\tthe\\tpH\\tis\\thigher\\tthan\\t6.\\tAlthough\\toral\\tforms\\tare\\tnot well absorbed in animals, methadone has been combined in oral mixtures with juices and\\tsyrups\\tand\\tremained\\tstable\\tfor\\tat\\tleast\\t14\\tdays. M Methazolamide 583","original_category":"Analgesic, opioid"},{"name":"Morphine Sulfate","active_ingredient":"Morphine Sulfate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnalgesia:\\t0.5\\tmg/kg\\tq2h\\tIV\\tor\\tIM.\\tHowever,\\tthe\\tfull\\tdose\\trange\\tis\\t0.1\u20131\\tmg/kg IV,\\tIM,\\tor\\tSQ\\tq4h,\\tdepending\\ton\\tthe\\tdesired\\teffect\\t(dosage\\tis\\tescalated\\tas\\tneeded to control severity of pain). \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t0.2\\tmg/kg\\tIV\\tfollowed\\tby\\t0.1\\tmg/kg/h.\\tThis\\tmay\\tbe increased\\tto\\ta\\tloading\\tdose\\tof\\t0.3\\tmg/kg\\tfollowed\\tby\\t0.17\\tmg/kg/h\\tfor\\tmore severe\\tpain.\\tDoses\\tas\\thigh\\tas\\ta\\tloading\\tdose\\tof\\t0.6\\tmg/kg\\tfollowed\\tby\\t0.34\\tmg/kg IV have been used in experimental dogs without producing adverse effects. \u2022\\t\\tOral\\t  dosing:\\tRegular\\ttablets\\t   should\\t   not\\t  be\\t used.\\t   Sustained-\\trelease\\t   tablets\\t   have\\t  been used\\tat\\ta\\tdosage\\tof\\t15\\tor\\t30\\tmg\\tper\\tdog\\tq8\u201312h\\tPO,\\tbut\\tstudies\\thave\\tshown\\tthese tablets to be inconsistently and poorly absorbed in dogs. \u2022\\t\\tEpidural:\\t0.1\\tmg/kg. \u2022\\t\\tCombination\\tof\\tMLK:\\tmixed\\tas\\t100\\tmg/mL\\tof\\tketamine\\t(1.6\\tmL\\tper\\t500\\tmL fluids)\\t+\\t20\\tmg/mL\\tof\\tlidocaine\\t(30\\tmL\\tper\\t500\\tmL\\tfluids),\\tand\\t15\\tmg/mL\\tof morphine\\t(1.6\\tmL\\tper\\t500\\tmL\\tfluids)\\tand\\tinfused\\tat\\ta\\trate\\tof\\tmorphine,\\t0.24\\tmg/ kg\\th;\\tlidocaine,\\t3\\tmg/kg/h;\\tand\\tketamine,\\t0.6\\tmg/kg/h,\\tadministered\\tas\\tCRI\\tfor perioperative analgesia. Cats \u2022\\t\\tAnalgesia:\\t0.1\u20130.2\\tmg/kg\\tIM,\\tIV,\\tor\\tSQ\\tq3\u20136h\\t(or\\tas\\tneeded). \u2022\\t\\tCRI:\\tloading\\tdose\\tof\\t0.2\\tmg/kg\\tIV\\tfollowed\\tby\\t0.05\u20130.1\\tmg/kg/h\\tIV. \u2022\\t\\tEpidural\\t0.1\\tmg/kg\\tdiluted\\tin\\tsaline\\tto\\t0.3\\tmL/kg.  Horses \u2022\\t\\tFor\\tlight\\tchemical\\trestraint,\\tuse\\t0.3\u20130.5\\tmg/kg\\tIV,\\tin\\tcombination\\twith\\tother sedatives. M Moxidectin 629 \u2022\\t\\tFor\\tmild\\tpain,\\tstart\\twith\\t0.1\u20130.2\\tmg/kg\\tIV\\tor\\tIM\\tq6h.\\tFor\\tmore\\tsevere\\tpain, gradually\\tincrease\\tto\\t0.5\u20131\\tmg/kg\\tIV\\tor\\tIM.\\tGive\\tIV\\tdoses\\tslowly.\\tMorphine\\tmay cause excitement in horses, and it is advised to first sedate with an alpha 2 agonist or another sedative. \u2022\\t\\tIntra-\\t   articular\\t(use\\tpreservative-\\tfree\\tsolutions):\\t0.05\\tmg/kg;\\tstart\\twith\\tinitial concentration\\tof\\t20\\tmg/mL\\tsolution\\tand\\tdilute\\tin\\tsaline\\tto\\t5\\tmg/mL\\tand administered\\tat\\ta\\trate\\tof\\t1\\tmL\\tper\\tjoint\\tper\\t100\\tkg\\tof\\tbody\\tweight. Ruminants \u2022\\t\\tThe\\tbenefits\\tof\\tusing\\tmorphine\\tin\\truminants\\tare\\tcontroversial.\\tHowever, 0.05\u20130.1\\tmg/kg\\tIV\\tand\\tup\\tto\\t0.4\\tmg/kg\\tIV\\thave\\tbeen\\tused\\tto\\ttreat\\tpain\\tand\\tin perioperative situations. Regulatory Information Morphine is a Schedule II controlled drug. Avoid use in animals intended for food. If used in a food producing animal, consult\\tFARAD\\tat\\twww.FARAD.org, for information on withdrawal times. RCI\\tClassification:\\t1 Moxidectin moks- ih- dek\u2032tin Trade and other names: ProHeart, ProHeart 6, ProHeart 12 (canine), Coraxis, Quest (equine), and Cydectin (bovine and ovine)","contraindications":"Contraindications and Precautions Morphine is a Schedule II controlled substance. Cats and horses are more sensitive to excitement than other species. Drug Interactions Like\\tother\\topiates,\\tit\\tpotentiates\\tother\\tdrugs\\tthat\\tcause\\tCNS\\tdepression.","indications":"Indications and Clinical Uses Morphine\\tis\\tindicated\\tfor\\tshort-\\tterm\\tanalgesia,\\tfor\\tsedation,\\tand\\tas\\tan\\tadjunct to anesthesia. It is compatible with most anesthetics and can be used as part of a multimodal approach to analgesia and anesthesia. Administration of morphine may lower dose requirements for other anesthetics and analgesics used. Morphine also has been used in animals for treatment of pulmonary edema. Presumably, this effect is attributed to vasodilation and reduction of preload in animals. M Although oral morphine (regular and sustained release) has been used in dogs, its absorption\\tis\\tpoor\\tand\\tinconsistent.\\tThe\\toral\\tdose\\tformulations\\tshould\\tnot\\tbe\\trelied on for treating severe pain in dogs. Morphine oral administration has not been investigated in cats. Injectable forms can be used in cats, but doses are generally lower than in dogs to prevent excitement. In horses, it is rarely used alone or without other sedatives because undesirable behavior and cardiovascular effects may occur at doses that are needed for analgesia. At\\ta\\tdose\\tof\\t0.3\u20130.6\\tmg/kg\\tin\\thorses,\\tit\\tsignificantly\\tincreases\\tlocomotor\\tactivity, produces\\texcitement,\\tand\\tdecreases\\tGI\\tmotility.\\tIt\\tproduces\\tcolic\\tat\\t1.0\\tmg/kg\\tand severe\\tataxia\\tand\\tcollapse\\tat\\t2.4\\tmg/kg.\\tAt\\tlower\\tdoses\\tof\\t0.1\u20130.2\\tmg/kg,\\tit\\tdid not\\tproduce\\tcolic\\tor\\texcitement\\tor\\tadverse\\tGI\\teffects,\\tbut\\tthese\\tlow\\tdoses\\twere\\tnot adequate to produce analgesia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like\\tall\\topiates,\\tside\\teffects\\tfrom\\tmorphine\\tare\\tpredictable\\tand\\tunavoidable.\\tSide effects from morphine administration include sedation, vomiting, constipation, urinary retention, and bradycardia. Panting may occur in dogs as a result of changes in thermoregulation. Histamine release occurs from administration of morphine, but it may be less likely than with other opioids such as hydromorphone.\\tExcitement\\tcan\\toccur\\tin\\tsome\\tanimals,\\tbut\\tit\\tis\\tmore\\tcommon in\\tcats\\tand\\thorses.\\tRespiratory\\tdepression\\toccurs\\twith\\thigh\\tdoses. As with other opiates, a slight decrease in heart rate is expected. In most cases, this decrease does not have to be treated with anticholinergic drugs (e.g., atropine),\\tbut\\tit\\tshould\\tbe\\tmonitored.\\tTolerance\\tand\\tdependence\\toccur\\twith chronic administration. In horses, there were ileus, constipation, and CNS stimulation\\t(pawing\\tand\\tpacing)\\tafter\\t0.5\\tmg/kg.\\tIn\\thorses,\\tundesirable\\tand\\teven dangerous behavior actions can follow rapid IV opioid administration. Muscle twitching, fasciculations, and sweating also occur in horses. If used in horses, they should receive a preanesthetic of acepromazine or an alpha 2 agonist.","notes":"Instructions for Use Effects\\tfrom\\tmorphine\\tadministration\\tare\\tdose\\tdependent.\\tLow\\tdoses\\t(0.1\u20130.25\\tmg/ kg)\\tproduce\\tmild\\tanalgesia.\\tHigher\\tdoses\\t(up\\tto\\t1\\tmg/kg)\\tproduce\\tgreater\\tanalgesic effects\\tand\\tsedation.\\tUsually\\tmorphine\\tis\\tadministered\\tIM,\\tIV,\\tor\\tSQ.\\tCRIs\\talso have been used, and doses that are listed later produce morphine concentrations in a therapeutic\\trange.\\tPO\\tmorphine\\tis\\tavailable\\tin\\tsustained-\\trelease\\tforms,\\tbut\\tPO\\tdosing can\\tbe\\thighly\\tvariable\\tand\\tinconsistent.\\tEpidural\\tadministration\\thas\\tbeen\\tused\\tfor surgical\\tprocedures.\\tCombination\\tprotocols\\tinclude\\tMMK,\\twhich\\tis\\tmorphine\\t(0.2 mg/kg)\\t+\\tmedetomidine\\t(60\\tmcg/kg)\\t(or\\tdexmedetomidine)\\t+\\tketamine\\t(5\\tmg/ kg), which are mixed in one syringe and administered intramuscularly to produce short-\\t   term\\tanalgesia\\tand\\tanesthesia\\tfor\\tapproximately\\t120\\tminutes.\\tAnother\\tmixture is\\tMLK,\\twhich\\tis\\tmorphine\\t(or\\tfentanyl),\\tlidocaine,\\tand\\tketamine\\t(see\\tdosing\\tsection for\\tformula).\\tEvaluation\\tof\\tthe\\tefficacy\\tMLK\\tprotocols\\tis\\tbased\\tmostly\\ton\\tanecdotal experience\\tor\\tsmall\\tobservational\\tstudies.\\tOne\\tstudy\\tdid\\tnot\\tfind\\tany\\tbenefit\\tof\\tMLK over\\tmorphine\\talone\\tin\\tan\\tincision-\\tinduced\\tpain\\tmodel\\tin\\tdogs. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\theart\\trate\\tand\\trespiration.\\tAlthough\\tbradycardia\\trarely\\tneeds\\tto\\tbe treated when it is caused by an opioid, if necessary, atropine can be administered. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations \u2022\\t\\tInjection\\tformulations:\\tMorphine\\tis\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\t4-\\t ,\\t5-\\t ,\\t8-\\t ,\\t10-\\t  ,\\t15-\\t  ,\\t25-\\t  ,\\tand 50-\\t mg/mL\\tinjection\\t(most\\tcommon\\tis\\t15\\tmg/mL) \u2022\\t\\tOral\\tformulations:\\t15-\\t\\tand\\t30-\\tmg\\ttablets\\tand\\textended-\\trelease\\ttablets\\tin\\t15,\\t30, 60,\\t100,\\tand\\t200\\tmg\\t(MS\\tContin,\\tOramorph\\tSR,\\tor\\tgeneric\\tbrands).\\tMorphine pentahydrate\\t(Avinza)\\tis\\tavailable\\tin\\t60-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Protect from freezing. Morphine sulfate is slightly water soluble and soluble in ethanol.\\tIt\\tis\\tmore\\tstable\\tat\\ta\\tpH\\tless\\tthan\\t4.\\tIf\\tmixed\\twith\\thigh-\\tpH\\tvehicles, oxidation occurs, which may darken the formulation (brownish yellow). Solutions may\\tbe\\trepackaged\\tin\\tplastic\\tsyringes\\tand\\tkept\\tstable\\tfor\\t70\\tdays.\\tIf\\tmixed\\twith sodium\\tchloride\\t(0.9%)\\tfor\\tepidural\\tinjection,\\tit\\tis\\tstable\\tfor\\t14\\tweeks.\\tMorphine has been mixed with other analgesic and sedative agents in the same syringe and in fluids.\\tAn\\texample\\tof\\tsuch\\ta\\tcombination\\tis\\tMLK,\\twhich\\tis\\tmorphine,\\tlidocaine,\\tand ketamine\\t(concentration\\tof\\teach\\tingredient\\tlisted\\tearlier).\\tThis\\tcombination\\thas\\tbeen when mixed prior to dosing.","original_category":"Analgesic, opioid"},{"name":"Naloxone Hydrochloride","active_ingredient":"Naloxone Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.01\u20130.04\\tmg/kg\\tIV,\\tIM,\\tor\\tSQ\\tas\\tneeded\\tto\\treverse\\topiate.\\tA\\tfull\\tantagonist dose is 0.04 mg/kg. \u2022\\t\\tLow\\tdose\\tto\\tpartially\\treverse\\tdysphoric\\treaction:\\tAdminister\\t1\\tmL\\tevery\\t30 seconds (0.04 mg/mL solution) as needed.  Horses \u2022\\t\\t0.02\u20130.04\\tmg/kg\\tIV\\t(duration\\tof\\teffect\\tis\\tonly\\t20\\tminutes). Regulatory Information No withdrawal times are established. It is anticipated that naloxone is cleared rapidly after administration. Because of a low risk of residues, short (24\u201348 hours) withdrawal times are suggested. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 N Naltrexone 641 Naltrexone nal- treks\u2032one Trade and other names: Trexan and Vivitrol","contraindications":"Contraindications and Precautions Administration to an animal that is experiencing pain precipitates extreme reactions because of blockade of endogenous opioids. Drug Interactions Naloxone reverses the action of several opioid drugs in all animal species. N","indications":"Indications and Clinical Uses Naloxone is used to reverse the effects of opiate agonists on receptors. Naloxone is usually the first drug of choice for reversing overdoses, toxicity, or adverse central nervous system (CNS) effects such as dysphoria or excitement. It will reverse effects of morphine, oxymorphone, butorphanol, hydromorphone, fentanyl, and other opioids. It is less effective for reversing buprenorphine because buprenorphine is a partial agonist. When administering naloxone to reverse opiates, the dose may be titrated gradually to achieve the optimum degree of reversal. The dose for full reversal is typically 0.04 mg/kg (40 mcg/kg), but doses this high may not be needed, and smaller doses (producing partial reversal) can be used when it is necessary to reduce dysphoria or excitement, without reducing the analgesic effects. At very low doses (one fifth of the dose needed to fully reverse opiates), it has been used to treat opioid- induced side effects such as vomiting, nausea, and dysphoria. (This use has been referred to as microdosing.) A formulation for wildlife use (Trexonil) is more concentrated and used to reverse tranquilization in wild animals. Naloxone may have some temporary benefit for behavior modification (e.g., to suppress compulsive disorders), but the effects are short lived. For example, in horses, it temporarily decreases crib biting, but the duration of action is short. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tachycardia and hypertension have been reported in people. In animals, reversal of opioid may precipitate a severe reaction that includes high blood pressure, excitement, pain, tachycardia, and cardiac arrhythmias. Because of these reactions, less than a full reversal often is recommended unless the reversal is needed for a life- threatening  problem.","notes":"Instructions for Use Administration may have to be individualized based on response in each patient. Naloxone\u2019s duration of action is short in animals (60 minutes), and the dose may have to be repeated when treating an overdose of a long- acting opioid. Start at the low end of the dosage rate and increase the dose to effect. Higher doses may be needed to reverse drugs that are mixed agonists\u2013antagonists such as butorphanol or buprenorphine compared with reversing drugs that are pure agonists. Low doses may be used to reduce opioid- induced dysphoria in animals. For this use, start with the 0.04- mg/mL solution and administer increments of 1 mL every 30 seconds until vocalization or signs of dysphoria stop. A dose of 0.01 mg/kg IV has been given for this purpose without losing analgesic effects. As a general guideline, a dose of 1 mL (0.4 mg) reverses 1.5 mg of oxymorphone, 15 mg of morphine, 100 mg of meperidine, and 0.4 mg of fentanyl. Patient Monitoring and Laboratory Tests Naloxone is used to reverse opioid analgesic drugs. When opioids are reversed in some animals, serious reactions may occur. In some patients, changes in blood pressure, tachycardia, and discomfort may result. Formulations Available \u2022\\t\\tNaloxone\\tis\\tavailable\\tin\\tinjectable\\tvials\\twith\\tpreservatives\\tin\\t0.4\\tor\\t1\\tmg/ mL; without preservatives in 0.02 mg (20 mcg), 0.4 mg, or 1 mg/mL; and as Trexonil in 50 mg/mL. Stability and Storage When used intravenously, it may be diluted in other fluids. For IV infusion, it may be added to 0.9% sodium chloride solution or 5% dextrose solution. An amount of 2 mg of naloxone may be mixed with 500 mL of fluids to produce 4 mcg/mL. After dilution, it should be used within 24 hours. Do not mix with other drugs or solutions that are alkaline. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Opioid antagonist"},{"name":"Naltrexone","active_ingredient":"Naltrexone","species":["Canine","Equine","Feline"],"dosage":"Dogs \u2022\\t\\tFor\\tbehavior\\tproblems:\\t2.2\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t \\tCrib\\tbiting:\\t0.04\\tmg/kg\\tIV\\tor\\tSQ.\\t(Because\\tinjectable\\tformulations\\tare\\tnot available, it must be compounded for this indication.) Duration of effect is 1\u20137 hours. \u2022\\t\\tFor\\treversal\\tof\\topiates:\\t100\\tmg/animal\\tIV\\tor\\tSQ.\\t(Because\\tinjectable\\tformulations are not available, it must be compounded for this indication.) Regulatory Information Withdrawal times are not established for animals that produce food. In wild animals that are captured with opiates and administered naltrexone for reversal, a 45- day withdrawal time is suggested. For additional extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. RCI\\tClassification:\\t3 Pharmacology and Mechanism of Action Nandrolone is an anabolic steroid. Nandrolone is a derivative of testosterone used as an anabolic agent. Anabolic agents are designed to maximize anabolic effects while minimizing androgenic action.","contraindications":"Contraindications and Precautions Do not administer to animals in pain, or it may elicit a severe reaction. Drug Interactions Naltrexone reverses the action of other opioid drugs. Contraindications and Precautions Use cautiously in patients with hepatic disease. Do not use in pregnant animals. These drugs are controlled substances and have been abused in people to increase athletic performance and muscle mass. Drug Interactions No drug interactions have been reported. Nandrolone Decanoate nan\u2032droe- lone  dek- ah- noe\u2032ate Trade and other names:  Deca- Durabolin","indications":"Indications and Clinical Uses For treating overdoses of opioids, naloxone administered IV, IM, or intranasal is preferred over naltrexone. Naltrexone is used in people for treatment of opiate dependence and alcoholism. In animals, some obsessive- compulsive disorders are believed to be mediated by endogenous opioids. It has been used successfully for treatment of some obsessive- compulsive behavioral disorders, such as tail chasing in dogs, acral lick granuloma in dogs, and crib biting in horses. The effect for each of these disorders is short lived. Precautionary Information Indications and Clinical Uses Anabolic agents have been used for reversing catabolic conditions, promoting weight gain, increasing muscling in animals, and stimulating erythropoiesis. There are no documented differences in efficacy among the anabolic steroids reported in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. In people, it can precipitate opioid withdrawal signs. Adverse Reactions and Side Effects Adverse effects from anabolic steroids can be attributed to the pharmacologic action of these steroids. Increased masculine effects are common. There has been an increased incidence of some tumors in people. Some of the oral anabolic steroids that are 17- alpha methylated (oxymetholone, stanozolol, and oxandrolone) are associated with hepatic toxicity.","notes":"Instructions for Use For\\tacute\\ttreatment\\tof\\topiate\\ttoxicity,\\tuse\\tnaloxone\\tinstead\\tbecause\\tit\\tcan\\tbe\\tinjected\\twith\\ta more rapid onset of effects. Treatment for obsessive- compulsive disorders (canine compulsive disorder) in animals has been reported with naltrexone. Relapse rates may be high. Patient Monitoring and Laboratory Tests Monitor heart rate in treated animals. Formulations \u2022\\t\\tNaltrexone\\tis\\tavailable\\tin\\t50-\\tmg\\ttablets.\\tVivitrol\\tfor\\thumans\\tis\\tan\\tencapsulated microsphere\\tthat\\tcan\\tbe\\tinjected\\tto\\tproduce\\ta\\tlong-\\tlasting\\teffect\\t(one\\tinjection\\tper month) to treat opioid use disorder. One vial contains 380 mg in microspheres in a 4-\\t mL\\tinjection\\tfor\\tIM\\tuse. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Naltrexone\\tis\\tsoluble\\tin\\twater.\\tIt\\thas\\tbeen\\tmixed\\twith\\tjuices\\tand\\tsyrups\\tto\\tmask\\tthe bitter taste and is stable for 60\u201390 days. 642    Nandrolone Decanoate","original_category":"Opioid antagonist"},{"name":"Oxymorphone Hydrochloride","active_ingredient":"Oxymorphone Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnalgesia:\\t0.1\u20130.2\\tmg/kg\\tIV,\\tSQ,\\tor\\tIM\\t(as\\tneeded);\\tredose\\twith\\t0.05\u20130.1\\tmg/ kg q1\u20132h. A dosage of 0.25 mg/kg SQ q6h may be used for less severe pain. \u2022\\t\\tPreanesthetic:\\t0.025\u20130.05\\tmg/kg\\tIM\\tor\\tSQ. \u2022\\t\\tSedation:\\t0.05\u20130.2\\tmg/kg\\t(with\\tor\\twithout\\tacepromazine)\\tIM\\tor\\tSQ. Cats \u2022\\t\\t0.03\\tmg/kg\\tbolus\\tIV\\tfollowed\\tby\\t0.02\\tmg/kg\\tq2h\\tor\\tCRI\\twith\\ta\\tloading\\tdose\\tof 5 mcg/kg followed by a 5- mcg/kg/h infusion.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Schedule II controlled drug. RCI Classification: 1 and dependence occur with chronic administration. In horses, undesirable and\\teven\\tdangerous\\tbehavior\\tactions\\tcan\\tfollow\\trapid\\tIV\\topioid administration. Horses should receive a preanesthetic of acepromazine or an alpha 2 agonist.","contraindications":"Contraindications and Precautions Oxymorphone is a Schedule II controlled substance. Cats and horses may be more sensitive to excitement caused by opiates. Drug Interactions Like\\tother\\topiates,\\toxymorphone\\tpotentiates\\tother\\tdrugs\\tthat\\tcause\\tCNS depression. O Oxytetracycline 689 Oxytetracycline oks\u2032ih- tet- rah- sye\u2032kleen Trade and other names: Terramycin, Terramycin Soluble Powder, Terramycin Scours Tablets, Bio- Mycin, Oxy- Tet, and Oxybiotic Oxy 500 and Oxy 1000. Long- acting","indications":"Indications and Clinical Uses Oxymorphone is indicated for short- term analgesia, for sedation, and as an adjunct to anesthesia. It is compatible with most anesthetics and can be used as part of a multimodal approach to analgesia and anesthesia. Although oxymorphone is FDA approved for dogs, other opiates, such as hydromorphone and morphine, are used more commonly. Administration of oxymorphone may lower dose requirements for other anesthetics and analgesics used. The duration of action in dogs is short (2\u20134 hours) and requires frequent administration for effective use. The oral dose","side_effects":"Adverse Reactions and Side Effects Like all opiates, side effects from oxymorphone are predictable and unavoidable. Side effects from opiate administration include sedation, vomiting, constipation, urinary retention, and bradycardia. Panting may occur in dogs as a result of changes in thermoregulation. Histamine release, known to occur from administration of morphine, may be less likely with oxymorphone. Excitement can occur in animals, but it is more common in cats and horses. Respiratory depression occurs with high doses. As with other opiates, a slight decrease in heart rate is expected. In most cases, this decrease does not have to be treated with anticholinergic drugs (e.g., atropine), but it should be monitored. Tolerance","notes":"formulations are only 10% absorbed in people but should not be relied on for treating severe pain in dogs. Precautionary Information Instructions for Use There is some evidence that oxymorphone may have fewer cardiovascular effects than morphine. Oxymorphone is more readily absorbed systemically from epidural administration compared with morphine. Oxymorphone can be used in combination with other anesthetics and anesthetic adjuncts in the peri- operative period and post- surgery to enhance analgesia. It has been used with sedatives such as acepromazine, benzodiazepines, and alpha 2 - agonists. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, atropine can be administered if necessary. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations \u2022\\t\\tOxymorphone\\tis\\tavailable\\tin\\t1.5-\\t\\tand\\t1-\\tmg/mL\\tinjections. \u2022\\t\\tOral\\tforms:\\t5-\\t\\tand\\t10-\\tmg\\ttablets\\tare\\tavailable\\tbut\\thave\\tnot\\tbeen\\tshown\\tto\\tbe absorbed in animals. Stability and Storage The pH of solution is 2.7\u20134.5. Oxymorphone is compatible with most fluid solutions. Store in a tightly sealed container, protected from light, and at room temperature. formulations include Liquamycin- LA 200 and Bio- Mycin 200.","original_category":"Analgesic, opioid"},{"name":"Pentazocine","active_ingredient":"Pentazocine","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1.65\u20133.3\\tmg/kg\\tq4h\\tIM\\tor\\tas\\tneeded. Cats \u2022\\t\\t2.2\u20133.3\\tmg/kg\\tq4h\\tIM,\\tIV,\\tor\\tSQ\\tor\\tas\\tneeded.  Horses \u2022\\t\\t200\u2013400\\tmg\\tper\\thorse\\tIV. Regulatory Information Pentazocine is a Schedule IV controlled drug. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Pentobarbital Sodium pen- toe- bar\u2032bih- tahl  soe\u2032dee- um Trade and other names: Nembutal and generic brands","contraindications":"Contraindications and Precautions Pentazocine has few contraindications or precautions, except that use in horses can potentially cause behavior changes and reduced intestinal motility. Drug Interactions Pentazocine may potentiate other sedative drugs such as alpha 2 agonists. Pentazocine may interfere with mu- opiate effects of other drugs, such as morphine or fentanyl. 714    Pentobarbital Sodium","indications":"Indications and Clinical Uses Pentazocine\\thas\\tbeen\\tused\\tfor\\tsedation\\tand\\tanalgesia,\\tprimarily\\tin\\thorses.\\tHowever, because of the availability of other opioids with better efficacy, the use of pentazocine has declined. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are similar to those of other opioid analgesic drugs and include constipation, ileus, vomiting, and bradycardia. Sedation is common at analgesic doses. Respiratory depression can occur with high doses. Dysphoric effects are possible in some sensitive individuals and in some species (e.g., horses).","notes":"Instructions for Use Pentazocine is a mixed agonist\u2013antagonist. It is relatively modest to weak in efficacy for pain control, and other opioids should be considered for better pain management. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, atropine can be administered if necessary. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations Pentazocine is available in a 30- mg/mL injection (availability has been limited). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Analgesic, opioid"},{"name":"Pregabalin","active_ingredient":"Pregabalin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnticonvulsant\\tdosage:\\t2\\tmg/kg\\tq8h\\tPO.\\tStart\\twith\\ta\\tlow\\tdose\\tand\\tgradually increase to the maximum tolerated dose of 3\u20134 mg/kg PO. \u2022\\t\\tNeuropathic\\tpain:\\tStart\\twith\\t4\u20135\\tmg/kg\\tq12h\\tPO\\tand\\tincrease\\tdose\\tgradually\\tif necessary. Cats \u2022\\t\\tAnticonvulsant\\tdosage\\tor\\tneuropathic\\tpain\\tdosage:\\tStart\\twith\\t2\\tmg/kg\\tq12h\\tPO and increase to 4 mg/kg q12h PO.  Horses \u2022\\t\\t4\\tmg/kg\\tPO\\tq8h. 776    Primidone Regulatory Information Pregabalin\\tis\\ta\\tSchedule\\tV\\tcontrolled\\tsubstance.\\tNo\\twithdrawal\\ttimes\\tare\\tavailable for food animals. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Primidone prih\u2032mih- done Trade and other names: Mylepsin, Neurosyn, and Mysoline (in Canada)","contraindications":"Contraindications and Precautions There are no known contraindications in animals. Pregabalin, like gabapentin, is excreted in the urine, and liver disease or drug metabolism interactions are not expected to affect the pharmacokinetics. Protein binding is low. In people, it has been used with other anticonvulsants and anesthetics without producing a pharmacokinetic drug interaction. Fetal abnormalities have been observed in research animals given high doses of pregabalin during pregnancy, but this has not been reported with routine use. Drug Interactions There are no reported drug interactions that affect the pharmacokinetics of pregabalin, but it could exacerbate sedation and lethargy when used with other drugs\\tthat\\tdepress\\tthe\\tCNS.","indications":"Indications and Clinical Uses In people, pregabalin is popular for treating neuropathic pain syndromes associated with diabetes, postherpetic neuralgia, and fibromyalgia. Pregabalin is also used as an anticonvulsant. As an analgesic in animals, it has been used to treat neuropathic pain that\\tdoes\\tnot\\trespond\\tto\\tNSAIDs\\tor\\topioids.\\tIt\\tmay\\tbe\\tcombined\\twith\\tthese\\tagents. When used to treat epilepsy, pregabalin has reduced seizure frequency in refractory patients when combined with phenobarbital and potassium bromide. Therefore it is considered when the seizures have become refractory to other drugs in conjunction with other anticonvulsants. For treating pain in animals, there are no clinical studies available, except for a study in dogs with syringomyelia, that provide evidence of efficacy for treating neuropathic pain. The regimens used have primarily been derived from anecdotal evidence, opinions of experts, or extrapolation from human medicine. In horses, it can produce concentrations in the therapeutic range for people, but safety and effectiveness have not been studied. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation and ataxia are reported adverse effects that can occur at doses as high as 3\u20134 mg/kg. As the dose increases in dogs, sedation is more likely. In people, there may be a withdrawal syndrome from abrupt discontinuation. This has not been reported in animals, but abrupt discontinuation after long- term treatment is discouraged.","notes":"Instructions for Use Pregabalin may be administered with or without food. Pregabalin has been used in some animals with other drugs such as phenobarbital and bromide. It also has been used\\tto\\ttreat\\tneuropathic\\tpain\\tsyndromes\\tand\\tcan\\tbe\\tused\\twith\\tNSAIDs\\tand\\topioids. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary.\\tRoutine\\tmeasurement\\tof\\tplasma\\tconcentrations is not widely available, but therapeutic concentrations in people (2.8\u20138.2 mcg/mL) have been used as a guideline. In some dogs, mild increases in liver enzymes may be observed during treatment. Formulations \u2022\\t \\tPregabalin\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\t75-\\t  ,\\t100-\\t   ,\\t150-\\t   ,\\t200-\\t   ,\\t225-\\t   ,\\tand\\t300-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light and humidity. Stability of compounded formulations has not been evaluated.","original_category":"Analgesic, anticonvulsant"},{"name":"Romifidine Hydrochloride","active_ingredient":"Romifidine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tDoses\\tnot\\testablished\\tfor\\tsmall\\tanimals.  Horses \u2022\\t\\tSedation\\tand\\tanalgesia:\\t40\u2013120\\tmcg/kg\\tIV.\\t(A\\tdose-\\tdependent\\tdegree\\tof\\tsedation is observed.) \u2022\\t\\tPreanesthetic:\\t100\\tmcg/kg\\tIV. Regulatory Information Do not administer in animals intended for food. Ronidazole roe- nid\u2032ah- zole Trade and other names: Generic","contraindications":"Contraindications and Precautions Romifidine, like other alpha 2 agonists, should be used cautiously in animals with heart disease. The use may be contraindicated in older animals with preexisting cardiac disease. Xylazine causes problems in pregnant animals, and this also should be considered for other alpha 2 agonists. Use cautiously in animals that are pregnant; it may induce labor. In addition, it may decrease oxygen delivery to fetuses in late gestation. In case of overdose, reverse with atipamezole or yohimbine. Drug Interactions Do not use with other drugs that may cause cardiac depression. It may be used in horses with other sedatives and anesthetics such as benzodiazepines or ketamine. Do not mix in vial or syringe with other anesthetics. Use with opioid analgesic drugs greatly enhances CNS depression. Consider lowering doses if administered with opioids. Romifidine can interfere with conversion of thyroid hormone (T 4 ) to the active form of triiodothyronine (T 3 ).","indications":"Indications and Clinical Uses Romifidine, like other alpha 2 agonists, is used as a sedative and anesthetic adjunct and for analgesia. It produces the longest duration of sedative effects compared with other agents followed by detomidine, medetomidine, and xylazine. A dose of 80 mcg/kg of\\tromifidine\\tIV\\tis\\tequipotent\\tto\\t1\\tmg/kg\\tof\\txylazine\\tIV\\tand\\t20\\tmcg/kg\\tdetomidine IV. Its use is primarily limited to horses in which it is used as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures and for use as a preanesthetic prior to the induction of general anesthesia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Romifidine, like other alpha 2 agonists, decreases sympathetic output. Bradycardia is common, and cardiovascular depression may occur. Cardiac effects can include sinoatrial block, first- degree and second- degree AV block, bradycardia, and sinus arrhythmia. In horses, it causes effects similar to other alpha 2 agonists, including ataxia, head drooping, sweating, and bradycardia. Facial edema is common, especially with higher doses. Even at high doses in experimental horses (up to 600 mcg/kg), there were no deaths.","notes":"Instructions for Use Romifidine, like other alpha 2 agonists, can be administered with ketamine or benzodiazepines. It can be reversed with alpha 2 antagonists such as atipamezole or yohimbine. The doses administered to horses has ranged from 40 to 120 mcg/kg IV. The most common dose is 80 mcg/kg. These doses produce sedation, cardiac effects, and analgesia that are dose- dependent effects. At a dose of 80 mcg/kg, strong 824    Ronidazole sedation is produced in horses that lasts for approximately 45\u201360 minutes. Deeper sedation occurs with higher doses. Each dose produced effects for at least 60 minutes, and some are observed for 180 minutes. A duration of 180 minutes is more likely with higher doses. Patient Monitoring and Laboratory Tests Monitor vital signs during anesthesia. Monitor heart rate, blood pressure, and ECG if possible during anesthesia. Formulations \u2022\\t\\tRomifidine\\tis\\tavailable\\tin\\ta\\t1%\\tinjection\\t(10\\tmg/mL). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Analgesic, alpha"},{"name":"Sufentanil Citrate","active_ingredient":"Sufentanil Citrate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t2\\tmcg/kg\\tIV\\t(0.002\\tmg/kg)\\tup\\tto\\ta\\tmaximum\\tdose\\tof\\t5\\tmcg/kg\\t(0.005\\tmg/kg).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Schedule II controlled drug. Avoid use in animals intended for food. Withdrawal times are not established. However,\\tfor\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat www.FARAD.org. RCI Classification: 1 Sulfachlorpyridazine sul- fah- klor- peer- id\u2032ah- zeen Trade and other names: Vetisulid. (Name previously used was Sulphachlorpyridazine.)","contraindications":"Contraindications and Precautions Use cautiously in animals with respiratory disease. Because of its high potency compared with morphine and other opiates, calculate dose carefully. Drug Interactions Like other opiates, sufentanil may potentiate other sedatives and anesthetics. 858    Sulfachlorpyridazine","indications":"Indications and Clinical Uses Sufentanil, like other opiate derivatives, is used for sedation, general anesthesia, and analgesia. It can be used as part of a regimen for balanced general anesthesia. It can be used with other agents or as a primary agent in patients intubated and delivered oxygen. Sufentanil has a rapid onset of effect and rapid recovery. It does not accumulate in tissues; therefore recovery is rapid after an anesthetic procedure. It can also be administered by the epidural route. Compared with other opioids, such as fentanyl, the use of sufentanil has been uncommon in animals. The use is derived from limited clinical observations and extrapolation of the uses from human medicine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are similar to those of morphine. Like all opiates, side effects are predictable and unavoidable. Side effects include sedation, constipation, and bradycardia. Respiratory depression occurs with high doses.","notes":"Instructions for Use When used for anesthesia, animals are often premedicated with acepromazine or a benzodiazepine. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s heart rate and respiration. Although bradycardia rarely needs to be treated when it is caused by an opioid, atropine can be administered if necessary. If serious respiratory depression occurs, the opioid can be reversed with naloxone. Formulations \u2022\\t\\tSufentanil\\tis\\tavailable\\tin\\ta\\t50-\\tmcg/mL\\tinjection\\tin\\tampules\\tof\\t1,\\t2,\\tand\\t5\\tmL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Sufentanil is a Schedule II drug and should be stored in a locked compartment.","original_category":"Analgesic, opioid"},{"name":"Tramadol Hydrochloride","active_ingredient":"Tramadol Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tq6\u20138h\\tPO.\\tIf\\tan\\tinjectable\\tform\\tis\\tavailable\\tat\\t4\\tmg/kg\\tIV\\tq6\u20138h. Drug Interactions Drug interactions are possible because of the complex metabolism of tramadol in animals. Fluconazole has been shown to inhibit the metabolism of tramadol to the inactive metabolites and increase the concentration of the active metabolite (M1) in dogs. This may occur with other drugs that have a capability to inhibit cytochrome P450 enzymes (see Appendix I). Administration of cimetidine or ketoconazole to dogs increased the oral bioavailability but did not increase the concentrations of the active metabolite, M1. Other drug interactions have not been reported in animals, but because of multiple effects from tramadol (serotonin reuptake inhibition, adrenergic effects, and opiate effects), interactions are possible with other drugs that act via similar mechanisms. Serotonin syndrome is theoretically possible when used with other serotonin reuptake inhibitors (SSRIs), but such interactions have not been reported in animals. It has been used safely with NSAIDs. It has been administered with inhalant anesthetics without any signs of adverse drug interaction. T Trandolapril 925 Cats \u2022\\t\\tStart\\tat\\t2\\tmg/kg\\tand\\tincrease\\tup\\tto\\t4\\tmg/kg\\tq8\u201312h\\tPO.\\tWhen\\tinjectable\\tforms have been available, it also has been injected at a dosage of 2 mg/kg IV and 2\u20134 mg/kg SQ q8h.  Horses \u2022\\t\\t2\\tmg/kg\\tIV\\t(slowly)\\tand\\t4\u20135\\tmg/kg\\tPO.\\tIn\\thorses,\\tthe\\toptimum\\tdosing\\tinterval is\\tnot\\tknown,\\tbut\\tbecause\\tof\\tthe\\tshort\\thalf-\\tlife,\\tevery\\t6\\thours\\tmay\\tbe\\tappropriate and extended to q12h in patients that respond favorably. Do not exceed 2 mg/kg IV or 5 mg/kg PO in horses. Regulatory Information Tramadol was moved to Drug Enforcement Administration\u2013controlled drug status in 2015. It is now a Schedule IV controlled drug. It is not recommended for food animals, but the half- life in most animals is short, and extended withdrawal times may not be necessary in food- producing animals. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 2 Trandolapril tran- doe\u2032lah- pril Trade and other names: Mavik","contraindications":"Contraindications and Precautions Use cautiously with other drugs that have CNS- depressing effects, such as opiates, alpha 2 agonists, or serotonin uptake inhibitors (e.g., antidepressants and behavior- modifying drugs). Tramadol may potentiate their actions. Use cautiously in animals with seizure disorders because high doses can lower the threshold for a seizure. Metabolites may be eliminated via the urine. Use with caution in animals with kidney disease.","indications":"Indications and Clinical Uses Tramadol has been used as an analgesic in people, dogs, cats, horses, and minor species (e.g., rabbits, goats, birds). It is an alternative analgesic to pure opiate analgesics and NSAIDs in patients that require treatment for mild to moderate pain. In people, it is regarded as a mild analgesic, but the pharmacokinetics of tramadol are different in people compared with animals, and clinical effects in humans cannot necessarily be extrapolated to animals. In animal studies, both clinical and experimental, the results have been variable and inconsistent to demonstrate its effectiveness as an analgesic. The studies have varied in the dose, route, and pain stimulus evaluated. There has been some evidence of analgesia after administration for treating pain associated with elective surgery, but there is a lack of evidence for T an antinociceptive effect when experimental models of pain have been used. When oral administration was tested for treating osteoarthritis in dogs, efficacy has been poor or produced only mild benefit. When tested in dogs for treating pain from orthopedic surgery, the results have been inconsistent with some studies showing little benefit and other studies showing a mild benefit. The clearance is increased with repeated administration in dogs, which makes chronic treatment less effective than short- term treatment. Some studies that have demonstrated efficacy have used injectable formulations (at 2\u20134 mg/kg) rather than oral forms, but injectable","side_effects":"Adverse Reactions and Side Effects In cats, some vomiting, behavior changes, excitement, and mydriasis may be observed, which are dose related. Both euphoria and dysphoria have been observed in cats. In horses, there may be short- term (approximately 20\u201340 minutes) agitation, head nodding, decreased gut sounds, trembling, muscle fasciculation, tachycardia, sweating, and ataxia. The effects in horses are most prominent after a rapid IV injection and minimized if the injection is administered slowly over 10 minutes. In dogs, adverse effects have been rare. Some sedation has been observed, which is dose related. There have been minimal cardiovascular or GI problems in dogs. At very high doses in dogs, seizures may occur. If adverse effects occur, they are only partially antagonized by naloxone.","notes":"formulations are not available in North America. It may be more effective when used with an NSAID or other analgesics such as ketamine or alpha 2 agonists. Tramadol has also been administered by the epidural route (diluted in saline) in horses, dogs, and cats (1\u20132 mg/kg). Although some analgesic was documented in these studies, the effects and pharmacokinetics were similar to other parenteral routes of administration, and it is assumed that tramadol is rapidly distributed systemically after epidural administration. Cats produce more of the active opiate metabolite (O- desmethyl tramadol) than other animal species. Tramadol administration may produce opiate effects in cats, and limited clinical trials suggest some efficacy. It has improved outcomes in cats with osteoarthritis at 2 mg/kg twice daily for 5 days, but higher doses were less effective. Adverse\\teffects\\toccurred\\tin\\t70%\\tof\\ttreated\\tcats\\tand\\tincluded\\teuphoria,\\tdysphoria, sedation, decreased appetite, and diarrhea. In horses, the efficacy of tramadol has been variable and evaluated only in small observational studies. It may produce transient analgesia, but there has been significant variation among horses. Tramadol is not a routinely used analgesic in horses. It was not effective in antinociceptive studies. However, some clinical use has been documented. When tested for treatment of laminitis in horses, it had only limited efficacy when used alone at a dosage of 5 mg/kg q12h PO but had greater efficacy\\twhen\\tcombined\\twith\\ta\\tketamine\\tinfusion\\t(ketamine\\tdosage,\\t0.6\\tmg/kg/h infusion). Precautionary Information Instructions for Use Dosing information is based on experimental studies in dogs, cats, and horses and some clinical studies. In most animals the oral immediate- release tablets are administered either whole or crushed and mixed with a vehicle. In some countries an injectable formulation is available that has been injected IV, IM, SQ, and epidurally. Tramadol ER tablets have been used in people, but in dogs, these tablets show delayed absorption and plasma levels five times less than people at equivalent (mg/kg) doses. Therefore, ER tablets for people may be inequitable in dogs and cats. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Tramadol is not routinely measured, but effective concentrations have been reported to be in ranges of 200\u2013400 ng/mL for tramadol and 20\u201340 ng/mL for the active metabolite (M1). Formulations \u2022\\t\\tTramadol\\timmediate-\\trelease\\ttablets\\tare\\tavailable\\tin\\t50-\\tmg\\ttablets. \u2022\\t\\tTramadol\\tER\\tis\\tavailable\\tin\\t100-\\t,\\t200-\\t   ,\\tor\\t300-\\tmg\\ttablets. \u2022\\t\\tInjection\\t(not\\tavailable\\tin\\tthe\\tUnited\\tStates):\\tIn\\tEurope\\tand\\tother\\tcountries,\\tan injectable formulation is available as a 50- mg/mL injection that can be diluted further\\tin\\t0.9%\\tsaline\\tsolution\\tfor\\tIV\\tadministration. \u2022\\t\\tCompounded\\tformulations\\tof\\ttramadol\\thave\\tbeen\\tprepared\\tin\\tsterile\\twater\\tat\\ta concentration of 10 mg/mL. This solution is stable up to 1 year if stored in the refrigerator protected from light. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Tramadol is water soluble. When mixed with aqueous vehicles, it has maintained potency and is stable for weeks. However, stability of compounded formulations that may contain flavorings and other excipients has not been evaluated.","original_category":"Analgesic"}]},{"category":"Anti-inflammatories","drugs":[{"name":"Betamethasone","active_ingredient":"Betamethasone","species":["Canine","Feline"],"dosage":"Dogs and Cats (Oral\\tformulations\\tmay\\tnot\\tbe\\tavailable.) \u2022\\t\\tAnti-\\t  inflammatory\\teffects:\\t0.1\u20130.2\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t\\tImmunosuppressive\\teffects:\\t0.2\u20130.5\\tmg/kg\\tq12\u201324h\\tPO.  \u2022\\t\\t0.05\u20130.1\\tmg/kg\\tq24h\\tIM\\tor\\tPO. \u2022\\t\\tIntra-\\t   articular\\tinjection.\\tThe\\tequine\\tintra-\\tarticular\\tproduct\\tcan\\tbe\\tinjected\\tat\\ta dose\\tof\\t1.5\\tmL\\tper\\tjoint\\t(9\\tmg). Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). RCI\\tClassification:\\t4 Bethanechol Chloride beh- than\u2032eh- kole  klor\u2032ide Trade and other names: Urecholine","contraindications":"Contraindications and Precautions Use cautiously in patients prone to ulcers or infection or in animals in which wound healing is necessary. Use cautiously in diabetic animals, animals with renal failure,\\tand\\tpregnant\\tanimals.\\tDo\\tnot\\tinject\\tequine\\tproduct\\tintra-\\tarticular\\tif\\tthere are signs of infection in the joint. Drug Interactions No drug interactions are reported in animals. However, co- administration with other drugs may increase risk of adverse effects. For example, administration with NSAIDs may increase the risk of GI problems. 82    Bethanechol Chloride","indications":"Indications and Clinical Uses Betamethasone is used for treatment of inflammatory and immune- mediated disease. It\\tis\\tused\\tfor\\tsimilar\\tindications\\tas\\tprednisolone\\tand\\tdexamethasone.\\tThe\\tequine formulation (BetaVet) is a combination of a slow- release component (betamethasone acetate) and a rapid- acting form (betamethasone sodium phosphate) in a combination for injection intra- articularly for control of pain and inflammation associated with osteoarthritis in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There are many side effects from corticosteroids, which include polyphagia, polydipsia/polyuria, and hypothalamic\u2013pituitary\u2013adrenal axis suppression. Adverse effects include gastrointestinal (GI) ulceration, hepatopathy, increased risk of diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal\\tinfections,\\tand\\turinary\\ttract\\tinfections.\\tIn\\thorses,\\tsome\\tequine\\tclinicians have suggested that the use may increase risk of laminitis, but this has not been supported with clinical research.","notes":"Instructions for Use Betamethasone is used for similar indications as dexamethasone because of similar potency and duration of effect. Topical forms of betamethasone also are available. Patient Monitoring and Laboratory Tests Monitor complete blood count (CBC) and plasma cortisol. Formulations \u2022\\t\\tBetamethasone\\tis\\tavailable\\tin\\t600-\\tmcg\\t(0.6-\\tmg)\\ttablets\\tand\\t3-\\tmg/mL\\tsodium phosphate injection. (Tablets have been discontinued from some manufacturers and are difficult to obtain.) \u2022\\t\\tEquine\\tformulation\\t(BetaVet)\\tcontains\\tbetamethasone\\tsodium\\tphosphate\\t(rapid acting) and betamethasone acetate (slow release) in a suspension for intra- articular use\\tat\\ta\\tconcentration\\tof\\t6\\tmg/mL\\t(3.15\\tmg\\tin\\tbetamethasone\\tsodium\\tphosphate and 2.85 mg in betamethasone acetate). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. After opening the equine\\tproduct\\t(BetaVet),\\tuse\\tonce\\tand\\tdiscard\\tvial\\tafter\\tuse.","original_category":"Corticosteroid"},{"name":"Budesonide","active_ingredient":"Budesonide","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.12\u20130.15\\tmg/kg\\tq8\u201312h\\tPO.\\tDose\\tinterval\\tmay\\tbe\\tincreased\\tto\\tq24h\\twhen condition improves. \u2022\\t\\tIn\\tdogs,\\tintact\\t3-\\tmg\\tcapsules,\\tonce\\tper\\tday,\\thave\\tbeen\\tadministered,\\tbut\\tin\\tcats, doses of 0.5\u20130.75 mg per cat per day are administered by reformulating capsules. \u2022\\t\\tFull\\trange\\tof\\tdoses\\tfor\\tdogs:\\t3\u20137\\tkg,\\t1\\tmg\\tq24h;\\t7\u201315\\tkg,\\t2\\tmg\\tq24h;\\t15\u201330\\tkg, 3\\tmg\\tq24h;\\tgreater\\tthan\\t30\\tkg,\\t5\\tmg\\tq24h.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. Because of minimal systemic absorption expected, no withdrawal time is suggested. RCI\\tClassification:\\t4 Bunamidine Hydrochloride byoo- nam\u2032ih- deen  hye- droe- klor\u2032ide Trade and other names: Scolaban","contraindications":"Contraindications and Precautions No known contraindications. However, some of the drug may be absorbed systemically; therefore, use with caution in animals that should not receive corticosteroids. Drug Interactions Do not administer with drugs that increase stomach pH (antacids, antisecretory drugs).\\tBecause\\tbudesonide\\tis\\tmetabolized\\tby\\tcytochrome\\tP450\\tenzymes,\\tother drugs that inhibit these enzymes (see Appendix I) may inhibit metabolism.","indications":"Indications and Clinical Uses In animals, it has been used to treat inflammatory bowel disease. The most common use has been for treating colitis in dogs or inflammatory bowel disease in cats. It has been safe and effective for treating inflammatory bowel disease in dogs, but it may produce\\tsome\\tside\\teffects\\tthat\\tare\\tsimilar\\tto\\tprednisone.\\tOther\\treports\\tof\\tsuccessful treatment are mostly anecdotal. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There is some systemic absorption, as evidenced by decreased response to ACTH and decreased cortisol after 30- day treatment to dogs at 3 mg/m 2 . The incidence of adverse effects was similar to prednisone in dogs, but other side effects were not observed, and other variables were not affected. Some mild elevation of liver enzymes may occur in dogs.","notes":"Instructions for Use Use in animals has been limited to anecdotal experience and small clinical studies. The capsules should not be crushed or compounded for animals unless action in the proximal portion of the intestine is desired. Patient Monitoring and Laboratory Tests Monitor corticosteroid effects and, preferably, conduct an ACTH- stimulation test to determine degree of adrenal suppression with chronic use. Some elevations in liver enzymes may occur in dogs. Formulations \u2022\\t\\tBudesonide\\tis\\tavailable\\tin\\t3-\\tmg\\tcapsule\\tin\\tthe\\tconventional\\tform.\\tThe\\tnew extended-\\trelease\\tformulation\\t(Uceris)\\tis\\ta\\t6-\\t\\tand\\t9-\\tmg\\ttablet\\tand\\tdesigned\\tto release at a pH greater than 7. 96    Bunamidine Hydrochloride Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not crush capsules.","original_category":"Anti- inflammatory,  corticosteroid"},{"name":"Desoxycorticosterone Pivalate","active_ingredient":"Desoxycorticosterone Pivalate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.2\\tmg/kg\\tq25\\tdays\\tSQ\\tor\\tIM.\\tAdjust\\tdose\\tby\\tmonitoring\\telectrolytes.\\tThe\\tmost consistent\\tdosage\\tfor\\tDOCP\\thas\\tbeen\\t2.2\\tmg/kg\\tSQ\\tonce\\tper\\t25\\tdays,\\tbut\\tmany dogs\\tcan\\tbe\\tmanaged\\twith\\ta\\tstarting\\tdose\\tof\\t1.5\\tmg/kg\\twith\\ta\\ttarget\\tinterval ranging\\tfrom\\t28\\tto\\t30\\tdays. Cats \u2022\\t\\t2.2\\tmg/kg\\tSQ\\tevery\\t25\\tdays\\t(adjust\\tdose\\tby\\tmonitoring).  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\tbecause\\tof\\tlow\\trisk\\tof\\tresidues,\\tno withdrawal times are suggested. RCI\\tClassification:\\t4 Detomidine Hydrochloride deh- toe \u0301mih- deen  hye- droe- klor \u0301ide Trade and other names: Dormosedan and Dormosedan Gel","contraindications":"Contraindications and Precautions Do not use in pregnant animals. It must be used cautiously in patients with congestive heart failure or renal disease. Dogs with congestive heart failure may have exacerbation\\tof\\tclinical\\tsigns\\tfrom\\ttreatment\\twith\\tDOCP.\\tIn\\tthese\\tcases,\\treduce\\tdose (by half, for example). If the dose is too high, the patient can become hypokalemic (clinical signs include weakness and lethargy). Severe hypernatremia is rare. Drug Interactions Aldosterone antagonists (spironolactone) will blunt the effect.","indications":"Indications and Clinical Uses Desoxycorticosterone is used as replacement therapy for animals with mineralocorticoid deficiency. It is used for adrenocortical insufficiency (hypoadrenocorticism,\\talso\\treferred\\tto\\tas\\tAddison\u2019s\\tdisease).\\tSome\\tdogs\\talso\\tmay require\\tconcurrent\\tglucocorticosteroid\\ttherapy\\twhen\\tit\\tis\\tused\\tto\\ttreat\\tinsufficiency. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Excessive mineralocorticoid effects are possible with high doses of desoxycorticosterone, but hypernatremia is rare. Patients receiving a dose that is too high may have hypokalemia, which may manifest as weakness, lethargy, and potential cardiac problems. Signs of iatrogenic hyperadrenocorticism are not expected with this drug.","notes":"Instructions for Use Initial dose of desoxycorticosterone is based on average response in clinical patients, but individual doses may be based on monitoring electrolytes in patients. The actual interval between\\tdoses\\tmay\\trange\\tfrom\\t14\\tto\\t40\\tdays,\\tand\\tthe\\toptimum\\tdose\\tmay\\trange\\tfrom 1\\tto\\t2.2\\tmg/kg.\\tIn\\teach\\tpatient,\\tthe\\toptimum\\tdose\\tshould\\tbe\\tone\\tthat\\tmaintains\\tthe electrolyte concentrations in the desired range throughout the dose interval. In patients with severe hypovolemia and other signs attributed to acute Addisonian crisis, treat with aggressive sodium- containing fluids before administering this product. Some dogs may also need a glucocorticoid (because desoxycorticosterone had no glucocorticoid effects). In these cases, prednisone supplementation at physiologic\\tdoses\\tis\\tappropriate\\t(e.g.,\\t0.2\\tmg/kg\\tprednisone\\tper\\tday). When\\tadministering\\tthe\\tsuspension\\tformulation,\\tshake\\tbefore\\tinjection. Desoxycorticosterone has only mineralocorticoid activity. If glucocorticoid activity is needed,\\tadminister\\tprednisone\\tat\\ta\\tdosage\\tof\\t0.2\\tmg/kg\\tper\\tday. 244    Detomidine Hydrochloride Patient Monitoring and Laboratory Tests If\\tinitiating\\ta\\tnew\\ttreatment,\\tbegin\\tmonitoring\\tafter\\t14\\tdays.\\tAt\\t14\\tdays,\\tmeasure\\tthe sodium\\tand\\tpotassium\\tconcentration\\tand\\tadjust\\tthe\\tdose\\tto\\tmaintain\\tthese\\telectrolytes in the normal reference range. Thereafter, monitor serum sodium and potassium as frequently\\tas\\tnecessary\\tto\\tadjust\\tthe\\tdose\\tand\\tdose\\tinterval\\tfor\\teach\\tpatient. Formulations \u2022\\t \\tDesoxycorticosterone\\tpivalate\\tis\\tavailable\\tin\\t25-\\tmg/mL\\tsuspension\\tfor\\tinjection.\\tIt is\\tavailable\\tin\\ta\\tclear\\tvial\\tcontaining\\t4\\tmL.\\tThere\\tare\\ttwo\\tformulations,\\tPercorten-\\tV, and Zycortal, that differ slightly in the amounts of excipients and preservatives. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Do not freeze.","original_category":"Corticosteroid"},{"name":"Dexamethasone","active_ingredient":"Dexamethasone","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tAnti-\\t  inflammatory:\\t0.07\u20130.15\\tmg/kg\\tq12\u201324h\\tIV,\\tIM,\\tor\\tPO. \u2022\\t\\tOral\\tdosage\\t(cats):\\t0.1\u20130.2\\tmg/kg\\tq24h\\tPO,\\tadded\\tto\\tfood.\\tAfter\\tthe\\tinitial\\tdose, lower\\tto\\ta\\tmaintenance\\tdosage\\tof\\t0.05\\tmg/kg\\tq48\u201372h\\tPO. \u2022\\t\\tImmunosuppressive:\\t0.125\u20130.25\\tmg/kg\\tq24h\\tIV,\\tIM,\\tor\\tPO\\tfor\\tinitial\\ttreatment. \u2022\\t\\tPulse\\tdose:\\t0.5\\tmg/kg\\tPO\\tfor\\t4\\tconsecutive\\tdays;\\tthen\\trepeated\\tevery\\t28\\tdays. \u2022\\t\\tLow-\\t  dose\\tdexamethasone\\tsuppression\\ttest:\\t0.01\\tmg/kg\\tIV\\t(dog)\\tand\\t0.1\\tmg/kg IV (cat). \u2022\\t\\tHigh-\\t   dose\\tdexamethasone\\tsuppression\\ttest:\\t0.1\\tmg/kg\\tIV\\t(dog)\\tand\\t1.0\\tmg/kg IV (cat). \u2022\\t\\tDexamethasone-\\t21-\\t isonicotinate:\\t0.03\u20130.05\\tmg/kg\\tIM.  Cattle and Horses \u2022\\t\\t0.04\u20130.15\\tmg/kg\\tper\\tday\\tIV\\tor\\tIM.\\tSome\\tproduct\\tlabeling\\tlists\\ta\\ttotal\\tdose\\tof 5\u201320\\tmg/animal,\\twhich\\tcorresponds\\tto\\t0.01-\\t0.04\\tmg/kg/day.\\tHowever,\\tfor\\tsome conditions, higher doses may be needed. \u2022\\t\\tHorses,\\ttreatment\\tof\\tequine\\tasthma\\tsyndrome\\t(airway\\tdisease\\tcaused\\tby\\tRAO): 0.05\u20130.1\\tmg/kg\\tIV\\tor\\tIM\\tq24h\\tor\\t0.165\\tmg/kg\\tPO\\tq24h,\\tusually\\tfor\\t2\u20133\\tdays, but\\toral\\ttreatment\\thas\\tbeen\\tcontinued\\tfor\\t7\\tdays;\\tthen\\ttapered\\tto\\thalf\\tthe\\tdose\\tfor another\\t7\\tdays. \u2022\\t\\tInduction\\tof\\tparturition\\t(cattle):\\t0.05\\tmg/kg\\t(25\\tmg/animal)\\tas\\ta\\tsingle\\tdose during\\tthe\\tlast\\tweek\\tor\\t2\\tweeks\\tof\\tpregnancy.\\tA\\tdose\\tof\\tprostaglandin\\t(PG)\\tF 2 alpha\\tmay\\tbe\\tadministered\\tconcurrently\\t(0.5\\tmg/animal). \u2022\\t\\tDexamethasone-\\t21-\\t isonicotinate:\\t0.01\u20130.04\\tmg/kg\\tIM. Sheep \u2022\\t\\tInduction\\tof\\tparturition:\\t0.15\\tmg/kg/day\\tIM\\tfor\\t1\u20135\\tdays\\tduring\\tthe\\tlast\\tweek\\tof gestation. Regulatory Information Dexamethasone is approved for use in cattle, but withdrawal times are not established. Although\\twithdrawal\\ttimes\\tare\\tnot\\tlisted\\ton\\tthe\\tlabel,\\tat\\tleast\\t96\\thours\\tshould\\tbe used\\tfor\\tmilk\\tand\\t4\u20138\\tdays\\tfor\\tmeat.\\tAllow\\tat\\tleast\\t3\\tweeks\\tto\\teliminate\\tresidues\\tfrom the\\tkidneys\\tand\\tliver\\tand\\t6\\tweeks\\tto\\tdeplete\\tthe\\tdrug\\tfrom\\tthe\\tIM\\tinjection\\tsite.\\tFor other extralabel uses, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Trade and other names: Sodium phosphate: DexaJect SP, Dexavet, and Dexasone; Decadron and generic brand tablets","contraindications":"Contraindications and Precautions Use cautiously in patients prone to ulcers or infection or in animals in which wound healing is necessary. Use cautiously in animals with diabetes or renal failure\\tand\\tin\\tpregnant\\tanimals.\\tIV\\tinjections\\tshould\\tbe\\tdone\\tslowly\\tbecause","indications":"Indications and Clinical Uses Dexamethasone is used for treatment of inflammatory and immune- mediated disease. The use of dexamethasone at high doses for treatment of shock is controversial. Most recent evidence does not support administration of dexamethasone for this use unless there is adrenal deficiency. Dexamethasone is\\toften\\tused\\tshort\\tterm\\tin\\tsmall\\tanimals\\tas\\tan\\tinjection\\t(sodium-\\tphosphate form) when oral treatment with prednisone is not possible. Dexamethasone is\\talso\\tused\\tas\\ta\\tdiagnostic\\ttest\\tof\\tadrenal\\tfunction.\\tLarge\\tanimal\\tuses\\tinclude induction of parturition (cattle) and treatment of inflammatory conditions. In cattle, corticosteroids also have been used in the treatment of ketosis. In horses,\\tdexamethasone\\thas\\tbeen\\tused\\tto\\ttreat\\tequine\\tasthma\\tsyndrome,\\twith bronchoconstriction\\tcaused\\tby\\trecurrent\\tairway\\tobstruction\\t(RAO). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and\\tpolyuria,\\tand\\thypothalamic\u2013pituitary\u2013adrenal\\t(HPA)\\taxis\\tsuppression. Adverse\\teffects\\tinclude\\tGI\\tulceration,\\thepatopathy,\\tincreased\\trisk\\tof\\tdiabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include infections from Demodex spp., toxoplasmosis,\\tfungal\\tinfections,\\tand\\turinary\\ttract\\tinfections\\t(UTIs).\\tHigh- dose glucocorticoids in animals with neurologic disease can lead to excitotoxic cell\\tdeath\\tand\\toxidative\\tinjury\\tvia\\tincreased\\texcitatory\\tamino\\tacids.\\tIn\\thorses, dexamethasone adverse effects have included risk of laminitis, although this effect is controversial and not supported by strong evidence.","notes":"formulations contain polyethylene glycol, which can cause reactions from rapid\\tIV\\tinjection\\t(hemolysis,\\thypotension,\\tand\\tcollapse).\\tDo\\tnot\\tadminister dexamethasone-\\t21-\\t isonicotinate\\tIV\\t(IM\\tuse\\tonly). Drug Interactions Administration\\tof\\tcorticosteroids\\twith\\tNSAIDs\\tincreases\\tthe\\trisk\\tof\\tGI\\tinjury. The\\tpH\\tof\\tthe\\tsolution\\tis\\t7\u20138.5.\\tDo\\tnot\\tmix\\twith\\tacidifying\\tsolutions,\\tor\\tit\\tmay not\\tbe\\tcompatible.\\tOtherwise,\\tit\\tis\\tcompatible\\twith\\tmost\\tIV\\tfluid\\tsolutions. Instructions for Use For IV administration, the dexamethasone sodium phosphate solution is preferred (Dex- S-   P) because of better water solubility for IV use. (See Dexamethasone Sodium Phosphate.) Dosing schedules are based on the condition treated. Anti- inflammatory effects\\toccur\\tat\\tdoses\\tof\\t0.1\u20130.2\\tmg/kg,\\tand\\timmunosuppressive\\teffects\\toccur\\tat 0.2\u20130.5\\tmg/kg. Dexamethasone is used to test for hyperadrenocorticism. For the low- dose dexamethasone\\tsuppression\\ttest,\\tadminister\\tto\\tdogs,\\t0.01\\tmg/kg\\t(or\\t0.015\\tmg/kg\\tin some\\treferences)\\tIV,\\tand\\tto\\tcats,\\t0.1\\tmg/kg\\tIV;\\tcollect\\tsamples\\tat\\t0,\\t4,\\tand\\t8\\thours. For\\thigh-\\tdose\\tdexamethasone\\tsuppression\\ttest:\\tadminister\\tto\\tdogs,\\t0.1\\tmg/kg\\t(or 1.0\\tmg/kg\\tin\\tsome\\treferences),\\tand\\tto\\tcats,\\t1.0\\tmg/kg. Patient Monitoring and Laboratory Tests For\\tthe\\tlow-\\t\\tand\\thigh-\\tdose\\tdexamethasone\\tsuppression\\ttests,\\tadminister\\teither\\t0.01 or\\t0.1\\tmg/kg\\tand\\tcollect\\tcortisol\\tsamples\\tat\\t0,\\t4,\\tand\\t8\\thours\\tafter\\tadministration. The normal cortisol concentration after suppression test should be less than 30\u201340 nmol/L\\t(1.1\u20131.3\\tmcg/dL).\\tFor\\tthe\\tdexamethasone\\tsuppression\\ttest\\tfor\\thorses, administer\\t0.04\\tmg/kg\\tIM\\tand\\tcollect\\tpostcortisol\\tsample\\t24\\thours\\tlater.\\tNormal suppression\\tin\\thorses\\tis\\tless\\tthan\\t1\\tmcg/dL. Formulations \u2022\\t\\tDexamethasone\\tis\\tavailable\\tin\\ta\\t2-\\tmg/mL\\tsolution,\\twhich\\tcontains\\t500\\tmg\\tof polyethylene\\tglycol;\\t0.25-\\t,\\t0.5-\\t  ,\\t0.75-\\t   ,\\t1-\\t ,\\t1.5-\\t  ,\\t2-\\t ,\\t4-\\t ,\\tand\\t6-\\t    mg\\ttablets;\\t0.1- and\\t1-\\t   mg/mL\\toral\\tsolution;\\tand\\t10\\tmg\\tper\\t15\\tg\\tpowder.\\tDexamethasone-\\t21- isonicotinate\\tslow-\\trelease\\tsuspension\\tin\\tan\\taqueous\\tvehicle\\tis\\t1\\tmg/mL. D Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Dexamethasone formulated in various oral mixtures to enhance flavoring was stable for\\t26\\tweeks\\tat\\troom\\ttemperature\\tor\\trefrigerated.\\tDexamethasone\\tsodium\\tphosphate is freely soluble in water, but dexamethasone solution (in polyethylene glycol) is practically insoluble in water.","original_category":"Corticosteroid"},{"name":"Dexamethasone Sodium Phosphate","active_ingredient":"Dexamethasone Sodium Phosphate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tAnti-\\t  inflammatory:\\t0.07\u20130.15\\tmg/kg\\tq12\u201324h\\tIV\\tor\\tIM. \u2022\\t \\tShock,\\tspinal\\tinjury\\t(efficacy\\tis\\tquestionable\\tand\\trisks\\tmay\\tbe\\thigh):\\t2.2\u20134.4\\tmg/kg\\tIV. \u2022\\t\\tLow-\\t  dose\\tdexamethasone\\tsuppression\\ttest:\\t0.01\\tmg/kg\\tor\\t0.015\\tmg/kg\\tIV\\t(for dogs)\\tand\\t0.1\\tmg/kg\\tIV\\t(for\\tcats)\\tand\\tcollect\\tsample\\tat\\t0,\\t4,\\tand\\t8\\thours. \u2022\\t\\tHigh-\\t   dose\\tdexamethasone\\tsuppression\\ttest:\\t0.1\\tmg/kg\\tor\\t1.0\\tmg/kg\\tIV\\t(for dogs)\\tand\\t1.0\\tmg/kg\\tIV\\t(for\\tcats).  Cattle And Horses \u2022\\t\\tTreatment\\tof\\tinflammation:\\t0.04\u20130.15\\tmg/kg/day\\tIV\\tor\\tIM. \u2022\\t\\tKetosis\\t(cattle):\\t0.01\u2013\\t0.04\\tmg/kg\\tIV\\tor\\tIM. \u2022\\t\\tInduction\\tof\\tparturition\\t(cattle):\\t0.05\\tmg/kg\\t(25\\tmg\\tper\\tanimal)\\tas\\ta\\tsingle dose\\tduring\\tthe\\tlast\\tweek\\tor\\t2\\tweeks\\tof\\tpregnancy.\\tA\\tdose\\tof\\tPGF 2 alpha may be administered\\tconcurrently\\t(0.5\\tmg/animal). \u2022\\t\\tDexamethasone\\tsuppression\\ttest\\tin\\thorses:\\t40\\tmcg/kg\\tand\\tcollect\\tsamples\\tat\\t17 and\\t19\\thours. Sheep \u2022\\t\\tInduction\\tof\\tparturition:\\t0.15\\tmg/kg/day\\tIM\\tfor\\t1\u20135\\tdays\\tduring\\tthe\\tlast\\tweek\\tof gestation. Regulatory Information Although\\twithdrawal\\ttimes\\tare\\tnot\\testablished,\\tat\\tleast\\t96\\thours\\tis\\trequired\\tfor\\tmilk and\\t4\u20138\\tdays\\tfor\\tmeat.\\tHowever,\\tat\\tleast\\t3\\tweeks\\tare\\trequired\\tto\\teliminate\\tresidues from\\tkidneys\\tand\\tliver\\tand\\t6\\tweeks\\tfor\\tIM\\tinjection\\tsite. Dexmedetomidine Hydrochloride dex- meh- deh- toe \u0301mih- deen  hye- droe- klor \u0301ide Trade and other names: Dexdomitor (injection) and Sileo (transmucosal gel)","contraindications":"Contraindications and Precautions Use cautiously in patients prone to ulcers or infection or in animals in which wound healing is necessary. Use cautiously, or not at all, in animals receiving NSAIDs because\\tthese\\tdrugs\\tadministered\\tconcurrently\\tincrease\\tthe\\trisk\\tof\\tGI\\tulceration. Use cautiously in animals with diabetes or renal failure and in pregnant animals. Drug Interactions Administration\\tof\\tcorticosteroids\\twith\\tNSAIDs\\tincreases\\tthe\\trisk\\tof\\tGI\\tinjury.","indications":"Indications and Clinical Uses Use of dexamethasone is for treatment of inflammatory and immune- mediated disease. The use of dexamethasone at high doses for treatment of shock is controversial. Most recent evidence does not support administration of dexamethasone\\tfor\\t this\\t  use.\\t  Large\\t   animal\\t   uses\\t  include\\tinduction\\tof\\t parturition\\t(cattle) and treatment of inflammatory conditions. In cattle, corticosteroids also have been used in the treatment of ketosis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and polyuria,\\tand\\tHPA\\taxis\\tsuppression.\\tAdverse\\teffects\\tinclude\\tGI\\tulceration,\\thepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include Demodex spp., toxoplasmosis, fungal infections, and UTIs. In horses, additional adverse effects include risk of laminitis.","notes":"Instructions for Use Dosing schedules are based on desired effect. Anti- inflammatory effects are seen at doses\\tof\\t0.1\u20130.2\\tmg/kg,\\tand\\timmunosuppressive\\teffects\\tare\\tseen\\tat\\t0.2\u20130.5\\tmg/ kg. Dexamethasone is used for testing hyperadrenocorticism. For the low- dose dexamethasone\\tsuppression\\ttest\\t(for\\tdogs),\\tuse\\t0.01\\tmg/kg\\t(or\\t0.015\\tmg/kg\\tin some\\treferences)\\tIV\\tand\\t0.1\\tmg/kg\\tIV\\t(for\\tcats).\\tFor\\tthe\\thigh-\\tdose\\tdexamethasone suppression\\ttest\\tin\\tdogs,\\tuse\\t0.1\\tmg/kg\\t(or\\t1.0\\tmg/kg\\tin\\tsome\\treferences),\\tand\\tin cats,\\tuse\\t1.0\\tmg/kg.\\tFor\\tthe\\ttest\\tin\\thorses,\\tadminister\\t40\\tmcg/kg. Patient Monitoring and Laboratory Tests Monitor CBC periodically during treatment to assess effects. For monitoring a low- dose dexamethasone suppression test, collect samples at 4 and 8 hours after D Dexmedetomidine Hydrochloride 251 dexamethasone. A normal suppression test result should be cortisol less than 30\u201340\\tnmol/L\\t(1.1\u20131.4\\tmcg/dL).\\tFor\\tdexamethasone\\tsuppression\\tin\\thorses,\\tcollect samples\\tat\\t 17\\t and\\t  19\\t hours.\\t   Normal\\thorses\\t   should\\t   have\\t  cortisol\\tless\\t  than\\t  1.0\\t  mcg/dL. Formulations \u2022\\t\\tSodium\\tphosphate\\tsolution\\tis\\tavailable\\tas\\t4\\tmg/mL,\\tequivalent\\tto\\t3\\tmg/mL\\tof dexamethasone base. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Dexamethasone\\tsodium\\tphosphate\\tin\\tother\\taqueous\\tsolutions\\thas\\tbeen\\tstable\\tfor\\t28 days. Dexamethasone sodium phosphate is freely soluble in water, but dexamethasone solution (in polyethylene glycol) is practically insoluble in water. If dexamethasone sodium\\tphosphate\\tis\\tmixed\\twith\\t5%\\tdextrose\\tsolution\\tor\\tsaline,\\tit\\tis\\tstable\\tfor\\t24\\thours.","original_category":"Corticosteroid"},{"name":"Fludrocortisone Acetate","active_ingredient":"Fludrocortisone Acetate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t10\\tmcg/kg/day\\tPO\\t(0.01\\tmg/kg).\\tThe\\tdosage\\tcan\\tbe\\tincreased\\tto\\t30\\tmcg/kg/ day (0.03 mg/kg) PO if necessary based on electrolyte monitoring. Cats \u2022\\t\\t0.1\u20130.3\\tmg/cat\\tq24h\\tPO\\t(100\u2013300\\tmcg\\tper\\tcat). \u2022\\t\\tTo\\ttest\\tfor\\tprimary\\taldosteronism,\\tadminister\\t0.05\\tmg/kg\\tq12h\\tfor\\t4\\tdays\\tand measure effect with urine aldosterone- to- creatinine ratio. (The range is greater than 7.5 \xd7 10 - 9 in cats with hyperaldosteronism.)  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Extralabel withdrawal times are not established. However, 24- hour withdrawal times are suggested because this drug has little risk from residues. RCI Classification: 4 Flumazenil floo- may\u2032zeh- nil Trade and other names: Romazicon","contraindications":"Contraindications and Precautions Although used as a mineralocorticoid, it may produce glucocorticoid side effects. Use cautiously in animals that may be at risk for corticosteroid side effects. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Fludrocortisone is used as replacement therapy in animals with adrenocortical insufficiency (Addison disease). It has high mineralocorticoid potency compared with the glucocorticoid potency. Desoxycorticosterone pivalate (DOCP) is used as an alternative in dogs when an intermittent injectable is desired rather than daily oral doses of fludrocortisone. One injection of DOCP can last 25 days or longer, which avoids daily administration of fludrocortisone. In cats, fludrocortisone has been used to treat primary hyperaldosteronism. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to glucocorticoid effects with high doses. Polyuria and polydipsia may occur in some animals. Long- term treatment for hypoadrenocorticism may result in glucocorticoid side effects. Administration of fludrocortisone causes a significant reduction in urine aldosterone.","notes":"Instructions for Use Dose should be adjusted by monitoring patient response (i.e., monitoring electrolyte concentrations). In some patients, it is administered with a glucocorticoid (e.g., prednisolone/prednisone at a dosage of 0.2\u20130.3 mg/kg/day), accompanied with F Flumazenil 377 sodium supplementation. However, because it has retained some glucocorticosteroid activity, some animals may not require additional supplementation with glucocorticoids when receiving fludrocortisone. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s electrolytes (especially sodium and potassium). Dose adjustment should be based on electrolyte monitoring to maintain these within a desired range. Fludrocortisone is used as a diagnostic test for primary hyperaldosteronism in cats. This suppression test can be performed as a confirmatory test in cats with basal urine aldosterone:creatinine ratio greater than 7.5 \xd7 10 - 9 ; suppression less than 50% indicates inappropriate aldosterone secretion. See the dosing section for protocol. Formulations \u2022\\t\\tFludrocortisone\\tis\\tavailable\\tin\\t100-\\tmcg\\t(0.1-\\tmg)\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is insoluble in water. When crushed tablets were prepared in various suspensions, they were stable for 14 days.","original_category":"Corticosteroid"},{"name":"Flumethasone","active_ingredient":"Flumethasone","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tAnti-\\t  inflammatory\\tuses:\\t0.15\u20130.3\\tmg/kg\\tq12\u201324h\\tPO,\\tIV,\\tIM,\\tor\\tSQ.\\tNote\\tthat the manufacturer\u2019s label dosage is 0.06\u20130.25 mg per dog per day, and 0.03\u20130.125 mg per cat per day (\u22480.01\u20130.02 mg/kg), but this may be low based on relative potency.  Horses \u2022\\t\\t1.25\u20132.5\\tmg\\tper\\tanimal\\tas\\ta\\tsingle\\tdose\\tIM\\tor\\tIV\\t(\u22480.003\u20130.006 mg/kg). This is the dose frequently listed on the product label. However, many experts prefer doses of 0.04\u20130.15 mg/kg as a single dose IV or IM. \u2022\\t\\tIntra-\\t   articular\\tuse\\tin\\thorses:\\t6\u201310\\tmg\\tper\\tjoint\\tof\\tthe\\t2-\\tmg/mL\\tsuspension. Cattle \u2022\\t\\t1.25\u20135\\tmg/animal\\tas\\ta\\tsingle\\tdose\\tIV\\tor\\tIM.\\tThis\\tis\\tthe\\tdose\\tfrequently\\tlisted\\ton the product label. However, many experts prefer doses of 0.04\u20130.15 mg/kg as a single dose IV or IM. Regulatory Information There are no US withdrawal times established. Consult FARAD if withdrawal times are needed for food producing animals (www.FARAD.org). In Canada, cattle withdrawal time (meat): 4 days. RCI Classification: 4 Flunixin Meglumine floo- nix\u2032in meg\u2032loo- meen Trade and other names: Banamine, Banamine- S, Resflor (with florfenicol), and Hexasol (with oxytetracycline)","contraindications":"Contraindications and Precautions Use cautiously in patients prone to ulcers or infection and in animals in which wound healing is necessary. Use cautiously in animals with kidney disease or diabetes and in pregnant animals. The manufacturer has warned that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Drug Interactions Administration of corticosteroids with NSAIDs will increase the risk of GI injury.","indications":"Indications and Clinical Uses Flumethasone, like other corticosteroids, is used to treat a variety of inflammatory and immune- mediated diseases. The dosing section contains the range of doses for replacement therapy, anti- inflammatory therapy, and immunosuppressive therapy. Flumethasone is used more often in large animals than small animals. Large- animal uses include treatment of inflammatory conditions, especially musculoskeletal disorders, and is used intra- articularly. In horses, flumethasone has been used for treatment of equine asthma syndrome accompanied by recurrent airway obstruction (RAO; formerly called chronic obstructive pulmonary disease). In cattle, corticosteroids have been used in the treatment of ketosis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and polyuria, and hypothalamic\u2013pituitary\u2013adrenal axis suppression. Adverse effects include GI ulceration, hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, and delayed wound healing and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal infections, and urinary tract infections (UTIs). In horses, additional adverse effects include risk of laminitis.","notes":"Instructions for Use Doses are based on severity of underlying disease. For example, anti- inflammatory conditions require lower doses than immune- mediated conditions. For all conditions, cats often require higher doses than dogs. Note that the approved label dose for cattle and horses is in the range of 1.25\u20135 mg per animal or approximately 0.003\u20130.006 mg/ kg (3\u20136 mcg/kg) for an adult animal. Considering that the potency of flumethasone may be similar to dexamethasone, many experts believe that the dose should be higher, in the range of 0.04\u20130.15 mg/kg to obtain a full therapeutic effect. The manufacturer\u2019s label dose\\tfor\\tdogs\\tand\\tcats\\tis\\tapproximately\\t0.01\u20130.02\\tmg/kg/day,\\tPO,\\tIV,\\tIM,\\tor\\tSQ.\\tBut based on comparative potency, the manufacturer\u2019s dose may be low for some conditions. 380    Flunixin Meglumine Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients for signs of secondary infections. Perform an adrenocorticotropic hormone (ACTH) stimulation test to monitor adrenal function. Formulations Flumethasone is available in a 0.5- mg/mL solution for injection, 0.0625- mg tablets for small animal use, 2 mg/mL flumethasone acetate suspension for small animals, and 2- mg/mL liquid suspension for intra- articular use in horses. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Corticosteroid"},{"name":"Fluticasone Propionate","active_ingredient":"Fluticasone Propionate","species":["Feline","Equine","Canine"],"dosage":"When doses were compared in experimental cats, the low dosage of 44 mcg twice daily was as effective as 110 or 220 mcg twice daily. In horses, the most common use is for equine asthma syndrome characterized by RAO. Precautionary Information  Dogs \u2022\\t\\tStart\\twith\\t220\\tmcg\\tper\\tdose\\tq12h\\tdelivered\\twith\\tan\\tMDI.\\tAs\\tpatient\\tis\\tstabilized, decrease dose gradually to 110 mcg per dose, lower if possible. Cats \u2022\\t\\tStart\\twith\\t44\\tmcg\\tper\\tdose\\t(1\\tpuff\\tfrom\\ta\\t44-\\tmcg\\tinhaler)\\ttwice\\tdaily.\\tIncrease\\tthe dose as needed to 110 mcg and then to 220 mcg.  Horses \u2022\\t\\t1\u20132\\tmg\\tper\\thorse\\t(6\u201312\\tpuffs\\tfrom\\t220-\\tmcg\\tinhaler)\\ttwice\\tdaily\\tfor\\tairway\\tdisease. \u2022\\t\\tFor\\tlong-\\tterm\\tmanagement\\tin\\thorses,\\tstart\\twith\\t2\\tmg\\tper\\thorse\\tq24h;\\tthen gradually taper to 1.5 mg per horse every other day. Regulatory Information There are no US withdrawal times established. RCI classification: not established. Fomepizole foh- meh\u2032pih- zole Trade and other names: 4- Methylpyrazole, Antizol- Vet, and Antizol (human preparation)","contraindications":"Contraindications and Precautions Use cautiously in patients with oral or respiratory tract infections because immunosuppression may occur. Drug Interactions Some systemic effects are possible but minimal. Administration of corticosteroids with NSAIDs will increase the risk of GI injury.","indications":"Indications and Clinical Uses Fluticasone is used as an inhaled (topical) corticosteroid for treatment of airway disease. Most of the use has been established for cats, but it also could be used for dogs, horses, or other animals in which a special adapter can be used to deliver the drug via a metered- dose inhaler (MDI). In dogs and cats, the most common use is for inflammatory airway diseases such as asthma, bronchitis, or bronchospasm. For example, if a cat is given 2 puffs twice a day of a potent inhaled corticosteroid (e.g., budesonide, fluticasone) and allowed 5\u20137 breaths (10 seconds) from a chamber (spacer), it may reduce the need for oral prednisolone in cats with feline asthma.","side_effects":"Adverse Reactions and Side Effects Although fluticasone systemic absorption is low, some systemic exposure will occur in animals. Side effects can occur but are not expected to be as severe as with systemic corticosteroids. Adrenal suppression is expected to occur in treated animals (suppressed ACTH response) but may recover once treatment is discontinued.","notes":"Instructions for Use The use is based on administration of fluticasone for treatment of airway diseases. It is delivered via an MDI. These inhalers can be used in animals if special adaptations, F Fomepizole 391 such as a spacer device, which are available for cats, dogs, and horses, are used. When treating dogs and cats, doses listed in the dosing section can be used initially and are then adjusted depending on response. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients for signs of secondary infections. Perform ACTH stimulation test if it is necessary to monitor adrenal function. Fluticasone, although minimally absorbed systemically, will suppress the ACTH response. Formulations \u2022\\t\\tMDI\\tat\\t44,\\t110,\\tor\\t220\\tmcg\\tper\\tpuff. Stability and Storage Store in original container (MDI). Do not puncture container or attempt to remove drug from pressurized container. Stability of compounded formulations has not been evaluated.","original_category":"Corticosteroid"},{"name":"Grapiprant","active_ingredient":"Grapiprant","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tOsteoarthritis,\\tpain,\\tand\\tinflammation:\\t2\\tmg/kg\\tonce\\tdaily.\\tThere\\tis\\tno\\tlimit\\tto\\tthe duration of treatment. Cats \u2022\\t\\tSafe\\tand\\teffective\\tdoses\\thave\\tnot\\tbeen\\testablished\\tfor\\tcats.  Horses \u2022\\t\\tSafe\\tand\\teffective\\tdoses\\thave\\tnot\\tbeen\\testablished\\tfor\\thorses.\\tThe\\tcanine\\tdose (2 mg/kg) did not achieve effective concentrations in horses. Other Large Animals \u2022\\t\\tThere\\tare\\tno\\treports\\tof\\tuse\\tin\\tfood\\tanimals. Regulatory Information No regulatory information is available. Grapiprant should be avoided in food animals. If administered to a food animal, consult FARAD for withdrawal time information (www.FARAD.org). Griseofulvin grizs- ee- oh- ful\u2032vin Trade and other names: Microsize: Fulvicin U/F, Grisactin, and Grifulvin; ultramicrosize: Fulvicin P/G and Gris- PEG","contraindications":"Contraindications and Precautions Like other NSAIDs, grapiprant should be used cautiously in dogs with a history of GI disease. Drug Interactions There are no known drug interactions from grapiprant.","indications":"Indications and Clinical Uses Grapiprant is approved for dogs to treat pain and inflammation associated with osteoarthritis. It has also been used to treat other painful conditions. Clinical use is based on the approved indication, field studies, and published reports. It was safe and effective compared with placebo treatment when used in dogs to reduce signs associated with osteoarthritis. Grapiprant is the first from this group approved for any animal or human. There is no approval at this time for cats, but new studies are emerging that may help for treatment of cats in the future. The use in horses has been examined only through pharmacokinetic studies. These studies\\tshowed\\tthat\\tat\\ta\\tdose\\tof\\t2\\tmg/kg\\tPO,\\tit\\tdid\\tnot\\tachieve\\tconcentrations considered effective in other animals. There are no studies that have demonstrated efficacy in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects were reported from the field studies used for US Food and Drug Administration approval. Adverse reactions in dogs have been minimal and are typical as for traditional NSAIDs. These may include vomiting, diarrhea, and decreased appetite. These events have been mild and usually transient. In a safety study with research dogs, they tolerated a dose equivalent to 30 mg/kg of the tablet for 9 months with adverse effects attributed to the gastrointestinal (GI) tract as mild and infrequent.","notes":"Instructions for Use Grapiprant can be used in animals with a history of pain and inflammation associated with osteoarthritis. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. As with other NSAIDs, monitor liver enzymes and renal parameters during regular check- ups. Formulations \u2022\\t\\tGrapiprant\\ttablets\\tare\\tavailable\\tin\\t20-\\t,\\t60-\\t  ,\\tand\\t100-\\tmg\\ttablets. Stability and Storage Store in the manufacturer\u2019s packaging. 420    Griseofulvin","original_category":"Analgesic, anti-inflammatory"},{"name":"Hydrocortisone","active_ingredient":"Hydrocortisone","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tReplacement\\ttherapy:\\t1\u20132\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tAnti-\\t  inflammatory:\\t2.5\u20135\\tmg/kg\\tq12h\\tPO. 438    Hydromorphone \u2022\\t\\tHypoadrenocorticism\\t(adrenal\\tcrisis):\\t0.625\\tmg/kg/h,\\tIV\\tCRI. \u2022\\t\\tShock:\\t(not\\ta\\trecommended\\tuse)\\t50\u2013150\\tmg/kg\\tIV\\tfor\\ttwo\\tdoses\\t8\\thours apart. \u2022\\t\\tAnti-\\t  inflammatory:\\t5\\tmg/kg\\tq12h\\tIV.  Horses \u2022\\t\\tHydrocortisone\\tsodium\\tsuccinate:\\t5\\tmg/kg\\tq12h\\tIV. Foals \u2022\\t\\tReplacement\\ttherapy\\tfor\\tcritical\\tillness:\\t1\u20133\\tmg/kg/day\\tIV. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Hydromorphone hye- droe- mor\u2032fone Trade and other names: Dilaudid, Hydrostat, and generic brands","contraindications":"Contraindications and Precautions Use cautiously in patients prone to ulcers or infection or in animals in which wound healing is necessary. Use cautiously in diabetic animals, animals with renal failure, or pregnant animals. Drug Interactions Glucocorticoids are often synergistic with other anti- inflammatory and immunosuppressive drugs. Administration of corticosteroids with nonsteroidal anti- inflammatory drugs increases the risk of GI injury.","indications":"Indications and Clinical Uses Hydrocortisone is used most often for adrenal corticosteroid replacement treatment in patients with adrenal insufficiency. It is less often used for its anti- inflammatory effects and not used as commonly as other corticosteroids such as prednisolone or dexamethasone except when hormone replacement to mimic the effects of cortisol is needed. Hydrocortisone sodium succinate is a rapid- acting injectable product that can be used when a prompt response is needed. H Precautionary Information","side_effects":"Adverse Reactions and Side Effects At the doses used for replacement therapy, serious adverse effects are uncommon. Other side effects from corticosteroids are many and include polyphagia, polydipsia/polyuria,\\tand\\thypothalamic\u2013pituitary\u2013adrenal\\taxis\\tsuppression. Adverse effects include gastrointestinal (GI) ulceration, hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal infections, and urinary tract infections. In horses, additional adverse effects may include risk of laminitis, but this is poorly documented in horses unless they have predisposing factors.","notes":"Instructions for Use Because the most common use is for adrenal replacement therapy in adrenal insufficiency, the doses administered are intended to mimic the natural release of cortisol in the body. Typically for replacement therapy (e.g., in animals with hypoadrenocorticism) dosages start at 1 mg/kg/day. Patient Monitoring and Laboratory Tests Monitor electrolytes (sodium and potassium) in animals being treated for hypoadrenocorticism. Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients for signs of secondary infections. Perform adrenocorticotropic hormone (ACTH) stimulation test to monitor adrenal function. Formulations \u2022\\t\\tHydrocortisone\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\tand\\t20-\\tmg\\ttablets,\\tand\\thydrocortisone sodium succinate is available in various size vials for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Hydrocortisone is slightly soluble in water and is soluble in alcohol. Degradation\\toccurs\\tat\\ta\\thigh\\tpH\\tabove\\t7\u20139.\\tCompounded\\tsuspensions\\thave\\tbeen stable for 30 days. Most compounded topical ointments and lotions are stable for 30 days.","original_category":"Corticosteroid"},{"name":"Isoflupredone Acetate","active_ingredient":"Isoflupredone Acetate","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tNo\\t  doses\\t   are\\t listed\\t   for\\t isoflupredone\\tbecause\\tit\\t is\\t generally\\tnot\\t  administered\\tto\\t small animals. However, based on anti- inflammatory potency, dosages of 0.125\u20130.25 mg/ kg/day IM can be considered.  Cattle \u2022\\t\\t10\u201320\\tmg\\ttotal\\tdose\\tper\\tanimal\\tq12\u201324h\\tIM. \u2022\\t\\tKetosis:\\t10\u201320\\tmg\\tas\\ta\\ttotal\\tsingle\\tdose\\tper\\tanimal\\tq12\u201324h\\tIM. Horses \u2022\\t\\t5\u201320\\tmg\\ttotal\\tdose\\tper\\tanimal\\tq12\u201324h\\tIM. \u2022\\t\\tPulmonary\\tdisease:\\t0.02\u20130.03\\tmg/kg\\tq24h. \u2022\\t\\tIntraarticular:\\t5\u201320\\tmg\\tper\\tjoint. 474    Isoflurane Pigs \u2022\\t\\t0.036\\tmg/kg/day\\tIM. Regulatory Information Cattle and pig withdrawal time (meat): 7 days. No milk withdrawal time is listed for US labeling. In Canada, withdrawal times are listed as 5 days for meat and 72 hours for milk. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Isoflurane eye- soe- floo\u2032rane Trade and other names: Aerrane","contraindications":"Contraindications and Precautions Use with caution in patients prone to infection or GI ulcers. Administration of isoflupredone may induce hepatopathy, diabetes mellitus, or hyperlipidemia. Use cautiously in pregnant animals or in young, rapidly growing animals. Use of corticosteroids may impair healing. Drug Interactions Corticosteroids will increase risk of GI ulceration when administered with NSAIDs.","indications":"Indications and Clinical Uses Isoflupredone acetate is used for treating various musculoskeletal, allergic, and systemic inflammatory diseases. Large animal uses include inflammatory disorders, especially musculoskeletal inflammation, and equine asthma syndrome characterized by recurrent airway obstruction in horses. Isoflupredone acetate, like other corticosteroids, has been used to treat ketosis in cattle. In large animals, it also has been used to treat septic shock. However, efficacy for using corticosteroids to treat septic shock is not supported by good evidence. I Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and polyuria, and hypothalamic\u2013pituitary\u2013adrenal axis suppression. Adverse effects include GI ulceration, hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal infections, and urinary tract infections. In horses, additional adverse effects include risk of laminitis, although a clear association between laminitis and corticosteroids has not been established.","notes":"Instructions for Use When administered to treat primary ketosis in cattle, it is advised to also administer IV glucose. When administered for conditions in cattle horses, follow label instructions for injections. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients\\tfor\\tsigns\\tof\\tsecondary\\tinfections.\\tPerform\\tadrenocorticotropic\\t(ACTH) stimulation test to monitor adrenal function. Formulations \u2022\\t\\tIsoflupredone\\tis\\tavailable\\tin\\ta\\t2-\\tmg\\tinjection\\tin\\t10-\\t\\tand\\t100-\\tmL\\tvials. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Corticosteroid"},{"name":"Methylprednisolone","active_ingredient":"Methylprednisolone","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tMethylprednisolone\\toral\\ttablets:\\t0.25\u20130.5\\tmg/kg\\tq12\u201324h\\tPO,\\twith\\tthe\\tdose dependent\\ton\\tthe\\tseverity\\tof\\tthe\\tdisease.\\tThe\\tlabel\\tdosage\\tis\\t0.22\u20130.44\\tmg/kg q12\u201324h\\tPO.\\tAfter\\tstarting\\tthe\\tinitial\\tdose,\\tslowly\\ttaper\\tthe\\tdose\\tand\\tfrequency to\\tthe\\tlowest\\tdose\\tpossible\\tthat\\twill\\tcontrol\\tthe\\tdisease\\tcondition.\\tLong-term maintenance\\tdoses\\tare\\tin\\tthe\\trange\\tof\\t0.3\u20130.5\\tmg/kg\\tevery\\tother\\tday,\\tPO. \u2022\\t\\tMethylprednisolone\\tacetate:\\t1\\tmg/kg\\t(or\\t20\u201340\\tmg/dog)\\tIM\\tevery\\t1\u20133\\tweeks. \u2022\\t\\tMethylprednisolone\\tsodium\\tsuccinate\\t(for\\temergency\\tuse):\\t30\\tmg/kg\\tIV\\tand repeat\\tat\\t15\\tmg/kg\\tin\\t2\u20136\\thours\\tIV. \u2022\\t\\tReplacement\\ttherapy\\tfor\\tadrenal\\tinsufficiency:\\t0.2\\tmg/kg/day. Cats \u2022\\t\\tMethylprednisolone\\toral\\ttablets:\\t0.25\u20130.5\\tmg/kg\\tq12\u201324h\\tPO,\\twith\\tthe\\tdosage dependent\\ton\\tthe\\tseverity\\tof\\tthe\\tdisease.\\tThe\\tlabel\\tdosage\\tis\\t0.22\u20130.44\\tmg/kg q12\u201324h\\tPO.\\tAfter\\tstarting\\tthe\\tinitial\\tdose,\\tslowly\\ttaper\\tthe\\tdose\\tand\\tfrequency\\tto the lowest dose possible that will control the disease condition. \u2022\\t\\tMethylprednisolone\\tacetate:\\t10\u201320\\tmg/cat\\tIM\\tevery\\t1\u20133\\tweeks. \u2022\\t\\tMethylprednisolone\\tsodium\\tsuccinate\\t(for\\temergency\\tuse):\\t30\\tmg/kg\\tIV\\tand repeat\\tat\\t15\\tmg/kg\\tin\\t2\u20136\\thours\\tIV.  Horses \u2022\\t\\t200\\tmg\\tas\\ta\\tsingle\\ttotal\\tdose\\tinjected\\tintramuscularly. \u2022\\t\\tIntra-\\t   articular\\tdose:\\t40\u2013240\\tmg\\ttotal\\tdose,\\twith\\tthe\\taverage\\tdose\\tof\\t120\\tmg injected in the joint space using sterile technique. M Methyltestosterone 601 Regulatory Information In\\thorses,\\t200\\tmg\\tper\\tjoint\\twas\\tdetected\\tin\\thorses\\tfor\\t18\\tdays;\\t100\\tmg\\tper\\tjoint was\\tdetected\\tfor\\t7\\tdays.\\tFor\\tfood\\tanimals,\\twithdrawal\\ttimes\\tare\\tnot\\testablished.\\tFor extralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Methyltestosterone meth- ill- tess- toss\u2032teh- rone Trade and other names: Android and generic brands","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tpatients\\tprone\\tto\\tGI\\tulcers\\tand\\tinfection\\tor\\tin\\tanimals\\tin\\twhich wound\\thealing\\tis\\tnecessary.\\tUse\\tcautiously\\tin\\tdiabetic\\tanimals,\\tanimals\\twith kidney\\tdisease,\\tand\\tpregnant\\tanimals.\\tUse\\tcautiously\\tin\\tcats\\tbecause\\tof\\tvolume expansion, especially cats at risk of CHF. Drug Interactions Like\\tother\\tcorticosteroids,\\tif\\tmethylprednisolone\\tis\\tadministered\\twith\\tNSAIDs, there\\tis\\tincreased\\trisk\\tof\\tGI\\tulcers.","indications":"Indications and Clinical Uses Methylprednisolone\\tacetate\\tis\\ta\\tlong-\\tacting\\tdepot\\tformulation\\tof\\tmethylprednisolone. It\\tis\\tslowly\\tabsorbed\\tfrom\\tthe\\tIM\\tinjection\\tsite\\tproducing\\tglucocorticoid\\teffects\\tfor\\t3\u20134 weeks\\tin\\tsome\\tanimals.\\tMethylprednisolone\\tacetate\\tis\\tused\\tfor\\tintralesional\\ttherapy,\\tintra- articular administration for joint disease, and for treating other inflammatory conditions. Methylprednisolone\\tsodium\\tsuccinate\\tis\\ta\\twater-\\tsoluble\\tformulation\\tintended\\tfor\\tacute therapy when high IV doses are needed for rapid effect. It has been administered IV for treatment of shock and trauma of the CNS. Methylprednisolone oral tablets are used for\\ttreatment\\tof\\tconditions\\tin\\tanimals\\tthat\\trequire\\tshort-\\tto\\tlong-\\tterm\\ttherapy\\twith\\tan intermediate-\\tacting\\tcorticosteroid.\\tThe\\tindications\\tfor\\tmethylprednisolone\\ttablets\\tare similar to the use of prednisolone or prednisone tablets except that methylprednisolone is slightly\\tmore\\tpotent.\\tConditions\\ttreated\\tinclude\\tdermatitis,\\timmune-\\tmediated\\tdiseases, intestinal diseases, and neurologic and musculoskeletal diseases. Although high doses have been used to treat spinal cord trauma, this use has questionable benefit in animals. In large animals, methylprednisolone acetate is used for treatment of inflammatory conditions of the\\tmusculoskeletal\\tsystem.\\tIntra-\\tarticular\\tadministration\\tis\\tcommon\\tin\\thorses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and\\tpolyuria,\\tand\\thypothalamic\u2013pituitary\u2013adrenal\\taxis\\tsuppression.\\tHowever, the manufacturer suggests that methylprednisolone causes less polyuria and polydipsia\\tthan\\tprednisolone.\\tAdverse\\teffects\\tinclude\\tGI\\tulceration,\\thepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, and immunosuppression. Dogs that receive high doses of methylprednisolone\\tsuccinate\\t(e.g.,\\t30\\tmg/kg)\\thave\\ta\\thigh\\trisk\\tof\\tGI\\tbleeding. Secondary infections can occur as a result of immunosuppression and include demodicosis,\\ttoxoplasmosis,\\tfungal\\tinfections,\\tand\\tUTIs. In cats, injections of methylprednisolone may activate latent feline herpes virus infections in some cats. In cats, there is a concern that corticosteroids such as methylprednisolone can exacerbate congestive heart failure (CHF) through volume expansion\\tand\\tfluid\\tshifts\\tsecondary\\tto\\tsteroid-\\tinduced\\thyperglycemia.\\tThis\\thas occurred in susceptible cats after injections of methylprednisolone acetate. In cats, methylprednisolone\\tacetate\\tinjections\\thave\\tcaused\\tinjection-\\tsite\\talopecia. In horses, additional adverse effects may include risk of laminitis (although a direct link to induction of laminitis is controversial).","notes":"Instructions for Use The\\tlist\\tof\\tdoses\\tbelow\\tare\\tinitial\\tdoses.\\tIf\\tthe\\tpatient\\tresponds\\tand\\tis\\tstabilized,\\tthe dose\\tmay\\tbe\\ttapered\\tto\\tthe\\tlowest\\tdose\\tpossible\\t(as\\tlow\\tas\\t0.25\\tmg/kg/day)\\tand possibly administered every other day. Use\\tof\\tmethylprednisolone\\tis\\tsimilar\\tto\\tother\\tcorticosteroids,\\tsuch\\tas\\tprednisone or prednisolone. Dose adjustment should be made to account for difference in potency if interchanged with prednisone, dexamethasone, or triamcinolone acetonide. Use\\tof\\tmethylprednisolone\\tacetate\\tshould\\tbe\\tevaluated\\tcarefully\\tbecause\\tone\\tinjection will\\tcause\\tglucocorticoid\\teffects\\tthat\\tpersist\\tfor\\tseveral\\tdays\\tto\\tweeks.\\tThere\\tare\\tno published studies that have evaluated the use of methylprednisolone sodium succinate in animals, but the use has been extrapolated from human medicine. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and kidney function during therapy. Monitor patients for signs of secondary infections. Perform an adrenocorticotropic hormone stimulation test to monitor adrenal function. Monitor cats for diabetes and heart disease when treated with methylprednisolone acetate. Formulations \u2022\\t\\tMethylprednisolone\\tis\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\t4-\\t ,\\t8-\\t ,\\t18-\\t  ,\\tand\\t32-\\tmg\\ttablets. \u2022\\t\\tMethylprednisolone\\tacetate\\tis\\tavailable\\tin\\t20-\\t\\tand\\t40-\\tmg/mL\\tsuspension\\tfor injection. \u2022\\t\\tMethylprednisolone\\tsodium\\tsuccinate\\tis\\tavailable\\tin\\t1-\\t\\tand\\t2-\\tg\\tand\\t125-\\t\\tand\\t500- mg vials for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Methylprednisolone is insoluble in water and slightly soluble in ethanol. Methylprednisolone acetate is slightly soluble in water. Methylprednisolone sodium succinate is highly soluble in water. When methylprednisolone sodium succinate is\\treconstituted,\\tit\\tshould\\tbe\\tused\\twithin\\t48\\thours\\tif\\tkept\\tat\\troom\\ttemperature. Decomposition\\toccurs\\twith\\tlonger\\tstorage.\\tIt\\tmay\\tbe\\tfrozen\\tat\\t\u221220\xb0C\\tfor\\t4\\tweeks with no loss of potency.","original_category":"Corticosteroid"},{"name":"Prednisolone, Prednisolone Acetate","active_ingredient":"Prednisolone, Prednisolone Acetate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tAnti-\\t  inflammatory:\\tThe\\tinduction\\tdose\\tis\\t0.5\u20131\\tmg/kg,\\tper\\tday,\\twhich\\tmay\\tbe split into q12h doses, IM, or PO. Then taper the dose to 0.3\u20130.5 mg/kg, q48h, for long-term treatment. \u2022\\t\\tImmunosuppressive:\\t2.2\u20136.6\\tmg/kg/day\\tIV,\\tIM,\\tor\\tPO\\tinitially;\\tthen\\ttaper\\tto\\t2\u20134 mg/kg q48h. Initial dosages rarely need to exceed 4 mg/kg per day. \u2022\\t\\tNeurologic\\tdisease\\t(steroid\\tresponsive):\\tStart\\twith\\t2\\tmg/kg\\tq12h\\tPO\\tfor\\t2\\tdays followed by gradual tapering to 1 mg/kg, then 0.5 mg/kg, and eventually to 0.5 mg/kg every other day. \u2022\\t\\tReplacement\\ttherapy\\tfor\\tadrenal\\tinsufficiency:\\t0.2\u20130.3\\tmg/kg/day\\tPO. \u2022\\t\\tCancer\\ttherapy\\t(e.g.,\\tCHOP\\tprotocol):\\t40\\tmg/m 2 q24h for 7 days; then 20 mg/ m 2 every other day PO. Cats \u2022\\t\\tSame\\tas\\tfor\\tdogs,\\texcept\\tthat\\tfor\\tmany\\tconditions\\tthey\\trequire\\ttwice\\tthe\\tdog\\tdose.  Horses \u2022\\t\\tPrednisolone\\tacetate\\tsuspension:\\t100\u2013200\\tmg\\ttotal\\tdosage\\tIM. \u2022\\t\\tPrednisolone\\ttablets:\\t0.5\u20131\\tmg/kg\\tq12\u201324h\\tPO.\\tTaper\\tto\\tlower\\tdose\\tfor\\tlong- term treatment. Cattle \u2022\\t\\tTreatment\\tof\\tketosis:\\t100\u2013200\\tmg\\ttotal\\tdosage\\tIM. Regulatory Information Cattle\\twithdrawal\\ttimes\\tfor\\tprednisolone\\tacetate:\\t5\\tdays\\tfor\\tmeat;\\t72\\thours\\tfor\\tmilk (in Canada). Withdrawal times are not established for animals that produce food in the United States. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 770    Prednisolone Sodium Succinate Prednisolone Sodium Succinate pred- niss- oh\u2032lone soe\u2032dee- um  suk\u2032sih- nate Trade and other names:  Solu- Delta- Cortef","contraindications":"Contraindications and Precautions Use cautiously in patients with a risk of GI ulcers or infection and in animals in which growing or healing is necessary. Use prednisolone cautiously in patients with kidney disease because it may increase azotemia. Use prednisolone cautiously in pregnant animals because fetal abnormalities have been reported in laboratory rodents. Use cautiously in dogs and cats with heart disease because in cats it can increase\\tvolume\\texpansion\\tin\\tcats\\tat\\trisk\\tof\\tCHF,\\tand\\tin\\tdogs,\\tit\\tcan\\tincrease vascular resistance and blood pressure. Do not administer prednisolone acetate intravenously. In some species, particularly horses and cats, prednisolone (the active form) is preferred for oral treatment rather than prednisone. Drug Interactions Administration\\tof\\tcorticosteroids\\twith\\tNSAIDs\\twill\\tincrease\\tthe\\trisk\\tof\\tGI\\tinjury. Corticosteroids may inhibit conversion of T 4 thyroid hormone to the active form T 3 .\\tHowever,\\tin\\tdogs,\\tthe\\tconcentration\\tof\\ttotal\\tT 4 but not free T 4 , is decreased. Therefore the effect on thyroid status in canine patients is expected to be minimal.","indications":"Indications and Clinical Uses Prednisolone, like other corticosteroids, is used to treat a variety of inflammatory and immune- mediated disease. The accompanying dosing section lists a range of doses for replacement therapy, anti- inflammatory therapy, and immunosuppressive therapy. Large animal uses include treatment of inflammatory conditions, especially musculoskeletal disorders. In horses, prednisolone is used for treatment of equine asthma syndrome when recurrent airway obstruction (RAO) occurs. In cattle, corticosteroids have been used in the treatment of ketosis. The prednisolone and trimeprazine formulation (Temaril- P) has been effective for treating pruritus in dogs. (See Trimeprazine for further details.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects There are many side effects from corticosteroids, which include polyphagia, polydipsia and polyuria, behavior changes, and hypothalamic\u2013pituitary\u2013adrenal (HPA)\\t   axis\\t  suppression.\\tAdverse\\teffects\\t   include\\t    GI\\t ulceration,\\tsteroid\\t   hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, delayed wound healing, increased risk of diabetes, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal infections, and UTIs. In cats, there is a concern that corticosteroids such as prednisolone can exacerbate\\tCHF\\tthrough\\tvolume\\texpansion\\tsecondary\\tto\\tsteroid-\\tinduced hyperglycemia. This has occurred in susceptible cats after injections of methylprednisolone acetate. This has not been a clinical problem in otherwise healthy cats. In dogs, there was not an expansion of plasma volume, but short- term use can increase vascular resistance, systolic blood pressure, and increase cardiac afterload.\\tThis\\tcould\\tpotentially\\texacerbate\\tCHF\\tin\\tsome\\tdogs.\\tThe\\tmechanism is through increased sensitivity of the alpha receptors and angiotensin II. Thus, in both cats and dogs with heart disease, prednisolone should be used carefully. In horses, in addition to the previously listed adverse effects, there may be an increased risk of laminitis, although documentation of this effect has been controversial and not supported by clinical evidence.","notes":"Instructions for Use Doses for prednisolone are of a broad range and based on severity of underlying condition. Generally, after initial treatment, if the patient responds favorably, the doses for long- term maintenance treatment can be tapered to less than 0.5 mg/kg q48h PO. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients\\tfor\\tsigns\\tof\\tsecondary\\tinfections.\\tPerform\\tan\\tACTH\\tstimulation\\ttest\\tto monitor adrenal function. Corticosteroids can increase liver enzymes, especially ALP, without inducing liver pathology. Prednisone can increase white blood cell (WBC) count and decrease lymphocyte count. It can increase serum albumin, glucose, P triglycerides, and cholesterol. Corticosteroid administration may decrease conversion of thyroid hormones to active form, but free T 4 concentrations should be unaffected. Prednisolone and prednisone at high doses for several weeks may produce significant proteinuria and glomerular changes in some dogs. Formulations \u2022\\t\\tOral\\tprednisolone\\tis\\tavailable\\tin\\t5-\\t\\tand\\t20-\\tmg\\ttablets\\tand\\t3-\\tmg/mL\\tsyrup. \u2022\\t\\tInjection\\tis\\tavailable\\tas\\ta\\t25-\\tmg/mL\\tacetate\\tsuspension\\tinjection\\t(10\\tand\\t50\\tmg/ mL in Canada). \u2022\\t \\tPrednisolone\\tsodium\\tphosphate\\torally\\tdisintegrating\\ttablets\\tare\\tavailable\\tfor\\tpeople but not widely used in animals. These tablets are available in sizes of 5, 10, 15, and 30 mg. \u2022\\t\\tPrednisolone\\tis\\talso\\tavailable\\tin\\tcombination\\twith\\ttrimeprazine\\t(Temaril-\\tP).\\t(See Trimeprazine for more information.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Prednisolone is slightly soluble in water, but it is more soluble in ethanol. If diluted first in ethanol, it may be compounded into oral liquid formulations with good stability for 90 days. Prednisolone acetate is insoluble in water. Do not freeze.","original_category":"Corticosteroid"},{"name":"Prednisolone Sodium Succinate","active_ingredient":"Prednisolone Sodium Succinate","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t \\tShock\\t   (effectiveness\\tof\\t this\\t  use\\t  is\\t controversial):\\t15\u201330\\t   mg/kg\\t    IV\\t (repeat\\t   in\\t 4\u20136\\t  hours). \u2022\\t\\tCNS\\ttrauma:\\t15\u201330\\tmg/kg\\tIV,\\ttaper\\tto\\t1\u20132\\tmg/kg\\tq12h. \u2022\\t\\tAnti-\\t  inflammatory:\\t1\\tmg/kg/day\\tIV. \u2022\\t\\tReplacement\\ttherapy\\tfor\\tadrenal\\tinsufficiency:\\t0.25\u20130.5\\tmg/kg/day\\tIV. \u2022\\t\\tIntermittent\\ttreatment\\t(pulse\\ttherapy)\\tof\\tpemphigus\\tfoliaceus:\\t10\\tmg/kg\\tIV.  Horses \u2022\\t\\t0.5\u20131\\tmg/kg\\tq12\u201324h\\tIM\\tor\\tIV.\\tIV\\tdose\\tshould\\tbe\\tgiven\\tslowly\\tover\\t30\u201360 seconds. \u2022\\t\\tTreatment\\tof\\tshock\\t(although\\tefficacy\\tfor\\ttreating\\tshock\\thas\\tnot\\tbeen\\testablished): 15\u201330\\tmg/kg\\tIV;\\trepeat\\tdose\\tin\\t4\u20136\\thours. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Prednisone pred\u2032nih- sone Trade and other names: Deltasone, Meticorten, and generic brands","contraindications":"Contraindications and Precautions Use cautiously in patients with a risk of GI ulcers and bleeding or infection or in animals in which growing or healing is necessary. Use prednisolone sodium succinate cautiously in patients with kidney disease because it may increase azotemia. Use cautiously in pregnant animals because fetal abnormalities have been reported in laboratory rodents. Drug Interactions Administration\\tof\\tcorticosteroids\\twith\\tNSAIDs\\tincreases\\tthe\\trisk\\tof\\tGI\\tinjury.\\tDo not mix prednisolone sodium succinate with solutions containing calcium.","indications":"Indications and Clinical Uses Prednisolone sodium succinate has similar uses as other forms of prednisolone except this is used when prompt response is needed from injection, especially at high doses. Methylprednisolone sodium succinate (Solu- Medrol) has also been used for similar indications. The uses include treatment of immune- mediated diseases (e.g., pemphigus and hemolytic anemia), spinal cord trauma, and adrenocortical insufficiency. Large animal uses include treatment of inflammatory conditions and treatment of RAO, which is a component of equine asthma syndrome. In cattle, corticosteroids have been used in the treatment of ketosis. The use of prednisolone for treatment of shock, snakebites, and head trauma is discouraged because of lack of proven efficacy or high risk of adverse effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\tare\\tnot\\texpected\\tfrom\\tsingle\\tadministration.\\tHowever,\\twith\\trepeated use, other side effects are possible. Side effects from corticosteroids are many and include\\tpolyphagia,\\tpolydipsia\\tand\\tpolyuria,\\tand\\tHPA\\taxis\\tsuppression.\\tAdverse effects include GI ulceration, diarrhea, steroid hepatopathy, diabetes mellitus, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, impaired wound healing, and immunosuppression. In cats, polyuria is less common than in dogs, and it has not increased calcium excretion or calcium- containing calculi. With high doses of prednisolone sodium succinate, there is a risk of GI bleeding. In horses, in addition to the previously listed adverse effects, there may be an increased risk of laminitis, although documentation of this effect has been controversial.","notes":"Instructions for Use Use of prednisolone sodium succinate is often at high doses for acute treatment, and oral prednisolone or prednisone is used for maintenance treatment. Doses for prednisolone are based on the severity of the underlying condition. P Prednisone 771 Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients\\tfor\\tsigns\\tof\\tsecondary\\tinfections.\\tPerform\\tan\\tACTH\\tstimulation\\ttest\\tto\\tmonitor adrenal function. Corticosteroids can increase liver enzymes, especially ALP, because of enzyme induction, without inducing liver pathology. Prednisolone can increase WBC count and decrease lymphocyte count. It can increase serum albumin, glucose, triglycerides, and cholesterol. Corticosteroid administration may decrease conversion of thyroid hormones to its active form. Prednisolone and prednisone at high doses for several weeks may produce significant proteinuria and glomerular changes in some dogs. Formulations \u2022\\t\\tPrednisolone\\tsodium\\tsuccinate\\tis\\tavailable\\tin\\t100-\\t\\tand\\t500-\\tmg\\tvials\\tfor\\tinjection (10, 20, and 50 mg/mL). For some indications, methylprednisolone sodium succinate (Solu- Medrol) has been substituted. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Prednisolone sodium succinate should be used immediately after reconstitution. Do not freeze. If solution becomes cloudy, do not administer intravenously.","original_category":"Corticosteroid"},{"name":"Prednisone","active_ingredient":"Prednisone","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnti-\\t  inflammatory:\\t0.5\u20131\\tmg/kg,\\tper\\tday,\\twhich\\tmay\\tbe\\tdivided\\tinto\\ttwice-daily treatments, IM, or PO initially; then taper to q48h at a dose of 0.3\u20130.5 mg/kg. \u2022\\t\\tImmunosuppressive:\\t2.2\u20136.6\\tmg/kg/day\\tIV,\\tIM,\\tor\\tPO\\tinitially;\\tthen\\ttaper\\tto 2\u20134 mg/kg q48h. Initial doses rarely need to exceed 4 mg/kg per day. \u2022\\t\\tReplacement\\ttherapy\\tfor\\tadrenal\\tinsufficiency:\\t0.2\u20130.3\\tmg/kg/day\\tPO. \u2022\\t\\tNeurologic\\tdisease\\t(steroid\\tresponsive):\\tStart\\twith\\t2\\tmg/kg\\tq12h\\tPO\\tfor\\t2\\tdays followed by gradual tapering to 1 mg/kg, then 0.5 mg/kg, and eventually to 0.5 mg/kg every other day. \u2022\\t\\tCancer\\ttherapy\\t(e.g.,\\tCOAP\\tprotocol):\\t40\\tmg/m 2 q24h for 7 days; then 20 mg/ m 2 every other day PO. Cats \u2022\\t\\tNot\\trecommended\\tfor\\tcats\\tbecause\\tof\\tan\\tinability\\tto\\tform\\tactive\\tmetabolite. However,\\tif\\tuse\\tis\\tattempted,\\thigher\\tdoses\\tthan\\tused\\tin\\tdogs\\tare\\tneeded.  Horses \u2022\\t\\tPrednisone\\tsuspension\\t(Meticorten)\\t(label\\tdosage):\\t100\u2013400\\tmg\\tper\\thorse (0.22\u20130.88\\tmg/kg)\\tas\\ta\\tsingle\\tdose\\tIM\\tto\\tbe\\trepeated\\tevery\\t3\u20134\\tdays.\\tNo\\toral doses are listed for horses because of an inability of oral treatment to produce active prednisolone concentrations. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 774    Pregabalin Pregabalin pree- ga\u2032bah- lin Trade and other names: Lyrica","contraindications":"Contraindications and Precautions Use corticosteroids cautiously in patients with a risk of GI ulcers or infections and in animals in which growing or healing is necessary. Use prednisone cautiously in patients with renal disease because it may cause azotemia. Use prednisone cautiously in pregnant animals because fetal abnormalities have been reported in laboratory rodents. Drug Interactions Administration\\tof\\tcorticosteroids\\twith\\tNSAIDs\\tincreases\\tthe\\trisk\\tof\\tGI\\tinjury. Corticosteroids may inhibit conversion of T 4 thyroid hormone to the active form T 3 .\\tHowever,\\tin\\tdogs,\\tthe\\tconcentration\\tof\\ttotal\\tT 4 , but not free T 4 , is decreased. Therefore, the effect on thyroid status in a canine patient is expected to be minimal.","indications":"Indications and Clinical Uses Prednisone, like other corticosteroids, is used to treat a variety of inflammatory and immune- mediated diseases. In cats, prednisone may produce therapeutic failures, and prednisolone (active drug) is preferred. There is evidence of poor conversion of prednisone to prednisolone or poor absorption of prednisone in cats and horses. Prednisolone or another active drug (e.g., triamcinolone, dexamethasone) should be used instead for these animals. There are several large animal doses cited (similar to prednisolone); however, because of poor activity in horses, the use is discouraged. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There are many side effects from corticosteroids that include polyphagia, polydipsia\\tand\\tpolyuria,\\tbehavior\\tchanges,\\tand\\tHPA\\taxis\\tsuppression.\\tAdverse effects include GI ulceration, diarrhea hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone (but not free T 4 ), decreased protein synthesis, delayed wound healing, and immunosuppression. Secondary infections can occur as a result of immunosuppression and include demodicosis, toxoplasmosis, fungal infections, and UTIs. In dogs, prednisolone administration increased vascular resistance, systolic blood pressure, and increase cardiac afterload. This could potentially exacerbate CHF\\tin\\tsome\\tdogs.\\tThus,\\tin\\tdogs\\twith\\theart\\tdisease,\\tprednisolone\\tshould\\tbe used carefully.","notes":"Instructions for Use Prednisolone\\tand\\tprednisone\\tcan\\tbe\\tused\\tinterchangeably\\tin\\tdogs.\\tHowever,\\tcats and horses may have problems converting prednisone to the active prednisolone or problems with oral absorption of prednisone, and prednisolone should be used instead. (Alternatively, methylprednisolone or triamcinolone can be used.) As for P prednisolone, the doses vary across a broad range based on severity of the underlying condition. Consult the dosing section for the range of doses administered for each condition. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients\\tfor\\tsigns\\tof\\tsecondary\\tinfections.\\tPerform\\tan\\tACTH\\tstimulation\\ttest\\tto\\tmonitor adrenal function. Corticosteroids can increase liver enzymes, especially ALP, without inducing liver pathology. Corticosteroid administration may decrease conversion of thyroid\\thormones\\tto\\tactive\\tform.\\tHowever,\\tin\\tdogs\\treceiving\\tanti-\\tinflammatory\\tdoses\\tof prednisone, total T 4 concentrations, but not freeT 4 , may be decreased. Formulations \u2022\\t\\tPrednisone\\toral\\tforms:\\t1-\\t,\\t2.5-\\t  ,\\t5-\\t ,\\t10-\\t  ,\\t20-\\t  ,\\t25-\\t  ,\\tand\\t50-\\tmg\\ttablets;\\t1-\\tmg/mL syrup (Liquid Pred in 5% alcohol); and 1- mg/mL oral solution (in 5% alcohol) \u2022\\t\\tPrednisone\\tfor\\tinjection:\\t10-\\t\\tand\\t40-\\tmg/mL\\tprednisone\\tsuspension\\tfor\\tinjection (Meticorten; availability has been limited). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Prednisone is slightly soluble in water, and it is soluble in ethanol. Prednisone has been prepared by first dissolving in ethanol and then mixing with syrups and flavorings.\\tNo\\tloss\\toccurred,\\tbut\\tcrystallization\\tis\\tcommon\\tin\\taqueous\\tvehicles. Prednisone tablets have been crushed and mixed with syrups and other flavorings, stored\\tfor\\t60\\tdays,\\tand\\tfound\\tto\\tproduce\\tequal\\tbioavailability\\tas\\ttablets\\tin\\tpeople.","original_category":"Corticosteroid"},{"name":"Triamcinolone Diacetate","active_ingredient":"Triamcinolone Diacetate","species":["Canine","Feline","Equine","Bovine"],"dosage":"\u2022\\t\\tDogs:\\tFor\\tanti-\\tinflammatory\\ttreatment,\\tstart\\twith\\t0.1\u20130.2\\tmg/kg\\tper\\tday\\tPO; then gradually taper to 0.1 mg/kg every other day. Eventually, some conditions can be\\tcontrolled\\twith\\t0.03\u20130.055\\tmg/kg\\tq48h\\tPO.\\t(The\\tmanufacturer\\trecommends dosages of 0.11\u20130.22 mg/kg/day.) \u2022\\t \\tCats:\\tFor\\tanti-\\tinflammatory\\ttreatment,\\tstart\\twith\\t0.2\\tmg/kg\\tper\\tday\\tPO.\\tGradually taper to a dosage of 0.1 mg/kg (0.5 mg per cat [one tablet] is a common dose) every other day. Some cats can be controlled with low dosages of 0.05 mg/kg q48h. \u2022\\t\\tImmune-\\tmediated\\tdisease\\t(dogs\\tand\\tcats):\\ttriamcinolone\\ttablets\\tat\\tdoses\\tof 0.2\u20130.6\\tmg/kg/day,\\twith\\tmaintenance\\tdoses\\tof\\t0.1\u20130.2\\tmg/kg\\tq48h\\tPO. \u2022\\t\\tTriamcinolone\\tacetonide:\\t0.1\u20130.2\\tmg/kg\\tIM\\tor\\tSQ;\\trepeat\\tin\\t7\u201310\\tdays. \u2022\\t\\tIntralesional:\\t1.2\u20131.8\\tmg\\tor\\t1\\tmg\\tfor\\tevery\\tcentimeter\\tdiameter\\tof\\ttumor\\tevery 2 weeks or longer. \u2022\\t\\tIntra-\\t   articular:\\t5\u201315\\tmg\\tper\\tjoint\\tfor\\tlarge\\tjoints;\\t2.5\u20135\\tmg\\tfor\\tsmall\\tjoints. Injections in tendon sheaths are in the range of 2.5\u20135 mg.  Horses \u2022\\t\\t12\u201320\\tmg\\tper\\thorse\\tIM.\\tThe\\tmaximum\\trecommended\\tdose\\tis\\t0.05\\tmg/kg\\tIM. \u2022\\t\\tTriamcinolone\\tacetonide\\tsuspension:\\t0.022\u20130.044\\tmg/kg\\tas\\ta\\tsingle\\tdose\\tIM. \u2022\\t\\tRAO:\\t0.09\\tmg/kg\\tas\\ta\\tsingle\\tdose\\tIM. \u2022\\t\\tIntra-\\t   articular:\\t6\u201318\\tmg\\tas\\ta\\ttotal\\tdose\\tper\\tjoint\\t(usually\\t9\u201312\\tmg).\\tRepeat\\tin 4\u201313\\tdays\\tif\\tnecessary. Cattle \u2022\\t\\tTriamcinolone\\tacetonide\\tis\\tnot\\tapproved\\tin\\tcattle,\\tand\\tthere\\tare\\tno\\testablished doses. If triamcinolone acetonide suspension is injected in cattle, the same dose regimens as used in horses can be used, and extralabel withdrawal times should be followed. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 4 Triamterene trye- am\u2032ter- een Trade and other names: Dyrenium","contraindications":"Contraindications and Precautions Do not administer injectable suspension IV. The injectable product is intended for IM, intra- articular, or intralesional injection. Use cautiously in patients prone to ulcers or infection and in animals in which wound healing is necessary. Do not use the ocular form in animals with corneal ulcers. Use cautiously in animals with diabetes or renal failure and in pregnant animals. Because of the high potency (equal to or slightly greater potency than dexamethasone), high doses should be avoided. Drug Interactions Use cautiously in conjunction with NSAIDs because it may potentiate the GI adverse effects.","indications":"Indications and Clinical Uses Triamcinolone acetonide, like other corticosteroids, is used to treat inflammatory and immune- mediated diseases in animals. It is used for similar purposes as prednisolone, except with higher potency. It is an acceptable substitute for prednisolone in cats. Triamcinolone acetonide suspension is also used for intralesional and intra- articular injections to produce local anti- inflammatory effects. When injected IM, the suspension is absorbed slowly. Therefore, the IM injection may have a duration 930    Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triamcinolone Diacetate of activity lasting 2\u20134 weeks. After intra- articular injection, the duration may be maintained for several weeks. In addition to joint infections, other large animal uses include treatment of inflammatory and immune- mediated conditions and for RAO, formerly called chronic obstructive pulmonary disease, in horses associated with equine asthma syndrome. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects from corticosteroids are many and include polyphagia, polydipsia and polyuria, and hypothalamic\u2013pituitary\u2013adrenal axis suppression. Injections of triamcinolone acetonide can have long- lasting effects. In people, injections can produce\\tadrenal\\tsuppression\\tfor\\t30\\tdays. Other adverse effects include GI ulceration, hepatopathy, diabetes, hyperlipidemia, decreased thyroid hormone, decreased protein synthesis, impaired wound healing, and immunosuppression. When triamcinolone acetonide is used for ocular injections, there is some concern that granulomas may occur at the injection site. When administered to horses at a dose of 0.05 mg/kg IM, it induces\\thyperglycemia\\tfor\\t3\\tdays,\\tbut\\tthis\\tdoes\\tnot\\tlead\\tto\\tlaminitis.\\tAlthough adverse effects typically include increased risk of laminitis in horses, evidence for this effect has been controversial and not supported by well- controlled studies.","notes":"Instructions for Use Triamcinolone acetonide, like other corticosteroids such as prednisolone, is administered in a variety of doses, depending on the severity of the condition being treated. The injectable product is a suspension. Shake well before using. Note that cats may require higher doses than dogs. Patient Monitoring and Laboratory Tests Monitor liver enzymes, blood glucose, and renal function during therapy. Monitor patients for signs of secondary infections. Perform an adrenocorticotropic hormone (ACTH) stimulation test to monitor adrenal function. Formulations \u2022\\t\\tVetalog\\t(veterinary\\tpreparation\\tof\\ttriamcinolone\\tacetonide)\\tis\\tavailable\\tin\\t0.5-\\t\\tand 1.5- mg  tablets. \u2022\\t\\tHuman\\tpreparations\\tof\\ttriamcinolone\\tacetonide\\tare\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\t4-\\t ,\\t8-\\t ,\\tand 16-\\t mg\\ttablets,\\tbut\\tmany\\ttablet\\tsizes\\thave\\tbeen\\tdiscontinued.\\tHuman\\ttablets\\tof 4 mg (scored tablet) are usually available. T Triamterene 931 \u2022\\t\\tTriamcinolone\\thexacetonide\\t(Canadian\\tproduct)\\tis\\tavailable\\tin\\ta\\t5-\\t\\tand\\t20-\\tmg/mL suspension. \u2022\\t\\tTriamcinolone\\tdiacetate\\tis\\tavailable\\tin\\ta\\t25-\\tmg/mL\\tsuspension. \u2022\\t\\tTriamcinolone\\tacetonide\\tfor\\tinjection\\tis\\tavailable\\tin\\t10-\\t\\tor\\t40-\\tmg/mL\\tsuspension (human\\tform)\\tor\\t2-\\t\\tand\\t6-\\tmg/mL\\tsuspension\\t(veterinary\\tform). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Avoid freezing of injectable suspension. Stability of compounded formulations has not been evaluated.","original_category":"Corticosteroid"}]},{"category":"Antibiotics","drugs":[{"name":"Amikacin","active_ingredient":"Amikacin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t15\\tmg/kg\\tq24h\\tIV,\\tIM,\\tor\\tSQ. Cats \u2022\\t\\t10\\tmg/kg\\tq24h\\tIV,\\tIM,\\tor\\tSQ. A Amino Acid Solution 31  Horses \u2022\\t\\tAdult:\\t10\\tmg/kg\\tq24h\\tIV\\tor\\tIM. \u2022\\t\\tFoal:\\t20\\tmg/kg\\tq24h\\tIV. \u2022\\t\\tIntrauterine\\tuse:\\tAdminister\\t2\\tg\\t(8\\tmL)\\tdiluted\\tin\\t200-\\tmL\\tsterile\\tsaline\\tsolution\\tin uterus once per day for 3 days. \u2022\\t\\tRegional\\tlimb\\tperfusion:\\tDoses\\thave\\tranged\\tfrom\\t125\\tto\\t500\\tmg\\tper\\tlimb,\\tdiluted in 60 mL of saline. Cattle (not recommended in food- producing animals) \u2022\\t\\tAdult:\\t10\\tmg/kg\\tq24h\\tIM,\\tIV,\\tor\\tSQ. \u2022\\t\\tCalf\\t(younger\\tthan\\t2\\tweeks\\tof\\tage):\\t20\\tmg/kg\\tq24h\\tIV\\tor\\tIM. Regulatory Information Withdrawal times have not been established for extralabel use in animals used for food. Long persistence of drug in tissues (renal) is expected after administration. Amikacin, like other aminoglycoside antibiotics, should not be administered to animals that produce food because of a risk of residue problems. If extralabel doses have been administered, the meat withdrawal time may be as long as 18\\tmonths.\\tContact\\tFARAD\\tat\\twww.FARAD.org for specific withdrawal time information. Amino Acid Solution Trade and other names: Travasol","contraindications":"Contraindications and Precautions Do not use in animals with renal insufficiency or renal failure. Do not use in dehydrated animals. Drug Interactions Do not mix in vial or syringe with other antibiotics. Amikacin is incompatible with other drugs and compounds when mixed in the same vial or syringe. This effect is particularly important when mixing with other antibiotics. When used with anesthetic agents, neuromuscular blockade is possible.","indications":"Indications and Clinical Uses Amikacin is indicated in bacterial infections, especially for treatment of serious infections caused by gram- negative bacteria. When resistance to gentamicin is anticipated, amikacin is often used in its place because bacteria resistant to gentamicin are still susceptible to amikacin. In horses, amikacin also is used for local administration as an intrauterine lavage to treat metritis and other infections of the genital\\ttract\\tcaused\\tby\\tgram-\\tnegative\\tbacteria.\\tFor\\tthis\\tpurpose,\\tit\\thas\\tbeen\\tused\\tas\\tan intrauterine flush. In horses, amikacin also is used for regional limb perfusion. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nephrotoxicity is the most dose- limiting toxicity. Ensure that patients have adequate fluid and electrolyte balance during therapy. Ototoxicity and vestibulotoxicity also are possible.","notes":"Instructions for Use Once- daily doses are designed to maximize peak- to- minimum inhibitory concentration (MIC) ratio. Consider therapeutic drug monitoring to decrease risk of renal toxicosis. Activity against some bacteria (e.g., Pseudomonas) may be enhanced when combined with a beta- lactam antibiotic, but this action is controversial. Nephrotoxicity is increased with persistently high trough concentrations. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tMIC breakpoint is \u22644 mcg/mL for dogs and horses and \u2264 2 mcg/mL for foals. The canine\\tbreakpoint\\talso\\tcan\\tbe\\tapplied\\tto\\tbacterial\\tisolates\\tfrom\\tcats.\\tMonitor\\tBUN, serum creatinine, and urine for evidence of renal toxicity. Plasma or serum drug concentrations can be monitored to measure for problems with systemic clearance. When monitoring trough levels in patients during once- daily administration, the trough levels should fall below the limit of detection. Alternatively, the half- life and clearance can be measured from samples taken at 1 hour and 2\u20134 hours post- dosing. Clearance in most animals should be above 1.0 mL/kg/min, and half- life should be less than 2 hours. Formulations \u2022\\t\\tAmikacin\\tis\\tavailable\\tin\\t50-\\t\\tor\\t250-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Amikacin will be unstable if mixed with other drugs.","original_category":"Antibacterial"},{"name":"Amoxicillin","active_ingredient":"Amoxicillin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t22\\tmg/kg\\tq12h\\tPO. A Cats \u2022\\t\\t12.5\\tmg/kg\\tq12h\\tPO.  Calves \u2022\\t\\tNonruminating:\\t10\u201322\\tmg/kg\\tq8\u201312h\\tPO. Cattle and horses \u2022\\t\\t6.6\u201322\\tmg/kg\\tq8\u201312h\\tPO\\t(suspension).\\tNote:\\tOral\\tdoses\\tin\\tlarge\\tanimals\\tare not well absorbed (except in foals), and amoxicillin is not recommended by this route. Regulatory Information Withdrawal\\ttime\\t(cattle\\tonly):\\t25\\tdays\\tfor\\tmeat,\\t96\\thours\\tfor\\tmilk.\\tAmoxicillin intramammary\\tinfusion:\\twithdrawal\\ttime\\t12\\tdays\\tfor\\tmeat,\\t60\\thours\\tfor\\tmilk. ah- mox- ih- sill \u0301in  and  klav- yoo- lan \u0301ate  poe- tah \u0301see- um Trade and other names: Clavamox (veterinary preparation) and Augmentin (human preparation)","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\tallergic\\tto\\tpenicillin-\\tlike\\tdrugs. Drug Interactions Do not mix with other drugs in compounded formulations.","indications":"Indications and Clinical Uses Amoxicillin\\tis\\tused\\tfor\\ta\\tvariety\\tof\\tinfections\\tin\\tall\\tspecies,\\tincluding\\tlower\\tUTIs,\\tsoft tissue infections, and pneumonia. It is generally more effective for infections caused by gram- positive bacteria. Because of a short half- life, frequent administration is needed for treating gram- negative infections. Oral absorption in horses is less than 10%, and it is not suitable for treatment of adult horses. However, oral absorption in foals is 36%\u201343%. Oral absorption in small animals is 50%\u201360%. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Amoxicillin is usually well tolerated. Allergic reactions are possible. Diarrhea and vomiting are common with oral doses. Oral administration to horses or cattle can cause diarrhea or enteritis.","notes":"Instructions for Use Dose requirements are based on the approved label dose, or the dose used to determine susceptibility testing interpretive categories. Amoxicillin is not a preferred choice for gram- negative infections caused by Enterobacteriaceae bacteria because most are clinically resistant. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tFor\\ttesting\\tfor\\tsusceptibility,\\tthe\\tCLSI\\trecommends\\tusing ampicillin to test for amoxicillin susceptibility. The CLSI breakpoint for susceptible organisms is \u22640.25 mcg/mL for staphylococci, streptococci, and gram- negative bacilli.\\tFor\\tuncomplicated\\tcanine\\tlower\\turinary\\ttract\\tpathogens,\\tuse\\ta\\tbreakpoint of \u22648\\tmcg/mL\\t(this\\tbreakpoint\\talso\\tcan\\tbe\\tapplied\\tto\\tcats\\tfor\\tuncomplicated infections).\\tFor\\tcattle\\tpathogens,\\tuse\\ta\\tbreakpoint\\tof\\t\u22640.25\\tmcg/mL.\\tFor\\tequine respiratory pathogens (streptococci), use a break point of \u22640.25 mcg/mL. At this breakpoint for susceptibility (0.25 mcg/mL), gram- negative Enterobacteriaceae bacteria test resistant, and testing of these isolates is unnecessary. Formulations \u2022\\t\\tAmoxicillin\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\t150-\\t   ,\\t200-\\t   ,\\t400-\\t   ,\\t500-\\t   ,\\tand\\t875-\\tmg\\ttablets and 250-  and 500- mg capsules (human preparations). Chewable tablets are available in 125- , 200- , 250- , and 400- mg sizes. \u2022\\t\\tAmoxicillin\\ttrihydrate\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\t200-\\t   ,\\tand\\t400-\\tmg\\ttablets;\\t50-\\tmg/ mL amoxicillin trihydrate oral suspension; and 100-  or 250- mg/mL amoxicillin trihydrate for injection. Stability and Storage Store in a tightly sealed container at room temperature. Oral liquid suspensions are stable for 14 days. Other formulations should be protected from moisture. Optimum stability\\tis\\tat\\tpH\\t5.8\u20136.5.\\tAbove\\tthis\\tpH,\\thydrolysis\\toccurs.","original_category":"Antibacterial"},{"name":"Amoxicillin and Clavulanate Potassium","active_ingredient":"Amoxicillin and Clavulanate Potassium","species":["Canine"],"dosage":"Dogs \u2022\\t\\t12.5\\tmg/kg\\tq12h\\tPO.\\t(Dose\\tis\\tbased\\ton\\tcombined\\tingredients:\\tamoxicillin\\tand clavulanate.)  \u2022\\t\\tAmoxicillin\\t+\\tclavulanate\\tis\\tonly\\tavailable\\tin\\tan\\toral\\tformulation.\\tBecause\\tthese components are not absorbed orally in large animal species, this drug is not recommended. Regulatory Information No regulatory information is available. However, it is anticipated that withdrawal times are similar to those of amoxicillin. Amphotericin B am- foe- tare \u0301ih- sin Trade and other names: Fungizone (traditional formulation) and liposomal forms of Amphotec, ABLC, ABCD, Abelcet, and AmBisome","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\tallergic\\tto\\tpenicillin-\\tlike\\tdrugs.\\tOral\\tadministration\\tto horses and ruminants may produce diarrhea. Drug Interactions No drug interactions are reported in animals. A Amphotericin B 47 Cats \u2022\\t\\t62.5\\tmg/cat\\tq12h\\tPO;\\tequivalent\\tto\\t12.5\\tmg/kg\\tamoxicillin\\tand\\t3.12\\tmg/kg clavulanate q12h.","indications":"Indications and Clinical Uses Amoxicillin and clavulanate is a broad- spectrum antibacterial drug used for skin and\\tsoft\\ttissue\\tinfections,\\tUTIs,\\twound\\tinfections,\\tand\\trespiratory\\tinfections.\\tIt is indicated for treatment of bacterial infections that may otherwise be resistant to amoxicillin because of bacterial beta- lactamase production. Amoxicillin and clavulanate is particularly useful for treating beta- lactamase\u2013producing strains of Staphylococcus spp. Precautionary Information","side_effects":"Adverse Reactions and Side Effects It is usually well tolerated. Allergic reactions are possible. Diarrhea is common with oral doses and has also caused vomiting in some animals. As the dose of clavulanate increases because of a high proportion of clavulanate in some","notes":"formulations, vomiting is more likely. Instructions for Use Dose requirements are based on the approved label dose, or the dose used to determine susceptibility testing interpretive categories. If treating infections that test in the Intermediate category, more frequent or higher doses are needed. It is not recommended for treatment of infections caused by the Enterobacteriaceae (Escherichia coli), because most strains are clinically resistant, unless the infection is in the\\tlower\\tUTI. Some dermatologists recommend using a higher dose than recommended on the label to treat skin infections (i.e., 25 mg/kg q12h). Oral human dose forms are sometimes substituted for veterinary drugs. Note that veterinary dose formulations contain\\tamoxicillin\\tand\\tclavulanate\\tin\\ta\\t4:1\\tratio.\\tHuman\\tdose\\tforms\\t(Augmentin) contain\\tthese\\tdrugs\\tin\\tratios\\tof\\t2:1\\tto\\tas\\thigh\\tas\\t7:1.\\tDespite\\tthe\\tdifferent\\tratios of amoxicillin to clavulanate in the human formulations, they have been used interchangeably with the veterinary formulations. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsensitive\\torganisms\\tis\\t\u22640.25/0.12 mcg/ mL for staphylococci, streptococci, E. coli, and Pasteurella multocida. (The \u201c/\u201d distinguishes the amoxicillin from the clavulanate concentrations.) When treating an\\tuncomplicated\\tlower\\tUTI,\\ta\\tsusceptibility\\tbreakpoint\\tis\\t\u22648/4\\tmcg/mL. Although this higher breakpoint is listed only for dogs, it may apply to cats if it is an uncomplicated\\tlower\\tUTI. Formulations \u2022\\t\\tAmoxicillin\\t+\\tclavulanate\\tis\\tavailable\\tin\\tveterinary\\tdose\\tform:\\t62.5-\\t,\\t125-\\t   , 250- , and 375- mg tablets and 62.5- mg/mL suspension in a ratio of amoxicillin:clavulanate\\tratio\\tof\\t4:1. \u2022\\t\\tAmoxicillin\\t+\\tclavulanate\\tis\\tavailable\\tin\\thuman\\tdose\\tform:\\t250/125-\\t,\\t500/125-\\t, and\\t875/125-\\tmg\\ttablets. \u2022\\t\\tAmoxicillin\\t+\\tclavulanate\\tis\\tavailable\\tin\\t125/31.25-\\t,\\t200/28.5-\\t,\\t250/62.5-\\t,\\tand 400/57- mg chewable tablets \u2022\\t\\tOral\\tsuspension\\t125/31.25,\\t200/28.5,\\t250/62.5,\\tand\\t400/57\\tmg\\tper\\t5\\tmL. Stability and Storage Store in a tightly sealed container, protected from light, and below 24\xb0C. Avoid exposure to humidity or moisture. Reconstituted oral products are stable for 10 days. Clavulanate is particularly unstable in compounded formulations, and compounded products can exhibit a dramatic loss of potency, particularly in aqueous suspensions with acidic pH.","original_category":"Antibacterial"},{"name":"Ampicillin and Ampicillin Sodium","active_ingredient":"Ampicillin and Ampicillin Sodium","species":["Canine","Feline","Equine","Bovine"],"dosage":"Ampicillin Sodium, Injectable and Oral Dogs and Cats \u2022\\t\\t10\\tmg/kg\\tq8h\\tIV,\\tIM,\\tor\\tSQ\\tor\\t20\\tmg/kg\\tq8h\\tPO. Ampicillin Trihydrate Injection Dogs \u2022\\t\\t10\u201350\\tmg/kg\\tq12\u201324h\\tIM\\tor\\tSQ. Cats \u2022\\t\\t10\u201320\\tmg/kg\\tq12\u201324h\\tIM\\tor\\tSQ.  Horses and Ruminants Ampicillin Sodium Injectable \u2022\\t\\t22\\tmg/kg\\tq12h\\tIM\\tor\\tIV. Cattle and Calves Ampicillin Trihydrate \u2022\\t\\t11\\tmg/kg\\tq12h\\tIM. Pigs Ampicillin Trihydrate \u2022\\t\\t15\\tmg/kg\\tq24h\\tIM Regulatory Information Cattle\\twithdrawal\\ttime:\\t6\\tdays\\tfor\\tmeat;\\t48\\thours\\tfor\\tmilk\\t(at\\t6\\tmg/kg). Pig\\twithdrawal\\ttime:\\tIn\\tCanada,\\t6\\tdays. Ampicillin + Sulbactam am- pih- sill \u0301in  +  sul- bak \u0301tam Trade and other names: Unasyn","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\tallergic\\tto\\tpenicillin-\\tlike\\tdrugs.\\tAmpicillin\\tcontains\\t3 mEq of sodium per gram. Rapid IV bolus injection can produce CNS excitement and convulsive seizures. Drug Interactions Do not mix in vials with other drugs. A","indications":"Indications and Clinical Uses Ampicillin is indicated in patients with infections caused by susceptible bacteria, such\\tas\\tskin\\tand\\tsoft\\ttissue\\tinfections,\\tUTIs,\\tand\\tpneumonia.\\tGram-\\tpositive bacteria (except beta- lactamase\u2013producing strains of Staphylococcus spp.) are usually susceptible. However, infections caused by most gram- negative bacteria of the Enterobacteriaceae\\tare\\tclinically\\tresistant.\\tFastidious\\tgram-\\tnegative\\tbacteria\\t(e.g., Pasteurella) are usually clinically susceptible. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects of penicillin drugs are most commonly caused by drug allergy. This can range from acute anaphylaxis when administered IV to other signs of allergic reaction when other routes are used. When used for prophylaxis during surgery, ampicillin can be administered IV to anesthetized patients without affecting cardiovascular parameters. Diarrhea is possible when administered orally, especially with high doses.","notes":"Instructions for Use Dose requirements are based on the approved label dose or the dose used to determine susceptibility testing interpretive categories. Ampicillin is absorbed approximately 50% less compared with amoxicillin when administered orally. Because of better absorption, amoxicillin is preferred when oral treatment is needed. When preparing injectable solutions, the stability is dependent on the concentration. Concentrated solutions (250 mg/mL) should be injected within 1\\thour\\tof\\treconstitution\\teither\\tIM,\\tSQ,\\tor\\tslowly\\t(over\\t3\\tminutes)\\tIV.\\tLess concentrated solutions prepared in IV fluids (e.g., 30 mg/mL) are stable for longer periods. See the Stability and Storage section for more detail. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tFor\\ttesting\\tfor\\tsusceptibility,\\tCLSI\\tbreakpoint\\tfor\\tsusceptible organisms is \u22640.25 mcg/mL for staphylococci, streptococci, and gram- negative bacilli. Most Enterobacteriaceae bacteria (e.g., E. coli) test clinically resistant to ampicillin. At this breakpoint for susceptibility (0.25 mcg/mL), gram- negative Enterobacteriaceae bacteria test resistant, and testing of these isolates is unnecessary. When\\ttreating\\tan\\tuncomplicated\\tlower\\tUTI,\\ta\\tsusceptibility\\tbreakpoint\\tfor\\tdogs\\tis\\t\u22648 mcg/mL. Although this higher breakpoint is listed only for dogs, it may apply to cats if\\tit\\tis\\tan\\tuncomplicated\\tlower\\tUTI.\\tFor\\tcattle\\tpathogens,\\tuse\\ta\\tsusceptible\\tbreakpoint of \u22640.25\\tmcg/mL.\\tFor\\tequine\\trespiratory\\tpathogens\\t(streptococci),\\tuse\\ta\\tsusceptible breakpoint of \u22640.25 mcg/mL. Formulations \u2022\\t\\tAmpicillin\\tis\\tavailable\\tin\\t125-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\tcapsules. \u2022\\t\\tSolutions:\\t125-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\tvials\\tof\\tampicillin\\tsodium.\\tAmp-\\tEquine\\tis available in 1- , 2- , and 3- g vials for injection. (However, this formulation has been discontinued by some suppliers.) \u2022\\t\\tAlthough\\t1-\\tand\\t2-g\\tvials\\tare\\tprimarily\\tfor\\tIV\\tuse\\t(if\\tavailable),\\tthey\\tmay\\tbe administered IM when the 250-  and 500- mg vials are unavailable. In such instances,\\tdissolve\\tthese\\tvials\\tin\\t3.5\\tor\\t6.8\\tof\\tmL\\tsterile\\twater,\\tfor\\tthe\\t1-\\tand\\t2-g vials, respectively (resulting concentration is 250 mg/mL). When using 1-  or 2- g vials\\tfor\\tIV\\tadministration,\\tdissolve\\t7.4\\tor\\t14.8\\tmL\\tof\\tsterile\\twater\\tand\\tadminister over 15 minutes. \u2022\\t\\tSuspensions:\\tampicillin\\ttrihydrate\\tsuspension\\t(Polyflex)\\tis\\tavailable\\tin\\t10-\\t\\tand 25- g vials for injection, and when reconstituted, each milliliter contains ampicillin trihydrate equivalent to 50, 100, or 250 mg of ampicillin. Stability and Storage Store in a tightly sealed container at room temperature. Solutions: After reconstitution of ampicillin sodium, stability is concentration dependent. After reconstitution with sterile water at a concentration of 250 mg/mL, it is stable for 1 hour at room temperature. If diluted to a concentration of up to 30 mg/mL using 0.9% saline or lactated Ringer\u2019s solution (e.g., in IV fluids), stability is\\tmaintained\\tfor\\t8\\thours\\tat\\troom\\ttemperature.\\tIn\\trefrigerated\\ttemperatures,\\twhen reconstituted\\tto\\t30\\tmg/mL,\\tit\\tis\\tstable\\tfor\\t48\\thours\\tin\\tsterile\\twater\\tor\\t24\\thours\\tin sodium chloride or Ringer\u2019s solution. At 20 mg/mL, it is stable for 72 hours in sterile water\\tor\\t48\\thours\\tin\\tsodium\\tchloride.\\tIf\\tthis\\tconcentration\\tis\\tprepared\\tin\\t5%\\tdextrose in water, stability is maintained for only 1 hour. Suspensions: Oral suspensions are stable for 14 days if refrigerated. Ampicillin trihydrate for injection is stable for 12 months refrigerated and 3 months at room temperature. Other formulations should be protected from moisture. Optimum stability\\tis\\tat\\tpH\\t5.8.\\tAbove\\tthis\\tpH,\\thydrolysis\\toccurs. 52    Ampicillin + Sulbactam","original_category":"Antibacterial"},{"name":"Ampicillin + Sulbactam","active_ingredient":"Ampicillin + Sulbactam","species":["Canine","Feline","Equine","Bovine"],"dosage":"Cats and Dogs \u2022\\t\\tDoses\\tare\\tsimilar\\tto\\tthose\\tused\\tfor\\tampicillin\\t(when\\tdosed\\taccording\\tto\\tampicillin component)\\t10\\tmg/kg\\tq8h\\tIV\\tor\\tIM.  Horses and Ruminants \u2022\\t\\t11\\tmg/kg,\\tor\\t22\\tmg/kg\\tq12h,\\tIM\\tor\\tIV. Regulatory Information Withdrawal time exists for ampicillin but not sulbactam. Because sulbactam has a similar half- life and presents little risk for toxicity, the withdrawal times listed for ampicillin are suggested. Cattle\\twithdrawal\\ttime:\\t6\\tdays\\tfor\\tmeat;\\t48\\thours\\tfor\\tmilk\\t(at\\t6\\tmg/kg). Pig\\twithdrawal\\ttime:\\tIn\\tCanada,\\t6\\tdays. Amprolium am- proe \u0301lee- um Trade and other names: Amprol and Corid","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\tallergic\\tto\\tpenicillin-\\tlike\\tdrugs. Drug Interactions Do not mix in vials with other drugs.","indications":"Indications and Clinical Uses This combination is indicated for infections caused by susceptible strains of bacteria. It has been used for acute infections such as pneumonia, sepsis, and prophylaxis in patients with neutropenia. Because of the addition of sulbactam, it has a broader spectrum than ampicillin alone. Therefore, it is used for treating infections for A which ampicillin resistance may be expected. Many gram- negative bacilli (e.g., Enterobacteriaceae) have MIC values that are in the clinically resistant range for ampicillin\u2013sulbactam, and other agents should be considered when these bacteria are suspected, such as piperacillin\u2013tazobactam. Ampicillin\u2013sulbactam\\tcan\\tonly\\tbe\\tadministered\\tby\\tinjection.\\tFor\\toral\\tuse, amoxicillin\u2013clavulanate (e.g., Clavamox and Augmentin) may be used as an equivalent alternative. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects of penicillin drugs are most commonly caused by drug allergy. This can range from acute anaphylaxis when administered to other signs of allergic reaction when other routes are used.","notes":"Instructions for Use Dose requirements are based on extrapolation of the approved label dose in people or the dose that is used most often for ampicillin sodium. Concentrated solutions (250 mg/mL)\\tshould\\tbe\\tinjected\\twithin\\t1\\thour\\tof\\treconstitution\\tIM,\\tSQ,\\tor\\tslowly\\t(over 3 minutes) IV. Vials for IM use may be reconstituted in lidocaine hydrochloride to decrease pain from injection. Less concentrated solutions prepared in IV fluids (e.g., 45 mg/mL) are stable for longer periods. See the Stability and Storage section for more details. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsensitive\\torganisms\\tis\\t\u22648/4\\tmcg/mL for staphylococci and gram- negative bacilli, based on the human breakpoint. (The \u201c/\u201d distinguishes the ampicillin from the sulbactam concentrations.) However, CLSI has lower breakpoints for ampicillin in dogs, cats, horses, and cattle, and it is highly likely that the human ampicillin/sulbactam breakpoint is too high to predict susceptibility for isolates from animals. Therefore, the lower susceptibility breakpoint of ampicillin (\u22640.25 mcg/mL) should be applied to the use of ampicillin\u2013sulbactam in animals. Formulations \u2022\\t\\tAmpicillin\\t+\\tsulbactam\\tis\\tavailable\\tin\\ta\\t2:1\\tcombination\\tfor\\tinjection\\tand\\t1.5-\\t\\tand 3- g  vials. Stability and Storage Store vial in a tightly sealed container at room temperature. Vials may be reconstituted with sterile water for immediate use at an ampicillin concentration of 250 mg/mL. The vial should be used within 1 hour of reconstitution. When the reconstituted vial is diluted with sterile water or 0.9% sodium chloride at a concentration\\tof\\t45\\tmg/mL,\\tstability\\tis\\tmaintained\\tfor\\t8\\thours\\tat\\troom\\ttemperature and\\t48\\thours\\tif\\trefrigerated.\\tStability\\tis\\tmaintained\\tfor\\t8\\thours\\tat\\troom\\ttemperature and 24 hours refrigerated if lactated Ringer\u2019s solution is used. Optimum stability is at pH\\t5.8.\\tAbove\\tthis\\tpH,\\thydrolysis\\toccurs. 54    Amprolium","original_category":"Antibacterial"},{"name":"Atovaquone","active_ingredient":"Atovaquone","species":["Feline","Canine"],"dosage":"Cats \u2022\\t\\t15\\tmg/kg\\tq8h\\tPO\\tin\\tcombination\\twith\\tazithromycin\\t(10\\tmg/kg\\tq24h). 68    Atracurium Besylate Dogs \u2022\\t\\tAntiprotozoal\\ttreatment:\\t13\u201315\\tmg/kg\\tq8h\\tPO\\tfor\\t10\\tdays,\\tusually\\tin combination with azithromycin (10 mg/kg q24h PO).  \u2022\\t\\tNo\\tdose\\treported. Regulatory Information There is no withdrawal time established for food animals. Atracurium Besylate ah- trah- kyoor \u0301ee- um  bess \u0301ih- late Trade and other names: Tracrium","contraindications":"Contraindications and Precautions Avoid use in pregnancy. Drug Interactions No drug interactions are reported in animals. In people, coadministration with rifampin decreases effective concentrations.","indications":"Indications and Clinical Uses In people, atovaquone is an antiprotozoal that is primarily used in individuals who cannot tolerate sulfonamides. In animals, it has been used, often in combination with azithromycin, to treat refractory protozoan diseases and blood- borne pathogens. It is the drug of choice for the treatment of B. gibsoni infections in combination with azithromycin. Administer with high- fat meal to increase oral absorption. Precautionary Information","side_effects":"Adverse Reactions and Side Effects One formulation (Malarone) also contains proguanil HCl. It may increase the risk of diarrhea in dogs when combined with proguanil. Otherwise, adverse effects have not been reported in animals. In people, adverse reactions consist of skin rash, cough, and diarrhea.","notes":"Instructions for Use There has been only limited experience with use of atovaquone for treatment of infections in animals. A few clinical trials have shown efficacy when combined with azithromycin for treatment of protozoa infections. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAtovaquone\\tis\\tavailable\\tas\\ta\\t750-\\tmg/5-\\t   mL\\tliquid\\toral\\tsuspension\\t(150\\tmg/mL). The 250- mg tablets have been discontinued, but it has been compounded into 250 capsules by some compounding pharmacies. Stability and Storage Store at room temperature protected from light. Do not freeze.","original_category":"Antibacterial, antiprotozoal"},{"name":"Azithromycin","active_ingredient":"Azithromycin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tA\\trange\\tof\\tdosages\\thas\\tbeen\\tused,\\tstarting\\twith\\t10\\tmg/kg\\tonce\\tdaily\\tPO\\tfor\\t5\u20137 days and then decreasing to every other day. Alternatively, 5 mg/kg/day has been used by some veterinarians, either once per day or once every other day. Cats \u2022\\t\\t5\u201310\\tmg/kg\\tonce\\tdaily\\tfor\\t7\\tdays\\tPO\\tfollowed\\tby\\tadministration\\tq48h;\\tor\\t10\u201315 mg/kg daily for 3 days followed by the same dose twice weekly PO. \u2022\\t \\tUpper\\t   respiratory\\tinfection:\\t15\\t mg/kg\\t    initially\\t    for\\t the\\t  first\\t  3\\t days\\t  and\\t  then\\t  q72h\\t   PO.  Horses \u2022\\t\\tFor\\tR. equi:\\t10\\tmg/kg\\tq24h\\tPO\\tinitially\\tfor\\t5\\tdays\\tand\\tthen\\tq48h\\tafter\\ta\\tresponse is seen. \u2022\\t\\tFoals:\\t10\\tmg/kg\\tq48h,\\tPO.\\tFor\\tfoals,\\tthe\\t1-\\tg\\tpacket\\tcan\\tbe\\tmixed\\twith\\twater\\tto create suspension for oral administration. \u2022\\t\\tAdult\\thorses:\\t10\\tmg/kg\\tPO,\\tq48h. Cattle \u2022\\t\\t10\\tmg/kg\\tIM. Drug Interactions Drug interactions have not been reported in animals. This class of drugs has the potential to inhibit some cytochrome P450 enzymes that are involved in drug metabolism, but azithromycin is less likely than erythromycin or clarithromycin to interfere with cytochrome P450 enzymes. Calves \u2022\\t\\tFor\\tcryptosporidiosis:\\t33\\tmg/kg\\tonce\\tdaily\\tfor\\t7\\tdays\\tPO. Regulatory Information Withdrawal times have not been established for animals producing food, but when administered to cattle, it persisted in milk with a half- life of approximately 160 hours and persisted longer in mastitic milk than in normal milk. B Benazepril Hydrochloride 79 Benazepril Hydrochloride ben- ay\u2032zeh- pril  hye- droe- klor\u2032ide Trade and other names: Lotensin (human preparation) and Fortekor, Benazecare (veterinary preparation)","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\ta\\thistory\\tof\\tvomiting.\\tAdministration\\tto\\tadult horses has been associated with diarrhea. Do not administer IV solution as a bolus or IM. A","indications":"Indications and Clinical Uses Azithromycin is indicated for treatment of bacterial infections. It also has been used in people for a variety of respiratory infections in which the benefits are believed to be partially, if not predominantly, caused by the immunomodulatory properties. Antimicrobial spectrum is primarily against gram- positive bacteria. Azithromycin is not recommended for serious gram- negative infections. It may be used to treat infections caused by Mycoplasma and other atypical organisms. Azithromycin has been used to treat intracellular organisms because of its ability to concentrate in leukocytes. One of the uses has been to treat infections caused by Rhodococcus equi in foals. However, in one comparative study, clarithromycin plus rifampin had better clinical success in foals than azithromycin plus rifampin. In\\tfoals,\\tazithromycin,\\tadministered\\tat\\ta\\tdosage\\tof\\t10\\tmg/kg\\tq48h\\toral\\tduring the first 2 weeks after birth has been used prophylactically to decrease Rhodococcus spp. infection in foals at high risk (farms with high endemic risk). In horses, azithromycin also has been used to treat proliferative enteritis caused by Lawsonia intracellularis. Azithromycin has been used in cats to treat upper respiratory infections. There are no controlled clinical trials to document success for this use; however, this treatment has been common among veterinarians. Azithromycin administered to cats with infections caused by Chlamydophila felis (formerly Chlamydia psittaci), at 10\u201315 mg/kg once daily for 3 days and thereafter two times per week, was not effective for eliminating the organism, although clinical signs improved (perhaps via the immunomodulatory effects). However, azithromycin was not effective in cats for treatment of Mycoplasma haemofelis (hemobartonellosis). When azithromycin was administered to dogs with pyoderma at either 10 mg/ kg on day 1 followed by 5 mg/kg on days 2 through 5 or 5 mg/kg given 2 days/ wk for 3 weeks, the response was equal statistically to cephalexin at 22 mg/kg twice daily. However, azithromycin is not a preferred drug for treating pyoderma in dogs. In dairy calves, azithromycin administration significantly suppressed shedding of Cryptosporidium parvum and improved clinical signs. However, in cattle and pigs, other injectable long- acting macrolides approved for those species are recommended over azithromycin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Azithromycin has a history of a favorable safety profile after many years of use in people. However, because it is not approved for animals, adverse reaction reports are few and inconsistent. Severe adverse effects to azithromycin have not been reported in publications in which it was administered to animals. However, vomiting is likely with high doses. Diarrhea may occur in some patients. Changes in the consistency of the feces and diarrhea have been reported in horses that were administered recommended doses. The long- term safety in adult horses is not known. A warning occurs on the human label warning of potentially serious cardiac arrhythmias from azithromycin use, but these problems have not been observed in animals.","notes":"Instructions for Use Azithromycin may be better tolerated than erythromycin. A primary difference from other antibiotics is the high intracellular concentrations achieved and long half- life that allows for intermittent administration. Although azithromycin has been commonly used for infections in dogs and cats, there is insufficient clinical trial evidence for most of these uses. Doses listed in the dosage section are based primarily on anecdotal accounts and clinical experience rather than efficacy studies. To\\tprepare\\tIV\\tsolution,\\tadd\\t4.8\\tmL\\tof\\tsterile\\twater\\tto\\teach\\t500-\\tmg\\tvial\\tand\\tshake. Further\\tdilute\\tthis\\tsolution\\twith\\teither\\ta\\t500-\\t\\tor\\t250-\\tmL\\tdiluent\\tto\\ta\\tsolution\\tof\\t1\\tor 2 mg/mL. When administered IV, a 1- mg/mL solution should be administered over a 3- hour period, or 2 mg/mL should be administered over 1 hour. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsensitive\\torganisms\\tis\\t\u22642 mcg/mL based on a human clinical breakpoint. Formulations \u2022\\t\\tAzithromycin\\tis\\tavailable\\tin\\t250-\\t,\\t500-\\t   ,\\tand\\t600-\\tmg\\ttablets;\\t100-\\t\\tand\\t200-\\tmg/5 mL oral suspension; and 500- mg vials for injection. Also, 1- g packets are available for mixing with water. Stability and Storage Azithromycin is stable if maintained in manufacturer\u2019s original formulation. Stability has not been reported for compounded formulations. IV solution is stable after reconstitution\\tfor\\t48\\thours\\tat\\troom\\ttemperature.","original_category":"Antibacterial"},{"name":"Carbenicillin","active_ingredient":"Carbenicillin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tCarbenicillin:\\t40\u201350\\tmg/kg\\tand\\tup\\tto\\t100\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tSQ.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Carbimazole kar- bih\u2032mah- zole Trade and other names: Neomercazole, Vidalta","contraindications":"Contraindications and Precautions Use cautiously in patients sensitive to penicillins (e.g., allergy). Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tDo\\tnot\\tmix\\tin\\tvial\\twith\\tother\\tdrugs because inactivation may result.","indications":"Indications and Clinical Uses Carbenicillin has been used to treat gram- negative infections in animals, including infections caused by P. aeruginosa, but carbenicillin has been discontinued and is no longer available. It has been replaced by other broad- spectrum agents such as piperacillin\u2013tazobactam. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Carbenicillin, like other penicillin drugs, may cause allergy. Carbenicillin may cause bleeding problems in some animals by interfering with platelets.","notes":"Instructions for Use Carbenicillin has a short half- life and should be administered frequently for optimum bactericidal effect. Carbenicillin injection often is administered with an aminoglycoside when treating Pseudomonas infections. Do not mix with aminoglycosides prior to administration, or inactivation will result. Carbenicillin indanyl sodium is the oral formulation of carbenicillin but attains concentrations that are only sufficient for treating urinary tract infections (UTIs). Do not use for systemic infections. 126    Carbimazole Patient Monitoring and Laboratory Tests Culture and sensitivity testing recommended to guide therapy. Clinical and Laboratory Standards Institute (CLSI) breakpoints are \u2264128 mcg/mL when testing for Pseudomonas- susceptible organisms and \u226416 mcg/mL for other gram- negative organisms. Formulations \u2022\\t\\tCarbenicillin\\thas\\tbeen\\tunavailable\\tbecause\\tother\\tdrugs\\tare\\tused\\tas\\ta\\treplacement. However, older formulations include 1- , 2- , 5- , 10- , and 30- g vials for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stable at pH of 6.5, but rate of degradation is greater at higher or lower pH. Use quickly after reconstitution of vials for injection.","original_category":"Antibacterial"},{"name":"Cefaclor","active_ingredient":"Cefaclor","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t15\u201320\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\t15\u201320\\tmg/kg\\tq8h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. C Cefadroxil 137 Cefadroxil sef- ah- drox\u2032il Trade and other names: Cefa- Tabs and Cefa- Drops (veterinary preparations) and Duricef and generic (human preparation)","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These\\tcephalosporins\\tare\\tthose\\tthat\\thave\\tan\\tN-\\tmethylthiotetrazole\\t(NMTT)\\tside chain and include cefotetan, cefamandole, and cefoperazone. Oral absorption has not been measured in large animals, and cefaclor is not recommended unless information derived from pharmacokinetic or efficacy studies is available. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs in a compounded formulation because inactivation may result.","indications":"Indications and Clinical Uses Cefaclor is not used commonly in veterinary medicine because other cephalosporins are in more widespread use. However, it may be indicated for treatment of infections caused by bacteria that are resistant to first- generation cephalosporins. Although it has been used as oral therapy, the extent of oral absorption and efficacy information is not available for dogs or cats. Dosing regimens and indications are primarily derived from extrapolation and anecdotal information. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Oral administration can potentially produce vomiting and diarrhea in small animals.","notes":"Instructions for Use It is used primarily when resistance has been demonstrated to first- generation cephalosporins and other alternatives have been considered. Because there is very little information to guide dosing for cefaclor, other oral cephalosporins should be considered before using cefaclor, such as cefpodoxime or cephalexin. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\tbacteria\\tis\\t\u22648 mcg/mL for humans, but this may not apply to isolates from animals. The breakpoint for cefazolin could potentially be used to predict activity for treating lower UTIs in dogs. Formulations \u2022\\t\\tCefaclor\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules\\tand\\t25-\\t,\\t37.5-\\t   ,\\t50-\\t  ,\\tand 75- mg/mL oral suspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Cefadroxil","active_ingredient":"Cefadroxil","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t22\\tmg/kg\\tq12h\\tPO,\\tup\\tto\\t30\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t22\\tmg/kg\\tq24h\\tPO.  Foals \u2022\\t\\t30\\tmg/kg\\tq12h\\tPO.\\tNote:\\tOral\\tabsorption\\tis\\tadequate\\tonly\\tin\\tfoals\\tand\\tnot\\tin adults or ruminants. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefazolin Sodium sef- ah\u2032zoe- lin  so\u2032dee- um Trade and other names: Ancef, Kefzol, and generic brands","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs in a compounded formulation because inactivation may result. 138    Cefazolin Sodium","indications":"Indications and Clinical Uses Like other first- generation cephalosporins, it is indicated for treating common infections in animals, including UTIs, skin and soft tissue infections, pyoderma and other dermal infections, and pneumonia caused by susceptible bacteria. Efficacy against infections caused by anaerobic bacteria is unpredictable. The use in horses is rare. Although there is adequate oral absorption in foals, it is poorly absorbed in adult horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Cefadroxil has been known to cause vomiting after oral administration in dogs. Some estimates show that this can occur in up to 10% of treated dogs. If administered orally to adult horses, diarrhea is possible. Oral treatment to horses is.","notes":"Instructions for Use Spectrum of cefadroxil is similar to other first- generation cephalosporins. The FDA-\\t   approved\\tlabel\\tis\\tappropriate\\tfor\\tdosing\\tranges;\\thowever,\\tthe\\tavailability\\tin most\\tcountries\\thas\\tdiminished,\\tand\\tcephalexin\\tis\\tused\\tmore\\twidely\\tinstead.\\tFor susceptibility test, use cephalothin or cephalexin as test drug to predict susceptibility to cefadroxil. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22642 mcg/mL using cephalexin as the test to predict susceptibility to cefadroxil. Cephalothin or cephalexin can be used as a marker to test for sensitivity to cefadroxil, but cephalexin is preferred. For\\turine\\tisolates,\\ta\\thigher\\tbreakpoint\\tof\\t\u226416 mcg/mL can be used using cefazolin or other first- generation cephalosporins in the test. Formulations \u2022\\t\\tCefadroxil\\tis\\tavailable\\tin\\t50-\\tmg/mL\\toral\\tsuspension\\tand\\t50-\\t,\\t100-\\t   ,\\t200-\\t   ,\\tand 1000- mg tablets for veterinary use. However, availability of veterinary- labeled tablets has been inconsistent. It is also available in 500- mg capsules and 25- , 50- , and 100- mg/mL suspension for human use. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Avoid moisture to prevent hydrolysis. Suspension is stable for 14 days refrigerated and 10 days at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Cefazolin Sodium","active_ingredient":"Cefazolin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t25\\tmg/kg\\tq6h\\tIV\\tor\\tIM. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\t1.3\\tmg/kg\\tloading\\tdose\\tfollowed\\tby\\t1.2\\tmg/kg/h. \u2022\\t\\tPerisurgical\\tuse:\\t22\\tmg/kg\\tIV\\tq2h\\tduring\\tsurgery.  Horses \u2022\\t\\t25\\tmg/kg\\tq6h\\tIM\\tor\\tIV. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefdinir sef\u2032dih- neer Trade and other names: Omnicef","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result. 140    Cefdinir","indications":"Indications and Clinical Uses Cefazolin, because it is injectable, is the most common drug to be administered prophylactically prior to surgery. It is one of the most frequently injected cephalosporin antibiotics used in small animals. Like other first- generation cephalosporins, it is indicated for treating common infections in animals, including UTIs, soft tissue infections, pyoderma and other dermal infections, and pneumonia. Efficacy against infections caused by anaerobic bacteria is unpredictable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins; however, bleeding problems have not been observed from cefazolin. Some cephalosporins have caused seizures, but this is a rare problem. When administered during surgery, it did not adversely affect cardiovascular function in dogs.","notes":"Instructions for Use Cefazolin is a commonly used first- generation cephalosporin as an injectable drug for prophylaxis for surgery and for acute therapy for serious infections. When performing susceptibility testing, cefazolin should be tested separately because it may be more active than some of the other first- generation cephalosporins. Cefazolin is slightly more active against some gram- negative bacilli compared with other first-generation cephalosporins. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22642 mcg/mL for coagulase- positive  staphylococci, Pasteurella multocida, streptococci beta- hemolytic group, and E. coli. It may be used to predict susceptibility to other first- generation cephalosporins when testing isolates from lower UTIs. The breakpoint for testing urinary isolates is \u226416 mcg/mL. Formulations \u2022\\t\\tCefazolin\\tis\\tavailable\\tin\\t50\\tand\\t100\\tmg/50\\tmL\\tfor\\tinjection\\tin\\t1-\\tg\\tor\\t500-\\tmg vials. Reconstituted to produce 275 or 330 mg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. If slight yellow discoloration occurs, the solution is still stable. After reconstitution, it is stable for 24 hours at room temperature and 14 days refrigerated. It remains stable if frozen for 3 months.","original_category":"Antibacterial"},{"name":"Cefdinir","active_ingredient":"Cefdinir","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tDose\\tnot\\testablished.\\tHuman\\tdosage\\tis\\t7\\tmg/kg\\tq12h\\tPO,\\tand\\tsimilar\\tdosages\\tof 10 mg/kg q12h PO have been used in animals.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. 142    Cefepime Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefepime sef\u2032ah- peem Trade and other names: Maxipime","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an\\tNMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Oral absorption has not been measured in large animals, and cefdinir is not recommended unless information derived from pharmacokinetic or efficacy studies is available. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs in a compounded formulation because inactivation may result.","indications":"Indications and Clinical Uses Cefdinir is an oral third- generation cephalosporin used in people. Although it has been used as oral therapy, the extent of oral absorption and efficacy information is not available for dogs or cats. Dosing regimens and indications are primarily derived from extrapolation and anecdotal information. It has potential efficacy for infections of the skin, soft tissues, and urinary tract; however, in most instances, other cephalosporins such as cefpodoxime proxetil may be substituted instead. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Rare bleeding disorders have been known to occur with some cephalosporins. Oral cephalosporins can produce vomiting and diarrhea in small animals.","notes":"Instructions for Use Use in veterinary medicine has not been reported. Use and doses are extrapolated from human preparations. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22641 mcg/mL using the human breakpoint. Breakpoints for isolates from animals are not available. Formulations \u2022\\t\\tCefdinir\\tis\\tavailable\\tin\\t300-\\tmg\\tcapsules\\tand\\t25-\\tmg/mL\\toral\\tsuspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Cefepime","active_ingredient":"Cefepime","species":["Canine","Equine"],"dosage":"Dogs \u2022\\t\\t40\\tmg/kg\\tq6h\\tIM\\tor\\tIV. \u2022\\t\\tCRI:\\t1.4\\tmg/kg\\tloading\\tdose\\tfollowed\\tby\\t1.1\\tmg/kg/h.  Foals \u2022\\t\\t11\\tmg/kg\\tq8h\\tIV. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefixime sef- iks\u2032eem Trade and other names: Suprax","contraindications":"Contraindications and Precautions Do not administer to patients with sensitivity or allergy to cephalosporins. Reduce dose to less frequent intervals (e.g., q12h or q24h) in patients with renal failure. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Cefepime is a fourth- generation cephalosporin. Although it has a broader spectrum than other cephalosporins, the use has been limited in veterinary medicine. Some studies in humans have not shown advantages over other antibacterial agents. Experimental studies have been conducted in foals, adult horses, and dogs to establish doses, but reports of efficacy are not available. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cefepime is generally safe. However, clinicians should consider the same possible side effects as for other cephalosporins, which include the possibility of bleeding disorders, allergy, vomiting, and diarrhea.","notes":"Instructions for Use Reconstitute with sterile water, sodium chloride, and 5% dextrose. It may be reconstituted with 1% lidocaine if pain from injection is a problem. Reconstituted C Cefixime 143 solutions are stable for 24 hours at room temperature and 7 days in the refrigerator. Do not mix with other injectable antibiotics. Injection vials also contain L- arginine. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22642 mcg/mL using the human breakpoint for Enterobacteriaceae and \u22648 mcg/mL for testing P. aeruginosa. Breakpoints for isolates from animals are not available. Formulations \u2022\\t\\tCefepime\\tis\\tavailable\\tin\\t500-\\tmg,\\t1-\\t   g,\\tand\\t2-\\tg\\tvials\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Observe manufacturer\u2019s recommendations for stability after vial is reconstituted.","original_category":"Antibacterial"},{"name":"Cefixime","active_ingredient":"Cefixime","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tUTI:\\t5\\tmg/kg\\tq12\u201324h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. C Cefotaxime Sodium 145 Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefotaxime Sodium sef- oh- taks\u2032eem so\u2032dee- um Trade and other names: Claforan and generic","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants.\\tThese\\tcephalosporins\\tare\\tthose\\tthat\\thave\\tan\\tNMTT\\tside\\tchain\\tand include cefotetan, cefamandole, and cefoperazone. Oral absorption has not been measured in large animals, and cefixime is not recommended unless information derived from pharmacokinetic or efficacy studies is available. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs in a compounded formulation because inactivation may result.","indications":"Indications and Clinical Uses Cefixime is not used clinically often in veterinary medicine because availability of oral products has diminished and because other oral agents are available. Cefixime is one of the few oral third- generation cephalosporins. It has been administered orally in dogs and cats to treat infections of the skin, soft tissues, and urinary tract. It is not as active as cefpodoxime against Staphylococcus spp. Because of greater availability of cefpodoxime for animals, it is substituted instead for most indications. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Vomiting and diarrhea are possible from oral cephalosporins.","notes":"Instructions for Use Although not approved for veterinary use, pharmacokinetic studies in dogs have provided\\trecommended\\tdoses.\\tNote\\tthat\\tbreakpoint\\tfor\\tsensitivity\\tis\\tlower\\tthan for other cephalosporins, indicating that organisms tested as susceptible to other cephalosporins may not be susceptible to cefixime. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22641 mcg/mL using the human breakpoint. Breakpoints for isolates from animals are not available. Formulations \u2022\\t\\tCefixime\\tis\\tavailable\\tin\\t20-\\t\\tor\\t40-\\tmg/mL\\toral\\tsuspension\\tand\\t400-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Cefotaxime Sodium","active_ingredient":"Cefotaxime Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t25\\tmg/kg\\tq8\\th\\tIV,\\tIM,\\tor\\tSQ. \u2022\\t\\tCRI:\\t3.2\\tmg/kg\\tloading\\tdose\\tfollowed\\tby\\t5\\tmg/kg/h. Cats \u2022\\t\\t25\\tmg/kg\\tq8h\\tIV,\\tIM,\\tor\\tSQ.  Foals \u2022\\t\\t40\\tmg/kg\\tq6h\\tIV\\tbolus\\tinjection\\tover\\t1\\tminute. \u2022\\t\\tCRI\\tdose\\tfor\\tfoals:\\tAdminister\\t4\\tmg/kg\\tIV\\tloading\\tdose\\tfollowed\\tby\\t2.5\\tmg/kg per hour, IV infusion. Horses \u2022\\t\\t25\\tmg/kg\\tq6h,\\tIV. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefotetan Disodium sef\u2032oh- tee- tan  dye- soe\u2032dee- um Trade and other names: Generic","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result. 146    Cefotetan Disodium","indications":"Indications and Clinical Uses Cefotaxime is used when resistance is encountered to other antibiotics, or in severe infections when highly active antibiotics are needed. The availability has diminished in recent years, and ceftazidime can be used as a substitute. It should not be used for routine infections in\\tveterinary\\tmedicine\\twhen\\tother\\tdrugs\\twill\\tbe\\tactive.\\tAlthough\\tcefotaxime\\tis\\tnot\\tFDA approved for use in animals, it can be legally administered as an extralabel injectable third- generation cephalosporins used in small animals. The use in large animals is uncommon, and extralabel administration of cephalosporins is illegal in the United States. Cefotaxime has a short half- life and must be injected frequently. It is not absorbed from oral administration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins.","notes":"Instructions for Use Third- generation cephalosporin is used when resistance to first-  and second- generation cephalosporins is encountered. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tA\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\thas\\tnot\\tbeen established for animals. The human susceptible breakpoint of \u22641 mcg/mL for gram- negative Enterobacteriaceae bacteria (e.g., E. coli) can be used as an approximation until animal- specific data are available. Formulations \u2022\\t\\tCefotaxime\\tis\\tavailable\\tin\\t500-\\tmg\\tand\\t1-\\t,\\t2-\\t ,\\tand\\t10-\\tg\\tvials\\tfor\\tinjection. Availability of commercial formulations has diminished. Use ceftazadime as an alternative. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Maximum stability is at pH of 5\u20137. Do not mix with alkaline solutions. Yellow or amber color does not indicate instability. After reconstitution, cefotaxime is stable for 12 hours at room temperature; it is stable for 5 days when stored in plastic syringes or a vial if kept in refrigerator. It is stable for 13 weeks if frozen. IV solutions in 1000 mL are stable for 24 hours at room temperature or 5 days in a refrigerator. Do not refreeze.","original_category":"Antibacterial"},{"name":"Cefotetan Disodium","active_ingredient":"Cefotetan Disodium","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t30\\tmg/kg\\tq8h\\tIV\\tor\\tSQ.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefovecin sef- oh- ve\u2032sin Trade and other names: Convenia","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Cefotetan, a second- generation cephalosporin of the cephamycin group, has greater activity against anaerobic bacteria and gram- negative bacilli than other cephalosporins. Therefore it has been used to treat infections in dogs and cats in which enteric gram- negative bacilli or anaerobes are suspected, including abdominal infections and soft tissue wounds and prior to surgery. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Rare bleeding disorders have been known to occur with some cephalosporins.","notes":"Instructions for Use Cefotetan is a second- generation cephamycin cephalosporin, and if there is no availability, consider cefoxitin as a substitute. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22648 mcg/mL for gram- negative and gram- positive organisms. Formulations \u2022\\t\\tCefotetan\\twas\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\tand\\t10-\\tg\\tvials\\tfor\\tinjection.\\tFormulations\\tmay\\tno longer be commercially available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Observe manufacturer\u2019s recommendations for stability after vial is reconstituted. 148    Cefovecin","original_category":"Antibacterial"},{"name":"Cefovecin","active_ingredient":"Cefovecin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t8\\tmg/kg\\tSQ\\tevery\\t14\\tdays.\\tFor\\tsome\\tindications,\\tinjections\\tmay\\tbe\\trepeated\\tat\\t7 days.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished.\\tIt\\tis\\tnot\\trecommended\\tfor\\tlarge\\tanimal\\tspecies because of pharmacokinetic differences. Regulatory Information Withdrawal times are not established for animals that produce food, and cefovecin should not be administered to food- producing animals. The extralabel administration of cephalosporins to food- producing animals in the United States is a violation of FDA\\tregulations. Cefoxitin Sodium se- fox\u2032 i- tin soe\u2032dee- um Trade and other names: Mefoxitin, Mefoxin, Cefoxil, and generic","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Cefovecin is approved for use in dogs and cats. It is approved in the United States for skin and soft tissue infections but also has been used to treat UTIs, for which it is approved in some countries. The efficacy of cefovecin for treating infections in other sites,\\tsuch\\tas\\tthe\\trespiratory\\ttract,\\tbone,\\tand\\tCNS,\\thas\\tnot\\tbeen\\testablished.\\tThe\\thigh protein binding may limit penetration to some of these sites. In cats, it is approved for treating skin and soft tissue infections that are caused by highly susceptible bacteria such as strains of P. multocida. Experience is limited to administration of cefovecin in dogs and cats; the use in other species, such as horses, large animals, birds, and reptiles, is not recommended until specific dosing recommendations are published. Protein binding is lower in these species, which causes a much shorter half- life compared with dogs or cats. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects The animal safety studies have produced few serious adverse reactions. In dogs and cats, vomiting and diarrhea have been observed in a dose- related manner. With approved doses, mild GI upset may be observed for 2\u20133 days. Injection- site irritation and transient edema occurred with increasing frequency in a dose- related manner and with repeat injections. The long half- life indicates that drug concentrations persist in animals for at least 60 days after an injection, but at this time, this has not produced adverse reactions attributed to a long persistence of drug in tissues. Allergic reactions are possible with any cephalosporin, but cross- reactivity between penicillin allergy and cephalosporin allergy is low.","notes":"Instructions for Use The approved label in the United States indicates that therapeutic concentrations are maintained for an interval of 7 days in dogs. However, pharmacokinetic studies indicated that drug concentrations persist long enough for a 14- day interval for some\\tindications.\\tIn\\tCanada\\tand\\tEurope,\\tthe\\tapproved\\tlabel\\tdose\\tis\\t8\\tmg/kg\\tSQ once every 14 days, and efficacy has been demonstrated with a 14- day interval for administration. The injection may be repeated for infections that require longer than 14 days for a cure (e.g., canine pyoderma). Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tThe\\tapproved\\tCLSI-\\tapproved\\tbreakpoints\\tfor\\tsusceptibility testing are \u22640.5 mcg/mL for canine S. pseudintermedius isolates from skin and soft tissues and \u22640.12 mcg/mL for Streptococcus spp. Isolates of the gram- negative Enterobacteriaceae may test clinically resistant using these breakpoints. The breakpoint is \u22640.12\\tmcg/mL\\tfor\\tfeline\\tskin\\tand\\tsoft\\ttissue\\tisolates.\\tFor\\tisolates from the lower urinary tract in dogs and cats, the susceptible breakpoint is \u22642 mcg/mL. Formulations \u2022\\t\\tCefovecin\\tis\\tavailable\\tin\\t10-\\tmL\\tvials\\tcontaining\\t800\\tmg.\\tWhen\\treconstituted,\\tit\\tis 80 mg/mL. Stability and Storage Store in original vial in the refrigerator protected from light. Do not freeze. Once reconstituted, vial should be used within 56 days (the original label had a limitation of 28 days). The reconstituted solution may turn slightly yellow, which does not affect potency. 150    Cefoxitin Sodium","original_category":"Antibacterial"},{"name":"Cefoxitin Sodium","active_ingredient":"Cefoxitin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t30\\tmg/kg\\tq8h\\tIM,\\tSQ,\\tor\\tIV.\\t22\\tmg/kg\\tIV\\tfor\\tpresurgical\\tuse.  Horses \u2022\\t\\t20\\tmg/kg\\tq4\u20136h\\tIV\\tor\\tIM. 152    Cefpodoxime Proxetil Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefpodoxime Proxetil sef- poe- doks\u2032eem prahx\u2032ih- til Trade and other names: Simplicef (veterinary preparation), Vantin (human preparation), and generic","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that\\thave\\tan\\tNMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand cefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Cefoxitin, a cephalosporin of the cephamycin group, has greater activity against anaerobic bacteria and gram- negative bacilli than other cephalosporins. Therefore, it has been used to treat infections in dogs and cats in which enteric gram- negative bacilli or anaerobes are suspected, including abdominal infections and soft tissue wounds, and prior to surgery. Because cefoxitin is of the cephamycin group of cephalosporins, it may be resistant to many ESBLs and may be used to treat some multidrug- resistant bacterial infections as an alternative to carbapenems. Susceptibility should be confirmed with a test before considering treatment. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Cefoxitin has been administered to dogs during surgery without adversely affecting their cardiovascular function.","notes":"Instructions for Use Second- generation cephalosporin is often used when activity against anaerobic bacteria is desired. Cefoxitin is similar to another cephamycin, cefotetan, but because cefotetan is no longer available, cefoxitin can be used as a substitute. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22648 mcg/mL using the human breakpoint for Enterobacteriaceae. Breakpoints for isolates from animals are not available. Cefoxitin should not be used to test for methicillin- resistant strains of S. pseudintermedius from animals. Formulations \u2022\\t\\tCefoxitin\\tis\\tavailable\\tin\\t1-\\t\\tand\\t2-\\tg\\tvials\\tfor\\tinjection\\t(20\\tor\\t40\\tmg/mL). Stability and Storage Store in a tightly sealed container, in the freezer at \u201325\xb0C to \u201310\xb0C unless otherwise instructed by the manufacturer. Thaw at room temperature or in refrigerator to dissolve crystals before administration. Do not heat or place in microwave oven. After thawing, solution is potent for 24 hours at room temperature or for 21 days in refrigerator. Protect from light. After it has thawed, do not refreeze.","original_category":"Antibacterial"},{"name":"Cefpodoxime Proxetil","active_ingredient":"Cefpodoxime Proxetil","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\u201310\\tmg/kg\\tq24h\\tPO. Cats \u2022\\t\\tA\\tdose\\thas\\tnot\\tbeen\\testablished\\tby\\tthe\\tmanufacturer\\tfor\\tcefpodoxime\\tproxetil. Some veterinarians have extrapolated from the canine dose. 154    Cefquinome Sulfate  Horses \u2022\\t\\t10\\tmg/kg\\toral\\tq6\u201312h.\\tThe\\t12-\\thour\\tinterval\\tis\\tappropriate\\tfor\\tKlebsiella spp., Pasteurella spp., and streptococci. More frequent intervals may be needed for more resistant organisms. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Cefquinome Sulfate sefs quin- ome sul\u2032 fate Trade and other names: Cobactan and Cephaguard","contraindications":"Contraindications and Precautions This drug is best taken with food to improve oral absorption. Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants.\\tThese\\tcephalosporins\\tare\\tthose\\tthat\\thave\\tan\\tNMTT\\tside\\tchain\\tand include cefotetan, cefamandole, and cefoperazone. Drug Interactions There are no important drug interactions reported for animals, but oral absorption of cefpodoxime in people is inhibited by H 2 - blockers (e.g., cimetidine and ranitidine) and antacids, which can decrease oral absorption by 30%. Cephalosporins may be administered with other antibiotics to increase the spectrum of activity. However, do not mix with other drugs in a compounded formulation because inactivation may result.","indications":"Indications and Clinical Uses Cefpodoxime is indicated for treatment of skin and other soft tissue infections in dogs caused by susceptible organisms. Efficacy has been established in dogs for treatment of skin and soft tissue infections. Cefpodoxime has greater activity against gram- negative bacilli than first- generation cephalosporins; therefore it may be effective for some gram- negative infections that would not respond to first- generation cephalosporins. Although not currently registered for treatment of UTIs, approximately 50% of administered dose is excreted in urine and expected to be active for treating UTIs caused by common pathogens. Although not registered for cats or tested in cats, no adverse effects have been reported from occasional use. However, oral absorption in cats has not been examined. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Vomiting and diarrhea can occur from oral administration of cephalosporins, but because cefpodoxime proxetil is administered as an inactive pro- drug, the GI reactions may be less than other oral cephalosporins.","notes":"Instructions for Use US\\tFDA\\tapproval\\tin\\tdogs\\tincludes\\tskin\\tand\\tsoft\\ttissue\\tinfections.\\tIt\\talso\\thas\\tbeen\\tused for UTIs, and based on spectrum and tissue distribution, it has been used for other infections. There has also been occasional anecdotal use in cats on an extralabel basis. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tisolated\\tfrom animals is \u22642 mcg/mL. Strains of E. coli and Klebsiella spp. that are ESBLs may be clinically resistant. MRS are resistant to cefpodoxime. Formulations \u2022\\t\\tCefpodoxime\\tproxetil\\tis\\tavailable\\tin\\t100-\\t\\tand\\t200-\\tmg\\ttablets\\tand\\t10-\\t\\tand\\t20-\\tmg/ mL oral suspension (human preparation). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded tablets has not been evaluated. Avoid exposure to moisture.","original_category":"Antibacterial"},{"name":"Cefquinome Sulfate","active_ingredient":"Cefquinome Sulfate","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t2\\tmg/kg\\tIV,\\tIM,\\tor\\tSQ\\tq12h.  (Based on Registration Label in Europe) Cattle \u2022\\t\\tBRD:\\t2.5\\tmg/kg\\tIM\\tq48h\\t(1\\tmL\\tof\\t7.5%\\tsuspension\\tper\\t30\\tkg). \u2022\\t\\tRespiratory\\tdisease\\tand\\tfoot\\trot:\\t1\\tmg/kg\\t(2\\tmL\\tper\\t50\\tkg\\tof\\t2.5%\\tsuspension)\\tIM once daily for 3\u20135 days. \u2022\\t\\tMastitis\\t(E. coli)\\tsystemic\\tinvolvement:\\t1\\tmg/kg\\t(2\\tmL\\tper\\t50\\tkg\\tof\\t2.5% suspension) IM once daily for 2 days. \u2022\\t\\tSepticemia\\tin\\tcalves\\t(E. coli):\\t2\\tmg/kg\\t(4\\tmL\\tper\\t50\\tkg\\tof\\t2.5%\\tsuspension)\\tIM once daily for 3\u20135 days. Pigs \u2022\\t\\tRespiratory\\tinfections:\\t2\\tmg/kg\\t(2\\tmL\\tof\\t2.5%\\tsuspension)\\tIM\\tin\\tthe\\tneck\\tonce daily for 2 days. \u2022\\t\\tMeningitis,\\tarthritis,\\tor\\tdermatitis\\tin\\tpiglets:\\t2\\tmg/kg\\t(2\\tmL\\tof\\t2.5%\\tsuspension) once daily IM for 5 days. Horses \u2022\\t\\tRespiratory\\tinfections\\tcaused\\tby\\tS. equi:\\t1\\tmg/kg\\t(1\\tmL\\tsolution\\tper\\t45\\tkg)\\tof solution IV or IM q24h for 5\u201310 days. \u2022\\t\\tSystemic\\tinfection\\t(especially\\tsepticemia\\tin\\tfoals)\\tcaused\\tby\\tE. coli:\\t1\\tmg/kg\\t(1\\tmL per 45 kg) IV or IM q12h for 6\u201314 days. Regulatory Information For\\tcefquinome\\tsuspension,\\tdo\\tnot\\tuse\\tin\\tlactating\\tcattle\\tproducing\\tmilk\\tfor\\thuman consumption (during lactation or the dry period). Do not use within 2 months prior to first calving in heifers intended for the production of milk for human consumption. In Europe, the\\tmeat\\twithdrawal\\ttimes\\tare\\t13\\tdays\\tafter\\t2.5\\tmg/kg\\tSQ,\\t5\\tdays\\tafter\\t1\\tmg/kg\\tIM,\\tand 3 days in pigs. Milk withdrawal time after systemic use is 24 hours. After intramammary administration, the meat withdrawal time is 4 days, and the milk discard time is 5 days. Cefquinome is not approved in the United States, and the extralabel administration of it to food-\\t  producing\\tanimals\\tin\\tthe\\tUnited\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations. Ceftazidime sef- tah\u2032zih- deem Trade and other names: Fortaz, Ceptaz, Tazicef, and Tazidime","contraindications":"Contraindications and Precautions Do not administer to animals prone to sensitivity to beta- lactams. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Cefquinome is used in cattle, pigs, and horses to treat infections caused by susceptible pathogens. It is registered in Europe for treatment of respiratory disease, E. coli sepsis in calves, and interdigital necrobacillosis (foot rot) in lactating cows in many countries. Cefquinome ointment has been administered intramammary for treatment of E. coli mastitis in dairy cattle. In Europe, it is also registered for treatment of swine respiratory disease (SRD), arthritis, meningitis, and dermatitis caused by P. multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae, Streptococcus suis, Staphylococcus hyicus, and other cefquinome- sensitive organisms and mastitis- metritis- agalactia (MMA) syndrome with involvement of E. coli, Staphylococcus spp., Streptococcus spp., and other cefquinome- sensitive organisms. In horses, it is registered for respiratory infection caused by S. equi subsp. zooepidemicus and systemic bacterial infection (sepsis) caused by E. coli. The use of cefquinome for small animals is very limited, but in some countries where it is available, it has been injected for short- term treatments. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals\\t(allergy).\\tCefquinome\\tinjection\\tSQ\\tmay\\tcause\\tsome\\tinjection-\\tsite reactions. High doses may produce diarrhea in horses, but if doses are maintained within the range listed in the dosing section, it has been safe in most horses.","notes":"Instructions for Use Cefquinome is registered in Europe for treatment of infections in cattle, pigs, and horses.\\tIn\\tthe\\tUnited\\tStates,\\twithout\\tFDA\\tapproval,\\tthe\\tuse\\twould\\tbe\\ta\\tviolation. Cefquinome\\tin\\tcattle\\tcan\\tbe\\tadministered\\tSQ\\tor\\tIM,\\tdepending\\ton\\tthe\\tformulation. In pigs, it is administered IM. In horses, the solution can be administered IV initially and then switched to IM injections. Patient Monitoring and Laboratory Tests Monitor\\tCBC\\tif\\thigh\\tdoses\\tare\\tadministered\\tfor\\tlong\\tperiods.\\tSusceptibility\\ttesting: CLSI guidelines for susceptible bacteria are not available. Formulations \u2022\\t\\tIn\\tcountries\\twhere\\tcefquinome\\tis\\tavailable,\\tit\\tis\\ta\\t7.5%\\t(75-\\tmg/mL)\\tinjectable suspension, 2.5% (25- mg/mL) injectable suspension, a powder for reconstitution to be used IV in horses and foals (4.5% or 45 mg/mL in a 30-  or 100- mL vial), and an intramammary ointment (75 mg in an 8- g syringe). Stability and Storage After\\tthe\\tcontainer\\tis\\topened,\\tthe\\tshelf\\tlife\\tis\\t28\\tdays.\\tFor\\tthe\\t4.5%\\tIV\\tsolution,\\tthe shelf life after reconstitution is 10 days when stored in a refrigerator (2\xb0C\u20138\xb0C). 156    Ceftazidime","original_category":"Antibacterial"},{"name":"Ceftazidime","active_ingredient":"Ceftazidime","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t25\\tmg/kg\\tq8h\\tIV,\\tSQ,\\tor\\tIM.\\t(There\\tmay\\tbe\\tsome\\tslight\\tsting\\tfrom\\tSQ\\tand\\tIM injection.) \u2022\\t\\tConstant\\tIV\\tinfusion:\\tGive\\tloading\\tdose\\tof\\t2\\tmg/kg\\tfollowed\\tby\\t2\\tmg/kg/h delivered in IV fluids.  Horses \u2022\\t\\t20\\tmg/kg\\tq8h\\tIV\\tor\\tIM. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. Ceftiofur Crystalline- Free Acid sef\u2032tee- oh- fer Trade and other names: Excede and Naxcel XT","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions Do not mix in a vial or syringe with other drugs because inactivation may result. In particular, there may be mutual inactivation if mixed with aminoglycosides. If mixed with vancomycin, precipitation may occur.","indications":"Indications and Clinical Uses Ceftazidime is a third- generation cephalosporin with activity against many gram- negative bacteria resistant to other drugs, especially gram- negative Enterobacteriaceae bacilli (e.g., E. coli, Klebsiella spp.) and P. aeruginosa.\\tAlthough\\tit\\tis\\tnot\\tan\\tFDA-\\tapproved\\tdrug\\tfor animals, it is used often in zoo, exotic, and companion animals because of its activity against many organisms that are resistant to other drugs. Its activity against P. aeruginosa, distinguishes it from other cephalosporins; therefore, it has been used to treat infections in dogs and cats in which enteric gram- negative bacilli or P. aeruginosa, are suspected, including abdominal infections, skin infections, soft tissue wounds, and prior to surgery. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins. Slight\\tirritation\\tor\\ta\\tsting\\tmay\\toccur\\tfrom\\tSQ\\tor\\tIM\\tinjections.","notes":"Instructions for Use Ceftazidime may be reconstituted with 1% lidocaine for IM injection to reduce pain. Ceftazidime contains l- arginine. To make up vials containing sodium carbonate, carbon dioxide will form on reconstitution. Venting may be necessary to release gas. Doses listed for dogs and cats are sufficient for treating infections caused by susceptible bacteria, including P. aeruginosa. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22644 mcg/mL for testing Enterobacteriaceae (e.g., E. coli, Klebsiella spp.) and \u22648 mcg/mL for testing P. aeruginosa. Some ESBL- producing strains of E. coli or Klebsiella spp. may be clinically susceptible to ceftazidime. Formulations \u2022\\t\\tCeftazidime\\tis\\tavailable\\tin\\t0.5-\\t,\\t1-\\t ,\\t2-\\t ,\\tand\\t6-\\t    g\\tvials\\treconstituted\\tto\\t280\\tmg/mL. 158    Ceftiofur Crystalline- Free Acid Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Slight discoloration to yellow or amber may occur without losing potency. Do not mix in vial with other drugs, but it may be mixed with IV fluid solutions. When reconstituted with sterile water for injection, it maintains potency for 12 hours at room temperature or for 3 days under refrigeration. Other testing has confirmed stability for 5 days in the refrigerator. Solutions in sterile water for injection can be frozen after reconstitution in the original container and are stable for 3 months when stored at \u221220\xb0C. If individual dose aliquots are stored in plastic syringes in the freezer for long periods (\u221218\xb0C) it will retain potency for at least 25 days. After it has thawed, it should not be refrozen.","original_category":"Antibacterial"},{"name":"Ceftiofur Crystalline- Free Acid","active_ingredient":"Ceftiofur Crystalline- Free Acid","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tDose\\tnot\\testablished\\tfor\\tthis\\tproduct.\\tSee\\tCeftiofur\\tSodium\\tfor .  Cattle \u2022\\t\\t6.6\\tmg/kg\\twith\\ta\\tsingle\\tSQ\\tinjection\\tin\\tthe\\tmiddle\\tthird\\tof\\tthe\\tposterior\\taspect\\tof the ear. Horses and Foals \u2022\\t\\t6.6\\tmg/kg\\tIM\\tin\\tthe\\tneck\\tmuscle\\t(15\\tmL\\tper\\t1000\\tlb).\\tAdminister\\ta\\tsecond\\tdose in 4 days. Do not administer more than 20 mL in one site. Pigs \u2022\\t\\t5.0\\tmg/kg\\tIM\\tinjection\\tin\\tthe\\tpostauricular\\tregion\\tof\\tthe\\tneck. Regulatory Information Pig\\twithdrawal\\ttimes:\\t14\\tdays. Cattle\\twithdrawal\\ttime\\t(slaughter):\\t13\\tdays.\\tA\\twithdrawal\\tperiod\\thas\\tnot\\tbeen established in preruminating calves. Do not use in calves to be processed for veal. Milk\\twithdrawal:\\tzero\\tdays.\\tThe\\textralabel\\tadministration\\tof\\tcephalosporins\\tto\\tfood- producing\\tanimals\\tin\\tthe\\tUnited\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations. Ceftiofur Hydrochloride sef\u2032tee- oh- fer  hye- droe- klor\u2032ide Trade and other names: Excenel, RTU EZ suspension, and Spectramast DC and Spectramast LC suspension for intramammary treatment","contraindications":"Contraindications and Precautions Do not administer this formulation (suspension) IV. Do not administer to animals prone to sensitivity to beta- lactams. Do not administer to animals at doses higher than label indication. In horses, do not administer more than 20 mL per injection site. Ceftiofur crystalline- free acid should not be used interchangeably with ceftiofur sodium or ceftiofur hydrochloride without consulting label information for differences in dosing and withdrawal times. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Ceftiofur crystalline- free acid is indicated for treatment of SRD caused by A. pleuropneumoniae, P. multocida, S. enterica, H. parasuis, and S. suis. In cattle, it is used for treatment of BRD caused by M. haemolytica, P. multocida, and H. somni. C It also can be administered to control respiratory disease in cattle at high risk of developing BRD (metaphylaxis) associated with M. haemolytica, P. multocida, and H. somni. This formulation also is approved for treating foot rot in cattle (interdigital necrobacillosis) caused by Fusobacterium necrophorum, Porphyromonas levii, and Bacteroides melaninogenicus. It is approved for treatment of acute metritis in dairy cattle via a two- dose regimen. It is approved for treatment and control of SRD associated with A. pleuropneumoniae, P. multocida, H. parasuis, and S. suis. This formulation also is approved for use in horses for treatment of respiratory tract infections caused by susceptible S. equi (S. zooepidemicus) after administration of two injections. Ceftiofur hydrochloride and ceftiofur crystalline- free acid have also been administered extralabel intramammary to dairy cattle. However, there are specific products designed for intramammary use (Spectramast). Ceftiofur crystalline- free acid has been administered to zoo and exotic animals for treatment of infections, but the dose has not been established and is extrapolated from use in livestock. The use of this product in small animals has not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Rare bleeding disorders have been known to occur with some\\tcephalosporins.\\tFor\\tceftiofur,\\tdoses\\tthat\\thave\\texceeded\\tthe\\tapproved label recommendations have caused bone marrow suppression in dogs. Thrombocytopenia and anemia occurred at doses of 6.6 and 11 mg/kg when administered to dogs. High doses have caused diarrhea in horses. Injections of the crystalline- free acid formulation to small animals have caused injection- site lesions in some animals, and this is generally not recommended. In some horses, injections of ceftiofur crystalline- free acid has caused injection- site reactions, consisting of swelling and pain, at the injection site.","notes":"Instructions for Use Dosing information is available for pigs, horses, and cattle; it is not available for other animals. There is no information on the use of ceftiofur crystalline- free acid in dogs or\\tcats.\\tWhen\\tadministering\\tto\\tcattle,\\tthe\\tdose\\tis\\t6.6\\tmg/kg.\\tFor\\tSQ\\tinjection,\\tthe injection should be in the middle third of the posterior aspect of the ear or in the posterior aspect of the ear where it attaches to the head (base of the ear) in beef and nonlactating\\tdairy\\tcattle.\\tSQ\\tinjection\\tis\\tdone\\tin the posterior aspect of the ear where it\\tattaches\\tto\\tthe\\thead\\t(base\\tof\\tthe\\tear)\\tin\\tlactating\\tdairy\\tcattle.\\tFor\\thorses,\\tadminister two\\tIM\\tinjections,\\t4\\tdays\\tapart,\\tat\\ta\\tdose\\tof\\t6.6\\tmg/kg.\\tFor\\tpigs,\\tadminister\\t5\\tmg/kg IM in the postauricular region of the neck. 160    Ceftiofur Hydrochloride Patient Monitoring and Laboratory Tests Monitor\\tCBC\\tif\\thigh\\tdoses\\tare\\tadministered\\tfor\\tlong\\tperiods.\\tSensitivity\\ttesting: CLSI guidelines for susceptible bacteria indicate that susceptible bacteria have MIC values \u22642\\tmcg/mL.\\t(Note\\tthat\\tfor\\tsome\\tcephalosporins\\tused\\tin\\thumans,\\tthe\\tMIC values for susceptibility may be \u22648 mcg/mL.) Formulations \u2022\\t\\tCeftiofur\\tcrystalline-\\tfree\\tacid\\tis\\tavailable\\tin\\tan\\tinjectable\\tsuspension\\tfor\\tcattle\\tat 200 mg/mL ceftiofur equivalents (CE). \u2022\\t\\tCeftiofur\\tcrystalline-\\tfree\\tacid\\tis\\tavailable\\tin\\tan\\tinjectable\\tsuspension\\tfor\\tpigs\\tat 100 mg/mL CE. Stability and Storage Store at room temperature. Shake well before administration. Protect from freezing. Contents should be used within 12 weeks after the first dose is removed.","original_category":"Antibacterial"},{"name":"Ceftiofur Hydrochloride","active_ingredient":"Ceftiofur Hydrochloride","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats Dose not established for this product. See Ceftiofur Sodium for small animal dose.  Cattle \u2022\\t\\t1.1\u20132.2\\tmg/kg\\tq24h\\tfor\\t3\\tdays\\tIM\\tor\\tSQ\\t(1\u20132\\tmL\\tof\\tsuspension\\tper\\t100\\tlb). Maximum injection- site volume is 15 mL. \u2022\\t\\tBRD:\\t2.2\\tmg/kg,\\tSQ\\tor\\tIM\\ton\\tdays\\t1\\tand\\t3\\tof\\ttreatment\\t(48\\thours\\tapart). Dairy Cows \u2022\\t\\tIntrauterine\\t(retained\\tfetal\\tmembranes):\\t1\\tg\\tof\\tceftiofur\\tdiluted\\tin\\t20\\tmL\\tof\\tsterile water infused in uterus once at 14\u201320 days after calving. \u2022\\t \\tIntramammary:\\tSpectramast\\tDC\\t(dry\\tcow):\\t500\\tmg\\t(one\\tsyringe)\\tinjected\\tper quarter\\tat\\tthe\\ttime\\tof\\tdrying\\toff.\\tSpectramast\\tLC\\t(lactating\\tcow):\\tInfuse\\tone\\tsyringe (125 mg) into each affected quarter q24h. This may be continued for 8 days. \u2022\\t\\tTreatment\\tof\\tpostpartum\\tmetritis:\\t2.2\\tmg/kg\\tonce\\tdaily\\tfor\\t5\\tdays\\tSQ\\tor\\tIM. Pigs \u2022\\t\\t3\u20135\\tmg/kg\\tq24h\\tfor\\t3\\tdays\\tIM.\\tMaximum\\tinjection-\\tsite\\tvolume\\tis\\t15\\tmL. Regulatory Information Cattle\\twithdrawal\\ttime:\\t0\\tdays\\tfor\\tmilk;\\t3\\tdays\\tfor\\tmeat.\\tFor\\tthe\\tintramammary suspension, a 16- day slaughter withdrawal time should be used. Pig\\twithdrawal\\ttime:\\t4\\tdays.\\tThe\\textralabel\\tadministration\\tof\\tcephalosporins\\tto food-\\t  producing\\tanimals\\tin\\tthe\\tUnited\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations. Ceftiofur Sodium sef\u2032tee- oh- fer  soe\u2032dee- um Trade and other names: Naxcel","contraindications":"Contraindications and Precautions Do not administer to animals prone to sensitivity to beta- lactams. Do not administer to animals at high doses. Ceftiofur hydrochloride is a sterile suspension and should not be used interchangeably with ceftiofur sodium, which is a solution. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Ceftiofur hydrochloride is used in cattle and pigs for treatment and control of infections caused by susceptible pathogens. It is registered for treatment of respiratory disease in cattle caused by M. haemolytica, P. multocida, and H. somni. It is used for interdigital necrobacillosis (foot rot) in cattle caused by F. necrophorum or B. melaninogenicus. Ceftiofur hydrochloride has been shown to be effective for treatment of acute postpartum metritis in dairy cows when administered at 2.2 mg/kg or for treatment of retained fetal membranes by instilling into the uterus (1 g). Ceftiofur hydrochloride is used for treatment of SRD in pigs caused by A. pleuropneumoniae, P. multocida, S. enterica, and S. suis. Ceftiofur hydrochloride and ceftiofur crystalline- free acid have also been\\tadministered\\tvia\\tthe\\tintramammary\\troute\\tto\\tdairy\\tcattle.\\tFor\\tintramammary\\tuse, there is a specific formulation is recommended (Spectramast DC) for the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with S. aureus, S. dysgalactiae, and S. uberis, and another formulation (Spectramast LC) for treatment of mastitis in lactating cows for treatment of clinical mastitis associated with coagulase- negative staphylococci, S. dysgalactiae, and E. coli. Although ceftiofur sodium has been used in horses and dogs to treat infections, there is little experience with administration of ceftiofur hydrochloride in these species. There is a concern that injections of ceftiofur hydrochloride may produce injection- site irritation and lesions. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Rare bleeding disorders have been known to occur with some\\tcephalosporins.\\tFor\\tceftiofur,\\tdoses\\tthat\\thave\\texceeded\\tthe\\tapproved label recommendations have caused bone marrow suppression in dogs. Thrombocytopenia and anemia occurred at doses of 6.6 and 11 mg/kg when administered to dogs. High doses have caused diarrhea in horses.","notes":"Instructions for Use Dosing information is not available for species other than pigs and cattle. Dosing in cattle may be extended beyond 3 days if necessary. Alternatively, doses have been administered to cattle for BRD at 2.2 mg/kg at 48- hour intervals. Ceftiofur also is approved for 162    Ceftiofur Sodium dry- cow and lactating- cow treatment (depending on the formulation). Cows with systemic clinical signs caused by mastitis should receive other appropriate therapy under the direction of a licensed veterinarian. Ceftiofur sodium has been used in horses and dogs, but there is no information available on the use of ceftiofur hydrochloride in these species. Patient Monitoring and Laboratory Tests Monitor\\tCBC\\tif\\thigh\\tdoses\\tare\\tadministered\\tfor\\tlong\\tperiods.\\tSusceptibility\\ttesting: CLSI guidelines for susceptible bacteria indicate that susceptible bacteria have MIC values \u22642\\tmcg/mL.\\t(Note\\tthat\\tfor\\tsome\\thuman-\\tlabeled\\tcephalosporins,\\tthe\\tMIC values for susceptibility may be \u22648 mcg/mL.) Formulations \u2022\\t\\tCeftiofur\\thydrochloride\\tis\\tavailable\\tin\\t50-\\tmg/mL\\tsterile\\tsuspension.\\tCeftiofur hydrochloride\\thas\\tbeen\\tmarketed\\tin\\ttwo\\tforms:\\tExcenel\\tRTU\\tand\\ta\\treformulated form\\tExcenel\\tRTU\\tEZ.\\tThese\\tformulations\\tare\\tbioequivalent\\tand\\tinterchangeable. \u2022\\t\\tSterile\\tsuspension\\tfor\\tintramammary\\tuse.\\tEach\\tplastic\\tsyringe\\tof\\tSpectramast DC contains 500 mg of ceftiofur hydrochloride (50 mg/mL). Each syringe of Spectramast LC contains 125 mg of ceftiofur in a 10- mL syringe. Stability and Storage Store at room temperature. Shake well before administration. Protect from freezing.","original_category":"Antibacterial"},{"name":"Ceftiofur Sodium","active_ingredient":"Ceftiofur Sodium","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tUTI:\\t2.2\u20134.4\\tmg/kg\\tq24h\\tSQ. Cats \u2022\\t\\tDose\\tnot\\testablished\\tbut\\thas\\tbeen\\textrapolated\\tfrom\\tcanine\\tdose.  Horses \u2022\\t\\t4.4\\tmg/kg\\tq24h\\tIM\\tor\\t2.2\\tmg/kg\\tq12h\\tIM\\tfor\\tas\\tlong\\tas\\t10\\tdays.\\tTreatment\\tof some gram- negative infections may require doses at the higher range, and up to 11 mg/kg/day IM has been given to horses. \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t2.4\\tmg/kg\\tfollowed\\tby\\t0.2\\tmg/kg/h\\tto\\tachieve\\ta\\ttarget concentration of 4 mcg/mL. Foals \u2022\\t\\t5\\tmg/kg\\tq12h\\tIV\\tor\\tCRI\\tof\\t1\\tmg/kg/h\\tIV. Cattle \u2022\\t\\tBRD:\\t1.1\u20132.2\\tmg/kg\\t(0.5\u20131.0\\tmg/lb)\\tq24h\\tfor\\t3\\tdays\\tIM.\\tAdditional\\tdoses may be given on days 4 and 5 if necessary. In cattle, these doses also may be administered\\tSQ,\\twhich\\tis\\tbioequivalent\\tto\\tother\\troutes\\tof\\tadministration. Pigs \u2022\\t\\tRespiratory\\tinfections:\\t3\u20135\\tmg/kg\\t(1.36\u20132.27\\tmg/lb)\\tq24h\\tfor\\t3\\tdays\\tIM. Sheep and Goats \u2022\\t\\t1.1\u20132.2\\tmg/kg\\t(0.5\u20131.0\\tmg/lb)\\tq24h\\tfor\\t3\\tdays\\tIM\\tor\\tSQ.\\tAdditional\\tdoses\\tmay be given on days 4 and 5 if necessary. C Cephalexin 165 Regulatory Information Cattle\\twithdrawal\\ttime:\\t0\\tdays\\tfor\\tmilk\\tand\\t4\\tdays\\tfor\\tmeat. Sheep\\tand\\tgoat\\twithdrawal\\ttime:\\t0\\tdays\\tfor\\tmeat. Pig\\twithdrawal\\ttime:\\t4\\tdays. The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations. Cephalexin sef- ah- lex\u2032in Trade and other names: Keflex, Rilexine, Vetolexin (Canada), and generic brands. (In European countries, it is spelled cefalexin.)","contraindications":"Contraindications and Precautions Do not administer to animals prone to sensitivity to beta- lactams. Do not administer to animals at high doses. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\tin\\ta\\tvial\\tor syringe with other drugs because inactivation may result.","indications":"Indications and Clinical Uses Ceftiofur sodium is used in cattle and pigs for treatment and control of infections caused by susceptible pathogens. It is registered for treatment of respiratory disease and interdigital necrobacillosis (foot rot) in lactating cows in many countries. Ceftiofur has been used for treatment of salmonella in calves. At 5 mg/kg q24h IM, it decreased diarrhea and temperature but did not eradicate the organism. Ceftiofur sodium has been administered on an intramammary basis for treatment of coliform mastitis, but this is an extralabel use. It is used in horses for treatment of streptococcal respiratory infections (approved label treatment) and extralabel use for treating other infections such as those caused by gram- negative bacilli, including E. coli, K. pneumoniae, and Salmonella spp. Higher doses should be used for nonstreptococcal bacteria in horses. Ceftiofur\\tsodium\\tis\\tregistered\\tfor\\ta\\tdaily\\tSQ\\tinjection\\tfor\\ttreatment\\tof\\tUTIs\\tin\\tdogs, but it has not been evaluated for treatment of other infections. Ceftiofur sodium has been administered as a CRI to maintain plasma concentrations above a desired range throughout the infusion period. In food- producing animals, extralabel doses or routes of administration are not allowed. However, when ceftiofur sodium was administered either\\tIM\\tor\\tSQ\\tto\\tcattle,\\tthere\\twas\\tsimilar\\tsafety\\tand\\ttherapeutic\\tefficacy,\\twith\\talmost identical plasma concentration profiles, from both routes of administration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All cephalosporins are generally safe; however, sensitivity can occur in individuals (allergy). Rare bleeding disorders have been known to occur with some cephalosporins.\\tFor\\tceftiofur,\\tdoses\\tthat\\thave\\texceeded\\tthe\\tapproved\\tlabel recommendations have caused bone marrow suppression in dogs. Thrombocytopenia and anemia occurred at doses of 6.6 and 11 mg/kg when administered to dogs. High doses have caused diarrhea in horses, but if doses are maintained within the range listed in the dosing section, it has been safe in most horses.","notes":"Instructions for Use Although dosing information is not available for other species, it has been used safely in dogs, sheep, pigs, horses, and cattle and is expected to be safe for other animals.\\tCeftiofur\\tsodium\\tis\\tbioequivalent\\twhether\\tadministered\\tSQ\\tor\\tIM.\\tIn dogs and cats, it has not been evaluated to treat infections other than UTIs in dogs. Higher systemic concentrations may be needed in dogs and cats to treat other infections. Patient Monitoring and Laboratory Tests Monitor CBC if high doses are administered for long periods. Susceptibility testing:\\tCLSI\\tguidelines\\tfor\\tsusceptible\\tbacteria\\tindicate\\tthat\\tsusceptible\\tbacteria causing respiratory infections in cattle and pigs have MIC values \u22642 mcg/mL. The breakpoint for Streptococcus spp. in horses is \u22640.25\\tmcg/mL.\\t(Note\\tthat\\tfor many human- labeled cephalosporins, the MIC values for susceptibility may be \u22648 mcg/mL.) Formulations \u2022\\t\\tCeftiofur\\tsodium\\tis\\tavailable\\tin\\t50-\\tmg/mL\\tvials\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. If not reconstituted, it may be stored at 20\xb0C\u201325\xb0C (room temperature). After reconstitution, solutions are potent for 7 days if refrigerated and 12 hours at room temperature. If solutions are prepared in fluids for CRI, the solution should be replaced q24h. If frozen, solutions are stable for 8 weeks. Do not refreeze. Slight discoloration may occur without losing potency.","original_category":"Antibacterial"},{"name":"Cephalexin","active_ingredient":"Cephalexin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tPyoderma,\\tother\\tskin\\tand\\tsoft\\ttissue\\tinfections,\\tand\\tUTIs:\\t22\u201325\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t22\u201325\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t \\t30\\tmg/kg\\tq8h\\tPO\\tfor\\tsusceptible\\tgram-\\tpositive\\tbacteria\\tthat\\thave\\ta\\tMIC\\t\u22640.5 mcg/mL. Regulatory Information The extralabel administration of cephalosporins to food- producing animals in the United\\tStates\\tis\\ta\\tviolation\\tof\\tFDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished for animals that produce food. in individuals (allergy). Cross- reactivity between penicillin allergy and cephalosporin allergy is low. Rare bleeding disorders have been known to occur with some cephalosporins.","contraindications":"Contraindications and Precautions Do not use in animals with allergic sensitivity to other beta- lactams, especially other cephalosporins. However, the incidence of cross- sensitivity between penicillins and cephalosporins is small (less than 10% in people). Some cephalosporins should not be used in animals with bleeding problems or that are receiving warfarin anticoagulants. These cephalosporins are those that have an NMTT\\tside\\tchain\\tand\\tinclude\\tcefotetan,\\tcefamandole,\\tand\\tcefoperazone. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs in a compounded formulation because inactivation may result. C Cetirizine Hydrochloride 167 Cetirizine Hydrochloride seh- teer\u2032ih- zeen  hye- droe- klor\u2032ide Trade and other names: Zyrtec","indications":"Indications and Clinical Uses Like other first- generation cephalosporins, cephalexin is indicated for treating common infections in animals, including UTIs, soft tissue infections, pyoderma and other dermal infections, and pneumonia. It is approved in the United States and other countries for treating skin infections in dogs caused by S. pseudintermedius. There are published efficacy studies documenting its effectiveness for this indication. Efficacy against infections caused by anaerobic bacteria is unpredictable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Gastrointestinal upset, including vomiting, is the most common adverse effect observed in small animals. Diarrhea also is possible. It is usually self- limiting and not an indication of a more serious problem. All cephalosporins are generally safe; however, sensitivity can occur","notes":"Instructions for Use Cephalexin is approved in most countries for use in dogs, but the use has been extrapolated to cats and other species. The most common use is for treatment of skin and soft tissue infections, but UTIs will respond to cephalexin. The oral absorption in horses is low, and clinical use in horses is rare. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22642 mcg/mL for skin and soft tissue infections and \u226416 mcg/mL for isolates from the lower urinary tract. Cephalothin is no longer recommended as a marker to test for susceptibility to cephalexin. MRS species are clinically resistant to cephalexin. Cephalexin may cause a false- positive test for urine glucose. The test may be positive with test strips that use either the copper reduction test or an enzymatic reaction. Formulations \u2022\\t\\tCephalexin\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules,\\t75-\\t,\\t150-\\t   ,\\t300-\\t   ,\\tand\\t600-\\tmg chewable tablets (for dogs), 100- mg/mL oral suspension, and 125-  and 250- mg/5 mL oral suspension. In Canada, a 100- and 250-mg/mL oral paste is available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Suspensions should be stored in refrigerator and discarded after 14 days. Cephalexin is compatible with enteral products if used immediately after mixing.","original_category":"Antibacterial"},{"name":"Chloramphenicol","active_ingredient":"Chloramphenicol","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t40\u201350\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\t12.5\u201320\\tmg/kg\\tq12h\\tPO\\t(or\\t50\\tmg/cat). (Rarely available commercially.) Dogs \u2022\\t\\t40\u201350\\tmg/kg\\tq6\u20138h\\tIV\\tor\\tIM. Cats \u2022\\t\\t12.5\u201320\\tmg/cat\\tq12h\\tIV\\tor\\tIM.  Horses \u2022\\t\\t35\u201350\\tmg/kg\\tq6\u20138h\\tPO. Regulatory Information It is illegal to administer chloramphenicol to animals that produce food; therefore, no withdrawal times are established. Chlorothiazide klor- oh- thye\u2032ah- zide Trade and other names: Diuril","contraindications":"Contraindications and Precautions Avoid use in pregnant or neonatal animals. Avoid long- term use in cats. Because exposure to humans can potentially produce severe consequences, veterinarians should caution pet owners about handling the medications and to ensure that accidental exposure to humans does not occur at home (e.g., to young children). Drug Interactions Chloramphenicol is notorious for producing drug- drug interactions. Chloramphenicol is a CYP 450 and CYP2B11 inhibitor and possibly other CYP enzymes in dogs. As such, chloramphenicol decreases the clearance of other drugs that are metabolized by the same metabolic enzymes. Chloramphenicol inhibits the metabolism of opiates, barbiturates, propofol, phenytoin, salicylate, and perhaps other drugs. Therefore, caution should be exercised when administering other drugs metabolized by CYP450 enzymes, particularly anesthetics, concurrently with chloramphenicol.","indications":"Indications and Clinical Uses Chloramphenicol has been used to treat infections caused by a broad spectrum of organisms, including gram- positive cocci, gram- negative bacilli (including Enterobacteriaceae), anaerobic bacteria, and Rickettsia. However, effectiveness against all these organisms has not been verified in clinical studies. Chloramphenicol has been used to treat infections caused by bacteria that are resistant to other common drugs (e.g., MRS in dogs). Chloramphenicol has been used in horses for oral treatment of a variety of infections. However, recent pharmacokinetic analysis have demonstrated that chloramphenicol has a short half-life, highly variable oral absorption, and not likely to reach\\teffective\\tlevels\\tconsidered\\t\u201csusceptible\u201d\\twhen\\ttested\\tusing\\tcurrent\\tsusceptibility breakpoints. Therefore, at an oral dose of 50 mg/kg every 6 hours, chloramphenicol is unlikely to be effective in horses unless the bacteria are highly susceptible with an MIC of \u22642\\tmcg/mL.\\tFlorfenicol\\tacts\\tvia\\ta\\tsimilar\\tmechanism\\tand\\thas\\tbeen substituted\\tin\\tsome\\tanimals\\t(see\\tFlorfenicol). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Chloramphenicol has a narrow margin of safety. High doses can produce toxicity in dogs and cats. GI disturbances are rather common. A decrease in protein synthesis in the bone marrow may be associated with prolonged treatment. The effect on the bone marrow is most prominent in cats, especially after 14 days of treatment, but is uncommon in dogs. Bone marrow suppression in animals is reversible. Idiosyncratic aplastic anemia has been described in humans. The incidence of aplastic anemia is rare, but the consequences are severe because it is irreversible. The risk of human exposure led to the ban of chloramphenicol use in food animals. Another problem recognized in dogs is peripheral neuropathy. The mechanism is unknown but may be due to de- myelination of nerve fibers. This causes ataxia and weakness, particularly in the hind limbs of dogs. Large- breed dogs may be more susceptible to this problem. The peripheral neuropathy is reversible if the drug is discontinued.","notes":"Instructions for Use Chloramphenicol use is based primarily on clinical experience and small observational studies. There were no well-controlled studies that have shown efficacy in animals. Although rarely available commercially, chloramphenicol palmitate requires active enzymes and should not be administered to fasted (or anorectic) animals. C Chlorothiazide 173 Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22644 mcg/mL for streptococci and \u22648 mcg/mL for other organisms using the human breakpoint. Caution is advised when using the human breakpoint for interpretation because it may not apply to veterinary use. In horses, bacteria should not be considered susceptible unless the MIC is below 2 mcg/mL, which only includes Streptococcus equi and Actinobacillus equuli. Formulations \u2022\\t\\tChloramphenicol\\tpalmitate\\tis\\tavailable\\tin\\ta\\t30-\\tmg/mL\\toral\\tsuspension. Chloramphenicol is available in 250- mg capsules and 100- , 250- , and 500- mg tablets. Chloramphenicol sodium succinate injection has a concentration of 100 mg/mL (1- g but is no longer available commercially in the United States. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Chloramphenicol tablets or powder dissolved in a water solution are stable for 24 hours. Chloramphenicol palmitate is insoluble in water. Chloramphenicol is stable at a pH of 2\u20137. Chloramphenicol sodium succinate, if available, is stable for 30 days at room temperature and 6 months if frozen.","original_category":"Antibacterial"},{"name":"Chlortetracycline","active_ingredient":"Chlortetracycline","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tRarely\\tused,\\tbut\\tdoses\\tof\\t25\\tmg/kg\\tq6\u20138h\\tPO\\thave\\tbeen\\tadministered\\teven though there is no evidence of efficacy.  Cattle \u2022\\t\\tProphylaxis\\tfor\\tanaplasmosis:\\t0.36\u20130.7\\tmg/kg/day\\t(approximately\\tone\\tblock\\tper 10 animals). \u2022\\t\\tTablets:\\t11\\tmg/kg\\tq12h\\tfor\\t3\u20135\\tdays\\tPO. \u2022\\t\\tPowdered\\tfeed\\tadditive:\\t22\\tmg/kg/day\\tadded\\tto\\twater.\\tActual\\tdose\\tis\\taffected\\tby feed and water consumption for each animal. Pigs \u2022\\t\\tPowdered\\tfeed\\tadditive:\\t22\\tmg/kg/day\\tadded\\tto\\twater.\\tActual\\tdose\\tis\\taffected\\tby feed and water consumption for each animal. Regulatory Information Cattle\\twithdrawal\\ttime\\tfor\\tmeat:\\tWithdrawal\\ttimes\\tvary\\tfrom\\tproduct\\tto\\tproduct from 1, 2, 5, or 10 days. Most products list a withdrawal time of 1 day for cattle. Pig\\twithdrawal\\ttime\\tfor\\tmeat:\\t1\u20135\\tdays. Note\\tthat\\tfor\\tchlortetracycline,\\twithdrawal\\ttimes\\tmay\\tvary\\tconsiderably\\tfrom\\tone product to another. One should consult specific product packaging to determine exact withdrawal time. Chondroitin Sulfate kon- droy\u2032ten sul\u2032fate Trade and other names: Cosequin and Glyco- Flex","contraindications":"Contraindications and Precautions Avoid use in young animals, except where permitted by label for young pigs or cattle. Adding chlortetracycline to feed and water of livestock will require a veterinary\\torder\\tusing\\tthe\\tVeterinary\\tFeed\\tDirective. Drug Interactions Chlortetracycline, like other tetracyclines, binds to other orally administered cations, which prevent its absorption. Oral absorption is decreased if it is administered with products with calcium, zinc, aluminum, magnesium, or iron. C Chondroitin Sulfate 179","indications":"Indications and Clinical Uses It has been used for routine infections and intracellular pathogens, mostly in livestock. Most of the use is in feed and water and often used as a preventive agent for anaplasmosis. Treatment of serious infections is limited because chlortetracycline is poorly absorbed orally, and other tetracyclines are preferred for systemic treatment of infections. A common use for chlortetracycline is as a feed additive to control respiratory and enteric infections in livestock. The clinical use in small animals and horses is rare. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Chlortetracycline may bind to bone and developing teeth in young animals. High doses have caused renal injury. Oral administration to horses may produce diarrhea.","notes":"Instructions for Use Chlortetracycline is not administered for systemic use in small animals. Doxycycline has replaced most other tetracyclines for treatment in small animals. Most chlortetracycline used is in powdered form and added to feed or drinking water of livestock. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\ttetracycline\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22642 mcg/mL for streptococci and \u22644 for other organisms. Tetracycline is used as a marker to test susceptibility for other drugs in this class such as doxycycline, minocycline, and oxytetracycline, but these breakpoints should not apply to chlortetracycline because of its low oral absorption. Formulations \u2022\\t\\tChlortetracycline\\tis\\tavailable\\tas\\ta\\tpowdered\\tfeed\\tadditive\\tin\\t25\\tor\\t64\\tg/lb.\\tIt\\tis\\talso available as an anaplasmosis block in 2.5 g/lb and in 25-  and 500- mg tablets. (A range of concentrations exists for premix.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with ions that may chelate tetracyclines (calcium, magnesium, iron, aluminum, etc.).","original_category":"Antibacterial"},{"name":"Ciprofloxacin Hydrochloride","active_ingredient":"Ciprofloxacin Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t25\\tmg/kg\\tq24h\\tPO. \u2022\\t\\t15\\tmg/kg\\tq24h\\tIV. Cats \u2022\\t\\t20\\tmg/kg\\tq24h,\\tPO. \u2022\\t\\t10\\tmg/kg\\tq24h\\tIV.  \u2022\\t\\tNo\\tdosing\\tdata\\tare\\tavailable.\\tCiprofloxacin\\thas\\tpoor\\toral\\tabsorption\\tin\\thorses\\t(less than 10%) and is not recommended. Regulatory Information There are no withdrawal times established because this drug should not be administered to animals that produce food. The extralabel administration of fluoroquinolones to food- producing animals in the United States is a violation of FDA\\tregulations.\\tWithdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood. Cisapride siss\u2032ah- pride Trade and other names: Propulsid (Prepulsid in Canada), not currently available commercially","contraindications":"Contraindications and Precautions Avoid use in young animals because of risk of cartilage injury. Use cautiously in animals that may be prone to seizures, such as epileptics. It is not recommended to administer ciprofloxacin to horses. Drug Interactions Fluoroquinolones\\tmay\\tincrease\\tconcentrations\\tof\\ttheophylline\\tand\\tpossibly\\tother drugs if used concurrently. Coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), iron, and calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur.","indications":"Indications and Clinical Uses Ciprofloxacin, although a human drug, has been used in small animals for treatment of a wide variety of infections, including skin infections, pneumonia, and soft tissue infections. Ciprofloxacin is not approved for animals. However, it can be prescribed by veterinarians as long as it is not administered to animals that produce food or are intended for food. The administration of ciprofloxacin to animals is considered extralabel and subject to other extralabel restrictions. The variable and potentially low ciprofloxacin oral availability for dogs and cats suggests that doses should be higher than the doses currently used for drugs such as enrofloxacin, marbofloxacin, or orbifloxacin. If administered at an oral dose of 25 mg/kg once daily to dogs, the breakpoint for human susceptibility testing will not apply, and bacteria should be considered susceptible only if the MIC is less than 0.06 mcg/mL. Because of the inconsistent oral absorption in dogs, if a human generic fluoroquinolone is used in dogs, levofloxacin is preferred. (See Levofloxacin for more details.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tconcentrations\\tof\\tfluoroquinolones\\tmay\\tcause\\tCNS\\ttoxicity,\\tespecially\\tin animals with renal failure. Ciprofloxacin causes occasional vomiting. Intravenous solution should be given slowly (over 30 minutes). At high doses, it may cause some nausea, vomiting, and diarrhea. Blindness in cats has not been reported for ciprofloxacin. All of the fluoroquinolones may cause arthropathy in young animals. Dogs are most susceptible to quinolone- induced arthropathy in the age group of 4\u201328 weeks of age. Large, rapidly growing dogs are the most susceptible. Intravenous infusions have elicited an anaphylactoid reaction in some dogs. Dogs sensitive to these reactions have shown evidence of hypotension and cardiac abnormalities, including arrhythmia. Observe dogs for signs of reactions during IV infusions. Administration to horses has caused colic, enteritis, and diarrhea.","notes":"Instructions for Use Doses are based on plasma concentrations needed to achieve sufficient plasma concentration above the MIC. Efficacy studies have not been performed in dogs or cats, and clinical use is based primarily on anecdotal experience and pharmacokinetic and pharmacodynamic analysis. Injectable ciprofloxacin is available in a human preparation, usually 10 mg/mL (in sterile water) or 2 mg/mL (premixed with 5% dextrose). Dilute the concentrated form to 1\u20132 mg/mL prior to IV use with an IV solution and infuse slowly. Do not infuse concurrently with other medications (e.g., in a piggyback) because inactivation may occur. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\thas\\tnot\\tbeen determined for animals, but for humans, the breakpoints are \u22640.25 mcg/mL for gram- negative Enterobacteriaceae bacteria and \u22640.5 mcg/mL for P. aeruginosa. The human breakpoint for susceptibility should not be applied to dogs and cats. In dogs, at a dosage of 25 mg/kg per day PO, the cutoff for susceptible bacteria is \u22640.06 mcg/mL. Most susceptible gram- negative Enterobacteriaceae bacteria have MIC values less than 0.12 mcg/mL, but the MIC for P. aeruginosa, is typically higher (less than 0.5 mcg/ mL). Staphylococcus spp. typically have MIC values less than 1 mcg/mL. C Cisapride 185 Formulations Available Ciprofloxacin is available in 100- , 250- , 500- , and 750- mg tablets; 500-  and 1000- mg extended- release tablets; 50-  and 100- mg/mL oral suspension; 10- mg/mL injection; and 2- mg/mL infusion (in dextrose). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Aqueous solutions of 0.5\u20132 mg/mL retain potency up to 14 days when stored. Do not mix with products that contain ions (e.g., iron, aluminum, magnesium, and calcium).","original_category":"Antibacterial"},{"name":"Clarithromycin","active_ingredient":"Clarithromycin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t7.5\\tmg/kg\\tq12h\\tPO.  Foals \u2022\\t\\t7.5\\tmg/kg\\tq12h\\tPO\\t(often\\tcombined\\twith\\trifampin\\tat\\t10\\tmg/kg\\tq12h). Pigs \u2022\\t\\t7.5\\tmg/kg\\tPO\\tq12h. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Clemastine Fumarate klem\u2032ass- teen  fyoo\u2032mar- ate Trade and other names: Tavist and generic brands","contraindications":"Contraindications and Precautions Administer with caution to adult horses, ruminants, rodents, and rabbits because diarrhea and enteritis may develop. Clarithromycin is contraindicated for use in pregnant women. Although problems have not been identified in animals, use with caution in pregnant animals. Drug Interactions Many macrolide antibiotics are CYP450 enzyme inhibitors and can decrease metabolism\\tof\\tother\\tdrugs.\\tFor\\texample,\\tin\\tpeople,\\tit\\tincreased\\tdigoxin concentrations, and it is possible that it can affect other drugs. Clarithromycin administered to animals may decrease the clearance of other co- administered drugs.\\tFor\\texample,\\tclarithromycin\\tdecreased\\tclearance\\tof\\tcyclosporine\\tand increased oral absorption of cyclosporine in cats. Clarithromycin is often administered with rifampin for treatment of horses with R. equi infections. Because of induction of enzymes and transporters, co- administration with rifampin decreases plasma drug concentrations of clarithromycin by greater than 90%. (See Rifampin for more details.)","indications":"Indications and Clinical Uses The most common use in people is for treatment of Helicobacter gastritis and respiratory infections, where it has retained activity against most respiratory tract pathogens (e.g., Streptococcus spp., mycoplasma, chlamydia). In small animals, clarithromycin has been used for indications such as skin infections and respiratory infections, but the use in small animals is not common. In foals, clarithromycin has been used for treatment of infections caused by Rhodococcus equi (in combination with rifampin). It is more active than other macrolides against R. equi and produced better clinical success than azithromycin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effects from clarithromycin and related drugs are diarrhea and nausea. Many animals may develop soft feces or mild diarrhea. In studies in healthy foals, diarrhea was uncommon from oral doses and was self- limiting. However, if diarrhea becomes severe, treatment should be discontinued.","notes":"Instructions for Use Clarithromycin should be given twice daily to animals because of a short half- life and need for a long time above the MIC. Patient Monitoring and Laboratory Tests In the absence of a specific value for clarithromycin, use susceptibility for erythromycin to guide use of clarithromycin. Although the CLSI- derived breakpoint for susceptible bacteria is 1 mcg/mL, cures have been observed when treating respiratory pathogens with MIC values as high as 8 mcg/mL, which is attributed to high respiratory concentrations achieved. MIC values for R. equi were 0.12 mcg/mL. Organisms resistant to erythromycin and azithromycin will most likely be resistant to clarithromycin. 190    Clemastine Fumarate Formulations \u2022\\t\\tClarithromycin\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\ttablets\\tand\\t25-\\t\\tand\\t50-\\tmg/mL oral suspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. 250- mg tablets have been dissolved in water (50 mL) and administered immediately to foals orally. However, the long- term stability of compounded formulations has not been evaluated.","original_category":"Antibiotic"},{"name":"Clindamycin Hydrochloride","active_ingredient":"Clindamycin Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tStaphylococcal\\tinfections:\\t11\\tmg/kg\\tq12h\\tPO\\tor\\t22\\tmg/kg\\tq24h\\tPO.\\t(Label dosage for dogs is 5.5\u201333 mg/kg q12h PO.) \u2022\\t\\tRefractory\\tinfections:\\tDoses\\tup\\tto\\t33\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tAnaerobic\\tinfections\\tand\\tperiodontal\\tinfections:\\t11\u201333\\tmg/kg\\tq12h\\tPO. \u2022\\t\\t10\\tmg/kg\\tq12h\\tIV\\tor\\tIM.\\t(For\\tIV\\tuse,\\tit\\tshould\\tbe\\tdiluted\\tand\\tadministered\\tby slow infusion.) Cats \u2022\\t\\t5.5\\tmg/kg\\tq12h\\tor\\t11\\tmg/kg\\tq24h\\tPO.\\t(Label\\tdosage\\tfor\\tcats\\tis\\t11\u201333\\tmg/kg q24h PO.) \u2022\\t\\tRefractory\\tinfections:\\tDoses\\tup\\tto\\t33\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tAnaerobic\\tinfections\\tand\\tperiodontal\\tinfections:\\t11\u201333\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tToxoplasmosis:\\t12.5\\tmg/kg,\\tup\\tto\\t25\\tmg/kg\\tq12h\\tfor\\t4\\tweeks\\tPO\\t(see  \u2022\\t\\tDo\\tnot\\tadminister\\tclindamycin\\torally\\tto\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Clodronate cloe- dronate Trade and other names: OSPHOS","contraindications":"Contraindications and Precautions Do not administer to rodents or rabbits because it may cause diarrhea. Do not administer orally to horses or ruminants because diarrhea, enteritis, and perhaps death can result. The oral liquid (Antirobe) contains 8.6% ethyl alcohol, which may be unpalatable to cats. Clindamycin hydrochloride has caused esophageal lesions in cats. When administering orally, be sure that all of the medication passes through the esophagus to the stomach. Drug Interactions Clindamycin injection should not be mixed with other drugs in the same vial, syringe, or IV line.","indications":"Indications and Clinical Uses Clindamycin is primarily used for gram- positive or anaerobic bacterial infections involving the skin, respiratory tract, or oral cavity. Resistance with Staphylococcus spp. may occur with frequent use. It is effective for some oral infections and anaerobic infections. It also has been used for Mycoplasma infections. Efficacy of clindamycin for treating toxoplasmosis is controversial. Some studies have shown that clindamycin improved clinical signs, but it did not resolve the infection. Another study showed that clindamycin inhibited killing of Toxoplasma organisms by leukocytes. In people, it is a second- choice for treating Toxoplasma spp. that requires high doses. Precautionary Information Indications and Clinical Uses). \u2022\\t\\t10\\tmg/kg\\tq12h\\tIV\\tor\\tIM.\\t(For\\tIV\\tuse,\\tit\\tshould\\tbe\\tdiluted\\tand\\tadministered\\tby slow infusion.)","side_effects":"Adverse Reactions and Side Effects Oral clindamycin hydrochloride has been associated with esophageal lesions in cats. Oral liquid product may be unpalatable to cats, possibly because of the high alcohol content (8.6%). High doses have caused vomiting and diarrhea in cats. Clindamycin may alter the bacterial population in the intestine and cause diarrhea. In people, it is one of the most common drugs to cause antibiotic associated diarrhea (enteritis) and pseudomembranous colitis caused by Clostridioides difficile. Fortunately,\\tthis\\thas\\tnot\\tbeen\\ta\\tcommon\\tproblem\\twhen\\ttreating\\tdogs\\tand\\tcats. However, in animals with fermenting intestinal tracts (horses, ruminants, rodents, rabbits), clindamycin administration can cause serious problems, such as enteritis and diarrhea. It should not be administered orally to these species.","notes":"Instructions for Use Most doses are based on manufacturer\u2019s drug approval data and efficacy trials. Although every- 12- hour frequency is recommended most often for dogs, there are studies that demonstrate efficacy when administered at 11 mg/kg q24h for treatment of pyoderma. An injectable formulation is also available (Cleocin), which is clindamycin phosphate. This may be injected either IV or IM. If administering clindamycin IV, it should be diluted and administered by slow infusion\\t(30\u201360\\tminutes).\\tDilution\\tis\\tusually\\t10:1\\tin\\t0.9%\\tsaline.\\tIt\\tcontains benzyl alcohol, and this vehicle has produced toxic reactions in young infants (and perhaps small animals). Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22640.25 mcg/mL for streptococci and \u22640.5 mcg/mL for other organisms. Formulations \u2022\\t \\tClindamycin\\tis\\tavailable\\tin\\toral\\tliquid\\t(Aquadrops)\\t25\\tmg/mL;\\t25-\\t,\\t75-\\t  ,\\t150-\\t   ,\\tand 300- mg capsules; 25- , 75- , and 150- mg tablets; and 150- mg/mL injection (Cleocin). C Clodronate 195 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Protect from freezing. Reconstituted solutions are stable for 2 weeks. Stability of compounded formulations is at least 60 days.","original_category":"Antibacterial"},{"name":"Clofazimine","active_ingredient":"Clofazimine","species":["Feline","Bovine"],"dosage":"Cats \u2022\\t\\t1\\tmg/kg\\tup\\tto\\ta\\tmaximum\\tof\\t4\\tmg/kg/day\\tPO.  \u2022\\t\\tCattle:\\t600\u20131000\\tmg\\toral\\tto\\tadult\\tcattle\\tper\\tday\\t(2\\tmg/kg\\tper\\tday). Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Clomipramine Hydrochloride kloe- mip\u2032rah- meen  hye- droe- klor\u2032ide Trade and other names: Clomicalm (veterinary preparation) and Anafranil (human preparation)","contraindications":"Contraindications and Precautions No\\tcontraindications\\treported\\tfor\\tanimals. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Clofazimine has had limited use in veterinary medicine because it is not available in the United States. Its use is limited to treating infections caused by Mycobacterium spp., such as feline leprosy. The clinical experience with using clofazimine in cats has been limited, and efficacy has not been compared with other agents. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in cats. In people, the most serious adverse effects are GI related.","notes":"Instructions for Use Doses based on empiricism or extrapolation of human studies. 198    Clomipramine Hydrochloride Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tClofazimine\\tis\\tnot\\tavailable\\tin\\tthe\\tUnited\\tStates\\tbut\\tis\\tavailable\\tin\\tother\\tcountries as 50- mg capsules. Some compounding pharmacies will prepare this drug for use in the United States. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Cloxacillin Sodium","active_ingredient":"Cloxacillin Sodium","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t20\u201340\\tmg/kg\\tq8h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tThe\\tonly\\tformulation\\tapproved\\tfor food animals is Dariclox, a 20- mg/mL intramammary infusion. The dosage is 10 mL (200 mg) per infected quarter q12h for three treatments. Regulatory Information Dairy\\tcows\\t(intramammary\\tuse)\\twithdrawal\\ttime\\tfor\\tmilk:\\t30\\tdays\\tfor\\tdry-\\tcow treatment. Cattle\\twithdrawal\\ttime\\tfor\\tmeat:\\t10\\tdays\\tfor\\tmeat\\tand\\t48\\thours\\tfor\\tmilk\\tfor\\tthe lactating cow treatment. Codeine koe\u2032deen Trade and other names: Generic, codeine phosphate, and codeine sulfate","contraindications":"Contraindications and Precautions Use cautiously in animals allergic to penicillin- like drugs. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother drugs because inactivation may result. 208    Codeine","indications":"Indications and Clinical Uses The spectrum of cloxacillin includes gram- positive bacilli, including beta- lactamase\u2013producing strains of Staphylococcus spp. Therefore, it has been used to treat staphylococcal infections in animals, including pyoderma. Because of better availability of other beta- lactam drugs for treating gram- positive infections such as those caused by Staphylococcus spp., cloxacillin is used infrequently in small animals. The intramammary formulations are used in dairy cattle. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects of penicillin drugs are most commonly caused by drug allergy. This can range from acute anaphylaxis when administered to other signs of allergic reaction when other routes are used. When administered orally (especially with high doses), diarrhea is possible.","notes":"Instructions for Use Doses\\tbased\\ton\\tempiricism\\tor\\textrapolation\\tfrom\\thuman\\tstudies.\\tNo\\tclinical\\tefficacy studies available for dogs or cats. Oral absorption is poor; if possible, administer on an empty stomach. Patient Monitoring and Laboratory Tests Culture\\tand\\tsensitivity\\ttesting:\\tUse\\toxacillin\\tas\\ta\\tguide\\tfor\\tsensitivity\\ttesting.\\tIf\\tthe strain is susceptible to oxacillin (methicillin- susceptible), cloxacillin and other agents active against Staphylococcus spp. can be used (e.g., cephalexin). Formulations \u2022\\t\\tCloxacillin\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules\\tand\\t25-\\tmg/mL\\toral\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Danofloxacin Mesylate","active_ingredient":"Danofloxacin Mesylate","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tNo\\tsmall\\tanimal\\tdose\\thas\\tbeen\\treported.  Cattle \u2022\\t\\t6\\tmg/kg\\t(1.5\\tmL\\tper\\t100\\tlb)\\tonce\\tper\\t48\\thours\\tSQ.\\tOr\\t8\\tmg/kg,\\tsingle\\tinjection. Equine and Swine \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported. Regulatory Information Do not use in calves intended for veal. Cattle\\twithdrawal\\ttime\\t(for\\tmeat):\\t4\\tdays.\\tNot\\testablished\\tfor\\tmilk\\tbecause\\tit\\tcannot be used in lactating cattle. It is prohibited to use extralabel in food-producing animals. D Dantrolene Sodium 233 Dantrolene Sodium dan \u0301troe- leen  soe \u0301dee- um Trade and other names: Dantrium, Revonto, Ryanodex","contraindications":"Contraindications and Precautions Do\\tnot\\tinject\\tmore\\tthan\\t15\\tmL\\tin\\tone\\tsite.\\tDo\\tnot\\tuse\\textralabel.\\tDo\\tnot\\tuse\\tin other species for which safety information is not available. Do not use in animals prone to seizures. Drug Interactions Fluoroquinolones\\tmay\\tincrease\\tconcentrations\\tof\\tother\\tdrugs\\tused\\tconcurrently through inhibition of drug metabolism, but this has not been shown for danofloxacin. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur.","indications":"Indications and Clinical Uses Danofloxacin is indicated for the treatment of BRD caused by P. multocida, M. haemolytica, and H. somni.\\tAs\\ta\\tfluoroquinolone\\twith\\ta\\tbroad\\tspectrum\\tof\\tactivity, other\\torganisms\\tare\\tsusceptible.\\tHowever,\\textralabel\\tuse\\tfor\\tother\\tdiseases\\tin\\tanimals intended for food is prohibited. There are no published reports of danofloxacin use in other animals except some exotic and zoo animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All\\tfluoroquinolones\\tat\\thigh\\tconcentrations\\tmay\\tcause\\tcentral\\tnervous\\tsystem (CNS) toxicity. In safety studies in cattle, when high doses were administered, they caused lameness, articular cartilage lesions, and CNS problems (tremors, nystagmus).\\tSQ\\tinjections\\tmay\\tcause\\ttissue\\tirritation.\\tAll\\tof\\tthe\\tfluoroquinolones have a potential to produce arthropathy in young animals, and during field trials, danofloxacin\\twas\\tassociated\\twith\\tlameness\\tin\\tsome\\tcalves.\\tFluoroquinolones have caused blindness in cats, but this has not been reported in any species from danofloxacin.","notes":"Instructions for Use Inject\\tSQ\\tin\\tneck\\tof\\tcattle. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary.\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute (CLSI)\\tbreakpoints\\tfor\\tsensitive\\torganisms\\tare\\t\u22640.25\\tmcg/mL\\tfor\\tcattle\\trespiratory pathogens. Most organisms have MIC values \u22640.06\\tmcg/mL. Formulations \u2022\\t\\tDanofloxacin\\tis\\tavailable\\tin\\tan\\tinjectable\\tsolution\\tof\\t180\\tmg/mL\\t(with 2-\\t pyrrolidone\\tand\\tpolyvinyl\\talcohol). Stability and Storage Store below 30\xb0C, protected from light, and protected from freezing. A slight yellow or amber color is acceptable.","original_category":"Antibacterial"},{"name":"Dapsone","active_ingredient":"Dapsone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1.1\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\tDo\\tnot\\tuse.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Darbepoetin Alfa dar\u2032be- poe\u2032e- tin  al\u2032fa Trade and other names: Aranesp","contraindications":"Contraindications and Precautions Do not administer to cats. Do not administer to animals that are sensitive to sulfonamides. Drug Interactions Use\\tcaution\\twhen\\tadministering\\tdapsone\\twith\\ttrimethoprim\u2013sulfonamide combinations. (Concurrent administration should be avoided.) Trimethoprim may increase blood concentrations of dapsone because it inhibits excretion and potentiates dapsone adverse effects. 236    Darbepoetin Alfa","indications":"Indications and Clinical Uses The original use in human medicine was for treatment of leprosy caused by susceptible strains of susceptible strains of Mycobacterium leprae. It is also used for dermatitis herpetiformis.\\tHowever,\\tthe\\tuse\\tfor\\ttreating\\tleprosy\\tin\\tanimals\\tis\\tuncommon. It also has been used for various immune- mediated disorders. It may be effective in people for bullous systemic lupus erythematosus, immune- mediated thrombocytopenia, and\\tpemphigus\\tvulgaris.\\tHowever,\\tthe\\tclinical\\tefficacy\\tfor\\tthese\\tdiseases\\tremains\\tuncertain because of a lack of well- controlled studies. In veterinary medicine, it has been used for dermatologic diseases in dogs, especially subcorneal pustular dermatosis and dermatitis herpetiformis. It also has been used for canine pemphigus. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hepatitis\\tand\\tblood\\tdyscrasias\\tmay\\toccur.\\tBecause\\tit\\tshares\\tsimilar\\tproperties\\tas\\ta sulfonamide, the same reactions seen with sulfonamides can be seen with dapsone and\\tinclude\\tanemia,\\tneutropenia,\\tthrombocytopenia,\\thepatotoxicosis,\\tand\\tskin\u2013 drug eruptions. It is toxic to cats and causes neurotoxicosis and anemia.","notes":"Instructions for Use Doses are derived from extrapolation of human doses or empiricism. No well- controlled clinical studies have been performed in veterinary medicine. Patient Monitoring and Laboratory Tests Monitor for signs of hepatic reactions. Monitor CBC occasionally because bone marrow toxicity has occurred in some animals. Formulations \u2022\\t\\tDapsone\\tis\\tavailable\\tin\\t25-\\t\\tand\\t100-\\tmg\\ttablets.\\tFormulations\\talso\\tmay\\tbe compounded. See Stability and Storage. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Dapsone may discolor without change in potency. Compounded suspension formulations\\thave\\tbeen\\tstable\\tfor\\t21\\tdays\\twhen\\tmixed\\twith\\tcitric\\tacid. For\\tdosing\\tsmaller\\tpatients,\\ta\\t2-\\tmg/mL\\toral\\tsuspension\\tmay\\tbe\\tmade\\tfrom\\tthe tablets\\tin\\ta\\t1:1\\tmixture\\tof\\tOra-\\tSweet\\tand\\tOra-\\tPlus.\\tTo\\tprepare\\tthis\\tformulation, crush\\teight\\t25-\\tmg\\ttablets\\tin\\ta\\tmortar\\tand\\treduce\\tto\\ta\\tfine\\tpowder.\\tAdd\\tsmall portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental\\tproportions\\tto\\talmost\\t100\\tmL;\\ttransfer\\tto\\ta\\tcalibrated\\tbottle,\\trinse mortar\\twith\\tvehicle,\\tand\\tadd\\tquantity\\tof\\tvehicle\\tsufficient\\tto\\tmake\\t100\\tmL.\\tLabel \u201cShake well.\u201d Stable for 90 days at room temperature or refrigerated.","original_category":"Antibacterial"},{"name":"Dicloxacillin Sodium","active_ingredient":"Dicloxacillin Sodium","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t11\u201355\\tmg/kg\\tq8h\\tPO. 268    Diethylcarbamazine Citrate  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tOral\\tabsorption\\tis\\tlow. Regulatory Information No regulatory information is available. Because oral absorption is expected to be minimal, when using systemically in food animals, apply similar withdrawal times as for ampicillin. Alternatively, contact FARAD at www.FARAD.org. Diethylcarbamazine Citrate dye- eth- il- kar- bam \u0301eh- zeen  sih \u0301trate Trade and other names: Caricide, Filaribits, and Nemacide","contraindications":"Contraindications and Precautions Use cautiously in animals allergic to penicillin- like drugs. Drug Interactions There are no specific drug interactions. Dicloxacillin is absorbed better on an empty stomach in dogs.","indications":"Indications and Clinical Uses Dicloxacillin\\thas\\ta\\trelatively\\tnarrow\\tspectrum\\tof\\tactivity.\\tLike\\tcloxacillin\\tand oxacillin, the spectrum of dicloxacillin includes gram- positive bacilli, including beta- lactamase\u2013producing\\tstrains\\tof\\tStaphylococcus spp. Therefore it has been used to treat staphylococcal infections in animals, including pyoderma. It is not active against methicillin- resistant Staphylococcus\\tspp.\\tGram-\\tnegative\\tEnterobacteriaceae\\tbacteria are clinically resistant. Because of availability of other drugs for small animals to treat this spectrum of bacteria, dicloxacillin is not used commonly. Because it is an oral drug with limited absorption in large animals, its use is limited to small animal oral administration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects of penicillin drugs are most commonly caused by drug allergy. This can range from acute anaphylaxis when administered to other signs of allergic reaction when other routes are used. When administered orally (especially with high doses), diarrhea is possible.","notes":"Instructions for Use No clinical efficacy studies are available for dogs or cats. In dogs, oral absorption is low and may not be suitable for therapy. Administer on an empty stomach, if possible. Patient Monitoring and Laboratory Tests Use oxacillin as a guide for sensitivity testing. Breakpoints for oxacillin apply to dicloxacillin. Formulations Some\\tformulations\\thave\\tbeen\\tdiscontinued.\\tDicloxacillin\\thas\\tbeen\\tavailable\\tin\\t125-\\t, 250-\\t  ,\\tand\\t500-\\tmg\\tcapsules\\tand\\t12.5-\\tmg/mL\\toral\\tsuspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not\\tmix\\twith\\tother\\tdrugs.\\tReconstituted\\toral\\tsuspension\\tis\\tstable\\tfor\\t14\\tdays\\trefrigerated. Compounded\\tformulations,\\tespecially\\taqueous\\tformulations,\\tmay\\tnot\\tbe\\tstable.","original_category":"Antibacterial"},{"name":"Difloxacin Hydrochloride","active_ingredient":"Difloxacin Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\u201310\\tmg/kg\\tq24h\\tPO. Cats \u2022\\t\\tNo\\tdosing\\tinformation\\tfor\\tcats\\tis\\tavailable.\\tThere\\tis\\tno\\tsafety\\tinformation\\tavailable. D Digoxin 273  \u2022\\t\\tHorses:\\t5\\tmg/kg\\tPO,\\tq24h. Regulatory Information Do not administer to animals intended for food. Digitoxin dih- jih- toks \u0301in Trade and other names: Digimerck (European)","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tyoung\\tanimals\\tbecause\\tof\\trisk\\tof\\tcartilage\\tinjury.\\tUse\\tcautiously\\tin animals that may be prone to seizures, such as epileptics. Avoid use in cats unless safety has been established. Drug Interactions Fluoroquinolones\\tmay\\tincrease\\tconcentrations\\tof\\ttheophylline\\tif\\tused concurrently. Coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), iron, or calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur.","indications":"Indications and Clinical Uses Difloxacin,\\tlike\\tother\\tfluoroquinolones,\\thas\\tbeen\\tused\\tfor\\ta\\tvariety\\tof\\tinfections, including skin infections, wound infections, and pneumonia. Unlike other fluoroquinolones,\\tdifloxacin\\tdoes\\tnot\\thave\\thigh\\trenal\\tclearance.\\tUrine\\tconcentrations may not be sufficient for some UTIs. Despite\\tthe\\tfeatures\\tthat\\tare\\ttypical\\tof\\tother\\tfluoroquinolones,\\tdifloxacin\\thas\\tnot been in common use and is not available in most countries. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tconcentrations\\tmay\\tcause\\tCNS\\ttoxicity,\\tespecially\\tin\\tanimals\\twith\\trenal failure. Difloxacin may cause some nausea, vomiting, and diarrhea at high doses. All\\tof\\tthe\\tfluoroquinolones\\tmay\\tcause\\tarthropathy\\tin\\tyoung\\tanimals.\\tDogs\\tare most\\tsensitive\\tat\\t4\\tweeks\\tto\\t28\\tweeks\\tof\\tage.\\tLarge,\\trapidly\\tgrowing\\tdogs\\tare\\tthe most susceptible. Safety in cats has not been reported. It has not been reported if there\\tis\\ta\\tpotential\\tto\\tcause\\tretinal\\tocular\\tinjury\\tin\\tcats.","notes":"Instructions for Use Dose\\trange\\tcan\\tbe\\tused\\tto\\tadjust\\tdose\\tdepending\\ton\\tseverity\\tof\\tinfection\\tand susceptibility of bacteria. Bacteria with low MIC values can be treated with a low dose; susceptible bacteria with higher MIC values should be treated with a higher dose. Difloxacin is primarily eliminated in feces rather than urine (urine is less than 5% of clearance). Sarafloxacin is an active desmethyl metabolite but produced in low amounts.\\tOral\\tabsorption\\tin\\thorses\\tis\\tlow\\tand\\tshould\\tonly\\tbe\\tused\\tfor\\tbacteria\\twith MIC\\tless\\tthan\\t0.12\\tmcg/mL. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsensitive\\torganisms\\tis\\t\u22640.5\\tmcg/mL\\tfor canine pathogens. Formulations \u2022\\t\\tDifloxacin\\tis\\tno\\tlonger\\tmarketed\\tand\\tmay\\tnot\\tbe\\tavailable.\\tIt\\twas\\tpreviously available\\tin\\t11.4-\\t,\\t45.4-\\t   ,\\tand\\t136-\\tmg\\ttablets.\\t(In\\tsome\\tcountries,\\t5%\\tinjectable\\tis available.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated but has been mixed with\\tsimple\\tsyrup\\t(100\\tmg/mL)\\tfor\\thorses.","original_category":"Antibacterial"},{"name":"Doripenem","active_ingredient":"Doripenem","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t8\\tmg/kg\\tq8h\\tIV.\\tInfuse\\tover\\t30\\tminutes\\tto\\t1\\thour.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported.\\tHowever,\\tdoses\\tsimilar\\tto\\tthe\\trange used in small animals are suggested for foals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Doxapram Hydrochloride doks \u0301ah- pram  hye- droe- klor \u0301ide Trade and other names: Dopram, Respiram","contraindications":"Contraindications and Precautions Some slight yellowish discoloration may occur after reconstitution. Slight discoloration\\twill\\tnot\\taffect\\tpotency.\\tHowever,\\ta\\tdarker\\tamber\\tor\\tbrown discoloration may indicate oxidation and loss of potency. Drug Interactions Do not mix in vial or syringe with other antibiotics or with solutions containing other drugs.","indications":"Indications and Clinical Uses Doripenem is indicated primarily for resistant infections caused by bacteria resistant to other drugs. It is especially valuable for treating resistant infections caused by P. aeruginosa, E. coli, and Klebsiella pneumoniae. Doripenem is only FDA approved for people, and use in animals is extralabel. It has not used in veterinary medicine as commonly as meropenem or imipenem. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Carbapenems pose similar risks as other beta- lactam antibiotics, but adverse effects are\\trare.\\tDoripenem\\tdoes\\tnot\\tcause\\tseizures\\tas\\tfrequently\\tas\\timipenem.","notes":"Instructions for Use Doses in animals have been based on pharmacokinetic studies rather than efficacy\\ttrials.\\tTo\\tprepare\\tIV\\tinjection,\\tmix\\t500-\\tmg\\tvial\\twith\\t10\\tmL\\tof\\tsterile water\\tfor\\tinjection\\tor\\tsodium\\tchloride\\t0.9%\\tinjection,\\tgently\\tshaking\\tvial\\tto form\\ta\\tsuspension\\t(concentration,\\t50\\tmg/mL).\\tWithdraw\\tsuspension\\tand\\tadd to\\tinfusion\\tbag\\tcontaining\\tnormal\\tsaline\\t100\\tmL\\tor\\tdextrose\\t5%,\\tgently\\tshaking until\\tclear\\t(concentration,\\t4.5\\tmg/mL).\\tTo\\tprepare\\t250-\\tmg\\tdose,\\tmix\\twith\\t10 mL\\t  of\\t sterile\\t   water\\t   for\\t  injection\\tor\\t sodium\\tchloride\\t0.9%\\t   injection,\\tgently\\t   shaking vial\\tto\\tform\\ta\\tsuspension\\t(concentration,\\t50\\tmg/mL).\\tWithdraw\\tsuspension and\\tadd\\tto\\tinfusion\\tbag\\tcontaining\\tnormal\\tsaline\\t100\\tmL\\tor\\tdextrose\\t5%,\\tgently shaking\\tuntil\\tclear\\t(concentration,\\t4.5\\tmg/mL).\\tRemove\\t55\\tmL\\tof\\tthis\\tsolution from the bag and discard. Infuse the remaining solution (concentration, 4.5\\tmg/mL). Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tUse\\tsusceptibility\\tto\\timipenem\\tto\\tguide\\ttesting\\tfor\\tdoripenem. Enteric\\tgram-\\tnegative\\tbacteria\\tusually\\thave\\tMIC\\tvalues\\tless\\tthan\\t0.5\\tmcg/mL.\\tP. aeruginosa\\tusually\\thave\\tMIC\\tvalues\\tless\\tthan\\t2\\tmcg/mL. Formulations \u2022\\t\\tDoripenem\\tis\\tavailable\\tin\\ta\\t500-\\tmg\\tvial\\tfor\\tinjection. 306    Doxapram Hydrochloride Stability and Storage Store\\tvial\\tat\\t59\xb0F\u2013\\t86\xb0F.\\tConstituted\\tsuspension\\tin\\tvial\\tmay\\tbe\\tstored\\tfor\\t1\\thour prior to dilution in infusion bag. Infusion solution prepared in saline may be stored at room temperature for 8 hours (includes infusion time) or under refrigeration for 24\\thours\\t(includes\\tinfusion\\ttime).\\tInfusion\\tsolution\\tprepared\\tin\\tdextrose\\t5%\\tmay\\tbe stored at room temperature for 4 hours (includes infusion time) or under refrigeration for\\t24\\thours.","original_category":"Antibacterial"},{"name":"Doxycycline Hyclate and Doxycycline Monohydrate","active_ingredient":"Doxycycline Hyclate and Doxycycline Monohydrate","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t5\\tmg/kg\\tq12h\\tPO\\tor\\tIV.\\t10\\tmg/kg\\tq24h\\tPO. \u2022 \\t \\tRickettsia\\t(dogs):\\t5\\tmg/kg\\tq12h. \u2022 \\t \\tEhrlichia\\t(dogs):\\t5\\tmg/kg\\tq12h\\tfor\\tat\\tleast\\t14\\tdays. D Dronabinol 315 \u2022\\t\\tHemoplasmosis\\t(cats):\\t10\\tmg/kg,\\tPO,\\tonce\\tdaily\\tfor\\t7\\tdays. \u2022\\t\\tHeartworm\\ttreatment\\t(dogs):\\t10\\tmg/kg\\tq12h\\tPO\\tadministered\\tfor\\t28\\tdays\\tprior to adulticide treatment. It may be administered in combination with ivermectin. Birds \u2022\\t\\tMix\\tfour\\t100-\\tmg\\tdoxycycline\\thyclate\\tcapsules\\twith\\t1\\tL\\tof\\twater\\t(400\\tmg/L). Shake to make solution and offer as only source of water to birds to eliminate bacteria.\\tAlternatively,\\t25\\tmg/kg\\tPO\\tq12h\\tfor\\t3\\tweeks.  \u2022\\t\\tHorses:\\t20\\tmg/kg\\tq12h\\tPO.\\t(Do not administer IV.) \u2022\\t\\tFor\\tLawsonia intracellularis:\\t20\\tmg/kg\\tPO\\tq24h\\tfor\\t3\\tweeks. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Dronabinol droe- nab \u0301ih- nole Trade and other names: Marinol","contraindications":"Contraindications and Precautions Ordinarily,\\ttetracyclines\\tshould\\tnot\\tbe\\tadministered\\tto\\tyoung\\tanimals\\tbecause it\\tcan\\taffect\\tbone\\tand\\tteeth\\tformation.\\tHowever,\\tit\\thas\\tbeen\\tbetter\\ttolerated in children than other tetracyclines and has been used in children up to 8 years old. Doxycycline is less likely to discolor teeth if used for short- term treatment. If solid- dose forms are administered to cats, lubricate the tablet or capsule or follow with food or water to ensure passage into stomach. Do not administer rapidly IV. Do not administer solution directly IM or SQ. Do not administer IV to horses under any circumstances; acute death has been reported from this use. Pregnancy\\tprecaution:\\tavoid\\tuse\\tduring\\tpregnancy\\tif\\tpossible. Drug Interactions Tetracyclines bind to compounds containing calcium, which decreases oral absorption.\\tHowever,\\tthis\\tis\\tless\\tof\\ta\\tproblem\\twith\\tdoxycycline\\tthan\\twith\\tother tetracyclines. Doxycycline has been mixed with milk prior to oral administration to children without decreasing efficacy. Doxycycline can bind to aluminum- containing products (e.g., sucralfate, antacids), which decreases its oral absorption.","indications":"Indications and Clinical Uses Doxycycline is usually the drug of choice for treating vector- borne diseases in animals, such as those transmitted by ticks and fleas. Efficacy has been demonstrated in research studies and in some clinical studies. It is used for treating infections caused by bacteria, some protozoa, Rickettsia spp., and Ehrlichia spp. Doxycycline administered to cats with infections caused by Mycoplasma spp. or Chlamydophila felis (formerly Chlamydia psittaci)\\tat\\t10\u201315\\tmg/kg\\tonce\\tdaily\\tPO\\tor\\t5\\tmg/kg\\tq12h PO,\\thas\\tbeen\\teffective\\tin\\teliminating\\tthe\\torganism\\tand\\timproving\\tclinical\\tsigns. In\\tdogs,\\t5\\tmg/kg\\tq12h\\tPO\\tfor\\t3\u20134\\tweeks\\thas\\tcleared\\tEhrlichia canis from blood and\\ttissues.\\tDoxycycline\\tis\\trecommended\\tby\\tthe\\tAmerican\\tHeartworm\\tSociety\\tto be added to treatment of canine heartworm disease and initiated 30 days prior to adulticide treatment. It is used for heartworm disease because of the activity against the organism Wolbachia. This may improve microfilaricidal effect when combined with ivermectin, improve response to adulticidal treatment with melarsomine, and decrease\\tinjury\\tto\\tpulmonary\\tvessels.\\tIn\\thorses,\\tit\\thas\\tbeen\\tused\\tnot\\tonly\\tto\\ttreat D Doxycycline Hyclate and Doxycycline Monohydrate 313 ehrlichiosis but also to treat other diseases (e.g., respiratory infections) when oral treatment is indicated. If doxycycline is too expensive or the availability is limited, other alternatives can be considered, such as minocycline hydrochloride, which has been shown to be an acceptable substitute and more active against some organisms (see Minocycline for more details). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tetracyclines may cause renal tubular necrosis at high doses and can affect bone and teeth formation in young animals. Doxycycline is less likely to cause chelation with calcium and teeth discoloration than other tetracyclines. If administered for a short time, it has not caused teeth discoloration in children. Doxycycline administered orally to cats has caused esophageal irritation, tissue\\tinjury,\\tand\\tesophageal\\tstricture.\\tThis\\tmay\\tbe\\tcaused\\tby\\tsolid- dose formulations (primarily doxycycline hyclate rather than doxycycline monohydrate) becoming entrapped in the esophagus. Passage into the stomach by giving the cat water or food after administration is recommended to prevent this effect. Doxycycline given IV to horses has been fatal; however, it has been administered\\tsafely\\tto\\thorses\\tPO,\\talthough\\tdiarrhea\\tis\\tpossible.\\tIn\\ttwo\\tequine studies, there were no adverse effects reported from oral administration. In another study, one of the horses in a pharmacokinetic trial developed signs of enteritis and colic.","notes":"Instructions for Use To\\tprepare\\tdoxycycline\\tIV\\tinfusion\\tsolution,\\tadd\\t10\\tmL\\tto\\ta\\t100-\\tmg\\tvial\\tor\\t20 mL\\tto\\ta\\t200-\\tmg\\tvial\\tand\\tthen\\tfurther\\tdilute\\tfor\\tIV\\tuse\\tin\\t100\u20131000\\tmL\\tof\\tlactated Ringer\u2019s\\tsolution,\\tsodium\\tchloride,\\tor\\t5%\\tdextrose.\\tInfuse\\tover\\t1\u20132\\thours\\t(see\\tthe Stability and Storage section). 314    Doxycycline Hyclate and Doxycycline Monohydrate Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsensitive\\torganisms\\tare\\t\u22640.25\\tmcg/mL\\tfor testing isolates from dogs. Breakpoints for cats are not established, but similar values are recommended. The breakpoint for testing isolates from horses is \u22640.12\\tmcg/mL using\\ta\\tdosage\\tof\\t20\\tmg/kg\\tPO\\ttwice\\tdaily.\\tDo\\tnot\\ttest\\ttetracycline\\tas\\ta\\tsurrogate\\tfor doxycycline in horses. For other animals, tetracycline can be used as a surrogate for testing.\\tOrganisms\\tthat\\tare\\tsusceptible\\tto\\ttetracycline\\tare\\talso\\tconsidered\\tsusceptible\\tto doxycycline.\\tHowever,\\tsome\\torganisms\\tthat\\tare\\tintermediate\\tor\\tresistant\\tto\\ttetracycline may be susceptible to doxycycline or minocycline or both. Formulations \u2022\\t\\tDoxycycline\\tis\\tavailable\\tin\\ta\\t10-\\tmg/mL\\toral\\tsuspension;\\t20-\\t,\\t50-\\t  ,\\t75-\\t  ,\\t100-\\t   ,\\tand 150-\\t  mg\\ttablets;\\tand\\t50-\\t\\tand\\t100-\\tmg\\tcapsules\\t(doxycycline\\thyclate).\\tDoxycycline monohydrate\\tis\\tavailable\\tas\\t50-\\t\\tor\\t100-\\tmg\\ttablets\\tor\\tcapsules.\\tA\\tcontrolled-\\trelease formulation\\t(Oracea)\\tcontains\\t10-\\tmg\\tdelayed\\trelease\\tand\\t30-\\tmg\\timmediate\\trelease in one capsule. \u2022\\t\\tDoxycycline\\thyclate\\tinjection\\tis\\tavailable\\tin\\ta\\t100-\\t\\tand\\t200-\\tmg\\tinjection\\tvial.\\tThe vial\\tshould\\tbe\\tdiluted\\tto\\t10\\tmg/mL\\tinitially\\tand\\tthen\\tto\\t1\\tmg/mL\\tbefore\\tslow\\tIV infusion. Administer IV only and not via the SQ or IM routes. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Avoid\\tmixing\\twith\\tcations\\tsuch\\tas\\tiron,\\tcalcium,\\taluminum,\\tand\\tzinc.\\tHowever, doxycycline tablets have been mixed with milk and immediately administered to children without loss of potency. Doxycycline\\thyclate\\tfor\\tIV\\tinjection\\twill\\tretain\\tpotency\\tfor\\t48\\thours\\twhen\\tdiluted with\\tsodium\\tchloride\\tor\\t5%\\tdextrose\\tsolution\\tto\\tconcentrations\\tbetween\\t1\\tand\\t0.1 mg/mL\\tif\\tstored\\tat\\t25\xb0C\\t(room\\ttemperature).\\tProtect\\tfrom\\tdirect\\tlight\\texposure, but exposure to fluorescent lights is acceptable for 48 hours. Reconstituted solutions may\\tbe\\tstored\\tup\\tto\\t72\\thours\\tif\\trefrigerated\\tand\\tprotected\\tfrom\\tlight.\\tIf\\tfrozen\\tafter reconstitution\\twith\\tsterile\\twater,\\tsolutions\\tof\\t10\\tmg/mL\\tare\\tpotent\\tfor\\t8\\tweeks.\\tIf thawed, do not refreeze. Doxycycline calcium or doxycycline monohydrate commercial oral suspension for people\\tis\\tstable\\tfor\\t2\\tweeks\\tat\\troom\\ttemperature\\tif\\tstored\\tin\\tlight-\\tresistant\\tcontainer after reconstitution with water. Doxycycline tablets may be crushed and mixed with drinks\\tor\\tfood\\t(milk\\tor\\tpudding),\\tand\\tare\\tstable\\tfor\\t24\\thours\\tat\\troom\\ttemperature. If doxycycline is prepared in a compounded formulation, it may be unstable. Doxycycline\\thyclate\\ttablets\\tformulated\\tin\\tOra\\tPlus\\tand\\tOra\\tSweet\\tas\\ta\\tsuspension (50:50)\\tretained\\tpotency\\tfor\\tonly\\t7\\tdays;\\tstability\\tbeyond\\t7\\tdays\\tcannot\\tbe\\tassured. Other\\tsuspensions\\tprepared\\tfor\\tanimals\\talso\\tmay\\tbe\\tunstable.\\tObserve\\tfor\\tdark\\tcolor change (dark brown) as evidence of loss of potency. When doxycycline hyclate and doxycycline monohydrate was compounded in an oil- based suspension, it was stable for\\t180\\tdays.\\tHowever,\\tthe\\tsuspension\\tprecipitates\\tin\\tthe\\tcontainer\\tand\\tvigorous mixing is suggested prior to administration.","original_category":"Antibacterial"},{"name":"Enrofloxacin","active_ingredient":"Enrofloxacin","species":["Canine","Feline","Bovine","Equine"],"dosage":"A\\tlow\\tdosage\\tin\\tdogs\\tand\\tcats\\tof\\t5\\tmg/kg/day\\tis\\tused\\tfor\\tsusceptible\\torganisms\\twith minimum\\tinhibitory\\tconcentration\\t(MIC)\\tvalues\\tof\\t0.5\\tmcg/mL\\tfor\\tall\\tindications. The dose can be increased for bacteria with higher MIC values, but bacteria with MIC\\tvalues\\tgreater\\tthan\\t2\\tmcg/mL\\tare\\tresistant.\\tMaximum\\tdosage\\tfor\\tcats\\tis\\t5 mg/kg\\tonce\\tdaily\\tbut\\tcan\\tbe\\tincreased\\tup\\tto\\t20\\tmg/kg\\tonce\\tdaily\\tfor\\tdogs.\\tThe injectable solution is not approved for IV use, but it has been administered via this route safely if given slowly. Enrofloxacin was not absorbed in cats after transdermal application in a pluronic gel vehicle. Concentrated\\tenrofloxacin\\tsolution\\t(cattle\\tformulation\\tat\\t100\\tmg/mL)\\tis basic\\t(pH\\t10.5);\\ttherefore,\\tit\\tcan\\tbe\\tirritating\\tto\\tsome\\tanimals\\twhen\\tinjected intramuscularly.\\tDo\\tnot\\tinject\\tmore\\tthan\\t20\\tmL\\tat\\teach\\tsite.\\tAlso,\\tthis\\tformulation may precipitate out of solution if pH is decreased by other solutions.  Dogs \u2022\\t\\t5\u201320\\tmg/kg/day\\tIM,\\tPO,\\tor\\tIV.\\tHigher\\tdoses\\tare\\tused\\tfor\\tbacteria\\twith\\thigh MIC values in the intermediate range of susceptibility. For uncomplicated lower urinary\\ttract\\tinfection,\\t18\u201320\\tmg/kg\\tonce\\tdaily\\tPO\\tevery\\t3\\tdays. Cats \u2022\\t\\t5\\tmg/kg/day\\tPO\\tor\\tIM.\\tAvoid\\tIV\\tuse\\tin\\tcats.\\tDo\\tnot\\texceed\\t5\\tmg/kg\\tin\\tcats. Exotic Animals \u2022\\t\\tUsually\\t5\\tmg/kg/day\\tIM\\tor\\toral\\tin\\treptiles\\tevery\\tother\\tday\\tor\\tevery\\tthird\\tday. Birds \u2022\\t\\t15\\tmg/kg\\tq12h\\tIM\\tor\\tPO.  Horses \u2022\\t\\t5\\tmg/kg\\tq24h\\tIV. \u2022\\t\\t7.5\\tmg/kg\\tq24h\\tPO. \u2022\\t\\t5\\tmg/kg\\tof\\t100\\tmg/mL\\tsolution\\t(Baytril-\\t100)\\tIM\\tonce\\tper\\tday\\t(rotate\\tinjection sites). Cattle (BRD) \u2022\\t\\tSingle\\tdose:\\t7.5\u201312.5\\tmg/kg\\tonce\\tSQ\\t(3.4\u20135.7\\tmL/100\\tlb). \u2022\\t\\tMultiple\\tdose:\\t2.5\u20135\\tmg/kg\\tSQ\\t(1.1\u20132.3\\tmL/100\\tlb)\\tonce\\tdaily\\tfor\\t3\u20135\\tdays. Swine (SRD) \u2022\\t\\t7.5\\tmg/kg\\tIM\\tor\\tSQ\\tbehind\\tthe\\tear\\tonce.\\tDo\\tnot\\tadminister\\tmore\\tthan\\t5\\tmL\\tper injection site. Regulatory Information Cattle\\twithdrawal\\ttime:\\t28\\tdays\\tfor\\tmeat.\\tNot\\tto\\tbe\\tused\\tin\\tlactating\\tdairy\\tcattle\\tor calves\\tintended\\tto\\tbe\\tused\\tas\\tveal.\\tDo\\tnot\\tuse\\tin\\tfemale\\tdairy\\tcattle\\t20\\tmonths\\tof\\tage or\\tolder.\\tPig\\twithdrawal\\ttime:\\t5\\tdays. Extralabel use of fluoroquinolones in animals that produce food is illegal. Ephedrine Hydrochloride eh- fed \u0301rin  hye- droe- klor \u0301ide Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tyoung\\tdogs\\tbecause\\tof\\trisk\\tof\\tcartilage\\tinjury.\\tDo\\tnot\\tadminister to\\tyoung\\tfoals;\\tinjury\\tto\\tarticular\\tcartilage\\thas\\tbeen\\treported.\\tUse\\tcautiously in animals that may be prone to seizures, such as those with epilepsy. Do not administer\\tto\\tcats\\tat\\tdoses\\tgreater\\tthan\\t5\\tmg/kg/day.\\tAvoid\\tuse\\tin\\tolder\\tcats. Drug Interactions Fluoroquinolones may increase concentrations of theophylline and possibly other drugs if used concurrently. Coadministration with divalent and trivalent cations, such as products containing aluminum, magnesium (e.g., antacids), iron, and calcium, may decrease absorption. Sucralfate suspension, but not intact tablets, may inhibit oral absorption because aluminum chelates with enrofloxacin. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur. Enrofloxacin may precipitate in an IV line if injected directly into IV fluids. 328    Ephedrine Hydrochloride the\\tsolution\\tin\\tfluids\\t(e.g.,\\t1:10\\tdilution)\\tand\\tinfuse\\tslowly.\\tThe\\t100-\\tmg/mL\\tsolution is\\talkaline\\tand\\tcontains\\tbenzyl\\talcohol\\tand\\tl-\\targinine\\tas\\ta\\tbase\\t(pH\\t10).\\tThe\\tpH\\tof\\tthis solution\\tis\\talkaline,\\tand\\tif\\tthe\\tpH\\tis\\tlowered,\\tthe\\tdrug\\tmay\\tprecipitate.\\tThe\\t22.7-\\tmg/ mL\\tformulation\\thas\\ta\\tpH\\tof\\t11.5\\tand\\tmay\\tnot\\tbe\\tcompatible\\twith\\tsome\\tsolutions.","indications":"Indications and Clinical Uses Enrofloxacin,\\tlike\\tother\\tfluoroquinolones,\\tis\\tused\\tto\\ttreat\\tsusceptible\\tbacteria\\tin\\ta\\tvariety of\\tspecies.\\tTreatment\\thas\\tincluded\\tinfections\\tof\\tskin\\tand\\tsoft\\ttissue,\\turinary\\ttract\\tinfections in dogs and cats, Chlamydophila felis infections in cats, and ulcerative colitis caused by E. coli in dogs. Enrofloxacin has been shown effective for treating Rickettsia infections in dogs. However, it is not effective for treating Ehrlichia infections (see Doxycycline). In horses, it has been used for a variety of soft tissue infections and respiratory infections, although this use is based primarily on anecdotal experience. Enrofloxacin is approved for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis. It is approved in weaned pigs where colibacillosis associated with E. coli has been diagnosed. It is also approved for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, P. multocida, and Haemophilus somni. Enrofloxacin is also used in most exotic animal species because of its safety and activity against a wide variety of pathogens. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tconcentrations\\tmay\\tcause\\tCNS\\ttoxicity.\\tAnimals\\twith\\tkidney\\tdisease\\tmay\\tbe more susceptible. It may cause occasional vomiting and, at high doses, may cause some nausea and diarrhea. All of the fluoroquinolones may cause arthropathy in young\\tanimals.\\tDogs\\tare\\tmost\\tsensitive\\tat\\t4\\tweeks\\tto\\t28\\tweeks\\tof\\tage.\\tLarge, rapidly growing dogs are the most susceptible. Cats are relatively resistant to cartilage injury, but foals are susceptible. Blindness in cats that is caused by retinal degeneration has been reported from enrofloxacin. Affected cats have had permanent\\tblindness.\\tThis\\tmay\\tbe\\ta\\tdose-\\trelated\\teffect.\\tCats\\tadministered\\tdoses of\\t20\\tmg/kg\\tdeveloped\\tretinal\\tdegeneration\\tbut\\tdid\\tnot\\tat\\t5\\tmg/kg.\\tTherefore, dose restrictions in cats have been used. Administration of concentrated solution (100\\tmg/mL)\\tgiven\\torally\\tto\\thorses\\thas\\tcaused\\toral\\tmucosal\\tlesions.\\tWhen injected,\\tthis\\tsolution\\t(pH\\t10.5)\\tmay\\tbe\\tirritating\\tto\\tsome\\ttissues. Problems reported in people from use of fluoroquinolones include tendon injury and rupture (mostly Achilles tendon) and aortic artery dissection and rupture.\\tThese\\tevents\\toccur\\tas\\ta\\tresult\\tof\\tfluoroquinolone\u2019s\\tability\\tto\\tupregulate cell matrix metalloproteinases, resulting in a reduction of collagen fibrils of types I and III collagen, which comprise the majority of collagen in tendons and the aorta. Fluoroquinolones can affect glucose homeostasis in people with diabetes. However, despite the reports of these effects in people, there are no reported instances of these problems in animals with current use. E","notes":"Instructions for Use Patient Monitoring and Laboratory Tests Susceptibility\\ttesting\\t(from\\tthe\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t[CLSI]): For\\tdogs\\tand\\tcats,\\tthe\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tis\\t\u22640.5\\tmcg/mL,\\tand bacteria\\tabove\\t2\\tmcg/mL\\tare\\tclinically\\tresistant.\\tFor\\tcattle,\\tthe\\tbreakpoint\\tfor susceptible bacteria (BRD pathogens) is \u22640.25\\tmcg/mL.\\tFor\\tpigs,\\tthe\\tbreakpoint for susceptible bacteria is \u22640.25\\tmcg/mL\\tfor\\tSRD\\tpathogens\\tbut\\t\u22640.5\\tmcg/mL\\tfor Streptococcus suis.\\tFor\\thorses,\\tthe\\tbreakpoint\\tfor\\tsusceptible\\tbacteria\\tis\\t\u22640.12\\tmcg/mL at\\tan\\toral\\tdose\\tof\\t7.5\\tmg/kg\\tonce\\tdaily.\\tThese\\tbreakpoints\\tmay\\tbe\\tapplied\\tto\\tother species\\twhen\\tspecific\\tbreakpoints\\tare\\tnot\\tavailable. Formulations Enrofloxacin\\tis\\tavailable\\tin\\t22.7-\\t\\tand\\t68-\\tmg\\ttablets;\\tTaste\\tTabs\\tare\\t22.7,\\t68,\\tand\\t136 mg.\\tIt\\tis\\talso\\tavailable\\tin\\ta\\t22.7-\\tmg/mL\\tinjection\\tand\\ta\\t100-\\tmg/mL\\tpreparation\\tfor large\\tanimals\\t(Baytril-\\t100). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations have been evaluated, and it was found to be stable\\twith\\tmany\\tmixtures.\\tA\\t1%\\tsolution\\tdiluted\\tin\\tother\\tvehicles\\t(chlorhexidine, salicylic\\tacid,\\tEDTA,\\tand\\twater)\\twas\\tstable\\tfor\\t28\\tdays.\\tHowever,\\tdo\\tnot\\tmix\\twith solutions that contain ions that may chelate with enrofloxacin (iron, magnesium, aluminum, and calcium). If administered intravenously, it is recommended to first dilute","original_category":"Antibacterial"},{"name":"Ertapenem","active_ingredient":"Ertapenem","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t30\\tmg/kg\\tqh8\\t(q8h)\\tIV\\tor\\tSQ.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Erythromycin eh- rith- roe- mye \u0301 Trade and other names: Gallimycin- 100, Gallimycin- 200, Erythro- 100, and generic brands","contraindications":"Contraindications and Precautions Some slight yellowish discoloration may occur after reconstitution. Slight discoloration\\twill\\tnot\\taffect\\tpotency.\\tHowever,\\ta\\tdarker\\tamber\\tor\\tbrown discoloration may indicate oxidation and loss of potency. Drug Interactions Do not mix in vial or syringe with other antibiotics.","indications":"Indications and Clinical Use Ertapenem is indicated primarily for resistant infections caused by bacteria resistant to other drugs. It may be valuable for treating resistant infections caused by E. coli and Klebsiella pneumoniae but is not useful for P. aeruginosa. The use of ertapenem has not been as common as for meropenem or imipenem. High protein binding\\tand\\ta\\tlong\\thalf-\\tlife\\tin\\tpeople\\thave\\tallowed\\tless\\tfrequent\\tadministration compared with other carbapenems. However, dosing protocols have not been tested in dogs and cats. 338    Erythromycin Precautionary Information","side_effects":"Adverse Reactions and Side Effects Carbapenems\\tpose\\t  similar\\t   risks\\t  as\\t other\\t   beta-\\t  lactam\\t   antibiotics,\\tbut\\t  adverse\\teffects are\\trare.\\tThere\\tis\\ta\\trisk\\tof\\tCNS\\ttoxicity\\t(seizures\\tand\\ttremors)\\twith\\thigh\\tdoses.","notes":"Instructions for Use Doses in animals have been based on extrapolation from human studies rather than efficacy trials. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tin\\thumans\\tis\\t\u22644 mcg/mL.\\tVeterinary\\tbreakpoints\\tare\\tnot\\testablished.\\tMost\\tbacteria\\thave\\tan\\tMIC\\tless than\\t2\\tmcg/mL.\\tSensitivity\\tto\\timipenem\\tcan\\tbe\\tused\\tas\\ta\\tmarker\\tfor\\tertapenem. Formulations \u2022\\t\\tErtapenem\\tis\\tavailable\\tin\\ta\\t1-\\tg\\tvial\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Erythromycin","active_ingredient":"Erythromycin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t10\u201320\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tProkinetic\\teffects\\t(GI):\\t0.5\u20131\\tmg/kg\\tq8\u201312h\\tPO\\tor\\tIV.  Horses \u2022 \\t \\tR. equi:\\tErythromycin\\tphosphate\\tor\\terythromycin\\testolate\\t37.5\\tmg/kg\\tq12h\\tPO or\\t25\\tmg/kg\\tq8h\\tPO.\\tNote\\tthat\\tin\\thorses,\\terythromycin\\tbase\\t(plain\\ttablets)\\tare poorly absorbed, and other forms should be used. (See Instructions for Dosing regarding dosage forms.) \u2022\\t\\tErythromycin\\tlactobionate\\tinjection:\\t5\\tmg/kg\\tq4\u20136h\\tIV.\\tTo\\tstimulate\\tGI\\tmotility: 1\\tmg/kg. In small animals, the most common side effect is vomiting (probably caused by cholinergic-\\tlike\\teffect\\tor\\tmotilin-\\tinduced\\tmotility).\\tIn\\tsmall\\tanimals,\\tit\\talso\\tmay cause diarrhea. In rodents and rabbits, the diarrhea caused by erythromycin can be serious and even fatal.","contraindications":"Contraindications and Precautions Do not administer orally to rodents or rabbits. Do not administer erythromycin solutions intended for IM administration by IV injection. Only the gluceptate and lactobionate salts should be used intravenously (gluceptate is rarely available). Drug Interactions Erythromycin,\\tlike\\tother\\tmacrolides,\\tis\\tknown\\tto\\tinhibit\\tthe\\tcytochrome\\tP450 enzymes and may decrease the metabolism of other coadministered drugs. See Appendixes H and I. E Esmolol Hydrochloride 341 Cattle \u2022\\t\\tAbscesses,\\tpododermatitis:\\t2.2\u20138.8\\tmg/kg\\tq24h\\tIM. \u2022\\t\\tPneumonia:\\t2.2\u20138.8\\tmg/kg\\tq24h\\tIM\\tor\\t15\\tmg/kg\\tq12h\\tIM. \u2022\\t\\tStimulate\\trumen\\tmotility:\\tcalves,\\t8.8\\tmg/kg\\tIM;\\tcows,\\t10\\tmg/kg\\tIM. Regulatory Information Cattle\\twithdrawal\\ttimes:\\t6\\tdays\\tmeat\\t(at\\t8.8\\tmg/kg).\\tDo\\tnot\\tuse\\tin\\tfemale\\tdairy cattle\\tolder\\tthan\\t20\\tmonths\\tof\\tage.\\tDo\\tnot\\tslaughter\\ttreated\\tanimals\\twithin\\t6\\tdays\\tof last\\ttreatment.\\tTo\\tavoid\\texcess\\ttrim,\\tdo\\tnot\\tslaughter\\twithin\\t21\\tdays\\tof\\tlast\\tinjection. In\\tCanada,\\twithdrawal\\ttimes\\tare\\t14\\tdays\\tfor\\tmeat\\tand\\t72\\thours\\tfor\\tmilk. Esmolol Hydrochloride ez \u0301moe- lole  hye- droe- klor \u0301ide Trade and other names: Brevibloc","indications":"Indications and Clinical Uses Erythromycin has been used in a variety of species to treat infections caused by susceptible bacteria. Infections treated include respiratory infections (pneumonia), soft\\ttissue\\tinfections\\tcaused\\tby\\tgram-\\tpositive\\tbacteria,\\tand\\tskin\\tand\\trespiratory infections. In foals, it has been used to treat Rhodococcus equi pneumonia, often in combination with rifampin. In some species, including horses, it has been used at low doses to stimulate intestinal motility, but demonstration of this activity has been limited in clinical patients. In horses, the dose of erythromycin to stimulate GI\\tmotility\\tis\\tlower\\tthan\\tthe\\tantibacterial\\tdose\\t(1\\tmg/kg),\\tbut\\tthe\\tclinical\\tefficacy for\\tthis\\tuse\\thas\\tnot\\tbeen\\tshown.\\tIn\\texperimental\\tcalves,\\t8.8\\tmg/kg\\tIM\\tsignificantly increased\\trumen\\tmotility.\\tAt\\ta\\tdose\\tof\\t10\\tmg/kg\\tIM\\tin\\tcows\\tundergoing\\tsurgery\\tfor left displaced abomasum, it increased rumen contractions. The use of erythromycin has diminished because of decreased availability of some dose forms (erythromycin estolate), adverse effects in small animals (frequent vomiting),\\ta\\tshort\\thalf-\\tlife\\tthat\\trequires\\tfrequent\\tdosing,\\tand\\tdiarrhea\\tin\\thorses.\\tOther macrolides have become used more often in each species. For example, azithromycin and clarithromycin are used in small animals and horses, and tilmicosin, gamithromycin, tildipirosin, and tulathromycin are used more often in cattle instead of erythromycin.","side_effects":"Adverse Reactions and Side Effects Diarrhea in large animals is the most common adverse effect. This is believed to be caused by a disruption of the normal bacterial intestinal flora and more common from oral administration. Nursing mares have developed diarrhea through exposure to treated foals. Hyperthermia (febrile syndrome) in association with erythromycin treatment has been observed in foals.","notes":"Instructions for Use There are several forms of erythromycin, including the ethylsuccinate and estolate esters and stearate salt for oral administration. However, the estolate form is only available as a suspension. There are no convincing data to suggest that one form is absorbed better than another, and the same dosage is applied for all. Only erythromycin gluceptate and lactate are to be administered IV (gluceptate is rarely available).\\tA\\tmotilin-\\tlike\\teffect\\tto\\tstimulate\\tGI\\tmotility\\toccurs\\tat\\tlow\\tdoses\\tand\\thas been studied primarily in experimental horses. Erythromycin may be administered to cattle in conjunction with surgical procedures to stimulate rumen motility postsurgery. Precautionary Information Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsensitive\\torganisms\\tare\\t\u22640.25\\tmcg/ mL\\tfor\\tstreptococci\\tand\\t\u22640.5\\tfor\\tother\\torganisms,\\tusing\\tthe\\thuman\\tbreakpoint.\\tA veterinary\\tbreakpoint\\thas\\tnot\\tbeen\\testablished.\\tSusceptibility\\tto\\terythromycin\\ttends to predict susceptibility to other macrolide antibiotics. Formulations \u2022\\t\\tErythromycin\\tis\\tavailable\\tin\\tseveral\\tforms\\tthat\\tcontain\\teither\\ta\\t250-\\t\\tor\\t500-\\tmg erythromycin\\tbase.\\tOral\\tformulations\\tinclude\\t25-\\t\\tand\\t50-\\tmg/mL\\terythromycin estolate\\tsuspension,\\t40-\\tmg/mL\\terythromycin\\tethylsuccinate\\tsuspension,\\t400-\\tmg ethylsuccinate\\ttablets,\\tand\\t250-\\t\\tand\\t500-\\tmg\\terythromycin\\tstearate\\ttablets. \u2022\\t\\tIV\\tformulations\\tinclude\\terythromycin\\tlactobionate,\\tbut\\terythromycin\\tgluceptate\\tis rarely available. \u2022\\t\\tErythromycin\\tphosphate,\\ta\\tfeed\\tadditive\\tavailable\\tas\\ta\\tpowder,\\thas\\tbeen administered in horses and shown to produce adequate absorption. Erythromycin phosphate\\tis\\t260\\tmg/g,\\twhich\\tis\\tequivalent\\tto\\t231-\\tmg\\terythromycin\\tbase\\tper gram. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Protect\\tfrom\\tfreezing.\\tErythromycin\\tbase\\tis\\tmost\\tstable\\tat\\ta\\tpH\\tof\\t7\u20137.5.\\tIn acidic\\tsolution,\\tit\\tmay\\tdecompose.\\tEthylsuccinate\\tformulations\\tare\\tstable\\tfor\\t14 days.","original_category":"Antibacterial"},{"name":"Florfenicol","active_ingredient":"Florfenicol","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\t20\\tmg/kg\\tq6h\\tIM\\tor\\tPO. Cats \u2022\\t\\t22\\tmg/kg\\tq8h\\tIM\\tor\\tPO.  Cattle, Bovine Respiratory Disease \u2022\\t\\t20\\tmg/kg\\tq48h\\tSQ\\tor\\tIM\\t(in\\tthe\\tneck). \u2022\\t\\t40\\tmg/kg\\tSQ\\tas\\ta\\tsingle\\tinjection\\tor\\tq72h\\tSQ\\tin\\tthe\\tneck\\tregion\\t(also\\tcombined with flunixin at 2.2 mg/kg and Nuflor Gold at 40- mg/kg single injection). Horses \u2022\\t\\tAlthough\\tflorfenicol\\thas\\tbeen\\tadministered,\\tsome\\treferences\\tcite\\tadverse\\teffects after administration. Until more safety data become available, it is suggested to avoid use of florfenicol in horses. Sheep \u2022\\t\\t20\u201330\\tmg/kg\\tIM\\tor\\t40\\tmg/kg\\tSQ\\tadministered\\tdaily\\tfor\\t3\\tdays. Pigs \u2022\\t\\t15\\tmg/kg\\tIM\\tin\\tthe\\tneck\\tq48h. \u2022\\t\\tAdminister\\tin\\tdrinking\\twater\\tat\\t400\\tmg/gallon\\t(100\\tparts\\tper\\tmillion)\\tfor\\t5 consecutive days. F Fluconazole 373 Fish \u2022\\t\\t10\u201315\\tmg/kg\\tbody\\tweight/day\\tfor\\t10\\tconsecutive\\tdays Regulatory Information Cattle withdrawal time (meat): 28 days if administered IM; 38 days if administered SQ.\\tNuflor\\tGold\\twithdrawal\\ttime\\t(40\\tmg/kg\\tSQ)\\tis\\t44\\tdays. Sheep: Apply at least 42- day slaughter withdrawal time. Do not use in calves to be processed for veal; not to be used in dairy cattle 20 months of age or older or in veal calves younger than 1 month. A withdrawal period has not been established in preruminating calves, but FARAD (www.FARAD.org) recommends 90 days. Do not use in dairy cattle. If administered intramammary, 5 days is needed for depletion. Pig withdrawal time: 16 days after last treatment when administered in water; 13 days after last treatment when administered with feed. Fluconazole floo- kahn\u2032ah- zole Trade and other names: Diflucan and generic brands","contraindications":"Contraindications and Precautions Long- term use in animals may cause bone marrow suppression. Administration to horses has caused diarrhea, colitis, and elevations in bilirubin. Administration to horses is not recommended. Do not administer more than 10 mL in a single site. Drug Interactions No drug interactions are reported for animals. However, chloramphenicol is well known to inhibit cytochrome P450 enzymes and decrease metabolism of other drugs (see Appendix I). Therefore, it is possible\u2014but not documented\u2014that florfenicol could cause drug interactions.","indications":"Indications and Clinical Uses Because florfenicol is a derivative of chloramphenicol, it has been used in situations in which chloramphenicol is unavailable or illegal. (Chloramphenicol is illegal to use in food animals in the United States.) Florfenicol has been shown to be effective for treatment of BRD in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Administration of florfenicol (40 mg/ kg\\tonce\\tSQ)\\tat\\ttime\\tof\\tarrival\\tto\\tthe\\tfeedlot\\tdecreased\\tthe\\tincidence\\tof\\tBRD.\\tIt\\talso is used for treatment of bovine interdigital phlegmon (foot rot, acute interdigital necrobacillosis, and infectious pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus and for treatment of infectious bovine keratoconjunctivitis caused by Moraxella bovis. Resflor Gold contains both florfenicol and flunixin. It is used for the same BRD pathogens and provides anti- inflammatory activity with the addition of flunixin meglumine, including BRD- associated pyrexia in beef and nonlactating dairy cattle. In pigs, florfenicol is used for treatment of swine respiratory disease (SRD) caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis. In cats, effective concentrations can be achieved with twice- daily administration. In dogs, the half- life is short, and frequent administration is necessary to produce effective concentrations. Florfenicol also has been administered to fish. There is a feed- additive formulation that also has been approved for fish (10\u201315 mg/kg body weigh/day for 10 consecutive days). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Florfenicol use in dogs and cats has been limited; therefore, adverse effects have not been reported. Long- term use should be avoided in dogs and cats. Chloramphenicol has been linked to dose- dependent bone marrow depression, and similar reactions may be possible with florfenicol. However, there is not a risk of aplastic anemia as for chloramphenicol. At high doses, florfenicol may cause testicular degeneration. In horses, doses of 20 mg/kg q48h IM changed the bacterial flora and increased risk of diarrhea.","notes":"Instructions for Use The florfenicol dose form available is only approved for use in cattle and pigs (with an exception for the oral form for fish). The doses, intervals, and indications for livestock have been established through well- controlled studies and FDA evaluation and approval. However, there is insufficient information available for dogs and cats. The doses listed below in the dosing section have not been thoroughly evaluated in small animals and were derived only from pharmacokinetic studies in\\thealthy\\tanimals.\\tSustained\\teffect\\tin\\tcattle\\tfrom\\tIM\\tand\\tSQ\\tadministration does not appear to be long lasting in dogs. Injectable formulation for cattle has been administered orally to small animals, if necessary, but the taste is bitter. Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow depression. Clinical and Laboratory Standards Institute (CLSI) breakpoints for florfenicol susceptible organisms are \u22642 mcg/mL for bovine and swine respiratory pathogens and \u22644 mcg/mL for Streptococcus suis. Formulations \u2022\\t\\t300-\\t  mg/mL\\tinjectable\\tsolution\\t(cattle).\\tNuflor\\tGold\\tcontains\\t300\\tmg/mL\\tof florfenicol with excipients triacetin and 2- pyrrolidone added. Nuflor contains 300 mg/mL of florfenicol with propylene glycol added as an excipient. \u2022\\t\\t23-\\t mg/mL\\tsolution\\tto\\tbe\\tadded\\tto\\tdrinking\\twater\\tfor\\tpigs\\t(400\\tmg/gallon). \u2022\\t\\tType\\tA\\tmedicated\\tfeed\\tformulation\\tcontains\\t500\\tg/kg\\t(227.27\\tg/lb)\\tto\\tbe\\tadded to fish feed. \u2022\\t\\tFlunixin\\tis\\tcombined\\twith\\tflorfenicol\\tin\\tResflor\\tGold,\\twhich\\thas\\t300\\tmg\\tof florfenicol and 16.5 mg of flunixin per milliliter with vehicles of 2- pyrrolidone, 35- mg malic acid, and triacetin. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Light yellow or straw color does not affect potency. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Fosfomycin Tromethamine","active_ingredient":"Fosfomycin Tromethamine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tPrecise\\tdoses\\tare\\tnot\\testablished\\tfor\\tdogs;\\t75\u2013150\\tmg/kg\\tq12h\\tPO\\thas\\tbeen recommended based on pharmacokinetic studies. Additional cited doses used are empiric and include a recommendation of a 3- g packet divided equally into three daily doses (1 g dissolved in 30 mL) and administered daily to dogs. Cats \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\testablished\\tfor\\tcats.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No withdrawal times are established for animals intended for food. Furazolidone fyoo- rah- zole\u2032ih- done Trade and other names: Furoxone","contraindications":"Contraindications and Precautions Do not administer in dry form; mix with water. There are no other known contraindications. Fosfomycin should not be substituted for antibiotics with established efficacy. Drug Interactions No known drug interactions, but the use in animals has been very rare and not sufficient to assess potential drug interactions.","indications":"Indications and Clinical Uses Fosfomycin has been used as treatment or adjunctive treatment for UTIs. In women, it is used as a single dose to treat acute UTIs. Although this may be an accepted treatment for people, the use in animals has been primarily derived from empirical use and small observational studies. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects have been reported, but use in animals has been very limited. It has been safe and well tolerated in dogs up to 120\u2013200 mg/kg.","notes":"Instructions for Use Fosfomycin has been used to treat UTIs in animals, primarily when other drugs have failed or were inactive as a result of resistance. Alternatively, fosfomycin has been used intermittently (pulse therapy) to prevent recurrences of UTIs. The efficacy of any of these indications is not established in animals and based on only small observational studies or anecdotal use. Patient Monitoring and Laboratory Tests Monitor UTI with culture and urinalysis. The susceptibility testing breakpoints may not apply to bacteria isolated from animals. Formulations \u2022\\t\\tFosfomycin\\tis\\tavailable\\tin\\ta\\t3-\\tg\\tpacket.\\tThe\\tpacket\\talso\\tcontains\\tsaccharin\\tand sucrose for flavoring. This packet may be mixed with water and administered immediately orally. 394    Furazolidone Stability and Storage Store in original package, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial (urinary)"},{"name":"Gamithromycin","active_ingredient":"Gamithromycin","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tNo\\tsmall\\tanimal\\tdoses\\thave\\tbeen\\testablished.  Cattle \u2022\\t\\t6\\tmg/kg\\tSQ\\t(neck)\\tas\\ta\\tsingle\\tinjection\\t(2\\tmL\\tper\\t110\\tlb). Pigs \u2022\\t\\tNot\\trecommended. 402    Gemfibrozil Horses \u2022\\t\\tFor\\ttreatment\\tof\\tStreptococcus zooepidemicus or R. equi: 6 mg/kg IM administered every 7 days if needed. Regulatory Information No milk withdrawal times are established; do not use in lactating dairy cattle and do not use in female dairy cattle 20 months of age or older. Do not treat cattle within 35 days of slaughter. No withdrawal period has been established for young preruminating calves; do not use in veal calves. Gemfibrozil jem- fih\u2032broe- zil Trade and other names: Lopid","contraindications":"Contraindications and Precautions No specific contraindications have been reported. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses In cattle, gamithromycin is used for treatment of bovine respiratory disease (BRD) caused by M. haemolytica, P. multocida, and Histophilus somni. It is also effective for treating infections caused by Mycoplasma spp. It also may be used for control of respiratory disease in beef and nonlactating dairy cattle at high risk of developing BRD (metaphylaxis) associated with M. haemolytica and P. multocida. In horses, experimental studies indicate that it may have efficacy for treating infections caused by S. equi and R. equi. For this use, it may be substituted for erythromycin or azithromycin and administered with rifampin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Serious adverse reactions have not been observed. Injection- site reactions are possible in some animals, with swelling or irritation at the injection site. When injected in horses, 58% had pain at the injection site, and there were mild signs of colic in some (6%) of the horses.","notes":"Instructions for Use In cattle, administer as a single SQ injection in the neck. In horses, an injection IM can be administered every 6\u20137 days to maintain effective concentrations in respiratory fluids. Patient Monitoring and Laboratory Tests Clinical and Laboratory Standards Institute (CLSI) breakpoint for susceptibility is \u22644.0 mcg/mL. Formulations \u2022\\t\\tGamithromycin\\tis\\tavailable\\tin\\ta\\t150-\\tmg/mL\\tsolution\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Gentamicin Sulfate","active_ingredient":"Gentamicin Sulfate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t9\u201314\\tmg/kg\\tq24h\\tSQ,\\tIM,\\tor\\tIV. Cats \u2022\\t\\t5\u20138\\tmg/kg\\tq24h\\tSQ,\\tIM,\\tor\\tIV.  Horses \u2022\\t\\tAdult:\\t4\u20136.6\\tmg/kg\\tq24h\\tIM\\tor\\tIV. \u2022\\t\\tFoals\\tyounger\\tthan\\t2\\tweeks:\\t12\u201314\\tmg/kg\\tq24h\\tIM\\tor\\tIV. Pigs \u2022\\t\\t15\\tmg/kg\\tfor\\tyoung\\tpigs\\tand\\t10\\tmg/kg\\tfor\\tolder\\tpigs\\tonce\\tdaily\\tSQ\\tor\\tIM. \u2022\\t\\tColibacillosis,\\tswine\\tdysentery:\\t1.1\u20132.2\\tmg/kg\\tfor\\t3\\tdays\\tin\\tdrinking\\twater. Calves \u2022\\t\\tYounger\\tthan\\t2\\tweeks:\\t12\u201315\\tmg/kg\\tq24h\\tIV\\tor\\tIM. \u2022\\t\\tAdult\\tcattle:\\t5\u20136\\tmg/kg\\tq24h\\tIM\\tor\\tIV. Regulatory information With the exception of licensed products for pigs, aminoglycosides should not be administered to food animals because of residue concerns. Withdrawal\\ttime\\tfor\\tpigs:\\t3\\tdays\\tfor\\tmeat\\tat\\t1.1\\tmg/kg\\tPO\\tand\\t40\\tdays\\tfor\\tmeat at\\t5\\tmg/kg\\tIM;\\t14\\tdays\\tfor\\tmeat\\tat\\t5\\tmg/kg\\tPO. If gentamicin is administered systemically to cattle, an extended withdrawal time is necessary because of persistence of residues in the kidney. FARAD recommends 18 months. After systemic administration of 5 mg/kg, milk withdrawal time should be 5 days. If gentamicin is administered intramammarily (500 mg per quarter), a milk withdrawal time of at least 10 days and a meat withdrawal time of 180 days should be used. Contact FARAD for additional information at www.FARAD.org. Glipizide glip- ih\u2032zide Trade and other names: Glucotrol","contraindications":"Contraindications and Precautions Do not administer to animals with compromised renal function, renal insufficiency, kidney disease, or renal failure. Kidney disease impairs renal clearance of gentamicin and increases the risk of kidney injury. Use in young animals is acceptable, but higher doses may be necessary. Drug Interactions When gentamicin is used with anesthetic agents, neuromuscular blockade is possible. Do not mix in vial or syringe with other antibiotics; otherwise, inactivation can occur. Ototoxicity and nephrotoxicity are potentiated by loop diuretics such as furosemide.","indications":"Indications and Clinical Uses Gentamicin has a rapid, bactericidal action and is indicated for acute serious infections, such as those caused by gram- negative bacilli. Gentamicin has been administered IM, SQ, and IV. It is not absorbed after oral administration, and this use is restricted to labeled use in pigs for treatment of diarrhea. Gentamicin, like other aminoglycosides, can be used with beta- lactam antibiotics because it broadens the spectrum when used with drugs such as penicillins, ampicillin, or cephalosporins. Although gentamicin is generally active against most gram- negative bacilli, amikacin is more consistently active against resistant strains. The use should be avoided in food- producing animals because of risk of residues. The only approved use in food animals is oral treatment in pigs for swine dysentery. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nephrotoxicity is the most dose- limiting toxicity. Ensure that patients have adequate fluid and electrolyte balance during therapy. Electrolyte depletion increases the risk of nephrotoxicity. Kidney injury is increased with persistently high trough concentrations. High levels of calcium and protein in the diet decrease the risk of nephrotoxicity. Ototoxicity and vestibulotoxicity also are possible but have not been often reported in animals. With high doses, neuromuscular toxicity is possible, although rare.","notes":"Instructions for Use Dosing regimens in most animals emphasize once- daily administration to maximize efficacy and decrease adverse effects. Once- daily administration is as efficacious and possibly more effective than administration more than once per day. The once daily treatment is also safer because of less kidney exposure, as multiple treatments. Activity against some bacteria (e.g., Pseudomonas aeruginosa) may be enhanced when combined with a beta- lactam antibiotic, such as ceftazidime, but there is no strong evidence that it is synergistic with beta- lactam antibiotics when treating other bacteria. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tThe\\tCLSI\\tminimum\\tinhibitory\\tconcentration\\tbreakpoint for susceptibility testing is \u22642 mcg/mL. Monitor blood urea nitrogen, creatinine, and urine for evidence of renal toxicity. Blood levels can be monitored to measure for problems with systemic clearance. When monitoring trough levels in patients that are administered gentamicin once per day, the trough levels should be near or below the limit of detection. Alternatively, measure half- life from samples taken at 1 hour and 2\u20134 hours postdosing. Clearance should be approximately equal to the GFR (greater than 1.0 mL/kg/min), and the half- life should be less than 2 hours. G Glipizide 405 Formulations \u2022\\t\\tGentamicin\\tis\\tavailable\\tin\\ta\\t50-\\t\\tand\\t100-\\tmg/mL\\tsolution\\tfor\\tinjection,\\ta\\t50-\\tmg/ mL oral solution for pigs, and a 5- mg/mL injection for turkeys. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Gentamicin is soluble in water. Do not mix with other drugs, especially in a vial, syringe, or fluid administration set. Inactivation may occur. Avoid long- term storage in plastic containers.","original_category":"Antibacterial"},{"name":"Imipenem + Cilastatin","active_ingredient":"Imipenem + Cilastatin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tSQ. Cats \u2022\\t\\t5\\tmg/kg\\tq6\u20138h\\tIV\\tor\\tIM,\\tor\\tq8h\\tfor\\tSQ.  Horses \u2022\\t\\t10\u201320\\tmg/kg\\tq6h\\tby\\tslow\\tIV\\t(10-\\tminute)\\tinfusion. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Imipramine Hydrochloride im- ip\u2032rah- meen  hye- droe- klor\u2032ide Trade and other names: Tofranil and generic brands","contraindications":"Contraindications and Precautions Use cautiously in patients prone to seizures. Seizures may be more likely in patients with renal failure. Drug Interactions There have been no drug interactions documented in veterinary medicine. Do not mix with other drugs in the vial.","indications":"Indications and Clinical Uses Imipenem is used primarily for infections caused by bacteria resistant to other drugs. The use in animals is based on extrapolation from human uses and results from experimental animals. There are no controlled clinical studies in veterinary medicine that have evaluated imipenem. Imipenem can be  valuable for treating resistant infections caused by P. aeruginosa, Escherichia coli, and Klebsiella pneumoniae. Although active against gram- positive bacteria such as staphylococci (but not methicillin- resistant strains), other drugs should be used for gram- positive infections. Meropenem and doripenem are newer drugs in the class of carbapenems and have some advantages with respect to activity and convenience of administration. Meropenem is often preferred for administration to dogs and cats because it is easier to administer and more stable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Allergic reactions may occur with beta- lactam antibiotics. With rapid infusion or in patients with renal insufficiency, neurotoxicity may occur. Neurotoxicity in animals has included tremors, nystagmus, and seizures. Nephrotoxicity is possible, but imipenem is combined with cilastatin to decrease renal metabolism. Vomiting and nausea are possible. IM injections can cause painful reactions.","notes":"Instructions for Use Efficacy studies are not available for animals. Recommendations are based on extrapolation of studies performed in humans or laboratory animals. Reserve the use of this drug for resistant, refractory infections, when other drugs cannot be used. Observe manufacturer\u2019s instructions carefully for proper administration. When the vial is initially reconstituted, it should not be given intravenously. It first must be diluted in a suitable IV fluid solution (at least 100 mL). For IV administration, it may be mixed with IV fluids. After reconstitution in vial, 250 or 500 mg should be added to not less than 100 mL of fluids and given intravenously over 30\u201360 minutes. IV fluid solutions are\\tstable\\tfor\\t48\\thours\\tif\\trefrigerated\\tor\\t8\\thours\\tat\\troom\\ttemperature.\\tFor\\tIM administration, 2 mL of lidocaine (1%) may be added to decrease pain from injection. The suspension intended for IM use is stable for only 1 hour. In some hospitals, the IV solution has been diluted in fluids and administered SQ without any sign of injection- site\\treactions\\t(usually\\t8\u201314\\tmL\\tper\\tinjection\\tin\\tdogs). I Imipramine Hydrochloride 455 Patient Monitoring and Laboratory Tests Susceptibility testing: Clinical and Laboratory Standards Institute (CLSI) breakpoints for sensitive organisms are \u22641 mcg/mL. Most veterinary pathogens have minimum inhibitory concentration (MIC) values less than 1.0 mcg/mL. Formulations \u2022\\t\\tIV\\t solution:\\tImipenem\\t+\\t cilastatin\\tis\\t available\\tin\\t 250-\\t\\t  and\\t  500-\\t  mg\\t  vials\\t  for\\t injection. \u2022\\t\\tIM\\tsuspension:\\tIM\\tsuspension\\tis\\tavailable\\tin\\t500-\\t\\tand\\t750-\\tmg\\tvials. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. After\\treconstitution,\\tit\\tis\\tstable\\tfor\\t4\\thours\\tat\\troom\\ttemperature\\tand\\t24\\thours refrigerated. Do not freeze IV fluid solutions. Slight yellow discoloration is acceptable but discard it if the color turns brown.","original_category":"Antibacterial"},{"name":"Isoniazid","active_ingredient":"Isoniazid","species":["Feline","Bovine"],"dosage":"\u2022\\t\\t5\\tmg/kg\\tper\\tday\\t(up\\tto\\t10\u201315\\tmg/kg/day)\\tPO,\\tIM,\\tor\\tIV.\\tIt\\talso\\tis\\tadministered as 15 mg/kg two to three times per week.  \u2022\\t\\tCattle:\\t10\u201320\\tmg/kg\\tper\\tday\\tIM. \u2022\\t\\tJohne\u2019s\\tdisease\\tin\\tcattle,\\tsheep,\\tand\\tgoats:\\t10\u201320\\tmg/kg\\tper\\tday\\tin\\tcombination with rifampin. Regulatory Information No withdrawal time has been established for large animals. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Isoproterenol Hydrochloride eye- soe- proe- teer\u2032eh- nole  hye- droe- klor\u2032ide Trade and other names: Isuprel and isoprenaline hydrochloride","contraindications":"Contraindications and Precautions No specific contraindications have been reported for animals. However, it should not be used in animals with evidence of hepatic disease. Do not exceed 30 mg/kg in large animals to avoid adverse effects. Drug Interactions Isoniazid metabolism may be decreased by itraconazole and increased by rifampin. 476    Isoproterenol Hydrochloride","indications":"Indications and Clinical Uses Isoniazid is used in people to treat tuberculosis. In animals, it is used to treat atypical bacterial infections, such as those caused by Mycobacterium spp. However, there is very little clinical information to guide dosing in animals or predict efficacy. The use is extrapolated from experience in human medicine or the opinions of experts. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The use is uncommon in animals, and adverse effects have not been well documented. Hepatic toxicity is the most serious concern when isoniazid is used in people, which is apparently caused by a metabolite and may have a delayed onset. If liver injury is recognized (elevated liver enzymes, nausea), a return to normal is possible if treatment is discontinued. Occurrence of liver injury in dogs is uncertain because it is related to acetylation of the drug in people, and dogs lack this enzyme pathway. Other reported adverse effects include rash and peripheral neuropathy.","notes":"Instructions for Use Isoniazid administration in animals is limited to indications where other drugs are not effective. Patient Monitoring and Laboratory Tests Monitor liver enzymes. Monitor patients for signs of neurologic toxicity. Formulations \u2022\\t\\tIsoniazid\\tis\\t available\\tin\\t 100-\\t\\t  and\\t  300-\\t  mg\\t  tablets;\\t    10-\\t mg/mL\\tsyrup;\\t   or\\t 100-\\t  mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Kanamycin Sulfate","active_ingredient":"Kanamycin Sulfate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t20\\tmg/kg\\tq24h\\tIV\\tor\\tIM.  Horses \u2022\\t\\t10\\tmg/kg\\tq24h\\tIV. Regulatory Information Avoid use in food- producing animals. Extended withdrawal times (as long as 18 months) may be needed for withdrawal time in cattle. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Kaolin and Pectin kay\u2032oh- lin + pek\u2032tin Trade and other names: Also called Kaopectate; generic brands","contraindications":"Contraindications and Precautions Do not use in animals with kidney disease. Do not use in dehydrated animals. Drug Interactions When used with anesthetic agents, neuromuscular blockade is possible with high doses. Do not mix in vial or syringe with other antibiotics. Ototoxicity and nephrotoxicity are potentiated by loop diuretics such as furosemide.","indications":"Indications and Clinical Uses Kanamycin is a broad- spectrum antibiotic used to treat gram- negative infections. It is less active than gentamicin, amikacin, or tobramycin. Therefore, there is little advantage for using kanamycin over the other drugs in this class. The use of kanamycin has greatly diminished, and gentamicin and amikacin are much more frequently used in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nephrotoxicity is the most dose- limiting toxicity. Ensure that patients have adequate fluid and electrolyte balance during therapy. Ototoxicity and vestibulotoxicity also are possible.","notes":"Instructions for Use Kanamycin is not as active as other aminoglycosides. For serious infections, consider gentamicin or amikacin. K K Kaolin and Pectin 491 Patient Monitoring and Laboratory Tests Susceptibility testing: Clinical and Laboratory Standards Institute (CLSI) minimum inhibitory concentration value breakpoint for susceptibility is \u226416 mcg/mL, but this is based on the human breakpoint and may be too high for testing bacteria isolated from animals. Monitor blood urea nitrogen, creatinine, and urine for evidence of renal toxicity. Formulations \u2022\\t\\tKanamycin\\tis\\tavailable\\tin\\t200-\\t\\tand\\t500-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water but is not stable in compounded formulations. Do not mix with other drugs. Do not freeze.","original_category":"Antibacterial"},{"name":"Levofloxacin","active_ingredient":"Levofloxacin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t25\\tmg/kg\\tq24h\\tPO. \u2022\\t\\t25\\tmg/kg\\tq24h\\tIV\\t(slow\\tinfusion). Cats \u2022\\t\\t20\\tmg/kg\\tq24h\\tPO. \u2022\\t\\t10\\tmg/kg\\tq24h\\tIV.  \u2022\\t\\tNo\\tdosing\\tdata\\tare\\tavailable. Regulatory Information There are no withdrawal times established because this drug should not be administered to animals that produce food. The extralabel administration of fluoroquinolones to food- producing animals in the United States is a violation of Food and Drug Administration (FDA) regulations. Withdrawal times are not established for levofloxacin in animals that produce food. Levothyroxine Sodium lee- voe- thye- roks\u2032een soe\u2032dee- um Trade and other names: T4, L- thyroxine, Thyro- Tabs (veterinary form), and Synthroid (human form). Equine powders include Equisyn- T4, Levo- Powder, Thyroid Powder, and  Thyro- L.","contraindications":"Contraindications and Precautions Avoid use in young animals because of risk of cartilage injury. Use cautiously in animals that may be prone to seizures, such as epileptics. Do not administer IV solution rapidly. Drug Interactions Coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), magnesium, iron, zinc, and calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur.","indications":"Indications and Clinical Uses Levofloxacin is a human drug without an approved label indication for dogs or cats. However, it has been used to treat a variety of infections, including skin infections, pneumonia, and soft tissue infections. Although not approved for animals, it can be prescribed by veterinarians as long as it is not administered to animals that produce food\\tor\\tare\\tintended\\tfor\\tfood.\\tOther\\tfluoroquinolones\\tthat\\tcan\\tbe\\tconsidered\\tfor treatment include enrofloxacin, marbofloxacin, and orbifloxacin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High concentrations may cause CNS toxicity, especially in animals with renal failure. Levofloxacin can produce occasional vomiting. IV solution should be given slowly (over 30 minutes) because rapid injections IV can produce an anaphylactoid reaction, histamine release, and hypotension. Safety studies have not been performed in cats, but blindness in cats has not been reported for levofloxacin. All of the fluoroquinolones, including levofloxacin, have the potential to produce arthropathy in young animals. Dogs are most susceptible to quinolone- induced arthropathy in the age group of 4\u201328 weeks of age. Large, rapidly growing dogs are the most susceptible. Levofloxacin has not been tested in horses, but arthropathy in young animals is a concern as well as enteritis and colic from oral administration. Tendinitis and tendon rupture are described as a warning for use in people, but this effect has not been observed in animals.","notes":"Instructions for Use Doses are based on plasma concentrations needed to achieve sufficient plasma concentration above the minimum inhibitory concentration (MIC). Efficacy studies have not been performed in dogs or cats, and clinical use is based primarily on anecdotal experience. 516    Levothyroxine Sodium Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\torganisms\\tin\\tdogs\\tis\\tidentical to the breakpoint established for humans. The breakpoint for susceptible bacteria is \u22640.5 mcg/mL for Enterobacteriaceae and \u22641 mcg/mL for P. aeruginosa. Formulations Available \u2022\\t\\tLevofloxacin\\tis\\tavailable\\tin\\t250-\\t,\\t500-\\t   ,\\tand\\t750-\\tmg\\ttablets,\\t25\\tmg/mL\\toral solution. \u2022\\t\\tInjection\\tsolution:\\t5-\\tmg/mL\\tsolution\\tin\\tvials\\tof\\t50,\\t100,\\tor\\t150\\tmL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Aqueous solutions of 0.5 to 2 mg/mL retain potency up to 14 days when stored. Do not mix with products that contain ions (e.g., iron, aluminum, magnesium, and calcium).","original_category":"Antibacterial"},{"name":"Monohydrate","active_ingredient":"Monohydrate","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t22\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tInjection\\t(100\\tmg/mL):\\t22\\tmg/kg\\tq24h\\tor\\t11\\tmg/kg\\tq12h\\tIV\\tslowly.  Pigs \u2022\\t\\tSwine\\tdysentery:\\t250\\tmg\\tper\\tgallon\\tof\\tdrinking\\twater,\\twhich\\tis\\tapproximately 8.4 mg/kg/day if given as the only source of drinking water for 5\u201310 days. \u2022 \\t \\tMycoplasma\\tinfections:\\t11\\tmg/kg\\tq24h\\tIM\\tinjection\\tfor\\t3\u20135\\tdays. Cattle \u2022\\t\\tSeptic\\tarthritis,\\tmastitis,\\tand\\tabscesses:\\t5\\tmg/kg\\tq24h\\tIM\\tfor\\t5\u20137\\tdays. \u2022\\t\\tRefractory\\tinfections:\\t10\\tmg/kg\\tq12h\\tIM. Sheep \u2022\\t\\tSeptic\\tarthritis:\\t5\\tmg/kg\\tq24h\\tfor\\t3\u20135\\tdays\\tIM. Regulatory Information Withdrawal\\ttime\\tfor\\tpigs:\\t0,\\t1,\\t2,\\tor\\t6\\tdays,\\tdepending\\ton\\tproduct\\tand\\troute\\tof administration. (For most products, allow 6 days for oral administration and 2 days for IM administration.) For extralabel use in cattle, FARAD recommends 7 days for meat\\tand\\t96\\thours\\tfor\\tmilk\\tat\\ta\\tdose\\tof\\t5\\tmg/kg. Linezolid lih- neh- zoe\u2032lide Trade and other names: Zyvox, Zyvoxam (Canada), and generic","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\torally\\tto\\trodents,\\thorses,\\truminants,\\tor\\trabbits.\\tPO administration to ruminants and horses can cause severe enteritis. Drug Interactions No drug interactions reported for animals.","indications":"Indications and Clinical Uses Lincomycin has a gram- positive spectrum with limited use for other infections. In small animals, it has been used for pyoderma and other soft tissue infections caused by susceptible gram- positive bacteria, but commercial availability of products for dogs and cats is limited. In pigs and birds, it is used primarily for the treatment of infections caused by Mycoplasma spp. In pigs, it is approved for IM use to treat infectious arthritis and pneumonia caused by Mycoplasma spp. and added to feed and water to control swine dysentery caused by Brachyspira hyodysenteriae, porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis, and respiratory disease caused by Mycoplasma hyopneumoniae. Although it has been injected IM in cattle and sheep for treatment of septic arthritis, laryngeal abscesses, and mastitis, this treatment is not currently recommended. Compared with lincomycin, clindamycin has better activity against anaerobic bacteria. Because of more frequent use and available dose forms, clindamycin is preferred over lincomycin for administration to small animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are uncommon  in dogs, cats, and pigs. Lincomycin has caused vomiting and diarrhea in animals. Severe and even fatal enteritis can be caused by PO\\tadministration\\tto\\truminants,\\thorses,\\tand\\tsmall\\trodents.","notes":"Instructions for Use Actions of lincomycin and clindamycin are similar enough that clindamycin can be substituted for lincomycin for most indications. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tbreakpoints for sensitive organisms are \u22640.25 mcg/mL for streptococci and \u22640.5 mcg/mL for other organisms. Formulations \u2022\\t\\tLincomycin\\thas\\tbeen\\tavailable\\tin\\t100-\\t,\\t200-\\t   ,\\tand\\t500-\\tmg\\ttablets,\\tbut\\tavailability can vary from country to country. \u2022\\t\\t25-\\t ,\\t50-\\t  ,\\t100-\\t   ,\\tand\\t300-\\tmg/mL\\tsolution\\tfor\\tinjection. L Linezolid 523 \u2022\\t\\tPoultry\\tand\\tswine\\tforms\\tinclude:\\t50-\\tg\\tpowder\\tfor\\tmixing\\twith\\twater;\\t20\\tand\\t50 g/lb of lincomycin for chickens and pigs. \u2022\\t\\tThere\\tare\\tseveral\\tforms\\tfor\\tpoultry\\tand\\tswine\\twith\\tlincomycin\\tcombined\\twith coccidiostats or ionophores for administration in feed or water. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Linezolid","active_ingredient":"Linezolid","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO\\tor\\tIV.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\tis\\tavailable. Regulatory Information This drug should not be administered to food- producing animals. If administered to a food animal, consult FARAD at www.FARAD.org for extralabel use guidelines. Liothyronine Sodium lye- oh- thye\u2032roe- neen  soe\u2032dee- um Trade and other names: Cytomel","contraindications":"Contraindications and Precautions No contraindications reported. The use in animals has been uncommon; therefore the full extent of precautions and potential adverse effects are not known. Drug Interactions Linezolid is a type A monoamine oxidase inhibitor. Possible interactions occur with serotonin reuptake inhibitors such as fluoxetine and selegiline to produce serotonin syndrome. Interactions are also possible if administered with adrenergic drugs such as phenylpropanolamine. However, this effect has not been reported from the limited use in animals. Linezolid is not expected to affect metabolism of other drugs. Rifampin may decrease plasma concentrations. The IV formulation is physically incompatible with other drugs in the IV line. If administered with other drugs intravenously, flush out the administration line first.","indications":"Indications and Clinical Uses Linezolid is active against streptococci and staphylococci and is indicated for treatment of infections that are resistant to other drugs, particularly when there is resistance to the beta- lactam antibiotics (penicillins, ampicillin derivatives, and cephalosporins). It is not indicated for gram- negative infections. Linezolid is indicated for treatment of methicillin- resistant and oxacillin- resistant strains of Staphylococcus (e.g., methicillin- resistant Staphylococcus aureus [MRSA] and methicillin- resistant Staphylococcus pseudintermedius [MRSP]) and penicillin- resistant Enterococcus spp. It should not be used in companion animals unless there is culture and susceptibility testing confirmation. Linezolid is the only agent with activity against all species of Nocardia spp. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include diarrhea and nausea. Rarely, anemia and leukopenia have been observed in people. The risk of bone marrow suppression, including thrombocytopenia, is most evident after 2 weeks of treatment but is reversible after treatment is discontinued. Thrombocytopenia has been rare based on limited experience with the use of linezolid in dogs and cats. Longer treatment courses should be accompanied by periodic CBC measurements. The mechanism of myelosuppression is likely caused by effects on mitochondria. Linezolid was originally investigated as an antidepressant medication for people. Therefore, some CNS changes are possible when administered to animals, but these are not well documented.","notes":"Instructions for Use Linezolid is reserved for infections that are resistant to other drugs, such as Enterococcus spp. and MRSA infections. Patient Monitoring and Laboratory Tests Choice of drug should be selected on the basis of susceptibility monitoring. CLSI lists the breakpoint for susceptibility as \u22644.0 mcg/mL for Staphylococcus spp. and \u22642.0 mcg/mL for Enterococcus spp. Ideal plasma drug concentrations are 2\u20137 mcg/mL. L Liothyronine Sodium 525 Formulations \u2022\\t\\tLinezolid\\tis\\tavailable\\tin\\t600-\\tmg\\ttablets,\\t20-\\tmg/mL\\toral\\tsuspension\\tpowder (orange flavor), and 2- mg/mL injection for IV use. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not\\tmix\\twith\\tother\\tdrugs.\\tOral\\tsuspension\\tis\\tstable\\tfor\\t21\\tdays\\tafter\\treconstitution\\tat room temperature.","original_category":"Antibacterial"},{"name":"Marbofloxacin","active_ingredient":"Marbofloxacin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2.75\u20135.5\\tmg/kg\\tonce\\tdaily\\tPO. Cats \u2022\\t\\t2.75\u20135.5\\tmg/kg\\tonce\\tdaily\\tPO.  Horses \u2022\\t\\t2\\tmg/kg\\tonce\\tdaily\\tIV\\tor\\tPO\\tfor\\ttreatment\\tof\\tsusceptible\\tgram-\\tnegative\\tbacteria (IV\\tformulation\\tnot\\tavailable\\tin\\tthe\\tUnited\\tStates).\\tBecause\\tof\\tthe\\tlow\\toral absorption\\tin\\thorses,\\ta\\tdose\\tof\\t2\\tmg/kg\\tmay\\tnot\\tbe\\tsufficient\\tfor\\ttreating\\tother cause\\tocular\\tlesions\\tor\\tvision\\tproblems\\tin\\tcats.\\tAt\\tdoses\\tof\\t17\\tand\\t28\\tmg/kg (three times and five times the upper limit of dosing, respectively), it did not produce ocular changes. Marbofloxacin has been administered to horses orally without\\tproducing\\tadverse\\teffects\\tin\\tthe\\tgastrointestinal\\t(GI)\\ttract.","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tyoung\\tanimals\\tbecause\\tof\\trisk\\tof\\tcartilage\\tinjury.\\tUse\\tcautiously\\tin animals that may be prone to seizures. Drug Interactions Fluoroquinolones may increase concentrations of theophylline if used concurrently; there may be interactions with other drugs, but this is not well documented in animals.\\tCo-\\tadministration\\twith\\tdivalent\\tand\\ttrivalent\\tcations,\\tsuch\\tas\\tproducts containing aluminum (e.g., sucralfate), iron, and calcium, may decrease oral absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur. Marbofloxacin may be administered with other antibiotics and anesthetic agents without evidence of drug interaction. 550    Maropitant Citrate bacteria\\tthat\\tcause\\tinfections\\tin\\thorses,\\tincluding\\tgram-\\tpositive\\tcocci.\\tHowever, higher doses have not been tested. Calves \u2022\\t \\t2\\tmg/kg,\\tIV,\\tSQ,\\tor\\tIM\\tin\\tthe\\tneck\\tonce\\tdaily\\tfor\\t3\u20135\\tdays\\tor\\t8\u201310\\tmg/kg\\tonce\\tIM. Pigs \u2022\\t\\t2\\tmg/kg\\tonce\\tper\\tday\\tIM\\t(neck)\\tfor\\t3\u20135\\tdays\\tor\\t8\\tmg/kg\\tonce. Regulatory Information Marbofloxacin\\tis\\tprohibited\\tfrom\\tuse\\tin\\tanimals\\tintended\\tfor\\tfood\\tin\\tthe\\tUnited States.\\tThere\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tit\\tshould\\tnot\\tbe administered\\tto\\tanimals\\tthat\\tproduce\\tfood.\\tIn\\tthe\\tUnited\\tStates,\\tit\\tis\\tillegal\\tto administer fluoroquinolones to food animals in an extralabel manner. Outside the United\\tStates,\\twithdrawal\\ttimes\\thave\\tbeen\\testablished:\\t6\\tdays\\twithdrawal\\tfor\\tmeat\\tin cattle\\tat\\t2\\tmg/kg\\tand\\t3\\tdays\\tat\\t8\\tmg/kg.\\tMilk\\twithdrawal\\tis\\t36\\thours\\tat\\t2\\tmg/kg and\\t72\\thours\\tat\\t8\\tmg/kg.\\tWithdrawal\\ttime\\tfor\\tpigs\\tis\\t4\\tdays. Maropitant Citrate mar- op\u2032i- tent Trade and other names: Cerenia","indications":"Indications and Clinical Uses Marbofloxacin, like other fluoroquinolones, is used to treat susceptible bacteria in a\\tvariety\\tof\\tspecies.\\tIt\\tis\\tapproved\\tfor\\tuse\\tin\\tdogs\\tand\\tcats\\tin\\tthe\\tUnited\\tStates\\tand in\\tother\\tspecies\\toutside\\tthe\\tUnited\\tStates.\\tInfections\\ttreated\\twith\\tmarbofloxacin include\\tskin\\tand\\tsoft\\ttissue\\tinfections,\\tbone\\tinfections,\\turinary\\ttract\\tinfections\\t(UTIs), pneumonia, and infections caused by intracellular organisms. Marbofloxacin has been effective\\tfor\\tsome\\tblood-\\tborne\\tpathogens\\tsuch\\tas\\tMycoplasma haemofelis in cats at a\\tdosage\\tof\\t2.75\\tmg/kg\\tq24h\\tPO\\tfor\\t14\\tdays.\\tMarbofloxacin\\talso\\thas\\tbeen\\tused\\tin horses to treat infections caused by susceptible bacteria. In calves, it has been used to treat\\trespiratory\\tinfections\\t(bovine\\trespiratory\\tdisease)\\tat\\t2\\tmg/kg\\tfor\\t3\u20135\\tdays\\tor a\\tsingle\\tdose\\tadministered\\tonce\\tat\\t8\u201310\\tmg/kg.\\tIn\\tsows\\tit\\tis\\tused\\tto\\ttreat\\tmastitis\u2013 metritis\u2013agalactia\\t(MMA)\\tsyndrome.\\tIn\\tpigs,\\tdoses\\tof\\t2\\tmg/kg\\tand\\thigher\\treached\\tthe therapeutic\\ttargets\\t   for\\t swine\\t   respiratory\\tdisease\\t   pathogens.\\t(See\\t  Regulatory\\tInformation regarding\\tlimitations\\tfor\\tuse\\tin\\tfood\\tanimals\\tin\\tthe\\tUnited\\tStates.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tconcentrations\\tmay\\tcause\\tCNS\\ttoxicity.\\tLike\\tother\\tfluoroquinolones,\\tit may cause some nausea, vomiting, weight loss, and diarrhea at high doses. When administered intravenously to anesthetized patients, it did not alter cardiovascular parameters. All of the fluoroquinolones may cause arthropathy in young animals. Dogs\\tare\\tmost\\tsensitive\\tat\\t4\u201328\\tweeks\\tof\\tage.\\tLarge,\\trapidly\\tgrowing\\tdogs\\tare the most susceptible. Marbofloxacin at a dose of twice the upper limit caused articular\\tdamage\\tin\\tdogs\\tthat\\twere\\t4\u20135\\tmonths\\told.\\tIn\\tcats\\t8\\tmonths\\told\\tat dosages\\tof\\t17\\tand\\t28\\tmg/kg\\tfor\\t42\\tdays,\\tarticular\\tcartilage\\tinjury\\twas\\tobserved. Blindness in cats has been reported from some quinolones such as enrofloxacin and\\tnalidixic\\tacid.\\tThere\\tare\\tno\\tknown\\tclinical\\treports\\tof\\tthis\\treaction\\twith marbofloxacin, and toxicity studies by the manufacturer showed that it does not M","notes":"Instructions for Use Within\\tthe\\tdose\\trange\\tlisted\\tfor\\tthe\\tapproved\\tproducts\\tin\\tthe\\tUnited\\tStates,\\tgenerally, a\\tdose\\tof\\t5\\tmg/kg\\tonce\\tdaily\\tPO\\tis\\tused\\tfor\\tmost\\tindications.\\tDoses\\tpublished\\tfor European\\tuse\\tare\\tlower\\tthan\\tUS-\\tapproved\\tdoses,\\tbut\\tthere\\tis\\tno\\tevidence\\tthat\\tthis has\\taffected\\tefficacy.\\tFor\\texample,\\tsuccessful\\ttreatment\\tof\\tpyoderma\\tin\\tEuropean studies\\thas\\tbeen\\taccomplished\\twith\\tdosages\\tof\\t2.0\\tmg/kg\\tonce\\tdaily,\\tbut\\tin\\tthe United\\tStates,\\tthe\\tlowest\\tdosage\\tis\\t2.75\\tmg/kg\\tonce\\tdaily. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tbreakpoints for susceptible organisms is \u22641\\tmcg/mL.\\tIf\\tother\\tfluoroquinolones\\tare\\tused\\tto\\ttest susceptibility to marbofloxacin, the breakpoints may be different. When testing marbofloxacin activity against P. aeruginosa, a susceptible breakpoint of \u22640.25\\tmcg/mL\\tshould\\tbe\\tused. Formulations \u2022\\t\\tMarbofloxacin\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\t100-\\t   ,\\tand\\t200-\\tmg\\ttablets. \u2022\\t\\tInjectable\\tmarbofloxacin\\t(Marbocyl\\t10%,\\t100\\tmg/mL)\\tis\\tapproved\\tin\\tother countries\\tbut\\tnot\\tin\\tthe\\tUnited\\tStates.\\tAnother\\tformulation\\tin\\tEurope\\tis\\tForcyl, which\\tis\\ta\\t16%\\tsolution\\tfor\\tIM\\tor\\tIV\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not compound with ingredients that may chelate with quinolones, such as iron or calcium.","original_category":"Antibacterial"},{"name":"Meropenem","active_ingredient":"Meropenem","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tEnterobacteriaceae\\t(E. coli, K. pneumoniae):\\t10\\tmg/kg\\tq8h,\\tIV,\\tIM,\\tor\\tSQ. \u2022 \\t \\tPseudomonas aeruginosa:\\t30\\tmg/kg,\\tq8h,\\tIV,\\tIM,\\tor\\tSQ. \u2022\\t\\tCRI:\\t1\\tmg/kg\\tIV;\\tfollow\\twith\\ta\\t1-\\tmg/kg/h\\tinfusion. 576    Mesalamine Cats \u2022\\t\\t10\\tmg/kg\\tIM,\\tSQ,\\tor\\tIV\\tq12h.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported.\\tHowever,\\tdoses\\tsimilar\\tto\\tthe\\trange used in small animals are suggested for foals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Mesalamine mez- ahl\u2032ah- meen Trade and other names: 5- aminosalicylic acid, Asacol, Mesasal, Pentasa, and Mesalazine","contraindications":"Contraindications and Precautions Some slight yellowish discoloration may occur after reconstitution. Slight discoloration will not affect potency. However, a darker amber or brown discoloration may indicate oxidation and loss of potency. Drug Interactions Do not mix in a vial or syringe with other antibiotics.","indications":"Indications and Clinical Uses Meropenem is indicated primarily for infections caused by bacteria resistant to other drugs. It is especially valuable for treating resistant infections caused by P. aeruginosa, M E. coli, and K. pneumoniae.\\tIt\\tis\\tactive\\tagainst\\tthese\\tstrains\\tthat\\tproduce\\textended- spectrum\\tbeta-\\tlactamase\\tthat\\tare\\tresistant\\tto\\tpenicillins,\\tcephalosporins,\\tand\\tother agents. Meropenem is slightly more active against some bacteria than imipenem and more active against P. aeruginosa\\tthan\\tertapenem.\\tThe\\tuse\\tof\\tmeropenem\\tin\\tanimals should be reserved for cases that have infections resistant to other antibiotics and when the infection is confirmed with a culture and susceptibility test. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Carbapenems\\tpose\\t  similar\\t   risks\\t  as\\t other\\t   beta-\\t  lactam\\t   antibiotics,\\tbut\\t  adverse\\teffects are rare. Meropenem does not cause seizures as frequently as imipenem and has been well tolerated even in critically ill patients. SQ injections may cause slight hair loss at the injection site but otherwise is well tolerated.","notes":"Instructions for Use Doses in animals have been based on pharmacokinetic studies rather than efficacy trials. Meropenem is more soluble than imipenem and can be injected via bolus rather than administered in fluid solutions. Meropenem has been injected SQ in dogs and cats with little pain or discomfort and no evidence of tissue reaction except for some slight hair changes at the injection site in cats. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\tbacteria\\tis\\t\u22641\\tmcg/mL\\tfor Enterobacteriaceae\\t(E. coli, Klebsiella pneumoniae), and \u22642\\tmcg/mL\\tfor\\tP. aeruginosa and Acinetobacter spp. If bacteria are susceptible to imipenem, they are also susceptible to meropenem. Formulations \u2022\\t\\tMeropenem\\tis\\tavailable\\tin\\ta\\t500-\\tmg\\tor\\t1-\\tg\\tvial;\\tboth\\tproduce\\t50\\tmg/mL\\tafter reconstitution\\tfor\\tinjection.\\tReconstitute\\twith\\tsodium\\tchloride,\\tRinger\u2019s\\tsolution, or\\tlactated\\tRinger\u2019s\\tsolution. Stability and Storage Stable\\tif\\tstored\\tin\\tmanufacturer\u2019s\\toriginal\\tvial.\\tIn\\theat\\tand\\talkaline\\tconditions,\\tthe drug may hydrolyze to meropenemic acid. At room temperature, IV solutions are stable\\tfor\\t12\\thours.\\tAfter\\treconstitution\\tto\\ta\\tconcentration\\tof\\t50\\tmg/mL,\\tit\\tis\\tstable in\\tthe\\trefrigerator\\tfor\\t3\\tdays.\\tAfter\\t3\\tdays,\\tthe\\tpotency\\tdeclines\\tto\\tbelow\\t90%.\\tSlight yellow discoloration may occur without loss of potency but observe for a darker color change as an indication that potency may be compromised during storage. Discard if particulates form in vial.","original_category":"Antibacterial"},{"name":"Methenamine","active_ingredient":"Methenamine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tMethenamine\\tmandelate\\t(if\\tavailable):\\t10\u201320\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\tMethenamine\\tmandelate\\t(if\\tavailable):\\t10\u201320\\tmg/kg\\tq8\u201312h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported.\\tIt\\tis\\tunlikely\\tto\\tbe\\teffective\\tin\\tlarge animals because their urine is more alkaline. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Methimazole meth- im\u2032ah- zole Trade and other names: Tapazole, Felimazole, Thiamazole, and generic","contraindications":"Contraindications and Precautions High doses may irritate the bladder mucosa. Do not administer with sulfonamides because\\tit\\tmay\\tform\\tformaldehyde\u2013sulfonamide\\tcomplexes.\\tDo\\tnot\\tuse\\tthe mandelate formulation in patients with renal insufficiency. Drug Interactions Do not administer with medications that may cause alkaline urine. Because methenamine is often administered with urine acidifiers, acid urine decreases the\\tactivity\\tof\\tsome\\tantibiotics\\tadministered\\tfor\\tUTIs\\tsuch\\tas\\tfluoroquinolone and aminoglycoside antibiotics. Methenamine can combine in the urine with sulfonamide drugs to produce antagonism.","indications":"Indications and Clinical Uses Methenamine\\tis\\tused\\tas\\ta\\turinary\\tantiseptic,\\tbut\\tthere\\tis\\ta\\tlack\\tof\\twell-\\tcontrolled clinical\\ttrials\\tto\\tshow\\tits\\teffectiveness.\\tThe\\tuse\\tis\\tbased\\ton\\textrapolation\\tof\\tuses\\tin people and clinical observations. It has been used in animals to prevent recurrences of\\tlower\\tUTIs,\\tbut\\tit\\tis\\tprobably\\tless\\teffective\\tfor\\ttreating\\tongoing\\tinfections.\\tIt\\tis critical that the urine pH be low for conversion to formaldehyde. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Although formaldehyde formation in bladder may be irritating, in people, high doses are\\trequired\\t(greater\\tthan\\t8\\tg/day).\\tIn\\tanimals,\\tno\\tadverse\\teffects\\thave\\tbeen\\treported.","notes":"Instructions for Use Results\\tof\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals\\tis\\tbased on\\texperience\\tin\\tpeople\\tor\\tanecdotal\\texperience\\tin\\tanimals.\\tUrine\\tmust\\tbe\\tacidic\\tfor methenamine to convert to formaldehyde (monitor pH periodically). A pH less than 5.5\\tis\\toptimal.\\tSupplement\\twith\\tascorbic\\tacid\\tor\\tammonium\\tchloride\\tto\\tlower\\tpH. The\\ttablets\\tshould\\tbe\\tenteric\\tcoated\\tto\\tprotect\\tfrom\\thydrolysis\\tin\\tthe\\tacid\\tof\\tthe\\tstomach and should be administered on an empty stomach. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Monitor urinalysis or culture of urine to guide therapy\\tof\\tUTI. 586    Methimazole Formulations \u2022\\t\\tMethenamine\\thippurate\\tis\\tavailable\\tin\\t0.6-\\t\\tand\\t1-\\tg\\ttablets.\\tMethenamine mandelate\\tis\\tno\\tlonger\\tavailable\\t(previous\\tformulations\\tincluded\\t1-\\tg\\ttablets, granules\\tfor\\toral\\tsolution,\\tand\\t50-\\t\\tand\\t100-\\tmg/mL\\toral\\tsuspension). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Methenamine is soluble in water and ethanol. In an acidic environment, it is hydrolyzed to form formaldehyde and ammonia. It has been physically incompatible when mixed with some foods and suspensions.","original_category":"Antibacterial"},{"name":"Metronidazole and Metronidazole Benzoate","active_ingredient":"Metronidazole and Metronidazole Benzoate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tAnaerobic\\tbacteria:\\t15\\tmg/kg\\tq12h\\tor\\t12\\tmg/kg\\tq8h\\tPO. \u2022\\t\\tAnaerobic\\tbacteria:\\tIV\\tdose:\\t15\\tmg/kg\\tIV\\tvia\\tslow\\tinfusion\\tover\\tat\\tleast\\t30 minutes\\tin\\ta\\tdiluted\\tform.\\tGive\\tslowly\\tto\\tavoid\\tadverse\\tCNS\\teffects. \u2022 \\t \\tGiardia\\tinfection:\\t12\u201315\\tmg/kg\\tq12h\\tfor\\t5\u20137\\tdays\\tPO. Cats \u2022\\t\\tAnaerobic\\tbacteria:\\t10\u201325\\tmg/kg\\tq24h\\tPO. \u2022 \\t \\tGiardia\\tinfection:\\t17\\tmg/kg\\t(one\\tthird\\ttablet\\tper\\tcat)\\tq24h\\tfor\\t8\\tdays. \u2022\\t\\tMetronidazole\\tbenzoate\\t(for\\ttreatment\\tof\\tGiardia\\tinfection):\\t25\\tmg/kg\\tPO\\t12h for\\t7\\tdays.\\tMetronidazole\\tbenzoate\\tis\\t62%\\tmetronidazole;\\ttherefore\\t20\\tmg/kg\\tof metronidazole\\tbenzoate\\tdelivers\\t12.4\\tmg/kg\\tof\\tmetronidazole.  Horses \u2022\\t\\tTreatment\\tof\\tanaerobic\\tbacteria\\tand\\tprotozoal\\tinfections:\\t10\\tmg/kg\\tq12h\\tPO. Note: Some clinicians have used higher doses (\u226415\u201320\\tmg/kg\\tq6h),\\tbut\\tat\\tthese doses, side effects are more likely. \u2022\\t\\tFoals:\\t10\u201315\\tmg/kg\\tIV\\tor\\tPO\\tq12h. Cattle \u2022\\t\\tTreatment\\tof\\ttrichomoniasis\\t(bulls):\\t75\\tmg/kg\\tq12h\\tIV\\tfor\\tthree\\tdoses.\\t(See Regulatory\\tInformation.) Regulatory Information Do not administer to animals that produce food. Administration of nitroimidazoles to animals\\tintended\\tfor\\tfood\\tis\\tprohibited.\\tTreated\\tcattle\\tmust\\tnot\\tbe\\tslaughtered\\tfor\\tfood. M Mexiletine 609 Mexiletine meks- il\u2032eh- teen Trade and other names: Mexitil","contraindications":"Contraindications and Precautions Fetal abnormalities have not been demonstrated in animals with recommended doses but use cautiously during pregnancy. Drug Interactions Like\\tother\\tnitroimidazoles,\\tit\\tcan\\tpotentiate\\tthe\\teffects\\tof\\twarfarin\\tand cyclosporine via inhibition of drug metabolism.","indications":"Indications and Clinical Uses Metronidazole is not approved for use in animal animals, and the use is derived from small observational studies, anecdotal experience, and opinions from experts. It has been used to treat diarrhea and other intestinal problems caused by intestinal protozoa such as Giardia, Trichomonas, and Entamoeba spp. It may be used in small animals and horses for treatment of a variety of anaerobic infections. Common uses in horses include treatment of infections caused by Clostridium spp., and Bacteroides fragilis.\\tMetronidazole\\thas\\tbeen\\tused\\tfor\\timmune-\\tmodulating\\tactivity\\tin\\tthe intestine of animals and administered for inflammatory bowel disease in animals. However,\\tevidence\\tof\\ta\\tdirect\\timmune-\\tmodulating\\teffect\\tor\\timmunosuppressive effect\\tis\\tlacking.\\tA\\tcommon\\tuse\\tof\\tmetronidazole\\tis\\tfor\\tshort-term\\ttreatment\\tof acute nonspecific diarrhea in animals. Clinical results have been mixed for this use. One controlled study in dogs showed that there is no benefit from this treatment compared to placebo. In another study, the duration of diarrhea was decreased by approximately\\t1.5\\tdays\\tcompared\\tto\\tplacebo\\ttreatment\\tin\\tdogs.\\tThe\\tdiarrhea\\tresolved in most dogs within several days, regardless of treatment. Metronidazole benzoate, an ester\\tpro-\\tdrug\\tof\\tmetronidazole,\\thas\\tbeen\\tused\\tin\\tcats\\tbecause\\tit\\tis\\tmore\\tpalatable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The\\tmost\\tsevere\\tadverse\\teffect\\tis\\tcaused\\tby\\ttoxicity\\tto\\tthe\\tCNS.\\tIt\\tis\\thighly lipophilic\\tand\\treadily\\tcrosses\\tthe\\tblood\u2013brain\\tbarrier.\\tHigh\\tdoses\\thave\\tcaused lethargy, CNS depression, ataxia, tremors, seizures, vomiting, and weakness. Most CNS toxicity caused from metronidazole in animals occurs at high doses (greater\\tthan\\t60\\tmg/kg/day).\\tThe\\tCNS\\tsigns\\tare\\trelated\\tto\\tinhibition\\tof\\taction of\\tgamma-\\taminobutyric\\tacid\\t(GABA)\\tand\\tare\\tresponsive\\tto\\tbenzodiazepines (diazepam\\t0.4\\tmg/kg\\tq8h\\tfor\\t3\\tdays). M","notes":"Instructions for Use Metronidazole is one of the most commonly used drugs for anaerobic infections. Although it is effective for giardiasis, other drugs used for Giardia spp. include albendazole, fenbendazole, and quinacrine. CNS toxicity is a concern, but it is dose related.\\tThe\\tmaximum\\tdose\\tthat\\tshould\\tbe\\tadministered\\tis\\t50\u201365\\tmg/kg/day\\tin\\tany species. Metronidazole is unpalatable and can produce a metallic taste. In cats, when the tablet is crushed or broken, the unpalatability is particularly a problem. Metronidazole benzoate has a bland taste and is better tolerated. Metronidazole benzoate is not commercially\\tavailable\\tin\\tthe\\tUnited\\tStates.\\tHowever,\\tit\\tmay\\tbe\\tavailable\\tfrom compounding pharmacies. Because of the weight of metronidazole benzoate versus metronidazole\\thydrochloride,\\ta\\tfactor\\tof\\t1.6\\ttimes\\tis\\tused\\tto\\tconvert\\ta\\tmetronidazole hydrochloride dose to a metronidazole benzoate dose. Metronidazole benzoate is 62%\\tmetronidazole;\\ttherefore,\\t20\\tmg/kg\\tof\\tmetronidazole\\tbenzoate\\tdelivers\\t12.4 mg/kg\\tof\\tmetronidazole. In horses, oral absorption of metronidazole is practically complete and not affected by feeding pattern (e.g., with or without food and similar with hay or concentrate). However, absorption from rectal administration to horses is low. Metronidazole should not be injected directly; it is too acidic. See Stability and Storage section for mixing instructions. In horses, adverse effects include peripheral neuropathy, hepatopathy, and decreased\\tappetite,\\tall\\tof\\twhich\\tare\\tmore\\tlikely\\twith\\thigh\\tdoses.\\tThe\\tdrug\\thas\\ta longer\\thalf-\\tlife\\tin\\tfoals,\\tand\\tfoals\\tmay\\tbe\\tmore\\tprone\\tto\\tadverse\\teffects\\tthan\\tadult horses. Like\\t  other\\t   nitroimidazoles,\\tmetronidazole\\thas\\t  the\\t  potential\\tto\\t produce\\tmutagenic changes\\tin\\tcells,\\tbut\\tthe\\tclinical\\tsignificance\\tof\\tthis\\teffect\\tis\\tuncertain.\\tThere\\tare\\tno reports of increased rated of cancer in patients that have received metronidazole. Like\\tother\\tnitroimidazoles,\\tit\\thas\\ta\\tbitter\\ttaste\\tand\\tcan\\tcause\\tvomiting\\tand anorexia.\\tAt\\ta\\tdose\\tof\\t25\\tmg/kg\\tin\\tdogs,\\tit\\tmay\\tdegrade\\tthe\\tolfactory\\tability. This\\tmay\\taffect\\tthe\\tability\\tof\\tworking\\tdogs\\t(e.g.,\\tlaw\\tenforcement\\tdogs)\\tto perform their duties to detect explosives, illegal drugs, and other agents. A total of\\t50%\\tof\\tthe\\ttreated\\tdogs\\thad\\tdecreased\\tolfactory\\tability\\tin\\tone\\tstudy. Metronidazole\\tbenzoate\\thas\\tbeen\\tused\\tin\\tsome\\tcats\\tsafely\\tat\\t25\\tmg/kg\\tq12h for\\t7\\tdays.\\tHowever,\\tthere\\tis\\ta\\tcaution\\tabout\\tthe\\teffect\\tof\\tbenzoate\\tsalts\\tin\\tcats because it is a benzoic acid derivative. Benzoic acid can be toxic to cats and causes ataxia, blindness, respiratory problems, and other CNS disorders. Despite this\\tconcern,\\tit\\tis\\testimated\\tthat\\t500\\tmg/kg/day\\tof\\tmetronidazole\\tbenzoate would be needed to provide a toxic dose of benzoic acid to cats. Nevertheless, any cat showing CNS or other signs of toxicity should have the metronidazole benzoate discontinued immediately. Patient Monitoring and Laboratory Tests Monitor\\tfor\\tneurologic\\tadverse\\teffects.\\tMICs\\tfor\\tanaerobic\\tbacteria\\tare\\ttypically\\t2\u20134 mcg/mL,\\tor\\tless.\\tThe\\tCLSI\\tbreakpoint\\tis\\t\u22648\\tmcg/mL. Formulations \u2022\\t\\tMetronidazole\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\ttablets,\\t375-\\tmg\\tcapsules,\\t50-\\tmg/ mL\\tsuspension,\\tand\\t5-\\tmg/mL\\tinjection. \u2022\\t\\tMetronidazole\\tbenzoate\\tis\\ta\\tformulation\\tnot\\tavailable\\tin\\tthe\\tUnited\\tStates but\\thas\\tbeen\\tcompounded\\tfor\\tveterinary\\tuse.\\tMetronidazole\\tbenzoate\\tis\\t62% metronidazole.\\tIt\\t has\\t  been\\t  formulated\\tin\\t Ora-\\t  Plus\\t  and\\t  Ora-\\t  Sweet\\t   (drug\\t   excipients) to\\ta\\tconcentration\\tof\\t16\\tmg/mL. Stability and Storage The\\tbase\\tis\\tslightly\\tsoluble\\tin\\twater.\\tThe\\tbenzoate\\tform\\tis\\tpractically\\tinsoluble;\\tthe hydrochloride form is soluble in water. Metronidazole has been crushed and mixed with some flavorings to mask the taste. When mixed with some syrups or water, with exceptions\\tlisted\\there,\\tdecomposition\\toccurs\\twithin\\t28\\tdays. Metronidazole\\tbenzoate\\tprepared\\tin\\tvehicles\\tsuch\\tas\\tOra-\\tPlus\\tor\\tOra-\\tSweet was\\tstable\\tfor\\t90\\tdays.\\tMetronidazole\\tbase\\t(from\\ttablets)\\talso\\twas\\tmixed\\twith\\tthese vehicles\\tand\\twas\\tfound\\tto\\tbe\\tstable\\tfor\\t90\\tdays. When\\treconstituted,\\tmetronidazole\\thydrochloride\\tis\\ttoo\\tacidic\\t(pH\\t0.5\u20132)\\tfor direct\\tinjection.\\tInjection\\tof\\t5\\tmg/mL\\tshould\\tbe\\tfurther\\tdiluted\\twith\\t100\\tmL\\t(0.9% saline,\\t5%\\tdextrose,\\tor\\tRinger\u2019s\\tsolution)\\tand\\tneutralized\\twith\\t5\\tmEq\\tof\\tsodium bicarbonate\\tper\\t500\\tmg\\tfor\\ta\\tpH\\tof\\t6\u20137.\\tReconstituted\\tinjectable\\tforms\\tare\\tstable\\tfor 96\\thours\\tbut\\tafter\\tdilution\\tshould\\tbe\\tdiscarded\\tafter\\t24\\thours.","original_category":"Antibacterial, antiparasitic"},{"name":"Minocycline Hydrochloride","active_ingredient":"Minocycline Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tq12h\\tPO\\tis\\tsufficient\\tin\\tmost\\tdogs.\\tFor\\thigher\\tMIC\\tvalues,\\tadminister\\t10 mg/kg\\ttwice\\tdaily,\\tbut\\tthe\\thigher\\tdosage\\tis\\tmore\\tlikely\\tto\\tproduce\\tvomiting. \u2022\\t\\tIf\\tIV\\tadministration\\tis\\tused,\\treduce\\tdose\\tby\\thalf\\tcompared\\twith\\tthe\\toral\\tdose. Cats \u2022\\t\\t8.8\\tmg/kg\\t(or\\t50\\tmg\\tper\\tcat)\\tPO\\tonce\\tdaily.  Horses \u2022\\t\\t4\u20135\\tmg/kg\\tq12h\\tPO\\tor\\t2.2\\tmg/kg\\tq12h\\tIV. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Mirtazapine mir- taz\u2032a- peen Trade and other names: Remeron (oral tablets), Mirataz transdermal for cats","contraindications":"Contraindications and Precautions No\\tspecific\\tprecautions\\thave\\tbeen\\treported\\tfor\\tanimals.\\tTetracyclines\\tare\\tnot administered for multiple doses to young children because of risk of teeth staining, and this may also apply to animals. It has been used in foals with no reported problems. 618    Mirtazapine","indications":"Indications and Clinical Uses Minocycline is used when tetracyclines are indicated for treating bacterial infections in animals that include skin and soft tissue infections, respiratory infections, and joint infections.\\tThe\\tuse\\tshould\\tbe\\tsupported\\tby\\ta\\tculture\\tand\\tsusceptibility\\ttest,\\tif\\tpossible. It may also be effective for Rickettsia and Ehrlichia infections. It was equally effective as doxycycline for Ehrlichia canis\\tadministered\\ttwice\\tdaily\\tfor\\t28\\tdays.\\tGenerally,\\tthe\\tclinical use is similar to doxycycline, with anticipated similar efficacy. It may be substituted for doxycycline\\tto\\ttreat\\theartworm-\\tpositive\\tdogs\\tbecause\\tof\\tits\\tactivity\\tagainst\\tWolbachia spp. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The\\tmost\\tcommon\\tadverse\\teffect\\tfrom\\tadministration\\tof\\tminocycline\\thas\\tbeen\\tGI problems,\\tprimarily\\tvomiting\\tand\\tnausea.\\tThe\\tGI\\teffects\\tare\\tmore\\tlikely\\tas\\tthe\\tdose is\\tincreased\\tfrom\\t5\\tto\\t10\\tmg/kg.\\tOtherwise,\\tit\\thas\\tbeen\\tused\\tsafely\\tin\\texperimental animals without adverse effects, and there are no clinical reports of serious injury. As with any oral tetracycline, changes in intestinal microflora could increase risk of diarrhea\\tin\\tsome\\tanimals.\\tRapid\\tIV\\tinjection\\thas\\tbeen\\tassociated\\twith\\tadverse\\tevents in people, but when administered intravenously to dogs, horses, and cats, no adverse events were observed.","notes":"Instructions for Use Minocycline can be substituted for doxycycline, especially when there have been shortages of other tetracyclines such as doxycycline. Minocycline is frequently used as an oral option for treating dogs, cats, and horses. In dogs, oral absorption is higher when\\tadministered\\twithout\\tfood.\\tIf\\tpossible,\\tadminister\\tminocycline\\tat\\tleast\\t30 minutes prior to a meal in dogs. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tThe\\tCLSI\\tbreakpoint\\tfor\\tsusceptible\\tbacteria\\tin\\tdogs\\tis\\t\u22640.5 mcg/mL,\\twhich\\talso\\tcan\\tbe\\tapplied\\tto\\tcats.\\tIn\\thorses,\\tthe\\tbreakpoint\\tfor\\tsusceptible bacteria is \u22640.12\\tmcg/mL\\tat\\ta\\tclinical\\tdosage\\tof\\t4\u20135\\tmg/kg\\tPO\\ttwice\\tdaily. Tetracycline\\thas\\tbeen\\tused\\tas\\ta\\tmarker\\tto\\ttest\\tsusceptibility\\tto\\tminocycline\\tin\\tdogs, but this should not be done for isolates from horses. Formulations \u2022\\t\\tMinocycline\\tis\\tavailable\\tin\\t50-\\t,\\t75-\\t  ,\\tand\\t100-\\tmg\\ttablets\\tand\\tcapsules\\tand\\t10-\\tmg/ mL\\tflavored\\toral\\tsuspension.\\tVials\\tfor\\tinjection\\tshould\\tbe\\treconstituted\\tin\\t5\\tmL and\\tthen\\tdiluted\\tin\\t500\u20131000\\tmL\\tfor\\tIV\\tinfusion.\\tSolution\\tmay\\tbe\\tstored\\tat\\troom temperature\\tfor\\t24\\thours. \u2022\\t\\tDelayed-\\trelease\\ttablets\\t(Solodyn):\\t45-\\t,\\t90-\\t  ,\\t135-\\t   mg\\ttablets.\\t(These\\tare\\thuman tablets,\\tand\\tit\\tis\\tnot\\tknown\\tif\\tthese\\thave\\tdelayed-\\trelease\\tproperties\\tin\\tanimals.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with other drugs.","original_category":"Antibacterial"},{"name":"Moxifloxacin","active_ingredient":"Moxifloxacin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmg/kg\\tq24h\\tPO.  Horses \u2022\\t\\t5.8\\tmg/kg\\tq24h\\tfor\\t3\\tdays,\\tbut\\tit\\tcauses\\tdiarrhea\\tin\\tsome\\thorses.\\tTherefore\\tthere may\\tbe\\trisks\\twith\\tlong-\\tterm\\tuse. Regulatory Information There\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tthis\\tdrug\\tshould\\tnot\\tbe administered to animals that produce food. Mycophenolate Mofetil mye- koe- fen\u2032oh- late Trade and other names: CellCept","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tyoung\\tanimals\\tbecause\\tof\\trisk\\tof\\tcartilage\\tinjury.\\tUse\\tcautiously\\tin animals that may be prone to seizures. Avoid use in horses, rodents, and rabbits because of risk of diarrhea. Drug Interactions Some fluoroquinolones may increase concentrations of theophylline if used concurrently, but it is not known of this occurs with moxifloxacin or applies to other metabolized drugs. Coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), iron, and calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur. M Mycophenolate Mofetil 635","indications":"Indications and Clinical Uses Although\\tmoxifloxacin\\tis\\ta\\thuman-\\tlabel\\tdrug\\tand\\tnot\\tlicensed\\tfor\\tveterinary\\tuse, it\\thas\\tbeen\\tused\\tin\\tnon\u2013food-\\tproducing\\tanimals\\tfor\\tmany\\tyears.\\tIt\\thas\\tbeen\\tused in small animals for treatment of infections refractory to other drugs, including skin\\tinfections,\\tpneumonia,\\tand\\tsoft\\ttissue\\tinfections.\\tThe\\tspectrum\\tof\\tactivity includes\\tgram-\\tpositive\\tcocci\\tand\\tanaerobic\\tbacteria\\tthat\\tmay\\tbe\\tresistant\\tto\\tother quinolones. Because other veterinary fluoroquinolones (enrofloxacin, orbifloxacin, and marbofloxacin) are preferred for initial use, moxifloxacin use is usually not considered for empirical use. Data for use in small animals are sparse, and regimens are primarily extrapolated from the human label and pharmacokinetic studies.\\tIn\\thorses,\\tit\\thas\\tbeen\\tadministered\\tat\\t5.8\\tmg/kg/day\\tfor\\t3\\tdays. Although pharmacokinetics were favorable in horses, it caused diarrhea, which may be a risk for more serious problems. It has been well tolerated for\\toral\\tadministration\\tto\\tdogs\\tand\\tcats.\\tHowever,\\tanother\\thuman-\\tlabeled fluoroquinolone, levofloxacin, has a similar spectrum of activity and availability of inexpensive\\tgeneric\\ttablets.\\t(See\\tLevofloxacin.)\\tTherefore,\\tlevofloxacin\\tis\\toften used for conditions that can also be treated with moxifloxacin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High concentrations of fluoroquinolones may cause CNS toxicity, especially in\\tanimals\\twith\\tkidney\\tdisease.\\tThis\\thas\\tnot\\tbeen\\treported\\tfrom\\tmoxifloxacin because of infrequent use but is possible. Moxifloxacin causes occasional vomiting. All of the fluoroquinolones may cause arthropathy in young animals. Dogs\\tare\\tmost\\tsensitive\\tat\\t4\u201328\\tweeks\\tof\\tage.\\tLarge,\\trapidly\\tgrowing\\tdogs\\tare the most susceptible. In horses, moxifloxacin at high doses caused diarrhea and is not recommended for routine use. Moxifloxacin at high doses has caused a dose-\\t  related\\tprolongation\\tof\\tthe\\tQT\\tinterval.\\tThe\\tclinical\\tconsequences\\tof\\tthis observation for animals are not known.","notes":"Instructions for Use The\\tdoses\\tlisted\\tare\\tbased\\ton\\tpharmacokinetics\\tin\\tanimals\\tand\\tplasma\\tconcentrations needed\\tto\\tachieve\\tsufficient\\tplasma\\tconcentration\\tabove\\tthe\\tMIC\\tvalue.\\tEfficacy studies have not been performed in dogs or cats. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsensitive\\torganisms\\tare\\t\u22641.0\\tmcg/mL, using\\tthe\\thuman\\tbreakpoint.\\tMost\\tsensitive\\tgram-\\tnegative\\tbacteria\\tof\\tthe Enterobacteriaceae\\thave\\tMIC\\tvalues\\t\u22640.1\\tmcg/mL. Formulations \u2022\\t\\tMoxifloxacin\\tis\\tavailable\\tin\\t400-\\tmg\\ttablets\\tand\\t1.6-\\tmg/mL\\tIV\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with products that contain ions (iron, aluminum, magnesium, and calcium).","original_category":"Antibacterial"},{"name":"Neomycin","active_ingredient":"Neomycin","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t10\u201320\\tmg/kg\\tq6\u201312h\\tPO.  Calves, Sheep, Goats, and Pigs \u2022\\t\\t22\\tmg/kg/day\\tPO. Regulatory Information Slaughter\\twithdrawal\\ttimes:\\tcattle,\\t1\\tday;\\tsheep,\\t2\\tdays;\\tswine\\tand\\tgoats,\\t3\\tdays.\\tOral administration may cause residues in animals intended for food; therefore do not administer to veal calves. Pharmacology and Mechanism of Action Neostigmine is a cholinesterase inhibitor (anticholinesterase). This drug inhibits the enzyme that metabolizes acetylcholine into inactive products. Therefore it prolongs\\tthe\\taction\\tof\\tacetylcholine\\tat\\tthe\\tsynapse.\\tThe\\tmajor\\tdifference\\tbetween physostigmine and neostigmine or pyridostigmine is that physostigmine crosses the blood\u2013brain barrier, and the others do not.","contraindications":"Contraindications and Precautions N- butylscopolammonium bromide decreases intestinal motility. Use cautiously in conditions in which decreased motility is a concern. Drug Interactions N- butylscopolammonium bromide is an anticholinergic drug and therefore antagonizes all other medications that are intended to produce a cholinergic response (e.g., metoclopramide). N It is bactericidal with a broad spectrum of activity except against streptococci and anaerobic bacteria. Neomycin differs from other aminoglycosides because it is only administered topically or orally. Systemic absorption is minimal from oral absorption. Contraindications and Precautions Use neomycin cautiously in animals with kidney disease. If oral absorption occurs because of compromised mucosal integrity, absorption may occur from the intestine. Do not use longer than 14 days. Neomycin has been mixed with water and\\tinjected,\\tbut\\tthis\\tpractice\\tis\\tstrongly\\tdiscouraged. Drug Interactions Neomycin should not be mixed with other drugs before administration. Other drugs may bind and become inactivated.","indications":"Indications and Clinical Uses Neomycin is commonly available in topical formulations. It is often combined with other antibiotics (triple antibiotics) in ointments for topical treatment of superficial infections. It is also used for oral administration to produce a local effect in the intestine for treatment of intestinal infections (colibacillosis). It is given orally, and because it is not absorbed systemically, it produces a local effect limited to the intestinal lumen. Precautionary Information Indications and Clinical Uses Neostigmine is used as an antidote for anticholinergic intoxication. It is also used as a treatment for myasthenia gravis, treatment (antidote) for neuromuscular blockade, and treatment for ileus. It also has been used as a treatment of urinary retention\u2014such as the retention observed in postoperative patients\u2014by increasing the tone of bladder smooth muscle. In ruminants, it has been used to stimulate rumen and intestinal motility. In horses, it has been used to stimulate GI motility, but results have been mixed. It may increase intestinal motility and increase fecal output but may not increase stomach emptying. For these uses, there are no clinical studies to guide the use and doses administered. The clinical use is based on anecdotal experience, studies in research animals, or clinical observations. Neostigmine nee- oh- stig\u2032meen Trade and other names: Prostigmin, Stiglyn, Neostigmine bromide, and Neostigmine methylsulfate","side_effects":"Adverse Reactions and Side Effects Although oral absorption is so small that systemic adverse effects are unlikely, some oral absorption has been demonstrated in young animals (calves) if intestinal integrity is compromised. Alterations in intestinal bacterial flora from therapy may cause diarrhea.","notes":"Instructions for Use Efficacy for treatment of diarrhea, especially for nonspecific diarrhea, is questionable. Patient Monitoring and Laboratory Tests Monitor for signs of diarrhea. If sufficiently absorbed systemically, it could cause\\tkidney\\tinjury;\\ttherefore\\tmonitor\\tblood\\turea\\tnitrogen\\tand\\tcreatinine\\twith chronic use. Formulations \u2022\\t\\tNeomycin\\tis\\tavailable\\tin\\t500-\\tmg\\tbolus,\\t50-\\tmg/mL\\t(equivalent\\tto\\t35\\tmg/ mL of neomycin base) and 200- mg/mL oral liquid (equivalent to 140 mg/ mL of neomycin base), and 325- mg soluble powder (equivalent to 20.3 g/oz of neomycin base). Stability and Storage It may be added to drinking water or milk. Do not add to other liquid supplements. Prepare\\ta\\tfresh\\tsolution\\tdaily.\\tIt\\tis\\tfreely\\tsoluble\\tin\\twater\\tand\\tslightly\\tsoluble\\tin ethanol. Aqueous solutions are stable over a wide pH range with optimum stability at a pH of 7. Store in a tightly sealed container, protected from light, and at room temperature. 648    Neostigmine","original_category":"Antibacterial"},{"name":"Nitrofurantoin","active_ingredient":"Nitrofurantoin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t4\\tmg/kg\\tq8h,\\tPO,\\tor\\t2\\tmg/kg\\tq6h\\tPO.\\t(Macrocrystalline\\tformulation administered with food preferred.) \u2022\\t\\tFor\\tcomparison,\\tthe\\tdose\\tused\\tin\\tpeople\\tis\\t0.7\\tmg/kg\\t(50\\tmg)\\tq6h\\tPO\\tor\\t1.4 mg/kg\\t(100\\tmg)\\tq8h\\tPO,\\tfor\\tno\\tlonger\\tthan\\t5\\tdays.  Horses \u2022\\t\\t2\\tmg/kg\\tq8h\\tPO. Regulatory Information It is prohibited from use in animals intended for food. Pharmacology and Mechanism of Action Nitroglycerin is a nitrate nitrovasodilator. Like other nitrovasodilators, it relaxes vascular smooth muscle (especially venous) through generation of nitric oxide (NO). The nitrate vasodilators are esters of nitrous acid. They are metabolized to inorganic nitrite and denitrated metabolites. Nitrites, organic nitrates, and nitroso compounds all act to activate the enzyme guanylate cyclase, which in turn produces cyclic guanosine\\tmonophosphate\\t(GMP)\\tin\\tvascular\\tsmooth\\tmuscle\\tand\\trelaxes\\tsmooth muscle. NO is also known as the endothelium- derived relaxing factor. Nitroglycerin nye- troe- glih\u2032ser- in Trade and other names: Nitrol, Nitro- Bid, and Nitrostat","contraindications":"Contraindications and Precautions Do not use in patients with azotemia. Do not administer during pregnancy, especially at term, because it may cause hemolytic anemia of the newborn. Do not administer to neonates. Do not rely on nitrofurantoin for systemic infections or infections of the kidney or prostate. It is active against lower UTIs only. Do not use nitrofurantoin to treat infections caused by Proteus spp., or P. aeruginosa. Drug Interactions Do not give medications that may alkalinize the urine because this may reduce effectiveness.","indications":"Indications and Clinical Uses Nitrofurantoin has been an important drug for short- term treatment of urinary tract infections (UTIs) in people. The use in animals is not as common but has been considered for some cases of lower UTI, especially when infections are caused by bacteria resistant to other common antimicrobial agents. There are small observational studies and case reports available for dogs to show that it can be effective at a dose of approximately 4 mg/kg every 8 hours oral. However, failure rates are high, and adverse effects (GI and neurologic) may occur in dogs. It should not be used to treat infections caused by Proteus spp. or P. aeruginosa because these organisms are intrinsically resistant. It should not be used to treat infections in azotemic patients. Studies on the effects in cats are not available. It is advised to use the macrocrystalline form to reduce GI upset and prolong effects. Although there are no well- controlled clinical studies or efficacy trials to document clinical effectiveness in veterinary medicine, the in vitro microbiologic studies demonstrate activity against a broad spectrum of bacteria, including those resistant to other antimicrobials. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include nausea, vomiting, and diarrhea. It turns urine color rust- yellow brown. In people, respiratory problems (pneumonitis) and peripheral neuropathy have been reported. The polyneuropathies in people are caused by a demyelination and are more common from long- term use or in patients with renal compromise. The respiratory problems have not been reported in animals, but neuropathy has been observed in dogs; the risk may be higher if there is renal insufficiency.","notes":"Instructions for Use Two dosing forms exist. Microcrystalline is rapidly and completely absorbed. Macrocrystalline (Macrodantin) is more slowly absorbed and causes less GI irritation. This form can be administered with food to slow absorption and delay the effects in the intestine. Urine should be at acidic pH for maximum effect. The dosing N Nitroglycerin 657 guidelines for animals are derived from small observational studies, retrospective studies, or pharmacokinetic studies in experimental dogs. In people, there is an advantage for frequent administration q6h compared with q8h or q12h. There is no advantage for increasing the dose higher than recommended because excretion into urine is saturable. Patient Monitoring and Laboratory Tests Monitor urine cultures or urinalysis. A microbiologic susceptibility test may overestimate the true activity against some bacteria. There are no approved breakpoints to predict susceptibility of bacteria isolated from animals to nitrofurantoin. Formulations \u2022\\t\\tMacrodantin\\tand\\tgeneric\\tbrands\\tare\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t100-\\tmg\\tcapsules (macrocrystalline), and Furalan, Furantoin, and generic brands are available in 50- and 100- mg tablets (microcrystalline). Furadantin is available in 5- mg/mL oral suspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is slightly soluble at a concentration less than 1 mg/mL in water and ethanol. It decomposes if exposed to metals other than stainless steel or aluminum.","original_category":"Antibacterial"},{"name":"Norfloxacin","active_ingredient":"Norfloxacin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t22\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information It is prohibited from use in animals intended for food.","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tyoung\\tanimals\\tbecause\\tof\\trisk\\tof\\tcartilage\\tinjury.\\tUse\\tcautiously in animals that may be prone to seizures. Coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), may decrease absorption. Drug Interactions No drug interactions are reported for animals, but the use of norfloxacin has been uncommon. However, like other quinolones, coadministration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), iron, and calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur. 664    Oclacitinib Maleate Oclacitinib Maleate (ok\u2032la sye\u2032ti nib mal\u2032ee ate) Trade and other names: Apoquel","indications":"Not specified in source","side_effects":"Adverse Reactions and Side Effects High concentrations may cause CNS toxicity, especially in animals with renal failure. Norfloxacin may cause some nausea, vomiting, and diarrhea at high doses. All of the fluoroquinolones may cause arthropathy in young animals. Dogs are most sensitive at 4\u201328 weeks of age. Large, rapidly growing dogs are the most susceptible. N","notes":"Instructions for Use Use in animals (and doses) is based on pharmacokinetic studies in experimental animals, experience in people, or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\tbreakpoints\\tfor sensitive organisms are \u22644 mcg/mL. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Orbifloxacin","active_ingredient":"Orbifloxacin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tTablets:\\t2.5\u20137.5\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tSuspension\\tin\\tcats:\\t7.5\\tmg/kg\\t(1\\tmL/kg)\\tq24h\\tPO. \u2022\\t\\tSuspension\\tin\\tdogs:\\t2.5\u20137.5\\tmg/kg\\tq24h\\tPO.  Horses \u2022\\t\\t5\\tmg/kg\\tq24h\\tPO. Regulatory Information Do not use fluoroquinolones off label to animals that produce food. Orbifloxacin is prohibited from use in animals intended for food. Ormetoprim + Sulfadimethoxine or- met\u2032oe- prim  +  sul- fa- dye- meth- oks\u2032een Trade and other names: Primor","contraindications":"Contraindications and Precautions Avoid use in young animals because of risk of cartilage injury. Use cautiously in animals that may be prone to seizures. Drug Interactions Fluoroquinolones may increase concentrations of theophylline and perhaps other drugs administered concurrently because of enzyme interactions. However, interactions with other drugs have not been reported. Co- administration with divalent and trivalent cations, such as products containing aluminum (e.g., sucralfate), iron, and calcium, may decrease absorption. Do not mix in solutions or in vials with aluminum, calcium, iron, or zinc because chelation may occur.","indications":"Indications and Clinical Uses Orbifloxacin is approved for use in dogs and cats for a variety of infections. Like other fluoroquinolones, it is used to treat susceptible bacteria in a variety of species. Treatment of infections has included skin, soft tissue, and urinary tract infections (UTIs) in dogs and cats and soft tissue infections in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tconcentrations\\tmay\\tcause\\tcentral\\tnervous\\tsystem\\t(CNS)\\ttoxicity,\\tespecially in animals with kidney disease. It may cause some nausea, vomiting, and diarrhea at high doses. All of the fluoroquinolones may cause arthropathy in young animals. Dogs are most sensitive at 4\u201328 weeks of age. Large, rapidly growing dogs are the most susceptible. Blindness in cats has been reported from administration of some quinolones (nalidixic acid and enrofloxacin), but at doses up to 15 mg/kg (higher than approved label dose), orbifloxacin has not produced this effect.","notes":"Instructions for Use). In horses, it has a half- life of 5 hours and oral absorption of 68%. Instructions for Use At the approved label dose, orbifloxacin is active against bacteria that tests \u201csusceptible\u201d with the current breakpoint. For isolates that test \u201cintermediate,\u201d higher doses can be used. In cats, orbifloxacin oral suspension and orbifloxacin tablets are not bioequivalent. On a milligram- per- kilogram basis, orbifloxacin oral suspension provides lower and more variable plasma levels of orbifloxacin than the tablets. The dose of orbifloxacin oral suspension in the cat is 7.5 mg/kg of body weight administered once daily, but the tablet dose is lower. The oral suspension was designed for palatability with an ion- exchange agent that masks the taste until it reaches the pH of the stomach. Patient Monitoring and Laboratory Tests Susceptibility testing: Clinical and Laboratory Standards Institute (CLSI) breakpoint for susceptible organisms in dogs and cats is \u22641 mcg/mL. O Ormetoprim + Sulfadimethoxine 675 Formulations \u2022\\t\\tOrbifloxacin\\tis\\tavailable\\tin\\t5.7-\\t,\\t22.7-\\t   ,\\tand\\t68-\\tmg\\ttablets.\\tOral\\tsuspension\\t(malt flavor) is 30 mg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Orbifloxacin is slightly water soluble. It has been mixed with various syrups, flavorings, and vehicles and was stable at room temperature for 7 days. Do not mix with vehicles that contain aluminum, calcium, or iron because this may decrease oral absorption via chelation.","original_category":"Antibacterial"},{"name":"Ormetoprim + Sulfadimethoxine","active_ingredient":"Ormetoprim + Sulfadimethoxine","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t55\\tmg/kg\\ton\\tthe\\tfirst\\tday\\tfollowed\\tby\\t27.5\\tmg/kg\\tq24h\\tPO.\\tDoses\\tcan\\tbe divided into twice- daily treatments. (All doses are based on the combined milligram amount of both ormetoprim and sulfadimethoxine.) Cats \u2022\\t\\tAlthough\\tdoses\\tare\\tnot\\treported\\tby\\tthe\\tmanufacturer,\\tdoses\\tsimilar\\tto\\tthose\\tfor dogs have been administered.  Horses \u2022\\t\\tLoading\\tdose\\tof\\t55\\tmg/kg\\t(of\\tthe\\tcombined\\tdrugs)\\tfollowed\\tby\\t27.5\\tmg/kg\\t(of the combined drugs) q24h PO. O Oxacillin Sodium 677 Regulatory Information Withdrawal times are not established for animals that produce food. Oral absorption has not been established for ruminants. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Oxacillin Sodium oks- ah- sill\u2032in soe\u2032dee- um Trade and other names: Prostaphlin and generic brands","contraindications":"Contraindications and Precautions Do not administer to animals sensitive to sulfonamides. Discontinue treatment if abnormal\\tCNS\\teffects\\tare\\tobserved. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine.","indications":"Indications and Clinical Uses Ormetoprim combined with sulfadimethoxine is used in small animals to treat a variety of bacterial infections caused by susceptible organisms, including pneumonia, skin, soft tissue, and UTIs in dogs and cats. In horses, it may be administered orally for infections caused by susceptible gram- positive bacteria (Actinomyces spp., Streptococcus spp., and Staphylococcus spp.), but higher doses may be needed for gram- negative infections. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), keratoconjunctivitis sicca (KCS), and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to inactive metabolites. As a consequence, other more toxic metabolites may persist. Ormetoprim has been associated\\twith\\tsome\\tCNS\\teffects\\tin\\tdogs,\\twhich\\tinclude\\tbehavioral\\tchanges, anxiety,\\tmuscle\\ttremors,\\tand\\tseizures.\\tIn\\thorses,\\twhen\\tIV\\tdoses\\twere\\tadministered to\\texperimental\\thorses\\t(IV\\tformulation\\tnot\\tcommercially\\tavailable),\\tnervous system reactions such as tremors and muscle fasciculations were observed.","notes":"Instructions for Use Doses listed are based on manufacturer\u2019s recommendations and FDA- approved form for animals. Controlled trials have demonstrated efficacy for treatment of pyoderma in dogs on a once- daily schedule. Patient Monitoring and Laboratory Tests Monitor tear production with long- term use because of risk of KCS in dogs from sulfonamides. For susceptibility testing, breakpoint ranges have not been determined for ormetoprim\u2013sulfadimethoxine combinations. Use a test for trimethoprim\u2013 sulfamethoxazole combinations as a guide for susceptibility to ormetoprim\u2013 sulfadimethoxine combinations. CLSI breakpoint for susceptible organisms is \u22642/38 mcg/mL (trimethoprim + sulfonamide). Formulations \u2022\\t\\tOrmetoprim\u2013sulfadimethoxine\\tcombination\\tis\\tavailable\\tin\\t120-\\t,\\t240-\\t   ,\\t600-\\t   ,\\tand 1200- mg tablets in a 5:1 ratio of sulfadimethoxine:ormetoprim. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Oxacillin Sodium","active_ingredient":"Oxacillin Sodium","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t22\u201340\\tmg/kg\\tq8h\\tPO.  \u2022\\t\\tNo\\tdoses\\tare\\treported.\\tOral\\tabsorption\\thas\\tnot\\tbeen\\testablished\\tfor\\tlarge animals. Regulatory Information Withdrawal times are not established for animals that produce food. Oral absorption has not been established for ruminants. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Oxazepam oks- ay\u2032zeh- pam Trade and other names: Serax","contraindications":"Contraindications and Precautions Use cautiously in animals allergic to penicillin- like drugs. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.\\tFood\\tmay\\tinhibit\\toral\\tabsorption. 678    Oxazepam","indications":"Indications and Clinical Uses Oxacillin has had limited use in small animals for treating soft tissue infections caused by gram- positive bacteria. The most common use has been for pyoderma in dogs, but the use has diminished because of limited pharmacokinetic information to guide oral dosing and the increased availability of other drugs, such as oral cephalosporins and amoxicillin and clavulanate combination. Oxacillin is used as a marker to test for mec- A\u2013mediated resistance of PBP2a in Staphylococcus spp. Methicillin- resistant Staphylococcus (e.g., methicillin- resistant Staphylococcus aureus [MRSA] or methicillin- resistant Staphylococcus pseudintermedius [MRSP]) spp. can be identified by using oxacillin breakpoints (see Patient Monitoring and Laboratory Tests). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects of penicillin- like drugs are most commonly caused by drug allergy. This can range from acute anaphylaxis when administered or other signs of allergic reaction when other routes are used. When administered orally, vomiting and diarrhea are possible, especially with high doses.","notes":"Instructions for Use Oral forms are often unavailable and other agents with similar activity are used instead (e.g., cephalexin, amoxicillin\u2013clavulanate). Doses are based on empiricism or extrapolation\\tfrom\\thuman\\tstudies.\\tNo\\tclinical\\tefficacy\\tstudies\\tare\\tavailable\\tfor\\tdogs or cats, but the use is extrapolated from studies in people. Administer on an empty stomach if possible. Patient Monitoring and Laboratory Tests Culture and sensitivity testing: CLSI breakpoints to define mec- A\u2013mediated resistance in Staphylococcus aureus is a MIC \u22654 mcg/mL, and the zone size is \u226410 mm. All other Staphylococcus spp. with mec- A- mediated resistance, including S. pseudintermedius (e.g., MRSP), are disk diffusion \u226417 mm and MIC \u22650.5 mcg/mL. If staphylococci are resistant to oxacillin, they should be interpreted as resistant to all cephalosporins and penicillins regardless of sensitivity result. Oxacillin resistance is usually interpreted as equivalent to methicillin resistance; therefore, oxacillin- resistant staphylococci are also referred to as MRSA or MRSP. Formulations \u2022\\t\\tOxacillin\\thas\\tbeen\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules\\tand\\t50-\\tmg/mL\\toral solution, but availability may be limited because other drugs with similar activity are used more often. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Oxacillin is soluble in water and alcohol. The reconstituted oral solution is stable for 3 days at room temperature and 14 days in the refrigerator.","original_category":"Antibacterial"},{"name":"Oxytetracycline","active_ingredient":"Oxytetracycline","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t7.5\u201310\\tmg/kg\\tq12h\\tIV\\tor\\t20\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t\\tTreatment\\tof\\tehrlichiosis\\t(Potomac\\tfever\\tcaused\\tby\\tN. risticii) and other infections: 10\\tmg/kg\\tq24h\\tIM\\tor\\tIV\\t(slowly).\\t(IM\\tinjections\\tcan\\tcause\\tpain\\tand\\treactions\\tat injection site.) \u2022\\t\\tTreatment\\tof\\tequine\\tpiroplasmosis:\\t5\u20136\\tmg/kg\\tonce\\tdaily\\tIV\\tfor\\t7\\tdays. Foals \u2022\\t\\tTreatment\\tof\\tflexural\\tlimb\\tdeformities:\\t44\\tmg/kg,\\tup\\tto\\t70\\tmg/kg\\t(2\u20133\\tg\\tper foal),\\ttwo\\tdoses\\t24\\thours\\tapart,\\tinjected\\tslowly\\tIV. Calves \u2022\\t\\t11\\tmg/kg/day\\tPO. \u2022\\t\\tTreatment\\tof\\tpneumonia:\\t11\\tmg/kg\\tq12h\\tPO. Cattle \u2022\\t\\tInjection\\tfor\\ttreatment\\tof\\tanaplasmosis,\\tenteritis,\\tpneumonia,\\tand\\tother\\tinfections: 11\\tmg/kg\\tq12h\\tIV. \u2022\\t\\tLong-\\t   acting\\tformulations:\\t20\\tmg/kg\\tIM\\tas\\ta\\tsingle\\tdose. Pigs \u2022\\t\\t6.6\u201311\\tmg/kg,\\tup\\tto\\t10\u201320\\tmg/kg,\\tq24h\\tIM\\tor\\t20\\tmg/kg\\tq48h\\tIM. Regulatory Information Cattle and pig withdrawal times for meat: 7 days (oral tablets). For oral soluble powder, the withdrawal times vary greatly from one product to another for cattle and pigs. Generally, they are at least 5 days for meat, but consult specific product label for withdrawal times. Cattle withdrawal times for injection: 18\u201322 days, depending on the product. Cattle withdrawal times for long- acting formulations: 28 days. Cattle withdrawal times for milk: 96 hours at a dose of 20 mg/kg. Cattle withdrawal times (intrauterine administration): 7 days for milk and 28 days for meat. Cattle withdrawal times (intramammary administration): 6 days for milk and 28 days for meat. Pig withdrawal times: 28 days and up to 42 days, depending on product. 692    Oxytocin Oxytocin oks- ih- toe\u2032sin Trade and other names: Pitocin, Syntocinon (nasal solution), and generic brands","contraindications":"Contraindications and Precautions Use cautiously in young animals because teeth discoloration is possible, especially with prolonged administration. Avoid injection volumes for IM greater than 10 mL per site in cattle and greater than 5 mL in pigs because of injection- site lesions. Drug Interactions Tetracyclines bind to compounds containing calcium, which decreases oral absorption. Do not mix with solutions that contain iron, calcium, aluminum, or magnesium.","indications":"Indications and Clinical Uses Oxytetracycline is used to treat infections of the respiratory tract (pneumonia), urinary tract, soft tissues, and skin. It is used for infections caused by a wide spectrum of bacteria except that resistance is common among gram- negative bacilli of enteric origin and staphylococci. One of the most common uses is in cattle for treatment of bovine respiratory disease caused by Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni. In pigs, tetracyclines have been used to treat atrophic rhinitis, pneumonic pasteurellosis, and Mycoplasma infections. In small animals, doxycycline, rather than oxytetracycline, is used as a treatment for Rickettsia spp. and Ehrlichia spp. infections. In horses, oxytetracycline has been administered to treat equine piroplasmosis caused by Theileria equi but was not effective for Babesia caballi. Oxytetracycline has been used for treating Potomac fever in horses caused by Neorickettsia risticii, as well as respiratory and soft tissue infections. In newborn horses, oxytetracycline has been administered at high doses for the purpose of correcting angular limb deformities. The dosages have been as high as 50\u201370 mg/ kg\\tIV\\tq48h.\\tThis\\teffect\\tmay\\tbe\\tcaused\\tby\\ta\\tdecrease\\tin\\tthe\\tviscoelastic\\tproperties\\tin the tendons of young animals. Because this produces tendon or ligament laxity, it may correct angular limb deformities in young foals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tetracyclines have produced kidney injury, but this has been rare with recommended doses and current formulations. Toxicity reported in older publications was attributed to outdated formulations that produced nephrotoxic degradation products. This ingredient that caused toxicity is no longer present, and this problem has been eliminated. Azotemia can be seen with high doses, which is attributed to inhibition of protein synthesis in mammalian cells. Therefore, this is caused by inhibition of protein synthesis with high doses rather than a direct nephrotoxic effect. At very high doses, oxytetracycline can injure other organs (e.g., liver) or cause metabolic acidosis, hemoglobinemia, or myoglobinemia, and the kidneys are injured as a consequence. Tetracyclines can affect bone and teeth formation in young animals, but this is usually not a problem with short- term administration. It was not observed when administered for two doses for treatment of angular limb deformities in young foals. Tetracyclines have caused drug fever in cats, but the mechanism is unknown. Oxytetracycline administration to horses has been associated with colic and diarrhea because of changes in the intestinal bacterial flora.","notes":"formulations to control the release rate from an injection from an IM or SQ injection.\\tVehicles\\tinclude\\tpolyethylene\\tglycol,\\tpropylene\\tglycol,\\tpovidone,\\tand pyrrolidine. Although oral preparations are available, oral absorption is poor. For example, oral absorption of 44 mg/kg in dogs was variable and too low to produce therapeutic effects. In pigs, oral absorption was only 4% (compared with chlortetracycline, which is 13%). Most pharmacokinetic studies have been performed with injectable oxytetracycline. After IM injection in cattle, the half- life is approximately 21 hours, with a maximum concentration (C MAX ) of 5.6 mcg/ mL.\\tIn\\thorses,\\tthe\\thalf-\\tlife\\t(IV)\\tis\\tapproximately\\t10\u201313\\thours.\\tIn\\tpigs,\\tthe\\thalf- life\\t(IV)\\tis\\tapproximately\\t4\u20136\\thours. Instructions for Use Oral dose forms are intended for large animal use and there are no tablets for small animals. Use of injectable long- acting forms has not been studied in small animals. Use of tetracyclines in small animals has primarily relied on doxycycline or minocycline. For large animals, there is both a conventional and a long-acting formulation of oxytetracycline. The long- acting formulation contains a viscosity excipient used to prolong the absorption from the injection site. One such excipient is 2- pyrrolidone. When using long- acting formulations, the long- acting properties only apply to IM use,\\tnot\\tIV\\tadministration.\\tWhen\\tproducts\\tthat\\tare\\tlong\\tacting\\tare\\tcompared\\twith conventional injectable products, the long- acting products usually allow for longer dose intervals. However, in pigs, there were no differences in duration of plasma concentrations when equivalent doses were administered. Patient Monitoring and Laboratory Tests Susceptibility testing: CLSI breakpoints for susceptible respiratory pathogens are \u22642 mcg/mL and \u22640.5 mcg/mL for cattle and swine, respectively. For other organisms, the breakpoints are \u22642 mcg/mL for streptococci and \u22644 for other organisms. Tetracycline can be used as a marker to test susceptibility for oxytetracycline, provided that CLSI methods and standards are used. O Formulations \u2022\\t\\tOxytetracycline\\tis\\tavailable\\tin\\t250-\\tmg\\ttablets;\\t500-\\tmg\\tbolus;\\t100-\\t\\tand\\t200-\\tmg/ mL injection; and 25- , 166- , and 450- g/lb of powder. \u2022\\t\\tFeed\\tand\\twater\\tadditive:\\tOxytetracycline\\thydrochloride\\tsoluble\\tpowder\\tis\\tavailable to be added to drinking water for poultry, cattle, and pigs in a variety of forms. Oxytetracycline is also available as a medicated feed for cattle, poultry, fish, and pigs. \u2022\\t\\tLong-\\t   acting\\tformulations\\tare\\tavailable\\tin\\ta\\t200-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. If solutions are diluted prior to injection, they should be discarded if not used immediately. Solution may darken slightly without losing potency.","original_category":"Antibacterial"},{"name":"Penicillin G","active_ingredient":"Penicillin G","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tPenicillin\\tG\\tpotassium\\tor\\tsodium:\\t20,000\u201340,000\\tunits/kg\\tq6\u20138h\\tIV\\tor\\tIM. \u2022\\t\\tProcaine\\tpenicillin\\tG:\\t20,000\u201340,000\\tunits/kg\\tq12\u201324h\\tIM. \u2022\\t \\tPenicillin\\tV:\\t10\\tmg/kg\\tq8h\\tPO.\\t(Not\\trecommended\\tbecause\\tof\\tpoor\\toral\\tabsorption.)  Cattle and Sheep \u2022\\t\\tProcaine\\tpenicillin\\tG:\\t22,000\u201366,000\\tunits/kg\\tq24h\\tIM.\\tSQ\\tuse\\tis\\tdiscouraged. \u2022\\t\\tSodium\\tor\\tpotassium\\tpenicillin\\tG:\\t20,000\\tunits/kg\\tIM\\tor\\tIV\\tq6h. Pigs \u2022\\t\\tProcaine\\tpenicillin\\tG:\\t15,000\u201325,000\\tunits/kg\\tq24h\\tIM. Horses \u2022\\t\\tPenicillin\\tsodium\\tor\\tpenicillin\\tpotassium:\\t20,000\u201324,000\\tunits/kg\\tq6\u20138h\\tIV. (Dosages\\tup\\tto\\t44,000\\tunits/kg\\tq6h\\thave\\tbeen\\tused\\tfor\\trefractory\\tcases.) \u2022\\t\\tProcaine\\tpenicillin\\tG:\\t20,000\u201324,000\\tunits/kg\\tq24h\\tIM. \u2022\\t\\tPotassium\\tpenicillin\\tG:\\t20,000\u201324,000\\tunits/kg\\tq12h\\tIM. \u2022\\t\\tCRI:\\tsodium\\tpenicillin\\tG\\tloading\\tdose\\tof\\t1.3\\tmg/kg\\tfollowed\\tby\\t2.5\\tmcg/kg/h CRI to achieve a target of 2 mcg/mL. Regulatory Information Horses:\\tInjections\\tof\\tprocaine\\tpenicillin\\tmay\\tcause\\ta\\tpositive\\ttest\\tresult\\tfor\\tprocaine prior to racing for as long as 30 days after an injection. Withdrawal\\ttimes\\tfor\\tbenzathine\\tpenicillin\\tat\\tlabel\\tdose\\tof\\t6000\u20137000\\tunits/kg\\tin cattle:\\t30\\tdays\\tfor\\tmeat\\t(14\\tdays\\tin\\tCanada). Withdrawal\\ttimes\\tfor\\tprocaine\\tpenicillin\\tat\\tlabel\\tdose\\tof\\t6000\u20137000\\tunits/kg\\tin cattle:\\t10\\tdays\\tfor\\tmeat,\\t4\\tdays\\tfor\\tmilk;\\t9\\tdays\\tfor\\tsheep;\\tand\\t7\\tdays\\tfor\\tswine. Withdrawal\\ttimes\\tfor\\tprocaine\\tpenicillin\\tG\\tat\\ta\\tdose\\tof\\t15,000\\tunits/kg\\tin\\tpigs:\\t8\\tdays. Withdrawal\\ttimes\\tfor\\tprocaine\\tpenicillin\\tG\\tat\\ta\\tdose\\tof\\t21,000\\tunits/kg\\tin\\tcattle: 10\\tdays\\tfor\\tmeat\\tand\\t96\\thours\\tfor\\tmilk. Procaine\\tpenicillin\\tG\\tat\\ta\\tdose\\tof\\t60,000\\tunits/kg:\\t21\\tdays\\tfor\\tcattle\\tand\\t15\\tdays for pigs. 712    Pentastarch RCI\\tClassification:\\t3\\tfor\\tprocaine;\\tpenicillin\\tis\\tnot\\tclassified Pentastarch Trade and other names: Pentaspan","contraindications":"Contraindications and Precautions Use cautiously in animals allergic to penicillin- like drugs. Avoid injection volumes greater than 30 mL per site. Administration of the long- acting benzathine form of penicillin G increases the risk of residues in food- producing animals. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Penicillin G is administered by injection either intravenously (potassium or sodium penicillin) or intramuscularly (procaine or procaine/benzathine penicillin G). Penicillin G is indicated for treatment of gram- positive cocci that cause respiratory infections, abscesses, and urinary tract infections (UTIs). Many staphylococci are resistant because of beta- lactamase synthesis. Streptococci are usually susceptible. Other susceptible organisms include gram- positive bacilli and anaerobic bacteria. Most gram- negative bacilli, especially those of enteric origin, such as the Enterobacteriaceae, are resistant. Some gram- negative respiratory pathogens such as Pasteurella multocida and Mannheimia haemolytica are susceptible. Penicillin concentrations in the urine are at least 100- fold higher than plasma concentrations in treated animals; therefore some urinary pathogens may be more susceptible. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Penicillin G has a high safety margin and is usually well tolerated. Allergic reactions are possible. Diarrhea is common with oral doses, but oral forms are rarely used. Pain and tissue reactions may occur with IM or SQ injections.","notes":"Formulations of penicillin G are designed to control the absorption from site of injection.\\tFormulations\\tinclude: \u2022\\t\\tSodium\\tor\\tpotassium\\tpenicillin\\tG\\t(crystalline\\tpenicillin),\\twhich\\tis\\twater\\tsoluble\\tand can be administered intravenously or intramuscularly. It may also be mixed with fluids for IV administration. \u2022\\t\\tPenicillin\\tG\\tbenzathine,\\twhich\\tis\\tinsoluble\\tand\\tavailable\\tas\\ta\\tsuspension.\\tIt\\tis slowly absorbed from an injection site to produce low but prolonged (several days of) penicillin concentrations. All benzathine penicillin G forms are combined with procaine\\tpenicillin\\tG\\tin\\tcommercial\\tformulation\\t(1:1\\tratio). \u2022\\t\\tPenicillin\\tG\\tprocaine\\tis\\ta\\tpoorly\\tsoluble\\tsuspension\\tfor\\tIM\\tor\\tSQ\\tadministration.\\tIt is absorbed slowly, producing concentrations for 12\u201324 hours after injections. \u2022\\t\\tPenicillin\\tV,\\toral\\tpenicillin,\\tis\\tnot\\thighly\\tabsorbed\\tand\\thas\\ta\\tnarrow\\tspectrum\\tin comparison with other penicillin derivatives. Formulations of procaine penicillin G contain varying amounts of free procaine (depending on the formulation). Free procaine in the formulation may elicit a central\\tnervous\\tsystem\\t(CNS)\\treaction\\tafter\\tinjection\\tin\\tsome\\thorses.\\tLarge\\tdoses of sodium penicillin IV can decrease potassium concentrations. Instructions for Use The approved dose listed on the injectable product labels are outdated and do not reflect the current clinical use of penicillin. Penicillin G benzathine is not recommended for most infections because concentrations are too low to provide therapeutic drug concentrations. A possible exception is for treatment of streptococcal infections. Avoid SQ injection with procaine penicillin G because of tissue injury and food- animal residue problems. Penicillin V is not well absorbed orally and should be avoided for serious infections. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tbreakpoint for susceptible equine pathogens (Streptococcus equi and Staphylococcus spp.) is \u22640.5 mcg/mL. The breakpoint for bovine isolates causing bovine respiratory disease is \u22640.25 mcg/mL. The CLSI breakpoints for susceptible organisms isolated from people are \u22648 mcg/mL for enterococci and \u22640.12 mcg/mL for staphylococci and streptococci. P Formulations Note\\ton\\tunitage:\\tPenicillin\\tis\\tone\\tof\\tthe\\tfew\\tantibiotics\\tthat\\tis\\tstill\\tmeasured\\tin\\tterms of units rather than weight in milligrams or micrograms, and the conversion depends on the formulation. One unit of procaine penicillin is approximately 1.03 mcg, or there are approximately 975 units/mg. One unit of potassium penicillin is approximately 0.64\\tmcg,\\tor\\tthere\\tare\\tapproximately\\t1560\\tunits/mg.\\tAn\\tapproximate\\tconversion\\tis 1000 units/mg for procaine penicillin and 1500 units/mg for potassium penicillin. \u2022\\t\\tPenicillin\\tG\\tpotassium\\tis\\tavailable\\tin\\t5-\\t\\tto\\t20-\\tmillion-\\t    unit\\tvials. \u2022\\t\\tPenicillin\\tG\\tbenzathine\\tis\\tavailable\\tin\\t150,000\\tunits/mL\\tand\\tis\\tusually\\tcombined with 150,000 units/mL of procaine penicillin G suspension. Benzathine penicillin products are not recommended. \u2022\\t\\tProcaine\\tpenicillin\\tG\\tis\\tavailable\\tin\\t300,000-\\tunits/mL\\tsuspension. \u2022\\t \\tPenicillin\\tV\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\ttablets\\t(250\\tmg\\tis\\tequal\\tto\\t400,000\\tunits). Stability and Storage Sodium and potassium forms of penicillin G retain their potency for 72 hours at room temperature, but refrigeration is recommended. It is stable for 7 days if refrigerated and retains 90% potency for 14 days. Solutions of sodium penicillin prepared in fluids for CRI infusion should be replaced q12h. Penicillin potassium and penicillin sodium are freely soluble in water. One gram of penicillin dissolves in 250 mL of water (4 mg/mL). Degradation and inactivation of penicillin solutions are accelerated at high pH\\t(pH\\tgreater\\tthan\\t8),\\tstrong\\tacids,\\tor\\toxidizing\\tagents.","original_category":"Antibacterial"},{"name":"Piperacillin Sodium and Tazobactam","active_ingredient":"Piperacillin Sodium and Tazobactam","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t50\\tmg/kg\\tq6h\\tIV\\tor\\tIM.\\tAlternatively,\\ta\\tCRI\\tcan\\tbe\\tadministered\\tby\\tinjecting\\ta loading dose of 4 mg/kg (bolus) followed by 3.2 mg/kg/h. P Piperazine 741  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals,\\tbut\\tdoses\\tsimilar\\tto\\tthose\\tcited for dogs or extrapolated from human use would likely reach the same targets in horses.\\tHuman\\tdose\\tis\\tapproximately\\t50\\tmg/kg\\tIV,\\tevery\\t6\\thours,\\tdelivered\\tas\\ta 30-minute infusion. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tHowever, because of rapid elimination, it is anticipated that withdrawal times will be similar to that of other beta- lactams such as ampicillin. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Piperazine pih- peer\u2032e- zeen Trade and other names: Pipa- Tabs and generic brands","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\tallergic\\tto\\tpenicillin\\tdrugs.\\tHigh\\tdoses\\tcontribute\\tto\\tthe sodium load in a patient. Drug Interactions Do not mix in vials or syringes with other drugs.","indications":"Indications and Clinical Uses Piperacillin and tazobactam is one of the most popular IV antibiotics for in- hospital use in people. The use includes septicemia, UTIs, skin, soft tissue, respiratory infections, intra- abdominal infections, and gynecologic infections. Targeted organisms include bacteria of the Enterobacterales (Escherichia coli, Klebsiella pneumoniae) and P. aeruginosa. The activity includes some ESBL- producing strains of the Enterobacterales. The in vitro activity against some gram- negative bacteria is enhanced when administered with an aminoglycoside (e.g., gentamicin or amikacin). The addition of tazobactam further increases the spectrum to include beta- lactamase\u2013producing strains. In veterinary medicine, other penicillin\u2013beta- lactamase inhibitor combinations have been ampicillin and sulbactam (Unasyn) and ticarcillin and clavulanate. However,\\tampicillin\\tand\\tsulbactam\u2019s\\tspectrum\\tof\\tcoverage\\toften\\tdoes\\tnot\\tinclude many gram-negative bacteria. Ticarcillin and clavulanate (Timentin), once a popular injectable antibiotic in veterinary medicine, is no longer available. Therefore piperacillin and tazobactam is a logical substitute as a penicillin\u2013beta- lactamase inhibitor combination for in- hospital veterinary use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Allergy\\tto\\tpenicillin\\tis\\tthe\\tmost\\tcommon\\tadverse\\teffect.\\tHigh\\tdoses\\tmay\\tinhibit platelet function.","notes":"Instructions for Use Piperacillin\\tis\\tcombined\\twith\\ttazobactam\\t(beta-\\tlactamase\\tinhibitor)\\tin\\tZosyn,\\twhich increases the spectrum to include beta- lactamase\u2013producing strains of Staphylococcus and gram- negative bacteria. Ticarcillin\u2013clavulanate has a similar spectrum of activity but is no longer available. Piperacillin\u2013tazobactam has a more active spectrum of activity against gram- negative bacteria than ampicillin\u2013sulbactam. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tCLSI\\tbreakpoints\\tfor\\tsusceptible\\torganisms\\tare\\t\u22648/4 mcg/mL (piperacillin/tazobactam). Formulations \u2022\\t\\tPiperacillin\\tand\\ttazobactam\\tare\\ttypically\\tin\\t8:1\\tratio\\tof\\tpiperacillin:tazobactam. It is available in vials containing 2 g of piperacillin and 0.25 g of tazobactam, 3 g of piperacillin and 0.375 g of tazobactam, or 4 g of piperacillin and 0.5 g of tazobactam. Vials are reconstituted with sterile water, 0.9% saline solution, or 5% dextrose in water and further diluted to desired volume for IV fluid administration. \u2022\\t \\tPreparation\\tof\\tIV\\tinfusion:\\tTo\\tprepare\\tthe\\tformulation\\tfor\\tIV\\tinfusion,\\tfirst\\tremove 10 mL from a 50- mL infusion bag and use this volume to reconstitute a 2.25- g vial. Add the contents back to the 50- mL infusion bag to make a 45- mg/mL solution. Refrigerate it. This solution will expire in 7 days. Alternatively, remove 15 mL from a 100- mL bag and reconstitute a 3.375- g vial. Add the contents back to the infusion bag for a concentration of 33.75 mg/mL. Refrigerate. This expires 7 days after mixing. Stability and Storage Reconstituted solution should be used within 24 hours or 7 days if refrigerated.","original_category":"Antibacterial,  beta- lactam"},{"name":"Polymyxin B Sulfate","active_ingredient":"Polymyxin B Sulfate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tAntibacterial:\\t15,000\u201325,000\\tunits/kg\\tq12h\\tIV.\\tTo\\tprepare\\tsolution,\\tmix\\t500,000 polymyxin B units with 300\u2013500 mL of 5% dextrose for CRI. \u2022\\t\\tAntibacterial:\\t30,000\\tunits/kg/day\\tIM.\\tTo\\tprepare\\tsolution,\\tmix\\t500,000 polymyxin B units in 2 mL of sterile water for injection or sodium chloride injection or 1% procaine hydrochloride. IM injections can be painful. \u2022\\t\\tAntiendotoxin:\\t1\\tmg/kg\\tdiluted\\tin\\t10\\tmL\\tof\\t0.9%\\tsaline\\tsolution\\tgiven\\tas\\tan\\tIV infusion. (See earlier information for converting milligrams to units.) \u2022\\t\\tIntrathecal\\t(to\\ttreat\\tmeningitis):\\tMix\\t500,000\\tpolymyxin\\tB\\tunits\\tin\\t10\\tmL of sodium chloride (50,000 units/mL). Administer 20,000 units PO daily intrathecally; then continue 25,000 units once every other day.  Horses \u2022\\t\\tEndotoxemia:\\t1000\u201310,000\\tunits/kg\\t(usually\\t6000\\tunits/kg,\\tequivalent\\tto approximately 1 mg/kg) administered q8h. The repeat treatments may be necessary if there is ongoing sepsis. The infusion may be mixed in a 1- L saline solution and administered over 15 minutes q8h for five treatments. Regulatory Information Cattle:\\tWithdrawal\\ttime\\tafter\\tintramammary\\tadministration\\tis\\t7\\tdays\\tfor\\tmilk\\tand\\t2 days for meat. Other withdrawal times have not been reported for food animals. For other extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Polysulfated Glycosaminoglycan pahl- ee- sul\u2032fate- ed  glye- koe- sah- mee- noe- glye- kan Trade and other names: Adequan Canine, Adequan IA, and Adequan IM","contraindications":"Contraindications and Precautions Use cautiously, if at all, in patients with renal disease. Animals receiving polymyxin B should receive adequate fluid support to maintain hydration and renal perfusion. Drug Interactions Use cautiously with other potentially nephrotoxic agents such as aminoglycosides. Do not administer with curariform muscle relaxant and other neurotoxic drugs because of risk of respiratory depression. Polymyxin antibacterial activity is decreased in the presence of pus, in tissues containing acidic phospholipids, and in the presence of anionic detergents.","indications":"Indications and Clinical Uses Polymyxin B for injection is in powder form suitable for preparation of sterile solutions for IM, IV drip, intrathecal, or ophthalmic use. Polymyxin B is most often administered as a topical ointment for managing infections. It is one of the components of \u201ctriple antibiotic\u201d ointments used for topical use. Systemically, polymyxin has been used to treat infections that are resistant to other drugs. Bacteria such as P. aeruginosa and Acinetobacter spp. may develop resistance to other drugs that can be treated only with drugs such as colistin and polymyxin. In people, polymyxin B is used to treat UTI, meningitis, and septicemia. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness in animals for treating bacterial infections. In veterinary medicine, particularly horses, polymyxin has been used because of its property to bind to the lipid A portion of bacterial endotoxin in the blood and prevent signs of bacterial septicemia without producing kidney injury. Infusions ranging from 1000\\tto\\t10,000\\tunits/kg\\t(a\\tcommon\\tdose\\tis\\t6000\\tunits/kg,\\tequivalent\\tto\\t1\\tmg/kg) administered q8h. These infusions have been shown to be safe and effective for treating endotoxemia in horses. The action is attributed to the cationic portion of polymyxin B binding to the anionic lipid A portion of this endotoxin. This effectively renders the endotoxin inactive, thereby decreasing adverse effects attributed to gram- negative endotoxin. This effect also has been demonstrated in an experimental model of feline endotoxemia in which it had antiendotoxin effects in vivo. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Intramuscular injections cause pain. Because of its ability to bind to phospholipid membranes and cause injury, the most severe adverse reaction is caused by renal injury. Kidney injury is a dose- dependent problem caused by increased membrane permeability and influx of cations, anions, and water, causing kidney cell swelling. However,\\tat\\tdosages\\tthat\\thave\\tbeen\\tused\\tfor\\ttreating\\tendotoxemia\\t(6000\\tunits/ kg\\tIV\\tq8h),\\tit\\thas\\tnot\\tcaused\\tkidney\\tinjury\\tin\\thorses.\\tHowever,\\tat\\thigher\\tdoses (18,000\u201336,000\\tunits/kg)\\tor\\tfor\\tlonger\\ttreatment\\tprotocols,\\trenal\\tinjury risk increases. Allergic reactions are also possible. At high doses administered intravenously to cats (3 mg/kg and higher), it produced respiratory depression.","notes":"Instructions for Use Use in veterinary medicine has been primarily confined to topical use and the use in horses to treat endotoxemia. Doses and regimens have been derived from experimental studies. Routes of administration have been topical IM, IV infusion, intrathecal, or ophthalmic. 748    Polysulfated Glycosaminoglycan Patient Monitoring and Laboratory Tests Monitor patient hydration and electrolyte status. Monitor renal parameters (e.g., creatinine\\tand\\tBUN)\\tfor\\tevidence\\tof\\trenal\\tdisease. Formulations \u2022\\t\\tPolymyxin\\tB\\tis\\tavailable\\tin\\tvials\\tcontaining\\t500,000\\tpolymyxin\\tB\\tunits.\\tIn\\tsome dosage protocols, the dose is listed in milligrams instead of units. One milligram of polymyxin B base is equivalent to 10,000 units of polymyxin B, and each microgram of pure polymyxin B base is equivalent to 10 units of polymyxin B. Stability and Storage Store\\tat\\troom\\ttemperature\\t20\xb0C\u201325\xb0C\\t(68\xb0F\u201377\xb0F),\\tprotected\\tfrom\\tlight.\\tPolymyxin B\\tis\\tsoluble\\tin\\twater\\tat\\t0.5%\\tsolution\\twith\\ta\\tpH\\tof\\t5\u20137.5.\\tAqueous\\tsolutions\\tof polymyxin B sulfate have been stored up to 12 months without significant loss of potency if refrigerated. Do not mix with strong acid or alkaline solutions. It is not compatible with calcium or magnesium salts.","original_category":"Antibacterial agent"},{"name":"Pradofloxacin","active_ingredient":"Pradofloxacin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t3\u20135\\tmg/kg\\tq24h\\tPO. Cats \u2022\\t\\tTablets:\\t3\u20135\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tOral\\tsuspension:\\t5\u20137.5\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\tapproved\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. Extralabel use of fluoroquinolones in food- producing animals is prohibited. Pralidoxime Chloride prah- lih- doks\u2032eem klor\u2032ide Trade and other names: 2- PAM and Protopam chloride","contraindications":"Contraindications and Precautions No\\tcontraindications\\tor\\tprecautions\\tare\\tavailable.\\tBecause\\tit\\tis\\tsimilar\\tto\\tother fluoroquinolones, use cautiously in young dogs that may be susceptible to articular cartilage injury. Risks during pregnancy in dogs and cats are not known, but pradofloxacin induced eye malformations at high doses in rats. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tfrom\\tthe\\tuse\\tthus\\tfar\\tin\\tanimals. However,\\tsome\\tof\\tthe\\tsame\\tdrug\\tinteractions\\tthat\\taffect\\tother\\tfluoroquinolones are possible with pradofloxacin, such as chelation with oral calcium, magnesium, iron, and aluminum supplements. 762    Pralidoxime Chloride","indications":"Indications and Clinical Uses Pradofloxacin has been evaluated in dogs and cats, with efficacy studies published on the approved label, research abstracts and clinical reports in which it has been used for treating skin and soft tissue infections in dogs and cats, oral infections (periodontal therapy), respiratory infections in cats, and UTIs. At a dose of 3 mg/kg PO, it was effective for treatment of UTIs in dogs, and at 3 or 5 mg/kg, it was effective for canine pyoderma. At a dose of 5 mg/kg in a 2.5% oral suspension, it was effective for UTIs in cats. It has been used to effectively treat infections caused by Chlamydophila felis or Mycoplasma spp. in cats (5 mg/kg q12h PO for 28 days) and was as effective as doxycycline. It has been used to treat feline rhinitis caused by Mycoplasma spp., Bordetella spp., streptococci, or staphylococci at a dosage of 5 mg/kg once daily for seven doses. It has been effective (5 mg/kg per day) for treatment of feline blood infections caused by Mycoplasma haemofelis. Precautionary Information indications as for other fluoroquinolones in addition to those listed in the Indications and Clinical Uses sections.","side_effects":"Adverse Reactions and Side Effects Safety studies have been completed in cats associated with approval in the United States and in dogs and cats in Europe. It has been tolerated well in cats with no adverse effects that are different from other approved fluoroquinolones. Field trials in cats in the United States showed that the most common adverse effect was diarrhea or loose stools. In cats, administration at high doses of six times the label dose did not cause ocular problems. In dogs and cats, at high doses, pradofloxacin has caused bone marrow suppression, but this has not been reported from clinical use at approved doses.","notes":"Instructions for Use Pradofloxacin may be used for a variety of infections in dogs and cats with similar Patient Monitoring and Laboratory Tests The CLSI breakpoint for susceptibility is \u22640.25 mcg/mL for both dogs and cats. Formulations \u2022\\t\\tFormulations\\tcontain\\tpradofloxacin\\tin\\ta\\t2.5%\\toral\\tsuspension\\tin\\tthe\\tUnited\\tStates and\\tEurope\\tand\\t15-\\t,\\t60-\\t  ,\\tand\\t120-\\tmg\\ttablets\\tin\\tEurope. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Pyrimethamine","active_ingredient":"Pyrimethamine","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1\\tmg/kg\\tq24h\\tPO\\tfor\\t14\u201321\\tdays\\t(5\\tdays\\tfor\\tNeospora caninum). Cats \u2022\\t\\t0.5\u20131\\tmg/kg\\tq24h\\tPO\\tfor\\t14\u201328\\tdays.  \u2022\\t\\tHorses,\\tEPM\\tcaused\\tby\\tS. neurona:\\t1\\tmg/kg\\tq24h\\tPO\\tin\\tcombination\\twith\\ta sulfonamide (see details under Pyrimethamine + Sulfadiazine). P Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. peer- ih- meth\u2032ah- meen  and  sul- fa- dye\u2032ah- zeen Trade and other names: ReBalance","contraindications":"Contraindications and Precautions Use cautiously in pregnant animals because of effects of folate inhibition on the fetus. Drug Interactions Drug\\tinteractions\\tare\\tnot\\treported\\tfor\\tanimals.\\tHowever,\\ta\\tcombination\\tof pyrimethamine with trimethoprim\u2013sulfonamides enhances the bone marrow toxicity.","indications":"Indications and Clinical Uses Pyrimethamine is used to treat protozoal infections in animals. It is most often combined with a sulfonamide, either separately or in a combined formulation. See Pyrimethamine + Sulfadiazine for additional information. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There is a risk of folic acid anemia when pyrimethamine and sulfonamide combinations are administered for prolonged treatment. This has been observed in 12% of treated horses in a field trial. Folic or folinic acid (preferably folinic acid) has been supplemented to prevent anemia, but the benefit of this treatment is unclear. Bone marrow suppression usually resolves after discontinuation of treatment. Diarrhea may occur after oral administration.","notes":"Instructions for Use Pyrimethamine is used either alone or in combination with sulfonamides. (See Pyrimethamine + Sulfadiazine for further details.) Patient Monitoring and Laboratory Tests Monitor CBC periodically in animals receiving treatment. Formulations \u2022\\t\\tPyrimethamine\\tis\\tavailable\\tin\\t25-\\tmg\\ttablets.\\t(Human-labeled\\ttablets\\tmay\\tbe\\tvery expensive.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Pyrimethamine is poorly soluble in water, but it is more soluble in ethanol. Tablets have been crushed to make extemporaneous suspensions in syrups and other flavorings. These formulations have been stable for 7 days and up to 90 days, depending on the formulation.","original_category":"Antibacterial"},{"name":"Rifampin","active_ingredient":"Rifampin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t5\\tmg/kg\\tq12h\\tPO\\tor\\t10\\tmg/kg\\tq24h\\tPO.\\t(Low\\tdose;\\ttwice\\tdaily\\tis\\tpreferred.)  Horses \u2022\\t\\t10\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tFoals\\tfor\\ttreatment\\tof\\tR. equi:\\t5\\tmg/kg\\tq12h\\tPO.\\tIn\\tsome\\tprotocols,\\trifampin is\\tcombined\\twith\\terythromycin\\t(25\\tmg/kg\\tq8h\\tPO)\\tor\\tother\\tmacrolides\\t(e.g., azithromycin), but it is not established if combination treatment is more effective than monotherapy. Cattle, Sheep, and Goats \u2022\\t\\t20\\tmg/kg\\tq24h\\tPO.\\tFor\\ttreatment\\tof\\tJohne\u2019s\\tdisease\\tcombine\\twith\\tisoniazid. Regulatory Information Avoid administration in food- producing animals. Withdrawal times have not been established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Ringer\u2019s Solution Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Use cautiously in animals that are at risk for pancreatitis. Because of a risk of hepatitis, use cautiously with any other drug that may be potentially hepatotoxic (e.g., sulfonamides, anticonvulsants, acetaminophen). Avoid use in pregnant animals. Drug Interactions Multiple drug interactions are possible. Rifampin is one of the most potent inducers of\\tcytochrome\\tP450\\thepatic\\tenzymes.\\tElevation\\tof\\tcytochrome\\tP450\\tenzyme\\tactivity may persist for 4 days but returns to baseline by 8 days in people. The duration of this activity is not known in animals. Drugs that may have decreased levels because of rapid metabolism when administered with rifampin include barbiturates, chloramphenicol, progestins, digitalis, warfarin, corticosteroids (prednisolone), and potentially many other drugs concurrently administered with rifampin. Rifampin has decreased\\tclarithromycin\\tby\\t90%\\tin\\thorses\\tbecause\\tof\\tincreased\\tclearance.\\tRifampin is\\talso\\tan\\tinducer\\tof\\tmembrane\\tefflux\\tpump\\t(P-\\tglycoprotein),\\twhich\\tmay\\thave\\tthe consequence\\tof\\tdecreasing\\toral\\tabsorption\\tof\\tother\\tdrugs.","indications":"Indications and Clinical Uses Rifampin is used in people primarily for treatment of tuberculosis. In veterinary medicine, rifampin has been used to treat susceptible gram- positive and intracellular bacteria, including Staphylococcus spp. (including methicillin- resistant strains); Streptococcus spp.; Rhodococcus equi; Corynebacterium pseudotuberculosis; and most strains of Bacteroides spp., Clostridium spp., Neisseria spp., and Listeria spp. Gram- negative organisms are not affected at typical doses. In small animals, the most common use is to treat staphylococcal infections, particularly methicillin- resistant strains. Resistance among bacteria (e.g. Staphylococcus spp.) may develop, but this occurrence is generally not common and should not prevent its use in animals. One of the most common uses of rifampin is for treating infections caused by R. equi\\tin\\thorses.\\tFor\\tthis\\ttreatment,\\tit\\tis\\tfrequently\\tcombined\\twith\\terythromycin, azithromycin, or clarithromycin. Rifampin also may have activity against bacteria in biofilms. This effect may assist treatment of staphylococcal infections on orthopedic implants. However, there are insufficient reports to confirm the clinical effectiveness for treating biofilm bacteria in animals. R Precautionary Information","side_effects":"Adverse Reactions and Side Effects In people, hypersensitivity and flulike symptoms are reported. Hepatotoxicity is seen more commonly in dogs than other animals. It is more common when high doses are administered (10 mg/kg and higher). In one study, adverse effects occurred in\\t16%\\tof\\ttreated\\tdogs\\t(vomiting,\\tanorexia,\\tdiarrhea),\\tand\\t27%\\thad\\treversible elevations of liver enzymes. When treating dogs, clinicians are advised to check liver enzymes and bilirubin periodically during rifampin treatment. If elevations occur, rifampin should be discontinued, and most animals are expected to recover. Urine is colored orange to reddish- orange in treated patients. It also discolors saliva, tears, feces, sclera, and mucous membranes to a reddish- orange color. The discoloration is not pathogenic and is a normal occurrence. Rifampin is unpalatable and may be\\tdifficult\\tto\\tadminister\\tto\\tsome\\tanimals.\\tPancreatitis\\thas\\tbeen\\tassociated\\twith rifampin administration but not well documented in dogs or cats.","notes":"Instructions for Use Most of the documented clinical experience has been for treating R. equi infections in horses, primarily foals. In these protocols, it is often combined with a macrolide antibiotic (erythromycin, clarithromycin, or azithromycin), but it is not known if combination therapy is more effective than single-drug treatment. When selecting a dose,\\tthe\\t10-\\tmg/kg\\tPO\\tdose\\twas\\tadequate\\tfor\\tsusceptible\\tgram-\\tpositive\\tinfections\\tin the adult horse. Use in small animals (and doses) is based on experience, primarily in dogs in which rifampin was used to treat methicillin- resistant Staphylococcus infections. It is often recommended to administer rifampin in small animals in combination with other drugs to decrease emergence of resistance. However, there is no clinical evidence in animals or analysis of studies from people that addition of other antibiotics is necessary when treating infections caused by Staphylococcus spp. Rifampin may be used as monotherapy in these cases. Administer on an empty stomach whenever possible. Patient Monitoring and Laboratory Tests Susceptibility\\ttesting:\\tClinical\\tand\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tbreakpoint for susceptible organisms isolated from people is \u22641.0 mcg/mL, but a breakpoint is not available for isolates from animals. Whereas minimum inhibitory concentrations (MICs) for gram- positive organisms generally occur at 0.1 mcg/mL, gram- negative 816    Ringer\u2019s Solution organisms have MIC values ranging from 8\u201332 mcg/mL and are considered resistant. Because of the risk of liver injury in dogs, it is advised to periodically, initially after the first 7\\tdays\\tand\\tthen\\tregularly\\tevery\\t10\u201314\\tdays.\\tDuring\\tmonitoring,\\tcheck\\tthe\\tliver\\tenzymes and serum bilirubin to monitor for signs of liver injury. Formulations \u2022\\t\\tRifampin\\tis\\tavailable\\tin\\t150-\\tmg\\tand\\t300-\\tmg\\tcapsules\\tand\\t600-\\tmg\\tRifadin\\tIV injectable solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Rifampin is slightly soluble in water and ethanol. It is more soluble at acidic pH. Acid should be added to solutions (e.g., ascorbic acid) to prevent oxidation and improve solubility. Rifampin has been mixed with syrups and flavorings for oral administration and is stable for 4\u20136 weeks. The injectable solution is prepared by adding 10 mL of saline\\tto\\ta\\t600-\\tmg\\tvial\\tand\\tmixing\\t(60\\tmg/mL).\\tIt\\tmay\\tbe\\tinfused\\twith\\t0.9%\\tsaline or\\t5%\\tdextrose\\tsolution.\\tReconstituted\\tinjectable\\tsolution\\tis\\tstable\\tfor\\t24\\thours.","original_category":"Antibacterial"},{"name":"Ronidazole","active_ingredient":"Ronidazole","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported. Cats \u2022\\t\\t30\\tmg/kg\\tq24h\\tPO\\tfor\\t2\\tweeks.\\tEarly\\tclinical\\tstudies\\twere\\tperformed\\twith\\t30 mg/kg\\t    q12h,\\t   but\\t  twice-\\t   daily\\t  administration\\tis\\t more\\t   likely\\t   to\\t produce\\tCNS\\t  toxicity, and\\tan\\tinterval\\tof\\tq24h\\tmay\\tbe\\tequally\\teffective.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals that produce food. Administration of nitroimidazoles to animals intended for food is prohibited. Treated cattle must not be slaughtered for food. 826    S-Adenosylmethionine S- Adenosylmethionine  (SAMe) ess\u2032ah- den\u2032oh- sill- meh- thye\u2032oh- neen Trade and other names: Denosyl, Denamarin, and SAMe","contraindications":"Contraindications and Precautions Fetal abnormalities have not been demonstrated in animals with recommended doses, but use cautiously during pregnancy. Drug Interactions Like other nitroimidazoles, it may potentiate the effects of warfarin and cyclosporine via inhibition of drug metabolism.","indications":"Indications and Clinical Uses Ronidazole is currently not an FDA- approved drug, but it has been used in cats to treat intestinal protozoal parasites. Studies for treatment of other organisms are not available. For treatment of feline Tritrichomonas foetus intestinal infections, it has been administered orally at a dosage of 30 mg/kg twice daily for 2 weeks. However, twice- daily administration is more likely to produce CNS adverse reactions, and pharmacokinetic\\tdata\\tindicate\\tthat\\t30\\tmg/kg\\tonce\\tdaily\\tmay\\tbe\\tequally\\teffective. R Efficacy for long- term remission has not been established, but temporary resolution of feline T. foetus intestinal infections has been observed. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other nitroimidazoles, the most severe adverse effect is caused by toxicity to the CNS. High doses may cause lethargy, CNS depression, ataxia, tremors, hyperesthesia, seizures, vomiting, and weakness. The CNS signs are related to inhibition of action of gamma- aminobutyric acid (GABA) and are responsive to benzodiazepines (diazepam). Dogs show neurotoxicity at doses of 50\u2013200 mg/kg (seizures, tremors, and ataxia). Avoid dosages that exceed 60 mg/kg per day in cats. Like other nitroimidazoles, it has the potential to produce mutagenic changes in cells, but this has not been demonstrated in animals. Like other nitroimidazoles, it has a bitter taste and can cause vomiting and anorexia.","notes":"Instructions for Use Ronidazole is currently not a marketed drug but has been prepared from bulk powder in compounding pharmacies. Patient Monitoring and Laboratory Tests Monitor for neurologic adverse effects. Formulations \u2022\\t\\tNo\\tavailable\\tformulation\\texists;\\tit\\tis\\tcompounded\\tfrom\\tbulk\\tchemicals.\\tIV formulations\\thave\\tbeen\\tprepared\\tby\\tdissolving\\tronidazole\\tpure\\tpowder\\tin\\t5% dextrose in water (D5W) to a concentration of 3.2 mg/mL. This formulation has been safely administered to research animals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial, antiparasitic"},{"name":"Pentahydrate","active_ingredient":"Pentahydrate","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t22\\tmg/kg\\tq12h\\tPO\\tfor\\t4\\tdays. \u2022\\t\\t5.5\u201311\\tmg/kg\\tq12h\\tIM\\tfor\\t4\\tdays.  Pigs \u2022\\t\\t6.6\u201322\\tmg/kg\\tq12\u201324h\\tIM\\tor\\t50\u2013100\\tmg\\tper\\tpig\\tPO. Cattle \u2022\\t\\t10\u201315\\tmg/kg\\tq24h\\tSQ\\t(in\\tneck)\\tfor\\t3\u20135\\tdays. Regulatory Information Cattle withdrawal time for meat: 11 days. Discoloration of meat at site of injection may persist for 15 days. Pig withdrawal time for meat: 21 days. At doses of 20 mg/kg, the withdrawal time is 30 days. Do not administer to calves to be slaughtered for veal. A milk discard time has not been established. Do not administer to dairy cattle 20 months of age or older. Spinosad spin- oh\u2032sad Trade and other names: Comfortis and Trifexis (with milbemycin)","contraindications":"Contraindications and Precautions The powder intended to be used in drinking water should not be formulated with water or saline for IV injection. This solution has produced severe pulmonary edema and death. Drug Interactions No drug interactions are reported. S Spinosad 847","indications":"Indications and Clinical Uses Spectinomycin has in vitro activity against some gram- negative bacteria and has also been administered orally for treatment of bacteria enteritis caused by Escherichia coli and as an injection for treatment of respiratory infections. Spectinomycin has been used in cattle to treat bovine respiratory disease infections caused by Pasteurella spp., Mannheimia spp., and Histophilus somni. It also has activity against Mycoplasma spp. It has been used in dogs, but this use is uncommon. The approved indication for dogs is oral treatment \u201cof infectious diarrhea and gastroenteritis caused by organisms susceptible to spectinomycin.\u201d The injectable or oral formulation is for \u201ctreatment of infections caused by gram-negative and gram-positive organisms susceptible to spectinomycin.\u201d However, these are outdated indications, and the use in small animals is uncommon. It is approved for pigs for treatment and control of infectious bacterial enteritis associated with E. coli in pigs younger than 4 weeks of age. It is also approved for poultry to be added to drinking water. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Injection- site lesions may occur from administration to cattle.","notes":"Instructions for Use Injections in cattle should be made in the neck muscle. Patient Monitoring and Laboratory Tests The Clinical and Laboratory Standards Institute (CLSI) approved breakpoint for susceptible bacteria is \u226432 mcg/mL. Formulations \u2022\\t\\tInjectable\\tsolution:\\t100-mg\\tspectinomycin\\tsulfate\\tper\\tmilliliter\\tof\\tsolution. \u2022\\t\\tThe\\tlincomycin\u2013spectinomycin\\tcombination\\tcontains\\t50\\tmg\\tof\\tlincomycin\\twith 100 mg of spectinomycin (Linco-Spectin)\\tper\\tmilliliter.\\tFormulations\\tfor\\tpoultry include 500 mg/g of water-soluble powder. \u2022\\t\\tOral\\tsolution\\tfor\\tpigs:\\t50\\tmg/mL. \u2022\\t\\tInjection\\tfor\\tdogs:\\t50-\\tor\\t100-mg/mL\\tsolution. \u2022\\t\\tTablets\\tfor\\tdogs:\\t100-mg\\ttablet. Stability and Storage Store at room temperature. Protect from freezing. Stability of compounded formulations has not been evaluated.","original_category":"Antibiotic, aminocyclitol"},{"name":"Sulfachlorpyridazine","active_ingredient":"Sulfachlorpyridazine","species":["Canine","Feline","Bovine"],"dosage":"\u2022\\t\\tNo\\tdoses\\treported\\tfor\\tdogs\\tand\\tcats.  Cattle \u2022\\t\\t33\u201350\\tmg/kg\\tq12h\\tPO\\tor\\tIV. Pigs \u2022\\t\\t22\u201339\\tmg/kg\\tq12h\\tPO\\tor\\t44\u201377\\tmg/kg/day\\tPO\\tin\\tthe\\tdrinking\\twater. Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. Cattle withdrawal time for meat: 7 days. Pig withdrawal time for meat: 4 days. Sulfadiazine sul- fa- dye\u2032a- zeen Trade and other names: Generic brands and combined with trimethoprim as Tribrissen and Equisul- SDT","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Drug Interactions Several interactions have been reported for sulfonamide administration in small animals. (See Sulfonamide.) However, these interactions have not been relevant for its use in cattle and pigs.","indications":"Indications and Clinical Uses Sulfachlorpyridazine is used as a broad- spectrum antimicrobial to treat or prevent infections caused by susceptible organisms. Infections treated may include pneumonia, intestinal infections (especially coccidia), soft tissue infections, and urinary tract infections (UTIs). However, resistance is common. The use of sulfachlorpyridazine has not been reported for small animals. It is used primarily for pigs and cattle and not used as frequently as other agents for these infections. S Sulfadiazine 859 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides (primarily in dogs) include allergic reactions, type II and III hypersensitivity, hepatotoxicity, hypothyroidism (with prolonged therapy), keratoconjunctivitis sicca (KCS), and skin reactions.","notes":"Instructions for Use The most common use of sulfachlorpyridazine is for treatment of enteritis in pigs and calves. Indications and dosages are based on the approved labeling. Patient Monitoring and Laboratory Tests Sulfonamides are known to decrease thyroxine (T 4 ) concentrations in dogs after 6 weeks of treatment. Susceptibility testing: CLSI breakpoint for susceptible organisms is \u2264256 mcg/mL, but according to CLSI, susceptibility tests for sulfonamides should only be used to interpret urinary bacteria isolates. The susceptibility test results should not be applied to testing of bovine or swine pathogens. Formulations \u2022\\t\\tSulfachlorpyridazine\\tis\\tavailable\\tin\\ta\\t2-\\tg\\tbolus\\tand\\ta\\t200-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Sulfadiazine","active_ingredient":"Sulfadiazine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t100\\tmg/kg\\tIV\\tPO\\t(loading\\tdose)\\tfollowed\\tby\\t50\\tmg/kg\\tq12h\\tIV\\tor\\tPO.\\tIn\\tthe combination with trimethoprim, it is administered at a dose of 25 mg/kg (see Trimethoprim for more information).  \u2022\\t\\tFor\\thorses,\\tsee\\tdosing\\tfor\\ttrimethoprim\\tcombinations.\\tIn\\tthe\\tcombination,\\tit\\tis administered at a dose of 25 mg/kg. Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. No withdrawal times are established. However,\\tfor\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat www.FARAD.org. Sulfadimethoxine sul- fah- dye- meth- oks\u2032een Trade and other names: Albon, Bactrovet, and generic brands","contraindications":"Contraindications and Precautions Do not administer to animals with sensitivity to sulfonamides. Doberman pinschers may be more sensitive than other canine breeds to reactions from sulfonamides. Use cautiously in this breed. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, dapsone, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increases the metabolism of cyclosporine, resulting in decreased plasma concentrations. Methenamine is metabolized to formaldehyde that may form a complex and precipitate with sulfonamides. Sulfonamides administered to horses that are receiving detomidine may develop cardiac arrhythmias. This precaution for horses is only listed for IV forms of trimethoprim\u2013sulfonamides.","indications":"Indications and Clinical Uses Sulfadiazine is used alone occasionally; however, efficacy is not established for many infections. Most often, it is used with trimethoprim to treat a variety of infections, including UTIs and skin infections. (See Trimethoprim\u2013Sulfonamides for a more complete description.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), KCS, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites. Other more toxic metabolites may persist.","notes":"Instructions for Use Usually, sulfonamides are combined with trimethoprim or ormetoprim in a 5:1 ratio, and sulfonamides are rarely used alone in small animals and horses. There is no clinical evidence that one sulfonamide is more or less toxic or efficacious than another sulfonamide. S Sulfadimethoxine 861 Patient Monitoring and Laboratory Tests Sulfonamides are known to decrease T 4 concentrations in dogs after 6 weeks of treatment. Susceptibility testing: CLSI breakpoint for susceptible organisms is \u2264256 mcg/mL, but according to CLSI, susceptibility tests for sulfonamides should only be used to interpret urinary bacteria isolates. Formulations \u2022\\t\\tSulfadiazine\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets.\\tSee\\tTrimethoprim\u2013Sulfadiazine\\tfor information on those formulations. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Sulfadimethoxine","active_ingredient":"Sulfadimethoxine","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t55\\tmg/kg\\tPO\\t(loading\\tdose)\\tfollowed\\tby\\t27.5\\tmg/kg\\tq12h\\tPO.\\t(For\\tdoses\\tof combination with ormetoprim, see Primor.)  Cattle \u2022\\t\\tTreatment\\tof\\tpneumonia\\tand\\tother\\tinfections:\\t55\\tmg/kg\\tas\\tthe\\tinitial\\tdose followed by 27 mg/kg q24h PO for 5 days. \u2022\\t\\tSustained-\\trelease\\tbolus\\t(Albon-\\tSR):\\t137.5\\tmg/kg\\tPO\\tas\\ta\\tsingle\\tdose. S Sulfamethazine 863 Regulatory Information Cattle withdrawal time for meat: 7 days. Cattle withdrawal time for milk: 60 hours. Withdrawal time for sustained- released bolus: 21 days. Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. Currently, sulfadimethoxine is the only sulfonamide with approved indications in dairy cattle. Sulfamethazine sul- fah- meth\u2032ah- zeen Trade and other names: Sulmet and generic brands","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Doberman pinschers may be more sensitive than other canine breeds to reactions from sulfonamides. Use cautiously in this breed. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, dapsone, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase the metabolism of cyclosporine, resulting in decreased plasma concentrations. Methenamine is metabolized to formaldehyde, which may form a complex and precipitate with sulfonamides. When sulfonamides are administered to horses that are receiving detomidine, these horses may develop cardiac arrhythmias. This precaution is only listed for IV forms of trimethoprim\u2013sulfonamides.","indications":"Indications and Clinical Uses Sulfadimethoxine is used as a broad- spectrum antimicrobial to treat or prevent infections caused by susceptible organisms, usually in livestock. Infections treated may include pneumonia, intestinal infections (especially coccidia), soft tissue infections, and UTIs. It is also approved for treatment of calf diphtheria and foot rot associated with Fusobacterium necrophorum susceptible to sulfadimethoxine. However, resistance is common unless combined with ormetoprim (see Primor). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), KCS, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites. Other more toxic metabolites may persist.","notes":"Instructions for Use Usually, sulfonamides such as sulfadimethoxine are rarely used alone in small animals and horses. There is no clinical evidence that one sulfonamide is more or less toxic or efficacious than another sulfonamide. Sulfadimethoxine has been combined with ormetoprim in Primor. Patient Monitoring and Laboratory Tests Sulfonamides are known to decrease T 4 concentrations in dogs after 6 weeks of treatment. Susceptibility testing: CLSI breakpoint for susceptible organisms is \u2264256 mcg/mL, but according to CLSI, susceptibility tests for sulfonamides should only be used to interpret urinary bacteria isolates. Formulations \u2022\\t\\tSulfadimethoxine\\tis\\tavailable\\tin\\t125-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\ttablets;\\t400-\\tmg/mL injection; and 50- mg/mL suspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Sulfamethazine","active_ingredient":"Sulfamethazine","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t100\\tmg/kg\\tPO\\t(loading\\tdose)\\tfollowed\\tby\\t50\\tmg/kg\\tq12h\\tPO.\\t(The use is rare in small animals.)  Cattle \u2022\\t\\tTreatment\\tof\\tpneumonia\\tand\\tother\\tinfections:\\t220\\tmg/kg\\tas\\tthe\\tinitial\\tdose followed by 110 mg/kg q24h IV. \u2022\\t\\tUse\\tof\\tsoluble\\tpowder\\tas\\ta\\tdrench\\tor\\tin\\tdrinking\\twater:\\t237\\tmg/kg\\tas\\tthe\\tinitial dose followed by 119 mg/kg q24h PO. \u2022\\t\\tSustained-\\trelease\\tbolus:\\t350\u2013400\\tmg/kg\\tPO\\tas\\ta\\tsingle\\tdose. \u2022\\tCalves:\\t180\\tmg/kg,\\tPO\\tper\\tday. Pigs \u2022\\t\\tUse\\tof\\tsoluble\\tpowder\\tas\\ta\\tdrench\\tor\\tin\\tdrinking\\twater:\\t237\\tmg/kg\\tas\\tthe\\tinitial dose followed by 119 mg/kg q24h PO. Horses \u2022\\t222\\tmg/kg\\tPO\\tper\\tday,\\ton\\tday\\t1,\\tand\\t111\\tmg/kg\\tPO\\tper\\tday\\tthereafter. Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. Cattle withdrawal time for meat: 10 or 11 days. Cattle withdrawal time for meat (soluble powder): 10 days. Pig withdrawal time for meat (soluble powder): 15 days. Cattle withdrawal time for meat (sustained- release bolus): 8\u201318 days, depending on the product. Sulfamethoxazole sul- fah- meth- oks\u2032ah- zole Trade and other names: Gantanol","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Doberman pinschers may be more sensitive than other canine breeds to reactions from sulfonamides. Use cautiously in this breed. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, dapsone, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase metabolism of cyclosporine, resulting in decreased plasma concentrations. Methenamine is metabolized to formaldehyde, which may form a complex and precipitate with sulfonamides. Sulfonamides administered to horses that are receiving detomidine may develop cardiac arrhythmias. This precaution is only listed for IV forms of trimethoprim\u2013sulfonamides. 864    Sulfamethoxazole","indications":"Indications and Clinical Uses Sulfamethazine is used as a broad- spectrum antimicrobial to treat or prevent infections caused by susceptible organisms. Infections treated may include pneumonia, intestinal infections (especially coccidia caused by Eimeria bovis and Eimeria zuernii), soft tissue infections, calf diptheria, foot rot, and UTIs. However, resistance is common, and this agent should not be considered a first- line agent for these infections. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), KCS, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites. Other more toxic metabolites may persist.","notes":"Instructions for Use Usually sulfonamides are combined with trimethoprim or ormetoprim in a 5:1 ratio. Sulfonamides such as sulfamethazine are not as effective as other agents that are used to treat infections in livestock. There is no clinical evidence that one sulfonamide is more or less toxic or efficacious than another sulfonamide. Patient Monitoring and Laboratory Tests Sulfonamides are known to decrease T 4 concentrations in dogs after 6 weeks of treatment. Susceptibility testing: CLSI breakpoint for sensitive organisms is \u2264256 mcg/mL, but according to CLSI, susceptibility tests for sulfonamides should only be used to interpret urinary bacteria isolates. Formulations \u2022\\tInjectable\\tsolution:\\t250\\tmg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Sulfamethoxazole","active_ingredient":"Sulfamethoxazole","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Antibacterial"},{"name":"Sulfaquinoxaline","active_ingredient":"Sulfaquinoxaline","species":["Canine","Feline","Bovine"],"dosage":"\u2022\\t\\tNo\\tdoses\\treported\\tfor\\tdogs\\tand\\tcats.  Calves \u2022\\t\\t13.2\\tmg/kg/day\\tPO\\t(usually\\tadministered\\tin\\tthe\\tdrinking\\twater\\tas\\ta\\t0.015% solution for 5 days). Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. Cattle withdrawal time: 10 days. Sheep withdrawal time: 10 days. Poultry withdrawal time: 10 days. Rabbit withdrawal time: 10 days. Sulfasalazine sul- fah- sal\u2032ah- zeen Trade and other names: Azulfidine and Salazopyrin (in Canada)","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Avoid contact with skin or mucous membranes when mixing in water. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, dapsone, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase the metabolism of cyclosporine, resulting in decreased plasma concentrations. Sulfonamides administered to horses that are receiving detomidine may develop cardiac arrhythmias. This precaution is only listed for IV forms of trimethoprim\u2013sulfonamides.","indications":"Indications and Clinical Uses Sulfaquinoxaline is used as a broad- spectrum antimicrobial to treat or prevent infections caused by susceptible organisms. This agent is used primarily in food animals but is not used frequently because of availability of other more effective antimicrobial agents. The approved indication for cattle is coccidiosis caused by Eimeria bovis or E. zurnii. Treatment of other infections may include pneumonia, intestinal infections, soft tissue infections, and UTIs. However, resistance is common. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects associated with sulfonamides include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), KCS, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites. Other more toxic metabolites may persist.","notes":"Instructions for Use Mix in the drinking water. Make fresh solutions daily. The most common use of sulfaquinoxaline is for treatment of enteritis caused by coccidia in calves, sheep, and poultry. 866    Sulfasalazine Patient Monitoring and Laboratory Tests Sulfonamides are known to decrease T 4 concentrations in dogs after 6 weeks of treatment. Susceptibility testing: CLSI breakpoint for sensitive organisms is \u2264256 mcg/mL, but according to CLSI, susceptibility tests for sulfonamides should only be used to interpret urinary bacteria isolates. Formulations \u2022\\t\\tSulfaquinoxaline\\tis\\tavailable\\tin\\t34.4-\\t,\\t128.5-\\t,\\t192-\\t   ,\\t200-\\t   ,\\t286.2-\\t,\\tand\\t340-\\tmg/mL solution. Some formulations have been voluntarily withdrawn by the sponsor. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Sulfasalazine","active_ingredient":"Sulfasalazine","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t10\u201330\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\t20\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle older than 20 months of age. RCI Classification: 4 868    Tacrolimus Tacrolimus tak- roe- lih\u2032mus Trade and other names: Protopic, FK506","contraindications":"Contraindications and Precautions Do not administer to animals that are sensitive to sulfonamides. Drug interactions are possible but have not been reported in animals, probably because low systemic drug concentrations are achieved. Mesalamine can potentially interfere with thiopurine methyltransferase and therefore increase the risk of toxicity from azathioprine. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, methenamine, dapsone, and etodolac. They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase metabolism of cyclosporine, resulting in decreased plasma concentrations.","indications":"Indications and Clinical Uses Sulfasalazine is used in small animals for the treatment of idiopathic colitis and other inflammatory intestinal diseases. It is often used for treatment when dietary therapy has been unsuccessful. Although sulfasalazine has been commonly used in small animals, use in animals has been primarily derived from empirical use and opinions S from gastroenterologist specialists. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. The section on mesalamine has additional information on clinical use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributed to the sulfonamide component. Adverse effects are associated with sulfonamides and include allergic reactions, type II and III hypersensitivity, hypothyroidism (with prolonged therapy), KCS, and skin reactions. KCS has been reported in dogs that received sulfasalazine for chronic treatment. The amount of salicylate absorbed appears to be small in cats; therefore, adverse effects from salicylate in cats are unlikely.","notes":"Instructions for Use Sulfasalazine is usually used for treatment of idiopathic colitis, often in combination with\\tdietary\\ttherapy.\\tFor\\tanimals\\tsensitive\\tto\\tsulfonamides,\\tconsider\\tother\\tforms\\tof mesalamine (see Mesalamine for more details). Patient Monitoring and Laboratory Tests Monitor tear production in dogs that receive chronic therapy. Formulations \u2022\\t\\tSulfasalazine\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets\\tand\\thas\\tbeen\\tcompounded\\tas\\tan\\toral suspension for smaller animals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial, antidiarrheal"},{"name":"Tetracycline, Tetracycline Hydrochloride","active_ingredient":"Tetracycline, Tetracycline Hydrochloride","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t15\u201320\\tmg/kg\\tq8h\\tPO. \u2022\\t\\t4.4\u201311\\tmg/kg\\tq8h\\tIV\\tor\\tIM. \u2022\\t\\tRickettsial\\tinfection\\t(dogs):\\t22\\tmg/kg\\tq8h\\tfor\\t14\\tdays\\tPO.  Calves and Pigs \u2022\\t\\tFor\\ttreatment\\tof\\tenteritis\\tand\\tpneumonia:\\t11\\tmg/kg\\tq12h\\tor\\t22\\tmg/kg\\tonce daily administered in the water or as a bolus. When administered in the water, the dose may actually vary among animals, depending on their water intake. Regulatory Information Cattle and pig withdrawal times: 5 days for meat with the oral powder; 18 days for meat and 72 hours for milk when used as intrauterine bolus in cattle; and 12, 14, and 24 days when oral tablets are used for intrauterine treatment, depending on product (check label of individual products). Thenium Closylate thee\u2032nee- um  kloe\u2032sill- ate Trade and other names: Canopar","contraindications":"Contraindications and Precautions Avoid repeated systemic use in young animals because it can affect bone and teeth formation. Drug Interactions Tetracyclines bind to compounds that contain calcium, which decreases oral absorption. Do not mix with solutions that contain iron, calcium, aluminum, or magnesium.","indications":"Indications and Clinical Uses Tetracyclines are used to treat a variety of infections, including soft tissue infections, pneumonia, and urinary tract infections (UTIs). Tetracycline is not often used for treatment in animals because there are few dosage forms (except topical), and other derivatives in this group are used more frequently in animals for treatment include oxytetracycline, minocycline, and doxycycline. Consult sections containing those drugs in this book for a more complete list of clinical use and indications. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tetracycline is usually used topically, and adverse reactions are rare. Tetracyclines can affect bone and teeth formation in young animals. They have been implicated in drug fever in cats. Hepatotoxicity may occur at high doses in susceptible individuals. PO administration can cause diarrhea in some animals.","notes":"Instructions for Use Pharmacokinetic and experimental studies have been conducted in small animals but not in clinical studies. Use of tetracyclines in small animals has primarily been replaced by doxycycline or minocycline. In cattle, pigs, and other large animals, the most commonly administered tetracycline is oxytetracycline, either in feed or water, or by injection. The most common oral tetracycline in horses is doxycycline or minocycline. Patient Monitoring and Laboratory Tests Tetracycline can be tested as the class representative for susceptibility to chlortetracycline, doxycycline, minocycline, and oxytetracycline. Organisms that are susceptible to tetracycline are often susceptible to the other tetracyclines. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline or minocycline or both. Susceptibility testing: Clinical and Laboratory Standards Institute (CLSI) breakpoints for sensitive organisms are \u22642 mcg/mL for streptococci and \u22644 mcg/ mL for other organisms, based on the human breakpoint. However, on the basis of plasma concentrations achieved in animals, the human breakpoint cannot always be extrapolated to predict susceptibility of pathogens from animals. When testing Staphylococcus spp. from dogs, the breakpoint for susceptible isolates is \u22640.25 mcg/ mL. When using tetracycline to test for susceptibility to oxytetracycline in pathogens from cattle, use a breakpoint of \u22642 mcg/mL for susceptible bacteria. When using tetracycline to test for susceptibility to oxytetracycline in pathogens from swine, use a breakpoint of \u22640.5 mcg/mL for susceptible bacteria. Formulations \u2022\\t\\tTetracycline\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules,\\t500-\\tmg\\tcalf\\tbolus,\\t100-\\tmg/ mL\\toral\\tsuspension,\\tand\\t25\\tand\\t324\\tg/lb\\tof\\tpowder. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Tetracycline has poor aqueous solubility. However, tetracycline hydrochloride is more soluble (100 mg/mL). The pH of tetracycline hydrochloride solution T Thenium Closylate 885 is approximately 2.0. It decomposes if kept at an alkaline pH. Tetracycline hydrochloride is unstable, and compounded preparations are better prepared from tetracycline base as a suspension. Tetracycline darkens with exposure to light. Protect from freezing.","original_category":"Antibacterial"},{"name":"Ticarcillin Disodium","active_ingredient":"Ticarcillin Disodium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t33\u201350\\tmg/kg\\tq4\u20136h\\tIV\\tor\\tIM.  Horses \u2022\\t\\t44\\tmg/kg\\tq6\u20138h\\tIV\\tor\\tIM. \u2022\\t\\tTicarcillin\\talso\\thas\\tbeen\\tused\\tin\\thorses\\tas\\tan\\tintrauterine\\tinfusion\\tat\\ta\\tdose\\tof\\t12.4 mg/kg\\tdiluted\\tin\\t60\u2013100\\tmL\\tsaline. Regulatory Information Withdrawal times are not established. However, excretion is similar to that of other beta- lactam antibiotics, such as ampicillin. Follow ampicillin guidelines for withdrawal times. Ticarcillin and Clavulanate Potassium tye- kar- sill\u2032in + klav\u2032yoo- lan\u2032ate Trade and other names: Timentin","contraindications":"Contraindications and Precautions Administer cautiously, if at all, to animals with penicillin allergies. Drug Interactions Do not combine in same syringe or in vial with aminoglycosides. 900    Ticarcillin and Clavulanate Potassium","indications":"Indications and Clinical Uses Ticarcillin has been used in animals for treatment of various infections, including pneumonia, soft tissue infections, and bone infections. It has similar activity as ampicillin but is extended to include many organisms that otherwise are resistant to ampicillin, such as Pseudomonas aeruginosa and other gram- negative bacilli. Its activity against Pseudomonas spp. may be enhanced when administered with an aminoglycoside. Use in animals has been primarily derived from empirical use and from pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) information. It is administered intravenously in most animals because IM administration can be painful. Ticarcillin also has been infused directly in the uterus of horses to treat metritis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are uncommon. However, allergic reactions are possible. High doses can produce seizures and decreased platelet function.","notes":"Instructions for Use Ticarcillin may be combined with clavulanic acid (see Ticarcillin and Clavulanate for more details). Ticarcillin is synergistic with and often combined with aminoglycosides (e.g.,\\tamikacin\\tand\\tgentamicin).\\tLidocaine\\t(1%)\\tmay\\tbe\\tused\\tfor\\treconstitution\\tto decrease pain from IM injection (see Formulations). Patient Monitoring and Laboratory Tests Susceptibility testing: CLSI breakpoints for sensitive organisms are \u226464\\tmcg/mL\\tfor Pseudomonas spp. and \u226416\\tmcg/mL\\tfor\\tgram-\\tnegative\\tenteric\\torganisms. Formulations \u2022\\t\\tNote:\\tThe\\tavailability\\tof\\tcommercial\\tformulations\\tmay\\tbe\\tlimited.\\tTicarcillin has\\tbeen\\tavailable\\tin\\t3-\\tg\\tvials.\\tMix\\ta\\t3-\\tg\\tvial\\twith\\t6\\tmL\\tof\\tsterile\\twater,\\tsodium chloride,\\tor\\t1%\\tlidocaine\\thydrochloride\\tsolution\\t(without\\tepinephrine)\\tto\\tproduce a\\tfinal\\tconcentration\\tof\\t384.6\\tmg/mL.\\tTicarcillin\\t+\\tclavulanate\\talso\\thas\\tbeen\\tused, but commercial forms have been voluntarily withdrawn from the market. (See the next section for more information.) Stability and Storage Store powder for injection in original vial, protected from light, and at room temperature. Use reconstituted solution immediately. If diluted for IV administration with\\tsodium\\tchloride\\tor\\t5%\\tdextrose,\\tit\\tmay\\tbe\\tstable\\tfor\\tup\\tto\\t72\\thours\\tat\\troom temperature or 14 days if refrigerated. IV solution prepared in lactated Ringer\u2019s solution is stable for up to 48 hours at room temperature or 14 days if refrigerated. If diluted\\tIV\\tsolutions\\tare\\tfrozen,\\tthey\\tare\\tstable\\tfor\\tup\\tto\\t30\\tdays\\tbut\\tshould\\tbe\\tused within 24 hours after being thawed. Do not refreeze thawed solutions.","original_category":"Antibacterial"},{"name":"Ticarcillin and Clavulanate Potassium","active_ingredient":"Ticarcillin and Clavulanate Potassium","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Antibacterial"},{"name":"Tildipirosin","active_ingredient":"Tildipirosin","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tNo\\tsmall\\tanimal\\tdoses\\thave\\tbeen\\testablished.  Cattle \u2022\\t\\t4\\tmg/kg\\t(equivalent\\tto\\t1\\tmL/100\\tlb)\\tSQ\\t(neck)\\tas\\ta\\tsingle\\tinjection. Pigs \u2022\\t\\t4\\tmg/kg\\t(equivalent\\tto\\t1\\tmL/10\\tkg)\\tIM\\tas\\ta\\tsingle\\tinjection.\\tCheck\\tapproval status in each country before considering use. It is not approved in the United States. Horses \u2022\\t\\tNo\\tdosing\\tinformation\\tis\\tavailable\\tfor\\thorses. Regulatory Information No milk withdrawal times are established. Do not use in female dairy cattle 20 months of age or older. Do not use in veal calves. Cattle withdrawal time for meat: 21 days. Pig withdrawal time for meat: 7 days. Tiletamine and Zolazepam till- eh\u2032tah- meen  and  zole- az\u2032eh- pam Trade and other names: Telazol and Zoletil","contraindications":"Contraindications and Precautions The FDA- approved label in the United States lists the following precautions: For subcutaneous injection in beef and nonlactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. Do not use tildipirosin (Zuprevo) in swine. Fatal adverse events have been reported after the use of tildipirosin in swine. Drug Interactions No drug interactions have been reported. Macrolide antibiotics may interfere with cytochrome P450 enzyme activity, but this has not been studied for tildipirosin. Antibacterial activity is decreased in an acidic environment.","indications":"Indications and Clinical Uses Tildipirosin has been approved for the treatment and control/prevention of cattle with bovine respiratory disease (BRD) associated with M. haemolytica, P. multocida, and H. somni and in some European countries (but not the United States) for the treatment of pigs with swine respiratory disease (SRD) associated with A. pleuropneumoniae, P. multocida, B. bronchiseptica, and H. parasuis. The use in other animals for treatment of respiratory disease has not been reported. Other long- acting macrolide antibiotics used in cattle include tilmicosin, tulathromycin, and gamithromycin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Serious systemic adverse reactions have not been observed. In cattle, tildipirosin injection may cause injection- site swelling and inflammation, which may be severe.\\tSwelling\\tand\\tvisible\\tlesions\\tin\\tedible\\ttissue\\tcan\\tpersist\\tat\\tleast\\t35\\tdays\\tafter injection. Adverse effects may be seen in pigs. See Contraindications and Precautions. Because of structural similarities between tildipirosin and tilmicosin (both are 16-\\t membered\\tmacrolides),\\tcardiotoxic\\tstudies\\twere\\tperformed\\tin\\tdogs.\\tAt\\t10 mg/kg IM, there was no effect, and at 20 mg/kg, there were changes in pulse pressure. In an oral dose study in dogs, there were no electrocardiogram (ECG) changes\\tafter\\tsingle\\t(300\\tmg/kg\\tbody\\tweight)\\tor\\trepeated\\t(150\\tor\\t200\\tmg/kg daily for 2 days and 200 mg/kg daily for 7 days) doses.","notes":"Instructions for Use In cattle, administer as a single SQ injection in the neck. Do not inject more than 10 mL per injection site. In pigs (in countries where approved), administer as a single IM injection. Patient Monitoring and Laboratory Tests The CLSI breakpoints for susceptible bacteria are \u22644 mcg/mL for P. multocida in pigs and M. haemolytica in cattle; \u22648 mcg/mL for B. bronchiseptica in pigs, H. somni in cattle, and P. multocida in cattle; and \u226416\\tmcg/mL\\tfor\\tA. pleuropneumoniae in pigs. T Tiletamine and Zolazepam 903 Formulations Tildipirosin\\tis\\tavailable\\tin\\ta\\t180-\\tmg/mL\\t(18%)\\tsolution\\tfor\\tinjection\\tfor\\tcattle\\tand,\\tin some European countries, 40- mg/mL solution for injection for pigs. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial, Macrolide"},{"name":"Tilmicosin Phosphate","active_ingredient":"Tilmicosin Phosphate","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tIt\\tis\\tnot\\trecommended\\tfor\\tsmall\\tanimals. T Tiludronate Disodium 907  Cattle \u2022\\t\\t10\u201320\\tmg/kg\\tSQ\\tsingle\\tdose.\\tAvoid\\tIV\\tor\\tIM\\tadministration. \u2022\\t\\tAdded\\tto\\tfeed:\\t568\u2013757\\tg\\tper\\tton\\tof\\tfeed\\tto\\tprovide\\t12.5\\tmg/kg\\tbody\\tweight\\tfor 14 days. Sheep \u2022\\t\\t10\\tmg/kg\\tSQ\\tsingle\\tdose. Goats \u2022\\t\\tDo\\tnot\\tuse. Horses Do not use. Safety not established. Pigs \u2022\\t\\tPneumonia:\\t181\u2013383\\tg\\tper\\tton\\tof\\tfeed.\\tFeed\\tonly\\tthis\\tration\\tfor\\t21\\tdays, beginning at the time of disease outbreak. \u2022\\t\\tDrinking\\twater:\\tAdd\\t200\\tmg\\ttilmicosin/L\\t(200\\tppm)\\tfor\\t5\\tconsecutive\\tdays. Regulatory Information Cattle withdrawal time for meat: 28 days. No withdrawal time established for milk; if injected intramammary to lactating cows, discard milk for a minimum of 82 days. Pig withdrawal time for meat: 7 days. Sheep withdrawal time for meat: 28 days. Tiludronate Disodium til- u- droe\u2032nate  dye- soe\u2032dee- um Trade and other names: Tildren (veterinary form) and Skelid (human form)","contraindications":"Contraindications and Precautions Do not administer intravenously to any species. People handling tilmicosin should take precautions to prevent accidental injection. Fatal cardiac reactions caused by injections have been reported in people and accidental injection in people requires immediate treatment. People who receive an accidental injection should be taken to an emergency facility for treatment immediately. Treatment consists of beta- adrenergic agonists (e.g., dobutamine) and supportive care. Tilmicosin reaches high concentrations in milk for up to 42 days. Do not administer to lactating dairy cattle. Do not administer to goats. Do not allow horses or other equine access to feeds containing tilmicosin. Do not administer to any animals intravenously or death can result. Drug Interactions The cardiac adverse effects are exacerbated by administration of beta blockers such as propranolol. Dobutamine and administration of calcium may offset cardiac effects.","indications":"Indications and Clinical Uses Tilmicosin is active against respiratory pathogens and is effective for prevention and treatment of BRD and ovine respiratory disease in sheep associated with M. haemolytica. One injection has duration of at least 72 hours, based on prolonged half- life. When used to control BRD in calves that are entering feedlots, the use of tilmicosin at the time of feedlot arrival has reduced incidence of respiratory disease in cattle. Tilmicosin can also be added to feed of cattle for the control of BRD associated with M. haemolytica, P. multocida, and H. somni in groups of beef and nonlactating dairy\\tcattle\\twhen\\tactive\\tBRD\\thas\\tbeen\\tdiagnosed\\tin\\tat\\tleast\\t10%\\tof\\tthe\\tanimals\\tin\\tthe group. Tilmicosin (Pulmotil) is used in medicated feed and water for swine for control of SRD associated with A. pleuropneumoniae, P. multocida, and H. parasuis. It should not be injected in pigs. Other long- acting macrolide antibiotics used in cattle include gamithromycin, tildipirosin, and tulathromycin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tilmicosin may be cardiotoxic in some animals. Injections to pigs have been fatal because of cardiotoxicity. The cardiac effects are increased heart rate and decreased contractility. However, administration of tilmicosin oral premix in feed of pigs has been safe. In dogs, tilmicosin injections have caused cardiac toxicosis and may be caused by calcium- channel blockade; it was reversed by administration of calcium. In goats, injections greater than 10 mg/kg IM or SQ can cause toxicity. In horses, injections of tilmicosin IM or SQ greater than 10 mg/kg can lead to toxicity.","notes":"Instructions for Use Administer SQ. If a person handling the drug is accidentally injected, consult a physician immediately. Severe cardiac toxicity has occurred in some species of animals. Tilmicosin can also be added to feed and drinking water for pigs. Patient Monitoring and Laboratory Tests Susceptibility information: CLSI breakpoints for susceptible organisms are \u22648 mcg/mL for bovine respiratory pathogens and \u226416\\tmcg/mL\\tfor\\tswine\\trespiratory pathogens. Formulations \u2022\\t\\tTilmicosin\\tis\\tavailable\\tin\\t300-\\tmg/mL\\tinjection\\t(Micotil)\\tand\\t200\\tg/kg\\t(90.7\\tg/ lb) of premix (Pulmotil). For mixing with water for pigs, it is available as 250 mg/ mL of tilmicosin. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial"},{"name":"Tobramycin Sulfate","active_ingredient":"Tobramycin Sulfate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t9\u201314\\tmg/kg\\tq24h\\tSQ,\\tIM,\\tor\\tIV. \u2022\\t\\tNebulization\\ttherapy\\tis\\tsometimes\\tused\\tin\\tsmall\\tanimals.\\t(See\\tInstructions\\tfor\\tUse for details on nebulization therapy.) Cats \u2022\\t\\t5\u20138\\tmg/kg\\tq24h\\tSQ,\\tIM,\\tor\\tIV.  Horses \u2022\\t\\t4\\tmg/kg\\tattains\\ttargeted\\tconcentrations\\tfor\\tmost\\tbacteria,\\tbut\\tto\\treach\\tthe\\ttarget for bacteria at the breakpoint of 4 mcg/mL, a dose of 7.2 mg/kg is needed. These doses may be administered IV or IM once daily. Regulatory Information Do not administer to animals intended for food or animals that produce food. Other drugs in this class require extralabel withdrawal times of 18 months. Tocainide Hydrochloride toe- kay\u2032nide  hye- droe- klor\u2032ide Trade and other names: Tonocard","contraindications":"Contraindications and Precautions Avoid use in patients with kidney disease. Aminoglycosides may exacerbate already- existing renal compromise. When used with anesthetic agents, neuromuscular blockade is possible. Do not mix in a vial or syringe with other antibiotics. Drug Interactions Avoid mixing in vials with other drugs. It is incompatible with other antibiotics, and inactivation occurs rapidly.","indications":"Indications and Clinical Uses Tobramycin, like other aminoglycosides, is used to treat serious systemic infections caused by gram- negative bacteria. It is often administered simultaneously with beta- lactam antibiotics to broaden the spectrum to include more gram- positive bacteria and anaerobes. It may produce a synergistic effect against some bacteria, but whether or not this translates to clinical effects is uncertain. The infections treated with tobramycin include pneumonia, soft tissue infections, and sepsis. Like many off- label antibiotics in animals, the use in animals has been primarily derived from empirical use and from PK\u2013PD information. Tobramycin has also been used topically. It has been used in nebulizing solutions for respiratory infections. For nebulization, there is a unique formulation used in people (Tobi) that is without preservatives and is intended to treat infections caused by P. aeruginosa in the airways of human cystic fibrosis patients. After administration by this route, tobramycin remains concentrated primarily in the airways, and concentrations in plasma or serum are very low and unlikely to cause toxicity. This method of administration has been used in veterinary patients, but the efficacy has not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nephrotoxicity is the most dose- limiting toxicity. Ensure that patients have adequate fluid and electrolyte balance during therapy. Ototoxicity and vestibulotoxicity also are possible.","notes":"Instructions for Use Inject intravenously or intramuscularly. Synergistic effects with beta- lactam antibiotics have been demonstrated in vitro, but it is not known if this translates to a clinical effect. For nebulization treatment of respiratory infections, dosing guidelines for animals have not been determined. In people (including pediatric patients), the nebulization\\tprotocol\\tuses\\tan\\tadministration\\tof\\t300\\tmg\\tof\\ttobramycin\\t(total\\tdose) 914    Tocainide Hydrochloride twice daily for 28 days. The solution used for nebulization (in individual packets with no preservatives) is called Tobi, but it is more expensive than injectable formulations. Tobramycin injectable has been used instead, but it contains preservatives that could induce\\tbronchospasm.\\tIf\\tthis\\tform\\tis\\tused\\tin\\tanimals,\\tuse\\tdiluted\\ttobramycin\\twith\\t3 mL of saline and administer albuterol before nebulization to decrease bronchospasm. Patient Monitoring and Laboratory Tests Susceptibility testing: The CLSI MIC value breakpoint for susceptibility is \u22644 mcg/ mL. Monitor blood urea nitrogen, creatinine, and urine for evidence of kidney injury. Blood concentrations can be monitored to detect problems with systemic clearance. When monitoring trough levels in a patient dosed once daily, the trough levels should be below the limit of detection. Alternatively, measure half- life from samples taken at 1 hour and 2\u20134 hours after dosing. Clearance should be above 1.0 mL/kg/min, and the half- life should be less than 2 hours. Formulations \u2022\\t\\tTobramycin\\tis\\tavailable\\tin\\t40-\\tmg/mL\\tinjections.\\tThe\\tsolution\\tfor\\tnebulization (Tobi)\\tis\\t60\\tmg/mL\\tcontained\\tin\\t5-\\tmL\\tampules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Store powder at room temperature. Reconstituted solutions are stable for 24 hours at\\troom\\ttemperature\\tand\\t96\\thours\\trefrigerated.\\tDo\\tnot\\tuse\\tdiscolored\\tsolutions. Tobramycin\\tsulfate\\tdiluted\\tin\\tfluids\\tcan\\tbe\\tfrozen\\tand\\tstable\\tfor\\t30\\tdays.\\tOphthalmic solutions have been compounded and shown to be stable for 90 days. Do not mix in a vial or syringe with other antibiotics, especially beta- lactam agents (penicillins and cephalosporins) because inactivation may occur.","original_category":"Antibacterial"},{"name":"Trimethoprim and Sulfadiazine","active_ingredient":"Trimethoprim and Sulfadiazine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats Doses are listed as the combined sulfonamide and trimethoprim. \u2022\\t\\t15\\tmg/kg\\tq12h\\tPO\\tor\\t30\\tmg/kg\\tq12\u201324h\\tPO. \u2022 \\t \\tToxoplasma\\tinfection:\\t30\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t\\tThe\\tapproved\\tlabel\\tdosage\\tfor\\tthe\\toral\\tsuspension\\tis\\t24\\tmg/kg\\t(20\\tmg/kg\\tof sulfadiazine and 4 mg/kg of trimethoprim) twice daily for 10 days. Many equine clinicians\\tuse\\ta\\tslightly\\thigher\\tdosage\\tof\\t25\u201330\\tmg/kg\\t(approximately\\t25\\tmg\\tof sulfonamide and 5 mg of trimethoprim) q12h PO for most treatments. Cattle \u2022\\t\\tNo\\tapproved\\tdoses\\thave\\tbeen\\testablished.\\tTrimethoprim\\tis\\tnot\\tabsorbed\\torally in ruminants, but it is absorbed in calves. Trimethoprim and sulfadoxine has been T Trimethoprim and Sulfamethoxazole 945 used\\tin\\tcattle\\t(16\\tmg/kg\\tcombined\\tdrug\\tevery\\t24\\thours\\tIV\\tor\\tIM),\\tbut\\tthis combination is not available in the United States. Regulatory Information Withdrawal times are not available. Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle. Do not use in horses intended for food. Trimethoprim and Sulfamethoxazole trye- meth\u2032oh- prim  and  sul- fah- meth- oks\u2032ah- zole Trade and other names: Bactrim, Septra, and generic brands","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Doberman pinschers may be more sensitive than other canine breeds to reactions from sulfonamides. Use cautiously in this breed. At the first sign of potential adverse drug reaction in dogs, discontinue treatment and substitute another antibiotic and pursue appropriate diagnostic tests. If diarrhea develops in horses, discontinue treatment. Pregnancy precaution: Use in pregnant mares is justified when the benefits outweigh the risk to the fetus. Use of potentiated sulfonamides during pregnancy has been associated with increased risk of congenital abnormalities that may be caused by folate deficiency. In humans, sulfonamides exposure to the newborn (via placenta and milk) can cause hyperbilirubinemia- induced neurotoxicity. However, this syndrome has not been described in animals. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, dapsone, and some NSAIDs (etodolac). They may potentiate adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase metabolism of cyclosporine, resulting in decreased plasma concentrations. The urinary antiseptic methenamine is metabolized to formaldehyde, which may form a complex and precipitate with sulfonamides. Sulfonamides administered to horses that are receiving detomidine may develop cardiac arrhythmias. This precaution is only listed for IV forms of trimethoprim and sulfonamides.","indications":"Indications and Clinical Uses Trimethoprim and sulfadiazine is used to treat a variety of infections in dogs, cats, horses, and some exotic animals. For many indications, the use of trimethoprim\u2013 sulfadiazine and trimethoprim\u2013sulfamethoxazole has been interchangeable. The combination has efficacy for susceptible bacterial infections (gram- negative and T gram- positive bacteria), including respiratory infections, soft tissue and skin infections, wounds, abscesses, and urogenital infections. In horses, the combination has been used for respiratory infections, joint infections, abdominal infections, prostate infections, soft tissue infections, and infections of the CNS. In horses, it is approved for treatment of respiratory infections caused by Streptococcus equi for 10 days. The combination also is used occasionally for infections caused by protozoa (e.g., coccidial and Toxoplasma infections). The combination has not been successful for treating infections in abscesses or infections caused by anaerobic bacteria, possibly because of interactions with material in necrotic tissues. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In horses, oral administration of trimethoprim and sulfonamides may be associated with diarrhea. Other effects observed in horses include idiosyncratic neurologic reactions consisting of behavior changes, gait abnormalities, and hyperesthesia. These effects improved soon after discontinuing the medication. Adverse effects associated with sulfonamides in dogs include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, keratoconjunctivitis sicca (KCS), and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites; therefore, more toxic metabolite may accumulate in some animals. Dogs should be observed for signs of adverse reactions because some of these problems may resemble other disease (e.g., arthropathy, hepatopathy, skin reactions). Trimethoprim and sulfonamides may decrease thyroid hormone after treatment in dogs. Effects on thyroid function are most apparent after 2 weeks of treatment, but they are reversible.","notes":"Instructions for Use The\\tdose\\tlisted\\tin\\tthe\\tdosing\\tsection\\tis\\tof\\tthe\\tcombined\\tcomponents.\\tThus,\\t30 mg/kg = 5 mg/kg of trimethoprim and 25 mg of sulfonamide. There is evidence that\\t30\\tmg/kg\\tonce\\tper\\tday\\tis\\tefficacious\\tfor\\tcanine\\tpyoderma,\\tbut\\tfor\\tother infections,\\t30\\tmg/kg\\ttwice\\tdaily\\thas\\tbeen\\trecommended.\\tOral\\ttrimethoprim\\tis\\tnot absorbed in ruminants. Patient Monitoring and Laboratory Tests Culture and susceptibility testing: All susceptibility testing is based on a 1:19 ratio of trimethoprim:sulfonamide. The CLSI breakpoint for susceptible organisms is \u22642/38\\tmcg/mL.\\tFor\\tstreptococci,\\tthis\\tbreakpoint\\tis\\t\u22642/38\\tmcg/mL.\\tValues\\tlisted are the concentration of trimethoprim:sulfonamide ratio and are based on human breakpoints. There are no specific breakpoints established for animals. Trimethoprim and sulfonamides may affect the monitoring of thyroid hormones. In dogs, trimethoprim and sulfadiazine may cause a functional hypothyroidism and lower total thyroid T 4 concentrations. Trimethoprim and sulfamethoxazole decreased thyroid\\tfunction\\tat\\t30\\tmg/kg\\tq12h\\tand\\tat\\t15\\tmg/kg\\tq12h.\\tTrimethoprim\\tand sulfadiazine at 15 mg/kg q12h for 4 weeks did not affect thyroid function in one study. Effects of trimethoprim and sulfonamides on thyroid function in dogs are reversible. In horses, trimethoprim and sulfadiazine did not affect assays of thyroid function. Monitor tear production in treated dogs because sulfonamides may produce KCS. Formulations \u2022\\t\\tTablets:\\tTrimethoprim\\tand\\tsulfadiazine\\thas\\tbeen\\tavailable\\tin\\t30-\\t,\\t120-\\t   ,\\t240-\\t   , 480-\\t  ,\\tand\\t960-\\tmg\\ttablets.\\t(All\\tformulations\\thave\\ta\\tratio\\tof\\t5:1,\\tsulfadiazine\\tto trimethoprim.) However, some tablet sizes have become unavailable. \u2022\\t\\tEquine\\tformulations:\\tAvailable\\tas\\tan\\toral\\tpaste\\tand\\tsuspension\\t(333\\tmg\\tof sulfadiazine\\tand\\t67\\tmg\\tof\\ttrimethoprim)\\tfor\\thorses.\\tAs\\ta\\tpowder\\tfor\\thorses,\\teach gram\\tcontains\\t67\\tmg\\tof\\ttrimethoprim\\tand\\t333\\tmg\\tof\\tsulfadiazine.\\tIt\\thas\\talso\\tbeen available\\tas\\ta\\t48%\\tinjectable\\tsuspension\\tfor\\thorses,\\tbut\\tthe\\tavailability\\tof\\tinjectable formulations has diminished. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antibacterial"},{"name":"Trimethoprim and Sulfamethoxazole","active_ingredient":"Trimethoprim and Sulfamethoxazole","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats Doses are listed as the combined sulfonamide and trimethoprim. \u2022\\t\\t15\\tmg/kg\\tq12h\\tPO\\tor\\t30\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t\\t30\\tmg/kg\\tq12h\\tIV.\\t(See\\tInstructions\\tfor\\tUse\\tfor\\tpreparation\\tof\\tIV\\tformulation.)  Horses \u2022\\t\\t30\\tmg/kg\\t(25\\tmg\\tof\\tsulfonamide\\tand\\t5\\tmg\\tof\\ttrimethoprim)\\tq12h\\tPO.\\tConsult protocols for trimethoprim\u2013sulfadiazine for more specific instructions. Cattle \u2022\\t\\tNo\\tdose\\tis\\testablished.\\tTrimethoprim\\tis\\tnot\\tabsorbed\\torally\\tin\\truminants,\\tbut\\tit is absorbed in calves. The combination of trimethoprim and sulfadoxine has been used\\tin\\tcattle\\t(16\\tmg/kg\\tcombined\\tdrug\\tevery\\t24\\thours\\tIV\\tor\\tIM),\\tbut\\tthis\\tdrug is not available in the United States. Regulatory Information Extralabel use of sulfonamides is prohibited from use in lactating dairy cattle. However, trimethoprim and sulfadoxine has a withdrawal time in Canada for cattle of 10\\tdays\\tfor\\tmeat\\tand\\t96\\thours\\tfor\\tmilk. 948    Tripelennamine Citrate and Tripelennamine Hydrochloride Tripelennamine Citrate and Tripelennamine Hydrochloride tri- peh- len\u2032eh- meen  sih\u2032trate Trade and other names: Pelamine, Histanin, and PBZ","contraindications":"Contraindications and Precautions Do not administer in animals with sensitivity to sulfonamides. Doberman pinschers may be more sensitive than other canine breeds to reactions from sulfonamides. Use cautiously in this breed. The injectable preparation contains benzyl alcohol, which may cause reactions in small patients. The injectable preparation should be diluted and injected slowly intravenously using instructions listed later. At the first sign of potential adverse drug reaction, discontinue treatment and substitute another antibiotic and pursue appropriate diagnostic tests. If horses develop diarrhea, treatment should be discontinued. Drug Interactions Sulfonamides may interact with other drugs, including warfarin, dapsone, and some NSAIDs (etodolac). They may potentiate the adverse effects caused by methotrexate and pyrimethamine. Sulfonamides increase metabolism of cyclosporine, resulting in decreased plasma concentrations. The urinary antiseptic methenamine is metabolized to formaldehyde, which may form a complex and precipitate with sulfonamides. Sulfonamides administered to horses that are receiving detomidine may develop cardiac arrhythmias, but this precaution is only listed for IV forms of trimethoprim and sulfonamides.","indications":"Indications and Clinical Uses The combination of trimethoprim and sulfamethoxazole has been used to treat a variety of infections in dogs, cats, horses, and some exotic animals. For many indications, the use of trimethoprim\u2013sulfadiazine and trimethoprim\u2013 sulfamethoxazole has been interchangeable. Trimethoprim is used for treatment of UTIs, skin and soft tissue infections, prostate infections, pneumonia, and CNS infections. The combination also is used occasionally for infections caused by protozoa (e.g., coccidial and Toxoplasma infections). In horses, trimethoprim\u2013sulfamethoxazole has been used for respiratory infections, joint infections, abdominal infections, soft tissue infections, and infections of the CNS. However, there is more information available for the equine- approved formulation of trimethoprim\u2013sulfadiazine. The combination of trimethoprim\u2013sulfonamide has not been successful for treating infections in abscesses or infections caused by anaerobic bacteria. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In horses, oral administration of trimethoprim and sulfonamides may be associated with diarrhea. Other effects observed in horses include idiosyncratic neurologic reactions consisting of behavior changes, gait abnormalities, and hyperesthesia. These effects improved soon after discontinuing the medication. Adverse effects associated with sulfonamides administered to dogs include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, KCS, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites and higher levels of more toxic metabolites. Dogs should be observed for signs of adverse reactions because some of these problems may resemble other disease (e.g., arthropathy, hepatopathy, skin reactions). Trimethoprim and sulfonamides may decrease thyroid hormone after treatment in dogs. Effects on thyroid function are most apparent after 2 weeks of treatment, but they are reversible.","notes":"Instructions for Use The\\tdosage\\tlisted\\tis\\tof\\tthe\\tcombined\\tcomponents;\\tthus,\\t30\\tmg/kg\\t=\\t5\\tmg/kg\\tof trimethoprim\\tand\\t25\\tmg\\tof\\tsulfonamide.\\tThere\\tis\\tevidence\\tthat\\t30\\tmg/kg\\tonce daily\\tis\\tefficacious\\tfor\\tpyoderma,\\tbut\\tfor\\tother\\tinfections,\\t30\\tmg/kg\\ttwice\\tdaily\\thas been recommended. When using the injectable formulation, each 5- mL vial should be\\tdiluted\\tin\\t75\u2013125\\tmL\\tof\\t5%\\tdextrose.\\tThe\\tdiluted\\tformulation\\tshould\\tthen\\tbe administered\\tby\\tIV\\tinfusion\\tover\\t60\\tminutes. Patient Monitoring and Laboratory Tests Culture and susceptibility testing: All susceptibility testing is based on a 1:19 ratio of trimethoprim:sulfonamide. The CLSI breakpoint for susceptible organisms is T \u22642/38\\tmcg/mL.\\tFor\\tstreptococci,\\tthis\\tbreakpoint\\tis\\t\u22642/38\\tmcg/mL.\\tValues listed are the concentration of trimethoprim and sulfonamide ratio and are based on human breakpoints because animal- specific breakpoints have not been established. In dogs, trimethoprim and sulfadiazine may cause a functional hypothyroidism and lower total thyroid T 4 concentrations. Trimethoprim and sulfamethoxazole decreased\\tthyroid\\tfunction\\tat\\t30\\tmg/kg\\tq12h\\tand\\tat\\t15\\tmg/kg\\tq12h. Trimethoprim and sulfadiazine at 15 mg/kg q12h for 4 weeks did not affect thyroid function in one study. Effects of trimethoprim and sulfonamides on thyroid function in dogs are reversible. In horses, trimethoprim and sulfadiazine do not affect assays of thyroid function. Monitor tear production in treated dogs because sulfonamides may produce KCS. Formulations \u2022\\t\\tOral\\tforms:\\tTrimethoprim\\tand\\tsulfamethoxazole\\tis\\tavailable\\tin\\t480-\\t\\tand\\t960-\\tmg tablets and a 240- mg/5 mL (48 mg/mL) oral suspension. (All formulations have a ratio of 5:1 sulfamethoxazole to trimethoprim.) \u2022\\t\\tInjection:\\t80\\tmg\\tof\\tsulfamethoxazole\\tand\\t16\\tmg\\tof\\ttrimethoprim\\tper\\tmilliliter\\tin 5-   mL vials or as 400 mg of sulfamethoxazole and 80 mg of trimethoprim per 5- mL injection. The solution can be further diluted; for example, the vial can be mixed by adding\\t5\\tmL\\tto\\t75\\tmL\\t5%\\tdextrose\\tsolution,\\tor\\tfor\\tlarger\\tdilutions,\\tadd\\tthe\\tvial\\tto a\\t125-\\t   mL\\t5%\\tdextrose\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Injectable formulations should be stored at room temperature and not refrigerated. Injectable\\tformulation\\tcontains\\t0.3%\\tsodium\\thydroxide.\\tAfter\\tpreparation of\\tthe\\tIV\\tsolution,\\tthe\\t80\\tmg\\tper\\t125\\tmL\\tsolution\\thas\\t6-\\thour\\tstability\\tat\\t0.64 mg/mL, the 80 mg per 100 mL solution has a stability of 4 hours at 0.8 mg/ mL, and the 80 mg per 75 mL solution has a stability of 2 hours. If upon visual inspection there is cloudiness or evidence of crystallization, the solution should be discarded.","original_category":"Antibacterial"},{"name":"Tulathromycin","active_ingredient":"Tulathromycin","species":["Feline","Bovine","Equine"],"dosage":"\u2022\\t\\tNo\\tsmall\\tanimal\\tdoses\\thave\\tbeen\\testablished. T Tylosin 951  Cattle \u2022\\t\\t2.5\\tmg/kg\\tSQ\\t(neck)\\tas\\ta\\tsingle\\tinjection\\t(1.1\\tmL\\tper\\t100\\tlb\\tfor\\t100-\\tmg/mL solution). Pigs \u2022\\t\\t2.5\\tmg/kg\\tIM\\t(neck)\\tas\\ta\\tsingle\\tinjection. Foals \u2022\\t\\t2.5\\tmg/kg\\tIM\\tonce\\tper\\tweek. Regulatory Information No milk withdrawal times are established. Do not use in female dairy cattle 20 months of age or older. Do not use in veal calves. Cattle withdrawal time for meat: 18 days when using Draxxin 100 mg/mL; when using 25 mg/mL, the withdrawal time is 22 days. Pig withdrawal time for meat: 5 days. Tylosin tye\u2032loe- sin Trade and other names: Tylocine, Tylan, and tylosin tartrate","contraindications":"Contraindications and Precautions In cattle, do not administer to female dairy cattle 20 months of age or older. In cattle, do not inject more than 10 mL per injection site. In pigs, do not inject more than 2.5 mL per injection site. Drug Interactions No drug interactions have been reported. However, macrolide antibiotics are known to inhibit some cytochrome P450 enzymes. Therefore some drugs interactions are possible but not well documented.","indications":"Indications and Clinical Uses In cattle, tulathromycin is used for treatment of BRD caused by M. haemolytica, P. multocida, and H. somni. It is also effective for treating infections caused by Mycoplasma bovis. It also may be used to prevent infections caused by these pathogens when used in high- risk calves. It is also used for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii. A single dose has been effective for bovine infectious keratoconjunctivitis (Moraxella bovis). In pigs, it has been used for control and treatment of SRD associated with A. pleuropneumoniae, P. multocida, B. bronchiseptica, Mycoplasma hyopneumoniae, and H. parasuis. In foals (extralabel use), tulathromycin has been used for treatment of pulmonary abscesses. Uses in small animals have not been explored. Other long- acting macrolide antibiotics used in cattle include tilmicosin, tildipirosin, and gamithromycin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Serious adverse reactions have not been observed except in experimental animals at high doses. Injection- site reactions are possible in some animals with swelling or irritation at the injection site. High doses (five times the dose) produce myocardial lesions in some animals. However, most animals have tolerated up to 10 times the labeled dose without toxicity. In treated foals (IM injection once per week), self- limiting diarrhea and injection- site reactions (IM injection) developed in approximately one third of the foals. It is ordinarily not administered to dogs, but in toxicity tests performed in dogs, it did not produce significant toxicity unless high doses were administered. There were no drug- related effects on heart rate, respiration rate, body temperature, blood pressure, or ECG parameters in dogs even at high doses.","notes":"Instructions for Use In cattle, administer as a single SQ injection in the neck. In pigs, administer as a single IM injection in the neck. Patient Monitoring and Laboratory Tests CLSI breakpoint for susceptible bacteria is \u226416\\tmcg/mL\\texcept\\tthat\\tswine\\tisolates\\tof A. pleuropneumoniae use a susceptible breakpoint of \u226464\\tmcg/mL. Formulations Tulathromycin is available in a 25-  and 100- mg/mL solution for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial, macrolide"},{"name":"Tylosin","active_ingredient":"Tylosin","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t7\u201315\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t\\t8\u201311\\tmg/kg\\tq12h\\tIM. \u2022\\t\\tColitis:\\t12\u201320\\tmg/kg\\tq8h\\twith\\tfood;\\tthen\\tif\\tthere\\tis\\ta\\tresponse,\\tincrease\\tthe interval to q12h and eventually to q24h. (20 mg/kg is approximately 1/8 teaspoon of tylosin phosphate or Tylan for a 20- kg dog.) Cats \u2022\\t\\t7\u201315\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t\\t8\u201311\\tmg/kg\\tq12h\\tIM.  Swine \u2022\\t\\tTreatment\\tof\\tarthritis,\\terysipelas,\\tand\\tswine\\tdysentery:\\t8.8\\tmg/kg\\tq12h\\tIM. Cattle \u2022\\t\\tPododermatitis\\tand\\tpneumonia:\\t17.6\\tmg/kg\\tq24h\\tIM. T \u2022\\t\\tSwine:\\tMedicated\\tfeed\\tdose\\tis\\tadministered\\tat\\ta\\tdose\\tof\\t22\u2013220\\tg/kg\\t(of\\tthe premix), with the dose depending on the specific product. Consult package information. Regulatory Information Pig withdrawal time for meat: 14 days. Cattle withdrawal time for meat: 21 days. Not to be used in lactating cattle. 954    Urofollitropin Urofollitropin yoo- roe- fah\u2032lih- troe- pin Trade and other names: Metrodin, FSH, and Fertinex","contraindications":"Contraindications and Precautions Do not administer orally to rodents or rabbits. Do not administer to horses. Avoid IV administration. Do not inject more than 10 mL in one IM site to avoid local reactions. Drug Interactions Although other macrolides have been associated with inhibition of cytochrome P450 enzymes, no drug interactions have been reported for animals.","indications":"Indications and Clinical Uses In cattle, tylosin is used for treatment of BRD caused by Mannheimia spp., P. multocida, and H. somni. It is used for interdigital necrobacillosis (foot rot) in cattle caused by F. necrophorum or B. melaninogenicus. In pigs, it is used for treatment of swine arthritis caused by Mycoplasma hyosynoviae, swine pneumonia caused by Pasteurella spp., swine erysipelas caused by Erysipelothrix rhusiopathiae, swine dysentery associated with Serpulina (Treponema) hyodysenteriae, and proliferative enteropathy caused by L. intracellularis. For treatment in pigs, it is also added to feed (type A\u2013medicated feed article) or drinking water. In small animals, it is used for gram- positive soft tissue and skin infections. However, this use is uncommon, and the most frequent use in dogs is for treatment of diarrhea, referred to as antibiotic- responsive diarrhea, that has not responded to other treatments. The etiology of the diarrhea is not known but may be caused by Clostridium or Campylobacter spp. For this use, the powdered formulation (swine formulation) has been added to food daily for maintenance. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tylosin may cause diarrhea in some animals. However, for oral treatment for colitis in dogs, it has been administered for several months with safety. Skin reactions have been observed in pigs. Oral administration to horses has been fatal.","notes":"Instructions for Use Tylosin is used in pigs and cattle for controlling BRD and SRD and the other diseases listed in the Indications section. It is rarely used in small animals for uses other than intestinal disease. Powdered formulation (tylosin tartrate) has been administered on food for control of signs of colitis in dogs. Tablets are approved for treatment of colitis in Canada. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tTylosin\\tis\\tavailable\\tas\\ttylosin\\tphosphate\\tand\\ttylosin\\ttartrate.\\tIt\\tis\\tavailable\\tin\\ta soluble\\tpowder\\tof\\t100\\tg/lb\\tof\\ttylosin\\tphosphate\\tor\\tapproximately\\t3\\tg\\tper\\tteaspoon \u2022\\t\\tTylosin\\ttartrate\\tis\\tequal\\tto\\t800\\tmcg/mg\\tof\\ttylosin\\tbase. \u2022\\t\\tTylosin\\tis\\tavailable\\tas\\ta\\t50-\\t\\tand\\t200-\\tmg/mL\\tinjection\\t(with\\tpropylene\\tglycol). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antibacterial, macrolide"},{"name":"Vancomycin","active_ingredient":"Vancomycin","species":["Canine","Feline","Equine"],"dosage":"convenient dosage that can be used because of the short half- life in dogs.) This dose should\\tbe\\tinfused\\tslowly\\tover\\t30\u201360\\tminutes,\\tor\\tat\\ta\\trate\\tof\\tapproximately\\t10\\tmg/ min. The total dose to be administered can be diluted in 0.9% saline or 5% dextrose solution but not alkalinizing solutions.  Dogs \u2022\\t\\t15\\tmg/kg\\tq6\u20138h\\tIV\\tinfusion.\\t(Start\\twith\\tthis\\tdose\\tq8h,\\tand\\tif\\tnecessary,\\tbased\\ton monitoring, increase interval to q6h.) \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\tLoading\\tdose\\tof\\t3.5\\tmg/kg\\tfollowed\\tby\\tCRI\\tof 1.5 mg/kg/h mixed in 5% dextrose in water. Cats \u2022\\t\\t12\u201315\\tmg/kg\\tq8h\\tIV\\tinfusion.  Horses \u2022\\t\\t4.3\u20137.5\\tmg/kg\\tq8h\\tIV\\tgiven\\tas\\tan\\tinfusion\\tover\\t1\\thour. \u2022\\t\\tRegional\\tlimb\\tperfusion:\\tInfuse\\t300\\tmg\\tdiluted\\tin\\ta\\t0.5%\\tsolution. Regulatory Information Do\\tnot\\tadminister\\tto\\tanimals\\tintended\\tfor\\tfood.\\tThe\\tFood\\tand\\tDrug\\tAdministration (FDA)\\thas\\tprohibited\\tthe\\textralabel\\tuse\\tof\\tglycopeptides\\tin\\tfood-\\tproducing\\tanimals because of a risk of producing glycopeptide- resistant bacteria. Vasopressin vay- zoe- press\u2032in Trade and other names: Arginine vasopressin (AVP), antidiuretic hormone (ADH), and Pitressin","contraindications":"Contraindications and Precautions Do not administer rapidly intravenously. It causes pain if injected by other routes (IM, SQ). Administer by slow infusion to avoid acute adverse reactions. Drug Interactions Do not mix with other drugs in infusion solution; incompatibilities are reported for many drugs. Incompatible drugs include beta- lactam antibiotics, fluoroquinolones, aminoglycosides, macrolides, propofol, anticonvulsants, corticosteroids, and furosemide. It is incompatible with alkaline solutions.","indications":"Indications and Clinical Uses Vancomycin is used for resistant strains of Staphylococcus or Enterococcus spp. in animals. It is commonly used in people as an injectable drug to treat methicillin- resistant Staphylococcus spp. and drug- resistant Enterococcus spp. It is not effective against gram- negative bacteria. The use in animals is much less frequent than in people because it is inconvenient to administer, and some countries have placed restrictions on use in animals. However, it can be valuable for treatment of enterococci or staphylococci that are resistant to other antibiotics when other options are not available. It has been administered orally to people for diarrhea caused by Clostridium spp., but this use has not been explored in animals. Occasionally, it has been used in horses intravenously, or for local infiltration, such as with regional limb perfusion. It is not allowed in food animals. V Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects reported in animals have been reported from small observational or retrospective studies. Because of limited use, a full range of possible adverse effects has not been recognized. Adverse effects in people include neutropenia, kidney\\tinjury,\\tand\\thistamine\\trelease.\\tReactions,\\tespecially\\tthose\\tassociated\\twith histamine release, are more likely with a rapid IV injection. In dogs, reactions attributed to histamine release have not been observed. Kidney injury can occur because\\tof\\toxidative\\tstress.\\tThe\\trisk\\tis\\tgreater\\tafter\\t4\u20138\\tdays\\tof\\ttreatment\\tbut resolves\\tafter\\ttreatment\\tis\\tdiscontinued.\\tCombination\\twith\\taminoglycosides\\tmay increase risk of kidney injury. Acute kidney injury (AKI) has been reported in dogs and cats, but other underlying factors (co- administered drugs, underlying disease) may have contributed to these observations. The frequency of kidney injury in people is less than in the past because the formulations used today are purer and of better quality.","notes":"Instructions for Use Vancomycin must be administered via IV infusion, although in rare instances, intraperitoneal administration has been used in people. (Oral administration is limited to intestinal infections.) Vancomycin systemic use in horses is rare. Local administration in horses via regional limb perfusion has been used for localized joint or bone infections. Doses are derived from pharmacokinetic studies in each species. In dogs, to maintain the plasma concentration between a suggested range of 10 and 30 mcg/ mL, a dosage of 15 mg/kg q8h IV is recommended. (This dosage actually produces peaks and troughs of approximately 40 and 5 mcg/mL, respectively, but it is the most Patient Monitoring and Laboratory Tests Monitoring of trough plasma concentrations is recommended to ensure proper dose. Ideally, the dose and frequency should be adjusted to maintain trough concentration above 10 mcg/mL or an area under the curve/minimum inhibitory concentration\\t(AUC/MIC) ratio greater than 400. There may be better outcomes with\\tserious\\tinfections\\twhen\\ttrough\\tconcentrations\\tare\\t15\u201320\\tmcg/mL.\\tThe\\tClinical and\\tLaboratory\\tStandards\\tInstitute\\t(CLSI)\\tguidelines\\tfor\\tsusceptibility\\ttesting\\tlist breakpoints of \u22644 mcg/mL for Enterococcus spp., \u22641 mcg/mL for Streptococcus spp., and \u22642 mcg/mL for Staphylococcus spp. Monitor kidney parameters during treatment because of the risk of AKI. 962    Vasopressin Formulations \u2022\\t\\tVancomycin\\tis\\tavailable\\tin\\t500-\\tmg\\tand\\t1-\\t,\\t5-\\t ,\\tand\\t10-\\tg\\tvials\\tfor\\tinjection. Stability and Storage Stability may be compromised if mixed with other drugs in infusion solutions. Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water and ethanol. After reconstitution with sterile water, it may be further diluted in 5% dextrose or saline. Solutions may have a dark color. After reconstitution, it is stable for 14 days either at room temperature or in the refrigerator. A concentrated solution of\\tup\\tto\\t83\\tg/L\\tis\\tstable\\tfor\\t72\\thours\\tat\\t37\xb0C.\\tSome\\tophthalmic\\tcompounded formulations are not stable and have a low pH that can be irritating to the eyes.","original_category":"Antibacterial"}]},{"category":"Antifungals","drugs":[{"name":"Amphotericin B","active_ingredient":"Amphotericin B","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tConventional\\tformulation:\\t0.5\\tmg/kg\\tq48\\th\\tIV\\t(slow\\tinfusion)\\tto\\ta\\tcumulative dose\\tof\\t4\u20138\\tmg/kg. \u2022\\t\\tLiposomal\\tformulations:\\tStart\\twith\\t0.5\\tmg/kg\\tfor\\tthe\\tfirst\\tdose;\\tthen\\tincrease\\tfrom 1 to 3 mg/kg/day for subsequent treatments if well tolerated. The IV dose should be infused over 60\u2013120 minutes for up to 9\u201312 treatments if needed. This dose may be administered three times per week or every other day. A goal for the total cumulative dose for liposomal formulations is 12\u201336 mg/kg if necessary, but many patients are transitioned to oral azole antifungal agents (e.g., itraconazole) before they reach this limit. \u2022\\t\\tIntrathecal\\tuse:\\tSee\\tprevious\\tinstructions.\\tStart\\twith\\t0.05\\t(total\\tdose)\\tq48h\\tand increase to 0.1 and 0.2 mg (total dose). \u2022\\t\\tSQ\\tdose:\\t0.5\u20130.8\\tmg/kg\\tdiluted\\tin\\t500\\tmL\\tof\\t0.45%\\tsaline\\tand\\t2.5%\\tdextrose solution for dogs weighing less than 20 kg and in 1000 mL for dogs weighing more than 20 kg. Drug concentration in fluid should not exceed 20 mg/L. Administer\\tthis\\tdose\\ttwo\\tor\\tthree\\ttimes\\tper\\tweek\\tSQ.\\tNote:\\tAn\\timportant complication from this method is sterile abscess at site of injection. \u2022 \\t \\tLeishmania\\tinfections:\\t0.5\\tmg/kg\\tIV\\tby\\tslow\\tinfusion\\ton\\talternate\\tdays\\tfor 4 weeks. (To avoid resistance, the World Health Organization has discouraged this use.) Cats \u2022\\t\\tCats\\thave\\treceived\\tsimilar\\tregimens\\tto\\tthose\\tused\\tfor\\tdogs\\t(e.g.,\\t0.25-\\tmg/kg conventional formulation). However, many clinicians will start with lower doses in cats.\\tFor\\tliposomal\\tformulations\\tin\\tcats,\\tuse\\t1\\tmg/kg\\tIV\\tthree\\ttimes\\tper\\tweek\\tfor up to 12 treatments.  Horses \u2022\\t\\t0.3\\tmg/kg\\tIV\\ton\\tday\\t1\\tfollowed\\tby\\t3\\tconsecutive\\tdays\\tand\\trepeat\\tafter\\ta\\t24-\\t\\tto 48-\\t hour\\tdrug-\\tfree\\tinterval.\\tHigh\\tcost\\tof\\ttreatment\\thas\\tprevented\\tcommon\\tusage\\tin horses. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. 50    Ampicillin and Ampicillin Sodium Ampicillin and Ampicillin Sodium am- pih- sill \u0301in Trade and other names: Omnipen, Principen, Totacillin, and Polycillin (human preparations); Omnipen- N, Polycillin- N, and Totacillin- N (injectable preparations); and Amp- Equine and Ampicillin trihydrate (Polyflex), and Ampi- Tab (veterinary preparations)","contraindications":"Contraindications and Precautions Do not use in patients who have renal disease or when renal clearance is not known. Do not use in dehydrated animals or animals with electrolyte imbalances. Drug Interactions When preparing IV solution, do not mix amphotericin B with electrolyte solutions; instead, use 5% dextrose in water. Nephrotoxicity is increased when administered with aminoglycosides.","indications":"Indications and Clinical Uses Amphotericin B is indicated in patients with a variety of systemic mycoses. It is used to treat blastomycosis, coccidioidomycosis, and histoplasmosis. It also has been used to treat leishmaniasis in dogs. It may be administered for treatment of aspergillosis, but this is not a common use in veterinary medicine, and some species of Aspergillus are resistant. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Amphotericin B produces a dose- related nephrotoxicity. It also produces fever, phlebitis, and tremors. Renal toxicity is dose dependent and cumulative. Toxicity is more likely when cumulative doses approach or exceed 6 mg/kg. With repeated use, amphotericin B can cause renal potassium wasting because of loss of potassium in the collecting duct.","notes":"formulations is that they are less toxic. These new formulations are lipid- based complexes or cholesteryl complexes of amphotericin B that allow higher doses to be administered\\twith\\tless\\tnephrotoxicity.\\tThree\\tlipid\\tformulations\\tare\\tavailable: \u2022\\t\\tAmphotericin\\tB\\tlipid\\tcomplex\\t(Abelcet,\\tABLC)\\tis\\ta\\tsuspension\\tof\\tamphotericin B complexed with two phospholipids at a concentration of 100 mg/20 mL. This formulation was shown to be safe and effective for treating blastomycosis in dogs at a\\tcumulative\\tdose\\tof\\t8\u201312\\tmg/kg\\tby\\tadministering\\t1\\tmg/kg\\tevery\\tother\\tday. \u2022\\t\\tAmphotericin\\tB\\tcholesteryl\\tsulfate\\tcomplex\\t(Amphotec,\\tABCD)\\tis\\ta\\tcolloidal dispersion of amphotericin B. It has been effective in studies in which it was administered at doses higher than the traditional amphotericin B formulation. \u2022\\t\\tThe\\tliposomal\\tcomplex\\tof\\tamphotericin\\tB\\t(AmBisome)\\tis\\ta\\tunilaminar\\tliposomal formulation. When reconstituted, it produces small vesicles of encapsulated amphotericin B. This formulation has been used safely and effectively in some dogs for blastomycosis. Instructions for Use When administering proprietary forms of liposomal amphotericin B, follow the instructions on the label carefully. Administer IV via slow infusion diluted in 5% dextrose in water and monitor renal function closely. Administer sodium chloride fluid loading IV to patients before therapy to decrease risk of renal toxicosis. Amphotericin B has been mixed as a solution of amphotericin B in which one vial of 50 mg is mixed with 40 mL of sterile water and 10 mL of Intralipid 10% (soybean oil). Doses of this mixture of 1\u20132 mg/kg have been used for treating systemic leishmaniasis.\\tFor\\tother\\tindications,\\tthis\\tmixture\\thas\\tbeen\\tadministered\\tat\\ta\\tdosage of\\t1\u20132.5\\tmg/kg\\ttwo\\ttimes\\tper\\tweek\\tfor\\t8\u201310\\ttreatments.\\tThis\\tliposomal\\tcomplex\\tof amphotericin B was used in a study for treatment of canine Leishmania infantum at a dose of 3\u20133.3 mg/kg. Although there was rapid clinical improvement, dogs remained positive for leishmaniasis. For\\tadministration\\tof\\tAbelcet\\t(liposomal\\tformulation),\\tthe\\tmost\\tcommon\\tdosage is 0.5 mg/kg IV infused over 90\u2013120 minutes for the first dose. If the first dose is tolerated, increase to 2\u20133 mg/kg on alternate days. A goal for a total accumulative dose of 12\u201336 mg/kg, but the patient can be switched to oral azole antifungal agents (e.g.,\\titraconazole)\\tbefore\\treaching\\tthis\\tlimit.\\tFor\\tIV\\tuse,\\tthe\\tdose\\tshould\\tbe\\tdiluted in\\t5%\\tdextrose\\tto\\t1\\tmg/mL\\tfor\\tinfusion.\\tFor\\tsome\\tpatients,\\tgreater\\tdilution\\t(more fluid) can be used to facilitate a slow infusion. Although intrathecal use is rare, only the conventional formulation should be used for\\tthis\\tadministration.\\tStart\\twith\\t0.05\\t(total\\tdose)\\tq48h\\tand\\tincrease\\tto\\t0.1\\tand\\t0.2 mg (total dose) if it is tolerated well. Prepare intrathecal solution with a 5- mg/mL solution in sterile water, further diluting to 0.25 mg/mL by adding 1 mL (5 mg) of the solution to another 19 mL of 5% dextrose and inject directly intrathecally. Patient Monitoring and Laboratory Tests Monitor renal function closely during treatment. After treatment, many animals have\\tan\\televated\\tcreatinine\\tand\\tBUN.\\tPersistent\\tazotemia\\tmay\\tbe\\ta\\tcause\\tfor discontinuation of treatment and replacement with another antifungal agent. Hypokalemia and hypomagnesemia may occur during use because of renal tubular acidosis. A Formulations \u2022\\t\\tThe\\tconventional\\tform\\tof\\tamphotericin\\tB\\tis\\tavailable\\tin\\ta\\t50-\\tmg\\tinjectable vial. \u2022\\t\\tLiposomal\\tforms\\tare\\tavailable\\tas\\t50-\\t\\tand\\t100-\\tmg\\tinjectable\\tvial\\t(Amphotec;\\tlipid complex). \u2022\\t\\tAmphotericin\\tB\\tphospholipid\\tcomplex\\t(Abelcet)\\tis\\tavailable\\tin\\ta\\t100\\tmg\\tvial\\tat\\t5 mg/mL. Stability and Storage Stable if stored in original vial. Amphotericin B for IV infusion reacts with light and should be protected from light during infusions. Store reconstituted solutions in refrigeration. However, unrefrigerated solutions may be stable for up to 1 week. Optimum pH is 6\u20137.","original_category":"Antifungal"},{"name":"Enilconazole","active_ingredient":"Enilconazole","species":["Equine","Feline"],"dosage":"\u2022\\t\\tNasal\\taspergillosis:\\t10\\tmg/kg\\tq12h\\tinstilled\\tinto\\tnasal\\tsinus\\tfor\\t14\\tdays\\t(10% solution\\tdiluted\\t50/50\\twith\\twater). \u2022\\t\\tDermatophytes:\\tDilute\\t10%\\tsolution\\tto\\t0.2%\\tand\\twash\\tlesion\\twith\\tsolution\\tfour times\\tat\\t3-\\t\\tto\\t4-\\tday\\tintervals.\\tSolution\\tmay\\tbe\\tsponged\\tdirectly\\ton\\tanimal.\\tAllow solution to air dry.  Horses \u2022\\t\\tDilute\\t10%\\tsolution\\tto\\t0.2%\\tand\\twash\\tlesions\\twith\\tsolution\\tfour\\ttimes\\tat\\t3-\\t\\tto 4-\\t day\\tintervals. \u2022\\t\\tTreatment\\tof\\taspergillus\\trhinitis:\\tInfuse\\tin\\tnasal\\tcatheter\\ta\\t2%\\tsolution\\tq12h (25\u2013100\\tmL). Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Enoxaparin Sodium en- oks \u0301ah- pare- in Trade and other names: Lovenox and low- molecular- weight heparin (LMWH)","contraindications":"Contraindications and Precautions No specific contraindications are reported. Drug Interactions No\\tspecific\\tinteractions\\tare\\treported.\\tHowever,\\tlike\\tother\\tazoles,\\tsystemic treatment\\tmay\\tresult\\tin\\tcytochrome\\tP450\\tenzyme\\tinhibition.","indications":"Indications and Clinical Uses Enilconazole is only used topically. It is used as a topical agent for treatment of dermatophytes;\\tas\\ta\\tspray,\\tit\\tis\\tused\\tto\\ttreat\\tthe\\tenvironment.\\tIt\\tmay\\tbe\\tapplied\\tto animal bedding, stalls, and cages. In addition to dermatologic use, enilconazole has been instilled into the nasal sinuses of dogs for treatment of nasal aspergillosis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported. However, it is reported that if used on cats, they\\tshould\\tbe\\tprevented\\tfrom\\tlicking\\tfur\\tafter\\tapplication\\tuntil\\tthe\\tdrug\\thas\\tdried.","notes":"Instructions for Use Enilconazole\\tis\\tonly\\tused\\ttopically.\\tImaverol\\tis\\tavailable\\tin\\tCanada\\tas\\t10%\\temulsion. In\\tthe\\tUnited\\tStates,\\tClinafarm\\tEC\\tis\\tavailable\\tfor\\tuse\\tin\\tpoultry\\tunits\\tas\\t13.8% solution.\\tDilute\\tsolution\\tto\\tat\\tleast\\t50:1\\tand\\tapply\\ttopically\\tevery\\t3\u20134\\tdays\\tfor\\t2\u20133 weeks.\\tEnilconazole\\talso\\thas\\tbeen\\tinstilled\\tas\\t1:1\\tdilution\\tinto\\tthe\\tnasal\\tsinus\\tfor\\tnasal aspergillosis. In addition, enilconazole has been used in a diluted form as a spray to kill\\tfungi\\ton\\tbedding,\\tequine\\ttack,\\tand\\tcages. E Enoxaparin Sodium 323 Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations Available \u2022\\t\\tEnilconazole\\tis\\tavailable\\tas\\t10%\\tor\\t13.8%\\temulsion. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. When the emulsion is mixed, it should be used immediately and not stored.","original_category":"Antifungal"},{"name":"Fluconazole","active_ingredient":"Fluconazole","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tq12h\\tPO\\tor\\tIV.\\tIn\\trefractory\\tcases,\\tincrease\\tdosage\\tto\\t10\\tmg/kg\\tq12h PO or IV. \u2022\\t\\tBlastomycosis:\\t10\\tmg/kg/day. \u2022 \\t \\tMalassezia treatment: 5 mg/kg q12h PO. Cats \u2022\\t\\t50\\tmg/cat\\tper\\tonce\\tdaily\\tPO;\\tin\\trefractory\\tcases,\\tincrease\\tto\\t50\\tmg\\tper\\tcat\\tq12h PO (10 mg/kg q12h). In most cases, it is administered once daily.  Horses \u2022\\t\\t5\\tmg/kg\\tq24h\\tPO.","contraindications":"Contraindications and Precautions Use cautiously in pregnant animals. At high doses in laboratory animals, it has caused fetal abnormalities. Drug Interactions Fluconazole can be an inhibitor of cytochrome P450 enzymes, which can increase other drug concentrations. It causes an increase in cyclosporine concentrations in dogs. It may decrease the metabolism of other drugs, such as anesthetics, sedatives (e.g., midazolam), and analgesics (tramadol). Horses administered fluconazole had prolonged recovery from anesthesia, presumably caused by decreased anesthetic metabolism. F Flucytosine 375 Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). Consult FARAD if extralabel withdrawal information is needed (www.FARAD.org). Flucytosine floo- sye\u2032toe- seen Trade and other names: Ancobon","indications":"Indications and Clinical Uses Fluconazole is effective against dermatophytes, yeasts, and a variety of systemic fungi. In dogs, cats, horses, and exotic animals, it is used to treat systemic fungal infections, yeast infections, and dermatophytes, including Malassezia dermatitis. In cats, it has been used to treat Cryptococcus infection and histoplasmosis. In dogs, it is not as active against coccidioidomycosis as other azole antifungal drugs, but it has been effective in some patients. Higher dosages may be needed (e.g., 10 mg/kg q12h) for coccidioidomycosis. It has been as effective as for treatment of blastomycosis in dogs with efficacy similar to itraconazole. Because it is water soluble, it is excreted in the urine in an active form and has been used to treat fungal cystitis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported from fluconazole administration, but it is a human- label drug, and a complete adverse event profile is not available. Compared with ketoconazole, it has less effect on endocrine function. However, increased liver enzyme concentrations and hepatopathy are possible.","notes":"Instructions for Use Doses for fluconazole are primarily based on studies performed in cats for treatment of cryptococcosis. Efficacy for other infections has not been reported. The primary difference between fluconazole and other azoles is that fluconazole attains higher concentrations in the CNS. Oral absorption of fluconazole is more predictable than itraconazole and ketoconazole and less affected by administration without food. Patient Monitoring and Laboratory Tests Monitor hepatic enzymes periodically in treated animals. Susceptibility testing is possible, but ranges are only established for Candida spp. Fluconazole may cause mild elevations of liver enzymes in some dogs. Formulations \u2022\\t\\tFluconazole\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\t150-\\t   ,\\tand\\t200-\\tmg\\ttablets;\\t10-\\t\\tand\\t40-\\tmg/ mL oral suspension; and 2- mg/mL IV injection. Stability and Storage Fluconazole is stable for 14 days after reconstituting oral suspension. Because it is water soluble at a concentration of 8\u201310 mg/mL, it also may be compounded in formulations for administration to small animals. Tablets have been crushed and mixed with liquid vehicles for oral administration. However, long- term stability of compounded formulations beyond 15 days has not been determined. Suspensions made for animals in concentrations of 30 and 100 mg/mL by compounding pharmacies had poor accuracy and precision of the formulation.","original_category":"Antifungal"},{"name":"Flucytosine","active_ingredient":"Flucytosine","species":["Canine","Feline"],"dosage":"Cats (Not Recommended For Dogs) \u2022\\t\\t25\u201350\\tmg/kg\\tq6\u20138h\\tPO,\\tup\\tto\\ta\\tmaximum\\tdosage\\tof\\t100\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tCryptococcal\\tmeningitis:\\t20\u201340\\tmg/kg\\tq6h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No withdrawal times are established for animals that are intended for food (extralabel use). Fludrocortisone Acetate floo- droe- kor\u2032tih- sone  ass\u2032ih- tate Trade and other names: Florinef","contraindications":"Contraindications and Precautions No specific contraindications have been identified for animals. Use in dogs is not recommended because of eruptions of skin reactions. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Flucytosine is an antifungal drug that has been limited in veterinary medicine to treat cryptococcal meningitis. It should be used in combination with amphotericin B (but not azole antifungal drugs) for treatment of cryptococcosis to improve efficacy and decrease resistance. The use is primarily confined to treatment of cryptococcosis in cats because it causes toxic reactions in dogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Anemia and thrombocytopenia are the most common adverse effects. Cutaneous and mucocutaneous eruptions have been observed with use of flucytosine in dogs. Therefore, it is not recommended for use in dogs.","notes":"Instructions for Use Flucytosine is used primarily to treat cryptococcosis in animals. Efficacy is based on its ability to attain high concentrations in cerebrospinal fluid. Flucytosine may be synergistic with amphotericin B. Patient Monitoring and Laboratory Tests Monitor CBC during treatment. Formulations Available \u2022\\t\\tFlucytosine\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded oral suspensions have been stable for 60 days. 376    Fludrocortisone Acetate","original_category":"Antifungal"},{"name":"Griseofulvin","active_ingredient":"Griseofulvin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tMicrosize:\\t25\\tmg/kg\\tq12h\\tPO\\tup\\tto\\ta\\tmaximum\\tdosage\\tof\\t50\u201360\\tmg/kg\\tq12h. Start\\twith\\t25\\tmg/kg\\tq12h\\tPO\\tand\\tthen\\tincrease\\tto\\t50\u201360\\tmg/kg\\tq12h\\tPO\\tfor refractory cases. \u2022\\t\\tUltramicrosize:\\t30\\tmg/kg/day\\tin\\tdivided\\ttreatments\\tPO. 422    Growth Hormone Cats \u2022\\t\\tMicrosize\\tformulation:\\t25\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t\\tDermatophytosis:\\t5.6\\tmg/kg\\tq24h\\tof\\tthe\\toral\\tmicrosize\\tpowder,\\twhich\\tmay\\tbe mixed with feed. Treatment should be continued for a minimum of 10 days. Regulatory Information No regulatory information is available for food animals. Because of potential for teratogenic effects, do not administer to food animals. Growth Hormone Trade and other names: Somatrem, Somatropin, Protropin, Humatrope, and Nutropin","contraindications":"Contraindications and Precautions Do not administer to pregnant cats. Caution should be used when administering griseofulvin to cats with viral infections (FIV) because this may exacerbate bone marrow effects. Drug Interactions Griseofulvin\\tis\\tan\\tenhancer\\tof\\tcytochrome\\tP450\\tdrug\\tenzymes.\\tTherefore,\\tother concurrent drugs may be metabolized and cleared more quickly if given with griseofulvin.","indications":"Indications and Clinical Uses Griseofulvin is one of the drugs of choice when systemic treatment is needed for dermatophyte infections caused by Microsporum spp. and Trichophyton spp. in dogs and cats. It is sometimes used in combination with topical therapy. Griseofulvin is not effective for the treatment of yeasts or bacteria. At least 4 weeks, and sometimes 3 months or more, is needed for successful therapy. Its use has been replaced by azole antifungal drugs in most cases (itraconazole, fluconazole, etc.), so the use of griseofulvin has declined. G Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects in animals include teratogenicity in cats, anemia and leukopenia in cats, anorexia, depression, vomiting, and diarrhea. In cats, feline immunodeficiency virus (FIV) infection may increase the risk of bone marrow toxicosis. Whether the bone marrow problems are caused by high doses or this is an idiosyncratic (non\u2013dose- related) reaction is not understood. These effects resolve in cats when treatment is stopped, but irreversible idiosyncratic pancytopenia has been reported.","notes":"Instructions for Use A wide range of doses has been reported. Doses listed here represent the current consensus. Oral absorption is favored in the presence of fat, and administration of the drug with a high- fat meal can tremendously enhance the extent of absorption. Two\\tformulations\\tare\\tavailable:\\tmicrosize\\tand\\tultramicrosize.\\tAdministration\\tof a formulation made up of fine particles (microsize) is preferred because the small particles improve oral absorption. Veterinary formulations are generally composed of microsize preparations, and this is reflected in the dosage regimens. If the ultramicrosized preparations are used, the dose may be decreased by half. Shake oral suspension well before using. Consider 25 mg/kg q12h initially and then increase to 50\u201360 mg/kg q12h for problem cases. Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow toxicity. Formulations \u2022\\t\\tGriseofulvin\\tis\\tavailable\\tin\\t125-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\tmicrosize\\ttablets;\\t25-\\tmg/mL oral suspension; 125- mg/mL oral syrup; and 125- , and 250- mg, ultramicrosized tablets. It is also available as microsized griseofulvin powder in 15- g pouches that contain 2.5 g of the active ingredient. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Griseofulvin is insoluble in water but is soluble in alcohol.","original_category":"Antifungal"},{"name":"Itraconazole","active_ingredient":"Itraconazole","species":["Canine","Equine","Feline"],"dosage":"Dogs \u2022\\t\\tRegardless\\tof\\tformulation\\t(oral\\tcapsule\\tor\\toral\\tsolution),\\tadminister\\ta\\tloading\\tdose of\\t20\\tmg/kg\\tfollowed\\tby\\t10\\tmg/kg\\tonce\\tq24h.\\tAlternatively,\\tthe\\tdosage\\tcan  Horses \u2022\\t\\t5\\tmg/kg/day\\t(2.5\\tmg/kg\\tq12h)\\tPO.\\tIn\\thorses,\\tthe\\tcapsules\\tare\\tabsorbed\\tpoorly and inconsistently. Use the oral solution (Sporanox) for optimum oral absorption. Regulatory Information No regulatory information is available. If itraconazole is administered to food animals, contact FARAD at www.FARAD.org for extralabel withdrawal time information. Ivermectin eye- ver- mek\u2032tin Trade and other names: Heartgard, Ivomec, Eqvalan liquid, Equimectrin, IverEase, Zimecterin, Privermectin, Ultramectin, Ivercide, Ivercare, and Ivermax. Acarexx is a topical form for cats.","contraindications":"Contraindications and Precautions Administer with food for best oral absorption. Compounded formulations are not bioequivalent to proprietary forms and should be avoided for use in animals. Use itraconazole cautiously in any animal with signs of liver disease. Use cautiously in pregnant animals. At high doses in laboratory animals, it has caused fetal abnormalities. Drug Interactions Antacid drugs (proton pump inhibitors or H 2 - receptor blockers) decrease oral absorption.\\tItraconazole\\tis\\ta\\tcytochrome\\tP450\\tenzyme\\tinhibitor.\\tIt\\tmay\\tcause drug\\tinteractions\\tbecause\\tof\\tinhibition\\tof\\tP450\\tenzymes.\\tThis\\tincreases\\tthe concentrations of other drugs administered concurrently, such as cyclosporine. The\\textent\\tof\\tcytochrome\\tP450\\tinhibition\\tmay\\tbe\\timportant\\tfor\\tmany\\tdrugs\\tthat have a narrow safety margin (see Appendixes H and I). 484    Ivermectin be\\tsplit\\tinto\\t5\\tmg/kg\\tq12h\\tPO.\\tHighly\\tsusceptible\\tfungi\\tsuch\\tas\\tsome\\tstrains\\tof Blastomyces spp. can be treated with lower doses of 5 mg/kg once daily. \u2022\\t\\tDermatophytes:\\t3\\tmg/kg/day\\tPO\\tfor\\t15\\tdays. \u2022\\t\\tCryptococcosis:\\t5\\tmg/kg\\tq12h\\tPO. \u2022 \\t \\tMalassezia\\tdermatitis:\\t5\\tmg/kg\\tq24h\\tPO\\tfor\\t2\\tdays,\\trepeated\\teach\\tweek\\tfor\\t3 weeks. Cats \u2022\\t\\tGeneral\\tinfections:\\t5\\tmg/kg\\tPO\\tonce\\tdaily.\\tAlternatively,\\t50\\tmg\\t(total\\tdose)\\tonce per day or 100 mg per cat once every other day. \u2022\\t\\tDermatophytes:\\t5\\tmg/kg\\tPO\\tonce\\tdaily\\ton\\talternating\\tweeks\\tfor\\t3\\tcycles.\\tFor example,\\ttreat\\tonce\\tdaily\\tduring\\tweeks\\t1,\\t3,\\tand\\t5,\\tbut\\tnot\\ton\\tweeks\\t2\\tand\\t4.\\tSome cats may need an additional course of therapy to eliminate the infection.","indications":"Indications and Clinical Uses Itraconazole is often considered the first choice for dermatophyte infections in cats. Itraconazole has regulatory approval for treating dermatophytes in cats but is also used for this treatment in dogs. In addition to treating dermatophytes, it is also used to treat systemic fungi, such as Blastomyces, Histoplasma, and Coccidioides spp., in a variety of species, including exotic and zoo animals. It also has been shown effective for treatment of Malassezia dermatitis, but Malassezia doses are lower than for other infections (see dosing section). Although it has been used to treat infections caused by Aspergillosis spp., efficacy has not been as good as with other antifungal drugs such as voriconazole or amphotericin B. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Itraconazole is better tolerated than ketoconazole. Ketoconazole inhibits hormone synthesis and can lower concentrations of cortisol, testosterone, and other hormones in animals. However, itraconazole has less effect on these enzymes and does not produce endocrine effects. However, vomiting and hepatotoxicity are possible with itraconazole administration, especially at high doses. Approximately 10%\u201315% of dogs develop high liver enzyme levels. Itraconazole has produced skin lesions in dogs, consisting of vasculitis, sterile suppurative skin lesions, and ulcerative skin lesions. High doses in cats caused vomiting and anorexia. I","notes":"formulations produce similar concentrations in dogs. In cats, the oral solution is absorbed approximately five times higher than the oral capsule. After absorption in cats, the half- lives are approximately 18 hours for the capsule and 25 hours for the oral solution. This produces a prolonged effect that allows for intermittent dosing (see dosing section). Instructions for Use Administer with food for best absorption unless the oral solution is used. The doses are based on studies in animals in which pharmacokinetics have been analyzed, as well as clinical studies to treat blastomycosis, histoplasmosis, dermatophytes, and other infections. Compared with systemic fungal diseases, lower doses may be used in cats and dogs for dermatophytes and in dogs for treating Malassezia dermatitis. Other less common uses or doses are based on empiricism or extrapolation from human literature. Doses in horses are based primarily on specific pharmacokinetic studies. Ordinarily, oral formulations are administered. However, it may be administered intravenously if needed. If IV solutions are used, infuse over 30 minutes. Patient Monitoring and Laboratory Tests Monitor liver enzyme concentrations. If plasma/serum drug concentrations are monitored, the trough concentration (immediately before next dose) should be in the range of 0.5\u20131 mcg/mL. Formulations Available \u2022\\t\\tItraconazole\\tis\\tavailable\\tin\\t100-\\tmg\\tcapsules\\tand\\t10-\\tmg/mL\\toral\\tliquid. \u2022\\t\\tItrafungol\\tfor\\tcats\\tis\\ta\\t10-\\tmg/mL\\toral\\tcherry-\\tflavored\\tliquid\\tsolution\\tcomplexed with cyclodextrin (52- mL bottle). This product is identical in formulation and composition to the human formulation of Sporanox solution. \u2022\\t\\tInjection\\tform\\t(if\\tavailable)\\tis\\t10\\tmg/mL\\tsupplied\\tin\\t25-\\tmL\\tampules\\t(250\\tmg). Stability and Storage Itraconazole is practically insoluble in water but is soluble in ethanol. It is unstable and may lose potency if not maintained in manufacturer\u2019s original formulation (capsules and solution). Compounded formulations are highly unstable and insoluble. Oral absorption of compounded itraconazole suspensions and capsules is poor or barely detectable and is not recommended. Oral commercial formulation (in cyclodextrin) has a pH of approximately 2.0, and the pH should be maintained to ensure optimal absorption. Do not freeze. The 10- mg/mL injection solution can reconstituted with saline (but not\\tdextrose\\tor\\tlactated\\tRinger\u2019s\\tsolution)\\tand\\tstored\\tat\\teither\\t2\xb0\\tC\u20138\xb0C\\tor\\troom temperature\\tfor\\tup\\tto\\t48\\thours\\tafter\\treconstitution.\\tDo\\tnot\\tmix\\twith\\tother\\tdrugs.","original_category":"Antifungal"},{"name":"Ketoconazole","active_ingredient":"Ketoconazole","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t10\u201315\\tmg/kg\\tq8\u201312h\\tPO. \u2022 \\t \\tMalassezia\\tinfection:\\t5\\tmg/kg\\tq24h\\tPO\\tevery\\t3\\tweeks. \u2022\\t\\tHyperadrenocorticism:\\tStart\\twith\\t5\\tmg/kg\\tq12h\\tinitially;\\tthen\\tincrease\\tafter\\t7\\tdays to\\t12\u201315\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t5\u201310\\tmg/kg\\tq8\u201312h\\tPO.  Horses Poorly absorbed. Fluconazole, itraconazole, and voriconazole are more completely absorbed. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Ketoprofen kee- toe- proe\u2032fen Trade and other names: Orudis- KT (human over- the- counter tablet), Ketofen (veterinary injection), and Anafen (outside the United States)","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. At high doses in laboratory animals, it caused embryotoxicity and fetal abnormalities. Some of these effects on pregnancy may be because of the inhibition of estrogen synthesis by ketoconazole. Drug Interactions It is a potent inhibitor of CYP3A12 and inhibits the metabolism of many drugs. Ketoconazole also inhibits the transporter P- glycoprotein. These properties inhibit metabolism and clearance of other drugs (anticonvulsants, cyclosporine, warfarin, and cisapride). This property has been used to reduce doses\\tof\\tcyclosporine\\t(ketoconazole\\tdose\\tof\\t5\u201310\\tmg/kg).\\tParticular\\tcaution should be exercised when administering ketoconazole with ivermectin. This combination may produce ivermectin toxicity by decreasing clearance and enhancing penetration across the blood\u2013brain barrier. Antacid drugs (proton pump inhibitors, H 2 -receptor antagonists) will inhibit oral absorption of ketoconazole.","indications":"Indications and Clinical Uses Ketoconazole is used in dogs, cats, and some exotic animals to treat dermatophytes and systemic fungi, such as Blastomyces, Histoplasma, and Coccidioides spp. It also has been shown effective for treatment of Malassezia dermatitis. It does not have good activity against Aspergillus spp. Ketoconazole should not be used in horses because oral absorption is poor unless administered with a highly acidic vehicle. In\\tdogs,\\tit\\thas\\ta\\tprofound\\teffect\\ton\\tcytochrome\\tP450\\tenzymes,\\twhich\\taffects metabolism\\tof\\tother\\tdrugs.\\tIt\\tis\\talso\\tvia\\tthe\\tinhibition\\tof\\tsteroid\\tP450\\tbiosynthesis\\tthat ketoconazole has been used as a short- term treatment for canine hyperadrenocorticism (canine Cushing\u2019s disease). However, for canine Cushing\u2019s disease, many animals do not respond adequately, and there are more adverse effects than with trilostane. Because of the availability of other drugs for treating hyperadrenocorticism (e.g., trilostane), ketoconazole has fallen out of use for this indication. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects in animals include dose- related vomiting (most common), diarrhea, hepatic injury, and rare thrombocytopenia in dogs. Liver enzyme elevations are common. Ketoconazole inhibits hormone synthesis and can lower concentrations of cortisol, testosterone, and other hormones in animals. Ketoconazole may produce a lighter hair coat color in some animals. It has been associated with cataract formation in dogs.","notes":"Instructions for Use Oral absorption depends on acidity in the stomach. Do not administer with drugs that decrease stomach acid, such as proton pump inhibitors (omeprazole), histamine H 2 blockers (famotidine), or antacids. Because of endocrine effects, ketoconazole has been used for short- term treatment of hyperadrenocorticism. However, many experts believe that ketoconazole is not an effective long- term treatment for canine Cushing\u2019s disease, and this use is no longer common. Trilostane is the preferred treatment for canine hyperadrenocorticism. 498    Ketoprofen Patient Monitoring and Laboratory Tests Monitor liver enzymes (alanine aminotransferase, alkaline phosphatase) for evidence of toxicity. Ketoconazole lowers serum cortisol levels. Formulations \u2022\\t\\tKetoconazole\\tis\\tavailable\\tin\\t200-\\tmg\\ttablets\\tand\\t100-\\tmg/mL\\toral\\tsuspension (Canada). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ketoconazole is practically insoluble in water but is soluble in ethanol. When ketoconazole was compounded extemporaneously from tablets with syrups and flavorings, it was stable for 60 days. However, ketoconazole requires acidity for solubility and may not be absorbed from these formulations. If compounded in alkaline conditions, it may precipitate.","original_category":"Antifungal"},{"name":"Posaconazole","active_ingredient":"Posaconazole","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tOral\\tsuspension:\\t10\\tmg/kg\\tPO\\tq24h. \u2022\\t\\tOral\\tdelayed-\\trelease\\ttablet:\\t5\\tmg/kg\\tPO,\\tinitially\\tadministered\\tq48h.\\tIn\\tsome animals, this interval has been increased to q72h or longer if trough concentrations can be maintained above the level of 0.5 mcg/mL. Cats \u2022\\t\\tFor\\tmild\\tinfections\\tor\\tfor\\tpreventive\\tuse,\\tadminister\\t15\\tmg/kg\\tPO\\tfollowed\\tby 8 mg/kg PO q48h of the oral liquid suspension. For more severe invasive fungal infections, administer an oral loading dose of 30 mg/kg followed by 15 mg/kg every other day PO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates, contact FARAD at www.FARAD.org. Potassium Chloride Trade and other names: Generic brands","contraindications":"Contraindications and Precautions No\\tcontraindications\\tand\\tprecautions\\thave\\tbeen\\treported\\tfor\\tanimals. Drug Interactions Drugs\\tthat\\tdecrease\\tstomach\\tacid\\t(PPIs,\\tH 2 blockers) reduce oral absorption of posaconazole. Like other azole antifungal drugs, posaconazole is a strong inhibitor of cytochrome P450 enzymes (CYP3A4) and may increase concentrations of other drugs metabolized by these enzymes.","indications":"Indications and Clinical Uses The use of posaconazole has been limited to a few case reports and anecdotal experience. The doses in dogs and cats are based on pharmacokinetic studies in healthy animals. In cats, it has been used to treat fungal infections such as aspergillosis and Mucor infections that were refractory to other drugs. In dogs, it has been used to treat fungal infections that were refractory to other treatments. In humans, it is used for invasive fungal infections, including those caused by Aspergillus and Candida spp. It is also active against dermatophytes, H. capsulatum, B. dermatitidis, C. immitis, and C. neoformans. Its advantage over other azole drugs is the activity against Fusarium and Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus spp. The only formulations available for systemic use are the human products, except for topical ear products for dogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The use has been relatively infrequent, and information regarding the full range of adverse effects possible from clinical use is not available. In people, similar adverse\\teffects\\thave\\tbeen\\tobserved\\tas\\twith\\tother\\tazole\\tantifungal\\tdrugs:\\theadache, diarrhea, nausea, and increased liver enzymes, but there is some indication that the safety profile may be better for posaconazole than other azoles. In toxicity studies, dogs have tolerated 30 mg/kg/day for 1 year without any clinical signs. However,\\thistologically,\\tsome\\tneuronal\\tvacuolation\\twas\\tobserved\\tat\\tthis\\tdose.\\tIt should not be used during pregnancy because of inhibition of steroidogenesis.","notes":"Instructions for Use Use in animals has been based primarily on some isolated case reports and extrapolation from human use. Dosing recommendations are based on pharmacokinetic studies in P Potassium Chloride 753 dogs\\tand\\tcats.\\tNo\\tcontrolled\\tclinical\\tstudies\\tfor\\tanimals\\thave\\tbeen\\treported.\\tThe\\toral absorption is enhanced when administered with food; therefore administer with a small meal. The injection can be administered as a loading dose in patients not amenable to oral treatment, but the injection formulation is very expensive. Patient Monitoring and Laboratory Tests Monitor liver enzymes in treated animals. Although plasma concentrations are generally not measured, trough concentrations above 0.5\u20130.7 mcg/mL for mild infections or 1 mcg/mL for severe invasive infections are associated with efficacy. Formulations \u2022\\t\\tPosaconazole\\tis\\tavailable\\tin\\ta\\t40-\\tmg/mL\\toral\\tsuspension,\\t100-\\tmg\\tdelayed-\\trelease tablet, and 18- mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antifungal"},{"name":"Potassium Iodide","active_ingredient":"Potassium Iodide","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tFungal\\tinfections:\\tstart\\twith\\t5\\tmg/kg\\tq8h\\tPO\\tand\\tincrease\\tgradually\\tto\\t25\\tmg/kg q8h PO. \u2022\\t\\tEmergency\\ttreatment\\tafter\\tradiation\\texposure:\\t2\\tmg/kg\\tPO\\tper\\tday.\\tContinue\\tfor 10 to 14 days or until risk of exposure has passed. \u2022\\t\\tExpectorant:\\t5\\tmg/kg\\tq8h\\tPO.  Cattle \u2022\\t\\t10\u201315\\tg/day\\t(adult\\tcattle)\\tPO\\tfor\\t30\u201360\\tdays. \u2022\\t\\t5\u201310\\tg/day\\t(calves)\\tPO\\tfor\\t30\u201360\\tdays. \u2022\\t\\tFeed\\tsupplement\\tand\\tother\\tindications:\\t(see\\tIodide\\tfor EDDI doses and Sodium Iodide for other doses). Horses \u2022\\t\\t10\u201340\\tmg/kg\\tper\\tday\\t(using\\tinorganic\\tpotassium\\tiodide). \u2022\\t\\t10\u201315\\tg/day\\t(adult\\thorses)\\tPO\\tfor\\t30\u201360\\tdays. \u2022\\t\\t5\u201310\\tg/day\\t(ponies)\\tPO\\tfor\\t30\u201360\\tdays. \u2022\\t\\tSee\\tIodide\\tfor\\tEDDI\\tdoses\\tand\\tSodium\\tIodide\\tfor\\tother\\tdoses. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tBecause\\tof\\ta\\tlow\\trisk\\tof\\tresidues,\\tno withdrawal times are suggested. Potassium Phosphate Trade and other names: K- Phos, Neutra- Phos- K, and generic brands","contraindications":"Contraindications and Precautions Do not administer to foals or pregnant animals (abortion is possible). Do not administer intravenously. Drug Interactions No\\tknown\\tdrug\\tinteractions.","indications":"Indications and Clinical Uses Potassium iodide has been used to treat fungal granulomatous disease and infections associated with zygomycetes. In small animals, it has been used for sporotrichosis. The antifungal treatment has been questioned for animals because the efficacy is not established through clinical studies. Because it may increase respiratory secretions, it has been used as an expectorant, but the efficacy has not been established. In people, iodide has been used to treat hyperthyroidism, but effectiveness for this use in cats has not been established. Potassium iodide is also used to protect the thyroid gland from radiation injury in the event of a radiation emergency (accidental exposure to radiation) or after administration of radioactive iodide. Ethylenediamine dihydroiodide (EDDI) is another source of iodide that is used as a nutritional source of iodine in cattle. Sodium iodide also is used, particularly in large animals. See Sodium Iodide and Iodide for more information. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tdoses\\tcan\\tproduce\\tsigns\\tof\\tiodism,\\twhich\\tinclude\\tlacrimation,\\tirritation\\tof mucous membranes, swelling of eyelids, cough, dry scruffy coat, and hair loss. Potassium iodide has a bitter taste and can cause nausea and salivation. Potassium iodide administration has been associated with cardiomyopathy in cats. Its use may cause abortion in horses or limb deformities in foals.","notes":"Instructions for Use Clinical use in animals is primarily empirical. The doses and indications listed have not been tested in clinical trials. Other, more proven drugs for these indications should be considered as alternatives, especially for treating serious fungal infections. Patient Monitoring and Laboratory Tests Monitor iodine concentrations of monitoring is available. Formulations \u2022\\t\\tPotassium\\tiodide\\tsolution:\\t65-mg/mL,\\tor\\tsaturated\\t1\\tg/mL.\\tThe\\tsaturated solution (SSKI) (1 g/mL) yields 38 mg per drop. \u2022\\t \\t10%\\tpotassium\\tiodide\\tsolution.\\tThe\\t5%\\tiodine\\tsolution\\tcan\\tbe\\tadministered\\torally\\twith food.\\tThe\\t10%\\tsolution\\tof\\tpotassium\\tiodide\\t(10%)\\tyields\\t6.3\\tmg\\tof\\tiodine\\tper\\tdrop. \u2022\\tTablets:\\t130\\tand\\t65\\tmg\\t(both\\ttablets\\tare\\tscored). \u2022\\t\\tCombination\\ttablets:\\tephedrine,\\tphenobarbital,\\tpotassium\\tiodide,\\tand\\ttheophylline are combined in one tablet (Quadrinal), but there is no evidence of use in animals. P Potassium Phosphate 759 Compounded Formulations \u2022\\t\\t3.25\\tmg/mL\\toral\\tsolution\\tmade\\twith\\ttablets.\\tCrush\\tone\\t130-mg\\ttablet\\tand\\treduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of milk, juice, or syrup. Stable for 7 days under refrigeration. \u2022\\t\\t1.6\\tmg/mL\\toral\\tsolution\\tmade\\twith\\ttablets.\\tCrush\\tone\\t65-mg\\ttablet\\tand\\treduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of milk, juice, or syrup. Stable for 7 days under refrigeration. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not freeze solutions. Inorganic potassium iodide is unstable in light, heat, and excess humidity.","original_category":"Iodine supplement, antifungal, expectorant"},{"name":"Terbinafine Hydrochloride","active_ingredient":"Terbinafine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t30\u201340\\tmg/kg\\tq24h\\tPO\\t(with\\tfood)\\tfor\\t2\u20133\\tweeks. Cats \u2022\\t\\t30\u201340\\tmg/kg/day\\tPO\\tfor\\tat\\tleast\\t2\\tweeks.\\tOr\\tadminister\\tone\\tquarter\\tof\\ta\\ttablet for\\tsmall\\tcats\\t(62.5\\tmg),\\thalf\\ta\\ttablet\\tfor\\tmedium-\\tsize\\tcats\\t(125\\tmg),\\tand\\tone tablet for large cats (250 mg), all administered once daily. 880    Terbutaline Sulfate  Horses \u2022\\t\\t30\\tmg/kg\\tPO\\tq12h.\\tHowever,\\tthere\\tare\\tno\\tstudies\\tto\\tdemonstrate\\tefficacy\\tin horses. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Terbutaline Sulfate ter- byoo\u2032tah- leen  sul\u2032fate Trade and other names: Brethine and Bricanyl","contraindications":"Contraindications and Precautions No contraindications have been reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Terbinafine has been used for treatment of dermatophyte infections in dogs, cats, birds, and some exotic animals. Clinical evidence of efficacy has not been established for these uses in well-controlled clinical trials. For dermatophytes in animals, the doses necessary for efficacy are much higher than those used in people. Although there has been experience with using terbinafine in animals, primarily for dermatophytes, there is no evidence that terbinafine is more effective than other oral antifungal agents. In T dogs, it was partially effective for the treatment of Malassezia dermatitis when given at 30\\t mg/kg\\t    PO\\t  once\\t  a\\t day\\t  or\\t twice\\t   a\\t week\\t   for\\t at\\t least\\t  3\\t weeks.\\t   However,\\tthis\\t  treatment produced insufficient resolution and only partial remission even though there was clinical improvement. In cats (e.g., shelter cats), it has not been consistently effective for dermatophyte infections. Treatment of infections in horses with terbinafine has not been successful, probably because of poor oral absorption. Doses are listed later for horses based on limited observations, but there are no clinical efficacy studies available. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vomiting has been the most common adverse effect. Adverse effects, including nausea and anorexia, have been observed in dogs. Liver enzymes may be elevated in some animals. Hepatotoxicity is possible, but it has not been reported from use in animals. Facial pruritus has been observed in some treated cats. In people, a persistent taste disturbance, GI problems, and headache have been reported. Tablets crushed and mixed with molasses for oral administration in horses produced oral mucosal irritations.","notes":"Instructions for Use Treatment of dogs and cats requires much higher doses than the doses used in people. Despite the in vitro activity of terbinafine against many fungi and the favorable pharmacokinetics in dogs and cats, the clinical results have not consistently produced clinical resolution in some patients. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t \\tTerbinafine\\tis\\tavailable\\tin\\t250-\\tmg\\ttablets,\\t1%\\ttopical\\tsolution,\\tand\\t1%\\ttopical\\tcream. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Terbinafine is slightly soluble in water and alcohol. When suspensions are prepared from crushed tablets in a vehicle (Ora- Sweet), it is stable for 42 days.","original_category":"Antifungal"},{"name":"Voriconazole","active_ingredient":"Voriconazole","species":["Feline","Canine","Equine"],"dosage":"Doses of 10 mg/kg have caused neurologic problems in cats. A lower dosage of\\t2\u20133\\tmg/kg\\tevery\\tother\\tday\\tmay\\tbe\\tsafe\\tif\\tadministered\\tfor\\tmultiple\\tdoses, but an evaluation of the long- term safety has not been conducted in cats. Use cautiously in any animal with signs of liver disease. Use cautiously in pregnant animals. At high doses in laboratory animals, drugs in this class have caused fetal abnormalities. Use the oral formulation rather than the IV form in animals with renal disease. Drug Interactions Voriconazole\\tis\\ta\\tpotent\\tcytochrome\\tP450\\tenzyme\\tinhibitor.\\tIt\\tmay\\tcause\\tdrug interactions\\tbecause\\tof\\tinhibition\\tof\\tP450\\tenzymes.\\tDrugs\\taffected\\tby\\tthis inhibition can include cyclosporine, vincristine, cyclophosphamide, and perhaps others.  Dogs \u2022\\t\\t5\u20136\\tmg/kg\\tq12h\\tPO\\tis\\tthe\\tpublished\\tdose\\tbased\\ton\\tstudies\\tin\\tresearch\\tdogs. However,\\ta\\tdosage\\tof\\t2.5\u20133.3\\tmg/kg\\tq12h\\tPO\\tin\\ta\\tclinical\\treport\\tproduced adequate plasma concentrations. (The safety of repeated doses in dogs has not been confirmed.) Cats \u2022\\t\\tAdminister\\ta\\tloading\\tdose\\tof\\t25\\tmg\\tper\\tcat\\t(range,\\t4.2\u20134.6\\tmg/kg)\\tPO,\\tfollowed by\\t12.5\\tmg\\t(2\u20132.3\\tmg/kg)\\tevery\\tother\\tday.\\tAccumulation\\tmay\\toccur\\tafter repeated doses; therefore observe for signs of adverse effects with multiple dosing. Birds \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO\\tadministered\\tas\\ta\\tpowder\\tor\\tcrushed\\ttablets\\tmixed\\twith\\twater in a liquid suspension (0.5 mg/mL).  Horses \u2022\\t\\t2\u20134\\tmg/kg\\tq24h\\tor\\t3\\tmg/kg\\tq12h\\tPO. \u2022\\t\\t1.5\\tmg/kg\\tq24h\\tIV. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. 976    Warfarin Sodium Warfarin Sodium war\u2032far- in  soe\u2032dee- um Trade and other names: Coumadin and generic brands","contraindications":"Contraindications and Precautions","indications":"Indications and Clinical Uses Voriconazole has been used to treat dermatophytes and systemic fungi, such as Blastomyces, Histoplasma, and Coccidioides spp. It has been used to treat infections caused by Aspergillus and Fusarium spp. The efficacy in humans for treating Aspergillus spp. is better than with other oral antifungal drugs and comparable to amphotericin B. Penetration\\tinto\\tthe\\tCNS\\tand\\teye\\tis\\thigh\\tenough\\tto\\ttreat\\tinfections\\tin\\tthese\\tareas. Most of the use in veterinary medicine has been empirical or extrapolated from the use in humans. The doses for small animals are listed in the dosing section that follows.\\tClinical\\texperience\\tin\\thorses\\thas\\tused\\ta\\tdosage\\tof\\t2\\tmg/kg\\tonce\\tdaily\\tPO. However,\\tresearch\\tstudies\\thave\\tshowed\\tthat\\ta\\tdosage\\tof\\t4\\tmg/kg\\tonce\\tdaily\\tPO\\tor\\t3 mg/kg\\tq12h\\tPO\\tproduces\\tadequate\\tin-\\tplasma\\tand\\ttissue\\tconcentrations\\t(ocular\\ttear film, cerebrospinal fluid, urine, epithelial lining fluid of the lung, and synovial fluid) for susceptible fungi, including Aspergillus spp. It has also been administered topically in horses for ocular fungal infections (using the IV 1% solution every 4 hours). Voriconazole also has been used in birds to control infections caused by Aspergillus spp., but some birds develop toxicity from this use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Voriconazole has been associated with neurotoxicity in cats at doses of 10 mg/kg via an unknown mechanism. Some cats administered therapeutic doses exhibited CNS\\tsigns\\tthat\\tresolved\\tafter\\tdiscontinuation\\tof\\tthe\\tdrug.\\tThese\\treactions\\thave\\tnot been\\treported\\tin\\tother\\tanimals\\t(dogs,\\thorses,\\tbirds)\\ttreated\\twith\\tvoriconazole.\\tCats also had signs of anorexia, ataxia, paresis, arrhythmias, and hypokalemia. In a study with\\tlower\\tdoses\\t(4\u20136\\tmg/kg),\\tit\\twas\\tgenerally\\ttolerated\\tmuch\\tbetter,\\tbut\\tmiosis and hypersalivation were common effects observed in cats. Although it is generally better tolerated than ketoconazole in most species, increased liver enzymes, neurologic adverse effects, and decreased appetite have been observed in some dogs. Vomiting and hepatotoxicity are more likely at high doses. In people, transient ocular problems (blurred vision, photophobia) also have been reported.","notes":"Instructions for Use The dosages listed for voriconazole are based on experimental studies in animals or clinical reports. Some uses in animals are based on empiricism, small observational studies, or extrapolation from human literature. When used intravenously, the 10- mg/mL solution should be further diluted with fluids to a concentration greater than 5 mg/mL and infused slowly. IV solutions should be used immediately or stored in a refrigerator no longer than 24 hours. If mixed with\\tfluid\\tsolutions,\\tit\\tis\\tcompatible\\twith\\tlactated\\tRinger\u2019s\\tsolution,\\t5%\\tdextrose, or sodium chloride 0.9%. Do not mix IV solution with blood products or concentrated electrolytes. Patient Monitoring and Laboratory Tests Monitor\\tliver\\tenzyme\\tconcentrations\\tduring\\ttreatment.\\tPlasma\\tconcentration monitoring can help predict clinical success. Higher treatment success has been observed in people when trough concentrations were kept above 0.5 mcg/mL and a worse\\toutcome\\twhen\\tthe\\tconcentrations\\twere\\tbelow\\t0.5\\tmcg/mL.\\tConcentrations greater than 3 mcg/mL are associated with a higher risk of hepatic toxicity, and concentrations above 4 mcg/mL are associated with neurotoxicity. Therefore, administer sufficient doses to maintain the trough concentration above 0.5 or 1 mcg/ mL but below 3 mcg/mL. Avoid exceeding a peak plasma concentration greater than 4\u20136\\tmcg/mL. Formulations \u2022\\t\\tPO:\\tVoriconazole\\tis\\tavailable\\tin\\t50-\\t\\tand\\t200-\\tmg\\tfilm-\\tcoated\\ttablets\\tand\\ta\\t40- mg/mL oral liquid suspension. The suspension has a 14- day shelf life after reconstitution. \u2022\\t\\tInjection:\\t200-\\tmg\\t(10\\tmg/mL)\\tinjection.\\tThe\\tIV\\tsolution\\trequires reconstitution to 10 mg/mL; then dilution to \u22645\\tmg/mL\\tfor\\tCRI\\t(3\\tmg/kg/h for\\t1\u20132\\thours). \u2022\\t\\tCompounded\\tforms:\\tA\\tvariety\\tof\\tcompounded\\tforms\\thave\\tbeen\\tprepared\\tfor animals: A drug suspension for animals has been prepared by mixing crushed tablets V (200\\tmg)\\twith\\t20\\tmL\\tof\\twater\\tand\\t60\\tmL\\tof\\tOra-\\tPlus\\tto\\tmake\\ta\\tsuspension\\tof 2.5 mg/mL. After mixing, this suspension retained the original strength for 17 days. A compounded mixture also has been prepared by mixing two 200- mg tablets crushed to a powder and mixed with 10 mL of a suspending agent and flavoring agent\\t(Ora\\tPlus/Ora\\tSweet\\tin\\ta\\tratio\\tof\\t1:1\\tor\\tOra\\tPlus\\tand\\twater\\tin\\ta\\t3:1\\tratio). The suspension should be stored in a brown plastic (not glass) bottle in refrigerator or room temperature. The final formulation is 40 mg/mL and is stable for 30 days.\\tFor\\thorses,\\tcrushed\\ttablets\\thave\\tbeen\\tmixed\\twith\\t30\\tmL\\tof\\tcorn\\tsyrup\\tto\\ta concentration\\tof\\t33\\tmg/mL\\tand\\tare\\tstable\\tfor\\t48\\thours\\tat\\t8\xb0C.\\tThis\\tformulation can be administered to horses orally via syringe. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. The commercial suspension has a 14- day shelf- life after reconstitution. See the previous\\tFormulations\\tsection for stability information on compounded preparations. Use the IV formulation immediately after mixing or store it in a refrigerator for no longer than 24 hours. Do not mix IV solutions with concentrated electrolytes or blood products.","original_category":"Antifungal"}]},{"category":"Antineoplastic","drugs":[{"name":"Paclitaxel","active_ingredient":"Paclitaxel","species":["Canine"],"dosage":"Dogs \u2022\\t \\tNot\\tusually\\trecommended\\tbecause\\tof\\tadverse\\teffects.\\tThere\\thas\\tbeen\\tsome experience with 150 mg/m 2 IV over 15\u201330 minutes once every 3 weeks for up to four doses. (Dose range has been 130\u2013150 mg/m 2 .) If adverse reactions develop, reduce dose by increments of 10 mg/m 2 or delay the time for administration.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because this is an anticancer agent, it is forbidden to administer to food- producing animals. Pamidronate Disodium pam- ih- droe\u2032nate  dye- soe\u2032dee- um Trade and other names: Aredia","contraindications":"Contraindications and Precautions Because this is an anticancer agent, standard precautions should be applied when using this agent in animals. These precautions include following manufacturer\u2019s recommendations for safe handling of the vials and syringes and disposing of infusion supplies. Do not use in dogs that are pregnant, lactating, or intended for breeding. Paclitaxel is a teratogen and can affect female and male fertility. Drug Interactions No\\tknown\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tdogs.\\tHowever,\\tpaclitaxel is metabolized by cytochrome P450 isoenzymes and is a P- glycoprotein (P- gp) substrate. Therefore, interactions are possible when administered with other drugs that may inhibit these systems or in dogs that have a deficiency in P- gp. Because most anticancer agents are often administered with other agents, complications from multiple drugs are possible. 696    Pamidronate Disodium Cats \u2022\\t \\tThere\\thas\\tbeen\\tlimited\\texperience\\tin\\tcats.\\tHowever,\\tit\\thas\\tbeen\\tadministered at a dosage of 80 mg/m 2 (approximately 5 mg/kg) IV every 21 days for two doses.","indications":"Indications and Clinical Uses Paclitaxel and the related drug docetaxel are used for a variety of cancers in people (e.g., breast cancer) as part of a chemotherapy regimen. In dogs, paclitaxel has been used for mammary carcinoma and squamous cell carcinoma and mast cell tumors (MCTs). Paclitaxel is not soluble in water; therefore, it must be administered in other vehicles. The vehicle with polyoxyethylated castor oil (Cremophor EL) administered to animals produces toxicity and should not be used. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects The human formulation, which contains Cremophor EL (polyoxyethylated castor oil) as a carrier vehicle, can cause severe anaphylactoid reactions in dogs and should be avoided. Drugs in this class can produce bone marrow suppression. The most severe neutropenia usually occurs in 5\u20137 days after administration. Thrombocytopenia, vomiting, and constipation also are possible. As with many other anticancer agents, vomiting, diarrhea, and nausea are common. Do not use in dogs that are pregnant, lactating, or intended for breeding. Paclitaxel is a teratogen and can affect female and male fertility. Laboratory studies in the rat have shown reduced fertility, embryotoxicity, teratogenicity, and maternal toxicity. P","notes":"Instructions for Use The previously available veterinary formulation is no longer available. This form was conditionally approved, but such approval has been canceled. The only form available currently is the human form, which can produce adverse effects in dogs. Patient Monitoring and Laboratory Tests The most severe adverse effect is bone marrow suppression. Monitor complete blood count (CBC) to determine if doses need adjustment to prevent severe neutropenia. If dogs develop severe neutropenia (less than 2000 cells/\u03bcL) or have a concurrent serious infection, withhold treatment. Paclitaxel can cause gastrointestinal (GI) adverse reactions because of transient GI mucosal cell toxicity. Monitor patients carefully for vomiting, diarrhea, and dehydration. Provide supportive care as clinically indicated. Formulations \u2022\\t\\tThe\\thuman\\tformulation\\tis\\tformulated\\tin\\tCremophor\\tEL\\t(polyoxyethylated\\tcastor oil). This vehicle is associated with significant anaphylactoid reactions in dogs and should be avoided. Stability and Storage Follow the manufacturer\u2019s label carefully for the proper preparation and storage of the vials for injection.","original_category":"Anticancer agent, antineoplastic"}]},{"category":"Antiparasitics","drugs":[{"name":"Afoxolaner","active_ingredient":"Afoxolaner","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.5\\tmg/kg\\t(1.14\\tmg/lb),\\tPO,\\tonce\\tper\\tmonth\\tduring\\tflea\\tand\\ttick\\tseason.\\tFor treatment of Demodex, it has been administered twice- weekly. Cats \u2022\\t\\tNo\\tdose\\tfor\\tcats\\thas\\tbeen\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information Although risk of harmful residues is low, do not administer to food- producing animals. 14    Aglepristone Aglepristone ag- le \u0301- pri- stone Trade and other names: Alizine or Alzin","contraindications":"Contraindications and Precautions The isoxazoline group of insecticides have been associated with seizures in animals.\\tUse\\tcautiously\\tin\\tanimals\\tthat\\tmay\\tbe\\tprone\\tto\\tseizures.\\tSafety\\thas\\tnot been established in breeding or lactating animals. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Afoxolaner is indicated to kill adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of black- legged tick (Ixodes scapularis), American dog tick (Dermacentor variabilis), Lone Star tick (Amblyomma americanum), and brown dog tick (Rhipicephalus sanguineus)\\tinfestations\\tin\\tdogs\\tand\\tpuppies\\t8\\tweeks\\tof\\tage\\tand\\tolder,\\tweighing\\t4 lb of body weight or greater, for 1 month. It is also effective for the treatment of demodicosis caused by the Demodex mite. A Because of this action, afoxolaner can reduce the risk that these vectors may pose for\\tdisease\\ttransmission.\\tFor\\texample,\\tit\\tmay\\tprevent\\tinfections\\tcaused\\tby\\tBorrelia burgdorferi (Lyme disease) and Babesia canis. The approved label indication for afoxolaner is treatment of fleas and ticks, but extralabel uses, using the approved label dose, have included treatment of generalized demodicosis caused by Demodex canis. Dogs with Demodex treated with afoxolaner had greater mite reductions than treatment with moxidectin/imidacloprid. Afoxolaner can eliminate sarcoptic mange (Sarcoptes scabiei) in dogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Afoxolaner\\thas\\tbeen\\tsafe\\tfor\\tuse\\tin\\tdogs\\tat\\tleast\\t8\\tweeks\\tof\\tage.\\tTarget\\tanimal safety studies performed in dogs indicate good tolerance at the therapeutic dose. Beagle dogs treated at up to five times the therapeutic dose showed no signs of intoxication. In clinical field studies with the isooxazoline group of insecticides, adverse effects reported include vomiting, diarrhea, anorexia, and lethargy.","notes":"Instructions for Use Administer orally once per month. Other measures for flea and tick control in the pet\u2019s environment also may be used. Patient Monitoring and Laboratory Tests No specific monitoring is needed. Formulations Afoxolaner\\tis\\tavailable\\tin\\tchewable\\ttablets\\tcontaining\\t11.3,\\t28.3,\\t68,\\tor\\t136\\tmg\\tof afoxolaner. Stability and Storage Store at room temperature protected from light in manufacturer\u2019s packaging.","original_category":"Antiparasitic agent (flea and tick insecticide)"},{"name":"Albendazole","active_ingredient":"Albendazole","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tAnthelmintic\\tdosage:\\t25\u201350\\tmg/kg\\tq12h\\tPO\\tfor\\t3\\tdays. \u2022\\t\\tRespiratory\\tparasites:\\t50\\tmg/kg\\tq24h\\tPO\\tfor\\t10\u201314\\tdays. \u2022\\t\\tGiardia:\\t25\\tmg/kg\\tq12h\\tPO\\tfor\\t2\\tdays. Birds \u2022\\t\\t50\u2013100\\tmg/kg\\tonce\\tper\\tday\\tfor\\t2\u20139\\tdays.  Cattle \u2022\\t\\tAntiparasitic:\\tSingle\\tdose\\tof\\t10\\tmg/kg\\toral\\tpaste\\tor\\t10\\tmg/kg\\t(suspension)\\tPO. Horses \u2022 \\t \\tDictyocaulus arnfieldi: 25 mg/kg q12h for 5 days. \u2022 \\t \\tStrongylus vulgaris: 50 mg/kg q12h for 2 days. Sheep and goats \u2022\\t\\tSingle\\tdose\\tof\\t7.5\\tmg/kg\\toral\\tsuspension. Regulatory Information Cattle\\twithdrawal\\ttime:\\t27\\tdays\\tfor\\tmeat.\\tDo\\tnot\\tuse\\tin\\tlactating\\tdairy\\tcattle.\\tSheep withdrawal\\ttime:\\t7\\tdays\\tfor\\tmeat. Albuterol Sulfate al- byoo \u0301ter- ole  sul \u0301fate Trade and other names: Proventil, Ventolin, and Torpex equine inhaler. Also known as Salbutamol outside the United States.","contraindications":"Contraindications and Precautions Adverse effects are more likely when administered for longer than 5 days. Avoid high\\tdoses.\\tPregnancy\\tcaution:\\tDo\\tnot\\tuse\\tduring\\tfirst\\t45\\tdays\\tof\\tpregnancy. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Albendazole is used to treat a variety of intestinal helminth parasites. It has been used for treating parasitic infections of the respiratory tract, including Capillaria aerophila, Paragonimus kellicotti, Aelurostrongylus abstrusus, Filaroides spp., and Oslerus osleri. It is also effective for treatment of Giardia in small animals. However, because albendazole has been associated with bone marrow suppression in dogs and cats, other drugs are preferred in small animals for Giardia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include anorexia, lethargy, and bone marrow toxicity. Leukopenia and thrombocytopenia are possible in dogs and cats. Albendazole has an affinity for rapidly dividing cells and may cause toxicity to bone marrow and intestinal epithelium. High doses have been associated with bone marrow toxicity in dogs and cats, and it should be used cautiously in small animals. In other species, at approved doses, there has been a wide margin of safety.","notes":"Instructions for Use Used\\tprimarily\\tas\\tantihelmintic\\tbut\\talso\\thas\\tdemonstrated\\tefficacy\\tfor\\tgiardiasis.\\tIn small animals, other agents are generally preferred for treating infections caused by Giardia. 16    Albuterol Sulfate Patient Monitoring and Laboratory Tests Monitor CBC in animals experiencing signs suspicious of adverse effects. If high doses are accidentally administered to small animals, CBC should be examined for evidence of suppression. Formulations \u2022\\t\\tAlbendazole\\tis\\tavailable\\tin\\ta\\t113.6-\\t\\tand\\t45.5-\\tmg/mL\\tsuspension\\tand\\t300-\\tmg/mL paste. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been investigated.","original_category":"Antiparasitic"},{"name":"Amitraz","active_ingredient":"Amitraz","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t10.6\\tmL/7.5\\tL\\twater\\t(0.025%\\tsolution).\\tApply\\tthree\\tto\\tsix\\ttopical\\ttreatments every\\t14\\tdays.\\tFor\\trefractory\\tcases,\\tthis\\tdosage\\thas\\tbeen\\texceeded\\tto\\timprove efficacy. Dosages that have been used include 0.025%, 0.05%, and 0.1% concentration\\tapplied\\tonce\\tor\\ttwice\\tper\\tweek.\\tFor\\trefractory\\tcases,\\ta\\tdose\\tof 0.125% has been used by applying to only half of the dog\u2019s body one day, then to the other half of the body the following day. This alternating schedule has been repeated every day for 4 weeks and up to 5 months to achieve cures but should be considered only in extreme cases.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t3 Amitriptyline Hydrochloride am- ih- trip \u0301tih- leen  hye- droe- klor \u0301ide Trade and other names: Elavil and generic brands","contraindications":"Contraindications and Precautions Adverse effects are more common when high doses are administered. Drug Interactions Do not administer with MAOIs, such as selegiline (Deprenyl, Anipryl). Do not administer with other alpha 2 - agonists. 38    Amitriptyline Hydrochloride","indications":"Indications and Clinical Uses Amitraz is indicated for the topical treatment of mites, including Demodex. It is applied topically as a dip or sponge- on. It should not be administered systemically. The approved dose is effective in many animals; however, in more resistant cases of Demodex, higher doses have been applied. As the dose increases, the risk of adverse effects also increases. Because of the availability of newer oral agents to treat mites in animals (drugs in the isoxazoline class, such as afoxolaner, fluralaner, sarolaner, and lotilaner), the use of amitraz has declined. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Amitraz causes sedation in dogs caused by the agonist activity on alpha 2 - adrenergic receptors, which may be reversed by yohimbine or atipamezole. When high doses are used, other side effects reported include pruritus, polyuria and polydipsia, bradycardia, hypotension, heart block, hypothermia, hyperglycemia, and (rarely) seizures.","notes":"Instructions for Use Manufacturer\u2019s dose should be used initially, but for refractory cases, this dose has been exceeded to produce increased efficacy. Patient Monitoring and Laboratory Tests Monitor by performing periodic skin scrapings and examining for presence of mites. Formulations \u2022\\t\\tAmitraz\\tis\\tavailable\\tin\\t10.6-\\tmL\\tconcentrated\\tdip\\t(19.9%). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Amprolium","active_ingredient":"Amprolium","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tTreatment\\tof\\tcoccidiosis:\\tAdd\\t1.25\\tg\\tof\\t20%\\tamprolium\\tpowder\\tto\\tdaily\\tfeed\\tor\\t30 mL\\tof\\t9.6%\\tamprolium\\tsolution\\tto\\t3.8\\tL\\tof\\tdrinking\\twater\\tfor\\t7\\tdays.  Calves \u2022\\t\\tPrevention\\tof\\tcoccidiosis:\\t5\\tmg/kg\\tq24h\\tfor\\t21\\tdays. \u2022\\t\\tTreatment\\tof\\tcoccidiosis:\\t10\\tmg/kg\\tq24h\\tfor\\t5\\tdays\\tPO. Regulatory Information Withdrawal\\ttime\\tfor\\tcattle\\t(meat):\\t24\\thours\\tbefore\\tslaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Apomorphine Hydrochloride ah- poe- mor \u0301feen  hye- droe- klor \u0301- ide Trade and other names: Apokyn and generic brands","contraindications":"Contraindications and Precautions Do not administer to debilitated animals. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Amprolium is used to control and treat coccidiosis in calves, sheep, goats, puppies, and birds. It is administered orally, often mixed with food. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity is observed only at high doses. CNS signs are caused by thiamine deficiency, which may be reversed by adding thiamine to the diet.","notes":"Instructions for Use Usually\\tadministered\\tas\\tfeed\\tadditive\\tto\\tlivestock.\\tFor\\tdogs,\\t30\\tmL of\\t9.6%\\tamprolium\\thas\\tbeen\\tadded\\tto\\t3.8\\tL\\tof\\tdrinking\\twater\\tfor\\tcontrol of coccidiosis. A Apomorphine Hydrochloride 55 Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAmprolium\\tis\\tavailable\\tin\\t9.6%\\t(9.6\\tg/100\\tmL)\\toral\\tsolution\\tand\\ta\\tsoluble\\tpowder in a 22.6- g packet. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Bunamidine Hydrochloride","active_ingredient":"Bunamidine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t20\u201350\\tmg/kg\\tonce\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Bupivacaine Hydrochloride byoo- piv\u2032ah- kane  hye- droe- klor\u2032ide Trade and other names: Nocita, Marcaine, Exparel, and generic brands","contraindications":"Contraindications and Precautions Avoid use in young animals. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Bunamidine is used as an anticestodal agent to treat tapeworm infections in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vomiting and diarrhea have occurred after use.","notes":"Instructions for Use Do not break tablets. Administer tablets on empty stomach. Do not feed animal for 3 hours after administration. B Bupivacaine Hydrochloride 97 Patient Monitoring and Laboratory Tests Monitor fecal samples for evidence of parasites. Formulations \u2022\\t\\tBunamidine\\tis\\tavailable\\tin\\t400-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Dichlorvos","active_ingredient":"Dichlorvos","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t26.4\u201333\\tmg/kg\\tonce\\tPO. Cats \u2022\\t\\t11\\tmg/kg\\tonce\\tPO.  Pigs \u2022\\t \\t11.2\u201321.6\\tmg/kg\\t   once\\t  PO.\\t  For\\t  pregnant\\tsows,\\t   mix\\t  into\\t  a\\t gestation\\tfeed\\t  to\\t provide\\t    1000 mg/head\\tdaily\\tduring\\tthe\\tlast\\t30\\tdays\\tof\\tgestation,\\tmixed\\tat\\ta\\trate\\tof\\t334\u2013500\\tg/ton\\tof feed.\\tFor\\tother\\tpigs,\\tmix\\tat\\t334\\tper\\tton\\tof\\tfeed\\tand\\tfeed\\tas\\tsole\\tration\\tfor\\t2\\tconsecutive days (rate of 8.4 lb of feed per head until the medicated feed has been consumed). Horses \u2022\\t\\t31\u201341\\tmg/kg\\tonce\\tPO. Regulatory Information Do not administer to horses intended for food. For other animals, no regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Diclazuril dih- klaz \u0301yoor- il Trade and other names: Clincox and Protazil pellets for horses","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\theartworms.\\tDo\\tnot\\tadminister\\twithin\\t2\\tdays\\tof administration of another cholinesterase- inhibiting drug. Use a split- dosage schedule in animals that are old, heavily parasitized, anemic, or otherwise debilitated.\\tDo\\tnot\\tuse\\tin\\tyoung\\tfoals,\\tkittens,\\tor\\tpuppies\\tweighing\\tless\\tthan\\t2 lb. Its use may exacerbate clinical signs in animals with respiratory disease, such as bronchitis and obstructive pulmonary disease. Do not allow birds access to feed containing this preparation or to fecal excrement from treated animals. Drug Interactions Do not use with other anticholinesterase drugs. Do not use with other antifilarial agents,\\tmuscle\\trelaxants,\\tCNS\\tdepressants,\\tor\\ttranquilizers.","indications":"Indications and Clinical Uses Dichlorvos is used primarily to treat intestinal parasites. Parasites that may be treated include Toxocara canis and Toxascaris leonina (roundworms), Ancylostoma caninum, Uncinaria stenocephala (hookworms), and Trichuris vulpis\\t(whipworms).\\tHowever, efficacy against T. vulpis may be erratic. In horses, it may be used for the removal and control of bots (Gastrophilus intestinalis, Gastrophilus nasalis), large strongyles (Strongylus vulgaris, Strongylus equinus, Strongylus edentatus), small strongyles (of the genera Cyathostomum, Cylicocercus, Cylicodontophorus, Triodontophorus, and Poteriostomum), pinworms (Oxyuris equi), and large roundworm (Parascaris equorum). In pigs, it is used to treat and control mature, immature, and fourth- stage larvae of the whipworm (Trichuris suis), nodular worm (Oesophagostomum spp.), large roundworm (Ascaris suum), and thick stomach worm (Ascarops strongylina). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdoses\\tcan\\tcause\\torganophosphate\\tintoxication\\t(treat\\twith\\tpralidoxime chloride and atropine). Signs of toxicity include salivation, diarrhea, difficulty breathing, and muscle twitching.","notes":"Instructions for Use Administer in about one third of the regular canned dog food ration or in ground meat. Dogs may be treated with any combination of capsules and pellets so that the animal\\treceives\\ta\\tsingle\\tdose.\\tOne\\thalf\\tof\\tthe\\tsingle\\trecommended\\tdosage\\tmay\\tbe given,\\tand\\tthe\\tother\\thalf\\tmay\\tbe\\tadministered\\t8\u201324\\thours\\tlater.\\tFor\\thorses,\\tadminister in the grain portion of the ration. It may be administered at one half of the single recommended\\tdose\\tand\\trepeated\\t8\u201312\\thours\\tlater\\tfor\\ttreatment\\tof\\told,\\temaciated, or\\tdebilitated\\tsubjects\\tor\\tthose\\treluctant\\tto\\tconsume\\tmedicated\\tfeed.\\tSplit\\tthe\\tdose\\tif heavy parasitism may cause concern over mechanical blockage of the intestinal tract. Patient Monitoring and Laboratory Tests Monitor for parasites as part of a regular parasite control program. Formulations \u2022\\t\\tDichlorvos\\tis\\tavailable\\tin\\t10-\\t\\tand\\t25-\\tmg\\ttablets.\\tManufacture\\tof\\tequine formulations has been discontinued, and other forms must be used in horses. D Diclazuril 265 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Diethylcarbamazine Citrate","active_ingredient":"Diethylcarbamazine Citrate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tHeartworm\\tprophylaxis:\\t6.6\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tTreatment\\tof\\tascarids:\\t55\u2013110\\tmg/kg\\tPO\\tas\\ta\\tsingle\\ttreatment\\t(the\\t110-\\tmg/kg dose may be divided into twice per day). Cats \u2022\\t\\tAscarid\\ttreatment:\\t55\u2013110\\tmg/kg\\tPO.\\tWhen\\ttreating\\tascarid\\tparasites,\\tconsider repeating\\ttreatment\\tin\\t10\u201320\\tdays\\tto\\tremove\\timmature\\tworms.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Diethylstilbestrol dye- eth- il- stil- bess \u0301trole Trade and other names: DES and generic brands","contraindications":"Contraindications and Precautions Dogs with established heartworm infections caused by Dirofilaria immitis should not receive diethylcarbamazine until they have been treated with an adulticide to kill the adult heartworms followed by appropriate microfilaricidal treatment. Reactions\\tcan\\toccur\\tin\\tanimals\\twith\\tpositive\\tmicrofilaria.\\tHowever,\\tthere\\tare\\tno breed sensitivities or other specific contraindications. Drug Interactions No specific drug interactions are reported. D Diethylstilbestrol 269","indications":"Indications and Clinical Uses The commercial tablets (e.g., Caricide) and some other brands used for heartworm prevention have been voluntarily withdrawn by the sponsor. Because of the availability of other heartworm preventatives that are effective and easy to administer (e.g., once per month or less), the use of diethylcarbamazine has diminished significantly. Diethylcarbamazine has been used to prevent infection caused by heartworms in dogs. It has been administered regularly during heartworm season in endemic areas. It\\tis\\tnot\\teffective\\tto\\ttreat\\theartworms\\tonce\\tinfection\\tis\\testablished.\\tOther\\tuses\\tof diethylcarbamazine have included control of ascarids infections (T. canis and T. leonina)\\tand\\tas\\tan\\taid\\tin\\ttreatment\\tof\\tascarid\\tinfections\\tat\\thigher\\tdoses\\t(55\u2013110 mg/kg).\\tIn\\tcats,\\tdiethylcarbamazine\\thas\\tbeen\\tused\\tto\\ttreat\\tascarid\\tworm\\tinfections (55\u2013110\\tmg/kg). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdoses\\tcause\\tvomiting.\\tIf\\tadministered\\tto\\tan\\tanimal\\twith\\tpositive\\tmicrofilaria, reactions, including pulmonary reactions, are possible. This drug is a piperazine derivative, which is a class of antiparasitic drugs considered generally safe in animals.","notes":"Instructions for Use Specific protocols for heartworm administration may be based on the region of country\\tbecause\\tthe\\ttime\\t(season)\\trequired\\tfor\\theartworm\\tprevention\\tdepends\\ton the\\tduration\\tof\\tactive\\tmosquitoes\\tduring\\tthe\\tyear.\\tAlthough\\tdiethylcarbamazine is\\teffective\\tto\\tprevent\\theartworms,\\tit\\trequires\\talmost\\tcontinual\\tdaily\\ttreatment\\tfor efficacy.\\tTwo\\tor\\tthree\\tdoses\\tshould\\tnot\\tbe\\tmissed.\\tOccasionally,\\tsome\\tanimals\\tvomit immediately after dosing. Administration with food sometimes decreases this reaction. If\\tdiethylcarbamazine\\ttreatment\\thas\\tbeen\\tinterrupted,\\tthe\\tAmerican\\tHeartworm Society recommends switching chemoprophylaxis to macrocyclic lactones (ivermectin and related drugs). Patient Monitoring and Laboratory Tests Monitor heartworm status of patient. It is important to test for microfilaria in animals before prescribing. Manufacturers recommend that animals that are currently receiving\\tdiethylcarbamazine\\tbe\\tchecked\\tfor\\tmicrofilaria\\tevery\\t6\\tmonths.\\tReactions can occur in animals with positive microfilaria. Formulations \u2022\\t\\tAlthough\\tsome\\tbrands\\thave\\tbeen\\twithdrawn\\tby\\tthe\\tsponsor,\\tsome\\tavailability\\tof other diethylcarbamazine tablets may vary with manufacturer and brand name and country or region. Not every brand name is available in the sizes listed. Both plain and chewable tablets have been available. Tablet sizes include 30, 45, 50, 60,\\t100,\\t120,\\t150,\\t180,\\t200,\\t300,\\tand\\t400\\tmg.\\tSyrup\\thas\\tbeen\\tavailable\\tas 60\\tmg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Dithiazanine Iodide","active_ingredient":"Dithiazanine Iodide","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Antiparasitic"},{"name":"Doramectin","active_ingredient":"Doramectin","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\tDemodex\\ttreatment:\\t600\\tmcg/kg\\tonce\\tper\\tweek\\tfor\\t5\u201323\\tweeks\\tSQ\\tor\\tPO. Cats \u2022\\t\\tMite\\tinfection:\\t200\u2013270\\tmcg/kg\\tonce\\tSQ. \u2022\\t\\t0.1\\tmL\\tof\\t1%\\tsolution\\tgiven\\tonce\\tSQ.  Cattle \u2022\\t\\t200\\tmcg/kg\\t(0.2\\tmg/kg)\\tor\\t1\\tmL\\tper\\t50\\tkg\\t(110\\tlb),\\tsingle\\tinjection,\\tIM\\tor\\tSQ. \u2022\\t\\tTransdermal\\tsolution:\\tGive\\t500\\tmcg\\t(0.5\\tmg)\\tper\\tkg\\tor\\t1\\tmL\\tper\\t10\\tkg\\t(4.5\\tlb)\\tas a\\tsingle\\tdose\\talong\\tthe\\tanimal\u2019s\\tback,\\talong\\tthe\\tmidline. Pigs \u2022\\t\\t300\\tmcg/kg\\t(0.3\\tmg/kg)\\tor\\t1\\tmL\\tper\\t34\\tkg\\t(75\\tlb),\\tsingle\\tinjection,\\tIM. Regulatory Information Cattle\\twithdrawal\\ttime\\t(meat):\\t35\\tdays. Pig\\twithdrawal\\ttime\\t(meat):\\t24\\tdays. Do not administer to lactating dairy cattle. Do\\tnot\\tadminister\\tto\\tfemale\\tdairy\\tcattle\\tolder\\tthan\\t20\\tmonths\\tof\\tage. Cattle\\ttransdermal\\tsolution\\twithdrawal\\ttime\\t(meat):\\t45\\tdays.\\tDo\\tnot\\tadminister\\tto lactating\\tdairy\\tcattle;\\tdo\\tnot\\tadminister\\twithin\\t2\\tmonths\\tof\\tcalving. Doripenem dor- i- pen \u0301em Trade and other names: Doribax","contraindications":"Contraindications and Precautions Doramectin is only approved in cattle but there is extralabel use in other animals. Certain breeds of dogs (Shetland sheepdogs and collie- type breeds) are more sensitive to adverse effects than other breeds. Drug Interactions Use\\tcautiously\\twith\\tdrugs\\tthat\\tmay\\tinhibit\\tp-\\tglycoprotein\\tat\\tthe\\tblood\u2013brain barrier (see Appendix J). 304    Doripenem","indications":"Indications and Clinical Uses Doramectin\\tis\\tused\\tfor\\ttreatment\\tor\\tprevention\\tof\\tGI\\tparasite\\t(nematode)\\tinfections in livestock, lice infestation, lungworm infection, and treatment of scabies. There are reports\\tof\\ta\\tsingle\\tinjection\\t(200\u2013300\\tmcg/kg)\\tused\\tin\\tcats\\tfor\\ttreatment\\tof\\tnotoedric mange (infections from the mite Notoedres cati). In dogs, it has been used for treatment of Demodex infection, but there are other agents available that are effective and possibly safer. If used for treatment of Demodex infection, the typical time to remission with scheduled\\ttreatments\\tis\\t7\u20138\\tweeks,\\tbut\\tsome\\tdogs\\trequire\\t11\\tweeks. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity may occur at high doses and in breeds in which ivermectin- like drugs cross\\tthe\\tblood\u2013brain\\tbarrier.\\tSensitive\\tbreeds\\tinclude\\tcollies,\\tAustralian\\tshepherds, Shetland\\tsheepdogs,\\tOld\\tEnglish\\tsheepdogs,\\tand\\tsome\\trelated\\tbreeds.\\tToxicity\\tis neurotoxic, and signs include depression, ataxia, impaired vision, coma, and death. Sensitivity\\tto\\tivermectin-\\tlike\\tdrugs\\tmay\\tbe\\tbecause\\tof\\tmutation\\tin\\tthe\\tblood\u2013brain barrier (p- glycoprotein deficiency). Treatment of hypodermal larvae in cattle may elicit reactions in tissues from dead larvae. These drugs are safe for pregnant animals. No\\tadverse\\teffects\\twere\\tseen\\tin\\tcats\\ttreated\\twith\\tdoses\\tas\\thigh\\tas\\t345\\tmcg/kg.","notes":"Instructions for Use Doses vary depending on use. In cattle, treatment of hypodermal larvae should begin at\\tthe\\tend\\tof\\tfly\\tseason.\\tAdministration\\tto\\tcattle\\tshould\\tuse\\ta\\t16-\\t\\tor\\t18-\\tgauge\\tneedle for\\tSQ\\tadministration.\\tFor\\tIM\\tinjection,\\tuse\\ta\\t1.5-\\tinch\\tneedle\\tand\\tinject\\tin\\tthe\\tneck muscle. When administering the topical form, remove mud and manure from hide. If it\\trains\\twithin\\t2\\thours\\tof\\tadministration,\\tdecreased\\tefficacy\\tmay\\toccur. Patient Monitoring and Laboratory Tests Monitor for microfilaremia prior to administration in small animals. Formulations \u2022\\t\\tDoramectin\\tis\\tavailable\\tin\\ta\\t1%\\t(10-\\tmg/mL)\\tinjection\\tand\\ta\\t5-\\tmg/mL\\t(0.5%) topical transdermal solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Eprinomectin","active_ingredient":"Eprinomectin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tHeartworm\\tpreventative:\\tThe\\tdose\\tfor\\theartworm\\tprevention\\tin\\tdogs\\thas\\tnot\\tbeen established. Cats \u2022\\t\\tHeartworm\\tpreventative:\\t0.5\\tmg/kg\\tof\\teprinomectin\\tand\\t10\\tmg/kg\\tof praziquantel.\\tThis\\tsolution\\tis\\tapplied\\ton\\tthe\\tskin.  Horses: Doses have not been established for horses. Cattle (Beef and Dairy) \u2022\\t\\tPour-\\t   on:\\t1\\tmL/10\\tkg\\tof\\tbody\\tweight\\t(500\\tmcg/kg).\\tPour\\talong\\tthe\\tbackline\\tof the cattle from the shoulder to the tailhead. \u2022\\t\\tInjection:\\t1\\tmg/kg\\tinjected\\tSQ.","contraindications":"Contraindications and Precautions Animals with high numbers of microfilaremia may show adverse reactions to high doses. Do not administer to dogs at high doses if they are sensitive to the ivermectin class of drugs. Drug Interactions Do not administer with drugs that could potentially increase the penetration of these\\tdrugs\\tacross\\tthe\\tblood\u2013brain\\tbarrier.\\tSuch\\tdrugs\\tinclude\\tketoconazole, itraconazole,\\tcyclosporine,\\tand\\tcalcium-\\tchannel\\tblockers. E Epsiprantel 335 Regulatory Information Cattle\\tpour-\\ton\\tproduct:\\tmilk\\twithdrawal\\ttime,\\tzero\\tdays;\\tpreslaughter\\twithdrawal time, zero days. Cattle\\tinjectable\\tproduct:\\t48\\tdays\\twithdrawal\\tslaughter\\ttime. Epsiprantel ep- sih- pran \u0301til Trade and other names: Cestex","indications":"Indications and Clinical Uses Eprinomectin\\tis\\tindicated\\tfor\\ttreating\\tcattle\\twith\\tgastrointestinal\\t(GI)\\tnematodes, roundworms, lungworms, cattle grubs (all stages), lice, mange mites, and flies. The duration\\tof\\tthe\\tsustained-\\trelease\\tinjection\\tfor\\tGI\\tparasites\\tand\\tlungworms\\tis\\t100\u2013120 days.\\tThe\\tinjection\\tformulation\\tcan\\talso\\tbe\\tadministered\\tSQ\\tfor\\tthe\\ttreatment, protection, and control of Bunostomum phlebotomum\\tfor\\t150\\tdays\\tafter\\ttreatment. Eprinomectin is combined with praziquantel in a transdermal solution for cats for prevention of heartworm disease caused by D. immitis and treatment and control of roundworms,\\thookworms,\\tand\\ttapeworms. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity may occur at high doses and in canine breeds in which this class of drugs\\tcrosses\\tthe\\tblood\u2013brain\\tbarrier.\\tToxicity\\tis\\tneurotoxic,\\tand\\tsigns\\tinclude hypersalivation, depression, ataxia, difficulty with vision, coma, and death. Sensitivity to this class of drugs occurs in certain breeds because of a mutation in\\tthe\\tmultidrug\\tresistance\\tgene\\t(ABCB1,\\tformerly\\tMDR1\\tgene)\\tthat\\tcodes\\tfor the\\tmembrane\\tpump\\tP-glycoprotein.\\tThis\\tmutation\\taffects\\tthe\\tefflux\\tpump\\tin the\\tblood\u2013brain\\tbarrier.\\tNeurologic\\tsigns\\talso\\tmay\\toccur\\twhen\\tother\\tanimals\\tare administered high doses.","notes":"Instructions for Use Eprinomectin\\tis\\tapproved\\tin\\tcattle\\tfor\\ttreating\\tGI\\tnematodes,\\troundworms, lungworms, cattle grubs (all stages), lice, mange mites, and flies. It is approved as\\ta\\ttransdermal\\tsolution\\tin\\tcats\\tfor\\tpreventing\\theartworms\\tand\\tGI\\tparasites\\tin combination with praziquantel. Eprinomectin is used in animals for internal and external parasites. Dosage regimens vary, depending on the species, formulation, and parasite treated. Patient Monitoring and Laboratory Tests Monitor for microfilaremia prior to administration in small animals. For other parasitic\\tinfections,\\tconfirm\\tsuccessful\\ttreatment\\twith\\tfecal\\texaminations\\tor\\tskin scrapings. Formulations \u2022\\t\\tEprinomectin\\tis\\tavailable\\tas\\ta\\tpour-\\ton\\tfor\\tcattle\\tin\\ta\\tsolution\\tcontaining\\t5\\tmg/mL of\\teprinomectin.\\tAvailable\\tin\\t250-\\tmL,\\t1-\\t   L,\\t2.5-\\t   L,\\tand\\t5-\\tL\\tplastic\\tbottles. \u2022\\t\\t5%\\tsolution\\t(50\\tmg/mL)\\textended-\\trelease\\tfor\\tinjection\\tin\\t50-\\t,\\t250-\\t   ,\\tand\\t500-\\tmL bottles. \u2022\\t\\tEprinomectin\\tis\\tcombined\\twith\\tpraziquantel\\tin\\ta\\ttransdermal\\tsolution\\tfor\\tcats consisting\\tof\\t4\\tmg/mL\\tof\\teprinomectin\\tand\\t83\\tmg/mL\\tof\\tpraziquantel. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Epsiprantel","active_ingredient":"Epsiprantel","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5.5\\tmg/kg\\tPO. 336    Ergocalciferol Cats \u2022\\t\\t2.75\\tmg/kg\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Ergocalciferol er- go- kal- sif \u0301- role Trade and other names: Calciferol and Drisdol","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tanimals\\tyounger\\tthan\\t7\\tweeks\\tof\\tage.\\tAll\\tdoses\\tare\\tsingle\\tdose. Drug Interactions No drug interactions are reported.","indications":"Indications and Clinical Uses Like\\tpraziquantel,\\tepsiprantel\\tis\\tused\\tprimarily\\tto\\ttreat\\tinfections\\tcaused\\tby tapeworms. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vomiting occurs at high doses. Anorexia and transient diarrhea have been reported. Epsiprantel is safe in pregnant animals.","notes":"Instructions for Use Administer as directed to treat tapeworm infections. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tEpsiprantel\\tis\\tavailable\\tin\\t12.5-\\t,\\t25-\\t  ,\\t50-\\t  ,\\tand\\t100-\\tmg\\tcoated\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Febantel","active_ingredient":"Febantel","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\t10\\tmg/kg\\tfebantel\\talone\\tor\\tin\\tcombination\\twith\\t1\\tmg/kg\\tpraziquantel\\tPO\\twith food once daily for 3 days. \u2022\\t\\tPuppies:\\t15\\tmg/kg\\tfebantel\\talone\\tor\\tin\\tcombination\\twith\\t1.5\\tmg/kg\\tpraziquantel PO with food once daily for 3 days. \u2022\\t\\tFor\\ttreatment\\tof\\tGiardia infection, it has been combined with pyrantel (27\u201335 mg/kg febantel + 27\u201335 mg/kg pyrantel) q24h PO for 3 days. Cats \u2022\\t\\t10\\tmg/kg\\tfebantel\\talone\\tor\\tin\\tcombination\\twith\\t1\\tmg/kg\\tpraziquantel\\tPO\\tin\\tthe food once daily for 3 days. \u2022\\t\\tKittens:\\t15\\tmg/kg\\tfebantel\\talone\\tor\\tin\\tcombination\\twith\\t1.5\\tmg/kg\\tpraziquantel.  Cattle \u2022\\t\\t7.5\\tmL/100\\tkg\\tbody\\tweight\\tPO. Sheep and Goats \u2022\\t\\t1\\tmL/20\\tkg\\tbody\\tweight\\tor\\t5\\tmL/25\\tkg\\tPO. Horses \u2022\\t\\t6\\tmg/kg\\tPO. Regulatory Information Not for use in horses intended for food. No other regulatory restrictions are listed. If administered to food producing animals, consult Food Animal Residue Avoidance Databank (FARAD) for withdrawal time recommendations (www.FARAD.org). Felbamate fel\u2032bah- mate Trade and other names: Felbatol and generic","contraindications":"Contraindications and Precautions Do not use in pregnant animals. Do not use in animals with liver or kidney dysfunction. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses Febantel is indicated in the control and treatment of larvae and adult stages of intestinal nematodes. In horses, it is used for removal of large strongyles (Strongylus vulgaris, Strongylus edentatus, Strongylus equinus), ascarids (Parascaris equorum, sexually mature and immature), pinworms (Oxyuris equi, adult and fourth- stage larvae), and the various small strongyles. In dogs and cats, it is used for treatment of hookworms (Ancylostoma caninum and Uncinaria stenocephala), ascarids (Toxocara canis and Toxascaris leonina), and whipworms (Trichuris vulpis). In dogs, it is used in combination with praziquantel for treatment of hookworms (A. caninum and U. stenocephala), whipworms (T. vulpis), ascarids (T. canis and T. leonina), and tapeworms (Dipylidium caninum and Taenia pisiformis). A formulation of febantel, pyrantel, and praziquantel (Drontal Plus) has been used in cats for treatment of Giardia spp., roundworms, hookworms, and whipworms. In cats, it is also used in combination with praziquantel for removal of hookworms (A. tubaeforme), ascarids (Toxocara cati), and tapeworms (D. caninum and Taenia taeniaeformis). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ordinarily, adverse effects have been rare. Vomiting and diarrhea may occur after dosing.","notes":"Instructions for Use For horses, the paste may be administered on the base of the tongue or added to a portion of the normal grain ration. For most effective results, retreat in 6\u20138 weeks. Febantel suspension may be used in combination with trichlorfon oral liquid when combining 1 part febantel suspension with 5 parts trichlorfon liquid. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tFebantel\\tis\\tavailable\\tin\\tan\\tequine\\tpaste:\\t45.5%\\tfebantel\\t(455\\tmg/mL),\\tsuspension: 9.3% febantel (2.75 g/ounce), and 27.2-  and 163.3- mg tablets. \u2022\\t\\tFebantel\\tis\\talso\\tavailable\\tin\\tcombinations;\\teach\\tgram\\tof\\tpaste\\tcontains\\t34\\tmg\\tof febantel and 3.4 mg of praziquantel. \u2022\\t \\tChewable\\ttablets\\tare\\tavailable\\tfor\\tsmall\\tanimals\\tin\\tthree\\tsizes\\tcontaining\\tfebantel, pyrantel pamoate, and praziquantel in the following sizes: 22.7 mg praziquantel, 22.7 mg pyrantel, and 113.4 mg febantel; 68.0 mg praziquantel, 68.0 mg pyrantel, and 340.2 mg febantel; and 136.0 mg praziquantel, 136.0 mg pyrantel, and 680.4 mg febantel. 356    Felbamate Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Fenbendazole","active_ingredient":"Fenbendazole","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t50\\tmg/kg/day\\tfor\\t3\\tdays\\tPO.\\tDuration\\tmay\\tbe\\textended\\tto\\t5\\tdays\\tfor\\tsevere parasitic infestations. For pulmonary helminths (lungworms) in dogs, increase the duration of this dosage to 10\u201314 days. \u2022 \\t \\tGiardia treatment: 50 mg/kg q24h for 3\u20135 days. Cats \u2022\\t\\t50\\tmg/kg/day\\tfor\\t3\\tdays\\tPO. \u2022\\t\\tDuration\\tmay\\tbe\\textended\\tto\\t5\\tdays\\tfor\\tsevere\\tparasitic\\tinfestations.  Horses \u2022\\t \\tIntestinal\\tparasites,\\tsuch\\tas\\tstrongyles,\\tpinworms,\\tand\\tascarids:\\tPanacur\\tgranules\\tor\\tpaste is administered at a dose of 5.1 mg/kg (2.3 mg/lb) PO. Two packets of 1.15 g each will treat a 450- kg (1000- lb) horse. Panacur paste can be administered to horses at a dose of 5 mg/kg PO. Retreatment at 6\u20138 weeks may be necessary. For treatment of ascarids (Parascaris equorum) in horses, a higher dose of 10 mg/kg is recommended. Sheep and Goats \u2022\\t\\t5\\tmg/kg\\tPO. Cattle \u2022\\t\\t5\\tmg/kg\\tPO\\tor\\t5\\tmg/kg/day\\tprovided\\tin\\tfeed\\tfor\\t3\u20136\\tdays. Regulatory Information Cattle withdrawal time (meat): 8 days. There is no withdrawal period for milk. Goat withdrawal time: 6 days meat; 0 days milk. For additional withdrawal time information, contact FARAD at www.FARAD.org. Fenoldopam Mesylate fe- nol\u2032doe- pam Trade and other names: Corlopam","contraindications":"Contraindications and Precautions No known contraindications. It may be used in all ages of animals. Drug Interactions There are no known drug interactions.","indications":"Indications and Clinical Uses Fenbendazole is effective for treatment of numerous helminth intestinal parasites in animals, including Toxocara, Toxascaris, Ancylostoma, and Trichuris spp. In dogs, it is effective for most intestinal helminth parasites and against nematodes. In dogs, it also has been used for pulmonary helminths (lungworms), but a longer duration of treatment is needed. Fenbendazole has been effective for treatment of Giardia infection, but higher doses are needed and there may be failure rates as high as 50%. It is effective in cats for treatment of lungworms, flukes, and a variety of helminth parasites. In horses, it is used for the control of large strongyles, small strongyles, pinworms, and ascarids. In pigs, it is effective for lungworms, large roundworms, nodular worms, small stomach worms, and kidney worms. In beef and dairy cattle, it is effective for control of lungworms, stomach worms, barberpole worms, stomach worms,  and various intestinal worms. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Fenbendazole has a good safety margin, but vomiting and diarrhea have been reported. When evaluated at doses of three and five times the recommended dose at three times the recommended duration, fenbendazole was well tolerated, and no adverse effects were reported in the target species. It has been safe to use during pregnancy. There have been reports of pancytopenia associated with fenbendazole administration, but these are rare.","notes":"Instructions for Use Dose recommendations are based on clinical studies by the manufacturer. Granules may be mixed with food. Paste may be given to horses and cattle. Presence of food does not affect oral absorption. In studies for treatment of Giardia infection, it was safer than other treatments but less effective. Patient Monitoring and Laboratory Tests Fecal monitoring may be performed to determine the efficacy of treatment for intestinal parasites. F Fenoldopam Mesylate 359 Formulations \u2022\\t\\tFenbendazole\\tis\\tavailable\\tin\\t22.2%\\t(222\\tmg/g)\\t(Panacur)\\tgranules,\\t10%\\toral\\tpaste (92 g/32 oz), and 100- mg/mL oral suspension. Some formulations (e.g., Panacur Plus) may contain other ingredients such as ivermectin and praziquantel. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Fluralaner","active_ingredient":"Fluralaner","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t25\\tmg/kg\\tonce\\tevery\\t12\\tweeks\\tfor\\teither\\toral\\tchew\\ttablets\\tor\\ttopical\\tsolution. \u2022\\t\\tTreatment\\tof\\tDemodex infection: 25 mg/kg at 12- week intervals. Cats \u2022\\t\\t40\\tmg/kg\\ttopical\\tsolution\\tapplied\\tevery\\t12\\tweeks. \u2022\\t \\tThe\\tcombination\\tof\\tfluralaner\\tand\\tmoxidectin\\tfor\\tcats\\t(Bravecto\\tPlus)\\tshould\\tbe applied at a dose of 40 mg/kg fluralaner and 0.9 mg/kg moxidectin every 2 months.  No large animal doses have been established. Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). Fluticasone Propionate floo- tik\u2032ah- sone  proe- pee- oe- nayt Trade and other names: Flovent","contraindications":"Contraindications and Precautions There are no known contraindications. Fluralaner was studied at three times the dose in laboratory animals, and adverse effects on breeding, pregnancy, or lactation were not observed. However, safety in breeding cats has not been studied. Because of risk of seizures, use cautiously in animals prone to seizures. Drug Interactions There are no known drug interactions with fluralaner. It has been administered safely with vaccines, anthelmintics, antibiotics, and corticosteroids. It should not be used concurrently with other drugs in the isooxazoline class because this may increase the risk of neurologic problems. F Fluticasone Propionate 389","indications":"Indications and Clinical Uses Fluralaner, like the other isooxazolines is active against fleas, mites, and ticks. After oral administration or topical application, it can start killing fleas within 2\u20134 hours, with practically 100% of the fleas killed by 8 hours. The chew tablet for dogs has an approved indication for killing adult fleas and to prevent flea infestations (Ctenocephalides felis). It is also approved for treatment and control of tick infestations. Because of this action, fluralaner can reduce the risk that these vectors may pose for disease transmission. For example, it may prevent infections caused by Borrelia burgdorferi (Lyme disease) and Babesia canis. The approved label indication for fluralaner is treatment of fleas and ticks, but extralabel uses, using the approved label dose, have included treatment of generalized demodicosis caused by Demodex canis. In a clinical study, there were greater reductions in mites from treatment with fluralaner compared with treatment with  moxidectin and imidacloprid . A single dose was effective for eliminating sarcoptic mange (Sarcoptes scabiei) in dogs. It has also been effective for eliminating ear mites (Otodectes cynotis) in dogs and cats. The proper use of fluralaner involves administration of an oral chew tablets, administered with or without food, or application of a topical solution. A topical solution containing both fluralaner and moxidectin is available for cats (Bravecto Plus) for prevention of heartworm, roundworms, hookworms, and fleas and ticks. Exotic species: There have been successful accounts of treatment in zoo or exotic species, without adverse effects, such as rabbits, bears, and other zoo mammals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have been rare from administration of fluralaner. It has been safe in dogs at least 6 months of age. Collie breeds and other herding breeds with genetic mutations of the MDR gene or ABCB1 gene can be treated safely with fluralaner. It can also be used with other ectoparasiticides such as ivermectin and milbemycin. Adverse effects reported from the manufacturer\u2019s safety studies (some at high doses) of the chewable tablet include vomiting, diarrhea, lethargy, and reduced appetite. According to the manufacturer, it should not be used in puppies or kittens younger than 6 months of age, but they performed safety studies in puppies 8\u20139 weeks of age at five times the clinical dose and there were no adverse effects. For the topical solution, the most common adverse effects included vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis or rash and scabs or ulcerated lesions on the skin. It was safe in adult cats and kittens older than 6 months of age. In safety studies in kittens at least 11\u201313 weeks of age, it was safe at five times the dose. There is a concern about neurologic adverse effects, including seizures, from administration of isooxazolines in dogs. This has been reported primarily with sarolaner, but the manufacturer of fluralaner warns that it should be used cautiously in dogs or cats with a history of seizures. In cats, neurologic problems were observed in 2 of 244 cats involved with a field study.","notes":"Instructions for Use Doses for fluralaner are established from the approved label dosing. Interval of dosing is based on efficacy studies. It is effective for treatment of fleas and most ticks for 12 weeks but not beyond 8 weeks for the Lone Star tick (Amblyomma americanum). It can eliminate sarcoptic mange with a single dose. In cats, it was effective for fleas and ticks for 12 weeks but not beyond 8 weeks for the American dog tick (Dermacentor variabilis). The oral chew tablets can be administered with, or without food. To administer the topical solution, follow the instructions on the product label. The hair between the shoulder blades on dogs or behind the head on cats should be parted and the contents of the solution should be applied to the skin. Avoid contact with the application site until it has dried. Patient Monitoring and Laboratory Tests There is no routine monitoring required. Monitor response to treatment through clinical examination of skin at regular check- ups. Formulations \u2022\\t\\tFluralaner\\tis\\tavailable\\tin\\ta\\tflavored\\tchew\\ttablet\\tfor\\tdogs\\tin\\t112.5-\\t,\\t250-\\t   ,\\t500-\\t   , 1000- , and 1400- mg sizes. \u2022\\t\\tFluralaner\\tis\\tavailable\\tas\\ta\\ttopical\\tsolution\\twith\\t280\\tmg\\tof\\tfluralaner\\tper\\tmilliliter\\tin each tube. Each tube is packaged separately in sizes of 112.5- , 250- , 500- , 1000- , and 1400- mg per tube. \u2022\\t\\tFluralaner\\ttopical\\tsolution\\tfor\\tcats.\\tEach\\ttube\\tis\\tformulated\\tto\\tadminister\\ta\\t40-\\tmg/ kg dose. Each milliliter contains 280 mg of fluralaner in sizes of 112.5- , 250- , and 500- mg per tube. \u2022\\t\\tFluralaner\\tand\\tmoxidectin\\ttopical\\tsolution\\tfor\\tcats\\tis\\tavailable\\tas\\t280\\tmg\\tfluralaner and 14 mg moxidectin per milliliter. Stability and Storage Fluralaner should be stored in a dry place at controlled temperatures less than 25\xb0C.","original_category":"Antiparasitic, Ectoparasiticide"},{"name":"Furazolidone","active_ingredient":"Furazolidone","species":["Not specified in source"],"dosage":"\u2022\\t\\t4\\tmg/kg\\tq12h\\tfor\\t7\u201310\\tdays\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Furosemide fyoo- roe\u2032seh- mide Trade and other names: Lasix and generic brands","contraindications":"Contraindications and Precautions No contraindications reported for animals. Drug Interactions Do not use with MAOIs.","indications":"Indications and Clinical Uses Furazolidone has been used to treat protozoal intestinal parasites. However, because efficacy and safety of other oral antiprotozoal drugs are better established, they are used more often. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not reported in animals. In people, mild anemia, hypersensitivity, and disturbance of intestinal flora have been reported.","notes":"Instructions for Use Clinical studies have not been reported for animals. Doses and recommendations are based on extrapolation from humans. Other drugs, such as fenbendazole, may be preferred for treating Giardia infections. F Furosemide 395 Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t \\tFurazolidone\\thas\\tbeen\\tdiscontinued\\tin\\tthe\\tUnited\\tStates.\\tIt\\tmay\\tbe\\tavailable\\tthrough some compounding pharmacies. The previously available tablet was 100 mg. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Ivermectin","active_ingredient":"Ivermectin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tHeartworm\\tpreventative:\\t6\\tmcg/kg\\tevery\\t30\\tdays\\tPO. \u2022\\t\\tPrior\\tto\\tadulticide\\ttreatment:\\tAdminister\\tpreventative\\tdose\\tfor\\t2\\tmonths,\\tand\\tup\\tto 3 months prior to adulticide treatment. \u2022\\t\\tHeartworm\\ttreatment:\\tIvermectin\\tadministered\\tat\\tpreventive\\tdoses\\tcombined\\twith doxycycline\\tat\\t10\\tmg/kg\\tPO\\tper\\tday\\tfor\\t28\\tdays. \u2022\\t\\tEctoparasite\\ttherapy:\\t200\u2013400\\tmcg/kg\\t(0.2\u20130.4\\tmg/kg)\\tIM,\\tSQ,\\tor\\tPO. \u2022\\t\\tDemodicosis\\ttherapy:\\tStart\\twith\\t100\\tmcg/kg/day\\t(0.1\\tmg/kg)\\tand\\tincrease\\tdose by\\t100\\tmcg/kg/day\\tto\\t600\\tmcg/kg/day\\t(0.6\\tmg/kg)\\tfor\\t60\u2013120\\tdays\\tPO. (Successful treatment is confirmed with negative skin scrapings.) \u2022\\t\\tSarcoptic\\tmange\\tand\\tcheyletiellosis\\ttherapy:\\t200\u2013400\\tmcg/kg\\tevery\\t7\\tdays\\tPO\\tor every\\t14\\tSQ\\tfor\\t4\u20136\\tweeks. Cats \u2022\\t\\tHeartworm\\tpreventive:\\t24\\tmcg/kg\\tevery\\t30\\tdays\\tPO. \u2022\\t\\tEctoparasite\\ttherapy:\\t200\u2013400\\tmcg/kg\\t(0.2\u20130.4\\tmg/kg)\\tIM,\\tSQ,\\tor\\tPO,\\tevery\\t7 days or as needed based on skin scraping and clinical examination. \u2022\\t\\tEndoparasite\\ttherapy:\\t200\u2013400\\tmcg/kg\\t(0.2\u20130.4\\tmg/kg)\\tweekly\\tSQ\\tor\\tPO. \u2022\\t\\tTopical:\\t0.5\\tmL\\tper\\tear\\t(0.1\\tmg/mL)\\tfor\\ttreating\\tear\\tmites.  Horses \u2022\\t\\t200\\tmcg/kg\\t(0.2\\tmg/kg)\\tIM,\\toral\\tpaste,\\tor\\toral\\tsolution.\\tOral\\tsolution\\tdose\\tis\\t1 mL per 50 kg (110 lb). Administer once or as needed as part of a comprehensive worming program. Calves \u2022\\t\\tSlow-\\t   release\\tbolus:\\t5.7\u201313.8\\tmg/kg,\\tas\\ta\\tsingle\\tdose,\\twhich\\thas\\ta\\tduration\\tof\\t135 days. Cattle and goats \u2022\\t\\tInjection\\tsolution:\\t200\\tmcg\\t(0.2\\tmg)/kg\\tas\\ta\\tsingle\\tdose\\tSQ. \u2022\\tPour-on:\\t0.5\\tmg/kg\\tor\\t1\\tmL/10\\tkg\\t(22\\tlb)\\tof\\t5\\tmg/mL\\tsolution. Pigs \u2022\\t\\t300\\tmcg\\t(0.3\\tmg)/kg\\tSQ\\tas\\ta\\tsingle\\tdose. Sheep \u2022\\t\\tInjection\\tsolution:\\t200\\tmcg\\t(0.2\\tmg)/kg\\tas\\ta\\tsingle\\tdose\\tSQ. \u2022\\t\\t200\\tmcg/kg\\tPO. Regulatory Information Pigs\u2019\\twithdrawal\\ttime\\tfor\\tmeat:\\t18\\tdays\\tfor\\tSQ\\tinjection. Cattle and calves\u2019 withdrawal time (meat): 35 days for SQ injection or 180 days for slow- release bolus. Forty- eight days for topical (pour- on). Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. Sheep withdrawal time (meat): 11 days. Goats\u2019\\twithdrawal\\ttime:\\t11\u201314\\tdays\\t(meat)\\tand\\t6\u20139\\thours\\t(milk).\\tWhen administering\\tSQ\\tto\\tgoats,\\tuse\\t35\\thours\\tfor\\tmeat\\tand\\t40\\thours\\tfor\\tmilk. eye- ver- mek\u2032tin  +  pray- zih- kwon\u2032tel Trade and other names: Equimax","contraindications":"Contraindications and Precautions Do not administer to animals younger than 6 weeks of age. Animals with high numbers of microfilaremia may show adverse reactions to high doses. If dogs are sensitive to ivermectin (see earlier list of breeds), they may be sensitive to other drugs in this class (other avermectins). Ivermectin at approved clinical doses for treatment of endoparasites or heartworm prevention has been safe in pregnant animals. At high doses used for treating demodicosis, safety during pregnancy is not known, but there have been no reports of teratogenic effects. In the most sensitive laboratory animal (mouse), the lowest dose that is teratogenic is 400\\tmcg/kg.\\tDogs\\twith\\tthe\\tABCB1 (MDR) mutation may also be sensitive to other drugs such as loperamide, milbemycin, moxidectin, and anticancer drugs. Drug Interactions Except for low doses used for heartworm prevention, do not administer with drugs that could potentially increase the penetration of ivermectin across the blood\u2013brain barrier. Such drugs include ketoconazole, itraconazole, cyclosporine, and calcium- channel blockers. Do not administer with spinosad (Comfortis, Trifexis) because it may potentiate toxicity. I","indications":"Indications and Clinical Uses Ivermectin is used in horses for the treatment and control of large strongyles (adult) (Strongylus vulgaris, Strongylus edentatus, and Triodontophorus spp.), small strongyles (adult and fourth- stage larvae) (Cyathostomum spp., Cylicocyclus spp., Cylicostephanus spp.), pinworms (adult and fourth- stage larvae) (Oxyuris equi), large roundworms (adult) (Parascaris equorum), hairworms (adult) (Trichostrongylus axei),  large- mouth stomach worms (adult) (Habronema muscae), neck threadworms (microfilariae) (Onchocerca spp.), and stomach bots (Gastrophilus spp.). In cattle, it is used for treatment and control of GI nematodes (adults and fourth- stage larvae) (Haemonchus placei, Ostertagia ostertagi) (including inhibited larvae), Ostertagia lyrata, T. axei, T. colubriformis, Cooperia oncophora, Cooperia punctata, Cooperia pectinata, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), Nematodirus spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth- stage larvae) (Dictyocaulus viviparus); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); sucking lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); and mites (scabies) (Psoroptes ovis [syn. P. communis var. bovis], Sarcoptes scabiei var. bovis). In pigs, it is used for treatment and control of GI roundworms (adults and fourth- stage larvae) large roundworm, Ascaris suum; red stomach worm, Hyostrongylus rubidus; nodular worm, Oesophagostomum species; threadworm, Strongyloides ransomi (adults only); somatic roundworm larvae (threadworm, S. ransomi [somatic larvae]); lungworms (Metastrongylus spp. [adults only]); lice (H. suis); and mites (Sarcoptes scabiei var. suis). In small animals (dogs and cats), it is used as a heartworm preventative (low dose) or to treat external parasites (mites) and intestinal parasites at higher doses. The benefit for heartworm prophylaxis in animals is the ability to kill young larvae, older larvae, and immature or young adults and adult filariae. Ivermectin is an effective microfilaricide after adulticide therapy. It has been recommended by the American Heartworm Society to treat heartworm- positive dogs for 2\u20133 months prior to adulticide therapy. This allows immature worms to reach full maturity that are more susceptible to melarsomine, as well as preventing new infection. Ivermectin can also reduce numbers of adult heartworms when administered long term at preventive doses. For optimal heartworm adulticide effect, it is often administered with oral doxycycline (10 mg/kg per day for 28 days). Treatment of Demodex infections is effective but requires higher doses than for any other indication.  See Instructions for Use section later for instructions to treat Demodex. Precautionary Information indications,\\tlarge-\\tanimal\\tinjectable\\tproducts\\tare\\toften\\tadministered\\tPO,\\tIM,\\tor\\tSQ\\tto small animals. Do not administer intravenously. Injections in pigs should be made in the neck only. Because some dogs may be sensitive to ivermectin, if a dog has not previously received ivermectin and high doses are needed (e.g., to treat Demodex infection), start with a low dose (50\u2013100 mcg/kg) and then increase by increments of 50\u2013100 mcg/kg/day on subsequent doses every day. During this increase, the dog should be observed for signs of CNS toxicity (ataxia, tremors, sedation). When the maintenance dose\\tis\\tachieved\\t(300\u2013600\\tmcg/kg\\tPO),\\tit\\tshould\\tbe\\tadministered\\tonce\\tdaily\\tuntil 4\\tweeks\\tafter\\tthe\\tsecond\\tconsecutive\\tnegative\\tmonthly\\tskin\\tscraping.\\tWhen\\tusing extralabel formulations to treat dogs, the aqueous formulations have better palatability than the propylene- based formulations. They can be mixed with flavorings to improve palatability.","side_effects":"Adverse Reactions and Side Effects Toxicity may occur at high doses and in breeds in which ivermectin crosses the blood\u2013brain barrier. Sensitive breeds include collies, Australian shepherds, Old English sheepdogs, longhaired whippets, and Shetland sheepdogs. Toxicity is neurotoxic and signs include hypersalivation, depression, ataxia, difficulty with vision, coma, and death. Sensitivity to ivermectin occurs in certain breeds because of a mutation in the multidrug resistance gene (ABCB1, formerly MDR1 gene) that\\tcodes\\tfor\\tthe\\tmembrane\\tpump\\tP-\\tglycoprotein.\\tThis\\tmutation\\taffects\\tthe efflux pump in the blood\u2013brain barrier. Therefore, ivermectin can accumulate in the brain of these susceptible animals. High doses in normal animals may also produce similar toxicosis. Most nonsusceptible dogs can tolerate doses of 100\u2013400\\tmcg/kg.\\tBut\\tsensitive\\tbreeds\\t(dogs\\twith\\tthe\\tABCB1 mutation) may exhibit\\ttoxicity\\tat\\tdoses\\tof\\t150\u2013340\\tmcg/kg. Retinopathy has also been observed in dogs administered high doses. In affected animals, a sudden onset of blindness, mydriasis, or both may occur, but dogs recover if the drug is discontinued.","notes":"Instructions for Use Ivermectin is used in a wide range of animals for internal and external parasites. Dosage regimens vary, depending on the species and parasite treated. Heartworm prevention is\\tthe\\tlowest\\tdose;\\tother\\tparasites\\trequire\\thigher\\tdoses.\\tProducts\\tfor\\theartworm prevention and a topical form are the only forms approved for small animals; for other Patient Monitoring and Laboratory Tests Monitor for microfilaremia prior to administration in small animals. For other parasitic infections, confirm successful treatment with fecal examinations or skin scrapings. Ivermectin\\tat\\tdoses\\tof\\t400\\tmcg/kg\\thas\\tproduced\\tneurologic\\ttoxicosis\\tin Siamese kittens, and doses as low as 300 mcg/kg have been lethal in kittens. In horses, adverse reactions may include itching because of effects on microfilariae. Treatment of intoxication: Administer activated charcoal from excessive doses administered orally. Symptomatic treatment includes ventilation support and control of seizures. An IV administration of lipid emulsion can be used at a dose of 1.5 mL/kg bolus of a 20% emulsion. Formulations \u2022\\t\\tIvermectin\\tis\\tavailable\\tin\\t1%\\t(10\\tmg/mL),\\t2%\\t(20\\tmg/mL),\\tand\\t0.27%\\t(2.7\\tmg/ mL) injectable solution; 10- mg/mL oral solution; 5 mg/mL pour-on for cattle, 0.8- mg/mL oral sheep drench; 18.7- mg/mL oral paste; 68- , 136- , and 272- mcg tablets; and 55-  and 165- mg feline tablets. A water- soluble topical product 0.01% (0.1 mg/mL) is available in ampules in foil pouches for treating ear mites in cats. \u2022\\t\\tCompounded\\tformulations:\\tIvermectin\\tis\\tchemically\\tunstable\\tat\\tcertain\\tpH ranges and after exposure to water. Unless stability and strength are documented, compounded formulations are not recommended. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Ivermectin + Praziquantel","active_ingredient":"Ivermectin + Praziquantel","species":["Equine"],"dosage":"\u2022\\t\\tNo\\tdose\\tavailable\\tfor\\tsmall\\tanimals.  Horses \u2022\\t\\t200\\tmcg/kg\\tof\\tivermectin\\tand\\t1\\tmg/kg\\tof\\tpraziquantel\\tPO. Regulatory Information No withdrawal times are available for animals intended for food (extralabel use). 490    Kanamycin Sulfate Kanamycin Sulfate kan- ah- mye\u2032sin sul\u2032fate Trade and other names: Kantrim","contraindications":"Contraindications and Precautions Ivermectin can be administered to breeding, pregnant, and lactating animals without adverse effects. Drug Interactions Use cautiously with other drugs that may affect penetration across the blood\u2013 brain barrier.","indications":"Indications and Clinical Uses Ivermectin has properties as described in the Ivermectin monograph.\\tPraziquantel\\tis added to this formulation to increase the spectrum. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity may occur at high doses. Ivermectin appears to be safe for pregnant animals.","notes":"Instructions for Use Use of this drug is similar to the individual drugs ivermectin and praziquantel. Patient Monitoring and Laboratory Tests Fecal samples should be examined for parasites to monitor effectiveness. Formulations \u2022\\t\\tIvermectin\\t+\\tpraziquantel\\tis\\tavailable\\tin\\ta\\tpaste\\tcomposed\\tof\\t1.87%\\tivermectin\\tand 14.03%\\tpraziquantel. I Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Levamisole Hydrochloride","active_ingredient":"Levamisole Hydrochloride","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\tEndoparasites:\\t5\u20138\\tmg/kg\\tonce\\tPO\\t(up\\tto\\t10\\tmg/kg\\tPO\\tfor\\t2\\tdays). \u2022\\t\\tHookworms:\\t10\\tmg/kg/day\\tfor\\t2\\tdays. \u2022\\t\\tMicrofilaricide:\\t10\\tmg/kg\\tq24h\\tPO\\tfor\\t6\u201310\\tdays\\t(recommended\\tto\\tuse macrocyclic lactones instead). \u2022\\t\\tImmunostimulant:\\t0.5\u20132\\tmg/kg\\tthree\\ttimes\\tper\\tweek\\tPO.\\t(In\\thumans,\\tthe immunostimulant dose is given q8h for 3 days.) Cats \u2022\\t\\tEndoparasites:\\t4.4\\tmg/kg\\tonce\\tPO. \u2022\\t\\tLungworms:\\t20\u201340\\tmg/kg\\tq48h\\tfor\\tfive\\ttreatments\\tPO.  Cattle and Sheep \u2022\\t \\t8\\tmg/kg\\tonce\\tPO\\tor\\tapproximately\\tone\\t2.19-\\tg\\tbolus\\tper\\t450\u2013750\\tlb\\t(200\u2013340\\tkg). \u2022\\t\\tLevamisole\\tinjection\\t(for\\tcattle):\\t8\\tmg/kg\\tSQ\\tinto\\tthe\\tmidneck\\tarea\\tonce\\tor approximately 2 mL per 100 lb (45 kg). Pigs \u2022\\t\\t8\\tmg/kg\\tin\\tdrinking\\twater. Regulatory Information Cattle\\twithdrawal\\ttime\\tfor\\tmeat:\\t2\\tdays\\t(PO)\\tand\\t7\\tdays\\t(SQ\\tinjection). Sheep\\twithdrawal\\ttime\\tfor\\tmeat:\\t3\\tdays. Pig\\twithdrawal\\ttime\\t(meat):\\t3\\tdays. Horses:\\tThere\\tare\\tsome\\treports\\tthat\\tlevamisole\\tcan\\tbe\\tconverted\\tto\\taminorex\\tin horses, which is a CNS stimulant and a banned substance in racing horses. Levetiracetam lee- ve- tye- ra\u2032se- tam Trade and other names: Keppra, Spritam, and generic","contraindications":"Contraindications and Precautions Use cautiously in animals with high heartworm microfilaria burdens. Reactions are possible from the heavy kill rate of microfilaria. There are no adverse reactions on fertility and no effects on pregnancy. In rats and rabbits, there was no evidence of teratogenicity or embryotoxicity at doses of 180 mg/kg. Levamisole is abused in people and often mixed with cocaine to either potentiate the effects to produce additional central nervous system (CNS) stimulation or is added as a marker compound. When used in this form in people, it has produced agranulocytosis in some individuals. Levamisole may potentially be converted to aminorex, a CNS stimulant in horses with amphetamine properties, which may affect performance. Drug Interactions Do not use with pyrantel because they share the same mechanism of toxicity.","indications":"Indications and Clinical Uses In cattle and sheep, levamisole is used to treat a variety of nematodes, including stomach worms (Haemonchus, Trichostrongylus, and Ostertagia spp.), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, and Chabertia spp.), and lungworms (Dictyocaulus spp.). In pigs, it is used to treat nematodes such as large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), intestinal thread worms (Strongyloides ransomi), and lungworms (Metastrongylus spp.). Levamisole has been used for treatment of endoparasites in dogs and as a microfilaricide. Macrocyclic lactones (e.g., milbemycin oxime or ivermectin) are considered a preferred heartworm microfilaricide. In people, levamisole has been used as an immunostimulant to aid in treatment of colorectal carcinoma and malignant melanoma. In animals, levamisole also is used as an immunostimulant, but reports of efficacy are lacking. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Levamisole may produce cholinergic toxicity. It has produced vomiting in some dogs. The injectable formulation has caused some swelling at the site of injection. In humans, when used as an immunostimulant, it has caused stomatitis, agranulocytosis, and thrombocytopenia.","notes":"Instructions for Use In heartworm- positive dogs, it may sterilize female adult heartworms. Levamisole has also been used as an immunostimulant; however, clinical reports of its efficacy are not 510    Levetiracetam available. Because of the possibility of contamination at the injection site, use a clean needle with each animal and clean the injection site. Patient Monitoring and Laboratory Tests Monitor for microfilaria before treatment because of risk of reaction with a high heartworm burden. Formulations \u2022\\t \\tLevamisole\\tis\\tavailable\\tin\\t0.184-\\tg\\tbolus;\\t2.19-\\tg\\tbolus;\\t9-\\t,\\t11.7-\\t   ,\\tand\\t18.15-\\tg\\tper\\tpacket; 136.5- mg/mL and 182- mg/mL injection (levamisole phosphate); and 50- mg tablet. \u2022\\t\\tLevamisole\\tis\\talso\\tavailable\\tin\\tthe\\tUnited\\tStates\\tas\\ta\\t46.8-\\tg\\tpacket\\tfor\\tcattle\\tand sheep and an 18.15- g bottle for pigs. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Lotilaner","active_ingredient":"Lotilaner","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t \\t20\\tmg/kg\\tonce\\tevery\\tmonth.\\tAdminister\\twith\\tfood\\tor\\twithin\\t30\\tminutes\\tafter\\tfeeding. Cats \u2022\\t\\tA\\tdose\\tfor\\tcats\\thas\\tnot\\tbeen\\testablished.  No large animal doses have been established. Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). Lufenuron loo- fen\u2032yoo- rahn Trade and other names: Program","contraindications":"Contraindications and Precautions There are no known contraindications for use of lotilaner in dogs, except possibly a history of seizures. The manufacturer recommends that it should not be used in dogs younger than 8 weeks of age. The safety in breeding animals has not been evaluated. The use and safety in cats have not been evaluated. Drug Interactions There are no known drug interactions with lotilaner. It has been used safely with vaccines, anthelmintics, antibiotics, corticosteroids, NSAIDs, anesthetics, and antihistamines. It should not be used concurrently with other drugs in the isooxazoline class as this may increase the risk of neurologic problems.","indications":"Indications and Clinical Uses Lotilaner, like the other isooxazolines is active against fleas, mites, and ticks. After oral administration or topical application, it can kill fleas rapidly. The chew tablet for dogs has an approved indication for killing adult fleas and to prevent flea infestations (Ctenocephalides felis). It is also approved for treatment and control of tick infestations caused by Amblyomma americanum (Lone Star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black- legged tick), and Rhipicephalus sanguineus (brown dog tick) for 1 month in dogs. Because of this action, lotilaner can reduce the risk that these vectors may pose for disease transmission. For example, it may prevent infections caused by Borrelia burgdorferi (Lyme disease) and Babesia canis. The approved label indication for lotilaner is treatment of fleas and ticks, but extralabel uses, using the approved label dose, have included treatment of generalized demodicosis caused by Demodex canis. The proper use of lotilaner involves administration of oral chew tablets, administered with food. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have been rare from administration of lotilaner. In the field studies, there were rare incidences of weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. In safety studies, at up to five times the approved label dose, there were no clinically relevant treatment- related adverse effects. There is a concern about neurologic adverse effects, including seizures, from administration of isooxazolines in dogs. This has been reported primarily with sarolaner, but the manufacturer of lotilaner warns that it should be used cautiously in dogs with a history of seizures.","notes":"Instructions for Use Doses for lotilaner are established from the approved label dosing. Interval of dosing is based on efficacy studies. It is effective for treatment of fleas (C. felis) and most ticks, including the American dog tick (D. variabilis), the Lone Star tick (A. americanum), and brown dog tick (R. sanguineus) for 1 month after treatment. There is reduced oral absorption on an empty stomach; therefore, administer with a meal or within 30 minutes after feeding. Patient Monitoring and Laboratory Tests There is no routine monitoring required. Monitor response to treatment through clinical examination of skin at regular check- ups. L Lufenuron 537 Formulations \u2022\\t\\tLotilaner\\tis\\tavailable\\tin\\ta\\tbeef-\\tflavored\\tchew\\ttablet\\tfor\\tdogs\\tin\\tsizes\\tof\\t56.25-\\t, 112.5-\\t\\t225-\\t,\\t450-\\t   ,\\tand\\t900-\\tmg\\ttablets. Stability and Storage Lotilaner should be stored in a dry place at controlled temperatures less than 25\xb0C.","original_category":"Antiparasitic, ectoparasiticide"},{"name":"Lufenuron","active_ingredient":"Lufenuron","species":["Canine","Feline","Equine"],"dosage":"given to dogs at a dosage of 10 mg/kg every 30 days and to cats at a dosage of 30 mg/ kg every 30 days. It may also have some inhibition on fungal cell membranes because it inhibits the cell wall of fungi, which contain chitin, and other complex polysaccharides. However, the use as an antifungal agent is not well established in animals (see later). Pharmacokinetics: The pharmacokinetics are characterized by an initial rapid decline in plasma drug concentrations, followed by a slow decline and clearance. Systemic clearance is 0.56 L/kg/day and 0.54 L/kg/day, with a volume of distribution of 44.8 and 48.3 L/kg and a half-life of 60.7 and 65.2 days in cats and dogs, respectively. infections\\tin\\tsmall\\tanimals,\\tparticularly\\tcats,\\tat\\thigh\\tdosages\\tof\\t80\u2013100\\tmg/kg\\tPO. However, endorsement of this use has diminished, and dermatologists have observed a high incidence of recurrence and disputed the reports of efficacy. In horses, lufenuron was not absorbed orally and is not effective for treating fungal infections. It does not have any in vitro effect on Aspergillus fumigatus or Coccidioides immitis. Precautionary Information  Dogs \u2022\\t\\tFlea\\tcontrol:\\t10\\tmg/kg\\tevery\\t30\\tdays\\tPO. \u2022\\t\\tDermatophytes:\\t80\\tmg/kg\\tevery\\t2\\tweeks\\tPO\\t(but\\tthe\\tefficacy\\tof\\tthis\\tuse\\tis questionable and not recommended). Cats \u2022\\t\\tFlea\\tcontrol:\\t30\\tmg/kg\\tevery\\t30\\tdays\\tPO\\tor\\tinjection\\tof\\t10\\tmg/kg\\tSQ\\tevery\\t6 months. \u2022\\t\\tDermatophytes:\\t80\\tmg/kg;\\t100\\tmg/kg\\tPO\\tis\\tthe\\tminimum\\tdose\\tfor\\ttreating cats in a cattery. These doses should be repeated initially after the first 2 weeks and possibly once per month in animals that may be re- exposed. However, as stated earlier, the efficacy of this treatment is questionable and not generally recommended.  Horses \u2022\\t\\tNot\\teffective. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. L loo- fen\u2032yoo- rahn  +  mil- beh- mye\u2032sin oks\u2032eem Trade and other names: Sentinel tablets and Flavor Tabs","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Some animals may be sensitive to milbemycin, and additional details are found in that section. Drug Interactions No drug interactions reported for animals, except those that may pertain to milbemycin, when used in combination.","indications":"Indications and Clinical Uses Lufenuron is used to control flea infestations by preventing hatching of eggs. It has been used as part of flea control, often with other drugs that kill adult fleas. Lufenuron has been combined with milbemycin in formulations for small animals, and additional details may be found in the section on milbemycin. There are isolated clinical reports of the use of lufenuron for treating dermatophyte","side_effects":"Adverse Reactions and Side Effects Lufenuron has been well tolerated in animals. Refer to the section on lufenuron or milbemycin for details regarding this combination.","notes":"Instructions for Use Lufenuron is a highly lipophilic drug and is absorbed best with a meal. If cats have free access to their food, withhold their food until such time that a meal will be consumed readily before administering the lufenuron oral dose. Lufenuron may control flea development with administration once every 30 days in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tLufenuron\\tis\\tavailable\\tin\\t45-\\t,\\t90-\\t\\t135-\\t,\\t204.9-\\t,\\tand\\t409.8-\\tmg\\ttablets\\tand\\t135- and 270- mg suspension per unit pack. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Lufenuron + Milbemycin Oxime","active_ingredient":"Lufenuron + Milbemycin Oxime","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tAdminister\\tone\\ttablet\\tevery\\t30\\tdays\\tbased\\ton\\ttablet\\tsize\\tand\\tweight\\trange\\tlisted\\ton product label. \u2022\\t\\tEach\\ttablet\\tis\\tformulated\\tfor\\tthe\\tsize\\tof\\tthe\\tdog. Cats \u2022\\t\\tNo\\tdose\\tis\\treported.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. 540     Lysine  (L- Lysine) Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Lysine  (L- Lysine) lye\u2032seen Trade and other names:  Enisyl- F","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Lufenuron + milbemycin is used to protect against fleas, heartworms, roundworms, hookworms, and whipworms. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There is a high margin of safety at doses used for flea control or treatment of dermatophytes. Adverse effects have not been reported. Lufenuron appears to be relatively safe in pregnant and young animals.","notes":"Instructions for Use See Lufenuron or Milbemycin for details. Patient Monitoring and Laboratory Tests Monitor for heartworm status in dogs before initiating treatment with milbemycin. Formulations \u2022\\t\\tThe\\tmilbemycin/lufenuron\\tratio\\tis\\tas\\tfollows:\\t2.3/46-\\tmg\\ttablets\\tand\\t5.75/115-\\t, 11.5/230- , and 23/460- mg Flavor Tabs. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Mebendazole","active_ingredient":"Mebendazole","species":["Canine","Equine"],"dosage":"Dogs \u2022\\t\\t22\\tmg/kg\\t(mixed\\twith\\tfood)\\tq24h\\tfor\\t3\\tdays.\\tMay\\tbe\\trepeated\\tin\\t3\\tweeks.  Horses \u2022\\t\\t8.8\\tmg/kg\\tPO. Regulatory Information Do not administer to horses intended for food. Withdrawal times are not established for animals that produce food. For extralabel use\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank (FARAD)\\tat\\twww.FARAD.org. Meclizine mek\u2032lih- zeen Trade and other names: Antivert, Bonine, Meclozine (British name), and generic brands","contraindications":"Contraindications and Precautions No contraindications have been reported. Drug Interactions No drug interactions have been reported for animals. M Meclizine 555","indications":"Indications and Clinical Uses Mebendazole is used in horses for treatment of infections caused by large roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, Strongylus equinus, and Strongylus vulgaris), small strongyles, and mature and immature (fourth larval stage pinworms [Oxyuris equi]). In dogs, it has been used for treatment of infections of roundworms (Toxocara canis), hookworms (Ancylostoma caninum and Uncinaria stenocephala), whipworms (Trichuris vulpis), and tapeworms (Taenia pisiformis). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare. It has been used for many years and has a high margin of safety. Mebendazole causes occasional vomiting and diarrhea in dogs. Some reports suggest idiosyncratic hepatic reactions in dogs, but it is not known if this is a significant risk.","notes":"Instructions for Use The\\tpowder\\tfor\\thorses\\tmay\\tbe\\tsprinkled\\tdirectly\\ton\\tthe\\thorse\u2019s\\tgrain\\tor\\tdissolved\\tin\\t1\\tL of water and administered via stomach tube. For dogs, it may be added directly to food. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMebendazole\\tis\\tavailable\\tin\\t40-\\t\\tor\\t166.7-\\tmg/g\\tpowder,\\t200-\\tmg/g\\tequine\\tpaste, 33.3-\\t  mg/mL\\tsolution,\\tand\\t100-\\tmg\\tchewable\\ttablets\\t(human\\tpreparation).\\tEquine formulations\\tcontain\\teither\\t83.3\\tmg\\tof\\tmebendazole\\tplus\\t375\\tmg\\tof\\ttrichlorfon\\tor 100\\tmg\\tof\\tmebendazole\\tplus\\t454\\tmg\\tof\\ttrichlorfon\\tin\\teach\\tgram\\tof\\tpowder.\\tThe combination\\t(Telmin)\\tis\\ta\\t33-\\tmg/mL\\tliquid\\tsuspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Melarsomine Dihydrochloride","active_ingredient":"Melarsomine Dihydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tAdminister\\tvia\\t deep\\t  IM\\t  injection.\\tFollow\\t   guidelines\\tfrom\\t  the\\t  American\\tHeartworm Society for the safest and most effective use of melarsomine. \u2022\\t\\tThree-\\t   dose\\tprotocol:\\tOne\\tinjection\\ton\\tdays\\t60,\\t90,\\tand\\t91\\tafter\\tthe\\tinitial diagnosis. Cats \u2022\\t\\tNot\\trecommended\\tbecause\\tof\\tadverse\\treactions.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information There\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tthis\\tdrug\\tshould\\tnot\\tbe administered to animals that produce food. Meloxicam mel- oks\u2032ih- kam Trade and other names: Metacam, OroCAM, Meloxidyl, Loxicom (veterinary preparations), Mobic and Vivlodex (human preparation), Metacam suspension (equine preparation, Europe), and Mobicox (human formulation in Canada)","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\thigh\\theartworm\\tburden\\tand\\tuse\\tthe\\tthree-\\tdose protocol to reduce lung injury. Melarsomine may be contraindicated in dogs with class\\t4\\t(very\\tsevere)\\theartworm\\tdisease\\tuntil\\tthe\\tworm\\tburden\\tis\\treduced. Melarsomine is not recommended for cats because adulticide treatment can produce severe and even fatal reactions. Drug Interactions No drug interactions are reported. Administration of prednisolone does not affect efficacy of melarsomine.","indications":"Indications and Clinical Uses Melarsomine\\tis\\tused\\tfor\\theartworm\\tadulticide\\ttherapy.\\tSee\\tInstructions\\tfor\\tUse for proper administration. Melarsomine is highly effective for eliminating heartworms in dogs.\\tEfficacy\\tin\\tcats\\tis\\tonly\\t36%\\tand\\tnot\\trecommended.\\tUsually,\\tcats\\tare\\tnot\\ttreated because\\tit\\tis\\ta\\tself-\\tlimiting\\tdisease,\\tand\\tonly\\tsupportive\\ttreatment\\tis\\tadministered (corticosteroids, bronchodilators, and antiemetics). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Melarsomine\\tadministration\\tmay\\tlead\\tto\\tpulmonary\\tthromboembolism\\t7\u201320\\tdays after\\ttherapy,\\tanorexia\\t(13%\\tincidence),\\tinjection-\\tsite\\treaction\\t(32%\\tincidence of\\tmyositis),\\tor\\tlethargy\\tor\\tdepression\\t(15%\\tincidence).\\tIt\\tcauses\\televations\\tof hepatic\\tenzymes.\\tTo\\tprevent\\tadverse\\treactions\\tof\\tadulticide\\ttherapy,\\tthe\\tAmerican Heartworm\\tSociety\\trecommends\\ta\\tthree-\\tdose\\tprotocol,\\twhereby\\tthe\\tfirst\\tdose is\\tadministered\\tafter\\t2\\tmonths\\tof\\ta\\tmacrocyclic\\tlactone\\t(e.g.,\\tivermectin)\\tand doxycycline.\\tTo\\tlimit\\tlung\\tinjury,\\tadminister\\tprednisolone\\tor\\tprednisone\\tat\\ta dosage\\tof\\t0.5\\tmg/kg\\tq12h\\tfor\\tthe\\tfirst\\tweek\\tafter\\tadulticide\\ttreatment\\tand\\t0.5 mg/kg\\tq24h\\tfor\\tthe\\tsecond\\tweek\\tfollowed\\tby\\t0.5\\tmg/kg\\tevery\\tother\\tday\\tfor\\t1\u20132 weeks. High doses (three times the dose) can cause pulmonary inflammation and death.\\tIf\\thigh\\tdoses\\tare\\tadministered,\\tdimercaprol\\t(3\\tmg/kg\\tIM)\\tmay\\tbe\\tused\\tas antidote. Killing\\tadult\\theartworms\\tin\\tcats\\twith\\tadulticide\\ttreatment\\tcan\\tcause anaphylactic reactions, thromboembolism, and fatal reactions in cats.","notes":"Instructions for Use The\\tmost\\taccurate\\tand\\tup-\\tto-\\t date\\ttreatment\\tprotocol\\tis\\tavailable\\tfrom\\tthe American Heartworm Society (https://www.heartwormsociety.org). Follow the product insert carefully for instructions on proper injection technique. Also evaluate\\tpatient\\tto\\tdetermine\\tclass\\tof\\theartworm\\tdisease\\t(class\\t1\u20134)\\tbefore initiating\\ttreatment.\\tClass\\t1\\tand\\t2\\tare\\tleast\\tsevere.\\tClass\\t3\\tis\\tsevere,\\tand\\tclass\\t4 is the most severe and should not be treated with an adulticide before decreasing the heartworm burden. The\\tcurrent\\tthree-\\tdose\\tprotocol\\tincludes\\tstarting\\tpretreatment\\twith\\ta\\tmacrocyclic lactone\\t(e.g.,\\tivermectin)\\tand\\tdoxycycline\\t(or\\tminocycline)\\tfor\\t2\\tmonths\\tand\\tthen allowing\\ta\\t1-month\\twaiting\\tperiod\\tstarting\\ton\\tday\\t60.\\tAfter\\tthis\\twaiting\\tperiod, administer\\tmelarsomine\\ton\\tday\\t60,\\twait\\tanother\\tmonth,\\tand\\tadminister\\tthe\\tsecond and\\tthird\\tdoses\\tof\\tmelarsomine\\ton\\tdays\\t90\\tand\\t91.\\tEach\\tmelarsomine\\tdose\\tis M Meloxicam 565 2.5\\tmg/kg.\\tThis\\tprotocol\\twill\\treduce\\tlung\\tand\\tpulmonary\\tvessel\\treaction\\tassociated with heartworm treatment. Avoid human exposure by either washing hands after handling or wearing gloves.\\tThere\\tshould\\tbe\\tstrict\\texercise\\trestriction\\tin\\tdogs\\tduring\\tadulticide treatment. Patient Monitoring and Laboratory Tests Monitor heartworm status and microfilaria after treatment. Monitor treated patients carefully for signs of pulmonary thromboembolism. Formulations \u2022\\t\\tMelarsomine\\tis\\tavailable\\tin\\ta\\t25-\\tmg/mL\\tinjection. Stability and Storage After\\treconstitution,\\tsolution\\tretains\\tpotency\\tfor\\t24\\thours.\\tDo\\tnot\\tfreeze\\tsolutions after they are prepared.","original_category":"Antiparasitic"},{"name":"Metaflumizone","active_ingredient":"Metaflumizone","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Antiparasitic"},{"name":"Milbemycin Oxime","active_ingredient":"Milbemycin Oxime","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tHeartworm\\tprevention\\tand\\tcontrol\\tof\\tendoparasites:\\t0.5\\tmg/kg\\tq30days\\tPO. \u2022\\t\\tDemodicosis:\\t2\\tmg/kg\\tq24h\\tPO\\tfor\\t60\u2013120\\tdays\\tor\\t1\\tmg/kg/day\\tuntil\\ta\\tclinical cure\\tis\\tobserved\\tfollowed\\tby\\t3\\tmg/kg\\tonce\\tper\\tweek\\tuntil\\ta\\tparasitologic\\tcure (negative scraping) is observed. \u2022\\t\\tSarcoptic\\tmange:\\t2\\tmg/kg\\tq7days\\tfor\\t3\u20135\\tweeks\\tPO. \u2022\\t\\tCheyletiellosis:\\t2\\tmg/kg/wk\\tPO. Cats \u2022\\t\\tHeartworm\\tand\\tendoparasite\\tcontrol:\\t2\\tmg/kg\\tevery\\t30\\tdays\\tPO. \u2022\\t\\tDemodicosis\\tin\\tcats:\\t1\u20132\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Mineral Oil Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not use in dogs that have shown sensitivity to ivermectin or other drugs in this\\tclass\\t(see\\tprevious\\tbreed\\tlist).\\tTreatment\\tusing\\tthree\\ttimes\\tthe\\tdaily\\tdoses from mating to 1 week before weaning did not produce any adverse effects in the pregnant\\tbitch,\\tthe\\tfetus,\\tor\\tpuppies.\\tOne-\\ttime\\tdoses\\tof\\tthree\\ttimes\\tthe\\tmonthly rate before or shortly after whelping caused no adverse effects on the puppies. Milbemycin\\tis\\texcreted\\tin\\tmilk.\\tPuppies\\tgiven\\tmilbemycin\\tat\\t19\\ttimes\\tthe\\tregular dose\\tshowed\\tadverse\\teffects,\\tbut\\tsigns\\twere\\ttransient\\tfor\\tonly\\t24\u201348\\thours. M Mineral Oil 615","indications":"Indications and Clinical Uses Milbemycin is used as a heartworm preventative, miticide, and microfilaricide. It is also used to control infections of hookworm, roundworms, and whipworms. It has been used in combination with flea control drugs (see Sentinel, which contains milbemycin oxime and lufenuron). At high doses, it has been used to treat infections caused by Demodex in dogs (see dosing section). It is sometimes preferred over other macrocyclic lactones for treating Demodex infection\\tbecause\\tit\\tis\\tbetter\\ttolerated\\tat\\thigh\\tdoses.\\t(Note:\\tThe isooxazolines afoxolaner, fluralaner, lotilaner, and sarolaner are preferred for treating Demodex infection.) Milbemycin is widely used in animals, and the efficacy and dosing regimens are established through the approvals and clinical studies by the sponsors. Precautionary Information","side_effects":"Adverse Reactions and Side Effects At\\tdoses\\tof\\t5\\tmg/kg,\\tit\\twas\\twell\\ttolerated\\tin\\tmost\\tdogs\\t(10\\ttimes\\tthe\\theartworm preventative\\tdose).\\tAt\\t10\\tmg/kg\\t(20\\ttimes\\tthe\\theartworm\\tpreventative\\tdose),\\tit caused\\tdepression,\\tataxia,\\tand\\tsalivation\\tin\\tsome\\tdogs.\\tToxicity\\tmay\\toccur\\tat\\thigh doses\\tand\\tin\\tbreeds\\tin\\twhich\\tmilbemycin\\tcrosses\\tthe\\tblood\u2013brain\\tbarrier\\tat\\tdosages as\\tlow\\tas\\t1.5\\tmg/kg\\tper\\tday.\\tSensitive\\tbreeds\\tinclude\\tcollies,\\tAustralian\\tshepherds, Old\\tEnglish\\tsheepdogs,\\tlonghaired\\twhippets,\\tand\\tShetland\\tsheepdogs.\\tIn susceptible animals, the effects are neurotoxic, and signs include depression, ataxia, difficulty with vision, coma, and death. Sensitivity to milbemycin occurs in certain breeds because of a mutation in the multidrug resistance gene (ABCB1 gene) that regulates\\tthe\\tmembrane\\tpump\\tP-\\tglycoprotein.\\tThis\\tmutation\\taffects\\tthe\\tefflux pump\\tin\\tthe\\tblood\u2013brain\\tbarrier.\\tAnimals\\twith\\ta\\tgene\\tmutation\\tlack\\ta\\tfunctional membrane pump, and milbemycin can accumulate in the brains of susceptible animals. High doses in normal animals may also produce similar toxicosis. However, at doses used for heartworm prevention, this effect is unlikely. At high doses used for treating Demodex infections, diarrhea may occur in some dogs.","notes":"Instructions for Use Doses\\tvary\\tdepending\\ton\\tparasite\\ttreated.\\tTreatment\\tof\\tdemodicosis\\trequires\\ta higher dose administered daily than the heartworm preventative dose. For Demodex infection,\\tuse\\ta\\tprotocol\\tof\\t1\\tmg/kg/day\\tuntil\\tclinical\\tcure\\tfollowed\\tby\\t3\\tmg/kg/wk for\\ta\\tparasitological\\tcure.\\tTreatment\\tcan\\tbe\\tlong\\tbecause\\tit\\tmay\\trequire\\t4\\tmonths\\tfor a\\tclinical\\tcure\\tand\\t8\\tmonths\\tfor\\ta\\tparasitologic\\tcure. Patient Monitoring and Laboratory Tests Monitor for heartworm status in dogs before initiating treatment with milbemycin. Formulations Available \u2022\\t\\tMilbemycin\\tis\\tavailable\\tin\\t2.3-\\t,\\t5.75-\\t   ,\\t11.5-\\t   ,\\tand\\t23-\\tmg\\ttablets.\\tIt\\tis\\talso\\tfound\\tin other\\tcombination\\tproducts\\t(e.g.,\\twith\\tspinosad\\tin\\tTrifexis). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Moxidectin","active_ingredient":"Moxidectin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tHeartworm\\tprevention:\\t3\\tmcg/kg\\tevery\\t30\\tdays\\tPO.\\tTopical\\theartworm prevention\\t(Advantage\\tMulti,\\tor\\tCoraxis)\\t2.5\\tmg/kg\\tmonthly. \u2022\\t\\tMoxidectin\\tis\\tcombined\\twith\\tsarolaner\\tand\\tpyrantel\\tin\\ta\\tchewable\\ttablet\\tfor\\tdogs (Simparica\\tTRIO).\\tThe\\ttablet\\tis\\tdesigned\\tto\\tdeliver\\ta\\tdose\\tof\\t1.2\\tmg/kg\\tsarolaner, 24\\tmcg/kg\\tmoxidectin,\\tand\\t5\\tmg/kg\\tpyrantel,\\tonce\\ta\\tmonth\\toral. \u2022\\t\\t6-\\t month\\tformulation:\\t0.17\\tmg/kg\\tor\\t0.05\\tmL\\tof\\tthe\\tconstituted\\tsuspension/kg (0.0227\\tmL/lb),\\tadministered\\tas\\ta\\tsingle\\tSQ\\tinjection\\tonce\\tevery\\t6\\tmonths.\\tNo more\\tthan\\t3\\tmL\\tshould\\tbe\\tinjected\\tin\\ta\\tsingle\\tsite. \u2022\\t\\t12-\\t month\\tformulation:\\t0.5\\tmg/kg\\t(0.23\\tmg/lb)\\tor\\t0.05\\tmL\\tof\\tthe\\tconstituted suspension\\tper\\tkilogram\\t(0.023\\tmL/lb)\\tby\\tSQ\\tinjection.\\tThis\\tamount\\tof suspension\\twill\\tprovide\\t0.5\\tmg\\tmoxidectin\\tper\\tkilogram\\tof\\tbody\\tweight\\t(0.23\\tmg/ lb).\\tTo\\tensure\\taccurate\\tdosing,\\tcalculate\\teach\\tdose\\tbased\\ton\\tthe\\tdog\u2019s\\tweight\\tat\\tthe time of treatment. \u2022\\t\\tEndoparasite\\tcontrol:\\t25\u2013300\\tmcg/kg. \u2022\\t\\tSarcoptic\\tmange:\\t200\u2013250\\tmcg/kg\\t(0.2\u20130.25\\tmg/kg)\\tPO\\tor\\tSQ\\tonce\\tper\\tweek for\\t3\u20136\\tweeks. \u2022\\t\\tDemodicosis:\\t200\\tmcg/kg\\tSQ\\tweekly\\tor\\tevery\\tother\\tweek\\tfor\\tone\\tto\\tfour\\tdoses; alternatively,\\thigher\\tdoses\\tof\\t400\\tmcg/kg/day\\tPO.\\tHigher\\tdoses\\tare\\tused\\tfor refractory Demodex\\tcases,\\twith\\tdosages\\tof\\t500\\tmcg/kg\\t(0.5\\tmg/kg)/day\\tPO\\tfor 21\u201323\\tweeks\\tor\\t0.5\u20131.0\\tmg/kg\\tSQ\\tq72h\\tfor\\t21\u201322\\tweeks.\\tDuration\\tof\\ttreatment M Moxifloxacin 633 for\\tdemodicosis\\tis\\tvariable.\\tTreat\\tuntil\\ttwo\\tnegative\\tDemodex skin scrapings are achieved. Cats \u2022\\t\\tTopical\\theartworm\\tprevention\\twith\\tAdvantage\\tMulti\\tis\\t1\\tmg/kg\\tof\\tmoxidectin topically\\tevery\\t30\\tdays. \u2022\\t\\tTopical\\tsolution\\tfor\\tcats\\twith\\tfluralaner\\tand\\tmoxidectin\\t(Bravecto\\tPlus):\\tAdminister as\\ta\\tsingle\\tdose\\ttopically\\tat\\ta\\tdose\\tof\\t40\\tmg/kg\\tfluralaner\\tand\\t2\\tmg/kg\\tmoxidectin every\\t2\\tmonths.  Horses \u2022\\t\\tGI\\tparasites:\\t0.4\\tmg/kg\\tPO.\\tAvoid\\tuse\\tin\\tyoung\\thorses,\\tsmall\\tponies,\\tand debilitated animals. Cattle \u2022\\t\\t0.2\\tmg/kg\\tSQ\\tonce. \u2022\\t\\tIntestinal\\tparasites,\\tlungworms,\\tmites,\\tgrubs,\\tand\\tlice:\\tTopical\\ttreatment\\t(pour-\\ton): 0.5\\tmg/kg\\t(0.23\\tmg/lb\\tor\\t45\\tmL\\tper\\t1000\\tlb).\\tApply\\ttopically\\talong\\tthe\\tmidline from the withers to the tail head. Avoid exposure to human skin and to other animals. Sheep \u2022\\t\\t1\\tmL\\tper\\t5\\tkg\\t(1\\tmL\\tper\\t11\\tlb,\\tor\\t0.2\\tmg/kg)\\tby\\tmouth\\tof\\tthe\\t1-\\tmg/mL\\toral solution. Regulatory Information Do not use in horses intended for food. Cattle\\twithdrawal\\ttime\\t(meat):\\t21\\tdays. Sheep\\twithdrawal\\ttime\\t(meat):\\t7\\tdays. Goat\\twithdrawal\\ttime\\t(meat):\\t14\\tdays. No milk withholding time has been established. Do not use in female dairy cattle of breeding age. Do not use in female sheep providing milk for human consumption. Do not use in veal calves. Moxifloxacin moks- ih- floks\u2032ah- sin Trade and other names: Avelox","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tthe\\t2.5%\\ttopical\\tsolution\\tin\\tcats.\\tDo\\tnot\\tuse\\tin\\tdogs\\tyounger than\\t2\\tmonths\\tof\\tage.\\tDespite\\tthe\\tsafety\\tmargin\\tlisted\\tin\\tthe\\tAdverse Reactions\\tand\\tSide\\tEffects section, caution is advised when administering moxidectin\\tat\\thigh\\tdoses\\tto\\tivermectin-\\tsensitive\\tbreeds.\\tAffected\\tbreeds\\tmay include\\tcollies,\\tAustralian\\tshepherds,\\tOld\\tEnglish\\tsheepdogs,\\tlonghaired whippets,\\tand\\tShetland\\tsheepdogs.\\tAdministration\\tto\\tfoals\\tyounger\\tthan\\t6 months\\tof\\tage\\tis\\tnot\\trecommended.\\tDo\\tnot\\tapply\\tthe\\tlarge\\tanimal\\tpour-\\ton formulation to small animals. It has been used safely in queens and kittens during pregnancy and lactation. Drug Interactions Do not administer with drugs that could potentially increase the penetration\\tof\\tivermectin\\tacross\\tthe\\tblood\u2013brain\\tbarrier.\\tSuch\\tdrugs include\\tketoconazole,\\titraconazole,\\tcyclosporine,\\tand\\tcalcium-\\tchannel blockers\\t(see\\tAppendix\\tJ).","indications":"Indications and Clinical Uses Moxidectin is used in dogs to prevent infection of heartworm (Dirofilaria immitis). In dogs, it can also be used and for the treatment and control of A. caninum, U. stenocephala, T. canis, Toxascaris leonina, and T. vulpis. Moxidectin also has been used to treat Demodex infections in dogs at high doses. In cats, it is used for the prevention of heartworm disease caused by D. immitis; for the treatment and control of intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme). It is combined with fluralaner in a topical solution for cats (Bravecto Plus) to include treatment of fleas and ticks and in a combination tablet for dogs with sarolaner and pyrantel for treatment of roundworms, fleas, ticks, and heartworm prevention. In horses, it is used for treatment of a variety of parasites, including large strongyles (Strongylus vulgaris\\t[adults\\tand\\tL4/L5\\tarterial\\tstages], S. edentatus [adult and tissue stages], Triodontophorus brevicauda [adults], and T. serratus [adults]), and small strongyles ([adults] Cyathostomum spp., Cylicocyclus spp., Cyliocostephanus spp., Coronocyclus spp., and Gyalocephalus capitatus). It is also used to treat small strongyles, including larvae. It is used to treat ascarids, including Parascaris equorum\\t(adults\\tand\\tL4\\tlarval\\tstages),\\tpinworms\\t(Oxyuris equi [adults and\\tL4\\tlarval\\tstages]),\\thairworms\\t(Trichostrongylus axei\\t[adults]),\\tlarge-\\tmouth stomach worms (Habronema muscae [adults]), and horse stomach bots (Gasterophilus intestinalis [second and third instars] and Gasterophilus nasalis [third instars]). One\\tdose\\talso\\tsuppresses\\tstrongyle\\tegg\\tproduction\\tfor\\t84\\tdays.\\tSome\\tformulations for\\thorses\\talso\\tcontain\\tpraziquantel.\\tThis\\tincreases\\tthe\\tspectrum\\tto\\tinclude\\tother intestinal parasites such as tapeworms. In cattle, moxidectin injectable is used to treat intestinal roundworms (Ostertagia ostertagi\\t[adults\\tand\\tinhibited\\tfourth-\\tstage\\tlarvae],\\tHaemonchus placei [adults], Trichostrongylus axei [adults], T. colubriformis\\t[fourth-\\tstage\\tlarvae], Cooperia oncophora [adults], C. punctata\\t[adults\\tand\\tfourth-\\tstage\\tlarvae],\\tC. surnabada\\t[adults\\tand\\tfourth-\\tstage\\tlarvae],\\tOesophagostomum radiatum [adults and fourth-\\t   stage\\tlarvae],\\tTrichuris spp. [adults]), lungworms (Dictyocaulus viviparus [adults\\tand\\tfourth-\\tstage\\tlarvae]),\\tgrubs\\t(Hypoderma bovis and H. lineatum), mites (Psoroptes ovis [P. communis var. bovis]), and lice (Linognathus vituli and Solenopotes capillatus). One injection will protect cattle from reinfection with D. viviparous and O. radiatum\\tfor\\t42\\tdays,\\tH. placei\\tfor\\t35\\tdays,\\tand\\tO. ostertagi and T. axei for\\t14\\tdays\\tafter\\ttreatment.\\tIn\\tsheep,\\tthe\\toral\\tdrench\\tis\\tused\\tfor\\tthe\\ttreatment\\tand control\\tof\\tthe\\tadult\\tand\\tL4\\tlarval\\tstages\\tof\\tHaemonchus contortus, Teladorsagia circumcincta, Teladorsagia trifurcata, Trichostrongylus axei, T. colubriformis, Trichostrongylus vitrinus, Cooperia curticei, C. oncophora, Oesophagostomum columbianum, Oesophagostomum venulosum, Nematodirus battus, Nematodirus filicollis, and Nematodirus spathiger. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity\\tis\\tthe\\tresult\\tof\\tpotentiation\\tof\\tglutamate-\\tgated\\tchloride\\tchannels\\tand GABA\\tchannels,\\tresulting\\tin\\thyperpolarization\\tof\\tmembranes.\\tToxicity\\tmay\\toccur at\\thigh\\tdoses\\tand\\tin\\tbreeds\\tin\\twhich\\tmoxidectin\\tcrosses\\tthe\\tblood\u2013brain\\tbarrier. Sensitive\\tbreeds\\tmay\\tinclude\\tcollies,\\tAustralian\\tshepherds,\\tOld\\tEnglish\\tsheepdogs, longhaired\\twhippets,\\tand\\tShetland\\tsheepdogs.\\tToxicity\\tis\\tneurotoxic,\\tand\\tsigns include depression, ataxia, vision problems, coma, and death. Sensitivity to moxidectin occurs in certain breeds because of a mutation in the ABCB1 gene that codes\\tfor\\tthe\\tmembrane\\tpump\\tP-\\tglycoprotein.\\tAnimals\\twith\\tthis\\tmutation\\tlack\\ta functional\\tp-\\tglycoprotein\\tefflux\\tpump\\tin\\tthe\\tblood\u2013brain\\tbarrier.\\tAdverse\\teffects may occur when high doses of moxidectin are used to treat dogs for demodicosis. These\\teffects\\tinclude\\tlethargy,\\tdepressed\\tappetite,\\tvomiting,\\tand\\tlesions\\tat\\tthe site\\tof\\tan\\tSQ\\tinjection.\\tToxicity\\tis\\tmore\\tlikely\\tat\\thigh\\tdoses\\tin\\tdogs.\\tAt\\tfive\\ttimes M","notes":"formulations also contains praziquantel to control additional parasites. Instructions for Use Caution is recommended if the bovine or equine formulation is considered for use in\\tsmall\\tanimals.\\tToxic\\toverdoses\\tare\\tlikely\\tbecause\\tthese\\tformulations\\tare\\thighly concentrated. When\\tapplying\\tthe\\t2.5%\\ttopical\\tsolutions\\tto\\tdogs,\\tensure\\tthat\\tdogs\\tdo not lick the application site. Avoid exposure to people after applying the topical solution. The\\tapproved\\tformulations\\tfor\\tdogs\\tvary\\tin\\ttheir\\tconcentration\\tand\\tduration. For\\texample,\\tthere\\tare\\timmediate-\\trelease\\tproducts,\\t6-\\tmonth\\tproducts\\t(ProHeart-\\t6), and\\t12-\\t    month\\tproducts\\t(ProHeart-\\t12).\\tPay\\tattention\\tto\\tspecific\\tmixing\\tand\\tlabeling instructions when administering each product. Patient Monitoring and Laboratory Tests Animals should be checked for heartworm status prior to initiating treatment. the\\tlabel\\tdose\\trate\\t(15\\tmcg/kg)\\tonce\\tevery\\tmonth,\\tmoxidectin\\twas\\tadministered safely\\tto\\tcollies\\tthat\\twere\\tivermectin\\tsensitive.\\tHowever,\\tat\\ta\\tsingle\\tdose\\tof\\t90 mcg/kg\\t(30\\ttimes\\tthe\\tlabel\\tdose)\\tadministered\\tto\\tsensitive\\tcollies,\\tataxia,\\tlethargy, and\\tsalivation\\toccurred\\tin\\tone\\tsixth\\tof\\tdogs.\\tAt\\t30,\\t60,\\tand\\t90\\tmcg/kg\\t(10 times,\\t20\\ttimes,\\tand\\t30\\ttimes\\tthe\\tlabel\\tdose)\\tadministered\\tto\\tivermectin-\\tsensitive collies , no adverse effects were observed. Nevertheless, caution is advised when administering moxidectin to sensitive breeds listed previously. Because of concern about adverse reactions and deaths in dogs from the 6-\\t month\\tinjectable\\tformulation\\t(ProHeart\\t6),\\tthis\\tproduct\\twas\\ttemporarily discontinued several years ago. However, this safety concerns has been addressed by\\treformulating\\tthe\\tproduct,\\twhich\\tis\\tnow\\tavailable\\tin\\t6-\\tand\\t12-\\tmonth\\tforms. In horses, moxidectin has been safe at three times the label dose. However, adverse effects (ataxia, depression, and lethargy) have been reported in young horses\\t(younger\\tthan\\t6\\tmonths)\\tor\\tdebilitated\\tanimals\\tafter\\ttreatment.\\tOther adverse effects reported in horses include sedation, weakness, bradycardia, dyspnea, coma, and seizures. Neurologic toxicity in animals producing seizures can be treated with diazepam, barbiturates, or propofol. Formulations \u2022\\t\\t30-\\t ,\\t68-\\t  ,\\tand\\t136-\\tmcg\\ttablets\\tfor\\tdogs,\\tor\\t2.5%\\ttopical\\tsolution\\tfor\\tdogs. \u2022\\t\\t20-\\t mg/mL\\tequine\\toral\\tgel\\t(2%\\tgel).\\tQuest\\tPlus\\tgel\\tfor\\thorses\\tcontains\\t20\\tmg/mL (2%)\\tplus\\t125\\tmg\\tof\\tpraziquantel\\t(12.5%). \u2022\\t\\t5-\\t mg/mL\\tcattle\\tpour-\\ton;\\t1-\\t   mg/mL\\toral\\tdrench\\tfor\\tsheep;\\t10-\\tmg/mL\\tinjectable solution for cattle; \u2022\\t\\t6-\\t month\\tlong-\\tacting\\tformulation:\\tThe\\t6-\\tmonth\\tinjectable\\t(ProHeart\\t6) formulation\\tconsists\\tof\\ttwo\\tseparate\\tvials:\\tone\\tcontains\\t10%\\tmoxidectin microspheres, and the other contains a vehicle for constitution of the moxidectin microspheres.\\tEach\\tmilliliter\\tof\\tconstituted,\\tsustained-\\trelease\\tsuspension\\tcontains 3.4\\tmg\\tof\\tmoxidectin. \u2022\\t\\t12-\\t month\\tlong-\\tacting\\tformulation:\\t10\\tmg\\tof\\tconstituted\\tsuspension\\tper\\tmilliliter. This\\tproduct\\thas\\ttwo\\tseparate\\tvials\\tthat\\trequire\\tmixing\\tprior\\tto\\tadministration\\tor use.\\tOne\\tvial\\tcontains\\t10%\\tmoxidectin\\tsterile\\tmicrospheres\\tand\\tthe\\tsecond\\tvial contains sterile vehicle for constitution; only this sterile diluent should be used for\\tthe\\tconstitution.\\tThe\\tconstituted\\tsuspension\\tcan\\tbe\\tinjected\\t30\\tminutes\\tafter mixing. \u2022\\t\\tCombination\\tproducts:\\tThe\\tformulation\\tAdvantage\\tMulti\\tfor\\tdogs\\t2.5%\\t(25\\tmg/ mL)\\tincludes\\t25%\\timidacloprid.\\tAdvantage\\tMulti\\tfor\\tcats\\t1%\\t(10mg/mL)\\tincludes 10%\\timidacloprid.\\tMoxidectin\\tis\\tcombined\\twith\\tfluralaner\\tin\\ta\\ttopical\\tsolution\\tfor cats,\\twith\\t280\\tmg\\tof\\tfluralaner\\tand\\t14\\tmg\\tmoxidectin\\tper\\tmilliliter.\\tMoxidectin is combined with sarolaner and pyrantel in a chewable tablet for dogs (Simparica TRIO). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Nitenpyram","active_ingredient":"Nitenpyram","species":["Canine","Feline"],"dosage":"\u2022\\t\\t1\\tmg/kg\\tdaily\\tPO\\tas\\tneeded\\tto\\tkill\\tfleas.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\tis\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Pharmacology and Mechanism of Action Nitrofurantoin is an antibacterial drug that acts as a urinary antiseptic. It is a weak acid with low water solubility. Therapeutic concentrations are reached only in the urine. In the urine, it is reduced by bacterial flavoproteins, and the reactive metabolites bind to bacterial ribosomes and inhibit bacterial enzymes involved in the synthesis of DNA and RNA. The spectrum includes Escherichia coli, Staphylococcus spp., and Enterococcus spp., including strains that are resistant to other antimicrobial agents. Resistance among bacteria is unusual, although Proteus spp. and Pseudomonas aeruginosa are intrinsically resistant and nitrofurantoin should not be used to treat urinary tract infections caused by these pathogens. Nitrofurantoin has time-dependent effects on E. coli, which may necessitate frequent administration for optimal clinical outcome. Pharmacokinetics: The pharmacokinetics have been studied in laboratory animals, dogs, and people. There is no pharmacokinetic data to guide the use in cats. In people, the concentrations in urine reach 200 mcg/mL, but plasma concentrations are almost undetectable. In dogs, a similar profile is observed. The macrocrystalline form is slowly absorbed and less likely to cause gastric upset. The microcrystalline form is rapidly absorbed in the intestine. In dogs, oral absorption is not affected by feeding. Oral absorption is rapid in dogs, with an elimination half-life of approximately 30 minutes and oral bioavailability Nitrofurantoin nye- troe- fyoo\u2032ran- toyn Trade and other names: Macrodantin, Furalan, Furantoin, Furadantin, and generic brands","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"Instructions for Use Nitenpyram is often used with lufenuron to kill adult fleas and prevent flea eggs from hatching. Administer with or without food. Other flea prevention medications may be used once nitenpyram has been administered for initial elimination of fleas on the dog or cat. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tNitenpyram\\tis\\tavailable\\tin\\t11.4-\\t\\tand\\t57-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Oxfendazole","active_ingredient":"Oxfendazole","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tDose\\thas\\tnot\\tbeen\\testablished.  Horses \u2022\\t\\t10\\tmg/kg\\tPO. Cattle \u2022\\t\\t4.5\\tmg/kg\\tPO. Regulatory Information Do not use in dairy cattle. Cattle slaughter withdrawal time: 7 days for suspension; 11 days for paste. Oxibendazole oks- ih- ben\u2032dah- zole Trade and other names: Anthelcide EQ and Filaribits Plus Chewable tablets","contraindications":"Contraindications and Precautions Do not administer to sick or debilitated horses. Do not administer to female dairy cattle of breeding age. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.","indications":"Indications and Clinical Uses Oxfendazole is used in horses for treatment of large roundworms (Parascaris equorum), mature and immature pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, Strongylus vulgaris, and Strongylus equinus), and small strongyles. In cattle, oxfendazole is approved for treatment of lungworms (Dictyocaulus viviparus), stomach worms (barberpole worms [Haemonchus contortus and Haemonchus placei, adult]), small stomach worms (Trichostrongylus axei, adult), brown stomach worms (Ostertagia ostertagi), intestinal worms, nodular worms (Oesophagostomum radiatum, adult), hookworms (Bunostomum phlebotomum, adult), small intestinal worms (Cooperia punctata, Cooperia oncophora, and Cooperia momasteri), and tapeworms (Moniezia benedeni, adult). O Oxibendazole 681 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse reactions are rare.","notes":"Instructions for Use Administer to horses by mixing in a suspension and administering orally (e.g., via stomach tube) or mixing pellets with food. Administer to cattle orally with a dose syringe or intraruminally with a rumen injector. Treatment may be repeated in 6\u20138 weeks in horses or in 4\u20136 weeks in cattle. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tOxfendazole\\tis\\tavailable\\tin\\ta\\t90.6-\\t\\tor\\t225-\\tmg/mL\\tsuspension\\t(cattle),\\t185-\\tmg/g paste (cattle), 0.375 g/g of paste (equine), 90.6- mg/mL suspension (equine), and 6.49% pellets (equine). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. After mixing for oral administration, discard unused portion after 24 hours. Mix well before using, do not freeze suspension, and avoid excessive heat.","original_category":"Antiparasitic"},{"name":"Oxibendazole","active_ingredient":"Oxibendazole","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tof\\toxibendazole\\t(combined\\twith\\t6.6\\tmg/kg\\tof\\tdiethylcarbamazine) q24h PO. However, the product with diethylcarbamazine is no longer used for heartworm prevention. O Oxtriphylline 683 Cats \u2022\\t\\tNo\\tdose\\testablished.  Horses \u2022\\t\\t10\\tmg/kg\\tPO. \u2022\\t\\tThreadworms:\\t15\\tmg/kg\\tPO\\tonce.\\tRetreat\\tin\\t6\u20138\\tweeks\\tif\\tnecessary. Regulatory Information No\\twithdrawal\\ttimes\\tare\\testablished. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Oxtriphylline oks- trih\u2032fih- lin Trade and other names:  Choledyl- SA","contraindications":"Contraindications and Precautions Do not administer to dogs that may have heartworms. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.","indications":"Indications and Clinical Uses Oxibendazole is used in horses for treatment of large strongyles (S. edentatus, S. equinus, and S. vulgaris), small strongyles (species of the genera Cylicostephanus, Cylicocyclus, Cyathostomum, Triodontophorus, Cylicodontophorus, and Gyalocephalus), large roundworms (P. equorum), pinworms (O. equi) including various larval stages, and threadworms (Strongyloides westeri).","side_effects":"Adverse Reactions and Side Effects Adverse reactions are rare. Occasional vomiting and nausea may occur in dogs.","notes":"Formulations for dogs have contained both diethylcarbamazine citrate and oxibendazole for prevention of Dirofilaria immitis (heartworm disease) and Ancylostoma caninum (hookworm infection) and for treatment of Trichuris vulpis (whipworm infection) and intestinal Toxocara canis (Ascarid infection). However, diethylcarbamazine is no longer used for heartworm disease prevention in dogs because other alternate drugs are available. Precautionary Information Instructions for Use Administer suspension to horses by mixing with 1\u20132 L of water (3\u20134 pints) and administering orally (e.g., via stomach tube). Alternatively, mix powder with grain ration or use the paste. Horses should be retreated in 6\u20138 weeks if they are reexposed. For dogs, the tablets can be administered directly or mixed with food daily. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tOxibendazole\\tis\\tavailable\\tin\\t10%\\tsuspension;\\t22.7%\\tpaste\\tfor\\thorses. \u2022\\t\\tChewable\\ttablets\\tare\\tavailable\\tin\\t60-\\t,\\t120-\\t   ,\\tand\\t180-\\tmg\\tdiethylcarbamazine\\tcitrate + 45- , 91- , and 136- mg oxibendazole tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Mix well before using, do not freeze suspension, and avoid excessive heat.","original_category":"Antiparasitic"},{"name":"Paromomycin Sulfate","active_ingredient":"Paromomycin Sulfate","species":["Canine","Feline"],"dosage":"For treating Leishmania infections in dogs, it is used IM at a dosage of 11 mg/kg once daily for 21 days as a single agent. It is also used in combination with other anti- Leishmania\\tagents\\t(e.g.,\\t60\\tmg/kg\\tof\\tmeglumine\\tantimoniate\\tIM\\tq12h\\tfor\\t4\\tweeks, plus 5 mg/kg q12h, SQ of paromomycin once daily for 3 weeks).  Cats \u2022\\t \\tDoses\\tof\\t125\u2013165\\tmg/kg\\tq12h\\tPO\\tfor\\t7\\tdays\\thave\\tbeen\\trecommended. However,\\tcaution\\tis\\trecommended\\twhen\\tusing\\tdoses\\tthis\\thigh.\\tLower\\tdoses should be considered (see dog dosage) in animals that may be at risk of toxicity. Dogs \u2022\\t\\tThe\\tdose\\tin\\tdogs\\thas\\tbeen\\textrapolated\\tfrom\\thuman\\tmedicine,\\twhich\\tis\\t10\\tmg/kg q8h PO for 5\u201310 days.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. Although not absorbed systemically to a large extent, it is expected that concentrations may persist in the kidneys, producing long, extended withdrawal times for slaughter. Paroxetine par- oks\u2032eh- teen Trade and other names: Paxil","contraindications":"Contraindications and Precautions Extreme caution is recommended when administering this drug to animals that may have a compromised bowel resulting from intestinal disease. A compromised intestinal mucosa may lead to increased systemic absorption and adverse effects. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses The use of paromomycin is limited to intestinal infections. It is not absorbed systemically and should not be used for extraintestinal infections. Paromomycin has been used to treat intestinal infections, such as cryptosporidiosis. The use is based on limited accounts in animals and extrapolation from humans. Efficacy in animals has not been tested in controlled studies. Another use of paromomycin is for treatment of Leishmania infection, often combined with meglumine antimoniate. This treatment requires IM injection, which may not be available in many countries. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Paromomycin has been associated with renal failure and blindness when used in cats. Although systemic absorption is not expected to be high, cats treated with high doses for intestinal organisms developed problems.","notes":"Instructions for Use In\\tcats,\\tdoses\\tof\\t125\u2013165\\tmg/kg\\tq12h\\thave\\tbeen\\tadministered\\tfor\\t5\u20137\\tdays PO.\\tHowever,\\tthere\\tare\\treports\\tin\\tthe\\tveterinary\\tliterature\\tthat\\tthese\\tdoses\\thave produced toxicity in cats, including kidney injury. It is suggested to use lower doses to avoid toxicity and monitor the patient\u2019s renal parameters carefully. When there is a compromised integrity of the intestinal mucosa, as may occur with diarrhea, use of paromomycin is discouraged. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s renal function, such as urine- specific gravity, serum creatinine, and\\tblood\\turea\\tnitrogen\\t(BUN),\\tduring\\ttreatment. 706    Paroxetine Formulations Paromomycin is available in 250- mg capsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Piperazine","active_ingredient":"Piperazine","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t44\u201366\\tmg/kg\\tadministered\\tonce\\tPO.  Horses and Pigs \u2022\\t\\t110\\tmg/kg\\tPO\\tin\\tthe\\tdrinking\\twater\\tas\\tthe\\tsole\\twater\\tsource. \u2022\\t\\tOral\\tsolution\\t(horses):\\t30\\tmL\\t(1\\tounce)\\tof\\t17%\\tpiperazine\\tsolution\\tadministered PO for each 45 kg of body weight. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Piroxicam peer- oks\u2032ih- kam Trade and other names: Feldene and generic brands","contraindications":"Contraindications and Precautions No\\tcontraindications\\tin\\tanimals.\\tIt\\tmay\\tbe\\tused\\tin\\tall\\tages. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Piperazine is a common antiparasitic drug and is widely available, even over the counter (OTC). It is used primarily for treatment of roundworm (ascarid) infections in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Piperazine is remarkably safe in all species but can cause ataxia, muscle tremors, and changes in behavior.","notes":"Instructions for Use Piperazine is a widely used antiparasitic drug with a wide margin of safety. It may be used in combination with other antiparasitic drugs. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tPiperazine\\tis\\tavailable\\tin\\tan\\t860-\\tmg\\tpowder;\\t140-\\tmg\\tcapsules;\\t50-\\t\\tand\\t250-\\tmg tablets;\\tand\\t128-\\t,\\t160-\\t   ,\\t170-\\t   ,\\t340-\\t   ,\\t510-\\t   ,\\tand\\t800-\\tmg/mL\\toral\\tsolution. 742    Piroxicam Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Praziquantel","active_ingredient":"Praziquantel","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tDogs\\tweighing\\tless\\tthan\\t6.8\\tkg:\\t7.5\\tmg/kg\\tonce\\tPO. \u2022\\t\\tDogs\\tweighing\\tmore\\tthan\\t6.8\\tkg:\\t5\\tmg/kg\\tonce\\tPO. \u2022\\t\\tDogs\\tweighing\\tless\\tthan\\t2.3\\tkg:\\t7.5\\tmg/kg\\tonce\\tIM\\tor\\tSQ. \u2022\\t\\tDogs\\tweighing\\tmore\\tthan\\t2.7\u20134.5\\tkg:\\t6.3\\tmg/kg\\tonce\\tIM\\tor\\tSQ. \u2022\\t\\tDogs\\tweighing\\tmore\\tthan\\t5\\tkg:\\t5\\tmg/kg\\tonce\\tIM\\tor\\tSQ. \u2022\\t\\tParagonimus\\tin\\tdogs\\t(lung\\tworms):\\t23\\tmg/kg\\tPO\\tq8h\\tfor\\t3\\tdays. \u2022 \\t \\tSpirometra spp. and Diphyllobothrium\\tspp.\\ttreatment:\\t25\\tmg/kg\\tPO\\tonce\\tdaily\\tfor 2 consecutive days. Cats All doses are given once. \u2022\\t\\tCats\\tweighing\\tless\\tthan\\t1.8\\tkg:\\t11.4\\tmg/cat\\tPO. \u2022\\t\\tCats\\tweighing\\t1.8\u20132.2\\tkg:\\t11.4\\tmg/cat\\tSQ\\tor\\tIM. \u2022\\t\\tCats\\tweighing\\t2.3\u20134.5\\tkg:\\t22.7\\tmg/cat\\tSQ\\tor\\tIM. \u2022\\t\\tCats\\tweighing\\t2.3\u20135\\tkg:\\t23\\tmg/cat\\tPO. \u2022\\t\\tCats\\tweighing\\tmore\\tthan\\t5\\tkg:\\t34.5\\tmg/cat\\tPO\\tor\\t34.1\\tmg/cat\\tSQ\\tor\\tIM. \u2022 \\t \\tSpirometra spp. and Diphyllobothrium\\tspp.\\ttreatment:\\t25\\tmg/kg\\tPO\\tonce\\tdaily\\tfor 2 consecutive days.  Horses \u2022\\t\\t1.5\u20132.5\\tmg/kg\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Prazosin pray\u2032zoe- sin Trade and other names: Minipress","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tcats\\tyounger\\tthan\\t6\\tweeks\\tand\\tdogs\\tyounger\\tthan\\t4\\tweeks. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Praziquantel is widely used to treat intestinal infections caused by cestodes (tapeworms) (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) and removal and control of canine cestode Echinococcus multilocularis. In cats, it is used for removal of feline cestodes D. caninum and Taenia taeniaeformis. In horses, it is used to treat tapeworms (Anoplocephala perfoliata). Although there are no products approved for treatment of Spirometra spp. infections in dogs and cats, praziquantel has been used successfully, but a higher dose is needed (25 mg/kg PO) and administered for 2 consecutive days. Likewise, although no products are approved to treat Diphyllobothrium spp. in dogs and cats, praziquantel has been used to treat pseudophyllidean tapeworms. A dosage of 25 mg/kg PO for 2 consecutive days is used. A dose of 35 mg/kg once PO also has been used in cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vomiting occurs at high doses. Anorexia and transient diarrhea have been reported. It is safe in pregnant animals and during lactation.","notes":"Instructions for Use Praziquantel is one of the most common drugs used for tapeworm treatment. It has a wide margin of safety. Some formulations of praziquantel are available in combination (e.g., combination of praziquantel and febantel; combination of ivermectin and praziquantel, moxidectin, and praziquantel). Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tPraziquantel\\tis\\tavailable\\tin\\t23-\\t\\tand\\t34-\\tmg\\ttablets\\tand\\t56.8-\\tmg/mL\\tinjection\\tand\\tis also available in pastes and gels. P Prazosin 765 \u2022\\t\\tIn\\tcombination,\\tit\\tis\\tavailable\\tas\\t13.6\\tmg\\tof\\tpraziquantel\\tand\\t54.3\\tmg\\tof pyrantel,18.2\\tmg\\tof\\tpraziquantel\\tand\\t72.6\\tof\\tmg\\tpyrantel,\\tor\\t27.2\\tmg\\tof praziquantel\\tand\\t108.6\\tmg\\tof\\tpyrantel.\\tIt\\tis\\tcombined\\twith\\temodepside\\tin Profender. \u2022\\t\\tPraziquantel\\tis\\tavailable\\tin\\tpastes\\tand\\tgels\\tfor\\thorses\\tin\\tcombination\\twith\\tother drugs (e.g., ivermectin, moxidectin, febantel). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Pyrantel Pamoate and Pyrantel Tartrate","active_ingredient":"Pyrantel Pamoate and Pyrantel Tartrate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tonce\\tPO;\\trepeat\\tin\\t7\u201310\\tdays.\\t(Combination\\tproducts\\tmay\\tbe\\tdosed on a different schedule [e.g., once per month]. Consult specific labeling for dose intervals.) Cats \u2022\\t\\t20\\tmg/kg\\tonce\\tPO. \u2022\\t\\tDoses\\tmay\\tbe\\tmixed\\twith\\tfood.  Horses \u2022\\t\\tNematodes:\\t6.6\\tmg/kg\\tPO. \u2022\\t\\tCestodes:\\t13.2\\tmg/kg. \u2022\\t\\tMedicated\\tfeed:\\t12.5\\tmg/kg\\tas\\ta\\tsingle\\tdose\\tor\\t2.6\\tmg/kg/day\\tfor\\tprevention. Pigs \u2022\\t\\t22\\tmg/kg\\tadministered\\tin\\tfeed\\tas\\ta\\tsingle\\ttreatment. 798    Pyridostigmine Bromide Regulatory Information Pigs:\\t1-\\t    day\\twithdrawal\\t(United\\tStates);\\t7\\tdays\\t(Canada). Withdrawal times for other species are not established. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Pyridostigmine Bromide peer- id- oh- stig\u2032meen broe\u2032mide Trade and other names: Mestinon and Regonol","contraindications":"Contraindications and Precautions No\\tcontraindications\\tin\\tanimals.\\tIt\\tmay\\tbe\\tused\\tin\\tall\\tages\\tand\\tin\\tlactating\\tand pregnant animals. Drug Interactions Central nervous system toxicity may be more likely when co- administered with levamisole, but this is not reported from clinical use in animals. It can be safely administered with several other antiparasitic agents.","indications":"Indications and Clinical Uses Pyrantel is indicated for treatment of intestinal nematodes. In horses, it is used for treatment and prevention of nematodes, including pinworms (Oxyuris equi), large roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, Strongylus equinus, and Strongylus vulgaris), and small strongyles. When added to medicated feed, it is used to control nematodes, including pinworms (O. equi), large roundworms (P. equorum), large strongyles (S. edentatus, S. vulgaris, and Triodontophorus spp.), and small strongyles. In pigs, it is used for prevention of large roundworm (Ascaris suum) and prevention of the nodular worm Oesophagostomum spp. In dogs and cats, it is used for treatment of nematodes, including hookworms (Ancylostoma spp.) and roundworms (Toxocara cati, Toxocara canis, and Toxascaris leonina). There is some evidence that it is effective for control of some tapeworms, but ordinarily other drugs should be used for tapeworms (see Praziquantel). P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pyrantel\\thas\\ta\\tgood\\tsafety\\trecord.\\tNo\\tadverse\\teffects\\treported\\twith\\tregular\\tuse.","notes":"Instructions for Use Shake suspension prior to use. Doses listed are for single dose, but they may be repeated as part of a parasite management program. Lower doses may be added to daily feed for prevention of parasites. Patient Monitoring and Laboratory Tests Monitor fecal samples for presence of intestinal parasites. Formulations \u2022\\t \\tPyrantel\\tis\\tavailable\\tin\\t171-\\t,\\t180-\\t   ,\\tand\\t226-\\tmg/mL\\t(base)\\tpaste;\\t22.7-\\t\\tand\\t113.5-\\tmg (base) tablets; and 2.27- , 4.54- , and 50- mg/mL (base) suspension. Equine paste is 19.31%.\\tIt\\tis\\talso\\tavailable\\tin\\t10.6-\\t,\\t12.6-\\t   ,\\tand\\t21.1-\\tg/kg\\tof\\tpellets\\tfor\\tmedicated\\tfeed. \u2022\\t \\tPyrantel\\tpamoate\\tis\\ta\\tsalt\\tand\\tcontains\\t34.7%\\tpyrantel\\tbase.\\tDoses\\tare\\tbased\\ton\\tthe amount of pyrantel base. Pyrantel tartrate contains 57.9% pyrantel base. \u2022\\t \\tMany\\tof\\tthe\\tformulations\\tcontain\\tother\\tantiparasitic\\tdrugs\\t(e.g.,\\tpraziquantel).\\tFor example,\\tit\\tis\\tavailable\\tas\\t13.6\\tmg\\tof\\tpraziquantel\\tand\\t54.3\\tof\\tmg\\tpyrantel,\\t18.2\\tmg of\\tpraziquantel\\tand\\t72.6\\tmg\\tof\\tpyrantel,\\tor\\t27.2\\tmg\\tof\\tpraziquantel\\tand\\t108.6\\tmg\\tof pyrantel. The product Simparica Trio contains sarolaner, moxidectin, and pyrantel in a single chewable tablet for dogs for once per month administration. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Protect from freezing.","original_category":"Antiparasitic"},{"name":"Quinacrine Hydrochloride","active_ingredient":"Quinacrine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t6.6\\tmg/kg\\tq12h\\tPO\\tfor\\t5\\tdays. Cats \u2022\\t\\t11\\tmg/kg\\tq24h\\tPO\\tfor\\t5\\tdays.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Q 804    Quinidine, Quinidine Sulfate Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Quinidine, Quinidine Sulfate kwin- ih- deen Trade and other names: Quinidine gluconate (Duraquin), quinidine polygalacturonate (Cardioquin), and quinidine sulfate (Cin- Quin and Quinora)","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Quinacrine is used occasionally for treatment of protozoa (Giardia spp.), but other drugs (e.g., metronidazole and tinidazole) are preferred and used more often. Although it is not commercially available, veterinarians have obtained quinacrine through compounding pharmacies. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects are common. Vomiting occurs after oral administration.","notes":"Instructions for Use Doses listed are for treatment of giardiasis. Effects for other organisms are not reported. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tQuinacrine\\thas\\tbeen\\tavailable\\tin\\t100-\\tmg\\ttablets.\\tQuinacrine\\tmay\\tno\\tlonger\\tbe marketed in the United States, but it may be available from some pharmacies in a compounded formulation. Stability and Storage Store in a tightly closed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiparasitic"},{"name":"Sarolaner","active_ingredient":"Sarolaner","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t \\t2\\tmg/kg\\tPO\\t(one\\ttablet,\\taccording\\tto\\tdog\\tweight)\\tonce\\tper\\tmonth\\tduring\\tflea\\tand\\ttick season.\\tFor\\ttreatment\\tof\\tDemodex infection, it has been administered once per month. \u2022\\t\\tThe\\tcombination\\tproduct\\tis\\tadministered\\tat\\ta\\tdose\\tof\\t1.2\\tmg/kg\\tonce\\tper\\tmonth (with moxidectin and pyrantel). Cats \u2022\\t\\tNo\\tdose\\tfor\\tcats\\thas\\tbeen\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information \u2022\\t\\tAlthough\\tthe\\trisk\\tof\\tharmful\\tresidues\\tis\\tlow,\\tdo\\tnot\\tadminister\\tto\\tfood-\\tproducing animals. Selamectin sel- ah- mek\u2032tin Trade and other names: Selarid, Revolution","contraindications":"Contraindications and Precautions There are no known contraindications for use of sarolaner. The isooxazoline group of insecticides have been associated with seizures in animals. Use cautiously in animals that may be prone to seizures. Safety in breeding or lactating animals has not been established. Safety and use in cats have not been established. Drug Interactions No drug interactions are reported in animals. S Selamectin 829","indications":"Indications and Clinical Uses Sarolaner is indicated to kill adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of the Lone Star tick (Amblyomma americanum), Gulf Coast tick (Amblyomma maculatum), American dog tick (Dermacentor variabilis), black- legged tick (Ixodes scapularis), and brown dog tick (Rhipicephalus sanguineus) infestations in dogs and puppies 6 months of age and older, weighing 4 lb of body weight or greater, for 1 month. It is also effective for treatment of demodicosis caused by Demodex mites. Combination products contain moxidectin and pyrantel to prevent heartworms and intestinal roundworms. Because of this action, sarolaner can reduce the risk that these vectors may pose for\\tdisease\\ttransmission.\\tFor\\texample,\\tit\\tmay\\tprevent\\tinfections\\tcaused\\tby\\tBorrelia burgdorferi (Lyme disease) and Babesia canis. The approved label indication for sarolaner is treatment of fleas and ticks, but extralabel uses, using the approved label dose, have included treatment of generalized demodicosis caused by Demodex canis. Dogs with Demodex infection treated with sarolaner once a month had significant mite reduction after treatment. Sarolaner can eliminate sarcoptic mange (Sarcoptes scabiei) and ear mites (Otodectes cynotis) in dogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sarolaner has been safe for use in dogs at least 6 months of age. Adverse effects reported from field studies include vomiting, diarrhea, and lethargy. Other reported adverse effects include tremors, seizures, and hyperactivity. Target animal safety studies performed in dogs indicate good tolerance at the therapeutic dose, but beagles treated at three or five times the therapeutic dose have demonstrated tremors at three times the dose and other neurologic signs, including seizures at five times the dose. In clinical field studies with the isooxazoline group of insecticides, adverse effects reported include vomiting, diarrhea, anorexia, and lethargy. Based on clinical experience, there is a concern about neurologic adverse effects, including seizures, from administration of isooxazolines in dogs. This has been reported with the use of sarolaner, and the manufacturer warns that it should be used cautiously in animals with a history of seizures. Other neurologic signs possible include tremors and ataxia.","notes":"Instructions for Use Administer oral once per month with appropriate tablets for the dog\u2019s body weight. Other measures for flea and tick control in the pet\u2019s environment also may be used. Patient Monitoring and Laboratory Tests No specific monitoring is needed. Formulations \u2022\\t\\tSarolaner is available in chewable tablets containing 5- , 10- , 20- , 40- , 80- , and 120- mg  sarolaner. \u2022\\tSarolaner\\tis\\talso\\tavailable\\tin\\ta\\tcombination\\tproduct\\twith\\tmoxidectin\\tand\\tpyrantel. Stability and Storage Store at room temperature (below 30\xb0C) protected from light in the manufacturer\u2019s packaging.","original_category":"Antiparasitic agent (flea and tick insecticide)"},{"name":"Selamectin","active_ingredient":"Selamectin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tHeartworm\\tprevention:\\t6\u201312\\tmg/kg\\tapplied\\ttopically\\tevery\\t30\\tdays. \u2022\\t\\tOther\\tparasites:\\tThe\\tsame\\tdose\\tas\\tfor\\theartworm\\tprevention\\tmay\\tbe\\tapplied\\tfor treatment and prevention of ear mites and fleas. In cats, the preferred dosage is 6 mg/kg every 30 days. \u2022\\t\\tSarcoptic\\tmange\\ttreatment:\\t6\u201312\\tmg/kg\\ttwice\\t30\\tdays\\tapart.\\t(However,\\tmany dermatologists administer it at 2-  to 3- week intervals.)  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel use\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank (FARAD)\\tat\\twww.FARAD.org. Selegiline Hydrochloride se- leh\u2032jeh- leen  hye- droe- klor\u2032ide Trade and other names: Anipryl (also known as deprenyl and l- deprenyl), Eldepryl (human preparation), and Emsam transdermal patch","contraindications":"Contraindications and Precautions Do not use in dogs younger than 6 weeks of age. Do not use in cats younger than 8 weeks of age. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Selamectin is approved for prevention of heartworms; control of fleas, mites, and ticks in dogs; and prevention of heartworms, control of fleas, mites, hookworms, and roundworms in cats. Selamectin also can be used to treat scabies (Sarcoptes spp.) and is sometimes preferred over ivermectin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Transient, localized alopecia, with or without inflammation, at or near the site of application is observed in approximately 1% of treated cats. Other adverse effects include nausea, lethargy, salivation, tachypnea, and muscle tremors.","notes":"Instructions for Use Apply as indicated on product label to skin of dogs and cats. Patient Monitoring and Laboratory Tests Monitor heartworm status in animals. Formulations \u2022\\t\\tSelamectin\\tis\\tavailable\\tin\\t60-\\t\\tand\\t120-\\tmg/mL\\ttransdermal\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Spinosad","active_ingredient":"Spinosad","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t30\\tmg/kg\\t(13.5\\tmg/lb)\\tPO\\tadministered\\tonce\\tper\\tmonth. Cats \u2022\\t\\t50\u2013100\\tmg/kg\\tPO\\tonce\\tper\\tmonth.\\t(The\\tapproved\\tdosage\\tin\\tsome\\tcountries\\tfor cats is 50 mg/kg once per month.)  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Spironolactone speer- one- oh- lak\u2032tone Trade and other names: Aldactone and Prilactone (Europe)","contraindications":"Contraindications and Precautions It can be used safely with heartworm preventatives, including ivermectin but do not administer with high- dose ivermectin for treatment of Demodex infection. Use cautiously in pregnant and breeding animals. Some adverse effects on puppies have been reported from safety studies on pregnant dogs. Adverse effects in puppies nursing from dams administered spinosad also have been reported. Drug Interactions Spinosad significantly increased ivermectin concentrations when both drugs were administered together. The proposed interaction is caused by inhibition of P-   glycoprotein membrane transporter, which may increase the risk of adverse effects caused by ivermectin. Therefore, do not administer this agent with ivermectin. Spinosad has been used safely with other drugs, including heartworm preventatives.","indications":"Indications and Clinical Uses Spinosad is used as a monthly treatment for flea infestations. After administration, spinosad can kill fleas within 30 minutes and has complete kill within 4 hours. Efficacy may decline after the initial 2 weeks of treatment in areas with heavy flea populations, and efficacy for treating fleas may be better if administered every 2 weeks than once per month in some dogs. Spinosad plus milbemycin is indicated for prevention of heartworm disease (Dirofilaria immitis), as well as for killing fleas (Ctenocephalides felis) and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina), and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 2.5 kg of body weight or greater. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In safety studies, administration of high dosages (100 mg/kg once daily for 10 days) did not produce any serious adverse effects other than vomiting and mild elevation of liver enzymes. Oral administration of spinosad (300 mg/kg) to collie dogs with the multidrug resistant (MDR) gene mutation (p- glycoprotein deficient) did not cause signs of toxicosis. Occasional vomiting may be observed with routine use. (See Instructions for Use about dosing after vomiting.) In cats, the most common adverse event is vomiting.","notes":"Instructions for Use Spinosad should be administered with food for maximum absorption. If vomiting occurs within an hour of administration, redose with another full dose. If a dose is missed, administer Comfortis chewable tablets with food and resume a monthly dosing schedule. Treatment with spinosad may begin at any season of the year, preferably started before fleas emerge. It can also be used year round. Although not approved for cats in the United States (but approved in some countries), spinosad has been used safely with once- monthly treatment to control fleas. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. S Spironolactone 849 Formulations \u2022\\t\\tSpinosad\\tis\\tavailable\\tin\\tfive\\tchewable\\ttablet\\tsizes\\tcontaining\\t140,\\t270,\\t560,\\t810,\\tor 1620 mg. \u2022\\t\\tSpinosad\\t+\\tmilbemycin\\tchewable\\ttablets\\tare\\tavailable\\tas\\t140\\tmg\\tof\\tspinosad\\tand 2.3 mg of milbemycin oxime, 270 mg of spinosad and 4.5 mg of milbemycin oxime, 560 mg of spinosad and 9.3 mg of milbemycin oxime, 810 mg of spinosad and 13.5 mg of milbemycin oxime, and 1620 mg of spinosad and 27 mg of milbemycin oxime. Stability and Storage Store in blister packs and at room temperature.","original_category":"Antiparasitic"},{"name":"Thenium Closylate","active_ingredient":"Thenium Closylate","species":["Canine"],"dosage":"\u2022\\t\\tDogs\\tweighing\\tgreater\\tthan\\t4.5\\tkg:\\t500\\tmg\\tPO\\tonce\\tand\\trepeat\\tin\\t2\u20133\\tweeks. \u2022\\t\\tDogs\\tweighing\\t2.5\u20134.5\\tkg:\\t250\\tmg\\t(half\\ta\\ttablet)\\ttwice\\ta\\tday\\tPO\\tfor\\t1\\tday;\\trepeat in\\t2\u20133\\tweeks.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Theophylline thee- off\u2032ih- lin Trade and other names: Many generic brands and theophylline sustained release","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Thenium closylate is used to treat adult forms of the species Ancylostoma caninum and Uncinaria stenocephala (hookworms). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Thenium may cause occasional vomiting after oral administration.","notes":"Instructions for Use Tablet is bitter if coating is broken. 886    Theophylline Patient Monitoring and Laboratory Tests Monitor fecal samples for evidence of parasites. Formulations \u2022\\t\\tThenium\\tclosylate\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets\\t(veterinary\\tpreparation). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Thiabendazole","active_ingredient":"Thiabendazole","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t50\\tmg/kg\\tq24h\\tfor\\t3\\tdays;\\trepeat\\tin\\t1\\tmonth. \u2022\\t\\tTreating\\trespiratory\\tparasites:\\t30\u201370\\tmg/kg\\tq12h\\tPO. Cats \u2022 \\t \\tStrongyloides\\tspp:\\t125\\tmg/kg\\tq24h\\tfor\\t3\\tdays.  Horses \u2022\\t\\t44\\tmg/kg\\tPO\\t(single\\tdose). Sheep and Goats \u2022\\t\\t44\\tmg/kg\\tPO\\t(single\\tdose)\\tup\\tto\\t67\\tmg/kg\\tPO\\tfor\\tsome\\tinfections. Cattle \u2022\\t\\t67\\tmg/kg\\tPO\\t(single\\tdose)\\tup\\tto\\t111\\tmg/kg\\tPO\\tfor\\tmore\\tsevere\\tinfections. Pigs (baby pigs) \u2022\\t\\t67\u201390\\tmg/kg\\tPO. Regulatory Information Withdrawal\\ttime\\tfor\\tmilk:\\t96\\thours. Sheep\\tand\\tgoat\\twithdrawal\\ttime\\tfor\\tmeat:\\t30\\tdays. Cattle\\twithdrawal\\ttime\\tfor\\tmeat:\\t3\\tdays. Pig\\twithdrawal\\ttime\\tfor\\tmeat:\\t30\\tdays. 890    Thiacetarsamide Sodium Thiacetarsamide Sodium thye- ass- et- ars\u2032ah- mide  soe\u2032dee- um Trade and other names: Caparsolate","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Availability of commercial forms of thiabendazole has been limited. Some forms are no longer available. In horses, it has been used for control of large and small strongyles; Strongyloides; and pinworms of the genera Strongylus, Cyathostomum, and Cylicobrachytus and related genera Craterostomum, Oesophagodontus, Poteriostomum, and Oxyuris. In ruminants, it has been used for infections of GI roundworms in T sheep and goats (Trichostrongylus spp. Haemonchus spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomom spp., Strongyloides spp., Chabertia spp., Oesophagostomum spp., Trichostrongylus colubriformis, Trichostrongylus axei, and Ostertagia spp.). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are uncommon.","notes":"Instructions for Use Thiabendazole is ordinarily administered to horses and cattle. Experience in small animals is limited. Patient Monitoring and Laboratory Tests Monitor fecal samples for evidence of intestinal parasites. Formulations Available \u2022\\t\\tThiabendazole\\thas\\tbeen\\tavailable\\tin\\tpaste,\\tpellets,\\tand\\tsolution\\tfor\\toral administration and premix for feeds. Some formulations are no longer commercially available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiparasitic"},{"name":"Thiacetarsamide Sodium","active_ingredient":"Thiacetarsamide Sodium","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.2\\tmg/kg\\tIV\\ttwice\\tdaily\\tfor\\t2\\tdays. Cats \u2022\\t\\tNot\\trecommended.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Thiamine Hydrochloride thye\u2032ah- min  hye- droe- klor\u2032ide Trade and other names: Vitamin B 1 , Bewon, and generic brands","contraindications":"Contraindications and Precautions Its use is not recommended in cats unless they can be carefully monitored. Cats are less susceptible to arsenical toxicity than dogs, but they are more prone to pulmonary thromboembolism. If cats are treated, they should be confined under close\\tobservation\\tfor\\t3\u20134\\tweeks. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Thiacetarsamide has been used for treatment of adult heartworm infections. Caparsolate is no longer recommended as an adulticide heartworm treatment by the American Heartworm Society. Caparsolate is less effective in cats than in dogs, with a higher incidence of adverse reactions. In dogs, melarsomine is considered safer and has replaced thiacetarsamide for routine treatment. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are common, especially anorexia, vomiting, and hepatic injury. Pulmonary thromboembolism may occur as a consequence of heartworm kill.","notes":"Instructions for Use Thiacetarsamide is administered via four injections over 2 days; however, if severe adverse effects are observed, discontinue regimen. Extravasation can result in skin slough. It is recommended to substitute melarsomine for thiacetarsamide, if possible, for treating heartworm disease. Patient Monitoring and Laboratory Tests Monitor renal and hepatic function. Formulations \u2022\\t\\tThiacetarsamide\\twas\\tpreviously\\tavailable\\tin\\t10-\\tmg/mL\\tinjections.\\tThere\\tare\\tno longer commercial supplies of thiacetarsamide, and its availability is uncertain. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. T Thiamine Hydrochloride 891","original_category":"Antiparasitic"}]},{"category":"Antivirals","drugs":[{"name":"Acyclovir","active_ingredient":"Acyclovir","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tDogs:\\tSystemic\\tdoses\\thave\\tnot\\tbeen\\tdetermined\\tand\\tindications\\tfor\\twhich\\tit\\tmight be effective are not established. In rare instances when it has been used, the doses were\\textrapolated\\tfrom\\thuman\\tuse:\\t3\\tmg/kg\\tPO\\tfive\\ttimes\\tdaily\\tfor\\t10\\tdays,\\tup to\\t10\\tmg/kg\\tPO\\tfive\\ttimes\\tdaily\\tfor\\t10\\tdays.\\tAlternatively,\\t10\u201320\\tmg/kg\\tIV\\tq8h (slow infusion for 1 hour). \u2022\\t\\tCats:\\t   Acyclovir\\tis\\t not\\t  effective\\tagainst\\t   feline\\t   herpes\\t   virus\\t  infection,\\tit\\t is\\t toxic\\t  to\\t cats, and\\tother\\tagents\\tare\\tsuggested\\tas\\talternatives\\t(see\\tFamciclovir).  Horses \u2022\\t\\t10\\tmg/kg\\tq12h\\tIV\\tinfused\\tover\\t1\\thour.\\tEven\\tafter\\t20\\tmg/kg,\\toral\\tacyclovir\\tis\\tnot absorbed in horses well enough for systemic treatment, and other agents may be used for oral treatment (see Valacyclovir). Regulatory Information Because of mutagenicity, it should not be administered to animals intended for food. Afoxolaner a- fox\u2019- olan- er Trade and other names: NexGard","contraindications":"Contraindications and Precautions Do not use in animals with compromised renal function. Do not use in cats. Drug Interactions Do not mix with biological solutions (e.g., blood products). Do not mix with fluids that contain bacteriostatic preservatives. Do not use with other nephrotoxic drugs.","indications":"Indications and Clinical Uses Acyclovir\\tis\\tan\\tantiviral\\tdrug.\\tThere\\tis\\tvariability\\tin\\tsusceptibility\\tto\\tacyclovir.\\tFeline herpes\\tvirus-\\t1\\t(FHV-\\t1)\\tis\\tmuch\\tless\\tefficient\\t(by\\ta\\tfactor\\tof\\t1000)\\tfor\\tconverting acyclovir to the monophosphate form than human herpes simplex virus (HSV- 1). Therefore,\\tit\\thas\\tlittle\\tefficacy\\tfor\\ttreating\\tcats\\twith\\tFHV-\\t1.\\tIn\\taddition,\\tthe\\toral absorption is very low, producing ineffective plasma drug concentrations. More important, if high concentrations are achieved, toxicity is common in cats. Equine\\therpes\\tvirus\\t(EHV-\\t1)\\tis\\tmore\\tresponsive\\tto\\tacyclovir\\tthan\\tFHV-\\t1. Unfortunately,\\tit\\tis\\tnot\\tabsorbed\\torally\\tin\\thorses\\t(less\\tthan\\t3%).\\tThe\\tonly\\teffective use is from IV slow infusions (slow infusion necessary to prevent phlebitis). A typical dosage is 10 mg/kg q12h IV infused over 1 hour. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most serious adverse effect in humans is acute renal insufficiency. This may be prevented by slow IV infusion and proper hydration. Phlebitis can occur with IV administration. No adverse effects were identified in limited studies performed in horses, except in one study, the IV infusion caused sweating and muscle tremors when administered rapidly (15 minutes). In cats, significant adverse effects have been observed, which included myelosuppression, hepatotoxicity, and nephrotoxicity.","notes":"Instructions for Use To prepare injectable formulation, dilute each vial with 10 or 20 mL of water to make 50 mg/mL. Do not use bacteriostatic water that contains benzyl alcohol or parabens. Further\\tdilute\\tsolution\\tto\\tat\\tleast\\t100\\tmL\\tto\\ta\\tconcentration\\tof\\t7\\tmg/mL\\tor\\tless. Patient Monitoring and Laboratory Tests Monitor\\tblood\\turea\\tnitrogen\\t(BUN)\\tand\\tcreatinine\\tduring\\tuse.\\tIn\\thorses,\\tdoses should be administered to maintain plasma concentrations above 0.3 mcg/mL. Formulations \u2022\\t\\tAcyclovir\\tis\\tavailable\\tin\\t400-\\t\\tand\\t800-\\tmg\\ttablets,\\t200-\\tmg\\tcapsules,\\t1-\\tg\\tand\\t500- mg vials for injection (50 mg/mL), and 40- mg/mL oral suspension. Stability and Storage After reconstitution of solution at 50 mg/mL, it is stable for 12 hours at room temperature. More dilute solutions are stable for 24 hours. If refrigerated, a precipitate will form, which should be redissolved at room temperature before use. Store tablets and capsules in a tightly sealed container, protected from light, and at room temperature. 12    Afoxolaner","original_category":"Antiviral"},{"name":"Amantadine","active_ingredient":"Amantadine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tFor\\tpain\\ttreatment,\\t3\u20135\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t3\\tmg/kg\\tq24h\\tPO\\tfor\\ttreatment\\tof\\tpain,\\tup\\tto\\ta\\tdose\\tof\\t5\\tmg/kg\\tin\\tsome\\tcases.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information This drug should not be administered to food- producing animals, and no regulatory information\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact FARAD\\tat\\twww.FARAD.org. Amikacin am- ih- kay \u0301sin Trade and other names: Amiglyde- V (veterinary preparation), Amikin (human preparation), and generic brands","contraindications":"Contraindications and Precautions Pregnancy\\tcaution:\\tAmantadine\\tis\\tembryotoxic\\tand\\tteratogenic\\tat\\thigh\\tdoses\\tin laboratory animals. Avoid its use in pregnancy. Drug Interactions Do not use with other drugs that increase dopamine concentrations (e.g., selegiline). If used with other CNS stimulants, it may enhance the effects.","indications":"Indications and Clinical Uses Amantadine is an antiviral drug used to treat influenza infections in people but not used much anymore because many viruses are resistant. It also is used in people to treat Parkinson disease and extrapyramidal reactions, especially those that are drug induced. It also has been used to manage muscular weakness in humans with multiple sclerosis. However, its use in veterinary medicine has primarily been for treating pain in dogs and cats. It is used for treating pain when other drugs have been ineffective or when it is desirable to use in combination with multiple drugs in multimodal therapy analgesic protocols. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity has not been seen in dogs and cats until doses are exceeded by at least two times. Rarely, the side effects of anxiety states and dry mouth have been observed. Dizziness, confusion, and other CNS disturbances have been reported in people.","notes":"Instructions for Use Amantadine for treatment of pain may not be effective when used alone. Administer with another analgesic agent (e.g., NSAID) for best results. In post- surgical patients, it has been used for up to 21 days without adverse effects. Antiviral effects have not been adequately explored in animals. In people, the antiviral dosage is 1.5\u20133 mg/kg once or twice a day. A Amikacin 29 Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAmantadine\\tis\\tavailable\\tin\\t100-\\tmg\\tcapsules,\\t100-\\tmg\\ttablets,\\tand\\t10-\\tmg/mL syrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiviral"},{"name":"Famciclovir","active_ingredient":"Famciclovir","species":["Feline","Equine"],"dosage":"Cats \u2022\\t \\tTreatment\\tof\\tfeline\\therpes\\tvirus:\\tThe\\tpreferred\\tdose\\tis\\t90\\tmg/kg\\tq12h,\\tand\\tsome experts recommend q8h. Higher doses of 500 mg per cat (92\u2013227 mg/kg) also have been used. Lower dosages should be used in kittens (30\u201350 mg/kg q12h PO).  Horses \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\testablished. Regulatory Information Because of mutagenicity, it should not be administered to animals intended for food. Famotidine fah- moe\u2032tih- deen Trade and other names: Pepcid and generic","contraindications":"Not specified in source","indications":"Indications and Clinical Uses The most common use of famciclovir in veterinary medicine is to treat FHV1 associated with conjunctivitis, rhinosinusitis, keratitis, and FHV1- associated dermatitis. Famciclovir has been effective in cats with experimentally induced or spontaneous herpetic disease. Optimum doses for cats: Early studies with oral administration of famciclovir at 62.5 mg per cat failed to produce high enough blood concentrations of penciclovir to be consistently effective. Most experts recommend dosages of 90 mg/kg PO q8\u201312h. The most consistent positive results have been from 90 mg/kg q8h. Most of these recommendations are derived from small observational studies. There has been conflicting results in shelter cats. In one study, a single dose of 125 or 500 mg to cats (16\u201352 or 92\u2013227 mg/kg, respectively) at the time of shelter entry did not reduce shedding of FHV1 DNA or clinical disease scores compared with placebo. In another study, a dose of 30 or 90 mg/kg for 1 week did not reduce clinical signs of upper respiratory disease but reduced FHV1 shedding. In other studies, there were improvements in conjunctivitis, decreased conjunctival inflammation, decreased ocular discomfort, and decreased tearing. When treating cats with conjunctivitis or upper respiratory disease, a tetracycline (minocycline or doxycycline) may be administered concurrently. F Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects observed from famciclovir in cats include mild anemia. Mild increase in white blood cells may be seen. No adverse effects were identified in limited studies performed in cats. 352    Famotidine","notes":"Instructions for Use The dose listed for cats is based on limited studies in which 62.5 mg per cat was studied initially, but later evidence suggested that a more effective dosage is at least 125 mg per cat (or higher) q8\u201312h PO. Duration of treatment is undetermined, but generally 2 weeks may be needed. Patient Monitoring and Laboratory Tests Monitor blood urea nitrogen (BUN) and creatinine during use. Formulations \u2022\\t \\tFamciclovir\\tis\\tavailable\\tin\\t125-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\ttablets.\\tIt\\thas\\tbeen\\tcompounded into smaller tablets for kittens. A compounded oral suspension may be made by mixing 20 of the 500 mg famciclovir tablets (10 g), with 100 mL of a 1:1 mixture of Ora-Plus and Ora-Sweet. The final oral suspension is 100 mg/mL and is stable for 90 days if stored in a refrigerator. Label to indicate that it should be well shaken before use. Other compounded formulations for animals have not shown consistent quality or strength. Stability and Storage Store tablets and capsules in tightly sealed container, protected from light, and at room temperature.","original_category":"Antiviral"},{"name":"Valacyclovir","active_ingredient":"Valacyclovir","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t \\tCanine\\tdoses\\thave\\tnot\\tbeen\\tdetermined. Cats \u2022\\t\\tDo\\tnot\\tadminister\\tto\\tcats.  Horses \u2022\\t\\t27\\tmg/kg\\tPO\\tloading\\tdose\\tq8h\\tfor\\t2\\tdays.\\tThis\\tis\\tfollowed\\tby\\ta\\tmaintenance dosage\\tof\\t18\\tmg/kg\\tPO\\tq12h\\tfor\\t7\u201314\\tdays. Regulatory Information Because of mutagenicity, it should not be administered to animals intended for food. Valproic Acid, Valproate Sodium val- proe\u2032ik ass\u2032id, val\u2032proe- ate  soe\u2032dee- um Trade and other names: Depakene (valproic acid), Depakote (divalproex), and Epival (in Canada)","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Valacyclovir is an antiviral drug converted to acyclovir; therefore it can be used for similar indications as acyclovir but with better and more consistent oral absorption. Valacyclovir has been administered orally to horses because oral absorption of acyclovir is insufficient. Acyclovir is able to inhibit replication of EHV- 1 in vitro, and valacyclovir has been used for oral treatment of EHV- 1. The effectiveness of valacyclovir is better when administered for prophylaxis than as a treatment. When administered as oral treatment to horses for 7 or 14 days, it improved clinical signs, reduced viral shedding, and decreased viremia, and ataxia was not as severe. The activity against feline herpes virus is poor, and it produces adverse effects; therefore it is not recommended for cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most serious adverse effect in humans is acute renal insufficiency. This may be prevented by slow IV infusion and proper hydration. No adverse effects were identified in limited studies performed in horses. In cats, significant adverse effects have been observed, which included myelosuppression and kidney and liver injury, including fatal hepatic and renal necrosis. V 958    Valproic Acid, Valproate Sodium","notes":"Instructions for Use The dosages listed in the dosing section are based on pharmacokinetic studies to achieve the optimal plasma drug concentration in horses. Oral administration in horses is not affected by feeding. Patient Monitoring and Laboratory Tests Monitor blood urea nitrogen and creatinine during use. In horses, doses should be administered to maintain plasma concentrations above 0.3 mcg/mL. Formulations \u2022\\t\\tValacyclovir\\tis\\tavailable\\tin\\t500-\\tmg\\tand\\t1-\\tg\\ttablets.\\tFor\\tadministration\\tto\\thorses, the tablets have been crushed and mixed with corn syrup. Stability and Storage Store tablets in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiviral"},{"name":"Zidovudine","active_ingredient":"Zidovudine","species":["Feline"],"dosage":"(FIV) infection in cats. In cats, dosages of 25 mg/kg q12h IV or PO produced drug concentrations in the effective range to inhibit the virus. In experimentally infected cats with FeLV, it was effective to improve clinical signs. However, in naturally infected cats, it has not been effective, and the use in cats for this disease has been disappointing. In some cats, at a dosage of 5\u201310 mg/kg PO q12h, it may be more helpful for FIV than for FeLV and can improve quality of life, decrease virus load, and improve clinical signs in cats with FIV. AZT can reduce viral load and improve immunologic and clinical status, particularly in cats with stomatitis and neurologic signs. Precautionary Information  Cats \u2022\\t\\t5\u201310\\tmg/kg\\tPO\\tor\\tSQ\\tq12h.\\tIf\\tadministered\\tSQ,\\tdilute\\tin\\tsaline\\tfirst\\tto\\tavoid injection-\\tsite\\tirritation.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Zilpaterol Hydrochloride zil- pat\u2032e- role Trade and other names: Zilmax","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals. However, the use has been infrequent, and a full range of potential drug interactions is not known.","indications":"Indications and Clinical Uses In people, AZT is used to treat HIV (AIDS). In animals, it has been experimentally used for treatment of feline leukemia virus (FeLV) and feline immunodeficiency virus","side_effects":"Adverse Reactions and Side Effects Anemia and leucopenia have been observed in treated animals. Adverse effects are more common in cats at high doses (above 10 mg/kg q12h). It has not been used often in animals; therefore a full range of potential adverse effects has not been reported.","notes":"Instructions for Use At this time, experience with using AZT for treating viral disease in animals is largely experimental or anecdotal. This drug may help some cats with FIV and may prevent persistent FeLV, but documentation of clinical efficacy from well- controlled clinical trials is lacking. Patient Monitoring and Laboratory Tests Monitor the packed- cell volume in treated cats and perform a complete blood count. This should be done once per week initially and then once per month after the cat is stabilized. Formulations \u2022\\t\\tAZT\\tis\\tavailable\\tin\\ta\\t10-\\tmg/mL\\tsyrup\\tand\\ta\\t10-\\tmg/mL\\tinjection.\\tThe\\tsyrup\\thas been reformulated into capsules for cats. Z 984    Zilpaterol Hydrochloride Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiviral"}]},{"category":"Cardiovascular","drugs":[{"name":"Acetazolamide","active_ingredient":"Acetazolamide","species":["Canine","Feline","Equine"],"dosage":"Dogs Note:\\tThe\\tapproved\\tveterinary\\tformulation\\tlists\\ta\\tdose\\tof\\t10\u201330\\tmg/kg\\tfor\\tglaucoma and diuretic uses. \u2022\\t\\tGlaucoma:\\t5\u201310\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tOther\\tdiuretic\\tuses:\\t4\u20138\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\t7\\tmg/kg,\\tq8h,\\tPO.  Horses \u2022\\t\\tTreatment\\tof\\tHPP:\\t4\\tmg/kg\\tIV\\tor\\t8\\tmg/kg\\tPO\\tq8\u201312h. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Acetylcysteine ah- see- til- sis \u0301tay- een Trade and other names: Mucomyst, Cetylev, and Acetadote; also referred to as N- acetylcysteine","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tacidemia.\\tUse\\tcautiously\\tin\\tany\\tanimal\\tsensitive\\tto sulfonamides. Drug Interactions Acetazolamide produces alkaline urine, which may affect clearance of some drugs. Alkaline urine may potentiate the effects of some antibacterial drugs (e.g., macrolides and quinolones). 8    Acetylcysteine","indications":"Indications and Clinical Uses Acetazolamide is rarely used as a diuretic. More potent and more effective diuretic drugs are available, such as the loop diuretics (furosemide). It was once recommended for treatment of hydrocephalus in dogs, but it has been ineffective for this use. Acetazolamide, like other carbonic anhydrase inhibitors, is used primarily to lower intraocular pressure in animals with glaucoma. Methazolamide is used more often than acetazolamide for this purpose, and other treatment regimens are now used more often than carbonic anhydrase inhibitors. Acetazolamide also is sometimes used to produce more alkaline urine for management of some urinary calculi. In horses, acetazolamide is used to treat hyperkalemic periodic paralysis (HPP). This is a defect of sodium ion channels in muscle cells, and acetazolamide may alter potassium homeostasis by increasing potassium excretion. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Acetazolamide can potentially produce hypokalemia in some patients. Significant bicarbonate loss can occur with repeated administration. In dogs, a respiratory reaction has been observed, which is attributed to respiratory acidosis.","notes":"Instructions for Use Acetazolamide, in combination with other agents, is usually used to decrease intraocular pressure in the treatment of glaucoma. Acetazolamide has been used to produce alkaline urine to prevent formation of some urinary calculi. However, unless there is supplementation with bicarbonate, the urine alkalinization will not be sustained with repeated administration. Patient Monitoring and Laboratory Tests Monitor patient\u2019s ocular pressure when used to treat glaucoma. Formulations \u2022\\t\\tAcetazolamide\\tis\\tavailable\\tin\\t125-\\t\\tand\\t250-\\tmg\\ttablets\\tand\\ta\\tsoluble\\tpowder\\tfor dogs. Stability and Storage Stable if stored in tight containers. Compounded solutions are stable at least 60 days.","original_category":"Diuretic"},{"name":"Amiodarone Hydrochloride","active_ingredient":"Amiodarone Hydrochloride","species":["Canine","Equine"],"dosage":"Dogs \u2022\\t\\tVentricular\\tarrhythmias:\\t10\u201315\\tmg/kg\\tq12h\\tPO\\tfor\\t1\\tweek\\tand\\tthen\\t5\u20137.5\\tmg/ kg q12h for 2 weeks followed by a maintenance dose of 7.5 mg/kg q24h. \u2022\\t\\tRefractory\\tarrhythmias:\\t25\\tmg/kg\\tq12h\\tPO\\tfor\\t4\\tdays\\tfollowed\\tby\\t25\\tmg/kg q24h PO. \u2022\\t\\tAtrial\\tfibrillation:\\t15\\tmg/kg\\tloading\\tdose\\tfor\\t5\\tdays\\tfollowed\\tby\\t10\\tmg/kg\\tper\\tday PO thereafter. \u2022\\t\\tBoxer\\tor\\tDoberman:\\t200\\tmg\\tper\\tdog\\tq12h\\tfor\\t1\\tweek\\tPO\\tfollowed\\tby\\t200\\tmg once daily thereafter. Doses as high as two times these rates have been administered but with a higher risk of toxicity. No adverse clinical signs were observed in horses after single- administration IV, but for treating atrial fibrillation, mild signs of shifting weight and hind limb weakness were reported.  Horses \u2022\\t\\tTreatment\\tof\\tatrial\\tfibrillation\\tor\\tventricular\\ttachycardia:\\t5\\tmg/kg/h\\tfor\\t1 hour\\tfollowed\\tby\\t0.83\\tmg/kg/h\\tfor\\t23\\thours\\tIV.\\tOral\\tabsorption\\twas\\tlow\\tand inconsistent and has not been recommended. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Amitraz am \u0301ih- traz Trade and other names: Mitaban","contraindications":"Contraindications and Precautions Severe reactions, including hepatopathy and cardiac arrhythmias, have been seen in\\tdogs.\\tUse\\tonly\\twhen\\tarrhythmia\\thas\\tbeen\\trefractory\\tto\\tother\\ttreatments\\tor when dogs are at risk for sudden death. Drug Interactions Use\\tamiodarone\\twith\\tbeta\\tblockers,\\tcalcium-\\tchannel\\tblockers,\\tand\\tdigoxin cautiously because it may slow conduction. Do not mix IV solution with mixtures containing bicarbonate. A Amitraz 37 \u2022\\t\\tTreatment\\tof\\tarrhythmias\\twith\\tinjection\\tformulation:\\t5\\tmg/kg,\\tslowly\\tIV\\tover\\t10 minutes.\\tUse\\tcautiously\\tbecause\\tof\\trisk\\tof\\tadverse\\teffects. Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tcats.","indications":"Indications and Clinical Uses Amiodarone is used to treat refractory ventricular arrhythmias. It is reserved for treating life- threatening arrhythmias that have been refractory to other treatments. It has been used as a last resort for recurrent hemodynamically unstable ventricular tachycardia. In horses, IV amiodarone has been used to treat atrial fibrillation and ventricular arrhythmias. Amiodarone has been used for Chagas disease in combination with itraconazole. For\\tthis\\tuse,\\t15\\tmg/kg,\\tPO,\\tq12h,\\tfor\\t7\\tdays;\\tthen\\t15\\tmg/kg\\tPO,\\tq24h\\tfor\\t14\\tdays; then 7.5 mg/kg PO, q24h for 12 months. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The\\tmost\\tcommon\\teffect\\tin\\tdogs\\tis\\tdecreased\\tappetite.\\tProlonged\\tQ-\\tT\\tinterval also is a concern. Other adverse effects include bradycardia, congestive heart failure\\t(CHF),\\thypotension,\\tatrioventricular\\tblock,\\tthyroid\\tdysfunction\\t(decreased triiodothyronine [T 3 ] and tetraiodothyronine [T 4 ]), pulmonary fibrosis, neutropenia, and anemia. Hepatopathy is a serious concern and has been reported in dogs. Doberman dogs were particularly affected by amiodarone when treated for arrhythmias; there was a high incidence of adverse effects that included anorexia, lethargy, hepatic toxicity, and vomiting. Doses up to 12.5 mg/kg IV have produced no acute cardiovascular reactions; however, with acute IV administration, severe cardiac reactions, hypotension, vasodilation, pruritus, and edema (including swollen extremities) are possible. Adverse effects caused by IV treatment may be caused by the drug vehicle included\\tto\\tenhance\\tsolubility,\\tPolysorbate\\t80,\\twhich\\tis\\tknown\\tto\\telicit\\tallergic- type adverse events caused by histamine release. Pretreatment with antihistamines may help to decrease adverse events caused by IV treatment.","notes":"Instructions for Use Typically, loading doses are administered followed by maintenance dose. Oral dosing in dogs has used 10\u201315 mg/kg q12h for 1 week and then 5\u20137.5 mg/ kg q12h for 2 weeks followed by a maintenance dose of 7.5 mg/kg q24h. If IV therapy is used, doses should be given slowly; initial infusion rate should not exceed 30 mg/min. Prior to IV treatment, administer antihistamines to prevent allergic- type  reactions. Patient Monitoring and Laboratory Tests Because of a concern for adverse effects caused by amiodarone in dogs, therapy should be monitored carefully. It is highly recommended to monitor CBC for anemia and neutropenia and monitor hepatic indices with biochemical profile during treatment. Monitor electrocardiogram during IV treatment because prolonged Q-\\t T\\tinterval\\tmay\\toccur.\\tMonitor\\tthyroid\\tfunction\\tduring\\ttreatment\\tbecause\\tof adverse effects on thyroid function. Drug monitoring may be available from some laboratories. Therapeutic range of amiodarone in plasma is 1\u20132.5 mcg/mL. Formulations \u2022\\t\\tOral:\\tAmiodarone\\tis\\tavailable\\tin\\t100-\\t,\\t200-\\t   ,\\tand\\t400-\\tmg\\ttablets. \u2022\\t\\tInjection:\\t50-\\tmg/mL\\tinjection\\tand\\ta\\t1.5-\\t\\tand\\ta\\t1.8-\\tmg/mL\\tinjectable\\tunder\\tthe name Nexterone. \u2022\\t\\tA\\tnew\\tformulation\\t(PM101)\\tuses\\ta\\tdifferent\\tvehicle\\tto\\tenhance\\tsolubility\\trather than\\tPolysorbate\\t80.\\tThis\\tvehicle,\\tbeta-\\tcyclodextrin\\t(Captisol),\\tforms\\ta\\thydrophilic central core and is less likely to elicit an allergic- type reaction. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiarrhythmic"},{"name":"Benazepril Hydrochloride","active_ingredient":"Benazepril Hydrochloride","species":["Feline","Canine"],"dosage":"in cats, there was no benefit to dosages higher than 0.5\u20131 mg/kg/day.  Dogs \u2022\\t\\t0.25\u20130.5\\tmg/kg\\tq12\u201324h\\tPO\\t(0.5\\tmg/kg\\tq24h\\tin\\tmost\\tpatients).\\tIncrease\\tby 0.5\\tmg/kg\\tif\\tneeded,\\tto\\ta\\tmaximum\\tof\\t2\\tmg/kg\\tq24h. Cats \u2022\\t\\tSystemic\\thypertension:\\t0.5\u20131\\tmg/kg/day\\tq24h\\tPO.\\tAlternative\\tdosage\\tfor\\tcats\\tis 2.5\\tmg\\tper\\tcat\\tper\\tday\\tfor\\tcats\\tup\\tto\\t5\\tkg\\tof\\tbody\\tweight\\tPO. \u2022\\t\\tChronic\\tkidney\\tdisease:\\t0.25\u20130.5\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. B Betamethasone 81 Regulatory Information Do not administer to animals intended for food. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 Betamethasone bay- tah- meth\u2032ah- sone Trade and other names: Celestone, BetaVet, betamethasone acetate, and betamethasone benzoate","contraindications":"Contraindications and Precautions Discontinue ACE inhibitors in pregnant animals. ACE inhibitors cross the placenta and have caused fetal malformations and death of the fetus. Drug Interactions Use cautiously with other hypotensive drugs and diuretics. Nonsteroidal anti- inflammatory drugs (NSAIDs) may decrease vasodilating effects. Benazepril, like other ACE inhibitors, may be used with other cardiovascular drugs and furosemide. However, it does not prevent increases in aldosterone (caused by activation of the renin\u2013angiotensin\u2013aldosterone system) in patients treated with furosemide. It is possible that if ACE inhibitors are administered with spironolactone, there may be increases in serum potassium, but this is a rare occurrence in dogs and cats.","indications":"Indications and Clinical Uses Benazepril, like other ACE inhibitors, is used to treat hypertension and congestive heart failure (CHF). Evidence shows that it may decrease the likelihood of developing cardiomyopathy in some dogs, but other studies failed to show this benefit. For treatment of occult mitral valve disease in dogs, there has not been a benefit of therapy. It reduces blood pressure in some cats with kidney disease but is less effective in cats with spontaneous hypertension. Therefore, ACE inhibitors such as benazepril are not considered a primary treatment for hypertension in cats. Benazepril has been used in cats to treat proteinuria and hypertension in cats with chronic kidney disease. However, a survival benefit in cats with chronic kidney disease is not demonstrated. In studies in which it has been used in cats with renal insufficiency, it was associated with a small reduction in systemic hypertension, reduced glomerular filtration pressure, decreased glomerular hypertension, reduction in urine protein loss, and an increase in glomerular filtration rate (GFR) but no overall benefits on survival. For cats with kidney disease and hypertension, other agents are preferred such as amlodipine or telmisartan. In dogs, it produces similar benefits to animals with kidney disease (decreased proteinuria, increased GFR, and lower blood pressure), but it does not increase survival. Despite these limitations, some renal experts recommend including an ACE inhibitor (benazepril or enalapril) in the initial treatment for dogs with proteinuria caused by glomerular disease. B Precautionary Information","side_effects":"Adverse Reactions and Side Effects Benazepril has been well tolerated in dogs and cats with chronic renal failure. However, it may cause azotemia in some patients; carefully monitor renal parameters after initiation of treatment, particularly in patients receiving high doses of diuretics.","notes":"Instructions for Use Dose is based on approved use in dogs in Europe and Canada. Monitor renal function and electrolytes 3\u20137 days after initiating therapy and periodically thereafter. In studies Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes and renal function 3\u20137 days after initiating therapy and periodically thereafter. Monitor serum creatinine because some patients will show an increase in creatinine concentrations. Slight increases in creatinine in cats with chronic kidney disease may be tolerable and not a reason to discontinue treatment. Formulations \u2022\\t\\tBenazepril\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t20-\\t  ,\\tand\\t40-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vasodilator, angiotensin- converting enzyme (ACE)"},{"name":"Bisoprolol Fumarate","active_ingredient":"Bisoprolol Fumarate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished\\tfor\\tcats.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. 88    Bleomycin Sulfate Bleomycin Sulfate blee- oh- mye\u2032sin sul\u2032fate Trade and other names: Blenoxane","contraindications":"Contraindications and Precautions Use cautiously in animals with airway disease, myocardial failure, and cardiac conduction disturbances. Use cautiously in animals with low cardiac reserve. Drug Interactions Use cautiously with other drugs that may decrease cardiac contraction or heart rate. Concurrent use of rifampin may increase the metabolic clearance of bisoprolol.","indications":"Indications and Clinical Uses Bisoprolol is a beta 1 blocker that is somewhat cardioselective and therefore is indicated\\tfor\\tconditions\\tthat\\trequire\\ta\\treduction\\tin\\theart\\trate,\\theart\\tconductivity, or contractility. Such conditions include tachyarrhythmias and atrial fibrillation. In people, it is used to treat hypertension, but this use of bisoprolol has not been explored in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Beta blockade results in adverse effects that are attributed to decreased adrenergic tone in the heart. Bradycardia and heart block are possible. At high doses or in sensitive doses, bisoprolol may produce bronchospasm. Treat bradycardia from overdose with atropine.","notes":"Instructions for Use Dosing precautions are similar to other beta- blocking drugs. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm. Monitor blood pressure in patients prone to hypotension. Formulations \u2022\\t\\tBisoprolol\\tis\\tavailable\\tin\\t5-\\t\\tand\\t10-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiarrhythmic, beta blocker"},{"name":"Captopril","active_ingredient":"Captopril","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\u20132\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\t3.12\u20136.25\\tmg/cat\\tq8h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 C Carbenicillin 125 Carbenicillin kar- ben- ih- sill\u2032in Trade and other names: Formulations previously marketed were Geopen, Pyopen, and carbenicillin indanyl sodium","contraindications":"Contraindications and Precautions Discontinue ACE inhibitors in pregnant animals; they cross the placenta and have caused fetal malformations and fetal death. Drug Interactions Use\\tcautiously\\twith\\tdiuretics\\tand\\tpotassium\\tsupplements.\\tNonsteroidal\\tanti- inflammatory\\tdrugs\\t(NSAIDs)\\tmay\\tdiminish\\tantihypertensive\\teffect.","indications":"Indications and Clinical Uses Captopril, like other ACE inhibitors, has been used to treat hypertension and congestive heart failure. It was once used in dogs, but its use has declined substantially. Captopril was the first ACE inhibitor available for clinical use but has been replaced by other ACE inhibitors such as enalapril, benazepril, and lisinopril. Unlike benazepril and enalapril, there are no clinical studies that have been used to support its clinical use in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypotension is possible with excessive doses. Captopril may cause azotemia in some patients, especially when administered with potent diuretics (e.g., furosemide). GI side effects, predominantly anorexia, are common in dogs.","notes":"Instructions for Use Use of captopril has been replaced by enalapril and benazepril in small animal practices, and most clinical experts recommend these other drugs instead of captopril. Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes and renal function 3\u20137 days after initiating therapy and periodically thereafter. Formulations \u2022\\t\\tCaptopril\\tis\\tavailable\\tin\\t12.5-\\t,\\t25-\\t  ,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container at room temperature. More stable at acidic pH. Oral compounded solutions are stable for 30 days refrigerated. However, tap water should not be used; purified water is necessary to ensure stability.","original_category":"Vasodilator, angiotensin- converting enzyme inhibitor"},{"name":"Carvedilol","active_ingredient":"Carvedilol","species":["Canine","Feline"],"dosage":"titration study in dogs, the effective dosage was 0.2\u20130.4 mg/kg q24h PO.  Dogs \u2022\\t\\tInitial\\tdose:\\t0.2\\tmg/kg\\tq24h\\tPO\\tfollowed\\tby\\tincreases\\tup\\tto\\ta\\tmaximum\\tof\\t0.4 mg/kg q12h. There is some evidence that a higher dosage of 1.5 mg/kg q12h PO was more effective, but some dogs are refractory. Cats \u2022\\t\\tDose\\tnot\\testablished.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t3 Cascara Sagrada kass- kar\u2032ah  sah- grah\u2032dah Trade and other names: Nature\u2019s Remedy and generic brands","contraindications":"Contraindications and Precautions Use carefully in patients with limited cardiac reserve. Do not administer to dehydrated or hypotensive animals. Use carefully in patients with respiratory disease because the beta 2 - adrenergic blocking properties can worsen bronchoconstriction. Drug Interactions Use with other beta blockers will increase its effect. Do not administer with other drugs that may cause hypotension or depress the heart.","indications":"Indications and Clinical Uses Carvedilol has been used to treat arrhythmias in animals. It is also used to treat systemic hypertension and to block beta- adrenergic cardiac receptors in animals with rapid heart rates. Efficacy has been based on anecdotal accounts, extrapolation from humans, and limited studies in healthy dogs. In healthy dogs, 0.2 mg/kg PO decreased heart rate, and 0.4 mg/kg PO decreased heart rate and lowered blood pressure. At 0.4 mg/kg, the effects in healthy dogs persisted for 36 hours. However, in other studies, doses of 0.3 mg/kg were not effective. In clinical patients, the optimum dose is not known, and long- term benefits have not been established. Because oral absorption is inconsistent in dogs (discussed in the Pharmacology section), the response may be variable. Elimination is rapid after oral administration to dogs, but clinical pharmacodynamic effects may persist for up to 12 hours, possibly from the metabolites. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Bradycardia can occur resulting from beta- adrenergic receptor blockade. Carvedilol increases risk of myocardial depression and decreased cardiac output. Adverse effects from nonselective beta- adrenergic receptor blockade are possible in other tissues. In research dogs administered doses from 0.3 to 1.0 mg/kg, there was a dose- dependent increase in dizziness, bradycardia, and negative inotropic and chronotropic effects. There was a dose- dependent increase in exercise intolerance at higher doses.","notes":"Instructions for Use Doses in dogs established through clinical experience and limited trials. In a dose Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and rhythm carefully during treatment. During the initial phase of dosing, monitor patients for worsening of heart failure. Formulations \u2022\\t\\tCarvedilol\\tis\\tavailable\\tin\\t3.125-\\t,\\t6.25-\\t   ,\\t12.5-\\t   ,\\tand\\t25-\\tmg\\ttablets. C Cascara Sagrada 133 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Carvedilol is not soluble in water. Carvedilol compounded suspension has been prepared by adding 25- mg tablets to water to make a paste and then mixed with simple syrup to make a 2-  or 10- mg/mL suspension for oral administration. This suspension has been stable for 90 days at room temperature, protected from light.","original_category":"Antiarrhythmic"},{"name":"Chlorothiazide","active_ingredient":"Chlorothiazide","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t20\u201340\\tmg/kg\\tq12h\\tPO.  Cattle \u2022\\t\\tFor\\ttreatment\\tof\\tudder\\tedema,\\t125\u2013250\\tmg\\tIV\\tor\\tIM\\tinjection\\tonce\\tor\\ttwice\\tper day or a 2- g oral bolus once or twice per day. C Chlorpheniramine Maleate 175 Regulatory Information Withdrawal\\ttimes:\\tfor\\tmilk:\\t72\\thours\\t(6\\tmilkings);\\twithdrawal\\ttime\\tfor\\tmeat\\tis\\tnot established.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat www.FARAD.org. RCI\\tClassification:\\t4 Chlorpheniramine Maleate klor- fen- eer\u2032ah- meen  mal\u2032ee- ate Trade and other names: Chlor- Trimeton and Phenetron","contraindications":"Contraindications and Precautions These drugs enhance calcium absorption by decreasing intracellular sodium and enhance\\tthe\\tNa + /Ca 2+ exchange to decrease calcium excretion in urine. They should never be used in patients with hypercalcemia or at risk of hypercalcemia. Drug Interactions Avoid administering calcium and vitamin D supplements.","indications":"Indications and Clinical Uses Chlorothiazide use is not common in animals. There is an approved formulation for dogs (Diuril), but it is not often prescribed. In people, it is used primarily to treat hypertension. In animals, it has been used to treat hypercalciuria (increased calcium in the urine that may lead to urinary calculi). In dairy cattle, it is approved as an oral bolus or injection to treat postparturient udder edema. Because chlorothiazide decreases renal excretion of calcium, it also has been used to prevent uroliths containing calcium. Dosage regimens used are derived either empirically or from extrapolation of the human dose. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Chlorothiazide may cause electrolyte imbalance such as hypokalemia.","notes":"Instructions for Use Thiazide diuretics are used rarely in animals. Because they are not as effective as high- ceiling diuretics for producing diuresis, agents such as furosemide are used more often. Patient Monitoring and Laboratory Tests Electrolytes should be monitored during chronic therapy. Formulations \u2022\\t\\tChlorothiazide\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\ttablets,\\t50-\\tmg/mL\\toral suspension,\\tand\\tinjection\\tvials\\tof\\t500\\tmg\\t(with\\tmannitol).\\tCattle\\tformulation: available as 2- g oral bolus or 25 mg/mL as a hydrochlorothiazide injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Reconstituted solutions are stable for 24 hours.","original_category":"Diuretic"},{"name":"Dichlorphenamide","active_ingredient":"Dichlorphenamide","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t3\u20135\\tmg/kg\\tq8\u201312h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Dichlorvos dye \u0301klor- vos Trade and other names: Task, Atgard, DDVP, Verdisol, and Equigard. Also known as dichlorovos.","contraindications":"Contraindications and Precautions Use cautiously in animals sensitive to sulfonamides. Drug Interactions Dichlorphenamide produces alkaline urine, which may affect clearance of some drugs. Alkaline urine may potentiate the effects of some antibacterial drugs (e.g., macrolides\\tand\\tquinolones).","indications":"Indications and Clinical Uses Dichlorphenamide is rarely used as a diuretic any longer. More potent and effective diuretic drugs are available, such as the loop diuretics (furosemide). Dichlorphenamide, like other carbonic anhydrase inhibitors, is used primarily to reduce intraocular pressure in animals with glaucoma. Methazolamide is used more often than dichlorphenamide or acetazolamide for this purpose, and other treatment regimens for glaucoma are used more often than carbonic anhydrase inhibitors. Dichlorphenamide, like other carbonic anhydrase inhibitors, is sometimes used to produce a more alkaline urine for management of some urinary calculi. D Dichlorvos 263 Precautionary Information","side_effects":"Adverse Reactions and Side Effects With prolonged use, it depletes bicarbonate if not replenished. Dichlorphenamide is a sulfonamide derivative. Some animals sensitive to sulfonamides may be sensitive\\tto\\tdichlorphenamide.\\tHypokalemia\\tmay\\toccur\\tin\\tsome\\tpatients.\\tSevere metabolic acidosis is rare.","notes":"Instructions for Use Dichlorphenamide is not used as a diuretic, but the use for treating glaucoma or to produce alkaline urine is more common. When used for glaucoma, it has been combined with other antiglaucoma agents. Patient Monitoring and Laboratory Tests Monitor\\tocular\\tpressure\\tfor\\tglaucoma\\ttreatment.\\tMonitor\\tserum\\tpotassium\\tand\\tacid\u2013 base status during treatment. Formulations \u2022\\t\\tDichlorphenamide\\tis\\tno\\tlonger\\tcommercially\\tavailable.\\tHowever,\\tolder\\tforms\\twere available in 50- mg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Diuretic"},{"name":"Disopyramide","active_ingredient":"Disopyramide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t6\u201315\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\tNo\\tdose\\testablished.  \u2022\\t\\tNo\\tuse\\tin\\tlarge\\tanimals\\tis\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Dithiazanine Iodide dye- thye- az \u0301ah- neen  eye \u0301oe- dide Trade and other names: Dizan","contraindications":"Contraindications and Precautions At high doses, it may induce arrhythmias in some patients. Drug Interactions No drug interactions are reported for animals. Use cautiously with other drugs that may affect the cardiac rhythm.","indications":"Indications and Clinical Uses Disopyramide has been used for the control of ventricular arrhythmias. Its use in veterinary medicine is not as common as for other drugs because there are other more commonly used oral agents used for managing cardiac arrhythmias in animals. Studies of efficacy in animals have not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\thave\\tnot\\tbeen\\treported\\tin\\tanimals.\\tHigh\\tdoses\\tmay\\tcause\\tcardiac arrhythmias.","notes":"Instructions for Use Disopyramide is not commonly used in veterinary medicine because of its short half- life\\tin\\tdogs.\\tOther\\tantiarrhythmic\\tdrugs\\tare\\tpreferred. Patient Monitoring and Laboratory Tests Monitor\\tECG\\tin\\ttreated\\tanimals.\\tThis\\tdrug\\tcan\\tbe\\tproarrhythmogenic. Formulations \u2022\\t\\tDisopyramide\\tis\\tavailable\\tin\\t100-\\t\\tand\\t150-\\tmg\\tcapsules\\tand\\t10-\\tmg/mL\\tinjection (Canada only). 294    Dobutamine Hydrochloride Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded oral formulations have been stable for 30 days.","original_category":"Antiarrhythmic agent"},{"name":"Enalapril Maleate","active_ingredient":"Enalapril Maleate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.5\\tmg/kg\\tq12\u201324h\\tPO.\\tIn\\tsome\\tanimals,\\tit\\tmay\\tbe\\tnecessary\\tto\\tincrease\\tdose\\tto 1\\tmg/kg/day,\\tadministered\\tas\\t0.5\\tmg/kg\\tq12h. Cats \u2022\\t\\t0.25\u20130.5\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t\\t1\u20131.25\\tmg/cat/day\\tPO.  \u2022\\t\\tHorses:\\tAlthough\\tenalapril\\thas\\tbeen\\texamined\\tin\\tresearch\\thorses,\\tthere\\tare\\tno clinical studies available to establish doses. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank\\t(FARAD)\\tat www.FARAD.org. RCI Classification: 3 E Enflurane 321 Enflurane en- floor \u0301ane Trade and other names: Ethrane","contraindications":"Contraindications and Precautions Discontinue\\tACE\\tinhibitors\\tin\\tpregnant\\tanimals;\\tthey\\tcross\\tthe\\tplacenta\\tand\\thave caused fetal malformations and death of the fetus. Drug Interactions Use\\tcautiously\\twith\\tother\\tdrugs\\tknown\\tto\\tcause\\thypotension.\\tThe\\tuse\\tmay\\texacerbate effects\\tof\\tdiuretics.\\tNonsteroidal\\tanti-\\tinflammatory\\tdrugs\\t(NSAIDs)\\tmay\\tpotentially decrease vasodilating effects, but this has not been shown in studies in animals.","indications":"Indications and Clinical Uses Enalapril,\\tlike\\tother\\tACE\\tinhibitors,\\tis\\tused\\tto\\ttreat\\thypertension\\tand\\tcongestive heart failure (CHF). Efficacy for treating CHF has been established from clinical trials and can be used with other drugs such as pimobendan, furosemide, digoxin, and\\tspironolactone.\\tIf\\taldosterone\\tbreakthrough\\toccurs\\twith\\tadministration\\tof\\tACE inhibitors, spironolactone may be indicated. It is primarily used in dogs. In addition to its use for treatment of CHF, enalapril has been used to delay onset of CHF in dogs with mitral regurgitation. The benefit of enalapril and other ACE inhibitors for occult\\theart\\tdisease\\tis\\tcontroversial;\\tsome\\tstudies\\thave\\tshown\\ta\\tbenefit,\\tand\\tothers have not. Enalapril has been used in some cats in heart failure or with systemic hypertension.\\tUnfortunately,\\tapproximately\\t50%\\tof\\tcats\\twith\\thypertension\\tdo\\tnot respond to enalapril, and ACE inhibitors are not considered a primary treatment for hypertension\\tin\\tcats.\\tAn\\tangiotensin-\\treceptor\\tblocking\\tdrug\\t(e.g.,\\ttelmisartan)\\tor other vasodilators are preferred in cats. Angiotensin-\\tconverting\\tenzyme\\tinhibitors\\talso\\thave\\tbeen\\tshown\\tto\\tbe\\tbeneficial\\tin\\tthe management\\tof\\tcertain\\ttypes\\tof\\tkidney\\tdisorders\\t(nephropathy)\\tand\\tfor\\trenal\\thypertension. Renal benefits result from limiting systemic and glomerular capillary hypertension, the antiproteinuric\\teffect\\tto\\tdecrease\\tin\\turine\\tprotein-\\tto-\\t creatinine\\tratio\\tand\\tretarding\\tthe development of glomerular sclerosis and tubulointerstitial lesions. ACE inhibitors have decreased\\tproteinuria\\tin\\tpatients,\\tbut\\tlong-\\tterm\\tbenefits\\ton\\tsurvival\\thave\\tnot\\tbeen established. The benefits of ACE inhibitor treatment in cats with chronic renal disease are somewhat\\tmodest\\tand\\thave\\tlittle\\teffect\\ton\\tsurvival\\ttime\\tor\\tlong-\\tterm\\tprognosis. Large\\tanimal\\tuses\\thave\\tnot\\tbeen\\testablished,\\tbut\\tin\\thorses,\\tthe\\tmetabolite enalaprilat\\tat\\t0.5\\tmg/kg\\tIV\\tcompletely\\tinhibited\\tACE\\tactivity\\tbut\\tdid\\tnot\\tchange blood pressure or other hemodynamic variables in response to exercise. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Enalapril may cause azotemia in some patients, but this effect is uncommon. Nevertheless, monitor renal parameters in patients receiving ACE inhibitors, especially if they are receiving diuretics.","notes":"Instructions for Use The doses of enalapril are based on clinical trials conducted in dogs. For dogs, generally\\tstart\\twith\\tonce-\\tdaily\\tadministration\\tand\\tincrease\\tto\\tq12h\\tif\\tneeded\\t(see\\tthe dosing section).\\tIn\\tsome\\tdogs\\twith\\tmild\\tdisease,\\tstart\\twith\\t0.25\\tmg/kg\\tq12h\\tand then\\tincrease\\tto\\t0.5\\tmg/kg\\tq12h\\tat\\tthe\\tfirst\\trecheck.\\tOther\\tdrugs\\tused\\tfor\\ttreatment of heart failure, such as pimobendan and spironolactone, may be used concurrently. Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes\\tand\\trenal\\tfunction\\t3\u20137\\tdays\\tafter\\tinitiating\\ttherapy\\tand\\tperiodically\\tthereafter. Formulations \u2022\\t \\tEnalapril\\tis\\tavailable\\tas\\tVasotec\\t(human\\tpreparation)\\tin\\t2.5-\\t,\\t5-\\t ,\\t10-\\t  ,\\tand\\t20-\\tmg tablets\\tand\\tas\\tEnacard\\t(veterinary\\tpreparation)\\tin\\t1-\\t,\\t2.5-\\t  ,\\t5-\\t ,\\t10-\\t  ,\\tand\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Enalapril, compounded in a variety of oral suspensions and flavorings, was stable for 60\\tdays.\\tAbove\\ta\\tpH\\tof\\t5,\\tdegradation\\toccurs\\tmore\\tquickly.","original_category":"Vasodilator, angiotensin- converting enzyme (ACE) inhibitor"},{"name":"Esmolol Hydrochloride","active_ingredient":"Esmolol Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.5\\tmg/kg\\t(500\\tmcg/kg)\\tIV,\\twhich\\tmay\\tbe\\tgiven\\tas\\t0.05\u20130.1\\tmg/kg\\tslowly\\tevery 5\\tminutes. \u2022\\t\\tCRI:\\t0.5\\tmg/kg\\tslowly\\tover\\ta\\t30-\\t\\tto\\t60-\\tsecond\\tperiod\\tfollowed\\tby\\t50-\\t\\tto\\t200- mcg/kg/min\\tinfusion.  Horses \u2022\\t\\t0.2\\tmg/kg\\tover\\t1\\tminute\\tIV.\\tAfter\\t10\\tminutes,\\tadminister\\t0.5\\tmg/kg\\tover\\t1 minute IV. \u2022\\t\\tCRI:\\t0.5\\tmg/kg\\tIV\\tfollowed\\tby\\t25\\tmcg/kg/min\\tIV. Regulatory Information Withdrawal times are not reported. However, because of short duration of action and rapid metabolism, a short withdrawal period is suggested. RCI Classification: 3 Esomeprazole es- oh- mep \u0301rah- zole Trade and other names: Nexium","contraindications":"Contraindications and Precautions When\\tadministering\\tto\\tpatients\\twith\\tdilated\\tcardiomyopathy,\\tconsider\\tthe\\trisk\\tof negative cardiac effects. Use cautiously in patients with bronchospasm. Esmolol is contraindicated\\tin\\tpatients\\twith\\tbradycardia\\tor\\tatrioventricular\\tblock. Drug Interactions Use cautiously with digoxin, morphine, or warfarin.","indications":"Indications and Clinical Uses Esmolol\\tis\\tindicated\\tfor\\tshort-\\tterm\\tcontrol\\tof\\tsystemic\\thypertension\\tand tachyarrhythmias.\\tIt\\thas\\tbeen\\tused\\tfor\\temergency\\ttherapy\\tor\\tshort-\\tterm\\ttreatment. Long-\\t   term\\ttreatment\\tis\\tnot\\tpossible\\tbecause\\tof\\tthe\\tshort\\thalf-\\tlife.\\tOrdinarily,\\tif\\tan animal\\tshows\\ta\\tpositive\\tresponse\\tto\\tesmolol,\\tit\\tcan\\tbe\\tswitched\\tto\\tlonger-\\tacting\\tbeta blockers\\t(e.g.,\\tpropranolol\\tor\\tatenolol). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects related to beta 1 -\\tblocking\\teffects\\ton\\tthe\\theart\\tinclude\\tmyocardial depression, reduced cardiac output, and bradycardia.","notes":"Instructions for Use Esmolol\\tis\\tindicated\\tfor\\tshort-\\tterm\\tIV\\ttherapy\\tonly.\\tDoses\\tare\\tbased\\tprimarily\\ton empiricism or extrapolation of human dose. No clinical studies have been reported in animals. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. 342    Esomeprazole Formulations \u2022\\t\\tEsmolol\\tis\\tavailable\\tin\\t10-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Beta blocker, antiarrhythmic"},{"name":"Fenoldopam Mesylate","active_ingredient":"Fenoldopam Mesylate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.8\\tmcg/kg/min\\tCRI. Cats \u2022\\t\\t0.5\u20130.8\\tmcg/kg/min\\tCRI.  Foals \u2022\\t\\t0.04\\tmcg/kg/min. Regulatory Information There are no withdrawal times established for food animals. Because fenoldopam has a very short half- life, residues in food animals are not expected to be a problem. Fentanyl Citrate (Note: Transdermal Fentanyl Is Listed Separately in the Next Section) fen\u2032tah- nil  sih\u2032trate Trade and other names: Sublimaze and generic brands; Fentora buccal tablets","contraindications":"Contraindications and Precautions No known contraindications. Drug Interactions Use cautiously with other vasodilators; excessive hypotension can occur. Do not use with beta blockers.","indications":"Indications and Clinical Uses The use of fenoldopam in veterinary medicine is limited to a few research studies (primarily in cats and dogs), small observational studies, and some anecdotal evidence of efficacy for\\ttreating\\tacute\\tkidney\\tinjury\\t(AKI).\\tIn\\thealthy\\tdogs\\tat\\ta\\tdose\\tof\\t0.8\\tmcg/kg/min (CRI), it produced a significant increase in glomerular filtration rate, and renal plasma flow without inducing hypotension. This effect likely is produced through its action as a renal vasodilator and improvement in renal plasma flow. Despite this effect in healthy animals, at this time, there is insufficient evidence to recommend for routine treatment in patients with kidney failure as there has been no demonstrated difference in survival associated with\\ttreatment.\\tIn\\tpeople,\\tfenoldopam\\thas\\treplaced\\tdopamine\\tas\\ta\\ttreatment\\tof\\tAKI.\\tIt\\tis also used in people to treat severe hypertension, to prevent renal ischemia, and to increase gastrointestinal\\t(GI)\\tperfusion,\\tas\\twell\\tas\\tbeing\\ta\\ttreatment\\tfor\\tAKI.\\tThe\\tuse\\tis\\tlimited to short- term in- hospital use when rapid treatment of hypertension is needed. These indications in people have not been fully explored for use in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects It has been generally safe and well- tolerated in dogs and cats, but these studies were in healthy animals. The most common side effect is hypotension. The half- life of fenoldopam is short; therefore, if hypotension is observed, decrease the infusion rate. Other adverse effects described for small animals include reflex tachycardia and mild hypokalemia. Rarely, it has caused facial twitching and hypersalivation in cats. In people, adverse effects can include increased intraocular pressure (risk in glaucoma), low potassium, and tachycardia.","notes":"Instructions for Use Administer by CRI. There is no need to administer bolus doses because the onset of effects should occur within 15 minutes of starting the CRI. Dose recommendations are based on some limited research studies and anecdotal clinical experience from veterinarians. There have been no well- controlled studies of efficacy in animals, and the use is largely extrapolated from human recommendations. It is recommended that the solution be added to fluids (e.g., 5% dextrose) to make a 40- mcg/mL solution for infusion. For example, add 1 mL (10 mg) to 250 mL. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and blood pressure during treatment. Formulations \u2022\\t\\tFenoldopam\\tis\\tavailable\\tas\\ta\\t10-\\tmg/mL\\tinjection.\\tThe\\tpH\\trange\\tis\\t2.8\u20133.8. Stability and Storage Fenoldopam solution can be mixed with sodium chloride solution (0.9%) or 5% dextrose solution for infusion. After being mixed in fluids, it is stable under normal ambient light and temperature conditions for at least 24 hours. After 24 hours, discard the solution. F Fentanyl Citrate 361","original_category":"Vasodilator"},{"name":"Furosemide","active_ingredient":"Furosemide","species":["Canine","Feline","Equine","Bovine"],"dosage":"When administered to dogs at a dosage of 2 mg/kg q12h, it significantly increased RAAS activity by day 5 of treatment. When the RAAS is activated, increased concentrations of aldosterone can have persistent and deleterious effects\\ton\\tvasculature\\tand\\tcardiac\\tremodeling.\\tSQ\\tinjection\\tmay\\tcause\\tirritation (stinging) at the injection site.  Dogs \u2022\\t\\t2\u20136\\tmg/kg\\tq8\u201312h\\t(or\\tas\\tneeded)\\tIV,\\tIM,\\tSQ,\\tor\\tPO.\\tA\\tcommon\\tinitial\\tdose when treating heart failure patients is 2 mg/kg q12h PO; then lower to 1\u20132 mg/ kg q12h PO. \u2022\\t\\tIn\\tacute\\tcases\\tin\\twhich\\tintensive\\ttreatment\\tis\\tneeded,\\tadminister\\t2\\tmg/kg\\tIV followed by 2 mg/kg every 30 minutes until improvement is seen. \u2022\\t\\tCRI:\\t0.66\\tmg/kg\\tbolus\\tdose\\tIV\\tfollowed\\tby\\t0.66\\tmg/kg/h\\tfor\\t8\\thours. Alternatively, a dose of 2 mg/kg in 5% glucose can be infused over an 8- hour period IV. Cats \u2022\\t\\tStart\\twith\\t1\\tmg/kg;\\tthen\\tincrease\\tas\\tneeded,\\twithin\\ta\\trange\\tof\\t1\u20134\\tmg/kg\\tq8\u201324h IV,\\tIM,\\tSQ,\\tor\\tPO.  Horses \u2022\\t\\t1\\tmg/kg\\tq8h\\tor\\t250\u2013500\\tmg/horse\\tat\\t6-\\t\\tto\\t8-\\thour\\tintervals\\tIM\\tor\\tIV. \u2022\\t\\tCRI:\\t0.12\\tmg/kg\\tIV\\tfollowed\\tby\\t0.12\\tmg/kg/h\\tIV. \u2022\\t\\tPrevention\\tof\\tEIPH:\\t0.5\\tor\\t1\\tmg/kg\\tIV,\\tadministered\\t4\\thours\\tprior\\tto\\texercise\\tor administered 24 hours preracing. Consult local racetrack jurisdiction for restrictions on administration. Cattle \u2022\\t\\t500\\tmg/animal\\tonce\\ta\\tday\\tor\\t250\\tmg/animal\\ttwice\\ta\\tday\\tIM\\tor\\tIV. Regulatory Information Cattle withdrawal times: 2 days meat and 48 hours milk. Horses: Most racing regulations specify that a 250- mg/horse dose may be given by a single IV injection no later than 4 hours before racing post time. In most horses, this does not produce violations above 100 ng/mL urine threshold at 4 hours. Check local racetrack jurisdiction for restrictions for administration on race day. 398    Gabapentin Gabapentin gab\u2032ah- pen- tin Trade and other names: Neurontin and generic brands","contraindications":"Contraindications and Precautions Administer conservatively in animals receiving ACE inhibitors to decrease the risk of azotemia. Repeated administration may increase aldosterone levels via activation of RAAS. Drug Interactions Concurrent use with aminoglycoside antibiotics or amphotericin B may increase risk of nephrotoxicity and ototoxicity. Administration of NSAIDs with furosemide may diminish the effect. The pH of solution is 8\u20139.8. Furosemide is stable with alkaline drugs but it should not be mixed with acidifying drug solutions with a pH less than 5.5.","indications":"Indications and Clinical Uses In small animals, furosemide is the drug of choice to treat conditions that cause edema, including pulmonary edema, liver disease, heart disease, and vascular disease. It is recommended in dogs with clinical signs of stage C heart disease, to be used initially, until the patient\u2019s clinical signs have improved. Furosemide increases potassium and calcium excretion and is used to treat hyperkalemia and hypercalcemia. The\\tuse\\tof\\tfurosemide\\tfor\\tAKI\\ttreatment\\thas\\tno\\tbenefit\\tor\\teffect\\ton\\tpatient outcome based on available evidence. Furosemide promotes urine output by decreasing reabsorption of sodium but does not increase glomerular filtration rate. In horses, furosemide has been used to treat edema and syndromes associated with congestion. The most common use in horses is pretreatment prior to racing. Although it appears to produce faster racing times, the mechanism is unclear. It may decrease body weight via water loss and may decrease exercise- induced pulmonary hemorrhage (EIPH). The efficacy to reduce EIPH has been controversial in horses, but there is reported evidence to support this effect. In cattle, furosemide also is used for treating conditions of edema (e.g., udder edema) and for treatment of heart failure and pulmonary hypertension. In all animals, duration of effect is short, approximately 2\u20134 hours. Because of short duration, CRIs can produce greater efficacy in some animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to diuretic effect (loss of fluid and electrolytes). In dogs, hyponatremia is more common than hypokalemia. Tolerance and activation of the renin\u2013angiotensin\u2013aldosterone system (RAAS) occur with repeated administration, in which the diuretic effect is attenuated.","notes":"Instructions for Use Recommendations for use of furosemide are based on extensive clinical use of furosemide in animals. The onset of effect after an injection is usually 5 minutes, with the peak at 30 minutes to 2 hours and a duration of approximately 2\u20134 hours. CRIs in dogs and horses can be more effective than intermittent bolus. Long- term repeated administration may attenuate the effects because of tolerance and activation of the RAAS. Patient Monitoring and Laboratory Tests Monitor electrolyte concentrations (particularly potassium) and hydration status in patients during treatment. Formulations \u2022\\t\\tFurosemide\\tis\\tavailable\\tin\\t12.5-\\t,\\t20-\\t  ,\\t40-\\t  ,\\t50-\\t  ,\\tand\\t80-\\tmg\\ttablets;\\t20-\\t,\\t40-\\t  ,\\tand 80- mg tablets (human preparation); 10- mg/mL oral solution (syrup); and 50- mg/ F mL injection. Tablets usually can be easily split. A 2- g bolus is available for large animals, but oral absorption is uncertain. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with acidic solutions. It is compatible in plastic syringes and infusion sets. Furosemide is poorly soluble in water but may be mixed with 5% dextrose, 0.9% saline, or lactated Ringer\u2019s solution at a concentration of 10 mg/mL for IV administration. These solutions are stable for 8 hours. It is more soluble if the pH is greater than 8, but it readily precipitates when pH is less than 5.5. Compounded oral formulations in syrups and other flavorings are stable if kept at alkaline pH or in alcohol. However, lower pH results in instability of formulation. If discoloration occurs, discard formulation.","original_category":"Diuretic"},{"name":"Glycerin","active_ingredient":"Glycerin","species":["Canine","Feline"],"dosage":"(Dogs and Cats) \u2022\\t\\t1\u20132\\tmL/kg\\tq8h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. Because of the low risk of residues, no withdrawal times are suggested. 412    Glycopyrrolate Glycopyrrolate glye- koe- peer\u2032oe- late Trade and other names:  Robinul- V","contraindications":"Contraindications and Precautions Do not administer to dehydrated animals. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Glycerin is an osmotic agent that draws water into the intestine or renal tubule. Administered systemically, it acts as an osmotic diuretic agent, preventing water reabsorption from the renal tubules. Administered orally, it is not absorbed but acts as an osmotic laxative, drawing water into the intestine. The use of glycerin is uncommon in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Glycerin may cause dehydration with frequent use or high doses.","notes":"Instructions for Use Although glycerin may lower ocular pressure, other drugs are used to treat acute glaucoma. Patient Monitoring and Laboratory Tests Monitor ocular pressures. Monitor electrolytes in treated animals. Formulations Available \u2022\\t\\tGlycerin\\tis\\tavailable\\tin\\tan\\toral\\tsolution\\tor\\t40-\\tmg/mL\\temulsion. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Diuretic, laxative"},{"name":"Hydralazine Hydrochloride","active_ingredient":"Hydralazine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tIV\\tdose:\\t0.5\u20133\\tmg/kg\\tIV\\tbolus\\tq12h\\tor\\tafter\\tinitial\\tbolus;\\tfollow\\twith\\tCRI\\tof 1.5\u20135\\tmcg/kg/min\\tIV. \u2022\\t\\tOral\\tdose:\\t0.5\\tmg/kg\\t(initial\\tdose);\\ttitrate\\tto\\t0.5\u20132\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t2.5\\tmg/cat\\tq12\u201324h\\tPO.  Horses \u2022\\t\\t1\\tmg/kg\\tq12h\\tPO\\tor\\t0.5\\tmg/kg\\tIV\\tas\\tneeded\\tto\\treduce\\tblood\\tpressure. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Hydrochlorothiazide hye- droe- klor- oh- thye\u2032ah- zide Trade and other names: HydroDIURIL, Hydrozide (for cattle), and generic","contraindications":"Contraindications and Precautions Do not use in hypotensive animals. Drug Interactions No specific drug interactions are reported for animals. However, use cautiously with other drugs that may lower blood pressure. 432    Hydrochlorothiazide","indications":"Indications and Clinical Uses Hydralazine is used to dilate arterioles and decrease cardiac afterload. It is primarily used for treatment of congestive heart failure (CHF), valvular disease of the heart, and other cardiovascular disorders characterized by high peripheral vascular resistance. It may be used with other cardiac drugs such as angiotensin- converting enzyme (ACE) inhibitors and pimobendan. Use in animals has been primarily derived from empirical use and small observational studies. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. The most common use is as a vasodilator when canine patients have become refractory to other common cardiovascular agents such as ACE inhibitors and pimobendan. Candidates for hydralazine treatment are typically those in stage C or D of heart failure. Hydralazine is\\trecommended\\tby\\texperts\\twhen\\tafterload\\tis\\tneeded\\tin\\tsevere\\tcases\\t(0.5\u20132.0\\tmg/kg PO), starting at a low dose and titrating to effect. Because of the availability of other agents, the use is not as common for routine treatment compared with several years ago. It is more common to use other vasodilator drugs, such as the ACE inhibitors, pimobendan, and calcium- channel blocking drugs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributed to excess vasodilation and subsequent hypotension, which results in reflex tachycardia. Hydralazine may dangerously decrease cardiac output if not monitored carefully. Allergic reactions (lupus- like syndrome) have been reported in people and are related to acetylator status but have not been reported\\tin\\tanimals.\\tRepeated\\tuse\\twill\\tactivate\\tthe\\trenin\u2013angiotensin\u2013aldosterone system; therefore, consider adding an ACE inhibitor, spironolactone, or both to patients that become refractory to treatment.","notes":"Instructions for Use Use of hydralazine in heart failure may accompany other drugs, such as digoxin, pimobendan, ACE inhibitors, and diuretics. The optimum dosage in animals may be adjusted by monitoring blood pressure. Patient Monitoring and Laboratory Tests Monitor patients for hypotension. Monitor blood pressure to adjust dose. Formulations \u2022\\t\\tHydralazine\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets\\tand\\t20-\\tmg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Exposure to light may change color and cause decomposition. Hydralazine is unstable. Mixing with juices, syrups, and flavorings may cause decomposition in as little as 24 hours.","original_category":"Vasodilator"},{"name":"Hydrochlorothiazide","active_ingredient":"Hydrochlorothiazide","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t2\u20134\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tAntihypertensive\\tdose:\\t1\\tmg/kg\\tq12h\\tPO. 434    Hydrocodone Bitartrate Cats \u2022\\t\\tTo\\tdecrease\\texcretion\\tof\\tcalcium\\tin\\turine:\\t1\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tTo\\talkalinize\\turine:\\t2\\tmg/kg,\\tq12h\\tPO. \u2022\\t\\tCongestive\\theart\\tfailure:\\t1\u20132\\tmg/kg\\tq12\u201324h\\tPO.  Cattle 5\u201310\\tmL\\t(125\u2013250\\tmg)\\tIV\\tor\\tIM\\tonce\\tor\\ttwice\\ta\\tday.\\tAfter\\tonset\\tof\\tdiuresis, treatment may be continued with an orally administered maintenance dose. For oral treatment, use chlorothiazide boluses. Regulatory Information Withdrawal\\ttime\\tfor\\tcattle:\\t72-\\thour\\t(6\\tmilkings)\\tmilk\\twithdrawal;\\tno\\twithdrawal\\ttime for slaughter is established. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Hydrocodone Bitartrate hye- droe- koe\u2032done  bye- tar\u2032trate Trade and other names: Hycodan, Vicodin, Lortab, and generic","contraindications":"Contraindications and Precautions Do not use in patients with high serum calcium. Thiazide diuretics prevent calcium excretion. Drug Interactions Use carefully with other diuretics. It may enhance the effects of other diuretics and antihypertensive agents.","indications":"Indications and Clinical Uses Like other thiazide diuretics, hydrochlorothiazide is used to increase excretion of sodium, potassium, and water. It also has been used as an antihypertensive. Because thiazide diuretics decrease renal excretion of calcium, they also have been used to treat uroliths containing calcium (calcium oxolate uroliths). The use in small animals has been primarily derived from anecdotal experience or small observational studies. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. In cattle, hydrochlorothiazide is approved for use in dairy cattle as an aid in the treatment of postparturient udder edema. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hydrochlorothiazide may cause electrolyte imbalance such as hypokalemia.","notes":"Instructions for Use Hydrochlorothiazide is not as potent as loop diuretics (e.g., furosemide). Clinical efficacy has not been established in veterinary patients. Patient Monitoring and Laboratory Tests Monitor hydration status, electrolytes, and renal function. Monitor calcium in patients that may be prone to hypercalcemia. When used in cattle, animals should be regularly and carefully observed for early signs of fluid and electrolyte imbalance. Formulations \u2022\\t \\tHydrochlorothiazide\\tis\\tavailable\\tin\\t10-\\t\\tand\\t100-\\tmg/mL\\toral\\tsolution\\tand 25- , 50- , and 100- mg tablets. The combination of hydrochlorothiazide and spironolactone is Aldactazide. The cattle formulation is 25 mg/mL for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Diuretic"},{"name":"Irbesartan","active_ingredient":"Irbesartan","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t30\u201360\\tmg/kg\\tq12h\\tPO.\\tStart\\twith\\t30\\tmg/kg\\tto\\tavoid\\tprerenal\\tazotemia\\tand hypotension.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 3 Iron Dextran and Iron Sucrose (Note: Oral iron supplements are listed as ferrous sulfate and ferrous gluconate) Trade and other names: AmTech Iron dextran, Ferrodex, and HemaJect. Iron sucrose is Venofer.","contraindications":"Contraindications and Precautions Do not administer to hypotensive or dehydrated animals. No other contraindications have been reported for animals for the use of irbesartan. Drug Interactions No drug interactions have been reported for small animals. Use cautiously with other vasodilators.","indications":"Indications and Clinical Uses Angiotensin II blockers such as irbesartan are used in people as alternatives to ACE inhibitors. Animals tolerate ACE inhibitors better than humans, but ARBs are also effective (e.g., telmisartan). Initial experience with ARB in animals was derived from empirical use and studies in which 30 mg/kg of irbesartan was administered to animals with experimentally induced renal hypertension. Otherwise, there is little clinical evidence for the use of irbesartan in dogs or cats. An approved drug for cats, telmisartan, is preferred because there are clinical studies to support the safe use and efficacy. 470    Iron Dextran and Iron Sucrose Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects have been reported in animals, but this drug has been used rarely. Hypotension is a potential problem from overdosing.","notes":"Instructions for Use In dogs, irbesartan is preferred over losartan because losartan is not converted to active products in dogs. However, telmisartan is preferred over both agents because there are FDA- approved dose forms for animals, and clinical studies to support the use. Patient Monitoring and Laboratory Tests Monitor blood pressure and heart rate in treated animals. Monitor electrolytes if it is administered long term. Formulations \u2022\\t\\tIrbesartan\\tis\\tavailable\\tin\\t75-\\t,\\t150-\\t   ,\\tand\\t300-\\tmg\\ttablets.\\tOne\\tproduct\\t(Avalide) contains irbesartan in combination with hydrochlorothiazide. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Isosorbide Dinitrate and Isosorbide Mononitrate","active_ingredient":"Isosorbide Dinitrate and Isosorbide Mononitrate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tIsosorbide\\tdinitrate:\\t2.5\u20135\\tmg/animal\\tq12h\\tPO\\tor\\t0.22\u20131.1\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tIsosorbide\\tmononitrate:\\t5\\tmg/dog;\\tadminister\\ttwo\\tdoses\\tper\\tday\\t7\\thours\\tapart\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. There is a low risk of residue potential. RCI\\tClassification:\\t4 Isotretinoin eye- soe- tret\u2032ih- noe- in Trade and other names: Accutane and Absorica","contraindications":"Contraindications and Precautions Do not administer to patients with hypovolemia. Use cautiously in animals with low cardiac reserve. Drug Interactions No drug interactions are reported, but interactions are possible when used with other adrenergic agonists.","indications":"Indications and Clinical Uses Isosorbide dinitrate is used to reduce preload in patients with congestive heart failure. In people, it is primarily used to treat angina. The use in animals has not been established through clinical studies but is extrapolated from the human use. Nitroglycerin is used more frequently (topically), or infusions of nitroprusside IV are used in critical care situations. Use in animals has been primarily derived from empirical use or the opinions from experts. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to overdoses that produce excess vasodilation and hypotension. Tolerance may develop with repeated doses.","notes":"Instructions for Use Generally, doses are titrated to individuals depending on response. Isosorbide mononitrate is absorbed better than isosorbide dinitrate and may be preferred in clinical situations. Patient Monitoring and Laboratory Tests Monitor patient\u2019s cardiovascular status during treatment. Formulations \u2022\\t\\tIsosorbide\\tdinitrate\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t20-\\t  ,\\tand\\t40-\\tmg\\ttablets\\tand\\t40-\\tmg capsules. \u2022\\t\\tIsosorbide\\tmononitrate\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg\\ttablets. I Isotretinoin 479 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Isoxsuprine","active_ingredient":"Isoxsuprine","species":["Equine","Feline"],"dosage":"\u2022\\t\\tNo\\tsmall\\tanimal\\tdoses\\tare\\treported.  Horses \u2022\\t\\tNavicular\\tdisease\\tand\\tlaminitis:\\t0.6\\tmg/kg\\tq12h\\tPO\\tfor\\t6\u201314\\tweeks.\\tIn\\tsome dosing protocols, if 0.6 mg/kg q12h has not improved the horse\u2019s condition within 3 weeks, the dose is doubled. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Itraconazole it- rah- kahn\u2032ah- zole Trade and other names: Sporanox and Itrafungol (available for cats)","contraindications":"Contraindications and Precautions Do not use in hypotensive or dehydrated animals. Drug Interactions No drug interactions are reported.","indications":"Indications and Clinical Uses Isoxsuprine is used in horses for navicular disease and other diseases of the foot, such as laminitis. The efficacy has not been established for these indications even though the use has persisted for many years. There are no reports of its use in other animals. I Itraconazole 481 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypotension is the primary adverse effect. It lowers arterial pressure. In horses, side effects may also include rubbing noses on objects, hyperexcitability, sweating, tachycardia, and restlessness.","notes":"Instructions for Use When used in horses, it often is used with other vasodilators and anti- inflammatory drugs. It is not known if it acts synergistically with these other medications. Patient Monitoring and Laboratory Tests Monitor heart rate in treated animals. Formulations \u2022\\t\\tIsoxsuprine\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Although isoxsuprine is compounded for equine use, stability of compounded formulations has not been evaluated.","original_category":"Vasodilator"},{"name":"Lisinopril","active_ingredient":"Lisinopril","species":["Canine","Feline"],"dosage":"DogsCats \u2022\\t\\t0.5\\tmg/kg\\tq24h\\tPO. \\t\u2022\\t\\tNo\\tdose\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\tis\\tavailable. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. 528    Lithium Carbonate Lithium Carbonate lih\u2032thee- um  kar\u2032boe- nate Trade and other names: Lithotabs","contraindications":"Contraindications and Precautions Discontinue ACE inhibitors in pregnant animals; they cross the placenta and have caused fetal malformations and death of the fetus. Drug Interactions Use lisinopril cautiously with other hypotensive drugs and diuretics. NSAIDs may decrease vasodilating effects.","indications":"Indications and Clinical Uses Lisinopril, like other ACE inhibitors, is used to treat hypertension and congestive heart failure. Enalapril and benazepril have been used more often in animals, and there is much less experience using lisinopril. The use of lisinopril is based on extrapolation from the uses of other ACE inhibitors (enalapril, benazepril) or the uses in people. Lisinopril also may be used to treat some forms of kidney disease in animals. When glomerular filtration pressures are high, lisinopril may improve some patients with kidney disease, but effects on survival have not been established. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other ACE inhibitors, lisinopril may cause azotemia in some patients, but this effect has been uncommon. It can be exacerbated with administration of diuretics (e.g., furosemide); therefore, carefully monitor patients receiving high doses of diuretics.","notes":"Instructions for Use Clinical studies using lisinopril in animals have not been reported. The doses and clinical use have been extrapolated from human studies or limited anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes and renal function 3\u20137 days after initiating therapy and periodically thereafter. Formulations \u2022\\t\\tLisinopril\\tis\\tavailable\\tin\\t2.5-\\t,\\t5-\\t ,\\t10-\\t  ,\\t20-\\t  ,\\tand\\t40-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Lisinopril has been mixed with syrup for oral administration and found to be stable for 30 days at either room temperature or refrigerated.","original_category":"Vasodilator, angiotensin- converting enzyme inhibitor"},{"name":"Losartan","active_ingredient":"Losartan","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.125\\tmg/kg\\tper\\tday\\tin\\tazotemic\\tpatients;\\t0.5\\tmg/kg/day\\tin\\tnonazotemic patients. Cats \u2022\\t\\tNot\\teffective\\tin\\tcats.\\tIf\\tan\\tARB\\tdrug\\tis\\tindicated\\tfor\\tcats,\\tuse\\ttelmisartan.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t3 Lotilaner lote\u2032ah lan\u2032er Trade and other names: Credelio","contraindications":"Contraindications and Precautions No specific contraindications have been reported for animals. Do not use in pregnant animals. Drug Interactions Combined use of ARB and ACE inhibitor may increase risk of kidney injury. L Lotilaner 535","indications":"Indications and Clinical Uses Dogs do not convert losartan to the active metabolite, so it has little activity in dogs unless high doses are used. A related drug, irbesartan (30 mg/kg q12h) or telmisartan (see later), is more effective in dogs for blocking angiotensin II receptors. Losartan\u2019s effects in cats (2.5 mg/kg/day) for lowering blood pressure were not different than placebo. Telmisartan is in a veterinary formulation for cats and has received greater interest in dogs because of a longer half- life and higher lipophilicity. Therefore it may be more effective in dogs compared with losartan. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse reactions have been reported in animals. In people, hypotension may occur.","notes":"Instructions for Use In dogs, losartan is not converted to the active metabolite. Therefore, it has little bioactivity (J Pharmacol Exp Ther.\\t1999;268:1199\u20131205),\\tand high doses are needed to produce clinical effects. It is suggested instead to consider irbesartan at a dosage of 30\\tmg/kg\\tq12h\\tPO\\tor\\ttelmisartan\\tinstead\\t(see\\tTelmisartan\\tfor more information). Patient Monitoring and Laboratory Tests Monitor blood pressure in treated animals. Formulations \u2022\\t\\tLosartan\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vasodilator"},{"name":"Magnesium Sulfate","active_ingredient":"Magnesium Sulfate","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t \\t1\u20132\\tmEq/kg/day\\tPO,\\tequivalent\\tto\\t0.5\u20131.0\\tmmol/kg\\tPO\\t(or\\t8\u201325\\tg/dog\\tq24h PO). Cats \u2022\\t\\t2\u20135\\tg/cat\\tq24h\\tPO. Dogs and Cats \u2022\\t\\tIV\\tdose\\tfor\\tmagnesium\\tdeficiency\\tor\\tarrhythmias:\\t0.2\u20130.3\\tmEq/kg\\t(0.1\u20130.15 mmol/kg)\\tIV\\tat\\ta\\trate\\tof\\t0.12\\tmEq/kg/min\\t(0.06\\tmmol/kg/min). \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI)\\tfor\\ttreating\\tarrhythmias\\tor\\tongoing\\tdeficiency: 0.2\u20131.0\\tmEq/kg/day\\tIV\\t(0.1\u20130.5\\tmmol/kg/day). \u2022\\t\\tUse\\tduring\\tfluid\\ttherapy:\\tSupplement\\tfluid\\tsolutions\\twith\\t0.75\u20131\\tmEq/kg/day.  Cattle \u2022\\t\\t2\u20133\\tg\\tper\\tcow\\tIV\\tover\\t10\\tminutes.\\tThis\\tmay\\tbe\\tfollowed\\tby\\t200\u2013400\\tmL\\tper\\tcow of\\t25%\\tmagnesium\\tsulfate\\tSQ\\tto\\tsupply\\t50\u2013100\\tg\\tper\\tcow. Horses \u2022\\t\\t1\\tg/horse\\tq12\u201324h\\tPO\\tor\\t2\u20134\\tmg/kg\\tIV.\\tFor\\tventricular\\ttachycardia,\\tan\\tinfusion of\\t1\\tg/min,\\tup\\tto\\ta\\tmaximum\\tof\\t25\\tg,\\tcan\\tbe\\tadministered\\tintravenously.\\tAlso see\\tLidocaine\\tfor instructions on combining lidocaine infusions with magnesium infusions to treat refractory ventricular arrhythmias. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Mannitol man\u2032ih- tole Trade and other names: Osmitrol","contraindications":"Contraindications and Precautions Magnesium accumulation may occur in patients with renal impairment. Drug Interactions Magnesium\\tsulfate\\tcan\\tbe\\tadded\\tto\\tfluids\\tcontaining\\tsodium\\tchloride\\t(0.9%), dextrose\\t(5%),\\tand\\twater.\\tDo\\tnot\\tmix\\twith\\tcalcium-\\t,\\tbicarbonate-\\t,\\tand\\tlactate- containing solutions. Cathartics containing magnesium decrease oral absorption of ciprofloxacin and other fluoroquinolones. Magnesium sulfate is incompatible with alkaline solutions. Some metal ions (e.g., calcium) may form insoluble sulfates.","indications":"Indications and Clinical Uses Magnesium sulfate is used for constipation and bowel evacuation prior to certain procedures. An injectable solution of magnesium sulfate is used to treat magnesium deficiency and refractory arrhythmias in patients who are critically ill. (Magnesium chloride\\talso\\thas\\tbeen\\tused.)\\tA\\tdose\\tof\\t1\u20132\\tmEq/kg\\tof\\tmagnesium\\tsulfate\\tproduced M plasma\\tconcentrations\\tof\\t8.5\u201312.2\\tmEq/L\\tand\\tcan\\tincrease\\theart\\trate,\\tinotropy,\\tand cardiac output. In horses, magnesium sulfate is administered for ventricular tachycardia, often with\\tlidocaine\\tinfusions\\t(see\\tLidocaine), that is not responsive to other drugs. In cattle, magnesium sulfate is used to treat hypomagnesemia, especially in dairy cattle. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses may cause muscle weakness and respiratory paralysis. Mild signs of toxicity during magnesium treatment include vomiting, diarrhea, hypotension, and weakness. With repeated administration, fluid and electrolyte loss can occur with overuse. When treating arrhythmias, it has been\\tadministered\\tat\\tdoses\\tof\\t0.1\u20130.2\\tmEq/kg\\tsafely.\\tAt\\tdoses\\thigher\\tthan 1.0\\tmmol/kg\\t(2.0\\tmEq/kg),\\tdeterioration\\tof\\themodynamic\\tparameters\\tmay occur.","notes":"Instructions for Use When used as a laxative, magnesium sulfate is administered for its prompt action to evacuate the bowel prior to surgery or diagnostic procedures. Onset of action is rapid. For use in cattle (hypomagnesemia), an initial dose can be administered IV followed by an SQ dose to produce a sustained effect. Monitor animals for hypocalcemia, which can occur simultaneously. Patient Monitoring and Laboratory Tests When treating magnesium deficiency or arrhythmias with IV magnesium sulfate, monitor\\tthe\\telectrocardiogram\\t(ECG)\\tduring\\tinfusion\\tand\\tobserve\\tfor\\tbradycardia, QT\\tinterval\\tprolongation,\\tand\\tQRS\\tcomplex\\twidening.\\tMonitor\\tmagnesium, potassium, sodium, chloride, and calcium concentrations during treatment. Normal magnesium\\tconcentrations\\tin\\tanimals\\tare\\t1.32\u20132.46\\tmEq/L.\\tMany\\tcattle\\talso\\thave hypocalcemia,\\twhich\\tshould\\tbe\\taddressed\\twith\\tseparate\\ttreatment\\tusing\\tcalcium- containing solutions. Formulations \u2022\\t\\tMagnesium\\tsulfate\\tis\\tavailable\\tas\\tsolid\\tcrystals\\tin\\tgeneric\\tpreparations.\\tSolution for\\tinjection\\tis\\t12.5%\u201350%.\\tWhen\\tadministering\\tIV,\\tdilute\\tto\\tconcentration\\tbelow 20%\\tusing\\tsodium\\tchloride\\t(0.9%),\\t5%\\tdextrose,\\tor\\twater\\tas\\ta\\tdiluent.\\tIV\\tand\\tSQ solutions\\tfor\\tcattle\\tare\\tusually\\t1.5\u20134\\tg/L. Stability and Storage Crystals are stable if stored in a dry container. Store injectable solutions at room temperature, in a tightly sealed vial, protected from light. 546    Mannitol","original_category":"Laxative, antiarrhythmic"},{"name":"Mannitol","active_ingredient":"Mannitol","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tDiuretic:\\t1\\tg/kg\\tof\\t5%\u201325%\\tsolution\\tIV\\tto\\tmaintain\\turine\\tflow. \u2022\\t\\tFluid\\texpansion:\\t0.5\u20132\\tg/kg\\tIV\\t(or\\t0.1\\tg/kg/h). \u2022\\t\\tGlaucoma\\tor\\tcentral\\tnervous\\tsystem\\t(CNS)\\tedema:\\t0.25\u20132\\tg/kg\\tof\\t15%\u201325% solution\\tover\\t30\u201360\\tmin\\tIV\\t(repeat\\tin\\t6\\thours\\tif\\tnecessary). Cats \u2022\\t\\tFluid\\texpansion:\\t0.5\\tg/kg\\tto\\t0.8\\tg/kg\\tIV\\tover\\t5\\tminutes\\tfollowed\\tby\\ta\\tCRI\\tof\\t1 mg/kg/min.  \u2022\\t\\t0.25\u20131\\tg/kg\\t(20%\\tsolution)\\tIV\\tadministered\\tover\\t1\\thour. \u2022\\t\\tFoals:\\t0.25\u20131\\tg/kg\\tIV\\tadministered\\tas\\t20%\\tsolution\\tover\\t15\u201320\\tminutes. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. 548    Marbofloxacin Marbofloxacin mar- boe- floks\u2032ah- sin Trade and other names: Zeniquin and Marbocyl (European name)","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twho\\tare\\tdehydrated.\\tUse\\tcautiously\\twhen\\tintracranial bleeding\\tis\\tsuspected\\tbecause\\tit\\tmay\\tincrease\\tbleeding.\\t(This\\teffect\\tis\\tcontroversial when dealing with intracranial hemorrhage.) Drug Interactions Do not administer simultaneously with blood replacements. If blood is administered simultaneously, sodium chloride must be added to each liter of mannitol\\t(20\\tmEq/L).\\tMannitol\\tmay\\tincrease\\trenal\\tclearance\\tof\\tsome\\tdrugs.","indications":"Indications and Clinical Uses Mannitol is administered intravenously for treatment of cerebral edema, acute glaucoma, and conditions associated with tissue edema. Other agents are preferred for management of glaucoma, but mannitol can be administered in refractory cases. Mannitol also has been used to promote urinary excretion of certain toxins and in the management of anuric or oliguric renal failure. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Mannitol produces a profound diuresis and can cause significant fluid loss and electrolyte imbalance. An administration rate that is too rapid may expand the extracellular volume excessively.","notes":"Instructions for Use Use\\tonly\\tin\\tanimals\\tin\\twhich\\tfluid\\tand\\telectrolyte\\tbalance\\tcan\\tbe\\tmonitored. Patient Monitoring and Laboratory Tests Monitor hydration and electrolyte balance in treated animals. Monitor intraocular pressure when treating acute glaucoma. Formulations \u2022\\t\\tMannitol\\tis\\tavailable\\tin\\ta\\t5%,\\t10%,\\t15%,\\t20%,\\tand\\t25%\\tsolution\\tfor\\tinjection.\\tThe 25%\\tsolution\\tis\\tequivalent\\tto\\t1\\tg\\tin\\t4-\\tmL\\tvials. Stability and Storage Once solutions are prepared, discard unused portions. If solutions are chilled, crystals may form.","original_category":"Diuretic"},{"name":"Methazolamide","active_ingredient":"Methazolamide","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t2\u20133\\tmg/kg\\tq8\u201312h\\tPO.\\tThere\\tdoes\\tnot\\tseem\\tto\\tbe\\tany\\tbenefit\\tfor\\tincreasing\\tthe dose\\tto\\ta\\tmaximum\\tdose\\tof\\t4\u20136\\tmg/kg,\\tbut\\tmore\\tfrequent\\tadministration\\t(q8h) may be beneficial.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 M Methenamine 585 Methenamine meth- en\u2032ah- meen Trade and other names: Methenamine hippurate: Hiprex and Urex; Methenamine mandelate: Mandelamine and generic brands","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tacidemia.\\tUse\\tcautiously\\tin\\tany\\tanimal\\tsensitive\\tto sulfonamides. Do not use in patients with hepatic encephalopathy. Drug Interactions Use\\tcautiously\\twith\\tother\\ttreatments\\tthat\\tcould\\tcause\\tmetabolic\\tacidosis.","indications":"Indications and Clinical Uses Methazolamide is rarely used as a diuretic any longer. More potent and effective diuretic drugs are available, such as the loop diuretics (furosemide). Methazolamide, like other carbonic anhydrase inhibitors, is used primarily to lower intraocular pressure in animals with glaucoma. Its duration is relatively short in dogs; therefore, frequent administration may be required to maintain low ocular pressure. However, if a carbonic anhydrase inhibitor is needed, methazolamide is used more often than acetazolamide for this purpose because it is more effective and easily available. Nevertheless, other regimens are commonly used for the treatment of glaucoma compared with the carbonic anhydrase inhibitors. Methazolamide, like other carbonic anhydrase inhibitors, is sometimes used to produce more alkaline urine for management of some urinary calculi. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Methazolamide\\tmay\\tproduce\\thypokalemia\\tin\\tsome\\tpatients.\\tLike\\tother carbonic anhydrase inhibitors, it can produce significant bicarbonate loss, and patients should be supplemented with bicarbonate if repeated doses are administered.","notes":"Instructions for Use Methazolamide may be used with other glaucoma agents, such as topical drugs, to decrease intraocular pressure, and it may be used to produce alkaline urine to prevent some calculi from forming. However, use in animals has been primarily derived from\\tempirical\\tuse.\\tThere\\tare\\tno\\twell-\\tcontrolled\\tclinical\\tstudies\\tor\\tefficacy\\ttrials\\tto document clinical effectiveness. Patient Monitoring and Laboratory Tests Monitor ocular pressure in treated patients. Monitor urine pH if it is used to produce\\talkaline\\turine.\\tMonitor\\telectrolyte\\tand\\tacid\u2013base\\tstatus\\tif\\tmultiple\\tdoses\\tare administered. Formulations Available \u2022\\t\\tMethazolamide\\tis\\tavailable\\tin\\t25-\\t\\tand\\t50-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Diuretic"},{"name":"Mexiletine","active_ingredient":"Mexiletine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t6\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tChronic\\tpain\\tcaused\\tby\\tnerve\\tinjury:\\t4\u201310\\tmg/kg\\tPO\\tq8h. Cats No safe dose has been established.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Mibolerone mih- bole\u2032er- one Trade and other names: Cheque Drops","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tliver\\tdisease\\tor\\tmonitor\\tliver\\tparameters\\tduring\\tuse. Drug Interactions Sotalol will increase plasma drug concentrations.","indications":"Indications and Clinical Uses Mexiletine has been used to treat ventricular arrhythmias. Although lidocaine is often the\\tfirst\\tClass\\tI\\tantiarrhythmic\\tagent\\tused\\tfor\\tinjection\\tin\\tthe\\thospital,\\twhen\\tlonger- term treatment with an oral drug is needed, mexiletine is often the first choice. The\\tdoses\\tused\\tin\\tdogs\\tare\\tderived\\tfrom\\tempirical\\tuse\\tand\\textrapolation\\tfrom human medicine. It is often used in combination with atenolol or sotalol (Class II and Class III antiarrhythmic agents, respectively) because it may have better electrophysiological effects when used in combination. It may also counteract the adverse effects of sotalol on the action potential duration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In\\tdogs,\\tthe\\tmost\\tcommon\\tadverse\\teffects\\tare\\tGI\\tproblems.\\tHigh\\tdoses\\tmay cause excitement and tremors. Mexiletine can be arrhythmogenic in some animals. In people, related drugs (flecainide and encainide) can be proarrhythmogenic and associated with excessive mortality.","notes":"Instructions for Use Results\\tof\\tcontrolled\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals (and doses) is based on experience in people, research studies in experimental dogs, or anecdotal\\texperience\\tin\\tanimals.\\tAdminister\\twith\\tfood\\tto\\tdecrease\\tGI\\tproblems. Patient Monitoring and Laboratory Tests Monitor\\tECG\\tduring\\tuse.\\tEffective\\tplasma\\tdrug\\tconcentrations\\tare\\t0.75\u20132.0\\tmcg/ mL\\t(extrapolated\\tfrom\\tpeople). Formulations \u2022\\t\\tMexiletine\\tis\\tavailable\\tin\\t150-\\t,\\t200-\\t   ,\\tand\\t250-\\tmg\\tcapsules. 610    Mibolerone Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is freely soluble in water and ethanol.","original_category":"Antiarrhythmic"},{"name":"Nifedipine","active_ingredient":"Nifedipine","species":["Feline","Equine"],"dosage":"\u2022\\t\\tAnimal\\tdose\\tnot\\testablished.\\tIn\\tpeople,\\tthe\\tdosage\\tis\\t10\\tmg\\tper\\tperson\\tthree times a day and increased in 10- mg increments to effect.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Pharmacology and Mechanism of Action Nitazoxanide is an antiprotozoal drug that was once used for treating protozoa in horses but is no longer used for this indication. It has been used in other animals, Nitazoxanide nye- taz- oks\u2032ah- nide Trade and other names: Navigator (horse preparation) and Alinia (human preparation)","contraindications":"Contraindications and Precautions Do not administer to a patient with hypotension. Use cautiously with other agents that may lower blood pressure. Nifedipine may be teratogenic in pregnant laboratory animals or embryotoxic. Avoid use in pregnant animals. Drug Interactions Do not administer with drugs known to inhibit drug- metabolizing enzymes (e.g., ketoconazole).\\tNifedipine\\tmay\\tbe\\tsubject\\tto\\tinteractions\\tfrom\\tdrugs\\tthat\\tinhibit the\\tmembrane\\tmultidrug\\tresistance\\tpump,\\talso\\tknown\\tas\\tP-\\tglycoprotein,\\twhich may lead to toxicity. See Appendix J\\tfor\\tdrugs\\tthat\\tmay\\taffect\\tP-\\tglycoprotein.","indications":"Not specified in source","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in veterinary medicine because of the infrequent use. The most common side effect anticipated is hypotension.","notes":"Instructions for Use Use of nifedipine is limited in veterinary medicine. Other calcium- channel blockers, such as diltiazem, are used to control heart rhythm. Amlodipine is more commonly used for control of systemic hypertension. Patient Monitoring and Laboratory Tests Monitor blood pressure during therapy. Formulations \u2022\\t\\tNifedipine\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg\\tcapsules\\tand\\t30-\\t,\\t60-\\t  ,\\tand\\t90-\\tmg extended- release  tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is decomposed more rapidly if exposed to light. In extemporaneous solutions, nifedipine is unstable. If mixed with solutions, it should be used immediately.","original_category":"Calcium- channel blocker, vasodilator"},{"name":"Nitroglycerin","active_ingredient":"Nitroglycerin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t4\u201312\\tmg\\t(up\\tto\\t15\\tmg)\\ttopically\\tas\\tneeded.\\tIn\\tdogs,\\tit\\thas\\tbeen\\tused\\tas\\tone- fourths to three- fourths inch of 2% ointment q6h (1 inch equals 15 mg). Cats \u2022\\t\\t2\u20134\\tmg\\ttopically\\tor\\ttypically\\tone-\\teighth\\tto\\tone-\\tquarter\\tinch\\tq4\u20136h.  Horses \u2022\\t\\tTreatment\\tof\\tlaminitis:\\tApply\\t2%\\tointment\\tto\\tskin\\tabove\\tthe\\thoof.\\t(Efficacy\\tis questionable.) Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t3 Pharmacology and Mechanism of Action Nitroprusside is a nitrate vasodilator. Like other nitrovasodilators, it relaxes vascular smooth muscle (especially venous) via generation of NO. NO stimulates guanylate cyclase\\tto\\tproduce\\tGMP\\tin\\tsmooth\\tmuscle,\\twith\\ta\\tpredominant\\teffect\\tof\\trelaxing vascular smooth muscle. Nitroprusside is used only as an IV infusion in the hospital, and patients should be monitored carefully during administration. Nitroprusside has a rapid onset of effect (almost immediately) and a duration that lasts only minutes after discontinuation of IV administration.","contraindications":"Contraindications and Precautions Do not administer to patients with hypotension. Nitroglycerin is absorbed through human skin. Warn pet owners not to apply ointment without wearing gloves. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Nitroglycerin, like other nitrovasodilators, is used primarily in heart failure or pulmonary edema to reduce preload or decrease pulmonary hypertension. Nitrates relax smooth muscle in both arteries and veins, but they are often used clinically as preload reducers. When used as preload reducers, they decrease myocardial O 2 requirements (decrease workload of heart). Because of this effect, they have been commonly used to manage human patients with angina pectoris (chest pain caused by cardiovascular disease). Use in animals has been primarily derived from empirical use, recommendations from clinical experts, and experience extrapolated from human use. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. In small animals, primarily dogs, it has been used in the hospital to treat animals with advanced stages of heart failure. In horses, nitroglycerin has been used to improve blood flow to the feet in the management of laminitis. However, in experiments, this treatment was not effective in horses and did not increase blood flow to the feet. Precautionary Information Indications and Clinical Uses Nitroprusside is used for acute management of pulmonary edema and other hypertensive conditions. It is administered only by IV infusion, and the dose is titrated carefully by monitoring systemic blood pressure. Titrate to maintain the arterial blood pressure to 70 mm Hg. Use in animals has been primarily derived from empirical use and experience in humans or the opinions from clinical cardiology experts. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. The cost of nitroprusside has increased tremendously in recent years to as much as $750 per vial. Therefore, the high cost has discouraged use in animals. Nitroprusside (Sodium Nitroprusside) nye- troe- pruss\u2032ide Trade and other names: Nitropress","side_effects":"Adverse Reactions and Side Effects The most significant adverse effect is hypotension. Methemoglobinemia can occur with accumulation of nitrites, but it is a rare problem.","notes":"Instructions for Use Tolerance can develop with repeated chronic use. Tolerance may be caused by a progressive depletion of sulfhydryl groups necessary for the formation of NO. Efficacy is improved if the drug is used intermittently instead of continuously because intermittent use allows time for regeneration of sulfhydryl groups. Optimum intermittent use is to provide a nitrate- free interval of 8 hours or more during the day. Nitroglycerin has high presystemic metabolism, and oral availability is poor. When using ointment, 1 inch of ointment is approximately 15 mg. It is usually applied to an area on the patient that lacks hair and where the patient will not lick it off (e.g., pinnae of ears). Patient Monitoring and Laboratory Tests Monitor patient\u2019s blood pressure during therapy. N Nitroprusside (Sodium Nitroprusside) 659 Formulations \u2022\\t\\tNitroglycerin\\tis\\tavailable\\tin\\t0.5-\\t,\\t0.8-\\t  ,\\t1-\\t ,\\t5-\\t ,\\tand\\t10-\\tmg/mL\\tinjection;\\t2% ointment; 0.3- , 0.4- , and 0.6- mg sublingual tablets; translingual spray; and transdermal systems (0.2 mg/h patch). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Nitroglycerin tablets are very heat and light sensitive and should be stored in a tightly sealed glass bottle.","original_category":"Vasodilator"},{"name":"Phenoxybenzamine Hydrochloride","active_ingredient":"Phenoxybenzamine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.25\\tmg/kg\\tq8\u201312h\\tor\\t0.5\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tFor\\tpresurgical\\ttreatment\\tof\\tpheochromocytoma:\\t0.6\\tmg/kg\\tq12h\\t(range\\tis\\t1\u20132 mg/kg/day), given 2 weeks prior to surgery to stabilize blood pressure. Cats \u2022\\t\\t2\\tor\\t2.5\\tmg\\tper\\tcat\\tq8\u201312h\\tor\\t0.5\\tmg/kg\\tq12h\\tPO.\\tDoses\\tas\\thigh\\tas\\t0.5\\tmg/kg IV have been used to relax urethral smooth muscle. P Phentolamine Mesylate 725  Horses \u2022\\t\\t1\\tmg/kg\\tq24h\\tIV\\tor\\t0.7\\tmg/kg\\tq6h\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Phentolamine Mesylate fen- tole\u2032ah- meen  mess\u2032ih- late Trade and other names: Regitine and Rogitine (in Canada)","contraindications":"Contraindications and Precautions Use carefully in animals with cardiovascular compromise. Do not use in dehydrated animals. Use carefully in animals with low cardiac output. Drug Interactions Phenoxybenzamine is a potent alpha- adrenergic antagonist. It competes with other drugs that act on the alpha receptor. It causes vasodilation and should be used cautiously with drugs that may cause vasodilation or depress the heart.","indications":"Indications and Clinical Uses Phenoxybenzamine is used primarily to treat peripheral vasoconstriction. In some animals, it has been used to relax urethral smooth muscle to facilitate urine flow. Urethral smooth muscle is innervated by alpha 1 adrenergic receptors. This property has been used to treat urethral spasm in male cats after urethral blockage. Phenoxybenzamine also has been used for this purpose to decease recurrence of urethral obstruction in male cats. For example, it has been administered (2 mg per cat) for 2 weeks after treatment of urethral obstruction. Phenoxybenzamine may be used as a vasodilator when animals have been refractory to other vasodilator drugs. Severe vasoconstriction, such as that observed in cases of pheochromocytoma, have been treated with phenoxybenzamine. See dosing section for protocols in dogs. Experimentally, phenoxybenzamine has been used to relax vascular smooth muscle in\\thorses\\tfor\\ttreating\\tlaminitis.\\tHowever,\\tthis\\thas\\tnot\\tbeen\\ta\\tcommon\\tclinical\\tuse. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Phenoxybenzamine causes prolonged hypotension in animals. Signs of excessive hypotension may include rapid heart rate, weakness, and syncope. In horses, phenoxybenzamine has caused diarrhea.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or limited experimental experience in animals. Patient Monitoring and Laboratory Tests Phenoxybenzamine can lower blood pressure significantly. Monitor the patient\u2019s blood pressure and heart rate if possible during treatment. Formulations Phenoxybenzamine is available in 10- mg capsules. Smaller- sized tablets for cats have been prepared by compounding pharmacies for the purpose of treating male cats after urethral obstruction. Stability and Storage Phenoxybenzamine is only slightly soluble in water but soluble in propylene glycol and ethanol. It is not stable in aqueous solutions and undergoes rapid degradation; therefore, it may not be stable in some compounded formulations. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Phentolamine Mesylate","active_ingredient":"Phentolamine Mesylate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.02\u20130.1\\tmg/kg\\tIV.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Phenylbutazone fen- ill- byoo\u2032tah- zone Trade and other names: Butazolidin, PBZ, \u201cBute,\u201d and generic brands","contraindications":"Contraindications and Precautions Use carefully in animals with cardiovascular compromise. Do not use in dehydrated animals. Use carefully in animals with low cardiac output. Drug Interactions Phentolamine is an alpha- adrenergic antagonist. It competes with other drugs that act on the alpha receptor. It causes vasodilation and should be used cautiously with drugs that may cause vasodilation or depress the heart.","indications":"Indications and Clinical Uses Phentolamine is a potent vasodilator and is used primarily to treat acute hypertension. It is most useful in hypertensive emergencies but not used as often as phenoxybenzamine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Phentolamine may cause excess hypotension with high doses or in animals that are dehydrated and may cause tachycardia.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Titrate dose for each patient to produce desired vasodilation. Patient Monitoring and Laboratory Tests Phentolamine can lower blood pressure significantly. Monitor the patient\u2019s blood pressure and heart rate if possible during treatment. 726    Phenylbutazone Formulations Phentolamine has been available in 5- mg vials for injection but in the United States may only be available as a bulk powder that must be compounded into a solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Phenytoin, Phenytoin Sodium","active_ingredient":"Phenytoin, Phenytoin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAnticonvulsant:\\t20\u201335\\tmg/kg\\tq8h.\\t(Not\\trecommended.) \u2022\\t\\tAntiarrhythmic:\\t30\\tmg/kg\\tq8h\\tPO\\tor\\t10\\tmg/kg\\tIV\\tover\\t5\\tminutes. 734    Physostigmine Cats \u2022\\t\\tSafe\\tand\\teffective\\tdosage\\thas\\tnot\\tbeen\\testablished\\tin\\tcats.  Horses \u2022\\t\\tInitial\\tbolus\\tof\\t20\\tmg/kg\\tq12h\\tPO\\tfor\\tfour\\tdoses\\tfollowed\\tby\\t10\u201315\\tmg/kg\\tq12h PO. A single IV dose in horses of 7.5\u20138.8 mg/kg can be used followed by oral maintenance doses. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Physostigmine fye- zoe- stig\u2032meen Trade and other names: Antilirium","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Drug Interactions Phenytoin interacts with drugs undergoing hepatic metabolism. Phenytoin is a potent cytochrome P450 enzyme inducer. When used with cytochrome P450 inhibitors, increased levels of phenytoin may occur.","indications":"Indications and Clinical Uses Phenytoin is commonly used as an anticonvulsant in people, but it is not effective in dogs and not used in cats. In dogs, elimination is so rapid that dosing is impractical. P In horses, phenytoin has more uses than in small animals. Phenytoin has been used in horses for ventricular arrhythmias, controlling myotonia, rhabdomyolysis, hyperkalemic periodic paresis, and stringhalt. This use is more common in athletic horses on a racetrack than in other horses and is not related to the anticonvulsant property. Pharmacokinetic studies have shown that oral absorption of phenytoin is highly variable in horses. Because of this variability, it is difficult to maintain consistent plasma concentrations. Monitoring plasma concentrations may be necessary to adjust the dose to maintain an optimum level and prevent adverse effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include sedation, gingival hyperplasia, skin reactions, and CNS\\ttoxicity.\\tIn\\thorses,\\tat\\thigh\\tdoses,\\trecumbency\\tand\\texcitement\\thave\\tbeen observed. Sedation in horses may be an initial sign of high plasma concentrations. Monitoring plasma concentrations in horses can prevent adverse effects.","notes":"Instructions for Use Because of short half- life and poor efficacy in dogs, other anticonvulsants are used as the first choice before phenytoin. Although there are questions of safety in cats and little documented use, there are anecdotal accounts of successful use of phenytoin in cats for some neurologic problems. If used in racing horses, consult with local regulatory authorities for restrictions. Patient Monitoring and Laboratory Tests Therapeutic drug monitoring can be performed; however, therapeutic concentrations have not been established for dogs and cats. In horses, effective plasma concentrations are 5\u201320 mcg/mL (average, 8.8 mcg/mL). Therapy should be aimed at producing concentrations above 5 mcg/mL in horses. Formulations \u2022\\t\\tPhenytoin\\tis\\tavailable\\tin\\t25-\\tmg/mL\\toral\\tsuspension,\\t30-\\t\\tand\\t100-\\tmg\\tcapsules (sodium salt), 50- mg/mL injection (sodium salt), and 50- mg chewable tablets. Stability and Storage Store protected from light at room temperature. Phenytoin sodium absorbs carbon dioxide and must be kept in a tight container. Phenytoin is practically insoluble in water, but phenytoin sodium has a solubility of 15 mg/mL. It is soluble in ethanol and\\tpropylene\\tglycol.\\tThe\\tpH\\tof\\tphenytoin\\tis\\t10\u201312,\\tand\\tit\\tmay\\tnot\\tbe\\tcompatible with acidic solutions. It may precipitate from solution if mixed with solutions at a lower\\tpH.\\tProtect\\tfrom\\tfreezing.","original_category":"Anticonvulsant, antiarrhythmic"},{"name":"Prazosin","active_ingredient":"Prazosin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\u20132\\tmg\\tper\\tdog\\tq8\u201324h\\t(as\\tneeded). Cats \u2022\\t\\t0.25\u20131\\tmg\\tper\\tcat\\t(0.07\\tmg/kg\\tor\\tapproximately\\t1\\tmg\\tper\\t15\\tkg)\\tq8\u201312h\\tPO. \u2022\\t\\tCats\\twith\\turethral\\tobstruction:\\t0.5\\tmg\\tper\\tcat\\tPO\\tq8h\\tinitially;\\tthen\\t0.25\u20130.5\\tmg per cat once daily.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Prednisolone, Prednisolone Acetate Trade and other names: Delta- Cortef, PrednisTab, and generic brands","contraindications":"Contraindications and Precautions Use cautiously in animals with compromised cardiac function. It may lower blood pressure and decrease cardiac output. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals,\\tbut\\twhen\\tcombined\\twith other vasodilators, it may produce severe lowering of blood pressure.","indications":"Indications and Clinical Uses Prazosin has been used in people for vasodilation and the management of hypertension that is not responsive to other drugs. Prazosin has been used to a limited extent in veterinary medicine to produce balanced vasodilation. There are no controlled studies to establish efficacy and dose, and indications are derived from anecdotal use and extrapolation from human medicine. It has been used in cats with urethral obstruction to improve urine flow. There is some evidence that in comparison with phenoxybenzamine, it produced fewer recurrence rates of urethral obstruction (0.5 mg per cat q8h PO), but at lower doses (0.25 mg per cat q12h for 30 days) there was no difference compared with placebo for recurrence rate in cats with urethral obstruction. In dogs, there are no clinical studies that have examined effectiveness to relax the urethra. It has also been used experimentally in horses to improve digital perfusion in the treatment of laminitis. Long- term administration is not common because tolerance may develop with chronic use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tdoses\\tcause\\tvasodilation\\tand\\thypotension.\\tOral\\ttreatment\\tin\\tcats\\thas\\tcaused lethargy, ptyalism, and diarrhea.","notes":"Instructions for Use Titrate dose to the needs of the individual patient. Results of clinical studies in animals have not been reported; therefore use in animals (and doses) is based on experience in people or anecdotal experience in animals. For a more specific effect on the urethra smooth muscle, consider tamsulosin (Flomax), which is more specific for the alpha 1a receptor and can produce a more specific effect on the urethra. Patient Monitoring and Laboratory Tests Monitor for hypotension and reflex tachycardia. P Prednisolone, Prednisolone Acetate 767 Formulations Prazosin is available in 1- , 2- , and 5- mg capsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Procainamide Hydrochloride","active_ingredient":"Procainamide Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Because\\tdogs\\tdo\\tnot\\tproduce\\tthe\\tactive\\tmetabolite\\tNAPA,\\tthe\\tdosage\\tmay\\tbe\\thigher compared with dosage for people to control some arrhythmias. In animals, there is no evidence that slow- release oral formulations produce longer duration of sustained blood concentrations.  Dogs \u2022\\t\\t10\u201330\\tmg/kg\\tq6h\\tPO\\tto\\ta\\tmaximum\\tdose\\tof\\t40\\tmg/kg. P Prochlorperazine Edisylate and Isopropamide Iodide 779 \u2022\\t\\t8\u201320\\tmg/kg\\tIV\\tor\\tIM. \u2022\\t \\tCRI:\\tInitial\\tloading\\tdose\\tof\\t10\\tmg/kg\\tfollowed\\tby\\t20\\tmcg/kg/min\\tIV\\tCRI;\\tthe\\tCRI rate can be increased to 25\u201350 mcg/kg/min if needed for refractory arrhythmias. Cats \u2022\\t\\t3\u20138\\tmg/kg\\tq6\u20138h\\tIM\\tor\\tPO. \u2022\\t\\tCRI:\\t1\u20132\\tmg/kg\\tIV\\tslowly;\\tthen\\t10\u201320\\tmcg/kg/min\\tIV.  Horses \u2022\\t\\t25\u201335\\tmg/kg\\tq8h\\tPO. \u2022\\t\\t1\\tmg/kg\\tIV,\\tin\\tincrements,\\tup\\tto\\ta\\ttotal\\tmaximum\\tdose\\tof\\t20\\tmg/kg\\tIV. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Prochlorperazine Edisylate and Isopropamide Iodide, Prochlorperazine Maleate, and Isopropamide Iodide Trade and other names: Darbazine","contraindications":"Contraindications and Precautions Procainamide can suppress the heart and produce pro- arrhythmic effects. Use cautiously in animals receiving digoxin because it may potentiate arrhythmias. Drug Interactions Drugs that inhibit cytochrome P450 enzymes (e.g., cimetidine) can potentially increase procainamide concentrations.","indications":"Indications and Clinical Uses Procainamide has been used in small animals to suppress ventricular ectopic beats and treat ventricular arrhythmias. Studies in experimental dogs with induced arrhythmias have documented efficacy, but clinical use is based primarily on anecdotal experience. It is used primarily during acute treatment when it can be administered by injection or tablet. Rarely is long- term treatment used. Procainamide has occasionally been used in horses to suppress ventricular arrhythmias. The availability of commercial forms of procainamide has diminished, and the use has declined in favor of other antiarrhythmic agents. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include cardiac arrhythmias, cardiac depression, tachycardia, and hypotension. In people, procainamide produces hypersensitivity effects (lupus- like reactions), but these have not been reported in animals.","notes":"Instructions for Use Patient Monitoring and Laboratory Tests If assays are available, monitor plasma concentrations during chronic therapy. Effective\\tplasma\\tconcentrations\\tin\\texperimental\\tdogs\\tare\\t20\\tmcg/mL.\\tHowever,\\tin some references, concentrations as low as 8\u201310 mcg/mL are cited to be effective. The metabolite,\\tNAPA,\\tis\\tmonitored\\tin\\tpeople,\\tbut\\tdogs\\tdo\\tnot\\tproduce\\tthis\\tmetabolite. ECGs should be monitored in treated animals. Formulations \u2022\\t\\tProcainamide\\thas\\tbeen\\tavailable\\tin\\t250-\\t,\\t375-\\t   ,\\tand\\t500-\\tmg\\ttablets\\tor\\tcapsules\\tand 100-\\t\\tand\\t500-\\tmg/mL\\tinjections.\\tHowever,\\tbecause\\tof\\tdiminished\\tuse\\tin\\thuman medicine in favor of other alternatives, many of the human formulations are no longer available in the United States but are available in Canada. When oral doses are unavailable, procainamide can be compounded in pharmacies. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Procainamide is soluble in water. When stored, solutions may turn yellow without losing potency. Darker coloration indicates oxidation. Storage of injectable vials in the\\trefrigerator\\tprevents\\toxidation.\\tThe\\tpH\\tof\\toral\\tcompounded\\tproducts\\tshould\\tbe maintained\\tat\\tpH\\t4\u20136\\tfor\\tmaximum\\tstability.\\tCompounded\\toral\\tproducts\\tin\\tsyrups\\tand flavorings\\tmay\\tbe\\tstable\\tfor\\t60\\tdays\\tor\\tmore,\\tbut\\tthey\\tshould\\tbe\\tkept\\tin\\tthe\\trefrigerator.","original_category":"Antiarrhythmic"},{"name":"Quinidine, Quinidine Sulfate","active_ingredient":"Quinidine, Quinidine Sulfate","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\tQuinidine\\tgluconate:\\t6\u201320\\tmg/kg\\tq6h\\tIM\\tor\\t6\u201320\\tmg/kg\\tq6\u20138h\\tPO\\t(of\\tbase). \u2022\\t\\tQuinidine\\tpolygalacturonate:\\t6\u201320\\tmg/kg\\tq6h\\tPO\\t(of\\tbase). \u2022\\t\\tQuinidine\\tsulfate:\\t6\u201320\\tmg/kg\\tq68h\\tPO\\t(of\\tbase)\\tor\\t5\u201310\\tmg/kg\\tq6h\\tIV.  Cattle \u2022\\t\\tTreatment\\tof\\tatrial\\tfibrillation:\\tQuinidine\\tis\\tpoorly\\tabsorbed\\torally\\tin\\tcattle\\tand must\\tbe\\tgiven\\tintravenously.\\tA\\tloading\\tdose\\tof\\t49\\tmg/kg\\t(given\\tover\\t4\\thours)\\tto be\\tfollowed\\tby\\t42\\tmg/kg\\tIV\\tmaintenance\\tdose.\\tOr\\tgive\\t40\\tmg/kg\\tdiluted\\tin\\t4\\tL of\\tfluid\\tslowly\\tat\\ta\\trate\\tof\\t1\\tL/h\\tuntil\\tfibrillation\\tis\\tconverted. Horses \u2022\\t\\tAtrial\\tfibrillation\\ttreatment\\t(usually\\torally\\twith\\ta\\tstomach\\ttube):\\t5\\tg\\tper\\t450\\tkg of\\tbody\\tweight\\t(per\\t1000\\tlb)\\tfor\\tthe\\tfirst\\ttreatment;\\tthereafter\\tgive\\t10\\tg\\tper\\t450 kg\\tevery\\t2\\thours\\tuntil\\tthe\\tsinus\\trate\\tis\\tachieved.\\tIV\\tdosage\\tis\\t1\u20131.5\\tmg/kg\\tevery 10\u201315\\tminutes\\tto\\ta\\ttotal\\tdose\\tof\\t10\\tmg/kg\\tor\\tuntil\\tsinus\\trate\\tconversion. Regulatory Information Withdrawal times are not established for animals that produce food. Because of rapid elimination, short withdrawal times can be used. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Racing\\tCommissioners\\tInternational\\tClassification:\\t4 806    Racemethionine Racemethionine rah- see\u2032meth- eye\u2032oh- neen Trade and other names: Methio- Form, and generic brands and Pedameth, Uracid, and generic brands (human preparations); also listed as DL- methionine","contraindications":"Contraindications and Precautions Quinidine may increase the heart rate. Use cautiously in animals with heart disease. Drug Interactions Quinidine\\tis\\ta\\twell-\\tknown\\tmultidrug\\tresistance\\t(ABCB1, also known as MDR1) membrane\\tpump\\t(P-\\tglycoprotein)\\tinhibitor.\\tIt\\tinterferes\\twith\\tmembrane\\tchannels and increases concentrations of some coadministered drugs. Coadministration with digoxin may increase digoxin concentrations. See Appendix K for a list of potential\\tP-\\tglycoprotein\\tsubstrates. Q","indications":"Indications and Clinical Uses Quinidine is used to treat ventricular arrhythmias and occasionally to convert atrial fibrillation to sinus rhythm. In small animals, it is rarely used because other more effective and safer alternatives are available. For example, an oral alternative for dogs is mexiletine. In horses and cattle, quinidine has been the drug of choice to treat atrial fibrillation. However, other alternatives are considered because of the frequency of adverse effects in horses and the decreased availability of commercial forms of quinidine. Alternatives include diltiazem and electrical cardioversion. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects with quinidine are more common than procainamide and include nausea and vomiting. Adverse effects include hypotension and tachycardia (because of vagolytic effect). With IV dosing, adverse effects such as hypotension and tachyarrhythmias are common in cattle. In horses, adverse effects are common, which include hypotension, gastrointestinal problems, and supraventricular tachycardia. Sudden cardiac death is possible but uncommon in horses.","notes":"Instructions for Use Quinidine\\thas\\ta\\trapid\\tclearance\\tin\\tcattle\\t(half-\\tlife,\\t2.25\\thours),\\twhich\\tresults\\tin\\tthe need for frequent administration. Equine doses are usually administered orally via a stomach tube. Because of decreased availability of commercial forms and frequency of adverse effects, quinidine is not used as commonly as other Class I antiarrhythmic drugs. If quinidine is administered, calculate the dose to the amount of quinidine base in\\teach\\tformulation:\\t324\\tmg\\tof\\tquinidine\\tgluconate\\thas\\ta\\t202-\\tmg\\tquinidine\\tbase; 275\\tof\\tmg\\tquinidine\\tpolygalacturonate\\thas\\ta\\t167-\\tmg\\tquinidine\\tbase;\\tand\\t300\\tmg\\tof quinidine\\tsulfate\\thas\\ta\\t250-\\tmg\\tquinidine\\tbase. Patient Monitoring and Laboratory Tests Quinidine can be hypotensive and vagolytic. Monitor patient\u2019s electrocardiogram for arrhythmias and monitor blood pressure. Formulations \u2022\\t\\tIn\\tsome\\tcountries,\\tquinidine\\tis\\tbeing\\tdiscontinued\\tand\\tmay\\tbe\\tdifficult\\tto\\tobtain. Older\\tformulations\\tinclude\\tquinidine\\tgluconate\\t324-\\tmg\\ttablets\\tand\\t80-\\tmg/mL injection;\\tquinidine\\tpolygalacturonate\\tin\\t275-\\tmg\\ttablets;\\tand\\tquinidine\\tsulfate in\\t100-\\t   ,\\t200-\\t   ,\\tand\\t300-\\tmg\\ttablets,\\t200-\\t\\tand\\t300-\\tmg\\tcapsules,\\tand\\t200-\\tmg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Quinidine is slightly soluble in water. Quinidine salts may form a dark color when exposed to light and should not be used. Quinidine has been compounded for oral use\\tin\\tsyrups\\t(e.g.,\\tOra\\tSweet)\\tand\\tis\\tstable\\tfor\\t60\\tdays.","original_category":"Antiarrhythmic"},{"name":"Ramipril","active_ingredient":"Ramipril","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.125\u20130.25\\tmg/kg\\tdaily\\tPO\\tto\\ta\\tmaximum\\tof\\t0.5\\tmg/kg\\tper\\tday. Cats \u2022\\t\\t0.125\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Ranitidine Hydrochloride rah- nit\u2032ih- deen  hye- droe- klor\u2032ide Trade and other names: Zantac","contraindications":"Contraindications and Precautions Studies performed in experimental dogs indicated that dose adjustments are not necessary when administering ramipril in dogs with impaired kidney function. However, as with any ACE inhibitor, monitor patients carefully if they have renal insufficiency or decreased glomerular filtration rate that could be impaired with ACE inhibitor treatment. Discontinue use of ACE inhibitors in pregnant animals; they cross the placenta and have caused fetal malformations and death of the fetus. Drug Interactions Use cautiously with other hypotensive drugs and diuretics. Nonsteroidal anti- inflammatory drugs (NSAIDs) may decrease vasodilating effects.","indications":"Indications and Clinical Uses Ramipril is used to treat hypertension and congestive heart failure. It has not been studied as much as other ACE inhibitors in animals (e.g., enalapril or benazepril), but it is expected to have similar pharmacodynamic effects. Because no ACE inhibitor has been shown to be superior to another, there is little reason to use ramipril instead of enalapril or benazepril in dogs or cats. It has been primarily used in dogs. It has also been used safely in cats to control hypertension but has not been effective for treating hypertrophic cardiomyopathy. 808    Ranitidine Hydrochloride Precautionary Information","side_effects":"Adverse Reactions and Side Effects It has not been used as often as other drugs in this class; therefore a full range of potential adverse effects has not been reported. Ramipril was well tolerated in clinical studies in dogs, but adverse effects reported for other ACE inhibitors may be expected in dogs and cats.","notes":"Instructions for Use Clinical efficacy has been demonstrated in dogs with dilated cardiomyopathy. Other drugs used for treatment of heart failure may be used concurrently. Dogs also may receive pimobendan, digoxin, and/or furosemide with ramipril. Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes\\tand\\trenal\\tfunction\\t3\u20137\\tdays\\tafter\\tinitiating\\ttherapy\\tand\\tperiodically\\tthereafter. Formulations \u2022\\t\\tRamipril\\tis\\tavailable\\tin\\t1.25-\\t,\\t2.5-\\t  ,\\t5-\\t ,\\tand\\t10-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator, angiotensin- converting enzyme inhibitor"},{"name":"Sildenafil Citrate","active_ingredient":"Sildenafil Citrate","species":["Canine","Feline"],"dosage":"are tadalafil (Cialis) at a dosage of 1\u20132 mg/kg q12h PO in dogs. Sildenafil also relaxes smooth muscle in other sites, including portions of the GI tract, uterus, and gallbladder. Relaxation of the esophageal muscle may improve some dogs with clinical megaesophagus. Most of the esophagus in dogs is comprised of striated muscle, but the lower esophageal sphincter is made of smooth muscle, which can be relaxed by some agents. Pharmacokinetics: In dogs, the half- life is approximately 5 hours. hypertension and in dogs with megaesophagus. The dosages and clinical use are based on these limited reports.  Dogs \u2022\\t\\tPulmonary\\thypertension:\\t2\\tmg/kg\\tq12h\\tPO.\\tDose\\tinterval\\tmay\\trange\\tfrom\\t8\u201324 hours, and doses as high as 3 mg/kg have been administered to some dogs. There are variations in the dose range because of limitation in tablet sizes. \u2022\\t\\tMegaesophagus:\\t1\\tmg/kg\\tPO\\tq12h. Cats \u2022\\t\\t1\\tmg/kg\\tq8h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\testablished\\tfor\\tanimals\\tintended\\tfor\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Silymarin sill- ih- mare\u2032in Trade and other names: Silybin, Marin, milk thistle, and generic brands","contraindications":"Contraindications and Precautions Use cautiously in conjunction with other vasodilator drugs. Drug Interactions No drug interactions reported for animals, but in people, there are precautions about use with other vasodilators such as alpha blockers and nitrates. When used for treating megaesophagus in dogs, it should not be used with cisapride or metoclopramide because they antagonize the effect. S Silymarin 837","indications":"Indications and Clinical Uses Sildenafil and related drugs are used in people for treating erectile dysfunction via the effect on the corpus cavernosum. This effect has not been explored in veterinary medicine. The use in veterinary medicine has been limited to the treatment of pulmonary arterial hypertension and megaesophagus. In dogs, there is clinical evidence for the beneficial effects of sildenafil in patients with pulmonary hypertension. Results of prospective studies in dogs show that the response may be inconsistent but that many dogs have lower pulmonary artery pressure after treatment with sildenafil. On the other hand, some dogs do not respond. Sildenafil has been used to improve clinical signs in dogs with congenital idiopathic megaesophagus. This improvement occurs through relaxation of the lower esophageal sphincter muscle to facilitate emptying of the esophagus to the stomach. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cutaneous flushing of the inguinal area has been observed in dogs. Otherwise, adverse effects have not been reported with clinical use in dogs. Potential effects are attributed to the vasodilator action. If high doses or other vasodilators are administered, especially those that increase cyclic GMP levels, hypotension can occur.","notes":"Instructions for Use The use in veterinary medicine has been based on studies in dogs with pulmonary Patient Monitoring and Laboratory Tests No specific monitoring is necessary but monitor the patient\u2019s cardiovascular function (blood pressure and heart rate) in animals at risk for cardiovascular complications. Formulations \u2022\\t\\tSildenafil\\tis\\tavailable\\tas\\t20-\\t,\\t25-\\t  ,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Sotalol Hydrochloride","active_ingredient":"Sotalol Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/kg\\tq12h\\tPO.\\t(For\\tmedium-\\t\\tto\\tlarge-\\tbreed\\tdogs,\\tbegin\\twith\\t40\\tmg\\tper\\tdog q12h; then increase to 80 mg per dog if no response.) Cats \u2022\\t\\t1\u20132\\tmg/kg\\tq12h\\tPO.\\tA\\tdosage\\tof\\t10\u201320\\tmg\\tper\\tcat\\tq12h\\talso\\thas\\tbeen\\tused. 846    Spectinomycin and Spectinomycin Dihydrochloride Pentahydrate  Horses \u2022\\t\\tTreatment\\tof\\tatrial\\tfibrillation:\\t2\\tmg/kg\\tPO\\tq12h\\tfor\\t3\\tdays. \u2022\\t\\tVentricular\\ttachycardia:\\t1\\tmg/kg\\tPO\\tq12h\\tup\\tto\\t2\u20133\\tmg/kg\\tPO\\tq12h.\\t(Increase dose as needed to control the response.) Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI Classification: 3 Spectinomycin and Spectinomycin Dihydrochloride Pentahydrate spek- tih- noe- mye\u2032sin Trade and other names: Spectam, Spectogard, Prospec, Linco-Spectin, and Adspec","contraindications":"Contraindications and Precautions Sotalol should be administered cautiously to patients with heart failure or AV block. Use cautiously in patients with poor cardiac reserve because it may decrease cardiac contractility. In dogs with ventricular arrhythmias, it produces a mild decrease in left ventricular function; otherwise, it has been well tolerated in dogs with atrial enlargement and systolic dysfunction. Drug Interactions Use cautiously with other cardiovascular drugs that may depress the heart. A full range of drug interactions is not known for dogs because the use is extralabel, and such records are not kept. However, drug interactions are possible from other medications that interfere with drug metabolism.","indications":"Indications and Clinical Uses Sotalol is indicated for control of refractory ventricular arrhythmias. It has also been used for refractory atrial fibrillation. Although sotalol has been used as a preferred oral S antiarrhythmic agent administered to small animals, particularly dogs, there are no controlled studies to establish efficacy over other agents. The use and doses are derived primarily from small observational studies or anecdotal and clinical experience. In horses, sotalol (2 mg/kg q12h) produces lower peak concentrations than comparable doses in people. However, it has decreased heart rate and increased the QT\\tinterval,\\twhich\\tfacilitates\\tcardioversion\\tin\\thorses\\twith\\tatrial\\tfibrillation. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported for animals but are expected to be similar to those of propranolol. In people, reported adverse effects include atrioventricular (AV)\\tblock,\\thypotension,\\tdyspnea,\\tbronchospasm,\\tbradycardia,\\tand\\tQT\\tinterval prolongation. These effects are possible but not reported from the use in animals. Like many antiarrhythmic agents, sotalol may have some proarrhythmic activity. Negative inotropic effects may cause concern in some animals with poor cardiac contractility.","notes":"Instructions for Use The beta- blocking effects occur at low doses; Class III antiarrhythmic effects occur at higher doses. In people, sotalol has been a more effective maintenance agent for controlling arrhythmias than other drugs, and this may be true in animals also. Patient Monitoring and Laboratory Tests Monitor heart rate during treatment. Monitor the electrocardiogram for response to treatment. Formulations \u2022\\t\\tSotalol\\tis\\tavailable\\tin\\t80-\\t,\\t120-\\t   ,\\t160-\\t   ,\\tand\\t240-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Sotalol is soluble in both water and ethanol. It has been mixed with syrups and flavorings and is stable for 12 weeks, but it should be stored in the refrigerator.","original_category":"Beta blocker, antiarrhythmic"},{"name":"Spironolactone","active_ingredient":"Spironolactone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2\u20134\\tmg/kg/day\\t(or\\t1\u20132\\tmg/kg\\tq12h)\\tPO.\\tIn\\tdogs,\\tstart\\twith\\t2\\tmg/kg/day\\tand increase gradually, not to exceed 4 mg/kg/day. In Europe, the approved dosage for dogs is 2 mg/kg/day. Cats \u2022\\t\\tUse\\tin\\tcats\\tis\\tcontroversial\\tbecause\\tit\\tmay\\tproduce\\tdermatitis\\tand\\tbecause\\tthe efficacy is questionable. However, dosages in the range of 2\u20134 mg/kg/day (or 1\u20132 mg/kg q12h) PO have been administered for some conditions.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI Classification: 4 Stanozolol stan- oh\u2032zoe- lole Trade and other names:  Winstrol- V","contraindications":"Contraindications and Precautions Do not use in patients that are dehydrated. Nonsteroidal anti- inflammatory drugs (NSAIDs) may interfere with action. Avoid concurrent use of supplements that are high in potassium. Do not administer to patients with gastric ulcers or who may be prone to GI disease such as gastritis or diarrhea. Drug Interactions Spironolactone is often used together with ACE inhibitors, such as enalapril. It acts synergistically with ACE inhibitors and does not ordinarily produce adverse changes in potassium concentrations. However, in some animals, the dual treatment with spironolactone and an ACE inhibitor may increase the risk of kidney injury and may increase the risk of hyperkalemia. Therefore, some monitoring is advised to avoid this problem. Use cautiously with other drugs that can increase potassium concentrations such as trimethoprim and NSAIDs. Other cardiac treatments have been safely administered with spironolactone such as pimobendan, digoxin, and furosemide. S Stanozolol 851","indications":"Indications and Clinical Uses Spironolactone is used for treating high blood pressure and congestion caused by heart failure. It is approved in Europe (Prilactone) for dogs to be used with standard\\ttherapy\\tfor\\tthe\\ttreatment\\tof\\tcongestive\\theart\\tfailure\\t(CHF)\\tcaused\\tby valvular disease. (Other treatments can include pimobendan, digoxin, angiotensin- converting enzyme [ACE] inhibitors, and furosemide.) Spironolactone is not recommended for routine use to delay the onset of heart failure in patients with valvular disease (stage B2). Spironolactone may also be used with angiotensin- converting enzyme (ACE) inhibitors to achieve a synergistic effect for treatment of heart failure in animals. The addition of spironolactone to traditional cardiac therapy can reduce the risk of cardiac morbidity and mortality in dogs with valvular disease. The proposed benefit of spironolactone treatment is via aldosterone antagonism and can be used to inhibit the renin\u2013angiotensin\u2013aldosterone system (RAAS) activation that occurs from diuretic administration (e.g., furosemide) or with some diseases that produce congestion. Despite treatment with ACE inhibitors, some animals may still exhibit aldosterone synthesis, which has been known as aldosterone breakthrough. Spironolactone may be effective to decrease the effects caused by aldosterone breakthrough. Spironolactone has also been used for managing hepatic cirrhosis because it inhibits ascites formation caused by excess aldosterone. It has not been beneficial for treatment in cats with hypertrophic cardiomyopathy (see also Adverse Reactions and","side_effects":"Side Effects for more information on cats). Precautionary Information Adverse Reactions and Side Effects Spironolactone\\tcan\\tproduce\\thyperkalemia\\tin\\tsome\\tpatients.\\tFacial\\tdermatitis\\thas been reported from administration of spironolactone to cats, which may limit its clinical use in these animals. The mechanism of these reactions is not known. High doses and long- term use may produce some steroid- like side effects, but this has not been a significant clinical problem in dogs. However, in people, these endocrine effects have been associated with antiandrogenic effects such as gynecomastia, hirsutism, and impotence. The only antiandrogenic effects reported from its use in animals is prostatic atrophy, which has been observed in some male dogs.","notes":"Instructions for Use Spironolactone usually is administered with other drugs (e.g., ACE inhibitors, inotropic\\tagents,\\tvasodilators)\\tfor\\ttreating\\tCHF. Patient Monitoring and Laboratory Tests Monitor serum potassium concentration when administering with an ACE inhibitor (e.g., enalapril maleate). Administration of spironolactone may cause a slightly false- positive result for digoxin assay. Formulations \u2022\\t\\tSpironolactone\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets.\\tTablets\\tcan\\tbe\\tsplit easily. In Europe, there is an approved formulation for animals. In the United States, the human generic formulation is used. \u2022\\tOral\\tsuspension:\\t5\\tmg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Spironolactone is insoluble in water, but it is slightly more soluble in ethanol. It has been mixed with syrups for an oral suspension (after first mixing with ethanol) and found to be stable for 90\u2013160 days.","original_category":"Diuretic"},{"name":"Tadalafil","active_ingredient":"Tadalafil","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tPulmonary\\thypertension:\\t2\\tmg/kg\\tq24h\\tPO.\\tDose\\tinterval\\tmay\\tbe\\tvariable, depending on response. \u2022\\t\\tMegaesophagus:\\tdose\\tnot\\testablished T Tamsulosin Hydrochloride 871 Cats \u2022\\t\\tDose\\tnot\\testablished  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No withdrawal times are established for animals intended for food. Tamsulosin Hydrochloride tam- soo\u2032loe- sin Trade and other names: Flomax","contraindications":"Contraindications and Precautions Use cautiously in conjunction with other vasodilator drugs. Drug Interactions No drug interactions reported for animals, but in people, there are precautions about use with other vasodilators such as alpha blockers and nitrates.","indications":"Indications and Clinical Uses Tadalafil and related drugs are used in people for treating erectile dysfunction via the effect on the corpus cavernosum. This effect has not been explored in veterinary medicine. The use in veterinary medicine has been limited to the treatment of pulmonary arterial hypertension. In dogs, a comparison with sildenafil showed that both drugs were equally effective in patients with pulmonary hypertension. Sildenafil has been used to improve clinical signs in dogs with congenital idiopathic megaesophagus, but this use has not been explored for tadalafil. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Clinical use has been in only small observational studies and not sufficient to document the full range of potential adverse effects. Adverse effects observed in dogs have included decreased appetite, hindlimb weakness, and increased sexual behavior. Potential effects are attributed to the vasodilator action. If high doses or other vasodilators are administered, especially those that increase cyclic- GMP levels, hypotension can occur.","notes":"Instructions for Use The use in veterinary medicine has been based on small observational studies in dogs with pulmonary hypertension and extrapolation of the use in people. Although sildenafil has been used in dogs with megaesophagus, this has not been studied for tadalafil. Administer tablets with or without food. Do not split tablets. Patient Monitoring and Laboratory Tests No specific monitoring is necessary but monitor the patient\u2019s cardiovascular function (blood pressure and heart rate) in animals at risk for cardiovascular complications. Formulations \u2022\\t\\tTadalafil\\tis\\tavailable\\tas\\t2.5-\\t,\\t5-\\t ,\\t10-,\\t\\tand\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasodilator"},{"name":"Telmisartan","active_ingredient":"Telmisartan","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1\\tmg/kg\\tonce\\tper\\tday\\tPO\\tas\\ta\\tstarting\\tdosage.\\tIncrease\\tto\\t3\\tmg/kg\\tonce\\tper\\tday and then to twice daily if needed. Cats \u2022\\t\\t1.5\\tmg/kg\\tPO\\tq12h\\tinitially\\tfor\\tthe\\tfirst\\t14\\tdays.\\tThereafter,\\t2\\tmg/kg\\tPO\\tq24h. For the oral solution, this is equivalent to 0.2 mL/kg. May be administered directly or with small amount of food, but not mixed in with food. Adjust the dose by 0.5- mg/kg increments by monitoring the blood pressure. Cats that are hypotensive from 2 mg/kg are usually adjusted down to 1 mg/kg.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 Tepoxalin tep- oks\u2032ah- lin Trade and other names: Zubrin","contraindications":"Contraindications and Precautions No specific contraindications have been reported for animals. Safety in breeding, pregnant, or lactating animals has not been established. Drug Interactions Combined use of an ARB and an ACE inhibitor may increase the risk of kidney injury because of dual blockade. This may be associated with increased risks of hypotension, hyperkalemia, and changes in kidney function. T Tepoxalin 877","indications":"Indications and Clinical Uses Telmisartan is the only ARB that has been rigorously tested in cats. It was more effective than ACE inhibitors, irbesartan, and losartan. Compared with placebo, it significantly lowers the systolic blood pressure in cats after 14 days of treatment. In cats, the approved indication is for treatment of hypertension and proteinuria caused by CKD. In cats, it can be considered a first choice for treating hypertension and has been preferred over ACE inhibitors such as benazepril. The use in dogs is based on less rigorous studies, but studies in experimental animals and anecdotal experience support the use. In dogs, it is generally used for hypertension and proteinuria when other agents such as ACE inhibitors (e.g., enalapril, benazepril) are ineffective or not tolerated. In experimental dogs, telmisartan (1 mg/kg) was more effective than enalapril. It has also been administered concurrently with other antihypertensive agents in dogs. A related drug, irbesartan (30\\tmg/kg\\tq12h),\\thas\\talso\\tbeen\\tshown\\tto\\tblock\\tangiotensin\\tII\\treceptors\\tin\\tdogs, but losartan is less potent because it relies mostly on an active metabolite that dogs do not produce (see Losartan for more details). Because telmisartan is more active than losartan in dogs and easily available to veterinarians, it should be a preferred if an angiotensin II blocker is needed. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have been uncommon, but clinical trials in cats have shown vomiting, hypersalivation, weight loss, diarrhea, lethargy, anemia, and hypotension. Drugs that act on the RAAS can produce a decrease in red blood cell count. If hypotension is observed, a dose adjustment is appropriate. If severe hypotension is observed, treat with fluid therapy until the patient is stabilized; then re- evaluate the dose or the drug regimen. In\\tcats,\\tthere\\twas\\tno\\tincrease\\tin\\tcreatinine\\teven\\tin\\tcats\\twith\\tstage\\t2\\tor\\t3\\tCKD. During safety studies, up to five times the approved dose was administered to cats\\tfor\\t6\\tmonths,\\tand\\tadverse\\teffects\\twere\\tnot\\tobserved\\tother\\tthan\\tthose\\tlisted earlier, which included hypotension and decreased red blood cell count.","notes":"Instructions for Use In cats, the dose protocols are based on the FDA- approved indications and label instructions for treating proteinuria in cats with CKD. The oral solution is well tolerated in cats and can be administered directly or with small amounts of food. It should not be mixed in with food but can be given simultaneously with a meal. When using the dosing syringe, rinse with water between treatments. In dogs, the use is based more on anecdotal experience and studies in research dogs but is an accepted use by most cardiologists. Patient Monitoring and Laboratory Tests Monitor blood pressure in treated animals. Typically, the blood pressure should be checked within 7\u201310 days of initiating treatment. If the patient is stable, blood pressure measurements can be performed at the same time as regular checkups. If blood\\tpressure\\tis\\ttoo\\tlow\\t(defined\\tas\\tless\\tthan\\t120/60\\tmm\\tHg)\\twith\\tclinical\\tsigns of weakness, syncope, or tachycardia, the dose should be lowered by 0.5- mg/kg increments. Monitor the complete blood count (CBC) periodically during treatment because of a risk of lower red blood cell count. Formulations \u2022\\t\\tTelmisartan\\tis\\tavailable\\tfor\\tcats\\tas\\ta\\t10-\\tmg/mL\\toral\\tsolution\\tin\\ta\\t35-\\tmL\\tbottle. \u2022\\t\\tTablets:\\tformulation\\tfor\\tpeople\\tin\\tsizes\\tof\\t20-\\t,\\t40-\\t  ,\\tand\\t80-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vasodilator"},{"name":"Tocainide Hydrochloride","active_ingredient":"Tocainide Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t15\u201320\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. 916    Toceranib Phosphate Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 4 Toceranib Phosphate toe ser\u2032 a nib Trade and other names: Palladia","contraindications":"Contraindications and Precautions Use cautiously in animals that are also receiving beta blockers. Do not use in patients with heart block. Drug Interactions No drug interactions have been reported for animals, but the use is uncommon, and it is possible that a full range of adverse effects is not known.","indications":"Indications and Clinical Uses Tocainide is an oral substitute used for treatment and control of ventricular arrhythmias when injectable class I antiarrhythmic agents cannot be used. The use in veterinary medicine has been uncommon. Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. If an oral antiarrhythmic agent is needed in animals, consider mexiletine or sotalol (depending on the underlying clinical circumstances) as an alternative. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In\\tdogs,\\tanorexia\\tand\\tGI\\tadverse\\teffects\\thave\\tbeen\\treported.\\tIn\\tone\\tstudy,\\t35% of dogs showed GI adverse effects. Arrhythmias, vomiting, and ataxia also are possible.","notes":"Instructions for Use Tocainide has limited experience in animals. However, some small clinical observational studies demonstrated efficacy. Patient Monitoring and Laboratory Tests If\\tmonitoring\\tis\\tpossible,\\ttherapeutic\\tconcentrations\\treported\\tfor\\tpeople\\tare\\t6\u201310 mcg/mL. Formulations \u2022\\t\\tTocainide\\tis\\tavailable\\tin\\t400-\\t\\tand\\t600-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiarrhythmic"},{"name":"Torsemide","active_ingredient":"Torsemide","species":["Canine","Equine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t0.2\\tmg/kg\\tq12h\\tPO.\\tWhen\\tswitching\\tfrom\\tfurosemide\\tto\\ttorsemide,\\ttake\\tthe total daily dose of furosemide and divide by 10 and administer twice daily PO. (See  Horses \u2022\\t\\t0.5\u20131\\tmg/kg\\tq12h\\tPO. Cattle \u2022\\t\\tDoses\\tfor\\tcattle\\thave\\tnot\\tbeen\\testablished. Regulatory Information There are no withdrawal times available for food- producing animals. Consult FARAD at www.FARAD.org for information regarding withdrawal time after extralabel use. Tramadol Hydrochloride tram\u2032ah- dole Trade and other names: Ultram, and generic brands; outside the United States, Tramadol and Altadol","contraindications":"Contraindications and Precautions Administer conservatively in animals receiving ACE inhibitors to decrease the risk of azotemia. Repeated administration may increase aldosterone levels via activation of RAAS, but this may be less than with furosemide. Drug Interactions There are no specific drug interactions identified for torsemide use in animals. It is assumed that similar drug interactions that affect furosemide could affect torsemide. (See Furosemide for additional details.) T Tramadol Hydrochloride 921","indications":"Indications and Clinical Uses In small animals, torsemide is used in place of furosemide for refractory cases that require a longer duration of effect. It has been used in dogs when furosemide becomes ineffective (diuretic resistance) or if the dosages of furosemide exceed 4 mg/ kg\\tper\\tday\\t(or\\taccording\\tto\\tother\\tsources,\\tgreater\\tthan\\t6\u20138\\tmg/kg\\tper\\tday). Torsemide is also more potent and requires less of a dose than furosemide. Conditions appropriate for torsemide are mostly in dogs with stage C or D congestive heart failure (CHF). However, it may also be considered to treat conditions that cause edema, including pulmonary edema, liver disease, heart disease, and vascular disease. Torsemide increases potassium and calcium excretion and is used to treat hyperkalemia and hypercalcemia. There is no established use of torsemide for acute kidney disease treatment. Although furosemide is used to treat exercise- induced pulmonary hemorrhage in horses, torsemide is not allowed by racing authorities for this use. It has been considered for oral treatment in horses for other uses in which furosemide might be used, and doses are listed in the dosing section; however, there are no clinical trials to compare furosemide with torsemide. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to diuretic effect (loss of fluid and electrolytes). In dogs, hyponatremia can occur. In horses, there is a risk of hypokalemia and metabolic acidosis.","notes":"Instructions for Use Torsemide is used in dogs when patients become refractory to furosemide, or if the dose\\tof\\tfurosemide\\tis\\tgreater\\tthan\\t4\\tmg/kg\\tper\\tday\\t(or\\t6\u20138\\tmg/kg\\tper\\tday\\tin\\tsome references). When switching from furosemide to torsemide, take the total daily dose of furosemide and divide by 10 and divide this into twice daily administration, PO. For example, if the total daily dose of furosemide is 100 mg, this translates to 5 mg/ kg of torsemide q12h PO. Patient Monitoring and Laboratory Tests Monitor electrolyte concentrations (particularly potassium) and hydration status in patients during treatment. Formulations \u2022\\t\\tTorsemide\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t20-,\\t\\tand\\t100-\\tmg\\ttablet\\tsizes. \u2022\\t\\tInjection:\\t10\\tmg/mL. \u2022\\t \\tCompounded\\tformulation:\\t5-\\tmg/mL\\tsuspension\\tprepared\\tin\\tOra\\tPlus\\tand\\tOra Sweet vehicles in a 1:1 ratio. If not buffered, this suspension degrades in 7 days, but at\\ta\\tpH\\tof\\t8.3,\\tit\\tis\\tstable\\tfor\\t90\\tdays\\tstored\\tat\\troom\\ttemperature\\tor\\tin\\ta\\trefrigerator. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with acidic solutions. In a compounded formulation, the buffered suspension for oral administration had a 90- day beyond- use date. Instructions for Use, above.) Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported.\\tThe\\tdose\\tfor\\tdogs\\tcould\\tbe\\tconsidered\\tby\\treferring\\tto dosing guidelines.","original_category":"Diuretic"},{"name":"Trandolapril","active_ingredient":"Trandolapril","species":["Canine"],"dosage":"\u2022\\t\\tThe\\tdose\\thas\\tnot\\tbeen\\testablished\\tfor\\tdogs.\\tThe\\tdosage\\tin\\tpeople\\tis\\t1\\tmg/person/ day to start, which is then increased to 2\u20134 mg/day.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Trazodone Hydrochloride traz\u2032oh- done Trade and other names: Desyrel and generic","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Trandolapril, like other ACE inhibitors, is used for treatment of hypertension and for management of CHF. Compared with other ACE inhibitors, such as enalapril and benazepril, it is not used commonly in veterinary medicine, and the use has been derived from anecdotal experiences. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Trandolapril may cause azotemia in some patients; carefully monitor patients receiving high doses of diuretics. When administered with diuretics (furosemide), the RAAS may be activated. 926    Trazodone Hydrochloride","notes":"Instructions for Use Trandolapril has not been used extensively in veterinary patients. Most of the experience has been extrapolated from uses in people. Ordinarily, other ACE inhibitors, such as enalapril or benazepril, are used initially in animals. If patients cannot tolerate these drugs, consider an ARB such as telmisartan. Patient Monitoring and Laboratory Tests Monitor patients carefully to avoid hypotension. With all ACE inhibitors, monitor electrolytes\\tand\\trenal\\tfunction\\t3\u20137\\tdays\\tafter\\tinitiating\\ttherapy\\tand\\tperiodically thereafter. Formulations Available \u2022\\t\\tTrandolapril\\tis\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\tand\\t4-\\t    mg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vasodilator, ACE inhibitor"},{"name":"Triamterene","active_ingredient":"Triamterene","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20132\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 4 T Trientine Hydrochloride 933 Trientine Hydrochloride trye- en\u2032teen  hye- droe- klor\u2032ide Trade and other names: Syprine","contraindications":"Contraindications and Precautions Do not use in dehydrated patients. NSAIDs may interfere with action. Avoid supplements that are high in potassium. Drug Interactions No specific drug interactions are reported for animals, but it is used infrequently, and a full range of drug interactions is not documented. It could potentially increase the effects of ACE inhibitors. Use cautiously with other drugs that may contain potassium or cause potassium retention. Such drugs include trimethoprim.","indications":"Indications and Clinical Uses Triamterene has been used infrequently in veterinary medicine. For treating congestive diseases requiring aldosterone antagonism, spironolactone is the recommended agent. The use of triamterene in animals is derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness or compare the effects to spironolactone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Triamterene can produce hyperkalemia in some patients.","notes":"Instructions for Use There is little clinical experience available for triamterene. There is no convincing evidence that triamterene is more effective in animals than spironolactone. Patient Monitoring and Laboratory Tests Monitor hydration status, serum potassium levels, and renal function. Formulations \u2022\\t\\tTriamterene\\tis\\tavailable\\tin\\t50-\\t\\tand\\t100-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Diuretic"}]},{"category":"Endocrine","drugs":[{"name":"Aglepristone","active_ingredient":"Aglepristone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tTerminate\\tpregnancy:\\tTwo\\tdoses\\tof\\t10\\tmg/kg\\t(0.33\\tmL/kg)\\tSQ\\tonce\\tdaily\\tfor\\t2 days. A Albendazole 15 Cats \u2022\\t\\tTreatment\\tof\\tpyometra:\\t10\\tmg/kg\\tSQ,\\ton\\tdays\\t1,\\t2,\\t7,\\tand\\t14. \u2022\\t\\tTerminate\\tpregnancy\\t(should\\tnot\\tbe\\tused\\tlater\\tthan\\tthe\\tsecond\\ttrimester):\\t10\\tmg/ kg\\tSQ, q24h, for two doses. Can be administered with misoprostol at 200 mcg per cat oral q12h until the abortion begins.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information Do not administer to food- producing animals. Albendazole al- ben \u0301dah- zole Trade and other names: Valbazen","contraindications":"Contraindications and Precautions Aglepristone terminates pregnancy. It should be handled with caution by women. Owners should be cautioned about risks during pregnancy. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Aglepristone has also been used to terminate pregnancy in animals. It has been safe for terminating pregnancy in both dogs and cats. It can also be used to treat mammary hyperplasia in cats, induce parturition in dogs and cats, and treat pyometra. In cats, it was effective to terminate pregnancy when administered with misoprostol. It was more effective in this combination than misoprostol or aglepristone alone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects After termination of pregnancy in dogs, mucoid discharge may be observed. Other side effects include slight depression, transient anorexia, and mammary gland congestion. Otherwise, there have been no significant adverse effects reported in animals.","notes":"Instructions for Use For\\ttreatment\\tof\\tpyometra,\\tit\\tshould\\tbe\\tadministered\\ton\\tdays\\t1,\\t2,\\t7,\\tand\\t14\\tby\\tSQ injection. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAglepristone\\tis\\tnot\\tavailable\\tin\\tthe\\tUnited\\tStates\\tat\\tthis\\ttime.\\tIn\\tsome\\tEuropean countries, it is available as a 30- mg/mL injection. Stability and Storage Store at room temperature protected from light.","original_category":"Hormone, antiprogestin"},{"name":"Altrenogest","active_ingredient":"Altrenogest","species":["Equine"],"dosage":"\u2022\\t\\tNo\\tdose\\tavailable.  Horses \u2022\\t\\t0.044\\tmg/kg\\t(or\\t1\\tmL/110\\tlb)\\tPO\\tonce\\tper\\tday\\tfor\\t15\\tdays. Swine \u2022\\t\\tAdminister\\t6.8\\tmL\\t(15\\tmg\\taltrenogest)\\tper\\tgilt\\tonce\\tdaily\\tfor\\t14\\tconsecutive\\tdays by top dressing on a portion of each gilt\u2019s daily feed. Regulatory Information Do not use in horses intended for food. In pigs, gilts must not be slaughtered for human consumption for 21 days after the last treatment. Do not administer to other food- producing  animals. Aluminum Hydroxide and Aluminum Carbonate ah- loo \u0301mih- num  hye- droks \u0301ide,  ah- loo \u0301mih- num  kar \u0301boe- nate Trade and other names: Aluminum hydroxide gel (Amphojel) and aluminum carbonate gel (Basalgel)","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Humans handling altrenogest, particularly women, should wear gloves and avoid contact because altrenogest can be absorbed in humans through intact skin. Altrenogest should not be used in mares or gilts with a previous history of uterine problems (metritis).","indications":"Indications and Clinical Uses Altrenogest is indicated to suppress estrus in animals to facilitate induction of normal estrous cycle activity. It is used in mares to facilitate scheduled breeding activity. It is also used to suppress estrous behavior in performance horses. When treatment is discontinued, mares exhibiting regular estrous cycles return to estrus within 4\u20135 days after treatment and continue to cycle normally. In swine, altrenogest is used for synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Do not use in gilts having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Precautionary Information","side_effects":"Not specified in source","notes":"Instructions for Use Administer one dose of altrenogest daily for 15 days, orally on grain or directly on the horse\u2019s tongue. In pigs, administer as a top dressing or with feed. Patient Monitoring and Laboratory Tests Monitor for signs of estrous activity. Monitor CBC in cases of overdose. Formulations \u2022\\t\\tAltrenogest\\tis\\tavailable\\tin\\tan\\toil\\tsolution\\tof\\t0.22%\\t(2.2\\tmg/mL). Stability and Storage Store in well- closed containers at room temperature. 26    Aluminum Hydroxide and Aluminum Carbonate","original_category":"Hormone"},{"name":"Boldenone Undecylenate","active_ingredient":"Boldenone Undecylenate","species":["Equine","Feline"],"dosage":"\u2022\\t\\tDoses\\thave\\tnot\\tbeen\\treported\\tfor\\tsmall\\tanimals.  Horses \u2022\\t\\t1.1\\tmg/kg\\tIM.\\tInjection\\tmay\\tbe\\trepeated\\tevery\\t3\\tweeks. Regulatory Information Do not administer to animals intended for food. Schedule III controlled drug. RCI\\tClassification:\\t4 Bromide broe\u2032mide Trade and other names: Potassium bromide and sodium bromide","contraindications":"Contraindications and Precautions This drug is abused by humans to enhance athletic performance and is a controlled substance. Do not administer to animals intended for food. Do not administer to pregnant animals. Drug Interactions There are no significant drug interactions known; however, use cautiously with other drugs that may affect liver function. 90    Bromide","indications":"Indications and Clinical Uses Boldenone is an anabolic agent. It is used primarily in horses to improve nitrogen balance, reduce overexertion associated with exercise, and improve training. It may also improve appetite and improve weight gain when used with a well- balanced diet. Boldenone is a long- lasting agent, and effects may persist for 6 weeks after an IM injection. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects from anabolic steroids can be attributed to the androgenic action of these steroids. Increased masculine effects are common. Increased aggressiveness may be observed. Increased incidence of some tumors has been reported in people, and 17 alpha- methylated oral anabolic steroids (oxymetholone, stanozolol, and oxandrolone) are associated with hepatic toxicity.","notes":"Instructions for Use For many indications, use in animals is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor liver enzymes for signs of hepatic injury (cholestatic) during treatment. Formulations \u2022\\t\\tBoldenone\\tis\\tavailable\\tin\\t25-\\t\\tand\\t50-\\tmg/mL\\tinjection\\tin\\tsesame\\toil. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not\\tfreeze.\\tDo\\tnot\\tmix\\twith\\taqueous\\tsolutions.","original_category":"Hormone, anabolic agent"},{"name":"Carbimazole","active_ingredient":"Carbimazole","species":["Feline","Canine"],"dosage":"Cats \u2022\\t\\t5\\tmg\\tper\\tcat\\tq8h\\t(induction)\\tfollowed\\tby\\t5\\tmg/cat\\tq12h\\tPO.\\tIn\\tEurope,\\tVidalta (a newer sustained- release brand available) induction usually 15 mg once daily, and maintenance dosage ranges between 10 and 25 mg once daily. Dogs \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished\\tfor\\tdogs.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Carboplatin kar- boe- plat\u2032in Trade and other names: Paraplatin and generic","contraindications":"Contraindications and Precautions Do not use in cats with bone marrow suppression or thrombocytopenia. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Carbimazole has been used for treating hyperthyroidism, primarily in cats. Carbimazole has been more readily available in Europe, where there is more clinical experience, than in the United States. Experience in the United States is limited because of lack of availability. Sustained- release formulation in Europe (Vidalta) is administered to people as 15 mg once per day followed by 10\u201325 mg once daily. If switching from methimazole to carbimazole, they are not equivalent. C Carboplatin 127 Precautionary Information","side_effects":"Adverse Reactions and Side Effects In cats, lupus- like reactions are possible, such as vasculitis and bone marrow changes. In people, it has caused agranulocytosis and leukopenia. Other systemic effects reported for methimazole are expected to be similar for carbimazole (e.g., bone marrow effects). See Methimazole for additional information.","notes":"Instructions for Use Carbimazole is used in Europe; clinical experience in the United States is limited. Otherwise, the clinical indications and use are similar as for methimazole. Patient Monitoring and Laboratory Tests Monitor thyroid concentrations to adjust dose. Monitor complete blood count (CBC) periodically for evidence of bone marrow suppression. Formulations \u2022\\t\\tThis\\tdrug\\thas\\tnot\\tbeen\\tapproved\\tin\\tthe\\tUnited\\tStates.\\tThis\\tdrug\\thas\\tbeen\\tobtained in Europe. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is not stable in transdermal compounded formulations.","original_category":"Antithyroid drug"},{"name":"Corticotropin","active_ingredient":"Corticotropin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tACTH\\tresponse\\ttest:\\tCollect\\tpre-\\tACTH\\tsample\\tand\\tinject\\t2.2\\tsamples\\tand\\tinject 2.2 units (IU)/kg IM. Collect post- ACTH sample at 2 hours. Cats \u2022\\t\\tACTH\\tresponse\\ttest:\\tCollect\\tpre-\\tACTH\\tsample\\tand\\tinject\\t2.2\\tunits\\t(IU)/kg\\tIM. Collect post- ACTH sample at 1.5 and 2 hours.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tclearance\\tis\\trapid\\tand\\tthere\\tis\\tlittle\\trisk from residues, no withdrawal time is suggested for food animals. Cosyntropin koe- sin- troe\u2032pin Trade and other names: Cortrosyn, synthetic corticotropin, tetracosactrin, and tetracosactide","contraindications":"Contraindications and Precautions Do not administer IV. Drug Interactions There are no drug interactions reported for small animals.","indications":"Indications and Clinical Uses Adrenocorticotropic hormone is used for diagnostic purposes to evaluate adrenal gland function. Another closely related synthetic product, cosyntropin, is used for the same purpose. The availability of Acthar gel has been limited and is extremely expensive. Therefore, cosyntropin is often used as a substitute (see the Cosyntropin section for more details) and used more frequently. Compounded formulations of corticotropin may not be equivalent. C Cosyntropin 213 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects unlikely when used as a single injection for diagnostic purposes.","notes":"Instructions for Use Doses are established by measuring normal adrenal response in animals. See also Cosyntropin, which is sometimes preferred for clinical use. However, availability and cost of cosyntropin and ACTH are the factors that usually determine which is used in small animals. Patient Monitoring and Laboratory Tests Monitor\\tcortisol\\tconcentrations.\\tPost-\\tACTH\\tcortisol\\tresponse\\tshould\\tbe\\tas\\tfollows: \u2022\\t\\tDogs\\t5.5\u201320.0\\tmcg/dL;\\tgreater\\tthan\\t20\\tmcg/dL\\tis\\tconsistent\\twith hyperadrenocorticism. \u2022\\t\\tCats\\t4.5\u201315\\tmcg/dL;\\tgreater\\tthan\\t15\\tmcg/dL\\tis\\tconsistent\\twith hyperadrenocorticism. After treatment for hyperadrenocorticism (e.g., treatment with mitotane), response should be 1\u20135 mcg/dL. See Trilostane for instructions on monitoring response to trilostane treatment. Formulations \u2022\\t\\tACTH\\tis\\tavailable\\tin\\t80-\\tunits\\t(international\\tunits\\t[IU])/mL\\tgel.\\t(Extremely expensive) Stability and Storage Store in a tightly sealed container protected from light.","original_category":"Hormone"},{"name":"Cosyntropin","active_ingredient":"Cosyntropin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t \\tResponse\\ttest:\\tCollect\\tprecosyntropin\\tsample\\tand\\tinject\\t5\\tmcg/kg\\tIV\\tor\\tIM and collect postsample at 30 and 60 minutes or one sample may be sufficient, collected at 60 minutes. Maximum dose for dogs should be 250 mcg. The following\\tguidelines\\tcan\\tbe\\tused\\tfor\\tdosing:\\tless\\tthan\\t5\\tkg,\\t25\\tmcg;\\t5\u201310\\tkg,\\t50 mcg; 10\u201315 kg, 75 mcg; 15\u201320 kg, 100 mcg; 20\u201325 kg, 125 mcg; 25\u201330 kg, 150 mcg; 30\u201340 kg, 200 mcg; 40\u201350 kg, 225 mcg; and more than 50 kg, 250 mcg (1 vial). \u2022\\t\\tNote:\\t1\\tmcg/kg\\tIV\\thas\\tbeen\\tequivalent\\tas\\t5\\tmcg/kg\\tIV\\tfor\\ta\\tsimilar\\tresponse,\\tbut 5 mcg/kg is still the most often recommended dose. Cats \u2022\\t\\tResponse\\ttest:\\tCollect\\tprecosyntropin\\tsample\\tand\\tinject\\tcosyntropin\\tIV\\tor\\tIM and collect postsample either at 60 or 75 minutes after IV administration or at 30 and 60 minutes after IM administration. A dose of 5 mcg/kg produces an equally effective dose to stimulate a maximal response as a dose of 125 mcg per cat.  Horses \u2022\\t\\t0.1\\tmcg/kg\\tIV\\tproduces\\tmaximum\\tadrenal\\tstimulation,\\twith\\tpeak\\tcortisol concentration\\tin\\t30\u201390\\tminutes.\\tNot\\trecommended\\tas\\ta\\treliable\\ttest\\tin\\thorses. Foals \u2022\\t\\tACTH\\tstimulation\\ttest:\\t0.25\\tmcg/kg\\tIV.\\tPeak\\tcortisol\\toccurs\\tat\\t20\u201330\\tminutes. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tclearance\\tis\\trapid\\tand\\tthere\\tis\\tlittle risk from residues, no withdrawal time is suggested for animals intended for food. 216    Cyanocobalamin Cyanocobalamin sye- ahn- oh- koe- bahl\u2032ah- min Trade and other names: Cobalamin and vitamin B 12","contraindications":"Contraindications and Precautions Maximum dose for dogs should be 250 mcg. Drug Interactions There are no drug interactions reported for small animals.","indications":"Indications and Clinical Uses Cosyntropin is used for diagnostic purposes to evaluate adrenal gland function in dogs, cats, and horses. Maximum peak cortisol secretion occurs at 60\u201390 minutes in dogs, 60\u201375 minutes in cats, and 30 minutes in horses. It is used for the same purpose as corticotropin, but in humans, it is preferred over corticotropin because it is less allergenic. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are unlikely when used as a single injection for diagnostic purposes. In people, cosyntropin is preferred over ACTH gel because cosyntropin is less allergenic.","notes":"Instructions for Use Use for diagnostic purposes only; it is not intended for treatment of hypoadrenocorticism. Cosyntropin is preferred to ACTH gel because it is available in a formulation that is easier to use in dogs and cats. Preference of cosyntropin versus corticotropin gel is often determined by availability and cost. In dogs, cosyntropin has been administered at 5 mcg/kg IV or IM and 250 mcg/dog IM. All three protocols produce similar results, and IM injection produces similar results as IV injection. An IV dose of 1 mcg/kg has produced similar results as 5 mcg/kg IV in dogs. In cats, similar response is observed with 125 mcg per cat, or 5 mcg/kg. In horses, 0.1 mcg/kg IV produced maximum response in 30\u201390 minutes. Compounded formulations of ACTH may produce similar results at 60 minutes postinjection but may have lower cortisol concentrations at 90 and 120 minutes compared with a proprietary formulation. One may split reconstituted Cortrosyn into aliquots of 50 mcg each (250- mcg vial split into 5 aliquots) or 25 mcg each (250- mcg vial split into 10 aliquots) and frozen in plastic syringes. Patient Monitoring and Laboratory Tests Monitor\\tcortisol\\tconcentrations.\\tPost-\\tACTH\\tcortisol\\tresponse\\tshould\\tbe\\tas\\tfollows: Dogs:\\t5.5\u201320.0\\tmcg/dL;\\tgreater\\tthan\\t20\\tmcg/dL\\tis\\tconsistent\\twith hyperadrenocorticism. More specifically, 5.5\u201317 mcg/dL normal, 17\u201325 mcg/dL borderline, 25\u201330 mcg/dL suggestive, and greater than 30 mcg/dL highly likely for hyperadrenocorticism. C If monitoring sex hormones of adrenal origin, a sample for analysis should be taken at 60 minutes after injection. Cats:\\t4.5\u201315\\tmcg/dL;\\tgreater\\tthan\\t15\\tmcg/dL\\tis\\tconsistent\\twith hyperadrenocorticism. After treatment for hyperadrenocorticism (e.g., treatment with mitotane), response should be 1\u20135 mcg/dL. Formulations \u2022\\t\\tCosyntropin\\tis\\tavailable\\tin\\t250\\tmcg\\tper\\tvial.\\tThe\\tlyophilized\\tpowder\\tis reconstituted with 1 mL of saline in 2- mL vials for a final concentration of 250 mcg/mL. Stability and Storage Once prepared, this formulation can be kept in the refrigerator for 4 months. Frozen\\tcosyntropin\\tcan\\tbe\\tstored\\tin\\tplastic\\tsyringes\\tas\\tindividual\\tdose\\taliquots for\\textended\\tperiods.\\tFor\\texample,\\ta\\t250-\\tmcg\\t1-\\t   mL\\tdose\\tcan\\tbe\\tstored\\tin small plastic syringes and frozen at \u201320\xb0C for up to 6 months or kept in the refrigerator for 4 months. When needed, the 250- mcg aliquot can be added to 24 mL of sterile saline for injection for a final concentration of 10 mcg/mL. Some compounded formulations are stable and have produced reliable results at the 60- minute sample but may be lower at the 120- minute sample compared with the proprietary preparation.","original_category":"Hormone"},{"name":"Danazol","active_ingredient":"Danazol","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t5\u201310\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Danazol is an anabolic agent and should not be administered to animals intended for food. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t4 Danofloxacin Mesylate dan- oh- floks \u0301ah- sin  mess \u0301ih- late Trade and other names: Advocin (A180 is former name)","contraindications":"Contraindications and Precautions It is absolutely contraindicated in pregnancy. Drug Interactions It has been used with other drugs in the treatment of immune- mediated diseases without reported interactions. D Danofloxacin Mesylate 231","indications":"Indications and Clinical Uses Danazol has hormone effects (antiestrogen) that are used for endometriosis in women. Danazol (Danocrine) also has been used for treating refractory patients with immune- mediated thrombocytopenia and immune- mediated hemolytic anemia. However,\\tavailable\\tevidence\\tdoes\\tnot\\tshow\\ta\\tbenefit\\tin\\tdogs\\twhen\\tit\\thas\\tbeen\\tused\\tto treat immune- mediated hemolytic anemia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Danazol\u2019s\\tandrogenic\\teffects\\tshould\\tbe\\tconsidered\\tin\\ttreated\\tanimals.\\tHowever, adverse effects have not been reported in animals.","notes":"Instructions for Use When\\tused\\tto\\ttreat\\tautoimmune\\tdisease,\\tit\\tis\\tusually\\tused\\tin\\tconjunction\\twith\\tother drugs (e.g., corticosteroids). Patient Monitoring and Laboratory Tests Monitor CBC if used for treatment of immune- mediated diseases. Formulations \u2022\\t\\tDanazol\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\tand\\t200-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Darbepoetin Alfa","active_ingredient":"Darbepoetin Alfa","species":["Feline","Canine","Equine"],"dosage":"cats,\\tat\\ta\\tdosage\\tof\\t1\\tmcg/kg\\tper\\tweek\\tor\\thigher.\\tFor\\tcomparison,\\tthe\\ttypical\\tdosage in\\tpeople\\tis\\t2.25\\tmcg/kg\\tonce\\tevery\\t3\\tweeks\\tor\\ta\\tdosage\\tof\\t0.45\u20130.75\\tmcg/kg\\tper week. When switching from the use of erythropoietin (epoetin alpha) to darbepoetin, a conversion\\tfor\\ttreatment\\tis:\\t400\\tunits/wk\\tof\\tepoetin\\t=\\t1\\tmcg/kg\\tdarbepoetin. Precautionary Information  Dogs \u2022\\t\\tStart\\twith\\t0.5\\tmcg/kg\\tevery\\t7\\tdays\\tinjected\\tSQ.\\tAfter\\tinitial\\tevaluation,\\tincrease the\\tdosage\\tto\\t0.8\\tmcg/kg\\tonce\\tper\\tweek\\tif\\tneeded;\\tthen\\tincrease\\tor\\tdecrease\\tthe dosage\\tas\\tneeded\\tby\\tmonitoring\\tthe\\tpatient\u2019s\\tPCV. Cats \u2022\\t\\tStart\\twith\\t1\\tmcg/kg\\tonce\\tper\\tweek,\\tinjected\\tSQ,\\tuntil\\tthe\\ttarget\\tPCV\\tis\\tachieved. Then\\tthe\\tfrequency\\tcan\\tbe\\tdecreased\\tto\\tevery\\t2-\\t\\tto\\t3-\\tweek\\tintervals.\\tTypically,\\tthe expected\\tresponse\\tis\\ta\\tPCV\\tof\\t25%\u201335%.  No large animal doses are reported. Regulatory Information No withdrawal times are established for food animals. Erythropoietin or derivatives in any form are prohibited to be on the premises of racing horses. RCI\\tClassification:\\t2 Deferoxamine Mesylate deh- fer- oks \u0301ah- meen  mess \u0301ih- late Trade and other names: Desferal","contraindications":"Contraindications and Precautions Do not shake vial vigorously. Do not dilute with other fluids or solutions. Do not use\\tif\\tcloudy.\\tStop\\ttherapy\\tif\\tjoint\\tpain,\\tfever,\\tanorexia,\\tor\\tcutaneous\\treactions\\tare observed.\\tRotate\\tsites\\tof\\tinjection\\tto\\tavoid\\treactions. Drug Interactions No interactions are reported.","indications":"Indications and Clinical Uses Darbepoetin alfa is used to treat nonregenerative anemia. It has been used to treat myelosuppression caused by disease or chemotherapy. It has been used in people to treat anemia associated with chronic kidney disease (CKD) and has been used for this purpose in dogs and cats with CKD. It has been an effective treatment for anemia secondary to CKD in dogs with most dogs achieving a goal of greater than 30% improvement in the packed cell volume (PCV). It also has been effective for this use in","side_effects":"Adverse Reactions and Side Effects Injection-\\tsite\\tpain\\tand\\theadache\\thave\\toccurred\\tin\\tpeople.\\tAdverse\\teffects\\thave included\\tiron\\t  deficiency,\\thypertension,\\tjoint\\t  pain\\t  (arthralgia),\\tgastrointestinal\\t(GI) disturbance, and polycythemia. Because this product is a human- recombinant product,\\tit\\tmay\\tinduce\\tlocal\\tand\\tsystemic\\tallergic\\treactions\\tin\\tanimals.\\tHuman erythropoietin products can cause red cell aplasia caused by neutralizing anti- erythropoietin antibodies that cross- react with other forms of erythropoietin. This is less likely with darbepoetin than epoetin. The feline erythropoietin is 83% homologous to human erythropoietin. Increased red cell aplasia may occur in animals\\twhen\\tthere\\tis\\tless\\tthan\\t100% homology. Pure red cell aplasia (PRCA) in\\tcats\\twas\\t25%\u201330%\\twith\\tepoetin\\tcompared\\twith\\tonly\\t8%\\twith\\tdarbepoetin. Reported adverse reactions in cats and dogs included vomiting, hypertension, seizures, fevers, and PRCA. Adverse effects in dogs included hypertension, seizures, hyperkalemia (which may be caused by other drugs), and PRCA.","notes":"Instructions for Use The use of darbepoetin has been primarily in cats and dogs with anemia caused by CKD. It is preferred over epoetin alpha for this use. Iron supplementation is recommended when used in cats and dogs. By improving anemia, it may increase survival in animals with\\tCKD\\tand\\timprove\\tquality\\tof\\tlife.\\tAn\\timportant\\tadverse\\teffect\\tthat\\tmay\\tlimit\\tthe\\tuse in animals is PRCA, which is described in the Adverse Reaction section. The doses listed in the dosing section are based on initial treatment. This treatment may be initiated with once-\\t  weekly\\tinjections\\tfor\\t3\u20134\\tweeks\\tuntil\\tthe\\tdesired\\tPCV\\thas\\tstabilized.\\tThereafter,\\tthe interval\\tbetween\\tdoses\\tmay\\tbe\\tincreased,\\tbut\\tthis\\tshould\\tnot\\tbe\\tlonger\\tthan\\t21\\tdays. Patient Monitoring and Laboratory Tests Monitor\\thematocrit.\\tThe\\tdose\\tshould\\tbe\\tadjusted\\tto\\tmaintain\\thematocrit\\tin\\ta range\\tof\\t25%\u201335%.\\tBecause\\tdarbepoetin\\tcan\\tcause\\thypertension,\\tmonitor\\tblood pressure in treated animals. An increase may indicate a need for an increase in the antihypertensive drug dose. 238    Deferoxamine Mesylate Formulations Available Darbepoetin\\talfa\\tis\\tavailable\\tin\\ta\\tvariety\\tof\\tinjectable\\tsolution\\tconcentrations, including:\\t25,\\t40,\\t60,\\t100,\\t200,\\t300,\\tand\\t500\\tmcg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not freeze. Do not mix with other solutions or fluids.","original_category":"Hormone"},{"name":"Desmopressin Acetate","active_ingredient":"Desmopressin Acetate","species":["Canine"],"dosage":"\u2022\\t\\tDI:\\t2\u20134\\tdrops\\t(2\\tmcg)\\tq12\u201324h\\tintranasally\\tor\\tin\\teye.\\tAlternatively,\\t0.5\u20132\\tmcg/ dog\\tq12\u201324h\\tIV\\tor\\tSQ. \u2022\\t\\tOral\\tdosage:\\t0.05\u20130.1\\tmcg/kg\\tq12h\\tor\\tas\\tneeded.\\tThe\\toral\\tdose\\tmay\\tbe\\tincreased to\\t0.1\u20130.2\\tmcg/kg\\tas\\tneeded.\\tAlternatively,\\tadminister\\t0.1\\tmg\\t(total\\tdose)\\tper dog\\tPO\\tthree\\ttimes\\tdaily\\tand\\tadjust\\tdose\\tto\\tcontrol\\tclinical\\tsigns\\t(polyuria\\tand polydipsia).\\tIf\\tthis\\tdose\\tis\\tsuccessful,\\tdecrease\\tfrequency\\tto\\ttwice\\tdaily. \u2022\\t\\tvon\\tWillebrand\u2019s\\tdisease\\ttreatment:\\t1\\tmcg/kg\\t(0.01\\tmL/kg)\\tadministered\\tSQ\\tor diluted\\tin\\t20\\tmL\\tof\\tsaline\\tand\\tadministered\\tover\\t10\\tmin\\tIV.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\tthis\\tdrug\\thas\\trapid\\tclearance,\\twith\\tlittle risk from residues; therefore, a short withdrawal time is suggested for food animals. D Desoxycorticosterone Pivalate 243 Desoxycorticosterone Pivalate dess- oks- ih- kor- tik- oh- steer \u0301one  piv \u0301ah- late Trade and other names: Percorten- V, DOCP, Zycortal, and DOCA pivalate","contraindications":"Contraindications and Precautions There are no specific contraindications. Drug Interactions Administration of urea and fludrocortisone will increase the antidiuretic effects.","indications":"Indications and Clinical Uses Desmopressin is used as replacement therapy for patients with DI and has been used for\\ttreatment\\tof\\tpatients\\twith\\tmild\\tto\\tmoderate\\tvon\\tWillebrand\u2019s\\tdisease\\tprior\\tto surgery\\tor\\tanother\\tprocedure\\tthat\\tmay\\tcause\\tbleeding.\\tHowever,\\tthe\\tresponse\\tin\\tvon Willebrand\u2013deficient\\tdogs\\tis\\tnot\\tas\\tconsistent\\tor\\tas\\tgreat\\tas\\tin\\tpeople. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No side effects reported. In people, it has rarely caused thrombotic events.","notes":"Instructions for Use Desmopressin is used only for central forms of DI. Duration of effect is variable (8\u201320\\thours)\\tbut\\ttypically\\thas\\ta\\tduration\\tof\\t8\u201312\\thours.\\tIt\\tis\\tineffective\\tfor\\ttreatment of nephrogenic DI or polyuria from other causes. Intranasal product has been administered\\tas\\teye\\tdrops\\tin\\tdogs.\\tOnset\\tof\\teffect\\tis\\twithin\\t1\\thour.\\tOral\\ttablets\\tare available for humans, but the effects of oral tablets in dogs have not been reported, and the use is extrapolated from the human label. Patient Monitoring and Laboratory Tests Monitor water intake and urinalysis to assess therapy. Desmopressin may be used as a test for DI\\tin\\tanimals.\\tTo\\tperform\\tthis\\ttest,\\tadminister\\t2\\tmcg/kg\\tSQ\\tor\\tIV\\tor\\t20\\tmcg\\tintranasally or in the eye. This should be followed by the monitoring of urine concentration and the animal\u2019s\\tbody\\tweight.\\tIncrease\\tin\\turine-\\tconcentrating\\tability\\tmay\\tindicate\\ta\\tdiagnosis\\tof\\tDI. Formulations \u2022\\t\\tDesmopressin\\tis\\tavailable\\tin\\ta\\t4-\\tmcg/mL\\tinjection,\\tacetate\\tnasal\\tsolution\\t100- mcg/mL\\t(0.01%)\\tmetered\\tspray,\\tand\\t0.1-\\t\\tand\\t0.2-\\tmg\\ttablets\\t(scored). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Diethylstilbestrol","active_ingredient":"Diethylstilbestrol","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tDose\\tranges\\tfrom\\t0.1\u20131\\tmg\\tper\\tdog\\tq24h\\tPO.\\tThe\\tsize\\tof\\tthe\\tdose\\tis\\tproportional to\\tsize\\tof\\tthe\\tdog.\\tContinue\\tdaily\\tdose\\tfor\\t5\\tdays;\\tthen\\treduce\\tfrequency\\tof administration to two or three times per week. Cats \u2022\\t\\t0.05\u20130.1\\tmg/cat\\tq24h\\tPO.  \u2022\\t\\tNo\\tdose\\tis\\tavailable\\tfor\\tlarge\\tanimals.\\tUse\\tin\\tanimals\\tintended\\tfor\\tfood\\tis prohibited. Regulatory Information Administering DES to animals that produce food is prohibited. Difloxacin Hydrochloride dye- floks \u0301ah- sin  hye- droe- klor \u0301ide Trade and other names: Dicural","contraindications":"Contraindications and Precautions Diethylstilbestrol has been associated with the development of cancer, and human exposure should be minimized as much as possible. This drug is no longer used in people for estrogen replacement and is prohibited in food animals. Although not reported as a significant clinical problem with DES, problems with anemia have occurred with administration of high doses of other estrogens to animals. Drug Interactions No\\tsignificant\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tfor\\tanimals.\\tHowever,\\tin people, administration of estrogens increases thyroid- binding globulin and may decrease the active form of thyroid hormone (tetraiodothyronine [T 4 ]) in patients receiving thyroid supplementation.","indications":"Indications and Clinical Uses Diethylstilbestrol is most commonly used to treat estrogen- responsive incontinence in dogs. Phenylpropanolamine (PPA) has been used in dogs when DES therapy is no longer effective. DES also has been used to induce abortion in dogs. Commercial forms of DES are no longer available, but it is available through some compounding pharmacies.\\tConjugated\\testrogens\\t(e.g.,\\tPremarin\\tat\\t20\\tmcg/kg\\ttwice\\tweekly)\\thave been used in some dogs when DES or other estrogens have been unavailable. In addition, there is an approved form of estriol for dogs (Incurin) that can be used instead of DES for treatment of incontinence in female dogs (see Estriol for more details). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects attributed to excess estrogen may occur. Estrogen therapy may increase risk of pyometra and estrogen- sensitive tumors. Although bone marrow depression (particularly anemia) has been reported from administration of other estrogens in dogs and has been cited as a potential risk, it is a rare complication of DES therapy.","notes":"Instructions for Use Doses listed are for treating urinary incontinence and vary depending on response. Titrate\\tdose\\tto\\tindividual\\tpatient\u2019s\\tresponse.\\tAlthough\\tused\\tto\\tinduce\\tabortion,\\tit\\twas not\\tefficacious\\tin\\tone\\tstudy\\tthat\\tadministered\\t75\\tmcg/kg. Patient Monitoring and Laboratory Tests Monitor CBC to detect signs of bone marrow toxicity. Monitor T 4 levels if patients are hypothyroid and receiving supplementation. Formulations \u2022\\t\\tDES\\thas\\tbeen\\tavailable\\tin\\t1-\\t\\tand\\t5-\\tmg\\ttablets\\tand\\t50-\\tmg/mL\\tinjection.\\tDES is no longer marketed commercially in the United States, but it is available from compounding pharmacies. D Difloxacin Hydrochloride 271 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability\\tof\\tcompounded\\tformulations\\thas\\tnot\\tbeen\\treported.\\tHowever,\\tcompounded tablets are available from compounding pharmacies, and anecdotal information indicates that they are effective.","original_category":"Hormone"},{"name":"RCI\\tClassification:\\t2","active_ingredient":"RCI\\tClassification:\\t2","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t35\\tor\\t50\\tunits/kg\\tthree\\ttimes\\ta\\tweek,\\tup\\tto\\t400\\tunits/kg/wk\\tSQ\\t(adjust\\tdose\\tto maintain\\thematocrit\\tof\\t30%\u201334%). Cats \u2022\\t\\tStart\\twith\\t100\\tunits/kg\\tSQ\\tthree\\ttimes\\tweekly;\\treduce\\tto\\ttwice\\tweekly\\tand\\tthen to\\tonce\\tweekly\\twhen\\ttarget\\thematocrit\\tof\\t30%\u201340%\\tis\\tattained.\\tIn\\tmost\\tcats, maintenance\\tdosage\\tis\\t75\u2013100\\tunits/kg\\tSQ\\ttwice\\tweekly.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. E Eprinomectin 333 Regulatory Information No withdrawal times are established for food animals. Erythropoietin in any form is prohibited to be on the premises of racing horses. Eprinomectin e- prin- o- mek \u0301tin Trade and other names: Eprinex, LongRange, Eprizero, and Centragard","contraindications":"Contraindications and Precautions Stop therapy with epoetin when joint pain, fever, anorexia, or cutaneous reactions are observed. Drug Interactions No interactions are reported.","indications":"Indications and Clinical Uses Epoetin alfa is used to treat nonregenerative anemia. It has been used to treat myelosuppression caused by disease or chemotherapy. It also has been used to treat chronic anemia associated with chronic renal failure. The value of epoetin alpha to improve anemia in cats with chronic renal failure has been established in several studies. 332    Epoetin Alfa (Erythropoietin) In some animals, anemia is also caused by iron deficiency and can be combined with ferrous\\tsulfate\\tat\\ta\\tdose\\tof\\t50\u2013100\\tmg\\tper\\tcat\\tdaily.\\tDarbepoetin\\talfa\\t(Aranesp),\\ta similar drug, also has been used in small animals (see Darbepoetin Alfa). Because of several advantages, many experts now prefer darbepoetin instead of epoetin alfa. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Because\\tthis\\tproduct\\tis\\ta\\thuman-\\trecombinant\\tproduct,\\tit\\tmay\\tinduce\\tlocal\\tand systemic\\tallergic\\treactions\\tin\\tanimals.\\tInjection-\\tsite\\tpain\\tand\\theadache\\thave occurred in people. Seizures also have occurred. Delayed anemia may occur because\\tof\\tcross-\\treacting\\tantibodies\\tagainst\\tanimal\\terythropoietin\\t(reversible\\twhen drug\\tis\\twithdrawn).\\tAntiepoetin\\tantibodies\\tmay\\tincrease\\twith\\tlong-\\tterm\\tuse, which\\tmay\\toccur\\tin\\tas\\thigh\\tas\\t30%\\tof\\ttreated\\tcats,\\tleading\\tto\\tfailure\\tof\\ttreatment.","notes":"Instructions for Use The use of epoetin alfa has been limited primarily to dogs and cats. The only form currently\\tavailable\\tis\\ta\\thuman-\\trecombinant\\tproduct.\\tIt\\tis\\tused\\tin\\tanimals\\twhen hematocrit\\tfalls\\tbelow\\t25%.\\tIn\\tcats,\\t100\\tunits/kg\\tSQ\\tthree\\ttimes\\ta\\tweek\\tis\\tadministered until\\ta\\ttarget\\thematocrit\\tof\\t30%\u201340%\\tis\\tattained.\\tThereafter,\\ttwice-\\tweekly\\tinjections\\tare used.\\tMaintenance\\tdose\\tis\\tusually\\tin\\ta\\trange\\tof\\t75\u2013100\\tunits/kg\\tSQ\\tonce\\tor\\ttwice\\ta week.\\tConsider\\tswitching\\tto\\tdarbepoetin\\tif\\tlong-\\tterm\\tuse\\tis\\tneeded. Patient Monitoring and Laboratory Tests Monitor hematocrit. Dose should be adjusted to maintain hematocrit in a range of 30%\u201334%. Formulations Available \u2022\\t\\tEpoetin\\talfa\\tis\\tavailable\\tin\\ta\\trange\\tof\\tstrengths,\\tincluding\\t2000-\\t,\\t3000-\\t   ,\\t4000-\\t   , 10,000-\\t,\\t20,000-\\t,\\tand\\t40,000-\\tunits/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Estradiol Cypionate","active_ingredient":"Estradiol Cypionate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t22\u201344\\tmcg/kg\\tIM\\t(total\\tdose\\tnot\\tto exceed\\t1\\tmg). Cats \u2022\\t\\t250\\tmcg/cat\\tIM,\\tbetween\\t40\\thours and\\t5\\tdays\\tof\\tmating.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do\\tnot\\tuse\\tin\\tfood-\\tproducing\\tanimals. Estriol ess- tree- ole Trade and other names: Incurin and Theelol (previously called Oestriol)","contraindications":"Contraindications and Precautions Estradiol is contraindicated in pregnancy unless used to terminate pregnancy. Do not administer to ferrets. Do not administer to animals unless careful monitoring of complete blood count (CBC) is possible. Drug Interactions No drug interactions are reported for animals. It should not be used with other drugs that may suppress the bone marrow. In people, it has been recommended that these estrogen compounds should not be used with other drugs that may cause hepatotoxicity. Estradiol may increase cyclosporine concentrations.","indications":"Indications and Clinical Uses The most common use in small animals has been to terminate pregnancy. The estradiol\\tcypionate\\tformulation\\twas\\thighly\\teffective\\tto\\tterminate\\tpregnancy\\t(95%)\\tbut was associated with serious adverse effects and is no longer recommended. Estradiol cypionate is longer acting and more potent than other estrogen formulations. Estradiol\\tvalerate\\tinjection\\t(20\\tmg/mL)\\tis\\talso\\tavailable\\tfor\\thuman\\tmedicine\\tto\\ttreat hypoestrogenism. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Estradiol\\thas\\ta\\thigh\\trisk\\tof\\tcausing\\tendometrial\\thyperplasia\\tand\\tpyometra.\\tThere is\\ta\\tdose-\\tdependent\\trisk\\tof\\tbone\\tmarrow\\ttoxicity\\tin\\tanimals,\\tparticularly\\tin\\tdogs. Estradiol\\tcypionate\\tinjections\\thave\\tproduced\\tleukopenia,\\tthrombocytopenia,\\tand fatal aplastic anemia. Because stem cells can be affected, the bone marrow toxicity may not be reversible. These adverse effects can be severe, and other agents should be used instead of estradiol cypionate if possible.","notes":"Instructions for Use To\\tterminate\\tpregnancy,\\t22\\tmcg/kg\\tis\\tadministered\\tonce\\tIM\\tduring\\tdays\\t3\u20135\\tof estrus\\tor\\twithin\\t3\\tdays\\tof\\tmating.\\tHowever,\\tin\\tone\\tstudy,\\ta\\tdose\\tof\\t44\\tmcg/kg\\twas more\\tefficacious\\tthan\\ta\\tdose\\tof\\t22\\tmcg/kg\\twhen\\tgiven\\tduring\\testrus\\tor\\tdiestrus. Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow suppression. Formulations \u2022\\t\\tEstradiol\\tis\\tavailable\\tin\\ta\\t2-\\tmg/mL\\tinjection.\\tEstradiol\\tvalerate\\tis\\tavailable\\tas\\ta\\t20- mg/mL\\tinjection\\tin\\t5-\\tmL\\tvials. 346    Estriol Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Estriol","active_ingredient":"Estriol","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2\\tmg\\tper\\tdog\\tPO\\tq24h\\t(may\\tbe\\tcombined\\twith\\tPPA).\\tAfter\\tstarting\\twith\\t2\\tmg\\tper dog\\tper\\tday,\\tafter\\t1\\tweek,\\treduce\\tdose\\tto\\t1.5\\tmg\\tper\\tdog\\tper\\tday\\tfor\\t1\\tweek,\\tthen 1\\tmg\\tper\\tdog\\tper\\tday\\tfor\\t1\\tweek,\\tand\\ta\\tgradually\\ttapered\\tregimen\\tand\\tincreased interval\\t(every\\tother\\tday,\\tevery\\tthird\\tday,\\tand\\tso\\ton)\\tuntil\\ta\\tgoal\\tof\\t0.5\\tmg\\tper\\tdog once\\tper\\tweek\\tis\\tachieved. Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do\\tnot\\tuse\\tin\\tfood-\\tproducing\\tanimals. Etidronate Disodium eh- tih- droe \u0301nate  dye- soe \u0301dee- um Trade and other names: Didronel","contraindications":"Contraindications and Precautions Estriol is contraindicated in pregnancy. Do not administer to ferrets. Drug Interactions No drug interactions are reported for animals. It should not be used with other drugs that may suppress the bone marrow. In people, it has been recommended that these estrogen compounds not be used with other drugs that may cause hepatotoxicity, but such an interaction has not been shown in dogs for estriol. E Etidronate Disodium 347","indications":"Indications and Clinical Uses Estriol is an estrogen replacement. In small animals, it has most often been used to treat urinary incontinence that is associated with estrogen deficiency in female dogs. This problem is most common in dogs that have undergone ovariohysterectomy. An advantage of estriol is that one tablet can be used to treat all sizes of dogs, and if they respond to initial dosing, the frequency of administration can be tapered to the lowest effective level. Another approved drug for treating urinary incontinence in dogs is phenylpropanolamine (PPA) (see Phenylpropanolamine). It may be used instead of or concurrently with estriol. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In field studies, the most common adverse effects were loss of appetite, vomiting, excessive\\twater\\tdrinking,\\tand\\tswollen\\tvulva.\\tEstriol\\thas\\tnot\\tbeen\\tassociated\\twith pyometra or bone marrow suppression compared with estradiol.","notes":"Instructions for Use To\\ttreat\\turinary\\tincontinence,\\tit\\thas\\tbeen\\tused\\tin\\tcombination\\twith\\tPPA;\\thowever, the addition of PPA to the treatment regimen may not improve efficacy compared to estrogen drugs used alone. Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow suppression. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Finasteride","active_ingredient":"Finasteride","species":["Canine"],"dosage":"\u2022\\t\\t0.1\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tDogs\\t10\u201350\\tkg:\\t5-\\tmg\\ttablet\\tper\\tdog\\tq24h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No withdrawal times are established. Do not use in animals intended for food. Firocoxib feer- oh- koks\u2032ib Trade and other names: Previcox and Equioxx","contraindications":"Contraindications and Precautions Finasteride is contraindicated in pregnant animals. Drug Interactions No drug interactions are reported for animals. Finasteride may be used with smooth muscle relaxants that are intended to relax prostate and urethral smooth muscle to improve urine flow. Such drugs include tamsulosin, which is an antagonist of alpha 1A - adrenoreceptors in the prostate smooth muscle.","indications":"Indications and Clinical Uses Because DHT stimulates prostate growth, finasteride has been used for benign prostatic hypertrophy (BPH). In dogs with BPH, finasteride has been shown to reduce prostatic size without adversely affecting testosterone production or semen quality. It may be used concurrently with tamsulosin, an antagonist of alpha 1A - adrenoreceptors in the prostate smooth muscle to improve urine flow. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects have been reported in dogs.","notes":"Instructions for Use Doses are based on clinical studies in dogs, and information for other animals has not been reported. One study in dogs found significant effects at 0.1 mg/kg q24h. Another study used a dosage range of 0.1\u20130.5 mg/kg q24h and reported reduction in prostate size. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tFinasteride\\tis\\tavailable\\tin\\t1-\\t\\tand\\t5-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. 368    Firocoxib","original_category":"Hormone antagonist"},{"name":"Tetrahydrate","active_ingredient":"Tetrahydrate","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t50\u2013100\\tmcg/dog/day\\tq24\u201348h\\tIM. Cats \u2022\\t\\t25\\tmcg/cat\\tonce\\tIM.  Cattle \u2022\\t\\t100\\tmcg/cow\\tIM\\tor\\tIV\\tonce\\t(equivalent\\tto\\tapproximately\\t2\\tmL\\tper\\tcow\\tfor gonadorelin diacetate tetrahydrate). In lactating dairy cows, 100\u2013200 mcg/cow (2\u20134 mL) IM may be used. Regulatory Information No withdrawal times are necessary (zero days). Gonadotropin, Chorionic go- nad- o- tro\u2032pin,  kor- ee- ahn\u2032ik Trade and other names: Profasi, Pregnyl, A.P.L., Follutein, Ferti- Cept, Chortropin, Chorulon, and Improvest","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Extreme care should be used by people, particularly women, handling this medication. Human exposure may pose a risk to pregnant women. Drug Interactions No drug interactions in animals are reported. G Gonadotropin, Chorionic 415","indications":"Indications and Clinical Uses Gonadorelin is used to induce luteinization and ovulation in animals. Gonadotropin has been used to manage various reproductive disorders in which stimulation of ovulation is desired. The use is mostly confined to large animals. In dairy cattle, it is used to treat ovarian follicular cysts. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals, but effects are possible because of excessive effects from LH.","notes":"Instructions for Use For treatment of dairy cattle, with the diacetate tetrahydrate form, administer 100 mcg per cow as a single IM or IV injection for treatment of ovarian cysts. For the hydrochloride formulation, administer 100 mcg IM for the treatment of cystic ovaries (ovarian follicular cysts) in cattle to reduce the time to first estrus. In dairy cows, it may be used with dinoprost tromethamine or cloprostenol injection to synchronize estrous cycles to allow fixed- time artificial insemination in lactating dairy cows. Patient Monitoring and Laboratory Tests Monitor treated cattle for ovulation. Formulations \u2022\\t\\tGonadorelin\\tis\\tavailable\\tin\\t50-\\tmcg\\tgonadorelin\\tdiacetate\\ttetrahydrate\\tper milliliter (equivalent to 43 mcg/mL of gonadorelin) or 50- mcg gonadorelin (as hydrochloride) in aqueous solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Gonadotropin, Chorionic","active_ingredient":"Gonadotropin, Chorionic","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t22\\tunits/kg\\tq24\u201348h\\tIM\\tor\\t44\\tunits\\tonce\\tIM. Cats \u2022\\t\\t250\\tunits/cat\\tonce\\tIM.  Horses \u2022\\t\\tOvulation\\tinduction:\\t2500\u20135000\\tunits\\tper\\tmare\\tIM\\tor\\tIV. Cattle (Cows) \u2022\\t\\t10,000\\tunits\\tas\\ta\\tsingle,\\tdeep\\tIM\\tinjection;\\t500\u20132500\\tunits\\tfor\\tintrafollicular injection; 2500\u20135000 units IV. G Granisetron Hydrochloride 417 Pigs (Sows) \u2022\\t\\tConditions\\tof\\tuse:\\t400\\tunits\\tof\\tserum\\tgonadotropin\\twith\\t200\\tunits\\tof\\tchorionic gonadotropin per 5 mL dose per animal SQ. Regulatory Information No regulatory information is available for food animals. A tolerance for residues of gonadotropin in uncooked edible tissues of cattle or of fish is not required. Because of low risk of residues, no withdrawal times are suggested. Granisetron Hydrochloride grah- nih\u2032seh- tron  hye- droe- klor\u2032ide Trade and other names: Kytril","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Extreme care should be used by people, particularly women, handling this medication. Human exposure may pose a risk to pregnant women. Drug Interactions No specific drug interactions are reported.","indications":"Indications and Clinical Uses Gonadotropin is used to induce luteinization in animals. It has been used to manage various reproductive disorders when stimulation of ovulation is desired. Most of the use has been in large animals, but there are some conditions treated in dogs and cats in which stimulation of luteinization is necessary. In cows, it is used for treatment of nymphomania (frequent or constant heat) caused by cystic ovaries. In pigs, it is used for induction of fertile estrus (heat) in prepuberal (noncycling) gilts or for induction of estrus in healthy weaned sows experiencing delayed return to estrus. It is also used in pigs for the temporary immunologic castration (suppression of testicular function) and reduction of boar taint in intact male pigs intended for slaughter. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals.","notes":"Instructions for Use When used in horses, most ovulate 32\u201340 hours after treatment. In cows, it may be repeated in 14 days if the animal\u2019s behavior or rectal examination of the ovaries indicates the necessity for re- treatment. In pigs, use only in gilts older than 5\xbd months that weigh at least 85 kg (185 lb). Delayed return to estrus is most prevalent after the first litter. The effectiveness has not been established after later litters. Delayed return to estrus often occurs after periods of adverse environmental conditions, and sows mated after such conditions may farrow smaller than normal litters. Patient Monitoring and Laboratory Tests Monitor treated patients for signs of luteinization and estrus. Formulations \u2022\\t\\thCG\\tand\\tthe\\tcattle\\tformulation\\tis\\tavailable\\tin\\t5000-\\t,\\t10,000-\\t,\\tand\\t20,000-\\tunit vials for injection to be diluted in 10 mL of diluent. The swine formulation consists of 400 units of serum gonadotropin and 200 of chorionic gonadotropin as a freeze- dried powder to be reconstituted with 5 mL of sterile aqueous diluent. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Growth Hormone","active_ingredient":"Growth Hormone","species":["Canine","Feline"],"dosage":"Dogs and cats \u2022\\t\\t0.1\\tunits/kg\\tthree\\ttimes\\ta\\tweek\\tfor\\t4\u20136\\tweeks\\tSQ\\tor\\tIM.\\t(Usual\\thuman\\tpediatric dosage is 0.18\u20130.3 mg/kg/week SQ or IM.)  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals that produce food. Guaifenesin gwye- fen\u2032eh- sin Trade and other names: Glyceryl guaiacolate, Guaiphenesin, Gecolate, Guailaxin, Glycotuss, Hytuss, Glytuss, Fenesin, Humibid LA, and Mucinex","contraindications":"Contraindications and Precautions Except for diabetes, there are no other contraindications reported in animals. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Growth hormone is used to treat growth hormone deficiencies, but this use is rare in veterinary medicine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Growth hormone is diabetogenic in all animals. Excess growth hormone causes acromegaly.","notes":"Instructions for Use There is only limited clinical experience in animals. Dose form must be reconstituted with sterile diluent before use. Patient Monitoring and Laboratory Tests Monitor glucose periodically during treatment. Formulations \u2022\\t\\tGrowth\\thormone\\tis\\tavailable\\tin\\t5-\\t\\tand\\t10-\\tmg/vial\\t(1\\tmg\\tis\\tequal\\tto\\t3\\tunits). Stability and Storage Prepared\\tsolution\\tis\\tstable\\tif\\trefrigerated\\tfor\\t14\\tdays.\\tOtherwise,\\tit\\tis\\tstable\\tfor\\tonly 24 hours. G Guaifenesin 423","original_category":"Hormone"},{"name":"Insulin","active_ingredient":"Insulin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tShort-\\t   acting\\tregular\\tinsulin.\\tTreatment\\tof\\tketoacidosis\\tfor\\tdogs\\tweighing\\tless\\tthan 3 kg: 1 unit/animal initially; then 1 unit/animal q1h. For dogs 3\u201310 kg: 2 units/ animal initially; then 1 unit/animal q1h. For dogs weighing more than 10 kg: 0.25 unit/kg initially; then 0.1 unit/kg q1h IM. \u2022\\t\\tNPH\\tfor\\tdogs\\tweighing\\tless\\tthan\\t15\\tkg:\\t1\\tunit/kg\\tq12\u201324h\\tSQ\\t(adjust\\tdose\\twith monitoring); for dogs weighing more than 25\\tkg:\\t0.5\\tunit/kg\\tq12\u201324h\\tSQ\\t(adjust dose with monitoring). \u2022\\t\\tVetsulin:\\tInitial\\tdosage\\tis\\t0.5\\tunit/kg\\tonce\\tor\\ttwice\\tdaily\\tSQ.\\tAdjust\\tdose\\t(increase or decrease of 25% of dose) by monitoring. \u2022\\t\\tPZI\\thuman\\trecombinant:\\tCan\\tbe\\tused\\tas\\tan\\talternative\\tto\\tbeef/pork\\tPZI\\tinsulin. Start with 0.5 units/kg SQ q12h. Median dosage in well- controlled dogs is 0.9 units/kg\\t(range,\\t0.4\u20131.5\\tunits/kg)\\tSQ\\tq12h. \u2022\\t\\tGlargine\\tinsulin:\\tStart\\twith\\t0.3\\tunits/kg\\tSQ\\tq12h.\\tThen\\tmonitor\\tglucose\\tto\\tadjust dose. The dosage range in well- regulated dogs is 0.32\u20130.67 units/kg q12h SQ. \u2022\\t\\tDetemir\\tinsulin:\\t0.12\u20130.25\\tunits/kg\\tSQ\\tq12h\\t(adjust\\tdose\\tas\\tneeded).\\tBecause\\tof small dose in dogs, a specific diluent may be needed to obtain accurate dose in small dogs. 462    Interferon Cats \u2022\\t\\tShort-\\t   acting\\tregular\\tinsulin.\\tTreatment\\tof\\tketoacidosis:\\t0.2\\tunit/kg\\tIM\\tinitially, then 0.1 unit/kg IM every hour until glucose level is less than 300 mg/dL, and then\\tcontinue\\twith\\t0.25\u20130.4\\tunit/kg\\tSQ\\tq6h. \u2022\\t\\tNPH\\tinsulin\\tis\\tnot\\tordinarily\\trecommended\\tfor\\tcats\\tbut\\thas\\tbeen\\tused\\tat\\t0.25 units/kg SQ q12h or 1\u20133 units per cat SQ q12h. \u2022\\t\\tProtamine\\tzinc\\trecombinant\\thuman\\tinsulin\\t(ProZinc):\\tStart\\twith\\t0.2\u20130.7\\tunits/kg q12h SQ (average dose, 0.5 units/kg) or 1\u20132 units per cat SQ q12h. Adjust dose to achieve nadir of glucose of 80\u2013150 mg/dL. If transitioning from Caninsulin to protamine zinc insulin, start with 0.5 units/kg q12h SQ initially and adjust dose with monitoring. \u2022\\t\\tPZI\\tinsulin:\\tInitial\\tdose\\tis\\t0.5\\tunit/kg\\tSQ\\tand\\tthen\\tonce\\tor\\ttwice\\tdaily\\t(usually twice is needed) with subsequent doses adjusted to produce desirable glucose levels, usually no higher than 3 units per cat. Final adjusted dose for most cats is 0.9 (\xb1 0.4)\\tunit/kg. \u2022\\t\\tGlargine\\tinsulin:\\tStart\\twith\\t0.5\\tunit/kg\\tq12h\\tSQ.\\tSome\\tcats\\tcan\\tbe\\tmanaged with once- daily dosing, but twice daily is preferred. Adjust dose via monitoring. If treating DKA, one may start with glargine insulin administered intramuscularly and then switch to SQ injections for maintenance. \u2022\\t\\tDetemir\\tinsulin:\\tUse\\tsame\\tdosage\\tregimen\\tas\\tfor\\tglargine\\tinsulin. \u2022\\t\\tRegular\\tinsulin\\tfor\\tconstant-\\trate\\tinfusion\\t(CRI)\\tadministration:\\t1.1\u20131.5\\tunits/kg/ day as a CRI. Mix regular insulin with 250 mL of 0.9% sodium chloride solution. Administer at a rate of 10 mL per cat per hour. Discard the first 50 mL. Discard the entire\\tbag\\tafter\\t24\\thours\\tand\\tmake\\ta\\tfresh\\tbag\\tof\\tfluids. \u2022\\t\\tLispro\\tinsulin:\\tFor\\tDKA\\tin\\tcats,\\tstart\\twith\\t0.09\\tunits/kg/h\\tinfusion.\\tMix\\twith\\t0.9% normal saline for IV infusion by adding 2.2 units to a 250- mL bag of 0.95 saline. Consider potassium supplementation during treatment, depending on the extent of hypokalemia. Horses \u2022\\t\\tTreatment\\tof\\thyperkalemia:\\tStart\\twith\\tregular\\tinsulin\\t(100\\tunits/mL)\\tand administer at a dosage of 0.1\u20130.2 units/kg/hour IV infusion, with 5% dextrose solution. The IV solution can be prepared by adding 0.5 mL of regular insulin to 5 L of fluids containing 500 mL of 50% dextrose. Administer 5 L over 1 hour. Regulatory Information No regulatory information is available for animals intended for food. Because of a low risk of residues, no withdrawal times are suggested. Interferon in- ter- feer\u2032on Trade and other names: Virbagen omega","contraindications":"Contraindications and Precautions Do not use without the ability to monitor glucose in animals because of the risk of hypoglycemia. Mixing regular insulin and insulins containing zinc in the same syringe will prolong absorption of the regular insulin. Do not mix isophane insulin or phosphate- buffered insulin with zinc insulins (lente, ultralente, semilente). Do not use insulin products from compounding pharmacies. Studies to evaluate compounded insulin products for pets have shown that they are unreliable. Drug Interactions Administration of corticosteroids (prednisolone, dexamethasone, etc.) interfere with the action of insulin.","indications":"Indications and Clinical Uses Insulin in its various forms is used to treat diabetes mellitus in dogs and cats. It is used to replace insulin that is deficient. In some cats (approximately 50%), some oral hypoglycemic drugs have been used to reduce use of insulin. However, diabetic dogs are more insulin dependent. Regular insulin is short acting and more useful for emergencies such as DKA and acute nonketotic syndromes. Intermediate-  and long- acting insulin preparations are used for maintenance and are available in a variety of forms (see previous section). Most of the animal sources of insulin (beef and pork) have been discontinued, and human- recombinant insulin","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to overdoses that result in hypoglycemia. Glargine\\tinsulin\\thas\\ta\\tlow\\tpH\\t(4)\\tand\\tmay\\tsting\\tfrom\\tinjection.\\tOther\\tinsulins are more neutral.","notes":"formulations have been substituted without differences in efficacy. In cats, glargine insulin has shown better efficacy than other forms and has been associated with a better remission rate. Glargine also has been used to treat DKA in cats and shown to be effective when administered intramuscularly. In addition to diabetes mellitus, insulin is occasionally used to treat severe cases of hyperkalemia. Precautionary Information Instructions for Use Dietary management is essential for optimal glucose control. For proper management in cats, the mainstays of treatment are a low- carbohydrate, high- protein diet and twice- daily insulin. Many cats, if properly managed, may go into remission and not require lifelong insulin treatment. When treating dogs, feed dogs a high- fiber, low- fat diet. For all diabetic patients, the doses should be carefully adjusted in each patient depending on response. For cats with ketoacidosis, one dosing regimen has used 0.2 units/kg of regular insulin IM initially, then 0.1 units/kg IM every hour until the glucose level is less than 300,\\tand\\tthen\\t0.25\u20130.4\\tunits/kg\\tq6h\\tSQ. For maintenance therapy in cats, for most forms of insulin (including protamine zinc insulin and glargine insulin), twice- daily dosing usually is required. However, I consider once- daily dosing in cats if blood glucose nadir develops 10 hours or longer after administration. Pet\\towners\\tshould\\tbe\\tinstructed\\tto\\tuse\\tappropriate\\tsyringe\\ttypes\\tfor\\tadministration (e.g.,\\tU-\\t40\\tvs.\\tU-\\t100). Patient Monitoring and Laboratory Tests Monitor blood glucose, glycosylated hemoglobin, and fructosamine concentrations. When treating diabetes, it is desirable to maintain glucose concentrations between 100 and 300 mg/dL, with the nadir (lowest point) being 80\u2013150 mg/dL. Serum fructosamine concentrations also can be monitored with the following guidance: less than 350 \u03bcmol/L, excellent control or remission; \u2264450\\t\u03bcmol/L, good control;\\t450\u2013500\\t\u03bcmol/L, moderate control; and greater than 500, \u03bcmol/L poor control. Formulations See\\tdescriptions\\tof\\teach\\tform\\tin\\tPharmacology\\tand\\tMechanism\\tof\\tAction. \u2022\\t\\tHuman\\tinsulin\\tproducts\\tare\\tusually\\tavailable\\tin\\t100-\\tunits/mL\\tinjection\\t(U-\\t100), with\\tsome\\tveterinary\\tproducts\\tavailable\\tin\\tsmaller\\tconcentration\\tof\\t40\\tunits/mL (U-\\t  40,\\te.g.,\\tProZinc\\tor\\tVetsulin). \u2022\\t \\tProtamine\\tzinc\\tbeef\u2013pork\\t(PZI\\tVET)\\tinsulin\\talso\\tmay\\tbe\\tavailable\\tas\\t40\\tunits/ mL\\tinjection\\t(U-\\t40).\\tSome\\tpreviously\\tavailable\\tinsulin\\tproducts\\thave\\tbeen discontinued,\\tsuch\\tas\\tIletin\\tII\\tPork\\tInsulin\\t(regular\\tand\\tNPH\\tformulations), Humulin U Ultralente, and Humulin L Lente (Humulin U and Humulin L). Stability and Storage Proper\\tstorage\\tis\\tcritical\\tfor\\tproper\\taction\\tof\\tinsulin:\\tkeep\\trefrigerated.\\tWarm\\tgently and roll vial prior to injection to ensure proper mixing of vial contents. Do not shake vigorously. Do not freeze vials of insulin. Do not allow vials of insulin to be exposed to heat. Do not mix types of insulin in the same vial or syringe. Veterinarians should not use formulations of insulin that are compounded in unreliable conditions. Dilution of insulin should only be done by a pharmacist because specific diluents must be used.","original_category":"Hormone"},{"name":"Ipodate","active_ingredient":"Ipodate","species":["Feline"],"dosage":"Cats \u2022\\t \\tIpodate:\\t15\\tmg/kg\\tq12h\\tPO.\\tMost\\tcommon\\tdosage\\thas\\tbeen\\t50\\tmg\\tper\\tcat twice daily. Dose is equivalent regardless of whether sodium or calcium ipodate is used. \u2022\\t\\tIopanoic\\tacid:\\t50\\tmg\\tper\\tcat\\tq12h\\tPO.\\tIf\\tadequate\\tresponse\\tis\\tnot\\tobserved, increase\\tdosage\\tto\\t100\\tmg\\tper\\tcat\\tq12h\\tPO.\\tHowever,\\tthis\\tproduct\\tis\\tno\\tlonger available commercially in the United States.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. Irbesartan er- beh- sar\u2032tan Trade and other names: Avapro","contraindications":"Contraindications and Precautions Monitor for reduction of thyroid levels in animals or clinical signs. Relapses have occurred in cats after 10 weeks to 6 months of treatment. Drug Interactions No drug interactions have been reported for small animals.","indications":"Indications and Clinical Uses Ipodate is used as treatment for hyperthyroidism in cats. Reduction of T 3 levels should occur within 1 week, but longer term response needs more evaluation. The use is not as common as other treatments, but it has been administered as an alternative to methimazole, radiation therapy, or surgery. Initial response rate may be as high as 66% for\\tshort-\\tterm\\tuse.\\tIn\\tcats,\\tiopanoic\\tacid\\tdoses\\tof\\t50\u2013100\\tmg\\tPO\\tproduced\\tsome short- term benefits for acute treatment of thyrotoxicosis but was not suitable for long- term management of hyperthyroidism in cats. Ipodate formulations are not consistently available to veterinarians. Iopanoic acid is no longer available in the United States commercially but has been compounded. When iopanoic acid (Telepaque) was used as a substitute, it was less effective. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ipodate can cause hypothyroidism. No significant adverse effects have been reported in cats, but compounds containing iodide have caused hypersensitivity reactions in people. In humans, chronic high doses of compounds containing iodide can cause sore mouth, swollen tissues, skin reactions, or GI upset.","notes":"Instructions for Use Use of iopanoic acid for treatment of hyperthyroidism in cats has been evaluated in small numbers of cats in clinical studies. In one study, most treated cats responded, but it was not considered suitable for long- term treatment. More experience is needed to determine if response to treatment is transient. Patient Monitoring and Laboratory Tests Monitor serum thyroid T 3 3 levels, but T 4 levels may be unchanged or may increase because of decreased conversion of T 4 to T 3 . Formulations \u2022\\t\\tIpodate\\thas\\tbeen\\tavailable\\tas\\teither\\tcalcium\\tor\\tsodium\\tipodate,\\tbut\\tsome formulations have been discontinued. Oragrafin 500- mg capsules have been formulated into 50- mg capsules by pharmacists. (These may have to be specifically formulated for cats.) \u2022\\t\\tIopanoic\\tacid\\thas\\tbeen\\tused\\tin\\tthe\\tpast\\tbut\\tis\\tno\\tlonger\\tavailable\\tcommercially\\tin the United States. \u2022\\t\\tSodium\\tipodate\\tis\\tan\\toral\\tagent\\tbut\\tis\\tno\\tlonger\\tavailable\\tin\\tthe\\tUnited\\tStates. I Irbesartan 469 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antithyroid agent"},{"name":"Levothyroxine Sodium","active_ingredient":"Levothyroxine Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t18\u201326\\tmcg/kg\\t(0.018\u20130.026\\tmg/kg)\\tper\\tday\\tPO\\t(adjust\\tdose\\tvia\\tmonitoring). The\\taverage\\tstarting\\tdosage\\tis\\t22\\tmcg/kg\\tonce\\tdaily\\tPO,\\twhich\\tis\\tapproximately 0.1 mg per 10 lb. The entire daily dosage may be administered once per 24 hours or divided into two 12- hour treatments. It may be administered with or without food, but food decreases oral absorption by as much as 50%. To minimize the day- to- day variation in serum T 4 concentrations, the timing of administration and feeding should be consistent from day to day. \u2022\\t\\tIV\\ttherapy\\tfor\\tacute\\ttreatment:\\t4\u20135\\tmcg/kg\\tIV\\tadministered\\tonce\\tor\\tas\\tneeded q12h. L Lidocaine Hydrochloride 519 Cats \u2022\\t\\t10\u201320\\tmcg/kg/day\\t(0.01\u20130.02\\tmg/kg)\\tPO\\t(adjust\\tdose\\tvia\\tmonitoring).  Horses \u2022\\t \\t10\u201360\\tmcg/kg\\t(0.01\u20130.06\\tmg/kg)\\tq24h\\tor\\t5\u201330\\tmcg/kg\\t(0.005\u20130.03\\tmg/kg) q12h\\tPO.\\tWhen\\tusing\\tthe\\toral\\tpowder\\tfor\\tdosing\\tin\\thorses,\\t1\\tlevel\\tteaspoon\\tcontains 12 mg of T 4 , and 1 tablespoon contains 36 mg of T 4 . This powder may be mixed in with daily ration of grain (e.g., 4 level teaspoons mixed with 30 mL water and added to oats per day). \u2022\\t\\tHorses\\twith\\tpituitary\\tpars\\tintermedia\\tdysfunction:\\t0.1\\tmg/kg\\t(48\\tmg\\tper\\thorse) per day. Regulatory Information No regulatory information is available for animals intended for food. Because of a low risk of residues, no withdrawal times are suggested. Lidocaine Hydrochloride lye\u2032doe- kane  hye- droe- klor\u2032ide Trade and other names: Xylocaine and generic brands","contraindications":"Contraindications and Precautions No specific contraindications are reported for small animals. When switching from one brand to another, it is advised to follow up by testing to ensure that brands are therapeutically equivalent. Drug Interactions Patients receiving corticosteroids may have decreased ability to convert T 4 to the active T 3 . The following drugs may lower thyroid concentrations when administered\\tto\\totherwise\\thealthy\\tanimals:\\tnonsteroidal\\tanti-\\tinflammatory drugs (NSAIDs), sulfonamides, and phenobarbital, although these changes in many dogs may not be clinically significant. Although not reported in animals, in people, administration of estrogens increases thyroid- binding globulin and may decrease the active form of thyroid hormone (T 4 ) in patients receiving thyroid supplementation. Monitor T 4 levels in these patients and increase dose of thyroxine if necessary. Feeding may decrease oral absorption. Levothyroxine requires acid for dissolution in the GI tract and oral absorption. Acid- suppressing drugs (e.g., proton pump inhibitors) can decrease acid secretion\\tand\\tcan\\tinterfere\\twith\\toral\\tabsorption.\\tOther\\tdrugs\\tknown\\tto\\tinhibit oral absorption of levothyroxine in people but not confirmed in animals include ferrous sulfate, calcium carbonate, aluminum hydroxide, sucralfate, and raloxifene. These\\tfoods\\tinteract\\twith\\tthyroid\\tmedications:\\twalnuts,\\tliver,\\talbumin,\\tand soybeans. Patients receiving these in their diets should have thyroid levels checked to ensure proper concentrations are achieved.","indications":"Indications and Clinical Uses Levothyroxine is used for replacement therapy in animals with thyroid hormone deficiency (hypothyroidism). It has been used in many species, including dogs, cats, and horses. Although it has been suggested for use in treating dogs with von Willebrand disease, clinical studies failed to show an effect on clotting factors, bleeding times, or von Willebrand factor from levothyroxine treatment (0.04 mg/kg). Intravenous levothyroxine sodium may be used in dogs for acute treatment of hypothyroid dogs with myxedema coma (4\u20135 mcg/kg IV). Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses may produce thyrotoxicosis, but this is uncommon. Potential adverse effects from IV treatment include arrhythmias and pneumonia.","notes":"Instructions for Use Thyroid supplementation should be guided by testing to confirm diagnosis and post- medication monitoring to adjust dose. In 2016, the FDA announced that because there is only one FDA- approved canine form of levothyroxine (Thyro- Tabs), other marketed brands are unapproved and therefore, in violation of FDA regulations. Once-\\t   daily\\tdosing\\tis\\tadequate\\tfor\\tmost\\tdogs,\\tbut\\tmany\\tdogs\\trequire\\ttwice-\\tdaily administration. Studies with the FDA approved formulation (Thyro- Tabs) was administered at a dose of 0.22 mcg/kg once daily and had equivalent results as twice- daily dosing. The total daily dose may be split into twice- daily increments. Some dogs may require different doses and intervals; therefore, monitoring is recommended to\\tadjust\\tdose\\tappropriately.\\tOther\\toral\\ttablets\\tmay\\tnot\\tbe\\tequivalent\\tto\\tthe FDA- approved tablets for dogs, and post- pill testing is needed to ensure the proper dose is delivered. When prescribing human formulations, it is recommended to advise pharmacists that canine doses are much higher than human doses. Patient Monitoring and Laboratory Tests Monitor serum total thyroxine (T 4 ) concentrations to guide therapy. Normal thyroxine (T 4 ) baseline levels are 20\u201355 nmol/L (1.5\u20134.3 mcg/dL). Thyrotropin- releasing hormone injection should result in at least a 1.5- fold increase in T 4 . To monitor post- pill adequacy of therapy, it is best performed 4\u20136 hours after the dose is administered. When collecting a peak concentration blood sample 4\u20136 hours after administering the pill, the T 4 concentration should be between 30 and 60 nmol/L (2.3 and 4.6 mcg/dL). If administering the oral liquid, the peak concentration occurs at 2\u20132.5 hours. In horses, post- pill peak occurs at 1\u20132 hours. Formulations \u2022\\t\\tLevothyroxine\\tis\\tavailable\\tas\\tFDA-\\tapproved\\ttablets\\tfor\\tdogs\\tin\\tnine\\tstrengths from 0.1-  to 1- mg tablets (in 0.1- mg increments). These tablets are scored and color coded for easy administration and dose recognition. There have been other non- FDA approved tablets available in other sizes for dogs, but the FDA has taken action to remove these products from the market. There is also a formulation of 1-   g of thyroxine per 453.6 of oral powder (1 g/lb of the oral powder) used for horses. \u2022\\t\\tThere\\tare\\talso\\thuman\\tgeneric\\tformulations.\\tNote\\tthat\\tlevothyroxine\\tproducts\\tfor animals are not bioequivalent to the human- label tablets. \u2022\\t\\tHuman\\tformulations:\\t25-\\t,\\t50-\\t  ,\\t75-\\t  ,\\t88-\\t  ,\\t112-\\t   ,\\t125-\\t   ,\\t137-\\t   ,\\t150-\\t   ,\\t175-\\t   ,\\t200-\\t   ,\\tand 300- mcg  tablets. \u2022\\t\\tLiotrix\\t(human\\tform)\\tis\\ta\\tcombination\\tof\\tT 4 and T 3 in\\ta\\tratio:\\tAvailable\\tas (T 4 /T 3 ):\\t12.5/3.1-\\t,\\t25/6.25-\\t,\\t50/12.5-\\t,\\t100/25-\\t,\\tand\\t150/37.5-\\tmcg\\ttablets. \u2022\\t\\tDo\\tnot\\tassume\\tthat\\tall\\tlevothyroxine\\tproducts\\tare\\tbioequivalent\\tand\\tproduce\\tthe same response. When switching from one brand to another, follow- up testing is recommended to ensure the same response. Stability and Storage Levothyroxine is inherently unstable and can be markedly affected by heat, light, and humidity. Store in a tightly sealed container, protected from light, and at room temperature. Thyroxine is only slightly soluble in water or ethanol. It is more soluble at pH of less than 2 or greater than 8. It has been unstable in some compounded formulations. However, it may be added to food products if administered immediately. Powder may be mixed with water and added to horse\u2019s grain every day. When it was mixed with ethanol followed by mixing with a syrup, it was stable for 15 days at room temperature and 47 days refrigerated. However, other compounded preparations have been stable for only 15 days (refrigerated) or 11 days (room temperature). Therefore, use of compounded formulations should probably be limited to a storage time of 10\u201315 days.","original_category":"Hormone"},{"name":"Liothyronine Sodium","active_ingredient":"Liothyronine Sodium","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t4.4\\tmcg/kg\\tq8h\\tPO. \u2022 \\t \\tT 3 suppression\\ttest\\tin\\tcats:\\tCollect\\tpresample\\tfor\\tT 4 and T 3 , administer 25 mcg q8h for seven doses, and then collect postsamples for T 3 and T 4 after last dose.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\tis\\tavailable. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Lisinopril lye- sin\u2032oh- pril Trade and other names: Prinivil and Zestril","contraindications":"Contraindications and Precautions No contraindications reported. Drug Interactions No drug interactions reported for animals. 526    Lisinopril","indications":"Indications and Clinical Uses Liothyronine is used for similar indications as T 4 , except that in this instance, the active T 3 hormone is administered instead of relying on conversion from T 4 to T 3 . It may be indicated in cases in which there is failure to convert T 4 to the active T 3 hormone; however, this is a rare occurrence. In most cases, it is preferred to administer levothyroxine instead of liothyronine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported.","notes":"Instructions for Use Doses of liothyronine should be adjusted on the basis of monitoring T 3 concentrations in patients. It is rarely necessary to administer T 3 alone for treatment of hypothyroidism. In most patients, drugs that contain T 4 should be used (e.g., levothyroxine) and converted to T 3 . Liothyronine has been used as a diagnostic test for cats. Patient Monitoring and Laboratory Tests Monitor serum T 3 concentrations. Used for T 3 - suppressing test in cats. Formulations \u2022\\t\\tLiothyronine\\t(human\\tformulation)\\tis\\tavailable\\tin\\t5-\\t,\\t25-\\t  ,\\tand\\t50-\\tmcg\\ttablets. \u2022\\t\\tLiotrix\\tis\\ta\\tcombination\\tof\\tT 4 and T 3 in\\ta\\tratio:\\tAvailable\\tas\\t(T 4 /T 3 ):\\t12.5/3.1-\\t, 25/6.25- , 50/12.5- , 100/25- , and 150/37.5- mcg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Medroxyprogesterone Acetate","active_ingredient":"Medroxyprogesterone Acetate","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t1.1\u20132.2\\tmg/kg\\tevery\\t7\\tdays\\tIM. \u2022\\t\\tSuppression\\tof\\testrus\\tin\\tcats:\\t0.05\\tmg/kg\\toral\\tonce\\tdaily.\\tThis\\tdose\\tmay\\thave\\ta negative\\teffect\\ton\\tfertility\\tand\\tnewborn\\tkittens\\twhen\\ttreatment\\tis\\tdiscontinued.\\tTo suppress\\testrus\\twith\\tthe\\tIM\\tform,\\t2\u20132.5\\tmg/kg\\tis\\tinjected\\tand\\trepeated\\tonce\\tevery 4\u20136\\tmonths. \u2022\\t\\tBehavior\\tproblems:\\t5\\tmg\\tper\\tdog\\tonce\\tdaily\\tas\\tneeded. \u2022\\t\\tProstatic\\tdisease\\t(dogs):\\t3\u20135\\tmg/kg\\tIM\\tor\\tSQ\\tevery\\t3\u20134\\tweeks.  Horses \u2022\\t\\tPrevent\\testrus:\\t250\u2013500\\tmg/horse\\tIM. Regulatory Information There\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tthis\\tdrug\\tshould\\tnot\\tbe administered to animals that produce food. 562    Megestrol Acetate Megestrol Acetate meh- jess\u2032trole ass\u2032ih- tate Trade and other names: Ovaban and Megace","contraindications":"Contraindications and Precautions Do not use in animals at a high risk for diabetes. In humans, it increases the risk of thromboembolic problems. When used to suppress estrus in cats, it was effective\\tbut\\thad\\tnegative\\tafter-\\teffects\\ton\\tfertility\\tand\\tviability\\tof\\tkittens.\\tDo\\tnot use in pregnant animals. Do not use in male cats for dermatologic problems or behavior treatment because of the risk of adverse effects. Drug Interactions No drug interactions are reported. However, clearance of medroxyprogesterone is increased\\twith\\tdrugs\\tknown\\tto\\tinduce\\thepatic\\tP450\\tenzymes\\t(see\\tAppendix\\tH).","indications":"Indications and Clinical Uses Medroxyprogesterone acetate is used to replace progesterone in animals. Most often it is used as progesterone hormone treatment to control the estrus cycle, which is one of the uses in horses. It also is used for management of some behavioral and dermatologic disorders (e.g., urine spraying in cats and alopecia). However, its use for behavioral therapy in animals is discouraged because of high relapse rates and incidence\\tof\\thormone-\\trelated\\tadverse\\teffects. M Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include polyphagia, polydipsia, adrenal suppression (cats), increased risk of diabetes mellitus, pyometra, diarrhea, and increased risk of neoplasia. In cats, a single injection of medroxyprogesterone acetate has produced feline mammary fibroepithelial hyperplasia.","notes":"Instructions for Use Intervals of administration vary with condition. Intervals may range from once a week to once a month. Clinical\\tstudies\\tin\\tanimals\\thave\\tstudied\\tprimarily\\tthe\\treproductive\\tuse.\\tThe\\teffects on behavior and the dermatologic uses are based on anecdotal evidence or small observational studies. A similar drug is megestrol acetate and medroxyprogesterone acetate may have fewer side effects. Patient Monitoring and Laboratory Tests It may increase concentrations of serum cholesterol and some liver enzymes. Formulations \u2022\\t\\tMedroxyprogesterone\\tis\\tavailable\\tin\\t150-\\t\\tand\\t400-\\tmg/mL\\tsuspension\\tinjection and\\t2.5-\\t,\\t5-\\t ,\\tand\\t10-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Megestrol Acetate","active_ingredient":"Megestrol Acetate","species":["Feline","Canine","Equine"],"dosage":"development\\tof\\tdiabetes\\tmellitus.\\tHigh\\tdosages\\tin\\tcats\\t(0.625\u20131.25\\tmg/kg\\tonce daily\\tor\\t2.5\u20135\\tmg/kg/wk)\\tcan\\tlead\\tto\\tmammary\\tgland\\tlesions,\\tuterine\\tlesions, and more severe endocrine adverse effects.  Dogs \u2022\\t\\tProestrus:\\t2\\tmg/kg\\tq24h\\tPO\\tfor\\t8\\tdays\\t(early\\tproestrus). \u2022\\t\\tAnestrus:\\t0.5\\tmg/kg\\tq24h\\tPO\\tfor\\t32\\tdays. \u2022\\t\\tTreatment\\tof\\tbehavior\\tproblems:\\t2\u20134\\tmg/kg\\tq24h\\tfor\\t8\\tdays\\t(reduce\\tdose\\tfor maintenance). Cats (See precautions listed above.) \u2022\\t\\tDermatologic\\ttherapy\\tor\\turine\\tspraying:\\t2.5\u20135\\tmg/cat\\tq24h\\tPO\\tfor\\t1\\tweek;\\tthen reduce\\tto\\t5\\tmg\\tonce\\tor\\ttwice\\ta\\tweek\\tper\\tcat. \u2022\\t\\tSuppress\\testrus:\\t5\\tmg/day\\tper\\tcat\\tfor\\t3\\tdays;\\tthen\\t2.5\u20135\\tmg\\tonce\\ta\\tweek\\tfor\\t10 weeks\\t(0.02\\tmg/kg).\\tFor\\tlong-\\tterm\\tuse\\t(30\\tweeks),\\ta\\tlower\\tdosage\\tof\\t2.5\\tmg once per week should be used for greater safety.  Horses \u2022\\t\\tSuppress\\testrus:\\t0.5\\tmg/kg\\tq24h\\tPO. Regulatory Information There\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tthis\\tdrug\\tshould\\tnot\\tbe administered to animals that produce food. Melarsomine Dihydrochloride mel- ar\u2032soe- meen Trade and other names: Immiticide","contraindications":"Contraindications and Precautions Do not use in diabetic animals or animals that may be at risk for developing diabetes. Do not use in pregnant animals. Do not use prior to or during first estrus cycle in young animals. Do not use in the presence of a disease of the reproductive\\tsystem\\tor\\twith\\tmammary\\ttumors.\\tIf\\testrus\\toccurs\\twithin\\t30\\tdays after cessation of treatment, mating should be prevented. Avoid use in cats for dermatologic problems or behavior treatment because of risk of adverse effects. Drug Interactions No drug interactions are reported. However, clearance of medroxyprogesterone is increased\\twith\\tdrugs\\tknown\\tto\\tinduce\\thepatic\\tP450\\tenzymes,\\tand\\tthis\\tmay\\toccur with megestrol acetate (see Appendix H).","indications":"Indications and Clinical Uses Megestrol is used in animals as a progesterone hormone treatment to control the estrus cycle, which is most often to postpone the estrus cycle. It suppresses the ovulatory process by affecting secretion of estradiol by ovaries. It inhibits secretion of\\tfollicle-\\tstimulating\\thormone\\tand\\tluteinizing\\thormone\\tfrom\\tthe\\tpituitary.\\tIt\\tis\\talso used in female dogs for the alleviation of false pregnancy. It also has been used for management of some behavioral and dermatologic disorders (e.g., urine spraying in cats and alopecia). However, its use for behavioral therapy in animals is discouraged because\\tof\\thigh\\trelapse\\trates\\tand\\tthe\\tincidence\\tof\\thormone-\\trelated\\tadverse\\teffects. In horses, it has been used to prevent estrus, but efficacy for this indication has not been\\tgood\\tat\\tdoses\\tof\\t10\u201320\\tmg/day\\tper\\thorse. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include polyphagia, polydipsia, adrenal suppression (cats), increased risk of diabetes, pyometra, diarrhea, and increased risk of neoplasia. Adverse\\teffects\\tin\\tcats\\tare\\tdose\\trelated.\\tLow\\tdoses\\tof\\t2.5\\tmg/wk\\tcan\\tbe\\ttolerated for\\t30\\tweeks.\\tDosages\\tgreater\\tthan\\t0.625\\tmg/kg\\tonce\\tdaily\\tcan\\tpredispose\\tto","notes":"Instructions for Use Clinical\\tstudies\\tin\\tanimals\\thave\\tstudied\\tprimarily\\tthe\\treproductive\\tuse.\\tEffects on behavior and the dermatologic uses are based on anecdotal evidence or small M Melarsomine Dihydrochloride 563 observational studies. Medroxyprogesterone acetate, an alternate progestin, may have fewer side effects than megestrol acetate. When\\tused\\tfor\\tproestrus\\ttreatment,\\tadminister\\t2.2\\tmg/kg\\tfor\\t8\\tdays\\tadministered orally.\\tFor\\tanestrus\\ttreatment,\\tadminister\\t0.55\\tmg/kg/day\\tfor\\t32\\tdays.\\tTablets\\tcan be administered intact or crushed and mixed with food. When therapy is started, the animal\\tshould\\tbe\\tconfined\\tfor\\t3\u20138\\tdays\\tor\\tuntil\\tcessation\\tof\\tbleeding\\tbecause\\tdogs\\tin proestrus accept a male. Patient Monitoring and Laboratory Tests Because of risk of diabetes mellitus, monitor glucose concentrations during treatment periodically.\\tExamination\\tof\\tvaginal\\tsmears\\tis\\trecommended\\tto\\tconfirm\\tdetection\\tof proestrus. Formulations \u2022\\t\\tMegestrol\\tacetate\\tis\\tavailable\\tin\\t5-\\t\\tand\\t20-\\tmg\\ttablets\\t(veterinary\\tpreparation)\\tand 20-\\t\\tand\\t40-\\tmg\\ttablets\\t(human\\tpreparation). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Methimazole","active_ingredient":"Methimazole","species":["Feline"],"dosage":"Cats \u2022\\t\\t2.5\\tmg/cat\\tq12h\\tPO\\tfor\\t7\u201314\\tdays;\\tthen\\tadjust\\tdosage\\tup\\tto\\t5\u201310\\tmg/cat\\tPO q12h\\tif\\tneeded.\\tMonitor\\tT 4 concentrations and adjust dosage accordingly. Some cats\\tcan\\tbe\\tmaintained\\ton\\tonce-\\tdaily\\ttreatment. \u2022\\t\\tTransdermal\\tdosage:\\t10\\tmg\\tper\\tcat\\ttransdermally\\tonce\\tdaily.\\tAfter\\ta\\tperiod of adjustment, modification of dosage should be done by monitoring thyroid concentrations\\tin\\tcats.\\tSome\\tcats\\tmay\\trequire\\ttwice-\\tdaily\\tdosing,\\tand\\tsome\\tcats\\tcan be\\tmaintained\\ton\\ta\\tdosage\\tof\\t5\\tmg\\tper\\tcat\\tonce\\tdaily.\\tAlternate\\tears\\twith\\teach\\tdose and wear gloves when applying.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tThis\\tdrug\\tshould not be used in animals intended for food. Methionine  (DL- Methionine) meth- eye- o- nine Trade and other names: DL- methionine and Racemethionine","contraindications":"Contraindications and Precautions Do not administer to animals with thrombocytopenia or bleeding problems. Other drugs, such as beta blockers, are safe to administer with methimazole. Warn pet owners that transdermal methimazole can be absorbed through human skin.\\tIf\\tan\\tanimal\\thas\\thad\\tprevious\\tadverse\\treactions\\tto\\tPTU,\\tthere\\tmay\\talso\\tbe cross-\\t   sensitivity\\tto\\tmethimazole.\\tMethimazole\\thas\\tcaused\\tfetal\\tabnormalities\\tand should not be used in pregnant animals. Drug Interactions There\\tare\\tno\\tdrug\\tinteractions\\treported\\tfrom\\tthe\\tuse\\tin\\tanimals.\\tIt\\thas\\tbeen\\tused safely\\twith\\tbeta-\\tblockers,\\tcalcium-\\tchannel\\tblockers,\\tantihypertensive\\tdrugs,\\tand other cardiovascular drugs.","indications":"Indications and Clinical Uses Methimazole\\tis\\tused\\tto\\ttreat\\thyperthyroidism\\tin\\tanimals,\\tespecially\\tcats.\\tThere\\tis good evidence for efficacy, based on clinical studies, when administered to cats at recommended doses. Methimazole is preferred in cats instead of an older drug, propylthiouracil\\t(PTU),\\tbecause\\tmethimazole\\thas\\ta\\tlower\\tincidence\\tof\\tadverse\\teffects. Many\\tcats\\tare\\tcontrolled\\twith\\tonce-\\tdaily\\tdosing\\tof\\tmethimazole,\\tbut\\tthere\\tis\\tevidence that\\tsupports\\ttwice-\\tdaily\\tdosing\\tin\\tcats\\tas\\tmore\\teffective\\tthan\\tonce\\tdaily. Methimazole has been formulated for use in cats as a transdermal gel for skin absorption.\\tTransdermal\\tgels\\tfor\\tcats\\tuse\\teither\\ta\\tgel\\tcompounded\\tin\\tpluronic\\torganogel (PLO)\\tor\\tother\\tvehicles\\t(e.g.,\\tLipoderm)\\tto\\tenhance\\ttransdermal\\tpenetration.\\t(See","side_effects":"Adverse Reactions and Side Effects In\\tcats,\\tGI\\tproblems\\tare\\tthe\\tmost\\tcommon\\tadverse\\teffect\\tand\\tcan\\tinclude\\tanorexia and vomiting. Most adverse effects caused by methimazole are dose related and can be decreased by lowering the dose. In cats, polyarthritis, alopecia, and scaling and crusting of the head and face have been observed, which may be manifestations of\\tan\\tallergic\\treaction.\\tIn\\tcats,\\tlupus-\\tlike\\treactions\\tare\\tpossible,\\tsuch\\tas\\tvasculitis and bone marrow changes, but this was more common with older drugs such as PTU.\\tIn\\tcats,\\tabnormal\\tplatelet\\tcounts\\tand\\tlow\\tblood\\tcounts\\tcan\\tdevelop\\tafter\\t1\u20133 months of treatment. Bleeding abnormalities may be related to thrombocytopenia, but tests conducted in cats did not demonstrate prolongation of bleeding times (prothrombin\\ttime\\t  and\\t  activated\\tpartial\\t   antithromboplastin\\ttime).\\t   There\\t   were\\t  fewer adverse\\tGI\\teffects\\twhen\\tmethimazole\\twas\\tapplied\\tas\\ta\\ttransdermal\\tgel\\tcompared with administration as an oral tablet. But transdermal methimazole can produce skin irritation in some cats. Methimazole treatment may unmask hypothyroidism and renal failure in some cats. Monitor renal function with continued treatment.","notes":"Formulations.)\\tThese\\tformulations\\tare\\tgenerally\\tavailable\\tthrough\\tcompounding pharmacies.\\tOne\\tcommercial\\tproduct\\tis\\tavailable\\tin\\tNew\\tZealand\\tas\\tHyper-\\tT\\tEar\\tSpot. Published data indicate that transdermal methimazole is not as rapidly acting or as effective\\tas\\toral\\tdosing,\\tbut\\tit\\tcan\\tbe\\teffective\\tto\\treduce\\tT 4 concentrations in many cats. In\\tthe\\tavailable\\tstudies,\\ta\\tdose\\tof\\t10\\tmg\\tper\\tcat\\ttransdermal\\twas\\tmore\\teffective\\tthan\\t5\\tmg per cat transdermal and was as effective as oral treatments. An alternative oral drug that has been used is carbimazole, which is converted to the\\tactive\\tdrug\\tmethimazole.\\tIt\\tmay\\tproduce\\tless\\tfrequent\\tGI\\tproblems.\\tHowever, experience\\twith\\tcarbimazole\\tis\\tlimited\\tin\\tthe\\tUnited\\tStates\\t(see\\tCarbimazole\\tfor more details). If switching from methimazole to carbimazole, they are not equivalent. Six mg\\tof\\tmethimazole\\tis\\tequal\\tto\\t10\\tmg\\tof\\tcarbimazole. Precautionary Information Instructions for Use The\\tuse\\tin\\tcats\\tis\\tbased\\ton\\tclinical\\tstudies\\tin\\thyperthyroid\\tcats\\tand\\tinformation\\tfrom the\\tfeline\\tdrug\\tsponsor.\\tMethimazole\\thas,\\tfor\\tthe\\tmost\\tpart,\\treplaced\\tPTU\\tfor\\tuse in\\tcats.\\tAdjust\\tthe\\tmaintenance\\tdose\\tof\\tmethimazole\\tby\\tmonitoring\\tthyroid\\t(T 4 ) concentrations in plasma. Because it does not inhibit release of preformed thyroid, it\\tmay\\ttake\\t2\u20134\\tweeks\\tto\\tachieve\\tmaximum\\teffect.\\tAlthough\\tonce\\tthe\\tpatient\\tis stabilized,\\tthe\\tT 4 concentrations\\tare\\tsuppressed\\tfor\\t24\\thours,\\tone\\tstudy\\tthat\\tevaluated dosing\\tfrequency\\tfound\\tthat\\t5\\tmg/kg\\tq12h\\tPO\\twas\\tmore\\teffective\\tthan\\t5\\tmg/kg q24h\\tPO. Transdermal\\tgel\\tuse\\tin\\tcats:\\tMethimazole\\thas\\tbeen\\tprepared\\tas\\ta\\ttransdermal gel\\tby\\tcompounding\\tpharmacies.\\tThe\\tcompounded\\tvehicle\\tcontains\\tsolvents and penetration enhancers. (See Formulations.)\\tThe\\tLipoderm\\tformulation\\tis compounded\\tin\\ta\\tlipid\\tvehicle,\\tinstead\\tof\\tpreviously\\tused\\tPLO\\tgel,\\twhich\\tmay\\tbe more\\teffective.\\tOne\\tof\\tthe\\tcompounded\\tformulations\\tis\\tcompounded\\tas\\ta\\t10% concentration.\\tThe\\tmost\\tcommon\\tdose\\tadministered\\tis\\t10\\tmg\\tper\\tcat\\t(0.1\\tmL\\tof the\\tcompounded\\tproduct)\\tof\\ttransdermal\\tgel\\tapplied\\tto\\tthe\\tinner\\tear.\\tTransdermal gel may be less effective and more variable than oral tablets, and thyroid monitoring should\\tbe\\tperformed\\tto\\tassess\\tefficacy\\tto\\tensure\\tthat\\tT 4 is consistently within the reference range. Patient Monitoring and Laboratory Tests Monitor\\tserum\\tT 4 levels.\\tRecheck\\tT 4 levels after first month of treatment. Whether the concentration was measured before dosing or during the dose interval did not affect\\tthe\\tT 4 concentration.\\tAfter\\tmethimazole\\ttreatment\\tis\\tstabilized,\\tT 3 and\\tT 4 are\\tsuppressed\\tfor\\t24\\thours\\tafter\\teach\\tdose\\tof\\tmethimazole.\\tTherefore,\\tthe\\ttiming of blood sample after oral methimazole in cats does not appear to be a significant factor\\twhen\\tassessing\\tresponse\\tto\\ttreatment.\\tThyroid-\\tstimulating\\thormone\\t(TSH) concentrations\\tin\\tcats\\tmay\\talso\\tbe\\tused\\tto\\ttest\\teffectiveness\\tof\\ttreatment.\\t(Feline\\tTSH has\\t96%\\thomology\\twith\\tcanine\\tTSH.)\\tMonitor\\tCBC\\tand\\tplatelet\\tcount\\tin\\tcats\\tevery week\\tor\\t14\\tdays\\tfor\\tthe\\tfirst\\t30\\tdays\\tof\\ttreatment.\\tMonitor\\ttests\\tof\\trenal\\tfunction because of concern about increased risk of renal disease in some cats. Monitor liver enzymes before and during treatment. Some cats with hyperthyroidism also have elevated liver enzymes. Methimazole may affect thyroid scintigraphy tests because after\\ttreatment,\\tthere\\tmay\\tbe\\ta\\tstimulation\\tfrom\\tTSH\\tfor\\ttissues\\tto\\thave\\tenhanced uptake\\tof\\t99mTcO4\\tby\\tthe\\tthyroid\\tgland. Formulations \u2022\\t\\tMethimazole\\tis\\tavailable\\tin\\t2.5-\\t\\tand\\t5-\\tmg\\tcoated\\ttablets\\t(veterinary\\tform)\\tand\\t5- and\\t10-\\t    mg\\ttablets\\t(human\\tform). \u2022\\t\\tTransdermal:\\tThere\\tare\\tno\\tapproved\\ttransdermal\\tformulations\\tfor\\tcats\\tin\\tthe United\\tStates.\\tHowever,\\ta\\t10%\\ttransdermal\\tgel\\thas\\tbeen\\tprepared\\tby\\tcompounding pharmacies. For consideration of a transdermal gel, the pharmacist should consult\\tUS\\tPatent\\tnumber\\tUS2010/0137389\\tA1\\t(June\\t3,\\t2010),\\twhich\\tlists\\tthe ingredients and process for preparing the formulation. \u2022\\t\\tTransdermal:\\tThere\\tis\\ta\\ttransdermal\\tform\\tapproved\\tin\\tsome\\tcountries\\t(New Zealand)\\tfor\\tcats.\\tThis\\tproduct\\t(Hyper-\\tT\\tEarspot)\\tis\\tavailable\\tin\\ta\\t1-\\tmL\\tapplicator at\\ta\\tconcentration\\tof\\t100\\tmg/mL\\tand\\tapplied\\tas\\t0.1\\tmL\\t(10\\tmg)\\tonce\\tdaily\\tthe pinna\\tof\\tthe\\tear.\\tDose\\tadjustments\\tare\\trecommended\\tbased\\ton\\tmeasurement\\tof\\tT 4 concentrations. Stability and Storage Methimazole is stable if maintained in its original formulation. However, if prepared in compounded formulations for cats, potency and stability may be less if not prepared\\taccording\\tto\\tthe\\tinstructions\\tlisted\\tin\\tthe\\tUS\\tPatent.\\t(See\\tFormulations.) This\\tproduct\\twas\\tstable\\tfor\\t12\\tmonths\\tafter\\tpreparation\\tand\\tdispensed\\tin\\t1-\\tmL syringes\\tat\\ta\\t10%\\tconcentration\\t(100\\tmg/mL).\\tCarbimazole\\tis\\tnot\\tstable\\tin transdermal gel formulations. M Methocarbamol 589","original_category":"Antithyroid agent"},{"name":"Methyltestosterone","active_ingredient":"Methyltestosterone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5\u201325\\tmg/dog\\tq24\u201348h\\tPO. Cats \u2022\\t\\t2.5\u20135\\tmg/cat\\tq24\u201348h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not use in animals intended for food. Methyltestosterone is a Schedule III controlled drug. RCI\\tClassification:\\t4 Metoclopramide Hydrochloride met- oh- kloe- prah\u2032mide  hye- droe- klor\u2032ide Trade and other names: Reglan and Maxolon","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Drug Interactions No drug interactions have been reported for animals.","indications":"Indications and Clinical Uses Methyltestosterone is used for anabolic actions or testosterone hormone replacement therapy\\t(androgenic\\tdeficiency).\\tTestosterone\\thas\\tbeen\\tused\\tto\\tstimulate erythropoiesis. Other similar agents used include testosterone cypionate and testosterone propionate. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are caused by excessive androgenic action of testosterone. Prostatic hyperplasia is possible in male dogs. Masculinization can occur in female dogs. Hepatopathy is more common with oral methylated testosterone","notes":"formulations\\tthan\\twith\\tnon-\\tmethylated\\tforms.\\tTherefore,\\tmonitor\\tbilirubin\\tand hepatic enzymes for evidence of liver reactions. Instructions for Use Use\\tof\\ttestosterone\\tandrogens\\thas\\tnot\\tbeen\\tevaluated\\tin\\tclinical\\tstudies\\tin\\tveterinary medicine.\\tThe\\tclinical\\tuse\\tis\\tbased\\tprimarily\\ton\\texperimental\\tevidence\\tor\\texperiences in people. Patient Monitoring and Laboratory Tests Monitor hepatic enzymes and clinical signs for evidence of cholestasis and hepatotoxicity during treatment. Formulations \u2022\\t\\tMethyltestosterone\\tis\\tavailable\\tin\\t10-\\t\\tand\\t25-\\tmg\\ttablets. 602    Metoclopramide Hydrochloride Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone, anabolic agent"},{"name":"Mibolerone","active_ingredient":"Mibolerone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.6\u20135\\tmcg/kg/day\\tPO. \u2022\\t\\tBitches\\tweighing\\t0.45\u201311.3\\tkg:\\t30\\tmcg/day\\tPO. \u2022\\t\\tBitches\\tweighing\\t11.8\u201322.7\\tkg:\\t60\\tmcg/day\\tPO. \u2022\\t\\tBitches\\tweighing\\t23\u201345.3\\tkg:\\t120\\tmcg/day\\tPO. \u2022\\t\\tBitches\\tweighing\\tmore\\tthan\\t45.8\\tkg:\\t180\\tmcg/day\\tPO. Cats \u2022\\t\\tSafe\\tdose\\tnot\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals that produce food. Midazolam Hydrochloride mid- az\u2032oe- lam  hye- droe- klor\u2032ide Trade and other names: Versed","contraindications":"Contraindications and Precautions Do not use in Bedlington terriers. Do not administer to pregnant animals. Avoid administration in bitches before their first estrous period. Do not use with perianal adenoma or carcinoma. Do not use in cats. Mibolerone has been abused in people for\\tuse\\tas\\ta\\tbody-\\tbuilding\\tdrug.\\tTherefore\\textreme\\tcaution\\tshould\\tbe\\tused\\twhen dispensing this medication to animal owners. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses Mibolerone\\tis\\tused\\tto\\tsuppress\\testrus\\tin\\tanimals.\\tThe\\tprimary\\tindication\\tis\\tto\\tprevent estrus\\tin\\tadult\\tfemale\\tdogs.\\tThere\\tare\\tno\\tother\\testablished\\tindications. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Many bitches show clitoral enlargement or discharge from treatment.","notes":"Instructions for Use Treatment\\tordinarily\\tis\\tinitiated\\t30\\tdays\\tprior\\tto\\tonset\\tof\\testrus.\\tContinue\\ttreatment as\\tlong\\tas\\tneeded,\\tbut\\tit\\tis\\tnot\\trecommended\\tto\\tbe\\tused\\tfor\\tmore\\tthan\\t2\\tyears. Mibolerone should not be used in bitches before the first estrous period. It is not intended for animals being used primarily for breeding purposes. M Midazolam Hydrochloride 611 Patient Monitoring and Laboratory Tests Monitor hepatic enzymes periodically if used chronically because liver injury is possible. Formulations \u2022\\t \\tMibolerone\\thas\\tbeen\\tdiscontinued\\tby\\tthe\\tmanufacturer.\\tHowever,\\tit\\tmay\\tbe\\tavailable from\\tsome\\tother\\tsources.\\tOriginally,\\tit\\twas\\tavailable\\tin\\ta\\t100-\\tmcg/mL\\toral\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone"},{"name":"Nandrolone Decanoate","active_ingredient":"Nandrolone Decanoate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1\u20131.5\\tmg/kg/wk\\tIM. Cats \u2022\\t\\t1\\tmg/kg/wk\\tIM.  Horses \u2022\\t\\t1\\tmg/kg\\tevery\\t4\\tweeks\\tIM. Regulatory Information Nandrolone is a Schedule III controlled drug. Do not administer to animals intended for food. RCI\\tClassification:\\t4 Pharmacology and Mechanism of Action Naproxen is a nonsteroidal anti- inflammatory drug (NSAID) that is widely used in people, but infrequently used in animals. Naproxen and other NSAIDs produce analgesic and anti- inflammatory effects by inhibiting the synthesis of prostaglandins. The enzyme inhibited by NSAIDs is the cyclooxygenase (COX) enzyme. The COX enzyme\\texists\\tin\\ttwo\\tisoforms:\\tCOX-\\t1\\tand\\tCOX-\\t2.\\tCOX-\\t1\\tis\\tprimarily\\tresponsible for synthesis of prostaglandins important for maintaining a healthy gastrointestinal (GI) tract, renal function, platelet function, and other normal functions. COX- 2 is induced and responsible for synthesizing prostaglandins that are important mediators of pain, inflammation, and fever. However, there are overlapping functions of the mediators derived from these isoforms. Naproxen is a nonselective inhibitor of COX- 1  and  COX- 2. Naproxen nah- proks\u2032en Trade and other names: Naprosyn, Naxen, and Aleve (naproxen sodium)","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Nandrolone use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor liver enzymes in treated patients. Formulations \u2022\\t\\tNandrolone\\tdecanoate\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\tand\\t200-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone, anabolic agent"},{"name":"Oxymetholone","active_ingredient":"Oxymetholone","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20135\\tmg/kg/day\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. O Oxymorphone Hydrochloride 687 Regulatory Information Do not administer to animals intended for food. RCI Classification: 4 Oxymorphone Hydrochloride oks- ih- mor\u2032fone  hye- droe- klor\u2032ide Trade and other names: Numorphan","contraindications":"Contraindications and Precautions Oxymetholone and other anabolic steroids are abused in people to increase athletic performance and muscle gain. Care should be taken when prescribing multiple doses to animals and storing these agents in veterinary hospitals. Do not use in pregnant animals. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.","indications":"Indications and Clinical Uses Anabolic agents have been used for reversing catabolic conditions, increasing weight gain, increasing muscling in animals, and stimulating erythropoiesis. They also may stimulate appetite. Although other anabolic agents have been used in animals (methyltestosterone and stanozolol), there are no differences in efficacy among the anabolic steroids demonstrated in animals. The use of oxymetholone is based on anecdotal experience and extrapolation of uses from human medicine. There are no well- controlled studies using oxymetholone in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects from anabolic steroids can be attributed to the pharmacologic action of anabolic steroids. Increased masculine effects are common. Increased incidence of some tumors has been reported in people. The 17a- methylated oral anabolic steroids (oxymetholone, stanozolol, and oxandrolone) have been associated with hepatic toxicity.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor hepatic enzymes for evidence of cholestasis and hepatotoxicity. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Hormone, anabolic agent"},{"name":"Propylthiouracil","active_ingredient":"Propylthiouracil","species":["Feline"],"dosage":"Cats \u2022\\t\\t11\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Prostaglandin F 2 Alpha pross- teh- glan\u2032din Trade and other names: Lutalyse, Dinoprost, and PGF 2 alpha","contraindications":"Contraindications and Precautions Do not use in cats with low platelet counts or bleeding problems. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals,\\tbut\\tthe\\tuse\\thas\\tdeclined,\\tand these may not have been reported.","indications":"Indications and Clinical Uses Propylthiouracil has been used for the treatment of feline hyperthyroidism. Because of adverse effects, use of PTU in most cats has been replaced with methimazole or carbimazole. The only remaining indication for PTU in animals is to treat an acute \u201cthyroid storm\u201d because it rapidly inhibits conversion of T 3 to T 4 , which methimazole does not. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects in cats include hepatopathy, hemolytic anemia, thrombocytopenia, and other signs of immune- mediated disease. If these signs are observed, the medication should be changed to another antithyroid agent. Because of the frequency of adverse reactions, the use of PTU for long- term use is discouraged.","notes":"Instructions for Use Avoid the use of PTU because of the frequency of adverse effects. Other drugs, such as methimazole or carbimazole, can be used as a replacement. Patient Monitoring and Laboratory Tests Monitor CBC to look for evidence of hematologic abnormalities. Monitor T 4 levels to assess therapy. Formulations Propylthiouracil has been available in 50-  and 100- mg tablets. The availability of commercial formulations has diminished. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. PTU is slightly soluble in water and soluble in ethanol.","original_category":"Antithyroid"},{"name":"Stanozolol","active_ingredient":"Stanozolol","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/dog\\t(or\\trange\\tof\\t1\u20134\\tmg/dog)\\tq12h\\tPO.\\tThe\\tFDA-\\tapproved\\tdosages\\tare 1\u20132 mg per dog (small breeds) q12h and 2\u20134 mg per dog q12h for large breeds. The tablets may be crushed and administered in food. \u2022\\t\\t25\\t(small\\tbreeds)\\tto\\t50\\tmg/dog\\t(large\\tbreeds)\\tper\\tweek\\tIM. Cats \u2022\\t\\tOral:\\t1\u20132\\tmg/cat\\tq12h\\tPO.\\tThe\\ttablets\\tmay\\tbe\\tcrushed\\tand\\tadministered\\tin\\tfood. \u2022\\t\\tInjection:\\t25\\tmg/cat/wk\\tIM\\t(use\\tcautiously\\tin\\tcats). S Streptozocin 853  Horses \u2022\\t\\t0.55\\tmg/kg\\t(5\\tmL\\tper\\t1000\\tlb)\\tor\\t25\\tmg\\tper\\t100\\tlb\\tIM\\tonce\\ta\\tweek\\tfor\\tup\\tto 4 weeks. Regulatory Information Stanozolol is a Schedule III controlled drug and should not be administered to animals that produce food. RCI Classification: 4 Streptozocin strep- toe- zoe\u2032sin Trade and other names: Streptozotocin and Zanosar","contraindications":"Contraindications and Precautions Do not administer to cats with kidney disease. Use cautiously in dogs that have other pre- existing disease such as liver failure. Do not administer to pregnant animals. Stanozolol, like other anabolic steroids, has a high potential for abuse in humans. This drug is abused by humans to enhance athletic performance and increase muscle development. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Anabolic agents, such as stanozolol, have been used for reversing catabolic conditions, increasing weight gain, increasing muscling in animals, and stimulating erythropoiesis. It has been used in horses during training. Stanozolol has been used in animals with chronic kidney disease, and there is some evidence of an improvement in the nitrogen balance in dogs with renal disease treated with stanozolol. Use in cats is associated with toxicity. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects from these agents are attributed to the pharmacologic action of androgens on various body systems. Increased masculine effects are common. Increased incidence of some tumors has been reported in people. Some 17- alpha\u2013 methylated oral anabolic steroids (oxymetholone, stanozolol, and oxandrolone) are associated with hepatic toxicity. Stanozolol administration in cats with kidney disease has been shown to consistently produce increased hepatic enzymes and hepatic toxicosis.","notes":"Instructions for Use For\\tmany\\tindications,\\tuse\\tin\\tanimals\\t(and\\tdoses)\\tis\\tbased\\ton\\texperience\\tin\\tpeople\\tor anecdotal experience in animals. There is an approved formulation, but the indication is limited to treating debilitated animals when weight gain and appetite stimulation is needed. Other uses are considered extralabel. Patient Monitoring and Laboratory Tests Monitor liver enzymes for signs of hepatic injury (cholestatic) during treatment. Formulations \u2022\\t\\tOral:\\t2-\\tmg\\ttablets,\\tregular\\tand\\tchewable\\tfor\\tdogs. \u2022\\t \\tStanozolol\\tis\\tavailable\\tin\\ta\\t50-\\tmg/mL\\tinjection\\tas\\ta\\tsterile\\tsuspension.\\tHowever,\\tthere has been limited availability of veterinary injectable formulations. Commercial forms have been withdrawn from the market, but some compounding sources still persist. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Hormone, anabolic agent"},{"name":"Testosterone","active_ingredient":"Testosterone","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tTestosterone\\tcypionate\\tester:\\t1\u20132\\tmg/kg\\tevery\\t2\u20134\\tweeks\\tIM. \u2022\\t\\tTestosterone\\tpropionate\\tester:\\t0.5\u20131\\tmg/kg\\ttwo\\tto\\tthree\\ttimes\\tper\\tweek\\tIM.  There are no large animal formulations available except for implants for calves. Do not administer injections to animals intended for food. Regulatory Information RCI Classification: 4 Tetracycline, Tetracycline Hydrochloride tet- rah- sye\u2032kleen  and  tet- rah- sye\u2032kleen  hye- droe- klor\u2032ide Trade and other names: Panmycin, Duramycin powder, and Achromycin V","contraindications":"Contraindications and Precautions Use cautiously in patients with hepatic disease. Do not administer to pregnant animals. This drug has potential for abuse in humans for anabolic uses. Drug Interactions No drug interactions have been reported in animals. T Tetracycline, Tetracycline Hydrochloride 883","indications":"Indications and Clinical Uses Anabolic agents have been used for reversing catabolic conditions, increasing weight gain, increasing muscling in animals, and stimulating erythropoiesis. Testosterone and other anabolic agents have also been abused in people to enhance athletic performance and increase muscle development. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are caused by excessive androgenic action of testosterone. Prostatic hyperplasia is possible in male dogs. Masculinization can occur in female dogs. Hepatopathy is more common with oral methylated testosterone","notes":"formulations than with injected formulations. In men who take excessive testosterone supplements, there are cardiovascular risks. Instructions for Use Use of testosterone androgens has not been evaluated in clinical studies in veterinary medicine. Use is based primarily on experimental evidence or experiences in people. Patient Monitoring and Laboratory Tests Monitor hepatic enzymes in treated patients periodically. Formulations \u2022\\t\\tTestosterone\\tcypionate\\tester\\tis\\tavailable\\tin\\t100-\\t\\tand\\t200-\\tmg/mL\\tinjections. \u2022\\t\\tTestosterone\\tpropionate\\tester\\tis\\tavailable\\tin\\t100-\\tmg/mL\\tinjections. Stability and Storage Testosterone is insoluble in water but soluble in oils and ethanol. Protect from light, heat,\\tand\\tfreezing.\\tWhen\\tmixed\\twith\\toil,\\tit\\thas\\tbeen\\tstable\\tfor\\t60\\tdays.","original_category":"Hormone"},{"name":"Thyroid- Releasing  Hormone","active_ingredient":"Thyroid- Releasing  Hormone","species":["Equine"],"dosage":"\u2022\\t\\tCollect\\tbaseline\\tT 4 followed by 0.1 mg/kg IV. Collect the post- TRH T 4 sample at 4 hours.  \u2022\\t\\tTo\\ttest\\tfor\\tPPID\\tin\\thorses\\t(equine\\tCushing\u2019s\\tsyndrome),\\tadminister\\t1\\tmg\\tsynthetic TRH\\tIV\\tand\\tcollect\\tsamples.\\tThe\\toptimum\\tsample\\ttime\\tis\\t0\\tand\\t30\\tminutes. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Thyrotropin thye- roe- troe\u2032pin Trade and other names: Thytropar, Thyrogen, and TSH","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Thyroid- releasing hormone has been used for diagnostic testing. See Thyrotropin for diagnostic testing for hypothyroidism. There are no specific therapeutic uses. Thyrotropin- releasing hormone has been used to test for pituitary pars intermedia dysfunction (PPID) in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No significant adverse effects have been reported. Allergic reactions are possible. T Thyrotropin 897","notes":"Instructions for Use Used for diagnostic purposes. It is rarely used in small animals but has been used in protocols to test horses for PPID. Patient Monitoring and Laboratory Tests Monitor thyroid concentrations. Collect post- TRH T 4 sample at 4 hours after the test dose. When used for testing PPID in horses, it is used in combination with the insulin sensitivity test. Formulations \u2022\\t\\tThyrel\\tTRH\\t(Protirelin)\\tis\\tsupplied\\tas\\t1-\\tmL\\tampules.\\tEach\\tampule\\tcontains\\t500 mcg of protirelin. However, this form is currently difficult to obtain. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Hormone, thyroid"},{"name":"Thyrotropin","active_ingredient":"Thyrotropin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t50\u2013150\\tmcg\\tinjection\\tper\\tdog. \u2022\\t\\tDiagnostic\\ttesting\\tprocedure\\tfor\\tdogs:\\tReconstitute\\tone\\tvial\\t(1.1\\tmg)\\twith\\t6\\tmL\\tof sterile water and divide into 12 aliquots. Place 0.5 mL in plastic insulin syringes and store in a freezer for future use. For each dose, thaw the syringe and administer one syringe per dog intravenously. The dose that is effective has ranged from 75\u2013150 mcg per dog. The higher dose is reported to have better discriminating power. After injection, measure thyroid hormone (T 4 )\\tat\\t4\\tor\\t6\\thours\\tafter\\tinjection\\t(6 hours is optimal). Post- TSH response should be at least 1.9 mcg/dL over baseline. T Ticarcillin Disodium 899 Generally,\\ta\\tresponse\\tof\\t2.5\u20133.1\\tmcg/dL\\tis\\tconsistent\\twith\\teuthyroidism,\\tless than\\t1.6\\tmcg/dL\\tis\\tindicative\\tof\\thypothyroidism,\\tand\\t1.6\u20132.5\\tmcg/mL\\tis\\tin\\tthe intermediate range and may require follow- up testing.  \u2022\\t\\tNo\\tdosage\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Ticarcillin Disodium tye- kar- sill\u2032in  dye- soe\u2032dee- um Trade and other names: Ticar and Ticillin","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals. Recombinant human thyrotropin (rhTSH) also has been used for the diagnosis of hypothyroidism. Contraindications and Precautions No contraindications have been reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Thyroid- stimulating hormone is used to stimulate secretion of thyroid hormone for diagnostic testing. Because of the limited availability of TSH for diagnostic testing and the high cost of the human form, this test is rarely performed. Bovine TSH has been used in dogs, but anaphylactoid reactions and safety concerns led to a discontinuation of the use. Human recombinant thyrotropin can be administered intravenously and results in a total T 4 increase\\tat\\t4\\tand\\t6\\thours. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse reactions are rare. In people, allergic reactions have occurred.","notes":"Instructions for Use To prepare solution, add 2 mL of sodium chloride to a 10- unit vial. Consult the testing laboratory for specific guidelines for thyroid testing. If the patient is already receiving thyroxine supplement, withdraw treatment for 6\u20138\\tweeks\\tbefore\\ttesting. Patient Monitoring and Laboratory Tests After\\tIV\\tinjection,\\tcollect\\tpost-\\tTSH\\tsample\\tat\\t4\\tor\\t6\\thours\\t(6\\thours\\tis\\toptimal).\\tSee dosing section for complete information on testing in dogs. Formulations \u2022\\t\\tRecombinant\\thuman\\tTSH,\\talso\\tknown\\tas\\tthyrotropin\\talpha\\tor\\tThyrogen,\\thas\\tbeen available in a 1.1- mg vial containing thyrotropin alpha. After reconstitution with 1.2 mL of sterile water, the thyrotropin alpha concentration is 0.9 mg/mL. (See dosing section for specific instructions for preparing the canine dose.) The pH of the reconstituted solution is approximately 7.0. Other forms (Thytropar) are difficult to obtain. Bovine TSH caused reactions in dogs and is no longer available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Reconstituted solutions retain potency for 2 weeks at 2\xb0C\u20138\xb0C, for 4 weeks at 4\xb0C, and 12 weeks if frozen (\u221220\xb0C).","original_category":"Hormone, thyroid"},{"name":"Urofollitropin","active_ingredient":"Urofollitropin","species":["Not specified in source"],"dosage":"\u2022\\t\\tDosages\\tnot\\testablished.\\tHowever,\\tthe\\tusual\\thuman\\tdosage\\tis\\t75\\tunits/day\\tIM\\tfor 7\\tdays.\\tThis\\tmay\\tbe\\tincreased\\tto\\t150\\tunits/day\\tIM\\tfor\\tan\\tadditional\\t7\\tdays.  \u2022\\t\\tDosages\\tnot\\testablished.\\tHowever,\\tthe\\tusual\\thuman\\tdosage\\tis\\t75\\tunits/day\\tIM\\tfor 7\\tdays.\\tThis\\tmay\\tbe\\tincreased\\tto\\t150\\tunits/day\\tIM\\tfor\\tan\\tadditional\\t7\\tdays. Regulatory Information It is expected to pose little risk from residues in animals intended for food, and no withdrawal times are recommended. U U Ursodiol, Ursodeoxycholic Acid 955 Ursodiol, Ursodeoxycholic Acid er- soe- dye\u2032ole,  er- soe- dee- oks- ih- koe- lik  ass\u2032id Trade and other names: Actigall and Urso","contraindications":"Contraindications and Precautions Do not use in pregnant animals. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses Although urofollitropin is used in people in combination with hCG to stimulate ovulation, the use in animals is uncommon. Other than anecdotal accounts, there is little evidence of use in veterinary medicine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects have not been reported in animals, but the use is rare. In people, thromboembolism or severe ovarian hyperstimulation syndrome has been reported. In humans, ovarian enlargement and ovarian cysts have been reported.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals is extrapolated from the experience in people. Use in humans is followed by administration of hCG. Patient Monitoring and Laboratory Tests Monitor estrogen, or progesterone, or both with treatment. Formulations \u2022\\t\\tUrofollitropin\\tis\\tavailable\\tin\\t75\\tunits\\tper\\tvial\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Hormone"},{"name":"Vasopressin","active_ingredient":"Vasopressin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tAntidiuretic:\\t10\\tunits\\tIV\\tor\\tIM.\\t(Desmopressin\\tis\\tpreferred\\tin\\tanimals\\tfor\\ttreating diabetes insipidus.) \u2022\\t\\tVasopressor\\t(shock):\\t0.01\u20130.04\\tunits/min.\\tDo\\tnot\\texceed\\t0.04\\tunits/min\\t(0.5\u20135 milliunits/kg/min). \u2022\\t\\tCPR:\\t0.8\\tunits/kg\\tIV\\tbolus;\\tcan\\tbe\\trepeated\\tduring\\tcardiopulmonary resuscitation.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. 964    Verapamil Hydrochloride Verapamil Hydrochloride ver- ap\u2032ah- mill  hye- droe- klor\u2032ide Trade and other names: Calan and Isoptin","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Vasopressin is used for treatment of polyuria caused by central diabetes insipidus. It is not effective for polyuria caused by renal disease. Desmopressin is the preferred formulation used more frequently in animals for treating diabetes insipidus (see Desmopressin for more\\tdetails.)\\tVasopressin\\tis\\tused\\tto\\ttreat\\tvasodilatory\\tshock\\tvia\\tCRI\\tin\\taddition\\tto\\tfluid therapy. In shock caused by cardiogenic mechanisms or vasodilatory shock, protocols vary with respect to the vasopressor used in emergency situations. Some protocols still rely on catecholamines (e.g., norepinephrine) for their vasoconstrictive properties (via alpha 1 - adrenergic receptors), and some protocols advocate vasopressin. There are no clinical trials in veterinary medicine that establish a superiority of one treatment over another. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported for use in animals. Allergic reactions and increase in blood pressure have been reported in people.","notes":"Instructions for Use For\\tIV\\tuse,\\tdilute\\tin\\t0.9%\\tsaline\\tand\\ttitrate\\tdose\\tto\\teffect.\\tFor\\tantidiuretic\\tuse,\\tdoses are adjusted on the basis of monitoring of water intake and urine output. Patient Monitoring and Laboratory Tests Monitor blood pressure during infusion to maintain systolic blood pressure of 100\u2013120\\tmm\\tHg\\tand\\turine\\toutput\\tof\\t0.5\u20131.5\\tmL/kg/h.\\tTitrate\\tthe\\tinfusion\\trate\\tto achieve desired blood pressure response. When used for antidiuretic effects, monitor water intake, urine output, and urine- specific gravity. Formulations \u2022\\t\\tVasopressin\\tis\\tavailable\\tin\\ta\\t20-\\tunits/mL\\t(aqueous)\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Hormone"}]},{"category":"Gastrointestinal","drugs":[{"name":"Aluminum Hydroxide and Aluminum Carbonate","active_ingredient":"Aluminum Hydroxide and Aluminum Carbonate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAluminum\\thydroxide\\tgel:\\t10\u201330\\tmg/kg\\tq8h\\tPO\\t(with\\tmeals). \u2022\\t\\tAluminum\\tcarbonate\\tgel:\\t10\u201330\\tmg/kg\\tq8h\\tPO\\t(with\\tmeals). Cats \u2022\\t\\tAluminum\\thydroxide\\tgel:\\t10\u201330\\tmg/kg\\tq8h\\tPO\\t(with\\tmeals). \u2022\\t\\tAluminum\\tcarbonate\\tgel:\\t10\u201330\\tmg/kg\\tq8h\\tPO\\t(with\\tmeals).  Horses \u2022\\t\\tAntacid:\\t60\\tmg/kg\\tq8h\\tPO. Regulatory Information No regulatory information is available. Residues from administration to food- producing animals ordinarily are not a concern. However, for extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org.","contraindications":"Contraindications and Precautions Aluminum decreases oral absorption of some drugs (e.g., fluoroquinolones, tetracyclines). If fluoroquinolone antimicrobials are used concurrently, separation of oral doses should be considered. Drug Interactions Aluminum binds and chelates some drugs and prevents GI absorption. Drugs bound to aluminum include tetracyclines and quinolone antibiotics. 28    Amantadine Amantadine ah- man \u0301tah- deen Trade and other names: Symmetrel and generic brands","indications":"Indications and Clinical Uses Aluminum hydroxide is used for its antacid properties to treat or manage GI ulcers. A more common use in small animals is as a phosphate binder. It is indicated in animals with hyperphosphatemia associated with chronic renal failure, often in combination with phosphorus- restricted diets. Although this was once widely available, because of the decreased availability of products containing aluminum, other drugs are used more commonly to decrease hyperphosphatemia in patients, such as calcium carbonate and calcium citrate. A new oral phosphate binder is available in some countries for cats. This product (Lenziaren) consists of a complex of iron oxide/hydroxide and is administered orally to cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects These aluminum- containing compounds are generally safe. However, there has been some concern expressed that these drugs may increase the systemic levels of aluminum, which may lead to some forms of aluminum toxicoses. The evidence for this as a clinical problem in veterinary medicine is lacking. A","notes":"Instructions for Use Antacid doses are designed to neutralize stomach acid, but duration of acid suppression is short. Although aluminum hydroxide is often used to prevent hyperphosphatemia, this drug may not be available in some pharmacies. A substitute for this indication is calcium citrate or calcium carbonate. An oral product is also available for cats to administer as a phosphate binder (Lenziaren), which is a complex of iron oxide/hydroxide. Patient Monitoring and Laboratory Tests Phosphate plasma levels should be monitored to determine success of therapy. Formulations \u2022\\t\\tAluminum\\thydroxide\\tgel\\tis\\tavailable\\tin\\ta\\t64-\\tmg/mL\\toral\\tsuspension\\tand\\t600-\\tmg tablet. \u2022\\t\\tAluminum\\tcarbonate\\tgel\\tis\\tavailable\\tin\\tcapsules\\t(equivalent\\tto\\t500-\\tmg\\taluminum hydroxide). \u2022\\t\\tNote:\\tProducts\\tcontaining\\taluminum\\tmay\\tno\\tlonger\\tbe\\tavailable\\tfrom\\tmany sources, and other products may be used, such as Lenziaren, which is a complex of iron oxide/hydroxide for cats. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antacid"},{"name":"Aprepitant","active_ingredient":"Aprepitant","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tStart\\twith\\t1\\tmg/kg\\tq24h\\tPO\\tand\\tincrease\\tto\\t2\\tmg/kg\\tin\\trefractory\\tpatients.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Ascorbic Acid ah- skor \u0301bik  ass \u0301id Trade and other names: Vitamin C and sodium ascorbate. Many brand names are available.","contraindications":"Contraindications and Precautions No contraindications reported for animals. Drug Interactions Drug interactions are possible because aprepitant is both an inducer and inhibitor of cytochrome P450 enzymes. Potent inhibitors of cytochrome P450 can potentially affect aprepitant clearance. 58    Ascorbic Acid","indications":"Indications and Clinical Uses Aprepitant is an effective antiemetic for people, particularly when used to treat vomiting associated with cancer chemotherapy. It may be used with corticosteroids (dexamethasone) and serotonin antagonists. However, despite its broad effects to decrease vomiting in people, there are no reports of effective use in dogs or cats. Instead, a similar- acting drug, maropitant (Cerenia), is used in dogs and cats and produces similar antiemetic effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There are no reported adverse effects in animals.","notes":"Instructions for Use Use\\t  in\\t patients\\tthat\\t  are\\t  refractory\\tto\\t other\\t   antiemetic\\tdrugs.\\t   It\\t may\\t  be\\t combined\\twith other antiemetics. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAprepitant\\tis\\tavailable\\tin\\t80-\\t\\tand\\t125-\\tmg\\tcapsules\\tand\\tas\\tfosaprepitant dimeglumine in a 150- mg vial for IV use. Stability and Storage Do not crush or mix capsules. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiemetic"},{"name":"Bisacodyl","active_ingredient":"Bisacodyl","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t5\\tmg/animal\\tq8\u201324h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Bismuth Subsalicylate biz\u2032muth  sub- sal- iss\u2032ih- late Trade and other names:  Pepto- Bismol","contraindications":"Contraindications and Precautions Avoid use in patients with renal disease. Do not rely on this medication for long- term treatment of constipation. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Bisacodyl is used as a laxative or for procedures in which bowel evacuation is necessary. It may be used with polyethylene glycol electrolyte solution (e.g., GoLYTELY)\\tto\\tcleanse\\tthe\\tbowel\\tprior\\tto\\tendoscopy\\tor\\tsurgical\\tprocedures. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Abdominal discomfort. Fluid and electrolyte loss. Avoid chronic use.","notes":"Instructions for Use Bisacodyl\\tis\\tavailable\\tas\\tan\\tover-\\tthe-\\t  counter\\t(OTC)\\ttablet.\\tDoses\\tare\\tderived\\tfrom extrapolation of human doses or via empiricism. There are no well- controlled efficacy studies\\tavailable\\tfor\\tveterinary\\tspecies.\\tOnset\\tof\\taction\\tis\\tapproximately\\t1\\thour\\tafter administration. Patient Monitoring and Laboratory Tests Monitor electrolytes in animals if used chronically. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. B Bismuth Subsalicylate 85","original_category":"Laxative"},{"name":"Cascara Sagrada","active_ingredient":"Cascara Sagrada","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1\u20135\\tmg/kg/day\\tPO. Cats \u2022\\t\\t1\u20132\\tmg/cat/day\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Castor Oil kas\u2032tar oil Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not use in cases in which there may be intestinal obstruction. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Laxative used to treat constipation or evacuate bowel for procedures. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overuse can cause electrolyte losses.","notes":"Instructions for Use Available in various dietary supplements. This agent is not used clinically very often for GI procedures. 134    Castor Oil Patient Monitoring and Laboratory Tests Monitor electrolytes with chronic therapy. Formulations \u2022\\t\\tCascara\\tsagrada\\tis\\tavailable\\tin\\ta\\tvariety\\tof\\tstrengths,\\tincluding\\ttablets,\\tcapsules,\\tand liquids. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Laxative"},{"name":"Castor Oil","active_ingredient":"Castor Oil","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t8\u201330\\tmL/day\\tPO. Cats \u2022\\t\\t4\u201310\\tmL/day\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable. Cefaclor sef\u2032ah- klor Trade and other names: Generic","contraindications":"Contraindications and Precautions Do not use in pregnant animals. It may induce labor. Castor oil has been known to induce histamine release. Monitor patients for signs of histamine reaction. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals. C Cefaclor 135","indications":"Indications and Clinical Uses Castor oil is used as a laxative to treat constipation or to evacuate the bowel for procedures. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overuse can cause electrolyte losses. Castor oil has been known to stimulate premature labor in pregnancy.","notes":"Instructions for Use Use in animals is strictly empirical. The doses used are empirical or extrapolated from the human use. It is available as an OTC product. Pet owners should be discouraged from repeated administration to pets. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tCastor\\toil\\tis\\tavailable\\tin\\tan\\toral\\tliquid\\t(100%)\\tand\\t700-\\tmg\\t\u201cCastroclean\u201d\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Laxative"},{"name":"Chlorpromazine","active_ingredient":"Chlorpromazine","species":["Equine","Feline","Bovine"],"dosage":"Horses \u2022\\t\\tAvoid\\tuse. Cattle \u2022\\t\\t0.22\\tmg/kg\\tIV\\tor\\t1.1\\tmg/kg\\tIM,\\tsingle\\tdose. Sheep and Goats \u2022\\t\\t0.55\\tmg/kg\\tIV\\tor\\t2.2\\tmg/kg\\tIM,\\tsingle\\tdose. Pigs \u2022\\t\\t0.5\\tmg/kg\\tIM,\\tsingle\\tdose. 178    Chlortetracycline Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t2 Chlortetracycline klor- tet\u2032  rah- sye- kleen Trade and other names: Aureomycin soluble powder, Aureomycin tablets, Aureomycin soluble calf tablets, Anaplasmosis block, Calf Scour Bolus, Fermycin, and generic brands","contraindications":"Contraindications and Precautions Although a specific risk has not been shown, use with caution in animals with seizure disorders and animals prone to hypotension. Avoid use in horses. Drug Interactions It will potentiate effects from other sedatives.","indications":"Indications and Clinical Uses Use in animals has been primarily derived from empirical use. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Chlorpromazine is most often used as a centrally acting antiemetic for disorders that produce vomiting via a central- acting mechanism. These conditions include administration of emetic cancer chemotherapeutic agents and GI diseases. It is also used for sedation and preanesthetic purposes, although acepromazine has been more commonly used. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effect is sedation. Like acepromazine, it also may cause alpha- adrenergic blockade and vasodilation, but this effect has not been as well documented as for acepromazine. It may produce anticholinergic effects in some animals. Although phenothiazines are reported to decrease the threshold for producing seizures in some animals, this has not been shown in retrospective studies with acepromazine in animals and has not been reported specifically for chlorpromazine. Like other phenothiazines, it may produce extrapyramidal side effects (involuntary muscle movement) in some individuals. In horses, it has produced undesirable side effects, including violent reactions.","notes":"Instructions for Use Chlorpromazine is used for vomiting caused by toxins, drugs, or GI disease. Higher doses than\\tlisted\\tin\\tthe\\tdose\\tsection\\thave\\tbeen\\tused\\twith\\tcancer\\tchemotherapy\\t(2\\tmg/kg\\tq3h\\tSQ). Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tChlorpromazine\\tis\\tavailable\\tin\\ta\\t25-\\tmg/mL\\tinjection\\tsolution,\\tand\\t10-\\t,\\t25-\\t  ,\\t50-\\t  , 100- , and 200- mg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Slight discoloration does not affect stability. Some sorption (loss) occurs if stored in polyvinyl chloride (soft plastic) containers. Small Animal Dogs \u2022\\t\\t0.5\\tmg/kg\\tq6\u20138h\\tIM\\tor\\tSQ. Cats \u2022\\t\\t0.2\u20130.4\\tmg/kg\\tq6\u20138h,\\tup\\tto\\t0.5\\tmg/kg\\tq8h\\tIM\\tor\\tSQ.","original_category":"Antiemetic, phenothiazine"},{"name":"Cisapride","active_ingredient":"Cisapride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.5\\tmg/kg\\tq8\u201312h\\tPO\\t(up\\tto\\t0.5\u20131.0\\tmg/kg).\\t1\\tmg/kg\\tIV\\tif\\tused\\tto prevent gastroesophageal reflux during anesthesia. Cats \u2022\\t\\t2.5\u20135\\tmg/cat\\tq8\u201312h\\tPO\\t(up\\tto\\t1\\tmg/kg\\tq8h).  Horses \u2022\\t\\t0.1\\tmg/kg\\tIV.\\tNote:\\tThis\\tformulation\\tis\\tnot\\tcommercially\\tavailable,\\tbut\\tan\\tIV form\\thas\\tbeen\\tcompounded\\t(see\\tthe\\tFormulation\\tsection\\tearlier). Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it poses a risk to humans. Cisplatin sis- plah\u2032tin Trade and other names: Platinol","contraindications":"Contraindications and Precautions Contraindicated in patients with GI obstruction. Avoid use in dogs with megaesophagus because it will increase pressure of the lower esophageal sphincter. Drug Interactions Anticholinergic drugs, such as atropine, diminish the action. Cisapride should not be used with drugs that inhibit metabolism (CYP450 inhibitors) or drugs that inhibit P- glycoprotein. Toxicity may result (see list of drugs in Appendixes J and I).","indications":"Indications and Clinical Uses Cisapride is used to stimulate motility for treating gastric reflux, gastroparesis, ileus, and constipation. The most common uses in animals have been to prevent stomach regurgitation, reduce gastroesophageal reflux, decrease postoperative ileus, and treat constipation and megacolon in cats. In dogs, it was shown to be more effective than other treatments for preventing gastroesophageal reflux in anesthetized dogs. It is not effective to stimulate motility in dogs with megaesophagus. Cisapride has improved recovery of horses with postoperative ileus. Cisapride was removed from the human market and is no longer commercially available. Compounding pharmacies have made\\tcisapride\\tavailable\\tto\\tveterinarians\\tin\\tcompounded\\tforms\\t(see\\tthe\\tFormulations section). However, these formulations are not licensed and are unregulated. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse cardiac effects have been reported in people and are the cause for discontinuation in human medicine. These cardiac effects have not been reported in animals. High overdoses in dogs (18 mg/kg) have produced abdominal pain, aggression, ataxia, fever, and vomiting. With higher overdoses, diarrhea, ataxia, and\\tCNS\\treactions\\thave\\tbeen\\tobserved.","notes":"Instructions for Use Not\\tcurrently\\tavailable\\tcommercially.\\tCisapride\\twas\\tdiscontinued\\tby\\tthe manufacturer in July 2000. However, some veterinary pharmacies can fill some orders or prepare compounded formulations for animals. Consult local compounding pharmacist about availability. Doses are based on extrapolation from human doses, experimental studies, and anecdotal evidence. Efficacy studies have not been performed in dogs or cats. Patient Monitoring and Laboratory Tests In humans, cardiac effects have been reported (arrhythmias). Monitor ECG in susceptible patients. Formulations \u2022\\t\\tCisapride\\twas\\tonce\\tavailable\\tin\\ta\\t10-\\tmg\\ttablet\\tbut\\thas\\tbeen\\tdiscontinued\\tby the\\tmanufacturer.\\tFormulations\\tused\\tare\\tprepared\\tby\\tcompounding\\tfrom\\ta pure source. To prepare 1 mg/mL injectable solution (follow United States Pharmacopeia [USP] <797> sterile compounding standards), mix 0.104 g of cisapride monohydrate with 20 mL tartaric acid 6% solution. Add sterile water to make up a 100- mL total volume. Keep the solution in the refrigerator, in a sterile vial, protected from light, and labeled with Beyond Use Date of 14 days post- compounding. A 10- mg/mL oral suspension (follow USP <795> compounding standards) has been prepared by mixing 300 mg (0.3 g) of cisapride monohydrate with 15 mL of Ora Plus and enough Ora Sweet added to make a total of volume of 30 mL. (Oral Plus and Ora Sweet are oral formulation suspending agents and vehicles commonly used in commercial pharmacies.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Injectable solution should be used within 14 days. An oral suspension of 10 mg/mL in aqueous vehicle was stable for 30 days in a refrigerator. C Cisplatin 187","original_category":"Prokinetic agent"},{"name":"Docusate","active_ingredient":"Docusate","species":["Canine","Feline"],"dosage":"Dogs Cats  Regulatory Information No regulatory information is available for animals intended for food. Because docusate has primarily a locally acting effect in the intestine, there is a minimal risk of residues in animals intended for food. Dolasetron Mesylate doe- lah \u0301seh- tron  mess \u0301ih- late  (also,  dahl- ah \u0301set- rahn) Trade and other names: Anzemet","contraindications":"Contraindications and Precautions Some formulations of docusate calcium and docusate sodium products have contained the stimulant cathartic phenolphthalein, which should be used cautiously in cats. Examine label of products to ensure absence of phenolphthalein. Drug Interactions No specific drug interactions are reported for animals.","indications":"Indications and Clinical Uses Docusate is indicated for medical conditions in which softened feces are desirable, such as after intestinal or anal surgery, to help pass hardened feces, and when administering drugs that slow intestinal transit (e.g., opiates). Docusate is indicated for the treatment of constipation. The use of docusate in animals is based purely on anecdotal experience or extrapolations from uses in people. There are no clinical studies with docusate available for animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects reported in animals. In people, high doses have caused abdominal discomfort.","notes":"Instructions for Use Doses are based on extrapolations from humans or empiricism. No clinical studies have been reported for animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tDocusate\\tcalcium\\tis\\tavailable\\tas\\t60-\\tmg\\ttablets\\tand\\t240-\\tmg\\tcapsules. \u2022\\t\\tDocusate\\tsodium\\tis\\tavailable\\tas\\t50-\\t\\tand\\t100-\\tmg\\tcapsules\\tand\\t10-\\tmg/mL\\tliquid. D Dolasetron Mesylate 297 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Laxative"},{"name":"Dolasetron Mesylate","active_ingredient":"Dolasetron Mesylate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tPrevention\\tof\\tnausea\\tand\\tvomiting:\\t0.6\\tmg/kg,\\tq12\u201324h,\\tIV,\\tSQ,\\tor\\tPO,\\tor 1.2\\tmg/kg\\tonce.\\tOral\\tabsorption\\tis\\tlow\\tand\\tmay\\tnot\\tbe\\tsufficient\\tto\\tproduce clinical effects. \u2022\\t\\tTreating\\tvomiting\\tand\\tnausea:\\t1\\tmg/kg\\tonce\\tdaily\\tIV\\tor\\tPO.\\tOral\\tabsorption\\tis low and may not be sufficient to produce clinical effects.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported. Regulatory Information Use in animals intended for food is negligible. No regulatory information is available. D Domperidone 299 Domperidone dahm- pare \u0301ih- done Trade and other names: Motilium and Equidone Gel","contraindications":"Contraindications and Precautions There are no important contraindications identified in animals. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported.\\tHowever,\\tdolasetron\\tis\\tsubject\\tto effects\\tfrom\\tcytochrome\\tP450\\tinducers\\tand\\tinhibitors.\\t(See\\tAppendixes\\tH and I.) Dolasetron and others in this class have been used concurrently with maropitant without signs of adverse interactions.","indications":"Indications and Clinical Uses Like\\tother\\tserotonin\\tantagonists,\\tdolasetron\\tis\\tused\\tprimarily\\tfor\\tits\\tantiemetic\\teffects during chemotherapy, for which they generally have been highly effective. These drugs also may be used to control vomiting from surgery (postoperative nausea and vomiting). It is not effective for xylazine- induced vomiting in cats. These drugs are often used in combination, usually with maropitant (Cerenia), to provide a multi- modal treatment for vomiting in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Dolasetron adverse effects have not been reported in animals. These drugs have little\\taffinity\\tfor\\tother\\t5-\\tHT\\treceptors.","notes":"Instructions for Use Dolasetron has not been studied as much as other antiemetics in veterinary medicine. There are other antiemetics in this class (ondansetron) and other agents (maropitant) that are used more commonly. The dosages are derived from anecdotal experience or extrapolation from human studies, and no clinical studies are reported from animal studies. These drugs are more effective if used to prevent vomiting (administered prior to a chemotherapeutic agent) rather than to treat ongoing vomiting. This class of drugs may be combined with corticosteroids (e.g., dexamethasone) or maropitant to enhance the antiemetic action. Patient Monitoring and Laboratory Tests Monitor\\tGI\\tsigns\\tin\\tvomiting\\tpatient. Formulations \u2022\\t\\tDolasetron\\tis\\tavailable\\tin\\t50-\\t\\tand\\t100-\\tmg\\ttablets\\tand\\t20-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It may be added to fluid solutions (compatible in most IV fluid solutions) but do not mix\\twith\\tother\\tIV\\tdrugs.\\tDo\\tnot\\tuse\\tinjection\\tafter\\t24\\thours\\twhen\\tadded\\tto\\tfluids. Oral\\tformulations\\thave\\tbeen\\tadded\\tto\\tfruit\\tjuice\\tup\\tto\\t2\\thours\\tat\\troom\\ttemperature without loss of stability.","original_category":"Antiemetic"},{"name":"Domperidone","active_ingredient":"Domperidone","species":["Canine","Feline","Equine"],"dosage":"\u2022\\t\\tDog\\tand\\tcat:\\t2\\tmg\\tper\\tcat\\tor\\t2\u20135\\tmg\\tper\\tdog\\tq8\u201312h\\tPO. \u2022 \\t \\tLeishmania\\ttreatment\\tin\\tdogs:\\t1\\tmg/kg\\tq12h\\tfor\\t1\\tmonth. \u2022\\t\\tTreatment\\tto\\tincrease\\tprolactin\\tin\\tnursing\\tdogs\\tor\\tcats:\\t1.5\u20132\\tmg/kg\\tfor\\tcats\\tand 2.2\\tmg/kg\\tfor\\tdogs,\\tadministered\\tPO\\tfor\\t1\u20133\\tweeks\\tduring\\tnursing.  Horses \u2022\\t\\tFor\\tfescue\\ttoxicity\\tand\\tagalactia:\\tEquidone\\toral\\tgel\\t(11%)\\tadministered\\t10\\tdays prior\\tto\\tfoaling\\tat\\t1.1\\tmg/kg\\tdaily\\tPO,\\tstarting\\t10\\tdays\\tbefore\\tthe\\tscheduled foaling\\tdate.\\t(This\\tdose\\tis\\tequivalent\\tto\\t5\\tmL\\tper\\t500\\tkg\\tor\\t5\\tmL\\tper\\tadult\\thorse daily\\tPO\\tof\\tthe\\t11%\\toral\\tgel.)\\tContinue\\tuntil\\tfoaling.\\tIf\\tthere\\tis\\tnot\\tadequate\\tmilk production after foaling, continue for 5 additional days. D Dopamine Hydrochloride 301 \u2022\\t\\tTreatment\\tof\\tlaminitis:\\t1.1\\tmg/kg\\tPO. \u2022\\t\\tFor\\ttesting\\thorses\\twith\\tsuspect\\tPPID:\\tAdminister\\t5\\tmg/kg\\toral\\tdomperidone\\tand collect\\tblood\\tsamples\\tat\\t0,\\t2,\\t4,\\thours\\tfor\\tendogenous\\tACTH\\tmeasurement.\\tThe ACTH\\treference\\trange\\tis\\t9\u201335\\tpg/mL. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Dopamine Hydrochloride doe \u0301pah- meen  hye- droe- klor \u0301ide Trade and other names: Intropin (discontinued), and generic","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tGI\\tobstruction.\\tThere\\tare\\tno\\treported\\tadverse\\teffects during pregnancy. It has low milk concentrations in treated animals and no reported adverse effects from offspring during nursing of treated animals. Drug Interactions Acidity is needed for oral administration. Do not administer with stomach antacids, such as omeprazole, cimetidine, or antacids; or acid- suppressing drugs such\\tas\\tomeprazole;\\tor\\tH 2 receptor blockers (e.g., famotidine).","indications":"Indications and Clinical Uses In horses, domperidone is used to treat fescue toxicosis and periparturient agalactia in mares. Fescue toxicosis is caused by a fungus that produces a toxin that causes reproductive problems in horses. The action of domperidone to increase lactation is through the stimulation of prolactin. It increases follicular growth in seasonally anestrus mares and has been used (with altrenogest and estradiol) to induce lactation in barren mares. Domperidone is a dopamine antagonist and has been used to test for pituitary pars intermedia dysfunction (PPID) in horses, but there are other approved treatments (e.g., pergolide). Domperidone has been used for short- term treatment to increase prolactin and aid milk production in nursing dogs and cats. Domperidone\\thas\\tbeen\\tused\\tto\\ttreat\\tgastroparesis\\tin\\tanimals.\\tHowever,\\tat\\ta dose\\tof\\t1.1\\tmg/kg\\tPO\\tin\\thorses,\\tit\\tdoes\\tnot\\tproduce\\ta\\tsignificant\\tintestinal\\tmotility stimulating\\teffect,\\tbut\\tat\\t0.2\\tmg/kg\\tIV,\\tit\\tis\\teffective\\tat\\trestoring\\tmotility\\tin experimental horses (no IV form is available). Domperidone increases digital laminar blood flow in horses. Because of this effect, it has been administered orally to horses as part of a regiment for treating laminitis. Most of this evidence is obtained from healthy research horses, and clinical effects to improve laminitis have not been established. Domperidone has been used to improve clinical signs in dogs infected with Leishmania spp. This effect may occur through prolactin production. Dogs treated with\\t1\\tmg/kg\\tq12h\\tfor\\t1\\tmonth\\treduced\\tclinical\\tsigns\\tand\\tantibody\\ttiters.\\tIt\\talso has been used in dogs and cats to increase prolactin and increase milk production in lactating bitches. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects that are seen with metoclopramide are not as common with domperidone\\tbecause\\tit\\tdoes\\tnot\\tcross\\tthe\\tblood\u2013brain\\tbarrier\\tas\\treadily\\tas metoclopramide. It causes a transient increase in aldosterone and prolactin secretion. It has also caused a transient increase in plasma adrenocorticotropic hormone\\t(ACTH),\\twhich\\tcould\\texacerbate\\tequine\\tCushing\\tsyndrome.","notes":"Instructions for Use Domperidone\\tequine\\tgel\\tis\\tavailable\\tfor\\tuse\\tin\\thorses\\tfor\\tthe\\ttreatment\\tof\\tagalactia and fescue toxicosis. It is approved by the FDA for this indication in mares but has questionable\\tefficacy\\tas\\ta\\tprokinetic\\tagent\\tfor\\ttreatment\\tof\\tileus\\tin\\tanimals. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\trequired,\\tbut\\tclinical\\tmonitoring\\tof\\tGI\\tmotility\\tis important. Formulations \u2022\\t\\tFormulation\\tused\\tin\\thorses\\tis\\toral\\tgel\\tat\\t11%\\t(110\\tmg/mL).\\tIn\\tCanada,\\tit\\tis available\\tas\\t10-\\tmg\\ttablets\\tfor\\tpeople. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Prokinetic agent"},{"name":"Dronabinol","active_ingredient":"Dronabinol","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t5\\tmg/m 2 PO,\\tup\\tto\\t15\\tmg/m 2 for antiemetic administration prior to chemotherapy. \u2022\\t\\tAppetite\\tstimulation:\\tstart\\tat\\t2.5\\tmg\\tbefore\\tmeals.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Dronabinol is a Schedule III controlled drug. Do not administer to animals intended for food. E Edetate Calcium Disodium 317 Edetate Calcium Disodium ed \u0301eh- tate  kal\u2019see- um  dye- soe\u2019- dee- um Trade and other names: Calcium disodium versenate and calcium disodium ethylenediaminetetra- acetate  (EDTA)","contraindications":"Contraindications and Precautions No known contraindications. Drug Interactions No drug interactions reported for animals, but cannabinoids are known microsomal enzyme inhibitors.","indications":"Indications and Clinical Uses Cannabinoids have been used in people who have not responded to any other antiemetic drugs (e.g., patients who are receiving anticancer drugs). This agent and\\tanother\\tsynthetic\\tform\\tof\\tTHC\\tis\\tused\\tto\\tincrease\\tthe\\tappetite\\tin\\tpatients\\twith terminal disease, cancer, and AIDS. Their use has not been reported in veterinary patients, but they have been used by some veterinarians to increase the appetite in cats. The\\toral\\tsynthetic\\tTHC\\tagents\\thave\\tnot\\tbeen\\teffective\\tfor\\ttreatment\\tof\\tchronic\\tpain. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cannabinoids are relatively well tolerated in people, but side effects include drowsiness, dizziness, ataxia, and disorientation. Withdrawal signs may occur after abrupt discontinuation after repeated doses. Adverse effects have not been reported\\tin\\tanimals\\tbecause\\tof\\tinfrequent\\tuse.","notes":"Instructions for Use Dronabinol\\tis\\ta\\tform\\tof\\tsynthetic\\tmarijuana\\t(THC)\\tand\\tis\\tavailable\\tas\\tan antiemetic prescription drug. Most clinical use in animals has been anecdotal. It has been administered to decrease vomiting and improve appetite associated with chemotherapy. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tDronabinol\\tis\\tavailable\\tin\\t2.5-\\t,\\t5-\\t ,\\tand\\t10-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiemetic"},{"name":"Granisetron Hydrochloride","active_ingredient":"Granisetron Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.01\\tmg/kg\\tIV\\tor\\t0.02\\tmg/kg\\tPO.\\t(Oral\\tdoses\\thave\\tbeen\\textrapolated\\tfrom people:\\t2\\tmg/person\\tPO\\tas\\tsingle\\tdose.)  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available for food animals. Because of low risk of residues, no withdrawal times are suggested. Grapiprant grap\u2032ah- prant Trade and other names: Galliprant","contraindications":"Contraindications and Precautions No contraindications reported in animals. Drug Interactions No interactions are reported. It may be used with cancer chemotherapy agents. There are no known drug interactions in animals, but use has been infrequent for these to be fully documented. 418    Grapiprant","indications":"Indications and Clinical Uses Granisetron, like other serotonin antagonists, is used primarily as an antiemetic during chemotherapy, for which it has been effective. It can be used concurrently with maropitant, which acts through a different mechanism. These combinations are used commonly in small animals. Granisetron may be administered prior to chemotherapy to prevent nausea and vomiting or for GI diseases that stimulate vomiting in dogs and cats. Use in animals has been primarily derived from empirical use. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects None reported in dogs or cats. The use of granisetron is uncommon, and a full listing of adverse effects is not available. These drugs have little affinity for other serotonin receptors.","notes":"Instructions for Use There have been only limited uses of this class of antiemetic drugs in veterinary patients. Most doses have been extrapolated from human uses. Granisetron and other serotonin receptor antagonists may be combined with maropitant. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tGranisetron\\tis\\tavailable\\tin\\t1-\\tmg\\ttablets,\\t1-\\tmg/mL\\tinjection,\\tand\\t0.5-\\tmg/mL\\toral solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Discard opened vial after 30 days. Compounded solutions are stable in various fluids for 24 hours. Oral compounded formulations have been prepared in juices, syrups, and flavorings and were stable for 14 days.","original_category":"Antiemetic"},{"name":"Lactulose","active_ingredient":"Lactulose","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tConstipation:\\t1\\tmL/4.5\\tkg\\tq8h\\t(to\\teffect)\\tPO. \u2022\\t\\tHepatic\\tencephalopathy:\\t0.5\\tmL/kg\\tq8h\\tPO. Cats \u2022\\t\\tConstipation:\\t1\\tmL/4.5\\tkg\\tq8h\\t(to\\teffect)\\tPO. \u2022\\t\\tHepatic\\tencephalopathy:\\t2.5\u20135\\tmL/cat\\tq8h\\tPO.  Horses and Cattle \u2022\\t\\t0.25\u20130.5\\tmL/kg/day\\tPO. Regulatory Information There is little risk of residues in animals intended for food. No withdrawal times are necessary. Leflunomide le- floo\u2032noe- mide  or  leh- flew\u2032nah- mide Trade and other names: Arava and generic","contraindications":"Contraindications and Precautions Use lactulose with caution in animals with diabetes because it contains lactose and galactose. Drug Interactions No drug interactions are reported for animals. It potentially could change the oral absorption of some drugs by changing the intestinal pH.","indications":"Indications and Clinical Uses Lactulose is administered orally for treatment of hyperammonemia (hepatic encephalopathy) because it decreases blood ammonia concentrations via lowering the pH of the colon; thus, ammonia in the colon is not as readily absorbed. Lactulose also is administered orally to produce a laxative effect for treatment of constipation. The uses of lactulose in small animals are based on anecdotal observations and recommendations by experts. There are no clinical studies available to evaluate efficacy. L Leflunomide 505 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Excessive use may cause fluid and electrolyte loss.","notes":"Instructions for Use In veterinary medicine, clinical studies to establish efficacy are not available. In addition to doses cited, 20\u201330 mL/kg of 30% solution retention enema has been used in cats. Patient Monitoring and Laboratory Tests When used for treating hepatic encephalopathy, monitor the patient\u2019s hepatic status. Formulations \u2022\\t\\tLactulose\\tis\\tavailable\\tin\\t10-\\tg/15\\tmL\\tliquid\\tsolution\\t(3.3\\tg\\tper\\t5\\tmL). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water. Darkening of the solution may occur without affecting stability. Avoid freezing.","original_category":"Laxative"},{"name":"Magnesium Citrate","active_ingredient":"Magnesium Citrate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t2\u20134\\tmL/kg/day\\tPO.\\tFor\\tthe\\tPronefra\\tproduct\\t(in\\tcombination\\twith\\tcalcium carbonate),\\tadminister\\ttwice\\tdaily\\tat\\tmealtimes.\\t1\\tmL\\tper\\tcat\\tor\\t1\\tmL\\tper\\tdog twice daily PO, preferably at mealtimes.  Horses and Cattle \u2022\\t\\t2\u20134\\tmL/kg\\tonce\\tPO. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Magnesium Hydroxide Trade and other names: Milk of Magnesia, Carmilax, and Magnalax","contraindications":"Contraindications and Precautions Magnesium accumulation may occur in patients with renal impairment. Cathartics containing magnesium decrease oral absorption of ciprofloxacin and other fluoroquinolones. Drug Interactions No drug interactions have been reported for animals. However, it may increase clearance of some drugs administered orally.","indications":"Indications and Clinical Uses Magnesium citrate is administered orally for constipation and bowel evacuation prior to certain procedures. It also may be used to promote intestinal clearance of an ingested toxin. It is prompt in its cathartic action. In the formulation Pronefra (in combination with calcium carbonate), it is used as a phosphate binder to patients with kidney disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. However, fluid and electrolyte loss can occur with overuse.","notes":"Instructions for Use Magnesium citrate is commonly used to evacuate the bowel prior to surgery or diagnostic procedures. Doses are empirical and extrapolated from other species. Onset of action is rapid. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. However, monitor magnesium concentrations in patients if repeated treatments or high doses are administered. Formulations \u2022\\t\\tMagnesium\\tcitrate\\tis\\tavailable\\tin\\ta\\t6%\\toral\\tsuspension.\\tThe\\tformulation\\tPronefra also is available as calcium carbonate and magnesium carbonate. It is an oral syrup that may be administered as a phosphate binder in cats and dogs. Pronefra is a palatable liquid suspension with poultry liver flavoring. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. M M Magnesium Hydroxide 543","original_category":"Laxative"},{"name":"Magnesium Hydroxide","active_ingredient":"Magnesium Hydroxide","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022 \\t \\tAntacid:\\t5\u201310\\tmL/dog\\tq4\u20136h\\tPO. \u2022 \\t \\tCathartic:\\t15\u201350\\tmL/dog\\tq24h\\tPO. Cats \u2022 \\t \\tAntacid:\\t5\u201310\\tmL/cat\\tq4\u20136h\\tPO. \u2022 \\t \\tCathartic:\\t2\u20136\\tmL/cat\\tq24h.  Sheep and Cattle \u2022\\t \\t1\\tg/kg\\tor\\t1\\tbolus\\tper\\t27\\tkg\\t(60\\tlb)\\tPO\\tonce\\t(three\\tor\\tfour\\tboluses\\tfor\\tadult\\tcattle). \u2022\\t\\tFor\\tthe\\tpowder,\\tmix\\t1\\tlb\\t(0.45\\tkg)\\twith\\t1\\tgallon\\tof\\twater\\tand\\tadminister 500\\tmL/45\\tkg\\t(500\\tmL\\tper\\t100\\tlb).\\tFor\\tthe\\tproduct\\tPolyox,\\tadminister\\t180\\tmL for\\tanimals\\tweighing\\tless\\tthan\\t225\\tkg\\tand\\t360\\tmL\\tfor\\tanimals\\tweighing\\tgreater than\\t225\\tkg\\tbody\\tweight. Regulatory Information Withdrawal\\ttime\\tfor\\tanimals\\tintended\\tfor\\tfood:\\t12\u201324\\thours\\t(milk)\\tdepending\\ton\\tthe product. Magnesium Sulfate Trade and other names: Epsom salts","contraindications":"Contraindications and Precautions Magnesium accumulation may occur in patients with renal impairment. Drug Interactions Cathartics containing magnesium decrease oral absorption of ciprofloxacin and other fluoroquinolones.","indications":"Indications and Clinical Uses Magnesium hydroxide is used for constipation and bowel evacuation prior to certain procedures. It is commonly used to evacuate the bowel prior to surgery or\\tdiagnostic\\tprocedures.\\tThe\\tonset\\tof\\taction\\tis\\trapid\\tafter\\toral\\tadministration. Magnesium hydroxide also is used as an oral antacid to neutralize stomach acid. In large animals, it is used as an antacid and mild cathartic. In cattle, approximately 1\\tg/kg\\tas\\ta\\tsingle\\tdose\\tsignificantly\\tincreases\\trumen\\tpH\\tand\\tdecreases\\trumen microbial activity. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. However, fluid and electrolyte loss can occur with overuse.","notes":"Instructions for Use Administer to patients only if they are properly hydrated. Patient Monitoring and Laboratory Tests Monitor electrolytes with chronic use. 544    Magnesium Sulfate Formulations \u2022\\t\\tMagnesium\\thydroxide\\tis\\tavailable\\tas\\tan\\toral\\tliquid\\t400\\tmg/5\\tmL,\\tor\\t400\\tmg\\tper teaspoon\\t(Milk\\tof\\tMagnesia)\\tover\\tthe\\tcounter.\\tIt\\tis\\talso\\tavailable\\tas\\ta\\t27-\\t\\tor\\t90-\\tg bolus\\tfor\\tcattle\\tand\\tsheep\\tand\\tas\\ta\\tpowder\\t310\u2013360\\tg/lb\\t(approximately\\t745\\tg/ kg). As a powder, 1 lb of powder is equivalent to 1 gallon of Milk of Magnesia, and three\\t27-\\tg\\tboluses\\tare\\tequal\\tto\\t1\\tquart\\tof\\tMilk\\tof\\tMagnesia. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Laxative"},{"name":"Maropitant Citrate","active_ingredient":"Maropitant Citrate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1\\tmg/kg\\tSQ\\tor\\tIV\\tor\\t2\\tmg/kg\\tPO\\tonce\\tdaily\\tfor\\tup\\tto\\t5\\tdays\\tin\\tdogs\\t2\u20137\\tmonths of\\tage\\tand\\tuntil\\tthe\\tproblem\\tis\\tresolved\\tfor\\tdogs\\tolder\\tthan\\t7\\tmonths. \u2022\\t\\tMotion\\tsickness:\\t8\\tmg/kg\\tPO\\tonce\\tdaily\\tfor\\tup\\tto\\t2\\tconsecutive\\tdays. \u2022\\t\\tTo\\tprevent\\topioid-\\tinduced\\tvomiting:\\t2\u20134\\tmg/kg\\tPO\\tor\\t1\\tmg/kg\\tSQ\\tor\\tIV\\tprior to anesthetic procedure. Cats \u2022\\t\\t1\\tmg/kg\\tonce\\tdaily\\tIV,\\tSQ,\\tor\\tPO\\t(same\\tdose\\tfor\\tall\\tcauses\\tof\\tvomiting,\\tincluding motion sickness). \u2022\\t\\tTo\\tdecrease\\tvomiting\\tfrom\\thighly\\temetic\\tagents\\tin\\tcats,\\tadminister\\tat\\tleast\\t2\u20132.5 hours prior to the administration of another emetic drug. \u2022\\t\\tTo\\tdecrease\\tvomiting\\tand\\tnausea\\tfrom\\tkidney\\tdisease:\\t4\\tmg\\tper\\tcat\\tper\\tday\\tPO. \u2022\\t\\tPrior\\tto\\tanesthesia:\\tAdminister\\t8\\tmg\\tper\\tcat\\t(2.5\\tmg/kg)\\toral\\t18\\thours\\tprior to\\ta\\tscheduled\\tanesthetic\\tprocedure\\tto\\treduce\\tanesthesia-\\tinduced\\tvomiting. Alternatively,\\tadminister\\tan\\tSQ\\tinjection\\t20\\thours\\tprior\\tto\\tthe\\tscheduled\\tanesthetic procedure. other\\tneurokinin\\treceptors\\tare\\taffected\\tto\\ta\\tlesser\\tdegree.\\tTherefore,\\tbecause\\tof\\tthis unique mechanism of action, drug interactions have not been identified. Maropitant has been used safely with other drugs, including anesthetics, anticancer agents, and other antiemetic agents. Maropitant is highly protein bound, but it is not known if there\\tare\\tprotein-\\tbinding\\tinteractions\\twith\\tother\\tdrugs. M MCT Oil 553  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\tidentified. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable\\tfor\\tfood\\tanimals.\\tThere\\tare\\tno\\twithdrawal times established, and it is not recommended to be administered to animals that produce food. Note: Masitinib has been withdrawn from the market and is no longer available. Consult previous editions of this book for information on the pharmacology, clinical use, and dosing. MCT Oil Trade and other names: Medium- chain triglycerides (MCT) oil","contraindications":"Contraindications and Precautions Decreased clearance and accumulation occur after repeated doses with higher doses.\\tTherefore,\\tbecause\\tof\\trisk\\tof\\taccumulation,\\tthe\\toriginal\\tlabel\\tstated\\tthat it\\tshould\\tnot\\tbe\\tadministered\\tfor\\tmore\\tthan\\t5\\tconsecutive\\tdays,\\tand\\tone\\tshould allow\\ta\\t2-\\tday\\twashout\\tperiod\\tbefore\\tinstituting\\tanother\\tcourse\\tof\\ttreatment. However,\\tfollow-\\tup\\tstudies\\tand\\ta\\tnew\\trevised\\tlabel\\tindicate\\tthat\\tit\\tmay\\tbe\\tsafely administered\\tto\\tdogs\\tat\\t8\\tmg/kg\\tfor\\t14\\tconsecutive\\tdays,\\tand\\tthe\\tlabel\\thas\\tbeen extended to indicate that it may be administered until the condition has been resolved\\tin\\tdogs\\t7\\tmonths\\tof\\tage\\tand\\tolder.\\tWhen\\ttreating\\tprotracted\\tvomiting, veterinarians should attempt to identify any underlying disease whenever possible instead of relying on maropitant to control the clinical signs. Maropitant effects and pharmacokinetics are not affected by kidney disease. Drug Interactions Single doses have been administered in an IV line, but precipitation may be observed\\tif\\tmixed\\twith\\talkalinizing\\tsolutions.\\tMaropitant\\tis\\tan\\tNK1\\tinhibitor,\\tand","indications":"Indications and Clinical Uses Maropitant is approved for use as an antiemetic in dogs to inhibit vomiting from both central and peripheral sources. It has been effective to inhibit vomiting from chemotherapy,\\tGI\\tdisease,\\ttoxins,\\trenal\\tdisease,\\tvestibular\\tstimuli\\t(motion\\tsickness),\\tand circulating\\tstimuli\\tvia\\tthe\\tchemoreceptor\\ttrigger\\tzone\\t(CRTZ).\\tAfter\\tSQ\\tinjection,\\tit\\thas M a\\trapid\\tonset\\twith\\ta\\tpeak\\tconcentration\\t45\\tminutes\\tafter\\tinjection\\tand\\ta\\tduration\\tof\\t24 hours. Maropitant also is approved for use in cats and has been used safely and effectively in cats to treat vomiting from a variety of sources, such as motion sickness and stimulation by emetogenic agents (alpha 2 agonists,\\topioids),\\twith\\ta\\tduration\\tof\\taction\\tof\\t24\\thours. Maropitant can be administered oral, SQ, or IV route. A recent change in labeling allows for administration IV. For dogs and cats with nausea and vomiting, other antiemetic\\tagents\\tcan\\tsafely\\tbe\\tadded\\tto\\tthe\\ttreatment.\\tThese\\tagents\\tinclude\\tondansetron, metoclopramide, and dopamine antagonists. In people, for highly emetogenic cancer chemotherapeutic\\tagents,\\tan\\tNK1\\treceptor\\tblocker\\tis\\tcombined\\twith\\ta\\tserotonin\\tblocker (e.g., ondansetron) and dexamethasone. Although maropitant is an effective antiemetic agent, there are no studies to support the use for gastroesophageal reflux. Blockade\\tof\\tthe\\tNK1\\treceptor\\tmay\\thave\\tpotential\\tas\\tan\\tadjunctive\\ttreatment\\tfor some\\ttypes\\tof\\tpain\\t(e.g.,\\tvisceral\\tpain).\\tExperimental\\tstudies\\thave\\tshown\\teffects, but at this time, there are no clinical studies to demonstrate analgesic effects from maropitant. Maropitant may have some antitussive properties. It has been examined in\\thorses\\tat\\tan\\toral\\tdose\\tof\\t4\\tmg/kg,\\tbut\\tclinical\\teffects\\thave\\tnot\\tbeen\\treported. At\\ta\\tdosage\\tof\\t2\\tmg/kg\\tq48h,\\tit\\tcan\\tdecrease\\tcoughing\\tseverity\\tand\\tfrequency\\tof coughing in dogs with chronic bronchitis but does not decrease airway inflammation. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Maropitant may cause slight pain or irritation from SQ injection. It has been recognized that the pain is caused by alteration of the formulation, which may occur\\twhen\\tthe\\tinjectable\\tformulation\\tis\\tstored\\tat\\troom\\ttemperature.\\tThe cyclodextrin complex of maropitant is preserved at cold temperatures and is more stable\\tand\\tintact\\twhen\\tthe\\tformulation\\tis\\trefrigerated.\\tTherefore,\\tthe\\tadverse event associated with a painful injection can be reduced if injectable maropitant is stored in the refrigerator before use. Safety studies have been conducted with maropitant in both preclinical and clinical trials. In experimental dogs, it was safe at three and five times the labeled dose. Adverse effects observed in trials included excess salivation and muscle tremors.\\tIn\\tcats,\\tit\\thas\\tbeen\\twell\\ttolerated\\tat\\thigh\\tdoses\\t(of\\ta\\tfactor\\tof\\t10\\ttimes) and\\tis\\tsafe\\tat\\t5\\tmg/kg\\tfor\\t15\\tconsecutive\\tdays. In\\thorses,\\ta\\tdose\\tof\\t4\\tmg/kg\\toral\\tfor\\t5\\tdays\\tproduced\\tbradycardia\\tand\\theart block in some horses.","notes":"Instructions for Use Clinical trials in dogs have outlined the appropriate protocols for the use of maropitant. It has been effective for a wide range of causes of vomiting in dogs. In dogs,\\tit\\twas\\tmore\\teffective\\tto\\tprevent\\topiate-\\tinduced\\tvomiting\\tif\\tadministered\\tat least\\t30\\tminutes\\tprior\\tto\\tthe\\topiate\\tadministration,\\tbut\\tto\\tprevent\\tnausea, 60\\tminutes\\tprior\\tis\\tsuggested. It is also approved in cats for prevention of vomiting. It has been effective for a variety of causes of vomiting, including motion sickness and stimulation from emetogenic\\tagents.\\tThe\\teffective\\tdose\\tin\\tcats\\tis\\t1\\tmg/kg,\\tregardless\\tof\\tcause. Maropitant can be administered the day before a scheduled anesthetic procedure to reduce\\tanesthetic-\\tinduced\\tvomiting\\t(see\\tdosing\\tsection\\tfor\\tprotocol). If maropitant alone is not sufficient to control nausea and vomiting, consider adding other antinausea agents such as ondansetron, metoclopramide, or dopamine antagonists. Patient Monitoring and Laboratory Tests Monitor for clinical signs and disease that may be a cause for the vomiting. Other specific monitoring and tests are not needed to use maropitant safely. Formulations \u2022\\t\\tMaropitant\\tis\\tavailable\\tin\\t16-\\t,\\t24-\\t  ,\\t60-\\t  ,\\tor\\t160-\\tmg\\ttablets\\tand\\ta\\t10-\\tmg/mL injectable\\tsolution.\\tThe\\tpH\\tof\\tthe\\tsolution\\tis\\t4.1\u2013\\t4.7. Stability and Storage Store\\tin\\ta\\ttightly\\tsealed\\tcontainer,\\tprotected\\tfrom\\tlight.\\tThe\\tinjectable\\tformulation can be stored at room temperature and in the refrigerator, but as noted earlier, pain from injection can be reduced if the formulation is stored in the refrigerator. Discard vial\\tafter\\t28\\tdays\\tof\\tfirst\\tuse.","original_category":"Antiemetic"},{"name":"Meclizine","active_ingredient":"Meclizine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t \\t25\\tmg\\tper\\tdog\\tq24h\\tPO\\t(for\\tmotion\\tsickness,\\tadminister\\t1\\thour\\tprior\\tto\\ttraveling). Cats \u2022\\t \\t12.5\\tmg\\tper\\tcat\\tq24h\\tPO\\t(for\\tmotion\\tsickness,\\tadminister\\t1\\thour\\tprior\\tto\\ttraveling, but other agents are recommended because antihistamines are not effective in cats).  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Meclofenamate Sodium and Meclofenamic Acid mek\u2032loe- fen\u2032am- ate  soe- dee\u2032um and mek\u2032loe- fen- am\u2032ik ass\u2032id Trade and other names: Arquel and Meclofen","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tGI\\tobstruction\\tor\\tglaucoma. Drug Interactions No drug interactions have been reported for animals.","indications":"Indications and Clinical Uses Meclizine\\tis\\tused\\tto\\ttreat\\tvomiting,\\tparticularly\\tcentral-\\tinduced\\tvomiting,\\tsuch\\tas\\tmotion sickness.\\tIt\\tmay\\tsuppress\\tthe\\tCRTZ.\\tThe\\tmost\\tcommon\\tuse\\tin\\tpeople\\tis\\tfor\\ttreatment of motion sickness, but the use in animals has been primarily derived from empirical use and\\textrapolation\\tof\\tthe\\tuse\\tfrom\\thuman\\tmedicine.\\tThere\\tare\\tno\\twell-\\tcontrolled\\tclinical studies\\tor\\tefficacy\\ttrials\\tto\\tdocument\\tclinical\\teffectiveness.\\tThe\\tefficacy\\tin\\tdogs\\tis\\tnot 556    Meclofenamate Sodium and Meclofenamic Acid known, and antihistamines are not effective in cats for inhibiting vomiting. Other drugs with proven efficacy (e.g., maropitant) are often used instead of meclizine for vomiting. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\thave\\tnot\\tbeen\\treported\\tin\\tanimals.\\tAnticholinergic\\t(atropine-\\tlike) effects may cause side effects, but these are not serious.","notes":"Instructions for Use Results\\tof\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals\\tis\\tbased on experience in people or anecdotal experiences in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMeclizine\\tis\\tavailable\\tin\\t12.5-\\t,\\t25-\\t  ,\\tand\\t50-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiemetic, antihistamine"},{"name":"Methylnaltrexone Bromide","active_ingredient":"Methylnaltrexone Bromide","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.15\\tmg/kg\\tSQ\\tinjection\\tonce\\tper\\t24\\tor\\t48\\thours.  Horses \u2022\\t\\t0.75\\tmg/kg\\tIV\\tq12h\\tevery\\t4\\tdays. Regulatory Information No\\twithdrawal\\tinformation\\tis\\tavailable\\tfor\\tfood-\\tproducing\\tanimals. Methylprednisolone meth- il- pred- niss\u2032oh- lone Trade and other names: Methylprednisolone: Medrol; methylprednisolone acetate: Depo- Medrol; and methylprednisolone sodium succinate: Solu- Medrol","contraindications":"Contraindications and Precautions Do not use if there is intestinal obstruction. Drug Interactions No drug interactions have been reported for animals.","indications":"Indications and Clinical Uses Methylnaltrexone is approved for use in people to restore intestinal motility after surgery, after opiate administration, or when caused by a disorder (e.g., severe pain) that\\thas\\tstimulated\\tmu-\\topiate\\treceptors\\tin\\tthe\\tintestine.\\tUse\\tin\\tanimals\\tis\\tlimited and\\thas\\tbeen\\tprimarily\\tderived\\tfrom\\tempirical\\tuse.\\tThe\\tonly\\tstudies\\tavailable\\tare\\tin horses in which methylnaltrexone increased fecal weight and prevented the effects of 598    Methylprednisolone morphine\\ton\\tGI\\tmotility.\\tHowever,\\tat\\tthe\\tdose\\tstudied\\t(0.75\\tmg/kg),\\tit\\tdid\\tnot\\tfully antagonize the effects of morphine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are only reported for people and include abdominal pain and diarrhea. Although it is an opiate antagonist, it has not triggered breakthrough pain.","notes":"Instructions for Use The\\tuse\\tin\\tanimals\\tis\\tprimarily\\texperimental\\tand\\thas\\tbeen\\tlimited\\tin\\tclinical\\tpractice. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMethylnaltrexone\\tis\\tavailable\\tby\\tinjection\\tonly.\\tIt\\tis\\tavailable\\tin\\t12-\\tmg\\tvials\\t(0.6 mL),\\tequivalent\\tto\\t20\\tmg/mL\\tin\\teach\\tvial. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Prokinetic agent, intestinal stimulant"},{"name":"Metoclopramide Hydrochloride","active_ingredient":"Metoclopramide Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"dogs\\tto\\tincrease\\tlactation\\tin\\tbutches.\\tAt\\ta\\tdosage\\tof\\t0.2\\tmg/kg\\tPO\\tq6h,\\tit\\tincreases prolactin and milk lactose. Domperidone also has this activity and is preferred for this use in dogs and cats. (See Domperidone.) In horses, it has been used to treat intestinal postoperative ileus, but adverse effects have limited the use. It is not effective in ruminants. In people, metoclopramide has also been used to treat hiccups and lactation deficiency. Precautionary Information  Dogs and Cats \u2022\\t\\tAntiemetic\\tdosage:\\t0.5\\tmg/kg\\tq8h\\tIV,\\tIM,\\tor\\tPO. \u2022\\t\\tCRI:\\tAdminister\\ta\\tloading\\tdose\\tof\\t0.4\\tmg/kg\\tfollowed\\tby\\t0.3\\tmg/kg/h.\\tIn refractory\\tcases,\\tCRI\\tdose\\tmay\\tbe\\tincreased\\tup\\tto\\t1.0\\tmg/kg/h.\\tFor\\tantiemetic treatment\\twith\\tcancer\\tchemotherapy,\\tthe\\tdose\\tused\\tis\\tup\\tto\\t2\\tmg/kg\\tper\\t24\\thours. \u2022\\t\\tDosage\\tto\\tstimulate\\tlactation:\\t0.2\\tmg/kg\\tPO\\tq6h\\tfor\\t6\\tdays.  Horses \u2022\\t\\tInfusion\\tof\\tmetoclopramide\\t(0.125\u20130.25\\tmg/kg/h)\\tadded\\tto\\tIV\\tfluids\\tto\\treduce postoperative ileus in horses (see precautions regarding use in horses). Calves and cattle \u2022\\t\\tNot\\trecommended\\tbecause\\tit\\tis\\tnot\\ta\\tsuitable\\tprokinetic\\tagent\\tin\\truminants.\\tAt\\ta dose\\tof\\t0.1\\tmg/kg\\tIV\\tto\\tcattle,\\tit\\tdoes\\tnot\\tincrease\\tabomasal\\temptying.\\tAdverse reactions\\tdevelop\\tat\\thigher\\tdoses\\t(0.3\\tmg/kg). Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Metoprolol Tartrate meh- toe\u2032proe- lole  tar\u2032trate Trade and other names: Lopressor","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tepilepsy\\tor\\twith\\tdiseases\\tcaused\\tby\\tGI\\tobstruction.\\tUse cautiously in horses because dangerous behavior changes may occur. In people, it has been safe to use in the first trimester of pregnancy, but the effects on pregnancy in animals have not been studied. When used to increase lactation, metoclopramide is excreted into milk but not at a high enough level to harm newborn animals. Drug Interactions Efficacy\\tis\\tdiminished\\twhen\\tadministered\\twith\\tparasympatholytic\\t(atropine-\\tlike) drugs.","indications":"Indications and Clinical Uses Metoclopramide is used primarily for gastroparesis and treatment of vomiting. It is not effective for dogs with gastric dilation and should not be used in dogs with megaesophagus. In dogs, it is not very effective for decreasing gastroesophageal reflux or for increasing stomach emptying. One study demonstrated effects for gastroesophageal\\treflux\\tin\\tsurgical\\tpatients\\tat\\thigh\\tdoses\\tof\\t1\\tmg/kg\\tIV\\tfollowed M by\\tinfusion\\tof\\t1\\tmg/kg/h,\\tbut\\tother\\tstudies\\tshowed\\tno\\tbenefit.\\tThe\\tprimary\\teffect in dogs appears to be via its antiemetic properties (dopamine antagonism in the vomiting center). Because metoclopramide transiently increases prolactin secretion, there has been interest in using it for treating agalactia in animals. Metoclopramide increases prolactin and increases mammary gland development and lactation. In humans, it has been used as a galactagogue to\\tincrease\\tlactation.\\tThis\\tproperty\\talso\\thas\\tbeen\\tused\\tin","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily related to blockade of central dopaminergic receptors. Adverse effects similar to those that are reported for other centrally acting D 2 -\\treceptor\\tantagonists\\tsuch\\tas\\tphenothiazines.\\tIn\\thorses,\\tundesirable\\tside effects have been common and limit the therapeutic use. Adverse effects in horses include\\tbehavioral\\tchanges,\\texcitement,\\tand\\tabdominal\\tdiscomfort.\\tExcitement from\\tIV\\tinfusions\\tcan\\tbe\\tsevere.\\tIn\\tcalves\\tat\\tdoses\\tgreater\\tthan\\t0.1\\tmg/kg,\\tit produces neurologic effects.","notes":"Instructions for Use The\\tuse\\tin\\tanimals\\tis\\tbased\\tprimarily\\ton\\tstudies\\tin\\tresearch\\tanimals,\\texperience\\tin people,\\tor\\tanecdotal\\texperience\\tin\\tanimals.\\tThere\\thave\\tbeen\\tsmall\\tobservational studies\\tin\\tclinical\\tpatients\\tto\\tevaluate\\tefficacy\\tfor\\tgastroesophageal\\treflux.\\tThe\\tmost common use is for general antiemetic purposes, for which it has shown efficacy in dogs.\\tDoses\\tas\\thigh\\tas\\t2\\tmg/kg\\thave\\tbeen\\tused\\tto\\tprevent\\tvomiting\\tduring\\tcancer chemotherapy (higher doses may produce antiserotonin effects). In recent years, other antiemetic agents have become more popular and widely used\\tin\\tsmall\\tanimals\\tcompared\\tto\\tmetoclopramide.\\tThese\\tagents\\tinclude\\tmaropitant and serotonin antagonists (e.g., ondansetron). In horses, there is some increase in intestinal motility at recommended doses, but little effect on the large bowel has been seen. In calves, metoclopramide had little effect on rumen motility. Patient Monitoring and Laboratory Tests Monitor for signs of behavior disturbances from treatment, especially when IV doses are administered. 604    Metoprolol Tartrate Formulations Available \u2022\\t\\tMetoclopramide\\tis\\tavailable\\tin\\t5-\\t\\tand\\t10-\\tmg\\ttablets,\\t1-\\tmg/mL\\toral\\tsolution,\\tand 5-\\t mg/mL\\tinjection\\tin\\t2-\\t,\\t10-\\t  ,\\tand\\t30-\\tmL\\tvials. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is incompatible with other drugs when mixed in solution. Do not freeze. Stability\\tis\\tless\\tthan\\t24\\thours\\tif\\tnot\\tprotected\\tfrom\\tlight.\\tThe\\tsolution\\thas\\ta\\tpH of\\t4\u20135\\tand\\tis\\tstable\\tover\\ta\\tpH\\trange\\tof\\t2\u20139.\\tIndividual\\tdoses\\tmay\\tbe\\tstored\\tin plastic\\tsyringes\\tand\\tare\\tstable\\tfor\\t90\\tdays\\tin\\tthe\\trefrigerator\\tand\\t60\\tdays\\tat\\troom temperature.","original_category":"Antiemetic"},{"name":"Mineral Oil","active_ingredient":"Mineral Oil","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t10\u201350\\tmL/dog\\tq12h\\tPO. Cats \u2022\\t\\t10\u201325\\tmL/cat\\tq12h\\tPO.  Horses and Cattle \u2022\\t\\t500\u20131000\\tmL\\t(1\\tpint\\tto\\t1\\tquart)\\tper\\thorse\\tor\\tcow\\tPO\\tas\\tneeded.\\tUp\\tto\\t2\u20134\\tL\\tper adult horse or cow PO (usually administered via stomach tube). Sheep and Pigs \u2022\\t\\t500\u20131000\\tmL\\tPO\\tas\\tneeded. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. M Minocycline Hydrochloride 617 Minocycline Hydrochloride min- oh- sye\u2032kleen  hye- droe- klor\u2032ide Trade and other names: Minocin and Solodyn","contraindications":"Contraindications and Precautions Use\\tcaution\\twhen\\tadministering\\tvia\\tstomach\\ttube.\\tAccidental\\tadministration\\tinto the lungs has produced fatal reactions. Drug Interactions No\\tdrug\\tinteractions\\treported.\\tChronic\\tuse\\tmay\\tinhibit\\tabsorption\\tof\\tfat-\\tsoluble vitamins.","indications":"Indications and Clinical Uses Mineral oil is administered orally (via stomach tube in horses) to increase passage of feces for treatment of impaction and constipation. It is primarily used in large animals (especially horses), and small animal use is uncommon. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported. Chronic use may decrease absorption of fat-\\t soluble\\tvitamins.","notes":"Instructions for Use Use\\tis\\tempirical.\\tNo\\tclinical\\tresults\\treported. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMineral\\toil\\tis\\tavailable\\tin\\tan\\toral\\tliquid. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Laxative"},{"name":"Mirtazapine","active_ingredient":"Mirtazapine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\u20131\\tmg/kg\\tq12h\\tPO.\\tGenerally\\tin\\tthe\\trange\\tof\\t3.75\u20137.5\\tmg\\tper\\tdog\\tdaily\\tPO. Cats \u2022\\t\\t1.9\\tmg\\tper\\tcat\\tPO.\\tDoses\\thave\\tranged\\tfrom\\t3.75\u20137.5\\tmg\\tper\\tcat\\tper\\tday\\tPO\\t(one fourth\\tto\\tone\\thalf\\tof\\ta\\t15-\\tmg\\ttablet).\\tIn\\thealthy\\tcats,\\tit\\tcan\\tbe\\tadministered\\tonce daily.\\tIn\\tcats\\twith\\tchronic\\tkidney\\tdisease,\\tincrease\\tthe\\tinterval\\tto\\tq48h. \u2022\\t\\tTransdermal\\tformulations:\\tApply\\ta\\t1.5-\\tinch\\tribbon\\tof\\tointment\\t(approximately\\t2 mg/cat\\tor\\t0.5\\tmg/kg)\\ton\\tthe\\tinner\\tpinna\\tof\\tthe\\tcat\u2019s\\tear\\tonce\\tdaily\\tfor\\t14\\tdays.  No large animal doses are available. Regulatory Information No\\twithdrawal\\ttime\\tinformation\\tis\\tavailable\\tfor\\tfood-\\tproducing\\tanimals. Misoprostol mee- soe- pross\u2032tole Trade and other names: Cytotec","contraindications":"Contraindications and Precautions If the transdermal formulation is used, advise pet owners to wear disposable gloves when handling or applying mirtazapine to cats to prevent accidental 620    Misoprostol","indications":"Indications and Clinical Uses Mirtazapine\\tis\\tused\\tas\\tan\\tantiemetic\\tand\\tappetite\\tstimulant,\\tprimarily\\tin\\tcats.\\tThe FDA-\\t   approved\\tformulation\\tlists\\tthe\\tindication\\tas\\t\u201cFor\\tthe\\tmanagement\\tof\\tweight\\tloss in\\tcats.\u201d\\tAlthough\\tthere\\talso\\thas\\tbeen\\tsome\\tuse\\tin\\tdogs,\\tit\\tis\\tprimarily\\tanecdotal.\\tThere are other drugs that may be preferred if an antiemetic agent is needed for animals (e.g., maropitant).\\tIn\\tcats,\\tmirtazapine\\tadministered\\tat\\t1.9\\tmg\\tper\\tcat,\\toral,\\tevery\\t48\\thours for\\t3\\tweeks\\tincreased\\tappetite,\\tactivity,\\tand\\tweight\\tin\\tcats\\twith\\tkidney\\tdisease.\\tThe FDA-approved\\ttransdermal\\tdose\\tfor\\tcats\\tis\\t2\\tmg\\tper\\tcat\\tapplied\\tto\\tthe\\tear. Mirtazapine can produce antinausea effects in dogs, as well as increasing gastric emptying and increased colon transit (accelerated transit). Mirtazapine has been considered\\tfor\\tits\\tintestinal\\tpro-\\tkinetic\\teffects\\tin\\thorses;\\thowever,\\tthere\\tare\\tno\\tclinical studies\\tto\\tsupport\\tthis\\tuse.\\tThe\\tclinical\\teffects\\tin\\thorses\\tare\\tunknown. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\tobserved\\tin\\tcats\\tinclude\\tvocalization,\\tbegging\\tbehavior,\\tand\\tfood- seeking behavior. At high doses in cats, ataxia, restlessness, tremors, twitching, vomiting, hypersalivation, vocalization, and cardiovascular effects have been observed. In people, sedation and weight gain have been reported. Some antihistaminic effects have been reported, but sedation similar to what is observed in people has not been as common in animals. Although this drug acts through serotonergic mechanisms, the risk of development of serotonin syndrome is low and not reported in dogs or cats. Cyproheptadine (a serotonin antagonist) can be considered an antagonist in the event of\\toverdose\\tor\\tadverse\\teffects.\\tIf\\tcyproheptadine\\tis\\tneeded,\\tadminister\\t2\u20134\\tmg\\tper\\tcat PO\\tevery\\t4\u20138\\thours\\tuntil\\tadverse\\teffects\\tdiminish.","notes":"Instructions for Use Doses and recommendations are based on the clinical use in cats with chronic kidney disease\\tthrough\\tpublished\\tevidence\\tfrom\\tclinical\\tstudies\\tand\\tthe\\tFDA-\\tapproved\\tlabel. Other uses are anecdotal and not well documented. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMirtazapine\\tis\\tavailable\\tin\\t15-\\t,\\t30-\\t  ,\\tand\\t45-\\tmg\\ttablets.\\tThere\\tis\\talso\\ta\\trapidly disintegrating\\ttablet\\tin\\tthese\\tsizes\\tthat\\tdissolves\\teasily\\tin\\ta\\tpet\u2019s\\tmouth. \u2022\\t\\tTransdermal\\tformulation:\\tEach\\tgram\\tof\\tointment\\tcontains\\t20\\tmg\\tof\\tmirtazapine (2%),\\tsupplied\\tin\\ta\\t5-\\tg\\ttube\\tcontaining\\t100\\tmg\\t(0.1\\tg)\\tof\\tmirtazapine. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiemetic agent"},{"name":"Ondansetron Hydrochloride","active_ingredient":"Ondansetron Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tDuring\\tcancer\\tchemotherapy:\\t0.5\u20131\\tmg/kg\\tIV\\tor\\tSQ\\t30\\tminutes\\tprior\\tto administration of cancer drugs intravenously. \u2022\\t\\tVomiting\\tfrom\\tother\\tcauses:\\t0.1\u20130.2\\tmg/kg\\tslow\\tIV\\tinjection\\tand\\trepeated q6\u201312h. If this dosage is initially ineffective, it may be increased to 0.5 mg/kg. \u2022\\t\\tOral\\tadministration:\\tAlthough\\tan\\toral\\tform\\tis\\tavailable,\\toral\\tabsorption\\tis\\tlow\\tin dogs (less than 10%), which may compromise the effectiveness. Cats \u2022\\t\\tCat\\tdosages\\tare\\tsimilar\\tto\\tthose\\tfor\\tdogs:\\t0.5\\tmg/kg\\tq8h\\tSQ,\\tIV,\\tor\\tPO.\\tA\\tdose\\tof 2 mg per cat is common (half a tablet for the oral formulation), administered q8h. Reduce to twice daily in cats with liver disease. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\tAdminister\\t0.5\\tmg/kg\\tIV\\tloading\\tdose\\tfollowed\\tby 0.5\\tmg/kg/h\\tIV\\tinfusion.  \u2022\\t\\tNo\\tdosing\\tinformation\\tis\\tavailable. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tBecause\\tof\\ta\\tlow\\trisk\\tof\\tresidues,\\tno withdrawal times are suggested. Orbifloxacin or- bih- floks\u2032ah sin Trade and other names: Orbax","contraindications":"Contraindications and Precautions Ondansetron is eliminated via metabolic pathways and relies less on kidneys for elimination. In cats with liver disease, there was increased exposure and decreased clearance; therefore, ondansetron should be administered less frequently if cats have liver disease. Cats with kidney disease have no significant changes in clearance. Do not administer as a transdermal formulation to cats because it is not absorbed. Oral absorption in dogs is low and may not be effective. Drug Interactions If\\tinfused\\tthrough\\tan\\tIV\\tcatheter,\\tit\\tmay\\tprecipitate\\tif\\tmixed\\twith\\tother\\tdrugs\\t(e.g., metoclopramide). Other drug interactions have not been reported for animals.","indications":"Indications and Clinical Uses Ondansetron, like other serotonin antagonists, is used to treat nausea and prevent vomiting. It can be effective for various types of vomiting that originate from injury to the GI tract. It is effective to prevent vomiting from drug chemotherapy (cancer drugs and dexmedetomidine). Only limited efficacy information is available for ondansetron\u2019s effectiveness in animals, but oncologists have found it to be effective for managing vomiting from chemotherapy in animals. It has been effective in cats at blocking vomiting caused by administration of sedative and anesthetic agents. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ondansetron\u2019s adverse effects have not been reported in animals. These drugs have little affinity for other 5- HT receptors. Because some severe adverse effects can occur from concurrent cancer drugs, it may be difficult to distinguish these from ondansetron effects.","notes":"Instructions for Use Based on pharmacokinetic studies with ondansetron, it may be unlikely to maintain effective\\tconcentrations\\tat\\ta\\tdosage\\tof\\t0.5\\tmg/kg\\tq12h\\torally\\tor\\tIV,\\tbut\\tbecause\\tof\\ta longer SQ half- life, it may be better suited for administration via this route. In dogs, the oral absorption is low (less than 10%) because of high first- pass metabolism and a short- half- life, which raises questions about effectiveness of oral doses that have been recommended but not tested for efficacy. Granisetron is a similar drug that has been substituted for a similar purpose. O Orbifloxacin 673 Patient Monitoring and Laboratory Tests Monitor GI signs in a vomiting patient. Formulations \u2022\\t\\tOndansetron\\tis\\tavailable\\tin\\t4-\\t\\tand\\t8-\\tmg\\ttablets,\\t4-\\tmg/5-\\t   mL\\tflavored\\tsyrup,\\tand 2-   mg/mL injection. Ondansetron is not absorbed in cats when administered as a transdermal formulation. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ondansetron is soluble in water. Solutions are stable, but pH should be less than 6 to prevent precipitation. Oral preparations have been mixed with syrups, juices, and other oral vehicles (e.g., Ora Sweet). It was stable for 42 days as long as pH remained low.","original_category":"Antiemetic"},{"name":"Polyethylene Glycol Electrolyte Solution","active_ingredient":"Polyethylene Glycol Electrolyte Solution","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t25\\tmL/kg\\tPO;\\trepeat\\tin\\t2\u20134\\thours.  Horses and Cattle \u2022\\t\\tVia\\tstomach\\ttube:\\t500\\tmL\\tto\\t4\\tL\\tonce\\tPO. Regulatory Information No\\twithdrawal\\ttimes\\tnecessary. Polymyxin B Sulfate poly- mix- in  bee Trade and other names: Generic","contraindications":"Contraindications and Precautions Do not administer to animals that are dehydrated because it may cause fluid and electrolyte loss. It is not indicated for chronic use. Drug Interactions No\\tspecific\\tdrug\\tinteractions. 746    Polymyxin B Sulfate","indications":"Indications and Clinical Uses Polyethylene glycol electrolyte solution is a cathartic that is used primarily for evacuating the bowel and cleansing of the intestine prior to endoscopy and surgical procedures. It is administered orally and induces a rapid osmotic cathartic effect. It is effective for bowel cleansing, but it requires high volumes to be effective. In some human patients, smaller volumes can be used if it is combined with another laxative, such as bisacodyl. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Water and electrolyte loss with high doses or prolonged use are common. Large volumes required may cause nausea.","notes":"Instructions for Use Used for bowel evacuation prior to surgical or diagnostic procedures. Large volumes are required. In human patients, administration of only half the volume can be used if taken with bisacodyl (one to four tablets) 2 hours prior to the procedure. This combination\\tis\\tcalled\\tHalfLytely. Patient Monitoring and Laboratory Tests Monitor electrolytes if it is administered repeatedly. Formulations \u2022\\t\\tPolyethylene\\tglycol\\telectrolyte\\tis\\tan\\toral\\tsolution.\\tPreparations\\tcontain\\tPEG\\t3350, sodium chloride, potassium chloride, sodium bicarbonate, and sodium sulfate. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Laxative"},{"name":"Prochlorperazine Maleate, and Isopropamide Iodide","active_ingredient":"Prochlorperazine Maleate, and Isopropamide Iodide","species":["Feline","Canine"],"dosage":"Cats \u2022\\t\\t0.14\u20130.2\\tmL/kg\\tq12h\\tSQ. Dogs \u2022\\t\\t0.14\u20130.2\\tmL/kg\\tq12h\\tSQ. \u2022\\t\\t2\u20137\\tkg\\tbody\\tweight:\\t1\\tcapsule\\tq12h\\tPO. \u2022\\t\\t7\u201313\\tkg\\tbody\\tweight:\\t1\u20132\\tcapsules\\tq12h\\tPO.  No\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tThe\\tuse\\tis\\tdiscouraged\\tbecause isopropamide may decrease GI motility. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t2 Prochlorperazine Edisylate, Prochlorperazine Maleate proe- klor- pare\u2032ah- zeen  ed- iss\u2032ih- late  and  proe- klor- pare\u2032ah- zeen  mal\u2032ee- ate Trade and other names: Compazine","contraindications":"Contraindications and Precautions Use of antimuscarinic drugs is contraindicated in animals with gastroparesis and should be used cautiously in animals with diarrhea. Isopropamide should not be administered to animals with gastroparesis or decreased intestinal motility. Drug Interactions Isopropamide interferes with cholinergic drugs or drugs that promote motility (e.g., metoclopramide). Prochlorperazine potentiates other sedatives. 780    Prochlorperazine Edisylate, Prochlorperazine Maleate","indications":"Indications and Clinical Uses Prochlorperazine is a phenothiazine used to control vomiting, in combination with isopropamide, which is an anticholinergic used to decrease intestinal motility and GI secretions. Its use is not common because of decreased availability of formulations and lack of proven efficacy compared with each ingredient alone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects are attributed to each component. Prochlorperazine produces phenothiazine- like effects described more fully under Prochlorperazine. Isopropamide may produce effects attributed to excess anticholinergic (antimuscarinic) stimulation and include ileus, urine retention, tachycardia, xerostomia (dry mouth), and behavior changes. Treat overdoses with physostigmine.","notes":"Instructions for Use This combination should be used with caution, especially if considered for repeated doses, in animals with intestinal disease. It can produce ileus. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tProchlorperazine\\tedisylate\\t+\\tisopropamide\\tiodide\\tis\\tavailable\\tin\\t3.33-\\tmg prochlorperazine\\tand\\t1.67-\\tmg\\tisopropamide\\tcapsules,\\tand\\tprochlorperazine maleate + isopropamide iodide is available in 4 mg of prochlorperazine and 0.28 mg of isopropamide per milliliter injection. \u2022\\t\\tCapsule\\tfor\\tdogs\\t(Neo-Darbazine\\tSpansule\\tCapsule)\\tcontains\\tprochlorperazine, isopropamide, and neomycin. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiemetic, antidiarrheal"},{"name":"Promethazine Hydrochloride","active_ingredient":"Promethazine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.2\u20130.4\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tPO\\tup\\tto\\ta\\tmaximum\\tdose\\tof\\t1\\tmg/kg. P Propantheline Bromide 783  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Propantheline Bromide proe- pan\u2032theh- leen  broe\u2032mide Trade and other names:  Pro- Banthine","contraindications":"Contraindications and Precautions Promethazine may produce antimuscarinic side effects, but these have not been reported from clinical use in animals. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals,\\tbut\\tit\\texacerbates\\tCNS depression when used with other sedatives, phenothiazines, or antihistamines.","indications":"Indications and Clinical Uses Promethazine has dual effects. It is used for treatment of allergy (antihistamine effect) and as an antiemetic (motion sickness). The efficacy for treating allergies in animals has not been established or studied in clinical trials. The uses in animals have been derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Antihistamines have not been as effective for motion sickness in animals compared with other antiemetic agents. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Promethazine has a risk of producing phenothiazine effects such as sedation and other side effects attributed to other phenothiazines. There also may be anticholinergic effects produced by the antimuscarinic properties in some individuals.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Therefore the use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tPromethazine\\tis\\tavailable\\tin\\t6.25-\\t\\tand\\t25-\\tmg/5\\tmL\\tsyrup;\\t12.5-\\t,\\t25-\\t  ,\\tand\\t50-\\tmg tablets; and 25-  and 50- mg/mL injection. Stability and Storage Promethazine hydrochloride is soluble in water. If oxidized, it turns a blue color and should be discarded. It is sensitive to light and should be protected from light.","original_category":"Antiemetic, phenothiazine"},{"name":"RCI\\tClassification:\\t4","active_ingredient":"RCI\\tClassification:\\t4","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t1.1\u20134.4\\tmg/kg\\tq12\u201324h\\tPO. \u2022\\t \\t0.1\u20131.1\\tmg/kg\\tIV\\tor\\tIM\\t(range\\tof\\tinjectable\\tdoses\\tdepends\\ton\\tlevel\\tof\\tsedation\\tneeded).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tThe\\tuse\\tis\\tdiscouraged\\tin\\thorses and ruminants because it may inhibit GI motility. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Propofol proe\u2032poe- fole Trade and other names: Rapinovet, Rapanofal, PropoFlo, and PropoFlo 28 (veterinary preparations); Diprivan (human preparation)","contraindications":"Contraindications and Precautions It may lower blood pressure via alpha- adrenergic blockade. Drug Interactions Do not use with other phenothiazines, organophosphates, or procaine. Use cautiously\\twith\\tother\\tsedatives,\\ttranquilizers,\\tor\\tCNS\\tdepressants\\tbecause\\tit\\tmay exacerbate the effects.","indications":"Indications and Clinical Uses Propiopromazine has been used for its antiemetic and sedative effects, for which it acts either via the antihistamine receptors or by blocking dopamine receptors. It also has sedative and tranquilizing effects and has been used in cats and dogs to facilitate handling. It has also been used as a preanesthetic. The approved label use indicates that it is \u201cintended for administration to dogs as a tranquilizer. It is used as an aid in handling difficult, excited, and unruly dogs, and in controlling excessive kennel barking, car sickness, and severe dermatitis. It is also indicated for use in minor surgery and prior to routine examinations, laboratory procedures, and diagnostic procedures.\u201d Despite this labeling, some of these indications are outdated, and there are better treatments to manage these conditions. P Propofol 785 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Phenothiazines can cause sedation as a common side effect. Propiopromazine produces extrapyramidal side effects in some individuals.","notes":"formulations currently available are veterinary forms. A related drug is propiomazine. Instructions for Use Results of clinical studies in animals have not been reported despite indications listed on the product label. Use in animals (and doses) is based on anecdotal experience in animals and the product label. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t \\tPropiopromazine\\thas\\tbeen\\tavailable\\tas\\ta\\t20-\\tmg\\tchewable\\ttablet\\tand\\ta\\t5-\\t\\tor\\t10-\\tmg/ mL\\tinjection.\\tHuman\\tformulations\\tof\\tthis\\tmedication\\thave\\tbeen\\tdiscontinued. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiemetic, phenothiazine"},{"name":"Psyllium","active_ingredient":"Psyllium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t1\\tteaspoon/5\u201310\\tkg\\t(added\\tto\\teach\\tmeal).  Horses \u2022\\t\\tUp\\tto\\t1000\\tmg/kg\\tper\\tday\\tPO\\tvia\\tstomach\\ttube\\tor\\tadded\\tto\\tfeed.\\tNote precaution above about administering by a stomach tube in horses. It may form a gel when mixed with water and plug the tube. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tnecessary. Pyrantel Pamoate and Pyrantel Tartrate pye ran\u2032 tel Trade and other names: Nemex, Strongid, Priex, Pyran, and Pyr- A- Pam","contraindications":"Contraindications and Precautions No\\tcontraindications\\tare\\treported\\tfor\\tanimals. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Psyllium is administered orally for treatment of constipation and bowel evacuation. In horses, it has been used for treating sand colic, but the effectiveness for this indication has not been shown. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. Intestinal impaction can occur with overuse or in patients with inadequate fluid intake. In horses, it may be difficult to administer via stomach tube because it is prone to forming a gel when mixed with water.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Psyllium may lower serum cholesterol measurements. 796    Pyrantel Pamoate and Pyrantel Tartrate Formulations \u2022\\t\\tPsyllium\\tis\\tavailable\\tas\\tpowder,\\tusually\\t3.4\\tg\\tper\\tteaspoon. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Laxative"},{"name":"Senna","active_ingredient":"Senna","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tSyrup:\\t5\u201310\\tmL/dog/day\\tPO. \u2022\\t\\tGranules:\\t\x9e\u20131\\ttsp/dog/day\\tPO. Cats \u2022\\t\\tSyrup:\\t5\\tmL/cat\\tq24h. \u2022\\t\\tGranules:\\t\x9e\\ttsp/cat\\tq24h\\t(with\\tfood).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sevelamer Carbonate se- vel\u2032a- mer Trade and other names: generic","contraindications":"Contraindications and Precautions Do not administer to animals with gastrointestinal (GI) obstruction. Do not administer to dehydrated animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Senna has been used for management of constipation. The clinical use in veterinary medicine has been limited. The efficacy and doses listed are based on limited empirical evidence. S Sevelamer Carbonate 833 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects not reported for animals. However, excessive doses are expected to cause fluid and electrolyte loss.","notes":"Instructions for Use Doses and indications are not well established for veterinary medicine. Use is strictly based on anecdotal experience. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tSenna\\tis\\tavailable\\tin\\tgranules\\tin\\tconcentrate\\tor\\tsyrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Laxative"},{"name":"Tegaserod Maleate","active_ingredient":"Tegaserod Maleate","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Gastrointestinal stimulant"},{"name":"Trifluoperazine Hydrochloride","active_ingredient":"Trifluoperazine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.03\\tmg/kg\\tq12h\\tIM. \u2022\\t \\tOral\\ttreatment:\\tStart\\twith\\t0.03\\tmg/kg,\\toral,\\tq12h.\\tTitrate\\tdose\\tup\\tto\\tachieve\\tthe desired\\teffect.\\tIn\\tpeople,\\toral\\tdoses\\tas\\thigh\\tas\\t0.3\u20130.5\\tmg/kg\\thave\\tbeen\\tused\\tto control severe conditions.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 2 Triflupromazine Hydrochloride trye- floo- proe\u2032mah- zeen  hye- droe- klor\u2032ide Trade and other names: Vesprin and fluopromazine (former name)","contraindications":"Contraindications and Precautions Use cautiously in patients that are hypotensive because phenothiazines can cause vasodilation. If patients have been treated with multiple doses, do not stop treatment abruptly. Gradually taper the dose. Drug Interactions No drug interactions have been reported in animals, but use is infrequent, and a full range of drug interactions is not known. However, these drugs are metabolized and may be subject to cytochrome P450 drug interactions.","indications":"Indications and Clinical Uses Trifluoperazine is used for treatment of anxiety, to produce sedation, and as an antiemetic. It is a weaker sedative than some of the other phenothiazines. In people, it is used to treat psychotic disorders. Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled studies in animals to examine efficacy or to compare with the effects of other phenothiazines. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals but are expected to be similar to those of other phenothiazines. Phenothiazines can lower the seizure threshold in susceptible animals, although this is controversial for acepromazine. Phenothiazines can also cause sedation as a common side effect and extrapyramidal side effects (involuntary muscle movements) in some individuals.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tTrifluoperazine\\tis\\tavailable\\tin\\ta\\t10-\\tmg/mL\\toral\\tsolution;\\t1-\\t,\\t2-\\t ,\\t5-\\t ,\\tand\\t10-\\tmg tablets; and 2- mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Trifluoperazine is soluble in water and slightly soluble in ethanol. It is oxidized rapidly if exposed to air or light. T Triflupromazine Hydrochloride 935","original_category":"Antiemetic, phenothiazine"},{"name":"Triflupromazine Hydrochloride","active_ingredient":"Triflupromazine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.1\u20130.3\\tmg/kg\\tq8\u201312h\\tIM.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 2 Trilostane trye\u2032loe- stane Trade and other names: Modrenal and Vetoryl","contraindications":"Contraindications and Precautions Use cautiously in patients that are hypotensive because they can have vasodilating effects. If patients have been treated with multiple doses, do not stop treatment abruptly. Gradually taper the dose. Drug Interactions No drug interactions have been reported in animals, but use is infrequent, and a full range of drug interactions is not known. However, these drugs are metabolized and may be subject to cytochrome P450 drug interactions. 936    Trilostane","indications":"Indications and Clinical Uses Triflupromazine is used to produce sedation and as an antiemetic. In people, it is used to treat psychotic disorders. Use in animals has been primarily derived from empirical use and experience in humans. Little information on animal use is available, and the use is purely anecdotal. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals because of infrequent use but are expected to be similar to those of other phenothiazines. Phenothiazines can lower the seizure threshold in susceptible animals, but this is controversial and has not been a problem with acepromazine. Phenothiazines can cause sedation as a common side effect and extrapyramidal side effects (involuntary muscle movements) in some individuals.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tTriflupromazine\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg/mL\\tinjections. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiemetic, phenothiazine"},{"name":"Trimethobenzamide","active_ingredient":"Trimethobenzamide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t3\\tmg/kg\\tq8h\\tIM\\tor\\tPO. Cats \u2022\\t\\tNot\\trecommended.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Trimethoprim and Sulfadiazine trye- meth\u2032oh- prim  and  sul- fah- dye\u2032ah- zeen Trade and other names: Tribrissen, Uniprim, Tucoprim, Equisul- SDT, and Di- Trim","contraindications":"Contraindications and Precautions Not recommended for use in cats. Drug Interactions No drug interactions have been reported in animals, but use has been infrequent, and a full range of possible drug interactions is not known.","indications":"Indications and Clinical Uses Trimethobenzamide has been used for antiemetic treatment, especially when vomiting is induced from the CRTZ (e.g., from chemotherapeutic drugs). Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Other antiemetics (e.g., maropitant) are more often used for these indications in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects not reported in animals.","notes":"Instructions for Use Efficacy as antiemetic not reported in animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tTrimethobenzamide\\tis\\tavailable\\tin\\t100-\\tmg/mL\\tinjections\\tand\\t100-\\t\\tand\\t250-\\tmg capsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. 942    Trimethoprim and Sulfadiazine","original_category":"Antiemetic"},{"name":"Ursodiol, Ursodeoxycholic Acid","active_ingredient":"Ursodiol, Ursodeoxycholic Acid","species":["Canine","Feline"],"dosage":"in\\tdogs\\tand\\tcats.\\tThe\\toptimum\\tdosage\\tin\\tanimals\\tis\\tnot\\tknown,\\tbut\\tin\\tpeople,\\tthe most\\tcommon\\tdosage\\tis\\t13\u201315\\tmg/kg\\tper\\tday\\tPO.\\tOnce\\tor\\ttwice\\tdaily\\tis\\tas\\teffective as three to four times per day. Administer with meals.  Dogs and Cats \u2022\\t\\t10\u201315\\tmg/kg\\tq24h\\tPO;\\tthe\\tdosage\\tused\\tmost\\toften\\tin\\tanimals\\twith\\tliver\\tdisease\\tis 15\\tmg/kg\\tPO\\tq24h.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information It is expected to pose little risk from residues in animals intended for food, and no withdrawal times are recommended. V Valacyclovir 957 Valacyclovir val- a- sye\u2032kloe- veer Trade and other names: Valtrex","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been identified for animals. In people, it interferes with some cholesterol- lowering drugs.","indications":"Indications and Clinical Uses Ursodiol is used for treatment of liver diseases. It is used to treat primary biliary cirrhosis, cholestatic liver disorders, cholangitis, and chronic liver disease. Although experimental evidence exists for its benefit in dogs, there are no well- controlled clinical trials that demonstrate efficacy. In people, it has been used as a laxative and to prevent or treat gallstones. It has also been used to treat chronic constipation because it may increase water content of feces and stimulate colonic peristalsis. In people, the use for treating cholangitis is controversial. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Loose feces and pruritus are the most common problems in people. In animals, ursodiol may cause diarrhea. (It has been used as a laxative.) Adverse effects can be\\t lessened\\tby\\t gradually\\tincreasing\\tthe\\t  dose\\t  to\\t the\\t  target\\t   range\\t   over\\t  1\u20132\\t  weeks.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. It has been recommended by veterinary clinical experts for treatment of gallbladder disease Patient Monitoring and Laboratory Tests Monitor bile acids and hepatic enzymes during treatment to monitor effects. Formulations \u2022\\t\\tUrsodiol\\tis\\tavailable\\tin\\t300-\\tmg\\tcapsules\\tand\\t250-\\t\\tor\\t500-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Suspensions have been prepared in vehicles for oral use and found to be stable for 35\u201360\\tdays.","original_category":"Laxative, choleretic"}]},{"category":"Immunologic","drugs":[{"name":"Auranofin","active_ingredient":"Auranofin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Aurothioglucose or- oh- thye- oe- gloo \u0301kose Trade and other names: Solganal","contraindications":"Contraindications and Precautions Do not use in animals with suppressed bone marrow or in animals already receiving bone marrow\u2013suppressing agents. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Auranofin (gold therapy) is used primarily for immune- mediated diseases. It has been used with some success to control immune- mediated skin diseases, such as pemphigus and immune- mediated arthritis, but evidence of efficacy is lacking for small animal therapy. It has been observed by some clinicians that this product (oral) is not as effective as injectable products such as aurothioglucose. Auranofin has activity against some protozoan parasites, but the efficacy for treating protozoa, or optimum dose, has not been established in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include dermatitis, nephrotoxicity, and blood dyscrasias.","notes":"Instructions for Use Use\\tof\\tthis\\tdrug\\thas\\tnot\\tbeen\\tevaluated\\tin\\tveterinary\\tmedicine.\\tNo\\tcontrolled\\tclinical trials are available to determine efficacy in animals. The use in animals is based on anecdotal experience and small observational reports. Patient Monitoring and Laboratory Tests Monitor patient\u2019s CBC periodically because gold salts have caused blood dyscrasias. Formulations \u2022\\t\\tAuranofin\\tis\\tavailable\\tin\\t3-\\tmg\\tcapsules\\tbut\\thas\\tbeen\\tdiscontinued\\tby\\tsome\\tmanufacturers. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. 72    Aurothioglucose","original_category":"Immunosuppressive"},{"name":"Aurothioglucose","active_ingredient":"Aurothioglucose","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tDogs\\tweighing\\tless\\tthan\\t10\\tkg:\\t1\\tmg\\tIM\\tfirst\\tweek,\\t2\\tmg\\tIM\\tsecond\\tweek,\\t1\\tmg/ kg/wk\\tmaintenance.\\tDogs\\tweighing\\tmore\\tthan\\t10\\tkg:\\t5\\tmg\\tIM\\tfirst\\tweek,\\t10\\tmg IM second week, 1 mg/kg/wk maintenance. Cats \u2022\\t\\t0.5\u20131\\tmg/cat\\tevery\\t7\\tdays\\tIM.  Horses \u2022\\t\\t1\\tmg/kg/wk\\tIM. Regulatory Information Do not administer to animals intended for food. Azathioprine ay- za- thye \u0301oe- preen Trade and other names: Imuran and generic","contraindications":"Contraindications and Precautions Do not use in animals with suppressed bone marrow or animals already receiving bone marrow\u2013suppressing agents. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Aurothioglucose (gold therapy) is used primarily for immune- mediated diseases. It has been used with some success to control immune- mediated skin diseases, such as pemphigus and immune- mediated arthritis. However, because of a lack of controlled trials to demonstrate efficacy and adverse effects that have been observed, the use in veterinary medicine has been uncommon. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include dermatitis, nephrotoxicity, and blood dyscrasias.","notes":"Instructions for Use Use\\tof\\tthis\\tdrug\\thas\\tnot\\tbeen\\tevaluated\\tin\\tveterinary\\tmedicine.\\tNo\\tcontrolled clinical trials are available to determine efficacy in animals. This drug is often used in combination with other immunosuppressive drugs such as corticosteroids. Patient Monitoring and Laboratory Tests Monitor patient\u2019s CBC periodically because gold salts have caused blood dyscrasias. Formulations \u2022\\t\\tAurothioglucose\\thas\\tbeen\\tdiscontinued\\tand\\tis\\tno\\tlonger\\tavailable.\\tHowever, some forms still persist (e.g., from compounding pharmacies) in a 50- mg/mL injection. A Azathioprine 73 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. The stability of compounded formulations has not been evaluated.","original_category":"Immunosuppressive"},{"name":"Azathioprine","active_ingredient":"Azathioprine","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/kg\\tq24h\\tPO\\tinitially;\\tthen\\t0.5\u20131\\tmg/kg\\tq48h.\\tIn\\tdogs,\\tdosages\\tas\\thigh\\tas 1.5\\tmg/kg\\tq48h\\tPO\\thave\\tbeen\\tused\\twith\\tprednisolone. Cats (use cautiously) \u2022\\t\\tCats\\tare\\tsensitive\\tto\\tbone\\tmarrow\u2013suppressing\\teffects,\\tand\\tmany\\tclinicians\\tavoid azathioprine in cats altogether. However, if administered to cats, one should start with\\t0.3\\tmg/kg\\tq24h\\tPO\\tand\\tadjust\\tthe\\tdose\\tto\\tq48h\\tafter\\tcareful\\tmonitoring. Tablet size may be as low as 1/30th to 1/50th of a tablet, which requires careful compounding.  Horses \u2022\\t\\t3\\tmg/kg,\\tPO,\\tq24h. Regulatory Information Do not administer to animals intended for food. Azithromycin ay- zith- roe- my \u0301sin Trade and other names: Zithromax","contraindications":"Contraindications and Precautions Ordinarily, it should not be administered to cats, but if treatment is attempted, exercise extreme caution and careful monitoring. Drug Interactions Administer with caution with other drugs that may suppress the bone marrow (e.g., cyclophosphamide and anticancer drugs). There is some evidence that concurrent use with corticosteroids may increase the risk of pancreatitis. Do not administer with allopurinol because antagonism of xanthine oxidase may interfere with metabolism.","indications":"Indications and Clinical Uses Azathioprine is used to treat various immune- mediated diseases in animals, including immune- mediated hemolytic anemia, pemphigus, and inflammatory bowel disease. It is often the first drug of choice, in addition to corticosteroids, for treatment of immune- mediated hemolytic anemia and pemphigus in dogs and is often used for inflammatory bowel disease. It is usually combined with prednisone or prednisolone treatment, but benefits of this combination compared with each drug administered alone has not been confirmed. It is primarily used in dogs and is not recommended in cats. There are some case reports for its successful use to treat immune- mediated disease in horses, but experience is limited. Onset of action is delayed for 4\u20136 weeks in some human patients. The onset of effects in animals has not been determined, but observations indicate that it occurs more quickly than in people. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Bone marrow suppression is the most serious concern. Additional adverse effects in dogs include diarrhea, increased risk of secondary infections, and vomiting. Hepatotoxicosis after administration of azathioprine also has been reported. Toxicity may be related to the metabolites, particularly 6- MMP. The incidence of hepatotoxicity may occur in dogs after the first 2\u20134 weeks of treatment; therefore, this is the most critical time to monitor liver enzymes and bilirubin. Individuals who have higher sensitivity to the suppressing effects of bone marrow should have the dose reduced. There has been some association with development of pancreatitis when administered with corticosteroids, but this has not been confirmed. Susceptibility to the adverse effects, and prediction of therapeutic effects in people may be correlated with the levels of the metabolizing enzyme, TPMT. Some people are deficient and have a higher incidence of adverse effects. However, the TPMT levels in dogs are variable and have not been associated with either hepatotoxicity or myelotoxicity. Cats are deficient in TPMT and are particularly susceptible to toxicity.","notes":"Instructions for Use Azathioprine is usually used in combination with other immunosuppressive drugs (e.g., corticosteroids) to treat immune- mediated disease. Cats are very sensitive to the bone marrow\u2013suppressing effects of azathioprine. Doses of 2.2 mg/kg to cats have produced toxicity, but some veterinarians have used low dosages of 0.3 mg/kg/ day. Alternatively, chlorambucil has been used instead of azathioprine in cats when immunosuppressive action is needed. Patient Monitoring and Laboratory Tests Monitor patient\u2019s CBC periodically because some animals are sensitive to the effects of azathioprine and its metabolite, 6- MP. After 2 weeks of treatment, a CBC is essential. Because of risk of hepatotoxicity, monitor hepatic enzymes and bilirubin regularly. Formulations Azathioprine is available in 25- , 50- , 75- , and 100- mg tablets and 10- mg/mL for injection. Stability and Storage Store in a tightly sealed container at room temperature. Compounded oral suspensions are stable for 60 days. A Azithromycin 75","original_category":"Immunosuppressive"},{"name":"Cyclosporine, Cyclosporin A","active_ingredient":"Cyclosporine, Cyclosporin A","species":["Canine","Feline","Equine"],"dosage":"Dosages of ketoconazole of 2.5\u201310 mg/kg/day in dogs have been shown to substantially decrease the clearance of cyclosporine and reduce the required dose by one half or more. Grapefruit juice also inhibits clearance and reduces the required\\tdose,\\talthough\\thigh\\tdoses\\tare\\tneeded.\\tFor\\texample,\\t10\\tg\\tof\\tpowdered whole grapefruit is needed in dogs to substantially affect exposure (such a large dose\\tof\\t42\\tcapsules\\tis\\timpractical).\\tFood\\tdecreases\\toral\\tabsorption\\tby\\t15%\u201322%. Metoclopramide and rifampin (and possibly other drugs that induce enzymes) will lower cyclosporine blood concentrations. There is no evidence that cyclosporine enhances or inhibits allergen- specific immunotherapy (ASIT) treatment.  Dogs \u2022\\t\\t3\u20137\\tmg/kg/day\\tPO.\\tThe\\ttypical\\tstarting\\tdosage\\tis\\t5\\tmg/kg/day\\tPO.\\tAfter\\tthe induction period, some dogs with atopic dermatitis have been controlled with dosages as low as 5 mg/kg every other day to every third day. \u2022\\t\\tFor\\tperianal\\tfistulas\\tand\\timmune-\\tmediated\\tdiseases\\t(e.g.,\\tIMHA),\\thigher\\tdoses\\tand more frequent administration have been used (5\u20138 mg/kg q12h). When a response is observed, the dose and frequency can be reduced. \u2022\\t\\tFor\\timmune\\tsuppression\\tassociated\\twith\\torgan\\ttransplantation,\\tdoses\\tshould\\tbe higher (e.g., 7\u201310 mg/kg q12h PO). \u2022\\t\\tIBD:\\t5\\tmg/kg\\tPO\\tq12h;\\tthen\\treduce\\tthe\\tfrequency\\tto\\tq24h\\tafter\\ta\\tresponse\\tis observed. \u2022\\t\\tIdiopathic\\tchronic\\thepatitis:\\t5\u20138\\tmg/kg/day,\\tPO. Cats \u2022\\t\\t7.5\\tmg/kg\\tper\\tday\\tPO.\\tSome\\tcats\\tcan\\tbe\\tcontrolled\\twith\\tadministration\\tof\\tthis dose every other day or twice weekly. Administer on a small amount of food or at the time of feeding, but if mixed with food, some cats may refuse to eat. \u2022\\t\\tFor\\timmune\\tsuppression\\tassociated\\twith\\torgan\\ttransplantation,\\tdoses\\tshould\\tbe higher (e.g., 3\u20135 mg/kg q12h PO).  \u2022\\t\\tOnly\\tlocal\\tadministration\\thas\\tbeen\\tused\\tin\\thorses\\t(ocular).\\tNo\\tother\\tdose\\thas\\tbeen reported for large animals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it may have mutagenic potential. Cyproheptadine Hydrochloride sih\u2032proe- hep\u2032tah- deen  hye- droe- klor\u2032ide Trade and other names: Periactin","contraindications":"Contraindications and Precautions At high doses, cyclosporine has produced embryotoxic and fetotoxic effects in laboratory animals. It is not recommended to administer to pregnant animals, but there are no specific reports on adverse effects on pregnancy in dogs or cats. It is excreted in milk of lactating animals. Warn animal owners to keep out of reach of children. If used with other drugs, consult the Drug Interactions section for possible interference. A withdrawal time prior to allergen- specific allergy testing in dogs is not necessary. Drug Interactions Cimetidine, erythromycin, diltiazem, itraconazole, fluconazole, clarithromycin, or ketoconazole may increase cyclosporine concentrations when used concurrently.","indications":"Indications and Clinical Uses Systemic uses (usually oral) for cyclosporine include IMHA, atopic dermatitis in dogs, and perianal fistulas. Other diseases have been treated with cyclosporine, such as sebaceous adenitis, idiopathic sterile nodular panniculitis, vesicular cutaneous lupus erythematosus, IMHA, immune- mediated thrombocytopenia, IBD, immune- mediated polyarthritis, myasthenia gravis, idiopathic chronic hepatitis, and aplastic anemia. It has also been used for treatment of granulomatous meningoencephalitis (3\u20136\\tmg/kg\\tq12h).\\tFor\\tmany\\tof\\tthese\\tindications,\\tefficacy\\thas\\tnot\\tbeen\\testablished through well- controlled clinical studies, and the use is based on anecdotal experience and recommendations from clinical experts. In dogs, there is strong evidence for effective treatment of atopic dermatitis, for which there is similar efficacy as prednisolone. Treatment response may be delayed for 2 weeks and for as long as 4 weeks in some dogs. During this induction time, it is acceptable to administer other medications (e.g., corticosteroids or oclacitinib) to control pruritus in dogs with atopic dermatitis. There is minimal effectiveness for immune- mediated pemphigus foliaceus (PF)\\tin\\tdogs,\\tbut\\tit\\tmay\\thave\\tbenefits\\tfor\\ttreating\\tPF\\tin\\tcats.\\tIn\\tdogs,\\tsome dermatologists have reported improved efficacy when combined with azathioprine for\\t  immune-\\tmediated\\tdiseases\\t(e.g.,\\t   PF).\\t  Cyclosporine\\tuse\\t  for\\t  keratoconjunctivitis sicca is limited to topical administration. In cats, cyclosporine has shown beneficial effects for treatment of EGC, IBD, atopic dermatitis (60% effective), oral stomatitis, and airway disease (feline asthma). Cyclosporine (Atopica for cats) is approved for control of feline allergic dermatitis. Higher doses are needed in cats compared with dogs because the oral absorption is more variable. In horses, it is effective as a localized treatment of anterior uveitis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effects in dogs and cats are GI problems (vomiting, diarrhea, anorexia, and weight loss). Vomiting is often observed only during C initial treatment and may be transient. Hypersalivation has been observed in cats. Cyclosporine may induce shedding of hair and stimulate new hair growth in dogs of\\ta\\tdifferent\\tconsistency.\\tNeurotoxicity\\tfrom\\thigh\\tdoses\\thas\\tbeen\\tseen\\tin\\tdogs, which can be seen as tremors. However, this is uncommon from recommended doses. Although kidney injury has been reported with older formulations, it has not been reported from use of current formulations of cyclosporine. Less commonly, cyclosporine can produce gingival proliferation (gingival hyperplasia) in animals, which is caused by a growth factor- mediated proliferation of gingival tissues. There are some reports that administration of azithromycin has been successful to resolve gingival hyperplasia. Occasionally, gingivitis and periodontitis may occur, which can be reversed after discontinuing the drug. There is no confirmed evidence that cyclosporine is a risk factor for neoplasia in dogs or cats. Calcineurin inhibitors can inhibit pancreatic beta cells and increase risk of diabetes in people. It may increase tissue insulin resistance and impair insulin production or secretion to increase glycemia. However, diabetes has not been reported in pets from clinical use of cyclosporine. Papillomas have been observed in dogs with chronic use. Unlike other immunosuppressive drugs, it does not cause myelosuppression. Cyclosporine may\\tincrease\\tthromboxane\\tTXA 2 in platelets and increase platelet activation, but increased risk of thromboembolism has not been associated with cyclosporine treatment in dogs or cats. Aspirin can block this response. Effect on vaccination: At three times the clinical dose, it did not affect the immune response to killed rabies vaccine in dogs, but it failed to increase antibody titers from live parvovirus vaccine. Cats treated with cyclosporine, even at high doses, are capable of mounting a memory humoral immune response to booster vaccination (feline calicivirus, parvovirus, feline\\tleukemia\\tvirus\\t[FeLV],\\tfeline herpesvirus\\ttype\\t1\\t[FHV-\\t1],\\tand\\trabies)\\tthat\\tis\\tadequate\\tfor\\tprotection.\\tHowever, at high doses, a primary humoral response was not observed within 4 weeks of exposure\\tto\\ta\\tnovel\\tantigen\\t(feline\\timmunodeficiency\\tvirus\\t[FIV]).\\tTherefore, na\xefve cats vaccinated before cyclosporine treatment should be able to mount an adequate primary immune response, and subsequent cyclosporine treatment should not affect immune response from booster vaccinations. Effect on infections in cats: Administration to cats at 7.5 mg/kg did not increase the severity of infection by Toxoplasma gondii in cats that were previously exposed (seropositive). However, administration of cyclosporine to cats that are na\xefve (seronegative) may increase the severity of T. gondii\\tinfection.\\tNa\xefve\\tcats\\tmay\\thave a greater risk of developing clinical toxoplasmosis if they become infected while receiving\\tcyclosporine\\ttreatment.\\tDo\\tnot\\tadminister\\tto\\tcats\\tinfected\\twith\\tFeLV or\\tFIV.\\tIn\\tcats\\tinfected\\twith\\tFHV-\\t1,\\tadministration\\tof\\tcyclosporine\\tactivated\\tthe infection, but the disease was mild and self- limited in most cats.","notes":"Instructions for Use Atopica\\t(veterinary)\\tand\\tNeoral\\t(human)\\tare\\tidentical\\tformulations\\texcept\\tthe\\tsizes of capsules vary. After animals have been treated with initial doses (see the dosing section) and are stable, doses may be adjusted by increasing the interval to once every other day or every third day rather than lowering the daily dose. Individual doses may be adjusted by monitoring blood concentrations, but monitoring is not necessary for routine use. Most of the experience is with the approved dose to treat atopic dermatitis and allergic dermatitis with doses of 5 mg/kg in dogs and 7 mg/ kg in cats. When used to treat animals for immune- mediated disease and organ transplantation, the doses are generally higher, often administered twice daily, and the blood concentrations maintained at a higher level. Atopica\\tand\\tNeoral\\toral\\tproducts\\tare\\tabsorbed\\tmore\\tpredictably\\tthan Sandimmune,\\twhich\\tis\\tno\\tlonger\\trecommended.\\tAtopica\\tand\\tNeoral\\tmay\\tproduce 50% higher blood concentrations in some patients or reduce the variability in absorption that was associated with the Sandimmune formulations. The injectable formulation has been used infrequently in dogs and cats. It may produce some injection- site reactions such as hair loss, crusts, or injection- site swelling. There are more than 20 human generic formulations, but none has been tested for bioequivalence in dogs or cats. There is one generic formulation approved for dogs, which\\tis\\tbioequivalent\\tto\\tthe\\tproprietary\\tbrand.\\tFeeding\\tmay\\treduce\\toral\\tabsorption in\\tdogs\\tbut\\tdoes\\tnot\\tdecrease\\tefficacy.\\tFor\\tcats,\\tit\\tis\\trecommended\\tto\\tadminister\\twith food if it does not affect their appetite. If necessary, the oral solution can be diluted to make it more palatable. To reduce the dose or increase blood concentrations, some veterinarians have administered ketoconazole or other enzyme- inhibiting compounds concurrently. Patient Monitoring and Laboratory Tests Although routine blood concentration monitoring is not necessary, it may be helpful to identify drug interactions, poor absorption, adverse reactions, or poor compliance. However, there has been no correlations established between blood concentrations in dogs and cats and clinical response. When monitoring, collect whole blood in ethylenediaminetetraacetic acid (EDTA; purple top) tube for submission to laboratory. Suggested trough blood concentration range (whole blood assay) is 300\u2013400 ng/ mL, although in some studies, levels as low as 200 ng/mL have been effective. Peak concentrations (collected at approximately 2 hours after oral administration of 5 mg/ kg) should be in the range of 600\u20131200 ng/mL. Consult the laboratory to determine if the laboratory result is specific or if it also measures inactive metabolites and requires a conversion. Cyclosporine does not interfere with intradermal skin testing. C Cyproheptadine Hydrochloride 223 Formulations \u2022\\t\\tCyclosporine\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\t50-\\t  ,\\tand\\t100-\\tmg\\tcapsules\\t(Atopica)\\tand\\t25- and 100-mg microemulsion capsules. \u2022\\t\\tThere\\tis\\tone\\tFDA-\\tapproved\\tgeneric\\tformulation\\tof\\tcyclosporine\\tfor\\tdogs,\\twhich has shown to be bioequivalent with the proprietary form (original brand). It is approved in the same size capsules as the original formulation. \u2022\\t\\tAtopica\\tfor\\tcats\\tis\\tavailable\\tas\\ta\\t100-\\tmg/mL\\toral\\tsolution\\tas\\ta\\tmicroemulsion.\\tThis may be mixed with the cat\u2019s food if it does not affect their appetite. \u2022\\t \\tHuman\\tforms\\tare\\talso\\tavailable\\tas\\ta\\t100-\\tmg/mL\\toral\\tsolution\\t(Neoral,\\tfor microemulsion); 100- mg/mL oral solution and 25-  and 100- mg capsules (Sandimmune); and 0.2% ophthalmic ointment (Optimmune). Generic human capsules are available (e.g., Gengraf). The human generic formulations are therapeutically equivalent in people but have not been compared in dogs or cats to Atopica. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It does\\tnot\\trequire\\trefrigeration\\tbut\\tstore\\tbelow\\t30\xb0C.\\tFreezing\\tcapsules\\tat\\t\u221220\xb0C\\tfor 28 days did not affect stability or oral absorption. Compounded ophthalmic products are stable at room temperature for 60 days, but do not refrigerate.","original_category":"Immunosuppressive drug"},{"name":"Gold Sodium Thiomalate","active_ingredient":"Gold Sodium Thiomalate","species":["Canine","Feline"],"dosage":"Dogs and cats \u2022\\t\\t1\u20135\\tmg\\tper\\tanimal\\tIM\\tfirst\\tweek,\\tthen\\t2\u201310\\tmg\\tIM\\tsecond\\tweek,\\tand\\tthen\\t1\\tmg/ kg once per week IM for maintenance.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Gonadorelin Hydrochloride and Gonadorelin Diacetate Tetrahydrate goe- nad- oh- rell\u2032in  hye- droe- klor\u2032ide  and  goe- nad- oh- rell\u2032in  dye- ass\u2032eh- tate  tet- ra- hye\u2032drate Trade and other names: Factrel, Fertagyl, Cystorelin, Fertilin, OvaCyst, GnRh, and LHRH","contraindications":"Contraindications and Precautions Use cautiously in animals with bone marrow suppression or renal disease. Drug Interactions Use with penicillamine will increase risk of hematologic adverse effects.","indications":"Indications and Clinical Uses Gold therapy is used primarily for immune- mediated diseases (e.g., dermatologic disease) in animals. In people, it has been used for rheumatoid arthritis. In animals, there is a lack of controlled clinical trials to document efficacy, and the use is based only on anecdotal experiences and extrapolation of the use in people. Its use in animals is uncommon. Other immunosuppressive drugs are used more frequently. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include dermatitis, nephrotoxicity, and blood dyscrasias.","notes":"Instructions for Use Clinical studies have not been performed in animals. Aurothioglucose generally is used more often than gold sodium thiomalate. Patient Monitoring and Laboratory Tests Complete blood count (CBC) should be monitored periodically during treatment. 414    Gonadorelin Hydrochloride and Gonadorelin Diacetate Tetrahydrate Formulations Available \u2022\\t\\tNote:\\tMost\\tforms\\tof\\tthis\\tdrug\\tare\\tno\\tlonger\\tapproved\\tand\\tmay\\tnot\\tbe\\tavailable commercially. Gold sodium thiomalate has been available in 10- , 25- , and 50- mg/ mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Immunosuppressive"},{"name":"Leflunomide","active_ingredient":"Leflunomide","species":["Canine","Feline"],"dosage":"studies in dogs suggest that the dosage of 4 mg/kg per day may not produce drug levels that are considered therapeutic. Therefore, in patients that have not responded, there should be consideration for higher doses if it is tolerated by the patient.  Dogs \u2022\\t\\tStart\\twith\\t2\\tmg/kg\\tper\\tday\\tto\\tavoid\\tadverse\\teffects.\\tIt\\tthis\\tdosage\\tis\\twell\\ttolerated, increase to 4 mg/kg per day, usually in divided doses of 2 mg/kg q12h; then taper the\\tdosage\\tto\\t2\\tmg/kg\\tq24h\\tPO.\\tAfter\\tan\\tinitial\\tinduction\\tperiod,\\tthe\\tdose\\tmay be decreased by 25% increments until the patient is stabilized or until the disease resolves. Some patients may require higher starting doses. Cats \u2022\\t\\t2\\tmg/kg\\tper\\tday\\tfor\\t2\\tdays\\tPO;\\tthen\\t2\\tmg/kg\\tq48h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should be avoided in food- producing animals. Leucovorin Calcium loo- koe- vor\u2032in kal\u2032see- um Trade and other names: Wellcovorin and generic brands","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. This drug can be toxic to a developing fetus. Drug Interactions No interactions are reported. L Leucovorin Calcium 507","indications":"Indications and Clinical Uses This drug is used in people primarily for rheumatoid arthritis. In dogs, it has been used for a variety of immune- mediated diseases as a substitute for other drugs such as azathioprine or mycophenolate. These diseases include myasthenia gravis, Evan syndrome, immune- mediated hemolytic anemia and thrombocytopenia, and polymyositis/polyarthritis. Efficacy has not been studied in controlled clinical studies. Dosing recommendations have been reported in small observational studies or from uncontrolled retrospective studies. In most reports, it was administered with corticosteroids. In one case report, there was a positive response in most dogs with immune- mediated polyarthritis treated at 3\u20134 mg/kg once daily. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effects in dogs have been decreased appetite, lethargy, and diarrhea. Liver enzymes were elevated in some animals. Adverse gastrointestinal (GI) effects are more common with higher doses. Because of the GI effects, many clinicians start with a low dose and gradually titrate up to higher doses. Mild anemia and lethargy also have been observed. Although rare, leukopenia, anemia, and anorexia are possible with doses greater than 4 mg/kg. Periodic complete blood count (CBC) is recommended to monitor patients during treatment. In cats, the most common adverse effects have been intermittent vomiting, which is mild and transient.","notes":"Instructions for Use Leflunomide is used most often in dogs for immunosuppressive treatment when other drugs have failed or when the patient has become refractory to other drugs and a substitute is considered. The dosing protocols used currently are derived from extrapolation and some anecdotal reports. Most veterinarians start with 4 mg/kg per day and then lower the dose as the patient responds. Pharmacokinetic Patient Monitoring and Laboratory Tests Monitor CBC and platelet counts in treated animals. Anemia has been reported as a consequence of treatment. If blood monitoring is pursued, plasma samples may be collected and measured for A77 1726 (the active metabolite). This metabolite is stable in serum for up to 5 months under refrigerated conditions. Drug concentrations at 12 hours (trough) are considered effective if greater than 20 mcg/mL. Formulations \u2022\\t\\tAvailable\\tin\\t5-\\t,\\t10-\\t  ,\\tand\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Immunosuppressive drug"}]},{"category":"Neurologic","drugs":[{"name":"Bromide","active_ingredient":"Bromide","species":["Feline","Canine","Equine"],"dosage":"Cats \u2022\\t\\t30\\tmg/kg\\tq24h\\tPO.\\t(Not\\trecommended\\tfor\\tcats.) Dogs \u2022\\t \\t30\u201340\\tmg/kg\\tq24h\\tPO.\\tIf\\tadministered\\twithout\\tphenobarbital,\\thigher doses of up to 40\u201350 mg/kg may be needed. If animals are on diets high in chloride, higher doses may be needed. Adjust doses by monitoring plasma concentrations. \u2022\\t\\tOral\\tloading\\tdose:\\t600\\tmg/kg\\tdivided\\tover\\t3\u20135\\tdays\\t(200\\tmg/kg\\tonce\\ta\\tday\\tfor\\t5 days\\talso\\thas\\tbeen\\tused),\\tPO.\\tAlternatively,\\t60\\tmg/kg/day\\thas\\tbeen\\tadministered for\\t15\\tdays\\tto\\tachieve\\ta\\tplasma\\tconcentration\\tof\\t100\\tand\\t200\\tmg/dL\\tby\\t60\\tdays. \u2022\\t\\tIV\\tloading\\tdose\\tfor\\tsodium\\tbromide:\\t800\u20131200\\tmg/kg\\tinfused\\tover\\t8\\thours\\t(it\\tis critical to use sodium bromide instead of potassium bromide for this use).  Horses \u2022\\t\\t100\\tmg/kg\\tloading\\tdose\\tfollowed\\tby\\t25\\tmg/kg\\tq24h,\\tPO. \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tother\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. B Bromocriptine Mesylate 93 Bromocriptine Mesylate broe- moe- krip\u2032teen mess\u2032ih- late Trade and other names: Parlodel","contraindications":"Contraindications and Precautions Consider using sodium bromide, rather than potassium bromide, in patients with hypoadrenocorticism or in any patients in which potassium regulation is a problem.\\tLikewise,\\tconsider\\tthe\\tsodium\\tcontent\\tof\\tadministration\\tin\\tanimals\\twith CHF or hypertension. Diets high in chloride cause a shorter half- life and need for a higher dose. Monitor plasma concentrations and adjust dose as necessary whenever changing diets because increasing chloride in the diet shortens the half- life and vice versa. Drug Interactions Diets high in chloride cause a shorter half- life and need for a higher dose. Administration of bromide interferes with some blood chemistry analysis (e.g., false elevation of chloride).","indications":"Indications and Clinical Uses Bromide ordinarily is used in patients with seizure disorders that have been refractory to phenobarbital. Usually, patients are treated with both phenobarbital and bromide. However, some patients have been treated with B bromide as a single therapy for epilepsy. If bromide is added to phenobarbital therapy, it allows for a reduction in phenobarbital dose (reduce by 25% every 6 weeks). Despite clinical evidence of efficacy, the use of bromide for treating seizures in dogs has declined with the availability of other available agents, such as levetiracetam (Keppra). Bromide has not been as effective for treating cats with seizure disorders as in dogs, and the use in cats is discouraged. Cats have more adverse effects and are less well controlled; therefore, bromide is rarely recommended for a treatment in cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Common side effects include polyuria/polydipsia, polyphagia, ataxia, sedation, and GI upset. More serious adverse effects are related to high levels of bromide (bromism) and are more specific for the central nervous system (CNS). Signs of toxicosis are CNS depression, delirium, hyperexcitability, weakness, and ataxia. Hind limb stiffness and abnormal gait also may be signs of bromide toxicosis. If adverse effects occur, discontinuation of the medication usually results in resolution of the clinical signs in several days. Resolution may be faster (within hours) with aggressive saline diuresis. Nausea and pancreatitis have been reported in dogs, and there is evidence that a combination of bromide and phenobarbital in dogs may increase the risk of pancreatitis. However, there is no direct evidence that bromide alone produces pancreatic toxicity. There is no evidence available to indicate that bromide treatment affects thyroid function in dogs. Some dogs show paradoxical excitement with bromide treatment. In many cats, bronchitis resembling allergic airway disease has been observed. In cats, this may be characterized by coughing.","notes":"Instructions for Use Bromide usually is administered in combination with phenobarbital. Sodium bromide can be substituted for potassium bromide. When considering doses for sodium bromide,\\tslight\\tdose\\tadjustments\\tshould\\tbe\\tconsidered.\\tPotassium\\tbromide\\tis 67% bromide, and sodium bromide is 78% bromide; therefore, the dose of sodium bromide should be approximately 15% less (e.g., 30 mg/kg of potassium bromide is equivalent\\tto\\t25\\tmg/kg\\tof\\tsodium\\tbromide). Patient Monitoring and Laboratory Tests Monitor serum bromide concentrations to adjust dose. Effective plasma concentrations\\tshould\\tbe\\t1\u20132\\tmg/mL\\t(100\u2013200\\tmg/dL),\\tbut\\tif\\tused\\talone\\t(without phenobarbital),\\thigher\\tconcentrations\\tof\\t2\u20132.5\\tmg/mL\\t(200\u2013250\\tmg/dL)\\tand\\tas high\\tas\\t4\\tmg/mL\\tmay\\tbe\\tneeded.\\tMost\\tveterinary\\tlaboratories\\tcan\\tperform\\ta\\ttest\\tfor bromide in plasma or serum. Formulations \u2022\\t\\tBromide\\tis\\tusually\\tprepared\\tas\\tan\\toral\\tsolution.\\tAlthough\\tthere\\tare\\tno\\tcommercial forms approved by the US Food and Drug Administration, compounding pharmacists can prepare a solution. To prepare the oral solution, mix 25 g of potassium\\tbromide\\twith\\t60\\tmL\\tof\\tpurified\\twater;\\tthen\\tadd\\ta\\tsufficient\\tquantity\\tof corn\\t  syrup\\t   to\\t make\\t   100\\t  mL.\\t  This\\t  formulation\\tresults\\t   in\\t a\\t bromide\\tconcentration\\tof approximately\\t151\u2013185\\tmg/mL.\\tThis\\tsolution\\tis\\tstable\\tfor\\t180\\tdays.\\tFor\\tsodium bromide\\toral\\tsolution,\\tmix\\t21.6\\tg\\tsodium\\tbromide\\twith\\t60\\tmL\\tpurified\\twater; then\\tadd\\ta\\tsufficient\\tquantity\\tof\\tcorn\\tsyrup\\tto\\tmake\\t100\\tmL.\\tThis\\tformulation results\\tin\\ta\\tconcentration\\tof\\tapproximately\\t151\u2013185\\tmg/mL.\\tThis\\tsolution\\tis stable for 180 days. \u2022\\t \\tA\\tpharmacist\\tshould\\tprepare\\tthe\\tIV\\tsolution\\tin\\tsterile\\twater\\tand\\tfilter\\tit\\tto remove impurities. To prepare injectable solution, add 3 g of sodium bromide with\\ta\\tsufficient\\tquantity\\tof\\tsterile\\twater\\tto\\tmake\\t100\\tmL.\\tThis\\tformulation results\\tin\\ta\\tbromide\\tconcentration\\tof\\tapproximately\\t21\u201325.6\\tmg/mL.\\tIt\\tis\\tstable for 180 days and should be stored in the refrigerator to decrease the risk of microbial growth. Stability and Storage Store\\tin\\ta\\ttightly\\tsealed\\tcontainer.\\tCompounded\\tformulations\\tin\\taqueous\\tsolutions are stable for at least 180 days. Refrigerate injectable solution to prevent bacterial growth. Do not mix with salt- containing flavorants or solutions.","original_category":"Anticonvulsant"},{"name":"Clonazepam","active_ingredient":"Clonazepam","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tmg/kg\\tq8\u201312h\\tPO. Cats \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tq12\u201324h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Schedule IV controlled drug. RCI\\tClassification:\\t2 Clopidogrel kloe- pid\u2032oh- grel Trade and other names: Plavix","contraindications":"Contraindications and Precautions No\\tcontraindications\\treported\\tfor\\tanimals.\\tUse\\tof\\tbenzodiazepines\\tin\\tearly pregnancy has been associated with an increased risk of spontaneous abortions and fetal malformations in people. This incidence in animals is unknown. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tit\\tpotentiates\\teffects\\tfrom other\\tsedatives\\tand\\tCNS\\tdepressants.","indications":"Indications and Clinical Uses Clonazepam has been used as an anticonvulsant in dogs and cats, but this use is not common because there are other more effective anticonvulsant agents available. Tolerance may develop to the anticonvulsant effects with long- term use. Like other benzodiazepines, it also is used to treat behavior problems in dogs and cats, particularly those associated with anxiety. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects include sedation and polyphagia. Some animals may experience paradoxical excitement.","notes":"Instructions for Use The doses used clinically in dogs and cats are based primarily on reports from human medicine,\\tempiricism,\\tor\\texperimental\\tstudies.\\tNo\\tclinical\\tefficacy\\tstudies\\thave\\tbeen performed in dogs or cats. Some dogs are sensitive to the doses listed in the dosing section and lowered to 0.1\u20130.2 mg/kg in some animals. C Clopidogrel 201 Patient Monitoring and Laboratory Tests Samples of plasma or serum may be analyzed for concentrations of benzodiazepines. However, many veterinary laboratories may not have this capability, and laboratories that analyze human samples may be nonspecific for benzodiazepines. Formulations \u2022\\t\\tClonazepam\\tis\\tavailable\\tin\\t0.5-\\t,\\t1-\\t ,\\tand\\t2-\\t    mg\\ttablets.\\tOral\\tdisintegrating\\ttablets\\tare available as 0.125- , 0.25- , 0.5- , 1- , and 2- mg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Clonazepam, like other benzodiazepines, exhibits adsorption to plastic, especially soft plastic (polyvinyl chloride). Compounded oral products are stable for 60 days.","original_category":"Anticonvulsant"},{"name":"Clorazepate Dipotassium","active_ingredient":"Clorazepate Dipotassium","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\u20132\\tmg/kg\\tq8\u201312h\\tPO\\tand\\tas\\tfrequently\\tas\\t4\\thours.\\t(Total\\tdose\\tis\\tusually\\t3.75 mg or 7.5 mg.) Cats \u2022\\t\\t0.2\u20130.4\\tmg/kg\\tq12\u201324h\\tup\\tto\\t0.5\u20132.2\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t2 Cloxacillin Sodium kloks- ah- sill\u2032in soe\u2032dee- um Trade and other names: Cloxapen, Orbenin, and Tegopen","contraindications":"Contraindications and Precautions No\\tserious\\tcontraindications.\\tIn\\trare\\tindividuals,\\tbenzodiazepines\\thave\\tcaused paradoxical excitement. They may cause fetal abnormalities early in pregnancy, but this has not been reported with veterinary use. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.\\tHowever,\\tit\\tpotentiates\\teffects\\tfrom other\\tsedatives\\tand\\tCNS\\tdepressants.","indications":"Indications and Clinical Uses Clorazepate is used for anticonvulsant treatment, sedation, and treatment of some behavioral disorders. The use for treating seizures has diminished because there are other more effective agents available for dogs and cats, but it has been used with other drugs in refractory cases when other drugs are not effective. It is not recommended as a sole treatment for seizure disorders in dogs and cats. When used as an anticonvulsant, tolerance may develop to the anticonvulsant effects with long- term use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects include sedation and polyphagia. Some animals may experience paradoxical excitement. Chronic administration may lead to dependence and a withdrawal syndrome if discontinued.","notes":"Instructions for Use Doses are based primarily on reports from human medicine, empiricism, or experimental studies. Higher doses may be used for short- term treatment of noise phobia. However, for most indications, no clinical efficacy studies have been performed in dogs or cats. Patient Monitoring and Laboratory Tests Samples of plasma or serum may be analyzed for concentrations of benzodiazepines. If response to clorazepate is measured, the active metabolite, nordiazepam (desmethyldiazepam), should be measured. Plasma concentrations in the range of 100\u2013250 ng/mL have been cited as the therapeutic range for people, but some references have cited this range as 150\u2013300 ng/mL. The optimum range for dogs and cats has not been determined. There  are no readily available tests for monitoring in many veterinary laboratories. Laboratories that analyze human samples may have nonspecific tests for benzodiazepines. With these assays, there may be cross- reactivity among benzodiazepine metabolites. Formulations Available \u2022\\t\\tClorazepate\\tis\\tavailable\\tin\\t3.75-\\t,\\t7.5-\\t  ,\\tand\\t15-\\tmg\\ttablets. Stability and Storage Keep in original packaging or store in tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been C Cloxacillin Sodium 207 evaluated, but clorazepate tablets degrade quickly in the presence of light, heat, or moisture.","original_category":"Anticonvulsant"},{"name":"Diazepam","active_ingredient":"Diazepam","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tPreanesthetic:\\t0.5\\tmg/kg\\tIV. \u2022\\t\\tStatus\\tepilepticus:\\t0.5\\tmg/kg\\tIV,\\t0.5\u20131\\tmg/kg\\tsprayed\\tintranasal,\\tor\\t1\\tmg/kg rectal; repeat if necessary. \u2022\\t\\tCRI:\\t15\\tmcg/kg/min\\t(1\\tmg/kg/h),\\twhich\\tcan\\tbe\\tdecreased\\tby\\t50%\\tin\\tsome animals if excessive side effects are observed. \u2022\\t\\tAppetite\\tstimulant\\t(cats):\\t0.2\\tmg/kg\\tIV. \u2022\\t\\tBehavior\\ttreatment\\t(cats):\\t1\u20134\\tmg/cat\\tq12\u201324h\\tPO. \u2022\\t\\tBehavior\\ttreatment\\t(dogs):\\t0.5\u20132\\tmg/kg\\tq4\u20136h\\tPO.  Cattle, Sheep, and Goats \u2022\\t\\t0.02\u20130.08\\tmg/kg\\tIV,\\tup\\tto\\t0.5\\tmg/kg\\tslowly\\tIV.\\tDose\\taccording\\tto\\tdesired effect.\\tCows\\tmay\\tbe\\trecumbent\\tafter\\t0.5\\tmg/kg.\\tDo\\tnot\\tadminister\\tIM. Horses \u2022\\t\\tSeizures:\\t0.1\u20130.4\\tmg/kg\\tIV\\t(start\\twith\\t50\u2013100\\tmg\\tper\\thorse).\\tCRI\\tfor\\tfoals: 1\u20133\\tmg/h. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Schedule IV controlled drug RCI\\tClassification:\\t2 Dichlorphenamide dye- klor- fen \u0301ah- mide Trade and other names: Daranide","contraindications":"Contraindications and Precautions Diazepam is highly dependent on liver blood flow for metabolism. Do not administer\\tto\\tpatients\\twith\\timpaired\\tliver\\tfunction.\\tLong-\\tterm\\tuse\\tin\\tcats\\tshould be avoided because of risk of liver toxicity. Its use for ivermectin- induced CNS intoxication is controversial. Use of benzodiazepines in early pregnancy has been associated with an increased risk of spontaneous abortions and fetal malformations in people. This incidence in animals is unknown. Drug Interactions Diazepam is highly lipophilic and will bind to (adsorb) soft plastic containers, infusion, sets, and fluid bags. Storage of diazepam in such containers is not recommended.\\tDiazepam\\tis\\tnot\\tsoluble\\tin\\taqueous\\tsolutions.\\tAdmixing\\twith aqueous\\tsolutions\\tor\\tfluids\\tcan\\tresult\\tin\\tprecipitation.","indications":"Indications and Clinical Uses Diazepam\\tis\\tused\\tfor\\tsedation,\\tanesthetic\\tadjunct,\\tanticonvulsant,\\tand\\tbehavioral disorders. Although it is used as a muscle relaxant, the action as a muscle relaxant is not as profound as other benzodiazepines, and the efficacy for this use is not established in animals. In cats, diazepam has been administered IV for short- term stimulation of appetite, but other agents are preferred because of risks from repeated IV diazepam in cats. In cats, oral administration has been effective for decreasing urine spraying, but relapses are common when the drug is discontinued. Diazepam\\tis\\tusually\\tadministered\\torally\\tor\\tintravenously.\\tHowever,\\tit\\tis\\talso absorbed\\tin\\tdogs\\tfrom\\trectal\\tadministration\\tand\\tintranasal\\tadministration\\t(41% absorption from nasal spray in dogs and 80% from rectal administration). D Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. In dogs, ataxia and increased appetite can be observed. Diazepam may cause paradoxical excitement and agitation in dogs. In cats, idiopathic fatal hepatic necrosis has been reported. Chronic administration may lead to dependence and a withdrawal syndrome if discontinued. Administration IM or\\tSQ\\tcan\\tbe\\tpainful\\tand\\tirritating.\\tIV\\tinjection\\tcan\\tcause\\tphlebitis.","notes":"Instructions for Use Clearance\\tin\\tdogs\\tis\\tmany\\ttimes\\tfaster\\tthan\\tin\\tpeople\\trequiring\\tfrequent administration. For treatment of status epilepticus, diazepam solution may be administered intravenously, intranasally, or rectally. Avoid IM administration because of\\tpain\\tfrom\\tinjection\\tand\\tunpredictable\\tabsorption. Patient Monitoring and Laboratory Tests Plasma\\tconcentrations\\tin\\tthe\\trange\\tof\\t100\u2013250\\tng/mL\\thave\\tbeen\\tcited\\tas the therapeutic range for people, but some references have cited this range as 150\u2013300\\tng/mL.\\tAlthough\\tplasma\\tor\\tserum\\tmay\\tbe\\tanalyzed\\tfor\\tconcentrations of benzodiazepines, there are no readily available tests for monitoring in many\\tveterinary\\tlaboratories.\\tLaboratories\\tthat\\tanalyze\\thuman\\tsamples\\tmay have nonspecific tests for benzodiazepines. With these assays, there may be cross- reactivity among diazepam and the metabolites desmethyldiazepam and oxazepam. Formulations \u2022\\t\\tDiazepam\\tis\\tavailable\\tin\\t2-\\t,\\t5-\\t ,\\tand\\t10-\\tmg\\ttablets;\\t5-\\tmg/mL\\toral\\tsolution;\\tand 5-\\t mg/mL\\tsolution\\tfor\\tinjection. Stability and Storage Do not store in soft plastic (polyvinyl chloride [PVC]) containers or fluid bags. Significant\\tadsorption\\toccurs\\tto\\tsoft\\tplastic.\\tHowever,\\tit\\tis\\tcompatible\\twith\\thard plastic, such as syringes. Do not expose to light. Compounded formulations, especially those prepared for transdermal application, may not be stable. Diazepam is practically insoluble in water but is soluble in alcohol and propylene glycol. Diazepam undergoes\\thydrolysis\\tin\\twater.\\tDiazepam\\tprepared\\tas\\tan\\toral\\tsuspension\\t(1\\tmg/mL) in\\tvarious\\tvehicles\\t(pH\\t4.2)\\twas\\tstable\\tfor\\t60\\tdays. 262    Dichlorphenamide","original_category":"Anticonvulsant"},{"name":"Felbamate","active_ingredient":"Felbamate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tStart\\twith\\t15\u201320\\tmg/kg\\tq8h\\tPO;\\tincrease\\tas\\tneeded\\tto\\tcontrol\\tseizures.\\tMaximum dosage is approximately 70 mg/kg q8h PO. \u2022\\t \\tSmall\\tdogs:\\t200\\tmg/dog\\tq8h\\tPO;\\tincrease\\tto\\ta\\tmaximum\\tdosage\\tof\\t600\\tmg/dog\\tq8h. \u2022\\t \\tLarge\\tdogs:\\t400\\tmg/dog\\tq8h.\\tIncrease\\tdose\\tgradually\\tby\\t200-\\tmg\\t(15-\\tmg/kg) increments until seizure control. Maximum dosage for large dogs is 1200 mg/dog q8h.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No withdrawal times have been established. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 3 358    Fenbendazole Fenbendazole fen- ben\u2032dah- zole Trade and other names: Panacur and Safe- Guard","contraindications":"Contraindications and Precautions It may increase phenobarbital concentrations. It may be more likely to cause liver injury when used with phenobarbital. Drug Interactions Possible interactions exist with drugs that either alter or are substrates for hepatic cytochrome P450 enzymes. (See Appendixes H and I.) It may increase phenobarbital concentrations if used concurrently.","indications":"Indications and Clinical Uses Felbamate is used to treat epilepsy in dogs when they are refractory to other anticonvulsants. Other drugs are typically used first before attempting to add felbamate. It has been used in conjunction with other anticonvulsants. However, the use in animals has declined because of the availability of other drugs to treat refractory seizures, such as levetiracetam, zonisamide, gabapentin, and pregabalin. F Precautionary Information","side_effects":"Adverse Reactions and Side Effects In dogs, it has increased risk of liver injury. It also may cause tremors, salivation, restlessness,\\tand\\tagitation\\t(usually\\tat\\tthe\\thigh\\tdoses).\\tKeratoconjunctivitis\\tsicca also has been reported in dogs. Some blood abnormalities, such as neutropenia lymphopenia and thrombocytopenia, have been reported. In people, the most severe reactions have been hepatotoxicity and aplastic anemia.","notes":"Instructions for Use Dosing has been empirically in dogs. The use in dogs is based on small observational studies. There are no controlled studies to document efficacy, but it is usually administered when animals have been refractory to other drugs, such as phenobarbital or bromide. Patient Monitoring and Laboratory Tests Monitoring of plasma concentrations is helpful to assess therapy. Assays may be available in some commercial laboratories. Ideal plasma concentrations have not been established for animals. However, concentrations in humans of 24\u2013137 mcg/mL in plasma have been effective (mean, 78 mcg/mL). Monitor complete blood count (CBC) and chemistry panels periodically (e.g., every 6 months). Formulations \u2022\\t\\tFelbamate\\tis\\tavailable\\tin\\t120-\\tmg/mL\\toral\\tsuspension\\tand\\t400-\\t\\tand\\t600-\\tmg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticonvulsant"},{"name":"Imepitoin","active_ingredient":"Imepitoin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tEpilepsy\\ttreatment:\\t10\u201330\\tmg/kg\\tPO\\ttwice\\tdaily. \u2022\\t\\tNoise\\ttreatment:\\t30\\tmg/kg\\tPO\\tq12h\\tusing\\ta\\tsuitable\\tcombination\\tof\\twhole\\tand half tablets. Initiate therapy starting 2 days prior to the day of the expected noise event and continue through the noise event. Cats \u2022\\t\\tSafe\\tdose\\tnot\\testablished.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\testablished\\tfor\\tlarge\\tanimals. Regulatory Information No withdrawal times are established for animals intended for food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Imidocarb Hydrochloride and Imidocarb Dipropionate im- id\u2032oh- carb  hye- droe- klor\u2032ide Trade and other names: Imizol","contraindications":"Contraindications and Precautions Safe doses have not been established for cats. When administered with other CNS depressants, especially benzodiazepines, to dogs, there may be additional sedation. Anxiolytic drugs acting at the benzodiazepine receptor site, including imepitoin, may lead to disinhibition of fear- based behaviors and may therefore result in a change in aggression level. Careful observation by the owners is recommended during treatment. Drug Interactions Imepitoin is metabolized by the liver enzymes; therefore, interactions with other drugs\\tthat\\taffect\\tcytochrome\\tP450\\tenzymes\\tare\\tpossible\\tbut\\thave\\tnot\\tbeen\\tstudied in\\tdogs.\\tIt\\tdid\\tnot\\taffect\\tactivity\\tof\\tmost\\thuman\\tP450\\tisoforms,\\tbut\\tinhibition\\tof CYP1A1\\tis\\tpossible.\\tImepitoin\\thad\\tno\\teffect\\ton\\tenzyme\\tinduction\\tcompared\\twith phenobarbital. It is a partial agonist for the benzodiazepine receptor, but there is no evidence that it prevents the activity of co- administered benzodiazepines used for acute treatment (e.g., status epilepticus). In a small study, there was no evidence of interaction with co- administered phenobarbital in dogs. Imepitoin is poorly soluble and dissolves more readily at an acid pH. Therefore it is possible that suppressing acid in the stomach (e.g., with proton pump inhibitors such as omeprazole) could interfere with oral absorption. I Imidocarb Hydrochloride and Imidocarb Dipropionate 451","indications":"Indications and Clinical Uses Imepitoin is approved in the United States for treatment of noise aversion (noise phobia) associated with loud noises that cause anxiety and behavior problems in dogs. It is approved in Europe as an anticonvulsant (epilepsy treatment) but not the United States. In Europe, it is considered a first- line treatment for idiopathic epilepsy in dogs. It has not been evaluated for treatment of status epilepticus. There have been no studies reported in cats or other animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Imepitoin acts as a central nervous system (CNS) depressant. The most common adverse effects from imepitoin reported in field trials were lethargy and sedation, polyuria and polydipsia, ataxia, and increased appetite. Most reactions are mild and generally transient. Other reported effects are hyperactivity, hypersalivation, emesis, diarrhea, and sensitivity to sound. In some animals, there were signs of aggression\\t(see\\tContraindications\\tand\\tPrecautions). An important finding in clinical studies was that it produced fewer adverse effects than primidone or phenobarbital. In clinical studies, it did not elevate liver enzymes. Although it is a partial agonist for the GABA A binding site, there is no evidence of tolerance or dependence that develop from repeated administration of imepitoin. During safety studies in dogs, it was well- tolerated at the label dose, but at higher doses (three and five times the label dose), there were signs of sedation, tremors, and nystagmus. There were also dose- dependent salivation and vomiting.","notes":"Instructions for Use The use in dogs is based on the Food and Drug Administration (FDA) approval in the United States and the approval for anticonvulsant use in Europe. For anticonvulsant use, it is recommended to start with 10 mg/kg and then increase dose to obtain the desired response. There have been no guidelines thus far for plasma/serum concentration monitoring; therefore, dose adjustment should be made on the basis of clinical response. The dose can be increased by 50% to 100% increments up to a maximum dosage of 30 mg/kg administered twice daily. When compared with primidone in dogs for treating epilepsy in a US field trial, imepitoin efficacy was lower than primidone, but it produced fewer adverse effects in dogs than primidone. In the field trials in Europe, the efficacy of imepitoin was compared with phenobarbital in dogs with idiopathic epilepsy. Although there was lower overall efficacy for imepitoin compared with phenobarbital, some dogs were well- controlled with imepitoin treatment. It may also be considered as an add- on treatment for dogs with epilepsy. For treatment of noise aversion (noise phobia) in dogs, start treatment (30 mg/kg) 2 days prior to the anticipated noise event (e.g., fireworks). Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Monitor animals for signs listed in the adverse effects section. Formulations \u2022\\t\\tImepitoin\\tis\\tavailable\\tin\\t100-\\t\\tand\\t400\\tmg-\\ttablets.\\tTablets\\tcan\\tbe\\tsplit\\tif\\tnecessary. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. At this time, there is no information on stability of compounded formulations.","original_category":"Anticonvulsant, behavior drug"},{"name":"Levetiracetam","active_ingredient":"Levetiracetam","species":["Feline","Canine","Equine"],"dosage":"has been used to treat seizure disorders in cats at a dosage of 20 mg/kg q8h and found to be effective in some cases. Because dosing q8h can be difficult for some owners, the XR tablets have been examined. These may be administered q12h to dogs, and the 500- mg tablet may be administered once daily to cats. Clinical use in horses is uncommon, but there have been pharmacokinetic studies to guide dosing (see dosing section for horses). Precautionary Information  Dogs \u2022\\t\\t20\\tmg/kg\\tq8h\\tPO.\\tMore\\tfrequent\\tadministration\\tor\\thigher\\tdoses\\tmay\\tbe necessary with concurrent phenobarbital treatment. \u2022\\t\\tOral\\tXR\\ttablets:\\t30\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tIV\\tuse\\t(emergency\\tsituations):\\t20\\tmg/kg\\tIV\\tbolus,\\trepeated\\tif\\tnecessary,\\tup\\tto\\t60 mg/kg. Duration of injection is approximately 3 hours. \u2022\\t\\tRectal\\tadministration:\\t40\\tmg/kg\\trectal\\tadministration\\t(100-\\tmg/mL\\tsolution) has produced effective concentrations. However, in many dogs, the volume of the administered dose is too large to be practical. Cats \u2022\\t\\t20-\\t mg/kg\\tq8h\\tPO. \u2022\\t\\tXR\\tformulation:\\t500\\tmg\\tper\\tcat\\tonce\\tdaily\\tor\\tapproximately\\t94\\tmg/kg\\tonce\\tdaily. (Do not split tablets.) L Levodopa 513 \u2022\\t\\tTransdermal\\tformulations:\\tTransdermal\\tadministration,\\tusing\\tLipoderm\\tas\\ta vehicle, has been administered using a formulation of 350\u2013400 mg/mL. This form is administered at 60 mg/kg q8h (three times the oral dose). Systemic concentrations are low and highly variable.  Horses \u2022\\t\\t30\\tmg/kg\\tIV\\tfor\\tshort-\\tterm\\ttreatment\\tor\\t30\\tmg/kg\\tq24h\\tPO. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Levodopa lee\u2032voe- doe\u2032pah Trade and other names: Larodopa and L- dopa","contraindications":"Contraindications and Precautions No known contraindications. Drug Interactions Ordinarily,\\tthere\\tare\\tno\\tdirect\\tinteractions\\twith\\tdrugs\\tthat\\tinhibit\\tor\\tinduce cytochrome P450 enzymes. However, studies in dogs and people have confirmed that phenobarbital can enhance the clearance of levetiracetam. For example, the half- life is shorter, and clearance is more rapid when dogs are administered phenobarbital simultaneously. The mechanism for the interaction is unknown but may warrant higher doses or more careful monitoring when levetiracetam is used with phenobarbital. Interactions with other concurrently used anticonvulsants have not been reported.","indications":"Indications and Clinical Uses In dogs, levetiracetam has been used to treat seizures, especially those refractory to other anticonvulsants. In dogs, it has been considered a drug of choice as an add- on medication when patients are refractory to phenobarbital and bromide therapy. It often is used in combination with other anticonvulsants. Clinical efficacy as an add- on medication with phenobarbital and bromide is uncertain, and this use is based on anecdotal experiences and opinions from veterinary neurology experts. Levetiracetam","side_effects":"Adverse Reactions and Side Effects Weakness, lethargy, and dizziness have been reported in people. Adverse effects have been rare in animals, except for occasional lethargy and decreased appetite. Oral\\tadministration\\tcan\\tproduce\\thypersalivation\\tin\\tcats,\\tbut\\totherwise\\tit\\thas\\tbeen well tolerated in cats. Changes on behavior in people are frequently reported. In dogs, behavior changes are uncommon but may occur. These include increased anxiety and aggression, and other behavioral abnormalities.","notes":"Instructions for Use Levetiracetam is rapidly and completely absorbed, and absorption is not affected by feeding. An injectable formulation is available but not used often in veterinary medicine. However, the injectable solution has been administered at a dose of 20-mg/kg IV bolus increments to a maximum of 60 mg/kg in emergency situations. Levetiracetam ordinarily should be administered q8h to maintain effective concentrations. Higher doses may be needed if administered with phenobarbital because phenobarbital significantly increases clearance in dogs. The XR tablets may have longer effects and can be administered q12h to dogs or every 24 hours in cats. If there is difficulty administering tablets to dogs or cats, the rapidly disintegrating tablets can be considered after testing the palatability in animals. (See Formulations.) Patient Monitoring and Laboratory Tests Monitor seizure frequency. Currently no clinical monitoring test for serum exists in routine laboratories. However, some laboratories have this capability. Therapeutic plasma/serum concentrations in people are in the range of 10\u201340 mcg/mL. Formulations \u2022\\t\\tLevetiracetam\\timmediate-\\trelease:\\t250-\\t,\\t500-\\t   ,\\t750-\\t   ,\\tand\\t1000-\\tmg\\ttablets. \u2022\\t \\tRapidly\\tdisintegrating\\ttablet\\t(Spritam):\\t250-\\t,\\t500-\\t   ,\\t750-\\t   ,\\tand\\t1000-mg spearmint- flavored tablets. These tablets disintegrate in the mouth when administered with a small volume of liquid. Alternately, the tablet can be added to a small volume of liquid (one spoonful) and allow the tablet to disperse prior to administration to a pet. \u2022\\t\\tXR\\tformulation\\tavailable\\tin\\t500-\\t\\tand\\t750-\\tmg-\\t  tablets.\\tThere\\tare\\tseveral\\tXR\\tbrands available, but differences among the brands were not demonstrated in canine studies. \u2022\\t\\t100-\\t  mg/mL\\toral\\tsolution\\tand\\t100-\\tmg/mL\\tsolution\\tfor\\tinjection. \u2022\\t\\tCompounded\\tformulation\\tfor\\ttransdermal\\tadministration\\tto\\tcats:\\tFormulated\\tin Lipoderm at 350\u2013400 mg/mL. Plasma levels from this application are low and variable. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. It is soluble in water, and it may be acceptable to mix with other foods, syrups, or flavorings immediately prior to oral administration.","original_category":"Anticonvulsant"},{"name":"Lorazepam","active_ingredient":"Lorazepam","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.05\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tSeizures:\\t0.2\\tmg/kg\\tIV.\\tRepeat\\tevery\\t3\u20134\\thours\\tfor\\tseizure\\tcontrol\\tif\\tnecessary\\tor a 0.2- mg/kg bolus followed by 0.2\u20130.4 mg/kg/h IV CRI. Cats \u2022\\t\\t0.05\\tmg/kg\\tq12\u201324h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. Schedule IV controlled drug. RCI\\tClassification:\\t2 534    Losartan Losartan loe- zar\u2032tan Trade and other names: Cozaar","contraindications":"Contraindications and Precautions If animals have been receiving lorazepam or any other benzodiazepine for a prolonged time, dependence can occur, and if discontinued, it should be done gradually\\tto\\tavoid\\twithdrawal\\tsigns.\\tOral\\tadministration\\tof\\tanother\\tbenzodiazepine, diazepam, has caused idiosyncratic liver injury in cats, but this is unlikely for lorazepam because of a different route of metabolism. Use of benzodiazepines in early pregnancy has been associated with an increased risk of spontaneous abortions and fetal malformations in people. This incidence in animals is unknown. Drug Interactions Use cautiously with other drugs that may cause sedation. Do not mix with buprenorphine.","indications":"Indications and Clinical Uses Lorazepam acts as a traditional benzodiazepine and may be considered for anxiety disorders in animals, but it has not been used as commonly as other drugs such as diazepam, alprazolam, or midazolam. Lorazepam also is effective for treating seizures, but it is not used as often in animals as other anticonvulsants. In controlled studies, it has L been equally as effective as an anticonvulsant as diazepam in dogs, but the use for other indications is limited to anecdotal evidence and recommendations from clinical experts. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. Lorazepam causes polyphagia. Some animals may experience paradoxical excitement. Chronic administration may lead to dependence and a withdrawal syndrome if discontinued.","notes":"Instructions for Use Doses are based on empiricism and limited observations in animals. There have been no clinical trials in veterinary medicine, although it is expected to produce effects similar\\tto\\tother\\tbenzodiazepines.\\tFor\\tIV\\tuse,\\tdilute\\t50/50\\twith\\t0.9%\\tsaline\\tor\\t5% dextrose prior to use. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations Available \u2022\\t \\tLorazepam\\tis\\tavailable\\tin\\t0.5-\\t,\\t1-\\t ,\\tand\\t2-\\t    mg\\ttablets\\tand\\t2-\\t\\tand\\t4-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Lorazepam is practically insoluble in water. It is slightly soluble in some infusion solutions (e.g., 0.054 mg/mL in 5% dextrose). Solutions should be discarded if they turn a dark color.","original_category":"Anticonvulsant"},{"name":"Oxazepam","active_ingredient":"Oxazepam","species":["Feline","Canine"],"dosage":"Cats \u2022\\t\\tBehavior\\tdisorders:\\t0.2\u20130.5\\tmg/kg\\tq12\u201324h\\tPO\\tor\\t1\u20132\\tmg/cat\\tq12h\\tPO. \u2022\\t\\tAppetite\\tstimulant:\\t2.5\\tmg/cat\\tPO.\\tThe\\tmaximum\\teffect\\tis\\tfrom\\t1\\tmg/kg,\\tbut doses as low as 0.1 mg/kg have been effective. Dogs \u2022\\t\\tBehavior\\tdisorders\\tor\\tsedation:\\t0.2\u20131\\tmg/kg\\tq12\u201324h\\tPO.\\tIf\\tan\\tadequate response is not observed, the dose frequency has been increased to q8h and q6h.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Schedule\\tIV\\tcontrolled\\tdrug. RCI Classification: 2 Oxfendazole oks- fen\u2032dah- zole Trade and other names: Benzelmin and Synanthic","contraindications":"Contraindications and Precautions Oral administration of another benzodiazepine, diazepam, has caused severe idiosyncratic liver injury in cats. This does not appear to be a problem for oxazepam, which is a metabolite of diazepam. Use of benzodiazepines in early pregnancy has been associated with an increased risk of spontaneous abortions and fetal malformations in people. This incidence in animals is unknown. If oxazepam is administered long term, do not discontinue abruptly, or withdrawal signs may occur. Drug Interactions Use cautiously with other drugs that may cause sedation.","indications":"Indications and Clinical Uses Oxazepam is used for treating behavior disorders and sedation and to stimulate appetite. The appetite- stimulating effects have been used, particularly in cats, to stimulate appetite that may be diminished because of other primary diseases. It has been more potent than diazepam as an appetite stimulant in cats and preferred because of a low risk of liver injury. Other drugs are now available for appetite stimulation (e.g., mirtazapine for cats) and may be preferred. Like other benzodiazepines, it also may be considered for behavior problems and anxiety disorders in animals, but it has not been used as commonly as other drugs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. It may also produce polyphagia. Some animals may experience paradoxical excitement. Chronic administration may lead to dependence and a withdrawal syndrome if discontinued.","notes":"Instructions for Use Doses used in dogs and cats are based on empiricism and opinions from clinical experts. There have been no clinical trials in veterinary medicine, although it is widely believed to increase the appetite in cats. Patient Monitoring and Laboratory Tests Samples of plasma or serum may be analyzed in some laboratories for concentrations of benzodiazepines. Plasma concentrations in the range of 100\u2013250 ng/mL have been cited as the therapeutic range for people. Other references have cited this range as 150\u2013300 ng/mL. Laboratories that analyze human samples may have nonspecific tests for benzodiazepines. With these assays, there may be cross- reactivity among benzodiazepine metabolites. 680    Oxfendazole Formulations \u2022\\t\\tOxazepam\\tis\\tavailable\\tin\\t10-\\t,\\t15-\\t  ,\\tand\\t30-\\tmg\\tcapsules. Stability and Storage Stable if stored in manufacturer\u2019s original formulation. Although oxazepam has been compounded for veterinary use, the potency and stability have not been evaluated for compounded products.","original_category":"Anticonvulsant"},{"name":"Phenobarbital, Phenobarbital Sodium","active_ingredient":"Phenobarbital, Phenobarbital Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\u20138\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tStatus\\tepilepticus:\\tAdminister\\tin\\tincrements\\tof\\t10\u201320\\tmg/kg\\tIV\\tto\\teffect. Cats \u2022\\t\\t2\u20134\\tmg/kg\\tq12h\\tPO.\\tStart\\twith\\t1\u20132\\tmg/kg\\tinitially\\tto\\tavoid\\tadverse\\teffects\\tand gradually increase dose. \u2022\\t\\tStatus\\tepilepticus:\\tAdminister\\tin\\tincrements\\tof\\t10\u201320\\tmg/kg\\tIV\\tto\\teffect. \u2022\\t\\tTransdermal\\tcompounded\\tformulation:\\t9\\tmg/kg\\tq12h\\tof\\tthe\\tPLO\\tgel\\tor Lipoderm transdermal formulation. Serum concentrations may be more variable with transdermal application; therefore, adjust doses as needed to maintain serum concentrations within the recommended range.  Horses \u2022\\t\\t12\\tmg/kg\\tq24h\\tPO.\\tNote\\tthat\\tin\\tsome\\thorses,\\tafter\\tinitial\\ttherapy,\\thigher\\tdoses\\tof 12 mg/kg q12h may be needed. \u2022\\t\\t5\u201320\\tmg/kg\\tIV\\tover\\t30\\tminutes\\t(may\\tbe\\tdiluted\\tin\\tsodium\\tchloride). \u2022\\t\\tFoals:\\t2\u20135\\tmg/kg\\tIV\\tadministered\\tslowly\\tover\\t20\\tminutes.\\tStart\\twith\\tlower\\tdose and monitor for effect. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Schedule IV controlled drug. RCI\\tClassification:\\t2 Phenoxybenzamine Hydrochloride fen- oks- ih- ben\u2032zah- meen  hye- droe- klor\u2032ide Trade and other names: Dibenzyline","contraindications":"Contraindications and Precautions Administer with caution to animals with liver disease. Phenobarbital may induce its own metabolism, which shortens the half- life. Therefore chronic administration may lower plasma concentrations, resulting in increases in the dose requirement. Pregnant animals may have an increase in seizure frequency, and an increase in dose may be necessary. Drug Interactions Phenobarbital is one of the most potent drugs for inducing hepatic microsomal metabolizing enzymes. Therefore, many drugs administered concurrently have lower (and perhaps subtherapeutic) concentrations because of more rapid clearance. Drugs affected may include theophylline, digoxin and other cardiovascular drugs, corticosteroids, anesthetics, and other drugs that may be substrates for the P- 450 enzymes. Phenobarbital shortens the half- life of levetiracetam (Keppra) in dogs, which may require higher doses or more frequent administration of levetiracetam. Administration of phenobarbital may lower total tetraiodothyronine (T 4) thyroid concentrations, but thyroid- stimulating hormone (TSH)\\tand\\ttriiodothyronine\\t(T 3) concentrations are unaffected. The\\tsolutions\\tfor\\tinjection\\tare\\talkaline\\t(pH,\\t9\u201311);\\ttherefore\\tavoid\\tmixing with\\tacidic\\tsolutions\\tor\\tdrugs\\tthat\\tbecome\\tunstable\\tat\\talkaline\\tpH. Diet and dietary supplements can affect phenobarbital pharmacokinetics. Low- fat diets increase clearance. Alkaline urine increases renal clearance and shortens half- life. A diet or supplement that produces alkaline urine (e.g., potassium citrate) produces a more rapid clearance and shorter half- life for phenobarbital.","indications":"Indications and Clinical Uses Phenobarbital is widely used as a drug of choice for treating seizure disorders, such as idiopathic epilepsy, in dogs, cats, horses, and exotic animals. Phenobarbital has been used in foals for treating seizures associated with perinatal encephalopathy. Phenobarbital also has been used as a sedative and for the treatment of behavior disorders. Phenobarbital has been effective for the treatment of sialadenosis in dogs caused by submandibular salivary gland enlargement. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Most adverse effects are dose related. Phenobarbital causes polyphagia, sedation, ataxia, and lethargy. Some tolerance develops to side effects after initial therapy. Liver enzyme elevations, particularly alkaline phosphatase (ALP), are common but may not be associated with liver pathology unless other changes are observed, such\\tas\\tother\\tenzyme\\tor\\tbilirubin\\televations.\\tHowever,\\thepatotoxicity\\talso\\thas been\\treported\\tin\\tsome\\tdogs\\tand\\tis\\tmore\\tlikely\\twith\\thigh\\tdoses.\\tNeutropenia, anemia, and thrombocytopenia have been associated with phenobarbital therapy in dogs. These reactions are likely to be idiosyncratic, and recovery may occur if phenobarbital is discontinued. Combinations of phenobarbital and potassium bromide have increased the risk of pancreatitis in dogs through an unknown mechanism. In dogs, superficial necrolytic dermatitis has been associated with phenobarbital administration without concurrent liver pathology. Affected dogs may have high serum concentrations of phenobarbital.","notes":"Instructions for Use Adjust dose based on blood levels of phenobarbital, which can be measured in most laboratories. If bromide is used concurrently (sodium or potassium bromide), lower doses of phenobarbital may be used. Transdermal administration has been examined in cats. Therapeutic concentrations have been achieved if high doses are administered (9 mg/kg q12h) of the PLO gel or\\tLipoderm\\ttransdermal\\tformulation.\\tHowever,\\tmonitoring\\tis\\tsuggested\\tbecause phenobarbital serum concentrations in these cats can be highly variable. Patient Monitoring and Laboratory Tests Phenobarbital doses should be carefully adjusted via monitoring serum/plasma concentrations. Collect a sample at any time during the dose interval because the timing of the sample is not critical. Avoid the use of plasma separation devices if the tube is to be stored (these devices cause a false lowering of concentrations). The therapeutic\\trange\\tin\\tdogs\\tis\\tconsidered\\t15\u201340\\tmcg/mL\\t(65\u2013180\\tmmol/L).\\tIf\\tdogs are\\talso\\treceiving\\tbromide,\\tphenobarbital\\tconcentrations\\tin\\tthe\\trange\\tof\\t10\u201336\\tmcg/ mL have been considered therapeutic. To convert from mmol/L to mcg/mL, use a multiplication factor of 0.232. To convert from mcg/mL to mmol/L, multiply by 4.3. In cats, the optimum range for therapeutic effect has been reported as 23\u201328 mcg/mL (99\u2013120 mmol/L) or 15\u201345 mcg/mL and in another study was 28\u201331 mcg/mL. In\\thorses,\\tthe\\toptimum\\trange\\tfor\\ttherapeutic\\teffect\\tis\\t15\u201320\\tmcg/mL\\t(65\u201386 mmol/L). Monitor liver enzymes periodically in animals receiving phenobarbital because of risk of\\thepatopathy.\\tHowever,\\tsome\\tliver\\tenzyme\\televations\\tmay\\toccur,\\tespecially\\twith\\tALP, without liver pathology. Other liver tests may be needed to rule out hepatotoxicity. Liver enzymes usually return to baseline levels 1\u20135 weeks after discontinuing treatment. Phenobarbital can increase serum triglycerides because of delayed clearance of chylomicrons from the blood and decreased lipoprotein lipase activity. Monitor CBC periodically in animals treated with phenobarbital because of risk of neutropenia, anemia, and thrombocytopenia. Phenobarbital administration will lower\\tother\\tdrug\\tconcentrations.\\tPhenobarbital\\tdid\\tnot\\tinterfere\\twith\\tthe\\tACTH stimulation test or low- dose dexamethasone suppression test in dogs. It lowers thyroid T 4 and free T 4 but not T 3 and\\tTSH\\tconcentrations\\tin\\tdogs. Formulations \u2022\\t\\tPhenobarbital\\tis\\tavailable\\tin\\t15-\\t,\\t30-\\t  ,\\t60-\\t  ,\\tand\\t100-\\tmg\\ttablets;\\t30-\\t,\\t60-\\t  ,\\t65-\\t  ,\\tand 130- mg/mL injection; and 4- mg/mL oral elixir solution. Compounded Formulations \u2022\\t \\tBecause\\tof\\t the\\t  bitter\\t   taste\\t  and\\t  alcohol\\t    content\\tfrom\\t  the\\t  elixir\\t  oral\\t  liquid\\t   formulation, it has been compounded in other vehicles for patients. To prepare this formulation, crush\\tten\\t60-\\tmg\\ttablets\\t(600\\tmg\\ttotal)\\tand\\tmix\\twith\\t60\\tmL\\tOra\\tPlus\\tand\\tOra Sweet\\tin\\ta\\t1:1\\tratio\\tfor\\ta\\tfinal\\tconcentration\\tof\\t10\\tmg/mL.\\tThis\\tformulation\\twas stable for 115 days when stored in amber plastic bottles at room temperature. \u2022\\t\\tPhenobarbital\\thas\\tbeen\\tcompounded\\tinto\\ttransdermal\\tformulations\\tfor\\tcats. The most common transdermal formulation prepared by pharmacies for cats is a 250 mg/mL formulation prepared in a Lipoderm vehicle (a proprietary lipophilic liposomal cream). Prepared in this vehicle, phenobarbital maintained pharmaceutical strength for 8 weeks. The doses for transdermal compounded formulations are listed in the dosing section. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Phenobarbital is slightly soluble in water (100 mg/mL), but phenobarbital sodium is\\tmore\\tsoluble\\t(1\\tg/mL).\\tSolutions\\tprepared\\tin\\twater\\thave\\tan\\talkaline\\tpH\\t(9\u201311). Precipitation\\tmay\\toccur\\tat\\tlower\\tpH\\tvalues\\t(avoid\\tmixing\\twith\\tacidic\\tsyrups\\tor flavorings).\\tIt\\tis\\tsubject\\tto\\thydrolysis\\tin\\taqueous\\tsolutions.\\tHowever,\\tif\\tprepared\\tin P Phenoxybenzamine Hydrochloride 723 propylene\\tglycol,\\tit\\tis\\tstable\\tfor\\t56\\tweeks.\\tStability\\tof\\tcompounded\\tformulation\\tis described in the Formulations section.","original_category":"Anticonvulsant"},{"name":"Primidone","active_ingredient":"Primidone","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t8\u201310\\tmg/kg\\tq8\u201312h\\tas\\tinitial\\tdose\\tPO;\\tthen\\tadjust\\tvia\\tmonitoring\\tto\\t10\u201315\\tmg/ kg q8h.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Procainamide Hydrochloride proe- kane- ah\u2032mide  hye- droe- klor\u2032ide Trade and other names: Pronestyl and generic brands","contraindications":"Contraindications and Precautions There may be a higher risk of hepatic toxicity with primidone compared with other anticonvulsants. Primidone should be avoided in animals with liver disease. Drug Interactions Primidone is converted to phenobarbital, which is one of the most potent drugs for inducing hepatic microsomal metabolizing enzymes. Therefore, many drugs administered concurrently have lower (and perhaps subtherapeutic) concentrations because of more rapid clearance. Drugs affected may include theophylline, digoxin, corticosteroids, anesthetics, and other drugs that are substrated for cytochrome P450 enzymes. P Procainamide Hydrochloride 777","indications":"Indications and Clinical Uses Primidone is used for treating seizure disorders in animals, including epilepsy. The effects of primidone are primarily produced by the presence of the active metabolite, phenobarbital. Although it is possible that some patients with epilepsy that are refractory to phenobarbital alone respond better to primidone, the number of such cases is low. Primidone is approved for use in dogs, but its use has declined in favor of administration of phenobarbital, levetiracetam, bromide, and other anticonvulsants. The use of primidone in cats is rare. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Because primidone is converted to phenobarbital, adverse effects are the same as for phenobarbital. Primidone has been associated with idiosyncratic hepatotoxicity in dogs. Although the use in cats has been discouraged on the approved product label, one study in experimental cats determined that it is safe if used at recommended doses.","notes":"Instructions for Use The recommendations for use are similar to those for phenobarbital. When monitoring therapy with primidone, phenobarbital plasma concentrations should be measured to estimate anticonvulsant effect. When converting a patient from\\tprimidone\\ttherapy\\tto\\tphenobarbital,\\tthe\\tconversion\\tis\\tas\\tfollows:\\t60\\tmg phenobarbital is approximately 250 mg of primidone. Patient Monitoring and Laboratory Tests Doses should be carefully adjusted via monitoring serum/plasma phenobarbital concentrations. Collect a sample at any time during the dose interval because the timing of the sample is not critical. Avoid the use of plasma separation devices if the tube is to be stored. The therapeutic range in dogs is considered 15\u201340 mcg/mL (65\u2013180\\tmmol/L).\\tThe\\toptimum\\trange\\tin\\tcats\\tfor\\ttherapeutic\\teffect\\tis\\t23\u201328\\tmcg/ mL. Monitor liver function with bile acid determinations. Formulations \u2022\\t\\tPrimidone\\tis\\tavailable\\tin\\t50-\\t\\tand\\t250-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticonvulsant"},{"name":"Valproic Acid, Valproate Sodium","active_ingredient":"Valproic Acid, Valproate Sodium","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t50\u2013250\\tmg\\tper\\tdog\\t(adjust\\tthe\\tdose\\tproportional\\tto\\tthe\\tsize\\tof\\tthe\\tdog)\\tq8h\\tPO. \u2022\\t\\tDelayed-\\trelease\\tformulations:\\tStart\\twith\\t250\\tmg\\tper\\tdog\\tq12h\\tPO\\tand\\tincrease\\tto 500 mg per dog q12h as needed. 960    Vancomycin Cats \u2022\\t\\tDose\\tnot\\testablished.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank\\t(FARAD)\\tat\\t1-\\t888- USFARAD\\t(1-\\t888-\\t  873-\\t  2723). Vancomycin van- koe- mye\u2032sin Trade and other names: Vancocin and Vancoled","contraindications":"Contraindications and Precautions If perivascular injection occurs, immediate flushing of area with fluids is recommended. Drug Interactions No drug interactions have been reported in animals. V increase gamma- aminobutyric acid (GABA) concentrations in the central nervous system\\t(CNS).\\tValproic\\tacid\\tand\\tvalproate\\tsodium\\tare\\tslightly\\tdifferent\\tchemically, but both have been used. Divalproex is composed of both valproic acid and sodium valproate. Equivalent oral doses of divalproex sodium and valproic acid deliver equivalent quantities of valproate ion. Contraindications and Precautions Do not use in pregnant animals. Birth defects have been reported in people. Drug Interactions Valproate may cause bleeding if used with drugs that inhibit platelets.","indications":"Indications and Clinical Uses Valproate is used, usually in combination with phenobarbital, to treat refractory epilepsy in animals. Most of the experience has been in dogs, but the use is uncommon. The use of valproate in animals has declined because other anticonvulsants for treating refractory epilepsy have been identified such as gabapentin, pregabalin, zonisamide, and levetiracetam. The little clinical experience available is derived from small observational studies or anecdotal experience. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals, but hepatic failure has been reported in people. Sedation may be seen in some animals.","notes":"Instructions for Use This\\tdrug\\tis\\tusually\\tused\\tas\\tan\\tadd-\\ton\\twith\\tphenobarbital.\\tControlled-\\trelease\\tforms designed for people do not show the same oral absorption profile in dogs as in people. Patient Monitoring and Laboratory Tests Therapeutic drug monitoring can be performed; however, therapeutic concentrations have not been established for dogs and cats, and ranges cited for people are used: 50\u2013100\\tmcg/mL\\t(desired\\ttrough\\tconcentration).\\tConcentrations\\tgreater\\tthan\\t100 mcg/mL are associated with adverse effects. Formulations \u2022\\t \\tValproic\\tacid\\timmediate-\\trelease\\tformulations\\tare\\tavailable\\tin\\t250-\\tmg\\tcapsules\\tand 50- mg/mL syrup. Delayed- release formulations of valproic acid and divalproex are available in 125- , 250- , and 500- mg tablets or capsules. Divalproex is also available in 125- mg capsules and 250-  and 500- mg extended- release tablets. Valproate sodium (Depacon) is available in a 100- mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Valproic acid is slightly soluble in water, but valproate sodium is soluble in water. Extemporaneous emulsions have been prepared and were comparable to absorption of syrup.","original_category":"Anticonvulsant"},{"name":"Zonisamide","active_ingredient":"Zonisamide","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\tStart\\twith\\t5\\tmg/kg\\tq12h\\tPO\\tand\\tincrease\\tgradually\\tas\\tneeded\\tto\\tmaintain\\tplasma drug concentrations and control seizures. \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO\\twhen\\tadded\\tto\\tphenobarbital\\ttreatment. Cats \u2022\\t\\t5\\tmg/kg\\tPO\\tq12h\\tor\\t10\\tmg/kg\\tPO\\tq24h\\tand\\tincrease\\tdose\\tas\\tneeded\\tby monitoring.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 3 Information for Pharmacists 993 APPENDIX A Information for Pharmacists Excipients in Medications or Human Drugs That May Be Harmful to Pets Drug, Excipient, or FoodSpecies AffectedToxicity AcetaminophenDogs, catsHepatotoxicity (dogs) and red blood cell oxidative injury (cats) AlcoholsDogs, cats, birdsCentral nervous system toxicity AvocadoBirdsPulmonary congestion; nonsuppurative inflammation of the liver, kidney, pancreas, skin, and proventriculus BenzocaineCatsRed blood cell oxidative injury, hemolytic anemia ChamomileCatsEmesis, diarrhea, depression, lethargy, epistaxis ChocolateDogs, birdsCardiovascular and central nervous system stimulation EstrogenDogsBone marrow suppression Ethyl glycols (diethylene glycol, ethylene glycol) Dogs, catsCentral nervous system toxicity, nephrotoxicity Fat, fatty foodsDogsIncreased risk of pancreatitis Garlic and onionsDogs, catsHemolytic anemia Grapes and raisinsDogsRenal toxicity Macadamia nutsDogsNeurotoxicity Macrolide antibiotics, oral route Horses, rabbitsDiarrhea, enteritis, colic Methylene blueCatsRed blood cell oxidative injury, hemolytic anemia Nonsteroidal anti- inflammatory agents for humans (naproxen, ibuprofen) Dogs, catsGastrointestinal ulceration and perforation, nephrotoxicity PennyroyalCatsHepatotoxicity PermethrinCatsNeuromuscular and central nervous system toxicity PhenazopyridineCatsHepatotoxicity and red blood cell oxidative injury Phosphate enemasCatsProfound hypocalcemia PseudoephedrineDogs, catsCardiovascular and central nervous system stimulation Continued 994    Information for Pharmacists Drug, Excipient, or FoodSpecies AffectedToxicity Raw yeast doughDogsAlcohol poisoning, gastrointestinal dilatation and volvulus Salt (excessive)Dogs, catsHypernatremia, central nervous system toxicity Tobacco productsDogs, catsMuscle weakness, twitching, depression, tachycardia, shallow respiration, collapse, coma, cardiac arrest XylitolDogs, birdsProfound hypoglycemia and hepatocellular necrosis This table was created with the assistance of Gigi Davidson, RPh, North Carolina State University. Excipients in Medications or Human Drugs That May Be Harmful to Pets\u2014cont\u2019d Prescription Writing Reference 995 APPENDIX B Prescription Writing Reference Always Include \u2022\\t\\tPrescribing\\tveterinarian\u2019s\\tname \u2022\\t\\tPractice\\taddress \u2022\\t\\tPractice\\ttelephone\\tnumber \u2022\\t\\tDrug\\tEnforcement\\tAdministration\\t(DEA)\\tnumber.\\tInclude\\tyour\\tDEA\\tnumber\\tif written\\tfor\\ta\\tcontrolled\\tsubstance.\\tBut\\tavoid\\tsharing\\tyour\\tDEA\\tlicense\\tnumber\\tif the\\tprescription\\tis\\tnot a controlled substance. \u2022\\t\\tCurrent\\tdate Rx \u2022 \\t \\tDrug name:\\tPrint\\tFULL\\tbrand\\tname\\tor\\tgeneric\\tname;\\tNEVER\\tabbreviate. \u2022 \\t \\tDosage form:\\tSpecify\\ttablet,\\tcapsule,\\tsuspension,\\tor\\tother. \u2022 \\t \\tStrength:\\tSpecify\\tthe\\tstrength\\tin\\tmilligrams\\t(mg),\\tmicrograms\\t(mcg),\\tgram\\t(g), or\\tother\\tappropriate\\tunit\\tof\\tdose\\tstrength\\tor\\tconcentration\\t(mg/mL).\\tUse\\tmetric units\\tand\\tuse\\tmcg\\tfor\\t\u03bcg\\twhenever\\tpossible. \u2022 \\t \\tTotal quantity:\\t#\\t10\\t(for\\t10\\ttablets);\\t60\\tmL.\\tSpell\\tout\\tthe\\tquantity\\tif\\tthere\\tis\\ta risk\\tthat\\tthe\\tprescription\\tcould\\tbe\\taltered\\t(for\\texample,\\tadding\\tan\\textra\\tzero\\tto\\tthe quantity). \u2022 \\t \\tSig (Latin for \u201cwrite on label\u201d):\\tInclude\\tthe\\tdose\\t(individual),\\troute,\\tfrequency, duration,\\tindication,\\tand\\tuse. \u2022 \\t \\tNumber of refills:\\tDefine\\tthe\\tnumber\\tlegally\\tpermitted. \u2022 \\t \\tSubstitution permitted?\\tDesignate\\twhether\\tor\\tnot\\ta\\tgeneric\\tsubstitution\\tis permissible\\tor\\t\u201cdispense\\tas\\twritten\u201d\\t(DAW).\\tIf\\tyou\\tindicate\\t\u201cno\\tsubstitutions\u201d\\tor DAW\\tand\\tlist\\tthe\\tdrug\u2019s\\tbrand\\tname\\t(proprietary\\tname),\\tthe\\tpharmacist\\tcannot substitute\\tfor\\ta\\tgeneric\\tversion\\tof\\tthe\\tsame\\tdrug.\\tThe\\tcost\\tof\\tsome\\tbrand\\tname products\\tmay\\tbe\\t10\\ttimes\\thigher\\tthan\\tthe\\tgeneric\\tversion\\tof\\tthe\\tsame\\tdrug, and\\tthe\\tanimal\\towner\\tmight\\thave\\tto\\tpay\\tmuch\\tmore\\tfor\\tthe\\tprescription\\tthan anticipated. \u2022 \\t \\tSignature Owner Information Always Include \u2022\\t\\tPatient\u2019s\\tname\\t(in\\t\u201cquotes\u201d) \u2022\\t\\tPatient\u2019s\\tage\\tor\\tdate\\tof\\tbirth \u2022\\t\\tOwner\u2019s\\tname\\t(or\\tthat\\tof\\tan\\towner\\trepresentative) \u2022\\t\\tOwner\u2019s\\taddress \u2022\\t\\tOwner\u2019s\\tphone\\tnumber Common Prescription Writing Errors to Avoid \u2022\\t\\tAlways\\tuse\\tmetric\\tunits:\\tfor\\texample,\\tg\\t(gram)\\tfor\\tsolids;\\tml\\tor\\tmL\\t(milliliter)\\tfor liquids. \u2022\\t\\tUse\\tper\\tinstead\\tof\\ta\\tslash\\t(/),\\twhich\\tcan\\tbe\\tinterpreted\\tas\\tthe\\tnumber\\t1. \u2022\\t\\tWrite\\tout\\t\u201cunits\u201d\\tinstead\\tof\\tthe\\tabbreviation\\tu,\\twhich\\tcan\\tbe\\tinterpreted\\tas\\t0,\\t4,\\tor micro. \u2022\\t\\tUse\\t\u201conce\\tdaily\u201d\\tinstead\\tof\\tSID,\\twhich\\thas\\tbeen\\tinterpreted\\tas\\t5/d\\tor\\t5\\tper\\tday. (Note:\\tSID\\tis\\tnot\\ta\\tconventional\\tabbreviation\\trecognized\\tby\\tpharmacists.) \u2022\\t\\tUse\\t\u201cthree\\ttimes\\tdaily\u201d\\tinstead\\tof\\tTID\\tand\\tuse\\t\u201cfour\\ttimes\\tdaily\u201d\\tinstead\\tof\\tQID. 996    Prescription Writing Reference \u2022\\t\\tUse\\t\u201cevery\\tother\\tday\u201d\\tinstead\\tof\\tQOD\\tor\\tEOD. \u2022\\t\\tAVOID\\tCONFUSING\\tABBREVIATIONS.\\tAbbreviations\\tsuch\\tas\\tQD,\\tQID,\\tand QOD\\tare\\teasily\\tconfused\\twith\\teach\\tother. \u2022\\t\\tWhen\\tprescribing\\tgrams,\\tspell\\tout\\tand\\tavoid\\t\u201cgr\u201d\\tbecause\\tit\\tcan\\tbe\\tconfused\\twith grain.\\t(A\\tgrain\\tis\\t65\\tmg.) When writing numbers \u2022\\t\\tUse\\ta\\tleading\\tzero\\twith\\tdecimals\\t(e.g.,\\tuse\\t0.5\\tmL\\trather\\tthan\\t.5\\tmL). \u2022\\t\\tAvoid\\tusing\\ta\\ttrailing\\tzero\\t(e.g.,\\tuse\\t3\\trather\\tthan\\t3.0). \u2022\\t\\tSpell\\tout\\tnumbers\\tin\\tparentheses\\tto\\tavoid\\talterations. \u2022\\t\\tALWAYS:\\tWhen\\tin\\tdoubt,\\tspell\\tit\\tout. Calculation of Drug Doses 997 APPENDIX C Calculation of Drug Doses How to Calculate Milliliters (mL) Needed Dose (mg/kg) \xd7 kilograms body weight = Total dose needed (mg) Strength of solution (mg/mL) = Percent (%) strength \xd7 10 (e.g., 10% solution = 100 mg/mL) Total\xa0dose\xa0needed Strength\xa0of\xa0solution mg mL =mL needed Example \u2022\\t\\t20-\\t kg\\tdog\\tneeds\\t15\\tmg/kg\\tof\\ta\\t20%\\tsolution \u2022\\t\\t20\\tkg\\t\xd7\\t15\\tmg/kg\\t=\\t300\\tmg\\ttotal\\tdose\\tneeded \u2022\\t\\tStrength\\tof\\tsolution\\t=\\t20%\\t\xd7\\t10\\t=\\t200\\tmg/mL \u2022\\t\\tmL\\tneeded\\t=\\t300\\tmg/200\\tmg/mL\\t=\\t1.5\\tmL How to Calculate Tablets Needed Dose (mg/kg) \xd7 kilograms body weight = Total dose needed (mg) Total\xa0dose\xa0needed Strength\xa0of\xa0tablet = Number of tablets needed Example \u2022\\t\\t20-\\t kg\\tdog\\tneeds\\t12\\tmg/kg \u2022\\t\\tTablet\\tsize\\tis\\t100\\tmg \u2022\\t\\t15\\tkg\\t\xd7\\t12\\tmg/kg\\t=\\t240\\tmg\\ttotal\\tdose\\tneeded \u2022\\t\\t240\\tmg/100\\tmg\\ttablets\\t=\\t2.4\\ttablets (In\\tmost\\tinstances,\\tyou\\twould\\tround\\tup\\tto\\t2\xbd\\ttablets\\tif\\tthe\\tmedication\\thas\\tsufficient safety.\\tRefer\\tto\\tthe\\tend\\tof\\tthis\\tappendix\\tfor\\trecommendations\\ton\\tsplitting\\ttablets.) How to Calculate Infusion Rates Dose (mg/kg/h) \xd7 Body weight (kg) =Total dose (mg) needed per hour If\\tthe\\tdose\\tis\\tlisted\\tin\\tmicrograms\\tper\\tkilogram\\tper\\thour,\\tdivide\\tby 1000\\tfor\\tmg/kg/h. Strength of solution (mg/mL) = [% strength] \xd7 10 mL neededperhour= Total dose neededperhour Strengthof solution (mg/kg) Administer\\tthe\\ttotal\\tmilliliters\\tof\\tfluid\\tadministered\\tin\\teach\\thour\\tinterval.\\tIf\\tfluid\\tis\\tto be\\tadministered\\tover\\t24\\thours:\\tmL\\tneeded\\tper\\thour\\t\xd7\\t24\\t=\\tmL\\tneeded\\tper\\tday. Example \u2022\\t\\t15-\\t kg\\tdog\\tneeds\\t2\\tmg/kg/h\\tof\\ta\\t10%\\tsolution \u2022\\t\\tFluid\\trate\\t(lactated\\tRinger\u2019s\\tsolution)\\tis\\t60\\tmL/kg/day \u2022\\t\\t15\\tkg\\t\xd7\\t2\\tmg/kg/h\\t=\\t30\\tmg\\tneeded\\tper\\thour \u2022\\t\\tStrength\\tof\\tsolution\\t=\\t10%\\t\xd7\\t10\\t=\\t100\\tmg/mL 998    Calculation of Drug Doses \u2022\\t\\tmL\\tof\\tdrug\\tneeded\\tper\\thour\\t=\\t(30\\tmg/h)/(100\\tmg/mL)\\t=\\t0.3\\tmL/h \u2022\\t\\t0.3\\tmL\\tof\\tmedication\\tshould\\tbe\\tadded\\tto\\teach\\thour\\tof\\tfluids\\tto\\tbe\\tadministered \u2022\\t\\tFluid\\trate\\tis\\t60\\tmL/kg/day\\t=\\t2.5\\tmL/kg/h\\t=\\t37.5\\tmL/h\\tfor\\ta\\t15-\\tkg\\tdog To\\teach\\t37.5\\tmL/h\\tof\\tfluid\\tvolume\\tto\\tbe\\tinfused,\\tadd\\t0.3\\tmL\\tof\\tmedication.\\tIf\\tthe drug\\tis\\tstable\\tin\\tsolution\\tfor\\t24\\thours,\\tthe\\ttotal\\tamount\\tcan\\tbe\\tadded\\tto\\ta\\t24-\\thour volume\\tof\\tfluid: \u2022\\t\\tTotal\\tfluid\\tneeded\\tper\\t24\\thours\\t=\\t60\\tmL/kg/day\\t\xd7\\t15\\tkg\\t=\\t900\\tmL \u2022\\t\\t0.3\\tmL\\tper\\thour\\t\xd7\\t24\\thours\\t=\\t7.2\\tmL/day\\tadded\\tto\\t900\\tmL\\tof\\ttotal\\tfluid requirement,\\tor\\t8\\tmL\\tadded\\tto\\teach\\tliter\\tof\\tfluids.\\t(Be\\tsure\\tto\\tcheck\\tpackage insert\\tfor\\tthe\\tmedication\\tto\\tensure\\tthat\\tit\\twill\\tremain\\tstable\\tfor\\t24\\thours\\tat\\troom temperature\\tin\\ta\\tfluid\\tadministration\\tset.) When Splitting Tablets, When to Round Up and When to Round Down? \u2022\\t\\tAvoid\\ttrying\\tto\\tsplit\\ta\\ttablet\\tinto\\tless\\tthan\\tone\\tfourth\\tof\\ta\\ttablet.\\tSmaller\\tfractions cannot\\tbe\\taccurately\\tmeasured. \u2022\\t\\tFor\\t\u201csafe\u201d\\tdrugs\\twith\\thigh\\ttherapeutic\\tindexes\\t(e.g.,\\tantibiotics,\\tnutritional supplements,\\thormones,\\tantiparasitic\\tagents,\\tantacids),\\tround\\tup\\tto\\tthe\\tnext highest\\ttablet\\tsize\\tor\\tfraction\\tof\\ta\\ttablet. \u2022\\t\\tFor\\tdrugs\\twith\\tnarrow\\ttherapeutic\\tindexes\\t(cardiovascular\\tdrugs,\\tnonsteroidal anti-\\t  inflammatory\\tdrugs,\\tdrugs\\tthat\\tact\\ton\\tthe\\tcentral\\tnervous\\tsystem,\\tanticancer agents,\\tanticoagulants),\\tround\\tdown\\tto\\tthe\\tnext\\tlowest\\ttablet\\tsize\\tor\\tfraction\\tof\\ta tablet.\\tThen\\tincrease\\tthe\\tas\\tneeded\\t(cautiously)\\tto\\tobtain\\tthe\\tdesired\\ttherapeutic effect. Compounded Formulations: What to Look for to Detect Incompatibility or Instability 999 APPENDIX D Compounded Formulations: What to Look for to Detect Incompatibility or Instability Liquid- Dose  Forms \u2022\\t\\tColor\\tchange\\t(amber\\tto\\tdark\\tbrown) \u2022\\t\\tSigns\\tof\\tmicrobial\\tgrowth \u2022\\t\\tCloudiness,\\thaze,\\tflocculent,\\tor\\tfilm\\tformation \u2022\\t\\tSeparation\\tof\\tphases\\t(e.g.,\\toil\\tand\\twater,\\temulsion) \u2022\\t\\tPrecipitation,\\tclumping,\\tor\\tcrystal\\tformation \u2022\\t\\tDroplets\\tor\\tfog\\tforming\\ton\\tthe\\tinside\\tof\\tthe\\tcontainer \u2022\\t\\tGas\\tor\\todor\\trelease \u2022\\t\\tSwelling\\tof\\tcontainer Solid- Dose  Forms \u2022\\t\\tOdor\\t(sulfur\\tor\\tvinegar\\todor) \u2022\\t\\tExcessive\\tpowder\\tor\\tcrumbling \u2022\\t\\tCracks\\tor\\tchips\\tin\\ttablets \u2022\\t\\tSwelling\\tof\\ttablets\\tor\\tcapsules \u201cRules of Thumb\u201d \u2022\\t\\tDo\\tnot\\tmix\\tdrugs\\tthat\\trequire\\treconstitution\\tin\\ta\\tvial\\twith\\tother\\tdrugs.\\tDo\\tnot\\tadd other\\tdrugs\\tto\\ta\\treconstituted\\tvial. \u2022\\t\\tDo\\tnot\\tmix\\tdrugs\\tthat\\tare\\tnot\\tin\\tan\\taqueous\\tvehicle\\t(e.g.,\\tpropylene\\tglycol)\\twith water-\\t   based\\tIV\\tfluids. \u2022\\t\\tDo\\tnot\\tmix\\thydrochloride\\t(HCl)\\tsalts\\tor\\tdrugs\\twith\\tbuffers\\t(citrates,\\tbicarbonates, phosphates). \u2022\\t\\tIf\\ta\\tdrug\\thas\\tHCl,\\tacetate\\t(acetic\\tacid),\\tcitrate\\t(citric\\tacid),\\tor\\tsulfate\\t(sulfuric\\tacid) in\\tthe\\tname,\\tdo\\tnot\\tmix\\tit\\twith\\talkaline\\tsolutions. \u2022\\t\\tThe\\tbeyond-\\tuse-\\t  dates\\tfor\\tcompounded\\tdrugs\\t(the\\tdate\\tafter\\twhich\\ta\\tcompounded preparation\\tis\\tnot\\tto\\tbe\\tused)\\tare\\t14\\tdays\\tfor\\twater-\\tcontaining\\tformulations (refrigerated),\\t6\\tmonths\\tfor\\tnonaqueous\\tliquids\\tand\\tsolid\\tformulations,\\tand 60\\tdays\\tfor\\tother\\tformulations.\\tThese\\ttimes\\tmay\\tbe\\texceeded\\tif\\tthere\\tis\\tvalid scientific\\tstability\\tinformation. \u2022\\t\\tWhenever\\tpossible,\\tcompounded\\tformulations\\tshould\\tbe\\tprepared\\tfrom\\ta\\tUS\\tFood and\\tDrug\\tAdministration\u2013approved\\tformulation. \u2022\\t\\tCompounded\\tformulations\\tshould\\tretain\\tstrength\\tof\\t\xb110%\\t(i.e.,\\t90%\u2013110%)\\tof\\tthe nominal\\tstrength\\tof\\tthe\\tformulation. \u2022\\t\\tCompounded\\tformulations\\tshould\\tbe\\tprepared\\tin\\taccordance\\twith\\tcompendial standards\\tlisted\\tin\\tthe\\tUnited\\tStates\\tPharmacopeia\\t(USP). 1000    Controlled Substance Charts: United States and Canada APPENDIX E Controlled Substance Charts: United States and Canada For a complete alphabetical list, go to www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf. Drug ExamplesUnited States a Heroin, lysergic acid diethylamide (LSD), peyote, mescaline, methylenedioxymethamphetamine (ecstasy) Schedule I \u2022\\t \\tHigh\\tabuse\\tpotential \u2022\\t \\tNo\\tcurrently\\taccepted\\tmedical\\tuse \u2022\\t \\tNo\\tveterinary\\tuses\\tidentified Morphine and morphine derivatives and synthetic opioids. Drugs used in veterinary medicine include morphine, meperidine, etorphine, hydrocodone, hydromorphone, oxymorphone, codeine (in some forms), hydrocodone, and pentobarbital. Schedule II \u2022\\t \\tHigh\\tabuse\\tpotential;\\tpotentially\\tsevere psychological or physical dependence \u2022\\t \\tAccepted\\tmedical\\tuse\\tbut\\tmay\\tbe\\tseverely restricted \u2022\\t \\tTelephone\\torders\\tto\\ta\\tpharmacy\\tare allowed only in emergencies if written prescription follows promptly \u2022\\t \\tNo\\trefills\\tallowed \u2022\\t \\tThere\\tmay\\tbe\\tspecific\\trequirements\\tfor refills\\tand\\torders\\tin\\teach\\tstate Drugs used in veterinary medicine include anabolic steroids (stanozolol, oxymetholone, testosterone, methyltestosterone, boldenone, trenbolone), barbiturates (thiamylal, thiopental), opioids (buprenorphine and codeine in some forms), and ketamine and derivatives (ketamine and tiletamine zolazepam). Schedule III \u2022\\t \\tAbuse\\tpotential\\tless\\tthan\\tthe\\tdrugs\\tor substances\\tin\\tSchedules\\tI\\tand\\tII;\\tpotentially moderate or low physical dependence or high psychological dependence \u2022\\t \\tAccepted\\tmedical\\tuses\\tinclude\\tanesthetics, analgesics, anabolic steroids \u2022\\t \\tTelephone\\torders\\tto\\tpharmacies\\tare permitted \u2022\\t \\tVeterinarians\\tmay\\tauthorize\\tlimited\\trefills Drugs used in veterinary medicine include some opioids (butorphanol and pentazocine), benzodiazepines (diazepam, oxazepam, midazolam, clonazepam, clorazepate, and alprazolam), and phenobarbital. Tramadol\\twas\\tadded\\tin\\t2014. Schedule IV \u2022\\t \\tAbuse\\tpotential\\trelative\\tto\\tdrugs\\tor substances\\tin\\tSchedule\\tIII;\\tpotentially limited to physical or psychological dependence \u2022\\t \\tAccepted\\tmedical\\tuse\\tincludes\\tsedatives, analgesics, and anticonvulsants. \u2022\\t \\tTelephone\\torders\\tto\\tpharmacies\\tare permitted \u2022\\t \\tVeterinarians\\tmay\\tauthorize\\tlimited\\trefills. Codeine preparations used as antitussives and some opioids used as antidiarrheals (e.g., diphenoxylate), and pregabalin Schedule V \u2022\\t \\tLowest\\tabuse\\tpotential;\\tpotentially very limited physical or psychological dependence \u2022\\t \\tAccepted\\tmedical\\tuses\\tinclude antidiarrheal, antitussive, and analgesics. \u2022\\t \\tVeterinarians\\tcan\\tdetermine\\trefills. \u2022\\t \\tSome\\tproducts\\tcontaining\\tlimited\\tamounts of\\tSchedule\\tV\\tsubstances\\t(e.g.,\\tcough suppressants) are available over the counter a A\\tcomplete\\tlist\\tfor\\tthe\\tUnited\\tStates\\tcan\\tbe\\tlocated\\tat\\thttps://www.dea.gov/drug- scheduling. Controlled Substance Charts: United States and Canada 1001 Drug ExamplesCanada Sedatives such as barbiturates and derivatives (secobarbital), thiobarbiturates (pentothal sodium), and anabolic steroids Part G of the Food and Drug Regulation (FDR) \u2022\\t \\tControlled\\tdrugs \u2022\\t \\tMisuse\\tpotential \u2022\\t \\tVerbal\\tand\\twritten\\tprescriptions\\tunder certain conditions \u2022\\t \\tOnly\\tprescribed\\tif\\trequired\\tfor\\tmedical condition \u2022\\t \\tSpecified\\tnumber\\tof\\trefills\\t(conditions apply) \u2022\\t \\tRecords\\tmust\\tbe\\tkept \u2022\\t \\tMay\\tbe\\tadministered\\tunder\\temergency situations (conditions apply) AmphetaminesPart G of the FDR \u2022\\t \\tDesignated\\tcontrolled\\tdrug \u2022\\t \\tMay\\tbe\\tused\\tfor\\tdesignated\\tmedical conditions\\toutlined\\tin\\tFDR Benzodiazepine\\ttranquilizers,\\tsuch\\tas diazepam and lorazepam Benzodiazepines and Other Targeted Substances Regulations \u2022\\t \\tMisuse\\tpotential \u2022\\t \\tVerbal\\tand\\twritten\\tprescriptions\\tunder certain conditions \u2022\\t \\tOnly\\tprescribed\\tif\\trequired\\tfor\\tmedical condition \u2022\\t \\tSpecified\\tnumber\\tof\\trefills\\t(conditions apply) \u2022\\t \\tRecords\\tmust\\tbe\\tkept \u2022\\t \\tMay\\tbe\\tadministered\\tunder\\temergency situations (conditions apply) Opiates:\\theroin,\\tmorphine,\\tand\\tcodeine (in some forms) and analgesics such as pentazocine and fentanyl Narcotic Control Regulation \u2022\\t \\tHigh\\tmisuse\\tpotential \u2022\\t \\tWritten\\tprescriptions\\tfor\\tspecific\\tmedical conditions b \u2022\\t \\tRecords\\tof\\topiate\\tprescription\\tfile\\tmust\\tbe kept \u2022\\t \\tNo\\trefills\\t(limited\\tamounts\\tin\\ta prescription) \u2022\\t \\tHeroin\\tand\\tmethadone\\tare\\tsubject\\tto specific\\tcontrols Lysergic acid diethylamide (LSD), mescaline (peyote), harmaline, psilocin, and psilocybin (magic mushrooms) Part J of the FDR \u2022\\t \\tConsidered\\t\u201crestricted\\tdrugs\u201d \u2022\\t \\tHigh\\tmisuse\\tpotential \u2022\\t \\tNo\\trecognized\\tmedical\\tuse \u2022\\t \\tMarijuana\\texemption\\tfrom\\tFDR\\tif produced for medical reasons b Verbal\\tprescriptions\\tare\\tpermitted\\tfor\\tcertain\\topioid\\tpreparations\\t(e.g.,\\tTylenol\\tNo.\\t2\\tand\\tNo.\\t3)\\tbut\\tnot\\tfor opiate alone or opiates with one other active nonopioid ingredient. 1002    Drugs for Infections Commonly Seen in Small Animals APPENDIX F Drugs for Infections Commonly Seen in Small Animals Infection SiteFirst- Choice  DrugsAlternative- Choice  Drugs Skin: pyoderma or other skin infection Amoxicillin + clavulanate Cephalosporin, a clindamycin Trimethoprim + sulfonamides b Fluoroquinolone, c lincomycin, tetracycline d (doxycycline or minocycline) Lower urinary tractCephalosporin a Amoxicillin Amoxicillin + clavulanate Trimethoprim + sulfonamides b Fluoroquinolone c , tetracycline (doxycycline or minocycline) Respiratory tract (the choice may depend on the location of the infection [upper or lower respiratory tract]) Amoxicillin + clavulanate Fluoroquinolone c Cephalosporin a (excluding cefovecin) Macrolide (azithromycin) Aminoglycosides (amikacin, gentamicin) Doxycycline or minocycline Clindamycin Trimethoprim + sulfonamides b Chloramphenicol Ceftazidime Septicemia e Amoxicillin + clavulanate Cephalosporin a (excluding cefovecin) Fluoroquinolone Aminoglycoside Ceftazidime Piperacillin + tazobactam Carbapenem (meropenem, imipenem) Bone and jointCephalosporin a Amoxicillin + clavulanate Trimethoprim + sulfonamides b Clindamycin Fluoroquinolone c Intracellular pathogensDoxycycline or minocycline Fluoroquinolone c Azithromycin Clindamycin a Cephalosporin includes cephalexin, cefpodoxime proxetil, cefadroxil, or cefovecin. b Trimethoprim in combination with sulfonamides includes trimethoprim in combination with sulfadiazine, trimethoprim in combination with sulfamethoxazole, and ormetoprim in combination with sulfadimethoxine. c Fluoroquinolone includes enrofloxacin, marbofloxacin, orbifloxacin, or pradofloxacin (pradofloxacin is not approved for dogs in the United States). Human generic forms that are acceptable for treating dogs include levofloxacin. d First confirm with a susceptibility test. e Combinations of drugs are often used in acute febrile septicemia. Such combinations may include a beta- lactam plus an aminoglycoside or a fluoroquinolone plus amoxicillin + clavulanate. Antibiotic Drug Selection for Equine Bacterial Pathogens 1003 APPENDIX G Antibiotic Drug Selection for Equine Bacterial Pathogens PathogenDrug ChoiceAlternative Choice Gram- Positive  Organisms Rhodococcus equiRifampin, in combination with clarithromycin, azithromycin, or erythromycin One of the macrolides used alone Streptococcus equiPenicillin G, ampicillin sodium, ceftiofur, trimethoprim\u2013sulfadiazine Erythromycin, chloramphenicol, doxycycline, or minocycline Staphylococcus aureusTrimethoprim + sulfonamideEnrofloxacin, orbifloxacin, chloramphenicol, doxycycline, or minocycline Gram- Negative  Organisms Escherichia coliGentamicin, amikacinCeftiofur, enrofloxacin, orbifloxacin, marbofloxacin, trimethoprim + sulfonamide Klebsiella pneumoniaeGentamicin, amikacinCeftiofur, enrofloxacin, orbifloxacin, marbofloxacin, trimethoprim + sulfonamide Enterobacter spp.Gentamicin, amikacinCeftiofur, enrofloxacin, trimethoprim + sulfonamide Pseudomonas aeruginosaAmikacin, piperacillin + tazobactam Enrofloxacin, marbofloxacin, ceftazidime, meropenem Pasteurella spp.Ampicillin sodium, ceftiofur, trimethoprim + sulfonamide Enrofloxacin, orbifloxacin, marbofloxacin, chloramphenicol, doxycycline or minocycline Actinobacillus spp.Ampicillin sodium, penicillin G, trimethoprim + sulfonamides Enrofloxacin, amikacin, gentamicin, ceftiofur Anaerobes Clostridium, Fusobacterium, Peptostreptococcus, and Bacteroides spp. Metronidazole, penicillin GChloramphenicol, or cefoxitin (injectable) Other Lawsonia intracellularisOxytetracycline, doxycycline (doxycycline, PO only), minocycline Chloramphenicol, erythromycin, clarithromycin, azithromycin Ehrlichia spp.Oxytetracycline, doxycycline (doxycycline, PO only), minocycline Chloramphenicol Neorickettsia risticii (Potomac horse fever) Oxytetracycline, doxycycline (doxycycline, PO only), minocycline 1004    Drugs That May Induce Cytochrome P450 Enzymes APPENDIX H Drugs That May Induce Cytochrome P450 Enzymes \u2022\\t\\tChlorinated\\thydrocarbons \u2022\\t\\tDiazepam\\t(Valium) \u2022\\t\\tDiphenhydramine \u2022\\t\\tEstrogens \u2022\\t\\tGriseofulvin \u2022\\t\\tHyperthyroidism \u2022\\t\\tOmeprazole \u2022\\t\\tPentobarbital \u2022\\t\\tPhenobarbital \u2022\\t\\tPhenylbutazone \u2022\\t\\tPhenytoin\\t(Dilantin) \u2022\\t\\tProgestogens \u2022\\t\\tRifampin \u2022\\t\\tSt.\\tJohn\u2019s\\twort Drugs That May Inhibit Cytochrome P450 Enzymes 1005 APPENDIX I Drugs That May Inhibit Cytochrome P450 Enzymes \u2022\\t\\tAmiodarone \u2022\\t\\tChloramphenicol \u2022\\t\\tCimetidine \u2022\\t\\tCisapride \u2022\\t\\tClarithromycin \u2022\\t\\tClopidogrel \u2022\\t\\tCyclophosphamide \u2022\\t\\tDiltiazem \u2022\\t\\tErythromycin \u2022\\t\\tEsomeprazole \u2022\\t\\tFelbamate \u2022\\t\\tFluconazole \u2022\\t\\tFluoroquinolones\\t(some) \u2022\\t\\tFluoxetine \u2022\\t\\tGrapefruit\\tjuice \u2022\\t\\tInterferon\\t(vaccines) \u2022\\t\\tItraconazole \u2022\\t\\tKetoconazole \u2022\\t\\tOmeprazole \u2022\\t\\tOrganophosphates \u2022\\t\\tParoxetine \u2022\\t\\tPhenylbutazone \u2022\\t\\tPosaconazole \u2022\\t\\tQuinidine \u2022\\t\\tTetracycline \u2022\\t\\tVerapamil \u2022\\t\\tVoriconazole 1006    Drugs That May Inhibit the P- Glycoprotein Membrane Transporter Coded APPENDIX J Drugs That May Inhibit the P- Glycoprotein Membrane Transporter Coded by ABCB1 (formerly known as MDR1) \u2022\\t\\tBromocriptine \u2022\\t\\tCarvedilol \u2022\\t\\tChlorpromazine \u2022\\t\\tCyclosporine \u2022\\t\\tDiltiazem \u2022\\t\\tErythromycin \u2022\\t\\tFluoxetine \u2022\\t\\tGrapefruit\\tjuice \u2022\\t\\tItraconazole \u2022\\t\\tKetoconazole \u2022\\t\\tMethadone \u2022\\t\\tParoxetine \u2022\\t\\tPentazocine \u2022\\t\\tQuinidine \u2022\\t\\tSpinosad \u2022\\t\\tSt.\\tJohn\u2019s\\twort \u2022\\t\\tTamoxifen \u2022\\t\\tVerapamil References Mealey\\tKL.\\t Adverse\\tdrug\\t   reactions\\tin\\t veterinary\\tpatients\\tassociated\\twith\\t  drug\\t   transporters.\\tVet Clin North Am Small Anim Pract.\\t2013;43:1067\u20131078. Mealey\\t    KL,\\t Fidel\\t   J.\\t P-\\t glycoprotein\\tmediated\\tdrug\\t  interactions\\tin\\t animals\\tand\\t  humans\\twith\\t  can- cer.\\tVet Intern Med.\\t2015;29:1\u20136. Drugs That Are Substrates for the P-Glycoprotein 1007 APPENDIX K Drugs That Are Substrates for the P- Glycoprotein Membrane Transporter Coded by ABCB1 (formerly known as MDR1) P-   glycoprotein is a membrane transporter responsible for transporting many drugs and other chemicals across membranes. A functional p- glycoprotein at the blood\u2013 brain barrier protects the brain from harmful effects of systemically administered drugs. P- glycoprotein may also be found at other important sites, such as the liver, placenta, kidney, and intestinal mucosa. Mutation of the gene that codes for p- glycoprotein  (ABCB1) that produces a function deletion exposes some dogs (e.g., some herding breeds) to toxic concentrations of some drugs. Alternatively, if a drug is administered that is a p- glycoprotein inhibitor (see Appendix J), it may decrease the effect of the membrane transporter and produce toxicity. Below are some of the p-   glycoprotein substrates that may be affected by a mutation or drug inhibition. \u2022\\t\\tAcepromazine \u2022\\t\\tActinomycin\\tD \u2022\\t\\tAldosterone \u2022\\t\\tAmitriptyline \u2022\\t\\tButorphanol \u2022\\t\\tCortisol \u2022\\t\\tCyclosporine \u2022\\t\\tDexamethasone \u2022\\t\\tDigoxin \u2022\\t\\tDiltiazem \u2022\\t\\tDocetaxel \u2022\\t\\tDoramectin \u2022\\t\\tDocetaxel \u2022\\t\\tDoxorubicin \u2022\\t\\tDoxycycline \u2022\\t\\tEprinomectin \u2022\\t\\tErythromycin \u2022\\t\\tItraconazole \u2022\\t\\tIvermectin \u2022\\t\\tKetoconazole \u2022\\t\\tLevofloxacin \u2022\\t\\tLoperamide \u2022\\t\\tMethylprednisolone \u2022\\t\\tMilbemycin \u2022\\t\\tMorphine \u2022\\t\\tMoxidectin \u2022\\t\\tOndansetron \u2022\\t\\tPaclitaxel \u2022\\t\\tPhenothiazines \u2022\\t\\tQuinidine \u2022\\t\\tSelamectin \u2022\\t\\tTacrolimus \u2022\\t\\tTerfenadine \u2022\\t\\tTetracycline \u2022\\t\\tVerapamil \u2022\\t\\tVinblastine \u2022\\t\\tVincristine References Mealey\\tKL. Adverse drug reactions in veterinary patients associated with drug transporters. Vet Clin North Am Small Anim Pract. 2013;43:1067\u20131078. Mealey\\tKL, Fidel J. P- glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med. 2015;29:1\u20136. 1008 Fluid Solution Composition APPENDIX L Fluid Solution Composition Solution TypeNa + (mEq/L)K + (mEq/L)Cl \u2014 (mEq/L)Ca 2+ (mEq/L)Mg 2+ (mEq/L)Buffer (mEq/L)Osmolarity (mOsm/L)pH Ringer\u2019s solution14741564.4003105\u20137.5 Lactated Ringer\u2019s solution 13041122.7029 (lactate)2736\u20137.5 0.9% NaCl15401540003084\u20135 5% dextrose0000002524\u20136.5 2.5% dextrose/0.45% NaCl 770770002804.5 Plasma- Lyte1405980327 (acetate) 23 (gluconate) 2944\u20136.5 Dextran 6% and 0.9% NaCl 15401540003103.0\u20137.0 Hetastarch a 15401540003095.5 Pentastarch a 15401540003265.0 Hemoglobin glutamer (oxyglobin) 3007.8 Normosol- R1405980327 (acetate) 23 (gluconate) 2946.6 a See the Hydroxyethyl Startch section to find additional information on these solutions. How to Report an Adverse Drug Reaction 1009 APPENDIX M How to Report an Adverse Drug Reaction 1.   Phone the drug sponsor to report an adverse drug experience (ADE) if it is a US Food and Drug Administration (FDA)\u2013approved animal drug. Obtain drug sponsor phone numbers from the product label or from the company\u2019s website. When phoning the pharmaceutical company, inform them that you wish to speak with a veterinarian on their staff or technical services representative to report an ADE. 2.   Contact the FDA and complete Form 1932a. This form may be completed regardless of whether the drug is an animal- approved drug or human- approved drug. The FDA can be contacted from its website at https://www.fda.gov/animal- veterinary/report- problem/how- report- animal- drug- side- effects- and- product- problems. Send the complete form to: CVM1932a@fda.hhs.gov. The FDA also may be contacted at this address: \u2022\\t  \\tSend\\temail\\tto:\\tAskCVM@fda.hhs.gov \u2022\\t  \\tPhone:\\t1-\\t888-\\t  FDA-\\t   VETS\\t(1-\\t888-\\t  332-\\t  8387) \u2022\\t  \\tMail: Center for Veterinary Medicine Food and Drug Administration HFV- 1 7500\\tStandish\\tPlace Rockville,\\tMD\\t20855 When completing Form 1932a, supply as much history and clinical data as possible, including concurrent medications administered to the animal. Animal Biologics: Vaccines, Bacterins Contact the United States Department of Agriculture Animal and Plant Health Inspection\\tService(USDA\\tAPHIS)\\tCenter\\tfor\\tVeterinary\\tBiologics\\tat\\t800-\\t752- 6255\\tor\\tat\\thttps://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterin ary- biologics/adverse- event- reporting/ct_vb_adverse_event. Pesticides: Topically Applied External Parasiticides Note that some flea and tick products are regulated by the FDA, and some are regulated by the Environmental Protection Agency (EPA). To report a problem with a flea or tick product that is FDA approved, contact the FDA (see instructions above). The label of the product will determine if the product is an FDA- approved or an EPA- registered flea and tick product or other pesticide. All FDA- approved animal drugs have a six- digit New Animal Drug Application (NADA) number, or for generic animal drugs, an Abbreviated New Animal Drug Application (ANADA) number. If it is an EPA- registered product, look for an EPA registration number on the back panel of the package, usually near the manufacturer\u2019s address: \u201cEPA Reg. No.\u201d If the product is regulated by the EPA, contact the National Pesticide Information Center\\tat\\t800-\\t858-\\t  7378\\tor http://npic.orst.edu/incidents.html#anim. 1010    Drugs Prohibited from Use in Food- Producing Animals APPENDIX N Drugs Prohibited from Use in Food- Producing Animals Note: To locate the most updated list, go to www.FARAD.org. Because they present a risk to public health, the following drugs are prohibited in food- producing  animals: \u2022\\t\\tChloramphenicol \u2022\\t\\tClenbuterol \u2022\\t\\tDiethylstilbestrol\\t(DES) \u2022\\t\\tFurazolidone \u2022\\t\\tNitrofurazone\\t(and\\tother\\tnitrofurans) \u2022\\t\\tFluoroquinolones\\t(extralabel\\tuse) \u2022\\t\\tCephalosporins\\t(not\\tincluding\\tcephapirin\\tin\\tcattle,\\tswine,\\tchickens,\\tor\\tturkeys):\\t(1) for\\tdisease\\tprevention\\tpurposes;\\t(2)\\tat\\tunapproved\\tdoses,\\tdurations,\\tor\\troutes\\tof administration;\\tor\\t(3)\\tif\\tthe\\tdrug\\tis\\tnot\\tapproved\\tfor\\tthat\\tspecies\\tand\\tproduction class. \u2022\\t\\tGlycopeptide\\tantibiotics\\t(e.g.,\\tvancomycin) \u2022\\t\\tIpronidazole,\\tdimetridazole,\\tmetronidazole,\\tand\\tother\\tnitroimidazoles \u2022\\t\\tPhenylbutazone\\tin\\tfemale\\tdairy\\tcattle\\tyounger\\tthan\\t20\\tmonths\\tof\\tage \u2022\\t\\tSulfonamide\\tdrugs\\tin\\tlactating\\tdairy\\tcattle\\t(with\\tthe\\texception\\tof\\tsulfadimethoxine, sulfabromomethazine,\\tand\\tsulfamethoxypyridazine, which are approved for use in some\\tfeeds) \u2022\\t \\tAdamantane\\tand\\tneuraminidase\\tinhibitor\\tclasses\\tof\\tdrugs\\tapproved\\tfor\\ttreating or\\tpreventing\\tinfluenza\\tA\\tare\\tprohibited\\ttherapy\\tin\\tchickens,\\tturkeys,\\tand ducks. Performance Horse Drug Regulations and Restrictions 1011 APPENDIX O Performance Horse Drug Regulations and Restrictions Association of Racing Commissioners International, Inc., Uniform Classification Guidelines for Foreign Substances (Revised January 2020) The following definitions, regulations, and restrictions are adapted from the Racing Commissioners International (RCI) website (www.arci.com) and the F\xe9d\xe9ration Equestre Internationale (FEI) Clean Sport Prohibited Substances List (www.feicleansport.org). The RCI Drug Classification Scheme is based on (1) pharmacology, (2) drug use patterns, and (3) the appropriateness of a drug for use in the racing horse. Classification Definitions Class 1 Stimulant and depressant drugs that have the highest potential to affect performance and  that  have  no  generally  accepted  medical  use  in  the  racing  horse.  Many  of  these agents  are  Drug  Enforcement  Administration  (DEA)  Schedule  II  substances.  These include the following drugs and their metabolites: opiates, opium derivatives, synthetic opioids  and  psychoactive  drugs,  amphetamines,  and  amphetamine-  like  drugs,  as  well as related drugs, including but not limited to, apomorphine, nikethamide, mazindol, pemoline,  and  pentylenetetrazol.  Although  not  used  as  therapeutic  agents,  all  DEA Schedule  1  agents  are  included  in  Class  1  because  they  are  potent  stimulant  or depressant substances with psychotropic and often habituative actions. This class also includes all erythropoietin-stimulating substances and their analogues. Class 2 Drugs that have a high potential to affect performance but less of a potential than drugs in Class 1. These drugs are (1) not generally accepted as therapeutic agents in racing horses, or (2) they are therapeutic agents that have a high potential for abuse. Drugs in  this  class  include  psychotropic  drugs,  certain  nervous  system  and  cardiovascular system  stimulants,  depressants,  and  neuromuscular  blocking  agents.  Injectable  local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents. Class 3 Drugs that may or may not have generally accepted medical use in the racing horse but the pharmacology of which suggests less potential to affect performance than drugs  in  Class  2.  Drugs  in  this  class  include  bronchodilators,  anabolic  steroids and other drugs with primary effects on the autonomic nervous system, procaine, antihistamines with sedative properties, and the high- ceiling diuretics. Class 4 This  class  includes  therapeutic  medications  that  would  be  expected  to  have  less potential to affect performance than those in Class 3. Drugs in this class include less potent diuretics, corticosteroids, antihistamines and skeletal muscle relaxants without prominent  central  nervous  system  effects,  expectorants  and  mucolytics,  hemostatics, cardiac  glycosides  and  antiarrhythmics,  topical  anesthetics,  antidiarrheals,  and  mild analgesics.  This  class  also  includes  the  nonsteroidal  anti-  inflammatory  drugs  at concentrations greater than established limits. 1012    Performance Horse Drug Regulations and Restrictions Class 5 This class includes those therapeutic medications that have very localized actions only, such as antiulcer drugs and certain antiallergic drugs. The anticoagulant drugs are also included. Prohibited Substances in Racing Horses A.  The possession and/or use of a drug, substance, or medication, specified here, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized  analytical  method  has  not  been  developed  to  detect  and  confirm  the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing: 1.    Erythropoietin 2.    Darbepoetin 3.    Oxyglobin 4.    Hemopure B.      The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the U.S. Food and Drug Administration (FDA) for use in the United States. C.    The  practice,  administration,  or  application  of  a  treatment,  procedure,  therapy, or method identified here, which is performed on the premises of a facility under jurisdiction  of  a  regulatory  body  and  which  may  endanger  the  health  and  welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing. Equine Prohibited Drugs: F\xe9d\xe9ration Equestre Internationale Clean Sport Prohibited Substances Database (Revised January 2020) The FEI has published guidelines to assist veterinarians to make a distinction between the use of routine, legitimate medication and deliberate and calculated doping to affect a horse\u2019s performance. The prohibited substance searchable database is available at http://prohibitedsubstancesdatabase.feicleansport.org. Or access the FEI Clean Sport Prohibited Substances List (updated January 2020) at http://www.fei.org/fei/cleansport. INDEX 0.9% NaCl, 1008t 1,25- Dihydroxycholecalciferol, 112 2-    PAM, 762 2.5% Dextrose/0.45% NaCl, 1008t 4- Methylpyrazole,  391 5% Dextrose, 258, 1008t 5- Fluorouracil,  384 5-   Aminosalicylic acid, 576 50% Dextrose solution, 258 A A180, 231 ABCB1, 1006 ABCD, 47 Abelcet, 47 ABLC, 47 Abraxane, 694 Acarexx, 484 Accutane, 479 ACE, 1 AceproJect, 1 Acepromazine, 1007 Acepromazine maleate, 1\u20132, 5 AceproTabs, 1 Acetadote, 8 Acetaminophen, 3\u20135 toxicity, 993t\u2013994t Acetaminophen + codeine, 5\u20137 Acetazolamide, 7\u20138 Acetylcholine, 684 Acetylcysteine, 8\u201310 Acetylpromazine, 1 Acetylsalicylic acid, 61 Achromycin V, 883 Acta- char,  168 ACTH, 212 Acthar, 212 Actigall, 955 Actinobacillus spp., 1003 Actinomycin D, 1007 Activated charcoal, 168\u2013169 Acyclovir, 10\u201312, 957 Adalat, 651 Adequan Canine, 748 Adequan IA, 748 Adequan IM, 748 ADH, 962 Adrenaline, 330 Adrenergic receptors, 723 Adrenocorticotropic hormone (ACTH), 212, 718\u2013720 Adriamycin, 309 Adrucil, 384 Adspec, 846 Advil, 448 Advocin, 231 Aerrane, 474 Afoxolaner, 12\u201314 Aglepristone, 14\u201315 Albendazole, 15\u201316 Albon, 861 Albuterol sulfate, 16\u201318 Alcohol CYP450 inducer, 1004 toxicity, 993t\u2013994t Aldactone, 849 Aldosterone, 849, 1007 Alendronate, 18\u201319 Aleve, 643 Alfaxalone, 19\u201321 Alfaxan, 19\u201320 Alimemazine, 939 Alinia, 652 Alizine, 14 Alkaline phosphatase (ALP), 721 Alkeran, 569 Allopur, 22 Allopurinol, 22\u201323 Alpha- tocopherol,  969 Alphaxalone, 19\u201320 Alprazolam, 23\u201325, 1000t Altadol, 921 Altrenogest, 25\u201326 Aluminum carbonate, 26\u201328 Aluminum carbonate gel (Basalgel), 26 Aluminum hydroxide, 26\u201328 Aluminum hydroxide gel (Amphojel), 26 Alupent, 578 Alzin, 14 Amantadine, 28\u201329 Ambien, 989 AmBisome, 47 Amiglyde- V,  29 Amikacin, 1003, 29\u201331 Amikin, 29 Amino acid solution, 31\u201332 Aminopentamide, 32 Aminophylline, 33\u201335 Amiodarone, CYP450 inhibitor, 1005 Amiodarone hydrochloride, 35\u201337 Amitraz, 37\u201338 Amitriptyline, 1007 Amitriptyline hydrochloride, 38\u201340 Amlodipine besylate, 40 Ammonium chloride, 42\u201343 Amoxicillin, 43\u201345 Amoxicillin + clavulanate, infections, 1002t Amoxicillin and clavulanate potassium, 45\u201347 Amoxicillin trihydrate, 43 Amoxi- Drops,  43 Amoxi- Inject,  43 Amoxil, 43 Amoxi- Tabs,  43 Amp- Equine,  50 Amphetamines, 1001t Amphojel, 26 Amphotec, 47 Amphotericin B, 47\u201349 Ampicillin, 50\u201352 Ampicillin + sulbactam, 50, 53\u201354 Ampicillin sodium, 50\u201352, 1003 Ampicillin trihydrate, 50 Ampi- Tab,  50 Amprol, 54 Amprolium, 54\u201355 AmTech Iron dextran, 470 AmVet, 118 Anabolic steroids, 1001t Anadrol, 685 Anafen, 498 Anafranil, 198 Anaplasmosis block, 178 Anaprime suspension, 378 Ancef, 139 Ancobon, 375 Andro- Cyp,  882 Android, 601 Andronate, 882 Anipryl, 830 Anthelcide EQ, 681 Antidiuretic hormone (ADH), 962 Antilirium, 734 Antirobe, 193 Antisedan, 65 Antivert, 555 Antizol, 391 Antizol- Vet,  391 Anzemet, 297 Apidra, 459\u2013460 A.P.L., 415 Apokyn, 55 Apomorphine hydrochloride, 55\u201357 Apoquel, 664 Aprepitant, 57\u201358 Apresoline, 431 Aquaflor, 370 Page numbers followed by t indicate tables. 1014    Index AquaMEPHYTON, 971 AquaMephyton, 735 Aquasol E, 969 Aquasol- A,  968 Ara- C,  225 Aranesp, 236 Arava, 505 Aredia, 696 Arginine vasopressin (AVP), 962 Aristocort, 929 Arm & Hammer pure baking soda, 839 Arquel, 556 ASA, 61 Asacol, 576 Ascorbic acid, 58\u201359 Ascriptin, 61 Asparaginase, 60\u201361 L- Asparaginase,  60 Aspirin, 61\u201363 Atabrine, 803 Atarax, 444 Atenolol, 64\u201365 Atgard, 264 Atipamezole, 981 Atipamezole hydrochloride, 65\u201366 Ativan, 532 Atopica, 220 Atovaquone, 67\u201368 Atracurium besylate, 68\u201369 Atravet, 1 Atropine sulfate, 69\u201371 Augmentin, 45 Auranofin, 71\u201372 Aureomycin soluble calf tablets, 178 Aureomycin soluble powder, 178 Aureomycin tablets, 178 Aurothioglucose, 72 Avapro, 469 Avelox, 633 Avermectins, 829 Avocado, 993t\u2013994t AVP, 962 Axid, 661 Azathioprine, 73 Azidothymidine (AZT), 983 Azithromycin, 75\u201378 equine bacterial pathogens, 1003 infections, 1002t Azium solution in polyethylene glycol, 247 AZT, 983 Azulfidine, 866 B Bacterial pathogens, equine, 1003 Bacteroides spp., 1003 Bactrim, 945 Bactrovet, 861 Baking soda, 839 BAL, 280 Banamine, 380 Banamine-  S, Resflor (with florfenicol), 380 Barbiturates, 714, 1000t Basalgel, 26 Baycox, 918 Baytril, 325\u2013326 Benadryl, 287 Benazecare, 79 Benazepril hydrochloride, 79\u201381 Benylin, 257 BenzaPen, 709 Benzelmin, 680 Benzocaine, 993t\u2013994t Benzodiazepines, 679, 1000t Benzyl penicillin, 709 Berenil, 283 Beta blockers, 789 Beta- corticotropin,  214 Betamethasone, 81 Betamethasone acetate, 81 Betamethasone benzoate, 81\u201382 Betapace, 844 BetaVet, 81 Bethanechol chloride, 82\u201384 Bewon, 891 Biaxin, 188\u2013189 Biomox, 43 Bio- Mycin,  689 Bio- Mycin 200, 689 Biosol, 646 Bisacodyl, 84\u201385 Bismuth subsalicylate, 85\u201386 Bisoprolol fumarate, 86\u201387 Bisphosphonates, 696, 907 Blenoxane, 88\u201389 Bleomycin sulfate, 88 Boldenone, 1000t Boldenone undecylenate, 89\u201390 Bone and joint infection, 1002t Bonine, 555 Bovine TSH, 898 Bravecto, 387 Brethine, 880 Brevibloc, 341 Brevital, 591 Bricanyl, 880 British anti- lewisite (BAL), 280 Bromide, 90\u201392 Bromocriptine,  P- glycoprotein inhibitor, 1006 Bromocriptine mesylate, 93\u201394 bTSH, 898 Budesonide, 95\u201396 Bufferin, 61 Bunamidine hydrochloride, 96\u201397 Bupivacaine hydrochloride, 97\u201399 Buprenex, 100 Buprenorphine, 1000t Buprenorphine hydrochloride, 100\u2013103 Buscopan, 108\u2013109, 645 BuSpar, 104 Buspirone hydrochloride, 104\u2013105 Busulfan, 105 Butazolidin, 726 Butorphanol, 1000t, 1007 Butorphanol tartrate, 106\u2013107 Butorphine, 106 Butrans, 100 Butylscopolamine bromide, 645\u2013646 C Cabergoline, 110\u2013112 Calan, 964 Calciferol, 336 Calcijex, 112 Calci- mix,  114 Calcineurin, 868 Calcitriol, 112\u2013114 Calcium borogluconate, 118\u2013120 Calcium carbonate, 114\u2013117 Calcium chloride, 115 Calcium citrate, 117\u2013118, 755 Calcium disodium ethylenediaminetetra- acetate (EDTA), 317 Calcium disodium versenate, 317 Calcium gluconate, 118\u2013120 Calcium ipodate, 467 Calcium lactate, 120\u2013121 Calcium- EDTA,  854\u2013855 Calculation of drug doses, 997\u2013998 Calf scour bolus, 178 Cal- Nate,  118 Caninsulin, 458 Canopar, 885 Caparsolate, 563\u2013564, 890 Capoten, 123 Capromorelin, 121\u2013123 Capstar, 654 Captopril, 123\u2013125 Carafate, 855 Carbenicillin, 125\u2013126 Carbenicillin indanyl sodium, 125 Carbimazole, 126\u2013127 Carbocaine- V,  572 Carboplatin, 128\u2013129 Cardioquin, 804 Cardizem, 276 Cardoxin, 273 Acaricides, 268 Index 1015 Carmilax, 543 Carprofen, 129\u2013131 Carvedilol, 132\u2013133 P-   glycoprotein inhibitor, 1006 Cascara sagrada, 133\u2013134 Castor oil, 134 CCNU, 529 CeeNU, 529 Cefaclor, 135\u2013136 Cefa- Drops,  137 Cefadroxil, 137\u2013138 Cefa- Tabs,  137 Cefazolin sodium, 139\u2013140 Cefdinir, 140\u2013142 Cefepime, 142\u2013143 equine bacterial pathogens, 1003 Cefixime, 143\u2013145 Cefotaxime sodium, 145 Cefotetan disodium, 147\u2013148 Cefovecin, 148\u2013150 Cefoxil, 150 Cefoxitin, 1003 Cefoxitin sodium, 150\u2013152 Cefpodoxime proxetil, 152\u2013154 Cefquinome sulfate, 154\u2013156 Ceftazidime equine bacterial pathogens, 1003 infections, 1002t Ceftiofur, 1003 equine bacterial pathogens, 1003 Ceftiofur crystalline- free acid, 158\u2013160 Ceftiofur hydrochloride, 160\u2013162 Ceftiofur sodium, 163\u2013165 Celestone, 81 CellCept, 635 Centragard, 333 Centrine, 32\u201333 Cephaguard, 154 Cephalexin, 165\u2013167 Cephalosporin, 1010 infections, 1002t Ceptaz, 156\u2013158 Cerenia, 550 Cestex, 335 Cetirizine hydrochloride, 167\u2013168 Cetylev, 8 Chamomile, 993t\u2013994t Charcoal, activated, 168\u2013169 Charcodote, 168 Chemet, 854 Cheque Drops, 610 Chlorambucil, 170\u2013171 Chloramphenicol, 171\u2013173, 1010 CYP450 inhibitor, 1005 equine bacterial pathogens, 1003 Chloramphenicol palmitate, 171\u2013172 Chloramphenicol sodium succinate, 171\u2013172 Chlorinated hydrocarbons, 1004 Chloromycetin, 171\u2013172 Chlorothiazide, 173\u2013175 Chlorpheniramine maleate, 175\u2013176 Chlorpromazine, 176\u2013178, 779\u2013781 P-   glycoprotein inhibitor, 1006 Chlortetracycline, 178\u2013179 Chlor- trimeton,  175 Chocolate, 993t\u2013994t Choledyl- SA,  683 Chondroitin sulfate, 180\u2013181 Chorionic gonadotropin, 415\u2013417 Chortropin, 415 Chorulon, 415 Chronulac, 504 Cialis, 869 Ciclosporin, 220 Cimetidine, CYP450 inhibitor, 1005 Cimetidine hydrochloride, 181\u2013182 Cin- Quin,  804 Cipro, 183 Ciprofloxacin hydrochloride, 183\u2013185 Cisapride, 185\u2013187 CYP450 inhibitor, 1005 Cisplatin, 187\u2013188 Citracal, 117 Citrocarbonate, 839 Citroma, 542 Citro- Mag (Canada), 542 CitroNesia, 542 Claforan, 145\u2013146 Clarithromycin, 188\u2013190 CYP450 inhibitor, 1005 equine bacterial pathogens, 1003 Clavamox, 45 Clemastine fumarate, 190\u2013191 Clenbuterol, 192\u2013193, 1010 Cleocin, 193 Clinafarm- EC,  322 Clincox, 265 Clindamycin, infections, 1002t Clindamycin hydrochloride, 193\u2013195 ClindaTobe, 193 ClinDrops, 193 Clinsol, 193 Clintabs, 193 Clodronate, 195\u2013197, 908 Clofazimine, 197\u2013198 Clomicalm, 198 Clomipramine hydrochloride, 198\u2013200 Clonazepam, 200\u2013201, 1000t Clopidogrel, 201\u2013203 Cloprostenol, 792 Cloprostenol sodium, 203\u2013205 Clorazepate, 1000t Clorazepate dipotassium, 206\u2013207 Clostridium, 1003 Cloxacillin sodium, 207\u2013208 Cloxapen, 207 Cobactan, 154 Cobalamin, 216 Codeine, 208\u2013210, 1000t\u20131001t Codeine phosphate, 208 Codeine sulfate, 208 Colace, 296 Co- Lav,  745 Colchicine, 210\u2013211 Colcrys, 210 Colony- stimulating  factors, 211\u2013212 Colyte, 745 Comfortis, 847 Compazine, 780 Compounded formulations, 999 Constant- rate infusions (CRIs), 811 Controlled substances, 1000t\u20131001t Convenia, 148 Co- phenotrope,  288 Coraxis, 629 Cordarone, 35 Coreg, 132 Corid, 54 Corlopam, 359 Corrective mixture, 703 Cortef, 436 Corticosteroids, 768\u2013769, 771 Corticotropin, 212\u2013213 Cortisol, 1007 Cortrosyn, 214 Cosequin, 180, 407 Cosyntropin, 214\u2013216 Coumadin, 976 Cozaar, 534 Cremophor EL, 694\u2013695 Creon, 698, 699 CTX, 217 Cuprimine, 708 Cyanocobalamin, 216\u2013217 Cyclic adenosine monophosphate (cAMP), 683, 737, 886 Cyclooxygenase (COX), 726, 742 enzyme, 820 Cyclophosphamide, 217\u2013219 CYP450 inhibitor, 1005 1016    Index Cyclosporin A, 220\u2013223 Cyclosporine, 220, 1007 P-   glycoprotein inhibitor, 1006 Cycrin (tablets), 560 Cydectin (bovine and ovine), 629 CYP450 enzymes, 665 CYP450 inducers, 1004 Cyproheptadine hydrochloride, 224\u2013225 Cystorelin, 414 Cytarabine, 225\u2013226 Cytochrome P450 enzymes, 665 Cytochrome P450 inducers, 1004 Cytochrome P450 inhibitors, 1005 Cytomel, 525 Cytosar, 225 Cytosine arabinoside, 225 Cytotec, 620 Cytoxan, 217 D D5W, 258 Dacarbazine, 227\u2013228 Dalbavancin, 960 Dalteparin, 228\u2013230 Danazol, 230\u2013231 Danocrine, 230 Danofloxacin mesylate, 231\u2013232 Dantrium, 233 Dantrolene sodium, 233\u2013235 Dapsone, 235\u2013236 Daranide, 262 Daraprim, 799 Darbazine, 779 Darbepoetin, 1012 Darbepoetin alfa, 236\u2013238 DDAVP, 241 DDVP, 264 Decadron, 247, 250 Deca- Durabolin,  642 Dectomax, 303 Deferoxamine mesylate, 238\u2013239 Delta- Cortef,  767 Deltasone, 771 Demadex, 919 Demerol, 570 Demodex spp., 665 Denamarin, 826 Denosyl, 826, 827 Depakene, 958 Depakote, 958 Depen, 708 Depo- estradiol,  345 Depo- Medrol,  598 Depo- Provera (injection), 560 Depo- Testosterone,  882 L- Deprenyl,  831 Deracoxib, 240\u2013241 Deramaxx, 240 DES, 270 Desferal, 238 Desmethylpimobendan (DMP), 737 Desmopressin, 963 Desmopressin acetate, 241\u2013243 Desoxycorticosterone pivalate, 243\u2013244 Desyrel, 926 Detomidine hydrochloride, 244\u2013247 DexaJect, 247 DexaJect SP, 250 Dexamethasone, 247\u2013249, 1007 Dexamethasone sodium phosphate, 250\u2013251 Dexasone, 247, 250 Dexavet, 247, 250 Dexdomitor, 251\u2013252 Dexmedetomidine hydrochloride, 251\u2013255 Dextran, 255\u2013256 Dextran 6% and 0.9% NaCl, 1008t Dextran 70, 255 Dextromethorphan, 257\u2013258 Dextrose solution, 258\u2013260 DiaBeta, 409 Diaminodiphenylsulfone, 235 Diamox, 7 Diaphenylsulfone, 235 Diazepam, 260\u2013262 controlled substance, 1000t\u20131001t CYP450 inducer, 1004 Dibenzyline, 723 Dichlorovos, 264\u2013265 Dichlorphenamide, 262\u2013263 Dichlorvos, 264 Diclazuril, 265\u2013266 Dicloxacillin sodium, 267\u2013268 Dicural, 271 Didronel, 347 Diethylcarbamazine citrate, 268\u2013269, 682 Diethylene glycol, 993t\u2013994t Diethylstilbestrol (DES), 270\u2013271, 1010 Difloxacin hydrochloride, 271\u2013273 Diflucan, 373 Digimerck, 273 Digitoxin, 273 Digoxin, 273\u2013275, 1007 Dihydrotachysterol, 275\u2013276 Dihydroxycholecalciferol, 112 Dilacor, 276 Dilantin, 732 CYP450 inducer, 1004 Dilaudid, 438 Diltiazem, 1007 CYP450 inhibitor, 1005 P-   glycoprotein inhibitor, 1006 Diltiazem hydrochloride, 276\u2013278 Dimenhydrinate, 279\u2013280 Dimercaprol, 280\u2013281 Dimethyl sulfoxide (DMSO), 281\u2013283 Diminazene aceturate, 283 Diminazene diaceturate, 283\u2013285 Dinoprost, 791, 792 Dinoprost tromethamine, 285\u2013286 Dipentum, 576, 666 Diphenhydramine, CYP450 inducer, 1004 Diphenhydramine hydrochloride, 287\u2013288 Diphenoxylate, 288\u2013289, 1000t Diprivan, 785 Dipyridamole, 290\u2013291 Dipyrone, 291\u2013293 Dirlotapide, 293\u2013294 Disopyramide, 293\u2013294 Dispense as written (DAW), 995 Dithiazanine iodide, 294 Di- Trim,  942 Ditropan, 684 Diuril, 173\u2013174 Divalproex, 958\u2013959 Dizan, 294 DL- methionine, 589, 806 DMSO, 281\u2013282 Dobutamine hydrochloride, 294\u2013296 Dobutrex, 294 DOCA pivalate, 243 Docetaxel, 1007 DOCP, 243 Docusate, 296\u2013297 Docusate calcium, 296 Docusate sodium, 296 Dolasetron mesylate, 297\u2013299 Dolophine, 581 Dolorex, 106 Domitor, 558 Domoso, 281\u2013282 Domperidone, 299\u2013301 Dopamine hydrochloride, 301\u2013303 Dopamine receptors, 718 Dopram, 306 Doramectin, 303\u2013304, 1007 Doribax, 304\u2013305 Doripenem, 304\u2013306 Dormosedan, 244\u2013245 Dormosedan gel, 244\u2013245 Dostinex, 110 Doxan, 296 Doxapram hydrochloride, 306\u2013307 Doxepin, 308\u2013309 Index 1017 Doxidan, 296 Doxorubicin, 1007 Doxorubicin hydrochloride, 309\u2013312 Doxy caps, 312 Doxycycline, 1007 equine bacterial pathogens, 1003 infections, 1002t Doxycycline hyclate, 312\u2013315 Doxycycline monohydrate, 312\u2013315 Dramamine, 279 Draxxin, 949 Draxxin 25, 949 Drisdol, 336 Dronabinol, 315\u2013316 Droncit, 764 Drontal, 764 Drontal Plus, 354 Droxia, 443 Drug doses, calculation of, 997\u2013998 Drug Enforcement Administration (DEA) number, 995 DSS, 296 DTIC, 227 Dulcolax, 84 Duragesic (patches), 363 Duramycin powder, 883 Duraquin, 804 Duricef, 137 Dynapen, 267 Dyrenium, 931 E ECP, 345 EDDI, 464 Edetate calcium disodium, 317 Edluar, 989 Edrophonium chloride, 318\u2013319 Ehrlichia spp., 1003 Elavil, 38 Eldepryl, 830 Elspar, 60 Emend, 57, 550 Emsam transdermal patch, 830 Enacard, 319 Enalapril maleate, 319\u2013320 Enflurane, 321\u2013322 Enilconazole, 322\u2013323 Enisyl- F,  540 Enoxaparin, 818 Enoxaparin sodium, 323\u2013325 Enrofloxacin, 325\u2013328 equine bacterial pathogens, 1003 Enterobacter spp., 1003 Enterobacterials, 739\u2013740 Entocort, 95 Entyce, 121\u2013122 Ephedrine, 730 Ephedrine hydrochloride, 328\u2013329 Epinephrine, 330\u2013331 Epival, 958 Eplerenone, 849 Epoetin alfa (Erythropoietin), 331 Eprex, 331 Eprinex, 333 Eprinomectin, 333\u2013334, 1007 Eprizero, 333 Epsiprantel, 335\u2013336 Epsom salts, 544 Equidone gel, 299 Equigard, 264 Equimax, 488 Equimectrin, 484 Equine bacterial pathogens, 1003 Equine powders, 516 Equioxx, 368 Equipoise, 89 Equisul- SDT, 859, 942 Equisyn- T4,  516 Equizole, 888 Eqvalan liquid, 484 Ergamisol, 509 Ergocalciferol, 336\u2013337 Ertapenem, 337 Erythro- 100,  338\u2013339 Erythromycin, 338\u2013341, 1007 CYP450 inhibitor, 1005 equine bacterial pathogens, 1003 P-   glycoprotein inhibitor, 1006 Erythromycin + rifampin, 1003 Erythropoietin, 331\u2013332 racing horses, prohibited substances, 1012 Escherichia coli, 1003 Esmolol, 789 Esmolol hydrochloride, 341\u2013342 Esomeprazole, 342\u2013344, 668 CYP450 inhibitor, 1005 Estradiol cypionate, 345\u2013346 Estriol, 346\u2013347 Estrogen CYP450 inducer, 1004 toxicity, 993t\u2013994t Estrogens, 685 EstroPLAN, 203 Estrumate, 203 Ethrane, 321 Ethyl glycols, 993t\u2013994t Ethylene glycol, 993t\u2013994t Ethylenediamine dihydriodide, 464 Ethylenediamine dihydroiodide (EDDI), 758 Etidronate disodium, 347\u2013348 Etodolac, 349\u2013350 EtoGesic, 349 Etorphine, 1000t Excede, 158 Excenel, 160\u2013161 Excipients, 993t\u2013994t Exparel, 97 F Factrel, 414 Famciclovir, 351\u2013352 Famotidin, 352\u2013354 Famotidine, 668 Famvir, 351 Fat, fatty acids, 993t\u2013994t Febantel, 354\u2013356 Felbamate, 356\u2013358 CYP450 inhibitor, 1005 Felbatol, 356 Feldene, 742 Felimazole, 586 Fenbendazole, 358\u2013359, 680 Fenesin, 423 Fenoldopam mesylate, 359\u2013361 Fentanyl, 1001t Fentanyl citrate, 361\u2013363 Fentanyl, transdermal, 363\u2013365 Fentora buccal tablets, 361 Fermycin, 178 Ferospace, 365 Ferrodex, 470 Ferrous sulfate, 365\u2013367 Fertagyl, 414 Ferti- Cept,  415 Fertilin, 414 Fertinex, 954 Filaribits, 268 Filaribits Plus chewable tablets, 681 Filgrastim, 211\u2013212 Finasteride, 367\u2013368 Firocoxib, 368\u2013370 FK506, 868 Flagyl, 606 Flavonolignans, 837 Flavor Tabs, 539 Flomax, 871 Florfenicol, 370\u2013373 Florinef, 376 Flovent, 389 Fluconazole, 373\u2013375, 751\u2013752 CYP450 inhibitor, 1005 Flucort, 378 Flucytosine, 375\u2013376 Fludrocortisone acetate, 376\u2013377 Fluid solution composition, 1008t Flumazenil, 377\u2013378 Flumethasone, 378, 379\u2013380 1018    Index Flunixin, 370, 727\u2013728 Flunixin and florfenicol, 370 Flunixin meglumine, 380\u2013384 Fluopromazine, 935 Fluoroquinolones, 674, 760\u2013761, 1010 CYP450 inhibitor, 1005 Fluorouracil, 384\u2013385 Fluosmin suspension, 378 Fluothane, 426 Fluoxetine CYP450 inhibitor, 1005 P-   glycoprotein inhibitor, 1006 Fluoxetine hydrochloride, 385\u2013387 Fluralaner, 387\u2013389 Fluticasone propionate, 389, 390\u2013391 Folex, 592 Follicle- stimulating  hormone (FSH), 954, 954 Follutein, 415 Fomepizole, 391\u2013393 Food- producing animals, drugs prohibited in, 1010 Fortaz, 156\u2013157 Fortekor, 79 Fosamax, 18 Fosfomycin tromethamine, 393\u2013394 Fragmented heparin dalteparin, 228 enoxaparin sodium, 234 Fragmin, 228 FSH, 954 Fulvicin P/G, 420 Fulvicin U/F, 420 Fungizone, 47 Furadantin, 655 Furalan, 655 Furantoin, 655 Furazolidone, 394\u2013395, 1010 Furosemide, 395\u2013397, 738 Furoxone, 394 Fusobacterium, 1003 G Gabapentin, 398\u2013400, 774 Galastop, 110 Gallimycin- 100,  338\u2013339 Gallimycin- 200,  338\u2013339 Galliprant, 418 Gamithromycin, 400\u2013402 Gamma- aminobutyric  acid (GABA), 720 receptors, 827 Ganaseg, 283 Gantanol, 864 Garacin, 403 Garasol, 403 Garlic/onions, 993t\u2013994t GastroGard, 667 Gastrozol, 667, 670 Gecolate, 423 Gemfibrozil, 402\u2013403 Gengraf, 220 Gentamicin, 1003 Gentamicin sulfate, 403\u2013405 Gentocin, 403 Gentran- 70,  255 Geopen, 125 Glargine insulin, 458 Glibenclamide, 409 Glipizide, 405\u2013407 Glucophage, 579 Glucosamine chondroitin sulfate, 407\u2013409 Glucose transporter 2 (GLUT2), 853 Glucotrol, 405 Glutathione (GSH), 826 Glyburide, 409\u2013411 Glycerin, 411\u2013412 Glyceryl guaiacolate, 423 Glyco- Flex, 180, 407 Glycopeptide antibiotics, 1010 Glycopyrrolate, 412\u2013413 Glycotuss, 423 Glynase, 409 Glytuss, 423 GnRh, 414 Gold sodium thiomalate, 413\u2013414 GoLYTELY, 745 Gonadorelin diacetate tetrahydrate, 414\u2013415 Gonadorelin hydrochloride and gonadorelin diacetate tetrahydrate, 414\u2013415 Gonadotropin, chorionic, 415\u2013417 Gonadotropin- releasing  hormone (GnRH), 873 Granisetron, 672 Granisetron hydrochloride, 417\u2013418 Grapefruit juice, 1005\u20131006 Grapes/raisins, 993t\u2013994t Grapiprant, 418\u2013420 Gravol, 279 Grifulvin, 420 Grisactin, 420 Griseofulvin, 420\u2013422 CYP450 inducer, 1004 Gris- PEG,  420 Growth hormone, 422 Guaifenesin, 423\u2013425 Guailaxin, 423 Guaiphenesin, 423 H Halothane, 426\u2013427 Harmaline, 1001t hCG, 415 Heartgard, 484 Helicobacter, 667 HemaJect, 470 Hemoglobin glutamer (oxyglobin), 427\u2013428, 1008t Hemopure, 1012 Hepalean, 428 Heparin sodium, 428\u2013431 Heroin, 1000t\u20131001t HES, 440 Hespan, 440 Hetastarch, 440, 712, 1008t Hexasol (with oxytetracycline), 380 Hiprex, 585 Histanin, 948 HSS, 842 Humalog, 459\u2013460 human chorionic gonadotropin (hCG), 415 human recombinant thyrotropin, 898 Humatin, 704 Humatrope, 422 Humibid LA, 423 Humulin (human insulin), 458 Hycodan, 434 Hydralazine hydrochloride, 431\u2013432 Hydrea, 443 Hydrochlorothiazide, 432 Hydrocodone, 1000t Hydrocodone bitartrate, 434\u2013436 Hydrocortisone, 436\u2013438 Hydrocortisone sodium succinate, 436 HydroDIURIL, 432 Hydromorphone, 437\u2013440, 438, 1000t Hydrostat, 438 Hydroxyethyl starch, 440\u2013443 Hydroxyurea, 443\u2013444 Hydroxyzine hydrochloride, 444\u2013446 Hydrozide, 432 Hyoscyamine, 446\u2013447 Hyperthyroidism, CYP450 inducer, 1004 Hypertonic saline solution, 842 Hytuss, 423 I Ibuprofen, 448\u2013449, 993t\u2013994t Imaverol, 322 Index 1019 Imazalil, 322 Imepitoin, 449\u2013451 Imidocarb dipropionate, 451, 452\u2013453 Imidocarb hydrochloride and imidocarb dipropionate, 451, 452\u2013453 Imipenem + cilastatin, 453\u2013455 Imipramine hydrochloride, 455\u2013456 Imizol, 451 Immiticide, 563 Immunoglobulin G (IgG), 750\u2013751 Imodium, 531 Improvest, 415 Imuran, 73\u201375 Incurin, 346 Inderal, 789 Indocin, 456 Indomethacin, 456, 457\u2013458 Infusion rates, calculation of, 997\u2013998 INH, 475 Insulin, 458\u2013462 Insulin aspart, 459\u2013460 Insulin detemir, 459 Insulin glulisine, 459 Insulin lispro, 459\u2013460 Interceptor, 613 Interceptor Flavor Tabs, 613 Interferon, 462\u2013464 CYP450 inhibitor, 1005 Interleukin (IL)- 31, 664 Intermezzo, 989 Intracellular pathogens, 1002t Intropin, 301 Invanz, 337 Iodide (potassium iodide), 464\u2013466 Iodopanoic acid, 467 Iodopen, 843 Iopanoic acid, 467 Ipecac, 466\u2013467 Ipodate, 467, 468\u2013469 Ipronidazole, 1010 Irbesartan, 469\u2013470 Iron dextran, 470, 471\u2013472 Iron sucrose, 470, 471\u2013472 Isoflupredone acetate, 472\u2013474 Isoflurane, 474\u2013475 Isoniazid, 475\u2013476 Isonicotinic acid hydrazide, 475 Isooxazolines, 827\u2013828 Isophane, 458 Isoprenaline hydrochloride, 476 Isoproterenol hydrochloride, 476\u2013478 Isoptin, 964 Isordil, 478 Isosorbide dinitrate, 478\u2013479 Isosorbide mononitrate, 478\u2013479 Isotretinoin, 479\u2013480 Isoxsuprine, 480\u2013481 Isuprel, 476 Itraconazole, 481, 482\u2013484, 751\u2013752, 1007 CYP450 inhibitor, 1005 P-   glycoprotein inhibitor, 1006 Itrafungol, 481 Ivercare, 484 Ivercide, 484 IverEase, 484 Ivermax, 484 Ivermectin, 484\u2013488, 1007 Ivermectin + praziquantel, 488\u2013489 Ivomec, 484 J Janus kinase (JAK) inhibitor, 664 K Kalcinate, 118 Kanamycin sulfate, 490\u2013491 Kantrim, 490 Kaolin and pectin, 491\u2013493 Kaon, 756 Keflex, 165 Kefzol, 139 Keppra, 510 Ketalar, 493 Ketamine, 1000t Ketamine hydrochloride, 493\u2013496 Ketavet, 493 Ketoconazole, 496\u2013498, 1007 CYP450 inhibitor, 1005 P-   glycoprotein inhibitor, 1006 Ketofen, 498 Ketoprofen, 498\u2013500 Ketorolac tromethamine, 500\u2013502 Kinavet- CA1,  916 Klebsiella pneumoniae, 1003 Klonopin, 200 K- Phos,  759 Kytril, 417 L Lactated Ringer\u2019s solution, 503\u2013504, 1008t Lactulose, 504\u2013505 Lamisil, 878 Lamprene, 197 Lanoxin, 273 Lansoprazole, 667\u2013670 Lantus, 459 Largactil, 176 Larodopa, 513 Lasix, 395 L- Asparaginase,  60 Lawsonia intracellularis, 1003 L- Deprenyl,  831 L- dopa,  513 Leflunomide, 505, 506\u2013507 Lente insulin, 458\u2013459 Leucovorin calcium, 507\u2013509 Leukeran, 170 Leukine, 211 Levamisole hydrochloride, 509\u2013510 Levaquin, 514 Levasole, 509 Levemir, 459 Levetiracetam, 510\u2013513 Levodopa, 513\u2013514 Levofloxacin, 514\u2013516, 1007 Levo- Powder,  516 Levothyroxine sodium, 516\u2013519 Levsin, 446 LHRH, 414 Lidocaine, 900 Lidocaine hydrochloride, 519\u2013521 Lincocin, 521 Lincomix, 521 Lincomycin hydrochloride, 521, 522\u2013524 Lincomycin hydrochloride monohydrate, 521, 522\u2013524 Lincomycin- spectinomycin,  847 Linezolid, 523\u2013525 Liothyronine sodium, 525\u2013526 Liquaemin, 428 Liquamycin- LA 200, 689 Liqui- char,  168 Liquid- dose  compounded","contraindications":"Contraindications and Precautions Because zonisamide resembles sulfonamides in structure, use cautiously in animals that are sensitive to these drugs. (See Sulfonamide for full details on adverse effects.) Drug Interactions When administered concurrently with phenobarbital, the half- life of elimination is more rapid for zonisamide, which may necessitate higher doses. It is expected to potentiate other central nervous system depressants and anticonvulsants.","indications":"Indications and Clinical Uses Zonisamide is used to treat refractory seizures in dogs when other drugs have not been effective. It has been effective in experimentally induced seizures in dogs and\\tin\\tapproximately\\t50%\\tof\\tdogs\\twith\\trefractory\\tepilepsy.\\tIt\\thas\\tbeen\\tused\\tas an add- on with other anticonvulsant drugs such as phenobarbital and potassium bromide. When used as an add- on treatment, it may reduce the dose of other anticonvulsants (e.g., phenobarbital). It has been used in cats, as an add- on, or as a single treatment. Clinical efficacy has not been reported in cats, but at the doses Z listed, it suppressed electroencephalographic electrical activity in cats consistent with control of feline seizures. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects reported are based on limited case reports. These are usually mild and transient. In dogs, it may cause sedation, lethargy, ataxia, and vomiting. Liver\\tinjury\\tis\\tpossible,\\tand\\tdogs\\tshould\\tbe\\tmonitored\\tduring\\ttreatment. Zonisamide can affect thyroid hormones in dogs, and thyroid monitoring should be performed in dogs on long-term treatment with zonisamide. Zonisamide is a sulfonamide drug, and dogs that are sensitive to sulfonamides may be at higher risk for reactions to zonisamide. In safety studies, beagles received 75\\tmg/kg/day\\tfor\\t1\\tyear\\twith\\tminimal\\tside\\teffects.\\tIn\\tcats,\\tadverse\\teffects include mild GI problems, sedation, and ataxia.","notes":"Instructions for Use Most experience with zonisamide in animals has been preliminary work in dogs with refractory epilepsy. Although low doses may produce plasma concentrations within the therapeutic range reported for people, when administered with phenobarbital, drug concentrations may be lower because drug metabolism is increased. Zonisamide half- life was shorter in dogs receiving phenobarbital concurrently. These observations indicate that higher doses may be needed for combination therapy with phenobarbital compared with monotherapy. (Note that higher dose is listed later when used with phenobarbital.) With chronic treatment, some tolerance that reduces efficacy after 2\u20133 months may develop. Although zonisamide has been administered by the rectal route to animals, this is not recommended. The dose administered rectally was prepared by combining the contents of a capsule in water to a 100 mg/mL suspension. However, when delivered by the rectal route (20 or 30 mg/kg), it did not achieve plasma concentrations in the range that is considered therapeutic for dogs. Patient Monitoring and Laboratory Tests Effective plasma concentrations in animals have been suggested to be 10\u201340 mcg/mL. Concentrations above 20 mcg/mL in cats have produced adverse effects. Because of the potential for zonisamide to affect thyroid hormones in dogs, monitor tetraiodothyronine (T 4 ) levels periodically during treatment. Formulations \u2022\\t\\tZonisamide\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t100-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. formulations, 999 Lisinopril, 526\u2013528 Lithium carbonate, 528\u2013529 Lithotabs, 528 L- Lysine,  540\u2013541 Lodine, 349 Lomotil, 288 Lomustine, 529\u2013531 Longrange, 333 Loperamide, 1007 Loperamide hydrochloride, 531\u2013532 Lopid, 402 Lopressor, 604 Lopurin, 22 1020    Index Lorazepam, 532\u2013534, 1001t Lortab, 434 Losartan, 534\u2013535 Losec, 667 Lotensin, 79 Lotilaner, 535\u2013537 Lovenox, 323\u2013324 Low- molecular- weight  heparin (LMWH), 228, 323\u2013324 dalteparin, 228 enoxaparin sodium, 234 Loxicom, 565 LRS, 503 LSD, 1000t\u20131001t L- thyroxine,  516 Lufenuron, 537\u2013539 Lufenuron + milbemycin oxime, 539\u2013540 Luminal, 720 Lutalyse, 285, 791 Lyrica, 774 Lysergic acid diethylamide (LSD), 1000t\u20131001t Lysine (L-  Lysine), 540\u2013541 Lysodren, 622 M Macadamia nuts, 993t\u2013994t Macrodantin, 655 Macrolide antibiotics, 993t\u2013994t Magic mushrooms, 1001t Magnalax, 543 Magnesium citrate, 542\u2013543 Magnesium hydroxide, 543\u2013544 Magnesium sulfate, 544\u2013546 Malogen, 882 Mandelamine, 585 Mannitol, 546\u2013548 Marbocyl (European name), 548 Marbofloxacin, 548\u2013550 equine bacterial pathogens, 1003 Marcaine, 97 Marijuana, 316 Marin, 837 Marinol, 315 Maropitant citrate, 550\u2013553 Marquis, 749 Masitinib mesylate, 553 Masivet, 916 Matrix, 25 Mavik, 925 Maxipime, 142 Maxolon, 602 Mebendazole, 554\u2013555 Meclizine, 555\u2013556 Meclofen, 556 Meclofenamate sodium and meclofenamic acid, 556\u2013558 Meclofenamic acid, 556\u2013558 Meclozine, 555 Medetomidine hydrochloride, 558\u2013560 Medium-  chain triglyceride (MCT) oil, 553\u2013554 Medrol, 598 Medroxyprogesterone acetate, 560\u2013562 Mefoxin, 150 Mefoxitin, 150 Megace, 562 Megestrol acetate, 562\u2013563 Melarsomine dihydrochloride, 563\u2013565, 890 Meloxicam, 565\u2013569 Meloxidyl, 565 Melphalan, 569\u2013570 Menadiol, 735 Menaquinone, 971 Meperidine, 1000t Meperidine hydrochloride, 570\u2013572 Mephyton, 735, 971 Mepivacaine, 572\u2013573 Mepron, 67 Mercaptopurine, 573\u2013574 Meropenem, 574\u2013576 Merrem, 574 Mesalamine, 576\u2013578, 666 Mesalazine, 576 Mesasal, 576 Mescaline, 1000t\u20131001t Mestinon, 798 Metacam, 565 Metacam suspension, 565 Metaflumizone, 577 Metamizole, 291 Metamucil, 795 Metaprel, 578 Metaproterenol sulfate, 578\u2013579 Metformin, 579\u2013581 Methadone,  P- glycoprotein inhibitor, 1006 Methadone hydrochloride, 581\u2013583 Methadose, 581 Methampyrone, 291 Methazolamide, 573, 583\u2013584 Methenamine, 585\u2013586, 863 Methenamine hippurate, 585 Methenamine mandelate, 585 Methicillin- resistant Staphylococcus, 677 Methimazole, 586\u2013589 Methio- Form,  806 Methionine (DL-  methionine), 589 Methocarbamol, 589\u2013591 Methohexital sodium, 591\u2013592 Methotrexate, 592\u2013594 Methoxamine, 594\u2013595 Methoxyflurane, 595\u2013596 Methylene blue, 596\u2013597, 993t\u2013994t Methylene blue 0.1%, 596\u2013597, 993t\u2013994t Methylenedioxy- methamphetamine, 1000t Methylnaltrexone bromide, 597\u2013598 Methylprednisolone, 598\u2013601, 1007 Methylprednisolone acetate, 598 Methylprednisolone sodium succinate, 598, 770 Methyltestosterone, 601\u2013602, 1000t Meticorten, 771 Metoclopramide hydrochloride, 602\u2013604 Metofane, 595 Metoprolol tartrate, 604\u2013606 Metrodin, 954 Metronidazole, 606\u2013609, 1003 Metronidazole benzoate, 606\u2013609 Mexate, 592 Mexiletine, 609\u2013610 Mexitil, 609 Mibolerone, 610\u2013611 Micardis, 875 Micotil, 905 Micronase, 409 Midazolam, 1000t Midazolam hydrochloride, 611\u2013613 Milbemycin, 1007 Milbemycin oxime, 613, 614\u2013615 Milbemycins, 829 Milk of Magnesia, 543 Milk thistle, 837 Mineral oil, 615, 616\u2013617 Minipress, 765 Minocin, 617 Minocycline hydrochloride, 617\u2013618 infections, 1002t Mirataz, 618 Mirtazapine, 618, 619\u2013620, 679 Misoprostol, 620, 621\u2013622 Mitaban, 37 Mithracin, 744 Index 1021 Mithramycin, 744 Mitotane, 622\u2013624 Mitotic spindles, 694 Mitoxantrone hydrochloride, 624, 625\u2013626 Mitratapide, 626 Mobic, 565 Mobicox, 565 Modrenal, 936 Monoamine oxidase (MAO) type B, 831 Monodox, 312 Monoket, 478 Monurol, 393 Morphine, 703, 1000t\u20131001t, 1007 Morphine sulfate, 626\u2013629 Motilium, 299 Motrin, 448 Moxidectin, 629\u2013633, 1007 Moxifloxacin, 633\u2013635 MS Contin extended-  release tablets, 626 MTX, 592 Mucinex, 423 Mucomyst, 8 Mycophenolate mofetil, 635\u2013638 Mylepsin, 776 Myleran, 105 Myochrysine, 413 Mysoline, 776 N N-    acetyl procainamide (NAPA), 777\u2013778 N- acetylcysteine,  8 Naloxone hydrochloride, 639\u2013641 Naltrexone, 641\u2013642 Nandrolone decanoate, 642\u2013643 Naprosyn, 643 Naproxen, 643\u2013645, 993t\u2013994t Naproxen sodium, 643 Narcan, 639 Nature\u2019s Remedy, 133 Navigator, 652 Naxcel, 163 Naxcel XT, 158 Naxen, 643 N- butylscopolammonium bromide (butylscopolamine bromide), 107\u2013108, 645\u2013646 Nebcin, 912 Nemacide, 268 Nembutal, 714 Nemex, 796 Neomercazole, 126 Neomycin, 646\u2013648 Neoral, 220 Neorickettsia risticii, 1003 Neosar, 217 Neostigmine, 648\u2013650 Neostigmine bromide, 648 Neostigmine methylsulfate, 648 Neo- Synephrine,  729 Neptazane, 583 Neupogen, 211 Neurontin, 398 Neurosyn, 776 Neutral protamine hagedorn, 458 Neutra- Phos- K,  759 New Methylene Blue, 596 NexGard, 12 Nexium, 342 Niacinamide, 650\u2013651 Nicotinamide, 650 Nifedipine, 651\u2013652 Niravam, 23 Nitazoxanide, 652\u2013654 Nitenpyram, 654\u2013655 Nitro- Bid,  657 Nitrofurantoin, 655, 656\u2013657 Nitrofurazone, 1010 Nitroglycerin, 657\u2013659 Nitrol, 657 Nitropress, 659 Nitroprusside (sodium nitroprusside), 659\u2013661 Nitrostat, 657 Nizatidine, 661\u2013662 Nizoral, 496 N- methylthiotetrazole  (NMTT), 976 Nocita, 97 Nolvadex, 872 Nonsteroidal  anti- inflammatory agents, 726, 993t\u2013994t Norfloxacin, 662\u2013663 Normosol- R,  1008t Noroxin, 662 Norpace, 293 Norvasc, 40\u201342 Novantrone, 624 NovoLog, 459\u2013460 Noxafil, 751 NPH insulin, 458 Nuclear factor of activated T cells (NFAT), 868 Nuflor, 370 Nuflor Gold, 370 Numorphan, 687 Nuprin, 448 Nutropin, 422 O Oclacitinib maleate, 664\u2013666 O-    desmethyl tramadol, 922 Oestriol, 259 Olsalazine, 576 Olsalazine sodium, 576, 666\u2013667 Omeprazole, 667\u2013671, 701, 809 CYP450 inhibitor, 1005 Omnicef, 140 Omnipen, 50 Omnipen- N,  50 Omnizole, 888 Oncovin, 966 Ondansetron, 1007 Ondansetron hydrochloride, 671\u2013673 Onions, 993t\u2013994t Onsior, 820 op\u2019- DDD,  622 Opioids, 1000t Optimmune, 220 Oramorph SR extended- release tablets, 626 Orbax, 673 Orbenin, 207 Orbifloxacin, 673\u2013675 equine bacterial pathogens, 1003 Orciprenaline sulphate, 578 Organophosphates, 1005 Oritavancin, 960 Ormetoprim with sulfadimethoxine, 675\u2013677 OroCAM, 565 Orudis- KT,  498 Osmitrol, 546 OSPHOS, 195 Ovaban, 562 OvaCyst, 414 Oxacillin sodium, 677\u2013678 Oxazepam, 678\u2013680, 1000t Oxfendazole, 680\u2013681 Oxibendazole, 681, 682\u2013683 Oxpentifylline, 716 Oxtriphylline, 683\u2013684 Oxy 1000, 689 Oxybiotic Oxy 500, 689 Oxybutynin chloride, 684\u2013685 Oxyglobin, 427 racing horses, prohibited substances, 1012 Oxymetholone, 685, 686\u2013687, 1000t Oxymorphone, 1000t Oxymorphone hydrochloride, 687\u2013689 Oxy- Tet,  689 Oxytetracycline, 689\u2013692 equine bacterial pathogens, 1003 Oxytocin, 692\u2013693 1022    Index P Paccal Vet- CA1, 694 Paclitaxel, 694\u2013696, 1007 Palladia, 916 Pamidronate disodium, 696\u2013698 Panacur, 358 Pancreatic enzyme replacement, 698\u2013700 Pancreatic enzymes, 698 Pancreaze, 698, 699 Pancrelipase, 698\u2013700 Pancrezyme, 698 Pancuronium bromide, 700\u2013701 Panectyl, 939 Panmycin, 883 Pantoprazole, 667\u2013670, 701\u2013703, 701 Para- aminobenzoic acid (PABA), 675, 801, 858 Paracetamol, 3\u20134 Paraplatin, 128 Paregoric, 703\u2013704 Parlodel, 93 Paroxetine, 706\u2013708 P-   glycoprotein inhibitor, 1006 Pasteurella spp., 1003 Pavulon, 700 Paxil, 706 PBZ, 726, 948 Pedameth, 806 PEG, 745 Pelamine, 948 Penicillamine, 708\u2013709 Penicillin G, 709\u2013712 equine bacterial pathogens, 1003 Penicillin G benzathine, 709 Penicillin G potassium, 709 Penicillin G sodium, 709 Penicillin V (Pen- Vee), 709 Penicillin- binding proteins (PBPs), 677, 899 Pennyroyal, 993t\u2013994t Pentasa, 576 Pentastarch, 712\u2013713, 1008t Pentazocine, 713\u2013714, 1000t\u20131001t P-   glycoprotein inhibitor, 1006 Pentobarbital, 1000t CYP450 inducer, 1004 Pentobarbital sodium, 714\u2013716 Pentothal, 893 Pentothal sodium, 1001t Pentoxifylline, 716\u2013718 Pen- Vee,  709 Pepcid, 352 Peptizole, 667 Pepto- bismol,  85 Percorten- V,  243 Pergolide, 718\u2013720 Pergolide mesylate, 718 Periactin, 224 Permax, 718 Permethrin, 993t\u2013994t Persantine, 290 Pertzye, 698, 699 Pethidine, 570 Pexion, 449 Peyote, 1000t PGF 2 alpha, 285, 791 P-   glycoprotein, 695, 1007 P-   glycoprotein inhibitors, 1006 Phenazopyridine, 993t\u2013994t Phenergan, 782 Phenetron, 175 Phenobarbital, 720\u2013723, 776, 1000t CYP450 inducer, 1004 Phenobarbitone, 720 Phenothiazines, 2, 934, 1007 Phenoxybenzamine hydrochloride, 723\u2013725 Phentolamine mesylate, 725\u2013726 Phenylbutazone, 726\u2013729, 1010 CYP450 inducer, 1004 CYP450 inhibitor, 1005 Phenylephrine hydrochloride, 729\u2013730, 729 Phenylethylmalonamide (PEMA), 776 Phenylpropanolamine (PPA), 685 Phenylpropanolamine (PPA) hydrochloride, 730\u2013732 Phenytoin, 732\u2013734 CYP450 inducer, 1004 Phenytoin sodium, 732\u2013734 Phosphate enemas, 993t\u2013994t Phosphodiesterase (PDE 4) inhibitor, 716 Phosphodiesterase V (PDE V), 836, 869 Phylloquinone, 735, 971 Physostigmine, 734\u2013735, 734 Phytomenadione, 735, 971 Phytonadione, 735\u2013737 Pimobendan, 737\u2013739 Pipa- Tabs,  741 Piperacillin, 739\u2013741 Piperacillin + tazobactam, infections, 1002t Piperacillin sodium + tazobactam, equine bacterial pathogens, 1003 Piperazine, 741\u2013742 Pip- Taz,  739 Piroxicam, 742\u2013744 Pitocin, 692 Pitressin, 962 Plasma- Lyte,  1008t Platinol, 187 Plavix, 201 Plicamycin, 744\u2013745 Polycillin, 50 Polycillin- N,  50 Polyethylene glycol electrolyte solution, 745\u2013746 Polymox, 43 Polymyxin B sulfate, 746\u2013748 Polyoxyethylated castor oil, 694\u2013695 Polysulfated glycosaminoglycan (PSGAG), 748\u2013749 Ponazuril, 749, 750\u2013751 Posaconazole, 751\u2013753 Potassium bromide, 90 Potassium chloride, 753\u2013755 Potassium citrate (K 3 C 6 H 5 O 7 ), 755\u2013756 Potassium gluconate, 756\u2013757 Potassium iodide, 464, 757, 758\u2013759 Potassium phosphate, 759\u2013760 PPA, 730 Pradofloxacin, 760\u2013762 Pralidoxime chloride, 762\u2013764 Prascend, 718 Praziquantel, 764\u2013765 Prazosin, 765\u2013767 Predef 2X, 472 Prednisolone, 767\u2013770 Prednisolone acetate, 767\u2013770 Prednisolone sodium succinate, 770\u2013771 Prednisone, 771\u2013774 PrednisTab, 767 Pregabalin, 774\u2013776, 1000t Pregnyl, 415 Prepulsid, 185 Prescription writing reference, 995\u2013996 Previcox, 368 Priex, 796 Prilactone, 849, 850 Prilosec, 667 Primaxin, 453 Primidone, 776\u2013777 Primor, 675 Principen, 50 Prinivil, 526 Index 1023 Privermectin, 484 Pro- Banthine,  783 Procainamide hydrochloride, 777\u2013779 Procaine, 709 Procardia, 651 Prochlorperazine edisylate, 780\u2013782 Prochlorperazine edisylate and isopropamide iodide, 779\u2013780 Prochlorperazine maleate, 780\u2013782 Prochlorperazine maleate and isopropamide iodide, 779\u2013780 Procrit, 331 Profasi, 415 Progestogens, 1004 Program, 537 ProHeart, 629 ProHeart 6, 629 ProHeart 12, 629 Proin, 730 Proin ER, 730 PromAce, 1 ProMeris, 577 Promethazine hydrochloride, 782\u2013783 Pronestyl, 777 Propalin, 730 Propantheline bromide, 783\u2013784 Propentofylline, 887 Propiopromazine hydrochloride, 784\u2013785 PropoFlo, 785 PropoFlo 28, 785 PropoFlo Plus, 785 Propofol, 785\u2013789, 894 Propranolol hydrochloride, 789\u2013790 Propulsid, 185 Propylthiouracil (PTU), 790\u2013791 Propyl- Thyracil,  790 Proscar, 367 Prospec, 846 Prostaglandin F receptor- alpha, 692 Prostaglandin F2 alpha, 285 Prostaglandin (PGF 2 ) F 2 alpha, 791, 792\u2013793 ProstaMate, 285 Prostaphlin, 677 Prostigmin, 648 Prostin F2 alpha, 285 Protamine zinc insulin (PZI), 458, 459 Protazil, 265 Protirelin, 896 Protonix, 701 Protopam chloride, 762 Protopic, 868 Protropin, 422 Proventil, 16 Provera (tablets), 560 Prozac, 385 ProZinc, 458 Pseudoephedrine, 730 toxicity, 993t\u2013994t Pseudoephedrine hydrochloride, 793\u2013795 Pseudomonas aeruginosa, 1003 Psilocin, 1001t Psilocybin, 1001t Psyllium, 795\u2013796, 795 PTU, 790 Pulmotil AC, 905 Pulmotil tilmicosin premix, 905 Purinethol, 573 Pyopen, 125 Pyran, 796 Pyrantel pamoate, 796\u2013798 Pyrantel tartrate, 796\u2013798 Pyr- A- Pam,  796 Pyridostigmine bromide, 798\u2013799 Pyrimethamine, 799\u2013801 Pyrimethamine and sulfadiazine, 801\u2013802 PZI, 458 PZI Vet, 458 Q Quadrinal, 757 Quest, 629 Quinacrine hydrochloride, 803\u2013804 Quinidine, 804\u2013805 CYP450 inhibitor, 1005 P- glycoprotein inhibitor, 1006 Quinidine gluconate, 804 Quinidine polygalacturonate, 804 Quinidine sulfate, 804\u2013805 Quinora, 804 R Rabeprazole, 667\u2013670 Racemethionine, 589, 806\u2013807, 806 Ramipril, 807\u2013809 Ranitidine, 668 Ranitidine hydrochloride, 808, 809\u2013810 Rapinovet, 785 Raw yeast dough, 993t\u2013994t ReBalance, 801 Reclast, 987 Recombinant human thyrotropin (rhTSH), 898 Reconcile, 385 Recuvyra, 363 Regitine, 725 Reglan, 602 Regonol, 798 Regular insulin, 458 Regu- Mate,  25 Relistor, 597 Remeron, 618 Remifentanil hydrochloride, 810\u2013812 Renin- angiotensin- aldosterone system (RAAS), 850 Resflor, 370 Respiram, 306 Respiratory tract infection, 1002t Retavase, 911 Retinol, 968 Retrovir, 983 Revatio, 836 Revolution, 829 Revonto, 233 rG- CSG,  211 rGM- CSF,  211 Rheumatrex, 592 Rhodococcus equi, 1003 Riboflavin (vitamin B2), 812\u2013814 Ridaura, 71 Rifadin, 814 Rifampicin, 814 Rifampin, 814\u2013816 CYP450 inducer, 1004 Rilexine, 165 Rimactane, 814 Rimadyl, 129\u2013130 Ringer\u2019s acetate, 816 Ringer\u2019s lactate, 816 Ringer\u2019s solution, 816\u2013818, 1008t Rintal, 354 Ripercol, 509 Rivaroxaban, 818\u2013820 Robamox- V,  43 Robaxin- V,  589 Robenacoxib, 820\u2013822 Robinul- V,  412 Rocaltrol, 112 Rogitine, 725 Romazicon, 377 Romifidine, 978 Romifidine hydrochloride, 822\u2013824 Rompun, 978 Ronidazole, 824\u2013825 RTU EZ suspension, 160\u2013161 RU 46534, 14 Ryanodex, 233 Rythmodan, 293 1024    Index S S- adenosylmethionine  (SAMe), 826\u2013827 Safe- Guard,  358 Safeheart Milbemycin, 613 Salazopyrin, 866 Salbutamol, 16 Salt, 993t\u2013994t SAMe, 826\u2013827 Sandimmune, 220 Sargramostim, 211\u2013212 Sarolaner, 827\u2013829 Scolaban, 96 Sedivet, 822 Selamectin, 829\u2013830, 1007 Selective serotonin reuptake inhibitor (SSRI), 706 Selegiline hydrochloride, 830, 831\u2013832 Semintra, 875 Senna, 832\u2013833 Senokot, 832 Sentinel tablets, 539 Septicemia, 1002t Septra, 945 Serax, 678 Serotonin antagonists, 671\u2013672 Sevelamer carbonate, 833\u2013834 Sevoflurane, 834, 835\u2013836 Sildenafil citrate, 836\u2013837 Silodosin, 765\u2013766 Silybin, 837 Silymarin, 826, 837\u2013839 Simbadol, 100 Simparica, 827 Simplicef, 152 Sinequan, 308 Sivextro, 523 Skelid, 907 Skin infection, 1002t Slentrol, 293 Soda mint, 839 Sodium ascorbate, 58 Sodium bicarbonate, 839\u2013840 Sodium bromide, 90 Sodium chloride 0.9%, 840, 841\u2013842 Sodium chloride 7.2% and 7.5%, 842\u2013843 Sodium iodide, 758 Sodium iodide (20%), 843\u2013844 Sodium phosphate, 250 Solganal, 72\u201373 Solid- dose  compounded formulations, 999 Solodyn, 617 Solu- Cortef,  436 Solu- Delta- Cortef,  770 Solu- Medrol,  598 Somatrem, 422 Somatropin, 422 Sotalol hydrochloride, 844\u2013846 Spectam, 846 Spectinomycin, 846\u2013847 Spectinomycin dihydrochloride pentahydrate, 846\u2013847 Spectogard, 846 Spectramast DC, 160\u2013161 Spectramast LC suspension, 160\u2013161 Spinosad, 847\u2013849 P- glycoprotein inhibitor, 1006 Spironolactone, 849\u2013851, 932 Sporanox, 481 Spritam, 510 Squalene epoxidase (SE), 878 St. John\u2019s wort CYP450 inducer, 1004 P-   glycoprotein inhibitor, 1006 Stanozolol, 851\u2013853, 1000t Staphylococcus aureus, 678, 1003 Stelazine, 934 Stiglyn, 648 Streptococcus spp., 1003 Streptomyces tsukubaensis, 868 Streptozocin, 853\u2013854 Streptozotocin, 853 Strongid, 796 Sublimaze, 361 Succimer, 854\u2013855 Sucralfate, 855, 856\u2013857 Sudafed, 793 Sufenta, 857 Sufentanil citrate, 857\u2013858 Sulcrate, 855 Sulfachlorpyridazine, 858\u2013859 Sulfadiazine, 859, 860\u2013861, 942\u2013945 Sulfadimethoxine, 861\u2013863 Sulfamethazine, 863\u2013865 Sulfamethoxazole, 864, 865, 945\u2013948 Sulfa- Nox,  865 Sulfaquinoxaline, 865\u2013866 Sulfasalazine, 866\u2013867 Sulfonamides, 863 Sulmet, 863 Suprax, 143 Surfak, 296 Symmetrel, 28 Synthetic corticotropin, 214 Synthroid (human form), 516 Syntocinon, 692 Syprine, 933 Syrup of ipecac, 466 T T4, 516 Tablets calculating how many needed, 997 splitting, 998 Tacrolimus, 868\u2013869, 1007 Tadalafil, 869\u2013871 Tagamet, 181 Talwin- V,  713 Tamoxifen,  P- glycoprotein inhibitor, 1006 Tamoxifen citrate, 872, 873\u2013874 Tamsulosin, 765\u2013766 Tamsulosin hydrochloride, 871\u2013872 Tapazole, 586 Task, 264 Taurine, 874\u2013875 Tavist, 190 Taxanes, 694 Taxol, 694 Tazicef, 156\u2013157 Tazidime, 156\u2013157 Tazobactam, 739\u2013741 Tedizolid, 523 Tegaserod maleate, 875 Tegopen, 207 Telavancin, 960 Telazol, 903 Telmin, 554 Telmintic, 554 Telmisartan, 875\u2013878 Temaril, 939 Temaril- P, 767, 939 Tenormin, 64 Tensilon, 318 Tepoxalin, 877, 878 Terbinafine hydrochloride, 878\u2013880 Terbutaline sulfate, 880\u2013882 Terfenadine, 1007 Terramycin, 689 Terramycin Scours tablets, 689 Terramycin Soluble Powder, 689 Testex, 882 Testosterone, 882\u2013883, 1000t Testosterone cypionate ester, 882 Tetracosactide, 214 Tetracosactin, 214 Tetracycline, 883\u2013885, 1007 CYP450 inhibitor, 1005 Tetracycline hydrochloride, 883\u2013885 Tetraiodothyronine (T 4 ), 896 Index 1025 Tetrastarch, 440 Theelol, 346 Thenium closylate, 885\u2013886 Theophylline, 684, 886\u2013888 Theophylline sustained release, 886 Thiabendazole, 888\u2013890 Thiacetarsamide, 563\u2013564 Thiacetarsamide sodium, 890\u2013891 Thiamazole, 586 Thiamine hydrochloride, 891\u2013892 Thibenzole, 888 Thiobarbiturates, 1001t Thioguanine, 892\u2013893 Thiopental sodium, 893\u2013895 Thioplex, 895 Thiotepa, 895\u2013896 Thorazine, 176 Thymidine kinase (TK), 957 Thyrel, 896 Thyrogen, 897\u2013898 Thyroid Powder, 516 Thyroid- releasing hormone (TRH), 896\u2013897 Thyro- L,  516 Thyro- Tabs,  516 Thyrotropin, 896\u2013899, 897 Thyroxine (T 4 ), 859 Thytropar, 897 Ticar, 899 Ticarcillin + clavulanate potassium, 900\u2013901 Ticarcillin disodium, 899\u2013901 Ticillin, 899 Tigan, 941 Tildipirosin, 901\u2013903 Tildren, 907 Tiletamine, 903\u2013905, 1000t Tilmicosin, 901 Tilmicosin phosphate, 905\u2013907 Tiludronate disodium, 907\u2013909 Timentin, 900 Tindamax, 909 Tinidazole, 909\u2013911 Tissue plasminogen activator (tPA), 911\u2013912 Titralac, 114 Tobacco products, 993t\u2013994t Tobi, 912 Tobramycin sulfate, 912\u2013914 Tocainide hydrochloride, 914, 915\u2013916 Toceranib phosphate, 916\u2013918 Tocopherol, 969 Tofranil, 455 Tolterodine, 684 Toltrazuril, 918\u2013919 Toltrazuril sulfone, 750 Tonocard, 914 Toradol, 500 Torbugesic, 106 Torbutrol, 106 Torpex equine inhaler, 16 Torsemide, 919, 920\u2013921 Totacillin, 50 Totacillin- N,  50 Toujeo, 459 ToxiBan, 168 tPA, 911 Tracrium, 68 Tramadol, 921, 1000t Tramadol hydrochloride, 921, 922\u2013925 Tramisol, 509 Trandolapril, 925\u2013926 Transdermal fentanyl, 363\u2013365 Tranvet, 784 Tranxene, 206 Travasol, 31 Trazodone hydrochloride, 926\u2013929 Trental, 716 Tresiba, 459 Trexan, 641 Trexonil, 639 TRH, 896 Triamcinolone acetonide, 929\u2013931 Triamcinolone diacetate, 929\u2013931 Triamcinolone hexacetonide, 929\u2013931 TriamTabs, 929 Triamterene, 931, 932\u2013933 Tribrissen, 859, 942 Tricyclic antidepressants (TCAs), 706 Trientine, 708 Trientine hydrochloride, 933\u2013934 Trifexis, 847 Trifluoperazine hydrochloride, 934\u2013935 Triflupromazine hydrochloride, 935\u2013936 Trilostane, 936\u2013939 Trimeprazine tartrate, 939\u2013941 Trimeprazine- prednisolone, 939\u2013941 Trimethobenzamide, 941\u2013942 Trimethoprim, 942\u2013948 Trimethoprim + sulfonamide equine bacterial pathogens, 1003 infections, 1002t Trimethoprim sulfadiazine, 1003 Trimox, 43 Tripelennamine citrate, 948\u2013949 Tripelennamine hydrochloride, 948 TSH, 897 Tubulin, 965\u2013967 Tucoprim, 942 Tulathromycin, 901, 949\u2013951 Tumil- K,  756 Tums, 114 Tylan, 951 Tylenol, 3\u20134 Tylenol with codeine, 5 Tylocine, 951 Tylosin, 951\u2013953 Tylosin tartrate, 951 U Uceris, 95 UlcerGard, 667 Ultane, 834 Ultiva, 810 Ultralente insulin, 458, 459 Ultram, 921 Ultramectin, 484 Ultrase, 698 Unasyn, 50 Unfractionated heparin (UFH), 428 Uniprim, 942 Uracid, 806 Urecholine, 82 Urex, 585 UriCon, 730 Urinary tract infection, 1002t Urocit- K,  755 Urofollitropin, 954\u2013955 Urso, 955 Ursodeoxycholic acid, 955\u2013956 Ursodiol, 955\u2013956 V Valacyclovir, 957\u2013958 Valbazen, 15 Valium, 260 CYP450 inducer, 1004 Valproate sodium, 958\u2013960 Valproic acid, 958\u2013960 Valtrex, 957 Vancocin, 960 Vancoled, 960 Vancomycin, 960\u2013962, 1010 Vantin, 152 1026    Index Vascular endothelial growth factor (VEGF), 916 Vasodilan, 480 Vasopressin, 962\u2013964 Vasotec, 319 Vasotop, 807 Vasoxyl, 594 Veda- K1,  971 Velban, 965 Venofer, 470 Ventipulmin, 192 Ventolin, 16 Veraflox, 760 Verapamil, 1007 CYP450 inhibitor, 1005 P-   glycoprotein inhibitor, 1006 Verapamil hydrochloride, 964\u2013965 Vercom, 354 Verdisol, 264 Veriben, 283 Vermox, 554 Versed, 611 Vesprin, 935 Veta- K1, 735, 971 Vetalar, 493 Vetalog, 929 Vetamox, 7 Vetergesic, 100 Vetisulid, 858 Vetmedin, 737 Vetolexin, 165 Vetoryl, 936 Vetprofen, 129\u2013130 VetStarch, 440 Vetsulin, 458, 459 Vfend, 972 Viagra, 836 Vibramycin, 312 Vicodin, 434 Vidalta, 126 Vinblastine, 1007 Vinblastine sulfate, 965\u2013966 Vincasar, 966 Vincristine, 1007 Vincristine sulfate, 966\u2013968 Viokase, 698 Virbagen omega, 462 Vistaril, 444 Vitamin A, 968\u2013969 Vitamin AD, 968 Vitamin B 1 , 891 Vitamin B 2 , 812\u2013814 Vitamin B 3 , 650 Vitamin B 12 , 216 Vitamin C, 58 Vitamin D, 968 Vitamin E, 969\u2013971 Vitamin K, 971\u2013972 Vitamin K 1 , 735\u2013736 Vitamin K 2 , 971 Vitamin K 3 , 971 Vitamin K 4 , 735 Vitamins A and D, 968 Vivitrol, 641 Vivlodex (human preparation), 565 Voren suspension, 247 Voriconazole, 972\u2013975 CYP450 inhibitor, 1005 W Warfarin, 818 Warfarin sodium, 976\u2013977 Wellcovorin, 507 Winstrol- V,  851 Wymox, 43 X Xanax, 23 Xarelto, 818 Xylazine hydrochloride, 978\u2013980 Xylitol, 669, 993t\u2013994t Xylocaine, 519 Y Yarvitan, 626 Yobine, 981 Yohimbine, 981\u2013982 Z Zactran, 400 Zanosar, 853 Zantac, 808 Zebeta, 86\u201387 Zegerid, 667, 669\u2013670 Zelnorm, 875 Zeniquin, 548 Zenpep, 698, 699 Zestril, 526 Zidovudine, 983\u2013984 Zilmax, 984 Zilpaterol hydrochloride, 984\u2013985 Zimecterin, 484 Zimeta, 291 Zinc, 986, 985\u2013987 Zinecarp, 129\u2013130 Zithromax, 75 Zofran, 671 Zolazepam, 903\u2013905, 1000t Zoledronate, 987\u2013989 Zoledronic acid, 987 Zoletil, 903 Zolpidem, 989\u2013990 Zolpimist, 989 Zometa, 987 Zonegran, 990 Zosyn, 739 Zovirax, 10\u201311 Zubrin, 877 Zuprevo, 901 Zycortal, 243 Zygomycetes, 751\u2013752 Zyloprim, 22 Zyrtec, 167 Zyvox, 523 Zyvoxam, 523 This page intentionally left blank This page intentionally left blank","original_category":"Anticonvulsant"}]},{"category":"Other","drugs":[{"name":"Acetylcysteine","active_ingredient":"Acetylcysteine","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tAntidote:\\t140\\tmg/kg\\t(loading\\tdose);\\tthen\\t70\\tmg/kg\\tq4h\\tIV\\tor\\tPO\\tfor\\tfive\\tdoses. \u2022\\t\\tEye\\tsolution:\\t2%\\tsolution\\ttopically\\tq2h. \u2022\\t\\tTo\\tprevent\\tcontrast-\\tmedium\\tnephropathy:\\t17\\tmg/kg\\tIV\\tbolus\\tfollowed\\tby\\t17 mg/kg\\tq12h\\tfor\\t48\\thours. \u2022\\t\\tCRIs\\thave\\tbeen\\tused\\tto\\ttreat\\toxidative\\tstress\\t(50\\tmg/kg\\tdiluted\\tin\\tsaline\\tinfused over 1 hour).  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. However, because it is short acting and is used primarily\\tfor\\tthe\\ttreatment\\tof\\tintoxications,\\tno\\twithdrawal\\ttime\\tis\\tsuggested.\\tFor further\\tinformation,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Acyclovir ay- sye \u0301kloe- veer Trade and other names: Zovirax and generic brands","contraindications":"Contraindications and Precautions Acetylcysteine may cause sensitization with prolonged topical administration. It may react with certain materials in nebulizing equipment. Avoid delivering via aerosol to the airways of cats because it might worsen clinical airway disease. Because acetylcysteine is hyperosmolar (2600 mOsmol/L), it must be diluted in sterile water prior to injection. Visually inspect for particulate matter and discoloration prior to injection. Drug Interactions Acetylcysteine acts to donate sulfhydryl groups and may facilitate drug conjugation.","indications":"Indications and Clinical Uses As a donator of the sulfhydryl group, it is used as an antidote for intoxications (e.g., acetaminophen toxicosis in cats). It acts to replenish glutathione in animals that have been intoxicated with drugs that have reactive metabolites. When treating poisoning, it is important that acetylcysteine be administered as soon as possible for optimum effectiveness. Acetylcysteine also has been used to prevent contrast medium\u2013induced nephropathy. Acetylcysteine has been used as a treatment of oxidative stress because it is a scavenger of hydroxyl radicals and hypochlorous acid. It also has been used to treat heavy metal toxicosis when administered with chelating agents. Acetylcysteine can reduce cerebral edema, but this has not produced any established clinical uses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Allergic reactions have been reported in people, which resemble anaphylactic reactions when it is given IV. These reactions manifest as skin reactions, bronchospasm, tachycardia, and hypotension. Vomiting has been observed in cats, but this also may be caused by the toxicant (acetaminophen). When delivered via aerosol to the airways of cats, it increases airway resistance and could worsen airway disease in cats.","notes":"Instructions for Use Available as an agent for decreasing viscosity of respiratory secretions, but most common use is as a treatment for intoxications, primarily for cats to treat acetaminophen toxicosis. When treating an intoxication, doses are listed here, but also consult a poison control center for specific guidelines. The doses used in cats (and listed in the dosing section) are extrapolated from dosages used in humans for treatment of intoxication. However, pharmacokinetics are different in cats (shorter half- life and faster clearance), and higher doses may be needed in severe cases. For\\ttreatment\\tof\\toxidative\\tstress,\\tconstant\\trate\\tinfusions\\t(CRIs)\\thave\\tbeen\\tused in\\twhich\\t50\\tmg/kg\\tis\\tdiluted\\t1:4\\tin\\tsaline\\tsolutions\\tand\\tadministered\\tIV\\tover\\tthe course of 1 hour. Alternatively, the injection can be administered IV as a loading dose (150 mg/kg) over 60 minutes followed by 50 mg/kg over the next 4 hours followed by 100 mg/kg over the next 16 hours (21- hour total treatment time). When administered by injection, the solution is hyperosmolar and must be diluted first. Diluent for dilution can include 0.45% NaCl, 5% dextrose, or sterile water. An effervescent tablet of acetylcysteine (Cetylev) also is available and used in people to decrease hepatic injury caused by high doses of acetaminophen. Patient Monitoring and Laboratory Tests When used to treat acetaminophen toxicity, monitor complete blood count (CBC) and liver enzyme concentrations. 10    Acyclovir Formulations \u2022\\t\\tAcetylcysteine\\tis\\tavailable\\tin\\ta\\t20%\\toral\\tsolution\\t(200\\tmg/mL). \u2022\\t\\tAcetylcysteine\\ttablets\\tare\\tlemon-\\tflavored\\teffervescent\\ttablets\\tfor\\toral administration. 500- mg and 2.5- g tablets. \u2022\\t\\tInjectable\\tsolution:\\t6\\tg\\tof\\tacetylcysteine\\tin\\t30-\\tmL\\tvials\\tfor\\tIV\\tuse\\t(200\\tmg/mL). Stability and Storage Acetylcysteine is unstable in air and easily oxidizes. It should be protected from light. Discard open vials after 96 hours. The normal color of the solution ranges from colorless to a slight pink or purple after the stopper is punctured. This color change does not affect the quality of the product. After dilution, the solution can be stored for 24 hours at room temperature. Discard unused portion if stored for longer.","original_category":"Mucolytic, antidote"},{"name":"Albuterol Sulfate","active_ingredient":"Albuterol Sulfate","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t20\u201350\\tmcg/kg\\tq6\u20138h\\tPO,\\tup\\tto\\ta\\tmaximum\\tof\\t100\\tmcg/kg\\tq6h. 18    Alendronate  Horses \u2022\\t\\tDeliver\\tsufficient\\tactuations\\tof\\tthe\\tmetered-dose\\tinhaler\\tto\\tadminister\\t360\\tmcg\\tper horse\u2014equivalent to 4 actuations of a 90-mcg human metered-dose inhaler. This dose can be administered up to four times daily. \u2022\\t\\tFoals:\\t0.01\u20130.02\\tmg/kg\\tq8\u201312h\\tPO. Regulatory Information Do not administer to animals intended for food. When\\ttreating\\thorses,\\tallow\\t48\\thours\\tor\\tlonger\\tfor\\turine\\tclearance\\tin\\tperformance animals that may be tested. RCI\\tClassification:\\t3 Alendronate ah- len \u0301droe- nate Trade and other names: Fosamax and generic","contraindications":"Contraindications and Precautions Avoid\\tuse\\tin\\tpregnant\\tanimals.\\tIM\\tor\\tSQ\\tinjections\\tcan\\tbe\\tpainful. Drug Interactions All beta- agonists will interact with and potentiate other drugs that act on beta- adrenergic receptors.","indications":"Indications and Clinical Uses Albuterol is indicated in a variety of airway diseases for bronchodilation. Except for equine use, doses are primarily derived from extrapolation of human doses. Efficacy studies for small animal use are not reported. Onset of action is 15\u201330 minutes, and duration\\tof\\taction\\tmay\\tbe\\tas\\tlong\\tas\\t8\\thours. Albuterol was previously available as a metered-dose inhaler for horses (Torpex) for treatment of airway disease. It provided immediate relief of bronchospasm and bronchoconstriction in horses. However, the equine formulation is no longer commercially available. The human formulations can be used as a substitute. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Excessive beta- adrenergic stimulation at high doses results in tachycardia and muscle tremors. Arrhythmias are possible with high doses. All beta 2 - agonists  will inhibit uterine contractions at the end of gestation in pregnant animals. High doses of beta 2 - agonists can lead to hypokalemia because they stimulate Na + - K + - ATPase and increase intracellular K + , while decreasing serum K + and producing hyperglycemia. Treatment consists of KCl supplement at a rate of 0.5 mEq/kg/h.","notes":"Instructions for Use Administration to horses requires an adaptor to facilitate a metered- dose inhaler. For\\tinjection,\\tdilute\\tsolution\\tto\\t0.01\\tmg/mL\\t(10\\tmcg/mL)\\tbefore\\tinjection\\tand further dilute to 50/50 with saline or 5% dextrose before injection. When used for bronchoconstriction, it is helpful for acute exacerbations, used intermittently, with other drugs (e.g., corticosteroids) administered for maintenance. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm in animals with cardiovascular disease. Monitor potassium concentrations for evidence of hypokalemia if high doses are administered. Monitor glucose for evidence of hyperglycemia. Formulations \u2022\\t\\tAlbuterol\\tis\\tavailable\\tin\\t2-\\t\\tand\\t4-\\tmg\\ttablets\\tand\\t2-\\tmg/5-\\t   mL\\tsyrup.\\tSolutions for\\tinhalation\\tare\\t0.83\\tand\\t5\\tmg/mL.\\tThe equine formulation contained 6.7 g of formulated albuterol sulfate in a pressurized aluminum canister. This formulation is no longer commercially available for horses. Human metered-dose inhalers\\tare\\tavailable\\tin\\tvarious\\tsizes\\tranging\\tfrom\\t6.7\\tto\\t18\\tg,\\twith\\t90\\tmcg\\tper actuation. Stability and Storage Store in well- closed containers and protected from light. Aqueous solutions are stable if kept at an acidic pH (2.2\u20135).","original_category":"Bronchodilator, beta- agonist"},{"name":"Alendronate","active_ingredient":"Alendronate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\u20131\\tmg/kg\\tq24h\\tPO. Cats \u2022\\t\\tTreatment\\tof\\tionized\\thypercalcemia:\\t5\u201320\\tmg\\tper\\tcat\\tPO\\tq7d.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Alfaxalone al- fax\u2032ah- lone Trade and other names: Alfaxan (previous name was alphaxalone)","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Alendronate, like other bisphosphonate drugs, is used in people to treat osteoporosis and treatment of hypercalcemia of malignancy. Most doses for animals have been extrapolated from people (10 mg per person per day, or 70 mg once per week) because no animal- specific studies have identified the optimum dose. In animals, alendronate is used to decrease calcium in conditions that cause hypercalcemia, such as hyperparathyroidism, cancer, and vitamin D toxicosis. It may be helpful for managing neoplastic complications associated with pathologic bone resorption. It also may provide pain relief in patients with pathologic bone disease. Most experimental work in dogs has been performed with pamidronate rather than alendronate. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No serious adverse effects have been identified; however, use in animals has been uncommon. In people, esophageal injury and erosion are important problems. A Alfaxalone 19","notes":"formulations in animals may not be effective. In dogs, half- life in plasma is short (1\u20132 hours), but there is prolonged persistence of the drug in bone, in which the half- life is 300 days. Instructions for Use When administering oral medication, ensure that the drug is not trapped in the esophagus\\tto\\tavoid\\tinjury\\tto\\tesophageal\\ttissue.\\tFood\\tsignificantly\\treduces\\toral absorption. Wait at least 30 minutes before feeding. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Formulations \u2022\\t\\tAlendronate\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t35-\\t  ,\\t40-\\t  ,\\tand\\t70-\\tmg\\ttablets\\tand\\t70\\tmg/75\\tmL oral solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antihypercalcemic"},{"name":"Allopurinol","active_ingredient":"Allopurinol","species":["Canine","Equine"],"dosage":"Dogs \u2022\\t\\tUrate\\turolith\\tprevention:\\t10\\tmg/kg\\tq8h\\tPO;\\tthen\\treduce\\tto\\t10\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tLeishmaniasis:\\t10\\tmg/kg\\tq12h\\tPO\\tfor\\tat\\tleast\\t4\\tmonths\\tand\\tas\\tlong\\tas\\t6\\tmonths. For\\tleishmaniasis,\\tsome\\tclinicians\\thave\\tused\\t15\\tmg/kg\\tq12h,\\tand\\tthen\\tif\\tthere\\tis\\ta response, have administered 7\u201310 mg/kg q12\u201324h PO.  Horses \u2022\\t\\t5\\tmg/kg\\tPO. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Alprazolam al- pray \u0301zoe- lam Trade and other names: Xanax, Niravam, and generic","contraindications":"Contraindications and Precautions No contraindications reported for animals. Drug Interactions Allopurinol may inhibit metabolism of certain drugs. Do not use with azathioprine because it interferes with xanthine oxidase, an important enzyme for metabolizing azathioprine, and enhances toxicity.","indications":"Indications and Clinical Uses Allopurinol is indicated to decrease formation of uric acid uroliths in at- risk animals. Allopurinol also is used to treat clinical signs associated with leishmaniasis. When used for leishmaniasis, it is administered with pentavalent antimonial compounds such as meglumine antimonite (Glutamine) or sodium stibogluconate (Pentosan). With chronic treatment, allopurinol produces progressive remission and improvement in clinical signs associated with leishmaniasis, which include decreasing the damaging effects of Leishmania on the animal\u2019s kidneys by decreasing proteinuria and preventing\\tdeterioration\\tof\\tglomerular\\tfiltration\\trate.\\tFor\\tthis\\tuse,\\tit\\tis\\tused\\tat\\t10 mg/kg oral q12h for 6 months or more in combination with meglumine antimoniate at\\ta\\tdosage\\tof\\t100\\tmg/kg\\tSQ\\tonce\\tdaily\\tfor\\t4\\tweeks.\\t(Meglumine\\tantimoniate\\tis\\tnot approved\\tin\\tthe\\tUnited\\tStates.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects Allopurinol may cause skin reactions (hypersensitivity). In dogs that were treated for leishmaniasis for several months, no adverse effects were reported.","notes":"Instructions for Use In people, allopurinol is used primarily for treating gout. In animals, it is used to decrease formation of uric acid uroliths and for treating signs associated with leishmaniasis. No single drug or combination is completely effective for treating leishmaniasis, but allopurinol improves skin lesions. Allopurinol is usually\\tadministered\\twith\\tother\\tdrugs\\tfor\\tleishmaniasis.\\tFor\\texample,\\tit\\thas\\tbeen administered with either amphotericin B or pentavalent antimonial compounds such as meglumine antimonite (Glutamine) or sodium stibogluconate (Pentosan). Patient Monitoring and Laboratory Tests Dose adjustments for treating leishmaniasis are based on monitoring clinical signs. Formulations \u2022\\t\\tAllopurinol\\tis\\tavailable\\tin\\t100-\\t\\tand\\t300-\\tmg\\ttablets. Stability and Storage Store in well- closed containers at room temperature. Allopurinol is stable for at least 60 days in compounded formulations. Maximum stability in solutions at pH of 3\u20133.4. A Alprazolam 23","original_category":"Anti- inflammatory"},{"name":"Amino Acid Solution","active_ingredient":"Amino Acid Solution","species":["Canine"],"dosage":"Dogs \u2022\\t\\t25\\tmL\\tof\\ta\\t10%\\tsolution\\t(diluted\\tappropriately)\\tinfused\\tIV\\tvia\\ta\\tcentral\\tvein. Administer\\tinfusion\\tover\\t6\u20138\\thours\\tand\\trepeat\\tat\\t7-\\t\\tto\\t10-\\tday\\tintervals.\\tSolutions without electrolytes are preferred for treating hepatocutaneous syndrome. \u2022\\t\\tNote\\tthat\\tthe\\thuman\\tdose\\tis\\tmuch\\thigher\\t(1\\tg/kg).  \u2022\\t\\tNo\\tdose\\treported. Regulatory Information There is no withdrawal time necessary for food animals. Aminopentamide ah- mee- noe- pent \u0301ah- mide Trade and other names: Centrine","contraindications":"Not specified in source","indications":"Indications and Clinical Uses In animals, amino acid solutions are infused to provide supplement, particularly for treatment of liver disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects A hyperosmolar state can be induced if the infusion is too aggressive. If neurologic signs appear, the infusion should be stopped. In patients with liver disease\\tor\\trenal\\tfailure,\\thepatic\\tencephalopathy\\tor\\tincreases\\tin\\tBUN\\tare\\tpossible.","notes":"Instructions for Use A 10% solution may be diluted in 5% dextrose solution for peripheral vein administration. Otherwise, it should be administered via a central vein. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. 32    Aminopentamide Formulations Travasol sterile solution available as 10% amino acid solution in 500 mL, 1000 mL, and 2000 mL containers, which have essential and nonessential amino acids. Stability and Storage Store at room temperature protected from light.","original_category":"Amino acid solution"},{"name":"Aminopentamide","active_ingredient":"Aminopentamide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.01\u20130.03\\tmg/kg\\tq8\u201312h\\tIM,\\tSQ,\\tor\\tPO. Cats \u2022\\t\\t0.1\\tmg/cat\\tq8\u201312h\\tIM,\\tSQ,\\tor\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Aminophylline am- in- off \u0301ih- lin Trade and other names: Generic brands","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Aminopentamide has been used to decrease GI motility and decrease GI secretions in animals. It also has been used to treat diarrhea, but long- term use for this purpose is not recommended.","side_effects":"Not specified in source","notes":"Instructions for Use Dosing guidelines based on manufacturer\u2019s recommendation. There have not been any well- controlled studies in animals to establish optimum use and doses. Patient Monitoring and Laboratory Tests Monitor for problems caused by intestinal stasis because of anticholinergic effect. Formulations \u2022\\t\\tAminopentamide\\tis\\tavailable\\tin\\t0.2-\\tmg\\ttablets\\tand\\t0.5-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. A Aminophylline 33","original_category":"Anticholinergic"},{"name":"Aminophylline","active_ingredient":"Aminophylline","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t10\\tmg/kg\\tq8h\\tIM\\tor\\tIV. Cats \u2022\\t\\t6.6\\tmg/kg\\tq12h\\tIM\\tor\\tIV.  Horses \u2022\\t\\tTreatment\\tof\\trecurrent\\tairway\\tobstructions:\\t12\\tmg/kg\\tinitial\\tdose\\tfollowed\\tby 5 mg/kg q12h. Aminophylline administered IV to horses has caused transient excitement and restlessness. Give IV administration slowly. Cattle \u2022\\t\\t10\\tmg/kg\\tq8h\\tIV\\tor\\t23\\tmg/kg\\tPO,\\tadministered\\tonce\\tas\\ta\\tsingle\\tdose. Regulatory Information Cattle:\\tNo\\twithdrawal\\ttimes\\thave\\tbeen\\testablished\\tfor\\tfood\\tanimals. For\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat www.FARAD.org. RCI\\tClassification:\\t3 Drug Interactions Use\\tcautiously\\twith\\tother\\tPDE\\tinhibitors\\tsuch\\tas\\tsildenafil\\t(Viagra)\\tand pimobendan. Many drugs inhibit the metabolism of theophylline and potentially increase concentrations (e.g., cimetidine, erythromycin, fluoroquinolones, and propranolol). Some drugs decrease concentrations by increasing metabolism (e.g., phenobarbital and rifampin). A Amiodarone Hydrochloride 35 Amiodarone Hydrochloride ah- mee- oe \u0301dah- rone Trade and other names: Cordarone","contraindications":"Contraindications and Precautions Although adverse effects appear more common in people than small animals, use cautiously\\tin\\t animals\\twith\\t  cardiac\\t    arrhythmias.\\tUse\\t  cautiously\\tin\\t animals\\tprone\\t   to seizures. Horses may become excited from IV administration.","indications":"Indications and Clinical Uses Aminophylline is indicated for control of reversible airway constriction, to prevent bronchoconstriction, and as an adjunct with other respiratory disease treatment. The uses are similar to the indications for theophylline because it is a salt form of theophylline. It is used for inflammatory airway disease in cats (feline asthma), dogs, and horses. In dogs, the uses include collapsing trachea, bronchitis, and other airway diseases. It has not been effective for respiratory diseases in cattle. The oral forms have mostly been discontinued, and only the injection forms remain.\\tFor\\toral\\tadministration,\\ttheophylline\\tshould\\tbe\\tused.\\tConsult\\tthe Theophylline section for more information on dosing. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Aminophylline causes excitement and possible cardiac side effects with high concentrations. Cardiac adverse effects include tachycardia and arrhythmias. GI adverse effects include nausea, vomiting, and diarrhea. CNS adverse effects include excitement, tremors, and seizures.","notes":"Instructions for Use Therapeutic drug monitoring of theophylline is recommended for accurate dosing during chronic therapy. When dosing with salts or other formulations of theophylline, adjust dose for the amount of the parent drug. The oral forms have been\\tdiscontinued,\\tand\\tthe\\tdosing\\tlisted\\tapplies\\tto\\tinjection\\tformulation.\\tFor\\toral administration, use theophylline. Patient Monitoring and Laboratory Tests Plasma concentrations of theophylline should be monitored in patients receiving therapy with aminophylline. Targeted plasma concentrations range from 10 to 20 mcg/mL, but clinical effects may occur as low as 5 mcg/mL. Formulations \u2022\\t\\tAminophylline\\tis\\tavailable\\tin\\t25-\\tmg/mL\\tinjection.\\tA\\tdose\\tof\\t25\\tmg/mL\\tof anhydrous aminophylline is equivalent to 19.7 mg of anhydrous theophylline per milliliter. Oral forms have been discontinued; for oral administration, use theophylline instead. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded oral formulations have been stable for 60 days.","original_category":"Bronchodilator"},{"name":"Amitriptyline Hydrochloride","active_ingredient":"Amitriptyline Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1\u20132\\tmg/kg\\tq12\u201324h\\tPO. 40    Amlodipine Besylate Cats \u2022\\t\\t2\u20134\\tmg\\tper\\tcat/day\\tPO\\t(0.5\u20131.0\\tmg/kg\\tPO\\tper\\tday).\\tThe\\tdose\\tfor\\tcats\\tmay\\tbe divided into 12- hour intervals. \u2022\\t\\tIdiopathic\\tcystitis:\\t2\\tmg/kg/day\\tPO\\tor\\ta\\trange\\tof\\t2.5\u20137.5\\tmg/cat/day.\\t(This indication is controversial.)  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t2 Amlodipine Besylate am- loe \u0301dih- peen  bess \u0301ih- late Trade and other names: Norvasc","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tpatients\\twith\\theart\\tdisease. Drug Interactions Do not use with other behavior modification drugs, such as serotonin reuptake inhibitors. Do not use with MAOIs.","indications":"Indications and Clinical Uses Like other TCAs, amitriptyline is used in animals to treat a variety of behavioral disorders (e.g., anxiety). However, there are few studies documenting efficacy in animals,\\tand\\tmuch\\tof\\tthe\\tuse\\tis\\tbased\\ton\\tanecdotal\\tevidence.\\tFor\\ttreatment\\tof\\tsome disorders, such as obsessive- compulsive disorder (1 mg/kg q12h up to 2 mg/kg), it A was\\tnot\\tas\\teffective\\tin\\tanimals\\tas\\tclomipramine.\\tFor\\ttreatment\\tof\\taggressive\\tbehavior in dogs (2 mg/kg q12h), there was no difference between amitriptyline and placebo. Amitriptyline has been used in cats for chronic idiopathic cystitis, a condition that is not well understood. However, when used for short- term treatment of idiopathic cystitis (10 mg per cat q24h) it was not effective. In another study, at 5 mg/cat per day for 7 days (0.55\u20131.2 mg/kg), there was no difference on recovery from hematuria and pollakiuria between amitriptyline and placebo, leading to a conclusion that short- term treatment is not helpful. Amitriptyline, like other antidepressants, have been considered for treatment of chronic pain in animals, especially pain that may be maladaptive, or neuropathic in origin. Despite some use of this drug for treatment in people, no studies have established efficacy of amitriptyline in animals for this purpose. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Amitriptyline has a bitter taste and is difficult to administer orally. Multiple side effects are associated with TCAs, such as antimuscarinic effects (dry mouth and rapid heart rate) and antihistamine effects (sedation). High doses can produce life- threatening cardiotoxicity. In cats, reduced grooming, weight gain, and sedation are possible.","notes":"Instructions for Use Doses are primarily based on empiricism. There are no controlled efficacy trials available for animals. There is evidence for success treating idiopathic cystitis in cats, but more recent studies have been less supportive. Amitriptyline was not effective for treatment of aggressive behavior in dogs, compared with behavior modification alone, and other anti- anxiety drugs for dogs should be considered instead (e.g., fluoxetine, clomipramine). Amitriptyline applied transdermally is not systemically absorbed in cats. Patient Monitoring and Laboratory Tests Monitor patient\u2019s cardiovascular status during therapy, such as heart rate and rhythm. Like other TCAs, amitriptyline may decrease total T 4 and free T 4 concentrations in dogs. Formulations \u2022\\t\\tAmitriptyline\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\t50-\\t  ,\\t75-\\t  ,\\t100-\\t   ,\\tand\\t150-\\tmg\\ttablets. \u2022\\t\\tThe\\tinjectable\\tformulation\\tis\\tno\\tlonger\\tmarketed\\tin\\tthe\\tUnited\\tStates. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Behavior modification, tricyclic antidepressant"},{"name":"Amlodipine Besylate","active_ingredient":"Amlodipine Besylate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.5\\tmg/dog\\tor\\t0.1\u20130.5\\tmg/kg\\tq24h\\tPO.\\tThe\\thigher\\tdose\\tof\\t0.5\\tmg/kg\\tmay\\tbe needed in refractory cases to reduce blood pressure. Cats \u2022\\t\\t0.625\\tmg/cat\\tinitially\\tq24h\\tPO\\tand\\tincrease\\tif\\tneeded\\tto\\t1.25\\tmg/cat.\\tThe\\tdose of 0.625 mg is one eighth of a 5- mg human tablet. The average recommended dose\\tfor\\tmost\\tcats\\tis\\t0.18\\tmg/kg\\tonce\\tdaily\\tfor\\thypertension.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Ammonium Chloride ah- moe \u0301nee- um  klor \u0301ide Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tpoor\\tcardiac\\treserve\\tand\\tthat\\tare\\tprone\\tto hypotension. Do not use in dehydrated animals. Drug Interactions Use\\tcautiously\\twith\\tother\\tvasodilators.\\tDrug\\tinteractions\\tare\\tpossible\\tfrom concurrent use with phenylpropanolamine, theophylline, and beta- agonists. Concurrent use with ACE inhibitors may increase the risk of hypotension and decreased glomerular pressure.","indications":"Indications and Clinical Uses In both dogs and cats, amlodipine is effective for lowering systemic blood pressure. Therefore, it is used to treat systemic hypertension (high blood pressure). Amlodipine has been considered the drug of choice for many years by clinicians for treating hypertension in cats. Hypertension in cats has been defined as systolic blood pressure greater than 190 mm Hg and diastolic pressure greater than 120 mm Hg. By comparison, angiotensin- converting enzyme (ACE) inhibitors are less effective in cats, and they respond better to amlodipine than to ACE inhibitors. Amlodipine reduces blood pressure in hypertensive cats and can reduce proteinuria but may not improve survival in cats with hypertensive kidney disease. Beta blockers may be added to therapy for cats (e.g., atenolol) to control the heart rate in hypertensive and hyperthyroid cats, but beta blockers do not have a direct anti- hypertensive effect in cats. Although amlodipine has traditionally been considered the anti- hypertensive drug of choice for cats, recently, the angiotensin II blocker telmisartan has become a preferred agent because of proof of efficacy and available veterinary formulations (see Telmisartan for more information). A Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effect is hypotension. In dogs and cats, gingival hyperplasia has been observed, which may be caused by an up- regulation of circulating androgens or inhibition of transglutaminase. Other mechanisms may be involved but are speculative. Gingival hyperplasia usually resolves after discontinuation of the medication and replacement with another drug (e.g., hydralazine or telmisartan). In both dogs and cats, amlodipine may activate the renin\u2013angiotensin\u2013 aldosterone system (RAAS). When this occurs, ACE inhibitors may be somewhat effective in reducing activation of RAAS, but addition of this medication also may increase risk of hypotension and may decrease renal glomerular pressure. Less common adverse reactions include lethargy, decreased appetite, azotemia, mild hypokalemia, and weight loss. Reflex tachycardia can occur with excessive decrease in blood pressure. Amlodipine is a calcium- channel blocker, and although the action is more specific for vascular smooth muscle, it may depress the heart in some patients. Therefore, use carefully in patients with heart block or compromised cardiac contractility. For\\ttreatment\\tof\\ta\\ttoxic\\toverdose,\\tadminister\\tcalcium\\t(e.g.,\\tcalcium\\tgluconate) and vasopressors.","notes":"Instructions for Use In cats, efficacy has been established at 0.625 mg/cat once daily. If cats are large size (greater than 4.5 kg) or refractory, increase dose to 1.25 mg/cat q24h PO. In some cats, addition of a beta blocker to slow heart rate may be indicated. The goal of treatment is to decrease systolic pressure to less than 150/90 (systolic/diastolic). See the Patient Monitoring and Laboratory Tests section. Patient Monitoring and Laboratory Tests Monitoring the patient\u2019s blood pressure is essential to proper treatment. Cats with high blood pressures of systolic 160\u2013190 mm Hg and diastolic 100\u2013120 mm Hg should be considered at risk of clinical effects from hypertension. When using amlodipine, the target blood pressure should be less than 160 mm Hg. If this is not achieved, increase the dose to 1.25 mg per cat, but maximum dose per cat should not exceed 2.5 mg per cat. Formulations \u2022\\t\\tAmlodipine\\tis\\tavailable\\tin\\t2.5-\\t,\\t5-\\t ,\\tand\\t10-\\tmg\\ttablets.\\t(Tablets\\tare\\tdifficult\\tto\\tsplit for small animals.) 42    Ammonium Chloride Stability and Storage Amlodipine is an unstable drug, and potency and stability are not assured if the original formulation is disrupted or compounded. Store in a tightly sealed container and protect from light.","original_category":"Calcium- channel blocker"},{"name":"Ammonium Chloride","active_ingredient":"Ammonium Chloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t100\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t800\\tmg/cat\\tor\\t20\\tmg/kg\\t(approximately\\tone\\tthird\\tto\\tone\\tquarter\\tteaspoon) mixed with food daily.  Horses \u2022\\t\\tAcidifier:\\t100\u2013250\\tmg/kg\\tq24h\\tPO. Regulatory Information No regulatory information is available. It is not expected to pose a residue risk, and no withdrawal is recommended for food animals. Amoxicillin ah- moks- ih- sill \u0301in Trade and other names: Amoxicillin: Amoxi- Tabs, Amoxi- Drops, Amoxi- Inject, Robamox- V, Biomox, and other brands. Amoxil, Trimox, Wymox, Polymox (human preparation), and amoxicillin trihydrate","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tsystemic\\tacidemia.\\tUse\\tcautiously\\tin\\tpatients\\twith kidney disease. It may be unpalatable when added to some animals\u2019 food. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Compounds containing ammonium are administered to patients to acidify the urine, primarily\\tto\\tmanage\\tcystic\\tcalculi\\tor\\tchronic\\turinary\\ttract\\tinfections\\t(UTIs). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ammonium chloride has a bitter taste when added to food. It may cause acidemia in some patients if administered at high doses.","notes":"Instructions for Use Doses are designed to maximize urine acidifying effect. A Amoxicillin 43 Patient Monitoring and Laboratory Tests Monitor patient\u2019s acid\u2013base status. Formulations \u2022\\t\\tAmmonium\\tis\\tavailable\\tas\\tcrystals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Acidifier"},{"name":"Apomorphine Hydrochloride","active_ingredient":"Apomorphine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats (Less effective in cats.) \u2022\\t\\t0.03\u20130.05\\tmg/kg\\tIM. \u2022\\t\\t0.1\\tmg/kg\\tSQ. A Aprepitant 57 \u2022\\t\\tDissolve\\t6-\\tmg\\ttablet\\tin\\t1\u20132\\tmL\\tof\\t0.9%\\tsaline\\tsolution\\tand\\tinstill\\tdirectly\\tin\\tthe conjunctiva of the eye. After animal vomits, the conjunctiva may be rinsed of residual drug with an eye wash solution.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals\\tbecause\\tthey\\ttypically\\tdo\\tnot vomit. Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t1 Aprepitant ap- reh \u0301pih- tant Trade and other names: Emend","contraindications":"Contraindications and Precautions Apomorphine also may decrease vomiting stimulus in vomiting center; therefore, if the initial dose is not effective, emetic effects may be blocked during later attempts\\tto\\tinduce\\tvomiting.\\tUse\\tcautiously\\tin\\tcats\\tthat\\tmay\\tbe\\tsensitive\\tto opiates. (Xylazine is a more effective emetic agent in cats.) Drug Interactions No drug interactions are reported in animals. However, some drugs diminish the emetic action of apomorphine (e.g., acepromazine, atropine, and other antiemetics).","indications":"Indications and Clinical Uses Apomorphine is indicated for inducing emesis in animals that have ingested toxic agents.\\tAfter\\tSQ\\tadministration,\\tthe\\tonset\\tof\\teffect\\tis\\t10\\tminutes\\tor\\tshorter.\\tIt\\tis promptly effective for inducing vomiting in dogs but less so in cats. Apomorphine also is absorbed from mucosal administration after applying to the conjunctiva of the eye. Xylazine often is a more reliable emetic in cats. In dogs, 3% hydrogen peroxide (2.2 mL/kg) was equally effective for inducing emesis. (The dose of 3% hydrogen peroxide is typically 2.2 mL/kg or 1 mL/lb.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects Apomorphine produces emesis before serious adverse effects can occur, but at higher doses (0.1 mg/kg), sedation can occur, which can mask the signs of some toxic agents. The hydrochloride salt of this formulation has a pH of 3\u20134 and can be irritating to the ocular conjunctival membranes. At high doses (1 mg/kg), excitement can occur, possibly via stimulation of dopamine (D 1 and D 2 ) receptors.","notes":"Instructions for Use Apomorphine should be available in most emergency practices for prompt treatment of poisoning. If not, consult local poison center or pharmacist for availability. Apomorphine\\tcan\\t  be\\t administered\\tIM,\\t  SQ,\\t  or\\t to\\t the\\t  mucosa\\t(e.g.,\\t   in\\t the\\t  conjunctival sac of the eye). It should not be administered IV because the rapid diffusion to the CNS may block the emetic effects. In dogs, vomiting should occur within 3\u201310 minutes after administration. Limit administration to once. Consider other agent such as xylazine or dexmedetomidine to induce vomiting in cats. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. If used to induce vomiting from a toxicant, monitor for signs of toxicity because vomiting is able to eliminate less than half of the ingested toxicant. Formulations \u2022\\t\\tApomorphine\\tis\\tavailable\\tin\\t6-\\tmg\\ttablets\\tthat\\tcan\\tbe\\thydrolyzed\\tprior\\tto\\tuse\\tor is available in a 10- mg/mL concentration in a 2- mL ampule or 3- mL preloaded syringes. \u2022\\t\\tIf\\tapomorphine\\tis\\tnot\\tavailable\\tfrom\\tcommercial\\tsources,\\tit\\thas\\tbeen\\tprepared by compounding pharmacists. One approach is to mix 20 mg apomorphine in a sterile\\tvial\\twith\\t4.4\\tmL\\tof\\tsterile\\twater\\tto\\tmake\\ta\\tsolution\\tof\\t5\\tmg/mL.\\tFrom\\tthis solution, drops may be added to the eye to induce vomiting. Stability and Storage Store in a tightly sealed container at room temperature, protected from light. Solutions decompose when exposed to air and light. A green color indicates decomposition. One of the compounded formulations prepared in an aqueous solution (3 mg/mL) was stable at room temperature for 6 months after compounding.","original_category":"Emetic"},{"name":"Ascorbic Acid","active_ingredient":"Ascorbic Acid","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tDietary\\tsupplementation:\\t100\u2013500\\tmg/animal/day\\tPO. \u2022\\t\\tUrinary\\tacidification:\\t100\\tmg/animal\\tq8h\\tPO.\\tInjectable\\tdose\\tranges\\tfrom\\t1\\tto\\t10 mL (250 mg/mL), depending on size of animal, IM or IV. \u2022\\t\\tFor\\ttreatment\\tof\\toxidative\\tstress:\\tDogs:\\t500\u20131000\\tmg/dog\\tq24h,\\tPO;\\tcats:\\t125 mg/cat, PO, q12h. Guinea pigs \u2022\\t\\t16\\tmg/kg\\ttwice\\tweekly\\tIM\\tto\\ttreat\\tvitamin\\tdeficiency.  \u2022\\t\\tVitamin\\tC\\tsupplementation:\\t1\u201310\\tmL\\tIM\\tor\\tIV.\\tRepeat\\tdaily\\tas\\tneeded. \u2022\\t\\t1\u20132\\tg\\tq24h\\tPO. Regulatory Information Withdrawal\\ttime:\\t0\\tdays\\tfor\\tall\\tanimals\\tintended\\tfor\\tfood. Asparaginase  (L- Asparaginase) ah- spar \u0301a- jin- aze Trade and other names: Elspar and Asparaginase","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Ascorbic acid is used to treat vitamin C deficiency and occasionally used as a urine acidifier. Dogs are capable of synthesizing vitamin C, but it is used as a supplement to improve health and performance. There are insufficient data to show that ascorbic acid is effective for preventing cancer, treating infectious diseases, or preventing cardiovascular disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. High doses may increase the risk of oxalate urolith formation. A Asparaginase  (L- Asparaginase) 59","notes":"Instructions for Use Not necessary to supplement in animals with well- balanced diets. However, high doses have been used as adjunctive treatment for some diseases. Evidence shows that at doses of 15 and 50 mg/kg in dogs, the increase in absorption is nonlinear. Therefore, higher doses may not produce proportionately higher blood levels to the lower doses. Comparison of crystalline ascorbic acid and the vitamin C product, Ester- C, produced similar levels of vitamin C in the plasma. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tAscorbic\\tacid\\tis\\tavailable\\tin\\ttablets\\tof\\tvarious\\tsizes\\tand\\tinjections.\\tTypically,\\tthe injection form is 250 mg sodium ascorbate/mL. The formulation of Ester- C appears to be absorbed similarly to the crystalline form of vitamin C. Stability and Storage Light sensitive. It oxidizes, darkens, and decomposes when exposed to air and light. The injectable solution in a vial may build up pressure with storage, which may be decreased by storing in a refrigerator. Otherwise, store at room temperature protected from light.","original_category":"Vitamin"},{"name":"Aspirin","active_ingredient":"Aspirin","species":["Canine","Feline","Bovine","Equine"],"dosage":"Mild Analgesia Dogs \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t10\\tmg/kg\\tq48h\\tPO. Anti- inflammatory Dogs \u2022\\t\\t20\u201325\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t10\u201320\\tmg/kg\\tq48h\\tPO. Antiplatelet Dogs \u2022\\t\\tTypical\\tdoses\\tare\\tin\\tthe\\trange\\tof\\t1\u20135\\tmg/kg\\tbut\\thave\\tbeen\\tas\\thigh\\tas\\t5\u201310\\tmg/ kg\\tq24\u201348h\\tPO\\tto\\tobtain\\ta\\tgreater\\tresponse.\\t(Convincing\\tevidence\\tof\\ta\\tconsistent antiplatelet clinical benefit in dogs is lacking.) Cats \u2022\\t\\t80\\tmg/cat\\tq48h\\tPO.\\tDoses\\thave\\tranged\\tfrom\\t5\\tmg\\tper\\tcat\\tq72h\\tto\\t80\\tmg\\tper\\tcat (one tablet) q72h. No clinical studies have documented efficacy from either dose.  Ruminants \u2022\\t\\t100\\tmg/kg\\tq12h\\tPO.\\tDoses\\tas\\thigh\\tas\\t333\\tmg/kg\\thave\\tbeen\\tadministered\\tto cattle. Swine \u2022\\t\\t10\\tmg/kg\\tq6\u20138h\\tPO. Horses \u2022\\t\\t25\u201350\\tmg/kg\\tq12h\\tPO\\t(up\\tto\\t100\\tmg/kg\\tPO\\tper\\tday). Regulatory Information Extralabel\\tuse:\\tAlthough\\tconsidered\\textralabel\\tin\\tanimals\\tintended\\tfor\\tfood,\\tconsider a withdrawal time of at least 1 day for meat and 24 hours for milk. RCI\\tClassification:\\t4 64    Atenolol Atenolol ah- ten \u0301oe- lole Trade and other names: Tenormin","contraindications":"Contraindications and Precautions Cats\\tare\\tsusceptible\\tto\\tsalicylate\\tintoxication\\tbecause\\tof\\tslow\\tclearance.\\tUse cautiously in patients with coagulopathies because of platelet inhibition (e.g., von Willebrand disease). Do not administer to animals prone to GI ulcers. Drug Interactions Some animals are more susceptible to the gastric effects of aspirin if corticosteroids are included in the protocol. Do not administer with other drugs that may cause coagulopathy and increase risk of bleeding problems.","indications":"Indications and Clinical Uses Aspirin is used as an analgesic, anti- inflammatory, and antiplatelet drug. Aspirin has a long history of use for treating pain and inflammation, especially associated with osteoarthritis. Although it may be effective in animals, other agents specifically approved for animals are much more commonly used nowadays for osteoarthritis and other painful conditions. At low doses, aspirin is a more specific COX- 1 selective inhibitor and antiplatelet drug than other NSAIDs. Therefore, low doses have been used in animals to inhibit platelets and prevent thromboemboli formation. Inhibition of platelets is justified for some diseases because as platelets become hyper- reactive, they can release serotonin and other mediators that may exacerbate vascular diseases and produce blood clots. Although these low doses of aspirin are often used for antiplatelet therapy, aspirin does not provide complete inhibition of platelet stimulation. Low doses (e.g., 1\u20135 mg/kg) produce inconsistent platelet inhibition in dogs and cats. Some animals are refractory (aspirin resistance). Addition of other antiplatelet drugs such as clopidogrel (Plavix) provides more effective inhibition. Aspirin has been used to prevent complications from heartworm disease (thromboemboli). However, there is no convincing evidence that there is a clinical benefit from this treatment. Some evidence indicates that aspirin may be contraindicated in heartworm disease. In cats, exposure of feline platelets in vitro to aspirin can have an inhibitory effect. Platelets collected from cats ex vivo after treatment with aspirin (5 mg/kg) had decreased TXA2 production, but platelet aggregation was not affected. Although aspirin has been available for many years, it is not registered by the Food\\tand\\tDrug\\tAdministration\\t(FDA)\\tfor\\tuse\\tin\\tany\\tspecies.\\tThere\\tare\\tno\\tpublished controlled\\tstudies\\tto\\tdocument\\tefficacy.\\tUse\\tof\\taspirin\\tin\\tanimals\\tis\\tprimarily\\tbased\\ton empiricism rather than on published data. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Narrow therapeutic index. High doses frequently cause vomiting. Other GI effects can include ulceration and bleeding. Aspirin may inhibit platelets and increases risk of bleeding.","notes":"Instructions for Use Analgesic and anti- inflammatory doses have primarily been derived from empiricism. Antiplatelet doses are lower because of potent and prolonged effect of aspirin on platelets. The dosing section lists \u201cantiplatelet\u201d doses for aspirin in dogs and cats, but the efficacy of these doses has not been verified through clinical studies. Results from research animals have produced varied results. In some studies, 5\u201310 mg/kg was considered a consistent antiplatelet dose for dogs; in other studies, 1 mg/kg inhibited platelets in only one third of dogs; and in research dogs, doses as low as 0.5 mg/kg q12h impaired platelet aggregation. Aspirin is only available in oral form. Because it is a weak acid, it is ordinarily absorbed best in the acidic environment of the upper GI tract; however, considerable absorption also takes place farther in the intestine. In dogs, enteric- coated aspirin reduces gastric irritation, but absorption from this form is erratic and often incomplete. Buffering does not affect absorption but may protect the stomach from injury when high doses are administered. Buffering has less of a beneficial effect when low doses are administered and is not expected to protect the stomach from the more serious effects of GI ulceration, bleeding, and perforations. A Patient Monitoring and Laboratory Tests Monitor patients for signs of gastric upset, gastroduodenal ulcers, and bleeding. Effective\\tplasma\\tconcentrations:\\t20\u201350\\tmcg/mL\\tfor\\tpain\\tand\\tfever\\tand\\t150\u2013200 mcg/mL for inflammation. Aspirin decreased thyroid concentrations (T 4 , T 3 , and free T 4 ) in dogs after 2\u20134 weeks of dosing but returned to normal in 14 days. Formulations \u2022\\t\\tAspirin\\tis\\tavailable\\tin\\t81-\\tmg\\t(children\u2019s\\taspirin)\\tand\\t325-\\tmg\\ttablets. \u2022\\t\\tFor\\tlarge\\tanimals,\\taspirin\\tis\\tavailable\\tin\\ta\\t240-\\tgrain\\tbolus\\t(14,400\\tmg)\\tand\\t3.9-\\t, 15.6- , and 31.2- g tablets. \u2022\\t\\tExtended-\\trelease\\tform\\tfor\\tantiplatelet\\ttreatment\\t(Durlaza):\\t16.2\\tmg\\tcapsule.\\t(Do not open or break capsule.) Stability and Storage Store in a tightly sealed container at room temperature. After exposure to moisture, it decomposes to acetic acid and salicylic acid. If stored at pH 7 at 25\xb0C, it has a half- life of 52 hours.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Atenolol","active_ingredient":"Atenolol","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t6.25\u201312.5\\tmg/dog\\tq12\u201324h\\t(or\\t0.25\u20131.0\\tmg/kg\\tq12\u201324h)\\tPO.\\tStart\\twith\\t1 mg/kg PO q12h initially and lower dose as needed to maintain optimum heart rate. However, doses in dogs also have been increased to 3 mg/kg q12\u201324h PO for some conditions. Cats \u2022\\t\\t1\u20132\\tmg/kg\\tq12h\\tPO.\\tHowever,\\tbecause\\tof\\ttablet\\tsize,\\ta\\tcommon\\tdosage\\tis 6.25\u201312.5 mg/cat q12\u201324h PO (one quarter or one half tablet).  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t3 Atipamezole Hydrochloride ah- tih- pam \u0301eh- zole  hye- droe- klor \u0301ide Trade and other names: Antisedan","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tairway\\tdisease,\\tmyocardial\\tfailure,\\tand\\tcardiac conduction\\tdisturbances.\\tUse\\tcautiously\\tin\\tanimals\\twith\\tlow\\tcardiac\\treserve. Drug Interactions Use\\tcautiously\\twith\\tother\\tdrugs\\tthat\\tmay\\tdecrease\\tcardiac\\tcontraction\\tor\\theart rate.","indications":"Indications and Clinical Uses Atenolol is one of the most commonly administered beta blockers for dogs and cats. Atenolol is used primarily as an antiarrhythmic or for other cardiovascular conditions in which it is needed to slow the sinus rate. In cats, this drug is commonly used to treat heart disease from cardiomyopathy or hyperthyroidism, but it should not be used as monotherapy to treat primary hypertension. Although it is commonly administered to cats with hypertrophic cardiomyopathy to improve clinical signs, it did not slow progression of the disease. In dogs, it has been used for congenital cardiac conditions such as subaortic stenosis and pulmonary stenosis (0.5\u20131 mg/kg q12h). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Bradycardia and heart block are possible. Atenolol may produce bronchospasm in sensitive patients.","notes":"Instructions for Use Atenolol is reported to be less affected by changes in hepatic metabolism than other\\tbeta\\tblockers.\\tAlthough\\tit\\tis\\tnot\\tan\\tFDA-\\tapproved\\tdrug\\tfor\\tdogs\\tand\\tcats, dosing guidelines are based on published reports and experience of experts. In cats, amlodipine (calcium- channel blocker) may be used with atenolol to control hypertension. When administered as a transdermal gel to cats, it produced inconsistent and lower plasma concentrations compared to oral administration. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and rhythm. Although plasma and serum concentrations are not typically monitored, a concentration above 0.26 mcg/mL has been proposed as a target threshold for effective adrenergic beta- receptor blockade. A Atipamezole Hydrochloride 65 Formulations \u2022\\t\\tAtenolol\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t100-\\tmg\\ttablets.\\t(Tablets\\tcan\\tbe\\tsplit\\tfor\\tsmall animals.) Stability and Storage Store in a tightly sealed container at room temperature. Studies using a compounded flavored oral paste and oral suspension formulation for cats produced similar beta- adrenergic blocking effects as a commercial tablet (2.5 mg/kg). Stability studies indicate that extemporaneously prepared oral suspensions are stable for 14 days, and some compounded oral formulations have been stable for 60 days. Consult compounding pharmacist for beyond- use- day of prepared compounded formulations. Atenolol is water soluble and can be mixed with other water-based vehicles.","original_category":"Beta- antagonist"},{"name":"Atracurium Besylate","active_ingredient":"Atracurium Besylate","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.2\\tmg/kg\\tIV\\tinitially;\\tthen\\t0.15\\tmg/kg\\tq30min. \u2022\\t\\tCRI:\\t0.3\u20130.5\\tmg/kg\\tIV\\tloading\\tdose\\tfollowed\\tby\\t4\u20139\\tmcg/kg/min.  Horses \u2022\\t\\t0.05\u20130.07\\tmg/kg\\tIV. Regulatory Information Do not administer to animals intended for food. Atropine Sulfate ah \u0301troe- peen  sul \u0301fate Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not use in patients unless it is possible to provide ventilation support. The action of neuromuscular- blocking agents may be antagonized by acetylcholinesterase inhibitors. Drug Interactions Gentamicin (and possibly other aminoglycosides) potentiates neuromuscular blockade (gentamicin acts at the presynaptic site to decrease release of acetylcholine). No other drug interactions are reported in animals.","indications":"Indications and Clinical Uses Atracurium is a paralytic agent used to paralyze skeletal muscle during surgery and mechanical ventilation. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Atracurium produces respiratory depression and paralysis. Neuromuscular- blocking drugs have no effect on analgesia.","notes":"Instructions for Use Administer only in situations in which careful control of respiration is possible. Doses may need to be individualized for optimum effect. Do not mix with alkalinizing solutions or lactated Ringer\u2019s solution. Patient Monitoring and Laboratory Tests Monitoring of respiratory and cardiovascular indices is critical during use. If possible, monitor the oxygenation of the patient during use. Formulations \u2022\\t\\tAtracurium\\tis\\tavailable\\tin\\t10-\\tmg/mL\\tinjection. A Atropine Sulfate 69 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Muscle relaxant"},{"name":"Atropine Sulfate","active_ingredient":"Atropine Sulfate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.02\u20130.04\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tSQ\\t(complete\\tdose\\trange\\thas\\tbeen\\tfrom\\t0.01 mg/kg to 0.06 mg/kg, depending on the indication). \u2022\\t\\tSinus\\tbradycardia:\\t0.005\u20130.01\\tmg/kg,\\tbut\\tfor\\tuse\\tduring\\tcardiopulmonary resuscitation, up to 0.04 mg/kg. \u2022\\t\\tCardiac\\tarrest:\\t0.04\\tmg/kg\\tIV\\t(with\\tother\\tsupportive\\tmeasures). Cats \u2022\\t\\t0.02\u20130.04\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tSQ. Dogs \u2022\\t\\tFor\\torganophosphate\\tand\\tcarbamate\\ttoxicosis:\\t0.2\u20130.5\\tmg/kg\\tas\\tneeded,\\tIV,\\tIM, or\\tSQ. Cats \u2022\\t\\tFor\\torganophosphate\\tand\\tcarbamate\\ttoxicosis:\\t0.2\u20130.5\\tmg/kg\\tas\\tneeded,\\tIV,\\tIM, or\\tSQ.  Note that in large animals, atropine has a potent effect on inhibiting GI motility. Horses \u2022\\t\\tAntidote\\tto\\torganophosphates\\tor\\tcholinesterase\\tinhibitors:\\t0.02\u20130.04\\tmg/kg\\tIM or\\tSQ;\\trepeat\\tas\\tneeded. \u2022\\t\\tEquine\\tasthma\\tsyndrome\\tand\\trecurrent\\tairway\\tobstruction:\\t0.022\\tmg/kg,\\tonce, IV. Pigs \u2022\\t\\tAntidote\\tto\\torganophosphates\\tor\\tcholinesterase\\tinhibitors:\\t0.1\\tmg/kg\\tIV\\tfollowed by 0.4 mg/kg IM. \u2022\\t\\tAnesthesia\\tadjunct:\\t0.02\\tmg/kg\\tIV\\tor\\t0.04\\tmg/kg\\tIM. Ruminants \u2022\\t\\tAntidote\\tto\\torganophosphates\\tor\\tcholinesterase\\tinhibitors:\\t0.1\\tmg/kg\\tIV\\tfollowed by 0.4 mg/kg IM; repeat as needed. \u2022\\t\\tAnesthesia\\tadjunct\\tto\\tprevent\\tsalivation:\\t0.02\\tmg/kg\\tIV\\tor\\t0.04\\tmg/kg\\tIM. A Auranofin 71 Regulatory Information Withdrawal\\ttime:\\tNone\\testablished\\tin\\tthe\\tUnited\\tStates.\\tThe\\tmanufacturer\\tof\\tlarge animal products lists 0 days for milk and meat; however, it is listed as 3 days for milk and\\t14\\tdays\\tfor\\tmeat\\tin\\tthe\\tUnited\\tKingdom. RCI\\tClassification:\\t3 Auranofin or- an \u0301oe- fin Trade and other names: Ridaura","contraindications":"Contraindications and Precautions Do not use in patients with glaucoma, intestinal ileus, gastroparesis, or tachycardia.\\tUse\\thigh\\tdoses\\t(e.g.,\\t0.04\\tmg/kg)\\tcautiously\\tbecause\\tit\\tincreases oxygen demand. Drug Interactions Do not mix with alkaline solutions. Atropine antagonizes the effects of any cholinergic drugs administered (e.g., metoclopramide).","indications":"Indications and Clinical Uses Atropine is used primarily as an adjunct to anesthesia or other procedures to increase heart rate and decrease respiratory and GI secretions. Atropine is the drug of choice to overcome excess vagal stimulation associated with some clinical conditions. Atropine is used during cardiac arrest to overcome vagal influences. Atropine is also used as an antidote for organophosphate intoxication. In horses, atropine (single dose) may be used to relieve bronchoconstriction in horses with recurrent airway obstruction,\\talso\\tknown\\tas\\tequine\\tasthma\\tsyndrome.\\tFor\\tthis\\tuse,\\tonly\\ta\\tsingle\\tdose is recommended. N- butylscopolammonium bromide (Buscopan) also is used for this indication. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects include xerostomia, ileus, constipation, tachycardia, and urine retention.","notes":"Instructions for Use Atropine is used ordinarily as an adjunct with anesthesia or other procedures. Compared with lower doses, in dogs, 0.06 mg/kg was more effective than 0.02 mg/kg. Atropine may be used during cardiac resuscitation; however, high doses may cause sustained tachycardia and increased myocardial oxygen demand. During cardiac resuscitation, doses of 0.04 mg/kg IV may be used, but for treating sinus bradycardia, consider lower doses of 0.01 mg/kg. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and rhythm. Formulations \u2022\\t\\tAtropine\\tis\\tavailable\\tin\\t400-\\t,\\t500-\\t   ,\\tand\\t540-\\tmcg/mL\\tinjection\\tand\\t15-\\tmg/mL injection. Stability and Storage Store in a tightly sealed container at room temperature.","original_category":"Anticholinergic"},{"name":"Bethanechol Chloride","active_ingredient":"Bethanechol Chloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t5\u201315\\tmg\\tper\\tdog.\\t2.5\\tmg\\tper\\tdog\\tfor\\tsmall\\tdogs,\\t5\\tmg\\tper\\tdog\\tfor\\tmedium\\tdogs, and\\t15\\tmg\\tfor\\tlarge\\tdogs.\\tAll\\tdoses\\tadministered\\tq8h\\tPO.\\tThe\\tdose\\tcan\\tbe\\tinjected SQ, but oral administration is preferred. Cats \u2022\\t\\t1.25\u20135\\tmg/cat\\tq8h\\tPO.  Horses \u2022\\t\\t0.025\\tmg/kg\\tSQ,\\tonce. Cattle \u2022\\t\\t0.07\\tmg/kg\\tSQ,\\tonce. 84    Bisacodyl Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). However, the Food Animal Residue Avoidance Databank (FARAD) (1- 888- 873- 2723) recommends a 21- day withdrawal time for slaughter. RCI\\tClassification:\\t4 Bisacodyl biss- ah- koe\u2032dil Trade and other names: Dulcolax","contraindications":"Contraindications and Precautions Do not use in patients with suspected GI or urinary obstruction. Drug Interactions Anticholinergic drugs (e.g., atropine, scopolamine) antagonize the effects of bethanechol.","indications":"Indications and Clinical Uses Bethanechol is used in small animals to increase contraction of the urinary bladder, but efficacy has not been established in well- controlled studies. Adverse effects may preclude this use. In large animals, it may increase GI motility, but the efficacy for treating\\tGI\\tstasis\\tproblems\\tis\\tquestionable\\tand\\tnot\\trecommended. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses of cholinergic agonists increase motility of the GI tract and cause abdominal discomfort and diarrhea. Bethanechol can cause circulatory depression in sensitive animals.","notes":"Instructions for Use Administer injection SQ only. Doses are derived from extrapolation of human doses or via empiricism. There are no well- controlled efficacy studies available for veterinary species. Bethanechol is no longer available from commercial sources, but some veterinary compounding pharmacists may be able to supply veterinarians. Patient Monitoring and Laboratory Tests Monitor GI function. Formulations \u2022\\t\\tBethanechol\\thas\\tbeen\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t25-\\t  ,\\tand\\t50-\\tmg\\ttablets\\tand\\t5-\\tmg/ mL\\tinjection.\\t(Commercial\\tpreparations\\tare\\tno\\tlonger\\tavailable\\tbut\\tare\\tavailable through some compounding pharmacies.) Stability and Storage Store in a tightly sealed container at room temperature. Compounded oral suspensions prepared from tablets are not stable.","original_category":"Cholinergic"},{"name":"Bismuth Subsalicylate","active_ingredient":"Bismuth Subsalicylate","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20133\\tmL/kg/day\\t(in\\tdivided\\tdoses)\\tPO.  Calves \u2022\\t\\t30\\tmL\\tper\\tcalf,\\tq30min\\tfor\\t8\\tdoses\\tPO. Horses \u2022\\t\\t1\u20132\\tmL/kg\\tq6\u20138h\\tPO. Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). Because the salicylate component may be systemically absorbed, withdrawal times should be considered for the salicylate component (similar to aspirin). Bisoprolol Fumarate bis- oh\u2032- proe- lol Trade and other names: Zebeta","contraindications":"Contraindications and Precautions The salicylate component is absorbed systemically, and overuse should be avoided in animals that cannot tolerate salicylates, such as cats and animals allergic to aspirin. Drug Interactions No drug interactions are reported in animals. However, it may exacerbate effects of other NSAIDs administered to animals. The bismuth component may prevent oral absorption of some drugs. 86    Bisoprolol Fumarate","indications":"Indications and Clinical Uses Bismuth subsalicylate is used for symptomatic treatment of diarrhea in small and large animals. Efficacy has not been established for animals. However, in people, it has been shown effective for treating or preventing diarrhea caused by enterotoxigenic Escherichia coli. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\tare\\tuncommon.\\tOwners\\tshould\\tbe\\twarned\\tthat\\tbismuth\\twill discolor stools black.","notes":"Instructions for Use Bismuth\\tsubsalicylate\\tis\\tavailable\\tas\\tan\\tOTC\\tproduct.\\tDoses\\tare\\tderived\\tfrom extrapolation of human doses or via empiricism. There are no well- controlled efficacy studies available for veterinary species. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tBismuth\\tsubsalicylate\\tis\\tavailable\\tin\\toral\\tsuspension\\tin\\t262\\tmg/15\\tmL\\tor\\t525\\tmg/ mL\\tin\\textra-\\tstrength\\tformulation\\tand\\t262-\\tmg\\ttablets.\\tTwo\\ttablespoons\\t(30\\tmL) contain 270- mg salicylate. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidiarrheal"},{"name":"Bleomycin Sulfate","active_ingredient":"Bleomycin Sulfate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tUnits/kg,\\tIM\\tor\\tSQ, either once, or with other cancer protocols. \u2022\\t\\tAlternatively,\\tit\\tcan\\tbe\\tadministered\\tat\\ta\\tdosage\\tof\\t10\\tunits/m 2 IV or SQ for 3 days and then 10 units/m 2 weekly. (Maximum cumulative dose, 200 units/m 2 .) Cats \u2022\\t\\tNo\\tdose\\tis\\tavailable\\tfor\\tcats.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. Because it is an anticancer agent, do not administer to food- producing animals. Boldenone Undecylenate bole\u2032de- none  un- de- sil- en\u2032ate Trade and other names: Equipoise","contraindications":"Contraindications and Precautions Do not use in animals with suppressed bone marrow. Drug Interactions No drug interactions are reported in animals. It has been used with other anticancer agents, antihistamines, corticosteroids, and antiemetics.","indications":"Indications and Clinical Uses Bleomycin is used for treatment of various sarcomas and carcinomas. In people, it is used in multi- drug combinations for treatment of lymphoma and other forms of cancer. In dogs, it is usually used as a rescue agent for patients with lymphoma after they have already received other cancer treatment protocols. There are few clinical studies in animals to evaluate effectiveness. However, at a dose of 0.5 units/kg either IM or SQ,\\tthere\\twas\\ta\\tminimal\\tresponse\\tto\\ttreatment.\\tLow\\tresponse\\trate\\tmay\\tbe attributed to the selection of patients with advance stages of cancer. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include epithelial lesions (skin ulceration, ulceration of foot pads, and conjunctivitis), GI problems (anorexia, vomiting, diarrhea), elevation of liver enzymes, and kidney injury. Bleomycin causes local reaction at site of injection, pulmonary toxicity, fever, and chills in people.","notes":"Instructions for Use Injectable solution usually used in combination with other anticancer agents. Dilute\\tin\\t0.9%\\tsodium\\tchloride\\tprior\\tto\\tadministration.\\tAfter\\tdilution,\\tit\\tmay\\tbe administered either SQ or IM. Consult anticancer protocols for details regarding use. Patient Monitoring and Laboratory Tests Monitor CBC during treatment. If suppression of blood cells is extreme, withhold the next dose or reduce the dose. Formulations \u2022\\t\\tBleomycin\\tis\\tavailable\\tin\\t15-\\t\\tand\\t30-\\tunit\\tvials\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Refrigerate vials after opening. Stability of compounded formulations has not been evaluated. B Boldenone Undecylenate 89","original_category":"Anticancer agent"},{"name":"Bromocriptine Mesylate","active_ingredient":"Bromocriptine Mesylate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tTermination\\tof\\tpregnancy:\\t15\\tmcg/kg\\tq12h\\tPO\\ton\\tday\\t1,\\t20\\tmcg/kg\\t12h\\tPO\\ton days\\t2\\tand\\t3,\\tand\\t30\\tmcg/kg\\tq12h\\tPO\\tthereafter\\tfor\\tan\\taverage\\tof\\t4\u20135\\tdays.\\tFor treatment success, it should be administered in combination with prostaglandin F 2 alpha. \u2022\\t\\tReducing\\tmilk\\tproduction:\\t10\u2013100\\tmcg/kg\\tq12h\\tfor\\t10\u201314\\tdays. \u2022\\t\\tTreating\\tpseudopregnancy\\tin\\tbitches:\\t10\u201330\\tmcg/kg,\\tq12h,\\toral.\\tLower\\tthe\\tdose to 7.5 mcg/kg if adverse effects are observed. \u2022\\t\\tOther\\tconditions:\\t20\u201340\\tmcg/kg\\t(0.02\u20130.04\\tmg/kg)\\tq12h\\tPO. Cats \u2022\\t\\t20\u201340\\tmcg/kg\\t(0.02\u20130.04\\tmg/kg)\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Budesonide byoo- dess\u2032oh- nide Trade and other names: Entocort, Uceris, and generic","contraindications":"Contraindications and Precautions Except when used for termination of pregnancy, do not use in pregnant animals. Do not use in nursing animals. Women handling bromocriptine should use caution to avoid exposure. Drug Interactions No drug interactions have been reported in animals. However, it exacerbates the effects\\tof\\tselegiline.\\tDo\\tnot\\tadminister\\twith\\tmonoamine\\toxidase\\tinhibitors\\t(MAOIs). 94    Budesonide","indications":"Indications and Clinical Uses In people, bromocriptine is used for its antiparkinson effect and to inhibit lactation associated with excess prolactin. It also has been used to treat acromegaly. Bromocriptine has been used to treat disorders associated with dopamine deficiency in animals. In dogs, bromocriptine has been used to terminate pregnancy when used in combination with a prostaglandin (dinoprost or cloprostenol). In this combination, it was 100% effective for terminating pregnancy in dogs. Through the action to decrease prolactin, bromocriptine can be used in dogs to decrease milk production in bitches (e.g., to treat pseudopregnancy). In horses, bromocriptine may decrease ACTH release and has been used in treating\\tequine\\tpituitary\\tpars\\tintermedia\\tdysfunction\\t(Cushing\\tsyndrome),\\tbut pergolide is usually a preferred treatment. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pyometra\\tmay\\toccur\\tin\\tdogs\\tafter\\tit\\thas\\tbeen\\tused\\tto\\tinduce\\tabortion. Bromocriptine may cause mammary gland enlargement. When terminating pregnancy, bromocriptine is used in combination with prostaglandin F 2 alpha. Adverse effects (vomiting, nausea, and retching) may occur as a result of the prostaglandin. However, vomiting and retching also can occur through dopamine stimulation of the vomiting center. It can also produce vasodilation and lowering of blood pressure in some animals. Bromocriptine inhibits lactation, which is sometimes a desired clinical effect (e.g., to treat pseudopregnancy).","notes":"Instructions for Use Use of bromocriptine is limited to treatment of some endocrine disorders. Studies of efficacy are limited and based largely on anecdotal accounts. Bromocriptine has been used to terminate pregnancy in dogs in combination with prostaglandin F 2 alpha. For this\\tuse,\\tadminister\\t15\\tmcg/kg\\tq12h\\tPO\\ton\\tday\\t1,\\t20\\tmcg/kg\\t12h\\tPO\\ton\\tdays\\t2 and\\t3,\\tand\\t30\\tmcg/kg\\tq12h\\tPO\\tthereafter\\tfor\\tan\\taverage\\tof\\t4\u20135\\tdays.\\tTen\\tdays\\tmay be needed in some dogs for a complete effect. A prostaglandin agent (cloprostenol sodium)\\tshould\\tbe\\tused\\tat\\ta\\tdosage\\tof\\t1\\tmcg/kg\\tq48h\\tSQ\\tduring\\tthis\\tregimen. Patient Monitoring and Laboratory Tests Monitor pregnant animals carefully, especially if bromocriptine has been used to terminate pregnancy. Formulations \u2022\\t\\tBromocriptine\\tis\\tavailable\\tin\\t5-\\tmg\\tcapsules\\tand\\t2.5-\\tmg\\ttablets.\\tFor\\tuse\\tin\\tsmall animals,\\tthe\\tcommercial\\ttablet\\tof\\t2.5\\tmg\\trequires\\tfractioning\\tthe\\ttablet\\tinto\\tsmall increments\\tfor\\tdosing.\\tThe\\ttablet\\tcan\\tbe\\tdissolved\\tin\\t10\\tmL\\tof\\tdistilled\\twater\\tin\\tan amber\\tvial\\tto\\tprovide\\ta\\t250-\\tmcg/mL\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. If an oral solution is prepared from the tablet (see under Formulations), the 250- mcg/ mL\\tsolution\\tshould\\tbe\\tstored\\tin\\tan\\tamber\\tvial\\tin\\ta\\trefrigerator\\tand\\tused\\twithin\\t1 week of preparation.","original_category":"Dopamine agonist"},{"name":"Buspirone Hydrochloride","active_ingredient":"Buspirone Hydrochloride","species":["Feline","Canine","Equine"],"dosage":"Cats \u2022\\t\\t2.5\u20135\\tmg/cat\\tq12h\\tPO,\\twhich\\tmay\\tbe\\tincreased\\tto\\t5\u20137.5\\tmg\\tper\\tcat\\ttwice\\tdaily for\\tsome\\tcats\\t(0.5\u20131\\tmg/kg\\tq12h\\tPO). Dogs \u2022\\t\\t2.5\u201310\\tmg/dog\\tq24h\\tor\\tq12h\\tPO. \u2022\\t\\t1\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t\\t100\u2013250\\tmg/horse\\tq24h\\tPO\\t(0.5\\tmg/kg). B Busulfan 105 Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t2 Busulfan byoo- sul\u2032fan Trade and other names: Myleran","contraindications":"Contraindications and Precautions Do not use in animals with sensitivity to serotonin agonists. Drug Interactions Do not use with other serotonin antagonists, selective serotonin reuptake inhibitors,\\tor\\tMAOIs\\t(e.g.,\\tselegiline).","indications":"Indications and Clinical Uses In veterinary medicine, buspirone has been primarily used for the treatment of urine spraying (urine marking) in cats. In cats, there are published studies demonstrating efficacy. However, some cats relapse after treatment is discontinued. Buspirone also has been used as an antiemetic in cats (4 mg/kg SQ). In dogs, it has occasionally been used to treat behavior problems, such as anxiety disorders. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Few side effects are seen in cats compared with other drugs. Some cats show increased aggression, and some cats show increased affection and friendliness to owners. It may produce mild sedation.","notes":"Instructions for Use Some efficacy trials suggest effectiveness for treating urine spraying in cats. There may be a lower relapse rate compared with other drugs. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tBuspirone\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t15-\\t  ,\\tand\\t30-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Behavior modification"},{"name":"Busulfan","active_ingredient":"Busulfan","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t3\u20134\\tmg/m 2 q24h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in food animals because it is an anticancer agent. 106    Butorphanol Tartrate Butorphanol Tartrate byoo- tor\u2032fah- nole  tar\u2032trate Trade and other names: Torbutrol, Dolorex, Butorphine, and Torbugesic","contraindications":"Contraindications and Precautions Do not use in animals with suppressed bone marrow. Drug Interactions No drug interactions are reported in animals.","indications":"Indications and Clinical Uses Busulfan is used primarily for lymphoreticular neoplasia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Leukopenia\\tis\\tthe\\tmost\\tsevere\\tside\\teffect.","notes":"Instructions for Use Busulfan is usually used in combination with other anticancer agents. Consult specific protocol for details. Patient Monitoring and Laboratory Tests Monitor CBC in animals during treatment. Formulations \u2022\\t \\tBusulfan\\tis\\tavailable\\tin\\t2-\\tmg\\ttablets\\tand\\ta\\t6-\\tmg/mL\\tinjection\\tunder\\tthe\\tname\\tBusulfex. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticancer agent"},{"name":"Cabergoline","active_ingredient":"Cabergoline","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tPseudopregnancy:\\t5\\tmcg/kg\\tonce\\tdaily\\t(0.1\\tmL/kg\\tof\\tthe\\toral\\tliquid). \u2022\\t\\tDecrease\\tlactation:\\t5\\tmcg/kg\\tonce\\tdaily\\tPO\\tfor\\t5\\tdays. Cats \u2022\\t\\tQueens:\\t0.5\u20131\\tmL\\tof\\tthe\\toral\\tveterinary\\tliquid\\tper\\tcat\\t(liquid\\tis\\t50\\tmcg/mL).  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tDo\\tnot\\tadminister\\tto\\tfood\\tproducing animals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFood\\tAnimal\\tResidue\\tAvoidance\\tDatabank\\t(FARAD)\\tat www.FARAD.org.","contraindications":"Contraindications and Precautions Do not use in pregnant animals. Abortion may occur. It may cause hypotension. Use cautiously with other agents that can produce hypotension. Because of the possibility of hypotension, it should be discontinued prior to anesthesia. Human warning: Wash hands after use. Avoid contact with skin and eyes; wash off any splashes immediately. Care should be taken to avoid contact between the solution and women of childbearing age. Women of childbearing age should wear gloves when administering the product. Drug Interactions There are no direct drug interactions observed in animals, but it should be used with great caution with any other drugs that act as dopamine agonists because it may potentiate the action. If used with dopamine antagonists (e.g., phenothiazines, butyrophenones, metoclopramide), there will be antagonism. 112    Calcitriol Calcitriol kal- sih- trye\u2032ole Trade and other names: Rocaltrol and Calcijex","indications":"Indications and Clinical Uses Cabergoline is used in dogs to treat pseudopregnancy. Clinical studies in dogs showed over 90% efficacy in reduction of mammary gland and improvement in behavior within 10 days. This action is through the inhibition of prolactin, which reduces the signs of pseudopregnancy in dogs and inhibits the development of the mammary gland and lactation. It should be administered once daily (see the dosing section) for 4\u20136 days initially but can be repeated to fully resolve the problem. In dogs, it is also used for treatment of primary and secondary anestrus. The dosage used for anestrus is 5 mcg/kg PO once daily until 2 days after the onset of proestrus. One study also used a lower dosage of 0.6 mcg/kg PO once daily for treatment of anestrus. In people, cabergoline is used to treat diseases associated with high levels of prolactin, prolactinoma (prolactin- secreting adenomas), or idiopathic hyperprolactinemia. It is as effective and longer acting than bromocriptine. There are also fewer adverse effects in women compared with treatment with bromocriptine. It has been used in people for symptomatic management of parkinsonian syndrome, but other drugs are usually preferred. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects Because of dopamine agonist effects, adverse effects related to this action are possible. It can cause hypotension in some animals. Gastrointestinal (GI) problems are possible in dogs, with vomiting the most common, especially at doses higher than 5 mcg/kg. Anorexia and lethargy are also possible. These signs do not require discontinuation of treatment. C","notes":"Instructions for Use The use in animals is derived from the approved indication in Europe. Start with a once- daily dose for treatment of pseudopregnancy and treat for 4\u20136 days initially. Repeat the protocol if needed in refractory cases. It can be administered directly in the mouth or administered with food. Patient Monitoring and Laboratory Tests Monitor plasma cortisol concentrations if used long term. Formulations \u2022\\t\\tCabergoline\\tis\\tavailable\\tin\\ta\\tveterinary\\tformulation\\tas\\toral\\tdrops.\\tThe\\tformulation Galastop is available in 50- mcg/mL concentration in 7-  and 15- mL amber bottles. It is also available in a human formulation of 0.5- mg scored tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not refrigerate the oral solution. Discard the open container 28 days after opening of the oral liquid.","original_category":"Serotonin antagonist, prolactin inhibitor"},{"name":"Calcitriol","active_ingredient":"Calcitriol","species":["Canine","Feline"],"dosage":"treating dogs with CKD, the average dosage was 2.5 ng/kg/day, but it ranged from 0.75\u20135 ng/kg/day based on adjustments from measuring calcium concentrations. When used in CKD, it is often used with intestinal phosphate binders (e.g., C aluminum hydroxide) and dietary phosphorous restriction. Recommended phosphate concentrations should be maintained at less than 6 mg/dL. In cats, do not administer simultaneously with a meal to avoid increased calcium absorption. It is best administered in the evening before a meal. If ionized calcium increases above the reference range (above 4.5\u20135.5 mg/dL), stop treatment and then reintroduce it at a lower dose.  (Note:\\t   To\\t convert\\tfrom\\t  micrograms\\t(mcg)\\t   to\\t nanograms\\t(ng)\\t  refer\\t  to\\t the\\t  page\\t  facing the inside front cover.) Dogs \u2022\\t \\tRenal\\tsecondary\\thyperparathyroidism\\tin\\tchronic\\trenal\\tfailure:\\t2.5\\tng/kg\\tPO\\tonce daily. Adjust dose with calcium and PTH measurements. If PTH concentrations remain elevated and calcium is not elevated, increase the dosage to 3.5 ng/kg once daily. The dosage may be increased incrementally up to 5 ng/kg once daily. If dogs cannot be medicated once daily, an alternative dosing regimen is a 10 ng/kg twice per week PO. Cats \u2022\\t\\tHypocalcemia\\t(after\\tremoval\\tof\\tparathyroid\\tglands):\\t0.25\\tmcg/cat\\tq48h\\tPO\\tor 0.01\u20130.04 mcg/kg/day PO (10\u201340 ng/kg/day). \u2022\\t\\tRenal\\tsecondary\\thyperparathyroidism:\\t2.5\\tng/kg\\tPO\\tonce\\tdaily.\\tAdjust dose with calcium and PTH measurements. If PTH concentrations remain elevated and calcium is not elevated, increase the dose to 3.5 ng/kg once daily and incrementally up to a dose of 5 ng/kg/day. Do not exceed 5 ng/kg/ day. An alternative dosing regimen that has been used for cats that cannot be 114    Calcium Carbonate administered once daily is 10 ng/kg twice per week PO. Because the volumes for\\tdosing\\tcats\\tis\\tlow,\\trefer\\tto\\tthe\\tFormulation\\tsection\\tfor\\tcompounding\\ta\\tmore dilute solution.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Calcium Carbonate Trade and other names: Titralac, Calci- Mix, Tums, and generic brands","contraindications":"Contraindications and Precautions Do not use in patients that are at risk of hypercalcemia. Capsules made for humans may contain high overdoses for dogs and cats and should be reformulated. Drug Interactions Calcitriol may cause hypercalcemia if used with thiazide diuretics.","indications":"Indications and Clinical Uses Calcitriol is used to treat calcium deficiency and diseases such as hypocalcemia associated with hyperparathyroidism. It is also used to increase calcium in cats that have had parathyroid glands surgically removed. In this use, it is often administered with calcium supplements to the diet. It is used in dogs and cats to manage calcium and phosphorous balance with CKD. Although used by veterinarians to reduce renal secondary PTH concentrations in animals with CKD, this benefit is more controversial and not supported by strong evidence. Supplementation to cats with CKD may help slow progression of disease in some cats, but some cats do not show a benefit. Calcitriol should not be used as a vitamin D supplement. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdose can result in hypercalcemia. High doses can cause soft tissue mineralization.","notes":"Instructions for Use When comparing doses with vitamin D, 1 unit of vitamin D is equivalent to 0.025 mcg of cholecalciferol or ergocalciferol (400 units of vitamin D = 10 mcg of cholecalciferol). Doses should be adjusted in each patient according to response and monitoring calcium plasma concentration; thus, the maintenance dose in animals may\\tvary\\tdepending\\ton\\tthe\\tadjustment\\tto\\tcalcium\\tlevels.\\tFor\\texample,\\twhen\\tused\\tfor Patient Monitoring and Laboratory Tests Monitor plasma ionized calcium concentration. Adjust doses as necessary to maintain normal calcium, phosphorous, and PTH concentrations. Normal\\ttotal\\tcalcium\\tconcentrations\\tin\\tdogs\\tand\\tcats\\tare\\t9\u201311.5\\tmg/dL\\tand 8\u201310.5 mg/dL, respectively, or 1.2\u20131.5 mmol/L and 1.1\u20131.4 mmol/L, respectively. Monitor serum PTH concentrations (assays are available in many diagnostic laboratories). Monitor serum creatinine in animals when used to treat CKD. Formulations \u2022\\t\\tCalcitriol\\tis\\tavailable\\tas\\tinjection\\t(Calcijex)\\tin\\ta\\t1-\\t\\tand\\t2-\\tmcg/mL\\tand\\tin\\t0.25-\\t\\tand 0.5- mcg  capsules. \u2022\\t\\tCalcitriol\\toral\\tsolution\\tis\\tavailable\\tas\\t1\\tmcg/mL\\t(Rocaltrol).\\tThis\\tmay\\tbe\\tdiluted for administration to small animals. See the Stability and Storage section for instructions on dilutions. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded forms: Small animal veterinarians have compounded calcitriol in oil to facilitate dosing to small animals. One such recipe uses 1 part oral solution (Rocaltrol) mixed with 9 parts medium- chain triglyceride (MCT) oil or olive oil. Rocaltrol has been\\tmixed\\twith\\tcorn\\toil\\t(1:10\\tratio)\\tto\\tprepare\\ta\\t100-\\tng/mL\\toral\\tformulation. A more complex compounded formulation prepared by some pharmacies uses a diluent prepared from 400 mg of butylated hydroxyanisole (BHA) and 400 mg of butylated hydroxytoluene (BHT) in 2 mL of 100% ethyl alcohol. This should be mixed thoroughly to dissolve BHA and BHT. This mixture is added to 400 mL of extra- light olive oil and mixed thoroughly. This mixture is used as a diluent. 145.5 mL of this diluent is added to 4.5 mL of oral calcitriol (Rocaltrol) 1- mcg/mL oral solution. This mixture produces a 30- ng/mL (0.030 mcg/mL) oral solution. Store in an amber bottle. Beyond- use- date is 6 months from the time of preparation.","original_category":"Calcium supplement"},{"name":"Calcium Carbonate","active_ingredient":"Calcium Carbonate","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tCalcium\\tsupplementation:\\t70\u2013185\\tmg/kg/day\\tgiven\\twith\\tfood\\tPO. \u2022\\t\\tTreatment\\tof\\thypoparathyroidism:\\t30\u201360\\tmg/kg\\tper\\tday\\tin\\tdivided\\tdoses\\t(with meals). \u2022\\t\\tPhosphate\\tbinder:\\t60\u2013100\\tmg/kg/day\\tin\\tdivided\\tdoses,\\tusually\\tgiven\\twith\\tfood PO. \u2022\\t\\tPronefra\\t(calcium\\tcarbonate\\tand\\tmagnesium\\tcarbonate)\\tfor\\tuse\\tas\\ta\\tphosphate binder.\\tAdminister\\twith\\ta\\tmeal.\\tCats:\\t1\\tmL\\tper\\t4.4\\tkg\\t(8.8\\tlb)\\ttwice\\ta\\tday\\tat mealtime.\\tDogs:\\t1\\tmL/5\\tkg\\t(11\\tlb)\\ttwice\\ta\\tday\\tat\\tmealtime.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tUsually,\\tother\\tcalcium\\tsalts\\tare\\tused for supplementation in cattle. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\ta\\tnormal\\tdietary\\tsupplement\\twith little risk from residues, no withdrawal time is suggested for animals intended for food. Calcium Chloride Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not administer to animals predisposed to forming calcium- containing renal or cystic calculi. When calcium carbonate or calcium citrate is used as a phosphate binder to prevent hyperphosphatemia, caution is advised to avoid hypercalcemia in patients with kidney disease. Drug Interactions Oral administration of calcium supplements may interfere with absorption of other drugs such as fluoroquinolones (e.g., enrofloxacin, orbifloxacin, marbofloxacin, pradofloxacin), bisphosphonates, zinc, iron, and tetracyclines. Use cautiously with thiazide diuretics because this could cause a high increase in calcium concentrations.","indications":"Indications and Clinical Uses Calcium carbonate is used as an oral calcium supplement for hypocalcemia, sometimes used with vitamin D supplements or calcitriol. It contains 40% elemental calcium. It is used as antacid to treat gastric hyperacidity and GI ulcers and as an intestinal phosphate binder for hyperphosphatemia associated with CKD. Pronefra (calcium carbonate and magnesium carbonate) is administered as a palatable phosphate binder in dogs and cats. It is administered as an oral liquid suspension with meals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Few\\tside\\teffects.\\tHigh\\tcalcium\\tconcentrations\\tare\\tpossible.\\tWith\\tany\\tcalcium supplements, constipation and intestinal bloating can occur.","notes":"Instructions for Use Calcium carbonate is equivalent to 400 mg of calcium ion per gram. Doses are primarily derived from extrapolation of human doses. When used as a calcium supplement, doses should be adjusted according to serum calcium concentrations. Administer with food to improve oral absorption. Some tablets also contain vitamin C Calcium Chloride 115 D. Doses are based on calcium carbonate, not the ion concentration (e.g., a 650- mg tablet contains 260 mg of calcium ion). Patient Monitoring and Laboratory Tests Monitor\\tserum\\tcalcium\\tlevels,\\tparticularly\\tif\\tpatients\\thave\\tkidney\\tdisease.\\tNormal total calcium concentrations in dogs and cats are 9\u201311.5 mg/dL and 8\u201310.5 mg/dL, respectively, or 1.2\u20131.5 mmol/L and 1.1\u20131.4 mmol/L, respectively. Formulations Calcium carbonate is available in tablets or oral suspension, most of which are available over the counter (OTC). One gram of calcium carbonate is equivalent to 400 mg of calcium ion. Calci- Mix is available in 1.25- g capsules. OTC tablets are available in 500 and 600 mg and 1, 1.25, and 1.5 g. Oral suspension (Titralac) is 1.25 g/5 mL. The formulation Pronefra also is available as calcium carbonate and magnesium carbonate. It is an oral syrup that may be administered as a phosphate binder in cats. Pronefra is preferred by some cats because it is a palatable liquid suspension with poultry liver flavoring. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Do not mix with other compounds that may chelate with calcium.","original_category":"Calcium supplement"},{"name":"Calcium Chloride","active_ingredient":"Calcium Chloride","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.1\u20130.3\\tmL/kg\\tof\\t10%\\tsolution\\tIV\\t(slowly). \u2022\\t\\tTreatment\\tof\\tsevere\\thypocalcemia\\t(with\\ttetany\\tand\\tseizures):\\t5\u201315\\tmg/kg elemental calcium over 10\u201330 minutes IV slowly.  Cows \u2022\\t\\t2\\tg/100\\tkg\\tbody\\tweight,\\tIV\\tat\\ta\\trate\\tof\\t1\\tg/min. Horses \u2022\\t\\t1\u20132\\tg\\tper\\tadult\\thorse\\tIV\\tslowly. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\ta\\tnormal\\tsupplement\\twith\\tlittle\\trisk from residues, no withdrawal time is suggested for animals intended for food. Calcium Citrate Trade and other names: Citracal (OTC)","contraindications":"Contraindications and Precautions Do not administer by IV injection at a rapid rate because it can cause hypotension, cardiac arrhythmias, and cardiac arrest. Rapid IV administration to cows can cause cardiac arrhythmias and even death. Drug Interactions Calcium chloride precipitates with sodium bicarbonate. Do not mix with compounds known to chelate with calcium. These include some antibiotics such as tetracyclines and fluoroquinolones (e.g., enrofloxacin, ciprofloxacin). Do not mix calcium salts with medications that contain carbonate, phosphate, sulfate, or tartrate because they may cause chelation.","indications":"Indications and Clinical Uses Calcium chloride is used in acute situations to supplement as electrolyte replacement or as a cardiotonic. It is administered to cows for hypocalcemia (milk fever). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdose\\twith\\tcalcium\\tis\\tpossible.\\tDo\\tnot\\tadminister\\tIV\\tsolution\\tSQ\\tor IM because it may cause tissue necrosis. If calcium salts are inadvertently injected\\tperivascularly,\\tflush\\tthe\\tarea\\t(irrigate)\\twith\\t0.9%\\tNaCl\\tand\\tapply\\tlocal corticosteroids. IV administration can cause irritation, and calcium gluconate is preferred for IV use because it is not as irritating as calcium chloride.","notes":"Instructions for Use The injection formulation is 27.2 mg of calcium ion (1.36 mEq) per milliliter. It is usually used in emergency situations. Intracardiac administrations have been performed as an emergency but avoid injections into the myocardium. Patient Monitoring and Laboratory Tests Monitor\\tserum\\tcalcium\\tconcentration.\\tNormal\\ttotal\\tcalcium\\tconcentrations\\tin\\tdogs and cats are 9\u201311.5 mg/dL and 8\u201310.5 mg/dL, respectively, or 1.2\u20131.5 mmol/L and 1.1\u20131.4 mmol/L, respectively. Monitor heart rate, electrocardiogram (ECG), or both during IV administration. Formulations \u2022\\t\\tCalcium\\tchloride\\tis\\tavailable\\tin\\ta\\t10%\\t(100-\\tmg/mL)\\tsolution.\\tThis\\tsupplies\\t1.36 mEq calcium ion per milliliter or 27.2 elemental calcium per milliliter. Preparations for cattle usually contain 8.5\u201311.5 g calcium per 500 mL. Many formulations also contain magnesium. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Do not mix with other compounds that may chelate with calcium. C Calcium Citrate 117","original_category":"Calcium supplement"},{"name":"Calcium Citrate","active_ingredient":"Calcium Citrate","species":["Feline","Canine"],"dosage":"Cats \u2022\\t\\t10\u201330\\tmg/kg\\tq8h\\t(with\\tmeals)\\tPO. Dogs \u2022\\t\\t20\\tmg/kg/day\\t(with\\tmeals)\\tPO. Dogs and Cats \u2022\\t\\tPhosphate\\tbinder\\t(to\\tprevent\\thyperphosphatemia):\\t10\u201320\\tmg/kg\\tper\\tday\\tin divided doses with meals PO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\ta\\tnormal\\tdietary\\tsupplement\\twith little risk from residues, no withdrawal time is suggested for animals intended for food. Calcium Gluconate and Calcium Borogluconate Trade and other names: Kalcinate, AmVet, Cal- Nate, and generic brands","contraindications":"Contraindications and Precautions When calcium carbonate or calcium citrate is used as a phosphate binder to prevent hyperphosphatemia, caution is advised to avoid hypercalcemia in patients with renal failure. Drug Interactions Oral administration of calcium supplements may interfere with absorption of other drugs such as fluoroquinolones (e.g., enrofloxacin, orbifloxacin, marbofloxacin), bisphosphonates, zinc, iron, and tetracyclines. Calcium citrate does not require acid for absorption and may be administered with ulcer drugs that suppress stomach acid (e.g., omeprazole, H 2 - blockers). 118    Calcium Gluconate and Calcium Borogluconate","indications":"Indications and Clinical Uses Calcium citrate is used in the treatment of hypocalcemia, such as with hypoparathyroidism. It contains 21% elemental calcium. It also is used as an intestinal phosphate binder for hyperphosphatemia associated with kidney disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypercalcemia is possible with oversupplementation. With any calcium supplements, constipation and intestinal bloating can occur. Constipation and bloating are more likely with calcium citrate than calcium carbonate.","notes":"Instructions for Use Doses should be adjusted according to serum calcium concentration. Although calcium carbonate should be administered with a meal, this is not required for calcium citrate. Patient Monitoring and Laboratory Tests Monitor\\tserum\\tcalcium\\tlevels,\\tparticularly\\tif\\tpatients\\thave\\trenal\\tfailure.\\tNormal total calcium concentrations in dogs and cats are 9\u201311.5 mg/dL and 8\u201310.5 mg/dL, respectively, or 1.2\u20131.5 mmol/L and 1.1\u20131.4 mmol/L, respectively. If used as a phosphate binder, adjust doses based on serum phosphorous concentrations. Formulations \u2022\\t\\tCalcium\\tcitrate\\t   is\\t available\\tin\\t 950-\\t  mg\\t  tablets\\t   (contains\\t200\\t  mg\\t  of\\t calcium\\tion),\\t  and 1000- mg tablets. Some forms also contain vitamin D 3 . Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Do not mix with other compounds that may chelate with calcium.","original_category":"Calcium supplement"},{"name":"Calcium Gluconate and Calcium Borogluconate","active_ingredient":"Calcium Gluconate and Calcium Borogluconate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t75\u2013500\\tmg\\tIV\\t(slowly)\\tor\\t0.5\u20131.6\\tmL/kg\\tIV\\tof\\tthe\\t10%\\tsolution\\t(slowly). \u2022\\t\\tTreatment\\tof\\tsevere\\thypocalcemia\\t(with\\ttetany\\tand\\tseizures):\\t5\u201315\\tmg/kg elemental calcium over 10\u201330 minutes IV slowly. This dose is equivalent to 0.54\u20131.6 mL/kg of the 10% solution.  (Use Calcium Borogluconate) Cattle and Horses \u2022\\t\\t5\u201312\\tg\\tdiluted\\tin\\t500\\tmL\\tand\\tinfused\\tIV\\tslowly. Pigs and Sheep \u2022\\t\\t20\\tmg/kg\\tIV\\tslowly. Dairy Cows \u2022\\t\\t2\\tg/100\\tkg\\tbody\\tweight\\tslowly\\tat\\ta\\trate\\tof\\t1\\tg/min. Horses \u2022\\t\\t50\u201370\\tmg/kg\\tdiluted\\tin\\t5%\\tdextrose\\tand\\tinfused\\tslowly\\tIV. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\ta\\tnormal\\tdietary\\tsupplement\\twith little risk from residues, no withdrawal time is suggested for animals intended for food. Calcium Lactate Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not administer by IV injection at a rapid rate because it can cause hypotension, cardiac arrhythmias, and cardiac arrest. Avoid use in patients that are prone to calcium- containing renal or cystic calculi. Avoid administration of the IV solution IM\\tor\\tSQ\\tbecause\\tit\\twill\\tcause\\ttissue\\tnecrosis\\tand\\tcan\\tcause\\tpyogranulomatous panniculitis and adipocyte mineralization at the site of injection. Drug Interactions Do not mix with bicarbonates (e.g., sodium bicarbonate), phosphates, sulfates, and tartrates because it may cause precipitation. Specific drugs that can precipitate with calcium gluconate include oxytetracycline, promethazine, sulfamethazine, tetracycline, cephalothin, and amphotericin B. Calcium supplements may interfere with the oral absorption of iron, tetracyclines, and fluoroquinolones.","indications":"Indications and Clinical Uses Calcium gluconate and calcium borogluconate are used in the treatment of hypocalcemia, such as with hypoparathyroidism, but are used less commonly than other forms. However, if administered IV, calcium gluconate is not as irritating as calcium chloride. Calcium gluconate and calcium borogluconate are used in diseases that produce electrolyte deficiency. Calcium supplements are administered to cattle for treatment of hypocalcemia (milk fever). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypercalcemia is possible with oversupplementation. Calcium supplements may cause constipation.\\tSQ\\tor\\tIM\\tinjections\\tof\\tcalcium\\tsalts\\tmay\\tcause\\ttissue\\tinjury\\tand\\tnecrosis at the site of injection. If calcium salts are inadvertently injected perivascularly, flush the\\tarea\\t(irrigate)\\twith\\t0.9%\\tNaCl\\tand\\tapply\\tlocal\\tcorticosteroids.","notes":"Instructions for Use The 500- mg tablets contain 45 mg of calcium ion. The 10% injection contains 97 mg (9.3 mg of elemental calcium ion [0.47 mEq]) per milliliter. Patient Monitoring and Laboratory Tests Monitor\\tserum\\t   calcium\\tconcentration.\\tNormal\\ttotal\\t  calcium\\tconcentrations\\tin\\t dogs\\t  and cats are 9\u201311.5 mg/dL and 8\u201310.5 mg/dL, respectively, or 1.2\u20131.5 mmol/L and 1.1\u2013 1.4 mmol/L, respectively. Monitor heart rate, ECG, or both during IV administration. Formulations \u2022\\t\\tCalcium\\tgluconate\\tis\\tavailable\\tas\\t10%\\t(100-\\tmg/mL)\\tinjection.\\tCalcium\\tgluconate 10% contains 9.3 mg of calcium ion per milliliter, or 0.465 mEq/mL. \u2022\\t\\tTablets:\\tCalcium\\tgluconate\\tis\\tavailable\\tin\\ttablets\\tin\\tsizes\\tof\\t325,\\t500,\\t650,\\t975\\tmg, and 1 g. Each gram contains 90 mg of calcium ion. Chewable tablets intended for human use are available in 650- mg and 1- g tablets. \u2022\\t\\tCalcium\\tborogluconate\\tis\\tavailable\\tas\\t230\\tmg/mL,\\t23%\\tsolution\\t(AmVet\\tCalcium Gluconate\\t23%\\tand\\tCal-Nate).\\tThis\\tsolution\\tcontains\\t19.14\\telemental\\tcalcium\\tper milliliter. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Solutions should be clear. If crystals are present, warm vial up to 30\xb0C\u201340\xb0C (86\xb0F\u2013104\xb0F)\\tto\\tdissolve\\tcrystals.\\tStability\\tof\\tcompounded\\tformulations\\thas\\tnot\\tbeen evaluated. Do not mix with other compounds that may chelate with calcium. 120    Calcium Lactate","original_category":"Calcium supplement"},{"name":"Calcium Lactate","active_ingredient":"Calcium Lactate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tg/day\\t(500\\tmg)\\t(in\\tdivided\\tdoses)\\tPO. Cats \u2022\\t\\t0.2\u20130.5\\tg/day\\t(200\u2013500\\tmg)\\t(in\\tdivided\\tdoses)\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\ta\\tnormal\\tdietary\\tsupplement\\twith little risk from residues, no withdrawal time is suggested for animals intended for food. Capromorelin kap\u2032roe- moe- rel\u2032in Trade and other names: Entyce","contraindications":"Contraindications and Precautions Avoid use in patients that are prone to calcium- containing renal or cystic calculi. Drug Interactions Calcium supplements may interfere with the oral absorption of iron, tetracyclines, and fluoroquinolones. C Capromorelin 121","indications":"Indications and Clinical Uses Calcium lactate is used in treatment of hypocalcemia, such as with hypoparathyroidism, and in electrolyte deficiency. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypercalcemia possible with oversupplementation.","notes":"Instructions for Use Calcium lactate contains 130 mg of calcium ion per gram. Patient Monitoring and Laboratory Tests Monitor serum calcium concentrations. Formulations \u2022\\t\\tCalcium\\tlactate\\tis\\tavailable\\tin\\t325-\\tmg\\t(42.25\\tmg\\tof\\tcalcium\\tion)\\tand\\t650-\\tmg (84.5 mg of calcium ion) OTC tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Do not mix with other compounds that may chelate with calcium.","original_category":"Calcium supplement"},{"name":"Capromorelin","active_ingredient":"Capromorelin","species":["Canine","Feline"],"dosage":"in cats with CKD at a dosage of 2 mg/kg PO once daily. As for dogs, an increase by 1.5 times (3 mg/kg) can be considered in cats that do not respond to the initial dose. Precautionary Information  Dogs \u2022\\t\\t3\\tmg/kg\\tPO\\tonce\\tdaily. Cats \u2022\\t\\tSafe\\tclinical\\tdoses\\thave\\tnot\\tbeen\\testablished.\\tUntil\\ta\\tspecific\\tfeline\\tform\\tis\\tavailable, consider a dosage of 2 mg/kg PO once daily.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tthis\\tis\\tnot\\tapproved\\tfor\\tfood\\tanimals,\\tit should not be administered to animals intended for food. Captopril kap\u2032toe- pril Trade and other names: Capoten","contraindications":"Contraindications and Precautions The safety in dogs with liver or kidney disease has not been evaluated. It is metabolized by cytochrome P450 (CYP450) enzymes, and it is possible that other drugs that affect the CYP450 enzymes could alter the pharmacokinetics. It is excreted in both the urine and feces; use with caution in dogs with renal insufficiency or liver disease. Safety has not been evaluated in dogs used for breeding or pregnant or lactating bitches. The safety has not been evaluated in cats, but it was safe in healthy research cats. There are no known contraindications or restrictions for dogs. It can be used regardless of duration, weight of dog, or age. It can be administered as long as necessary as long as no adverse effects are observed. Drug Interactions There are no known drug interactions. C Captopril 123","indications":"Indications and Clinical Uses Capromorelin is used to increase appetite in dogs. It should be administered once daily at the approved dose, with no limit to the length of treatment. In severely ill dogs or those with multiple other problems, it may take a few days to see a response. Some dogs may not respond at all. Some clinicians have increased the dose by 1.5 times to obtain a more consistent positive response. If no response is seen in a few days, even with a higher dose, consider discontinuing the drug and pursuing other treatments.\\tIn\\tthe\\tclinical\\tstudies\\tperformed\\tto\\tobtain\\tFood\\tand\\tDrug\\tAdministration (FDA)\\tapproval,\\tat\\tthe\\tlabel\\tdose,\\tit\\tsignificantly\\timproved\\tappetite\\tand\\tbody\\tweight compared with placebo treatment. Other agents that have been used to increase appetite are mirtazapine, cyproheptadine, corticosteroids, and anabolic steroids, but capromorelin is the first drug approved specifically for this indication in dogs. The current approval is for dogs only. There are no clinical studies in sick cats that can\\tbe\\tused\\tto\\trecommend\\ttreatment.\\tIn\\thealthy\\tresearch\\tcats,\\tit\\tincreased\\tIGF-\\t1, increased\\tappetite,\\tand\\tincreased\\tbody\\tweight.\\tFuture\\tstudies\\tmay\\treveal\\toptimum doses and determine safety. It is proposed that it may be useful to stimulate appetite","side_effects":"Adverse Reactions and Side Effects In the clinical field trials, the most common adverse effect was diarrhea, vomiting, polydipsia, and hypersalivation. In the target animal safety studies, it was tolerated at 17.5 times the label dose for 12 months in healthy dogs.","notes":"Instructions for Use Capromorelin is available in a 30- mg/mL oral solution. Dispense the correct dose to pets using the syringe available in the packaging. Rinse the syringe with water between uses. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s body weight and appetite. Although guidelines are not available for cats, it is advised to monitor parameters for diabetes in treated cats until other information is available. If cortisol concentrations are measured, there is an increase in cortisol release seen approximately 1 hour after administration of capromorelin; it declines to baseline levels 4 hours after oral administration. Formulations \u2022\\t \\tCapromorelin\\tis\\tavailable\\tas\\tan\\toral\\tflavored\\tsolution\\tat\\ta\\tconcentration\\tof\\t30\\tmg/mL. It is available in sizes of 10- , 15- , and 30- mL bottles with a dispensing syringe. Stability and Storage Store in a tightly sealed container, protected from light, at temperatures less than 30\xb0C\\t(86\xb0F).\\tDo\\tnot\\tmix\\twith\\tother\\tdrugs\\tif\\tcompatibility\\tis\\tnot\\tknown.","original_category":"Appetite stimulant"},{"name":"Carboplatin","active_ingredient":"Carboplatin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t300\\tmg/m 2 IV every 3 weeks. Treatment may involve four to six cycles of administration every 3 weeks. Cats \u2022\\t\\t200\u2013227\\tmg/m 2 IV every 4 weeks for four treatments; for a 4- kg cat, the dose is equivalent to 14.7 mg/kg.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Carprofen car- proe\u2032fen Trade and other names: Rimadyl, Vetprofen, Zinecarp (Europe), and generic brands","contraindications":"Contraindications and Precautions In one study, small dogs were more prone than larger dogs to adverse effects. Drug Interactions Do not use with other nephrotoxic drugs.","indications":"Indications and Clinical Uses Carboplatin has been used for squamous cell carcinoma and other carcinomas, melanoma, osteosarcomas, and other sarcomas. It has produced a disease- free interval and survival in dogs with osteosarcoma that is similar to other protocols. When used in dogs, myelosuppression has been the most dose- limiting factor. Compared with cisplatin, carboplatin is preferred for cats because it is better tolerated. However, bone marrow suppression is the dose- limiting toxicity in cats. Some forms of carboplatin have been administered locally (e.g., incorporated into beads) and used for treatment of local sarcomas and other tumors. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Compared with cisplatin, carboplatin is less emetogenic and less nephrotoxic. In dogs, the other most common adverse effects relate to GI system toxicity (gastroenteritis, vomiting, anorexia, and diarrhea). The dose- limiting effect is myelosuppression, anemia, leukopenia, or thrombocytopenia. In dogs, the nadir of myelosuppression occurs at 14 days, but recovery occurs by 21\u201328 days. In cats, the nadir is 21 days, and recovery occurs by 28 days. Vomiting is not as much of a problem as for cisplatin, but GI toxicosis is still a problem, especially in smaller dogs. Because it is excreted by the kidneys, animals with diminished kidney function may have a higher rate of GI toxicosis.","notes":"Instructions for Use Available for reconstitution for injection. It is stable for 1 month when reconstituted with 5% dextrose. It may be frozen at \u20134\xb0C to prolong the stability of a reconstituted vial. Do not use with administration sets containing aluminum because of incompatibility. It is usually administered in specific anticancer protocols; consult oncology protocols for specific regimens. In dogs, it has been dosed on a milligram per square meter (mg/m 2 ) dose, which has produced a higher incidence of adverse effects in smaller dogs compared with larger dogs; however, smaller dogs also were more likely to respond. Carboplatin is excreted by the kidneys; therefore it should be avoided in patients with kidney disease, or the dose should be decreased in proportion to reduced glomerular filtration rate and creatinine clearance. C Carprofen 129 Patient Monitoring and Laboratory Tests Monitoring of CBC and platelets is recommended during treatment. Because of high risk of myelosuppression, a CBC is recommended before each treatment and again 7\u201314 days after each treatment. Formulations \u2022\\t\\tCarboplatin\\tis\\tavailable\\tin\\t50-\\t,\\t150-\\t   ,\\tand\\t450-\\tmg\\tvials\\tfor\\tinjection\\tand\\ta\\t10-\\tmg/ mL infusion. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stable for 1 month if reconstituted with 5% dextrose solution. It is stable if frozen at \u20134\xb0C.","original_category":"Anticancer agent"},{"name":"Carprofen","active_ingredient":"Carprofen","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t2.2\\tmg/kg\\tq12h\\tPO\\tor\\t4.4\\tmg/kg\\tq24h\\tPO. \u2022\\t\\t2.2\\tmg/kg\\tq12h\\tSQ\\tor\\t4.4\\tmg/kg\\tq24h\\tSQ. Cats \u2022\\t\\t4\\tmg/kg\\tgiven\\tonce\\tby\\tinjection\\tor\\t0.5\\tmg/kg\\tq24h\\tPO\\tfor\\tlong-\\tterm\\tuse\\t(safety for long- term use has not been established).  Horses \u2022\\t\\t0.7\\tmg/kg\\tq24h\\tIV\\t(in\\tEurope,\\toral\\tgranules:\\t0.7\\tmg/kg\\tPO). Cattle \u2022\\t\\t1.4\\tmg/kg\\tSQ,\\tIV. Regulatory Information Withdrawal times have not been established for carprofen in the United States. It is suggested, based on European labeling, that the withdrawal time for meat is 21 days but zero days for milk. Caution is advised when considering carprofen for cattle because it has a longer half- life in cows compared with other animals (30\u201340 hours). RCI\\tClassification:\\t4 Carvedilol kar- ved\u2032ih- lole Trade and other names: Coreg","contraindications":"Contraindications and Precautions Do not use in cats at doses intended for dogs. Do not administer to animals prone to GI ulcers. Do not administer with ulcerogenic drugs such as corticosteroids. If a\\tpatient\\thas\\thad\\tprevious\\tadverse\\teffects\\tfrom\\tNSAIDs,\\tcarprofen\\tshould\\tbe\\tused cautiously. Drug Interactions Use\\tNSAIDs\\tcautiously\\twith\\tother\\tdrugs\\tknown\\tto\\tcause\\tGI\\tinjury\\t(e.g., corticosteroids). The efficacy of ACE inhibitors and diuretics (e.g., furosemide) may\\tbe\\tdiminished\\twhen\\tadministered\\tconcurrently\\twith\\tNSAIDs. C Carvedilol 131","indications":"Indications and Clinical Uses Carprofen\\tis\\tone\\tof\\tthe\\tmost\\tcommon\\tNSAIDs\\tused\\tin\\tdogs\\tfor\\ttreatment\\tof musculoskeletal pain and acute pain related to surgery or trauma. It is used primarily for treatment of osteoarthritis and has been administered for long- term treatment safely in many dogs. Long- term safe use in cats has not been established. However, it is registered in Europe for one- time administration in cats at 4- mg/kg injection. Although use in large animals is uncommon, in cattle, carprofen has been shown to reduce inflammation in cows associated with Escherichia coli mastitis at a dose of 0.7 mg/kg IV. In cattle, carprofen is registered in Europe for treatment of fever associated with mastitis and used to reduce inflammation associated with bovine respiratory disease (BRD). Although carprofen has been used in horses, it does not show\\tthe\\tsame\\tCOX-\\t2\\tselectivity\\tof\\tinhibition\\tas\\tin\\tdogs\\tand\\thas\\tnot\\tbeen\\ta\\tuseful analgesic or anti- inflammatory agent. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The safety of carprofen in dogs was determined by the sponsor during preclinical studies. The most common adverse effect in dogs has been in the GI tract (vomiting, anorexia, and diarrhea). GI ulcers, perforation, and bleeding are uncommon in dogs but possible. In rare cases, carprofen has caused idiosyncratic acute hepatic toxicity in dogs. Signs of toxicity usually appear 2\u20133 weeks after exposure. There were no adverse effects on the kidneys when carprofen was evaluated in anesthetized dogs. Carprofen may lower total thyroid (T 4 ) concentrations in dogs but not free T 4 . In experimental dogs, it has inhibited bone healing in some models (4.4 mg/kg/day \xd7 120 days), but this has not been shown to be a clinical problem. Carprofen has produced toxicity in cats if administered at the same dose rates as for dogs.","notes":"Instructions for Use Doses are based on clinical investigations in dogs with arthritis and for treatment of pain associated with surgery. Dogs may receive carprofen either once daily (4.4 mg/kg) or twice daily (2.2 mg/kg) with similar effectiveness and safety. The only approved dose for cats is 4 mg/kg as a one- time injection for surgical pain. However, for long- term use, pharmacokinetic extrapolations suggest a long- term dosage of 0.5 mg/kg q24h PO. Long- term safety at this dosage has not been established. Patient Monitoring and Laboratory Tests After administration has begun, one should monitor hepatic enzymes for evidence of drug- induced hepatic toxicity approximately 7\u201314 days after treatment has started. If liver enzymes are elevated, discontinue the medication and contact the drug manufacturer. Formulations \u2022\\t\\tCarprofen\\tis\\tavailable\\tin\\t25-\\t,\\t75-\\t  ,\\tand\\t100-\\tmg\\tcaplets;\\t25-\\t,\\t75-\\t  ,\\tand\\t100-\\tmg chewable\\ttablets;\\tand\\tinjectable\\tsolution:\\t50\\tmg/mL. \u2022\\t\\tZinecarp\\tinjection\\thas\\talso\\tbeen\\tavailable\\tin\\tEurope. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Carprofen has been compounded by mixing tablets with methylcellulose gel (1%), simple syrup, and a suspending and flavoring vehicle to make a 1.25- , 2.5- , and 5-   mg/mL suspension. This formulation was stable if stored in the refrigerator or at room temperature for 28 days.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Cetirizine Hydrochloride","active_ingredient":"Cetirizine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t1\\tmg/kg\\tdaily\\tPO.\\tThe\\tmost\\tcommon\\tdose\\tis\\t5\\tmg\\tper\\tcat\\t(1\\ttablet).  Horses \u2022\\t\\t0.2\u20130.4\\tmg/kg\\tq12h\\tPO. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Charcoal, Activated Trade and other names: Acta- Char, Charcodote, Liqui- Char, ToxiBan, and generic brands","contraindications":"Contraindications and Precautions Because antimuscarinic effects (atropinelike effects) are possible, do not use in conditions for which anticholinergic drugs may be contraindicated, such as glaucoma, ileus, or cardiac arrhythmias. Discontinue administration a minimum of 7 days prior to allergen- specific allergy testing in dogs. Drug Interactions Do not use with other antimuscarinic drugs.","indications":"Indications and Clinical Uses Cetirizine is used to treat and prevent allergic reactions in people. It is preferred over older drugs because it has fewer side effects. In dogs and cats, it has been considered for pruritus therapy, allergic airway disease, rhinitis, and other allergic conditions. In cats, 1 mg/kg (5 mg/cat) has produced plasma concentrations considered effective. However, it was not effective in decreasing the inflammatory response in cats with hyperresponsive airways (experimentally induced asthma). In dogs, doses of 2 mg/ kg suppress histamine response for 8 hours. However, there are no published clinical trials to document efficacy for allergic conditions, pruritus in dogs, or airway diseases. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is not as likely as with other antihistamines. However, with higher doses, sedation is still possible. Antimuscarinic effects (atropinelike effects) also are possible, but cetirizine may produce fewer antimuscarinic effects than other antihistamines.","notes":"Instructions for Use Use of cetirizine has been mostly empirical. There are no clinical studies to document efficacy. 168    Charcoal, Activated Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tCetirizine\\thydrochloride\\tis\\tavailable\\tin\\t1-\\tmg/mL\\toral\\tsyrup\\tand\\t5-\\t\\tand\\t10-\\tmg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antihistamine"},{"name":"Charcoal, Activated","active_ingredient":"Charcoal, Activated","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20134\\tg/kg\\tPO\\t(granules)\\tor\\t6\u201312\\tmL/kg\\t(suspension).\\tAdminister\\ta\\tsingle\\tdose shortly after poisoning. A common dose for dogs is a single dose of 2 g/kg as soon as possible after ingestion of a toxin.  \u2022\\t \\tLarge\\t   animal\\t   use\\t  is\\t not\\t  reported,\\tbut\\t  it\\t may\\t  be\\t considered\\tfor\\t treatment\\tof\\t a\\t poisoning. Consider a dose of 1 g/kg PO (granules) or 6\u201310 mL/kg (suspension) PO. Regulatory Information No\\tresidue\\tconcerns.\\tWithdrawal\\ttime:\\t0\\tdays. Chlorambucil klor- am\u2032byoo- sil Trade and other names: Leukeran","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Used primarily to adsorb drugs and toxins in intestine to prevent their absorption. Ordinarily, a single dose is administered. In some studies, a single dose was as effective as multiple doses in dogs. Consult a poison control center to determine what other supportive measures should be used if a case of intoxication is treated. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Not\\tabsorbed\\tsystemically.\\tSafe\\tfor\\toral\\tadministration,\\texcept\\tthat\\tconstipation may occur; however, formulations that contain sorbitol may induce diarrhea. C Chlorambucil 169","notes":"Instructions for Use Dosing\\tof\\tactivated\\tcharcoal\\thas\\tused\\ta\\tratio\\tof\\t10:1\\t(charcoal:toxin)\\tto\\tadminister\\tfor treatment of intoxication. However, more recent evidence indicates that a ratio greater than\\t40:1\\tis\\tmore\\tappropriate,\\twhich\\tmay\\trequire\\thigher\\tdoses\\tthan\\tpreviously\\tthought. Activated charcoal is effective to treat intoxication if administered up to 4 hours after exposure, but after 4 hours, benefits decrease. Charcoal is available in a variety of forms and usually is used as treatment for poisoning. Many commercial preparations contain sorbitol, which acts as a flavoring agent and promotes intestinal catharsis. Patient Monitoring and Laboratory Tests When used as treatment for intoxication, careful monitoring of effects of toxin is necessary because charcoal will not adsorb all of the toxicant. Formulations \u2022\\t\\tCharcoal\\tis\\tavailable\\tin\\toral\\tsuspension\\tand\\tgranules.\\tStrengths\\tof\\tformulations\\tvary from 15 g/72 mL to 50 g/240 mL. Many formulations contain sorbitol, which is a sweetener and also can produce an intestinal cathartic effect. Stability and Storage Store in a tightly sealed container at room temperature. Do not mix with other compounds because it will adsorb other chemicals.","original_category":"Antidote"},{"name":"Chlorambucil","active_ingredient":"Chlorambucil","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t4\\tmg/m 2 q24h PO as a starting dose; then increase the interval to q48h PO. (Equivalent dose is 0.1\u20130.2 mg/kg.) \u2022\\t\\tIntestinal\\tdisease:\\tStart\\twith\\t4\u20136\\tmg/m 2 PO q24 for the first 7\u201321 days; then reduce dose. It may be administered with prednisolone in refractory cases. Cats \u2022\\t \\tImmune-\\tmediated\\tdisease:\\t0.1\u20130.2\\tmg/kg\\t(approximately\\tone-half\\ttablet)\\tq24h initially; then q48h PO. Often administered concurrently with corticosteroids. Cats with immune- mediated hemolytic anemia have been treated with 2 mg per cat q48h. \u2022\\t\\tIBD:\\t2\\tmg\\tper\\tcat\\t(one\\ttablet)\\tq48\u201372h\\tPO. \u2022\\t\\tCancer\\ttreatment:\\t2\\tmg\\tper\\tcat\\tPO\\tq48h.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Chloramphenicol klor- am  fen\u2032ih- kole Trade and other names: Chloramphenicol palmitate, Chloromycetin, Viceton, chloramphenicol sodium succinate, and generic brands","contraindications":"Contraindications and Precautions Used primarily as treatment for intoxication. If administered by gastric administration with a stomach tube, serious complications can occur if it is deposited in the airways. Drug Interactions Charcoal adsorbs most other drugs administered orally to prevent their absorption. Pharmacology and Mechanism of Action Chlorambucil is an immunosuppressive agent. Chlorambucil is an alkylating agent of the nitrogen mustard category. It is sometimes used as a substitute for cyclophosphamide. It has a similar action as cyclophosphamide but is one of the slowest acting of the class of nitrogen mustards. As an alkylating agent, it interferes with\\tDNA\\treplication\\tand\\tRNA\\ttranscription\\tby\\talkylation\\tand\\tcross-\\tlinking\\tthe strands\\tof\\tDNA.\\tWhen\\tused\\tin\\tmetronomic\\tdosing\\tprotocols\\tfor\\tcancer,\\tit\\tmay decrease angiogenesis in tumors. Contraindications and Precautions Cytotoxic, potentially immunosuppressive agent. Do not use in animals with suppressed bone marrow. Drug Interactions Chlorambucil will potentiate other immunosuppressive drugs.","indications":"Indications and Clinical Uses Chlorambucil is used for treatment of various tumors and immunosuppressive therapy. Although little has been published on the clinical use of chlorambucil, it may be effective in dogs and cats for immune- mediated disease. However, direct comparisons to other immunosuppressive drugs have not been reported. One of the most frequent uses has been for treatment of immune- mediated skin diseases of cats, for which it has been used to treat cats with pemphigus and eosinophilic granuloma complex (EGC). It is often administered concurrently with corticosteroids. It also has been used to treat inflammatory bowel disease (IBD) in cats and dogs and has been effective for chronic enteropathy characterized by protein losing enteropathy in dogs. Chlorambucil also has been used as an anticancer agent in some protocols. It also has been used in metronomic dosing protocols. At a dosage of 4 mg/m 2 PO q24h, it was well tolerated and produced partial remissions for transitional cell carcinoma. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Myelosuppression is possible, although most cats tolerate chlorambucil well. Cystitis does not occur with chlorambucil as with cyclophosphamide. Diarrhea and anorexia may occur in some patients. At low doses used in metronomic protocols in dogs, it was well tolerated.","notes":"Instructions for Use Chlorambucil may be combined with prednisolone for treatment of immune- mediated disorders, but it is not known if the combination is more effective than prednisolone alone. It also can be used in dogs as a continuous treatment (everyday dose) at low doses of 4 mg/m 2 every day. The cost of chlorambucil has increased dramatically, and some veterinarians have relied on compounded formulations.\\tIt\\tis\\tnot\\tknown\\tif\\tcompounded\\tforms\\tare\\tequivalent\\tto\\tthe\\tFDA- approved forms. Patient Monitoring and Laboratory Tests Monitor CBC in animals during treatment because myelosuppression is the most serious adverse effect. Formulations \u2022\\t\\tChlorambucil\\tis\\tavailable\\tin\\ta\\t2-\\tmg\\ttablet.\\tThe\\ttablet\\tmay\\tbe\\tdifficult\\tto\\tdivide\\tfor small animals. C Chloramphenicol 171 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Chlorambucil undergoes rapid hydrolysis (within 10 minutes) in the presence of water. Hydrolysis occurs most readily at pH greater than 2. Therefore chlorambucil can decompose rapidly in compounded aqueous formulations, such as those that contain simple syrup and other excipients. Hydrolysis is slower if mixed in alcohol- based solutions. If mixed with alcohol and stored in the freezer, it is stable for 31 days. Exposure to light reduces the drug\u2019s stability.","original_category":"Anticancer agent"},{"name":"Chlorpheniramine Maleate","active_ingredient":"Chlorpheniramine Maleate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t4\u20138\\tmg/dog\\tq12h\\tPO\\tup\\tto\\ta\\tmaximum\\tdosage\\tof\\t0.5\\tmg/kg\\tq12h. Cats \u2022\\t\\t2\\tmg/cat\\tq12h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Chlorpromazine klor- proe\u2032mah- zeen Trade and other names: Thorazine and Largactil","contraindications":"Contraindications and Precautions Antimuscarinic effects (atropine- like effects) are common. Do not use in conditions for which anticholinergic drugs may be contraindicated, such as glaucoma, ileus, or cardiac arrhythmias. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals. 176    Chlorpromazine","indications":"Indications and Clinical Uses Chlorpheniramine is used to prevent allergic reactions and for pruritus therapy in dogs and cats. However, success rates for treatment of pruritus have not been high. In addition to the antihistamine effect for treating allergies, these drugs block the effect of histamine in the vomiting center, vestibular center, and other centers that control vomiting in animals. Use in animals has been primarily derived from empirical use. There is a lack of well- controlled clinical studies or efficacy trials to document clinical effectiveness. Other antiemetic agents are more effective and more commonly used in small animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Antihistamines have a high margin of safety. Sedation is the most common side\\teffect,\\twhich\\tis\\tthe\\tresult\\tof\\tinhibition\\tof\\thistamine\\tN-\\tmethyltransferase. Sedation\\tmay\\talso\\tbe\\tattributed\\tto\\tblocking\\tof\\tother\\tCNS\\treceptors\\tsuch\\tas those for serotonin, acetylcholine, and alpha- receptors. Antimuscarinic effects (atropine- like effects) also are common, such as dry mouth and decreased GI secretions.","notes":"Instructions for Use Chlorpheniramine is included as an ingredient in many OTC cough, cold, and allergy medications. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tChlorpheniramine\\tmaleate\\tis\\tavailable\\tin\\t4-\\t\\tand\\t8-\\tmg\\ttablets,\\t2-\\tmg\\tchewable tablets, and 2-mg/5-mL syrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Protect from freezing. Stability of compounded formulations has not been evaluated.","original_category":"Antihistamine"},{"name":"Chondroitin Sulfate","active_ingredient":"Chondroitin Sulfate","species":["Canine","Feline","Equine"],"dosage":"Use the product Cosequin RS and DS Strength as a general guide. Dogs \u2022\\t\\t1\u20132\\tRS\\tcapsules\\tper\\tday. \u2022\\t\\t2\u20134\\tDS\\tcapsules\\tfor\\tlarge\\tdogs. Cats \u2022\\t\\t1\\tRS\\tcapsule\\tdaily.  \u2022\\t\\tHorses:\\t12\\tmg/kg\\tglucosamine,\\t3.8\\tmg/kg\\tchondroitin\\tsulfate\\ttwice\\tdaily\\tPO\\tfor 4 weeks, and then 4 mg/kg glucosamine; 1.3 mg/kg chondroitin sulfate thereafter. \u2022\\t\\tIt\\tis\\tcommon\\tto\\tinitiate\\ttreatment\\tin\\thorses\\twith\\ta\\thigher\\tdose\\tof\\t22\\tmg/kg glucosamine and 8.8 mg/kg chondroitin sulfate daily PO. Regulatory Information Withdrawal times are not established for animals that produce food. Chondroitin sulfate and glucosamine are found naturally, and withdrawal times may not be necessary\\tif\\tthese\\tsupplements\\tare\\tadministered\\tto\\tfood\\tanimals.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Cimetidine Hydrochloride sye- met\u2032ih- deen  hye- droe- klor\u2032ide Trade and other names: Tagamet (OTC and prescription)","contraindications":"Contraindications and Precautions No\\tcontraindications\\thave\\tbeen\\treported. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Chondroitin sulfate is used primarily as a dietary supplement to reduce clinical signs associated with degenerative joint disease. It is usually found in formulations in combination with glucosamine. (See Glucosamine for additional details.) Convincing evidence of clinical efficacy through well- controlled clinical trials is limited. Analyses of published clinical studies in dogs have concluded that there is a moderate level of evidence to indicate some benefit in osteoarthritis, but results may be inconsistent among studies. Benefits of treatment in horses with lameness also have been reported from oral administration of chondroitin\u2013glucosamine supplements. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported, although hypersensitivity is possible. Chondroitin is most often administered with glucosamine. See Glucosamine for potential adverse effects.","notes":"Instructions for Use Doses are based primarily on empiricism and manufacturer\u2019s recommendations. There are limited published trials of efficacy or dose titrations available to determine optimal dose. Doses listed are general recommendations, and products available may vary. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tBecause\\tseveral\\tchondroitin\\tsulfate\\tformulations\\tare\\tavailable,\\tveterinarians\\tare encouraged to carefully examine the product label to ensure proper strength. These products\\tare\\tnot\\tFDA\\tapproved.\\tVeterinary\\tdietary\\tsupplements\\tcan\\tbe\\thighly variable in quality. One product (Cosequin) is available in regular- strength (RS) and double- strength (DS) capsules. The RS capsules contain 250 mg glucosamine, 200 mg chondroitin sulfate and mixed glycosaminoglycans, 5 mg manganese, and 33 mg manganese ascorbate. The DS tablets contain double of each of these amounts. C Cimetidine Hydrochloride 181 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Nutritional supplement"},{"name":"Cimetidine Hydrochloride","active_ingredient":"Cimetidine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmg/kg\\tq6\u20138h\\tIV,\\tIM,\\tor\\tPO.  Horses \u2022\\t\\t3\\tmg/kg\\tdiluted\\tin\\tfluid\\tsolution\\tand\\tinfused\\tIV\\tover\\t2\\tminutes\\tq8h. \u2022\\t\\t40\u201360\\tmg/kg/day\\tPO.\\tHowever,\\toral\\tdoses\\tin\\thorses\\tproduce\\tinconsistent\\tresults. Calves \u2022\\t\\tAbomasal\\tulcers\\tin\\tmilk-\\tfed\\tcalves:\\t100\\tmg/kg\\tq8h\\tPO. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t5 C Ciprofloxacin Hydrochloride 183 Ciprofloxacin Hydrochloride sip- roe- floks\u2032ah- sin  hye- droe- klor\u2032ide Trade and other names: Cipro and generic brands","contraindications":"Contraindications and Precautions Use cautiously with drugs that rely on hepatic metabolism for clearance. Drug Interactions Cimetidine is a well- known CYP450 enzyme inhibitor. It may increase concentrations of other drugs used concurrently because of inhibition of hepatic enzymes. Cimetidine may increase the pH of the stomach, which can inhibit oral absorption of some drugs (e.g., itraconazole and ketoconazole). Cimetidine inhibits the oral absorption of iron supplements.","indications":"Indications and Clinical Uses Cimetidine has been used to treat gastric ulcers and gastritis, but the use has declined considerably because of availability of more effective agents, such as proton- pump inhibitors (PPIs). Although it has been administered to animals for treatment of vomiting, this is not an accepted indication. There also are no efficacy data to support its\\tuse\\tfor\\tpreventing\\tNSAID-\\tinduced\\tbleeding\\tand\\tulcers.\\tIn\\tdogs\\tand\\tcats,\\tother H 2 - blockers are preferred, such as famotidine and ranitidine. The PPIs (omeprazole) are\\tpreferred\\tfor\\tulcer\\ttreatment\\tin\\thorses.\\tFor\\texample,\\tstudies\\tin\\thorses\\tshowed that at 18 g/kg q8h PO, it did not cause healing of ulcers. The poor efficacy may be because of short duration of effect (2\u20136 hours). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported for animals because it is infrequently used. If\\tthey\\toccur,\\tit\\tis\\tmore\\tlikely\\tif\\tthere\\tis\\tdecreased\\trenal\\tclearance.\\tIn\\tpeople,\\tCNS signs may occur with high doses.","notes":"Instructions for Use Efficacy\\tfor\\ttreating\\tulcers\\tin\\tanimals\\thas\\tnot\\tbeen\\testablished.\\tFrequent\\tdosing\\tmay be necessary for suppression of stomach acid. Doses are derived from gastric secretory studies in experimental animals but not tested in clinical patients. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tCimetidine\\tis\\tavailable\\tin\\t100-\\t,\\t150-\\t   ,\\t200-\\t   ,\\t300-\\t   ,\\t400-\\t   ,\\tand\\t800-\\tmg\\ttablets;\\ta\\t60- mg/mL oral solution; and a 150- mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not store injection formulation in refrigerator. Solutions are stable for at least 14 days. Stable if mixed with various enteral products.","original_category":"Antiulcer agent"},{"name":"Cisplatin","active_ingredient":"Cisplatin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t60\u201370\\tmg/m 2 every 3\u20134 weeks IV. (Administer fluid for diuresis with therapy.) Cats \u2022\\t\\tDo\\tnot\\tuse\\tin\\tcats.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Clarithromycin klah- rith\u2032roe- mye\u2032sin Trade and other names: Biaxin and generic brands","contraindications":"Contraindications and Precautions Do not use in cats. Drug Interactions Cisplatin may be used with other cancer chemotherapy agents in some protocols. Do not use with other nephrotoxic drugs. 188    Clarithromycin","indications":"Indications and Clinical Uses Cisplatin is used for treating various solid tumors, including bronchiogenic carcinoma, osteosarcoma, transitional cell carcinoma, and mast cell tumors. It has been shown to be effective for increasing the survival of dogs that have undergone amputations for osteosarcoma. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nephrotoxicity\\tis\\tthe\\tmost\\tlimiting\\tfactor\\tto\\tcisplatin\\ttherapy.\\tMonitor\\tlaboratory indices for kidney injury during treatment. In cats, it causes a dose- related, species- specific, primary pulmonary toxicosis. Vomiting is common in dogs with administration. Cisplatin is one of the most emetic of the cancer agents. Transient thrombocytopenia may occur in dogs. Cisplatin has caused potassium wasting and depletion of magnesium.","notes":"Instructions for Use To avoid toxicity, fluid loading before administration using sodium chloride should be performed. Antiemetic agents are often administered before therapy to decrease vomiting.\\tFor\\ttransitional\\tcell\\tand\\tsquamous\\tcell\\tcarcinomas,\\tdosages\\tused\\tare 40\u201350 mg/m 2 every\\t21\u201328\\tdays.\\tFor\\tosteosarcoma,\\tit\\thas\\tbeen\\tused\\tat\\ta\\tdosage\\tof 70 mg/m 2 every 21 days for four treatments. Patient Monitoring and Laboratory Tests Monitor renal function in treated animals. Monitor CBC in patients between treatments. Formulations \u2022\\t\\tCisplatin\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Clemastine Fumarate","active_ingredient":"Clemastine Fumarate","species":["Canine","Equine","Feline"],"dosage":"Dogs \u2022\\t\\t0.05\u20130.1\\tmg/kg\\tq12h\\tPO,\\tup\\tto\\t0.5\u20131.5\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tDogs\\tweighing\\tless\\tthan\\t10\\tkg:\\thalf\\tof\\ttablet.\\t(Dose\\tbased\\ton\\tq12h\\ttreatment\\tand 1.34- mg  tablet.) \u2022\\t\\tDogs\\tweighing\\t10\u201325\\tkg:\\t1\\ttablet.\\t(Dose\\tbased\\ton\\tq12h\\ttreatment\\tand\\t1.34-\\tmg tablets.) \u2022\\t\\tDogs\\tweighing\\tmore\\tthan\\t25\\tkg:\\t1.5\\ttablets.\\t(Dose\\tbased\\ton\\tq12h\\ttreatment\\tand 1.34- mg  tablets.)  Horses \u2022\\t\\t50\\tmcg/kg\\t(0.05\\tmg/kg)\\tq8h\\tIV.\\tIt\\tis\\tnot\\tabsorbed\\torally\\tin\\thorses. Regulatory Information Do not administer to animals that produce food. RCI\\tClassification:\\t3 Clenbuterol klen- byoo\u2032ter- ole Trade and other names: Ventipulmin","contraindications":"Contraindications and Precautions No\\tcontraindications\\treported\\tfor\\tanimals. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Clemastine is used primarily for treatment of allergy, but efficacy in animals has not been well established. Some reports have suggested that clemastine is effective for pruritus in dogs, but other agents are preferred for standard treatment. The half- life in dogs is short (3.8 hours), and it has rapid clearance. After oral administration, the oral absorption is only 3% (20%\u201370% in humans). At a high dose of 0.5 mg/kg PO, it did not suppress intradermal skin reactions. This evidence suggests that oral administration may not be as effective in dogs as previously thought. Oral absorption studies in horses indicated that it is not absorbed when given orally (bioavailability was only 3%), and it would not likely be effective for oral treatment. C Clenbuterol 191 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. Sedation is the result of inhibition of histamine N-\\t methyltransferase.\\tSedation\\tmay\\talso\\tbe\\tattributed\\tto\\tblocking\\tof\\tother\\tCNS\\treceptors such as those for serotonin, acetylcholine, and alpha- receptors. Antimuscarinic effects (atropine- like effects) also are possible, such as dry mouth and decreased GI secretions.","notes":"Instructions for Use Clemastine fumarate has been used for short- term treatment of pruritus in dogs, but efficacy is low. It may be more efficacious when combined with other anti- inflammatory drugs. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tClemastine\\tfumarate\\tis\\tavailable\\tin\\t1.34-\\tmg\\ttablets\\t(OTC),\\t2.64-\\tmg\\ttablets (prescription), and 0.1- mg/mL syrup. If the syrup is use, consider that Tavist syrup contains 5.5% alcohol. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antihistamine"},{"name":"Clenbuterol","active_ingredient":"Clenbuterol","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tsmall\\tanimals.  Horses \u2022\\t\\tEquine\\tasthma\\tsyndrome\\t(recurrent\\tairway\\tobstruction):\\t0.8\\tmcg/kg\\t(0.008\\tmg/kg) twice daily PO. If initial dose is not effective, increase dose to two, three, and four times the initial dose, up to 3.2 mcg/kg. Duration of effect is approximately 6\u20138 hours. Regulatory Information There are no withdrawal times established because clenbuterol should not be administered to animals that produce food. In horses, clenbuterol can be detected in urine for 12 days. Although not an approved human drug, it is abused in humans for weight loss and muscle building. RCI\\tClassification:\\t3 Clindamycin Hydrochloride klin- dah- mye\u2032sin  hye- droe- klor\u2032ide Trade and other names: Antirobe, ClinDrops, ClindaTobe, Clintabs, Clinsol, and generic and Cleocin (human form)","contraindications":"Contraindications and Precautions Do not administer to animals intended for food. Veterinarians should be warned that clenbuterol is often abused in humans for the purpose of muscle building and weight loss. Subsequently, high doses in humans may cause cardiac toxicity, such as arrhythmias. Drug Interactions Because clenbuterol is a beta- agonist, other adrenergic drugs potentiate the action. In addition, beta- blocking drugs decrease action. Use with caution with any other drug that may stimulate the heart. C Clindamycin Hydrochloride 193","indications":"Indications and Clinical Uses Clenbuterol is indicated for treatment of animals with reversible bronchoconstriction such as horses with equine asthma syndrome and recurrent airway obstruction (RAO), formerly called chronic obstructive pulmonary disease. The response for treating RAO can be variable. Some horses that do not respond to a low dose respond better at four times the starting dose with a better response rate. At high doses, tachyphylaxis may occur with repeated high doses. Evidence for treating airway disease has been demonstrated in horses, but there are no reports of use in other species. The effects on repartitioning (producing more muscle and less fat) should not be used in performance horses. It should not be used in animals intended for food. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Clenbuterol may produce excessive beta- adrenergic stimulation at high doses (tachycardia and tremors). Arrhythmias occur at high doses. Chronic use may have adverse effects on cardiac function in healthy horses. There have been conflicting studies on the effects of clenbuterol on athletic performance of horses. In one study at approved doses, it did not have any adverse effects on equine cardiac or skeletal muscle. In other studies, it had negative effects on aerobic athletic performance, faster time to fatigue, decreased cardiac function, and decreased oxygen consumption. The negative effects may occur because after repeated doses it down- regulates the adrenergic beta 2 receptor and results in decrease in receptor expression in skeletal muscle and lungs.","notes":"Instructions for Use Oral administration for horses usually follows the approved label dose. Clenbuterol has not been used in small animals. It is prohibited for use in animals intended for food. Patient Monitoring and Laboratory Tests Monitor heart rate in animals during treatment. Clenbuterol can be detected in urine for 12 days. Effective plasma concentrations are 500 pg/mL. Formulations \u2022\\t\\tClenbuterol\\tis\\tavailable\\tin\\t100-\\t\\tand\\t33-\\tmL\\tbottles\\tof\\t72.5-\\tmcg/mL\\tsyrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Bronchodilator, beta agonist"},{"name":"Clodronate","active_ingredient":"Clodronate","species":["Canine","Feline","Equine"],"dosage":"\u2022\\t\\tNo\\tdoses\\thave\\tbeen\\tconfirmed\\tfor\\tdogs\\tor\\tcats,\\tbut\\tthere\\tare\\tanecdotal\\taccounts\\tof a dose of 20\u201325 mg/kg IV over 4 hours for treatment of hypercalcemia.  Horses \u2022\\t\\t1.8\\tmg/kg\\tIM.\\tMaximum\\tdose\\tis\\t900\\tmg\\tper\\thorse.\\tDivide\\tthe\\ttotal\\tvolume equally into three separate injection sites. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Clofazimine kloe- fah\u2032zih- meen Trade and other names: Lamprene","contraindications":"Contraindications and Precautions Do not use in horses with kidney disease. Use carefully in conditions associated with hypocalcemia. It is not recommended to administer bisphosphonates to young growing animals. Do not use in pregnant mares because the safety in pregnancy has not been evaluated, and bisphosphonates have caused fetal abnormalities of the bone when administered to laboratory animals. Use in young horses: The manufacturer states that the safety of clodronate in horses younger than 4 years of age has not been evaluated. They also state that the effect of bisphosphonates on the skeleton of growing horses has not been studied; however, bisphosphonates inhibit osteoclast activity, which impacts bone turnover and may affect bone growth. It is recommended not to administer bisphosphonates such as clodronate in young performance horses because the change in bone metabolism may predispose young horses to fracture, but one study that examined clodronate and tiludronate in young horses concluded that tiludronate and clodronate did not appear to significantly impact bone tissue on a structural or cellular level using standard dose and administration schedules in young horses. Drug Interactions Do not mix with solutions containing calcium (e.g., lactated Ringer\u2019s solution).","indications":"Indications and Clinical Uses Clodronate is approved in the United States for treatment of bone pain associated with navicular syndrome in horses. Other bisphosphonate drugs are used in people to treat osteoporosis and treatment of hypercalcemia of malignancy. Other drugs in this class are helpful for managing complications associated with pathologic bone resorption. The bisphosphonates may provide pain relief in patients with pathologic bone disease. However, they do not have a direct analgesic effect. In horses treated with clodronate or tiludronate they showed clinical improvements in their degree of lameness, but it is unclear whether the reduction in lameness was caused by the effect on bone remodeling, analgesia, or other mechanisms. Another bisphosphonate is tiludronate (Tildren), also approved for treating navicular disease in horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Reaction\\tto\\tclodronate\\thas\\tonly\\tbeen\\treported\\tfor\\thorses.\\tFrom\\tfield\\ttrials, the most commonly reported adverse effects were colic, agitation, and mild neurologic signs, such as tongue rolling and head shaking. Signs of colic usually occur shortly after drug administration (2 hours); therefore, monitor horses for at least 2 hours after injection. In most cases, these signs resolved within 5.5 hours following administration. Clinical pathology abnormalities associated with administration of OSPHOS included elevations in serum blood urea nitrogen, creatinine, glucose, and potassium concentrations and decreases in serum chloride concentrations. In safety studies, the most common adverse effects were clinical signs related to abdominal discomfort (colic), which was dose related (more common at doses that exceeded label dose).","notes":"Instructions for Use Make sure horses are well hydrated prior to use to avoid kidney injury. Observe horses for 2 hours after administration for signs of colic. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Monitor urea nitrogen, creatinine, urine- specific gravity, and signs of colic in treated animals. C Clofazimine 197 Formulations Clodronate is available as 60 mg clodronate disodium per milliliter in 20- mL vial containing. Stability and Storage Store at controlled room temperature 25\xb0C (77\xb0F)\\twith\\tdeviations\\tbetween\\t15\xb0C and 30\xb0C (59\xb0F\\tand\\t86\xb0F)\\tpermitted.","original_category":"Antihypercalcemic"},{"name":"Clomipramine Hydrochloride","active_ingredient":"Clomipramine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2\u20134\\tmg/kg/day,\\tPO,\\twhich\\tmay\\tbe\\tadministered\\tas\\ta\\tsingle\\tdose,\\tor\\tdivided\\tinto twice-daily doses. Start at lower dose and gradually increase to reach the desired effect. Increases in dose should be made approximately every 14 days until desired effect is observed. Cats \u2022\\t\\t1\u20135\\tmg\\tper\\tcat\\tq12\u201324h\\tPO\\t(0.5\\tmg/kg\\tper\\tday)\\tand\\tgradually\\tincrease. \u2022\\t\\tUrine\\tspraying\\tin\\tcats:\\tUp\\tto\\t5\\tmg\\tper\\tcat\\tonce\\ta\\tday. 200    Clonazepam  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t2 Clonazepam kloe- nah\u2032zih- pam Trade and other names: Klonopin and generic brands","contraindications":"Contraindications and Precautions Use cautiously in patients with heart disease. Drug Interactions Do not use with other behavior- modifying drugs such as serotonin reuptake inhibitors. Do not use with monoamine oxidase inhibitors, such as selegiline or amitraz. Although tramadol can produce some serotonin effects, there have been no reported interactions from administration of tramadol and clomipramine concurrently.","indications":"Indications and Clinical Uses Like other TCAs, clomipramine is used in animals to treat various behavioral disorders, including obsessive- compulsive disorders (also called canine compulsive disorder) and separation anxiety. In dogs, it has been superior to amitriptyline for treating compulsive disorders; however, it does not appear to be beneficial when used for dominance- related aggression. In cats, with long- term treatment, it has been effective for decreasing urine spraying. It was equally effective as fluoxetine for urine spraying in cats, but treated animals returned to urine marking abruptly after the drug was discontinued. It has not been effective for psychogenic alopecia in cats. C Precautionary Information","side_effects":"Adverse Reactions and Side Effects Reported adverse effects include sedation and reduced appetite. Vomiting may occur in dogs, which can be reduced if administered with a small amount of food. Clomipramine has a bitter taste and some animals may refuse the medication. Other side effects associated with TCAs are antimuscarinic effects (dry mouth, rapid heart rate, and urine retention) and antihistamine effects (sedation). In cats, sedation and weight gain have been observed. The antimuscarinic effects from clomipramine may be caused by an active metabolite. Clomipramine can decrease total T 4 and free T 4 thyroid concentrations in dogs, but it may still be within normal reference ranges. It has been safe in cats, with no significant adverse effects observed during clinical studies. Overdoses, especially in dogs that accidentally consume large amounts, can produce life- threatening cardiotoxicity. If an overdose occurs, immediately contact a poison control center.","notes":"Instructions for Use When adjusting doses, one may initiate therapy with a low dose and increase gradually. There may be a delayed onset of 2\u20134 weeks after initiation of therapy before beneficial effects are observed. After achieving a favorable response, the dose can be gradually lowered in some animals. To reduce incidence of vomiting in dogs, it may be administered with food. Patient Monitoring and Laboratory Tests Monitor animal\u2019s heart rate and rhythm periodically during treatment. Like other TCAs, clomipramine may decrease total T 4 and free T 4 concentrations in dogs. Formulations \u2022\\t \\tClomipramine\\tis\\tavailable\\tin\\t5-,\\t20-\\t,\\t40-\\t  ,\\tand\\t80-\\tmg\\ttablets\\t(veterinary\\tpreparation). \u2022\\t\\t25-\\t ,\\t50-\\t  ,\\tand\\t75-\\tmg\\tcapsules\\t(human\\tpreparation). Stability and Storage Store at room temperature. Protect from moisture. It has been compounded in a tuna- flavored liquid for cats without a decrease in efficacy.","original_category":"Behavior modification"},{"name":"Clopidogrel","active_ingredient":"Clopidogrel","species":["Canine","Feline","Equine"],"dosage":"one fourth. The dosage in dogs is usually 1\u20132 mg/kg q24h PO. At this dosage, the onset is 2 days, and steady- state is achieved in 5\u20137 days. Higher doses are often used initially in dogs for the first few days.  Cats \u2022\\t\\t18.75\\tmg\\tper\\tcat\\t(one\\tfourth\\tof\\ttablet)\\tq24h\\tPO.\\tThe\\ttaste\\tis\\tbitter\\tfor\\tcats,\\tand fractions of the tablets may be placed in gelatin capsules. \u2022\\t\\tSmaller\\tdoses\\tmay\\tbe\\teffective\\tbut\\thave\\tnot\\tbeen\\tevaluated\\tin\\tcats. Dogs \u2022\\t\\t2\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tAn\\toral\\tloading\\tdose\\tmay\\tbe\\tgiven\\tat\\t2\u20134\\tmg/kg\\tfollowed\\tby\\t1\u20132\\tmg/kg\\tq24h PO. In some cases, a higher oral loading dose of 10 mg/kg has been used.  Horses \u2022\\t\\tLoading\\tdose\\tof\\t4\\tmg/kg\\tfollowed\\tby\\t2\\tmg/kg\\tq24h\\tPO. Regulatory Information Do not administer to animals that produce food. Cloprostenol Sodium kloe- pros\u2032te- nole Trade and other names: Estrumate, estroPLAN","contraindications":"Contraindications and Precautions Do not use in patients that have a high risk of bleeding. Discontinue several days prior to a planned surgical procedure. Drug Interactions Use cautiously with other drugs that may inhibit blood clotting, such as anticoagulants. In people, omeprazole (oral antiulcer agent) inhibits the conversion of clopidogrel to the active metabolite. This does not occur in dogs. It is not known if this interaction occurs in cats or horses with clinical use.","indications":"Indications and Clinical Uses Clopidogrel is used to inhibit platelets in patients that are prone to forming blood clots. In patients with a high risk for thrombi and emboli, clopidogrel inhibits mechanisms that are not affected by aspirin alone. It has been used currently with aspirin treatment, but combined treatment is usually not necessary. Although clopidogrel is more consistently reliable as an antiplatelet drug than aspirin, some animals\\tmay\\tbe\\tnonresponders\\t(e.g.,\\t33%\\tof\\thorses,\\t15%\\tof\\tcats).\\tNevertheless,\\tthe consensus opinion by experts recommend that clopidogrel is preferred over aspirin for prevent of arterial thromboemboli in dogs and cats. In cats, clopidogrel has been recommended to prevent cardiogenic arterial thromboembolism associated with heart disease. Treatment can be initiated in cats based\\ton\\techocardiogram\\tstudies\\tthat\\tdemonstrate\\tthe\\tpresence\\tof\\t\u201csmoke\u201d\\tin\\tthe left atrium. In cats, clopidogrel produces antiplatelet effects that persist for 3 days after discontinuation of the drug. In dogs, it has been used to prevent embolism caused by heartworm disease and other conditions. In dogs, at a dose of either 0.5 or 1.0 mg/kg, decreased ADP- induced platelet aggregation occurs for 3 days after discontinuation of drug administration in some dogs and longer than 7 days in others. At 2 mg/kg PO q24h, clopidogrel significantly suppressed platelet activity in horses, which persisted for 6 days after the last dose. However, not all horses respond, and effects may not be sustained for 24 hours. This may be caused by rapid elimination of the active metabolite in some horses. A similar drug is ticlopidine (Ticlid), which should not be used in cats because it produces adverse reactions. Precautionary Information Avoid use in animals that have bleeding problems; use cautiously with other drugs that may inhibit platelets or blood clotting.","side_effects":"Adverse Reactions and Side Effects Bleeding problems can occur in susceptible patients, but this has not been reported to be a clinical problem in dogs or cats. In people, pruritus and skin rash have been reported, but this has not been observed in dogs and cats. The taste is bitter, and some cats may refuse oral administration.","notes":"Instructions for Use Administer with or without aspirin in patients prone to thrombi and emboli, but concurrent use with aspirin is not necessary. Because platelets are involved in arterial thromboembolism more than venous thromboembolism, the use for prevention of arterial thromboembolism is better established than the use for venous thromboembolism. The dose in cats of 19 mg is approximately one fourth of a human tablet. It is likely that smaller doses are effective, but they have not been evaluated because it is impractical to divide the human 75- mg tablet into fractions smaller than C Cloprostenol Sodium 203 Patient Monitoring and Laboratory Tests Monitor for bleeding. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiplatelet drug"},{"name":"Cloprostenol Sodium","active_ingredient":"Cloprostenol Sodium","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\tTerminate\\tpregnancy:\\t1\u20132.5\\tmcg/kg\\tonce\\tdaily\\tSQ\\tfor\\t4\u20135\\tdays,\\tstarting\\ton\\tday 25 after mating. (Side effects are lower with 1 mcg/kg.) \u2022\\t\\tStarting\\t35\u201345\\tdays\\tafter\\tmating,\\tadminister\\t1\\tmcg/kg\\tSQ\\t(after\\t10-\\tfold\\tdilution in saline) on days 1 and 3 of treatment. It can be administered with cabergoline (Galastop) 5 mcg/kg oral q24h on days 1\u20137 of treatment (see Cabergoline for more information). \u2022\\t\\t1\\tmcg/kg\\tq48h\\tSQ,\\tadministered\\twith\\tbromocriptine\\t(see\\tBromocriptine\\tfor additional information). Cats \u2022\\t\\tTerminate\\tpregnancy:\\t5\\tmcg/kg\\tSQ\\tonce\\tdaily\\tfor\\t3\\tdays.  Cattle \u2022\\t\\t2\\tmL\\t(500\\tmcg)\\tIM\\tonce\\tor\\trepeated\\tagain\\t11\\tdays\\tafter\\tthe\\tfirst\\tinjection. \u2022\\t\\tDairy\\tcattle:\\tAdminister\\tgonadorelin\\tinjection\\tIM\\t(86\\tmcg)\\tIM\\ton\\tday\\t0;\\tthen administer cloprostenol (500 mcg) IM 6\u20138 days later. Administer a second gonadorelin injection (86 mcg) 30\u201372 hours after the last cloprostenol injection and perform artificial insemination 8\u201324 hours later. Horses \u2022\\t\\tTerminate\\tpregnancy:\\t2\\tmL\\t(500\\tmcg)\\tper\\thorse,\\tIM.\\tIn\\tsome\\tconditions, repeated injections are administered (e.g., q12h). \u2022\\t\\tTo\\tinduce\\tpremature\\tlabor\\tin\\tthe\\tlast\\t2\u20134\\tweeks\\tof\\tpregnancy,\\tadminister\\ttwo doses 30 minutes apart (oxytocin also is used for this indication). \u2022\\t\\tFor\\tendometritis,\\t250\\tmcg\\t(1\\tmL)\\tIM\\ttwice,\\t12\\thours\\tapart,\\tusually\\tcombined with oxytocin. Regulatory Information To\\tbe\\tused\\tonly\\tby\\tlicensed\\tveterinarians.\\tNo\\twithdrawal\\ttimes\\tare\\tlisted\\ton\\tapproved label for food animals. Clorazepate Dipotassium klor- az\u2032eh- pate  dye- poe- tah\u2032see- um Trade and other names: Tranxene and generic","contraindications":"Contraindications and Precautions Synthetic PGs are much more potent than natural PGs, so observe doses carefully to avoid overdose of the synthetic forms. Handle with caution. Women of childbearing age, people with asthma, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. Cloprostenol is readily absorbed through the skin and may cause abortion or bronchospasms. Accidental spillage on the skin should be washed off immediately with soap and water.","indications":"Indications and Clinical Uses Cloprostenol has been used in cattle to induce luteolysis (beef and dairy cattle) to manipulate the timing of the estrus cycle to benefit breeding management practices. Cloprostenol has been used to terminate pregnancy in any animal that forms a corpus luteum. The indications to terminate pregnancy may be the result from undesired mating and to treat conditions associated with prolonged luteal function (e.g., pyometra, luteal cysts). In horses, it has been administered to induce premature labor in the last 2\u20134 weeks of pregnancy. Most reports on successful termination of pregnancy have been performed on cattle, horses, and dogs. In dogs, cloprostenol has been administered in combination with other drugs (e.g., cabergoline [Dostinex] and bromocriptine [Parlodel]) to terminate pregnancy. When used to terminate pregnancy, it has been almost 100% effective. In cats, it is effective for treatment of pyometra in cats with an open cervix. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Induces abortion in pregnant animals. High doses in cattle (50\xd7 and 100\xd7 dose) have caused discomfort, milk letdown, and some frothing. Endometritis can occur in some animals after treatment for pyometra. When used to treat pyometra in dogs, panting, vomiting, nausea, and diarrhea can be seen 15\u201345 minutes after injection. In dogs, for termination of pregnancy, side effects have been mild but may include vomiting, nausea, and panting, occurring shortly after the injection and lasting for approximately 15\u201320 minutes. To avoid vomiting, it is recommended to wait 8 hours after feeding before injection. Abortion may be followed by 1 week (approximately) of mucoid vulvar discharge. There are no long- term effects on fertility. Mammary enlargement and mild milk production may occur in some dogs. In cats, adverse effects after injection include vomiting, vocalization for up to 30 minutes, increased vaginal discharge, and diarrhea. side effects. Administer cloprostenol at least 8 hours after feeding to avoid vomiting.","notes":"Instructions for Use Give injections to cattle IM. When cloprostenol is injected in cattle, return to estrus activity usually occurs in 3\u20135 days, at which time animals may be inseminated. In some cases, a second injection may be given 11 days after the first injection (double- injection plan), with estrus occurring at 2\u20135 days after the second injection. In dairy cattle,\\tit\\tis\\tused\\twith\\tgonadorelin\\t(Fertagyl)\\tto\\tsynchronize\\testrous\\tcycles\\tand\\tallow for a fixed time for artificial insemination (see Gonadorelin and the dosing section below for more information). When used to terminate pregnancy in cattle, it can be used any time from day 7 to 5 months after breeding, and the fetus is expelled usually after 4\u20135 days. In dogs, it has been used to terminate pregnancy approximately 30\u201340 days after breeding. In dogs, when used to terminate pregnancy, it has been used in combination with other drugs (bromocriptine or cabergoline) to allow for a lower dose of 1 mcg/kg, which has fewer Patient Monitoring and Laboratory Tests Monitor for continued vulvar discharge after treatment. Measurement of serum progesterone may be used to monitor therapy, especially if termination of abortion is prolonged. C Clorazepate Dipotassium 205 Formulations \u2022\\t\\tCloprostenol\\tis\\tavailable\\tin\\tan\\tinjectable\\taqueous\\tsolution\\tcontaining\\t250\\tmcg\\tof cloprostenol per milliliter. Dilution in saline is recommended for accurate dosing to dogs and cats. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated, but prior to injection in small animals, it may be diluted with saline solution to produce a more accurate dose.","original_category":"Prostaglandin"},{"name":"Colchicine","active_ingredient":"Colchicine","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.01\u20130.03\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Colony- Stimulating Factors: Sargramostim and Filgrastim Trade and other names: Leukine and Neupogen","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. Drug Interactions There are no drug interactions reported for small animals. C Colony- Stimulating Factors: Sargramostim and Filgrastim 211","indications":"Indications and Clinical Uses In people, colchicine is used to treat gout. In animals, it has been used as an antifibrotic agent to decrease fibrosis and development of hepatic failure (possibly by inhibiting formation of collagen). However, the efficacy for controlling liver fibrosis in chronic liver disease is questionable and unproven. Anti- inflammatory effects may be caused by inhibition of neutrophil and mononuclear migration. Antifibrotic effects result from blockage of microtubular- mediated transcellular movement of proteins and to inhibit secretion of procollagen molecules into the extracellular matrix. It has also been used in animals to control amyloidosis. In Shar- Pei dogs, colchicine has been used to treat a fever syndrome, possibly because of its use in people for treating Mediterranean fever. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effects are nausea, vomiting, abdominal pain, and diarrhea. Because there is a risk of vomiting, diarrhea, and decreased appetite in dogs and there is little evidence of antifibrotic effect for chronic liver disease in dogs, the use in dogs with liver disease is discouraged. Colchicine may cause dermatitis in people, but this has not been reported in dogs or cats.","notes":"Instructions for Use Doses are based on empiricism and anecdotal reports. There are no well- controlled efficacy studies in veterinary species. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anti- inflammatory  agent"},{"name":"Cyanocobalamin","active_ingredient":"Cyanocobalamin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t100\u2013200\\tmcg/day\\tPO\\tor\\t250\u2013500\\tmcg/day\\tIM\\tor\\tSQ. Cats \u2022\\t\\t50\u2013100\\tmcg/day\\tPO\\tor\\t250\\tmcg\\tIM\\tor\\tSQ\\tweekly.\\tIf\\tlevels\\tare\\tmaintained\\twith once- weekly injections for 6 weeks, increasing the interval to 2 weeks, 4 weeks, and 6 weeks (incrementally) can be attempted.  Calves and Foals \u2022\\t\\t500\\tmcg\\tonce\\tper\\tfoal\\tor\\tcalf\\ttwice\\tweekly\\tIM\\tor\\tSQ. Lambs and Pigs \u2022\\t\\t500\\tmcg\\tonce\\tper\\tlamb\\tor\\tpig\\ttwice\\tweekly\\tIM\\tor\\tSQ. Cattle and Horses \u2022\\t\\t1000\u20132000\\tmcg\\tper\\thorse\\tor\\tcattle\\tonce\\tor\\ttwice\\tweekly\\tIM\\tor\\tSQ. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tavailable.\\tBecause\\tclearance\\tis\\trapid\\tand\\tthere\\tis\\tlittle\\trisk from residues, no withdrawal time is suggested for animals intended for food. Cyclophosphamide sye- kloe- foss\u2032fah- mide Trade and other names: Cytoxan, Neosar, and CTX","contraindications":"Contraindications and Precautions No\\tcontraindications\\treported\\tfor\\tanimals. Drug Interactions There are no drug interactions reported for small animals.","indications":"Indications and Clinical Uses Vitamin B 12 has been used to treat some conditions of anemia. Vitamin B 12 is used to manage vitamin B deficiencies associated with cobalt deficiency, inadequate intake, or intestinal malabsorption. In patients with exocrine pancreatic insufficiency or chronic enteropathies such as IBD, particularly cats, deficiency of cobalamin is common, and supplementation is recommended. Cobalamin deficiency may occur with pancreatic\\tdisease\\tbecause\\tit\\trequires\\tan\\tintrinsic\\tfactor\\t(IF)\\tfor\\tabsorption,\\tand\\tIF\\tis produced by the pancreas. Deficiencies produce metabolic consequences, including anorexia, weight loss, lethargy, central and peripheral neuropathy, villous atrophy, and malabsorption of various vitamins and minerals. Oral supplementation has been effective to normalize serum cobalamin in dogs with intestinal disease. Vitamin B 12 is a water- soluble vitamin and absorption in the intestine is a receptor- mediated\\tprocess.\\tIt\\tis\\tdependent\\ton\\tthe\\tIF\\tproduced\\tby\\tthe\\tpancreas,\\tand\\tanimals with intestinal disease may have difficulty with absorption. Cats are particularly susceptible because they cannot store cobalamin as well as people, and they lack the binding protein transcobalamin- 1. Thus, cats have a much more rapid turnover than people. The half- life in people is 1 year, but in healthy cats, it is 11\u201314 days, or 4.5\u20135.5 days in cats with intestinal disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare, except in high overdoses, because water- soluble vitamins are easily excreted in the urine.","notes":"Instructions for Use Not\\tnecessary\\tto\\tsupplement\\tin\\tanimals\\twith\\twell-\\tbalanced\\tdiets.\\tBut\\tin\\tdogs\\tand\\tcats with intestinal disease, supplementation is recommended. Many cats are deficient if supplementation is not provided (explanation provided above). In these cats, weekly supplementation is recommended. Patient Monitoring and Laboratory Tests Cobalamin concentrations can be measured in most laboratories. Recommended plasma/ serum concentrations are 252\u2013908 ng/L in dogs and 290\u20131500 ng/L in cats. Less than 160 ng/mL in cats is clearly deficient. Monitor CBC when used to treat anemia. C Cyclophosphamide 217 Formulations \u2022\\t\\tCyanocobalamin\\tis\\tavailable\\tin\\ttablets\\tranging\\tfrom\\t25\\tto\\t1000\\tmcg.\\tInjection formulations range from 1000 to 5000 mcg/mL (1\u20135 mg/mL). Vitamin B complex solutions may contain 10\u2013100 mcg/mL of vitamin B 12 . Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vitamin"},{"name":"Cyclophosphamide","active_ingredient":"Cyclophosphamide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tAnticancer\\tdosage:\\t50\\tmg/m 2 (\u22482.2 mg/kg) q48h or once daily 4 days/wk PO. Alternatively, some protocols use 150\u2013300 mg/m 2 IV and repeat in 21 days. \u2022\\t\\tMetronomic\\tdosage\\t(continuous\\tadministration\\tto\\tsuppress\\tT\\tcells):\\t10\u201315\\tmg/m 2 q24h PO (approximately 0.3 mg/kg). \u2022\\t\\tImmunosuppressive\\ttherapy:\\tDogs:\\t50\\tmg/m 2 q48h PO or 2.2 mg/kg once daily for 4 days/wk. \u2022\\t\\tPulse\\ttherapy:\\t200\u2013250\\tmg/m 2 (10 mg/kg) once every 3 weeks. Dividing the 250- mg/m 2 dose into three treatments over 3 days may reduce risk of sterile hemorrhagic cystitis. Cats \u2022\\t\\t6.25\u201312.5\\tmg/cat\\tonce\\tdaily\\t4\\tdays/wk,\\tPO.\\tIn\\tsome\\tprotocols,\\tthe\\tdosage\\thas been increased to 25 mg per cat twice per week PO. Alternatively, doses of 200 mg/m 2 have been used.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Cyclosporine, Cyclosporin A sye\u2032kloe- spor- een Trade and other names: Atopica (veterinary preparation), Neoral (human preparation), Sandimmune, Optimmune (ophthalmic), Gengraf, and generic brands. In the United States, it is called cyclosporine; the international name is ciclosporin.","contraindications":"Contraindications and Precautions Bone marrow suppressive and immunosuppressive. Use cautiously in animals at risk for infection. Teratogenic and embryotoxic. Do not use in pregnancy. Drug Interactions Use cautiously with other drugs that may cause bone marrow suppression. Although this drug is highly metabolized to active metabolites, it is not known what effect other drugs have on enzyme activity. C Cyclosporine, Cyclosporin A 219","indications":"Indications and Clinical Uses Cyclophosphamide is used primarily as an adjunct for cancer chemotherapy and as immunosuppressive therapy. Cyclophosphamide is the most potent of the nitrogen mustards. It is used in chemotherapy protocols for a variety of tumors, carcinomas, sarcomas, feline lymphoproliferative diseases, mast cell tumor, mammary carcinoma, and especially lymphoproliferative tumors (lymphoma). Cancer protocols such as cyclophosphamide, Oncovin, and prednisone (COP) and cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) incorporate cyclophosphamide as one of the agents. Cyclophosphamide is also used as continuous treatment for some cancers, also known as metronomic dosing. The advantage of metronomic dosing is decreased adverse effects (lower dose), and other benefits such as decreased angiogenesis in tumors (decreased proliferation), decreased vascular endothelial growth factor (VEGF),\\tand\\tdecreased\\tcirculating\\tT-\\tregulatory\\tcells\\t(T-\\treg).\\tHowever,\\tthe\\tbenefits of metronomic dosing in small animals has not been established, except for some limited experience. See the dosing section for metronomic protocol. Cyclophosphamide has been used as an immunosuppressive agent for some forms of immune- mediated disease. Although it has been used for various immune- mediated disorders in animals (immune- mediated hemolytic anemia [IMHA], pemphigus, systemic lupus erythematosus), efficacy has not been reported in controlled studies for\\tthese\\tdiseases.\\tFor\\ttreatment\\tof\\tIMHA\\t(50\\tmg/m 2 ), there was no benefit over prednisolone alone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cyclophosphamide is toxic to the bone marrow in a dose- dependent manner. After a single large bolus dose, the nadir of toxicity occurs in 7\u201310 days, but the effect is reversible because stem cells are usually unaffected. Recovery usually occurs in 21\u201328 days. Vomiting and diarrhea may occur in some patients. Sterile, hemorrhagic cystitis is a serious and limiting complication to therapy in dogs. It is caused by the toxic effects of metabolites on the bladder epithelium (especially acrolein) that are concentrated and excreted in the urine. Various attempts are used to decrease the injury to the bladder epithelium. Corticosteroids are usually administered with cyclophosphamide to induce polyuria and decrease inflammation of the bladder. The drug mesna (Mesnex, mercaptoethane sulfonate) provides free active thiol groups to bind metabolites of cyclophosphamide in the urine. Furosemide\\t(2.2\\tmg/kg)\\tadministered\\tat\\tthe\\tsame\\ttime\\tas\\tthe\\tcyclophosphamide dose may decrease risk of sterile hemorrhagic cystitis. Cats are less susceptible to developing cystitis than dogs. Cyclophosphamide may cause hair loss when used in some chemotherapeutic protocols. Dogs most susceptible are those with continuously growing hair (e.g., poodles and Old English sheepdogs). Cats do not tend to lose hair from cyclophosphamide treatment.","notes":"Instructions for Use Cyclophosphamide is usually administered with other drugs (other cancer drugs in cancer protocols or corticosteroids when used for immunosuppressive therapy). Consult specific anticancer\\tprotocols\\tfor\\tspecific\\tregimens.\\tFor\\texample,\\tthe\\tCOAP\\tprotocol\\t(COAP\\tis\\ta combination of cyclophosphamide, vincristine, prednisolone, and cytosine arabinoside) uses 50 mg/m 2 PO q48h, with vincristine, cytosine arabinoside, and prednisone for 8 weeks, but one CHOP protocol uses 100\u2013150 mg/m 2 IV on the first day of the protocol followed by other drugs such as doxorubicin, vincristine, and prednisone. In dogs, the maximum tolerated dose is 500 mg/m 2 IV (with autologous bone marrow support). Patient Monitoring and Laboratory Tests Monitor CBC in animals during treatment. Monitor urinalysis in dogs during treatment. Formulations \u2022\\t\\tCyclophosphamide\\tis\\tavailable\\tin\\t25-\\tmg/mL\\tinjection\\tand\\t25-\\t\\tand\\t50-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Tablets are coated and should not be split to retain stability. Do not let temperatures exceed 30\xb0C. Subject to hydrolysis in aqueous solutions. Use reconstituted solutions within 24 hours at room temperature and within 6 days if refrigerated, although some refrigerated solutions have been stable for 60 days.","original_category":"Anticancer agent"},{"name":"Cyproheptadine Hydrochloride","active_ingredient":"Cyproheptadine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tAntihistamine:\\t0.5\u20131.1\\tmg/kg\\tq8\u201312h\\tPO\\tor\\t2\u20134\\tmg/cat\\tPO\\tq12\u201324h. \u2022\\t\\tAppetite\\tstimulant:\\t2\\tmg/cat\\tPO. C Cytarabine 225 \u2022\\t\\tFeline\\tasthma:\\t1\u20132\\tmg/cat\\tPO\\tq12h. \u2022\\t\\tUse\\tfor\\tinappropriate\\turination:\\t2\\tmg/cat\\tq12h\\tPO;\\tthen\\treduce\\tdosage\\tto\\t1\\tmg/ cat q12h PO.  Horses \u2022\\t\\t0.5\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tHead\\tshaking:\\t0.3\\tmg/kg\\tq12h,\\tPO. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Cytarabine sye- tare\u2032ah- been Trade and other names: Cytosar, Ara- C, and cytosine arabinoside","contraindications":"Contraindications and Precautions None\\treported\\tfor\\tanimals. Drug Interactions There are no drug interactions reported for small animals.","indications":"Indications and Clinical Uses A common use of cyproheptadine is to stimulate the appetite in sick animals, especially cats, although, evidence based on controlled studies to demonstrate efficacy is\\t not\\t  available.\\tFor\\t  dogs\\t  and\\t  cats,\\t  other\\t   appetite\\tstimulants\\tare\\t  preferred:\\tmirtazapine for cats and capromorelin for dogs. Cyproheptadine is used in some cats for treatment of feline asthma if serotonin is considered a component of the airway inflammation. However, in cats with hyperresponsive airways, cyproheptadine failed to reduce eosinophilic inflammation (8 mg per cat q12h). It has been used in some instances for treating inappropriate urination (urine spraying) in cats. Cyproheptadine has been used to treat head shaking in horses. Cyproheptadine has been used to treat equine pituitary pars intermedia dysfunction (Cushing syndrome) at 0.6\u20131.2 mg/kg, but results have been controversial. It is not effective for treatment of canine pituitary- dependent hyperadrenocorticism (Cushing syndrome). It has been considered as a treatment\\tfor\\tanimals\\tthat\\thave\\t\u201cserotonin\\tsyndrome\u201d\\tfrom\\tantidepressant\\tdrugs,\\talthough efficacy has not been documented for this use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cyproheptadine may stimulate hunger. It can cause polyphagia and weight gain. Cyproheptadine also has antihistamine effects, antiserotonin effects, and antimuscarinic effects. In some cats, it has stimulated hyperactivity. In horses, it has been used at high doses without adverse effects.","notes":"Instructions for Use Clinical studies have not been performed in veterinary medicine. Use is based primarily on empiricism and extrapolation from human results. Syrup contains 5% alcohol. Patient Monitoring and Laboratory Tests Monitor weight gain in animals. Formulations Available \u2022\\t\\tCyproheptadine\\tis\\tavailable\\tin\\t4-\\tmg\\ttablets\\tand\\t2-\\tmg/5-mL\\tsyrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not freeze the syrup. Stability of compounded formulations has not been evaluated.","original_category":"Antihistamine"},{"name":"Cytarabine","active_ingredient":"Cytarabine","species":["Canine","Feline"],"dosage":"Dogs (Cancer Protocols, Administered Weekly) \u2022\\t\\t100\u2013150\\tmg/m 2 once daily or 50 mg/m 2 twice daily, each given for 4 days IV or SQ. \u2022\\t\\t600\\tmg/m 2 IV\\tor\\tSQ,\\tsingle\\tdose. \u2022\\t\\t300\\tmg/m 2 per day as a continuous IV infusion over 48 hours (600 mg/m 2 total). Dogs (Granulomatous Meningoencephalomyelitis) \u2022\\t\\t50\\tmg/m 2 twice\\tdaily\\tfor\\t2\\tdays\\tand\\trepeated\\tevery\\t3\\tweeks\\tSQ. \u2022\\t\\t200\\tmg/m 2 total dose administered as 50 mg/m 2 given\\tfour\\ttimes\\tover\\t2\\tdays\\tSQ or CRI IV administration at 25 mg/m 2 per hour for 8 hours. Cats \u2022\\t\\t100\\tmg/m 2 once daily for 2 days.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent.","contraindications":"Contraindications and Precautions Use cautiously in animals administered other bone marrow\u2013suppressing drugs. Drug Interactions There are no drug interactions reported for small animals. D Dacarbazine 227 Dacarbazine dah- kar \u0301bah- zeen Trade and other names: DTIC","indications":"Indications and Clinical Uses Cytarabine has been used for lymphoma, leukemia, and myelogenous leukemia in various\\tanticancer\\tdrug\\tprotocols.\\tIt\\tis\\tusually\\tadministered\\tas\\tan\\tIM\\tor\\tSQ\\tinjection because it has a short half- life (\u224820 minutes) when administered IV. It has also been administered to dogs for treatment of granulomatous meningoencephalomyelitis as an alternative to corticosteroids. Cytarabine penetrates the\\tblood\u2013CSF\\tbarrier\\tof\\tdogs\\tand\\thas\\tbeen\\treported\\tto\\timprove\\tthe\\ttemporary\\tand long- term remission and prognosis for dogs diagnosed with meningoencephalitis. Two protocols are used for this indication (see the dosing section). When administered via CRI to dogs, it maintains steady- state concentrations better than a SQ\\tinjection. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Cytarabine is bone marrow suppressive and can cause granulocytopenia, especially when delivered via CRIs. In addition, it may cause nausea and vomiting.","notes":"Instructions for Use Cytarabine has been administered to dogs using a variety of protocols (see the dosing section), depending on the study published and dependent on clinician preference. There is not strong evidence that one protocol is superior to another. When treating granulomatous\\tmeningoencephalomyelitis,\\tdose\\tprotocols\\t(either\\tIV\\tor\\tSQ)\\thave\\tused total doses of 200\u2013400 mg/m 2 total\\tdose,\\tdivided\\tover\\t2\\tdays,\\teither\\tas\\tSQ\\tinjections twice daily for 2 days or an IV infusion with the total dose given over 8 hours. The dose of cytarabine commonly used in the treatment of meningoencephalitis is a total dose of 200 mg/m 2 , which is lower than that used in the treatment of neoplasia (total dose of 400\u2013600 mg/m 2 ).\\tFor\\tmeningoencephalitis,\\tveterinary\\tneurologists\\thave recommended 200 mg/m 2 administered\\teither\\tas\\tfour\\tSQ\\tinjections\\tof\\t50\\tmg/m 2 given over 2 days or CRI IV administration at 25 mg/m 2 per hour for 8 hours. Patient Monitoring and Laboratory Tests Monitor CBC to assess toxicity. Formulations \u2022\\t\\tCytarabine\\tis\\tavailable\\tin\\ta\\t100-\\tmg\\tvial\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticancer agent"},{"name":"Dacarbazine","active_ingredient":"Dacarbazine","species":["Canine"],"dosage":"Dogs \u2022\\t\\t200\\tmg/m 2 for\\t5\\tdays\\tevery\\t3\\tweeks\\tIV\\tor\\t800\u20131000\\tmg/m 2 every 3 weeks IV.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. D 228    Dalteparin Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Dalteparin dahl \u0301tah- pare- in Trade and other names: Fragmin and low- molecular-weight heparin","contraindications":"Contraindications and Precautions Do not use in cats. Drug Interactions There are no drug interactions reported for small animals.","indications":"Indications and Clinical Uses DTIC has been primarily used for malignant melanoma and lymphoreticular neoplasms. It is rarely used as a primary agent but is used in protocols with other agents and after other drugs have become ineffective. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common adverse effects are leukopenia, nausea, vomiting, and diarrhea.","notes":"Instructions for Use Consult specific anticancer protocol for specific regimens. These are available from oncologists, and oncology textbooks. Patient Monitoring and Laboratory Tests Monitor complete blood count (CBC) during treatment. Formulations \u2022\\t\\tDTIC\\tis\\tavailable\\tin\\ta\\t200-\\tmg\\tvial\\tfor\\tinjection.\\tDilute\\tthe\\tsolution\\tin\\t50\u2013100\\tmL of\\t0.9%\\tnormal\\tsaline\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticancer agent"},{"name":"Dalteparin","active_ingredient":"Dalteparin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t150\u2013175\\tunits/kg\\tq8h\\tSQ\\t(see\\tPatient\\tMonitoring\\tand\\tLaboratory\\tTests\\tfor dose adjustment). Cats \u2022\\t\\t75\\tunits/kg\\tSQ\\tq6h.\\tThis\\tdosage\\tmay\\tbe\\tincreased\\tto\\t150\u2013175\\tunits/kg\\tq4h\\tSQ and\\tup\\tto\\t180\\tunits/kg\\tq6h,\\tSQ\\t(see\\tPatient\\tMonitoring\\tand\\tLaboratory\\tTests for dose\\tadjustment).  Horses \u2022\\t\\t50\\tunits/kg/day\\tSQ.\\tHigh-\\trisk\\tpatients\\tshould\\treceive\\t100\\tunits/kg/day. Regulatory Information Extralabel\\twithdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\t24-\\thour\\twithdrawal\\ttimes are suggested because this drug has little risk from residues. Danazol dan \u0301ah- zole Trade and other names: Danocrine","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\tIM\\tbecause\\tit\\tincreases\\ta\\trisk\\tof\\ta\\thematoma\\tat\\tthe\\tinjection site.\\tAdminister\\tSQ\\tonly.\\tLMWH\\tis\\texcreted\\tby\\trenal\\tclearance\\tin\\tanimals; therefore, if renal disease is present, the elimination will be prolonged. Rebound hypercoagulability may occur after discontinuation of heparin treatment; therefore, it may be advised to taper the dose slowly when discontinuing treatment. Drug Interactions Do\\tnot\\tmix\\twith\\tother\\tinjectable\\tdrugs.\\tUse\\tcautiously\\tin\\tanimals\\tthat\\tare already receiving other drugs that can interfere with coagulation, such as aspirin, clopidogrel, and warfarin. Although a specific interaction has not been identified, use cautiously in animals that may be receiving certain chondroprotective compounds such as glycosaminoglycans for treatment of arthritis. Some antibiotics, such as cephalosporins, may inhibit coagulation.","indications":"Indications and Clinical Uses Dalteparin,\\tlike\\tother\\tLMWHs,\\tis\\tused\\tto\\ttreat\\thypercoagulability\\tdisorders and prevent coagulation disorders such as thromboembolism, venous thrombosis, disseminated intravascular coagulopathy (DIC), and pulmonary thromboembolism. Clinical indications are derived from uses of conventional heparin\\tand\\tstudies\\tof\\tLMWH\\tin\\texperimental\\tanimals\\tor\\textrapolated\\tfrom human medicine. In people, enoxaparin has largely replaced dalteparin for routine use. There\\thas\\tbeen\\ta\\tlack\\tof\\tclinical\\tstudies\\tto\\tevaluate\\tefficacy\\tof\\tLMWH\\tin\\tanimals, and\\tthere\\tis\\tno\\tclear\\tbenefit\\tof\\tLMWH\\tin\\tanimals\\tcompared\\twith\\tconventional heparin.\\tDoses\\textrapolated\\tfrom\\thumans\\tmay\\tnot\\tbe\\taccurate\\tfor\\tachieving\\tadequate and\\tconsistent\\tanti-\\tXa\\tactivity\\tin\\tdogs\\tand\\tcats.\\tDoses\\tlisted\\tin\\tthe\\tdosing\\tsection\\tare primarily derived from experimental healthy animals. D Precautionary Information","side_effects":"Adverse Reactions and Side Effects Although\\tbetter\\ttolerated\\tthan\\tregular\\theparin,\\tbleeding\\tis\\ta\\trisk.\\tLMWHs\\tare associated\\twith\\ta\\tlower\\tincidence\\tof\\theparin-\\tinduced\\tthrombocytopenia\\t(HIT) in\\tpeople,\\tbut\\tHIT\\tfrom\\tany\\tform\\tof\\theparin\\thas\\tnot\\tbeen\\ta\\tclinical\\tproblem\\tin animals. If excessive anticoagulation and bleeding occur as a result of an overdose, protamine sulfate should be administered to reverse heparin therapy. The protamine dose\\tis\\t1.0\\tmg\\tof\\tprotamine\\tfor\\tevery\\t100\\tunits\\tof\\tdalteparin\\tadministered\\tby\\tslow IV infusion. Protamine complexes with heparin to form a stable, inactive compound.","notes":"Instructions for Use Dosing recommendations extrapolated from human medicine are not appropriate for animals, and animal- specific dosing recommendations should be used. Animal owners should\\tbe\\twarned\\tthat\\tLMWHs\\tare\\texpensive\\tcompared\\twith\\tconventional\\theparin. When dosing, do not interchange doses on a unit- for- unit basis with other heparins. Patient Monitoring and Laboratory Tests Monitor\\tpatients\\tfor\\tclinical\\tsigns\\tof\\tbleeding\\tproblems.\\tWhen\\tadministering\\tLMWH, activated partial thromboplastin time (aPTT) and prothrombin time (PT) clotting times are not reliable indicators of therapy, although prolonged aPTT is a sign of overdosing. In\\tpeople,\\ta-\\tXa\\tactivity\\tis\\tconsidered\\tthe\\tpreferred\\tlaboratory\\tmeasure\\tof\\tLMWH activity.\\tHowever,\\tin\\tstudies\\tin\\twhich\\tanti-\\tXa\\tactivity\\twas\\tmonitored\\tin\\tdogs,\\tit\\tresulted in\\tinconsistent\\tattainment\\tof\\tthe\\ttargeted\\trange.\\tIf\\tthe\\tanti-\\tXa\\tactivity\\tis\\tmeasured, the\\tpeak\\tanti-\\tXa\\tactivity\\toccurs\\t2\\thours\\tafter\\tdosing,\\tand\\tthe\\ttarget\\tranges\\tfor\\tanti-\\tXa activity\\tshould\\tbe\\t0.5\u20131.0\\tunits/mL\\tfor\\tcats\\tand\\t0.4\u20130.8\\tunits/mL\\tfor\\tdogs. Formulations \u2022\\t\\tDalteparin\\tis\\tavailable\\tin\\t2500\\tunits\\tof\\tantifactor\\tXa\\t(16\\tmg\\tdalteparin\\tsodium) per\\t0.2\\tmL\\tin\\ta\\tsingle-\\tdose\\tsyringe,\\t5000\\tunits\\tof\\tantifactor\\tXa\\t(32\\tmg\\tdalteparin sodium)\\tper\\t0.2\\tmL\\tin\\ta\\tsingle-\\tdose\\tsyringe,\\tand\\t10,000\\tunits\\tof\\tantifactor\\tXa\\t(64 mg\\tdalteparin\\tsodium)\\tper\\tmilliliter\\tin\\ta\\t9.5-\\tmL\\tmultiple-\\tdose\\tvial. Stability and Storage Use\\tmultiple-\\tdose\\tvial\\twithin\\t2\\tweeks\\tof\\tinitial\\tpenetration.\\tStore\\tin\\ta\\ttightly\\tsealed container protected from light. 230    Danazol","original_category":"Anticoagulant"},{"name":"Dantrolene Sodium","active_ingredient":"Dantrolene Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs Note:\\tDoses\\tcited\\tbelow\\tfor\\tdogs\\tare\\tfrom\\tanecdotal\\texperience\\tand\\textrapolation from humans. Pharmacokinetic studies suggest that these doses are unlikely to produce concentrations high enough to be effective in canine muscle. \u2022\\t\\tPrevention\\tof\\tmalignant\\thyperthermia:\\t2\u20133\\tmg/kg\\tIV\\t(up\\tto\\t5\u201310\\tmg/kg). \u2022\\t\\tMalignant\\thyperthermia\\tcrisis:\\tdoses\\tof\\t2.5\u20133\\tmg/kg\\tIV\\trapid\\tbolus\\t(up\\tto\\t5\u201310 mg/kg). \u2022\\t\\tMuscle\\trelaxation:\\t1\u20135\\tmg/kg\\tq8h\\tPO\\t(up\\tto\\t5\u201310\\tmg/kg). \u2022\\t \\tUrethral\\trelaxation:\\t1\u20135\\tmg/kg\\tq8h\\tPO\\tor\\t0.5\u20131.0\\tmg/kg\\tIV\\t(up\\tto\\t5\u201310\\tmg/kg). Cats \u2022\\t\\tMuscle\\trelaxation:\\t0.5\u20132\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tRelaxation\\tof\\turethra:\\t1\u20132\\tmg/kg\\tq8h\\tPO.  Horses \u2022\\t\\tThe\\tmost\\tcommon\\tdose\\tis\\t500\\tmg\\tPO\\tper\\thorse,\\tbut\\talternatively,\\ta\\tdose\\tof\\t4\\tmg/ kg\\tPO\\thas\\tbeen\\tused\\tin\\tsome\\tstudies. Pigs \u2022\\t\\tMalignant\\thyperthermia:\\t1\u20133\\tmg/kg\\tIV\\tonce. \u2022\\t\\tProphylaxis:\\t5\\tmg/kg\\tPO. D Dapsone 235 Regulatory Information For\\thorses,\\tthere\\tis\\ta\\trecommended\\t48-\\t\\tand\\t168-\\thour\\twithdrawal\\ttime\\tprior\\tto racing for detection in plasma and urine, respectively. For food animals, no regulatory information is available. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. RCI\\tClassification:\\t4 Dapsone dap \u0301sone Trade and other names: Also known as diaminodiphenylsulfone and diaphenylsulfone","contraindications":"Contraindications and Precautions Do not use in animals with hepatic disease. Use with caution in weak or debilitated animals. Drug Interactions Do not mix or reconstitute the IV solution with acidic solutions because they are incompatible.","indications":"Indications and Clinical Uses Dantrolene\\tis\\tused\\tas\\ta\\tmuscle\\trelaxant.\\tHowever,\\tin\\taddition\\tto\\tmuscle relaxation, it has been used to treat muscle excitability associated with malignant hyperthermia, and it also has been used to relax urethral muscle in cats. Although it has been used in dogs, the efficacy has not been shown, and pharmacokinetic studies\\tshow\\tthat\\tat\\ta\\tdose\\tof\\t2.8\\tmg/kg,\\tit\\tdoes\\tnot\\tproduce\\tconcentration\\thigh enough for activity in canine muscle. Although used as an immunosuppressive agent\\t(via\\tnuclear\\tfactor\\tof\\tactivated\\tthymocytes\\t[NFAT]\u2013regulated\\tcytokine suppression), it is unlikely to be effective for this use. In horses, it has improved clinical signs associated with exertional rhabdomyolysis (\u201ctying\\tup\u201d).\\tHowever,\\tthis\\teffect\\ton\\trhabdomyolysis\\tis\\tmostly\\tbased\\ton\\tanecdotal accounts because there are no clinical studies that demonstrate efficacy. It has reduced the release of muscle enzymes (creatine kinase). It can potentially prevent muscle damage in healthy horses. It has been used as a preanesthetic in horses to prevent anesthetic myopathy, but the optimum dose for this problem is undetermined. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Muscle relaxants can cause weakness in some animals. In people, dantrolene is known to cause muscle weakness, dyspnea, dysphagia, and dizziness. Use of dantrolene in people also has caused hepatitis in some cases. In horses, when administered\\tprior\\tto\\tanesthesia\\tat\\ta\\tdose\\tof\\t6\\tmg/kg\\tPO\\t(premedication),\\tit increased plasma potassium concentrations and increased risk of bradycardia and\\tarrhythmias\\tin\\tsome\\thorses.\\tHyperkalemia\\tfrom\\tdantrolene\\talso\\thas\\tbeen observed in dogs and pigs.","notes":"Instructions for Use It is usually recommended that oral doses should be given on an empty stomach. Doses have been primarily extrapolated from experimental studies or extrapolation of human studies. Few studies are available in veterinary medicine to guide optimum dosing.\\tTo\\trelax\\tthe\\turethra\\tin\\tcats,\\tthe\\tmost\\teffective\\tdose\\tis\\t1\\tmg/kg\\tIV. Equine\\tuse\\thas\\tbeen\\tfor\\tmuscle\\trelaxation\\tprior\\tto\\tsurgery\\tor\\tfor\\texertional rhabdomyolysis.\\tFor\\tequine\\tuse,\\tthe\\thuman\\toral\\tform\\t(usually\\tcapsules)\\tis\\tdissolved\\tin water and administered by the oral route. Alternatively, an oral paste can be made from the capsules and administered by the oral route. Capsules and paste formulations are absorbed\\tequally.\\tWhen\\tadministering\\tinjections\\tof\\tdantrolene\\tfor\\ttreatment\\tof\\tmalignant hyperthermia\\tin\\tlarge\\tanimals,\\tclinicians\\tshould\\tbe\\taware\\tthat\\tinjectable\\tforms\\tcan\\tbe expensive, and several vials may be needed because of dilute solution in each vial. Patient Monitoring and Laboratory Tests When used for treatment of malignant hyperthermia, monitor body temperature, acid\u2013base\\tbalance,\\tand\\telectrolytes.\\tIn\\tpeople,\\tdantrolene\\tmay\\tcause\\thepatitis,\\tand tests\\tof\\tliver\\tinjury\\t(e.g.,\\tliver\\tenzymes)\\tand\\tfunction\\tare\\tmonitored.\\tDantrolene\\tcan cause a persistent increase in plasma potassium concentration during anesthesia. The increase in potassium may lead to cardia arrhythmias and should be monitored. Formulations \u2022\\t\\tDantrolene\\tis\\tavailable\\tin\\t100-\\tmg\\tcapsules;\\twhen\\treconstituted,\\tthe\\t20-\\tmg\\tvial\\tis equal\\tto\\t0.33\\tmg/mL\\tinjection.\\tAlso\\tavailable\\tas\\ta\\tmore\\tconcentrated\\tsingle-\\tdose vial\\tcontaining\\t250\\tmg\\treconstituted\\tto\\t50\\tmg/mL. Stability and Storage When\\tIV\\tsolution\\tis\\tprepared,\\tit\\tis\\tstable\\tfor\\ta\\tshort\\ttime\\t(6\\thours).\\tIt\\tmay\\tbe\\tmixed with solutions such as 5% dextrose and 0.9% sodium chloride for IV use. Do not use IV solution if cloudiness or precipitation is present in vial. Compounded oral suspensions\\tare\\tstable\\tfor\\t150\\tdays\\tif\\tmixed\\twith\\tacid\\tsolutions\\t(e.g.,\\tcitric\\tacid). Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Muscle relaxant"},{"name":"Deferoxamine Mesylate","active_ingredient":"Deferoxamine Mesylate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t \\t15\\tmg/kg/h\\tIV\\tinfusion,\\t40\\tmg/kg\\tIM\\tq4\u20136h,\\tor\\t40\\tmg/kg\\tslow\\tIV\\tinjection\\tq4\u20136h for\\t chelation\\tof\\t iron.\\t  The\\t  treatment\\tis\\t generally\\tcontinued\\t24\\t hours\\t   but\\t  can\\t  be\\t extended longer based on clinical assessment and monitoring of serum iron concentrations.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. There are no anticipated problems from levels of\\tresidues\\tin\\tanimals.\\tHowever,\\tfor\\textralabel\\tuse\\twithdrawal\\tinterval\\testimates, contact FARAD at www.FARAD.org. Deracoxib dare- ah- koks \u0301ib Trade and other names: Deramaxx and generic","contraindications":"Contraindications and Precautions Administer IV formulation slowly to avoid precipitation of cardiac arrhythmias. Deferoxamine is teratogenic. Do not use in pregnant animals unless the benefits outweigh the risks. Drug Interactions Deferoxamine will chelate with cations; avoid mixing with cations prior to administration.","indications":"Indications and Clinical Uses Deferoxamine is indicated in cases of severe poisoning, especially iron toxicosis. It also has been used to chelate aluminum and facilitate removal. D Deracoxib 239 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. Allergic reactions and hearing problems\\thave\\toccurred\\tin\\tpeople.\\tPain\\tat\\tthe\\tinjection\\tsite\\toccurs\\twith\\tSQ\\tinjections.","notes":"Instructions for Use One\\thundred\\tmg\\tof\\tdeferoxamine\\tbinds\\t8.5\\tmg\\tof\\tferric\\tiron.\\tContact\\tthe\\tlocal poison control center for guidance on dosing after an overdose. Deferoxamine must\\tbe\\tinjected\\tto\\tbe\\teffective.\\tThere\\tare\\tno\\toral\\tforms,\\tbut\\ta\\tsynthetic\\tchelator, deferasirox, can be taken orally and could be obtained for animals. Patient Monitoring and Laboratory Tests Monitor serum iron concentrations to determine severity of intoxication and success of therapy. Successful therapy is indicated by monitoring urine color (orange- rose color change to urine indicates chelated iron is being eliminated). Formulations \u2022\\t\\tDeferoxamine\\tis\\tavailable\\tin\\ta\\t500-\\tmg\\tand\\t2-\\tg\\tvial\\tfor\\tinjection. Stability and Storage Deferoxamine\\tis\\tsoluble\\tin\\twater.\\tStable\\twhen\\tstored\\tin\\tsolution\\tfor\\t14\\tdays.\\tStore in a tightly sealed container, protected from light, and at room temperature. Do not refrigerate and do not mix solutions with other medications.","original_category":"Antidote, Chelating agent"},{"name":"Deracoxib","active_ingredient":"Deracoxib","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tPostoperative\\tpain:\\t3\u20134\\tmg/kg\\tonce\\tdaily\\tas\\tneeded\\tfor\\tup\\tto\\t7\\tdays. \u2022\\t\\tChronic\\tuse:\\t1\u20132\\tmg/kg\\tonce\\tdaily\\tPO. Cats \u2022\\t\\t1\\tmg/kg\\tPO,\\tsingle\\tdose.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals that produce food. RCI\\tClassification:\\t4 Desmopressin Acetate dess- moe- press \u0301in  ass \u0301ih- tate Trade and other names: DDAVP","contraindications":"Contraindications and Precautions Dogs\\t   and\\t  cats\\t  with\\t  preexisting\\tGI\\t or\\t renal\\t  problems\\tmay\\t  be\\t at\\t a\\t greater\\t   risk\\t  of\\t adverse effects from NSAIDs. Safety in pregnancy is not known, but adverse effects have not been reported. Safety studies are not available for dogs younger than 4 months of age, pregnant animals, or lactating animals. In cats, use only as a single dose. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have been\\tshown\\tto\\texacerbate\\tthe\\tGI\\tadverse\\teffects.\\tSome\\tNSAIDs\\tmay\\tinterfere\\twith the action of diuretic drugs and angiotensin- converting enzyme (ACE) inhibitors. D Desmopressin Acetate 241","indications":"Indications and Clinical Uses Deracoxib is used to decrease pain, inflammation, and fever. It has been used for the\\tacute\\tand\\tchronic\\ttreatment\\tof\\tpain\\tand\\tinflammation\\tin\\tdogs.\\tOne\\tof\\tthe\\tmost common uses is osteoarthritis, but it also has been used for pain associated with surgery. Except for experimental studies, the clinical use in cats has not been reported. There has been only limited use of deracoxib in horses, and administration to other large animals has not been reported. Deracoxib,\\tlike\\tother\\tCOX-\\t2\\tinhibitors,\\tmay\\thave\\tsome\\tantitumor\\tproperties.\\tIt has produced beneficial effects in dogs with transitional cell carcinoma. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Gastrointestinal\\tproblems\\tare\\tthe\\tmost\\tcommon\\tadverse\\teffects\\tassociated\\twith NSAIDs and can include vomiting, diarrhea, nausea, ulcers, and erosions of the GI\\ttract.\\tGastric\\tand\\tduodenal\\tulcers\\thave\\tbeen\\treported\\tfrom\\tuse\\tof\\tderacoxib\\tin dogs. In field trials with deracoxib, vomiting was the most often reported adverse effect. Renal toxicity, especially in dehydrated animals or animals with preexisting renal disease, has been shown for some NSAIDs. In studies performed in dogs, higher doses (five times the dose) caused azotemia in normal dogs.","notes":"Instructions for Use Chewable\\ttablets\\tcan\\tbe\\tadministered\\twith\\tor\\twithout\\tfood.\\tLong-\\tterm\\tstudies\\thave not been completed in cats; only single- dose studies have been reported. Patient Monitoring and Laboratory Tests Monitor\\tGI\\tsigns\\tfor\\tevidence\\tof\\tdiarrhea,\\tGI\\tbleeding,\\tor\\tulcers.\\tBecause\\tof\\trisk of\\trenal\\tinjury,\\tmonitor\\trenal\\tparameters\\t(water\\tconsumption,\\tblood\\turea\\tnitrogen, creatinine, and urine- specific gravity) periodically during treatment. Deracoxib does not appear to affect thyroid hormone assays in dogs. Formulations \u2022\\t\\tDeracoxib\\tis\\tavailable\\tin\\t12-\\t,\\t25-\\t  ,\\t75-\\t  ,\\tand\\t100-\\tmg\\tchewable\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Deracoxib\\thas\\tbeen\\tmixed\\tin\\ta\\tliquid\\tsuspension\\tin\\twater.\\tHowever,\\tstability\\tof compounded formulations has not been evaluated.","original_category":"Anti- inflammatory"},{"name":"Detomidine Hydrochloride","active_ingredient":"Detomidine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t5\\tmcg/kg\\tIV\\tor\\t10\u201320\\tmcg/kg\\tIM. \u2022\\t\\tOral\\tmucosal\\tapplication:\\tThe\\tdose\\tcan\\tbe\\tadjusted\\tfor\\tthe\\tdesired\\tclinical\\teffects. For\\tmild\\tsedation,\\t0.5\\tmg/m 2 ; for higher sedation and lateral recumbency, administer\\t1.0\\tmg/m 2 .\\t(Average\\tdose\\tis\\t35\\tmcg/kg.)\\tA\\thigh\\tdose\\tof\\t2\u20134\\tmg/m 2 produces more profound sedation. The gel should be applied applied to the upper gingiva\\tof\\tdogs.\\tReversal\\twith\\t0.1\\tmg/kg\\tof\\tatipamezole\\tIM. Cats \u2022\\t\\tOral\\t(injectable\\tsolution\\tapplied\\ttransmucosal):\\t0.5\\tmg/kg.\\tAdminister\\twith ketamine\\t(10\\tmg/kg)\\tby\\tspraying\\tinto\\tcat\u2019s\\tmouth. \u2022\\t\\tOral\\t(transmucosal\\tgel):\\tfor\\tsedation,\\tuse\\t2\u20134\\tmg/m 2 (anticipate vomiting at this dose).\\tA\\tdose\\tof\\t4\\tmg/m 2 of\\tthe\\toral\\tmucosal\\tgel\\tin\\tcats\\tis\\tapproximately\\t0.24 mg/kg,\\tor\\t0.14\\tmL\\tper\\tcat.\\tReversal\\twith\\t0.1\\tmg/kg\\tof\\tatipamezole\\tIM.  Horses A\\tdose\\tof\\t10\u201320\\tmcg/kg\\tis\\tequivalent\\tto\\t5\u201310\\tmg\\tper\\thorse. \u2022\\t\\tSedation:\\t20\u201340\\tmcg/kg\\t(0.02\u20130.04\\tmg/kg)\\tIV\\tor\\tIM.\\tLower\\tdoses\\tof\\t10\u201320 mcg/kg\\tare\\tsometimes\\tused\\tin\\tpractice\\tinitially\\tand\\tthen\\trepeated\\tas\\tneeded. For\\texample,\\tdoses\\tof\\t10\\tmcg/kg\\t(0.01\\tmg/kg)\\tproduce\\tslightly\\tless\\tataxia\\tand sedation.\\tDoses\\tas\\tlow\\tas\\t5\\tmcg/kg\\thave\\tbeen\\tused\\tin\\tdraft\\thorses. \u2022\\t\\tAnalgesia:\\t20\\tmcg/kg\\t(0.02\\tmg/kg)\\tIV\\tor\\tIM.\\tDuration\\tof\\tanalgesia\\tmay\\tbe longer\\tif\\ta\\tdose\\tof\\t40\\tmcg/kg\\tis\\tused. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\t10\\tmcg/kg\\tbolus\\tIV,\\tfollowed\\tby\\t0.5\\tmcg/kg/min for\\t15\\tmin;\\tthen\\tprogressively\\tdecreasing\\tthe\\trate\\tas\\tneeded\\tto\\t0.1\\tmcg/kg/min. \u2022\\t \\tOral\\tmucosal:\\t40\\tmcg/kg\\t(\u22482.5\\tmL\\tto\\ta\\t1000-\\tlb\\thorse)\\tadministered sublingually. This dose has also been used intravaginally in horses. Cattle \u2022\\t\\t2\u201310\\tmcg/kg\\t(0.002\u20130.1\\tmg/kg)\\tIV\\tor\\t5\u201340\\tmcg/kg\\t(0.005\u20130.04\\tmg/kg)\\tIM. D Dexamethasone 247 Calves \u2022\\t \\t30\\tmcg/kg\\tIV\\tor\\tdetomidine\\toral\\tmucosal\\tgel\\t(equine\\tformulation): 80\\tmcg/kg. Regulatory Information Cattle\\twithdrawal\\ttimes\\t(extralabel):\\t3\\tdays\\tmeat;\\t72\\thours\\tmilk.\\tFor\\textralabel\\tuses and doses, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Dexamethasone deks- ah- meth \u0301ah- sone Trade and other names: Azium solution in polyethylene glycol, DexaJect, Dexavet, Decadron, Dexasone, Voren suspension, and generic brands","contraindications":"Contraindications and Precautions Concurrent use of detomidine with sulfonamides IV can lead to cardiac arrhythmias.\\tXylazine\\tcauses\\tproblems\\tin\\tpregnant\\tanimals,\\tand\\tthis\\talso\\tshould\\tbe considered for other alpha 2 agonists. Use cautiously in animals that are pregnant because it may induce labor. In addition, it may decrease oxygen delivery to a fetus in late gestation. Detomidine gel can be absorbed across the skin and from eye and mouth contact in humans. If there is accidental exposure, immediately rinse with soap and water. Contact a physician if there are other concerns. Drug Interactions Other\\tdrugs\\tthat\\tdepress\\tthe\\theart\\tmay\\tincrease\\trisk\\tfor\\tarrhythmias.","indications":"Indications and Clinical Uses Detomidine\\tis\\tused\\tprimarily\\tas\\ta\\tsedative,\\tanesthetic\\tadjunct,\\tand\\tanalgesia.\\tIt is used in horses more often than in other species. When used to treat pain from colic\\tin\\thorses,\\tthe\\tduration\\tof\\teffect\\tis\\tapproximately\\t3\\thours\\t(20\\tor\\t40\\tmcg/kg). Detomidine also has been administered for epidural analgesia. For pain, detomidine appears to be more potent and longer acting than xylazine. Detomidine\\tin\\tthe\\tgel\\tform\\t(Dormosedan\\tGel)\\tfor\\thorses\\tis\\tadministered\\torally\\tto produce mucosal absorption. It is indicated for producing minor standing sedation to facilitate minor procedures (shoeing, clipping, trimming) or calming a fractious horse. Onset\\tof\\taction\\tis\\t40\\tminutes,\\tand\\tduration\\tis\\t90\u2013180\\tminutes.\\tThe\\tdetomidine\\tgel has\\talso\\tbeen\\tadministered\\tintravaginally\\tto\\thorses\\t(40\\tmcg/kg)\\tand\\tproduced\\treliable sedation. The detomidine gel form for oral mucosal use also has been used successfully in dogs, cats, and calves. These uses and doses are provided in the dosing section. When applied\\tto\\tdogs,\\tcats,\\tand\\tcalves,\\tthe\\tonset\\tfor\\teffect\\tis\\tapproximately\\t40\u201345\\tminutes with\\tmaximal\\tsedation\\tin\\t60\u201375\\tminutes.\\tThe\\tdose\\tcan\\tbe\\tadjusted\\tin\\tdogs\\t(e.g.,\\t0.5, 1,\\t2,\\tor\\t4\\tmg/m 2 ), depending on the degree of sedation desired. After absorption, it produces a duration of approximately 90 minutes. Precautionary Information","side_effects":"Adverse Reactions and Side Effects At typical doses, sedation, ataxia, swaying, sweating, and bradycardia are common in horses. It produces vasoconstriction and increased peripheral vascular resistance through\\tthe\\talpha-\\tadrenergic\\ttype\\t2B\\treceptors.\\tThis\\teffect\\tincreases\\tblood pressure\\tand\\tcan\\tlead\\tto\\treflex\\tbradycardia\\tin\\tall\\tanimals\\ttested.\\t\\tOrdinarily,\\tthe bradycardia does not have to be treated with antimuscarinic agents (e.g., atropine). In\\tsmall\\tanimals,\\tvomiting\\tis\\tcommon.\\tVomiting\\thas\\tbeen\\tobserved\\tin\\t100%\\tof research cats that received detomidine. Cardiac depression, atrioventricular (AV) block, and hypotension are possible with high doses. In some horses, hyperresponsiveness to stimuli occurs. Diuresis occurs\\tas\\ta\\tconsequence\\tof\\tthe\\thyperglycemia\\tproduced\\tby\\talpha 2 agonists such as\\tdetomidine.\\tYohimbine\\t(0.11\\tmg/kg)\\tcan\\tbe\\tused\\tto\\treverse\\teffects\\tof\\talpha 2 agonists such as detomidine. In small animals, atipamezole also can be used to reverse effects from detomidine.","notes":"Instructions for Use Detomidine is used primarily in horses, and although not approved for small animals, extralabel dosages are listed in the dosing section that follows.  Atropine (0.01\u20130.02\\tmg/kg)\\thas\\tbeen\\tused\\tto\\tprevent\\tbradycardia\\tbut\\tis\\tnot\\tnecessary\\tfor routine use. Detomidine may be administered with other anesthetics, analgesics, sedatives (including butorphanol), and benzodiazepines. When using the mucosal gel in dogs and cats, apply the calculated dose to the oral mucosa (the upper gumline has worked in experimental animals). Patient Monitoring and Laboratory Tests Monitor\\theart\\trate\\tand,\\tif\\tpossible,\\tthe\\telectrocardiogram\\t(ECG)\\tduring\\ttreatment with this class of drugs. If available, blood pressure monitoring may be indicated in some patients. Formulations \u2022\\t\\tDetomidine\\tis\\tavailable\\tin\\ta\\t10-\\tmg/mL\\tinjection.\\tOral\\tgel\\tis\\t7.6\\tmg/mL\\tin\\ta 3-\\t mL\\tsyringe. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Alpha"},{"name":"Dextran","active_ingredient":"Dextran","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t10\u201320\\tmL/kg/day\\tIV\\tto\\teffect,\\tover\\t30\u201360\\tminutes. Cats \u2022\\t\\t5\u201310\\tmL/kg/day\\tIV\\tover\\t30\u201360\\tminutes.  Horses and Cattle \u2022\\t\\t10\\tmL/kg/day\\tIV. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\tthis\\tdrug\\tpresents\\tlittle\\trisk\\tfrom residues; therefore, a short withdrawal time is suggested for animals intended for food. Dextromethorphan deks- troe- meth- or \u0301fan Trade and other names: Benylin and other over- the- counter antitussive brands","contraindications":"Contraindications and Precautions Do not use in animals that are prone to bleeding problems. Dextrans can interfere with cross- matching of blood for transfusion. Cats are more susceptible to fluid overload than dogs, and lower doses must be used in cats. Drug Interactions Compatible with most IV fluid solutions, including 0.9% saline solution and 5% dextrose solution.","indications":"Indications and Clinical Uses Dextran is a high- molecular- weight compound administered IV to maintain intravascular volume. It is used for acute treatment of hypovolemia and shock. Duration\\tof\\teffect\\tis\\tapproximately\\t24\\thours. 256    Dextromethorphan Precautionary Information","side_effects":"Adverse Reactions and Side Effects There is only limited use in veterinary medicine, and adverse effects have not been reported. The hydroxyethyl starch compounds are used more often in veterinary medicine when colloids are needed for IV use. In people, coagulopathies are possible because of decreased platelet function and antithrombotic effects. Acute renal failure has occurred, and anaphylactic shock also has occurred in people.","notes":"Instructions for Use Used primarily in critical care situations, such as hypovolemic shock. It should be delivered\\tslowly\\tvia\\tCRI\\t(60\u201390\\tminutes).\\tIn\\temergency\\tuse,\\tbolus\\tdoses\\tof\\t20\\tmL/ kg can be administered more rapidly. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\tcardiopulmonary\\tstatus\\tcarefully\\tduring\\tadministration.\\tDextrans can interfere with cross- matching of blood. Formulations \u2022\\t\\tDextran\\tis\\tavailable\\tin\\t250-\\t,\\t500-\\t   ,\\tand\\t1000-\\tmL\\tsolution\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Fluid replacement"},{"name":"Dextromethorphan","active_ingredient":"Dextromethorphan","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.5\u20132\\tmg/kg\\tq6\u20138h\\tPO.\\t(However,\\tuse\\tis\\tnot\\trecommended\\tbecause\\tefficacy\\tat these doses has not been shown.)  \u2022\\t\\tNo\\tdosing\\tinformation\\tavailable.\\tIt\\thas\\tlittle\\tvalue\\tfor\\ttreating\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Dextrose Solution deks \u0301trose Trade and other names: D5W (5% dextrose) and 50% dextrose solution","contraindications":"Contraindications and Precautions There\\t   are\\t  no\\t contraindications\\tidentified\\tfor\\t animals.\\tHowever,\\tpet\\t  owners\\t    should be\\tcautioned\\tthat\\tmany\\tover-\\tthe-\\t  counter\\t(OTC)\\tpreparations\\tcontain\\tother drugs that may produce significant side effects. For example, some combinations also contain acetaminophen, which can be toxic to cats. Some preparations also contain a decongestant, such as pseudoephedrine or phenylpropanolamine, which can cause excitement and other side effects. Drug Interactions There\\tare\\tno\\tdirect\\tinteractions\\tidentified\\tfor\\tdogs.\\tHowever,\\tinteractions\\tare possible when used with other drugs that may interfere with cytochrome P450 metabolism.","indications":"Indications and Clinical Uses Dextromethorphan has been used for suppression of nonproductive cough. However,\\tits\\tefficacy\\tfor\\treducing\\tcough\\thas\\tbeen\\tquestioned\\tbecause\\tof\\ta lack\\tof\\tproof.\\tDextromethorphan\\talso\\thas\\tbeen\\tused\\tas\\tan\\tadjunct\\tfor\\ttreating pain because of NMDA antagonism, but this is not a practical use in veterinary medicine. Pharmacokinetic studies in dogs indicated that dextromethorphan does not attain effective concentrations after oral administration. Even after IV administration, concentrations of the parent drug and active metabolite persisted for only a short time after dosing. Therefore, routine use in dogs is not recommended until more data are available to establish safe and effective doses. Pharmacokinetic data are available for dogs but have not been reported for cats or any other species. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects from oral administration are not reported in veterinary medicine. High\\toverdose\\tmay\\tpotentially\\tcause\\tsedation.\\tIn\\thealthy\\tresearch\\tdogs, dextromethorphan produced vomiting after oral doses and severe CNS reactions after IV administration. Some preparations contain alcohol, which can be unpalatable in small animals, especially cats.","notes":"Instructions for Use Many\\tOTC\\tpreparations\\tmay\\tcontain\\tother\\tingredients\\t(e.g.,\\tantihistamines, decongestants, ibuprofen, and acetaminophen). Adverse effects from each of these ingredients, such as toxic reactions caused by acetaminophen, CNS excitement from decongestants,\\tand\\tGI\\ttoxicity\\tfrom\\tibuprofen,\\tcan\\toccur\\tin\\tanimals. 258    Dextrose Solution Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tDextromethorphan\\tis\\tavailable\\tin\\tsyrup,\\tcapsules,\\tand\\ttablets\\tin\\tmany\\tOTC products.\\tMany\\tpreparations\\tare\\tavailable\\twithout\\ta\\tprescription\\tin\\tliquid\\tand\\ttablet form.\\tOTC\\tformulations\\tmay\\tvary\\tin\\tconcentration\\tbut\\ttypically\\tcontain\\t2,\\t5,\\t10, or\\t15\\tmg/mL\\tand\\tin\\t15-\\t\\tto\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antitussive"},{"name":"Dextrose Solution","active_ingredient":"Dextrose Solution","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tFive\\tpercent\\tdextrose\\tsolution:\\t40\u201350\\tmL/kg\\tq24h\\tIV. \u2022\\t \\tIn\\temergency\\thypoglycemic\\tcrisis:\\t1-\\tmL\\t50%\\tdextrose\\tsolution\\tIV\\tdiluted\\twith\\tsaline. 260    Diazepam  Horses:\\tTreatment\\tof\\thyperkalemia:\\t8\u201316\\tmg/kg\\tper\\tminute\\tinfusion\\tas\\tan emergency treatment for life- threatening hyperkalemia. See the Formulation section for\\tmixing\\tsolutions.\\tAn\\tinfusion\\tcan\\tbe\\tadministered\\tIV\\tover\\t1\\thour.\\tFor\\tmilder cases,\\tadminister\\t1\u20132\\tmg/kg\\tper\\tminute\\tIV. Calves, Cattle, and Horses \u2022\\t\\tFive\\tpercent\\tdextrose\\tsolution:\\t45\\tmL/kg\\tq24h\\tIV. \u2022\\t\\tCows:\\t0.1\u20130.2\\tgm/kg/h\\tIV\\tof\\tdextrose\\t50%\\tsolution\\tfor\\t5\\tdays\\tto\\ttreat\\thepatic lipidosis and ketosis. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\tthis\\tdrug\\tpresents\\tlittle\\trisk from residues; therefore, no withdrawal time is suggested for animals intended for food. Diazepam dye- ay \u0301zeh- pam Trade and other names: Valium and generic brands","contraindications":"Contraindications and Precautions Use cautiously in animals with low electrolyte concentrations. Five percent dextrose solution is not a suitable maintenance solution because it does not provide electrolytes. It should not be considered as a replacement solution or a\\tsource\\tof\\tenergy\\trequirements;\\tit\\tsupplies\\tonly\\t170\\tkcal/L\\tof\\tenergy.\\tWhen aggressive treatment is used with 50% dextrose, it may cause rapid decrease in plasma phosphorous and potassium (intracellular shift). Drug Interactions No interactions. Five percent dextrose solution is compatible with fluids and most IV drugs.","indications":"Indications and Clinical Uses Five percent dextrose is an isotonic fluid solution used for IV administration. Dextrose is considered only for short- term use because it is deficient in electrolytes. After the glucose is metabolized, the water is rapidly distributed out of the vascular space. For emergency treatment of hypoglycemia or to supplement fluids, a 50% dextrose solution (500\\tmg/mL)\\tis\\tused.\\tDextrose\\thas\\tbeen\\tadministered\\tas\\tan\\temergency\\ttreatment\\tto lower serum potassium in cases of hyperkalemia. It lowers potassium by inducing insulin release shifting of potassium from extracellular to intracellular stores. D Dextrose has been administered in a 50% solution to treat or prevent periparturient cows with ketosis and hepatic lipidosis or to support anorexic or recumbent cows. However,\\tthere\\tis\\tno\\testablished\\tbenefit\\tof\\t50%\\tdextrose\\ttreatment\\tfor\\tprevention of\\tketosis\\tin\\tdairy\\tcattle\\tas\\ta\\tsingle\\ttreatment\\tof\\t0.5\\tor\\t1.0\\tL\\tIV. There is a risk of hypophosphatemia with this treatment. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High\\tdoses\\tcan\\tproduce\\tpulmonary\\tedema.","notes":"Instructions for Use Dextrose is a commonly used fluid solution administered via CRI. It is often used as a\\tvehicle\\tto\\tdeliver\\tIV\\tdrugs\\tthat\\tare\\tnot\\tcompatible\\twith\\telectrolytes.\\tHowever,\\tit is not a maintenance solution. Dextrose 50% solution can also be added to fluids to supply\\tdextrose.\\tFor\\texample,\\t50\\tmL\\tof\\t50%\\tdextrose\\tis\\tadded\\tto\\t1000\\tmL\\tof\\tfluids to\\tachieve\\ta\\tfinal\\t2.5%\\tsolution. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\thydration\\tstatus\\tand\\tevidence\\tof\\tpulmonary\\tedema\\tduring\\tinfusion. Monitor\\tacid\u2013base\\tstatus. Formulations \u2022\\t\\tFluid\\tsolution\\tfor\\tIV\\tadministration\\tis\\t5%\\tdextrose,\\twhich\\tcontains\\t5\\tg\\tof\\tglucose per\\t100\\tmL\\t(50\\tg/L).\\tFifty\\tpercent\\tdextrose\\tcontains\\t500\\tmg/mL\\t(50\\tg/100 mL).\\tFor\\ttreatment\\tin\\tlarge\\tanimals,\\tadd\\ta\\t500-\\tmL\\tbottle\\tof\\t50%\\tdextrose\\tto\\ta\\t5-\\tL bag of IV fluids. Stability and Storage Store in a tightly sealed container at room temperature.","original_category":"Fluid replacement"},{"name":"Diclazuril","active_ingredient":"Diclazuril","species":["Equine"],"dosage":"\u2022\\t\\tNo\\tdosing\\tinformation\\thas\\tbeen\\treported\\tfor\\tsmall\\tanimals.  Horses \u2022\\t\\tTreatment\\tof\\tEPM:\\t1\\tmg/kg\\toral\\tas\\ta\\ttop\\tdress\\ton\\tfeed\\tfor\\t28\\tdays\\tadded\\tto\\tdaily ration. It has also been shown that with repeated administration to steady state, 0.5\\tmg/kg\\tbody\\tweight\\tachieves\\ta\\tsimilar\\tpharmacokinetic\\tprofile\\tas\\tdosing\\tat\\tthe Food\\tand\\tDrug\\tAdministration\\t(FDA)\u2013labeled\\tdose\\tof\\t1\\tmg/kg. \u2022\\t\\tFor\\tprevention\\tof\\tEPM:\\tTop\\tdress\\tfeed\\twith\\tpellets:\\t0.5\\tmg/kg\\tonce\\tevery\\t3\\tor\\t4 days. Regulatory Information Do not administer to horses intended for food. Withdrawal time for poultry is 5 days. For other animals, no regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Dicloxacillin Sodium dye- kloks- ah- sill \u0301in  soe \u0301dee- um Trade and other names: Dynapen and generic","contraindications":"Contraindications and Precautions No contraindications have been reported. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses Dosage information for diclazuril has been based on approved indications, experimental studies, pharmacokinetic data, and clinical experience. Ponazuril is another related agent used for treating EPM in horses. 266    Dicloxacillin Sodium Precautionary Information","side_effects":"Adverse Reactions and Side Effects No specific adverse effects have been reported.","notes":"Instructions for Use Administer orally to horses. It may be added to feed as pellets. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. The targeted concentration of diclazuril to inhibit merozoite production of S. neurona and Sarcocystis falcatula in bovine turbinate cell cultures\\tis\\t0.1\\tng/mL\\tto\\tachieve\\tgreater\\tthan\\t80%\\tinhibition\\tand\\t1.0\\tng/mL\\tto achieve greater than 95% inhibition. Formulations \u2022\\t\\tDiclazuril\\tpellets\\tfor\\thorses\\tis\\tavailable\\tas\\t1.56%\\tdiclazuril\\tto\\tbe\\tmixed\\tas\\ta\\ttop dress\\ton\\tfeed\\tfor\\ttreatment\\tof\\tEPM.\\tOne\\t2-\\tlb\\tbucket\\ttreats\\tone\\thorse\\tfor\\t28\\tdays. It is also available as a medicated feed additive for poultry. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiprotozoal"},{"name":"Digitoxin","active_ingredient":"Digitoxin","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Cardiac inotropic agent"},{"name":"Digoxin","active_ingredient":"Digoxin","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\t0.005\u20130.011\\tmg/kg\\tq12h\\tPO\\t(dose\\tused\\tby\\tmost\\tcardiologists). \u2022\\t\\tAlternatively,\\tdoses\\thave\\tvaried\\tbased\\ton\\tdog\u2019s\\tbody\\tweight:\\tdogs\\tweighing\\tless than\\t20\\tkg:\\t0.005\u20130.01\\tmg/kg\\tq12h\\tand\\tif\\tweighing\\tgreater\\tthan\\t20\\tkg:\\t0.22 mg/m 2 q12h\\tPO\\t(subtract\\t10%\\tfor\\telixir). \u2022\\t\\tRapid\\tdigitalization:\\t0.0055\u20130.011\\tmg/kg\\tq1h\\tIV\\tto\\teffect. \u2022\\t\\tAtrial\\tfibrillation:\\t0.005\\tmg/kg\\tq12h\\tPO\\t(may\\tbe\\tcombined\\twith\\tdiltiazem\\tat\\t3 mg/kg\\tq12h\\tPO). Cats \u2022\\t \\t0.008\u20130.01\\tmg/kg\\tq48h\\tPO.\\t(Approximately\\tone\\tfourth\\tof\\ta\\t0.125-\\tmg\\ttablet/cat.)  Cattle \u2022\\t\\t22\\tmcg/kg\\t(0.022\\tmg/kg)\\tIV\\tloading\\tdose\\tfollowed\\tby\\t0.86\\tmcg/kg/h\\tIV\\tor multiple\\tdoses\\tof\\t3.4\\tmcg/kg\\tq4h.\\tPlasma\\tconcentrations\\tto\\tmonitor\\tare\\tsimilar\\tas for other animals. Horses \u2022\\t\\t2\\tmcg/kg\\t(0.002\\tmg/kg)\\tIV\\tq12h. \u2022\\t\\t15\\tmcg/kg\\t(0.015\\tmg/kg)\\tq12h\\tPO. Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t4 Dihydrotachysterol dye- hye- droe- tak- iss \u0301ter- ole Trade and other names: Vitamin D","contraindications":"Contraindications and Precautions Some breeds of dogs (Doberman pinscher) and cats are more sensitive to adverse effects. Drug Interactions High\\tpotassium\\twill\\tdiminish\\tclinical\\teffect;\\tlow\\tpotassium\\twill\\tenhance\\teffect and toxicity. Because some animals may also be receiving diuretics, monitor the potassium concentrations during treatment. Digoxin is a substrate for cytochrome P450 enzymes and p- glycoprotein. Many drugs are capable of increasing digoxin\\tconcentrations,\\tincluding\\tquinidine,\\taspirin,\\tclarithromycin\\t(and\\tother macrolides), and chloramphenicol (see Appendixes I and J for list of inhibitors). Administration of phenobarbital chronically may decrease digoxin concentrations by increasing clearance. Calcium- channel blockers and beta blockers potentiate action on AV node conduction, increasing the risk of AV block. Digoxin is absorbed\\tbetter\\tin\\tan\\tacid\\tstomach,\\tand\\tproton\\tpump\\tinhibitors\\tor\\tH 2 blockers may reduce oral absorption.","indications":"Indications and Clinical Uses The use of digoxin for animals in heart failure has declined significantly because pimobendan\\tis\\tmore\\tfrequently\\tused\\tand\\tis\\tavailable\\tin\\ta\\tveterinary\\tformulation. Digoxin has been used for treatment of heart failure in dogs, cats, and occasionally other animals. Because the use for an inotropic effect has declined, the most common use is to decrease the heart rate in animals. This property is used for treatment of supraventricular arrhythmias to decrease ventricular response to atrial stimulation via suppression of the AV node. Digoxin may be used with other drugs for heart failure such as ACE inhibitors (e.g., enalapril), diuretics (furosemide), and vasodilators. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Digitalis glycosides such as digoxin have a narrow therapeutic index. They may cause a variety of arrhythmias in patients (e.g., AV and ventricular tachycardia) and\\tmay\\tproduce\\tdelayed\\tafter\\tdepolarization-\\tinduced\\tarrhythmias.\\tHeart block\\t(AV\\tblock)\\tis\\tpossible.\\tDigoxin\\tfrequently\\tcauses\\tvomiting,\\tanorexia,\\tand diarrhea. Digoxin adverse effects are potentiated by hypokalemia and reduced by hyperkalemia.","notes":"Instructions for Use When\\tdosing,\\tcalculate\\tdose\\ton\\tlean\\tbody\\tweight.\\tDoses\\tshould\\tbe\\t10%\\tless\\tfor elixir because of increased absorption. When used to treat atrial fibrillation in dogs, combined with diltiazem, it may produce greater reduction in ventricular rate than either drug alone. Patient Monitoring and Laboratory Tests Monitor patients carefully. Monitor serum digoxin concentrations in patients to determine\\toptimum\\ttherapy.\\tTherapeutic\\trange\\tis\\t0.8\u20131.5\\tng/mL\\t8\u201310\\thours\\tafter a\\tdose.\\tSome\\tcardiologists\\trecommend\\tconcentrations\\tof\\t0.9\u20131.0\\tng/mL\\tand\\tbelow for\\ttreating\\theart\\tfailure\\tand\\thigher\\tconcentrations\\tof\\tto\\treduce\\theart\\trate\\tto\\t140\u2013 160\\tbpm.\\tAdverse\\teffects\\tare\\tcommon\\tat\\tconcentrations\\tabove\\t3.5\\tng/mL,\\tbut\\tin some\\tsensitive\\tpatients,\\tthis\\tmay\\tbe\\tas\\tlow\\tas\\t2.5\\tng/mL.\\tPatients\\tmay\\tbe\\tmonitored with\\tECG\\tto\\tdetect\\tdigoxin-\\tinduced\\tarrhythmias. Formulations \u2022\\t\\tDigoxin\\tis\\tavailable\\tin\\t0.0625-\\t,\\t0.125-\\t,\\tand\\t0.25-\\tmg\\ttablets\\tand\\t0.05-\\t\\tand\\t0.15- mg/mL\\telixir. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is\\tnot\\tstable\\tif\\tmixed\\twith\\tlow-\\tpH\\tsolutions\\t(pH\\tless\\tthan\\t3).\\tDo\\tnot\\tcompound\\toral tablets with other medications. D Dihydrotachysterol 275","original_category":"Cardiac inotropic agent"},{"name":"Dihydrotachysterol","active_ingredient":"Dihydrotachysterol","species":["Canine","Feline"],"dosage":"Dog And Cats \u2022\\t\\t0.01\\tmg/kg/day\\tPO. \u2022\\t\\tAcute\\ttreatment:\\t0.02\\tmg/kg\\tinitially;\\tthen\\t0.01\u20130.02\\tmg/kg\\tq24\u201348h\\tPO thereafter.\\tThe\\tdose\\tshould\\tbe\\tadjusted\\ton\\tthe\\tbasis\\tof\\tmeasuring\\tcalcium concentrations.\\tEffective\\tdoses\\tcan\\trange\\tas\\thigh\\tas\\t0.1\u20130.3\\tmg/kg.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Diltiazem Hydrochloride dil- tye \u0301ah- zem  hye- droe- klor \u0301ide Trade and other names: Cardizem and Dilacor","contraindications":"Contraindications and Precautions Avoid use in pregnant animals because it may cause fetal abnormalities. Drug Interactions No\\tspecific\\tdrug\\tinteractions\\tare\\treported\\tfor\\tanimals.\\tHowever,\\tuse\\tcautiously\\twith high doses of preparations containing calcium. Use with caution with thiazide diuretics. 276    Diltiazem Hydrochloride","indications":"Indications and Clinical Uses Dihydrotachysterol is used as treatment of hypocalcemia, especially hypoparathyroidism associated with thyroidectomy. The most common use is for replacement in cats that have had thyroidectomy for treatment of hyperthyroidism. Calcitriol and calcium supplements are other drugs used to regulate calcium concentrations in animals (see Calcitriol). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdose\\tmay\\tcause\\thypercalcemia.","notes":"Instructions for Use Doses\\tfor\\tindividual\\tpatients\\tshould\\tbe\\tadjusted\\tby\\tmonitoring\\tserum\\tcalcium concentrations. Patient Monitoring and Laboratory Tests Monitor serum calcium concentration. Normal total calcium concentrations in dogs and\\tcats\\tare\\t9\u201311.5\\tmg/dL\\tand\\t8\u201310.5\\tmg/dL,\\trespectively,\\tor\\t1.2\u20131.5\\tmmol/L and\\t1.1\u20131.4\\tmmol/L,\\trespectively. Formulations \u2022\\t \\tNo\\tformulations\\tare\\tcurrently\\tavailable\\tin\\tthe\\tUnited\\tStates.\\tIt\\tcan\\tonly\\tbe\\tobtained from\\tsome\\tcompounding\\tpharmacies.\\tOlder\\tformulations\\tconsisted\\tof\\t0.125-\\tmg capsules;\\t0.5-\\tmg/mL\\toral\\tliquid\\t(20%\\talcohol);\\tand\\t125-\\t,\\t200-\\t   ,\\tand\\t400-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vitamin"},{"name":"Diltiazem Hydrochloride","active_ingredient":"Diltiazem Hydrochloride","species":["Feline","Canine","Equine"],"dosage":"See detailed instructions for cats in the  section.  Dogs \u2022\\t\\tFor\\tmost\\tuses:\\t0.5\u20131.5\\tmg/kg\\tq8h\\tPO.\\tFor\\tatrial\\tfibrillation,\\tdosages\\tas\\thigh\\tas\\t5 mg/kg\\tq12h\\tPO\\thave\\tbeen\\tused\\tas\\tmonotherapy,\\tor\\ta\\tcombination\\tof\\tdiltiazem\\t(3 mg/kg\\tq12h\\tPO)\\tplus\\tdigoxin\\t(0.005\\tmg/kg\\tq12h,\\tPO)\\thas\\tbeen\\tused. \u2022\\t\\tAtrial\\tfibrillation:\\t0.05\u20130.25\\tmg/kg\\tIV\\tadministered\\tevery\\t5\\tminutes\\tto\\teffect. \u2022\\t\\tSupraventricular\\ttachycardia:\\t0.25\\tmg/kg\\tover\\t2\\tminutes\\tIV\\t(repeat\\tif\\tnecessary). First,\\tinject\\t0.25\\tmg/kg;\\tthen\\twait\\t20\\tminutes\\tfor\\tresponse\\tbefore\\trepeating.\\tTo administer\\ta\\tCRI,\\tinject\\t0.15\u20130.25\\tmg/kg\\tIV\\tover\\t2\\tminutes;\\tthen\\tuse\\ta\\tCRI\\tof 0.1\u20130.2\\tmg/kg/h,\\tup\\tto\\ta\\tmaximum\\tof\\t0.4\\tmg/kg/h. \u2022\\t\\tAcute\\trenal\\tfailure:\\t0.2\\tmg/kg\\tIV\\t(slowly)\\tfollowed\\tby\\t3\u20135\\tmcg/kg/min\\tCRI. Cats \u2022\\t \\t1.75\u20132.4\\tmg/kg\\tq8h\\tPO.\\tMost\\tcommon\\tdosage\\tin\\tcats\\twith\\timmediate-\\trelease  Horses \u2022\\t\\t0.125\\tmg/kg\\tIV\\tover\\tat\\tleast\\t2\\tminutes.\\tRepeat\\tevery\\t10\\tminutes\\tas\\tneeded\\tor until\\ta\\ttotal\\tdose\\tof\\t1.1\\tmg/kg.\\tDoses\\tas\\thigh\\tas\\t1\u20132\\tmg/kg\\thave\\tbeen\\tused\\tin research animals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Dimenhydrinate dye- men- hye \u0301drih- nate Trade and other names: Dramamine (Gravol in Canada)","contraindications":"Contraindications and Precautions Do\\tnot\\tinject\\trapidly\\twhen\\tadministering\\tIV.\\tDo\\tnot\\tadminister\\tto\\tpatients\\twith hypotension. Drug Interactions Calcium- channel blocking drugs have been associated with drug interactions in people by interfering with drug metabolism. These interactions have not been documented in veterinary patients but are possible because of similar mechanisms. Therefore, use with caution when administering other drugs that may be p-   glycoprotein (efflux protein produced by multi- drug resistance [MDR] gene) substrates. (See Appendixes J and K.) Do not mix IV solutions with furosemide.","indications":"Indications and Clinical Uses Diltiazem is used primarily for control of supraventricular arrhythmias, atrial fibrillation, and hypertrophic cardiomyopathy. It also is used for atrial flutter, AV nodal reentry arrhythmias, and other forms of tachycardia. Diltiazem is more effective D on heart tissues (AV node and SA node) than on blood vessels. It can be used with digoxin and the action on cardiac rate and rhythm may be greater when used with digoxin. It should not be used as a primary treatment of hypertension and to produce vasodilation; one of the dihydropyridines calcium- channel blocking drugs (e.g., amlodipine) is preferred. In cats, diltiazem is considered one of the drugs of choice for treatment of feline hypertrophic cardiomyopathy. In dogs, diltiazem has been used to treat acute renal failure. It may improve renal perfusion by decreasing renal vasoconstriction and improving renal perfusion. In horses, diltiazem may be effective\\tfor\\tatrial\\tfibrillation.\\tHowever,\\ttreated\\thorses\\thad\\tvariable\\tresults,\\tand\\tsome developed hypotension and sinus arrest. Transdermal administration of diltiazem has not been shown to be effective in cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Hypotension,\\tmyocardial\\tdepression,\\tbradycardia,\\tand\\tAV\\tblock\\tare\\tthe\\tmost\\timportant adverse effects. If acute hypotension occurs, treat with aggressive fluid therapy and administration of calcium gluconate or calcium chloride. It may cause anorexia in some patients.\\tHigh\\tdoses\\tin\\tcats\\thave\\tcaused\\tvomiting.\\tWhen\\tcats\\twere\\tadministered\\t60\\tmg of\\tDilacor\\tXR,\\tit\\tproduced\\tlethargy,\\tGI\\tdisturbances,\\tand\\tweight\\tloss\\tin\\t36%\\tof\\tcats.","notes":"Instructions for Use Diltiazem is preferred over verapamil in patients with heart failure because of less myocardial depression. When used to treat atrial fibrillation in dogs, combined with digoxin, it may produce greater reduction in ventricular rate than either drug alone. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. Monitor blood pressure with acute treatment for atrial fibrillation. If blood concentrations are monitored, to produce a reduction\\tin\\theart\\trate,\\t80\u2013290\\tng/mL\\tare\\tnecessary\\tin\\tpeople\\tand\\t60\u2013120\\tng/mL in dogs. Formulations \u2022\\t\\tDiltiazem\\tis\\tavailable\\tin\\t30-\\t,\\t60-\\t  ,\\t90-\\t  ,\\tand\\t120-\\tmg\\ttablets. \u2022\\t\\tDiltiazem\\tis\\talso\\tavailable\\tas\\t120-,\\t180-,\\tand\\t240-mg\\textended-\\trelease\\tcapsules\\tand in\\ta\\t5-\\t   mg/mL\\tinjection\\tsolution. \u2022\\t\\tExtended-\\trelease\\tcapsules\\thave\\tthree\\tor\\tfour\\ttablets\\tin\\tone\\tunit.\\tThe\\tcapsule\\tmay be opened to release the individual tablets for oral dosing in dogs and cats. 278    Dimenhydrinate Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Extended- release tablets are difficult to manipulate for pet owners. Compounded transdermal formulations may not be stable. Compounded oral formulations, prepared with\\tvarious\\tsugars\\tand\\tflavorings,\\twere\\tstable\\tfor\\t50\u201360\\tdays.\\tInjectable\\tsolution\\tmay be\\tmixed\\twith\\tIV\\tfluids\\tbut\\tshould\\tbe\\tdiscarded\\tafter\\t24\\thours.\\tDo\\tnot\\tfreeze. formulations\\tis\\t7.5\u201310\\tmg\\tper\\tcat\\tq8h\\tPO,\\twith\\tfrequency\\treduced\\tto\\tq12h\\tin\\tsome\\tcats. \u2022\\t\\tDilacor\\tXR\\tor\\tCardizem\\tCD:\\t10\\tmg/kg\\tonce\\tdaily\\tPO.\\tExtended-\\trelease\\ttablets can be more difficult to use in cats compared to other tablets but have been used at 30\\tor\\t60\\tmg\\tper\\tcat\\t(see\\tlater). \u2022\\t\\tTablets\\tare\\tdifficult\\tto\\tbreak\\tfor\\tuse\\tin\\tcats.\\tNote\\tthat\\t\u201cXR,\u201d\\t\u201cSR,\u201d\\tand\\t\u201cCD\u201d\\tall refer\\tto\\tslow-\\trelease\\tformulations.\\tDilacor\\tXR-\\t240\\tmg\\tcontains\\tfour\\t60-\\tmg\\ttablets. XR-\\t  180\\tcontains\\tthree\\t60-\\tmg\\ttablets.\\tSlow-\\t\\tand\\textended-\\trelease\\ttablets\\tare\\tnot recommended for routine use in cats because they produce inconsistent plasma concentrations that may result in ineffective treatment in some and adverse effects in\\tothers.\\tThe\\tdose\\tof\\t30\\tmg\\tper\\tcat\\tof\\tDilacor\\tXR\\t(extended-\\trelease\\ttablets) produced\\tfewer\\tadverse\\teffects\\tthan\\t60\\tmg\\tper\\tcat.","original_category":"Calcium- channel blocker"},{"name":"Dimenhydrinate","active_ingredient":"Dimenhydrinate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t4\u20138\\tmg/kg\\tq8\u201312h\\tPO.\\tIM\\tor\\tIV\\tfor\\tthe\\tinjection\\tform. Cats \u2022\\t\\t12.5\\tmg/cat\\tq8\u201312h\\tPO.\\tIM\\tor\\tIV\\tfor\\tthe\\tinjection\\tform.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Dimercaprol dye- mer- cap \u0301role Trade and other names: British anti- lewisite (BAL) in oil","contraindications":"Contraindications and Precautions Antimuscarinic effects (atropine- like effects) are common. Do not use in conditions for which anticholinergic drugs may be contraindicated, such as glaucoma, ileus, or cardiac arrhythmias. Do not administer to patients in which theophylline products are contraindicated. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.\\tHowever,\\tuse\\twith\\tother\\tsedatives\\tand tranquilizers\\tmay\\tincrease\\tsedation.\\tSome\\tdrugs\\tdecrease\\tmetabolism\\tof theophylline and other methylxanthine drugs (see Appendix I). If these agents are used concurrently with this formulation, adverse effects are possible. 280    Dimercaprol","indications":"Indications and Clinical Uses Dimenhydrinate has used to prevent allergic reactions and for pruritus therapy in dogs\\tand\\tcats.\\tHowever,\\tsuccess\\trates\\tfor\\ttreatment\\tof\\tpruritus\\thave\\tnot\\tbeen\\thigh. In addition to the antihistamine effect for treating allergies, diphenhydramine, like other antihistamines, acts as an antiemetic via the drug effects on the centers that control vomiting in animals. Antihistamines used as antiemetics are administered for motion\\tsickness,\\tvomiting\\tinduced\\tby\\tchemotherapy,\\tand\\tGI\\tdisease\\tthat\\tstimulates vomiting. Antihistamines are not effective antiemetics for cats. They may be effective in some dogs; however, there are other antiemetics available for dogs and cats that are consistently more effective. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. Sedation is the result of inhibition of histamine N-    methyltransferase. Sedation may also be attributed to the block of other CNS receptors such as those for serotonin, acetylcholine, and alpha receptors. Antimuscarinic effects (atropine- like effects) also are common, including dry mouth and decreased GI\\tsecretions.\\tThis\\tproduct\\talso\\tcontains\\ta\\tmethylxanthine\\t(related\\tto\\tcaffeine\\tand theophylline); therefore, excess CNS stimulation could occur with high doses.","notes":"Instructions for Use Like\\tother\\tantihistamines,\\tthere\\thave\\tbeen\\tno\\tclinical\\tstudies\\ton\\tthe\\tuse\\tof dimenhydrinate. The use is based on clinical experience and anecdotal accounts. It is primarily used empirically for treatment of vomiting and to prevent allergic reactions. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations Dimenhydrinate\\tis\\tavailable\\tin\\t50-\\tmg\\ttablets\\tand\\t50-\\tmg/mL\\tinjection. Dimenhydrinate\\tis\\ta\\tsalt\\tconsisting\\tof\\t53.0%\u201355.5%\\tdiphenhydramine\\tand\\t44.0%\u2013 46.5%\\t8-\\tchlorotheophylline. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antihistamine"},{"name":"Dimercaprol","active_ingredient":"Dimercaprol","species":["Not specified in source"],"dosage":"\u2022\\t\\t4\\tmg/kg\\tq4h\\tIM.  \u2022\\t\\t4\\tmg/kg\\tq4h\\tIM. Regulatory Information Withdrawal\\ttime:\\t5\\tdays\\tfor\\tmilk\\tand\\tmeat\\t(extralabel\\tuse). Dimethyl Sulfoxide (DMSO) di- meth- il  sulf- oks \u0301ide Trade and other names: DMSO and Domoso","contraindications":"Contraindications and Precautions Drug Interactions There are no drug interactions reported, but chelation of metals will occur from administration.","indications":"Indications and Clinical Uses Dimercaprol is used to treat lead, gold, mercury, and arsenic toxicity. There are two\\tformulations:\\tdimercaptopropane-\\t1-\\t sulfonic\\tacid\\t(DMPS)\\tand\\tmeso-\\t2,3- dimercaptosuccinic acid. Because these are not readily available, they may be compounded from a bulk source. D Dimethyl Sulfoxide (DMSO) 281 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not reported in veterinary medicine. In people, sterile abscesses\\toccur\\tat\\tthe\\tinjection\\tsite.\\tHigh\\tdoses\\thave\\tcaused\\tseizures,\\tdrowsiness, and vomiting.","notes":"Instructions for Use Administer as soon as possible after intoxicant exposure has been identified. Alkalinization of urine will increase toxin removal. For lead intoxication, dimercaprol may be used with edetate calcium. It may be helpful to contact a Poison Control Center for additional instructions on treatment after an intoxication is identified. Patient Monitoring and Laboratory Tests Heavy\\tmetal\\tconcentrations\\tcan\\tbe\\tmeasured\\tto\\tassess\\ttreatment. Formulations \u2022\\t\\tDimercaprol\\tis\\tavailable\\tin\\tan\\tinjection\\tthat\\tmust\\tbe\\tprepared\\tby\\tcompounding. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidote"},{"name":"Diminazene Aceturate and Diminazene Diaceturate","active_ingredient":"Diminazene Aceturate and Diminazene Diaceturate","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022 \\t \\tBabesia\\ttreatment:\\t3.5\u20135\\tmg/kg\\tq12h\\tfor\\ttwo\\tdoses\\tIM. Cats \u2022\\t\\t4\\tmg/kg\\tIM\\tq24h\\tfor\\tfive\\tdoses.  Cattle \u2022\\t\\tTreatment\\tof\\tTrypanosoma cruzi or Babesia,\\t3.5\u20137\\tmg/kg\\tIM. Horses (See Precautionary Information.) \u2022\\t\\tEqune\\tpiroplasmosis:\\tdiminazene\\tdiaceturate:\\t3.5\u20135\\tmg/kg\\tIM,\\tq48h\\tfor\\ttwo treatments. \u2022 \\t \\tBabesia\\ttreatment,\\tdiminazene\\tdiaceturate:\\t3\u20135\\tmg/kg\\tIM\\tq12h\\tfor\\ttwo treatments. D Dinoprost Tromethamine 285 Regulatory Information If administered to food animals, consult FARAD at www.FARAD.org for withdrawal time\\tinformation.\\tDiminazene\\tis\\texcreted\\tinto\\tthe\\tmilk,\\twith\\tresidues\\tfor\\tup\\tto\\t6\\tdays in\\tsheep\\tand\\tgoats,\\tand\\tup\\tto\\t21\\tdays\\tin\\tcattle. Dinoprost Tromethamine dye \u0301noe- prahst  troe- meth \u0301ah- meen Trade and other names: Lutalyse, Prostin F2 alpha, ProstaMate, Prostaglandin F2 alpha, and PGF2 alpha","contraindications":"Contraindications and Precautions Because of adverse events in cats and lack of demonstration of clinical success, it is not recommended for cats. Drug Interactions There have been no interactions identified in animals.","indications":"Indications and Clinical Uses In dogs, imidocarb and diminazene have been used most widely, primarily for treatment of Babesia spp. and Hepatozoon canis\\tinfections.\\tHowever,\\tfor\\tthese infections,\\timidocarb\\thas\\tbeen\\tpreferred\\tover\\tdiminazene\\tbecause\\tof\\tdiminazene\u2019s narrow therapeutic index. Another use of diminazene has been for treatment of African trypanosomiasis (Trypanosoma spp.). Diminazene has been used to treat leishmaniasis in humans, but this is not a common use in dogs. It was used in experimental cats infected with Trypanosoma evansi\\tat\\ta\\tdose\\tof\\t3.5\\tmg/kg\\tvia\\tIM\\tinjection\\ton\\t5\\tconsecutive\\tdays\\tand\\twas\\t85.7% effective in eliminating the parasite, and no adverse effects were observed. It was used to treat Cytauxzoon felis\\tinfection\\tin\\tcats\\tand\\twas\\teffective\\twith\\ttwo\\tinjections administered\\tIM\\t2\\tmg/kg\\twithin\\ta\\t1-\\tweek\\tinterval\\tbut\\twas\\tnot\\teffective\\tto eradicate the organism. There have been mixed results in dogs for treating Babesia infections. It was more effective for Babesia canis but not as much for Babesia gibsoni. Diminazene\\thas\\tbeen\\tused\\tin\\thorses\\tfor\\tequine\\tpiroplasmosis\\t(Theileria equi and Babesia caballi). It has been effective in eliminating B. caballi infections in horses at 5 mg/kg\\tgiven\\ttwice\\tin\\ta\\t24-\\thour\\tinterval\\tIM.\\tIt\\twas\\teffective\\tin\\tcattle\\tat\\ta\\tdose\\tof\\t3\u20135 mg/kg\\tIM\\tfor\\tBabesia\\tinfections\\tand\\thas\\tbeen\\tused\\t(3.5\u20137\\tmg/kg\\tIM)\\tfor\\ttreating trypanosomiasis. Availability is an issue with use in the United States. It is available in both aceturate (molecular\\tweight,\\t515.5)\\tand\\tdiaceturate\\t(molecular\\tweight,\\t587.6)\\tsalts,\\tbut\\tit\\tis not approved for any animal species. 284    Diminazene Aceturate and Diminazene Diaceturate Precautionary Information","side_effects":"Adverse Reactions and Side Effects Because of limited use, there is not an adverse event profile for diminazene. It can\\tcause\\tpain\\ton\\tinjection.\\tIn\\thorses,\\tit\\tcaused\\tsevere\\tinjection-\\tsite\\treactions and\\tmuscle\\tdamage.\\tSingle\\tinjections\\tin\\tcats\\tfor\\ta\\tpharmacokinetic\\tstudy\\twere well tolerated. But in other studies, reactions in cats included severe ptyalism (salivation)\\tafter\\tinjection\\tdespite\\tatropine\\tadministration\\tconcurrently.\\tIt\\talso produced nausea and vomiting in cats for several hours and increased hepatic enzyme elevations. For these reasons, diminazene is not recommended for cats.","notes":"Instructions for Use Patient Monitoring and Laboratory Tests If\\tused\\tin\\tanimals,\\tmonitor\\tthe\\tinjection\\tsite\\tfor\\tsigns\\tof\\tadverse\\teffects.\\tMonitor\\tthe patient\u2019s\\tCBC\\tduring\\ttreatment. Formulations \u2022\\t\\tDiminazene\\tis\\tavailable\\tin\\ttwo\\tforms,\\tdiminazene\\taceturate\\tand\\tdiminazene diaceturate salts. The powdered formulation of diminazene diaceturate (Veriben) was\\treconstituted\\twith\\tsterile\\twater\\tto\\ta\\tconcentration\\tof\\t7\\tmg/mL\\tfor\\tIM injection\\tin\\tcats.\\tThis\\tformulation\\tcontained\\t3\\tmg/kg\\tdiminazene\\tdiaceturate (equivalent\\tto\\t1.68\\tmg/kg\\tbase\\tor\\t2.6\\tmg/kg\\tof\\tdiminazene\\taceturate). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiprotozoal agent"},{"name":"Dinoprost Tromethamine","active_ingredient":"Dinoprost Tromethamine","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\tPyometra:\\t0.1\u20130.2\\tmg/kg\\tonce\\tdaily\\tfor\\t5\\tdays\\tSQ. \u2022\\t\\tTerminate\\tpregnancy:\\t0.025\u20130.05\\tmg\\t(25\u201350\\tmcg)/kg\\tq12h\\tIM. Cats \u2022\\t\\tPyometra:\\t0.1\u20130.25\\tmg/kg,\\tonce\\tdaily\\tfor\\t5\\tdays\\tSQ. \u2022\\t\\tTerminate\\tpregnancy:\\t0.5\u20131\\tmg/kg\\tIM\\tfor\\ttwo\\tinjections.  Cattle \u2022\\t\\tTerminate\\tpregnancy:\\t25-\\tmg\\ttotal\\tdose,\\tadministered\\tonce\\tIM. \u2022\\t\\tEstrus\\tsynchronization:\\t25\\tmg\\t(5\\tmL),\\ttotal\\tdose,\\tIM\\tonce\\tor\\ttwice\\tat\\t10-\\t\\tto\\t12- day intervals. \u2022\\t\\tPyometra:\\t25\\tmg,\\ttotal\\tdose,\\tadministered\\tonce\\tIM. Horses \u2022\\t\\tEstrus\\tsynchronization:\\t1\\tmg/100\\tlb\\t(1\\tmg/45\\tkg)\\tor\\t1\u20132\\tmL\\tadministered\\tonce IM.\\tMares\\tshould\\treturn\\tto\\testrus\\twithin\\t2\u20134\\tdays\\tand\\tovulate\\t8\u201312\\tdays\\tafter treatment. Pigs \u2022\\t\\tInduction\\tof\\tparturition:\\t10\\tmg\\t(2\\tmL)\\tadministered\\tonce\\tIM.\\tParturition\\toccurs within 30 hours. Regulatory Information Do not administer to horses intended for food. To be used in beef cattle and nonlactating dairy cows only. D Diphenhydramine Hydrochloride 287 Diphenhydramine Hydrochloride dye- fen- hye \u0301drah- meen  hye- droe- klor \u0301ide Trade and other names: Benadryl and generic","contraindications":"Contraindications and Precautions Do not administer intravenously. Dinoprost induces abortion in pregnant animals. Use caution when handling this drug by veterinarians, animal owners, and technical help. It should not be handled by pregnant women. Absorption through intact human skin is possible. People with respiratory problems also should not handle dinoprost. Drug Interactions According to the label, dinoprost should not be used with NSAIDs because these drugs\\tinhibit\\tsynthesis\\tof\\tprostaglandins.\\tHowever,\\tNSAIDs\\tshould\\tnot\\taffect concentrations\\tof\\texogenous\\tPGF 2 alpha administered by this product. When using oxytocin concurrently, it should be used cautiously because there is a risk of uterine rupture.","indications":"Indications and Clinical Uses Dinoprost is used for estrus synchronization in cattle and horses by causing luteolysis. In horses and cattle, it is used to control timing of estrus in estrus- cycling females and in clinically anestrus females that have a corpus luteum. In pigs, dinoprost is used to induce parturition when given within 3 days of farrowing. In dogs, dinoprost has been used to treat open pyometra. In cattle, dinoprost has been used for treatment of chronic endometritis. In\\tlarge\\tanimals,\\tdinoprost\\tis\\tused\\tto\\tinduce\\tabortion\\tin\\tthe\\tfirst\\t100\\tdays\\tof gestation,\\tbut\\tuse\\tfor\\tinducing\\tabortion\\tin\\tsmall\\tanimals\\thas\\tbeen\\tquestioned. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Prostaglandin F 2 alpha causes increased smooth muscle tone, resulting in diarrhea, abdominal discomfort, bronchoconstriction, and increase in blood pressure. In small animals, other side effects include vomiting. Induction of abortion may cause retained placenta.","notes":"Instructions for Use Use in treating pyometra should be monitored carefully. If pyometra is not open, severe\\tconsequences\\tmay\\tresult.\\tWhen\\tused\\tin\\tcattle,\\tafter\\ta\\tsingle\\tinjection, cattle should be bred at the usual time relative to estrus. When administering two injections,\\tcattle\\tcan\\tbe\\tbred\\tafter\\tthe\\tsecond\\tinjection,\\teither\\tat\\tthe\\tusual\\ttime relative\\tto\\tdetected\\testrus\\tor\\tat\\tabout\\t80\\thours\\tafter\\tthe\\tsecond\\tinjection.\\tEstrus is\\texpected\\tto\\toccur\\t1\u20135\\tdays\\tafter\\tinjection\\tif\\ta\\tcorpus\\tluteum\\twas\\tpresent.\\tCattle that\\tdo\\tnot\\tbecome\\tpregnant\\twill\\tbe\\texpected\\tto\\treturn\\tto\\testrus\\tin\\tabout\\t18\u201324 days. When used in cattle to induce abortion, it should be used only during the\\tfirst\\t100\\tdays\\tof\\tgestation.\\tCattle\\tthat\\tabort\\twill\\tdo\\tso\\twithin\\t35\\tdays\\tafter injection. In pigs, administer within 3 days of predicted farrowing for parturition induction. Farrowing should start in approximately 30 hours. Patient Monitoring and Laboratory Tests When used for estrus synchronization, monitor for signs of estrus. Animals should be bred at usual time relative to estrus. Formulations \u2022\\t\\tDinoprost\\tis\\tavailable\\tin\\ta\\t5-\\tmg/mL\\tsolution\\tfor\\tIM\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Prostaglandin"},{"name":"Diphenhydramine Hydrochloride","active_ingredient":"Diphenhydramine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.2\\tmg/kg\\tq8\u201312h\\tPO,\\tIM,\\tor\\tSQ.\\tFor\\tlarge\\tdogs,\\tthis\\tis\\tequivalent\\tto\\tan\\toral dose\\tof\\t25\\tor\\t50\\tmg\\tper\\tdog. Cats \u2022\\t\\t2\u20134\\tmg/kg\\tq6\u20138h\\tPO. \u2022\\t\\t1\\tmg/kg\\tq8h\\tIV\\tor\\tIM.  \u2022\\t\\t0.5\u20131\\tmg/kg\\tas\\ta\\tsingle\\tdose,\\tas\\tneeded,\\tIM. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Diphenoxylate dye- fen- oks \u0301ih- late Trade and other names: Lomotil, also called Co- phenotrope","contraindications":"Contraindications and Precautions Antimuscarinic effects (atropinelike effects) are common. Do not use in conditions for which anticholinergic drugs may be contraindicated, such as glaucoma, ileus, or cardiac arrhythmias. Discontinue administration a minimum of 7\\tdays\\tprior\\tto\\tallergen-\\tspecific\\tallergy\\ttesting\\tin\\tdogs. Drug Interactions There\\tare\\tno\\tspecific\\tdrug\\tinteractions.\\tHowever,\\tbecause\\tof\\tanticholinergic (atropinelike) effects, it may counteract drugs that are administered for a parasympathomimetic action (e.g., drugs used to stimulate intestinal motility). 288    Diphenoxylate","indications":"Indications and Clinical Uses Diphenhydramine,\\tlike\\tother\\tantihistamines,\\tblocks\\thistamine\\ttype\\t1\\t(H 1 ) receptors to prevent action of histamine. It is used to prevent acute allergic reactions and for pruritus\\ttherapy\\tin\\tdogs\\tand\\tcats.\\tHowever,\\tsuccess\\trates\\tfor\\ttreatment\\tof\\tpruritus have not been high. Diphenhydramine has been used to treat acute allergy episodes caused by mast cell release, allergy, insect bites, and so on. In addition to the antihistamine effect for treating allergies, these drugs block the effect of histamine in the vomiting center, vestibular center, and other centers that control vomiting in animals. This may control some types of vomiting in dogs but not likely in cats. There are other more effective antiemetics available for dogs and cats that are preferred. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. Sedation is the result of inhibition of histamine N- methyltransferase. Sedation may also be attributed to blockade of other CNS receptors such as those for serotonin, acetylcholine, and alpha- receptors. Antimuscarinic effects (atropinelike effects) also are common, including dry\\tmouth\\tand\\tdecreased\\tGI\\tsecretions.\\tExcitement\\thas\\tbeen\\tobserved\\tin cats and other animals at high doses. Although it may induce some changes in cardiovascular parameters in some animals with IV administration, this has not been\\tshown\\tto\\tbe\\ta\\tproblem\\twhen\\tinjected\\tIV\\tin\\tdogs\\tundergoing\\tmast\\tcell removal surgery.","notes":"Instructions for Use Antihistamine used primarily for allergic disease in animals. These drugs also can be used to treat or prevent vomiting in animals, but antihistamines are not effective antiemetics in cats. Clinical studies documenting efficacy have been limited. Most use is empirical with doses extrapolated from human use. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tDiphenhydramine\\tis\\tavailable\\tOTC\\tin\\ta\\t2.5-\\tmg/mL\\telixir,\\t25-\\t\\tand\\t50-\\tmg\\tcapsules and\\ttablets,\\tand\\t50-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. Protect from freezing.","original_category":"Antihistamine"},{"name":"Diphenoxylate","active_ingredient":"Diphenoxylate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tAntitussive\\tuse:\\t0.2\u20130.5\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t0.05\u20130.1\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tuse\\tin\\tlarge\\tanimals\\tis\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Schedule V controlled drug. RCI\\tClassification:\\t4 Dipyridamole dye- peer- id \u0301ah- mole Trade and other names: Persantine","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\tin\\tpatients\\twith\\tdiarrhea\\tcaused\\tby\\tinfectious\\tcauses.\\tOpiates\\tshould not be used for chronic treatment of diarrhea. Drug Interactions There\\tare\\tno\\tspecific\\tdrug\\tinteractions\\treported.\\tHowever,\\tuse\\tcautiously\\twith\\tother opiates and other drugs that may cause constipation (e.g., antimuscarinic drugs).","indications":"Indications and Clinical Uses Diphenoxylate is used for the acute treatment of nonspecific diarrhea. It has a primarily\\tlocal\\teffect.\\tLoperamide\\t(Imodium)\\thas\\ta\\tsimilar\\taction\\tand\\thas\\tbecome more popular for this indication. An additional use, not often used in veterinary medicine, is as an antitussive. D Dipyridamole 289 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in veterinary medicine. Diphenoxylate is poorly absorbed systemically and produces few systemic side effects. Excessive use can cause constipation.","notes":"Instructions for Use Doses are based primarily on empiricism or extrapolation of human dose. Clinical studies have not been performed in animals. Diphenoxylate contains atropine, but the dose is not high enough for significant systemic effects. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tDiphenoxylate\\tis\\tavailable\\tin\\t2.5-\\tmg\\ttablets\\tthat\\talso\\tcontain\\t0.025\\tmg\\tatropine. \u2022\\t\\tOral\\tsolution:\\t2.5\\tmg\\tplus\\t0.025\\tmg\\tatropine\\tin\\t5\\tmL\\tof\\tsolution\\t(cherry\\tflavored, with\\t15%\\talcohol). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidiarrheal"},{"name":"Dipyridamole","active_ingredient":"Dipyridamole","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t4\u201310\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tuse\\tin\\tlarge\\tanimals\\tis\\treported. D Dipyrone 291 Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Dipyrone dye- pye\u2019- rone Trade and other names: Methampyrone. Known in many countries as metamizole. Zimeta, equine brand.","contraindications":"Contraindications and Precautions Do not use in animals with bleeding problems. Drug Interactions Aspirin may potentiate effects.","indications":"Indications and Clinical Uses In people, dipyridamole has been used to prevent thromboembolism and hypercoagulable\\tstates.\\tHowever,\\tthe\\tuse\\tof\\tdipyridamole\\thas\\tbeen\\tinfrequent\\tin animals. It may be indicated in clinical conditions in which platelet inhibition is desired but other antiplatelet drugs are preferred. It is indicated primarily to prevent thromboembolism. It is more common to administer other platelet inhibitors such as clopidogrel, with and without aspirin. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\thave\\tnot\\tbeen\\treported\\tin\\tanimals.\\tHowever,\\tbleeding problems are expected in animals prone to coagulopathies or receiving other anticoagulants.","notes":"Instructions for Use Dipyridamole is used primarily in people to prevent thromboembolism. Use in animals has not been reported. When used in people, it is combined with other antithrombotic agents (e.g., warfarin). Patient Monitoring and Laboratory Tests It may be necessary to monitor bleeding times in some animals. Formulations \u2022\\t\\tDipyridamole\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t75-\\tmg\\ttablets\\tand\\t5-\\tmg/mL\\tinjection.\\tIt is\\talso\\tavailable\\tcombined\\twith\\taspirin\\tas\\t200\\tmg\\tdipyridamole\\tplus\\t25\\tmg\\taspirin (Aggrenox). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Compounded\\toral\\tformulations\\thave\\tbeen\\tstable\\tfor\\t60\\tdays.","original_category":"Anticoagulant"},{"name":"Dirlotapide","active_ingredient":"Dirlotapide","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Obesity medication"},{"name":"Dobutamine Hydrochloride","active_ingredient":"Dobutamine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\u201320\\tmcg/kg/min\\tIV\\tinfusion.\\tGenerally\\tstart\\twith\\tlow\\tdose\\tand\\ttitrate\\tupward. Cats \u2022\\t\\t2\\tmcg/kg/min\\tIV\\tinfusion.  Horses \u2022\\t\\tDuring\\tanesthesia\\tto\\tsupport\\tcardiovascular\\tfunction:\\t0.5\\tmcg/kg/min\\tCRI. \u2022\\t\\tHigher\\tdoses\\tof\\t5\u201310\\tmcg/kg/min\\t(0.005\u20130.01\\tmg/kg/min\\tCRI\\tare\\tused\\tfor heart failure. \u2022\\t\\t5\u201310\\tmcg/kg/min\\t(0.005\u20130.01\\tmg/kg/min)\\tIV\\tinfusion.\\tObserve\\tfor\\tincreases in\\theart\\trate\\tand\\tventricular\\tarrhythmias.\\tAdjust\\tdose\\tas\\tneeded\\tbased\\ton\\tpatient response and heart rate. 296    Docusate Regulatory Information No regulatory information is available. Because of a short half- life, no risk of residue is anticipated in food animals. RCI\\tClassification:\\t3 Docusate dok \u0301yoo- sate Trade and other names: Docusate calcium: Surfak and Doxidan; Docusate sodium: DSS, Colace, and Doxan; and generic brands","contraindications":"Contraindications and Precautions Do not use in animals with ventricular arrhythmias. Do not use unless precise infusion and monitoring capabilities are available. Drug Interactions Do not mix with alkaline solutions, such as those containing bicarbonate. Do not\\tinfuse\\tin\\tIV\\tline\\twith\\theparin,\\tcephalosporins,\\tor\\tpenicillins.\\tOtherwise,\\tit is compatible with most fluid solutions. Do not administer to animals receiving monoamine\\toxidase\\tinhibitors\\t(MAOIs)\\t(e.g.,\\tselegiline),\\tor\\twithdraw\\tthe\\tMAOI before this drug is administered.","indications":"Indications and Clinical Uses Dobutamine is used primarily for the acute treatment of heart failure. It produces an inotropic effect without increasing heart rate. It is usually administered for short- term treatment\\tof\\theart\\tfailure\\twhen\\thospitalization\\tis\\trequired\\t(e.g.,\\tClass\\tC\\theart\\tfailure class). Short treatment regimens (e.g., 48 hours) can have a residual positive effect in D some\\tanimals.\\tIn\\thorses,\\tdobutamine\\tis\\tused\\tto\\timprove\\tperfusion\\tof\\tthe\\tGI\\ttract\\tand to support cardiovascular function in anesthetized horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Dobutamine may cause tachycardia and ventricular arrhythmias at high doses or in sensitive individuals. If tachycardia or arrhythmias are detected, stop the infusion rate\\tand\\tresume\\tat\\ta\\tlower\\trate.\\tIn\\thorses,\\t2\\tmcg/kg/min\\tcan\\tcause\\ta\\tsignificant increase in systemic blood pressure in conscious horses.","notes":"Instructions for Use Dobutamine has a rapid elimination half- life (minutes) and therefore must be administered\\tvia\\tcarefully\\tmonitored\\tCRI.\\tDose\\trates\\t(infusion\\trate)\\tcan\\tbe\\tadjusted by\\tmonitoring\\tpatient\\tresponse.\\tIn\\tdogs,\\tdoses\\tas\\tlow\\tas\\t2\\tmcg/kg/min\\thave improved cardiac output. Patient Monitoring and Laboratory Tests Monitor\\theart\\trate\\tand\\tECG\\tduring\\ttreatment.\\tCardiac\\tarrhythmias\\tare\\tpossible during infusions, especially at high doses. Formulations \u2022\\t\\tDobutamine\\tis\\tavailable\\tin\\ta\\t250-\\tmg/20-mL\\t(12.5-\\tmg/mL)\\tvial\\tfor\\tinjection. Stability and Storage Usually\\tdilute\\tin\\t5%\\tdextrose\\tsolution\\t(e.g.,\\t250\\tmg\\tin\\t1\\tL\\t5%\\tdextrose).\\tA\\tslight pink tinge to the solution can occur without loss of potency; however, do not use if color turns brown.","original_category":"Cardiac inotropic agent"},{"name":"Dopamine Hydrochloride","active_ingredient":"Dopamine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t2\u201310\\tmcg/kg/min\\tIV\\tinfusion.\\tDose\\trate\\tis\\tdependent\\ton\\tdesired\\teffects. Low\\tdose\\t(vasodilation,\\tD 1 receptor):\\t0.5\u20132\\tmcg/kg/min;\\tmedium\\tdose\\t(cardiac stimulating, beta 1 -\\treceptor):\\t2\u201310\\tmcg/kg/min;\\tand\\thigh\\tdose\\t(vasoconstriction, alpha-\\t   receptors):\\tgreater\\tthan\\t10\\tmcg/kg/min.  Horses and Cattle \u2022\\t\\t1\u20135\\tmcg/kg/min\\tIV\\tinfusion. Regulatory Information No regulatory information is available. Because of a short half- life, no risk of residue is anticipated in food animals. RCI\\tClassification:\\t2 D Doramectin 303 Doramectin dore- ah- mek \u0301tin Trade and other names: Dectomax","contraindications":"Contraindications and Precautions Dopamine is unstable in alkaline fluids. Drug Interactions Do\\tnot\\tmix\\twith\\talkaline\\tsolutions.\\tOtherwise,\\tit\\tis\\tcompatible\\twith\\tmost\\tfluid solutions.","indications":"Indications and Clinical Uses Dopamine is used therapeutically to stimulate myocardium via action on cardiac beta 1 - receptors. Dopamine infusions will increase both blood pressure and cardiac output. These effects are caused by stimulating cardiac contractility and heart rate by acting as an agonist for beta 1 - adrenergic receptors. In addition, dopamine increases the release of norepinephrine from nerve terminals (dopamine is a precursor for norepinephrine). It produces a greater chronotropic effect than dobutamine. It has been proposed that dopamine dilates renal arterioles, increases renal blood flow, and increases the glomerular filtration rate. This effect is proposed to\\toccur\\tvia\\tactivation\\tof\\trenal\\tdopamine-\\t1\\t(DA 1 ) receptors. Because of this proposed\\teffect,\\tin\\tthe\\tpast\\tit\\thas\\tbeen\\tused\\tfor\\tacute\\trenal\\tfailure.\\tHowever, recent evaluation has raised doubts about the clinical effectiveness of dopamine for treatment of acute renal failure. Cats do not have as many DA 1 receptors as other animals; therefore it has not been effective in cats to produce diuresis. In addition, evaluation in people and other animals has not produced desired effects. Therefore, there is little support for the use of dopamine to treat acute kidney disease in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Dopamine may cause tachycardia and ventricular arrhythmias at high doses or in sensitive individuals.","notes":"Instructions for Use Dopamine has a rapid elimination half- life (minutes) and therefore must be administered via carefully monitored CRI. Because the actions of dopamine are dose\\tdependent,\\tthe\\trate\\tadministered\\tis\\tadjusted\\tto\\treach\\tthe\\tdesired\\tclinical effect.\\tDopamine\\thas\\tbeen\\tadministered\\tat\\tdoses\\tof\\t2\u201310\\tmcg/kg/min\\tfor the acute management of heart failure and cardiogenic shock. When preparing IV\\tsolutions,\\tone\\tmay\\tadmix\\t200\u2013400\\tmg\\tof\\tdopamine\\twith\\t250\u2013500\\tmL\\tof fluid. Dopamine is unstable in alkaline fluid solutions, such as those containing bicarbonate. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm while administering dopamine. Formulations \u2022\\t\\tDopamine\\tis\\tavailable\\tin\\t40-\\t,\\t80-\\t  ,\\tand\\t160-\\tmg/mL\\tfor\\tIV\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It may be\\tadded\\tto\\tfluids\\tsuch\\tas\\t5%\\tdextrose,\\tsaline,\\tand\\tlactated\\tRinger\u2019s\\tsolution.\\tIt\\tis\\tstable for\\t24\\thours\\tafter\\tdilution.\\tDo\\tnot\\tuse\\tif\\tthe\\tsolution\\tturns\\ta\\tbrown\\tor\\tpurple\\tcolor.","original_category":"Cardiac inotropic agent"},{"name":"Doxapram Hydrochloride","active_ingredient":"Doxapram Hydrochloride","species":["Equine","Feline"],"dosage":"\u2022\\t\\t5\u201310\\tmg/kg\\tIV. \u2022\\t\\tNeonate:\\t1\u20135\\tmg\\tSQ,\\tsublingual,\\tor\\tvia\\tumbilical\\tvein.  \u2022\\t\\tFoals:\\tinitial\\tIV\\tdose\\tof\\t0.5\\tmg/kg\\tfollowed\\tby\\ta\\tCRI\\tof\\t0.03\u20130.08\\tmg/kg/min for\\t20\\tminutes\\tor\\tinitiate\\ttreatment\\twith\\t0.05\u20130.08\\tmg/kg/min\\tCRI\\tand\\tcontinue for\\t8\u201312\\thours. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t2 308    Doxepin Doxepin doks \u0301eh- pin Trade and other names: Sinequan","contraindications":"Contraindications and Precautions Do not use in animals with cardiac or respiratory arrest. Do not use with positive pressure ventilation. Drug Interactions Use with theophylline or aminophylline may increase CNS excitement.","indications":"Indications and Clinical Uses Doxapram may stimulate respiration in dogs, cats, and horses during and after general anesthesia. It has been used to stimulate respiration in newborn animals following dystocia or cesarean section surgery. Doxapram increases ventilation (tidal volume, respiratory rate) and reduces acidosis. In horses, it causes cardiac stimulation and respiratory stimulation. There have been reports that administration to neonates D may\\tincrease\\ttheir\\tsuckling\\tactivity\\tshortly\\tafter\\tbirth\\tand\\tsubsequently\\tdecrease the incidence of failure of passive transfer of immunoglobulins. The primary use of doxapram in horses is for the treatment of respiratory acidosis in foals caused by hypoxic-\\tischemic\\tencephalopathy\\t(perinatal\\tasphyxia\\tor\\tneonatal\\tmaladjustment syndrome) in neonatal foals. Administration to foals has restored normal ventilation and\\timproved\\tblood\\tpH,\\tPaO 2 , and respiratory rate in neonatal foals in a dose- dependent manner. Doxapram also has been used in dogs to assist in the diagnosis of laryngeal paralysis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. In people, it has caused panic, anxiety, sweating, seizures, and cardiovascular stimulation. CNS stimulation and excitement are possible with high doses or rapid infusions.","notes":"Instructions for Use Doxapram\\thas\\ta\\trapid\\tonset\\tof\\teffect\\t(usually\\toccurs\\tin\\t20\u201340\\tseconds\\twith\\tpeak effect\\tat\\t1\u20132\\tminutes)\\tand\\ta\\tshort\\tduration\\tof\\taction.\\tThe\\tduration\\tof\\teffect\\tvaries from\\t5\u201312\\tminutes.\\tTreatment\\tguidelines\\thave\\tbeen\\tdeveloped\\tprimarily\\tfor\\tfoals. Single-\\t   dose\\tinjections\\tmay\\tbe\\tadministered,\\tfollowed\\tby\\tCRIs. Patient Monitoring and Laboratory Tests Monitor\\tpatient\u2019s\\theart\\tand\\trespiratory\\trate. Formulations \u2022\\t\\tDoxapram\\tis\\tavailable\\tin\\ta\\t20-\\tmg/mL\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. The\\tpH\\tis\\t3.5\u20135\\tfor\\tIV\\tadministration,\\twhich\\tmay\\taffect\\tcompatibility\\twith\\tother drugs. Stability of compounded formulations has not been evaluated.","original_category":"Respiratory stimulant"},{"name":"Doxepin","active_ingredient":"Doxepin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t \\t1\u20135\\tmg/kg\\tq12h\\tPO.\\tStart\\twith\\tlow\\tdose\\t(e.g.,\\t0.5\u20131\\tmg/kg)\\tand\\tgradually\\tincrease. \u2022\\t\\tLick\\tgranuloma:\\t0.5\u20131\\tmg/kg\\tq12h\\tPO.\\t(For\\tcomparison,\\tantipruritic\\tdose\\tfor people\\tis\\t10\u201325\\tmg/person\\tone\\tto\\tthree\\ttimes\\tper\\tday\\tand\\tincreased\\tas\\tneeded.) Cats \u2022\\t\\t0.5\u20131\\tmg/kg\\tq12\u201324h.\\tStart\\twith\\tlow\\tdose\\tinitially.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t2 Doxorubicin Hydrochloride doks- oh- roo \u0301bih- sin  hye- droe- klor \u0301ide Trade and other names: Adriamycin","contraindications":"Contraindications and Precautions As with other TCAs, do not administer with other antidepressant drugs. Use cautiously in patients with glaucoma or seizure disorders. Drug Interactions Doxepin may increase sedative effects from antihistamines. Do not administer with\\tMAOIs.","indications":"Indications and Clinical Uses Doxepin has been used to treat anxiety disorders and dermatologic conditions in\\tdogs\\tand\\tcats.\\tSome\\tuse\\tfor\\tdermatitis\\tis\\trelated\\tto\\tthe\\tdrug\u2019s\\tantihistamine properties. Although it has been used for treating pruritus and dermatitis in small animals, it has not been effective for treating atopic dermatitis in dogs. Doxepin has been used to treat lick granuloma in dogs, which may be through its effects on modifying behavior. There are anecdotal reports of the use of doxepin for treating laryngeal paralysis in dogs, but there are no controlled studies to support this use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tricyclic antidepressants have some antimuscarinic effects that may increase heart rate, cause\\txerostomia,\\tand\\taffect\\tthe\\tGI\\ttract.\\tSome\\tsedation\\tis\\tpossible\\twith\\tdoxepin.","notes":"Instructions for Use Doxepin has primarily been administered to treat pruritus in dogs. The efficacy for this use has been disappointing. The used for other indications is purely anecdotal and not based on well- designed clinical studies. The dosages used are extrapolated from use in humans. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. D Doxorubicin Hydrochloride 309 Formulations \u2022\\t \\tDoxepin\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\t50-\\t  ,\\t75-\\t  ,\\t100-\\t   ,\\tand\\t150-\\tmg\\tcapsules\\tand\\t3-\\t\\tand\\t6-\\tmg tablets\\t(Silenor).\\tGeneric\\tand\\tSinequan\\tare\\tavailable\\tin\\ta\\t10-\\tmg/mL\\toral\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Oral\\tformulations\\tcan\\tbe\\tmixed\\twith\\tvarious\\tflavorings,\\tjuices,\\tand\\tfoods\\twithout\\tloss of stability.","original_category":"Behavior- modifying drug, tricyclic antidepressant (TCA)"},{"name":"Doxorubicin Hydrochloride","active_ingredient":"Doxorubicin Hydrochloride","species":["Feline","Canine","Equine"],"dosage":"Animal Dosage section). In cats, additional SQ fluids are administered to prevent renal toxicity.  Dogs \u2022\\t\\t30\\tmg/m 2 every\\t21\\tdays\\tIV. \u2022\\t\\tAlternatively,\\tdoxorubicin\\tmay\\tbe\\tadministered\\taccording\\tto\\tbody\\tweight:\\tdogs weighing\\tmore\\tthan\\t15\\tkg:\\t30\\tmg/m 2 ;\\tdogs\\tweighing\\tless\\tthan\\t15\\tkg:\\t1\\tmg/kg.  Horses \u2022\\t\\t70\\tmg/m 2 (0.84\u20130.96\\tmg/kg)\\tIV\\tevery\\t3\\tweeks\\tfor\\tsix\\tcycles. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Doxycycline Hyclate and Doxycycline Monohydrate doks- ih- sye \u0301kleen Trade and other names: Vibramycin, Monodox, Doxy Caps, and generic brands","contraindications":"Contraindications and Precautions Do not use in animals with cardiomyopathy. Monitor CBC in patients before and after treatment. If significant leukopenia (particularly neutropenia of fewer than\\t1000\\tcells)\\tis\\tpresent,\\twithhold\\ttreatment\\tor\\tuse\\ta\\tlower-\\tdose\\tintensity. Use cautiously in dogs with known mutation deficiency in the MDR membrane transporter\\t(p-\\tglycoprotein,\\tABCB1\\ttransporter)\\t(e.g.,\\tcollies\\tand\\trelated\\tbreeds). These dogs are more prone to toxicity. Boxer dogs are more prone to the cardiac toxicity. Drug Interactions Doxorubicin is commonly administered with other anticancer drugs, antiemetics,\\tand\\tantihistamines\\twithout\\tadverse\\teffects.\\tHowever,\\tdoxorubicin is a p- glycoprotein substrate and should not be used with drugs that are p-   glycoprotein inhibitors (e.g., cyclosporine or ketoconazole). (See Appendix J for a list of inhibitors.) 312    Doxycycline Hyclate and Doxycycline Monohydrate Cats \u2022\\t \\t20\\tmg/m 2 (\u22481.25\\tmg/kg)\\tevery\\t3\\tweeks\\tIV.\\tIn\\tsome\\tcats,\\thigher\\tdoses\\tof\\t25\\tmg/m 2 appear\\tto\\tbe\\tequally\\ttolerated.","indications":"Indications and Clinical Uses Doxorubicin\\tis\\ta\\twidely\\tused\\tanticancer\\tagent.\\tDoxorubicin\\tis\\ta\\tfrequently administered anticancer agent in humans for the treatment of breast tumors, various sarcomas, and osteosarcoma. In veterinary medicine, it has been used for lymphoma, osteosarcoma, and other carcinomas and sarcomas. It is considered one of the most effective single agents in the treatment of lymphoma, but in dogs, the response for T-   cell lymphoma is significantly less than for B- cell lymphoma. It is used commonly in cancer\\tprotocols\\twith\\tother\\tagents.\\tFor\\texample,\\tin\\tthe\\tCHOP\\tprotocol,\\tthe\\t\u201cH\u201d\\tin the protocol refers to doxorubicin (by an older name). For canine lymphoma, some oncologists believe that remission of cancer is best achieved when five treatments are administered\\t(target,\\t150\u2013180\\tmg/m 2 cumulative dose). In limited studies in horses, it was highly effective for the treatment of some tumors (lymphoma, carcinoma, and sarcoma) as a single agent. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\tlimit\\tthe\\tfrequency\\tand\\tcumulative\\tdoses\\tthat\\tcan\\tbe\\tadministered. Bone\\tmarrow\\ttoxicity\\tis\\tthe\\tmajor\\tadverse\\teffect\\tthat\\tlimits\\tthe\\tfrequency\\tof administration,\\tand\\tcardiotoxicity\\tis\\tthe\\tmajor\\teffect\\tthat\\tlimits\\tthe\\tchronic administration.\\tThe\\tnadir\\tof\\tbone\\tmarrow\\tdepression\\t(leukopenia)\\tis\\tat\\t7\u201310 days.\\tThe\\tstem\\tcells\\tare\\tusually\\tspared,\\tand\\trecovery\\toccurs\\twithin\\t21\\tdays\\tafter each\\tdose.\\tCardiac\\ttoxicity\\tis\\tobserved\\tin\\t4%\u20138%\\tof\\tcases\\tand\\tis\\tcaused\\tby\\tan acute effect during administration seen as arrhythmias and decreased systolic function and a chronic effect that manifests as cardiomyopathy and congestive heart failure. Cardiac toxicity is caused by production of reactive oxygen species that\\tinjure\\tcardiac\\tmyocytes\\tor\\tblockage\\tof\\ttopoisomerase\\ttype\\t2-\\tbeta,\\twhich\\tleads to mitochondrial dysfunction. Cardiac toxicity is dose related. The risk of chronic cardiac\\teffects\\tincreases\\tas\\ttotal\\tcumulative\\tdoses\\texceed\\t200\u2013240\\tmg/m 2 . At doses\\tabove\\t300\\tmg/m 2 , cardiac toxicity is likely, but in some dogs, cardiac changes\\tcan\\tbe\\tobserved\\tas\\tsoon\\tas\\tafter\\t120\\tmg/m 2 cumulative dose. Most oncologists\\tdo\\tnot\\texceed\\t180\\tmg/m 2 . Dexrazoxane (Zinecard) is a potent chelator of iron and has been used to decrease the adverse cardiac effects in some patients. The dose of dexrazoxane is 10\\ttimes\\tthe\\tdoxorubicin\\tdose\\tand\\tis\\tinfused\\tover\\t15\\tminutes\\tIV. Alopecia\\tis\\tcommon\\tin\\tpeople.\\tHowever,\\tthis\\teffect\\tis\\tseen\\tonly\\tin\\tdogs\\tthat have continuously growing hair (e.g., poodles). Cats may lose their whiskers. Gastrointestinal\\tacute\\tside\\teffects\\t(anorexia,\\tvomiting,\\tand\\tdiarrhea)\\tare the\\tmost\\tcommon\\tacute\\tside\\teffects\\tafter\\tadministration.\\tHypersensitivity (allergic) reactions are not life threatening, but they can occur commonly. They are probably not true allergic reactions but are simply the result of mast cell degranulation\\tthat\\toccurs\\tindependently\\tof\\timmunoglobulin\\tG\\t(IgG)\\tbinding. Signs of this reaction are head shaking (ear pruritus) and generalized urticaria and erythema. Antihistamines can be administered prior to treatment if these signs are anticipated. Cats are more sensitive to adverse effects than dogs; therefore, lower doses are used\\tin\\tcats.\\tAdverse\\teffects\\tin\\tcats\\tinclude\\tanorexia,\\tvomiting,\\tand\\trenal\\tinjury. In horses, adverse effects included bone marrow suppression, hair loss, dermatitis, and other skin reactions. Local\\treactions\\tmay\\toccur\\tif\\tthe\\textravasation\\tof\\tinjectable\\tdose\\tis\\tobserved.\\tIf this occurs, flush the area to dilute the drug. Dexrazoxane may be used to decrease local\\treaction\\tcaused\\tby\\textravasation\\tby\\tadministering\\t500\\tmg/m 2 within\\t6\\thours of\\textravasation.\\tLocal\\ttreatments\\talso\\tmay\\tbe\\tneeded. D","notes":"Instructions for Use The dose regimen listed in the dosing section may differ for various tumors. To prepare\\tsolution,\\tthe\\ttotal\\tdose\\tis\\tdiluted\\tin\\ta\\tsaline\\tfluid\\tsolution\\tof\\t25\\tor\\t50\\tmL\\tand infused\\tslowly\\tover\\t15\u201330\\tminutes.\\tAlternatively,\\ta\\t60-\\tminute\\tinfusion has been used in\\twhich\\tit\\tis\\tdiluted\\tin\\t25,\\t50,\\tor\\t100\\tmL\\tof\\t0.9\\t%\\tNaCl.\\tAlthough\\tsome\\texperts have suggested that a long duration of infusion may decrease some adverse effects, data\\tshow\\tthat\\ta\\trapid\\tinfusion\\tof\\t15\u201320\\tminutes\\tis\\tnot\\tmore\\tlikely\\tto\\tproduce adverse\\teffects\\tthan\\tan\\tinfusion\\tof\\t60\\tminutes. For\\tcats,\\tmix\\t1\\tmg/mL\\tin\\tsaline\\tsolution\\tand\\tadminister\\tIV\\tover\\t5\u201310\\tminutes with\\tfluids.\\tIn\\tcats,\\tSQ\\tfluids\\t(22\\tmL/kg)\\tmay\\tbe\\tadministered\\twith\\tdoxorubicin. This drug is very irritating, and special care must be made to ensure that extravasation from the vein does not occur. In chemotherapy protocols, it is sometimes administered with cyclophosphamide. Animals\\tmay\\trequire\\tantiemetic\\tand\\tantihistamine\\t(diphenhydramine)\\tprior\\tto therapy.\\tMost\\toften,\\tit\\tis\\tadministered\\ton\\ta\\tbody\\tsurface\\tarea\\trate\\t(mg/m 2 ); however, dose\\taccording\\tto\\tbody\\tweight\\t(mg/kg)\\tmay\\tbe\\tsafer\\tfor\\tsmall\\tdogs\\t(see\\tthe\\tSmall Patient Monitoring and Laboratory Tests Monitor\\tECG\\tduring\\ttherapy.\\tECGs\\tshould\\tbe\\tperformed\\tperiodically\\tin\\tdogs\\tto look for evidence of myocardial toxicity. CBC should be monitored regularly and prior to each treatment because of risk of myelotoxicity. Formulations \u2022\\t\\tDoxorubicin\\tis\\tavailable\\tin\\ta\\t2-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Edetate Calcium Disodium","active_ingredient":"Edetate Calcium Disodium","species":["Not specified in source"],"dosage":"\u2022\\t\\t25\\tmg/kg\\tq6h\\tfor\\t2\u20135\\tdays\\tSQ,\\tIM,\\tor\\tIV.  \u2022\\t\\t25\\tmg/kg\\tq6h\\tfor\\t2\u20135\\tdays\\tSQ,\\tIM,\\tor\\tIV. Regulatory Information Withdrawal\\ttime:\\t2\\tdays\\tfor\\tmeat;\\t2\\tdays\\tfor\\tmilk\\t(extralabel). E 318    Edrophonium Chloride Edrophonium Chloride ed- roe- foe \u0301nee- um  klor \u0301ide Trade and other names: Tensilon and generic brands","contraindications":"Contraindications and Precautions Do not use edetate disodium to substitute for edetate calcium disodium because it will chelate calcium in the patient. The loss of calcium can be fatal. Drug Interactions No specific drug interactions are reported. However, it has the potential to chelate other drugs if mixed together.","indications":"Indications and Clinical Uses Edetate calcium disodium is indicated for treatment of acute and chronic lead poisoning. It is sometimes used in combination with dimercaprol. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects reported in animals. In people, allergic reactions (release of histamine) have occurred after IV administration.","notes":"Instructions for Use Edetate calcium disodium may be used with dimercaprol. It is equally effective when administered intravenously or intramuscularly, but IM injection may be painful. Ensure adequate urine flow before the first dose is administered. Patient Monitoring and Laboratory Tests Monitor lead concentrations to assess treatment. Formulations \u2022\\t\\tEdetate\\tcalcium\\tdisodium\\tis\\tavailable\\tin\\ta\\t200-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidote"},{"name":"Edrophonium Chloride","active_ingredient":"Edrophonium Chloride","species":["Canine","Feline"],"dosage":"sensitive to edrophonium (see dose differences in the  section). Drug Interactions Use cautiously with other cholinergic drugs.  Dogs \u2022\\t\\t0.11\u20130.22\\tmg/kg\\tIV\\t(maximum\\tdose,\\t5\\tmg\\tper\\tdog). Cats \u2022\\t\\t0.25\u20130.5\\tmg/cat\\tIV. E Enalapril Maleate 319 Large Animal Dose \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tBecause\\tof\\ta\\tshort\\thalf-\\tlife,\\tno\\trisk\\tof\\tresidue is anticipated in food animals. Racing Commissioners International (RCI) Classification: 3 Enalapril Maleate eh- nal \u0301ah- prill  mal \u0301ee- ate Trade and other names: Enacard (veterinary preparation) and Vasotec (human preparation)","contraindications":"Contraindications and Precautions Edrophonium will potentiate effects of other cholinergic drugs. Cats are especially","indications":"Indications and Clinical Uses Because edrophonium is short acting, it ordinarily is only used for diagnostic purposes (e.g.,\\tmyasthenia\\tgravis).\\tIt\\talso\\thas\\tbeen\\tused\\tto\\treverse\\tneuromuscular\\tblockade\\tof nondepolarizing agents (pancuronium). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Edrophonium is short acting, and side effects are minimal. Overdose in nonmyasthenia animals may cause salivation, retching, vomiting, and diarrhea. If this is observed, administer\\tatropine\\tat\\t0.02\u20130.04\\tmg/kg.\\tExcessive\\tmuscarinic\\tand\\tcholinergic\\teffects may\\toccur\\twith\\thigh\\tdoses;\\tthese\\tmay\\talso\\tbe\\tcounteracted\\twith\\tatropine.","notes":"Instructions for Use Edrophonium is used primarily for determination of diagnosis of myasthenia gravis. An\\talternative\\tdrug\\tfor\\tthis\\tpurpose\\tis\\tneostigmine\\tmethylsulfate\\t(Prostigmin)\\tat\\t40 mcg/kg\\tIM\\tor\\t20\\tmcg/kg\\tIV. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tEdrophonium\\tis\\tavailable\\tin\\ta\\t10-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antimyasthenic, anticholinesterase"},{"name":"Enoxaparin Sodium","active_ingredient":"Enoxaparin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t \\t0.8\\tmg/kg\\tSQ\\tq6h\\t(see\\tPatient\\tMonitoring\\tand\\tLaboratory\\tTests\\tfor dose adjustment). The\\tdose\\tmay\\tneed\\tto\\tbe\\tadjusted\\tbecause\\tthis\\tmay\\tnot\\tachieve\\tadequate\\tanti-\\tXa\\tlevels\\tin all dogs. Cats \u2022\\t\\t0.75\u20131\\tmg/kg\\tSQ\\tq12h,\\tup\\tto\\t1.25\\tmg/kg\\tSQ\\tq6h.\\tEvery\\t6\\thours\\tis\\tpreferred\\tby many\\texperts.\\t(See\\tPatient\\tMonitoring\\tand\\tLaboratory\\tTests\\tfor dose adjustment.)  Horses \u2022\\t\\tProphylaxis:\\t0.5\\tmg/kg\\tq24h\\tSQ\\tand\\t1\\tmg/kg\\tq24h\\tSQ\\tfor\\thigh-\\trisk\\tpatients. Regulatory Information Extralabel\\twithdrawal\\ttimes\\tare\\tnot\\testablished.\\tHowever,\\t24-\\thour\\twithdrawal\\ttimes are\\tsuggested\\tbecause\\tthis\\tdrug\\thas\\tlittle\\trisk\\tfrom\\tresidues. Enrofloxacin en- roe- floks \u0301ah- sin Trade and other names: Baytril and generic","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\tIM\\tto\\tprevent\\thematoma;\\tadminister\\tSQ\\tonly.\\tLMWH\\tis excreted\\tby\\trenal\\tclearance\\tin\\tanimals;\\ttherefore,\\tif\\trenal\\tdisease\\tis\\tpresent,\\tthe elimination will be prolonged. Rebound hypercoagulability may occur after discontinuation\\tof\\theparin\\ttreatment;\\ttherefore,\\tit\\tmay\\tbe\\tadvised\\tto\\ttaper\\tthe dose slowly when discontinuing treatment. Drug Interactions Do not mix with other injectable drugs. Use cautiously in animals that are already receiving other drugs that can interfere with coagulation, such as aspirin, warfarin, and factor Xa inhibitors. Although a specific interaction has not been identified, use cautiously in animals that may be receiving certain chondroprotective compounds such as glycosaminoglycans for treatment of arthritis. Some antibiotics, such as cephalosporins, may inhibit coagulation.","indications":"Indications and Clinical Uses Enoxaparin,\\tlike\\tother\\tLMWHs,\\tis\\tused\\tto\\ttreat\\thypercoagulability\\tdisorders\\tand prevent coagulation disorders such as thromboembolism, venous thrombosis, disseminated intravascular coagulopathy, and pulmonary thromboembolism. In dogs\\tand\\tcats,\\tthere\\tis\\tinsufficient\\tevidence\\tto\\tshow\\tthat\\tLMWH\\tis\\tsuperior\\tto\\tUFH for treatment. Clinical indications are derived from uses of conventional heparin or extrapolated from human medicine. There have been few clinical studies to examine efficacy\\tof\\tLMWH\\tin\\tanimals.\\tPreviously\\tpublished\\tdoses\\textrapolated\\tfrom\\thumans have been shown not\\tto\\tproduce\\tadequate\\tand\\tconsistent\\tanti-\\tXa\\tactivity\\tin\\tdogs\\tand cats;\\ttherefore,\\tspecific\\tdoses\\tfor\\tdogs\\tand\\tcats,\\trather\\tthan\\textrapolated\\tfrom\\thuman medicine, should be used. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Although enoxaparin is better tolerated than regular heparin, bleeding is a risk.\\tHowever,\\tLMWHs\\tproduce\\tfewer\\tbleeding\\tproblems\\tthan\\tadministration of\\tconventional\\theparin.\\tLMWHs\\tare\\tassociated\\twith\\ta\\tlower\\tincidence\\tof heparin-\\tinduced\\tthrombocytopenia\\t(HIT)\\tin\\tpeople,\\tbut\\tHIT\\tfrom\\tany\\tform\\tof heparin has not been a clinical problem in animals. If excessive anticoagulation and bleeding occur as a result of an overdose, protamine sulfate should be administered\\tto\\treverse\\theparin\\ttreatment.\\tThe\\tprotamine\\tdose\\tis\\t1.0\\tmg protamine\\tfor\\tevery\\t1.0\\tmg\\tenoxaparin\\tadministered\\tby\\tslow\\tIV\\tinfusion. Protamine complexes with heparin to form a stable, inactive compound.","notes":"Instructions for Use Dosing recommendations extrapolated from human medicine are not appropriate for\\tanimals.\\tAnimal\\towners\\tshould\\tbe\\twarned\\tthat\\tLMWHs\\tare\\texpensive\\tcompared with\\tconventional\\theparin.\\tWhen\\tdosing,\\tdo\\tnot\\tinterchange\\tdoses\\ton\\ta\\tunit-\\tfor- unit\\tbasis\\twith\\theparin\\tor\\tother\\tLMWHs\\tbecause\\tthey\\tdiffer\\tin\\tmanufacturing process,\\tmolecular\\tweight\\tdistribution,\\tanti-\\tXa\\tand\\tanti-\\tIIa\\tactivities,\\tunits,\\tand dosage. E Enrofloxacin 325 Patient Monitoring and Laboratory Tests Monitor\\tpatients\\tfor\\t clinical\\t   signs\\t  of\\t bleeding\\tproblems.\\tWhen\\t   administering\\tLMWH, activated partial thromboplastin time (aPTT) and prothrombin time clotting times are not reliable indicators of therapy, although prolonged aPTT is a sign of overdosing. Anti-\\t  Xa\\tactivity\\tis\\tconsidered\\tthe\\tpreferred\\tlaboratory\\tmeasure\\tof\\tLMWH\\tactivity\\tin people,\\tbut\\tthe\\tuse\\tof\\tthis\\tparameter\\tis\\tcontroversial\\tin\\tanimals.\\tPeak\\tanti-\\tXa\\tactivity occurs\\t3\u20134\\thours\\tafter\\tdosing,\\tand\\tthe\\ttarget\\trange\\tfor\\tanti-\\tXa\\tactivity\\tshould\\tbe 0.5\u20131.0\\tunits/mL\\tfor\\tcats\\tand\\t0.5\u20132.0\\tunits/mL\\tfor\\tdogs. Formulations \u2022\\t \\tEnoxaparin\\tis\\tavailable\\tas\\t100\\tmg/mL\\tin\\tthe\\tfollowing\\tsizes:\\t30\\tmg\\tin\\t0.3-\\tmL,\\t40\\tmg in\\t0.4-\\t   mL,\\t60\\tmg\\tin\\t0.6-\\tmL,\\t80\\tmg\\tin\\t0.8-\\tmL,\\t100\\tmg\\tin\\t1-\\tmL,\\tand\\t300\\tmg/3-\\tmL injection;\\tand\\t150\\tmg/mL\\twith\\t120\\tmg/0.8\\tmL\\tand\\t150-\\tmg/mL\\tinjection. Stability and Storage Store\\tin\\ta\\ttightly\\tsealed\\tcontainer\\tprotected\\tfrom\\tlight.\\tThe\\tpH\\tof\\tthe\\tinjection\\tis\\t5.5\u20137.5.","original_category":"Anticoagulant"},{"name":"Ephedrine Hydrochloride","active_ingredient":"Ephedrine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tUrinary\\tincontinence:\\t4\\tmg/kg\\tor\\t12.5\u201350\\tmg/dog\\tq8\u201312h\\tPO. \u2022\\t\\tVasopressor:\\t0.75\\tmg/kg\\tIM\\tor\\tSQ;\\trepeat\\tas\\tneeded. Cats \u2022\\t\\tUrinary\\tincontinence:\\t2\u20134\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tVasopressor:\\t0.75\\tmg/kg\\tIM\\tor\\tSQ;\\trepeat\\tas\\tneeded.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information Withdrawal time: No withdrawal times are established. Ephedrine is metabolized after administration, and a short withdrawal is recommended. RCI\\tClassification:\\t2 Epinephrine eh- pih- nef \u0301rin Trade and other names: Adrenaline and generic brands","contraindications":"Contraindications and Precautions Use in animals with cardiovascular disease is not recommended. Drug Interactions No specific drug interactions are reported. However, ephedrine potentiates any other adrenergic agonist.","indications":"indications. E Epinephrine 329 Indications and Clinical Uses Ephedrine is used as a vasopressor (e.g., when it is administered during anesthesia). It also has been used as a CNS stimulant. Oral formulations have been used to treat urinary incontinence because of action on bladder sphincter muscle. However, this is no longer recommended, and most oral dose forms are no longer available. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to excessive adrenergic activity (e.g., peripheral vasoconstriction and tachycardia, or alternatively, reflex bradycardia).","notes":"Instructions for Use The most current use is from injection primarily in acute situations to increase blood pressure.\\tOral\\tuse\\tfor\\turinary\\tincontinence\\tin\\tdogs\\thas\\tdiminished\\tbecause\\tof\\tlack\\tof\\tavailable formulations and other agents to treat urinary incontinence (e.g., phenylpropanolamine). Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm in patients. Formulations \u2022\\t\\tMost\\tformulations\\tof\\tephedrine\\thave\\tbeen\\tremoved\\tfrom\\tthe\\tmarket.\\tPreviously available\\tas\\ta\\t25-\\t\\tand\\t50-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Adrenergic agonist"},{"name":"Epinephrine","active_ingredient":"Epinephrine","species":["Canine","Feline","Equine","Bovine"],"dosage":"\u2022\\t \\tCardiac\\tarrest:\\t10\u201320\\tmcg/kg\\tIV\\tor\\t100\u2013200\\tmcg/kg\\t(0.1\u20130.2\\tmg/kg) endotracheal (may be diluted in saline before administration). The low dose of 10\u201320\\tmcg/kg\\tIV\\tinitially\\tmay\\tbe\\tused\\tand\\tincreased\\tto\\t100\\tmcg/kg\\tIV\\tfor prolonged CPR. \u2022\\t\\tAnaphylactic\\tshock:\\t5\u201310\\tmcg/kg\\tIV\\tor\\tIM\\tor\\t50\\tmcg/kg\\tendotracheal\\t(may\\tbe diluted in saline). \u2022\\t\\tVasopressor\\ttherapy:\\t100\u2013200\\tmcg/kg\\t(0.1\u20130.2\\tmg/kg)\\tIV\\t(high\\tdose)\\tor\\t10\u201320 mcg/kg\\t(0.01\u20130.02\\tmg/kg)\\tIV\\t(low\\tdose).\\tAdminister\\tlow\\tdose\\tfirst;\\tif\\tno response, use high dose. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\t0.05\\tmcg/kg/min\\tIV. \u2022\\t\\tDuring\\temergency\\tuse,\\tthe\\tdose\\tmay\\tbe\\trepeated\\tevery\\t5\u201315\\tminutes,\\tbut\\tthe maximum\\tdoses\\tin\\tdogs\\tare\\t0.3\\tmg\\ttotal\\tfor\\tdogs\\tweighing\\tless\\tthan\\t40\\tkg\\tand\\t0.5 mg\\ttotal\\tfor\\tdogs\\tweighing\\tmore\\tthan\\t40\\tkg\\tbody\\tweight.  \u2022\\t\\t1\\tmg/mL\\t(1:1000)\\tsolution\\tmost\\toften\\tused. \u2022\\t\\tAnaphylactic\\tshock\\t(cattle,\\tpigs,\\thorses,\\tand\\tsheep):\\t20\\tmcg/kg\\t(0.02\\tmg/kg) IM\\tor\\t1\\tmL/45\\tkg\\t(1\\tmL/100\\tlb).\\t5\u201310\\tmcg/kg\\t(0.005\u20130.01\\tmg/kg)\\tIV\\tor 0.25\u20130.5\\tmL/45\\tkg\\t(100\\tlb). Regulatory Information No withdrawal times are established. Epinephrine is rapidly metabolized after administration, and zero days is recommended for withdrawal. RCI\\tClassification:\\t2 Epoetin Alfa (Erythropoietin) ee- poe \u0301eh- tin Trade and other names: Procrit, Eprex, and Erythropoietin","contraindications":"Contraindications and Precautions Avoid repeated administration in patients to prevent excessive adrenergic receptor stimulation. Drug Interactions Epinephrine interacts with other drugs that are used to either potentiate or antagonize\\talpha-\\tadrenergic\\tor\\tbeta-\\tadrenergic\\treceptors.\\tIt\\tis\\tincompatible\\twith alkaline\\tsolutions\\t(e.g.,\\tbicarbonate),\\tchlorine,\\tbromine,\\tand\\tsalts\\tof\\tmetals\\tor oxidizing solutions. Do not mix with bicarbonates, nitrates, citrates, and other salts.","indications":"Indications and Clinical Uses Epinephrine is used primarily for emergency situations to treat cardiopulmonary arrest and anaphylactic\\tshock.\\tIt\\tis\\tadministered\\tIV,\\tIM,\\tor\\tendotracheal\\tfor\\tacute\\tuse.\\tVasopressin (arginine vasopressin) has replaced epinephrine as a vasopressor in some cardiopulmonary resuscitation (CPR) protocols. Epinephrine has been used in horses to test for diagnosis of anhidrosis, but terbutaline sulfate challenge is used more frequently for this test. Precautionary Information","side_effects":"Adverse Reactions and Side Effects An overdose of epinephrine causes excessive vasoconstriction and hypertension. High doses can cause ventricular arrhythmias. When high doses are used for cardiopulmonary arrest, an electrical defibrillator should be available.","notes":"Instructions for Use Doses are based on experimental studies, primarily in dogs. Clinical studies are not available, but the doses and protocols are developed from the experience of clinical use. IV doses are ordinarily used, but endotracheal administration is acceptable when IV access is not available. When the endotracheal route is used, the dose is higher (up\\tto\\t10\\ttimes\\tthe\\tIV\\tdose\\tfor\\tCPR),\\tand\\tthe\\tduration\\tof\\teffect\\tmay\\tbe\\tlonger than with IV administration. When administering an endotracheal dose, one can dilute\\tthe\\tdose\\tin\\ta\\tvolume\\tof\\t2\u201310\\tmL\\tof\\tsaline.\\tThe\\tintraosseous\\troute\\talso\\thas been used, and doses are equivalent to IV doses. There appears to be no advantage to intracardiac injection compared with IV administration. Solutions are available in 1:1000\\tand\\t1:10,000\\t(either\\t1\\tmg/mL\\tor\\t0.1\\tmg/mL).\\tGenerally,\\tonly\\tthe\\t1:10,000 solution\\tis\\tgiven\\tIV.\\t1:1000\\tsolutions\\tare\\tintended\\tfor\\tIM\\tuse.\\tAvoid\\tthe\\tSQ\\troute\\tof administration because the vasoconstriction produced delays absorption from this site. For CPR, the doses have been controversial (see the dosing section). There is a low dose (10\\tmcg/kg\\tor\\t0.01\\tmg/kg)\\tand\\ta\\thigh\\tdose\\t(100\\tmcg/kg\\tor\\t0.1\\tmg/kg).\\tGenerally,\\tstart with\\tthe\\tlow\\tdose\\tevery\\t3\u20135\\tminutes\\tIV\\tin\\tCPR;\\tthen\\tuse\\tthe\\thigh\\tdose\\tafter\\tprolonged\\tCPR. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. E Epoetin Alfa (Erythropoietin) 331 Formulations \u2022\\t\\tEpinephrine\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\t(1:1000)\\tinjection\\tsolution\\tand\\t0.1-\\tmg/ mL\\t(1:10,000)\\tinjection\\tsolution.\\tThe\\t1:10,000\\tis\\toften\\tused\\tIV,\\tand\\tthe\\t1:1000 solution\\tis\\tused\\tIM\\tor\\tSQ.\\tAmpules\\tfor\\tpeople\\tare\\tdesigned\\tto\\tdeliver\\t1\\tmg/ person\\t(approximately\\t14\\tmcg/kg). Stability and Storage It is compatible with plastic in syringes. When solution becomes oxidized, it turns brown.\\tDo\\tnot\\tuse\\tif\\tthis\\tcolor\\tchange\\tis\\tobserved.\\tIt\\tis\\tmost\\tstable\\tat\\tpH\\tof\\t3\u20134.\\tIf the\\tpH\\tof\\tthe\\tsolution\\tis\\tgreater\\tthan\\t5.5,\\tit\\tbecomes\\tunstable.","original_category":"Adrenergic agonist"},{"name":"Ergocalciferol","active_ingredient":"Ergocalciferol","species":["Not specified in source"],"dosage":"\u2022\\t\\t500\u20132000\\tunits/kg/day\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Ertapenem er- tah- pen \u0301em Trade and other names: Invanz","contraindications":"Contraindications and Precautions Avoid use in pregnant animals because it may cause fetal abnormalities. Use cautiously with high doses of preparations containing calcium. Drug Interactions No drug interactions are reported.","indications":"Indications and Clinical Uses Ergocalciferol is used for vitamin D deficiency and as treatment of hypocalcemia associated with hypoparathyroidism. Calcitriol often is used in place of ergocalciferol in dogs and cats. See Calcitriol for more information. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Overdose may cause hypercalcemia.","notes":"Instructions for Use Ergocalciferol should not be used for renal secondary hypoparathyroidism because of an inability to convert to active compound. Doses for individual patients should be adjusted by monitoring serum calcium concentrations. Patient Monitoring and Laboratory Tests Monitor serum calcium concentration. Normal total calcium concentrations in dogs and\\tcats\\tare\\t9\u201311.5\\tmg/dL\\tand\\t8\u201310.5\\tmg/dL,\\trespectively,\\tor\\t1.2\u20131.5\\tmmol/L and\\t1.1\u20131.4\\tmmol/L,\\trespectively. Formulations \u2022\\t\\tErgocalciferol\\tis\\tavailable\\tin\\t50,000\\tunits\\tper\\tcapsule. E Ertapenem 337 Conversion of Units To\\tconvert:\\t1.0\\tunits\\tergocalciferol\\tis\\tequivalent\\tto\\t0.025\\tmcg\\tergocalciferol\\tor cholecalciferol. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vitamin"},{"name":"Esomeprazole","active_ingredient":"Esomeprazole","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t20\\tmg/dog\\tq24h\\tPO,\\t1\u20132\\tmg/kg\\tq12h\\tPO,\\tor\\t0.5\u20131\\tmg/kg\\tIV\\tq12h. Cats \u2022\\t\\t1\\tmg/kg\\tq12h\\tPO\\tor\\tIV.  Horses \u2022\\t\\tTreat\\tulcers:\\t4\\tmg/kg\\tonce\\tdaily\\tfor\\t4\\tweeks\\tPO.\\t(But\\tdoses\\tas\\tlow\\tas\\t2\\tmg/kg might be equally effective.) \u2022\\t\\tPrevent\\tulcers:\\t1\u20132\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tTreatment\\tof\\tulcers:\\tLoading\\tdose\\tof\\t1\\tmg/kg\\tPO\\tfollowed\\tby\\t0.5\\tmg/kg/day\\tfor 14\u201328\\tdays. Regulatory Information Not intended for administration to animals that produce food. Oral absorption in ruminants is not established. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t5 E Estradiol Cypionate 345 Estradiol Cypionate ess- trah- dye \u0301ole  sip \u0301ee- oh- nate Trade and other names: ECP, Depo- Estradiol, and generic brands","contraindications":"Contraindications and Precautions No contraindications have been reported for animals. There are concerns that long-\\t  term\\tadministration\\tof\\tPPIs\\tin\\tpeople\\tcan\\tlead\\tto\\tClostridium- associated diarrhea,\\trisk\\tof\\tfractures,\\tand\\thypomagnesemia.\\tThis\\thas\\tnot\\tbeen\\treported in\\tanimals.\\tLong-\\tterm\\tadministration\\tof\\tPPIs\\tin\\tpeople\\tcan\\tlead\\tto\\tbacterial overgrowth\\tin\\tthe\\tstomach\\tand\\tintestine,\\tbut\\tit\\tis\\tnot\\tknown\\tif\\tthis\\tis\\ta\\trisk\\tin animals. Drug Interactions Although esomeprazole has not been associated with drug interactions in animals, PPIs\\tmay\\tinhibit\\tsome\\tdrug-\\tmetabolizing\\tenzymes\\t(cytochrome\\tP450\\tenzymes). Because of stomach acid suppression, do not administer with drugs that depend on\\tstomach\\tacid\\tfor\\tabsorption\\t(e.g.,\\tketoconazole\\tand\\titraconazole).","indications":"Indications and Clinical Uses Esomeprazole,\\tlike\\tother\\tPPIs,\\tis\\tused\\tfor\\ttreatment\\tand\\tprevention\\tof\\tGI\\tulcers\\tand to decrease the esophageal irritation from gastroesophageal reflux. It has not been used in dogs, cats, or horses as often as omeprazole but is expected to be equally effective if equipotent doses are administered. In people, there is evidence that it might produce better results than omeprazole. See Omeprazole for more detailed information. In most studies, the PPIs have more consistently produced stomach pH that is above the minimum that is associated with ulcer healing compared with other agents such as histamine H 2 blockers.\\tTherefore,\\tthe\\tPPI\\tgroup\\tof\\tdrugs\\tis\\tpreferred over histamine H 2 blockers\\tfor\\ttreating\\tand\\tinhibiting\\tgastric\\tulcers,\\tbut\\tthere\\tis no evidence available to show that esomeprazole is more effective than other PPIs in dogs, horses, or cats. There is some evidence in experimental animals, but not confirmed in clinical studies, that it might produce more consistent acid suppression than\\tomeprazole.\\tIn\\tstudies\\tperformed\\tin\\thealthy\\tdogs,\\t0.5\\tmg/kg\\tor\\t1\\tmg/kg\\tq12h increased\\tthe\\tstomach\\tpH\\tabove\\t3\\tfor\\t75%\\tof\\tthe\\tdosing\\tinterval\\tand\\tabove\\tpH\\t4 for\\t67%\\tof\\tthe\\tdose\\tinterval.\\tThese\\tpH\\tthresholds\\tare\\toften\\tcited\\tas\\tthe\\ttargets\\tfor therapeutic effects. In horses it may be more effective than omeprazole for treatment of\\tulcers\\tin\\tthe\\tglandular\\tportion\\tof\\tthe\\tstomach\\t(EGGD),\\tbut\\tmore\\twork\\tis\\tneeded before recommendations can be made. Esomeprazole is available in an injectable formulation and may be substituted for injectable pantoprazole if necessary. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The use of esomeprazole has not been as common as with omeprazole. Therefore, adverse effects have not been reported in animals with esomeprazole. However, adverse\\teffects\\tare\\tassumed\\tto\\tbe\\tsimilar\\tduring\\tlong-\\tterm\\tuse\\tas\\tfor\\tomeprazole, and readers can consult the section on omeprazole for other information.","notes":"Instructions for Use Omeprazole is the most common drug of this class used in animals, but esomeprazole is expected to be equally effective if equipotent doses are administered. Other PPIs include pantoprazole (Protonix), lansoprazole (Prevacid), and rabeprazole (Aciphex). Little\\t   clinical\\t   experience\\twith\\t  these\\t   other\\t   products\\tis\\t reported\\tfor\\t veterinary\\tmedicine. Patient Monitoring and Laboratory Tests Esomeprazole and PPIs are generally considered safe. No routine tests for monitoring adverse effects are recommended. If gastrin concentrations are measured,\\ta\\t7-\\tday\\twithdrawal\\tfrom\\tesomeprazole\\ttreatment\\tshould\\tbe\\tused; otherwise, there is a significant increase in serum gastrin concentrations from esomeprazole treatment. Formulations \u2022\\t\\tOral\\tforms:\\tEsomeprazole\\tis\\tavailable\\tin\\t20-\\t\\tand\\t40-mg\\tdelayed-\\trelease\\tcapsules; 2.5-\\t  ,\\t5-\\t ,\\t10-\\t  ,\\t20-\\t  ,\\tand\\t40-\\tmg\\tpowder\\tfor\\tdelayed-\\trelease\\tsuspension,\\tand\\t24.65- and\\t49.3-\\tmg\\tdelayed-\\trelease\\tcapsules. \u2022\\t \\tOral\\tpackets\\tcontaining\\tgranules:\\tThere\\tare\\talso\\tpackets\\tavailable\\tin\\tsizes\\tof 2.5-\\t  ,\\t5-\\t  ,\\t10-\\t  ,\\t20-\\t  ,\\t40-\\t  mg.\\tTo\\tprepare\\tthis\\toral\\tform,\\tempty\\tthe\\tcontents\\tof\\teach 2.5-\\t\\tor\\t5-\\tmg\\tpacket\\tinto\\ta\\tcontainer\\twith\\t5\\tmL\\tof\\twater\\tor\\tempty\\tthe\\t10-\\t,\\t20-\\t  , or\\t40-\\t   mg\\tpacket\\tinto\\ta\\tcontainer\\twith\\t15\\tmL\\tof\\twater.\\tStir\\tand\\tleave\\tfor\\t2\u20133 minutes\\tuntil\\tit\\tthickens.\\tThen\\tit\\tmay\\tbe\\tadministered\\torally.\\tStore\\tat\\troom temperature. \u2022\\t \\tInjection\\tforms:\\t20-\\t\\tand\\t40-\\tmg\\tesomeprazole\\tsodium\\tvials\\tfor\\tinjection. Reconstitute\\twith\\t5\\tmL\\tof\\tnormal\\tsaline\\tand\\tinject\\tIV.\\tFor\\tIV\\tinfusion,\\tthis may\\tbe\\tfurther\\tdiluted\\tfor\\tIV\\tinfusion\\t(e.g.,\\t100\\tmL).\\tFifty\\tmL\\tof\\t0.9%\\tsaline may\\tbe\\tmixed\\twith\\ta\\t40-\\tmg\\tvial\\tto\\tproduce\\ta\\tconcentration\\tof\\t0.8\\tmg/mL, which\\tmay\\tbe\\tinfused\\tIV.\\tDiscard\\tfluid\\tbag\\tafter\\t5\\tdays.\\tFive\\tmL\\tof\\t0.9% saline\\tmay\\tbe\\tmixed\\tfor\\ta\\tconcentration\\tof\\t8\\tmg/mL\\tand\\tinjected\\tIV.\\tAfter dilution\\tin\\tnormal\\tsaline,\\tRinger\u2019s\\tsolution,\\tor\\t5%\\tdextrose,\\tthe\\tsolutions are\\tstable\\tin\\tfluid\\tbags\\tfor\\t48\\thours\\tat\\troom\\ttemperature\\tor\\t120\\thours\\tif refrigerated. Stability and Storage Esomeprazole\\tshould\\tbe\\tmaintained\\tin\\tthe\\tmanufacturer\u2019s\\toriginal\\tformulation (capsules or suspension) for optimum stability and effectiveness. After reconstitution of the injectable solutions retain in refrigerator or room temperature.","original_category":"Antiulcer agent"},{"name":"Etidronate Disodium","active_ingredient":"Etidronate Disodium","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg/day\\tPO. Cats \u2022\\t\\t10\\tmg/kg/day\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished;\\t24-\\thour\\twithdrawal\\ttimes\\tare\\tsuggested because\\tthis\\tdrug\\thas\\tlittle\\trisk\\tfrom\\tresidues. E Etodolac 349 Etodolac ee- toe \u0301doe- lak Trade and other names: EtoGesic (veterinary preparation) and Lodine (human preparation)","contraindications":"Contraindications and Precautions No contraindications have been identified in animals. There are concerns about the use of these agents in young horses. Consult the sections on clodronate (Osphos) and tiludronate (Tildren) for more information. Drug Interactions No drug interactions have been reported in animals. If mixed with other solutions or drugs, avoid mixtures containing calcium.","indications":"Indications and Clinical Uses The bisphosphonate group of drugs, which includes etidronate, is used primarily in people to treat osteoporosis and hypercalcemia of malignancy. In animals, they are used to decrease calcium in conditions that cause hypercalcemia, such as cancer and vitamin D toxicosis. Studies in people have shown that bisphosphonates may have action\\tin\\tcancer-\\tinduced\\tbone\\tdisease\\tthat\\tis\\tmore\\tsignificant\\tthan\\tthe\\teffect\\ton osteolysis and bone resorption and may decrease the tumor burden. In dogs, more experimental\\twork\\thas\\tbeen\\tperformed\\twith\\tpamidronate\\tthan\\tother\\tdrugs\\tin\\tthis group. Some bisphosphonates have been used to treat navicular disease and bone spavin in horses. There are two bisphosphonates approved for treating horses, which are used more often than other bisphosphonates. These drugs for horses include clodronate (Osphos) and tiludronate (Tildren) (see Tiludronate and Clodronate). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not reported for animals, but use has been uncommon and not sufficient\\tto\\trecord\\ta\\tfull\\trange\\tof\\tpossible\\tadverse\\teffects.\\tIn\\tpeople,\\tGI\\tproblems are common. Esophageal lesions have occurred because of reaction from contact with mucosa. If used in animals, ensure that tablets are completely swallowed.","notes":"Instructions for Use At high doses, etidronate may inhibit mineralization of bone. In people, alendronate has replaced etidronate because of side effects. There are no clinical studies demonstrating\\tefficacy\\tof\\tetidronate\\tin\\tanimals;\\tthe\\tuse\\tis\\textrapolated\\tfrom\\thuman medicine and anecdotal experience. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Monitor urea nitrogen, creatinine, and urine-\\t   specific\\tgravity\\tin\\ttreated\\tanimals\\tand\\tfood\\tintake. Formulations \u2022\\t\\tEtidronate\\tis\\tavailable\\tin\\t200-\\t\\tand\\t400-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antihypercalcemic agent"},{"name":"Etodolac","active_ingredient":"Etodolac","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t10\u201315\\tmg/kg\\tonce\\tdaily\\tPO\\tor\\t10\u201315\\tmg/kg\\tinjection\\tSQ\\tas\\ta\\tsingle dorsoscapular injection. Cats \u2022\\t\\tDose\\tnot\\testablished.  Horses \u2022\\t\\t23\\tmg/kg\\tq24h\\tPO.\\tLong-\\tterm\\tsafety\\twith\\tthis\\tregimen\\thas\\tnot\\tbeen\\testablished (see Instructions for Dosing). Regulatory Information No withdrawal times have been established. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Drug Interactions Use\\tNSAIDs\\tcautiously\\twith\\tother\\tdrugs\\tknown\\tto\\tcause\\tGI\\tinjury\\t(e.g., corticosteroids). The efficacy of ACE inhibitors and diuretics (furosemide) may be diminished when administered concurrently with NSAIDs. Etodolac may cross-\\t   react\\twith\\tsulfonamides\\tin\\tsensitive\\tanimals. F Famciclovir 351 Famciclovir fam- sye\u2032kloe- veer Trade and other names: Famvir","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\tto\\tanimals\\tprone\\tto\\tGI\\tulcers.\\tDo\\tnot\\tadminister\\twith\\tother ulcerogenic drugs, such as corticosteroids. Do not administer to dogs that may be prone to developing KCS. Do not administer to animals with compromised renal function.","indications":"Indications and Clinical Uses Etodolac is indicated for treatment of osteoarthritis in dogs. It also is used as an analgesic\\tand\\tmay\\tbe\\tused\\tfor\\tother\\tpainful\\tconditions.\\tLike\\tother\\tNSAIDs,\\tetodolac is expected to reduce fever. Uses in cats have not been established. Etodolac has been used in some horses to relieve pain associated with abdominal surgery and to treat lameness (e.g., caused by navicular disease). Dose regimens are different for horses compared with other animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Nonsteroidal\\tanti-\\tinflammatory\\tdrugs\\tmay\\tcause\\tGI\\tulceration.\\tOther\\tadverse\\teffects caused\\tby\\tNSAIDs\\tinclude\\tdecreased\\tplatelet\\tfunction\\tand\\tkidney\\tinjury.\\tIn\\tclinical trials with etodolac at recommended doses, some dogs showed weight loss, loose stools,\\tor\\tdiarrhea.\\tAt\\thigh\\tdoses\\t(above\\tlabel\\tdose),\\tetodolac\\tcaused\\tGI\\tulceration in\\tdogs.\\tEtodolac\\thas\\tbeen\\tassociated\\twith\\tkeratoconjunctivitis\\tsicca\\t(KCS)\\tin dogs, which in some cases has been severe. Resolution of KCS has occurred in only 10%\u201315%\\tof\\tcases\\tafter\\tdiscontinuing\\tmedication.\\tImprovement\\tin\\tKCS\\twas\\tgreater\\tif treatment\\tduration\\twas\\tshort.\\tIn\\thorses,\\tat\\thigh\\tdoses,\\tGI\\ttoxicity\\thas\\tbeen\\tobserved.","notes":"Instructions for Use Administer as directed and avoid concurrent use of other medications that may increase\\tGI\\ttoxicity.\\tMost\\tof\\tthe\\tuse\\tin\\tdogs\\thas\\tbeen\\tassociated\\twith\\ttreatment of osteoarthritis. In horses, it has been shown experimentally to improve lameness associated with navicular disease. When used in horses for this purpose, it was given at\\t23\\tmg/kg\\tPO\\tonce\\tor\\ttwice\\tdaily\\tfor\\t3\\tdays.\\tTreated\\thorses\\timproved\\twith\\teither regimen and showed no signs of adverse effects. Experimental horses treated with 20\\tor\\t23\\tmg/kg\\tdid\\tnot\\tdemonstrate\\tadverse\\teffects,\\tbut\\tlong-\\tterm\\tsafety\\thas\\tnot been reported. Patient Monitoring and Laboratory Tests Monitor\\tfor\\tsigns\\tof\\tGI\\tulcers\\tand\\tbleeding.\\tMonitor\\ttear\\tproduction\\tperiodically in dogs treated with etodolac and observe for ocular signs of KCS. Monitor liver enzymes in dogs treated with NSAIDs periodically for signs of liver toxicosis. Monitor urea\\tnitrogen\\tand\\tcreatinine\\tin\\ttreated\\tanimals\\tfor\\tsigns\\tof\\tkidney\\tinjury.\\tEtodolac has had varying effects on tetraiodothyronine (T 4 ), free T 4 ,\\tand\\tthyroid-\\tstimulating hormone concentrations in dogs. One study showed no effect, and another study showed a decrease in T 4 and free T 4 in\\ttreated\\tdogs\\tafter\\t2\\tweeks. Formulations Etodolac\\tis\\tavailable\\tin\\t150-\\t\\tand\\t300-\\tmg\\ttablets.\\tInjectable\\t100\\tmg/mL.\\tHuman formulations\\tinclude\\ta\\t400-\\tmg\\ttablet\\tand\\t200-\\t\\tand\\t300-\\tmg\\tcapsules.\\tSome formulations\\tare\\tno\\tlonger\\tmarketed\\tin\\tveterinary\\tmedicine. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Etodolac is insoluble in water but is soluble in alcohol or propylene glycol.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Famotidine","active_ingredient":"Famotidine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t \\t0.5\\tmg/kg\\tq12h\\tPO,\\tIV,\\tSQ,\\tor\\tIM.\\tA\\tdosage\\tof\\t40\\tmg/dog\\tq12h\\thas\\tbeen used empirically. Higher dosages of 1 mg/kg q12h have been recommended for more reliable suppression of stomach acid. \u2022\\t\\tCRI:\\t1\\tmg/kg\\tIV\\tloading\\tdose\\tfollowed\\tby\\t8\\tmg/kg/day\\tCRI. Cats \u2022\\t\\t0.2\\tmg/kg\\tq24h,\\tup\\tto\\t0.25\\tmg/kg\\tq12h\\tIM,\\tSQ,\\tPO,\\tor\\tIV\\t(slowly\\tover 5 minutes).  HorsesCattle \u2022\\t\\t1\u20132\\tmg/kg\\tq6\u20138h\\tPO\\tor\\t0.2\u20130.4\\tmg/kg\\tIV\\tq6h. \\t\u2022\\t\\t0.4\\tmg/kg\\tIV\\tq6h. Regulatory Information No restrictions on use in animals not intended for food. Racing Commissioners International (RCI) Classification: 5 Febantel feh- ban\u2032tel Trade and other names: Rintal and Vercom. Drontal Plus also contains two other drugs.","contraindications":"Contraindications and Precautions Reduce dose in animals with compromised renal function. Safety in pregnant cats has not been studied. Drug Interactions No interactions identified. F 2 blockers inhibit the action of histamine on the histamine H 2 receptor of parietal cells and inhibit gastric parietal cell gastric acid secretion. Famotidine increases stomach pH to help heal and prevent gastric and duodenal ulcers. Contraindications and Precautions Intravenous solutions contain benzyl alcohol. IV injections to small animals, especially cats, should be done slowly. Drug Interactions 2 - receptor blockers block secretion of stomach acid. Therefore, they interfere with oral absorption of drugs dependent on acidity, such as ketoconazole, itraconazole, and iron supplements. Unlike cimetidine, famotidine is not associated with inhibition of microsomal P450 enzymes.","indications":"Indications and Clinical Uses 2 - receptor blockers, is used to treat ulcers and gastritis in a variety of animals. Although it is often used for animals with vomiting, there are no efficacy data to indicate that it is effective as an antiemetic. There are no efficacy data to support its use for preventing nonsteroidal anti- inflammatory drug (NSAID)\u2013induced bleeding and ulcers. Famotidine has been used by veterinarians as a preferred H 2 blocker, but there is a lack of evidence to demonstrate superiority over other drugs in this class. Some studies have demonstrated efficacy at 1 mg/kg in dogs, while other studies have not demonstrated differences between famotidine and a placebo in dogs for increasing stomach pH. The target goal for stomach pH is greater than 3 for 75% of the dose interval or a pH greater than 4 for 67% of the dose interval. With oral doses, famotidine often does not meet these targets. Most evidence supports a lack of efficacy in dogs at a dosage of 1 mg/kg administered q12h, but it is more effective if administered as a constant- rate infusion (CRI) (1 mg/kg IV loading dose followed by 8- mg/kg/ day infusion). In dogs, it may have short-term effects on acid suppression, but it had a diminished effect if administered for more than 12 days. It had less effect to maintain the stomach pH above 3 on day 1 of dosing compared with day 12. Therefore, if used, famotidine may be better for short- term use than long- term administration. The use in large animals has received little attention. Omeprazole is preferred in horses for stomach acid suppression. In cattle, the half- life of famotidine is short and requires frequent administration (e.g., q6h) for effectiveness. Proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, and others are more effective for consistently suppressing stomach acid secretion and are preferred over histamine H 2 antagonists for dogs, horses, and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects usually are seen only with decreased renal clearance. In people, central nervous system (CNS) signs may occur with high doses. The IV solution contains benzyl alcohol, aspartic acid, and mannitol. Give IV injections slowly to cats (over 5 minutes) because rapid IV injections may cause hemolysis.","notes":"Instructions for Use Administer with food for best absorption. Clinical studies for famotidine have not been performed; therefore, optimal doses for ulcer prevention and healing are not known. Dose recommendations are extrapolated from human use, studies in experimental animals,  or from anecdotal experience. Experimental studies in dogs 354    Febantel have shown that doses of 0.1\u20130.2 mg/kg may inhibit stomach acid secretion, but most other studies have shown that higher doses of 1.0 mg/kg are needed to suppress stomach acid. Even at this dose, it has not been effective for reaching therapeutic targets in dogs but is more effective if administered as a CRI. For IV use, dilute with IV solutions (e.g., 0.9% saline) to a total volume of 5\u201310 mL. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tFamotidine\\tis\\tavailable\\tin\\t20-\\t\\tand\\t40-\\tmg\\ttablets,\\t8-\\tmg/mL\\toral\\tsuspension,\\tand 10- mg/mL  injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Famotidine is soluble in water. Compounded formulations in cherry syrup have been stable for 14 days. Diluted IV solutions in saline are stable for 48 hours at room temperature.","original_category":"Antiulcer agent"},{"name":"Ferrous Sulfate","active_ingredient":"Ferrous Sulfate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t100\u2013300\\tmg/dog\\tq24h\\tPO.\\tUsually\\tadministered\\twith\\ta\\tmeal. Cats \u2022\\t\\t50\u2013100\\tmg/cat\\tq24h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Extralabel withdrawal times are not established. However, 24- hour withdrawal times are suggested because this drug has little risk from residues. F Finasteride 367 Finasteride fin- ass\u2032ter- ide Trade and other names: Proscar","contraindications":"Contraindications and Precautions Do not use in animals prone to gastric ulcers. High doses or accidental ingestion may cause severe ulcers and perforation and should be treated as an emergency. Drug Interactions Iron supplements interfere with oral absorption of other drugs such as fluoroquinolones, tetracyclines, and other drugs that may chelate with iron. Histamine H 2 antagonists, PPIs such as omeprazole, and oral antacids decrease oral absorption because an acid environment favors absorption.","indications":"Indications and Clinical Uses Iron supplements are indicated in patients with diseases caused by iron deficiency, such as iron deficiency anemia. Oral iron supplements are considered one of the primary means of treatment iron deficiency in dogs and cats. The supplements most often used are ferrous sulfate or ferrous gluconate. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses cause stomach ulceration. Feces become dark with oral administration.","notes":"Instructions for Use The recommendations for iron supplementation are based on dose needed to increase hematocrit. In some animals, injectable iron dextran is used instead of oral therapy. Note that doses are often expressed in mg of elemental iron in the formulation. There are two forms of ferrous sulfate: tablets, and a dried form (desiccated). Ferrous sulfate tablets contain approximately 20% elemental iron; ferrous sulfate desiccated (dried) contains approximately 30% elemental iron. Patient Monitoring and Laboratory Tests Monitor hematocrit, serum iron levels, and total iron- binding capacity. Formulations \u2022\\t\\tOver-\\t   the-\\t  counter\\toral\\tformulations\\tare\\tavailable;\\t250-\\tmg\\tferrous\\tsulfate\\tcontains 50 mg of elemental iron. \u2022\\t\\t1\\tg\\tof\\tthe\\tdried\\tform\\t(desiccated\\tform)\\tcontains\\t300\\tmg\\tof\\telemental\\tiron.\\tOr\\teach tablet of 200 mg of dried ferrous sulfate contains 65 mg of elemental iron. \u2022\\t\\tInjectable\\tforms\\tare\\tusually\\tiron\\tdextran.\\t(Iron\\tdextran\\tis\\tlisted\\tin\\ta\\tseparate section.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not mix with other drugs because chelation may occur. Ferrous sulfate is soluble in water.","original_category":"Mineral supplement, iron supplement"},{"name":"Firocoxib","active_ingredient":"Firocoxib","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tonce\\tdaily\\tPO. Cats \u2022\\t\\t1.5\\tmg/kg\\tonce\\tPO.\\tLong-\\tterm\\tsafety\\tin\\tcats\\thas\\tnot\\tbeen\\tdetermined.  Horses \u2022\\t\\t0.1\\tmg/kg\\tq24h\\tPO\\tfor\\tup\\tto\\t14\\tdays. \u2022\\t\\tIV:\\t0.09\\tmg/kg\\tIV\\tonce\\tdaily\\t(2\\tmL\\tper\\t1000\\tlb,\\tor\\t2.6\\tmL/1250\\tlb;\\t1.5 mL/750 lb). Calves \u2022\\t\\tAn\\tapproved\\tdose\\tis\\tnot\\testablished,\\tbut\\t0.5\\tmg/kg\\tPO\\tor\\tIV\\thas\\tbeen\\tused\\tq24h. Regulatory Information Withdrawal time is not established for food animals, but 26 days for slaughter has been used for calves in other countries. Do not administer to horses that are used for human consumption. In racing horses, it is not permitted to be used 12 hours prior to competition. Florfenicol flore- fen\u2032ih- kole Trade and other names: Nuflor, Nuflor Gold, and Resflor (flunixin and florfenicol) Aquaflor (fish formulation)","contraindications":"Contraindications and Precautions Animals with preexisting GI problems or renal problems may be at a greater risk of adverse effects from NSAIDs. There is no information on the safety of firocoxib in the treatment of breeding, pregnant, or lactating animals, but adverse effects have not been reported in breeding animals. In horses, do not exceed recommended duration of treatment. During animal safety studies in horses, toxicity occurred at recommended doses if administration exceeded 30 days. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have been shown to exacerbate the GI adverse effects. Some NSAIDs may interfere with the action of diuretic drugs and angiotensin- converting enzyme (ACE) inhibitors.","indications":"Indications and Clinical Uses Firocoxib is used to decrease pain, inflammation, and fever. It has been used for the acute and chronic treatment of pain and inflammation in dogs. One of the most common uses is osteoarthritis, but it also has been used for pain associated with surgery. In horses, it is used for osteoarthritis and for pain associated with surgery. In cats, firocoxib has been demonstrated to be effective for attenuating acute febrile responses, but the use in cats is limited to short-term or long- term use at low doses. F Precautionary Information","side_effects":"Adverse Reactions and Side Effects Gastrointestinal problems are the most common adverse events associated with NSAIDs and can include vomiting, diarrhea, nausea, ulcers, and erosions of the GI tract. Both acute and long- term safety and efficacy have been established for firocoxib in dogs and horses prior to approval. In field trials, vomiting was the most often reported adverse effect in dogs. In studies performed in dogs, higher doses (five times the normal dose) caused GI problems. In studies of young juvenile dogs, administration of firocoxib was associated with periportal fatty hepatic changes in some animals. Renal toxicity, especially in dehydrated animals or animals with preexisting kidney disease, has been observed for some NSAIDs. Behavior changes have occurred in dogs and horses, but they are rare. In horses, adverse effects have included oral ulcerations, renal papillary necrosis, and GI effects after 42 days of dosing, but mucosal recovery after intestinal ischemia was less than other nonselective NSAIDs. In horses, GI problems (diarrhea, loose stool) have been reported in field trials, but they are rare at approved doses. At doses exceeding the labeled dose or duration in horses, ulcers, azotemia, renal injury, erosions of skin and oral mucosa, and prolonged bleeding times have been observed.","notes":"Instructions for Use Use according to manufacturer\u2019s dosing guidelines. Chewable tablets can be administered with or without food. Long- term studies have not been completed in cats, and only single- dose studies have been reported. The canine tablets have been administered orally to horses, with no significant differences in absorption compared with oral paste. Although this use is not allowed according to US Food and Drug Administration (FDA) regulations, the oral tablets have been bioavailable in horses. Patient Monitoring and Laboratory Tests Monitor GI signs for evidence of diarrhea, GI bleeding, or ulcers. Because of risk of renal injury, monitor renal parameters (water consumption, BUN, creatinine, and urine- specific gravity) periodically during treatment. Formulations \u2022\\t\\tFirocoxib\\tis\\tavailable\\tin\\t57-\\t\\tand\\t227-\\tmg\\ttablets. \u2022\\t\\tEquine\\toral\\tpaste\\tis\\tavailable\\tas\\t8.2\\tmg/g\\tof\\tpaste\\t(0.82%\\tw/w). 370    Florfenicol \u2022\\t\\tEquine\\tinjection\\tis\\tavailable\\tas\\t20-\\tmg/mL\\tsolution\\tfor\\tIV\\tuse\\t(with\\tpolyethylene glycol and glycerol vehicle). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. It is not ionized, and solubility is not affected by pH.","original_category":"Anti- inflammatory"},{"name":"Flumazenil","active_ingredient":"Flumazenil","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t0.02\\tmg/kg\\t(20\\tmcg/kg)\\tIV. \u2022\\t\\tTo\\treverse\\tbenzodiazepines:\\t0.2\\tmg\\t(total\\tdose),\\tas\\tneeded,\\tIV.  Horses, Cattle, Swine, and Sheep \u2022\\t\\tTo\\treverse\\tbenzodiazepines:\\t20\\tmcg/kg\\tIV\\t(0.02\\tmg/kg). Regulatory Information Do not use in animals intended for food. Flumethasone floo- meth\u2032ah- sone Trade and other names: Flucort, Fluosmin suspension, and Anaprime suspension","contraindications":"Contraindications and Precautions Flumazenil may precipitate a seizure if used with tricyclic antidepressants (TCAs) or other drugs that can lower seizure threshold. Drug Interactions Flumazenil may increase risk of seizures when used with other drugs known to inhibit the inhibitory neurotransmitter GABA.","indications":"Indications and Clinical Uses Flumazenil has no therapeutic benefits of its own, but it is used as a reversal agent after benzodiazepine administration in people (not commonly used in veterinary medicine). Because of high first- pass effects, it cannot be administered orally; it must be injected. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects reported in animals.","notes":"Instructions for Use Flumazenil is used primarily to block effects of benzodiazepine drugs. It has been used to reverse overdoses of benzodiazepines (e.g., diazepam). Although it has been used experimentally for treating hepatic encephalopathy, its efficacy for this condition is not established. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tFlumazenil\\tis\\tavailable\\tin\\ta\\t100-\\tmcg/mL\\t(0.1-\\tmg/mL)\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidote"},{"name":"Flunixin Meglumine","active_ingredient":"Flunixin Meglumine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t1.1\\tmg/kg\\tonce\\tIV,\\tIM,\\tor\\tSQ. \u2022\\t\\t1.1\\tmg/kg/day\\t3\\tday/wk\\tPO. \u2022\\t\\tOphthalmic\\tuse\\t(associated\\twith\\tocular\\tsurgery):\\t0.5\\tmg/kg\\tonce\\tIV.  Horses \u2022\\t\\t1.1\\tmg/kg\\tq24h\\tfor\\tup\\tto\\t5\\tdays\\tIV\\tor\\tIM.\\tNote:\\tIn\\tfoals,\\tit\\thas\\tbeen\\tshown\\tthat doses as low as 0.25 mg/kg inhibit prostaglandin synthesis during sepsis. Horses with colic are also often treated with low dosages of 0.25 mg/kg IV q8h. \u2022\\t\\tPaste:\\t1.1\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tGranules:\\t1.1\\tmg/kg/day\\tPO\\t(one\\tpacket\\tper\\t500\\tlb). Cattle \u2022\\t\\t1.1\u20132.2\\tmg/kg\\t(slowly)\\tonce\\ta\\tday\\tfor\\tup\\tto\\t3\\tdays\\tIV.\\tIt\\tmay\\tadministered\\tas\\ta single once- daily dose or divided and administered q12h for up to 3 days. \u2022\\t\\tVeal\\tcalves:\\t2.2\\tmg/kg\\tIV. \u2022\\t\\tIn\\tcombination\\twith\\tflorfenicol\\t(Resflor\\tGold):\\t40\\tmg/kg\\tof\\tflorfenicol\\tand\\t2.2 mg/kg\\tof\\tflunixin\\tadministered\\tSQ. \u2022\\t\\tTransdermal:\\t3.33\\tmg/kg\\tapplied\\ttopically\\tto\\tthe\\tskin.\\tApply\\tonly\\tonce\\talong\\tthe dorsal midline. Pigs \u2022\\t\\t2.2\\tmg/kg\\tonce\\tIM. Regulatory Information Cattle \u2022\\t\\tFor\\tthe\\tFDA-\\tapproved\\tIV\\tinjection\\tformulation,\\tthe\\twithdrawal\\ttimes\\tare\\t4\\tdays for meat and 36 hours for milk. Risk of residues is higher if dose is administered IM or\\tSQ,\\tand\\tthe\\twithdrawal\\ttime\\tshould\\tbe\\textended\\tif\\tother\\troutes\\tare\\tused\\t(see more details later). \u2022\\t\\tFor\\tthe\\ttransdermal\\tform\\tadministered\\tto\\tcattle\\tat\\t3.33\\tmg/kg,\\tthe\\tslaughter withdrawal time is 8 days. It should not be used in female dairy cattle 20 months of age or older, including dry dairy cows. It should not be used in suckling beef calves, dairy calves, and veal calves. \u2022\\t\\tFor\\tthe\\tformulation\\tcontaining\\toxytetracycline\\tand\\tflunixin,\\tthe\\tslaughter withdrawal\\ttime\\tis\\t21\\tdays\\twhen\\tadministered\\tIM\\tor\\tSQ\\tin\\tbeef\\tcattle,\\tnon- lactating dairy cattle, calves, and yearlings. \u2022\\t \\tIf\\tthe\\tinjection\\tformulation\\tis\\tadministered\\tby\\tother\\troutes,\\tFARAD\\trecommends that\\tafter\\tadministration\\tof\\ta\\tsingle\\tdose\\tto\\tadult\\tcattle\\tby\\tthe\\tIV,\\tIM,\\tSQ,\\tor\\tPO route, a milk withdrawal time of 84 hours for the IV route and 96 hours for the other routes, and 7 days for meat should be used. If multiple doses are administered, FARAD recommends a meat withdrawal time of 60 days. Because of differences in pharmacokinetics, FARAD (www.FARAD.org) recommends a meat withdrawal time of at least 14 days when flunixin is administered to dairy heifers, beef steers, and veal calves. Pigs \u2022\\t\\tAfter\\tadministration\\tof\\tformulations\\tthat\\tdo\\tnot\\thave\\ta\\tswine\\tlabel,\\tsuch\\tas\\t2.2 mg/kg IM once, FARAD recommends a meat withdrawal time of 13\u201315 days. 384    Fluorouracil \u2022\\t\\tAfter\\toral\\tor\\tIV\\tadministration\\tto\\tpigs,\\tof\\t2.2\\tmg/kg,\\tFARAD\\trecommends\\ta\\tmeat withdrawal time of 21 days. \u2022\\t\\tIf\\ta\\tspecific\\tswine-\\tlabeled\\tdose\\tform\\tis\\tused\\t(Banamine-\\tS),\\tthe\\twithdrawal\\ttime\\tis 12 days. RCI Classification: 4 Fluorouracil floo- roe- yoo\u2032rah- sil Trade and other names: 5- Fluorouracil and Adrucil","contraindications":"Contraindications and Precautions Avoid use in pregnant animals near term. Do not use in calves to be processed for veal. Do not use in bulls intended for breeding because reproductive effects in this class of cattle have not been studied. Flunixin is approved for IV treatment in\\tsome\\tfood\\tanimals,\\tbut\\tif\\tthe\\tdose\\tis\\tadministered\\tIM\\tor\\tSQ,\\tthere\\tis\\tan increased risk of meat residues. Administration to cows with mastitis showed that elimination may be prolonged more than healthy cows, thus increasing the risk of violative residues, even when withdrawal times are followed. Do not use for treating heat stroke in animals. Drug Interactions Ulcerogenic effects are potentiated when administered with corticosteroids. Coadministration with phenylbutazone will increase the risk of hypoproteinemia and gastric ulcers in horses. Flunixin, like other NSAIDs, may interfere with the action of diuretics such as furosemide and ACE inhibitors. Coadministration with enrofloxacin in dogs increased flunixin plasma concentrations because of reduced clearance.","indications":"Indications and Clinical Uses Flunixin is used primarily for short- term treatment of moderate pain and inflammation. It has been used to treat abdominal pain in horses and to decrease signs of sepsis in horses. In horses, as an adjunctive treatment for sepsis, it is often used at a low dose of 0.25 mg/kg. The dose of 0.25 mg/kg is not an \u201cantiendotoxin\u201d dose, as is popularly characterized, because it does not directly inhibit endotoxin. But at this low dose, it may inhibit prostaglandins responsible for hemodynamic effects during sepsis in horses. It is approved in the United States for treatment of pyrexia in cattle associated with BRD and to decrease clinical signs associated with coliform mastitis, as well as control of inflammation associated with endotoxemia. Flunixin has been used as a single dose for treatment of diarrhea in dairy calves. The transdermal formulation is the only NSAID approved in the United States for treatment of pain in cattle. Flunixin at 2.2 mg/kg IV in cows with endotoxin mastitis did not affect milk production, but it decreased fever and improved rumen motility. Flunixin has been used as an adjunctive treatment, with antibiotics, for treatment of BRD in which it reduces inflammatory lung reactions and reduces BRD- associated pyrexia. Resflor Gold contains both florfenicol and flunixin in the same formulation. Hexasol contains oxytetracycline and flunixin in the same formulation. In pigs, flunixin is used for pyrexia associated with SRD. In dogs and cats, flunixin has been used occasionally, but treatment is usually confined to one or two treatments because of risk of GI toxicity (ulcers and perforation). Generally, other NSAIDs that have a better safety profile are used in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Most severe adverse effects are related to the GI system. Flunixin causes gastritis and GI ulceration with high doses or prolonged use. Reduced renal perfusion has also been documented. In horses, flunixin administration may affect recovery after ischemic injury to the intestine. In horses, if given IM, it can result in myositis and abscess at the injection site. It can also cause irritation and injection- site lesions\\tif\\tinjected\\tSQ\\tor\\tIM\\tin\\tcattle.\\tIf\\tused\\tin\\tdogs,\\ttreatment\\tshould\\tnot\\tgo beyond 4 consecutive days.","notes":"Instructions for Use Flunixin use in food producing animals must follow the label instructions for the condition treated. Treatment interval in all animals is limited to once daily to avoid adverse effects on GI tract and kidney. It is not approved for small animals in the United States but has been approved for use in small animals in Europe for short- term use. Patient Monitoring and Laboratory Tests Monitor treated animals for signs of GI bleeding and ulcers during treatment. Monitor serum albumin in horses because repeated administration of NSAIDs has caused hypoproteinemia in some horses. Formulations \u2022\\t\\t250-\\t  mg\\tpacket\\tgranules\\tin\\ta\\t10-\\tg\\tpacket. \u2022\\t\\t10-\\t\\tand\\t50-\\tmg/mL\\tinjection. \u2022\\t\\tPaste\\tformulation,\\twith\\teach\\t30-\\tg\\tsyringe\\tcontaining\\tflunixin\\tmeglumine equivalent to 1500 mg of flunixin. \u2022\\t\\tFlunixin\\tis\\tcombined\\twith\\tflorfenicol\\tin\\tResflor\\tGold,\\twhich\\thas\\t300\\tmg\\tflorfenicol and 16.5 mg flunixin per milliliter with vehicles of 2- pyrrolidone, 35- mg malic acid, and triacetin. \u2022\\t\\tFlunixin\\tis\\tcombined\\twith\\toxytetracycline\\tin\\tHexasol,\\twith\\t300-\\tmg/mL oxytetracycline and 20- mg/mL flunixin. \u2022\\t\\tTransdermal\\tformulation:\\t50\\tmg/mL. F Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Fluorouracil","active_ingredient":"Fluorouracil","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t150\\tmg/m 2 once per week IV. Cats \u2022\\t\\tDo\\tnot\\tuse.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in food animals because it is an anticancer agent. Fluoxetine Hydrochloride floo- oks\u2032eh- teen  hye- droe- klor\u2032ide Trade and other names: Prozac (human formulation) and Reconcile (veterinary formulation)","contraindications":"Contraindications and Precautions Do not use in cats. Drug Interactions No drug interactions are reported for animals because of the limited use. However, with any anticancer agent, drug interactions are possible.","indications":"Indications and Clinical Uses Fluorouracil is used in various cancer protocols in dogs but infrequently compared with other agents. It has been used as a component with other combination cancer regimens. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The toxicity from fluorouracil is most evident in rapidly growing cells (bone marrow, intestinal epithelium, and epithelial cells). Fluorouracil causes mild leukopenia, thrombocytopenia, and CNS toxicity. In dogs, it has caused GI sloughing, vomiting, respiratory distress, myelosuppression, behavioral changes, seizures, other neurologic signs, and cardiac abnormalities. Dogs have been accidentally exposed by consuming topical formulations intended for people. Doses of 40 mg/kg in dogs result in death, and doses of 20, 10, and 5 mg/kg have caused high, intermediate, and low toxic effects in dogs, respectively.","notes":"Instructions for Use Consult anticancer treatment protocol for precise dosage and regimen. Patient monitoring and laboratory tests: Monitor CBC for evidence of bone marrow toxicity. F Fluoxetine Hydrochloride 385 Formulations \u2022\\t\\tFluorouracil\\tis\\tavailable\\tin\\ta\\t50-\\tmg/mL\\tvial.\\tIt\\tis\\talso\\tavailable\\tin\\ttopical\\tforms\\tas 0.5%, 1%, 2%, and 5% solutions and 1% and 5% creams. The topical forms are used in people for skin tumors and keratosis. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticancer agent"},{"name":"Fluoxetine Hydrochloride","active_ingredient":"Fluoxetine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1\u20132\\tmg/kg\\tonce\\tdaily\\tPO. Cats \u2022\\t\\t0.5\u20134\\tmg/cat\\tq24h\\tPO\\t(0.5\u20131\\tmg/kg/day).\\tStart\\twith\\t1/4\\ttablet\\t(2.5\\tmg)\\tper cat and increase as needed. \u2022\\t\\tUrine\\tmarking:\\t1\\tmg/kg\\tq24h\\tPO\\tand\\tincrease\\tto\\t1.5\\tmg/kg\\tif\\tthere\\thas\\tbeen inadequate response.  \u2022\\t\\tHorses:\\t0.25\u20130.5\\tmg/kg\\tPO\\tonce\\tdaily,\\tmixed\\twith\\tgrain. Regulatory Information Do not administer to animals intended for food. RCI Classification: 2 Fluralaner floor \u2032ah- lan\u2032er Trade and other names: Bravecto","contraindications":"Contraindications and Precautions Use cautiously in animals prone to aggression because it may decrease inhibition. In early pregnancy, it appears to be safe but has caused pulmonary hypertension in experimental animals late in pregnancy. Serotonin reuptake inhibitors can increase the risk of bleeding by inhibiting serotonin uptake by platelets, but this has not been reported in animals. Drug Interactions Do not use with other behavior- modifying drugs such as other SSRIs or TCAs. Do not use with monoamine oxidase inhibitors (MAOIs). Administration with selegiline may induce a reaction. Because it is highly metabolized by the liver, it may be subject to interactions caused by cytochrome P450 inhibitors. (See Appendix I.)","indications":"Indications and Clinical Uses Fluoxetine, like other SSRIs, is used to treat behavioral disorders such as separation anxiety, canine compulsive behaviors, and dominance aggression. In cats, it has been effective for decreasing urine spraying (1 mg/kg/day). In trials comparing fluoxetine with clomipramine for treating urine marking in cats, both drugs were equally effective for long- term use. However, the urine marking returned after discontinuation of the drug. In both dogs and cats, SSRIs have been used for pain syndromes, such as neuropathic pain, but there are no studies of efficacy published to confirm efficacy for this indication. In horses, fluoxetine has been used for \u201ccribbing behavior\u201d and other behavior disorders, but efficacy is based on small observational studies. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Fluoxetine has fewer adverse effects (especially antihistamine and antimuscarinic effects) compared with other antidepressant drugs. During clinical trials in dogs, adverse reactions included vomiting, decreased appetite, lethargy, depression, trembling, and shaking in some dogs; the most common were lethargy and decreased appetite. In rare cases, it may cause seizures. Adverse effects are more common at doses above 8\u201310 mg/kg, but occasionally, some of these signs may be seen at lower doses. In dogs, at high doses of 10\u201320 mg/kg, it caused tremors, anorexia, aggressive behavior, nystagmus, emesis, and ataxia. Seizures can occur at doses above 25 mg/kg. In cats, nervousness or increased anxiousness has been observed. In cats, 5 mg/kg produced tremors, and 3 mg/kg produced anorexia and vomiting. However, in trials used for treating urine spraying, few adverse effects were reported, and cats have tolerated doses up to 50 mg/kg.","notes":"Instructions for Use Always use in conjunction with a comprehensive behavior modification protocol. Clinical efficacy of fluoxetine for separation anxiety in dogs has been established from clinical studies. Because of a long half- life, accumulation in plasma may take several days to weeks. There may be a delay in the onset of action of 2 weeks. Do not apply transdermally; absorption is low, and it may cause skin irritation. In some animals, paroxetine (Paxil) is preferred, which is a human formulation available in tablets and has been used for smaller- size animals. Sudden discontinuation of serotonin reuptake inhibitors can produce other behavior problems, such as anxiety, signs of agitation and nervousness. If treatment is discontinued, gradually withdraw the medication. Patient Monitoring and Laboratory Tests Use in animals has been relatively safe, and one should only monitor behavior changes. Formulations \u2022\\t \\tFluoxetine\\tis\\tavailable\\tin\\thuman\\tformulations\\tof\\t10-\\t,\\t20-\\t  ,\\tand\\t40-\\tmg\\tcapsules;\\t10-\\t, 20- , and 60- mg tablets; and 4- mg/mL oral solution. The veterinary formulations have been available in sizes of 8- , 16- , 32- , and 64- mg tablets. F Fluralaner 387 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water at 14 mg/mL and in alcohol at 100 mg/mL. Fluoxetine hydrochloride solution has been mixed with various juices and flavorings and found to be stable for 8 weeks. In one trial, it was mixed in tuna- flavored water for cats and retained effectiveness.","original_category":"Behavior modification, selective serotonin reuptake inhibitor"},{"name":"Fomepizole","active_ingredient":"Fomepizole","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t20\\tmg/kg\\tinitially\\tIV,\\tthen\\t15\\tmg/kg\\tat\\t12-\\t\\tand\\t24-\\thour\\tintervals,\\tand\\tthen\\t5\\tmg at 36 hours. Cats \u2022\\t \\t125\\tmg/kg\\tinitially\\tfollowed\\tby\\t31.3\\tmg/kg\\tat\\t12,\\t24,\\tand\\t36\\thours\\tafter\\tthe\\tinitial dose. Continue doses q12h until ethylene glycol is no longer detected. If analysis of ethylene glycol is not available, treat with 31 mg/kg q12h through 60 hours.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No withdrawal times are established for animals intended for food. There is little risk of residues in food animals. F Fosfomycin Tromethamine 393 Fosfomycin Tromethamine fos- foe- mye\u2032sin  troe- meth\u2032ah- meen Trade and other names: Monurol","contraindications":"Contraindications and Precautions Treatment should be initiated early for optimum effect. In cats, treatment should be initiated within 3 hours using a dose that is higher than for dogs. Drug Interactions Fomepizole will inhibit the metabolism of other drugs and compounds that share a similar pathway as alcohol. Use cautiously with any other coadministered drugs.","indications":"Indications and Clinical Uses Fomepizole is used for treatment of acute ethylene glycol toxicosis in dogs and cats. In people, it is used for this purpose but also is registered for methanol poisoning. It should be used early for maximum success. Fomepizole was safe and effective in dogs in clinical trials if used within 8 hours of poisoning. In cats, it is effective if administered at high doses within 3 hours of ethylene glycol ingestion. When fomepizole is unavailable, ethanol can be used as an alternative. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects have been reported.","notes":"Instructions for Use The only use documented is for emergency management of ethylene glycol intoxication. Experimental studies have demonstrated effectiveness in dogs and cats (high doses in cats). In cats, administration of ethanol infusion is also effective. Administer 0.9% sodium chloride before administration of fomepizole. If used for treating methanol intoxication, include administration of folinic acid (Leucovorin) at a dose of 1 mg/kg. Patient Monitoring and Laboratory Tests Monitor renal function during treatment. Monitor urine output. Some human hospitals have assays for monitoring ethylene glycol in patients. These assays can be used to monitor treated cats. Formulations \u2022\\t\\tNote:\\tThe\\tveterinary-\\tapproved\\tproduct\\thas\\trecently\\tbeen\\twithdrawn\\tby\\tthe manufacturer. The human formulation, or ethanol, can be used as an alternative. Fomepizole is available in a 1- g/mL solution (Antizol), a human preparation. 1.5 g may be added to 30 mL saline solution for injection (50 mg/mL). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidote"},{"name":"Gemfibrozil","active_ingredient":"Gemfibrozil","species":["Canine","Feline"],"dosage":"Dogs and cats \u2022\\t\\t7.5\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Gentamicin Sulfate jen- tah- mye\u2032sin sul\u2032fate Trade and other names: Gentocin, Garasol, Garacin, and generic","contraindications":"Contraindications and Precautions No reported contraindications in animals, but in people, it is contraindicated in patients with gallbladder disease. It should be used cautiously in patients with kidney disease. It should be avoided in pregnant animals. Drug Interactions No drug interactions are reported for animals. In people, it may potentiate the effects of other drugs. The use with statins may increase the risk of myopathy.","indications":"Indications and Clinical Uses It is used for treatment of hyperlipidemia. It has been used in dogs for treatment of some hyperlipidemia syndromes, but the efficacy has not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. In people, GI effects are common.","notes":"Instructions for Use Used primarily in people to treat hyperlipidemia, but it is used occasionally in dogs. Clinical studies have not been performed in animals. Patient Monitoring and Laboratory Tests Monitor cholesterol concentrations. G Gentamicin Sulfate 403 Formulations \u2022\\t\\tGemfibrozil\\tis\\tavailable\\tin\\t600-\\tmg\\ttablets\\tin\\tthe\\tUnited\\tStates\\tand\\t300-\\tmg capsules in Canada only. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antihyperlipidemic agent"},{"name":"Glipizide","active_ingredient":"Glipizide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tNo\\teffective\\tdose\\tavailable. Cats \u2022\\t\\t2.5\u20137.5\\tmg/cat\\tq12h\\tPO.\\tUsual\\tdose\\tis\\t2.5\\tmg/cat\\tinitially;\\tthen\\tincrease\\tto\\t5 mg/cat q12h.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Glucosamine Chondroitin Sulfate gloo- koe\u2032seh- meen  kahn- droy\u2032ten sul\u2032fate Trade and other names: Cosequin, Glyco- Flex, and generic brands","contraindications":"Contraindications and Precautions Many cats do not respond and will require insulin therapy. Do not rely on glipizide in cats that are not stable or if they are dehydrated or debilitated. Do not rely on glipizide for treatment of diabetes in dogs. Drug Interactions Many drug interactions have been reported in people. It is not known if these occur in animals because of infrequent use. Use cautiously with beta blockers, antifungal drugs, anticoagulants, fluoroquinolones, sulfonamides, and others.","indications":"Indications and Clinical Uses Glipizide is used as oral treatment in the management of diabetes mellitus, particularly in cats. The use in other animals is rare. The response rate in cats is approximately 44%\u201365% (some reports are 30% or lower). The response rate in dogs is poor. It has been more common to administer the sulfonylurea class of drugs in cats than other oral hypoglycemic drugs because the sulfonylureas have had better efficacy. Glipizide is the most common of this class used in animals. Other oral hypoglycemic drugs include acetohexamide, chlorpropamide, glyburide (DiaBeta, Micronase), gliclazide, and tolazamide. Metformin is of the biguanide class of oral drugs for diabetes and has not had efficacy as high as glipizide in cats. Glipizide transdermal absorption from a pluronic transdermal gel (pluronic organogel\\t[PLO])\\tvehicle\\tis\\tpoor\\tin\\tcats\\t(less\\tthan\\t20%)\\tand\\tinconsistent.\\tThis\\troute is not recommended. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are dose related. These include vomiting, anorexia, increased bilirubin, and elevated liver enzymes in some cats (15%). It may exacerbate deposits of amyloid in the feline pancreas and increase the loss of pancreatic beta cells. Glipizide may cause hypoglycemia but less so than insulin. In people, increased cardiac mortality is possible, but this has not been reported in cats.","notes":"Instructions for Use Oral hypoglycemic agents are successful in people only for noninsulin- dependent diabetes. There has been only limited use in animals. Because response to oral hypoglycemic agents in cats is unpredictable, it is recommended to use a trial first of at least 4 weeks. If the cat responds, the drug can be continued; otherwise, insulin may be indicated. Feed cats a high- fiber diet when using oral hypoglycemic agents. Transdermal\\tglipizide\\t(5-\\tmg\\tdose)\\tin\\ta\\tPLO\\tgel\\twas\\tevaluated\\tin\\tcats.\\tAlthough the transdermal formulation produced a modest change in glucose concentrations, systemic absorption was only 20%. Patient Monitoring and Laboratory Tests Monitor blood glucose levels to determine if the drug is effective. Monitor liver enzymes. It may increase alanine transaminase and alkaline phosphatase. G Glucosamine Chondroitin Sulfate 407 Formulations \u2022\\t\\tGlipizide\\tis\\tavailable\\tin\\t5-\\t\\tand\\t10-\\tmg\\ttablets. Stability and Storage Store glipizide in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidiabetic agent, hypoglycemic agent"},{"name":"Glucosamine Chondroitin Sulfate","active_ingredient":"Glucosamine Chondroitin Sulfate","species":["Canine","Feline","Equine"],"dosage":"\u2022\\t\\tGeneral\\tdosing\\trequirements\\tfor\\tglucosamine:\\t22\\tmg/kg/day\\tPO,\\tincreased\\tto 44\\tmg/kg/day\\tPO\\tin\\tpatients\\tthat\\tdo\\tnot\\tinitially\\trespond.\\tAlternatively,\\ta\\tbetter response may be anticipated by starting with the higher dose. \u2022\\t\\tMany\\tpreparations\\tare\\tadministered\\tin\\tcombination\\twith\\tchondroitin.\\tFor\\tgeneral dosing, use the Cosequin RS and DS strength as a general guide. Dogs \u2022\\t\\t1\u20132\\tcapsules\\tper\\tday\\tand\\t2\u20134\\tcapsules\\tfor\\tlarge\\tdogs. Cats \u2022\\t\\t1\\tcapsule\\tdaily.  Horses \u2022\\t\\t12\\tmg/kg\\tglucosamine\\t+\\t3.8\\tmg/kg\\tchondroitin\\tsulfate\\ttwice\\tdaily\\tPO\\tfor\\t4 weeks; then 4 mg/kg glucosamine + 1.3 mg/kg chondroitin sulfate thereafter. It is common to initiate treatment in horses with a higher dosage of 22 mg/kg glucosamine\\t+\\t8.8\\tmg/kg\\tchondroitin\\tsulfate\\tdaily\\tPO. Regulatory Information No regulatory information is available. Because of low risk of residues, no withdrawal times are suggested. Glyburide glye\u2032byoor- ide Trade and other names: DiaBeta, Micronase, Glynase, and Glibenclamide (British name)","contraindications":"Contraindications and Precautions The safety of glucosamine has not been established in diabetic animals or obese animals that may be prone to developing diabetes. Otherwise, there are no known precautions. Drug Interactions No drug interactions are reported. Glucosamine-  and chondroitin- containing products may be used safely with NSAIDs.","indications":"Indications and Clinical Uses Glucosamine is used primarily as a disease- modifying agent in the management of degenerative joint disease in animals. It is regarded as a dietary supplement and has no claims of efficacy. It is usually found in formulations in combination with chondroitin sulfate. (See Chondroitin Sulfate for additional details.) Analyses of published clinical studies in dogs have concluded that there is a moderate level of evidence to indicate some benefit in osteoarthritis, but results may be inconsistent among studies. In some studies, the response was no better than a placebo treatment. Benefits of treatment in horses with lameness also have been reported from oral administration of chondroitin\u2013glucosamine supplements. In human medicine, the American College of Rheumatology has strongly recommended against the use of glucosamine for osteoarthritis. Although it has been promoted for other uses, there is a lack of supporting evidence that systemic administration is effective for reducing recurrent urinary tract infections in animals (via a beneficial effect on bladder mucosa). Precautionary Information","side_effects":"Adverse Reactions and Side Effects In some animals, soft stools and intestinal gas have been reported. In experimental rodents, injections of glucosamine can cause hyperglycemia, insulin resistance, and a decrease in the metabolic action of insulin via the hexosamine pathway. However, the clinical relevance of these findings has not been shown when oral dietary supplements are administered. Clinical studies in dogs have shown that short- term (21 days) administration of glucosamine does not affect glycemic control or cause diabetes mellitus in dogs. Otherwise, adverse effects have not been reported, although hypersensitivity is possible.","notes":"Instructions for Use The doses recommended are based primarily on empiricism and manufacturer\u2019s recommendations. There are few published trials of efficacy or dose titrations available to determine optimal dose. Doses listed are general recommendations and may\\tvary\\tamong\\tproducts.\\tProducts\\tmay\\tvary\\tin\\ttheir\\tstability,\\tpurity,\\tand\\tpotency. Use products from a reputable supplier. When comparing products, glucosamine hydrochloride is more bioavailable than glucosamine sulfate. Patient Monitoring and Laboratory Tests No routine patient monitoring is necessary. There is no evidence that glucosamine administration will increase serum glucose in animals with oral treatment. Glucosamine is produced by glucose in the body, but this is an irreversible reaction. Formulations \u2022\\t\\tSeveral\\tformulations\\tare\\tavailable.\\tVeterinarians\\tare\\tencouraged\\tto\\tcarefully\\texamine the product label to ensure proper strength. One product (Cosequin) is available as regular- strength (RS) and double- strength (DS) capsules. RS contains 250 mg of glucosamine, 200 mg of chondroitin sulfate, mixed glycosaminoglycans, 5 mg of G Glyburide 409 manganese, and 33 mg of manganese ascorbate. The DS tablets contain double of each of these amounts. \u2022\\t\\tProducts\\tfor\\thorses\\tcontain\\t3.3\\tg\\tper\\tscoop,\\tequal\\tto\\t1800\\tmg\\tof\\tglucosamine\\tand 570 mg of chondroitin. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Products\\tmay\\tvary\\tin\\tstability\\tand\\tpotency.","original_category":"Nutritional supplement"},{"name":"Glyburide","active_ingredient":"Glyburide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tNo\\teffective\\tdoses\\thave\\tbeen\\treported. Cats \u2022\\t\\t0.2\\tmg/kg\\tdaily\\tPO.\\tAlternatively,\\tstart\\twith\\t0.625\\tmg\\t(half\\tof\\ta\\t1.25-\\tmg\\ttablet) per cat once daily.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. No withdrawal information is available. G Glycerin 411 Glycerin glih\u2032ser- in Trade and other names: Generic","contraindications":"Contraindications and Precautions There are no known contraindications in animals. Drug Interactions Many drug interactions have been reported in people. It is not known if these occur in animals because clinical use has been rare. Use cautiously with beta blockers, antifungal drugs, anticoagulants, fluoroquinolones, and sulfonamides.","indications":"Indications and Clinical Uses Oral hypoglycemic agents are successful in people only for non\u2013insulin- dependent diabetes. There has been only limited use in animals. Glyburide is not effective in dogs but has been used in some cats. Some cats may initially respond to oral hypoglycemic agents but eventually need insulin treatment. Similar drugs include acetohexamide, chlorpropamide, glipizide, gliclazide, and tolazamide. There is more experience with glipizide than with other drugs, and it should be used as the first choice (see Glipizide for more details). Precautionary Information","side_effects":"Adverse Reactions and Side Effects It may cause dose- related vomiting, anorexia, increased bilirubin, and elevated liver enzymes in some cats. Glyburide causes hypoglycemia but less so than insulin. In people, increased cardiac mortality is possible.","notes":"Instructions for Use Because response to oral hypoglycemic agents in cats is unpredictable, it is recommended to use a trial first of at least 4 weeks. If the cat responds, the drug can be continued. Otherwise, insulin may be indicated. Feed cats a high- fiber diet when using oral hypoglycemic agents. Patient Monitoring and Laboratory Tests Monitor blood glucose levels to determine if the drug is effective. Monitor liver enzymes. Formulations \u2022\\t\\tGlyburide\\tis\\tavailable\\tin\\t1.25-\\t,\\t2.5-\\t  ,\\tand\\t5-\\t    mg\\ttablets\\t(DiaBeta\\tand\\tMicronase). Glynase is available in 1.5- , 3- , and 6- mg micronized tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidiabetic agent, hypoglycemic agent"},{"name":"Glycopyrrolate","active_ingredient":"Glycopyrrolate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and cats \u2022\\t\\t0.005\u20130.01\\tmg/kg\\tIV,\\tIM,\\tor\\tSQ.  Cattle and Horses \u2022\\t\\tUse\\tduring\\tanesthesia:\\t0.005\u20130.01\\tmg/kg\\tIM\\tor\\tSQ\\tor\\t0.0025\u20130.005\\tmg/kg\\tIV. A common dose is 1 mg per horse. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Gold Sodium Thiomalate gold soe\u2032dee- um  thye- oh- mah\u2032late Trade and other names: Myochrysine","contraindications":"Contraindications and Precautions Do not use in patients with glaucoma, intestinal ileus, gastroparesis, or tachycardia. Drug Interactions No specific drug interactions are reported for animals. However, it is expected that glycopyrrolate, like other anticholinergic drugs, antagonizes drugs that stimulate respiratory and GI secretions and GI motility.","indications":"Indications and Clinical Uses Glycopyrrolate is used to inhibit vagal effects and increase heart rate in animals. It also decreases respiratory, salivary, and GI secretions. It may be used as an adjunct to anesthesia when it is necessary to override vagal stimulus. In horses, glycopyrrolate has a half- life of 7\u201319 hours, but this varies depending on the breed of horse. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributed to antimuscarinic (anticholinergic) effects. Side effects of therapy include xerostomia, ileus, constipation, tachycardia, and urine retention. CNS effects are less than with atropine.","notes":"Instructions for Use Glycopyrrolate is often used in combination with other agents, particularly anesthetic drugs. Although some anesthetic agents such as alpha 2 agonists and opioids are associated with bradycardia, it is rarely necessary to administer anticholinergic agents such as glycopyrrolate to reduce the bradycardia. Patient Monitoring and Laboratory Tests Monitor heart rate during treatment. Formulations \u2022\\t\\tGlycopyrrolate\\tis\\tavailable\\tas\\ta\\t0.2-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. G Gold Sodium Thiomalate 413","original_category":"Anticholinergic"},{"name":"Guaifenesin","active_ingredient":"Guaifenesin","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tExpectorant:\\t3\u20135\\tmg/kg\\tq8h\\tPO. \u2022\\t\\tAnesthetic\\tadjunct:\\t2.2\\tmL/kg/h\\tof\\ta\\t5%\\tsolution\\tIV.\\tAdministered\\twith\\talpha 2 agonists and ketamine. Cats \u2022\\t\\tExpectorant:\\t3\u20135\\tmg/kg\\tq8h\\tPO.  Horses \u2022\\t\\t2.2\\tmL/kg\\tof\\ta\\t5%\\tsolution\\t(110\\tmg/kg)\\tinfused\\tIV\\tto\\thorses\\tprior\\tto\\tother anesthetic agents, such as ketamine. Guaifenesin solution may be infused rapidly. \u2022\\t\\tConstant-\\trate\\tinfusion:\\t2.2\\tmL/kg/h\\tof\\t5%\\tsolution\\t(50\\tmg/mL). \u2022\\t\\tInduction\\tdose\\t(with\\tpropofol):\\t90\\tmg/kg\\tIV\\tadministered\\tover\\t3\\tminutes followed by propofol 3- mg/kg IV bolus. \u2022\\t\\tEquine\\t\u201ctriple-\\tdrip\u201d:\\t1\\tL\\tof\\t5%\\tguaifenesin\\tin\\tdextrose,\\tmixed\\twith\\t500\\tmg\\tof xylazine and 2 g of ketamine. Administer as 1.1 mL/kg for induction and then 2\u20134 mL/kg/h infusion IV. Use yohimbine if necessary to speed recovery. \u2022\\t\\tPO\\t(powder\\tmixed\\twith\\twater):\\t3.5\\tmg/kg\\tq12h. Regulatory Information Withdrawal\\ttime\\t(extralabel):\\t3\\tdays\\tfor\\tmeat\\tand\\t48\\thours\\tfor\\tmilk. RCI\\tClassification:\\t4 426    Halothane Halothane hal\u2032oe- thane Trade and other names: Fluothane","contraindications":"Contraindications and Precautions Do not administer IV if visible precipitate is observed. Oral formulations for people (cough and cold remedies) may contain other ingredients such as dextromethorphan or decongestants (e.g., phenylephrine or pseudoephedrine). Do not use these combinations in animals sensitive to these drugs, and if possible, use only formulations that contain guaifenesin. Drug Interactions No significant drug interactions are reported. It has been safely used with acepromazine, xylazine, detomidine, ketamine, thiopental, and pentobarbital.","indications":"Indications and Clinical Uses Guaifenesin is administered IV (particularly in large animals) as an adjunct to anesthesia. Most often, it is used prior to induction of general anesthesia in horses. An example of this use in horses is \u201cGKX,\u201d which is 1000\u20132000 mg of ketamine, 500 mg of xylazine, and 5% of guaifenesin mixed and added to 1 L to infuse at 2 mL/kg/h IV or anesthesia. When administered with propofol to horses, it helped to prevent adverse anesthetic events that occur when propofol is administered as a sole agent. Guaifenesin is also administered orally in animals as an expectorant. It has been administered orally to horses (3.5 mg/kg) to clear mucus from airways. Supporting data for an expectorant effect are lacking, but it may increase the volume and reduce the viscosity of secretions in the trachea and bronchi. It may also facilitate removal of secretions. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Minor leakage outside the vein from an IV injection does not cause tissue injury. However, thrombophlebitis from IV injection may occur. Hypotension may occur from high doses. Some hemolysis has been observed from IV infusion, but this is not significant at a concentration less than 15%. In horses, when used alone for anesthetic induction, it may cause excitement, myotonus, and paddling. Therefore, it is often used with other agents in horses. A vagal effect (e.g., stimulation of secretions) may occur when the drug is used as an expectorant.","notes":"Instructions for Use For anesthetic purposes, it is used with other agents. For IV infusion, 5% guaifenesin is prepared from powder (50 g/L) dissolved in sterile water. It dissolves more readily if the water is warm. Infusion of 110 mg/kg can produce transient recumbency. It can be administered with a variety of other anesthetic agents for the benefit of producing a smoother induction in horses. One such combination is Equine  \u201cTriple- Drip\u201d listed in the dosing section. It also has been administered with propofol to horses (3 mg/kg of propofol and 90 mg/kg of guaifenesin infused over 3 minutes). Patient Monitoring and Laboratory Tests Monitoring of animals during anesthesia (heart rate, rhythm, and respiratory rate) is suggested. Hypotension is possible; therefore, blood pressure should be monitored. Formulations \u2022\\t\\tGuaifenesin\\tis\\tadministered\\tas\\tan\\tIV\\tsolution\\tprepared\\tprior\\tto\\tinfusion\\tfrom powder to a 5% solution. \u2022\\t\\tExpectorant\\tformulations:\\t100-\\t\\tand\\t200-\\tmg\\ttablet;\\t600-\\tmg\\textended-\\trelease tablets; and 20- mg/mL and 40- mg/mL oral solution. Human over- the- counter formulations may contain other ingredients such as dextromethorphan and decongestants. \u2022\\t\\tGuaifenesin\\toral:\\tGuaifenesin\\tpowder\\tcan\\tbe\\tmixed\\twith\\twater\\t(60\\tmL)\\tfor\\toral administration to horses. Stability and Storage Guaifenesin is soluble in water and in alcohol. It is more soluble in warm water. It precipitates if the temperature is 22\xb0C or colder. It should be administered orally shortly after preparation because stability is short. However, 10% solutions have been stable for as long as 7 days. For IV use, it has been mixed with xylazine and ketamine without apparent loss of stability. G","original_category":"Expectorant; muscle relaxant"},{"name":"Heparin Sodium","active_ingredient":"Heparin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tLow-\\t  dose\\tprophylaxis:\\t70\u2013100\\tunits/kg\\tq8h\\tSQ. \u2022\\t \\tTreatment\\tof\\tongoing\\tcoagulopathy:\\t100\u2013200\\tunits/kg\\tIV\\tor\\tSQ\\tloading dose;\\tthen\\t150\u2013300\\tunits/kg\\tq6h\\tSQ.\\tAdjust\\tdose\\tvia\\tmonitoring\\tof\\tanti-\\tXa response\\tand\\tincrease\\tto\\t500\u2013600\\tunits/kg\\tif\\tnecessary.\\tIn\\tmore\\tsevere\\tcases, start\\twith\\t500\\tunits/kg\\tSQ\\tas\\tthe\\tinitial\\tdose\\tand\\tthen\\tadminister\\t500\\tunits/ kg q12h. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\tLoading\\tdose\\tof\\t100\\tunits/kg\\tIV\\tfollowed\\tby\\tCRI 20\u201330\\tunits/kg/h.\\t(Total\\tdose\\tof\\t480\u2013720\\tunits\\tper\\t24\\thours.) Cats \u2022\\t\\tLow-\\t  dose\\tprophylaxis:\\t70\u2013100\\tunits/kg\\tq8h\\tSQ. \u2022\\t\\t250\\tunits/kg\\tSQ\\tq6h.\\tThe\\tdose\\tcan\\tbe\\tgradually\\tincreased\\tup\\tto\\t500\\tunits/kg\\tif necessary.  \u2022\\t\\t125\\tunits/kg\\tSQ\\tor\\tIM\\tq8\u201312h.\\t(Lower\\tdosages\\tof\\t80\\tunits/kg\\tSQ\\tq12h\\talso have been used in horses.) Regulatory Information No regulatory information is available for food animals. Because of low risk of residues, no withdrawal times are suggested. H Hydralazine Hydrochloride 431 Hydralazine Hydrochloride hye- drahl\u2032ah- zeen  hye- droe- klor\u2032ide Trade and other names: Apresoline","contraindications":"Contraindications and Precautions Do not use in animals unless able to monitor bleeding because it may be life threatening. Do not inject intramuscularly because it may create a hematoma. Drug Interactions Use cautiously in animals that are already receiving other drugs that can interfere with coagulation, such as aspirin and warfarin. Although a specific interaction has not been identified, use cautiously in animals that may be receiving certain chondroprotective compounds, such as glycosaminoglycans for treatment of arthritis.","indications":"Indications and Clinical Uses Heparin is administered to prevent and treat hypercoagulability disorders and prevent coagulation disorders such as thromboembolism, venous thrombosis, disseminated intravascular coagulopathy, and pulmonary thromboembolism. The use in specific situations in animals is primarily anecdotal or derived from the clinical experience and opinions of experts. No outcome- based studies to evaluate efficacy have been published to support specific guidelines for therapy. Although the LMWHs have shown advantages for human medicine, there are no studies in veterinary medicine that have shown an advantage of LMWH over UFH. Use for prevention of thrombosis in canine patients with immune- mediated hemolytic anemia was not initially\\teffective\\t(50\u2013300\\tunits/kg\\tSQ\\tq6h),\\tbut\\twhen\\tdoses\\twere\\tadjusted\\tbased\\ton anti-\\t  Xa\\tactivity,\\tit\\twas\\tmore\\teffective\\tand\\tdoses\\tin\\tindividual\\tdogs\\twere\\tas\\thigh\\tas\\t560 mg/kg q6h. In horses, it is used to prevent thrombosis in patients at risk, but efficacy has not been measured at the recommended doses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects caused by excessive inhibition of coagulation result in bleeding. Heparin- induced thrombocytopenia, a problem in people, has not been cited as a problem in animals. If excessive anticoagulation and bleeding occur as a result of an overdose, protamine sulfate should be administered to reverse heparin therapy. Protamine\\tshould\\tbe\\tadministered\\tby\\tslow\\tIV\\tinfusion.\\tIt\\tcomplexes\\twith\\theparin to form a stable, inactive compound.","notes":"Instructions for Use Dose adjustments should be performed by monitoring clotting times. For example, dose\\tis\\tadjusted\\tto\\tmaintain\\tactivated\\tpartial\\tthromboplastin\\ttime\\t(aPTT)\\tat\\t1.5\u20132 times normal. For information on other forms of heparin, such as LMWHs, see Enoxaparin and Dalteparin. Duration of anticoagulant effect may vary among patients, but in general, a 200- unit/kg dose in dogs has a duration of effect of approximately 6 hours. Only\\tthe\\tSQ\\troute\\tof\\tadministration\\thas\\tbeen\\tinvestigated\\tin\\tcats\\tand\\tthe\\tIV\\tor SQ\\troute\\tin\\tdogs.\\tThe\\tIM\\troute\\tof\\tadministration\\tis\\tnot\\trecommended\\tbecause\\tof risk of hematoma formation. The doses listed in the dosing section are based primarily on anecdotal experience and opinions of experts. Optimum doses are not established and likely vary in each individual. The doses vary depending whether it is intended for prevention in high- risk patients or treatment of ongoing coagulopathy. In high- risk patients, for prevention, it has been administered at doses as high as 500 units/kg\\tSQ\\tfollowed\\tby\\treduced\\tdoses\\tsuch\\tas\\tthose\\tlisted\\tin\\tthe\\tdosing\\tsection q8\u201312h\\t(see\\tthe\\tdosing\\tsection\\tfor\\tmore\\tinformation). Heparin also has been used to prepare heparinized saline solutions for flushing catheters. The advantage of using heparinized saline instead of regular saline for flushing saline has not been shown in clinical studies. However, the dose for providing this solution is listed in the dosing section. Patient Monitoring and Laboratory Tests Monitor\\teffect\\tusing\\taPTT\\tor\\tanti-\\tXa\\tactivity.\\tDose\\tis\\tadjusted\\tto\\tmaintain\\taPTT at\\t1.5\u20132\\ttimes\\tnormal.\\tTarget\\trange\\tfor\\tanti-\\tXa\\tactivity\\tis\\t0.35\u20130.70\\tunits/mL.\\tIf anti-\\t  Xa\\tactivity\\tis\\tgreater\\tthan\\t0.7\\tunits/mL,\\treduce\\tdose\\tby\\t25%. Formulations \u2022\\t\\tHeparin\\tsodium\\tis\\tavailable\\tin\\t1000-\\t\\tand\\t10,000-\\tunits/mL\\tinjection. Fluid supplementation \u2022\\t\\tTo\\tprepare\\theparinized\\tsaline\\tsolutions\\tfor\\tIV\\tuse:\\tthe\\trecommended\\tmixture ranges from 0.25 to 10 units/mL of fluids. This is equivalent to adding 0.25 mL of heparin (1000 units/mL concentration) per 1000 mL of fluids, or 1 mL heparin (10,000\\tunits/mL\\tconcentration)\\tper\\t1000\\tmL\\tof\\tfluids,\\trespectively.\\t(Note:\\tThe advantage\\tof\\tadding\\theparin\\tto\\tfluid\\tsolutions\\tfor\\tflushing\\tIV\\tcatheters\\thas\\tnot been demonstrated in clinical studies.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticoagulant"},{"name":"Hydroxyethyl Starch","active_ingredient":"Hydroxyethyl Starch","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tSmall-\\t   volume\\tresuscitation:\\t5\\tmL/kg\\tIV. \u2022\\t\\tLarge-\\t   volume\\tresuscitation:\\t5\u201315\\tmL/kg\\tIV. \u2022\\t\\tCRI:\\t10\u201320\\tmL/kg/day\\tIV\\t(0.4\u20130.8\\tmL/kg/h).\\tMaximum\\tdosages\\tare\\t33\u201350 mL/kg/day or 70 mL/kg cumulative dose over 4 days. Cats \u2022\\t\\tResuscitation:\\t2\u20135\\tmL/kg\\tIV. \u2022\\t\\tCRI:\\t5\u201310\\tmL/kg/day\\tIV\\t(0.2\u20130.4\\tmL/kg/h).  Horses \u2022\\t\\t8\u201310\\tmL/kg\\tbolus\\tdose\\tor\\tCRI\\t0.5\u20131\\tmL/kg/h. Regulatory Information No regulatory information is available for food animals. Because of low risk of residues, no withdrawal times are suggested. Hydroxyurea hye- droks\u2032ih- yoo- ree- ah Trade and other names: Droxia and Hydrea (Canada)","contraindications":"Contraindications and Precautions The most recent guidelines for treating severe sepsis and septic shock in people advise not to use synthetic colloids for fluid resuscitation. Do not use in animals with bleeding problems (coagulopathies), active hemorrhage, or preexisting coagulopathies. Do not use in animals with known kidney disease. Drug Interactions Hydroxyethyl starch is compatible with most fluid solutions.","indications":"Indications and Clinical Uses The use of hydroxyethyl starch for resuscitation in veterinary patients remains controversial. If used by emergency or critical care clinicians, hydroxyethyl starch is used primarily to treat acute hypovolemia and shock. It is administered intravenously in acute situations in which rapid restoration of circulating volume is needed. Hydroxyethyl starch solutions have a duration of effective volume expansion of 12\u201348\\thours. The formulations available are 6%, which is isotonic, and 10%, which is hypertonic. Because of more adverse reactions with the higher concentration 10% solution, they are not used commonly. Although hydroxyethyl starch is used by many clinical experts in critically ill hypovolemic and septic patients, other experts have recommended against its use because of its expense, lack of superiority over other treatments, and potential harm. These experts argue that because there is evidence of harm in people, this should warrant caution in animals also (see Adverse Reactions and Side Effects for more details). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Most of the serious adverse effects reported, such as kidney injury and coagulation abnormalities, have been observed in human studies. These products are no longer recommended in critically ill human patients with sepsis, burns, renal impairment, or coagulopathies. The human Surviving Sepsis Campaign recommends against the use of hydroxyethyl starch. The high- molecular- weight hetastarch may alter coagulation and alter viscoelastic measurements and fibrinolysis. Hydroxyethyl starch solutions may affect platelet function and produce coagulation abnormalities at clinically relevant doses for up to 24 hours. Tetrastarch solutions may have less tendency to cause coagulopathies than hetastarch; therefore the current recommendation is to use tetrastarch solutions of 6% and reduced molecular weight (130 kDa) to reduce risk of adverse effects. High- molecular- weight products with molecular weights more than 200 kDa are associated with higher risk of kidney injury. The proposed mechanism for kidney injury is through uptake by proximal epithelial tubular cells as lysosomes leading to injury to proximal tubular cells. The use in veterinary patients has become controversial. There have been conflicting results from studies, with some demonstrating evidence of kidney injury in dogs and conflicting results showing no kidney injury. It is possible that this difference is attributed to differences in molecular weight of the products with the lower molecular weight forms less likely to cause injury.","notes":"Instructions for Use Hydroxyethyl starch solutions are used in critical care situations and infused via CRI. Suspend in saline (0.9%) or 5% dextrose solution for use. Administer slowly in 5-   mL/kg increments to small animals; then reassess and increase the dose to rates listed in the dosing section. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s hydration status and blood pressure during administration. Monitor heart rate and rhythm. Monitor for signs of coagulopathy or platelet dysfunction and discontinue if there are bleeding problems. Monitor kidney parameters and discontinue use if signs of kidney injury are observed. Administration of hydroxyethyl starch solutions may increase patient\u2019s amylase for 2\u20133\\tdays. H Hydroxyurea 443 Formulations \u2022\\t\\tSee\\tearlier\\ttable\\tfor\\tlist\\tof\\tproducts.\\tHydroxyethyl\\tstarch\\tis\\tavailable\\tin\\t6%\\tinjectable solution\\tas\\tan\\tapproved\\tveterinary\\tformulation\\t(tetrastarch,\\tVetStarch).\\tSeveral other hydroxyethyl starch solutions (hetastarch, pentastarch, hexastarch) in concentrations of 6% and 10% are available. Stability and Storage Hydroxyethyl starch is stable in the original packaging and is compatible with most fluid administration sets.","original_category":"Fluid replacement"},{"name":"Hydroxyurea","active_ingredient":"Hydroxyurea","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t50\\tmg/kg\\tPO\\tonce\\tdaily\\t3\\tdays/wk. Cats \u2022\\t\\t25\\tmg/kg\\tPO\\tonce\\tdaily\\t3\\tdays/wk.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Hydroxyzine Hydrochloride hye- droks\u2032ih- zeen Trade and other names: Atarax and Vistaril","contraindications":"Contraindications and Precautions Avoid use in pregnant animals. Drug Interactions No specific drug interactions are reported for animals, but the use is uncommon, and the full range of drug interactions are not known.","indications":"Indications and Clinical Uses In people, hydroxyurea is used for treatment of sickle cell anemia and occasionally various carcinomas. In animals, it has been used in combination with other anticancer modalities for treatment of certain tumors. In animals, the use is uncommon but one of the uses has been treatment of polycythemia vera. 444    Hydroxyzine Hydrochloride Precautionary Information","side_effects":"Adverse Reactions and Side Effects Because of only limited use in veterinary medicine, no adverse effects have been reported. In people, hydroxyurea causes leukopenia, anemia, and thrombocytopenia.","notes":"Instructions for Use Hydroxyurea has been used on a limited basis in veterinary medicine. Most of the use is empirical from small observational studies or extrapolated from human medicine. Patient Monitoring and Laboratory Tests Monitor complete blood count in treated animals. Formulations \u2022\\t\\tHydroxyurea\\tis\\tavailable\\tin\\t200-\\t,\\t300-\\t   ,\\t400-\\t   ,\\tand\\t500-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Hydroxyzine Hydrochloride","active_ingredient":"Hydroxyzine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/kg\\tq8\u201312h\\tIM\\tor\\tPO. Cats \u2022\\t \\tEffective\\tdoses\\thave\\tnot\\tbeen\\testablished\\t(see\\tCetirizine\\tfor dosing information for cats).  Horses \u2022\\t\\tHydroxyzine\\tpamoate\\t500\\tmg\\tper\\thorse\\tPO\\ttwice\\tdaily\\t(efficacy\\tnot\\testablished). Regulatory Information No regulatory information is available for food animals. Because of low risk of residues, no withdrawal times are suggested. RCI\\tClassification:\\t2 Hyoscyamine hye- oh- sye\u2032ah- meen Trade and other names: Levsin","contraindications":"Contraindications and Precautions No contraindications reported in animals. It has been safe even at high doses. Discontinue administration a minimum of 7 days prior to allergen- specific allergy testing in dogs. Drug Interactions No specific drug interactions are reported for animals.","indications":"Indications and Clinical Uses In animals, hydroxyzine has been used to treat pruritus. Efficacy in animals for treating pruritus is low and not recommended by most dermatologists as the sole agent. Although it has been shown in experimental animals to suppress histamine response, it has not been consistently effective relieving pruritus in dogs with atopic dermatitis. Other uses include allergic airway disease and rhinitis. However, efficacy is not established for these uses. Hydroxyzine is sometimes prescribed for performance horses for treatment of hypersensitivity reactions and for the production of sedation. However, the efficacy is not established for these indications in horses. In people, additional uses include treatment of anxiety and psychoneurosis and as a sedative before and after general anesthesia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect. It is the result of inhibition of histamine N- methyltransferase in the CNS. Sedation may also be attributed to the blocking of other CNS receptors such as those for serotonin, acetylcholine, and alpha- receptors. Antimuscarinic effects (atropine- like effects), such as dry mouth and decreased GI secretions, also are common.","notes":"Instructions for Use Clinical studies have shown hydroxyzine to be effective for treatment of pruritus in some dogs, but these were small observational studies. Overall, efficacy rates are low. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tHydroxyzine\\thydrochloride\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\tand\\t50-\\tmg\\ttablets;\\t2-\\tmg/mL oral\\tsyrup;\\tand\\t25-\\tmg/mL\\tinjection.\\tIt\\tis\\talso\\tavailable\\tin\\ta\\tpamoate\\tform\\t(Vistaril) in 25- and 50- mg capsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Hydroxyzine is soluble in water. Compounded formulation with syrups was stable for 14 days. 446    Hyoscyamine","original_category":"Antihistamine"},{"name":"Hyoscyamine","active_ingredient":"Hyoscyamine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.003\u20130.006\\tmg/kg\\tq8h\\tPO. Cats \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\testablished\\tfor\\tcats.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not use in animals that produce food. Withdrawal\\ttime:\\tNone\\testablished\\tin\\tthe\\tUnited\\tStates\\t(manufacturer\\tof\\tlarge\\tanimal products lists zero days for milk and meat), but it is listed as 14 days for meat and 3 days for milk in the United Kingdom. 448    Ibuprofen Ibuprofen eye- byoo- proe\u2032fen Trade and other names: Motrin, Advil, Nuprin, and generic","contraindications":"Contraindications and Precautions Do not use in patients with glaucoma, intestinal ileus, gastroparesis, or tachycardia. Drug Interactions Do not mix with alkaline solutions. Hyoscyamine antagonizes the effects of any cholinergic drugs administered (e.g., metoclopramide).","indications":"Indications and Clinical Uses Hyoscyamine is an anticholinergic drug with actions similar to atropine and related drugs. The use in animals is uncommon. It can produce an antiemetic effect to decrease vomiting associated with motion sickness and some GI diseases, but these clinical effects are not established for animals. It is indicated in animals for similar conditions for which atropine is used, in which it is important to block parasympathetic responses. It has been used to decrease GI motility and secretions, decrease salivation, and increase heart rate (to treat bradycardia). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects include xerostomia, ileus, constipation, tachycardia, and urine retention.","notes":"Instructions for Use Hyoscyamine is used uncommonly in veterinary medicine and the use is based on anecdotal accounts in dogs and cats for some GI and cardiovascular conditions. H Patient Monitoring and Laboratory Tests Monitor heart rate and intestinal motility during treatment. Formulations \u2022\\t\\tHyoscyamine\\tis\\tavailable\\tin\\t0.125-\\tmg\\ttablets,\\t0.375-\\tmg\\textended-\\trelease\\ttablets, and 0.025- mg/mL solution. Stability and Storage Store in a tightly sealed container at room temperature.","original_category":"Anticholinergic"},{"name":"Ibuprofen","active_ingredient":"Ibuprofen","species":["Canine","Equine","Feline"],"dosage":"Avoid use in dogs. Safe dosages for other species have not been established, although there has been some extralabel use in ruminants and horses. The use in horses is based on small observational studies or opinions from equine clinicians.  Dogs and Cats \u2022\\t\\tSafe\\tdose\\tnot\\testablished.  Horses \u2022\\t\\t25\\tmg/kg\\tq8h\\tPO\\tfor\\tup\\tto\\t6\\tdays. Ruminants \u2022\\t\\t14\u201325\\tmg/kg/day\\tPO. Regulatory Information No withdrawal times are established for animals intended for food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t4 Imepitoin eye- mep\u2032i- toyn Trade and other names: Pexion","contraindications":"Contraindications and Precautions Safe doses have not been established for dogs and cats. Do not administer to animals prone to GI ulcers. Do not administer with other ulcerogenic drugs such as corticosteroids. Drug Interactions No specific drug interactions are reported. However, like other NSAIDs, ulcerogenic effects are potentiated when administered with corticosteroids. Ibuprofen, like other NSAIDs, may interfere with the action of diuretics, such as furosemide and angiotensin- converting enzyme (ACE) inhibitors. I I Imepitoin 449","indications":"Indications and Clinical Uses Ibuprofen is not approved for any animals in veterinary medicine. There are drugs in small animals that have been safer for the GI tract and are preferred. Use of ibuprofen in dogs is discouraged because of a high risk of GI ulceration. It has been used for musculoskeletal inflammation in horses and ruminants. Administration of 25 mg/kg IV to cows reduced some systemic variables in endotoxin- induced mastitis. In horses, doses of 10\u201325 mg/kg have been used, but clinical trials of efficacy have not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vomiting, severe GI ulceration, and hemorrhage have been reported in dogs. Like other NSAIDs, renal injury caused by decrease in renal perfusion has occurred with ibuprofen. Ibuprofen may inhibit platelets in animals.","notes":"Instructions for Use Patient Monitoring and Laboratory Tests Monitor for signs of GI ulcers. Monitor renal function during therapy. Formulations \u2022\\t\\tIbuprofen\\tis\\tavailable\\tin\\t200-\\t,\\t400-\\t   ,\\t600-\\t   ,\\tand\\t800-\\tmg\\ttablets.\\tOver-\\tthe-\\t  counter (OTC) formulations are available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ibuprofen has been compounded in alcohol (ethanol) and propylene glycol solutions without loss of stability. It is poorly soluble in water. Ibuprofen has been compounded as an oral paste for horses without compromising the oral absorption.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Imidocarb Hydrochloride and Imidocarb Dipropionate","active_ingredient":"Imidocarb Hydrochloride and Imidocarb Dipropionate","species":["Feline","Canine","Equine"],"dosage":"Cats \u2022\\t\\t5\\tmg/kg\\tIM\\ttwo\\tdoses\\tadministered\\t14\\tdays\\tapart. Dogs \u2022 \\t \\tEhrlichia canis:\\t6.6\\tmg/kg\\tIM\\t(0.25\\tmL\\tper\\t10\\tlb),\\ttwo\\tdoses\\tadministered\\t14\\tdays apart.  Horses \u2022\\t\\t4.4\\tmg/kg\\tonce\\tor\\t2.2\\tmg/kg\\tIM\\tfor\\twith\\tdoses\\twith\\t24-\\t\\tto\\t48-\\thour\\tintervals between doses. Inject in different locations. To eradicate B. caballi,\\tinject\\t4\\tmg/kg IM for four treatments q72h. Consider pretreating with anticholinergic drug (see Adverse Effects). Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Imipenem + Cilastatin ih- mih- pen\u2032em  +  sye- lah- stat\u2032in Trade and other names: Primaxin","contraindications":"Contraindications and Precautions Administer intramuscularly only. Do not administer intravenously. Donkeys and mules are more susceptible to adverse effects than are horses, and treatment should be avoided in these animals. Drug Interactions No drug interactions have been reported; however, the use is uncommon, and a full range of potential drug interactions is not available.","indications":"Indications and Clinical Uses Imidocarb has been used in animals to treat intracellular tick- borne pathogens. The use is based on small observational studies, anecdotal experience, or opinions from experts. It has been used to treat Babesia infections and has been used to treat feline hemoplasma infections caused by the organisms Mycoplasma haemofelis and Mycoplasma haemominutum. Imidocarb also has been used to treat Cytauxzoon felis infections in cats and ehrlichial infections in dogs and cats. In horses, it has been used to treat equine piroplasmosis caused by Theileria equi and Babesia caballi. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No toxic reactions were observed in trials with experimental cats. Transient pain or\\tdiscomfort\\toccurs\\tin\\tmost\\tanimals\\tat\\tthe\\tsite\\tof\\tinjection.\\tPost-\\ttreatment vomiting\\tmay\\toccur\\tin\\t10%\u201340%\\tof\\tanimals.\\tTransient\\tincrease\\tin\\tliver\\tenzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) may occur. After IM injection, it remains in tissues for a prolonged period. Adverse effects from high doses include kidney injury (tubular necrosis) and acute hepatic necrosis. Two forms are available: dipropionate salt and hydrochloride salt. The hydrochloride salt is more irritating when injected intramuscularly. In horses, anticholinesterase effects are common, resulting in increased endogenous acetylcholine, which causes sweating, agitation, bronchoconstriction, salivation, colic signs, intestinal spasmodic reactions, and diarrhea. These effects are transient and not life threatening, but these signs should be treated with atropine if they are severe. To prevent these signs, one may pretreat with atropine (0.02 mg/kg IV), glycopyrrolate (0.0025 mg/kg IV), or N- butylscopolammonium bromide (scopolamine).","notes":"Instructions for Use Use of imidocarb has been limited in animals. Most protocols are established from small clinical trials or extrapolation from human use. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. I Imipenem + Cilastatin 453 Formulations \u2022\\t\\tImidocarb\\tcompounded\\tformulations\\tare\\tavailable\\tfrom\\tsome\\tpharmacies. Imidocarb dipropionate is available as 12% solution (120 mg/mL). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiprotozoal"},{"name":"Imipramine Hydrochloride","active_ingredient":"Imipramine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2\u20134\\tmg/kg\\tq12\u201324h\\tPO. Cats \u2022\\t\\t0.5\u20131\\tmg/kg\\tq12\u201324h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. RCI Classification: 2 Indomethacin in- doe- meth\u2032ah- sin Trade and other names: Indocin","contraindications":"Contraindications and Precautions Use cautiously in patients with heart disease. Overdoses can produce severe arrhythmias. Drug Interactions Do not use with other behavior- modifying drugs, such as serotonin reuptake inhibitors. Do not use with monoamine oxidase inhibitors such as selegiline.","indications":"Indications and Clinical Uses Like other TCAs, imipramine is used in animals to treat a variety of behavioral disorders, including obsessive- compulsive disorders, separation anxiety, and inappropriate urination. There have been fewer studies of efficacy with imipramine than with clomipramine or amitriptyline. Generally, other behavior- modifying drugs such as selective serotonin reuptake inhibitors (e.g., fluoxetine) or other TCAs (clomipramine) are preferred by behavior experts for treating small animals. More information is available for these medications compared with imipramine. 456    Indomethacin Precautionary Information","side_effects":"Adverse Reactions and Side Effects Multiple side effects are associated with TCAs, such as antimuscarinic effects (dry mouth and rapid heart rate) and antihistamine effects (sedation). Overdoses can produce life- threatening cardiotoxicity.","notes":"Instructions for Use Doses are primarily based on empiricism, small observational studies, and opinions from behavior experts. There are few controlled efficacy trials available for animals to\\tcompare\\twith\\tother\\tdrugs\\tin\\tthis\\tclass.\\tThere\\tmay\\tbe\\ta\\t2-\\t\\tto\\t4-\\tweek\\tdelay\\tafter initiation of therapy before beneficial effects are seen. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm in treated animals. Like other TCAs, imipramine may decrease total tetraiodothyronine (T 4 ) and free (T 4 ) concentrations in dogs. Formulations \u2022\\t\\tImipramine\\tis\\tavailable\\tin\\t10-\\t,\\t25-\\t  ,\\tand\\t50-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Although imipramine has been compounded for veterinary use, the potency and stability have not been evaluated for compounded products.","original_category":"Behavior modification"},{"name":"Indomethacin","active_ingredient":"Indomethacin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tSafe\\tdose\\thas\\tnot\\tbeen\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Insulin in\u2032syoo- lin Trade and other names: ProZinc, Lente insulin, Ultralente insulin, Regular insulin, Glargine insulin, NPH insulin, Caninsulin, Protamine zinc insulin (PZI), Humulin (human insulin), Vetsulin is porcine insulin zinc suspension (veterinary), and PZI Vet (veterinary protamine zinc insulin)","contraindications":"Contraindications and Precautions Do not use in dogs or cats. Drug Interactions Like other NSAIDs, several drug interactions are possible. NSAIDs have the potential to interfere with the action of diuretics, such as furosemide, and ACE inhibitors, such as enalapril. Corticosteroids, when used with NSAIDs, increase the risk of ulceration.","indications":"Indications and Clinical Uses Indomethacin, like other NSAIDs, has been used to treat pain and inflammation in people. However, it has not been used often in clinical veterinary medicine because other safer, approved drugs are available. Indomethacin is used as a prototypical nonselective COX- 1 and COX- 2 blocker in research. In dogs, the high risk of GI ulceration prohibits its routine use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Indomethacin has produced severe GI ulceration and hemorrhage in dogs. Like other NSAIDs, it may cause kidney injury via inhibition of renal prostaglandins.","notes":"Instructions for Use Use cautiously, if at all, because safe doses have not been determined for clinical use in animals. Patient Monitoring and Laboratory Tests Monitor for signs of GI toxicity (hemorrhage, ulcers, and perforation). Formulations \u2022\\t\\tIndomethacin\\tis\\tavailable\\tin\\t20-\\t,\\t25-\\t  ,\\t40-,\\t\\tand\\t50-\\tmg\\tcapsules\\tand\\t5-\\tmg/mL\\toral suspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Indomethacin is practically insoluble in water but is soluble in ethanol. It decomposes in alkaline conditions and is maximally stable at pH 3.75. 458    Insulin","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Interferon","active_ingredient":"Interferon","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.5\\tmillion\\tunits/kg\\tIV\\tonce\\tdaily\\tfor\\t3\\tconsecutive\\tdays. Cats \u2022\\t\\tFeline\\tform\\tof\\tinterferon-\\tomega:\\t1\\tmillion\\tunits/kg\\tIV\\tor\\tSQ\\tonce\\tdaily\\tfor\\t5 consecutive days. Three separate 5- day treatments must be performed at day 0, day 14,\\tand\\tday\\t60. \u2022\\t\\tHuman\\tinterferon\\talpha:\\t10,000\\tto\\t1,000,000\\tunits/kg\\tq24h. \u2022\\t\\tHuman\\tinterferon\\talpha:\\t10\u201350\\tunits/kg\\thuman\\tinterferon\\talpha\\ton\\tan\\talternate- week\\tschedule\\tPO.\\t(Although\\toral\\tproducts\\tare\\tdestroyed\\tin\\tstomach\\tacid\\tand\\tmay not be absorbed, some efficacy has been demonstrated from this route. This may be caused by a local effect on the oral or pharyngeal area.)  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not administer to animals intended for food. Iodide (Potassium Iodide) eye\u2032oh- dyde Trade and other names: Potassium iodide, EDDI, and ethylenediamine dihydriodide","contraindications":"Contraindications and Precautions Do not vaccinate dogs or cats receiving interferon. If human interferon is used in cats, it may become ineffective after several weeks because of neutralizing antibodies. Drug Interactions Do not mix with any other vaccine/immunologic product, except the solvent supplied for use with the product. 464    Iodide (Potassium Iodide)","indications":"Indications and Clinical Uses Interferon is used to stimulate the immune system in patients. It has been used to stimulate immune cells in dogs with parvovirus and in cats with feline retrovirus (feline leukemia virus [FeLV] and feline immunodeficiency virus [FIV]). It has not been effective for feline infectious peritonitis in cats. It has not been effective for naturally infected FeLV in cats but has been effective in experimentally infected animals. Feline interferon is associated with clinical improvement in cats with stomatitis associated with calicivirus. Human interferon alpha, given orally, has improved clinical signs in cats with FIV. If human interferon is used by injection in cats, it becomes ineffective after 3\u20137 weeks because of development of neutralizing antibodies. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In people, injections of interferon alpha have been associated with influenza- like symptoms. Other effects, such as bone marrow suppression, also have been reported in people. Interferon may induce vomiting and nausea in animals. In some animals, it may induce hyperthermia 3\u20136 hours after injection. In cats, it may produce soft feces to mild diarrhea. A slight decrease in white blood cells, platelets, and red blood cells and an increase in the concentration of ALT may be observed. These parameters usually return to normal in the week following the last injection. In cats, it may induce transient fatigue during treatment.","notes":"Instructions for Use Doses and indications for animals have primarily been based on extrapolation of human recommendations, experimental studies, or specific studies in cats with viral infections. Patient Monitoring and Laboratory Tests Monitor complete blood count (CBC) during treatment. Formulations Available \u2022\\t\\tFeline\\torigin:\\tInterferon\\tis\\tavailable\\tin\\tsome\\tcountries\\tin\\t5\\tand\\t10\\tmillion\\tunits/vial. The freeze- dried fraction must be reconstituted with 1 mL of the specific diluent to obtain, depending on the presentation, a solution containing 5 million units or 10 million units of recombinant interferon. Feline- origin interferon is not available in the United States. Stability and Storage Interferon has a shelf life of 2 years. The product should be used immediately after reconstitution and should be stored in its original carton. Store and transport at 4\xb0C\\t\xb1\\t2\xb0C.\\tDo\\tnot\\tfreeze.","original_category":"Immunostimulant"},{"name":"Do not administer to animals intended for food.","active_ingredient":"Do not administer to animals intended for food.","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tFungal\\tinfections:\\tStart\\twith\\t5\\tmg/kg\\tq8h\\tPO\\tand\\tincrease\\tgradually\\tto\\t25\\tmg/kg q8h\\tPO. \u2022\\t\\tTreatment\\tof\\tSporothrix infection in cats: 15 mg/kg per day oral for 20 weeks. \u2022\\t\\tEmergency\\ttreatment\\tafter\\tradiation\\texposure:\\t2\\tmg/kg\\tPO\\tper\\tday. \u2022\\t\\tExpectorant:\\t5\\tmg/kg\\tq8h\\tPO.  Cattle \u2022\\t\\tFeed\\tsupplement:\\t50\u2013217\\tmg\\tEDDI\\tper\\thead\\tper\\tday\\t(mix\\twith\\tfeed). \u2022\\t\\tExpectorant\\tand\\tother\\tindications:\\t650\u20131300\\tmg\\tEDDI\\tper\\thead\\ttwice\\tdaily\\tPO\\tfor 7 days. Horses (treatment of fungal granuloma) \u2022\\t\\t20\u201340\\tmg/kg\\tper\\tday\\tIV\\tfor\\t7\u201310\\tdays\\t(using\\t20%\\tsodium\\tiodide). \u2022\\t\\t10\u201340\\tmg/kg\\tper\\tday\\tPO\\t(using\\tinorganic\\tpotassium\\tiodide). \u2022\\t\\t0.86\u20131.72\\tmg/kg\\tof\\tEDDI\\tor\\tuse\\t20\u201340\\tmg/kg\\tper\\tday\\tPO\\tof\\tthe\\t4.6%\\torganic iodine dextrose base of EDDI. Regulatory Information Withdrawal times in food- producing animals have not been established. Ipecac ih\u2032peh- kak Trade and other names: Ipecac and syrup of ipecac","contraindications":"Contraindications and Precautions Do not use in pregnant animals. Drug Interactions No drug interactions have been reported for small animals.","indications":"Indications and Clinical Uses Ethylenediamine dihydriodide (EDDI) is used as a nutritional source of iodine in cattle. In people, iodide has been used to treat hyperthyroidism, but effectiveness for\\tthis\\tuse\\tin\\tcats\\thas\\tnot\\tbeen\\testablished.\\tPotassium\\tiodide\\tis\\talso\\tused\\tto protect the thyroid gland from radiation injury in the event of a radiation emergency (accidental exposure to radiation) or following administration of radioactive iodide. Because iodide may increase respiratory secretions, it has been used as an expectorant, but the efficacy has not been established. Nevertheless, in cattle, in addition to a feed supplement, EDDI is used as an expectorant. EDDI is sometimes added to the feed of cattle for the purpose of decreasing foot rot infections, lumpy jaw (Actinomyces bovis), woody tongue (Actinobacillus lignieresii), and bronchitis. There is a lack of published scientific evidence for a beneficial effect. Iodide has been used to treat fungal granulomatous disease and infections associated with zygomycetes. The antifungal treatment has been questioned for animals because the efficacy is not established. In horses, iodine is used to treat sporotrichosis and occasionally other fungal infections such as basidiobolomycosis and conidiobolomycosis (zygomycosis). For horses, treatment is initiated with doses listed in the dosing section, and to prevent relapse, treatment is\\tcontinued\\tfor\\t4\\tweeks\\tbeyond\\tresolution\\tof\\tclinical\\tsigns. In cats, potassium iodide (administered as oral capsules) has been used to treat infections caused by Sporothrix schenckii. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Iodide- related adverse reactions (iodism) include excess lacrimation, swelling of eyelids, nonproductive cough, increased respiratory secretions, and dermatitis. Its use may cause abortion in horses or limb deformities in foals. Adverse effects are common when used for long periods in small animals. These effects include hepatotoxicity, lethargy, anorexia (most common), vomiting, diarrhea, hypothermia, and cardiomyopathy.","notes":"Instructions for Use Iodide has been administered as a 1- g/mL potassium iodine solution (SSKI) or as a 65- mg/mL solution. It also has been administered as a 10% potassium iodide/5% iodine solution given orally with food. In cattle, EDDI is administered in the feed or mixed with feed, salt, or mineral mixture or in the drinking water. Patient Monitoring and Laboratory Tests Monitor serum thyroid concentrations with prolonged use. 466    Ipecac Formulations \u2022\\t\\tAvailable\\tfor\\tfood\\tanimals\\tas\\tEDDI:\\tequivalent\\tto\\t4.6%\\tEDDI\\tor\\t46\\tmg/g\\tof EDDI. Also available as potassium iodide as 1 g/mL SSKI, a 65- mg/mL oral solution, or 10% potassium iodide/5% iodine solution. Inorganic potassium iodide has been used in horses orally but must be obtained as the chemical grade and compounded for horses. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not freeze solutions. Inorganic potassium iodide is unstable in light, heat, and excess humidity.","original_category":"Iodine supplement"},{"name":"Ipecac","active_ingredient":"Ipecac","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t3\u20136\\tmL\\tper\\tdog\\tPO.\\tDose\\tmay\\tbe\\tincreased\\tup\\tto\\t15\\tmL\\tper\\tdog\\tfor\\tlarge\\tbreeds. Cats \u2022\\t\\t2\u20136\\tmL\\tper\\tcat\\tPO.  \u2022\\t\\tNot\\trecommended\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available for animals intended for food. Because of a low risk of residues, no withdrawal times are suggested. Ipodate ih\u2032poe- date Trade and other names: Calcium ipodate and, Ipodate sodium, and Iopodate","contraindications":"Contraindications and Precautions Do not induce vomiting if the patient has ingested caustic chemicals or if there is a risk of aspiration pneumonia. Drug Interactions Ipecac is not as effective if drugs that act as antiemetics have been administered. Such drugs include tranquilizers (e.g., acepromazine), anticholinergics (e.g., atropine), antihistamines, cannabinoids, and prokinetic agents (e.g., metoclopramide).","indications":"Indications and Clinical Uses Ipecac is indicated for emergency treatment of poisoning. When used in animals, it should be administered promptly after poisoning. Inducing vomiting with ipecac is not effective beyond 30\u201360 minutes after poisoning. After successful administration, it is estimated that vomiting removes only 10%\u201360% of ingested toxicant. Therefore other systemic antidotes and activated charcoal should also be considered. I Ipodate 467 Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects with acute therapy for poisoning. Chronic administration can lead to myocardial toxicity.","notes":"Instructions for Use Ipecac is available as a nonprescription drug. Onset of vomiting may require 20\u201330 minutes. Patient Monitoring and Laboratory Tests Poisoned\\tanimals\\tshould\\tbe\\tmonitored\\tclosely\\tbecause\\tipecac\\tmay\\tnot\\tentirely eliminate ingested toxicant. Formulations \u2022\\t\\tIpecac\\tis\\tavailable\\tin\\ta\\t30-\\tmL/bottle\\toral\\tsolution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Emetic"},{"name":"Iron Dextran and Iron Sucrose","active_ingredient":"Iron Dextran and Iron Sucrose","species":["Canine","Feline"],"dosage":"\u2022\\t\\tIV\\tuse\\tfor\\ttreating\\tiron-\\tdeficiency\\tanemia:\\t2\u20133\\tmg/kg\\tIV\\tslowly\\tover\\t2\u20135\\tminutes. May\\tbe\\trepeated\\tfive\\ttimes\\tin\\ta\\t14-\\tday\\tperiod.\\tThe\\tdose\\tmay\\tbe\\tdiluted\\tin\\t0.9% saline solution and infused IV. Dogs \u2022\\t\\t10\u201320\\tmg/kg\\tIM\\tof\\tiron\\tdextran\\tonce\\tfollowed\\tby\\toral\\ttreatment\\twith\\tferrous sulfate. Cats \u2022\\t\\t50\\tmg\\tIM\\tof\\tiron\\tdextran\\tevery\\t3\u20134\\tweeks.  Pigs \u2022\\t\\t100\\tmg\\t(1\\tmL)\\tIM\\tto\\t2-\\t\\tto\\t4-\\tday-\\t  old\\tpigs;\\trepeat\\tin\\t10\\tdays. \u2022\\t\\t200\\tmg\\t(1\\tmL\\tof\\thigher\\tconcentration)\\tIM\\tto\\tpigs\\tat\\t1\u20133\\tdays\\tof\\tage. Regulatory Information No withdrawal time is necessary. Isoflupredone Acetate eye- soe- floo\u2032preh- done  ass\u2032ih- tate Trade and other names: Predef 2X","contraindications":"Contraindications and Precautions When treating patients for iron- deficiency anemia, the total cumulative dose in\\ta\\t14-\\t    day\\tperiod\\tshould\\tnot\\texceed\\t15\\tmg/kg.\\tDo\\tnot\\tadminister\\tsolutions intended for IV use by SQ or IM route. Drug Interactions No drug interactions are reported.","indications":"Indications and Clinical Uses Most of the experience with the use is in young pigs for treatment and prevention of iron-\\t  deficiency\\tanemia.\\tInjections\\tare\\tusually\\tmade\\tintramuscularly\\tat\\t1\u20134\\tdays\\tof\\tage. Iron dextran also can be administered intramuscularly for treatment of iron deficiency in dogs and cats. Another preparation is iron sucrose (Venofer) injection 20 mg/mL, which may be used to treat iron- deficiency anemia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Injections may produce transient myositis and muscle weakness. The dextran portion can cause anaphylactoid reaction. Use iron sucrose or iron gluconate if the dextran causes a reaction.","notes":"Instructions for Use Inject iron dextran in mid- portion of rear thigh muscle in pigs. For treatment of iron- deficiency anemia with iron sucrose, inject intravenously by slow infusion over 2\u20135 minutes in an undiluted form or diluted in 100 mL of sodium chloride 0.9% over 15 minutes. Patient Monitoring and Laboratory Tests Monitor iron concentrations in treated animals and CBC to monitor effectiveness. Iron dextran can cause a brown discoloration of serum, with false elevation of bilirubin and false decrease in serum calcium. Formulations \u2022\\t\\tIron\\tdextran\\tis\\t100\\tor\\t200\\tmg\\tof\\telemental\\tiron\\tper\\tmilliliter.\\tIron\\tsucrose\\tis\\t20 mg/mL injection. 472    Isoflupredone Acetate Stability and Storage Store in a tightly sealed container, at room temperature, protected from light. Do not mix with other solutions. Do not freeze. When using iron sucrose, use immediately after dilution in saline solutions.","original_category":"Mineral supplement"},{"name":"Isoproterenol Hydrochloride","active_ingredient":"Isoproterenol Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmcg/kg\\tq6h\\tIM\\tor\\tSQ. \u2022\\t\\tDilute\\t1\\tmg\\tin\\t500\\tmL\\tof\\t5%\\tdextrose\\tor\\tlactated\\tRinger\u2019s\\tsolution\\tand\\tinfuse\\tIV 0.5\u20131 mL/min (1\u20132 mcg/min) or to effect. \u2022\\t\\tCRI:\\tAdminister\\tto\\teffect\\tat\\t0.01\u20130.1\\tmcg/kg/min.  \u2022\\t\\t1\\tmcg/kg\\tevery\\t15\\tminutes\\tIV\\tuntil\\tdesired\\tresponse. Regulatory Information No regulatory information is available for animals intended for food. Because of a low risk of residues, no withdrawal times are suggested. RCI Classification: 2 478    Isosorbide Dinitrate and Isosorbide Mononitrate Isosorbide Dinitrate and Isosorbide Mononitrate eye- soe- sor\u2032bide  dye- nye\u2032trate  and  eye- soe- sor\u2032bide  mahn- oh- neye\u2032trate Trade and other names: Isosorbide dinitrate (Isordil) and Isosorbide mononitrate (Monoket)","contraindications":"Contraindications and Precautions Do not use if formulation turns pink or a dark color. The formulation can be unstable when mixed with other solutions. Follow the guidelines on the package insert for potential problems. Drug Interactions Isoproterenol potentiates other adrenergic agonists. Treatment potentiates cardiac arrhythmias and should be used cautiously with other arrhythmogenic drugs.","indications":"Indications and Clinical Uses Isoproterenol is administered when it is necessary for prompt stimulation of the heart (inotropic and chronotropic) or to relieve acute bronchoconstriction. It is short acting and must be administered intravenously or via inhalation. Because of availability of other agents and rare need for a rapid- onset adrenergic agent, isoproterenol is infrequently used in animals. I Precautionary Information","side_effects":"Adverse Reactions and Side Effects Isoproterenol causes adverse effects related to excessive adrenergic stimulation, seen primarily as tachycardia and tachyarrhythmias. High doses can cause calcium accumulation in myocardium and tissue injury. Adrenergic agonists can produce potassium imbalance in animals.","notes":"Instructions for Use Because of a short half- life, isoproterenol must be infused via CRI or repeated if administered IM or SQ. It is recommended for short- term use only because repeated treatment causes cardiac injury. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. Monitor serum potassium with repeated use. Formulations \u2022\\t\\tIsoproterenol\\tis\\tavailable\\tin\\t0.2-\\tmg/mL\\tampules\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water with good aqueous stability. It is susceptible to light, and if a dark color is observed, it should be discarded (pink to brownish color). Solutions above a pH of 6.0 may decompose more rapidly. In 5% dextrose solutions, it is stable for 24\\thours.\\tIt\\thas\\tbeen\\tadded\\tto\\tultrasonic\\tnebulizers\\tin\\tdistilled\\twater\\tfor\\trespiratory therapy\\tand\\tis\\tstable\\tin\\tsolution\\tfor\\t24\\thours.\\tIt\\talso\\tis\\tstable\\tif\\tmixed\\twith\\tcromolyn sodium.","original_category":"Beta- agonist"},{"name":"Isotretinoin","active_ingredient":"Isotretinoin","species":["Canine"],"dosage":"Dogs \u2022\\t\\t1\u20133\\tmg/kg/day\\t(up\\tto\\ta\\tmaximum\\trecommended\\tdosage\\tof\\t3\u20134\\tmg/kg/day\\tPO).  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not use in animals intended for food. Isoxsuprine eye- soks\u2032yoo- preen Trade and other names: Vasodilan and generic brands","contraindications":"Contraindications and Precautions Isotretinoin is absolutely contraindicated in pregnant animals because of fetal abnormalities. Drug Interactions No drug interactions are reported. 480    Isoxsuprine","indications":"Indications and Clinical Uses In people, it is primarily used to treat acne. In animals, dermatologists have used it to treat sebaceous adenitis, with apparent success. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not reported for animals, although experimental studies have demonstrated that it can cause focal calcification (e.g., in myocardium and vessels).","notes":"Instructions for Use Use in veterinary medicine is confined to limited clinical experience, recommendations from experts, and extrapolation from human reports. High expense of this medication has limited veterinary use. There is a restricted distribution for humans, and it may not be available for veterinary use because of prescribing restrictions. Patient Monitoring and Laboratory Tests No monitoring is necessary for animal use. Formulations \u2022\\t\\tIsotretinoin\\tis\\tavailable\\tin\\t10-\\t,\\t20-\\t  ,\\tand\\t40-\\tmg\\tcapsules.\\tCapsules\\tmay\\tnot\\tbe available for veterinary use. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Dermatologic agent"},{"name":"Kaolin and Pectin","active_ingredient":"Kaolin and Pectin","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20132\\tmL/kg\\tq2\u20136h\\tPO.  Horses and Cattle \u2022\\t\\t180\u2013300\\tmL\\tq2\u20133h\\tPO. Calves and Foals \u2022\\t\\t90\u2013120\\tmL\\tq2\u20133h\\tPO. K Ketamine Hydrochloride 493 Regulatory Information There is little risk of residues in animals that produce food. No withdrawal times are necessary. Ketamine Hydrochloride ket\u2032ah- meen  hye- droe- klor\u2032ide Trade and other names: Ketalar, Ketavet, and Vetalar","contraindications":"Contraindications and Precautions No specific contraindications in animals. Drug Interactions No drug interactions are reported. However, the kaolin component may prevent absorption of other drugs. Administer other oral drugs 30 minutes prior to kaolin\u2013pectin to avoid drug interaction.","indications":"Indications and Clinical Uses Kaolin and pectin combinations are used for the symptomatic treatment of acute diarrhea. Despite the lack of clinical evidence of efficacy, some veterinarians administer this drug for short- term treatment. Commercial forms that contain salicylate (8.68 mg/mL) may have anti- inflammatory effects to decrease secretory diarrhea caused by bacteria. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects are uncommon. There are 8.7 mg/mL of salicylate in the regular strength and 16 mg/mL in the extra- strength formulation. Because some animals may be sensitive to salicylates, this ingredient in the formulation should be considered before administering to animals.","notes":"Instructions for Use Kaolin\u2013pectin may not change the course of diarrhea but may change the character of the feces. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tKaolin\u2013pectin\\tis\\tno\\tlonger\\tfound\\tin\\tthe\\tproduct\\tKao-\\tPectate\\t(previously\\tavailable in a 12- oz oral suspension). All formulations for Kao- Pectate contain bismuth subsalicylate. Salicylate (8.68 mg/mL) is present in Kao- Pectate. \u2022\\t\\tVeterinary\\tformulations\\tof\\tkaolin\u2013pectin\\tare\\tavailable\\tunder\\tvarious\\tgeneric\\tnames in\\t1-\\t  quart\\tand\\t1-\\tgallon\\tcontainers\\tcontaining\\t5.8\\tg\\tof\\tkaolin\\tand\\t0.139\\tg\\tof\\tpectin per 30 mL (1 oz). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidiarrheal"},{"name":"Ketoprofen","active_ingredient":"Ketoprofen","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tSingle\\tdose:\\t2\\tmg/kg\\tSQ,\\tIM,\\tor\\tIV. \u2022\\t\\tMultiple\\tdose:\\t1\\tmg/kg\\tq24h\\tPO\\tfor\\tup\\tto\\t5\\tdays.\\tIf\\tlonger-\\tterm\\ttreatment\\tis needed,\\tlower\\tthe\\tdosage\\tto\\t0.25\\tmg/kg\\tonce\\tdaily\\tbecause\\tit\\tprovides\\ta\\tbetter safety profile.  Horses \u2022\\t\\t2.2\u20133.3\\tmg/kg/day\\tIV\\tor\\tIM. Pigs \u2022\\t\\t3\\tmg/kg/day\\tPO,\\tIV,\\tor\\tIM. Cattle and small ruminants \u2022\\t\\t3\\tmg/kg/day\\tIV\\tor\\tIM\\tfor\\tup\\tto\\t3\\tdays. Regulatory Information Extralabel use in the United States: Withdrawal time of at least 7 days for meat and 24\u201348\\thours\\tfor\\tmilk\\tat\\ta\\tdose\\tof\\t3.3\\tmg/kg\\tq24h\\tIM\\tor\\tIV.\\tHowever,\\tin\\tother countries, the withdrawal times are shorter. For example, it is approved in Canada. For swine and cattle with a meat withdrawal time of 1 day. RCI\\tClassification:\\t4 Ketorolac Tromethamine kee- toe\u2032role- ak  troe- meth\u2032eh- meen Trade and other names: Toradol","contraindications":"Contraindications and Precautions Do not administer to animals prone to GI ulcers. Do not administer with other ulcerogenic drugs such as corticosteroids. Drug Interactions Do not administer with other NSAIDs or with corticosteroids because these agents may exacerbate adverse GI effects. Some NSAIDs may interfere with the action of diuretic drugs and angiotensin- converting enzyme inhibitors.","indications":"Indications and Clinical Uses Ketoprofen is an NSAID that is used for treatment of moderate pain and inflammation. It has a half- life in most animals of less than 2 hours, but it has a duration\\tof\\taction\\tfor\\tup\\tto\\t24\\thours.\\tIn\\tthe\\tUnited\\tStates,\\tif\\tit\\tis\\tused\\tin\\tsmall animals, either the large- animal injectable formulation or the human oral OTC tablets are used. It is approved for treating horses using the injectable formulation. This form also has been administered to other large animals (cattle, sheep, pigs, and zoo animal hoofstock). Although ketoprofen is not approved in the United States for small animals, it has been approved for treatment dogs and cats in other countries. It has been given by injection for short- term treatment and by tablet for long- term use. In dogs and cats, it has been shown effective for treating pyrexia. In horses, ketoprofen is used for musculoskeletal inflammation and pain, abdominal pain, and other inflammatory conditions. Ketoprofen also has been used in cattle, goats, sheep, and pigs. In cattle, it has been effective for fever, pain, and inflammation associated with mastitis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects All NSAIDs share the similar adverse effect of GI injury. The most common side effect is vomiting. GI ulceration is possible in some animals. Ketoprofen has been\\tadministered\\tfor\\t5\\tconsecutive\\tdays\\tin\\tdogs\\twithout\\tserious\\tadverse\\teffects, but longer treatment should be avoided. Dogs that received ketoprofen for 30 consecutive\\tdays\\t(0.25\\tmg/kg/day)\\tinduced\\tpyloric\\tlesions\\tand\\tfecal\\toccult blood. In horses, ketoprofen has been less ulcerogenic than phenylbutazone or flunixin meglumine in one study. Bleeding problems can occur if ketoprofen is administered before or after surgery.","notes":"Instructions for Use Although not approved in the United States, ketoprofen is approved for small animals in other countries. It is approved for use in cattle in Canada but is not approved in the United States. Doses listed are based on approved use in those countries. It is 500    Ketorolac Tromethamine available as an OTC drug for humans in the United States, and these forms have been administered to dogs and cats. Patient Monitoring and Laboratory Tests Monitor patient for signs of GI intoxication (vomiting and diarrhea). Monitor renal function during chronic treatment. Formulations \u2022\\t\\tKetoprofen\\tis\\tavailable\\tin\\t12.5-\\tmg\\ttablets\\t(over\\tthe\\tcounter);\\t25,\\t50,\\tand\\t75\\tmg (human\\tpreparation);\\tand\\t100-\\tmg/mL\\tinjection\\tfor\\thorses.\\tIt\\tis\\tavailable\\tin\\t10- mg/mL injection outside the United States. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ketoprofen is insoluble in water, but it is soluble in ethanol. Stability of oral compounded formulations has not been evaluated.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Ketorolac Tromethamine","active_ingredient":"Ketorolac Tromethamine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tmg/kg\\tq8\u201312h\\tPO,\\tIM,\\tor\\tIV. Cats \u2022\\t\\tNo\\tsafe\\tdose\\tis\\testablished.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. L Lactated Ringer\u2019s Solution 503 Lactated Ringer\u2019s Solution Trade and other names: LRS","contraindications":"Contraindications and Precautions Do not administer more than two doses. Do not administer to animals prone to GI ulcers. Do not administer with other ulcerogenic drugs such as corticosteroids. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have been shown to exacerbate the GI adverse effects. Some NSAIDs may interfere with the action of diuretic drugs and ACE inhibitors.","indications":"Indications and Clinical Uses Ketorolac is infrequently used in veterinary medicine. The use is based on limited clinical experience and extrapolation from the use in people. There are only limited data on safety and efficacy for veterinary uses. It has occasionally been used to treat pain and inflammation in dogs, with the most common use for treatment of pain associated with surgery.  Ketorolac also has been used in exotic and zoo animal species for treating pain. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other NSAIDs, it may cause GI ulceration and renal ischemia. Ketorolac may cause GI lesions if administered more frequently than q8h.","notes":"Instructions for Use Limited clinical studies in dogs have been conducted. However, it may be effective in some patients for short- term use. Long- term administration is discouraged. Patient Monitoring and Laboratory Tests Monitor for signs of GI ulceration. Plasma concentrations are not generally monitored but levels of 0.1\u20130.3 mcg/mL in people are considered in the analgesic range. Formulations \u2022\\t\\tKetorolac\\tis\\tavailable\\tin\\t10-\\tmg\\ttablets\\tand\\t15-\\t\\tand\\t30-\\tmg/mL\\tinjection\\tin\\t10% alcohol. Stability and Storage Store in a tightly sealed container, protected from light and humidity, and at room temperature. Ketorolac tromethamine is soluble in water and slightly soluble in ethanol. Stability of oral compounded formulations has not been evaluated.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Lactated Ringer\u2019s Solution","active_ingredient":"Lactated Ringer\u2019s Solution","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tModerate\\tdehydration:\\t15\u201330\\tmL/kg/h\\tIV. \u2022\\t\\tSevere\\tdehydration:\\t50\\tmL/kg/h\\tIV. \u2022\\t\\tMaintenance\\trates: \u2022\\t  \\tCat:\\t2\u20133\\tmL/kg/h. \u2022\\t  \\tDog:\\t2\u20136\\tmL/kg/h. \u2022\\t\\tMaintenance\\t(per\\tday):\\t55\u201365\\tmL/kg/day\\tIV,\\tSQ,\\tor\\tIP\\t(2.5\\tmL/kg/h). \u2022\\t\\tDuring\\tanesthesia:\\tInitial\\trate\\t3\\tmL/kg/h\\tfor\\tcats\\tand\\t5\\tmL/kg/h\\tfor\\tdogs\\tIV.\\tIf necessary to replace losses, increase to 10 mL/kg/h IV. \u2022\\t\\tShock\\ttherapy:\\t90\\tmL/kg\\tIV\\tfor\\tdogs\\tand\\t60\u201370\\tmL/kg\\tIV\\tfor\\tcats.  Cattle, Horses, and Pigs \u2022\\t\\tMaintenance:\\t40\u201350\\tmL/kg/day\\tIV. \u2022\\t\\tModerate\\tdehydration:\\t15\u201330\\tmL/kg/h\\tIV. \u2022\\t\\tSevere\\tdehydration:\\t50\\tmL/kg/h\\tIV. Calves and Foals \u2022\\t\\tModerate\\tdehydration:\\t45\\tmL/kg\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h\\tIV. \u2022\\t\\tSevere\\tdehydration:\\t80\u201390\\tmL/kg\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h\\tIV.\\tIn\\tsevere\\tcases, it may be given as rapidly as 80 mL/kg/h. Regulatory Information There is no risk of harmful residues in animals intended for food. No withdrawal times are necessary. Lactulose lak\u2032tyoo- lose Trade and other names: Chronulac and generic brands","contraindications":"Contraindications and Precautions Administer IV fluids only in patients monitored carefully. Drug Interactions Lactated Ringer\u2019s solution has a pH of 6\u20137.4. Do not add medications to this solution if they are unstable at this pH. Lactated Ringer\u2019s solution contains calcium. Do not add drugs to this solution that may bind (chelate) to calcium.","indications":"Indications and Clinical Uses Lactated Ringer\u2019s solution is indicated as a replacement or maintenance fluid. It also is used as a vehicle to deliver IV medications via constant- rate infusion (CRI). It has been administered subcutaneously, intraosseously (in bone medullary cavity), and intraperitoneally (IP) in animals when IV access is not possible. It contains lactate, a metabolizable base but does not correct acidosis as quickly as bicarbonate. Severely acidemic animals may already have high lactate serum levels. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No significant adverse effects.","notes":"Instructions for Use Fluid requirements vary depending on animal\u2019s needs (replacement vs. maintenance). For shock therapy, administer half the calculated dose in the first 30 minutes and in 10- mL/kg increments every 15 minutes followed by a CRI. For severe acidemia, consider fluids supplemented with bicarbonate instead of lactate. Fluid rates used in dogs and cats during anesthesia have previously been 10 mL/kg/h, IV, but some experts have lowered these recommendations to 3 mL/kg/h in cats and 5 mL/kg/h in dogs. See dosing section for calculation of maintenance rates. Patient Monitoring and Laboratory Tests Monitor patient\u2019s hydration status and electrolyte balance (especially potassium, chloride, and sodium). With high administration rates, monitor patient for signs of pulmonary edema. Formulations \u2022\\t\\tLactated\\tRinger\u2019s\\tsolution\\tis\\tavailable\\tin\\t250-\\t,\\t500-\\t   ,\\tand\\t1000-\\tmL\\tfluid\\tbags. L 504    Lactulose Stability and Storage Store in a tightly sealed container. If container has been punctured or transferred to another container, sterility cannot be assured.","original_category":"Fluid replacement"},{"name":"Leucovorin Calcium","active_ingredient":"Leucovorin Calcium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tWith\\tmethotrexate\\tadministration:\\t3\\tmg/m 2 IV,\\tIM,\\tor\\tPO. \u2022\\t\\tTreatment\\tof\\tmethotrexate\\tintoxication:\\t25\u2013200\\tmg/m 2 q6h. As a general guideline, administer 15 mg/m 2 for mild toxicity, 30 mg/m 2 for mild toxicity, and 100 mg/m 2 for severe toxicity. An alternative approach is to administer the same dose as methotrexate. \u2022\\t\\tAs\\tantidote\\tfor\\tpyrimethamine\\ttoxicosis:\\t1\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported.\\tHowever,\\tif\\tpyrimethamine\\ttoxicosis\\tis suspected in horses, doses listed for small animals may be considered. Regulatory Information Withdrawal times are not established for animals that produce food. If this drug is administered to food animals, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org for extralabel use information. L Levamisole Hydrochloride 509 Levamisole Hydrochloride leh- vam\u2032ih- sole  hye- droe- klor\u2032ide Trade and other names: Levasole, Ripercol, Tramisol, and Ergamisol","contraindications":"Contraindications and Precautions No contraindications reported for animals. Drug Interactions Leucovorin interferes with the action of trimethoprim and pyrimethamine.","indications":"Indications and Clinical Uses Use of leucovorin is uncommon in animals. It may be used as an antidote for folic acid antagonists. In humans, it is primarily used as rescue for overdoses of folic acid antagonists such as methotrexate and treatment of adverse reactions from methotrexate, but it also may be considered for reactions caused by pyrimethamine and trimethoprim. Because methotrexate use is uncommon in animals, the use of leucovorin is rare. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse reactions reported for animals, but allergic reactions have been reported in people.","notes":"Instructions for Use Clinical studies have not been reported in veterinary medicine. Although leucovorin may prevent toxicity from trimethoprim, it does not prevent toxic reactions that may be caused by sulfonamides in animals. Patient Monitoring and Laboratory Tests Monitor CBC if this drug is used to treat overdose of folic acid antagonists. Formulations Available \u2022\\t\\tLeucovorin\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t15-\\t  ,\\tand\\t25-\\tmg\\ttablets\\tand\\t3-\\t\\tand\\t5-\\tmg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is soluble in water but is insoluble in ethanol. Reconstituted solutions have stability for 7 days at room temperature or refrigerated.","original_category":"Antidote"},{"name":"Levodopa","active_ingredient":"Levodopa","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tHepatic\\tencephalopathy:\\t6.8\\tmg/kg\\tinitially\\tPO;\\tthen\\t1.4\\tmg/kg\\tq6h\\tPO.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available for animals intended for food. Because of a low risk of residues, no withdrawal times are suggested. Levofloxacin lee- voe- flox\u2032a- sin Trade and other names: Levaquin and generic brands","contraindications":"Contraindications and Precautions There are no specific contraindications for use in animals. Drug Interactions Antidopamine drugs interfere with the action of levodopa. Such drugs include metoclopramide, phenothiazines (e.g., acepromazine), and risperidone.","indications":"Indications and Clinical Uses In people, levodopa is used for treating Parkinson disease, and it is used in combination with carbidopa (a peripheral decarboxylase inhibitor) and entacapone (an o- methyltransferase inhibitor) to potentiate therapy. In animals, it has been used for treating hepatic encephalopathy, but there is very limited experience to confirm efficacy. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects in animals have not been reported. In people, dizziness, mental changes, difficult urination, and hypotension are among the reported adverse effects.","notes":"Instructions for Use Clinical studies have not been reported in veterinary medicine, and the use has been uncommon to understand the efficacy and optimum doses. The use and doses have been extrapolated from human use; therefore, titrate the dose for each individual patient based on clinical response. 514    Levofloxacin Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tLevodopa\\tis\\tavailable\\tin\\t100-\\t,\\t250-\\t   ,\\tand\\t500-\\tmg\\ttablets\\tor\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Levodopa is slightly soluble in water but more soluble in acid solutions. It is rapidly oxidized with exposure to air, which is indicated by a darkening of the formulation. Injectable solutions have been prepared extemporaneously and found to be stable for 96\\thours.","original_category":"Dopamine agonist"},{"name":"Lithium Carbonate","active_ingredient":"Lithium Carbonate","species":["Canine","Feline"],"dosage":"DogsCats \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO. \\t\u2022\\t\\tNot\\trecommended.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\tis\\tavailable. L Lomustine 529 Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Lomustine loe- mus\u2032teen Trade and other names: CeeNU and CCNU","contraindications":"Contraindications and Precautions Not recommended in cats. Drug Interactions No drug interactions are reported.","indications":"Indications and Clinical Uses In people, lithium is used for treatment of depression. It has not been used for this purpose in animals. It has also been used experimentally to increase neutrophil counts after cancer therapy and to prevent cytotoxicity caused from anticancer drugs. This is also an uncommon use in animals and has not been studied with well- controlled clinical trials. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include nephrogenic diabetes insipidus, ptyalism, lethargy, and seizures. In people, cardiovascular problems, drowsiness, and diarrhea are among the adverse effects.","notes":"Instructions for Use Use in animals is uncommon, and little dosing information is available. The doses and intervals listed are extrapolated from the human use or limited clinical observations. Patient Monitoring and Laboratory Tests Monitor neutrophil count. Formulations \u2022\\t\\tLithium\\tis\\tavailable\\tin\\t150-\\t,\\t300-\\t   ,\\tand\\t600-\\tmg\\tcapsules;\\t300-\\tmg\\ttablets;\\tand\\t300- mg/5 mL syrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Immunostimulant"},{"name":"Lomustine","active_ingredient":"Lomustine","species":["Feline","Canine"],"dosage":"been well tolerated in cats. At dosages of approximately 10 mg per cat every 3 weeks, it produces minimal myelosuppression. The commercial formulations of Lomustine made for people may be unavailable. Therefore, veterinarians have resorted to using compounded formulations for use in animals. Precautionary Information  Dogs \u2022\\t\\t70\u201390\\tmg/m 2 every\\t4\\tweeks\\tPO. \u2022\\t\\tLymphoma:\\t60\\tmg/m 2 every 4 weeks for four treatments. \u2022\\t\\tBrain\\ttumors:\\t60\u201380\\tmg/m 2 every\\t6\u20138\\tweeks\\tPO. \u2022\\t\\tWhere\\tliver\\tinjury\\tis\\ta\\tconcern\\tin\\tdogs,\\tuse\\ta\\tlower\\tand\\tsafer\\tdose\\tof\\t40\\tmg/m 2 . Cats \u2022\\t\\t50\u201360\\tmg/m 2 every\\t3\u20136\\tweeks\\tPO.\\tAlternatively,\\tadminister\\t10\u201320\\tmg/cat\\tevery 3\u20136 weeks.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. In cats, neutropenia is the most dose- limiting effect of treatment. Thrombocytopenia also is possible. Cats resemble people in that bone marrow nadir of toxicity occurs at 3\u20134 weeks. Nitrosoureas also can be toxic to the rapidly dividing cells of mucosal tissues. In people, nitrosoureas also have caused pulmonary fibrosis and hepatotoxicity, but this has not been a reported problem in dogs or cats. Hepatotoxicity can occur as a delayed reaction. In people, carmustine (BCNU) has been associated with a higher rate of hepatic injury than lomustine, but hepatic injury has been observed in dogs from lomustine and has been irreversible.","contraindications":"Contraindications and Precautions Consider the risks to bone marrow with use in small animals. Commercial forms may no longer be available, and veterinarians may need to rely on compounded forms. However, compounded formulations have been known to be highly variable in potency compared with brand name formulations, and one should select a reputable compounding pharmacy to ensure high quality of the formulation. Drug Interactions Use with caution with any drugs that may cause bone marrow suppression. L Loperamide Hydrochloride 531 Regulatory Information Do not administer to animals that produce food. Loperamide Hydrochloride loe- pare\u2032ah- mide  hye- droe- klor\u2032ide Trade and other names: Imodium and generic brands","indications":"Indications and Clinical Uses Lomustine (CCNU) is used to treat tumors of the CNS (brain tumors), round cell tumors, mast cell tumors, sarcomas, and lymphoma in dogs and cats. It has occasionally been used to treat other forms of cancer, such as mast cell tumors. Lomustine has been used more often than carmustine. The use is based primarily on empirical evidence and small observational studies. It has the advantage of good oral absorption, and in dogs, it is used as an oral treatment for various cancers. It has also","side_effects":"Adverse Reactions and Side Effects Bone marrow effects are the most serious. In people, lomustine has a delayed nadir of bone marrow toxicity, which is as long as 4\u20136 weeks with slow recovery, but in dogs, the nadir of bone marrow effects generally is seen 6\u20137 days after dosing.\\tThe\\tmaximum\\ttolerated\\tdose\\tin\\tdogs\\tis\\t90\\tmg/m 2 . At higher doses (100 mg/m 2 ), myelosuppression has been reported. Thrombocytopenia also has been reported from lomustine administration as a cumulative effect. If severe neutropenia is observed in dogs, lower the dose to 40\u201350 mg/m 2 .","notes":"Instructions for Use The nitrosourea drugs are used to treat CNS tumors and other forms of cancer. Protocols used in small animals are different from those given to people, which are as high as 150\u2013200 mg/m 2 .\\tOral\\ttreatment\\tshould\\tbe\\tgiven\\ton\\tan\\tempty\\tstomach\\tif\\tpossible. Patient Monitoring and Laboratory Tests Monitor CBC and liver enzymes in treated patients. Formulations \u2022\\t\\tLomustine\\twas\\tavailable\\tin\\t10-\\t,\\t40-\\t  ,\\tand\\t100-\\tmg\\tcapsules.\\tHowever,\\tcommercial forms may be unavailable, and veterinarians have used compounded formulations. Caution is advised when using compounded forms because they have varied greatly in potency, with some (5- mg capsules) as low as 50% of the stated strength and may not produce the desired therapeutic effects. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"MCT Oil","active_ingredient":"MCT Oil","species":["Not specified in source"],"dosage":"\u2022\\t\\t1\u20132\\tmL/kg/day\\tin\\tfood.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Mebendazole meh- ben\u2032dah- zole Trade and other names: Telmintic, Telmin, Vermox (human preparation), and generic brands","contraindications":"Contraindications and Precautions No contraindications reported. Drug Interactions No drug interactions reported.","indications":"Indications and Clinical Uses Medium-\\tchain\\ttriglyceride\\toil\\tis\\tused\\tto\\ttreat\\tlymphangiectasia\\tand\\tas\\ta\\tcomponent\\tof enteral feeding formulas. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects not reported in veterinary medicine. It may cause diarrhea in some patients.","notes":"Instructions for Use Results\\tof\\tclinical\\ttrials\\tusing\\tMCT\\toil\\thave\\tnot\\tbeen\\treported.\\tMany\\tenteral\\tfeeding formulas\\tcontain\\tMCT\\toil\\t(many\\tpolymeric\\tformulations). Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMCT\\toil\\tis\\tavailable\\tas\\tan\\toral\\tliquid. Masitinib Mesylate 554    Mebendazole Stability and Storage Store in a tightly sealed container, protected from light, at room temperature, and in a cool place. Do not store in a plastic container. It may be mixed with fruit juices or food products prior to administration.","original_category":"Nutritional supplement"},{"name":"Meclofenamate Sodium and Meclofenamic Acid","active_ingredient":"Meclofenamate Sodium and Meclofenamic Acid","species":["Canine","Equine","Feline"],"dosage":"Dogs \u2022\\t\\t1.1\\tmg/kg/day\\tfor\\tup\\tto\\t5\\tdays\\tPO.  Horses \u2022\\t\\t2.2\\tmg/kg\\tq24h\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t4 Medetomidine Hydrochloride meh- deh- toe\u2032mih- deen  hye- droe- klor\u2032ide Trade and other names: Domitor","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\tto\\tanimals\\tprone\\tto\\tGI\\tulcers.\\tDo\\tnot\\tadminister\\twith\\tother ulcerogenic\\tdrugs\\tsuch\\tas\\tcorticosteroids.\\tThe\\toriginal\\tapproved\\tlabeling\\tfor animals\\tlimited\\tthe\\tduration\\tof\\ttreatment\\tto\\t5\u20137\\tdays. Drug Interactions Like\\tother\\tNSAIDs,\\tulcerogenic\\teffects\\tare\\tpotentiated\\twhen\\tadministered\\twith corticosteroids. Meclofenamic acid, like other NSAIDs, may interfere with the action of\\tdiuretics,\\tsuch\\tas\\tfurosemide,\\tand\\tangiotensin-\\tconverting\\tenzyme\\tinhibitors.","indications":"Indications and Clinical Uses Meclofenamate has been used in animals for treatment of pain and inflammation. The\\tmost\\tcommon\\tuse\\thas\\tbeen\\tmusculoskeletal\\tinflammation.\\tThis\\tis\\tan\\tolder NSAID\\tand\\tis\\tno\\tlonger\\tmarketed\\tin\\tmany\\tcountries.\\tTherefore,\\tthe\\tuse\\tin\\tanimals has diminished because of decreased availability and increased popularity of other drugs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not well known in animals because of infrequent use, but adverse\\teffects\\tcommon\\tto\\tother\\tNSAIDs\\tare\\tpossible.\\tThese\\tside\\teffects\\tare generally\\tGI\\tin\\tnature\\t(e.g.,\\tgastritis,\\tgastric\\tulcers).","notes":"Instructions for Use Most of the experience with meclofenamate has been with horses. Commercial formulations\\tare\\tno\\tlonger\\tmarketed\\tfor\\tanimals\\tin\\tthe\\tUnited\\tStates.\\tIf\\tit\\tis\\tavailable, administer with food. Patient Monitoring and Laboratory Tests Monitor\\tfor\\tsigns\\tof\\tGI\\tulceration\\tduring\\tuse. Formulations \u2022\\t\\tMeclofenamate\\thas\\tbeen\\tavailable\\tin\\t50-\\t\\tand\\t100-\\tmg\\tcapsules,\\tbut\\tthese\\tare\\trarely available commercially any longer. \u2022\\t \\t10-\\t\\tand\\t20-\\tmg\\ttablets\\t(formulation\\tfor\\tdogs)\\tand\\tgranules\\tfor\\thorses (5%\\tmeclofenamic\\tacid).\\tNeither\\tof\\tthese\\tforms\\tmay\\tbe\\tavailable\\tin\\tmost countries. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. 558    Medetomidine Hydrochloride","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Meloxicam","active_ingredient":"Meloxicam","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\t0.2\\tmg/kg\\tinitial\\tloading\\tdose\\tPO,\\tSQ,\\tor\\tIV\\tand\\tthen\\t0.1\\tmg/kg\\tq24h\\tthereafter PO, SQ, or IV. \u2022\\t\\tOral\\ttransmucosal\\tspray\\t(bioequivalent\\tto\\toral\\tsuspension):\\t0.1\\tmg/kg\\tsprayed\\tin the\\tdog\u2019s\\tmouth\\tonce\\tper\\tday. Cats \u2022\\t\\t0.05\\tmg/kg\\tq24h\\tPO,\\twith\\ta\\treduction\\tin\\tdose\\tif\\tchronic\\ttreatment\\tis\\tpursued. Long-\\t   term\\ttreatment\\tmay\\tbe\\treduced\\tto\\t0.03\\tmg/kg\\tq24h\\tor\\t0.05\\tmg/kg\\tq48h to\\t0.05\\tmg/kg\\tq72h\\tPO. \u2022\\t \\tSingle\\tdoses\\tof\\t0.15\u20130.3\\tmg/kg\\tSQ\\tmay\\tbe\\tadministered\\tfor\\tshort-\\tterm\\tuse.\\tThe manufacturer does not recommend a second dose of meloxicam injection to cats.  Pigs \u2022\\t\\t0.4\\tmg/kg\\tIM,\\twhich\\tmay\\tbe\\trepeated\\tin\\t24\\thours. Cattle \u2022\\t\\t0.5\\tmg/kg\\tq24h\\tIV,\\tIM,\\tor\\tSQ. Sheep and Small Ruminants \u2022\\t\\t1\\tmg/kg,\\tsingle\\tdose,\\tIV,\\tIM,\\tSQ,\\tor\\tPO. Horses \u2022\\t\\t0.6\\tmg/kg\\tq24h\\tIV\\tor\\tPO.\\tIn\\tfoals\\tyounger\\tthan\\t7\\tweeks\\tof\\tage,\\tthe\\tfrequency may\\tbe\\tincreased\\tto\\t0.6\\tmg/kg\\tq12h\\tbecause\\tof\\tmore\\trapid\\tclearance.\\tThe M Melphalan 569 various oral dose forms for horses (tablets, suspension, granules, paste) can be used interchangeably\\twith\\tsimilar\\tresults\\tThe\\toral\\tdose\\tfor\\thorses\\tmay\\tbe\\tadministered with or without food or with molasses without affecting oral absorption. Regulatory Information Recommended\\twithdrawal\\ttime\\tfor\\tracing\\thorses\\tis\\t3\\tdays\\tfor\\turine\\ttesting.\\tIn countries where meloxicam is approved for food animals, the withdrawal times are 15\\tdays\\tfor\\tmeat\\tand\\t5\\tdays\\tfor\\tmilk\\tat\\ta\\tdose\\tof\\t0.5\\tmg/kg\\tIM,\\tSQ,\\tor\\tIV.\\tThe Canadian\\twithdrawal\\ttimes\\tare\\t20\\tdays\\tfor\\tmeat,\\tand\\t96\\thours\\tfor\\tmilk. In\\tthe\\tUnited\\tStates,\\tFARAD\\t(www.FARAD.org)\\trecommends\\ta\\t21-\\tday\\twithdrawal time\\tafter\\toral\\tadministration\\t(single\\tdose)\\tand\\t30\\tdays\\twhen\\tmultiple\\tdoses\\tare administered.\\tWithdrawal\\ttime\\tfor\\tmilk\\tis\\t3.5\u20136\\tdays,\\tdepending\\ton\\tthe\\tstudy\\tand country of approval. RCI\\tClassification:\\t3 Melphalan mel\u2032fah- lan Trade and other names: Alkeran","contraindications":"Contraindications and Precautions Dogs\\tand\\tcats\\twith\\tpre-\\texisting\\tGI\\tproblems\\tor\\tkidney\\tdisease\\tmay\\tbe\\tat\\ta\\tgreater\\trisk of\\tadverse\\teffects\\tfrom\\tNSAIDs.\\tHowever,\\tat\\ta\\tdosage\\tof\\t0.02\\tmg/kg/day,\\tlong- term\\tuse\\tin\\tcats\\tdid\\tnot\\tcause\\tdeterioration\\tof\\trenal\\tdisease\\tin\\tcats\\twith\\tpre-\\texisting kidney disease. Safety in pregnant animals is not known, but adverse effects have not been\\treported.\\tThe\\toral\\tmeloxicam\\tsolution\\tof\\tmeloxicam\\tcontains\\txylitol.\\tXylitol\\tis an artificial sweetener that can be toxic to dogs and can produce hypoglycemia and liver\\tinjury\\twith\\thigh\\tdoses\\texceeding\\t0.1\\tg/kg.\\tWith\\tapproved\\tdoses\\tof\\tmeloxicam oral solution, the toxic level of xylitol is not likely to be exceeded, but one should be cautious about adding other drugs that also contain xylitol. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have\\tbeen\\tshown\\tto\\texacerbate\\tthe\\tGI\\tadverse\\teffects.\\tSome\\tNSAIDs\\tmay interfere\\twith\\tthe\\taction\\tof\\tdiuretic\\tdrugs\\tand\\tACE\\tinhibitors.","indications":"Indications and Clinical Uses Meloxicam is used to decrease pain, inflammation, and fever. It has been used for the acute and chronic treatment of pain and inflammation in dogs and cats. One of the most common uses is osteoarthritis, but it has also been used for pain associated with surgery.\\tBoth\\tacute\\tand\\tlong-\\tterm\\tsafety\\tand\\tefficacy\\thave\\tbeen\\testablished\\tfor\\tdogs. In\\tstudies\\tperformed\\tin\\tdogs,\\thigher\\tdoses\\t(up\\tto\\t0.5\\tmg/kg)\\twere\\tmore\\teffective than\\tlower\\tdoses\\tbut\\talso\\twere\\tassociated\\twith\\ta\\thigher\\tincidence\\tof\\tGI\\tadverse effects. The\\tinitial\\tlabeling\\tin\\tthe\\tUnited\\tStates\\tis\\tlimited\\tto\\teither\\tshort-\\tterm\\tuse,\\tbut long-\\t  term\\tuse\\tat\\tlow\\tdoses\\thas\\tbeen\\testablished\\tthrough\\tapproval\\tin\\tother\\tcountries and consensus guidelines from feline medicine experts. In cats, meloxicam has comparable, and even superior, effectiveness compared with butorphanol for treating pain associated with surgery. Acute response to treating fever in cats also has been demonstrated. In\\tEuropean\\tcountries,\\tit\\tis\\tregistered\\tfor\\tuse\\tin\\thorses,\\tpigs,\\tand\\tcattle,\\tbut\\tin the\\tUnited\\tStates,\\tthis\\tis\\tan\\textralabel\\tuse.\\tIn\\tpigs,\\tmeloxicam\\tis\\teffective\\tfor\\tMMA syndrome. In horses, meloxicam is effective for treating pain and inflammation associated\\twith\\tsurgery.\\tA\\tdosage\\tof\\t0.6\\tmg/kg\\tper\\tday\\tto\\thorses\\tfor\\tlong\\tperiods\\t(6 weeks) is well tolerated and produces plasma drug concentrations in the therapeutic range. In the countries where it is approved, the accepted use is adjunctive therapy of acute respiratory disease, diarrhea, and acute mastitis. It has also been effective to decrease discomfort associated with dehorning procedures in cattle. Meloxicam also is used extralabel in many exotic and zoo animals, including reptiles and birds, for treatment of pain and inflammation. M Precautionary Information","side_effects":"Adverse Reactions and Side Effects Major\\tadverse\\teffects\\tare\\tGI,\\tincluding\\tvomiting,\\tdiarrhea,\\tand\\tulceration. Because\\tmeloxicam\\tappears\\tto\\tbe\\trelatively\\tCOX-\\t1\\tsparing,\\tadverse\\teffects\\tare expected to be less than other NSAIDs that are not as selective. However, this property has not been demonstrated on controlled clinical trials and may be dependent\\ton\\tdose\\tand\\tspecies.\\tKidney\\tinjury,\\tespecially\\tin\\tdehydrated\\tanimals\\tor animals\\twith\\tpre-\\texisting\\trenal\\tdisease,\\thas\\tbeen\\tshown\\tfor\\tsome\\tNSAIDs.\\tKidney injury\\thas\\tbeen\\treported\\tin\\tdogs\\tfrom\\tdoses\\tof\\t0.3\u20130.5\\tmg/kg\\tand\\thigher.\\tGI ulceration has been observed when dogs were administered doses higher than approved doses. In cats at high doses (five times the dose), vomiting and other GI\\tproblems\\twere\\treported.\\tWith\\trepeated\\tdoses\\t(9\\tdays)\\tof\\t0.3\\tmg/kg/day\\tto cats,\\tinflamed\\tGI\\tmucosa\\tand\\tulceration\\twere\\tobserved.\\tAt\\ta\\tlower\\tdose\\tof\\t0.05 mg/kg\\tin\\tcats,\\tthere\\twere\\tnot\\tchanges\\ton\\tplatelet\\taggregation.\\tKidney\\tinjury\\thas been observed in cats, particularly when high doses were administered repeatedly or when administered at lower doses to dehydrated cats. However, there is no evidence\\tthat\\twell-\\thydrated\\tcats\\twith\\tkidney\\tdisease\\tare\\tmore\\tdependent\\ton renal prostaglandins to maintain kidney perfusion; therefore, meloxicam may be administered to these cats at low doses if hydration is maintained. At\\tthe\\trecommended\\tdose\\tof\\t0.6\\tmg/kg\\tto\\thorses,\\tit\\thas\\tbeen\\twell\\ttolerated, but\\tat\\thigh\\tdoses\\tto\\thorses\\t(3\u20135\\ttimes\\tthe\\trecommended\\tdose),\\tthere\\twere decreased\\tprotein,\\tGI\\tinjury,\\tand\\tkidney\\tinjury.","notes":"Instructions for Use The\\tliquid\\tmedication\\tmay\\tbe\\tadded\\tto\\tfood\\tfor\\tdosing.\\tWhen\\tusing\\tthe\\tveterinary liquid\\tformulation,\\tthe\\tdropper\\tbottle\\tfor\\tthe\\t1.5-\\tmg/mL\\tsuspension\\tis\\tdesigned\\tto deliver\\t0.05\\tmg\\tper\\tdrop\\tor\\t1\\tdrop\\tper\\tpound\\tbody\\tweight\\t(2\\tdrops\\tper\\tkilogram body\\tweight).\\tObserve\\tthe\\tmanufacturer\u2019s\\tinstructions\\twhen\\tusing\\tdosing\\tsyringes supplied with products. Some veterinarians have used the human generic tablets for administration to horses\\tand\\tdogs.\\tThe\\thuman\\tformulation\\thas\\tbeen\\tshown\\tto\\tbe\\tabsorbed\\tto\\tthe\\tsame extent as the veterinary formulations. However, caution is advised when administering the\\toral\\thuman\\ttablets\\tto\\tdogs.\\tThe\\ttablet\\tsize\\t(7.5\\tmg)\\tis\\tmuch\\tlarger\\tthan\\tthe highest dose that should be administered to most dogs. Administration\\tto\\tcats\\tin\\tthe\\tUnited\\tStates\\tis\\tonly\\tapproved\\tas\\ta\\tsingle\\tdose\\tof\\t0.3 mg/kg.\\tHowever,\\tlong-\\tterm\\tuse\\tat\\t0.05\\tmg/kg\\tq24h\\tPO\\thas\\tbeen\\tapproved\\tfor\\tcats in\\tother\\tcountries\\tfor\\tprolonged\\tuse,\\tand\\tlow\\tdoses\\tof\\t0.01\u20130.03\\tmg/kg\\tq24h\\thave been administered safely to older cats with kidney disease. Patient Monitoring and Laboratory Tests Monitor\\tGI\\tsigns\\tfor\\tevidence\\tof\\tdiarrhea,\\tGI\\tbleeding,\\tor\\tulcers.\\tBecause\\tof\\tthe risk of renal injury, monitor renal parameters (water consumption, blood urea nitrogen,\\tcreatinine,\\tand\\turine-\\tspecific\\tgravity)\\tperiodically\\tduring\\ttreatment.\\tPlasma concentration are usually not measured during treatment, but effective concentrations are\\tin\\tthe\\trange\\tof\\t0.13\u20130.27\\tmcg/mL. Formulations \u2022\\t\\tMeloxicam\\tis\\tavailable\\tin\\t0.5-\\tmg/mL\\t(0.02\\tmg\\tper\\tdrop)\\toral\\tsuspension,\\t1.5- mg/mL\\t(0.05\\tmg\\tper\\tdrop)\\toral\\tsuspension,\\tand\\t0.5%\\t(5-\\tmg/mL)\\tinjection. \u2022\\t\\tAn\\toral\\ttransmucosal\\tis\\tavailable\\tas\\ta\\tspray\\tusing\\tthe\\tPromist\\ttechnology.\\tThe\\tspray is\\tavailable\\tin\\tthree\\tsizes:\\t0.25\\tmg,\\t0.5\\tmg,\\tand\\t1.075\\tmg\\tper\\tspray. \u2022\\t\\tIn\\tEurope,\\t1.0-\\t\\tand\\t2.5-\\tmg/kg\\ttablets\\tare\\tavailable\\tfor\\tdogs,\\tand\\ta\\t15-\\tmg/mL oral suspension is available for horses. \u2022\\t\\tLarge\\tanimals:\\tIn\\tcountries\\tother\\tthan\\tthe\\tUnited\\tStates,\\tthere\\tis\\ta\\t50-\\tmg/g\\toral paste\\tavailable\\tfor\\thorses,\\ta\\t20-\\tmg/mL\\tinjectable\\tsolution,\\tand\\tgranules\\tfor\\thorses in\\ta\\t330\\tmg\\tper\\tsachet\\tfor\\toral\\tadministration. \u2022\\t\\tHuman-\\tlabel\\ttablets:\\t7.5-\\t\\tand\\t15-\\tmg\\ttablets\\t(generic)\\tand\\t5-\\t\\tand\\t10-\\t\\tmg\\tcapsules (Vivlodex). Stability and Storage Meloxicam\\thas\\tbeen\\tcompounded\\twith\\twater,\\t1%\\tmethylcellulose\\tgel,\\tand\\tsimple syrup or a suspending and flavoring vehicle in a ratio of 1:1 at concentrations of 0.25,\\t0.5,\\tand\\t1.0\\tmg/mL.\\tThese\\tformulations\\twere\\tstable\\tfor\\t28\\tdays\\tat\\troom temperature or under refrigeration.","original_category":"Anti- inflammatory"},{"name":"Melphalan","active_ingredient":"Melphalan","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t1.5\\tmg/m 2 (or\\t0.1\u20130.2\\tmg/kg)\\tq24h\\tPO\\tfor\\t7\u201310\\tdays\\t(repeat\\tevery\\t3\\tweeks)\\tor administer\\t7\\tmg/m 2 q24h\\tPO\\tfor\\t5\\tdays.\\tRepeat\\tthis\\tcycle\\tevery\\t21\\tdays. \u2022\\t\\tInjectable\\tforms\\thave\\tnot\\tbeen\\tused\\tin\\tanimals,\\tbut\\tin\\thumans,\\t16\\tmg/m 2 IV over 15\u201320\\tminutes\\thas\\tbeen\\tused\\tat\\t2-\\tweek\\tintervals\\tfor\\tmultiple\\tmyeloma. Cats \u2022\\t\\t2\\tmg\\tper\\tcat\\tPO\\t(equivalent\\tto\\t0.1\\tmg/kg\\tper\\tday).\\tThe\\tinterval\\tused\\thas\\tvaried for\\ttreatment\\tof\\tmultiple\\tmyeloma\\tfrom\\tevery\\t2\\tdays,\\tup\\tto\\tevery\\t7\\tdays.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tThis\\tdrug\\tshould not be used in animals intended for food because it is an anticancer agent. Meperidine Hydrochloride meh- pare\u2032ih- deen  hye- droe- klor\u2032ide Trade and other names: Demerol and Pethidine (European name)","contraindications":"Contraindications and Precautions Do not use in animals with bone marrow suppression. Drug Interactions No drug interactions are reported. It has been used with other anticancer drug protocols.","indications":"Indications and Clinical Uses Melphalan is not used as an anticancer agent as frequently as other alkylating agents. In animals, the most common use is to treat multiple myeloma and certain carcinomas. It has been used in dogs for refractory cases of lymphoma, in combination with prednisone. For canine multiple myeloma, the treatment of choice is a combination of melphalan and prednisone. For cats, the treatment is a combination of melphalan and prednisolone. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to its action as an anticancer agent. Melphalan causes myelosuppression, with neutropenia being the most common.","notes":"Instructions for Use Consult specific anticancer drug protocols for more dosing information. 570    Meperidine Hydrochloride Patient Monitoring and Laboratory Tests Monitor complete blood count (CBC) for evidence of bone marrow toxicity. Formulations Available \u2022\\t\\tMelphalan\\tis\\tavailable\\tin\\t2-\\tmg\\ttablets\\tand\\t50-\\tmg\\tvials\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is insoluble in water but is soluble in ethanol. After reconstitution, decomposition occurs\\trapidly\\tand\\tmay\\tprecipitate.\\tUse\\twithin\\t1\\thour\\tof\\treconstitution.\\tWhen prepared in a compounded formulation for oral use, it was unstable with rapid decomposition\\t(80%\\tloss\\tin\\t24\\thours).","original_category":"Anticancer agent"},{"name":"Mercaptopurine","active_ingredient":"Mercaptopurine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t50\\tmg/m 2 q24h\\tPO. Cats \u2022\\t\\tContraindicated.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tThis\\tdrug\\tshould not be used in animals intended for food because it is an anticancer agent. Meropenem meer- oh- pen\u2032em Trade and other names: Merrem","contraindications":"Contraindications and Precautions Do not use in animals with known sensitivity to azathioprine. Do not administer to cats. Drug Interactions No drug interactions are reported. It has been used with other anticancer drug protocols.","indications":"Indications and Clinical Uses Mercaptopurine has been used for various forms of cancer, including leukemia and lymphoma. Because of availability of other agents and lack of studies to evaluate protocols using mercaptopurine, it is infrequently used in veterinary medicine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Many side effects are possible that are common to anticancer therapy (many of which are unavoidable), including bone marrow suppression and anemia.","notes":"Instructions for Use Consult the specific anticancer protocol for specific regimen. 574    Meropenem Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow toxicity. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is prone to oxidation if mixed with alkaline solutions. pH of solutions should be below\\t8.\\tIf\\tmixed\\twith\\toral\\tvehicles,\\tsuch\\tas\\tsyrups,\\tit\\tis\\tstable\\tfor\\t14\\tdays.","original_category":"Anticancer agent"},{"name":"Mesalamine","active_ingredient":"Mesalamine","species":["Feline"],"dosage":"\u2022\\t\\tVeterinary\\tdoses\\thave\\tnot\\tbeen\\testablished.\\tThe\\tusual\\thuman\\tdosage\\tis\\t400\u2013500 mg\\tq6\u20138h\\tPO,\\tand\\tit\\thas\\tbeen\\tused\\tto\\textrapolate\\tan\\tanimal\\tdosage\\t(e.g.,\\t5\u201310 mg/kg\\tq8h\\tPO).  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. RCI\\tClassification:\\t5 Metaflumizone met- ah\u2032floo- mah- zone Trade and other names: ProMeris","contraindications":"Contraindications and Precautions Drug interactions are possible, but they have not been reported in animals, probably because low systemic drug levels are achieved. Mesalamine, if absorbed sufficiently, can potentially interfere with thiopurine methyltransferase and therefore increase the risk of toxicity from azathioprine. Drug Interactions No drug interactions are reported in animals. Omeprazole can potentially increase absorption by increasing intestinal pH.","indications":"Indications and Clinical Uses Mesalamine is used for treatment of inflammatory bowel disease, including colitis, in animals. Most often sulfasalazine is used; however, in some animals, especially those sensitive\\tto\\tsulfonamides,\\tmesalamine\\tmay\\tbe\\tindicated.\\tUse\\tin\\tanimals\\thas\\tbeen primarily derived from empirical use, anecdotal experience, and recommendations from\\tclinical\\texperts.\\tThere\\tare\\tno\\twell-\\tcontrolled\\tclinical\\tstudies\\tor\\tefficacy\\ttrials\\tto document clinical effectiveness. M Metaflumizone 577 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Mesalamine alone has not been associated with side effects in animals. Adverse effects associated with sulfasalazine are caused by the sulfonamide component. (See Sulfasalazine for more information.)","notes":"Instructions for Use Mesalamine usually is used as a substitute for sulfasalazine in animals that cannot tolerate sulfonamides. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMesalamine\\tis\\tavailable\\tin\\t400-\\tmg\\ttablets\\tand\\t250-\\tmg\\tcapsules.\\tDelayed-\\trelease tablets\\tare\\t400\\tmg\\t(Asacol)\\tand\\t1.2\\tg\\t(film-\\tcoated\\tLialda).\\tControlled-\\trelease capsules\\tare\\t250\\tand\\t500\\tmg\\t(ethylcellulose-\\tcoated\\tPentasa). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is slightly soluble in water and ethanol. It should be protected from air and moisture. Darkening may occur after exposure to air. Do not crush coated tablets.","original_category":"Antidiarrheal"},{"name":"Metaproterenol Sulfate","active_ingredient":"Metaproterenol Sulfate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.325\u20130.65\\tmg/kg\\tq4\u20136h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported.\\tThere\\tis\\tno\\tevidence\\tof\\toral\\tabsorption in large animals. Regulatory Information Do not administer to animals that produce food. Other beta agonists (clenbuterol) are banned for use in food animals. RCI\\tClassification:\\t3 Metformin met- for\u2032min Trade and other names: Glucophage","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tcardiac\\tdisease\\tthat\\tmay\\tbe\\tprone\\tto\\trapid\\theart rates or arrhythmias. Drug Interactions Do\\tnot\\tadminister\\twith\\tMAOIs.\\tUse\\tcautiously\\twith\\tother\\tdrugs\\tthat\\tmay cause cardiac arrhythmias in animals. It may be mixed with cromolyn sodium for\\tnebulization\\tif\\tused\\twithin\\t60\u201390\\tminutes.\\tIt\\talso\\thas\\tbeen\\tcombined\\twith dexamethasone without loss of stability.","indications":"Indications and Clinical Uses Metaproterenol has been used in animals to relax bronchial smooth muscle to treat bronchitis, obstructive pulmonary disease, airway obstruction caused by inflammation, and other airway diseases. It is indicated in animals with reversible bronchoconstriction,\\tsuch\\tas\\tcats\\twith\\tbronchial\\tasthma.\\tUse\\tin\\tanimals\\thas\\tbeen primarily\\tderived\\tfrom\\tempirical\\tuse\\tand\\tanecdotal\\texperiences.\\tThere\\tare\\tno\\twell- controlled clinical studies or efficacy trials to document clinical effectiveness. Other selective beta 2 agonists are used more often in animals, such as albuterol, delivered with an inhaler, or oral forms. Beta 2 agonists also have been used in people to delay labor (inhibit uterine contractions), but this use has not been explored in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Metaproterenol\\tcauses\\texcessive\\tbeta-\\tadrenergic\\tstimulation\\tat\\thigh\\tdoses (tachycardia and tremors) because of excessive beta 1 -\\tadrenergic\\tstimulation. Arrhythmias occur at high doses or in sensitive individuals. Beta agonists inhibit uterine contractions in animals in labor.","notes":"Instructions for Use Results\\tof\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals\\t(and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm of animals during treatment. M Metformin 579 Formulations \u2022\\t\\tMetaproterenol\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg\\ttablets,\\t5-\\tmg/mL\\tsyrup,\\tand inhalers. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Avoid exposure to air and moisture. Do not freeze. Do not use if formulation turns dark color.","original_category":"Bronchodilator, beta- agonist"},{"name":"Metformin","active_ingredient":"Metformin","species":["Feline","Equine"],"dosage":"Cats \u2022\\t\\t25\\tor\\t50\\tmg/cat\\tq12h\\tPO\\t(5\u201310\\tmg/kg\\tq12h).\\t(Efficacy\\tis\\tlimited.)  \u2022\\t\\tBecause\\tof\\thigh\\tclearance\\tand\\tpoor\\tbioavailability\\tin\\thorses\\t(4%\u20137%),\\tits\\tuse\\tis\\tnot recommended. Regulatory Information Do not administer to animals intended for food. M Methadone Hydrochloride 581 Methadone Hydrochloride meth\u2032ah- done  hye- droe- klor\u2032ide Trade and other names: Dolophine, Methadose, and generic brands","contraindications":"Contraindications and Precautions Metformin is cleared by the kidneys, so doses need to be adjusted in patients with renal failure. Drug Interactions Use\\tcautiously\\twith\\tdrugs\\tthat\\tmay\\taffect\\tglycemic\\tcontrol\\tsuch\\tas glucocorticoids.","indications":"Indications and Clinical Uses In\\tpeople,\\tmetformin\\tis\\tone\\tof\\tthe\\tmost\\tcommon\\tdrugs\\tused\\tto\\ttreat\\ttype\\t2\\tdiabetes, or for early stages of prediabetes. It has been used in people when the sulfonylurea drugs fail. It has been used in cats to treat diabetes. However, in cats treated with 50\\tmg/cat\\tq12h\\tPO,\\tit\\tshowed\\tsignificant\\tadverse\\teffects\\tand\\twas\\teffective\\tin only one fifth of treated cats. In cats, it has been more common to administer the sulfonylurea class of drugs if oral treatments are used instead of insulin injection. Sulfonylurea\\tdrugs\\tinclude\\tglipizide\\t(Glucotrol)\\tand\\tglyburide\\t(DiaBeta,\\tMicronase). Dogs with diabetes rarely respond to oral hypoglycemic agents, and metformin is not recommended for dogs. Metformin has been considered for treatment of insulin resistance in horses and ponies, but the bioavailability is very low in horses compared with that of humans. It may have shown temporary effects in some horses, but overall efficacy\\tis\\tlow,\\tprobably\\tbecause\\tof\\tpoor\\toral\\tbioavailability.\\tTherefore,\\tthe\\tuse\\tin horses is not recommended. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Metformin has caused lethargy, appetite loss, vomiting, and weight loss in cats.\\tUse\\thas\\tnot\\tbeen\\tcommon\\tenough\\tto\\tdocument\\tother\\teffects.\\tHowever, in people, it has caused lactic acidosis in some patients, which was serious. Metformin also has caused megaloblastic anemia by affecting vitamin B 12 absorption.","notes":"Instructions for Use Doses published for cats are based on pharmacokinetic studies that demonstrated oral absorption\\tin\\tcats\\tto\\tbe\\t35%\u201370%.\\tThe\\thalf-\\tlife\\twas\\t11.5\\thours,\\twhich\\tis\\tthe\\tbasis\\tfor the\\tq12h\\tdosage\\trecommendation.\\tConsistently\\teffective\\tdoses\\tfor\\thorses\\thave\\tnot been established. Patient Monitoring and Laboratory Tests Blood glucose should be monitored carefully. Doses should be adjusted on the basis of glucose monitoring. Some animals may require insulin injections to control hyperglycemia. Formulations Available \u2022\\t\\tMetformin\\tis\\tavailable\\tin\\t500-\\t\\tand\\t850-\\tmg\\ttablets. Stability and Storage Stable if maintained in original formulation.","original_category":"Antihyperglycemic"},{"name":"Methocarbamol","active_ingredient":"Methocarbamol","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t44\\tmg/kg\\tIV\\t(moderate\\tconditions)\\tor\\t55\\tmg/kg\\tand\\tup\\tto\\t222\\tmg/kg\\tfor severe\\tconditions\\tsuch\\tas\\ttetanus\\tor\\tstrychnine\\tpoisoning.\\tThe\\ttotal\\tcumulative dose\\tshould\\tnot\\texceed\\t333\\tmg/kg.\\t(These\\tdose\\tregimens\\tare\\tbased\\ton\\tthe\\tFDA- approved label.) \u2022\\t \\tOral\\tdosage:\\t44\\tmg/kg\\tq8h\\tPO\\tfollowed\\tby\\t22\u201344\\tmg/kg\\tq8h\\tPO,\\tnot\\tto exceed\\t14\u201321\\tdays.\\t(These\\tdosage\\tregimens\\tare\\tbased\\ton\\tthe\\tFDA-\\tapproved label.) M Methohexital Sodium 591  \u2022\\t \\t4.4\u201322\\tmg/kg\\tq8h\\tIV\\tfor\\tmoderate\\tconditions\\tand\\t22\u201355\\tfor\\tmore\\tsevere conditions.\\t(These\\tdosage\\tregimens\\tare\\tbased\\ton\\tthe\\tFDA-\\tapproved\\tlabel.) In\\thorses,\\thigher\\tdoses\\tabove\\t30\\tmg/kg\\tIV\\tand\\t50\u2013100\\tmg/kg\\tPO\\thave been administered but are more likely to produce mild to moderate depression. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t4 Methohexital Sodium meth- oe- heks\u2032ih- tahl  soe\u2032dee- um Trade and other names: Brevital","contraindications":"Contraindications and Precautions Use\\tcautiously\\twith\\tother\\tdrugs\\tthat\\tdepress\\tthe\\tCNS.\\tDo\\tnot\\trely\\ton methocarbamol as a treatment for pain because it has no direct analgesic properties. Drug Interactions No drug interactions reported for animals.","indications":"Indications and Clinical Uses Methocarbamol has been used for the treatment of skeletal muscle spasms and increased\\tmuscle\\ttone.\\tMethocarbamol\\t(Robaxin)\\thas\\tUS\\tFood\\tand\\tDrug Administration\\t(FDA)\\tapproval\\tfor\\ttreating\\tdogs,\\tcats,\\tand\\thorses.\\tThe\\tlabeling indication lists for all three species lists \u201cAs an adjunct for treating acute inflammatory and traumatic conditions of the skeletal muscles and to reduce muscular spasms.\u201d Methocarbamol has also been used to treat pain that is associated with increased muscle\\tspasms\\tor\\tmyositis,\\tbut\\tit\\tdoes\\tnot\\thave\\tdirect\\tanalgesic\\teffects.\\tThe\\thighest dose listed in the dosing section are only recommended if it is used for treating tetanus or strychnine poisoning. For some indications (e.g., muscle spasms), methocarbamol has been replaced by other muscle relaxants such as orphenadrine (Norflex)\\tor\\tbenzodiazepines.\\tIn\\thorses,\\tthe\\thalf-\\tlife\\tis\\tonly\\t60\u201390\\tminutes\\tand\\tmay need frequent administration for effectiveness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Methocarbamol\\tmay\\tcause\\tdepression\\tand\\tsedation\\tof\\tthe\\tCNS.\\tExcess salivation, emesis, weakness, and ataxia have been observed from methocarbamol administration. Adverse effects are usually short in duration because of rapid elimination.","notes":"Instructions for Use Results\\tof\\trecent\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals (and doses) is based on label recommendations on the FDA approval that was established many years ago, before substantial evidence of efficacy was required. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMethocarbamol\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets\\tand\\t100-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Muscle relaxant"},{"name":"Methotrexate","active_ingredient":"Methotrexate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t2.5\u20135\\tmg/m 2 q48h\\tPO\\t(dose\\tdepends\\ton\\tspecific\\tcancer\\tprotocol). \u2022\\t\\t0.3\u20130.5\\tmg/kg\\tevery\\tweek\\tIV. Cats \u2022\\t\\t0.8\\tmg/kg\\tIV\\tevery\\t2\u20133\\tweeks.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tThis\\tdrug\\tshould not be used in animals intended for food because it is an anticancer agent. RCI\\tClassification:\\t4 594    Methoxamine Methoxamine meh- thahk\u2032seh- meen Trade and other names: Vasoxyl","contraindications":"Contraindications and Precautions Do not administer to pregnant animals. It has been used to induce abortion. Drug Interactions Concurrent use with NSAIDs may cause severe methotrexate toxicity. Do not administer with penicillins, fluoroquinolones, pyrimethamine, trimethoprim, sulfonamides, or other drugs that may affect folic acid synthesis.","indications":"Indications and Clinical Uses Methotrexate is used for various carcinomas, leukemia, and lymphomas. In people, methotrexate is also commonly used for autoimmune diseases, particularly rheumatoid\\tarthritis.\\tUse\\tin\\tanimals\\thas\\tbeen\\tprimarily\\tderived\\tfrom\\tempirical use\\tand\\texperiences\\tin\\tpeople.\\tThere\\tare\\tno\\twell-\\tcontrolled\\tclinical\\tstudies\\tor efficacy trials to document clinical effectiveness. It is rarely used to treat arthritis in animals. M Precautionary Information","side_effects":"Adverse Reactions and Side Effects The\\timportant\\tadverse\\teffects\\tin\\tanimals\\tare\\tanorexia,\\tnausea,\\tmyelosuppression, and vomiting. Anticancer drugs cause predictable (and sometimes unavoidable) side effects that include bone marrow suppression, leukopenia, and immunosuppression. Hepatotoxicity has been reported in people from methotrexate therapy, but this has not been documented in veterinary medicine. In people, higher doses are often used compared to veterinary doses. In people, risk of systemic toxicity is high, and rescue therapy with leucovorin (tetrahydrofolic\\tacid)\\tis\\toften\\tused\\t(also\\tcalled\\tcalcium\\tfolinate).\\tLeucovorin rescue therapy is used because it is an antagonist of the action of methotrexate on\\tthe\\tDHFR\\tenzyme.\\t(See\\tLeucovorin\\tfor more information.) Dose range of\\tleucovorin\\tin\\tdogs\\tis\\t25\u2013200\\tmg/m 2 every\\t6\\thours,\\tdepending\\ton\\tplasma methotrexate concentration. Another approach is to administer a dose of leucovorin that is equal to the dose of methotrexate.","notes":"Instructions for Use Use\\tin\\tanimals\\thas\\tbeen\\tbased\\tprimarily\\ton\\texperience\\tin\\tresearch\\tanimals\\tor extrapolation of the use in people. Only limited veterinary clinical information is available. Consult specific anticancer protocols for the precise dosage and regimen. Patient Monitoring and Laboratory Tests Monitor CBC for evidence of bone marrow toxicity. Formulations \u2022\\t\\tMethotrexate\\tis\\tavailable\\tin\\t2.5-\\tmg\\ttablets\\tand\\t2.5-\\t\\tand\\t25-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anticancer agent"},{"name":"Methoxamine","active_ingredient":"Methoxamine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t200\u2013250\\tmcg/kg\\t(0.2\u20130.25\\tmg/kg)\\tIM\\tor\\t40\u201380\\tmcg/kg\\tIV;\\trepeat\\tdose\\tas needed.  Cattle and Horses \u2022\\t\\t100\u2013200\\tmcg/kg\\t(0.1\u20130.2\\tmg/kg)\\tIM\\tonce\\tor\\tas\\tneeded. M Methoxyflurane 595 Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Methoxyflurane meh- thahk\u2032seh- floo\u2032rane Trade and other names: Metofane","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\theart\\tdisease. Drug Interactions Do not use with MAOIs, such as selegiline.","indications":"Indications and Clinical Uses Methoxamine is used primarily in patients in need of critical care or during anesthesia to\\tincrease\\tperipheral\\tresistance\\tand\\tblood\\tpressure.\\tThere\\tis\\tlittle\\texperience\\twith this drug in veterinary medicine. Aggressive fluid administration is the first measure considered\\twhen\\tit\\tis\\tnecessary\\tto\\tincrease\\tthe\\tpatient\u2019s\\tblood\\tpressure.\\tOther vasopressor agents are often used if necessary. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to excessive stimulation of alpha 1 receptors (prolonged peripheral\\tvasoconstriction).\\tReflex\\tbradycardia\\tmay\\toccur.","notes":"Instructions for Use Methoxamine has a rapid onset and short duration of action. Patient Monitoring and Laboratory Tests Monitor heart rate and blood pressure in treated patients. Formulations \u2022\\t\\tMethoxamine\\tis\\tno\\tlonger\\tavailable\\ton\\tthe\\tUS\\tmarket.\\tSome\\tsolutions\\thave\\tbeen compounded.\\tIt\\twas\\tpreviously\\tavailable\\tas\\ta\\t20-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Vasopressor"},{"name":"Methylene Blue 0.1%","active_ingredient":"Methylene Blue 0.1%","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t1.5\\tmg/kg\\tIV\\tonce\\tslowly.  Cattle, Goats, and Sheep \u2022\\t\\t4\u201310\\tmg/kg\\tIV\\tas\\tneeded.\\tThis\\tdose\\tof\\tmethylene\\tblue\\tshould\\tbe\\tadministered over\\t15\\tminutes.\\tAfter\\tthe\\tinitial\\tdose,\\tlower\\tdoses\\tmay\\tbe\\trepeated\\tto\\ttitrate\\tto clinical\\tresponse.\\tHigher\\tdoses\\tmay\\tbe\\trepeated\\tevery\\t6\u20138\\thours\\tif\\tneeded.\\tHigher doses\\tare\\tused\\tfor\\tsevere\\ttoxicity\\t(15\u201320\\tmg/kg). Regulatory Information Cattle\\twithdrawal\\ttime\\t(meat):\\t14\\tdays. Cattle\\twithdrawal\\ttime\\t(milk):\\t4\\tdays. Methylnaltrexone Bromide meth\u2032ihl  nal- trex- own  broe\u2032mide Trade and other names: Relistor","contraindications":"Contraindications and Precautions The\\tadministration\\tfor\\ttreating\\tintoxication\\tmay\\tproduce\\tsome\\toxidative\\tdamage to erythrocytes (Heinz bodies and other morphologic changes) that is typically subclinical, but a risk of red cell damage and subsequent anemia increases with repeated\\tor\\thigher\\tdosing.\\tUse\\tcautiously\\tin\\tcats. Drug Interactions Methylene blue is a reversible MAOI. If administered with drugs that affect serotonergic mechanisms or increase serotonin, it can lead to serotonin syndrome (muscle twitching, sweating, increased temperature, shivering).","indications":"Indications and Clinical Uses Methylene blue is used to treat methemoglobinemia caused by chlorate and nitrate toxicosis. It also has been used to treat cyanide toxicosis. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In cats and dogs, administration of methylene blue to treat methemoglobinemia can cause oxidative damage to erythrocytes, including Heinz bodies, limiting the dose that can be used therapeutically. At the doses listed later, it has been safe, but monitoring of red blood cell effects is recommended. Heinz bodies can increase in cats from methylene blue treatment without producing anemia.","notes":"Instructions for Use For administration to large animals, the formulations must be compounded by a pharmacy. Consult a reliable pharmacy for instructions. For treating acetaminophen M Methylnaltrexone Bromide 597 intoxication in cats, use acetylcysteine first because it will produce the most reliable response, but methylene blue also was helpful. Patient Monitoring and Laboratory Tests Monitor CBC in patients treated with methylene blue. Monitor mucous membrane color (methemoglobinemia turns the blood and membranes a chocolate color). Formulations \u2022\\t\\tThere\\tare\\tno\\tcommercial\\tveterinary\\tmethylene\\tblue\\tproducts\\tfor\\tsystemic\\tuse.\\tThe human\\tproduct\\t(1%\\tsolution,\\t10\\tmg/mL)\\tmay\\tbe\\tappropriate\\tfor\\tuse\\tin\\tsome species, but treatment in large animals may require a compounded formulation. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidote"},{"name":"Metoprolol Tartrate","active_ingredient":"Metoprolol Tartrate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5\u201350\\tmg\\tper\\tdog\\t(0.5\u20131\\tmg/kg)\\tq8h\\tPO. Cats \u2022\\t\\t2\u201315\\tmg\\tper\\tcat\\tq8h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t3 606    Metronidazole and Metronidazole Benzoate Metronidazole and Metronidazole Benzoate meh- troe- nye\u2032dah- zole Trade and other names: Flagyl and generic brands","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\tprone\\tto\\tbronchoconstriction. Drug Interactions Lipophilic\\tbeta\\tblockers\\tsuch\\tas\\tmetoprolol\\tare\\tsubject\\tto\\thepatic\\tmetabolism\\tand may be prone to drug interactions that affect hepatic metabolizing enzymes. If administered\\twith\\tdigoxin,\\tit\\tmay\\tpotentiate\\tan\\tAV-\\tnodal\\tconduction\\tblock.","indications":"Indications and Clinical Uses Metoprolol is used to control tachyarrhythmias and to control the response from adrenergic stimulation in animals. Beta blockers effectively slow heart rate. Metoprolol is used in animals in which it is important to control ventricular rate, decrease conduction through the atrioventricular (AV) and sinoatrial nodes, and improve diastolic function. In animals, it has been used for tachyarrhythmias, hypertrophic cardiomyopathy,\\tatrial\\tfibrillation,\\tand\\tother\\tcardiac\\tdiseases.\\tUse\\tin\\tanimals\\thas\\tbeen primarily derived from empirical use and recommendations from cardiology experts. There\\tare\\tno\\twell-\\tcontrolled\\tclinical\\tstudies\\tor\\tefficacy\\ttrials\\tto\\tdocument\\tclinical effectiveness. Atenolol is used more often for oral treatment in dogs and cats. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are primarily caused by excessive cardiovascular depression (decreased inotropic effects). Metoprolol may cause AV block.","notes":"Instructions for Use Results\\tof\\tclinical\\tstudies\\tin\\tanimals\\thave\\tnot\\tbeen\\treported.\\tUse\\tin\\tanimals\\t(and doses) is based on experience in people or anecdotal experience in animals. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. Formulations \u2022\\t\\tMetoprolol\\tis\\tavailable\\tin\\t25-\\t,\\t37.5-\\t   ,\\t50-\\t  ,\\t75-\\t  ,\\tand\\t100-\\tmg\\ttablets\\tand\\t1-\\tmg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Metoprolol tartrate is soluble in water and ethanol. Protect tablets from moisture and freezing. Suspensions have been prepared in syrups and other flavorings with no loss of\\tstability\\tafter\\t60\\tdays\\tof\\tstorage.","original_category":"Beta blocker"},{"name":"Misoprostol","active_ingredient":"Misoprostol","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t2\u20135\\tmcg/kg\\tq12h\\tPO. \u2022\\t\\tAtopic\\tdermatitis:\\t5\\tmcg/kg\\tq8h\\tPO. Cats \u2022\\t\\t2\u20134\\tmcg/kg\\tq12h\\tPO \u2022\\t\\tInduce\\tabortion:\\t200\\tmcg\\tper\\tcat\\tq12h\\tPO\\tuntil\\tabortion\\tbegins,\\tadministered with aglepristone or mifepristone. Higher doses can induce abortion when administered alone but with more frequent and more severed adverse effects.  Horses \u2022\\t\\t5\\tmcg/kg\\tq12h\\tPO. Regulatory Information Do not use in animals that produce food. RCI\\tClassification:\\t4 Mitotane mye\u2032toe- tane Trade and other names: Lysodren and op\u2019- DDD","contraindications":"Contraindications and Precautions Do not administer to pregnant animals; it may cause abortion. Women should handle this medication carefully because it can induce abortion. Drug Interactions Misoprostol\\tmay\\tcompromise\\tthe\\tacid-\\tsuppressing\\teffects\\tof\\tomeprazole,\\tso\\tthese drugs should not be used together. 622    Mitotane","indications":"Indications and Clinical Uses Misoprostol\\tis\\tused\\tto\\tdecrease\\tthe\\trisk\\tof\\tGI\\tulceration\\twhen\\tadministered concurrently\\twith\\tNSAIDs.\\tEfficacy\\thas\\tbeen\\testablished\\tfor\\tthis\\tindication\\tin\\ttrials with\\taspirin\\tbut\\tnot\\twith\\tother\\tNSAIDs\\tin\\tanimals.\\tThere\\tis\\tno\\tevidence\\tto\\tshow\\tthat it\\tdecreases\\tGI\\tbleeding\\tcaused\\tby\\tother\\tdrugs\\t(e.g.,\\tcorticosteroids).\\tClinical\\ttrials also are available to show that misoprostol is effective for treating pruritus in patients with atopic dermatitis, although it is less effective than other drugs. The\\tGI\\teffects\\tin\\thorses\\thave\\tbeen\\texplored\\tthrough\\tsmall\\tobservational\\tstudies and anecdotal accounts. Misoprostol may be helpful in horses for treating right dorsal colitis.\\tEquine\\tGI\\texperts\\tconsider\\tmisoprostol\\ta\\tvalid\\tfirst-\\tline\\toption\\tfor\\tequine glandular\\tgastric\\tdisease\\tat\\ta\\tdose\\tof\\t5\\tmcg/kg\\tPO\\tand\\twas\\tsuperior\\tto\\tomeprazole and sucralfate. However, it should not be used with omeprazole in horses or in pregnant\\tmares.\\tThe\\toptimum\\tdose\\tin\\thorses\\thas\\tnot\\tbeen\\tdetermined,\\tbut\\ta\\tdose\\tof 5\\tmcg/kg\\toral\\tproduces\\tplasma\\tdrug\\tconcentrations\\tthat\\tare\\tsimilar\\tto\\teffective\\tdoses in people. Misoprostol has been used to induce abortion, but it is much more effective when used with other agents such as aglepristone or mifepristone. In people, it is used with mifepristone. It should not be used alone to induce abortion because high doses are needed, which can increase the risk of adverse effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse\\teffects\\tare\\tcaused\\tby\\teffects\\tof\\tprostaglandins.\\tThe\\tmost\\tcommon\\tadverse effects\\tare\\tGI\\tdiscomfort,\\tvomiting,\\tand\\tdiarrhea.\\tDiarrhea\\tand\\tabdominal discomfort have been reported in horses, but these effects are usually mild and self-\\t  limiting.\\tIt\\twas\\ttolerated\\tin\\texperimental\\thorses\\tat\\ta\\tdose\\tof\\t5\\tmcg/kg\\toral.","notes":"Instructions for Use Doses and recommendations are based on clinical trials in which misoprostol was administered\\tto\\tprevent\\tGI\\tmucosal\\tinjury\\tcaused\\tby\\taspirin.\\tThese\\teffects\\tcan\\tlikely be\\textended\\tto\\tother\\tNSAIDs.\\tThe\\teffects\\tin\\thorses\\tfor\\ttreating\\tright\\tdorsal\\tcolitis\\tand equine glandular gastric disease are from observations from clinical experts. Careful handling of misoprostol should be observed because of its potential to induce abortion. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tMisoprostol\\tis\\tavailable\\tin\\t0.1-\\tmg\\t(100-\\tmcg)\\tand\\t0.2-\\tmg\\t(200-\\tmcg)\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiulcer agent"},{"name":"Mitotane","active_ingredient":"Mitotane","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tPDH:\\t50\\tmg/kg/day\\t(in\\tdivided\\tdoses)\\tPO\\tfor\\t5\u201310\\tdays;\\tthen\\t50\u201370\\tmg/kg/ wk\\tPO\\tfor\\tlong-\\tterm\\tmaintenance. \u2022\\t\\tAdrenal\\ttumor:\\t50\u201375\\tmg/kg/day\\t(in\\tdivided\\tdoses)\\tfor\\t10\\tdays;\\tthen\\tevery\\tother day\\tfor\\t40\\tdays.\\tThere\\tmay\\tbe\\tfollow-\\tup\\tmaintenance\\ttreatment\\twith\\t75\u2013100\\tmg/ kg/wk\\tPO. Cats \u2022\\t\\t25\u201350\\tmg/kg/day\\tinduction\\tfollowed\\tby\\t25\u201350\\tmg/kg/wk\\tfor\\tmaintenance. However,\\tit\\tis\\tnot\\trecommended\\tby\\tmost\\texperts\\tbecause\\tof\\tpoor\\tresponse.\\tUse trilostane instead.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Do not use in animals that produce food. Mitoxantrone Hydrochloride mye- toe- zan\u2032trone  hye- droe- klor\u2032ide Trade and other names: Novantrone","contraindications":"Contraindications and Precautions Do not administer to animals unless there is an ability to monitor response with cortisol\\tserum\\tmeasurements,\\tpreferably\\tafter\\tACTH\\tstimulation.\\tMitotane\\tcan cause cytotoxicity and inhibition of other steroid hormones. Caution pet owners about handling mitotane. Children and pregnant women should not be exposed to mitotane. Drug Interactions No specific drug interactions are reported for animals.","indications":"Indications and Clinical Uses Mitotane\\tis\\tused\\tprimarily\\tto\\ttreat\\tpituitary-\\tdependent\\thyperadrenocorticism\\t(PDH) (Cushing\u2019s\\tdisease)\\tin\\tdogs.\\tIt\\talso\\thas\\tbeen\\tused\\tto\\ttreat\\tadrenal\\ttumors.\\tTreatment is initiated with a loading dose followed by weekly maintenance doses. Other drugs used to suppress cortisol in dogs include ketoconazole, selegiline, and trilostane. Treatment\\tof\\tdogs\\twith\\tmitotane\\thas\\tbeen\\tmostly\\treplaced\\tby\\tuse\\tof\\tthe\\tFDA- approved\\tdrug\\ttrilostane,\\tbut\\tmitotane\\tmay\\tbe\\tpreferred\\tin\\tsome\\tpatients.\\tTreatment with mitotane has been compared with trilostane and has shown that each drug, although acting through different mechanisms, produces similar survival times in dogs with PDH. However, in dogs with adrenal tumors, mitotane may be preferred because of its specific action to destroy adrenal cells. Mitotane is not recommended for cats, and trilostane is recommended instead. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects, especially during the induction period, include lethargy, weakness, anorexia, ataxia, depression, and vomiting. Discontinue if signs of liver\\tdisease\\tare\\tobserved.\\tAdverse\\teffects\\tmay\\toccur\\tin\\t25%\u201330%\\tof\\tdogs. Corticosteroid supplementation (e.g., hydrocortisone, prednisolone or prednisone) may be administered to minimize side effects (prednisone dosage, 0.25\\tmg/kg/day).\\tAldosterone\\tsecretion\\tmay\\tbe\\treduced\\tin\\tsome\\tdogs\\tafter treatment. In some dogs, adverse neurologic signs may be observed, which include ataxia, head pressing, and blindness. CNS effects are the result of enlargement of the pituitary gland in response to suppression of the adrenal cortex and lack of feedback\\tby\\tcortisol.\\tLoss\\tof\\tfeedback\\tcontrol\\tstimulates\\tcorticotropin-\\treleasing hormone,\\tpituitary\\tenlargement,\\tand\\tadrenocorticotropic\\thormone\\t(ACTH) secretion.","notes":"Instructions for Use Dose\\tand\\tfrequency\\tare\\toften\\tbased\\ton\\tpatient\\tresponse.\\tTypically,\\tthe\\tinduction period\\tlasts\\t5\u201314\\tdays\\tin\\tdogs.\\tDuring\\tthe\\tinduction\\tperiod,\\tmonitor\\twater consumption, appetite, and behavior. Adverse effects are common during initial therapy.\\tAdministration\\twith\\tfood\\tincreases\\toral\\tabsorption.\\tThe\\tmaintenance dose\\tshould\\tbe\\tadjusted\\ton\\tthe\\tbasis\\tof\\tperiodic\\tcortisol\\tmeasurements\\tand\\tACTH stimulation\\ttests.\\tPrednisolone\\tor\\tprednisone\\tat\\t0.2\u20130.25\\tmg/kg\\tis\\tsometimes 624    Mitoxantrone Hydrochloride administered as a replacement in patients with PDH during the induction treatment. When used to treat adrenal tumors (see dosing), the adrenal cells are destroyed as a goal\\tof\\ttherapy.\\tTherefore,\\tin\\tthese\\tpatients,\\tsupplementation\\twith\\tadrenal\\tsteroids (glucocorticoids\\tand\\tmineralocorticoids)\\tis\\timportant\\tfor\\tlong-\\tterm\\tmaintenance. Corticosteroid supplementation with prednisone or prednisolone is started usually on the third day of treatment. Trilostane,\\tan\\tapproved\\tdrug\\tfor\\tdogs,\\thas\\talso\\tbeen\\tused\\tinstead\\tof\\tmitotane in dogs and should be considered when dogs do not respond to or tolerate mitotane. Patient Monitoring and Laboratory Tests Monitor water consumption and appetite during the induction phase. Monitor ACTH\\tresponse\\ttest\\tto\\tadjust\\tdose.\\tThe\\turine\\tcortisol/creatinine\\tratio\\tcan\\tbe\\tused to measure whether or not the adrenal cells have been destroyed when treating an adrenal tumor. Successful treatment shows a very low ratio or undetectable cortisol levels. Monitor electrolytes periodically to screen for hyperkalemia that could result from adrenal destruction (iatrogenic hypoadrenocorticism). Formulations \u2022\\t\\tMitotane\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets\\tbut\\thas\\tbecome\\tunavailable\\tin\\tsome countries. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Mitotane is not stable in aqueous solutions and may lose potency in some compounded formulations.","original_category":"Adrenolytic agent"},{"name":"Mitoxantrone Hydrochloride","active_ingredient":"Mitoxantrone Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t5\u20135.5\\tmg/m 2 IV\\tevery\\t21\\tdays\\tand\\tup\\tto\\t6\\tmg/m 2 if dogs tolerate it well. Cats \u2022\\t\\t6\u20136.5\\tmg/m 2 IV\\tevery\\t21\\tdays.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. 626    Morphine Sulfate Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tThis\\tdrug\\tshould not be used in animals intended for food because it is an anticancer agent. Mitratapide mi- trat\u2032a- pyed Trade and other names: Yarvitan","contraindications":"Contraindications and Precautions Do not administer to animals with severe bone marrow suppression. If severe bone\\tmarrow\\tsuppression\\tis\\tobserved,\\twithhold\\ttreatment\\tand\\tresume\\twith\\ta\\t25% lower dose. Drug Interactions No specific drug interactions are reported for animals, but like any anticancer agent, there are effects on multiple organs that are affected by other drugs.","indications":"Indications and Clinical Uses Mitoxantrone has been used in anticancer drug protocols in animals for treatment of leukemia, lymphoma, and carcinomas. However, use in animals is uncommon compared with the use of doxorubicin. It has been substituted for doxorubicin in some anticancer protocols for treating lymphoma in dogs with a response that was as effective\\tas\\tdoxorubicin-\\tbased\\tprotocols. Precautionary Information","side_effects":"Adverse Reactions and Side Effects As with all anticancer agents, certain adverse effects are predictable and unavoidable and\\trelated\\tto\\tthe\\tdrug\u2019s\\taction.\\tMitoxantrone\\tproduces\\tmyelosuppression, vomiting,\\tanorexia,\\tand\\tGI\\tupset,\\tbut\\tit\\tmay\\tbe\\tless\\tcardiotoxic\\tthan\\tdoxorubicin.","notes":"Instructions for Use Proper use of mitoxantrone usually follows a specific anticancer protocol. Doses listed are based on input from reputable oncologists but consult specific protocol for dosing regimens that may deviate from these recommendations. Patient Monitoring and Laboratory Tests Monitor CBC to look for evidence of bone marrow toxicity. Formulations \u2022\\t\\tMitoxantrone\\tis\\tavailable\\tin\\t2-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Mitratapide","active_ingredient":"Mitratapide","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Weight loss medication"},{"name":"Mycophenolate Mofetil","active_ingredient":"Mycophenolate Mofetil","species":["Canine","Feline","Equine"],"dosage":"skin\\tdiseases\\tin\\tdogs,\\tit\\twas\\teffective\\tat\\tan\\taverage\\tdosage\\tof\\t14.7\\tmg/kg\\ttwice\\tdaily but was administered with corticosteroids in most dogs. In cats, the use is limited and based only on small case studies or anecdotal reports. In pharmacokinetic studies in cats in which investigators examined immune suppression, it did not effectively suppress immune cells in cats at doses that did not\\tcause\\tGI\\tproblems.\\tThere\\tare\\tno\\tpublished\\tdata\\tat\\tthis\\ttime\\ton\\tthe\\tuse\\tof mycophenolate in horses. Precautionary Information  Dogs \u2022\\t\\t10\\tmg/kg\\tq8h\\tPO\\tor\\t20\\tmg/kg\\tq8\u201312h\\tPO.\\t(Higher\\tdoses\\tmay\\tbe\\tneeded\\tfor clinical effects, but as the dose is increased, adverse effects are more common.) Cats \u2022\\t\\tNo\\teffective\\tdose\\thas\\tbeen\\tdefined.\\tA\\tcommon\\tdosage\\tis\\t10\\tmg/kg\\tq12h\\tPO \u226415\\tmg/kg\\tq8h,\\tbut\\tit\\tdid\\tnot\\tproduce\\teffects\\ton\\timmune\\tcells\\tat\\tthis\\tdosage.\\tAt dosages\\tless\\tthan\\t15\\tmg/kg\\tq12h,\\tit\\thas\\tbeen\\ttolerated\\tin\\tcats,\\tbut\\tat\\thigher\\tdoses, GI\\tproblems\\tare\\tmore\\tcommon.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdose\\thas\\tbeen\\treported. Regulatory Information There\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tbecause\\tthis\\tdrug\\tshould\\tnot\\tbe administered to animals that produce food. N Naloxone Hydrochloride 639 Naloxone Hydrochloride nal- oks\u2032one  hye- droe- klor\u2032ide Trade and other names: Narcan and Trexonil","contraindications":"Contraindications and Precautions Mycophenolate\\tis\\tan\\timmunosuppressive\\tdrug.\\tTherefore,\\tpatients\\tmay\\tbe\\tmore prone to infection when receiving mycophenolate. When combined with other immunosuppressive drugs, there may exacerbated adverse effects. Drug Interactions Some drug interactions that affect oral bioavailability in humans have been reported (e.g., antibiotics, cyclosporine, antacid drugs), but these drug interactions have not been reported in animals. Mycophenolate requires acid for oral\\tabsorption;\\ttherefore,\\tinterference\\tfrom\\tacid-\\tsuppressing\\tdrugs\\tis\\tpossible. Do not administer with azathioprine because it may increase the risk of adverse effects. However, it often administered with corticosteroids without any apparent adverse effects.","indications":"Indications and Clinical Uses Mycophenolate\\tis\\tused\\tto\\ttreat\\timmune-\\tmediated\\tdiseases\\tin\\tanimals.\\tIt\\tis\\tusually used in veterinary medicine (primarily dogs and cats) when other agents such as azathioprine, cyclosporine, chlorambucil, or glucocorticoids alone fail to achieve remission\\tof\\tan\\timmune-\\tmediated\\tdisease.\\tIt\\tis\\tusually\\tadministered\\tin\\tcombination with glucocorticoids, cyclosporine, or both. In dogs, mycophenolate has been used on\\ta\\tlimited\\tbasis\\tto\\ttreat\\tsome\\timmune-\\tmediated\\tdiseases\\tsuch\\tas\\taplastic\\tanemia, immune-\\tmediated\\themolytic\\tanemia,\\tmeningoencephalitis,\\tand\\tautoimmune\\tskin disease.\\tThe\\tuse\\tin\\tthese\\tdiseases\\tis\\tsupported\\tby\\tanecdotal\\taccounts\\tand\\tsmall retrospective\\tobservational\\tstudies.\\tResponses\\tin\\tdogs\\thas\\tbeen\\tvariable,\\tand\\tit is difficult to determine if mycophenolate was responsible for clinical effects or if\\timprovement\\twas\\tcaused\\tby\\tco-\\tadministered\\tcorticosteroids.\\tThere\\thas\\tbeen no difference in response shown between corticosteroids administered with mycophenolate compared with corticosteroids administered with other agents. There\\twas\\tno\\tbenefit\\tin\\tdogs\\twhen\\tit\\twas\\tadded\\tto\\ttreatment\\tfor\\timmune-\\tmediated hemolytic anemia. In dogs, the active metabolite (MPA) is produced inconsistently, which may explain the variable results observed in dogs. It has been used by neurologists for treatment of myasthenia gravis, but one clinical report indicated that it was not effective. For treatment of pemphigus foliaceous, it was given at a dosage of 22\u201339\\tmg/kg/day\\tdivided\\tinto\\tthree\\ttreatments.\\tIt\\twas\\twell\\ttolerated,\\tbut\\tonly\\tthree of\\teight\\tdogs\\tcompleted\\tthe\\tstudy\\tand\\twere\\timproved.\\tFor\\tother\\timmune-\\tmediated","side_effects":"Adverse Reactions and Side Effects In\\tdogs,\\tGI\\tproblems\\t(diarrhea,\\tweight\\tloss,\\tanorexia,\\tand\\tvomiting)\\thave\\tbeen the most common effects reported, which may be caused by a direct effect on intestinal\\tmucosa.\\tThe\\tadverse\\tGI\\teffects\\tmay\\tbe\\tdelayed\\tin\\tsome\\tdogs.\\tAt\\tthe low\\tdose\\tof\\t10\\tmg/kg,\\tit\\tis\\twell\\ttolerated,\\tbut\\tit\\tmay\\tnot\\tbe\\teffective\\tat\\tthis\\tdose. As\\tthe\\tdose\\tis\\tincreased\\tup\\tto\\t20\\tand\\t30\\tmg/kg,\\tadverse\\tGI\\teffects\\tare\\tmore common\\t(nausea,\\tdiarrhea,\\tweight\\tloss).\\tIn\\tcats\\tat\\t10\\tmg/kg\\tPO\\tq12h,\\tit\\twas well tolerated, but this dose did not suppress immune cells. At higher doses, it consistently\\tproduces\\tadverse\\tGI\\teffects\\tin\\tcats. M","notes":"Instructions for Use Mycophenolate is used in some patients that cannot tolerate other immunosuppressive drugs, such as azathioprine or cyclophosphamide. It has been used in combination with\\tcorticosteroids\\tand\\tcyclosporine.\\tThe\\tclinical\\teffects\\tin\\tdogs\\tand\\tcats\\tare\\tnot\\twell established but are based on small observational studies and anecdotal experiences. Patient Monitoring and Laboratory Tests Monitor for signs of infection in patients. Monitor CBC periodically when administering immunosuppressive agents. Formulations \u2022\\t\\tMycophenolate\\tis\\tavailable\\tin\\t250-\\tand\\t500-\\tmg\\tcapsules,\\t500-\\tmg\\ttablets; 200\\tmg/mL\\toral\\tsuspension\\t(fruit\\tflavor). \u2022\\t\\tFor\\tIV\\tuse,\\treconstitute\\tthe\\tvial\\tof\\tmycophenolate\\tpowder\\twith\\t5%\\tdextrose\\tin water\\tto\\ta\\tconcentration\\tof\\t6\\tmg/mL.\\tAdminister\\tover\\t2\\thours\\tslowly. \u2022\\t\\tCompounded\\tformulation:\\tA\\t50-\\tmg/mL\\toral\\tsuspension\\tmay\\tbe\\tmade\\twith mycophenolate\\tmofetil\\tcapsules\\tmixed\\twith\\tOra-\\tPlus\\tand\\tcherry\\tsyrup.\\tMix\\tsix 250\\tmg\\tcapsules\\twith\\t7.5\\tmL\\tof\\tOra-\\tPlus\\tand\\tstir\\tto\\ta\\tuniform\\tpaste.\\tAdd\\t15\\tmL of cherry syrup in incremental proportions and transfer to a bottle for dispensing. There\\tshould\\tbe\\tsufficient\\tcherry\\tsyrup\\tadded\\tto\\tmake\\ta\\ttotal\\tvolume\\tof\\t30\\tmL. Shake\\twell\\tbefore\\tusing.\\tIt\\tis\\tstable\\tduring\\tstorage\\tfor\\t210\\tdays\\tat\\t5\xb0C,\\tfor\\t28\\tdays at\\t25\xb0C\u201337\xb0C,\\tand\\tfor\\t11\\tdays\\tat\\t45\xb0C. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It is\\tslightly\\tsoluble\\tin\\twater.\\tIt\\tis\\tmore\\tstable\\tat\\tlow\\tpH\\tvalues\\t(less\\tthan\\t4).\\tIt\\tmay\\tbe prepared\\tin\\ta\\tsyrup\\tsuspension\\tfor\\tflavoring\\tand\\tremains\\tstable\\tfor\\t121\\tdays.\\tThe\\toral liquid\\tsuspension\\thas\\tbeen\\tstored\\tat\\t25\xb0C\\t(room\\ttemperature)\\tor\\tin\\tthe\\trefrigerator (5\xb0C);\\tit\\thas\\ta\\tshelf-\\tlife\\tof\\t28\\tdays\\tand\\t210\\tdays,\\trespectively.\\tShake\\tthe\\tsuspension before administration.","original_category":"Immunosuppressant"},{"name":"Naproxen","active_ingredient":"Naproxen","species":["Canine","Equine","Feline"],"dosage":"Dogs \u2022\\t\\t5\\tmg/kg\\tinitially,\\tthen\\t2\\tmg/kg\\tq48h\\tPO.\\t(The use is not recommended for dogs.)  Horses \u2022\\t\\t10\\tmg/kg\\tq12h\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Pharmacology and Mechanism of Action N- butylscopolammonium is an antispasmodic, antimuscarinic, anticholinergic drug. This is a quaternary ammonium compound derived from belladonna alkaloid. Butylscopolamine, like other antimuscarinic drugs (e.g., atropine), blocks cholinergic receptors and produces a parasympatholytic effect. It affects receptors throughout the body, but it is used more commonly for its GI effects. It effectively inhibits secretions and motility of the GI tract by blocking parasympathetic receptors. It has a short half- life (15\u201325 minutes) and short duration of action.","contraindications":"Contraindications and Precautions Caution is advised when using the OTC formulation designed for people because the tablet size is much larger than the safe dose for dogs. Therefore warn pet owners about administration to dogs without consulting a veterinarian first. Dosing rates for people are not appropriate for dogs. Do not administer to animals prone to GI ulcers. Do not administer with other ulcerogenic drugs, such as corticosteroids. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have been shown to exacerbate the GI adverse effects. Some NSAIDs may interfere with the action of diuretic drugs and angiotensin- converting enzyme inhibitors.","indications":"Indications and Clinical Uses Naproxen is approved for use in people and is popular for treating osteoarthritis. It has been used rarely for treatment of musculoskeletal problems, such as myositis and osteoarthritis in dogs and horses. There are no veterinary formulations marketed. Its use has diminished because there are US Food and Drug Administration\u2013approved drugs for these indications for horses and dogs. Precautionary Information Indications and Clinical Uses Butylscopolamine bromide is indicated for treating pain associated with spasmodic colic, flatulent colic, and intestinal impactions in horses. It is also used to relax the rectum and reduce intestinal strain to facilitate diagnostic rectal palpation. Because of effects to relax smooth muscle via anticholinergic mechanisms, it is effective\\tfor\\tshort-\\tterm\\ttreatment\\t(usually\\tone\\tinjection)\\tto\\thorses\\twith\\trecurrent airway obstruction (also known as \u201cheaves\u201d). N-    Butylscopolammonium Bromide (Butylscopolamine Bromide) en- byoo- til- skoe- pahl\u2032ah- moe- nee- um  broe\u2032mide Trade and other names: Buscopan","side_effects":"Adverse Reactions and Side Effects Naproxen is a potent NSAID. Adverse effects attributed to GI toxicity are common to all NSAIDs. Naproxen has produced serious ulceration in dogs because elimination in dogs is many times slower than in people or horses. Because it is available over the counter (OTC) for people, dogs have been exposed\\tfrom\\tpet\\towner\\tadministration.\\tKidney\\tinjury\\tcaused\\tby\\trenal\\tischemia also is possible with repeated doses.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on pharmacokinetic studies in experimental animals. Patient Monitoring and Laboratory Tests Monitor for signs of GI ulceration. Formulations \u2022\\t\\tNaproxen\\tis\\tavailable\\tin\\t220-\\tmg\\ttablets\\t(OTC).\\t(A\\t220-\\tmg\\tdose\\tof\\tnaproxen sodium is equivalent to 200- mg naproxen.) It is also available in 25- mg/mL oral suspension and 250- , 375- , and 500- mg tablets (prescription). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Naproxen is practically insoluble in water at low pH, but it increases at high pH. It is soluble in ethanol. N N-    Butylscopolammonium Bromide (Butylscopolamine Bromide) 645","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Neostigmine","active_ingredient":"Neostigmine","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t2\\tmg/kg\\tper\\tday\\tPO\\tin\\tdivided\\tdoses. \u2022\\t\\tAntimyasthenic\\ttreatment:\\t10\\tmcg/kg\\tIM\\tor\\tSQ\\tas\\tneeded.\\t(Not recommended for long- term  treatment.) \u2022\\t\\tAntidote\\tfor\\tneuromuscular\\tblockade:\\t40\\tmcg/kg\\tIM\\tor\\tSQ. \u2022\\t\\tDiagnostic\\taid\\tfor\\tmyasthenia:\\t40\\tmcg/kg\\tIM\\tor\\t20\\tmcg/kg\\tIV.  When used as a treatment for neuromuscular blocking agents (cholinesterase inhibitor), the frequency of administration is determined by clinical response. Horses \u2022\\t\\t0.02\u20130.04\\tmg/kg\\t(20\u201340\\tmcg/kg)\\tIV\\tor\\tSQ.\\tIt\\tmay\\tbe\\tdelivered\\tby\\tconstant-\\trate infusion at a dosage of 0.008 mg/kg/h. Cattle \u2022\\t\\t22\\tmcg/kg\\t(0.022\\tmg/kg)\\tSQ. Sheep \u2022\\t\\t22\u201333\\tmcg/kg\\t(0.022\u20130.033\\tmg/kg)\\tSQ. Swine \u2022\\t\\t44\u201366\\tmcg/kg\\t(0.044\u20130.066\\tmg/kg)\\tIM. Pyridostigmine\\tmay\\tbe\\tassociated\\twith\\tfewer\\tadverse\\teffects\\tthan\\tneostigmine\\tand is preferred for some indications (e.g., myasthenia gravis treatment).","contraindications":"Contraindications and Precautions Do not use in urinary obstruction, intestinal obstruction, asthma or bronchoconstriction, pneumonia, and cardiac arrhythmias. The administration to horses is discouraged because it may increase abdominal discomfort. Do not use in patients sensitive to bromide. If the patient is also receiving bromide (e.g., KBr) for treatment of seizures, this formulation may contribute to excess bromide accumulation. Drug Interactions Do not use with other cholinergic drugs. Anticholinergic drugs (atropine and glycopyrrolate) block the effects. 650    Niacinamide Ruminants \u2022\\t\\tStimulate\\trumen\\tmotility:\\t0.02\\tmg/kg\\tIM\\tor\\tSQ. Regulatory Information Withdrawal times are not established for animals that produce food. When used to stimulate rumen motility, no withdrawal time has been used. For additional extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Pharmacology and Mechanism of Action Niacinamide is a derivative of vitamin B and sometimes used for immune- mediated diseases. It is not a direct- acting immunosuppressant. The use is primarily to treat skin diseases, such as discoid lupus erythematosus and pemphigus erythematosus in dogs. The mechanism of action is not entirely known. Niacinamide may have some anti- inflammatory action such as suppression of inflammatory cells. Niacin and niacinamide are also used to treat vitamin B 3 deficiency. Do not confuse niacin with niacinamide. Niacin is converted to the active form niacinamide by intestinal bacteria. Niacin is used in people as a lipid- regulating compound used to lower circulating blood triglycerides and reduce low- density lipoproteins. The primary treatment in people for niacin is to treat dyslipidemias. Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions are reported. Niacinamide nye\u2032ah- sin\u2032ah- mide Trade and other names: Nicotinamide and vitamin B 3","indications":"Indications and Clinical Uses Niacinamide has been used to treat immune- mediated skin disease in small animals. For skin disorders, it is usually administered with tetracycline. It also has been used to treat vitamin B 3 deficiency. Use in animals has been primarily derived from a few clinical reports, small observational studies, and empirical use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are caused by the cholinergic action resulting from inhibition of cholinesterase. These effects are manifest in the GI tract as diarrhea, increased secretions, and smooth muscle contractions. Other adverse effects can include miosis, bradycardia, muscle twitching or weakness, and constriction of bronchi and ureters. Adverse effects can be treated with anticholinergic drugs such as atropine. N Adverse Reactions and Side Effects Side effects are not common but have included vomiting, anorexia, lethargy, and diarrhea. In people, when niacin is administered to treat dyslipidemias, side effects are common, including flushing of skin. The flushing effect of niacin is thought to occur through skin prostaglandin induction and activation of prostaglandin- associated receptors. When activated, the niacin receptor functions by increasing prostaglandin synthesis and activation of vasodilatory prostaglandin receptors in the\\tskin.\\tIn\\tpeople,\\tniacin\\talso\\thas\\tbeen\\tassociated\\twith\\tliver\\tinjury.","notes":"Instructions for Use Neostigmine is indicated primarily only for treatment of intoxication. For routine systemic use of an anticholinesterase drug, pyridostigmine may have fewer side effects. When neostigmine is used, the frequency of dose may be increased based on observation of effects. Patient Monitoring and Laboratory Tests Monitor GI signs, heart rate, and rhythm. Formulations \u2022\\t\\tNeostigmine\\tbromide\\tis\\tavailable\\tin\\t15-\\tmg\\ttablets,\\tand\\tneostigmine\\tmethylsulfate is\\tavailable\\tin\\t0.25-\\t,\\t0.5-\\t  ,\\tand\\t1-\\t    mg/mL\\tinjections. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticholinesterase"},{"name":"Niacinamide","active_ingredient":"Niacinamide","species":["Canine"],"dosage":"Dogs \u2022\\t\\t500\\tmg\\tof\\tniacinamide\\tq8h\\tPO\\tplus\\t500\\tmg\\tof\\ttetracycline.\\tThis\\tdosage\\tis approximate based on a 10- kg dog. Eventually taper dosage to q12h and then to q24h. For dogs less than 10 kg, start with 250 mg of each drug.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information No regulatory information is available. Because of a low risk of residues, no withdrawal times are suggested. Pharmacology and Mechanism of Action Nifedipine is a calcium- channel blocking drug of the dihydropyridine class. It acts as a vasodilator, with less effect on the calcium channels affecting cardiac conduction. It is not used as much in veterinary medicine as amlodipine, which is in the same class. The action of nifedipine is similar to other calcium- channel blocking drugs, such as amlodipine. They block voltage- dependent calcium entry into smooth muscle cells. Drugs of the dihydropyridine class are more specific for vascular smooth muscle than the cardiac tissue. Therefore they have less effect on cardiac conduction than diltiazem.","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Nifedipine is used for smooth muscle relaxation and to induce vasodilation. It is indicated for treatment of systemic hypertension. Use in animals is rare because there is more experience with amlodipine. The use of nifedipine in animals has been primarily derived from empirical use or some isolated anecdotal reports. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Nifedipine nye- fed\u2032ih- peen Trade and other names: Adalat and Procardia","side_effects":"Not specified in source","notes":"Instructions for Use For treatment of pemphigus skin disease, it is usually administered with a tetracycline. Patient Monitoring and Laboratory Tests Monitor blood CBC periodically during treatment. Formulations \u2022\\t\\tNiacinamide\\tis\\tavailable\\tin\\t50-\\t,\\t100-\\t   ,\\t125-\\t   ,\\t250-\\t   ,\\tand\\t500-\\tmg\\ttablets\\t(OTC)\\tand 100-\\t  mg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anti- inflammatory"},{"name":"Nitazoxanide","active_ingredient":"Nitazoxanide","species":["Feline","Equine","Canine"],"dosage":"effects. At a dosage of 25 mg/kg q12h in cats, most cats had adverse GI effects, with no effect on Cryptosporidium spp. Because it may disrupt normal intestinal flora, administration to other animals has produced diarrhea. The use is no longer approved for horses because of adverse effects.  \u2022\\t\\tThere\\tare\\tno\\tsmall\\tanimal\\tdosing\\tinstructions\\tavailable.\\tHowever,\\tone\\tdose\\tthat\\thas been\\tused\\tis\\t100\\tmg\\tper\\tanimal\\tq12h\\tPO\\tfor\\t3\\tdays.\\tThe\\thuman\\tpediatric\\tdosage is 100 mg (5 mL) q12h for 3 days.  Horses \u2022\\t\\t25\\tmg/kg\\tq24h\\tPO\\ton\\tdays\\t1\\tthrough\\t5\\tfollowed\\tby\\t50\\tmg/kg\\tq24h\\tPO\\ton\\tdays 6 through 28. (The equine product was withdrawn from the market by the sponsor because of severe adverse effects.) Regulatory Information Do not use in animals intended for food. Pharmacology and Mechanism of Action Nitenpyram is an antiparasitic drug used for treatment of fleas. It rapidly kills adult fleas. It is from the class of synthetic insecticides known as the neonicotinoids. It is related to imidacloprid and has the same mechanism of action, which is to inhibit postsynaptic nicotinic acetylcholine receptors, which produces influx of sodium ions. Pharmacokinetics: Nitenpyram is absorbed completely from oral administration and has half- lives in dogs and cats of 2.8 and 7.7 hours, respectively. After oral absorption, it produces a rapid kill of adult fleas that has been observed as quickly as 30 minutes after drug administration and is 98.6% effective in dogs and 98.4% effective in cats.","contraindications":"Contraindications and Precautions No known contraindications. Drug Interactions No known drug interactions. Contraindications and Precautions Do not use in dogs or cats weighing less than 1 kg (2 lb). Do not use in cats or dogs younger than 4 weeks of age. Drug Interactions No drug interactions have been reported. It is safe to use with lufenuron, milbemycin, and the isooxazolines (fluralaner, afoxolaner, sarolaner). Nitenpyram nye- ten- pye\u2032ram Trade and other names: Capstar","indications":"Indications and Clinical Uses Nitazoxanide\\twas\\tused\\tto\\ttreat\\tequine\\tprotozoal\\tmyeloencephalitis\\t(EPM)\\tas\\tthe equine paste Navigator (32% paste). However, because the adverse effects were common and included fatal enterocolitis at recommended doses, it was voluntarily withdrawn by the sponsor. It is still available in the human formulation (Alinia). This formulation for people is approved for treating protozoal infections, such as Cryptosporidium parvum and Giardia spp. There has been only limited use in dogs and cats for intestinal protozoal infections but no reports to document efficacy and safety. In people, it has been used to treat intestinal infections caused by Cryptosporidium spp. (500 mg per person q12h for 3 days) with good success, but there are no reports of its use to treat Cryptosporidium infection in animals. Precautionary Information Indications and Clinical Uses Nitenpyram is used to kill fleas on dogs and cats. It produces a rapid kill, with fleas killed within 1 hour of administration. It is often used with other drugs that act to prevent flea infestations as part of a comprehensive flea- control program. It may be used to produce an initial rapid kill of the fleas on the animal, then followed-up with a flea prevention program. Precautionary Information","side_effects":"Adverse Reactions and Side Effects When it was administered to cats at a dose of 75 mg/kg, all cats had adverse Adverse Reactions and Side Effects No adverse reactions are reported. It was safe in studies in dogs and cats in which up to 10 times the dose was administered. It was tolerated even in young animals at 8 weeks of age. Some transient pruritus may occur shortly after administration, which coincides with the initial killing of fleas.","notes":"Instructions for Use Nitazoxanide\\twas\\tadministered\\tfor\\thorses\\tto\\ttreat\\tEPM,\\tbut\\tthe\\tequine\\tproduct\\thas been withdrawn from the market. Use in small animals has been extrapolated from use in humans and includes treatment of intestinal protozoa. Patient Monitoring and Laboratory Tests When treating patients for diarrhea, monitor electrolytes and fecal samples. Formulations \u2022\\t\\tNitazoxanide\\twas\\tavailable\\tin\\ta\\t0.32-\\tmg/mL\\toral\\tpaste\\tfor\\thorses\\tbut\\thas\\tbeen withdrawn from the market by the sponsor. \u2022\\t \\tHuman\\tformulation\\tis\\ta\\tpink-\\tcolored\\tpowder\\tfor\\toral\\tdosing;\\t100\\tmg\\tof\\tpowder\\tis mixed with 48 mL of water to produce a 20- mg/mL strawberry flavored oral dose form. Stability and Storage Stable if stored in manufacturer\u2019s original formulation. The oral solution for people can be mixed and remain stable for 7 days. 654    Nitenpyram","original_category":"Antiprotozoal"},{"name":"Nizatidine","active_ingredient":"Nizatidine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t2.5\u20135\\tmg/kg\\tq24h\\tPO.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\treported. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t5 Pharmacology and Mechanism of Action Norfloxacin is one of the oldest fluoroquinolone antibacterial drugs that is used rarely in human or veterinary medicine. Norfloxacin acts via inhibition of DNA gyrase in bacteria to inhibit DNA and RNA synthesis. It is a bactericidal with a broad spectrum of activity but not as active as other newer fluoroquinolones. Susceptible bacteria include Staphylococcus spp., E. coli, Proteus spp., Klebsiella spp., and Pasteurella spp. P. aeruginosa is moderately sensitive.","contraindications":"Contraindications and Precautions No contraindications have been reported for animals. Drug Interactions No drug interactions are reported for animals.","indications":"Indications and Clinical Uses 2 - receptor blockers, is used to treat gastroesophageal reflux, gastric ulcers, and gastritis. These drugs inhibit secretion of stomach acid and have also been used to prevent ulcers caused from NSAIDs, but the efficacy for preventing NSAID- induced ulcers has not been demonstrated. The use in animals is uncommon because there are other H 2 - receptor  blocking drugs that are used more widely (famotidine), and the use of proton pump inhibitors such as omeprazole is more effective. The use of nizatidine in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness in animals. Precautionary Information Indications and Clinical Uses Norfloxacin has been replaced by other veterinary fluoroquinolones because they have more favorable pharmacokinetics and improved spectrum of activity. There\\tis\\tlittle\\tjustification\\tfor\\tthe\\tuse\\tof\\tnorfloxacin\\tin\\tanimals\\tbecause\\tof\\tthe availability of other fluoroquinolones. It has been used anecdotally to treat a variety of infections, including respiratory, urinary tract, skin, and soft tissue infections. Norfloxacin nor- floks\u2032ah- sin Trade and other names: Noroxin","side_effects":"Adverse Reactions and Side Effects Side effects from nizatidine have not been reported for animals, but the use has been uncommon.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. Nizatidine use in animals has not been as common as the use of other related drugs such as ranitidine or famotidine or the proton pump inhibitors (omeprazole). Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tNizatidine\\tis\\tavailable\\tin\\t150-\\t\\tand\\t300-\\tmg\\tcapsules\\tand\\t15-\\tmg/mL\\toral solution. 662    Norfloxacin Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.\\tNizatidine\\tis\\tslightly\\tsoluble\\tin\\twater.\\tIt\\thas\\tbeen\\tmixed\\twith\\tjuices and syrups for oral administration and was stable for 48 hours. Avoid mixing with Maalox liquid.","original_category":"Antiulcer agent"},{"name":"Oclacitinib Maleate","active_ingredient":"Oclacitinib Maleate","species":["Feline","Canine"],"dosage":"daily in small numbers of cats, it has produced good to excellent results. The dosage examined in some experimental cats has been approximately 0.5 mg/kg q12h. There may be a potential role for oclacitinib and other JAK inhibitors for treatment of feline asthma and allergic dermatitis, but further studies are necessary to establish clinical use. O Precautionary Information Adverse Effects During field studies, there was a low rate of adverse reactions (diarrhea, 2.3%\u2013 4.6% and vomiting, 2.3%\u20133.9%), which were not different from the placebo and O  Dogs \u2022    0.5 mg/kg (0.4\u20130.6 mg/kg with or without food) initially on a twice- daily schedule for the first 14 days and then tapered to a once- daily administration. Cats \u2022\\t\\tDose\\thas\\tnot\\tbeen\\testablished\\tfor\\tcats.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\testablished. Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tOclacitinib\\tshould\\tnot\\tbe\\tadministered\\tto animals intended for food. Olsalazine Sodium ole- sal\u2032ah- zeen  soe\u2032dee- um Trade and other names: Dipentum","contraindications":"Contraindications and Precautions Safety has not been evaluated in breeding animals or during pregnancy. The manufacturer warns that oclacitinib should not be administered to dogs younger than 12 months of age or dogs with serious infections. The manufacturer warns that oclacitinib may increase susceptibility to infection, including demodicosis, and exacerbate neoplastic conditions. When transitioning dogs from twice- daily administration to once- daily administration, approximately 30% of dogs may experience a flare- up of pruritus. Vaccination: At an oclacitinib dose that represented three times the therapeutic dose, dogs mounted an adequate immune response to killed rabies vaccination, modified-live canine distemper virus vaccination, and modified- live canine parvovirus vaccination in 16- week- old vaccine- na\xefve dogs. Approximately 80% of the dogs had adequate response to canine parainfluenza virus. Drug Interactions Dermatologists have used oclacitinib with other medications such as corticosteroids, cyclosporine, and other systemic agents safely, but the manufacturer warns that safety with these medications has not been evaluated. Inhibition of canine cytochrome P450 enzymes by oclacitinib is minimal with the inhibitor concentrations 50 times higher than the peak concentrations produced from the therapeutic dose. Oclacitinib does not interfere with the response from intradermal skin testing in dogs. 666    Olsalazine Sodium","indications":"Indications and Clinical Use Oclacitinib is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Oclacitinib has been equally effective for reducing pruritus in dogs as glucocorticoids or cyclosporine. In a comparison with cyclosporine, oclacitinib had similar efficacy as cyclosporine, but with a more rapid onset and less gastrointestinal (GI) problems. Use in cats: The clinical use in cats has been limited to some small observational studies. At a dosage of 0.4\u20130.6 mg/kg twice daily for 14 days and then tapered to once","side_effects":"Not specified in source","notes":"Instructions for Use Oclacitinib is indicated for dogs, and safe doses have not been established in other animals. It should not be administered to humans. Administer according to the sponsor\u2019s instructions with or without food. After the initial induction period of twice- daily dosing, it should be reduced to once- daily administration to decrease the risk of adverse effects. There may be risks if a dosage of 0.4\u20130.6 mg twice daily is continued for long- term use. There is a risk of infections associated with immunosuppression, including bacterial pneumonia and infections caused by Demodex spp., at a high dose (three times and five times dose) with twice- daily administration. Patient Monitoring If doses are continued at a twice- daily schedule for longer than the manufacturer recommends, monitor the complete blood count periodically to assess effects on bone marrow. Check dogs for skin lumps and signs of demodicosis. usually resolved after initial dosing. In a clinical study, there were a 9.2% incidence of vomiting and a 6% incidence of diarrhea in 283 dogs. Treated dogs had decreased leukocytes and serum globulin compared with the placebo group. In field trials there have been isolated cases of demodicosis, pyoderma, pneumonia, and mast cell tumor or other neoplasms, but it is not known if these were associated with the medication. If administration is continued for long- term twice daily rather than lowering the frequency to once daily, more adverse effects may be anticipated. There was a mild, dose- dependent reduction in hemoglobin, hematocrit, and reticulocyte counts during the twice- daily dosing period for 60 days with decreases in the leukocyte subsets of lymphocytes, eosinophils, and basophils. High doses can potentially cause impairment of immune surveillance against tumors; therefore, high doses should be avoided. Formulations \u2022\\t\\tOclacitinib\\tis\\tavailable\\tas\\t3.6-\\t,\\t5.4-\\t  ,\\tand\\t16-\\tmg\\ttablets.\\tDo\\tnot\\tuse\\tcompounded formulations because stability and potency have not been evaluated. Storage Conditions Store at room temperature between 20\xb0C and 25\xb0C (68\xb0F and 77\xb0F) in a manufacturer- recommended container. The pH can affect solubility. At a pH of 4, it is less soluble, and at a pH of 5.5, it is almost completely insoluble.","original_category":"Anti- inflammatory,  antipruritic"},{"name":"Olsalazine Sodium","active_ingredient":"Olsalazine Sodium","species":["Feline","Equine"],"dosage":"\u2022\\t\\tDosage\\tnot\\testablished,\\tbut\\t5\u201310\\tmg/kg\\tq8h\\thas\\tbeen\\tused.\\t(The\\tusual\\thuman dosage is 500 mg twice daily.)  \u2022\\t\\tNo\\tdoses\\tare\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Racing Commissioners International (RCI) Classification: 4 Omeprazole oh- mep\u2032rah- zole Trade and other names: Prilosec (formerly Losec; human preparation), Zegerid (human formulation), GastroGard, and UlcerGard (equine preparations); outside the United States, Peptizole and Gastrozol are available for horses","contraindications":"Contraindications and Precautions Do not administer to patients sensitive to salicylate compounds. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tfor\\tanimals.","indications":"Indications and Clinical Uses Olsalazine, like other forms of mesalamine, is used for treatment of inflammatory bowel disease, including colitis in animals. In small animals, most often sulfasalazine is used; however, in some animals, olsalazine may be indicated. Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. O Omeprazole 667 Precautionary Information","side_effects":"Adverse Reactions and Side Effects No\\tadverse\\teffects\\treported\\tin\\tanimals.","notes":"Instructions for Use Olsalazine is used in patients that cannot tolerate sulfasalazine. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tOlsalazine\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidiarrheal"},{"name":"Omeprazole","active_ingredient":"Omeprazole","species":["Canine","Feline","Equine"],"dosage":"studied in dogs and cats, with effective acid suppression at the dosages provided in the dosing section.  Dogs \u2022\\t\\t20\\tmg\\tper\\tdog\\tq24h\\tPO\\tor\\t1\u20132\\tmg/kg\\tq24h\\tPO.\\tFor\\ta\\tmore\\tconsistent\\tacid- suppressing effect, administer q12h instead of q24h. Cats \u2022\\t\\t1\\tmg/kg\\tq24h\\tPO.\\tFor\\ta\\tmore\\tconsistent\\tacid-\\tsuppressing\\teffect,\\tadminister\\tq12h instead of q24h.  Horses \u2022\\t\\tTreating\\tulcers:\\t4\\tmg/kg\\tonce\\tdaily\\tfor\\t4\\tweeks\\tPO.\\tTwice-\\tdaily\\tadministration may be more effective than once- daily administration for ulcers not responding to once-daily treatment. There is some evidence that 1\u20132 mg/kg is as effective for treatment as a higher dose. \u2022\\t\\tPreventing\\tulcers:\\t1\u20132\\tmg/kg\\tq24h\\tPO.\\t(1\\tmg/kg\\twas\\teffective\\tfor\\tprevention\\tin studies performed in horses.) \u2022\\t\\tIV\\tuse\\t(if\\ta\\tformulation\\tis\\tavailable):\\tLoading\\tdose\\tof\\t1\\tmg/kg\\tfollowed\\tby\\t0.5 mg/kg per day for 14\u201328 days. Ruminants \u2022\\t\\tOral\\tabsorption\\tmay\\tnot\\tbe\\thigh\\tenough\\tfor\\teffective\\ttherapy. Regulatory Information Not\\tintended\\tfor\\tadministration\\tto\\tanimals\\tthat\\tproduce\\tfood.\\tOral\\tabsorption\\tin ruminants is not established. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI Classification: 5 Ondansetron Hydrochloride on- dan\u2032sih- tron  hye- droe- klor\u2032ide Trade and other names: Zofran","contraindications":"Contraindications and Precautions One of the human formulations (Zegerid) is a packet to be mixed with water for oral administration. This formulation contains xylitol, which can be toxic to dogs if administered at high doses or with other medications that contain xylitol. Drug Interactions Although omeprazole has not been associated with drug interactions in animals, PPIs may inhibit some drug- metabolizing enzymes (CYP450 enzymes). In people, metabolism of clopidogrel to the active metabolite can be inhibited by omeprazole, but this inhibition was not demonstrated in studies in dogs and has not been studied in horses or cats. Metabolism of other drugs may be inhibited by omeprazole, but this has not been studied in domestic animals. Because all PPIs decrease stomach acid, do not administer with drugs that depend on stomach acid for absorption (e.g., ketoconazole and itraconazole). In people, there may be an increased risk of intestinal injury when PPIs are administered\\twith\\tNSAIDs,\\tbut\\tthis\\thas\\tnot\\tbeen\\tstudied\\tin\\tanimals. Omeprazole may be administered with sucralfate, which may increase efficacy for some gastric and esophageal diseases. However, in horses and perhaps other animals, the combination is more effective when sucralfate is administered 60\u201390 minutes after omeprazole.","indications":"Indications and Clinical Uses Omeprazole, like other PPIs, is used for treatment and prevention of GI ulcers and gastroesophageal reflux. It has been used in dogs, cats, and exotic species, but most efficacy data for animals have been produced in horses, in which it has been shown that omeprazole is effective for treating and preventing gastric ulcers. In foals, 4 mg/kg q24h suppresses acid secretion for 22 hours. By comparison, ranitidine suppresses acid up to 8 hours at a dose of 6.6 mg/kg. In studies performed in horses, omeprazole was more effective than ranitidine for treating gastric ulcers. For treatment of ulcers in horses, the approved label treatment in the United States is 4 mg/kg PO once per day. However, there is evidence to indicate that a dosage of 1 mg/kg per day is equally effective. For more effective healing of gastric ulcers, consider twice- daily administration instead of once daily. The equine formulations in the United States (GastroGard and UlcerGard) are buffered formulations. An enteric- coated formulation is available for horses in some countries (Gastrozol). Plasma omeprazole concentrations after single doses are significantly higher with GastroGard than Gastrozol when each is administered at the labeled dose. These formulations, when combined with environmental changes, promote healing of gastric ulcers in horses. The response to treatment will depend on the type of equine gastric ulcer syndrome being treated. Horses with equine squamous gastric disease (ESGD) respond much more favorably to acid suppression with omeprazole than those with equine glandular gastric disease (EGGD), reflecting the differences in pathogenesis and response between these two distinct forms of equine gastric disease. There was a 25% response rate for EGGD and a 78% response rate for ESGD at a dosage of 4 mg/kg once daily for 28\u201335 days. Some experts recommend oral omeprazole (4 mg/kg q24h) in combination with oral sucralfate 12 mg/kg q12h) for better healing rates for treating EGGD. In dogs, 1 mg/kg q24h PO is as effective as pantoprazole (1 mg/kg) and famotidine (0.5 mg/kg q12h) for maintaining stomach pH greater than 3\u20134, which is the recommended pH range for ulcer healing. Twice- daily administration of omeprazole may be more effective than once daily. Repeated doses may be necessary (two to five doses) for complete inhibition of acid secretion. In dogs and cats, PPIs may be more effective than other drugs (e.g., histamine H 2 blockers) because of the long duration of effect. In cats, the equine formulation and fractionated tablets were equally effective for suppressing acid secretion and were superior to an H 2 blocker (famotidine). In O a similar study performed in dogs, omeprazole tablets or equine paste administered once daily provided superior acid suppression compared to famotidine twice daily. Omeprazole, like other PPIs, may be effective for preventing nonsteroidal anti- inflammatory\\tdrug\\t(NSAID)\u2013induced\\tulcers.\\tOmeprazole\\thas\\talso\\tbeen\\tused\\tin combination with other drugs (antibiotics) for treatment of Helicobacter infections in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The only reported adverse effect in dogs has been diarrhea in some cases. Otherwise, adverse effects have not been reported in animals. In people, there is concern about hypergastrinemia with chronic use, but this has not been a concern in animals. Horses have tolerated 20 mg/kg q24h for 91 days and 40 mg/kg q24h PO for 21 days. Dogs and cats also have tolerated the regimens listed in the dosing section. Overgrowth of Clostridium bacteria has been a concern from chronic use because of chronic gastric acid suppression, but the clinical importance of this observation in animals has not been established. In people, long- term use of PPIs has been associated with a modest risk of hip fractures because of decreased oral absorption of calcium and increased bone resorption by osteoclasts. This problem has not been reported in animals. In cats with chronic kidney disease, omeprazole was well tolerated, but treatment increased sodium concentrations. The cause or the significance of this observation is undetermined. Although effects on bone have been a concern in people, when administered for 60 days to cats (1 mg/kg q12h), there was no change in cobalamin, calcium, magnesium, or bone mineral content or density.","notes":"Instructions for Use Omeprazole is the most common drug of this class used in animals. Other PPIs include pantoprazole (Protonix), lansoprazole (Prevacid), rabeprazole (Aciphex), and the S- isomer of omeprazole, esomeprazole. Less experience with these other products is reported for veterinary medicine. Pantoprazole and rabeprazole have the advantage in that they are available as tablets that can be crushed. The equine formulations available include GastroGard and UlcerGard, which are buffered formulations to enhance oral absorption. Gastrozol is an enteric- coated formulation for horses available in Australia (see Indications and Clinical Use for comparison). Rectal administration has been studied in horses but has produced low and inconsistent response. Treatment response varies in horses depending on the type of gastric ulcer syndrome treated. Patients with ESGD respond much more favorably to omeprazole than those with EGGD. In horses, it is recommended that at least 4 weeks of treatment is needed for full healing in addition to other changes in diet and feeding. To achieve the full extent of acid suppression, it is recommended to administer omeprazole to horses 60\u201390 minutes before feeding so that the peak concentration occurs at the time that the proton pumps in the stomach are maximally activated. This recommendation may also apply to treating other animals, such as dogs and cats. Twice- daily administration produces more consistent acid suppression to maintain the stomach pH above 3\u20134 than once- daily administration. Because there are no small animal formulations available, the human forms have been administered to dogs and cats, and the equine formulation has been diluted in oil to 10 and 40 mg/mL (see the Formulations section) for administration to small animals. Studies with the equine formulation compounded in oil have shown that the equine formulation administered orally to dogs can be efficacious. Patient Monitoring and Laboratory Tests Omeprazole\\tand\\tPPIs\\tare\\tgenerally\\tconsidered\\tsafe.\\tNo\\troutine\\ttests\\tfor\\tmonitoring adverse effects are recommended. If gastrin concentrations are measured, a 7- day withdrawal from omeprazole treatment should be used; otherwise, there is a significant increase in serum gastrin concentrations from omeprazole treatment. Formulations \u2022\\t\\tHuman\\tformulations:\\t20-mg\\tgeneric\\tcapsules.\\tZegerid\\tis\\tavailable\\teither\\tas\\t40-\\t\\tor 20- mg capsules with 1100 mg of sodium bicarbonate. Zegerid is also available either as 40- mg or 20- mg single- dose packets of powder for oral suspension with 1680 mg of sodium bicarbonate. \u2022\\t\\tEquine\\tpaste,\\tGastroGard.\\tThe\\tover-\\tthe-\\t  counter\\tequine\\tpaste\\tis\\tUlcerGard.\\tPaste for horses is 370 mg/g of paste in a buffered formulation to prevent degradation in the stomach. Gastrozol is an enteric- coated formulation in a paste for horses available in Australia but is not approved in the United States. Compounded Formulations \u2022\\t\\tStudies\\tusing\\tcompounded\\tproducts\\tfrom\\tnon\u2013Food\\tand\\tDrug\\tAdministration (FDA) formulations in horses failed to produce therapeutic effects. \u2022\\t\\tCompounded\\tformulations\\tfor\\tdogs\\tand\\tcats\\thave\\tused\\tthe\\tapproved\\tequine\\tpaste. The equine formulation can be diluted in corn oil, cod liver oil, or sesame oil for small animal use because otherwise, it is very concentrated. It has been diluted to 10 and 40 mg/mL by suspending the approved equine oral paste formulation in oil and stored at controlled cold temperature (7\xb0C) and protected from light. The formulation has been stable for 6 months. \u2022\\t\\tExtemporaneously\\tprepared\\tomeprazole\\tcan\\tbe\\tprepared\\tfrom\\toral\\tcapsules.\\tEmpty the contents of five 20- mg capsules in 50 mL of 8.4% sodium bicarbonate solution for a final concentration of 2 mg/mL. This solution is stable for up to 14 days at 24\xb0C and for up to 30 days at 5\xb0C and \u221220\xb0C. \u2022\\t\\tIV\\tforms\\tof\\tomeprazole\\thave\\tbeen\\tformulated\\tin\\tsterile\\twater\\tand\\tadministered\\tto experimental horses, but these formulations are not commercially available. O Ondansetron Hydrochloride 671 Stability and Storage Omeprazole should be maintained in the manufacturer\u2019s original formulation (capsules or paste) for optimum stability and effectiveness. It is stable at pH 11 but rapidly decomposes at a pH less than 7.8.","original_category":"Antiulcer agent"},{"name":"Oxtriphylline","active_ingredient":"Oxtriphylline","species":["Canine"],"dosage":"Dogs \u2022\\t\\t47\\tmg/kg\\t(equivalent\\tto\\t30\\tmg/kg\\ttheophylline)\\tq12h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tOral\\tabsorption\\thas\\tnot\\tbeen established for ruminants. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Oxybutynin Chloride oks- ih- byoo\u2032tih- nin  klor\u2032ide Trade and other names: Ditropan","contraindications":"Contraindications and Precautions Some patients may be at a higher risk for adverse effects. Such patients may include animals with cardiac disease, animals prone to arrhythmias, and animals at risk for seizures. Drug Interactions Drugs that inhibit cytochrome P450 enzymes may increase drug concentrations and cause toxicity. See Appendix I for a list of drugs that may be P450 inhibitors. 684    Oxybutynin Chloride","indications":"Indications and Clinical Uses Oxtriphylline has been used for similar respiratory conditions, as is theophylline. It is indicated in patients with reversible bronchoconstriction, such as dogs with airway disease. The use of oxtriphylline has diminished considerably, and it is more convenient and preferable to administer theophylline in most cases. Large animal uses have not been reported. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are the same as for theophylline and include nausea, vomiting, and diarrhea. With high doses, tachycardia, excitement, tremors, and seizures are possible. Cardiovascular\\tand\\t  CNS\\t  adverse\\t   effects\\t   appear\\t   to\\t be\\t less\\t  frequent\\tin\\t dogs\\t  than\\t  in\\t people.","notes":"Instructions for Use Some formulations (Theochron) contain oxtriphylline and guaifenesin. When administering a slow- release tablet, do not crush it. Theophylline, which may be more readily available for oral administration, may be substituted for oxtriphylline. Patient Monitoring and Laboratory Tests Therapeutic drug monitoring is recommended for chronic therapy. Interpretation of theophylline concentrations should be used to guide therapy. Generally, 10\u201320 mcg/ mL is considered therapeutic. Formulations \u2022\\t\\tOxtriphylline\\tis\\tavailable\\tin\\t400-\\t\\tand\\t600-\\tmg\\ttablets.\\t(Oral\\tsolutions\\tand\\tsyrup\\tare available in Canada but not in the United States.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Bronchodilator"},{"name":"Oxybutynin Chloride","active_ingredient":"Oxybutynin Chloride","species":["Canine"],"dosage":"Dogs \u2022\\t\\t0.2\\tmg/kg\\tq12h\\tPO;\\tfor\\tlarger\\tdogs,\\tuse\\t5\\tmg/dog\\tq6\u20138h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. Oral absorption has not been established for ruminants. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Oxymetholone oks- ih- meth\u2032oh- lone Trade and other names: Anadrol","contraindications":"Contraindications and Precautions Use cautiously in animals with heart disease or decreased intestinal motility. Use cautiously in animals with glaucoma. Drug Interactions Oxybutynin will potentiate other antimuscarinic drugs.","indications":"Indications and Clinical Uses Oxybutynin chloride has been used primarily to increase bladder capacity and to decrease spasms of the urinary tract. In people, it is used to treat urinary incontinence, but the use in animals is not common and not well documented. O Oxymetholone 685 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to anticholinergic effects (atropine- like effects), but they are less frequent compared with other anticholinergic drugs. Constipation, dry mouth, and dry mucous membranes are possible from routine use. If an overdose occurs, administer physostigmine for treatment to reverse the anticholinergic effects.","notes":"Instructions for Use Results of clinical studies in animals are not available. The use in animals (and doses) is based on extrapolation from the experience in people or anecdotal experience in animals. Although oxybutynin increases urine retention by decreasing bladder spasms, it may not be effective to treat incontinence in animals with decreased sphincter tone. Other agents are preferred for treatment of animals with incontinence caused by poor sphincter tone, such as phenylpropanolamine (PPA) and estrogens (e.g., estriol or diethylstilbestrol [DES]). Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tOxybutynin\\tis\\tavailable\\tin\\t5-\\tmg\\ttablets\\tand\\t1-\\tmg/mL\\toral\\tsyrup. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Oxybutynin is soluble in water and ethanol.","original_category":"Anticholinergic"},{"name":"Oxytocin","active_ingredient":"Oxytocin","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t5\u201320\\tunits\\tper\\tdog\\tIM\\tor\\tSQ\\t(repeat\\tevery\\t30\\tminutes\\tfor\\tprimary\\tinertia).\\tNote: The manufacturer\u2019s label lists higher doses of 5\u201330 units per dog. \u2022\\t\\tTo\\tfacilitate\\tmilk\\tletdown\\tin\\tthe\\tearly\\tstages\\tof\\tlactation:\\t2\u20135\\tunits\\tper\\tdog\\tIM administered 15\u201330 minutes prior to nursing. Cats \u2022\\t\\t2.5\u20133\\tunits\\tper\\tcat\\tIM\\tor\\tIV.\\tRepeat\\tup\\tto\\tthree\\ttimes\\tevery\\t30\u201360\\tminutes. (Maximum dose is 3 units/cat.)  \u2022\\t\\tNote:\\tThe\\tfollowing\\tdoses\\tare\\tall\\ton\\ta\\tper-\\tanimal\\tbasis\\trather\\tthan\\ta\\tper-\\tkilogram basis, and some doses from experts may vary from the approved label dose. Cattle \u2022\\t\\tTo\\tstimulate\\tuterine\\tcontractions:\\t30\\tunits\\tIM\\tand\\trepeat\\tin\\t30\\tminutes\\tif necessary. (Manufacturer lists 100 units per cow.) \u2022\\t\\tFor\\tretained\\tplacenta:\\t20\\tunits\\tIM\\tgiven\\timmediately\\tafter\\tcalving\\tand\\trepeated\\tin 2\u20134 hours. \u2022\\t\\tFor\\tmilk\\tletdown:\\t10\u201320\\tunits\\tper\\tcow\\tIV\\tor\\tIM. Mares \u2022\\t\\tTo\\tstimulate\\tuterine\\tcontractions:\\t20\\tunits\\tIM.\\t(Manufacturer\\tlists\\t100\\tunits\\tper mare.) \u2022\\t\\tFor\\tretained\\tplacenta:\\t30\u201340\\tunits\\tIM\\tat\\t60-\\t\\tto\\t90-\\tminute\\tintervals\\tor\\tadd\\t80\u2013100 units\\tto\\t500\\tmL\\tof\\tsaline\\tsolution\\tand\\tgive\\tIV. \u2022\\t\\tTo\\tsuppress\\testrus\\tbehavior\\tin\\tmares:\\t60\\tunits\\tper\\tmare\\tIM\\tonce\\tor\\ttwice\\tdaily\\ton days 7\u201314 post- ovulation. Small Ruminants and Sows \u2022\\t\\t5\u201310\\tunits\\tIM.\\t(Manufacturer\\tlists\\t30\u201350\\tunits\\tper\\tanimal.) Regulatory Information No\\twithdrawal\\ttimes\\thave\\tbeen\\treported.\\tBecause\\tof\\ta\\tlow\\trisk\\tof\\tresidues\\tand\\trapid clearance after administration, a 24- hour withdrawal time is suggested. 694    Paclitaxel Paclitaxel pak\u2032li tax\u2032el Trade and other names: Abraxane and Taxol (human formulations)","contraindications":"Contraindications and Precautions Do not administer to pregnant animals unless for induction of parturition. Do not administer unless the cervix is fully relaxed. Do not use if there is abnormal presentation of the fetus. Women, especially if pregnant, should take extra care when handling oxytocin. Drug Interactions Beta- adrenergic agonists will inhibit induction of labor. O","indications":"Indications and Clinical Uses Oxytocin is used to induce or maintain normal labor and delivery in pregnant animals. In surgery, it may be used postoperatively after cesarean section to facilitate involution and resistance to the large inflow of blood. In large animals, oxytocin is used to augment uterine contractions and stimulate lactation. Oxytocin does not increase milk production, but it stimulates contraction, leading to milk ejection. It contracts smooth muscle cells of the mammary gland for milk letdown if the udder is in a proper physiological state. It is also used to expel the placenta after delivery. However, efficacy for retained placenta is questionable, and some experts believe that estrogen should be administered in addition to oxytocin. Oxytocin administered prior to luteolysis (prior to day 10 postovulation in horses) prolongs corpus luteum function and suppresses estrus behavior in mares. In small animals, oxytocin is used as a treatment for nonobstructive dystocia caused by uterine inertia. The efficacy for this use is mostly based on anecdotal accounts from reproduction experts. Based on the mechanism described, it does not increase milk production in bitches or queens, but it may help empty the mammary gland of previously produced milk. Small doses administered to dogs prior to puppy suckling may help with milk letdown early in the lactation period. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are uncommon if used carefully. However, careful monitoring of labor is necessary during its use.","notes":"Instructions for Use Oxytocin is used to induce labor. In people, oxytocin is administered via injection, CRI, or intranasal solution. Animal uses are listed in the dosing section for each species. Patient Monitoring and Laboratory Tests Fetal stress and progression of normal labor should be monitored closely. Formulations \u2022\\t\\tOxytocin\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tunits/mL\\tinjection\\tand\\t40-\\tunits/mL\\tnasal solution. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Labor induction"},{"name":"Pamidronate Disodium","active_ingredient":"Pamidronate Disodium","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tTreatment\\tfor\\thypercalcemia:\\t1\u20132\\tmg/kg\\tIV\\tor\\tSQ. \u2022\\t\\tTreating\\tmalignant\\tosteolytic\\tdisease:\\t1\u20132\\tmg/kg\\tIV\\tevery\\t28\\tdays\\tas\\ta\\t2-\\thour\\tIV infusion. \u2022\\t\\tTreatment\\tof\\tcholecalciferol\\ttoxicosis:\\t1.3\u20132\\tmg/kg\\tIV\\tor\\tSQ\\tfor\\ttwo\\ttreatments after toxin exposure. Cats \u2022\\t\\tTreatment\\tof\\thypercalcemia:\\t1\u20131.5\\tmg/kg\\tIV.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. 698    Pancreatic Enzyme Replacement (Pancrelipase) Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Pancreatic Enzyme Replacement (Pancrelipase) pan- kreh- lye\u2032pase Trade and other names: Viokase, Pancrezyme, Creon, Pancreaze, Pertzye, Zenpep, and Ultrase","contraindications":"Contraindications and Precautions Although SQ administration is listed in dose protocols, the IV route is preferred. Do not administer to animals with kidney disease and ensure animals are well hydrated prior to administration. Do not administer to animals with conditions that may be associated with hypocalcemia. Drug Interactions Do not mix with solutions containing calcium (e.g., lactated Ringer\u2019s solution).","indications":"Indications and Clinical Uses Pamidronate, like other bisphosphonate drugs, is used in people to treat osteoporosis and treatment of hypercalcemia of malignancy. In animals, pamidronate is used to decrease calcium in conditions that cause hypercalcemia, such as cancer and vitamin D toxicosis. It is helpful for managing neoplastic complications and pain associated with pathologic bone resorption caused by cancer. It also may provide pain relief in patients with pathologic bone disease and may reduce glucocorticoid- induced osteoporosis. Experimental work performed in dogs has shown it to be effective for treating cholecalciferol toxicosis, but it did not prevent decreases in renal function. After treating for hypercalcemia in dogs, the duration of effect was 11 days to 9 weeks (median, 8.5 weeks). Some bisphosphonates (see Tiludronate and Clodronate) are approved to treat bone pain in horses caused by navicular disease. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Fever, joint pain, and myalgias have been observed from pamidronate administration, but otherwise no serious adverse effects have been identified. However,\\tthe\\tuse\\tin\\tanimals\\thas\\tnot\\tbeen\\tcommon\\tenough\\tto\\tidentify\\ta\\twider range of adverse effects. One study in dogs reported a slight decrease in food intake. In humans, acute renal necrosis after IV administration has been reported. Because pamidronate is eliminated by the kidneys in dogs, a dose- dependent nephropathy is possible, and the risk of renal injury is more likely with doses exceeding 3 mg/ kg IV. In people, there is some concern that the use of bisphosphonates produces excessive mineralization and hardening of the bone, which may result in a greater risk\\tof\\tfractures.\\tHowever,\\tthis\\teffect\\thas\\tnot\\tbeen\\treported\\tfor\\tanimals.","notes":"Instructions for Use For IV infusion, dilute in fluid solution (0.9% saline) and administer over 2 hours. (Dilute 30 mg pamidronate in 250 mL of fluids.) Infusion can be repeated every 7 days. Although the SQ route is listed for some veterinary applications, it is not recommended, and IV infusion is the preferred route. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Treatment of vitamin D toxicosis with pamidronate may result in decreased renal function. Monitor urea nitrogen, creatinine, urine- specific gravity, and food intake in treated animals. Formulations \u2022\\t\\tPamidronate\\tis\\tavailable\\tin\\t30-\\t,\\t60-\\t  ,\\tand\\t90-\\tmg\\tvials\\tfor\\tinjection\\tand\\t1\\tmg/mL\\tin single- use vials for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Vials may be diluted in fluid solutions (e.g., 250 mL 0.9% sodium chloride) and infused over 2 hours or as long as 24 hours. Diluted solutions are stable for 24 hours at room temperature.","original_category":"Antihypercalcemic"},{"name":"Pancuronium Bromide","active_ingredient":"Pancuronium Bromide","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.1\\tmg/kg\\tIV\\tor\\tstart\\twith\\t0.01\\tmg/kg\\tand\\tadditional\\t0.01-\\tmg/kg\\tdoses\\tevery 30 minutes. \u2022\\t\\tConstant-\\trate\\tinfusion\\t(CRI):\\t0.1\\tmg/kg\\tIV\\tfollowed\\tby\\ta\\t2-\\tmcg/kg/min infusion.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t2 Pantoprazole pan- toe- pray\u2032zole Trade and other names: Protonix","contraindications":"Contraindications and Precautions Do not use in patients unless mechanical ventilation support can be provided. Provide additional pain relief when administered during surgery. Drug Interactions Some drugs may potentiate the action (e.g., aminoglycosides) and should not be used concurrently.","indications":"Indications and Clinical Uses Pancuronium is a paralytic agent used during anesthesia or for mechanical ventilation. It is used primarily during anesthesia or other conditions in which it is necessary to inhibit muscle contractions. It is sometimes used as an alternative to atracurium because it is longer acting. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pancuronium\\tproduces\\trespiratory\\tdepression\\tand\\tparalysis.\\tNeuromuscular blocking drugs have no effect on analgesia.","notes":"Instructions for Use Administer only in situations in which careful control of respiration is possible. Doses may need to be individualized for optimum effect. Do not mix with alkalinizing solutions or lactated Ringer\u2019s solution. P Pantoprazole 701 Patient Monitoring and Laboratory Tests Monitor patient\u2019s respiration rate, heart rate, and rhythm during use. If possible, monitor the oxygenation status during anesthesia. Formulations \u2022\\t\\tPancuronium\\tis\\tavailable\\tin\\ta\\t1-\\t\\tand\\t2-\\tmg/mL\\tinjection. Stability and Storage Stable if stored in a tightly sealed container, protected from light, and at room temperature for 24 hours.","original_category":"Muscle relaxant"},{"name":"Pantoprazole","active_ingredient":"Pantoprazole","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.5\u20130.6\\tmg/kg,\\tup\\tto\\t1\\tmg/kg,\\ttwice\\tdaily\\tPO. \u2022\\t\\tIV\\tadministration\\t(24\\thours):\\t0.5\u20131\\tmg/kg\\tIV\\tinfusion\\tover\\t24\\thours.\\tThis\\tdose may be delivered in 2 or 15 minutes (see next section). \u2022\\t \\tIV\\tadministration\\t(2\\tor\\t15\\tminutes):\\tFirst\\tflush\\tthe\\tIV\\tline.\\tAdminister\\tpantoprazole via an IV line with dextrose 5% injection, sodium chloride 0.9% injection, or Ringer\u2019s lactate injection. For the 2- minute infusion, mix 40 mg of powder with 10 mL of sodium chloride 0.9% injection for a final concentration of 4 mg/mL. Infuse a 1-   mg/kg dose over 2 minutes. For a 15- minute infusion, mix a 40- mg vial with 10 mL of sodium chloride 0.9% injection. Then further admix this solution with 100 mL of dextrose 5% injection, sodium chloride 0.9% injection, or Ringer\u2019s lactate injection to a total volume of 110 mL, producing a solution with a final concentration of approximately 0.4 mg/mL. Administer the final dose (1 mg/kg) over 15 minutes.  \u2022\\t\\tNo\\tdose\\tis\\treported\\tfor\\tlarge\\tanimals.\\tDoses\\thave\\tbeen\\textrapolated\\tfrom\\thuman use (0.5 mg/kg q24h IV), and infusion protocols listed previously for small animals have been used. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t5 Paregoric pare- eh- gore\u2032ik Trade and other names: Corrective mixture","contraindications":"Contraindications and Precautions No\\tknown\\tcontraindications. Drug Interactions Do not mix IV solution with other drugs. Do not administer with drugs that depend on stomach acid for absorption (e.g., ketoconazole, itraconazole, iron supplements). PPIs may inhibit some drug- metabolizing enzymes (CYP450 enzymes), although in people, there was a low risk of drug interactions caused by enzyme inhibition. In people, there may be an increased risk of intestinal injury when PPIs are administered with nonsteroidal anti- inflammatory drugs (NSAIDs),\\tbut\\tthis\\thas\\tnot\\tbeen\\tstudied\\tin\\tanimals.","indications":"Indications and Clinical Uses Pantoprazole is used for treatment and prevention of GI ulcers and gastroesophageal reflux. Other PPIs include omeprazole, esomeprazole, lansoprazole (Prevacid), and rabeprazole\\t(AcipHex).\\tAll\\tPPIs\\tact\\tvia\\ta\\tsimilar\\tmechanism\\tand\\tare\\tequally\\teffective. However,\\tthere\\thas\\tbeen\\tmore\\texperience\\twith\\tomeprazole\\tin\\tanimals\\tthan\\tthe other drugs of this group. In dogs, pantoprazole (1 mg/kg) maintained a stomach pH\\tgreater\\tthan\\t3\u20134\\twhen\\tadministered\\tIV,\\twhich\\tis\\tthe\\tpH\\tnecessary\\tfor\\tulcer prevention and healing. Pantoprazole, being the only one in an IV formulation, is often used when an IV drug is preferred for treatment. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side\\teffects\\thave\\tnot\\tbeen\\treported\\tin\\tanimals.\\tHowever,\\tin\\tpeople,\\tthere\\tis concern about hypergastrinemia with chronic use. This has not been a concern in animals. Overgrowth of Clostridium bacteria has been a concern from chronic use because of chronic gastric acid suppression, but the clinical importance of this concern in animals has not been established. In people, the PPI may increase the risk of kidney disease, but this problem has not been reported in animals.","notes":"Instructions for Use For treating GI ulcers, administer once per day for 7\u201310 days. For gastrin- secreting tumors, use higher dose (1 mg/kg) twice daily. The primary advantage with pantoprazole compared with other PPIs is that it is available in an IV dosage formulation and can be mixed with fluid solutions. For IV use, mix a 40- mg vial with 10 mL of saline and further dilute with saline, lactated Ringer\u2019s solution, or 5% dextrose to 0.4 mg/mL. Administer IV infusion over 2 minutes or 15 minutes. Follow directions below for IV infusion. If administering the enteric- coated oral tablets, do not crush. Oral tablets can be administered with or without food. PPIs may be more effective if administered 30 minutes prior to feeding. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary.\\tWhen\\ttreating\\tulcers,\\tmonitor\\thematocrit\\tor CBC to detect bleeding. Monitor for signs of vomiting and diarrhea. Formulations \u2022\\t\\tPantoprazole\\tis\\tavailable\\tas\\t20-\\t\\tand\\t40-\\tmg\\tdelayed-\\trelease\\ttablets.\\tThere\\tare\\talso granules for oral suspension (40 mg), which have been mixed with apple juice or applesauce for administration in people. \u2022\\t\\tPantoprazole\\tfor\\tIV\\tuse:\\tAvailable\\tas\\ta\\t40-\\tmg\\tvial\\t(diluted\\tto\\t4\\tmg/mL).\\tFor\\tIV infusion, reconstitute the 40- mg/kg vial with 10 mL of normal saline. Further dilute this solution with 100 mL of 5% dextrose, normal saline, or lactated Ringer\u2019s solution to a final concentration of 0.4 mg/mL. To prepare a larger dose (80 mg), reconstitute two vials each with 10 mL of normal saline; combine the content of both vials; and further dilute with 80 mL of 5% dextrose, normal saline, or lactated Ringer\u2019s solution to a final concentration of 0.8 mg/mL. \u2022\\t\\tPantoprazole\\tcompounded\\toral\\tsuspension:\\tTo\\tprepare\\ta\\t2-\\tmg/mL\\tpantoprazole oral suspension, mix pantoprazole tablets with sterile water and sodium bicarbonate powder. Crush 40 tablets in a mortar and reduce to a fine powder. Mix in with 340\\tmL\\tof\\tsterile\\twater.\\tNext,\\tadd\\t16.8\\tg\\tof\\tsodium\\tbicarbonate\\tpowder\\tand P Paregoric 703 stir (approximately 20 minutes) until the tablets are fully disintegrated. Then add another\\t16.8\\tg\\tof\\tsodium\\tbicarbonate\\tpowder\\tand\\tstir\\tagain\\tfor\\t5\\tminutes\\tuntil\\tall the powder has dissolved. Add enough water to bring the final volume to 400 mL. Transfer the entire contents to an amber- colored bottle and store in a refrigerator. Label\\twith\\ta\\t\u201cshake\\twell\u201d\\tlabel.\\tThis\\tmay\\tbe\\tstable\\tif\\tstored\\tin\\trefrigerator\\tfor\\t62 days and administered at the doses listed. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Keep tablets at room temperature. Once reconstituted, the vials are stable at room temperature\\tfor\\t6\\thours.\\tDo\\tnot\\tfreeze\\treconstituted\\tsolutions.\\tWhen\\tfurther\\tdiluted for\\tIV\\tuse,\\tit\\tis\\tstable\\tfor\\tup\\tto\\t96\\thours\\tat\\troom\\ttemperature.\\tThe\\tdiluted\\t(4-\\tmg/mL) solution may be stored in refrigerator for 28 days. The oral compounded form prepared from\\ttablets\\t(see\\tearlier\\tdirections)\\tcan\\tbe\\tstored\\tin\\ta\\trefrigerator\\tfor\\t62\\tdays.","original_category":"Antiulcer agent"},{"name":"Paregoric","active_ingredient":"Paregoric","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.05\u20130.06\\tmg/kg\\tq12h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Schedule III Controlled Substance. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Paromomycin Sulfate pare- oe- moe- mye\u2032sin sul\u2032fate Trade and other names: Humatin; also known as aminosidine","contraindications":"Contraindications and Precautions Paregoric contains opium and may be abused by humans. Use cautiously in horses and ruminants because intestinal motility may be decreased. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Paregoric decreases signs of diarrhea via opiate effects, but its use is somewhat outdated. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like all opiates, side effects are predictable and unavoidable. Side effects may include sedation, constipation, and bradycardia. Respiratory depression occurs with high doses. Tolerance and dependence occur with chronic administration.","notes":"Instructions for Use Use of paregoric has been replaced by more specific products such as loperamide or diphenoxylate. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tFor\\tevery\\t5\\tmL\\tof\\tparegoric,\\tthere\\tis\\t2\\tmg\\tof\\tmorphine. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidiarrheal"},{"name":"Paroxetine","active_ingredient":"Paroxetine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tmg/kg/day\\tPO.\\tFor\\tsome\\tcompulsive\\tdisorders,\\tincrease\\tthe\\tdosage\\tto\\t1\\tmg/ kg q24h PO. Cats \u2022\\t \\tOne\\t  eighth\\t   to\\t one\\t  fourth\\t   of\\t a\\t 10-\\t mg\\t  tablet\\t   per\\t  cat\\t daily\\t  PO\\t  (approximately\\t0.5\\t  mg/kg q24h). For urine spraying in cats, some have responded to every- other- day treatment.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. RCI\\tClassification:\\t2 708    Penicillamine Penicillamine pen- ih- sill\u2032ah- meen Trade and other names: Cuprimine and Depen","contraindications":"Contraindications and Precautions Use cautiously in patients with heart disease. Do not use in pregnant animals. There is a risk of fetal malformations if used early in pregnancy. Serotonin- reuptake inhibitors can increase the risk of bleeding by inhibiting serotonin uptake by platelets, but this has not been reported in animals. Drug Interactions Do not use with monoamine oxidase inhibitors (MAOIs), such as selegiline. Do not use with other behavior- modifying drugs, such as other SSRIs or TCAs.","indications":"Indications and Clinical Uses Paroxetine, like other SSRI drugs, is used to treat behavioral disorders such as compulsive disorders (canine compulsive disorder), anxiety, and dominance aggression. In cats, it has been effective for decreasing urine spraying. Because of the small tablet size, some veterinarians have found it easy to administer to cats and small dogs. The use in animals is based on small observational studies, particularly in cats. Experts in veterinary behavior have recommended paroxetine as an alternative to other SSRI agents, and TCAs. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Paroxetine is similar to fluoxetine, but in some animals, paroxetine is better tolerated. Adverse effects observed in dogs and cats include constipation and decreased appetite. Decreased appetite in cats is more common at higher doses.","notes":"Instructions for Use Dosing recommendations are empirical. Paroxetine has been used for conditions similar to what has been treated with fluoxetine (Prozac, Reconcile). In cats, the small tablet size has made it easier to administer convenient doses compared with chewable tablets or other drugs available in capsules. Paroxetine has caused constipation in some animals, and veterinarians may administer a feline laxative for the first week of therapy to avoid problems. Sudden discontinuation of serotonin reuptake inhibitors can produce other behavior problems, such as anxiety, signs of agitation, and nervousness. If treatment is discontinued, gradually withdraw the medication. Patient Monitoring and Laboratory Tests Use in animals has been relatively safe, and one should only monitor behavior changes. Formulations \u2022\\t\\tParoxetine\\tis\\tavailable\\tin\\t10-\\t,\\t20-\\t  ,\\t30-\\t  ,\\tand\\t40-\\tmg\\ttablets\\tand\\t2-\\tmg/mL\\toral suspension. Stability and Storage Stable if stored in manufacturer\u2019s original formulation. Although paroxetine has been compounded for veterinary use, the potency and stability have not been evaluated for compounded products.","original_category":"Behavior modification"},{"name":"Penicillamine","active_ingredient":"Penicillamine","species":["Canine","Feline","Equine","Bovine"],"dosage":"agent. Trientine has been administered to dogs at a dosage of 10\u201315 mg/kg q12h PO. Precautionary Information  Dogs and Cats \u2022\\t\\t10\u201315\\tmg/kg\\tq12h\\tPO,\\tbest\\tadministered\\t30\\tminutes\\tbefore\\ta\\tmeal. \u2022\\t\\tDoberman\\tpinschers:\\tuse\\t250\\tmg\\tper\\tdog\\tq12h\\tPO.  Horses and Cattle \u2022\\t\\t10\u201315\\tmg/kg\\tq12h\\tPO. Regulatory Information Cattle\\twithdrawal\\ttime:\\t21\\tdays\\tfor\\tmeat;\\t3\\tdays\\tfor\\tmilk.\\tFor\\twithdrawal\\ttimes\\tfor doses administered extralabel, contact FARAD at www.FARAD.org. Penicillin G Trade and other names: Penicillin G potassium or sodium, Penicillin G benzathine (BenzaPen), Penicillin G, Procaine, and generic Penicillin V (Pen- Vee)","contraindications":"Contraindications and Precautions Do not use in pregnant animals. There appears to be little cross- reaction between penicillin and penicillamine in allergic animals. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Penicillamine has been used in people to treat rheumatoid arthritis. The primary use in animals is for treatment of copper toxicity and hepatitis associated with accumulation of copper. Treatment duration for animals with copper- storage hepatic disease may require 2\u20134 months. It also has been used to treat cystine calculi. Although it may inhibit collagen and reduce fibrosis in patients with hepatic disease, this effect has been disappointing in clinical patients. There is no clear demonstration that it is efficacious for this indication. Penicillamine has recently become highly expensive for use in animals, and other alternatives are being investigated. An alternative to consider, if formulations are available, is trientine (triethylenetetramine dihydrochloride), another copper chelating","side_effects":"Adverse Reactions and Side Effects The most common adverse effects are anorexia and vomiting. In people, allergic reactions, cutaneous reactions, agranulocytosis, and anemia have been reported. It has also produced proteinuria and hematuria and in cats has caused neutropenia. In dogs treated for liver disease, corticosteroid- like hepatopathy has been observed. Therefore it may produce steroid- like effects in the liver.","notes":"Instructions for Use Administer\\ton\\tan\\tempty\\tstomach\\t(at\\tleast\\t30\u201360\\tminutes\\tbefore\\tmeals). Patient Monitoring and Laboratory Tests Monitor liver biochemistry tests during treatment. Monitor metal concentrations if used to treat intoxication. P Penicillin G 709 Formulations Penicillamine is available in 125-  and 250- mg capsules and 250- mg tablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Penicillamine is soluble in water. Preparations of penicillamine in a suspension for oral use have been combined with syrups and flavorings and were stable for 5 weeks.","original_category":"Antidote"},{"name":"Pentastarch","active_ingredient":"Pentastarch","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tCRI:\\t10\u201325\\tmL/kg/day\\tIV. Cats \u2022\\t\\tCRI:\\t5\u201310\\tmL/kg/day\\tIV.  Horses \u2022\\t\\t8\u201315\\tmL/kg\\tor\\tdelivered\\tas\\tCRI\\t0.5\u20131\\tmL/kg/h\\tIV. \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tother\\tlarge\\tanimals. Regulatory Information No\\tregulatory\\trequirements. Pentazocine pen- taz\u2032oh- seen Trade and other names:  Talwin- V","contraindications":"Contraindications and Precautions No\\tcontraindications\\tare\\treported\\tfor\\tanimals. Drug Interactions Pentastarch is compatible with most fluid solutions.","indications":"Indications and Clinical Uses Pentastarch is used primarily to treat acute hypovolemia and shock. It is administered intravenously in acute situations. Pentastarch has a duration of effective volume expansion of 12\u201348 hours. Pentastarch is used in similar situations as hetastarch, but it is used less frequently. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There has only been limited use in veterinary medicine; therefore, adverse effects\\thave\\tnot\\tbeen\\treported.\\tHowever,\\tit\\tmay\\tcause\\tallergic\\treactions\\tand hyperosmotic renal dysfunction. Coagulopathies are possible but are rare and less likely than with hetastarch.","notes":"Instructions for Use Pentastarch is used in critical care situations and is infused via CRI. Pentastarch may be more effective and produce fewer side effects than Dextran. Because of lower molecular weight, it can be infused more quickly than hetastarch. Patient Monitoring and Laboratory Tests Monitor patient\u2019s hydration status and blood pressure during administration. Formulations \u2022\\t\\tPentastarch\\tis\\tavailable\\tin\\ta\\t10%\\tinjectable\\tsolution. Stability and Storage Pentastarch is stable in original packaging. Compatible with most fluid administration sets. P Pentazocine 713","original_category":"Fluid replacement"},{"name":"Pentoxifylline","active_ingredient":"Pentoxifylline","species":["Canine","Feline","Equine"],"dosage":"effective dosage may be as high as 30 mg/kg q8\u201312h in dogs to achieve effective levels. Indications for dermatology have used a regimen of q12h, but a frequency of q8h may be considered to get an optimum response in some patients.  Dogs \u2022\\t\\tDermatologic\\tuse:\\t10\\tmg/kg\\tq12h\\tPO,\\tup\\tto\\t15\\tmg/kg\\tq8h\\tPO. \u2022\\t\\tFamilial\\tcanine\\tdermatomyositis:\\t25\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tOther\\tuses:\\t10\u201315\\tmg/kg\\tq8\\tPO\\tor\\t400\\tmg/dog\\tfor\\tmost\\tanimals. 718    Pergolide, Pergolide Mesylate Cats \u2022\\t\\tOne\\tfourth\\tof\\ta\\t400-\\tmg\\ttablet\\tper\\tcat\\t(100\\tmg)\\tq8\u201312h\\tPO.  Horses \u2022\\t\\t8.5\\tmg/kg\\tq8h\\tIV\\tor\\t10\\tmg/kg\\tq8h\\tPO\\t(oral\\tabsorption\\tis\\tunpredictable). \u2022\\t\\tRespiratory\\tdisease\\t(airway\\tobstruction):\\t36\\tmg/kg\\tq12h\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Pergolide, Pergolide Mesylate per\u2032goe- lide Trade and other names: Prascend (equine formulation) and Permax","contraindications":"Contraindications and Precautions None\\treported.\\tBroken\\ttablets\\ttaste\\tunpleasant\\twhen\\tadministered\\tto\\tcats. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.\\tHowever,\\tbecause\\tpentoxifylline\\tis\\tfrom\\tthe methylxanthine class, adverse reactions are possible from coadministration with a cytochrome P450 inhibitor (see Appendix I).","indications":"Indications and Clinical Uses Most of pentoxifylline\u2019s use in animals (including doses) is based on anecdotal experience, small observational studies, or recommendations from clinical experts. P Pentoxifylline is used in dogs for some dermatoses, vasculitis, contact allergy, atopy, familial canine dermatomyositis, to improve survival of skin flaps, to improve healing from radiation injury, and erythema multiforme. In horses, pentoxifylline is used for a variety of conditions in which suppression of inflammatory cytokines or increased blood perfusion is desired. Such conditions have included\\tintestinal\\tischemia,\\tcolic,\\tsepsis,\\tlaminitis,\\tand\\tnavicular\\tdisease.\\tHowever, the efficacy for treating these diseases has not been shown. In experimental studies of sepsis in horses, it has improved efficacy of treatment and reduced inflammatory mediators\\twhen\\tcombined\\twith\\tan\\tNSAID\\t(flunixin). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pentoxifylline may cause effects similar to those of other methylxanthines, such\\tas\\tnausea,\\tvomiting,\\tand\\tdiarrhea.\\tNausea,\\tvomiting,\\tdizziness,\\tand headache have been reported in people. Vomiting is reported in dogs. Broken tablets taste unpleasant when administered to cats. If crushed tablets are used, plasma concentration increases more rapidly than with intact tablets, leading to headaches, nausea, and possible vomiting. In horses, IV doses have caused muscle fasciculations, increased heart rate, and sweating.","notes":"Instructions for Use Although pharmacokinetic studies in dogs and horses have been reported, results of clinical studies in animals have been more limited. The doses listed in the dosing section (recommended by experts) may need to be increased based on pharmacokinetic studies that show a short half- life in dogs. For example, the most Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tPentoxifylline\\tis\\tavailable\\tin\\t400-\\tmg\\ttablets.\\tIV\\tsolution\\tis\\t50\\tmg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Aqueous solubility is only 77 mg/mL, which limits the amount that can be dissolved in compounded preparations. Oral suspensions may be stable for up to 90 days, but they settle, requiring resuspension (shaking) before oral administration.","original_category":"Anti- inflammatory  agent"},{"name":"Pergolide, Pergolide Mesylate","active_ingredient":"Pergolide, Pergolide Mesylate","species":["Equine"],"dosage":"\u2022\\t\\tSmall\\tanimal\\tdosages\\thave\\tnot\\tbeen\\testablished\\tbut\\thave\\tbeen\\textrapolated\\tfrom human use, which is to start with 1 mcg/kg (0.001 mg/kg) daily PO and increase the dose gradually by 2 mcg/kg at a time until desired effects are observed.  Horses \u2022\\t\\tStarting\\tdosage:\\t0.002\\tmg/kg\\t(2\\tmcg/kg)\\tq24h\\tPO\\t(1\\tmg/day\\tfor\\t500-\\tkg horse). After the starting dose, the dosage may be adjusted as needed (e.g., by 1-   mcg/kg increments) to effect, up to 4 mcg/kg daily, although a dosage of 10 mcg/kg per day has been used in some horses. Regulatory Information Do not administer to animals intended for food. Phenobarbital, Phenobarbital Sodium fee- noe- bar\u2032bih- tahl  and  fee- noe- bar\u2032bih- tahl  soe\u2032dee- um Trade and other names: Luminal, Phenobarbitone, and generic brands","contraindications":"Contraindications and Precautions Unlike bromocriptine, pergolide can be used in pregnant animals, but pregnant women or lactating women should avoid exposure. If tablets are broken or crushed, pergolide tablets may cause eye irritation, an irritating smell, or headache. Women in particular should avoid human exposure and skin contact when preparing tablets for horses. Drug Interactions Pergolide may interact with droperidol and phenothiazines (e.g., acepromazine), and it exacerbates the effects of selegiline. Do not administer with MAOIs.","indications":"Indications and Clinical Uses In people, pergolide has been used for neurodegenerative disease in which dopamine is deficient, such as Parkinson disease. For these indications, pergolide is used with levodopa\\tor\\tcarbidopa.\\tHowever,\\tpergolide\\thas\\tbeen\\tcommercially\\tunavailable\\tfor humans, and human use has diminished because of reports of cardiac valve damage associated with pergolide. In animals, specifically horses, it is also has been used for dopamine- deficient states. It is believed that horses and some dogs develop hyperadrenocorticism (Cushing disease)\u2014pituitary-\\tdependent\\thyperadrenocorticism\\t(PDH)\u2014because\\tof\\ta\\tloss\\tof dopamine\\tantagonism\\tof\\tACTH\\trelease. In horses, there is clinical evidence that it has successfully controlled PPID (equine Cushing syndrome). It has been used horses for longer than 2 years with success. Most P horses with PPID have hyperplasia or adenoma of the pars intermedia of the pituitary. This\\tadenoma\\tis\\tdeficient\\tin\\tdopamine\\tand\\tproduces\\texcess\\tACTH.\\tTherefore, administration\\tof\\tdopamine\\tagonists\\tacts\\tto\\tsuppress\\tACTH\\trelease\\tfrom\\tthe\\tpituitary and subsequently restore cortisol levels to normal states. Although pergolide is effective for controlling PPID in horses, it does not prevent laminitis in horses with PPID. The benefits of pergolide administration have not been established for dogs or other animals. Because of the adverse effects produced and the availability of other medications\\t(e.g.,\\ttrilostane,\\tmitotane),\\tpergolide\\tis\\tnot\\tused\\tfor\\ttreating\\tPDH\\tin\\tdogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pergolide is FDA approved for use in horses and has been evaluated for safety. In field trials, decreased appetite occurred but was usually transient. Weight loss, anorexia, diarrhea, colic, lethargy, and behavioral changes have been observed in some\\thorses.\\tCNS\\teffects\\tmay\\tinclude\\tataxia\\tand\\tdyskinesia.\\tWorsening\\tof\\tlaminitis from pergolide (it is theoretically a vasoconstrictive drug) has not been proved. Because some horses may have decreased appetite with pergolide, one can start treatment with a lower dose (half the dose) for the first 2 days in these horses before starting the full dose. Pergolide was withdrawn from the human market because of evidence that drugs that activate the 2b- serotonin receptor (5-\\t HT 2b ) are associated with a distinct form of fibrotic damage to heart valves (valvulopathy). These effects have not been observed in animals. Pergolide inhibits secretion of prolactin and increases growth hormone. It may inhibit lactation. In dogs, at doses of 100 mcg/kg, it produces significant reactions, including vomiting, tremors, anorexia, restlessness, and diarrhea.","notes":"Instructions for Use Use\\tin\\thorses\\tis\\toften\\taccomplished\\tby\\tstarting\\twith\\tthe\\tlow\\tdose\\tlisted\\tfor\\t4\u20136 weeks and gradually increasing the dose until the desired results are obtained. Adjust the\\tdose\\tbased\\ton\\tclinical\\tresponse\\tand\\tdexamethasone\\tsuppression\\ttest\\tor\\tACTH measurement. It may be possible to obtain better efficacy when pergolide is used concurrently with cyproheptadine, but ordinarily it is used alone. When treating horses, consider supplementing their diet with magnesium and chromium to avoid deficiencies in these nutrients. Patient Monitoring and Laboratory Tests To monitor the clinical response in horses, observe water consumption, hair shedding, and\\tevidence\\tof\\tlaminitis.\\tAdjust\\tdoses\\tin\\thorses\\tby\\tmonitoring\\tACTH\\tlevels\\tin animals\\tto\\t document\\tpituitary\\tfunction.\\tIn\\t horses,\\t   endogenous\\tACTH\\t    concentrations that exceed 27\u201350 pcg/mL are considered abnormal. Dexamethasone suppression tests can also be performed to monitor treatment in horses. See Dexamethasone for the procedure to perform this test. If signs of excessive dosing are observed, decrease 720    Phenobarbital, Phenobarbital Sodium the dose by half for 3\u20135 days and then slowly increase in 2- mcg/kg increments every 2 weeks until the desired effect is observed. Formulations \u2022\\t\\tPergolide\\tis\\tavailable\\tfor\\thorses\\tin\\t1-\\tmg\\ttablets.\\tCompounded\\tformulations\\tshould not be used because it was shown that these degrade after 14 days. Stability and Storage Degradation of tablets is accelerated by light and warm temperatures. A color change in the formulation is an indication that degradation has occurred. Store in a tightly sealed container, protected from light. The stability of compounded formulations is limited, and use of compounded formulations is discouraged.","original_category":"Dopamine agonist"},{"name":"Phenylbutazone","active_ingredient":"Phenylbutazone","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t15\u201322\\tmg/kg\\tq8\u201312h\\t(44\\tmg/kg/day;\\t800\\tmg/dog\\tmaximum)\\tPO\\tor\\tIV. Cats \u2022\\t\\t6\u20138\\tmg/kg\\tq12h\\tIV\\tor\\tPO.  Horses \u2022\\t\\t4.4\u20138.8\\tmg/kg/day\\t(generally\\t2\u20134\\tg\\tper\\thorse)\\tPO.\\tTypically,\\ta\\tdose\\tof\\t4.4\\tmg/ kg is administered q12h for the first 2\u20133 days followed by a tapering dose to 2.2 mg/kg q12h (1 g per horse) and eventually once daily. It is not recommended to use\\tthe\\thighest\\tdose\\tfor\\tmore\\tthan\\t48\u201396\\thours. \u2022\\t\\tInjection:\\t2.2\u20134.4\\tmg/kg/day\\tfor\\t48\u201396\\thours.\\tGive\\tinjections\\tintravenously\\tonly because IM injections cause tissue irritation. Cattle \u2022\\t\\t17\u201325\\tmg/kg\\tloading\\tdose;\\tthen\\t2.5\u20135\\tmg/kg\\tq24h\\tor\\t10\u201314\\tmg/kg\\tq48h\\tPO or IV. (See Regulatory Information in cattle.) Pigs \u2022\\t\\t4\\tmg/kg\\tq24h\\tIV. Regulatory Information Phenylbutazone is prohibited from use in female dairy cattle younger than 20 months of age. Although FDA-approved withdrawal times have not been established for animals intended for food, recommended withdrawal times are 15 days in swine and 40\u201350 days for slaughter in cattle (PO or IV) and are extended to 55 days in cattle if administered intramuscularly. Residue\\tinformation\\tfor\\thorses:\\tAlthough\\tit\\tis\\tpossible\\tthat\\tphenylbutazone residues can occur in horses slaughtered for food, in jurisdictions where horses are slaughtered for food, the risk to human health is very low. Most experts do not regard this as a public health issue. P Phenylephrine Hydrochloride 729 Phenylephrine Hydrochloride fen- ill- ef\u2032rin  hye- droe- klor\u2032ide Trade and other names:  Neo- Synephrine","contraindications":"Contraindications and Precautions Do not administer injectable formulation intramuscularly. Do not administer to animals prone to GI ulcers or to animals with kidney disease that may become dehydrated. Do not administer with other ulcerogenic drugs, such as corticosteroids. Drug Interactions The\\tuse\\twith\\tother\\tNSAIDs\\tor\\twith\\tcorticosteroids\\tshould\\tbe\\tdone\\tcautiously because of the risk of GI injury. Phenylbutazone has been used in some horses in combination\\twith\\tflunixin\\tmeglumine\\t(NSAID\\t\u201cstacking\u201d),\\tbut\\tthis\\tcombination may increase risk of hypoalbuminemia and decreased total serum protein. Phenylbutazone interferes with the action of furosemide in horses.","indications":"Indications and Clinical Uses Many equine experts believe that phenylbutazone is the most cost- effective treatment for osteoarthritis in horses. The major use of phenylbutazone is in horses for musculoskeletal pain and inflammation, arthritis, soft tissue injury, and racing injuries. The duration of action in horses after a single administration to horses is approximately 24 hours. Phenylbutazone is approved for use in dogs (and cats in Europe); however, the use in small animals is not common because of the availability of other drugs. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Although adverse effects have been documented in horses, after more than 30 years of experience, most equine clinicians have observed good safety with phenylbutazone. Earlier studies that demonstrated common adverse effects may have been exaggerated because the studies were performed in ponies, which is a breed more sensitive than horses, or high doses were used. Likewise, draft horses appear to be more sensitive to adverse effects. Among the adverse effects in horses are GI ulcers, which may be more likely to appear in the glandular region of the equine stomach. Gastric ulcers are more likely\\tas\\tthe\\tdose\\tincreases\\tand\\tin\\tanimals\\tundergoing\\textensive\\ttraining.\\tHorses may also develop right dorsal colitis and hypoproteinemia, especially at high doses. Phenylbutazone also has been associated with kidney injury. In horses that are dehydrated or have renal compromise, phenylbutazone can cause ischemia and renal papillary necrosis. Renal injury is not common in otherwise healthy horses that are well hydrated. In experimental horses, phenylbutazone (4.4 mg/ kg q12h for 14 days) decreased proteoglycan synthesis in articular cartilage. However,\\tthis\\teffect\\ton\\tarticular\\tcartilage\\twith\\tclinical\\tuse\\thas\\tnot\\tbeen\\ta documented problem. Phenylbutazone is rarely used in people because it has caused bone marrow depression, including aplastic anemia. This effect also has been observed in animals. Phenylbutazone is generally well tolerated in dogs, but there are no data for cats. In these animals, adverse effects possible are GI toxicity such as gastritis and gastric ulcers.","notes":"Instructions for Use The doses administered are based primarily on manufacturer\u2019s recommendations and many years of clinical experience in horses. Although a range of 4.4\u20138.8 mg/ kg per day has been administered to horses, studies have not shown an advantage for the higher dose. The high dosage of 8.8 mg/kg per day is more likely to cause GI injury, hypoalbuminemia, and neutropenia. Generally, a safe starting dose in horses is 4.4 mg/kg q12h IV or PO for 2\u20133 days. This dose is equivalent to 2 g PO in most horses. Then the dosage should be tapered to 2.2\u20133.3 mg/kg q12h PO (approximately 1 g per horse). For long- term use, 2.2 mg/kg once daily can be used. Combining\\tother\\tNSAIDs\\twith\\tphenylbutazone,\\tsuch\\tas\\tflunixin\\t(referred\\tto\\tas \u201cstacking\u201d), may improve response when treating lameness and other musculoskeletal problems\\tcompared\\twith\\tphenylbutazone\\talone.\\tHowever,\\tthis\\tpractice\\tmust\\tbe weighed against an increased risk of GI injury. Patient Monitoring and Laboratory Tests Monitor CBC for signs of bone marrow toxicity with chronic use. Formulations \u2022\\t\\tPhenylbutazone\\tis\\tavailable\\tin\\t100-\\tmg,\\t200-\\tmg,\\t400-\\tmg\\tand\\t1-\\tg\\ttablets\\t(bolus); oral paste for horses; and 200- mg/mL (20%) solution for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Phenylbutazone is not water soluble. It should not be compounded in aqueous vehicles.","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Phenylephrine Hydrochloride","active_ingredient":"Phenylephrine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t10\\tmcg/kg\\t(0.01\\tmg/kg)\\tq15min\\tIV\\tas\\tneeded\\tor\\t0.1\\tmg/kg\\tq15min\\tIM\\tor\\tSQ. \u2022\\t\\tCRI:\\t10\\tmcg/kg\\t(0.01\\tmg/kg)\\tIV\\tfollowed\\tby\\t3\\tmcg/kg/min\\tIV.  \u2022\\t\\tHorses:\\tDilute\\t10\u201320\\tmg\\tin\\t500\\tmL\\tof\\t0.9%\\tsaline\\tsolution\\tand\\tinfuse\\tover\\t10\u201315 minutes or dilute 20 mg in 1000 mL of 0.9% saline and infuse over 10 minutes. Note\\tthat\\tthis\\tuse\\tfor\\tnephrosplenic\\tentrapment\\tis\\tcontroversial\\tbecause\\tof\\tthe potential for adverse effects. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Phenylpropanolamine Hydrochloride fen- ill- proe- pah- nole\u2032ah- meen  hye- droe- klor\u2032ide Trade and other names: PPA, Proin, Proin ER, UriCon, and Propalin (veterinary preparations)","contraindications":"Contraindications and Precautions Do not use in animals with compromised cardiovascular status. It causes vasoconstriction and can increases blood pressure. Drug Interactions Phenylephrine potentiates other alpha 1 agonists. Use cautiously with alpha 2 agonists such as detomidine, dexmedetomidine, or xylazine.","indications":"Indications and Clinical Uses If administered intravenously, phenylephrine has been used in critical care patients or during anesthesia to increase peripheral resistance and increase blood pressure.\\tHowever,\\tthis\\tuse\\tis\\trare.\\tPhenylephrine\\tis\\talso\\tused\\tmore\\tcommonly as topical vasoconstrictor (as in nasal decongestants or for ophthalmic use). It has been administered to horses with nephrosplenic entrapment because it causes vasoconstriction, which may produce splenic contraction and correct the entrapment. The\\tsuccess\\trate\\tin\\thorses\\twith\\tthis\\ttreatment\\tis\\t56%\u201392%.\\tAlthough\\tthe\\tincidence\\tof severe complications from this treatment in horses is low, phenylephrine- associated hemorrhage is possible with this procedure. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects related to excessive stimulation of alpha 1 receptors (prolonged peripheral vasoconstriction). Reflex bradycardia may occur. Prolonged topical use may cause tissue inflammation. When used for treatment of nephrosplenic entrapment in horses, the rate of severe complications is low, but it may cause fatal hemorrhagic shock. The risks and benefits must be considered before this treatment is used.","notes":"Instructions for Use Phenylephrine has a rapid onset and short duration of action. Patient Monitoring and Laboratory Tests When administered intravenously, monitor blood pressure and heart rate. Formulations \u2022\\t\\tInjection:\\tPhenylephrine\\tis\\tavailable\\tin\\t10-\\tmg/mL\\tinjection. \u2022\\t\\tTopical:\\t1%\\tnasal\\tsolution\\tand\\t2.5%\\tand\\t10%\\tophthalmic\\tsolutions. 730    Phenylpropanolamine Hydrochloride Stability and Storage Phenylephrine is soluble in water and may be mixed in IV solutions. It is also soluble in ethanol. It is subject to oxidation and turns a darker color in some solutions, especially alkaline solutions. Discard formulations that turn a dark color. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vasopressor"},{"name":"Phenylpropanolamine Hydrochloride","active_ingredient":"Phenylpropanolamine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tImmediate-\\trelease\\tformulation:\\t1\\tmg/kg\\tq8h\\tPO.\\tIncrease\\tdosage\\tto\\t1.5\u20132\\tmg/ kg q8h PO if necessary. In some animals, it may be possible to decrease frequency to q12h or q24h PO. \u2022\\t\\tER\\tformulation:\\t2\u20134\\tmg/kg\\tPO\\tonce\\tdaily. Cats \u2022\\t\\tNo\\tdosage\\thas\\tbeen\\tdetermined.\\tA\\tdosage\\tof\\t1\\tmg/kg\\tq12h\\tPO\\thas\\tbeen\\tused (extrapolated from the canine use), and the dosage has been adjusted as needed.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdosage\\tis\\tavailable. Regulatory Information There are no formulations currently marketed in the United States for human use because of abuse potential and adverse cardiovascular events. RCI\\tClassification:\\t3 Phenytoin, Phenytoin Sodium fen\u2032 i toyn soe\u2032dee- um Trade and other names: Dilantin","contraindications":"Contraindications and Precautions Use cautiously in any animal with cardiovascular disease. For the extended- release (ER) formulations, do not administer to dogs smaller than 4.5 kg because this will produce a dose higher than 4 mg/kg. Phenylpropanolamine has been abused by people and used as a recreational drug. PPA and a related drug, pseudoephedrine, can be diverted to clandestine laboratories for the manufacture of amphetamines. The Drug Enforcement Administration has issued a notice to inform individuals and businesses handling PPA that this chemical is used in the illicit manufacture of amphetamine. Most of the human preparations have been removed from the market, and the only forms readily available are those marketed for veterinary medicine. Drug Interactions Phenylpropanolamine and other sympathomimetic drugs can cause increased vasoconstriction and changes in heart rate. Use cautiously with other vasoactive drugs and alpha 2 agonists such as dexmedetomidine and xylazine. Use cautiously with other drugs that may lower the seizure threshold. Use of inhalant anesthetics with PPA may increase cardiovascular risk. Do not use with TCAs or MAOIs. However,\\tstudies\\tin\\tdogs\\thave\\tshown\\tthat\\talthough\\tselegiline\\tis\\ta\\tMAOI,\\tit\\tcan be administered safely with PPA.","indications":"Indications and Clinical Uses Phenylpropanolamine has been used as a decongestant, as a mild bronchodilator, and to increase tone of the urinary sphincter. Pseudoephedrine and ephedrine are related drugs that produce similar alpha- receptor and beta- receptor effects. The most common use in animals is for treating urinary incontinence. The mechanism for this action appears to be via stimulating receptors on the urethral sphincter. It has also been used to treat priapism (persistent erection) in dogs. Abuse potential and adverse effects have limited the routine use as a decongestant and appetite suppressant in human medicine. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributed to excess stimulation of adrenergic (alpha and beta) receptors. Side effects include tachycardia (or bradycardia), cardiac effects, CNS\\texcitement,\\trestlessness,\\tand\\tappetite\\tsuppression.\\tThere\\tare\\treports\\tof adverse effects caused by PPA in people. In particular, it has caused problems with blood pressure and increased risk of strokes. Such a concern should also apply to animals, but there have been no specific reports of these problems in animals. In animals exposed to high doses (accidental ingestion from the flavored canine tablets), it produces agitation, vomiting, mydriasis, tremors, panting and cardiovascular effects. Prognosis is good after accidental exposure if supportive care is provided.","notes":"Instructions for Use Although frequency of administration has been every 8\u201312 hours with the conventional product for dogs, an interval of q24h in dogs at a dose of 1.5 mg/ kg has been just as effective in some dogs. Alternatively, the ER form can be used once- daily. In some animals, pseudoephedrine has been substituted for PPA with good success, but these tablets are more tightly regulated because of the potential to divert to the manufacture of methamphetamine. Patient Monitoring and Laboratory Tests Monitor heart rate and blood pressure in animals receiving treatment. Animals with urinary incontinence should be checked periodically for presence of UTIs. Formulations \u2022\\t\\tPPA\\tis\\tavailable\\tin\\t25-\\t,\\t50-\\t  ,\\tand\\t75-\\tmg\\tflavored\\ttablets;\\t25-\\tmg\\tvanilla-\\tflavored liquid;\\tand\\t50-\\tmg\\tscored\\ttablets\\t(veterinary\\tpreparations).\\tHuman\\tformulations\\tof 15- , 25- , 30- , and 50- mg tablets are no longer available. 732    Phenytoin, Phenytoin Sodium \u2022\\t\\tPPA\\tER\\ttablets\\tare\\tavailable\\tin\\ttablets\\tof\\t18-\\t,\\t38-\\t  ,\\t74-\\t  ,\\tand\\t145-\\tmg.\\tDo\\tnot\\tsplit or crush the tablets \u2022\\t\\tHuman\\tformulations\\thave\\tbeen\\tremoved\\tfrom\\tthe\\tmarket. Stability and Storage The stability and potency of compounded formulations has not been evaluated. The ER tablets should not be broken or crushed.","original_category":"Adrenergic agonist"},{"name":"Physostigmine","active_ingredient":"Physostigmine","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.02\\tmg/kg\\tq12h\\tIV.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Phytonadione fye- toe- nah- dye\u2032one Trade and other names: AquaMephyton, Mephyton, Veta- K1, vitamin K 1 , phylloquinone, and phytomenadione","contraindications":"Contraindications and Precautions Do not administer with choline esters such as bethanechol. Drug Interactions Do not administer with other drugs that produce cholinergic effects. P Phytonadione 735","indications":"Indications and Clinical Uses Physostigmine is used as an antidote for anticholinergic intoxication and as a treatment (antidote) for neuromuscular blockade. It has also been used as a treatment of ileus and urinary retention (e.g., postoperative urine retention) by increasing the tone of the bladder smooth muscle. There are no well- controlled studies to measure the efficacy of physostigmine in animals. The use is based on anecdotal experience and recommendations from clinicians. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects caused by the cholinergic action result from inhibition of cholinesterase. These effects in the GI tract are seen as diarrhea and increased secretions (e.g., increased salivation). Other adverse effects can include miosis, bradycardia, muscle twitching or weakness, and constriction of bronchi and ureters. Adverse effects can be treated with anticholinergic drugs such as atropine.","notes":"Instructions for Use Physostigmine is indicated primarily only for treatment of intoxication. If longer- term or routine systemic use of an anticholinesterase drug is needed, neostigmine and pyridostigmine are used because they have fewer adverse effects. When used, frequency of dose may be increased based on observation of effects. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm and GI signs. Formulations \u2022\\t\\tPhysostigmine\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticholinesterase"},{"name":"Phytonadione","active_ingredient":"Phytonadione","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tTreatment\\tof\\tshort-\\tacting\\trodenticides:\\t1\\tmg/kg/day\\tfor\\t10\u201314\\tdays\\tSQ\\tor\\tPO. \u2022\\t\\tTreatment\\tof\\tlong-\\tacting\\trodenticides:\\t2.5\u20135\\tmg/kg/day\\tfor\\t3\u20134\\tweeks\\tIM,\\tSQ, or PO. Birds \u2022\\t\\t2.5\u20135\\tmg/kg\\tq24h.  Cattle, Calves, Horses, Sheep, and Goats \u2022\\t\\t0.5\u20132.5\\tmg/kg\\tSQ\\tor\\tIM. P Pimobendan 737 Regulatory Information Withdrawal times are not established for animals that produce food. It is anticipated that milk and meat withdrawal times will be short. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Pimobendan pim- oh- ben\u2032dan Trade and other names: Vetmedin","contraindications":"Contraindications and Precautions Accurate diagnosis to rule out other causes of bleeding is suggested. Other forms of vitamin K may not be as rapidly acting as vitamin K 1 ; therefore consider using a specific preparation. To avoid anaphylactic reactions, do not administer intravenously. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported.","indications":"Indications and Clinical Uses Phytonadione is used to treat coagulopathies caused by anticoagulant toxicosis (warfarin or other rodenticides). In large animals, it is used to treat sweet clover poisoning. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In people, a rare hypersensitivity- like reaction has been observed after rapid IV injection. Signs resemble anaphylactic shock. These signs also have been observed in animals. To avoid anaphylactic reactions, do not administer intravenously.","notes":"Instructions for Use Consult the poison control center for a specific protocol if specific rodenticide is identified. Use vitamin K 1 for acute therapy of toxicity because it is more highly bioavailable. Administer with food to enhance oral absorption. If an injection is used, it can be diluted in 5% dextrose or 0.9% saline but do not use other solutions. The preferred injectable route is SQ, but IM can also be used. Although vitamin K 1 veterinary labels have listed the IV route for administration, these labels have not been approved by the FDA. Therefore avoid IV administration of vitamin K 1 . Patient Monitoring and Laboratory Tests Monitoring bleeding times in patients is essential for accurate dosing of vitamin K 1 preparations and monitoring the response to treatment. When treating long- acting rodenticide poisoning, periodic monitoring of the bleeding times is suggested. Formulations \u2022\\t\\tPhytonadione\\tis\\tavailable\\tin\\t5-\\tmg\\ttablets\\t(Mephyton)\\tand\\t25-\\tmg\\tcapsules (Veta- K1). \u2022\\t\\tPhytonadione\\t(AquaMephyton)\\tis\\tavailable\\tin\\ta\\t2-\\t\\tor\\t10-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container at room temperature. It is light sensitive and should be\\tprotected\\tfrom\\tlight.\\tPhytonadione\\tis\\tpractically\\tinsoluble\\tin\\twater.\\tHowever,\\tit\\tis soluble in oils and slightly soluble in ethanol. Do not mix with aqueous solutions. If mixed as a suspension for oral use, administer soon after preparation. Do not freeze.","original_category":"Vitamin"},{"name":"Pimobendan","active_ingredient":"Pimobendan","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.25\u20130.3\\tmg/kg\\tq12h\\tPO.\\tIf\\tadministered\\twith\\tan\\tACE\\tinhibitor,\\tsome\\tdogs\\tare managed on 0.125 mg/kg q12h PO. Cats \u2022\\t\\t1.25\\tmg/cat\\tq12h\\tPO\\t(0.1\u20130.3\\tmg/kg\\tq12h).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Piperacillin Sodium and Tazobactam pih\u2032per- ah- sill\u2032in soe\u2032dee- um  taze\u2032oh- back- tam Trade and other names: Zosyn and generic; also referred to as \u201cPip- Taz\u201d","contraindications":"Contraindications and Precautions Use pimobendan cautiously in animals prone to cardiac arrhythmias. Do not use in animals with obstructive cardiomyopathy or a fixed obstruction of the outflow tract. Compounded formulations will not achieve the same absorption profile in dogs\\tas\\tthe\\tproprietary\\tform.\\tThere\\tis\\ta\\tcritical\\tpH\\tat\\twhich\\tthe\\toral\\tabsorption\\tis enhanced, and some compounded formulations may lack excipients to attain this effect. Drug Interactions Use cautiously with other PDE inhibitors such as theophylline, pentoxifylline, and sildenafil (Viagra) and related drugs. Sildenafil is a PDE V inhibitor, and theophylline is a PDE IV inhibitor. Pimobendan is insoluble unless in an acidic environment, and it is difficult to mix pimobendan into a solution.","indications":"Indications and Clinical Uses Pimobendan is indicated for use in dogs for treatment of congestive heart failure (CHF).\\tIt\\thas\\tbeen\\tused\\tin\\tdogs\\twith\\teither\\tvalvular\\tinsufficiency\\tor\\tcardiomyopathy. It is recommended in consensus guidelines for any dog with valvular disease with\\tstage\\tB2\\tor\\thigher\\tand\\tmay\\tdelay\\tonset\\tof\\tCHF.\\tIn\\tdogs\\twith\\theart\\tfailure caused by valvular disease, it decreased heart rate, decreased left ventricular and left atrial dimensions, reduced heart size, and reduced preload and natriuretic peptide concentrations. In dogs with stage C valvular heart disease, it has improved survival and quality of life. It is considered by many cardiologists as an essential initial treatment for dilated cardiomyopathy in dogs. When used in dogs, it has improved signs of heart failure and increased survival. When used in dogs, it may be administered with diuretics (furosemide), spironolactone, and angiotensin- converting enzyme (ACE) inhibitors. Pimobendan treatment has produced significant improvement compared with placebo in dogs treated with an ACE inhibitor and a diuretic. Pimobendan may be helpful for treating Doberman pinschers, and probably other breeds, with occult (asymptomatic) dilated cardiomyopathy by prolonging the onset of clinical signs, improving survival and overall outcome. It has not been recommended to administer positive inotropic agents such as\\tpimobendan\\tto\\tcats\\twith\\thypertrophic\\tcardiomyopathy.\\tHowever,\\tit\\thas\\tbeen associated with improvement in clinical signs and longer survival time in cats with heart failure associated with dilated cardiomyopathy as part of a therapeutic regimen that may include other drugs (e.g., furosemide). Although not FDA approved for cats, when administered at 1.25 mg/cat q12h (0.25 mg/kg), it has been well tolerated. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Pimobendan is potentially arrhythmogenic, but this effect (e.g., atrial fibrillation or ventricular arrhythmias) has been rare and seen primarily in animals with severe underlying cardiac disease. At doses of 0.25\u20130.5 mg/kg in dogs, pimobendan did not activate the renin\u2013angiotensin\u2013aldosterone system (RAAS), but if furosemide is added to treatment, some activation of the RAAS may occur. At therapeutic doses, there has been negligible effect on platelet aggregation.","notes":"Instructions for Use Follow the approved label instruction for use. Evaluate stage of heart failure in animals before use. Consider the addition of other drugs such as ACE inhibitors, spironolactone, furosemide, and digoxin in animals as the severity of the heart disease increases. If furosemide is used concurrently with pimobendan, consider the addition of an ACE inhibitor (e.g., enalapril, benazepril) or aldosterone antagonist (e.g., spironolactone) to inhibit RAAS activation. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s heart rate and rhythm during use. Formulations \u2022\\t\\tPimobendan\\tis\\tavailable\\tin\\tchewable\\ttablets\\tof\\t1.25,\\t2.5,\\tand\\t5\\tmg.\\tIn\\tEurope, pimobendan is available in 2.5-  and 5- mg capsules. P Piperacillin Sodium and Tazobactam 739 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Acidic\\tpH\\tconditions\\tare\\timportant\\tfor\\tthe\\tstability\\tof\\tthe\\tformulation\\tand\\tto\\tensure dissolution.","original_category":"Cardiac inotropic agent"},{"name":"Piroxicam","active_ingredient":"Piroxicam","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.3\\tmg/kg\\tq48h\\tPO. \u2022\\t\\tCancer\\ttreatment:\\t0.3\\tmg/kg\\tq24h\\tPO\\tinitially;\\tthen\\ttransitioned\\tto\\tq48h. Cats \u2022\\t\\t0.3\\tmg/kg\\tq24h\\tPO.\\tA\\tcommon\\tdosage\\tis\\t1\\tmg\\tper\\tcat\\tq24h\\tPO.  There is insufficient evidence to recommend doses for large animals. Single doses of 0.2 mg/kg PO have been administered to horses without any adverse effects. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Plicamycin plye- kah- mye\u2032sin Trade and other names: Mithracin and mithramycin","contraindications":"Contraindications and Precautions Use cautiously in dogs because the long half- life may increase risk of GI ulcers if administered once daily. The human formulation is too large a dose for most dogs and should be reformulated to avoid overdose. Warn pet owners about overdoses that could produce GI ulceration. Do not administer to animals prone to GI ulcers. Do not administer to pregnant animals. Use cautiously in animals with kidney disease that may be prone to dehydration or if administered with other drugs that may injure the kidney, such as cisplatin. Drug Interactions Do\\tnot\\tadminister\\twith\\tother\\tNSAIDs\\tor\\twith\\tcorticosteroids.\\tCorticosteroids have\\tbeen\\tshown\\tto\\texacerbate\\tthe\\tGI\\tadverse\\teffects.\\tSome\\tNSAIDs\\tmay interfere with the action of diuretic drugs and ACE inhibitors.","indications":"Indications and Clinical Uses Although piroxicam is not FDA- approved for animals, it is has been used extralabel, primarily used to treat pain and inflammation associated with arthritis and other musculoskeletal conditions. It is not used as much for these conditions as other approved\\tNSAIDs\\tfor\\tanimals.\\tAnother\\tuse\\tin\\tdogs\\tand\\tcats\\thas\\tbeen\\tas\\tan adjunct for treating cancer. This use is based on reports of its activity for treating or suppressing some tumors, including transitional cell carcinoma of the bladder, P squamous cell carcinoma, and mammary adenocarcinoma. (This effect is not unique to\\tpiroxicam\\tbecause\\tother\\tNSAIDs\\talso\\tmay\\thave\\tantitumor\\tproperties.)\\tPiroxicam has been used in combination with cisplatin to treat oral malignant melanoma and oral squamous cell carcinoma in dogs (0.3 mg/kg). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Elimination of piroxicam is slow. At 0.3 mg/kg q24h PO, adverse reactions have been observed in dogs, and an administration interval of q48h should be considered. Adverse effects are primarily GI toxicity (e.g., gastric ulcers). Renal toxicity also is a risk, especially in animals prone to dehydration or that have compromised renal function. Toxic epidermal necrolysis has been reported in some dogs. In cats, vomiting is possible during initial treatment for long- term management of some cancers. Long- term treatment was not associated with hematologic, renal, or liver toxicity in cats.","notes":"Instructions for Use Most experience with dosing has been accumulated from studies in which dogs were treated with piroxicam for transitional cell carcinoma of the bladder. Some of these dogs tolerated piroxicam better with respect to GI toxicity if the drug was administered with misoprostol. Piroxicam has also been used in dogs for treatment of squamous cell carcinoma. Patient Monitoring and Laboratory Tests Piroxicam has the potential of inducing GI ulceration. Monitor for signs of vomiting, bleeding, and lethargy. If bleeding is suspected, monitor patient\u2019s hematocrit or CBC. Monitor renal function in treated animals. Formulations \u2022\\t\\tPiroxicam\\tis\\tavailable\\tin\\t10-\\tmg\\tcapsules.\\tCapsules\\tmay\\thave\\tto\\tbe\\treformulated\\tto produce oral doses for small animals. Stability and Storage Exposure to light results in photodegradation. Piroxicam is only slightly soluble in water. It is soluble in basic solutions and some organic solvents. Compounded formulations made for small animals may be stable for only 48 hours. Although an IV formulation is not available commercially, a 2- mg/mL solution has been prepared from\\tmixing\\tthe\\tpure\\tpowder\\twith\\t0.1\\tN\\tof\\tNaOH\\tand\\tfound\\tto\\tbe\\tstable\\tif\\tstored\\tin a glass vial, refrigerated, and protected from light. 744    Plicamycin","original_category":"Nonsteroidal anti- inflammatory drug"},{"name":"Plicamycin","active_ingredient":"Plicamycin","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tAntihypercalcemic:\\t25\\tmcg/kg/day\\tIV\\t(slow\\tinfusion)\\tover\\t4\\thours. \u2022\\t\\tAntineoplastic\\t(dogs):\\t25\u201330\\tmcg/kg/day\\tIV\\t(slow\\tinfusion)\\tfor\\t8\u201310\\tdays.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Polyethylene Glycol Electrolyte Solution pahl- ee- eth\u2032ill- een  glye\u2032kole Trade and other names: GoLYTELY, PEG, Colyte, and Co- Lav","contraindications":"Contraindications and Precautions Do\\tnot\\tuse\\twith\\tdrugs\\tthat\\tmay\\tincrease\\tthe\\trisk\\tof\\tbleeding\\t(e.g.,\\tNSAIDs, heparin, or anticoagulants). Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported.","indications":"Indications and Clinical Uses Plicamycin is used in cancer protocols for carcinomas and treatment of hypercalcemia. Use in animals has been primarily derived from empirical use. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals. In people, hypocalcemia and GI toxicity have been reported. Plicamycin may cause bleeding problems.","notes":"Instructions for Use Results of clinical studies in animals have not been reported. Use in animals (and doses) is based on experience in people or anecdotal experience in animals. P Polyethylene Glycol Electrolyte Solution 745 Patient Monitoring and Laboratory Tests Monitor serum calcium concentrations. Formulations \u2022\\t\\tPlicamycin\\tis\\tavailable\\tin\\ta\\t2.5-\\tmg\\tvial\\tfor\\tinjection\\tand\\t0.5\\tmg/mL\\twhen\\tdiluted. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Polysulfated Glycosaminoglycan","active_ingredient":"Polysulfated Glycosaminoglycan","species":["Canine","Equine"],"dosage":"Dogs \u2022\\t\\t4.4\\tmg/kg\\tIM,\\ttwice\\tweekly\\tfor\\tup\\tto\\t4\\tweeks.  Horses \u2022\\t\\t500\\tmg\\tevery\\t4\\tdays\\tIM\\tfor\\t28\\tdays\\tor\\t250\\tmg\\tper\\tjoint\\tonce\\tweekly\\tfor\\t5\\tweeks intra- articular. Regulatory Information No\\twithdrawal\\ttimes\\tnecessary. Ponazuril poe- naz\u2032yoo- ril Trade and other names: Marquis","contraindications":"Contraindications and Precautions Intra- articular injections should be done using aseptic technique only by trained individuals. Use cautiously in animals receiving heparin therapy. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Polysulfated glycosaminoglycan is injected in dogs and horses to treat or prevent degenerative joint disease. This is an FDA- approved product; therefore, there are efficacy and safety studies to support the use for treating osteoarthritis in animals. Intra- articular injections have been effective, but IM doses may be too low to be effective in some animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare. Allergic reactions are possible. PSGAG has heparin- like effects and may elicit bleeding problems in some animals, but this has not been observed clinically.","notes":"Instructions for Use The doses used are supported by the FDA approval for animals. There has also been experience from studies in experimental animals and clinical studies. Although effective for acute arthritis, it may not be as effective for chronic arthropathy. In horses, it is sometimes combined with amikacin (125 mg) for intra- articular use to prevent infection. Patient Monitoring and Laboratory Tests Observe injected joints for signs of infection after treatment. Formulations \u2022\\t\\tPSGAG\\tis\\tavailable\\tin\\ta\\t100-\\tmg/mL\\tinjection\\tin\\ta\\t5-\\tmL\\tvial,\\t100\\tmg/mL\\tfor\\tIM administration, and 250 mg/mL for intra- articular use in horses. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiarthritic agent"},{"name":"Ponazuril","active_ingredient":"Ponazuril","species":["Canine","Feline","Equine"],"dosage":"coccidia infections in dogs and cats, and protozoa in other species. The dosage is 50 mg/kg PO once daily for 3 consecutive days for treatment of coccidiosis in dogs and cats. It has been used to treat piglets with diarrhea caused by Isospora suis. Precautionary Information  Cats \u2022\\t\\tToxoplasmosis:\\t50\\tmg/kg\\tonce\\tPO\\tor\\t20\\tmg/kg\\tonce\\tdaily\\tfor\\t2\\tdays\\tPO. \u2022\\t\\tCoccidiosis:\\t50\\tmg/kg\\tonce\\tdaily\\tfor\\t3\\tconsecutive\\tdays. Dogs \u2022\\t\\tCoccidiosis:\\t50\u201355\\tmg/kg\\tonce\\tdaily\\tPO\\tfor\\t3\u20135\\tdays.  Horses \u2022\\t\\tTreatment\\tof\\tEPM:\\t5\\tmg/kg\\tq24h\\tPO\\tfor\\t28\\tdays.\\tA\\tloading\\tdose\\tof\\t15\\tmg/ kg has been used initially (day 1) followed by maintenance daily doses for 28 days. When 50 mL of corn oil (approximately 2 ounces) was administered orally to horses 1\u20132 minutes prior to the ponazuril paste, there was greater oral absorption and higher concentrations in the CSF. Pigs \u2022\\t\\t5\\tmg/kg\\tPO\\tfor\\ttreatment\\tof\\tI. suis. Regulatory Information Recommended withdrawal time for pigs is 33 days. Withdrawal times for other food animals is not available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Posaconazole poe- sa- kon\u2032a- zole Trade and other names: Noxafil","contraindications":"Contraindications and Precautions Avoid use in pregnant or breeding mares until more information becomes available on safety. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported.","indications":"Indications and Clinical Uses Ponazuril is FDA approved for use as a treatment of equine protozoal myeloencephalitis (EPM) caused by S. neurona. In clinical studies in horses with EPM,\\t62%\\tof\\t101\\thorses\\twere\\ttreated\\tsuccessfully\\twith\\tdosages\\tof\\t5\\tor\\t10\\tmg/kg\\tfor 28 days. Although successful treatment was reported after 28 days, longer treatment duration may be needed in some animals to resolve the infection and prevent relapse. Toltrazuril, the parent drug, has been used for protozoa such as Isospora spp., Coccidia spp., Toxoplasma gondii, S. neurona, and Eimeria spp., which also have been considered as treatment targets for ponazuril. There is limited information available on its use in other animals, but it has been used for treating toxoplasmosis in cats,","side_effects":"Adverse Reactions and Side Effects Ponazuril is highly specific and relatively safe at approved doses. Administration of 50 mg/kg to horses (10 times the recommended dose) produces minor adverse effects. There are minimal changes in the serum analysis. Soft feces may occur at high doses.","notes":"Instructions for Use Use in horses is based on clinical studies, field trials conducted by the drug sponsor, and pharmacokinetic studies in horses. When ponazuril paste was administered orally to horses mixed with corn oil (2 ounces per dose), there was higher oral absorption and higher concentrations in the CSF (see the following dosing section). Patient Monitoring and Laboratory Tests In horses treated for EPM, monitor neurologic status during treatment. The immunoglobulin G (IgG) and albumin quotient has been measured in CSF of treated horses to monitor treatment, but this may not indicate clinical cure. When treating for P Posaconazole 751 coccidia infections in dogs, cats, zoo, and exotic animals, perform a fecal exam (fecal flotation) periodically to be sure that the organism has been eradicated. Formulations \u2022\\t\\tPonazuril\\tis\\tavailable\\tin\\t15%\\t(150-\\tmg/mL)\\toral\\tpaste\\tfor\\thorses.\\tOne\\ttube contains\\t127\\tg\\tor\\t150\\tmg/g\\tor\\tapproximately\\t165\\tmg/mL. \u2022\\t\\tCompounded\\tformulation:\\tTo\\tadminister\\tthe\\tequine\\tform\\tto\\tsmall\\tanimals,\\tit\\tmay be diluted and mixed with water or oral syrup for ease of administration and still maintain\\tstability.\\tOne\\tsuch\\tdilution\\tformulation\\tfor\\tsmall\\tanimals\\tis:\\t50\\tmL\\tof ponazuril equine paste + 12.5 mL of water + 12.5 mL of syrup for flavor = 75 mL containing\\t100-\\tmg/mL\\tsolution\\tfor\\toral\\tdosing.\\tOr\\tfor\\tsmaller\\tanimals:\\t20\\tmL\\tof ponazuril equine paste + 5 mL of water + 5 mL of syrup for flavor = 30 mL of 100- mg/mL solution for oral dosing. When using a compounded version, shake up the formulation prior to administration. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiprotozoal"},{"name":"Potassium Chloride","active_ingredient":"Potassium Chloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tSupplement:\\t0.5\\tmEq\\tpotassium/kg/day\\tor\\tadd\\t10\u201340\\tmEq/500\\tmL\\tof\\tfluids, depending on serum potassium. \u2022\\t\\tAcute\\ttreatment\\tof\\thypokalemia:\\t0.5\\tmEq\\tpotassium/kg/h. P Potassium Citrate 755  Cattle and Horses \u2022\\t\\tSupplement\\tin\\tIV\\tfluids\\tto\\t20\u201340\\tmEq\\tof\\tpotassium\\tper\\tliter\\tof\\tfluids.\\tDo\\tnot exceed a rate of 0.5 mEq/kg/h IV. \u2022\\t\\tOral\\tsupplement\\tto\\tcows\\teither\\tas\\ta\\tsolution\\tor\\tbolus:\\t52\\tg\\tof\\tpotassium\\t(100\\tg\\tof potassium chloride) per cow per day. Regulatory Information No\\twithdrawal\\ttimes\\tnecessary. Potassium Citrate Trade and other names: Generic and Urocit- K","contraindications":"Contraindications and Precautions Do not exceed a rate of 0.5 mEq/kg/h IV infusion. Use cautiously in animals with kidney disease. Do not use potassium chloride if metabolic acidosis and hyperchloremia are present. Use another potassium supplement instead. IV use should be done cautiously because of a risk of hyperkalemia. Use potassium cautiously in animals that are receiving digoxin for treatment of heart disease. Do not use with potassium penicillin or potassium bromide. (Use sodium salts of these drugs instead.) Drug Interactions Interactions\\tbetween\\tpotassium\\tsupplements\\tand\\tthe\\tfollowing\\tdrugs\\tmay\\toccur: digoxin, thiazide diuretics, spironolactone, amphotericin B, corticosteroids, penicillins, ACE inhibitors, and laxatives.","indications":"Indications and Clinical Uses Potassium\\tsupplements\\tare\\tindicated\\tfor\\ttreating\\thypokalemia.\\tHypokalemia\\tmay occur\\twith\\tsome\\tdiseases\\tor\\tas\\ta\\tconsequence\\tof\\tdiuretic\\tuse.\\tHypokalemia\\tmay\\talso occur as a consequence of beta 2 - adrenergic agonist overdose. In cattle, potassium deficiency may occur when they are off feed. In cattle, this can be important for conditions such as retained placenta, mastitis, lipidosis, and abomasal displacement. In most patients, potassium chloride is the supplement of choice for hypokalemia. It is better absorbed than other supplements, and the chloride ion may be helpful because hypochloremia may also occur in some patients. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity\\tfrom\\thigh\\tpotassium\\tconcentrations\\tcan\\tbe\\tdangerous.\\tHyperkalemia can lead to cardiovascular toxicity (bradycardia and arrest) and muscular weakness. Oral potassium supplements can cause nausea and stomach irritation. Administration that is too rapid can cause muscle tremors, diarrhea, convulsions, and even death.","notes":"Instructions for Use One gram of potassium chloride provides 13.41 mEq of potassium. It is usually added to fluid solutions. When potassium is supplemented in fluids, do not administer at a rate faster than 0.5 mEq/kg/h. Patient Monitoring and Laboratory Tests Monitor serum potassium levels. Monitor electrocardiogram (ECG) in patients that may\\tbe\\tprone\\tto\\tarrhythmias.\\tNormal\\tpotassium\\tconcentrations\\tare\\t4\u20135.5\\tmEq/L (dogs)\\tand\\t4.3\u20136.0\\tmEq/L\\t(cats). Formulations Potassium chloride is available in various concentrations for injection (usually 2 mEq/ mL). It is available in an oral suspension and oral solution as 10\u201320 mEq of potassium per packet. Oral bolus forms are available for cattle, also containing calcium and magnesium. One gram of potassium chloride contains 14 mEq of potassium ion. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Potassium chloride is freely soluble in water.","original_category":"Potassium supplement"},{"name":"Potassium Citrate","active_ingredient":"Potassium Citrate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t2.2\\tmEq/100\\tkcal\\tof\\tenergy/day\\tPO\\tor\\t0.5\\tmEq/kg\\tper\\tday\\tPO.\\tHigher\\tdoses have been used safely in some animals. (1000 mg potassium citrate is equivalent to 9.26\\tmEq\\tof\\tpotassium.) \u2022\\t\\t50\u201375\\tmg/kg\\tPO\\tq12h \u2022\\t\\tFor\\talkalinizing\\turine:\\tAdd\\t150\\tmg/kg\\tper\\tday,\\tmixed\\twith\\tthe\\tanimal\u2019s\\tfood. \u2022\\t\\tFor\\tcats\\tthat\\tneed\\tpotassium\\tsupplement\\tfor\\tchronic\\tkidney\\tdisease,\\tstart\\twith\\t1\u20134 mEq potassium per cat q12h (equivalent to approximately 30\u2013100 mg/kg q12h).  No\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tnecessary. Potassium Gluconate Trade and other names: Kaon, Tumil- K, and generic brands","contraindications":"Contraindications and Precautions Use cautiously in animals with kidney disease. Do not use with potassium penicillin or potassium bromide. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Potassium citrate is used for prevention of calcium oxalate urolithiasis. It is also used for renal tubular acidosis. In dogs, after administration of 150 mg/kg (of potassium citrate)\\tq12h\\tPO,\\tthe\\turine\\tpH\\tdoes\\tnot\\tsignificantly\\tincrease,\\tbut\\turine\\tconcentration of calcium oxalate decreases. It has been administered as a potassium supplement to cats with chronic kidney disease, which also serves as an alkalinizing agent; thus, it serves a dual purpose of treating both hypokalemia and acidosis. Administration to cats is based on serum potassium levels. If the serum potassium is less than 3.5 mmol/L (less than 3.5 mEq/L), a recommended dosage is 1\u20134 mEq potassium per cat q12h. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity\\tfrom\\thigh\\tpotassium\\tconcentrations\\tcan\\tbe\\tdangerous.\\tHyperkalemia\\tcan lead to cardiovascular toxicity (bradycardia and arrest) and muscular weakness. Oral potassium supplements can cause nausea and stomach irritation.","notes":"Instructions for Use One\\tgram\\tof\\tpotassium\\tcitrate\\tprovides\\t9.26\\tmEq\\tof\\tpotassium.\\tAdminister\\twith\\tmeals. 756    Potassium Gluconate Patient Monitoring and Laboratory Tests Monitor\\tserum\\tpotassium\\tlevels\\tin\\torder\\tto\\tregulate\\tthe\\tdose.\\tNormal\\tpotassium concentrations\\tare\\t4\u20135.5\\tmEq/L\\t(dogs)\\tand\\t4.3\u20136.0\\tmEq/L\\t(cats).\\tMonitor\\tECG\\tin patients that may be prone to arrhythmias. Formulations \u2022\\t\\tPotassium\\tcitrate\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t\\tand\\t15-\\tmEq\\ttablets.\\tFive-\\tmEq\\ttablets\\tare equivalent to 540 mg, 10- mEq tablets are equivalent to 1080 mg, and 15- mEq tablets\\tare\\tequivalent\\tto\\t1620\\tmg.\\tSome\\tformulations\\tare\\tin\\tcombination\\twith potassium chloride. Potassium citrate tablets in a delayed- released tablet are also available. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Alkalinizing agent"},{"name":"Potassium Gluconate","active_ingredient":"Potassium Gluconate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.5\\tmEq/kg\\tq12\u201324h\\tPO. Cats \u2022\\t\\t2\u20138\\tmEq/day\\tdivided\\ttwice\\tdaily\\tPO.\\tFor\\tcats\\tthat\\tneed\\tpotassium\\tsupplement\\tfor chronic kidney disease, start with 1\u20134 mEq of potassium per cat q12h.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tnecessary. Potassium Iodide Trade and other names: KI, SSKI, ThyroSafe, iOSAT","contraindications":"Contraindications and Precautions Use cautiously in animals with kidney disease. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Potassium gluconate is one of the supplements used for the treatment of hypokalemia and\\trenal\\ttubular\\tacidosis.\\tHypokalemia\\tmay\\toccur\\twith\\tsome\\tdiseases\\tor\\tas\\ta consequence of diuretic use. It has been administered as a potassium supplement to cats with chronic kidney disease. The dose is based on monitoring serum potassium concentrations. If the serum potassium concentration is less than 3.5 mmol/L (less P Potassium Iodide 757 than 3.5 mEq/L), a recommended dosage is 1\u20134 mEq potassium per cat q12h. Despite the availability of potassium gluconate, in most patients, potassium chloride is the supplement of choice for hypokalemia. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Toxicity\\tfrom\\thigh\\tpotassium\\tconcentrations\\tcan\\tbe\\tdangerous.\\tHyperkalemia\\tcan lead to cardiovascular toxicity (bradycardia and arrest) and muscular weakness. Oral potassium supplements can cause nausea and stomach irritation.","notes":"Instructions for Use One gram of potassium gluconate provides 4.27 mEq of potassium. Patient Monitoring and Laboratory Tests Monitor\\tserum\\tpotassium\\tlevels.\\tNormal\\tpotassium\\tconcentrations\\tare\\t4\u20135.5\\tmEq/L (dogs)\\tand\\t4.3\u20136.0\\tmEq/L\\t(cats).\\tMonitor\\tECG\\tin\\tpatients\\tthat\\tmay\\tbe\\tprone\\tto arrhythmias. Formulations \u2022\\t\\tPotassium\\tgluconate\\tis\\tavailable\\tin\\ta\\t2-\\tmEq\\ttablet\\t(equivalent\\tto\\t500\\tmg\\tof potassium gluconate). \u2022\\t\\tKaon\\telixir\\tis\\ta\\t20-\\tmEq\\tpotassium\\tper\\t15-\\tmL\\telixir\\t(containing\\t4.68\\tg\\tof potassium gluconate). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Potassium gluconate is soluble in water.","original_category":"Potassium supplement"},{"name":"Potassium Phosphate","active_ingredient":"Potassium Phosphate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.03\u20130.12\\tmmol/kg/h\\tIV\\tfor\\tacute\\ttreatment. \u2022\\t\\t0.1\\tmmol/kg/day\\tIV\\tfor\\tdaily\\tsupplementation. \u2022\\t\\t4\\tmg/kg\\tphosphorus\\t(approximately\\t0.1\\tmmol/kg)\\tPO\\tup\\tto\\tfour\\ttimes\\tdaily.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No\\twithdrawal\\ttimes\\tare\\tnecessary. Pradofloxacin pray  doe- floks\u2032ah- sin Trade and other names: Veraflox","contraindications":"Contraindications and Precautions Use cautiously in animals with renal disease. Drug Interactions No\\tdrug\\tinteractions\\tare\\treported\\tin\\tanimals.","indications":"Indications and Clinical Uses Potassium phosphate has been used to reduce calcium urinary secretion in patients prone to calcium urinary calculi and to promote a more acid urine. This drug should not be used to supplement potassium. Instead, potassium chloride is the supplement of choice for hypokalemia. 760    Pradofloxacin Precautionary Information","side_effects":"Adverse Reactions and Side Effects Intravenous administration can cause hypocalcemia.","notes":"Instructions for Use Potassium phosphate use in animals is primarily as a urinary acidifier or treatment of hypophosphatemia. Patient Monitoring and Laboratory Tests Monitor calcium, potassium, and phosphorus levels in treated animals. Formulations \u2022\\t\\tPotassium\\tphosphate\\tis\\tcurrently\\tnot\\tavailable\\tin\\ttablets\\t(previously\\t500\\tmg containing 114 mg [3.7 mmol] of phosphorus). Oral solutions can be made from powdered concentrate mixed with water for oral administration. \u2022\\t\\tPotassium\\tphosphate\\tis\\tavailable\\tin\\t224\\tmg\\tof\\tmonobasic\\tpotassium\\tphosphate and\\t236\\tmg\\tof\\tdibasic\\tpotassium\\tphosphate\\t(3\\tmmol\\t[93\\tmg]\\tof\\tphosphorus)\\tper milliliter injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Phosphate supplement"},{"name":"Pralidoxime Chloride","active_ingredient":"Pralidoxime Chloride","species":["Feline","Bovine"],"dosage":"\u2022\\t\\t20\\tmg/kg\\tup\\tto\\t50\\tmg/kg\\tq8\u201312h\\tIM\\tor\\tIV\\t(initial\\tdose\\tslow).\\tDilute\\tsolution\\tin glucose and infuse slowly IV.  Cattle, Sheep, and Pigs \u2022\\t\\t20\u201350\\tmg/kg\\tq8h\\t(administered\\tas\\ta\\t10%\\tsolution)\\tIM\\tor\\tvia\\tslow\\tIV\\tinfusion\\tor as needed. Frequency can be assessed by monitoring clinical signs. Regulatory Information Cattle\\tand\\tpig\\twithdrawal\\ttimes\\t(extralabel):\\t6\\tdays\\tfor\\tmilk\\tand\\t28\\tdays\\tfor\\tmeat. 764    Praziquantel Praziquantel pray- zih- kwon\u2032tel Trade and other names: Droncit and Drontal (combination with febantel)","contraindications":"Contraindications and Precautions Pralidoxime treatment should not be used for carbamate intoxication. Do not administer rapidly intravenously, or it may cause respiratory depression and other problems. Drug Interactions No\\tdrug\\tinteractions\\thave\\tbeen\\treported.\\tHowever,\\tother\\tdrugs\\tshould\\tbe avoided when treating organophosphate poisoning. These drugs include aminoglycosides, barbiturates, phenothiazine tranquilizers (acepromazine), and neuromuscular blocking agents.","indications":"Indications and Clinical Uses Pralidoxime chloride is used for treatment of organophosphate toxicosis. It should be administered promptly after organophosphate intoxication is recognized. It also has been used to treat overdoses of other anticholinesterase drugs such as neostigmine, pyridostigmine, and edrophonium. P Precautionary Information","side_effects":"Adverse Reactions and Side Effects Intramuscular injections cause pain. Rapid IV injections may bind calcium and cause muscle spasms. Rapid injections also may cause heart and respiratory problems. Use during pregnancy may produce teratogenic effects.","notes":"Instructions for Use Dilute formulation in glucose solution before IV administration. Give slowly IV. Administer atropine (0.1 mg/kg) when using pralidoxime to minimize adverse effects. Recovery from organophosphate poisoning may take 48 hours. When treating intoxication, consult a poison control center for precise guidelines. Patient Monitoring and Laboratory Tests Monitor for signs of organophosphate poisoning to determine if repeated doses are necessary. Monitor heart rate and rhythm and respiratory rate. It may be possible to monitor cholinesterase activity from a blood sample to confirm organophosphate poisoning (consult local diagnostic laboratory). Formulations \u2022\\t\\tPralidoxime\\tchloride\\tis\\tavailable\\tin\\ta\\t1-\\tg\\tvial\\tto\\tbe\\treconstituted\\tin\\t20\\tmL\\tof\\twater (50-\\t  mg/mL\\tinjection).\\tpH\\tof\\tsolution\\tis\\t3.5\u20134.5. Stability and Storage Store powder at room temperature and protect from light. Reconstituted solution should\\t   be\\t stored\\t   below\\t   25\xb0C\\t   and\\t  protected\\tfrom\\t  light.\\t   Discard\\treconstituted\\tsolution after 3 hours.","original_category":"Antidote"},{"name":"Propantheline Bromide","active_ingredient":"Propantheline Bromide","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.25\u20130.5\\tmg/kg\\tq8\u201312h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tThe\\tuse\\tis\\tdiscouraged\\tbecause\\tof adverse effect on GI motility. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t4 Propiopromazine Hydrochloride (Propionylpromazine) proe- pee- oh- prom\u2032ah- zeen  hye- droe- klor\u2032ide Trade and other names: Tranvet","contraindications":"Contraindications and Precautions Do not use in animals with decreased intestinal motility. Use cautiously in animals with heart disease because it may increase heart rate. Do not use in animals with glaucoma. Drug Interactions Propantheline interferes with cholinergic drugs or drugs that promote motility (e.g., metoclopramide). Bromide concentration in the formulation should be considered for animals also receiving other sources of bromide (e.g., potassium bromide for treatment of epilepsy). 784    Propiopromazine Hydrochloride (Propionylpromazine)","indications":"Indications and Clinical Uses Propantheline is used to decrease smooth muscle contraction and secretion of the GI tract. Through these anticholinergic effects, it also has been used to treat vagal- mediated cardiovascular effects, such as bradycardia and heart block. Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Because it produces a profound decrease in GI tract motility, its use should be carefully weighed against the potential for adverse effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects are attributed to excess anticholinergic (antimuscarinic) effects and include ileus, urine retention, tachycardia, xerostomia (dry mouth), and behavior changes. Treat overdoses with physostigmine.","notes":"Instructions for Use Propantheline has not been evaluated in clinical trials in animals, but propantheline has been used for oral therapy in cases in which an anticholinergic effect is desired. Patient Monitoring and Laboratory Tests No\\tspecific\\tmonitoring\\tis\\tnecessary. Formulations \u2022\\t\\tPropantheline\\tis\\tavailable\\tin\\t7.5-\\t\\tand\\t15-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antidiarrheal"},{"name":"Propranolol Hydrochloride","active_ingredient":"Propranolol Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t20\u201360\\tmcg/kg\\tover\\t5\u201310\\tminutes\\tIV\\t(titrate\\tdose\\tto\\teffect). \u2022\\t\\t0.2\u20131\\tmg/kg\\tq8h\\tPO\\t(titrate\\tdose\\tto\\teffect). Cats \u2022\\t\\t0.4\u20131.2\\tmg/kg\\t(2.5\u20135\\tmg/cat)\\tq8h\\tPO.  Horses \u2022\\t\\t0.1\\tmg/kg\\tIV\\tslowly.\\tRepeat\\tin\\t6\u20138\\thours\\tif\\tnecessary.\\tIf\\tlow\\tdose\\tis\\tnot\\teffective, administer 0.5 mg/kg and increase the dose to 2 mg/kg IV gradually until desired response. \u2022\\t\\t0.4\u20130.8\\tmg/kg\\tq8h\\tPO. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Propylthiouracil pro- pil- thye- oh- yoo\u2032rah- sil Trade and other names: Propyl- Thyracil, PTU, and generic brands","contraindications":"Contraindications and Precautions Do not administer to animals with low cardiac reserve, bradycardia, or poor systolic function. Use cautiously in animals with respiratory problems because bronchoconstriction can occur from beta 2 effects.\\tHyperthyroid\\tcats\\tmay\\thave reduced clearance and increased risk of toxicity. Drug Interactions Lipophilic beta blockers, such as propranolol, rely on the liver for clearance. These drugs are subject to interactions from drugs that affect liver blood flow and interact with hepatic enzymes. Decreased liver blood flow reduces propranolol\u2019s clearance.","indications":"Indications and Clinical Uses Propranolol is used primarily to decrease heart rate, decrease cardiac conduction, control tachyarrhythmias, and decrease blood pressure. It is effective in controlling the response from adrenergic stimulation. Beta blockers such as propranolol are among the most effective drugs for slowing heart rate, but propranolol is not used as commonly as other more specific agents such as atenolol or metoprolol. Esmolol is preferred for short- term use. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The adverse effects from propranolol are related to beta 1 - blocking effects on heart. Propranolol causes cardiac depression and decreases cardiac output. Beta 2 - blocking effects can cause bronchoconstriction and decrease insulin secretion. Switch to a more specific beta 1 - blocker (see Instructions for Use) if beta 2 - blocking effects are undesirable and a more specific agent is needed. Weakness and fatigue can be caused by beta blockers, which can indicate that a reduction in dose is needed.","notes":"Instructions for Use There may be high individual variability in clinical response. The dose should be titrated according to patient\u2019s response (e.g., by monitoring the heart rate). Start with a low dose and increase gradually to desired effect. Clearance relies on hepatic blood flow; therefore, it should be administered cautiously to animals with impaired hepatic 790    Propylthiouracil perfusion. In cats with hyperthyroidism, consider reducing the dose to prevent adverse effects. Cats with hyperthyroidism may have decreased clearance or increased oral absorption compared with other cats. Propranolol is a nonspecific beta- blocker. If a more specific blocker is needed (i.e., specific for the beta 1 receptor), consider atenolol or metoprolol, which are listed in other sections of this book. Patient Monitoring and Laboratory Tests Monitor heart rate during treatment. Monitor respiratory function in patients prone to bronchoconstriction. Formulations \u2022\\t\\tOral:\\tPropranolol\\tis\\tavailable\\tin\\t10-\\t,\\t20-\\t  ,\\t40-\\t  ,\\t60-\\t  ,\\tand\\t80-\\tmg\\ttablets\\tand\\t4-\\t\\tand 8-   mg/mL oral solution. \u2022\\t\\tInjection:\\tPropofol\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Propranolol is soluble in water and ethanol. Suspensions prepared in various syrups and flavorings were stable for 4 months, but some settling may occur (shake before administration).\\tpH\\tof\\tformulations\\tshould\\tbe\\tkept\\tat\\t2.8\u20134\\tfor\\tmaximum\\tstability. In alkaline solutions, it decomposes.","original_category":"Beta blocker"},{"name":"Alpha","active_ingredient":"Alpha","species":["Canine","Feline","Bovine","Equine"],"dosage":"Dogs \u2022\\t\\tPyometra:\\t0.1\u20130.2\\tmg/kg\\tonce\\tdaily\\tfor\\t5\\tdays\\tSQ. \u2022\\t\\tTermination\\tof\\tpregnancy:\\t0.1\u20130.25\\tmg/kg\\tq\\t8\u201312h\\tSQ.\\tFewer\\tadverse\\teffects\\tare seen with 0.1 mg/kg q8h SQ for 2 days; then increase to 0.2 mg/kg q8h, SQ until abortion is complete, usually within 9 days. It may be combined with misoprostol to shorten the protocol. Cats \u2022\\t\\tPyometra:\\t0.1\u20130.25\\tmg/kg\\tonce\\tdaily\\tfor\\t5\\tdays\\tSQ. \u2022\\t\\tTermination\\tof\\tpregnancy:\\t0.5\u20131\\tmg/kg\\tIM\\tfor\\ttwo\\tinjections.\\tA\\tlower\\tdosage and longer protocol for cats is a dosage of 0.2 mg/kg q12h, SQ on day 1 and then 0.5 mg/kg q12h SQ for up to 5 days.  Cattle \u2022\\t\\tTermination\\tof\\tpregnancy:\\t25\\tmg\\ttotal\\tdosage\\tadministered\\tonce\\tIM. \u2022\\t\\tEstrus\\tsynchronization:\\t25\\tmg\\tonce\\tIM\\tor\\ttwice\\tat\\t10-\\t\\tto\\t12-\\tday\\tintervals. \u2022\\t\\tPyometra:\\t25\\tmg\\tIM\\tadministered\\tonce. Horses \u2022\\t\\tEstrus\\tsynchronization:\\t1\\tmg/100\\tlb\\t(1\\tmg/45\\tkg)\\tIM\\tor\\t1\u20132\\tmL\\tadministered once IM. Mares should return to estrus within 2\u20134 days and ovulate 8\u201312 days after treatment. Pigs \u2022\\t\\tInduction\\tof\\tparturition:\\t10\\tmg\\tadministered\\tonce\\tIM.\\tParturition\\toccurs\\twithin 30 hours. Regulatory Information No\\twithdrawal\\ttime\\trequired\\tfor\\tmeat\\tor\\tmilk. Pseudoephedrine Hydrochloride soo- doh- eh- fed\u2032rin  hye- droe- klor\u2032ide Trade and other names: Sudafed and generic brands","contraindications":"Contraindications and Precautions Do not administer intravenously. PGF 2 alpha induces abortion in pregnant animals. Use caution when handling this drug. It should not be handled by pregnant women. Absorption through the intact skin is possible. People with respiratory problems also should not handle dinoprost because absorption across the skin may lead to bronchoconstriction. Drug Interactions According\\tto\\tthe\\tlabel,\\tdinoprost\\tshould\\tnot\\tbe\\tused\\twith\\tNSAIDs\\tbecause\\tthese drugs\\tinhibit\\tsynthesis\\tof\\tprostaglandins.\\tHowever,\\tNSAIDs\\tshould\\tnot\\taffect concentrations of PGF 2 alpha after administration with this product. When using oxytocin concurrently, it should be used cautiously because there is a risk of uterine rupture.","indications":"Indications and Clinical Uses Prostaglandin F 2 alpha has been used to treat open pyometra in animals. In cattle, dinoprost has been used for treatment of chronic endometritis. Use for inducing abortion in small animals has been questioned, and other drugs are usually used instead. For example, synthetic PGF 2 alpha analogs such as cloprostenol are more potent with fewer adverse effects. Occasionally, in large animals, dinoprost is used to induce abortion in the first 100 days of gestation. It is also used for estrous synchronization in cattle and horses by causing luteolysis. In pigs, dinoprost is used to induce parturition when given within 3 days of farrowing. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Prostaglandin F 2 alpha causes increased smooth muscle tone, resulting in diarrhea, abdominal discomfort, bronchoconstriction, and an increase in blood pressure. In small animals, other side effects include vomiting, which occurs within 20 minutes of injection. Induction of abortion may cause retained placenta.","notes":"Instructions for Use Use in treating pyometra should be monitored carefully because adverse effects can occur as a consequence of treatment for pyometra. Patient Monitoring and Laboratory Tests Monitor for signs of estrus after treatment. Formulations \u2022\\t\\tPGF 2 is available in a 5- mg/mL solution for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. It should be stored in a manner to avoid skin contact with humans. P Pseudoephedrine Hydrochloride 793","original_category":"Prostaglandin"},{"name":"Pseudoephedrine Hydrochloride","active_ingredient":"Pseudoephedrine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.2\u20130.4\\tmg/kg\\t(or\\t15\u201360\\tmg/dog)\\tq8\u201312h\\tPO. P Psyllium 795  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of abuse in humans, many forms are now Controlled Schedule V substances. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Psyllium sill\u2032ee- um Trade and other names: Metamucil and generic brands","contraindications":"Contraindications and Precautions Pseudoephedrine may cause some effects that are similar to PPA. Use cautiously in patients with cardiovascular disease. Use cautiously with drugs that are MAOIs. Beta agonists such as pseudoephedrine may increase blood glucose. Pseudoephedrine has been used in clandestine laboratories to illegally manufacture methamphetamine. Therefore, the availability of pseudoephedrine has been restricted in most states. Drug Interactions Pseudoephedrine, like other sympathomimetic agents, is expected to potentiate other alpha-  and beta- receptor agonists. It may cause increased vasoconstriction and changes in heart rate. Use cautiously with other vasoactive drugs. Use cautiously with other drugs that may lower the seizure threshold. Use of inhalant anesthetics may increase cardiovascular risk. Do not use with TCAs or MAOIs.","indications":"Indications and Clinical Uses Pseudoephedrine has been used as a decongestant, as a mild bronchodilator, and to increase tone of urinary sphincter. Pseudoephedrine, PPA, and ephedrine have similar alpha- receptor and beta- receptor effects. The most common use in animals is for treating urinary incontinence. The mechanism for this action appears to be via stimulating receptors on the sphincter. In\\tpeople,\\tit\\thas\\tbeen\\tused\\tas\\ta\\tdecongestant.\\tHowever,\\tbecause\\tpseudoephedrine is easily diverted to manufacture of methamphetamine, the availability in human medicine has diminished because of restrictions for obtaining the tablets from a pharmacy. Most of the OTC forms and combination products for people have been removed. For animals, PPA produces similar effects and may be substituted. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributed to adrenergic effects. These include excitement, rapid heart rate, increased blood pressure, and arrhythmias.","notes":"Instructions for Use Although clinical trials have not been conducted for comparison, it is believed that the action and efficacy of pseudoephedrine are similar to those of ephedrine and PPA. Patient Monitoring and Laboratory Tests Monitor heart rate in patients. If possible, monitor blood pressure and ECG in patients that may be susceptible to cardiovascular problems. Formulations Available Pseudoephedrine\\thas\\tbeen\\tavailable\\tin\\t30-\\t\\tand\\t60-\\tmg\\ttablets,\\t120-\\tmg\\tcapsules,\\tand 6-\\t mg/mL\\tsyrup,\\tbut\\tthe\\tavailability\\tof\\thuman\\tformulations\\thas\\tdiminished\\tbecause of reasons cited earlier. (Some combination formulations have other ingredients such as antitussives or antihistamines.) Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Pseudoephedrine is soluble in water and ethanol. Keep compounded formulations at a low\\tpH\\tfor\\tmaximum\\tstability.\\tProtect\\tfrom\\tfreezing.","original_category":"Adrenergic agonist"},{"name":"Pyridostigmine Bromide","active_ingredient":"Pyridostigmine Bromide","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tAntimyasthenic:\\t0.02\u20130.04\\tmg/kg\\tq2h\\tIV\\tor\\t0.5\u20133\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tAntidote\\tfor\\tmuscle\\tblockade:\\t0.15\u20130.3\\tmg/kg\\tIM\\tor\\tIV\\tas\\tneeded. Cats \u2022\\t\\t0.1\u20130.25\\tmg/kg\\tq24h\\tPO.\\tCRI:\\t0.01\u20130.03\\tmg/kg/h\\tIV.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Pyrimethamine peer- ih- meth\u2032ah- meen Trade and other names: Daraprim","contraindications":"Contraindications and Precautions Do not use in patients with urinary obstruction, intestinal obstruction, asthma or bronchoconstriction, pneumonia, or cardiac arrhythmias. Do not use in patients sensitive to bromide. Consider the amount of bromide in dose in any patient also receiving bromide for treatment of seizures. Drug Interactions Bromide concentration in the formulation should be considered for animals also receiving bromide (e.g., potassium bromide) for treatment of epilepsy. (Sodium bromide may be used as an alternative.) P Pyrimethamine 799","indications":"Indications and Clinical Uses Pyridostigmine is used as an antidote for anticholinergic intoxication and treatment (antidote) for neuromuscular blockade. It is also used as a treatment of myasthenia gravis, ileus, and retention of urine (e.g., postoperative ileus and urine retention) by increasing tone of bladder smooth muscle and stimulating bowel motility. The most common regular used for pyridostigmine is the first drug of choice for myasthenia gravis. It is preferred over neostigmine. If animals with myasthenia gravis do not respond to pyridostigmine alone, immunosuppressive agents are added. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are caused by the cholinergic action resulting from inhibition of cholinesterase. These effects can be seen in the GI tract as diarrhea and increased secretions. Other adverse effects can include miosis, bradycardia, muscle twitching or weakness, and constriction of bronchi and ureters. Pyridostigmine may be associated with fewer adverse effects than neostigmine, but the effects of pyridostigmine may persist longer. If adverse effects are observed, treat with anticholinergic drugs, such as 0.125 mg of hyoscyamine sulfate. Atropine also may be used as an antagonist to reverse adverse effects or an overdose.","notes":"Instructions for Use Pyridostigmine\\tis\\tused\\tfor\\ttreatment\\tof\\tmyasthenia\\tgravis.\\tNeostigmine\\tand pyridostigmine have fewer side effects than physostigmine. When used, the frequency of dose may be increased based on observation of effects. After administration, pyridostigmine\u2019s benefits should be observed in approximately 15\u201330 minutes. The duration of action may be 3\u20134 hours. Patient Monitoring and Laboratory Tests Monitor GI effects. Monitor cardiac rate and rhythm. Formulations Pyridostigmine\\tis\\tavailable\\tin\\t12-\\tmg/mL\\toral\\tsyrup,\\t60-\\tmg\\ttablets\\t(scored),\\tand 5- mg/mL  injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Pyridostigmine is soluble in water. Store in acid solutions; it may decompose in alkaline vehicles.","original_category":"Anticholinesterase, antimyasthenic"},{"name":"Pyrimethamine and Sulfadiazine","active_ingredient":"Pyrimethamine and Sulfadiazine","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t1\\tmg/kg\\tof\\tpyrimethamine\\tand\\t20\\tmg/kg\\tof\\tsulfadiazine\\tonce\\tdaily\\tPO. (Equivalent to one third a milliliter [0.33 mL] of the equine formulation per 4 kg of body weight.)  \u2022\\t\\tEPM\\tcaused\\tby\\tS. neurona:\\t1\\tmg/kg\\tof\\tpyrimethamine\\tand\\t20\\tmg/kg\\tof sulfadiazine q24h PO (4 mL per 110 lb). Treatment duration in horses varies from 90\u2013270 days. Regulatory Information Do not administer to animals intended for food. Q Quinacrine Hydrochloride 803 Quinacrine Hydrochloride kwin\u2032eh- krin  hye- droe- klor\u2032ide Trade and other names: Atabrine (no longer available in the United States)","contraindications":"Contraindications and Precautions Do not administer to animals that may be prone to anemia or in which a CBC cannot be monitored. Do not administer to animals with a history of sensitivity to sulfonamides. Drug Interactions Drug\\tinteractions\\tare\\tnot\\treported\\tfor\\tanimals.\\tHowever,\\ta\\tcombination\\tof pyrimethamine with trimethoprim\u2013sulfonamides enhances the bone marrow toxicity.","indications":"Indications and Clinical Uses Pyrimethamine + sulfadiazine is used to treat horses with EPM. Although not approved for use to treat other animals, the equine formulation has been administered to small animals to treat protozoal infections caused by Toxoplasma, Neospora, and Sarcocystis spp. The equine formulation has extensive clinical studies to support safety and efficacy through the FDA approval. The uses in other animals are based on anecdotal experience and recommendations from experts. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In horses, at high doses, decreased blood count has been observed but without evidence of anemia. Although anemia is possible, it resolves after discontinuing medication. Folic or folinic acid has been supplemented to prevent anemia, but the benefit of this treatment is unclear. Because this combination contains a sulfonamide, adverse effects are possible. Multiple adverse effects have been documented from administration of sulfonamides, particularly in dogs. These include allergic reactions, type II and III hypersensitivity, arthropathy, anemia, thrombocytopenia, hepatopathy, hypothyroidism (with prolonged therapy), keratoconjunctivitis sicca, and skin reactions. Dogs may be more sensitive to sulfonamides than other animals because dogs lack the ability to acetylate sulfonamides to metabolites.","notes":"Instructions for Use Use of pyrimethamine\u2013sulfadiazine has been primarily for treatment of protozoal infections\\tin\\thorses.\\tHowever,\\tthere\\tis\\tanecdotal\\tevidence\\tthat\\tpyrimethamine\\t+ sulfadiazine may be indicated for treatment of some protozoa (e.g., Toxoplasma, Neospora, or Sarcocystis spp.) in small animals. Patient Monitoring and Laboratory Tests Monitor CBC periodically in animals receiving treatment. A CBC should be performed at least monthly in treated animals. Formulations \u2022\\t\\tPyrimethamine\\t+\\tsulfadiazine\\tis\\tavailable\\tin\\tan\\toral\\tsuspension\\tfor\\thorses\\tthat\\tis\\t250 mg of sulfadiazine and 12.5 mg of pyrimethamine per milliliter. This formulation may be diluted if necessary for small animals. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not freeze.","original_category":"Antiprotozoal"},{"name":"Racemethionine","active_ingredient":"Racemethionine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t150\u2013300\\tmg/kg/day\\tPO. \u2022\\t\\tManufacturers\\tof\\t\u201clawn-\\tsaver\u201d\\tproducts\\t(use\\tis\\tdescribed\\tearlier)\\trecommend 15\u2013266 mg/kg, depending on the product. A typical dose for a large dog is 23 mg/kg. Cats \u2022\\t\\t1\u20131.5\\tg\\tper\\tcat\\tPO\\t(added\\tto\\tfood\\teach\\tday).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Ramipril ram\u2032ih- pril Trade and other names: Vasotop","contraindications":"Contraindications and Precautions Do not use in animals with metabolic acidosis. Do not use in young cats. Do not use in animals with hepatic disease. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Racemethionine is used as a urinary acidifier. In people, it also is used to treat dermatitis caused by urinary incontinence by reducing irritation to the skin (reduces urine ammonia). Another use is to administer to dogs for the purpose of acidifying dog urine to prevent urine- induced damage to lawns. The so- called \u201clawn- saver\u201d products contain 133\u2013500 mg of methionine per pill, biscuit, or chew and may be obtained over the counter (OTC). It is also used as a nutritional supplement and feed supplement for livestock. DL- methionine has been administered to cats for lowering the urine pH, but this use is no longer recommended. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are reported because of the common use to acidify urine in animals and because animals can be exposed from food supplements. In dogs exposed to high doses, the most common adverse effects are gastrointestinal (GI) and neurologic. Vomiting is the most common GI sign. The most common neurologic sign is ataxia. Neurologic signs are identified when the dose is greater than 95 mg/kg. When discontinued, dogs recover from adverse effects within 48 hours. Doses of 0.5\u20131 mg/kg per day to cats can produce Heinz body anemia and methemoglobinemia.","notes":"Instructions for Use Use for acetaminophen toxicity has been replaced by acetylcysteine. Patient Monitoring and Laboratory Tests Monitor complete blood count and hepatic enzymes if used to treat toxicity. Formulations \u2022\\t\\tRacemethionine\\tis\\tavailable\\tin\\t500-\\tmg\\ttablets,\\t75-\\tmg/5-\\t   mL\\tpediatric\\toral solution, 200- mg capsules, and powders to add to an animal\u2019s food. R R Ramipril 807 \u2022\\t\\tMethionine\\t(identified\\tas\\tDL-\\tmethionine)\\tis\\tavailable\\tin\\tseveral\\tfeed\\tsupplements. \u2022\\t\\tProducts\\tlisted\\tas\\t\u201clawn-\\tsaver\u201d\\tproducts\\tfor\\tdogs\\tusually\\tcontain\\t133\\tmg\\tof racemethionine per tablet or chew. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Acidifier"},{"name":"Ranitidine Hydrochloride","active_ingredient":"Ranitidine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t2\\tmg/kg\\tq8h\\tIV\\tor\\tPO. Cats \u2022\\t\\t2.5\\tmg/kg\\tq12h\\tIV\\tor\\t3.5\\tmg/kg\\tq12h\\tPO.  Horses \u2022\\t\\t2.2\u20136.6\\tmg/kg\\tq6\u20138h\\tPO.\\tThe\\thigher\\tdose\\t(6.6\\tmg/kg)\\tis\\tmore\\teffective\\tat suppressing stomach acid. \u2022\\t\\t2\\tmg/kg\\tq6\u20138h\\tIV. Calves \u2022\\t\\t50\\tmg/kg\\tq8h\\tPO\\tin\\tmilk-\\tfed\\tcalves. \u2022\\t\\tAdult\\tcattle:\\t6.6\\tmg/kg\\tIM\\t(only\\teffective\\tfor\\t1\\thour). Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t5 Remifentanil Hydrochloride rem- i- fen\u2032ta- nil Trade and other names: Ultiva","contraindications":"Contraindications and Precautions Fewer drug interactions are possible with ranitidine compared with cimetidine because\\tranitidine\\tdoes\\tnot\\tinhibit\\tcytochrome\\tP450\\tenzymes. Drug Interactions Ranitidine and other H 2 - receptor blockers block secretion of stomach acid. Therefore they interfere with oral absorption of drugs dependent on acidity, such as ketoconazole, itraconazole, and iron supplements. Unlike cimetidine, ranitidine is\\tnot\\tknown\\tto\\tinhibit\\tmicrosomal\\tP450\\tenzymes.","indications":"Indications and Clinical Uses Ranitidine has been used to treat GI ulcers, gastritis, and reflux esophagitis. It does not produce as much of a sustained increase in stomach pH as proton pump inhibitors (omeprazole).\\tProton\\tpump\\tinhibitors\\tsuch\\tas\\tomeprazole\\thave\\tbeen\\tpreferred\\tin\\tdogs, cats, and horses because they produce a more consistent and sustained suppression of gastric acid secretion for ulcer healing, preventing ulcers, and preventing reflux esophagitis. The\\tdose\\trequirements\\tused\\tclinically\\tmay\\tnot\\tbe\\tsufficient\\tto\\tmaintain\\tstomach\\tpH\\tin the\\trange\\tto\\tprevent\\tulcers\\tin\\tdogs.\\tRanitidine\\t(6.6\\tmg/kg\\tPO)\\tin\\tfoals\\tsuppressed\\tacid for 6 hours, but omeprazole is superior and suppresses acid for 22 hours at 4 mg/kg. Ranitidine has been used to prevent NSAID- induced ulcers in animals, but the efficacy has not been demonstrated for this effect. In horses, ranitidine does not improve healing of ulcers induced by NSAIDs, and it is not as effective as omeprazole for treating gastric ulcers from other causes. Ranitidine may stimulate stomach emptying and colon motility via anticholinesterase action. In horses, the effect on gastric emptying is minimal. Precautionary Information","side_effects":"Adverse Reactions and Side Effects See the note at the top of the page regarding removal of ranitidine products from the market. Other adverse effects are usually seen only with decreased renal clearance. In people, central nervous system (CNS) signs may occur with high doses. Ranitidine may have fewer effects on endocrine function and drug interactions compared with cimetidine.","notes":"Instructions for Use Pharmacokinetic\\tinformation\\tin\\tdogs\\tsuggests\\tthat\\tranitidine\\tmay\\tbe\\tadministered less often than cimetidine to achieve continuous suppression of stomach acid 810    Remifentanil Hydrochloride secretion. However, ranitidine may be less effective in dogs and cats to produce effective suppression of stomach acid secretion than previously thought. Use in horses and foals is based on experimental studies and pharmacokinetic data, and these studies show that it is less effective than omeprazole. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tRanitidine\\twas\\tavailable\\tin\\t75-\\t,\\t150-\\t   ,\\tand\\t300-\\tmg\\ttablets;\\t150-\\t\\tand\\t300-\\tmg capsules; and 25- mg/mL injection. Some forms were available OTC. However, in 2020, the FDA announced a removal of ranitidine products from the market. Therefore, these formulations may not be available in the United States. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ranitidine hydrochloride is soluble in water. Tablets have been crushed and mixed with\\twater\\tand\\tsyrup\\tand\\twere\\tstable\\tfor\\t7\\tdays.\\tProtect\\tfrom\\tfreezing.","original_category":"Antiulcer agent"},{"name":"Riboflavin (Vitamin B","active_ingredient":"Riboflavin (Vitamin B","species":["Canine","Feline","Equine","Bovine"],"dosage":"DogsCats \u2022\\t\\t10\u201320\\tmg/day\\tPO.\\t\u2022\\t\\t5\u201310\\tmg/day\\tPO. \u2022\\t\\t1\u20134\\tmg/dog\\tq24h\\tSQ. \\t\u2022\\t\\t1\u20132\\tmg/cat\\tq24h\\tSQ.  LambsCattle and Horses \u2022\\t\\t2\u20134\\tmg\\tq24h\\tIM\\tor\\tSQ.\\t\\t\u2022\\t\\t20\u201340\\tmg\\tq24h\\tIM\\tor\\tSQ. Calves and FoalsSheep and Pigs \u2022\\t\\t6\u201310\\tmg\\tq24h\\tIM\\tor\\tSQ. \\t\u2022\\t\\t10\u201320\\tmg\\tq24h\\tIM\\tor\\tSQ. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is necessary. 814    Rifampin Rifampin rih- fam\u2032pin Trade and other names: Rifadin, Rimactane, and rifampicin","contraindications":"Contraindications and Precautions Do not administer injectable solution by IV rapidly if it contains thiamine (vitamin B 12 ) because this may cause an anaphylactic reaction. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Riboflavin is used as a vitamin B 2 supplement. It is usually administered for maintenance in patients who are vitamin B 2 deficient. It is often added to infusion fluids to patients that are suspected of being vitamin B deficient. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare because water- soluble vitamins are easily excreted. Riboflavin may discolor the urine.","notes":"formulations, it is available as 5\u2032 phosphate sodium riboflavin. Vitamin B complex often contains thiamine (B 1 ), riboflavin, niacinamide, and cyanocobalamin B 12 . R 2 ) 813 Instructions for Use It is not necessary to supplement in animals with well- balanced diets. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tRiboflavin\\tis\\tavailable\\tin\\tvarious-\\tsized\\ttablets\\tin\\tincrements\\tfrom\\t10\u2013250\\tmg. Riboflavin is most commonly formulated with other vitamins in a \u201cvitamin B complex\u201d\\taqueous\\tsolution\\tfor\\tinjection\\t(2\\tand\\t5\\tmg/mL\\tof\\triboflavin). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vitamin"},{"name":"Ringer\u2019s Solution","active_ingredient":"Ringer\u2019s Solution","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t55\u201365\\tmL/kg\\tday\\t(2.5\\tmL/kg/h)\\tIV,\\tSQ,\\tor\\tintraperitoneal\\t(IP)\\tfor\\tmaintenance. \u2022\\t\\t15\u201330\\tmL/kg/h\\tIV\\tfor\\tmoderate\\tdehydration. \u2022\\t\\t50\\tmL/kg/h\\tIV\\tfor\\tsevere\\tdehydration.  Large Animals \u2022\\t\\t40\u201350\\tmL/kg\\tday\\tIV,\\tSQ,\\tor\\tIP\\tfor\\tmaintenance. \u2022\\t\\t15\u201330\\tmL/kg/h\\tIV\\tfor\\tmoderate\\tdehydration. \u2022\\t\\t50\\tmL/kg/h\\tIV\\tfor\\tsevere\\tdehydration. Calves \u2022\\t\\tModerate\\tdehydration:\\t45\\tmL/kg\\tgiven\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h. \u2022\\t\\tSevere\\tdehydration:\\t80\u201390\\tmL/kg\\tgiven\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h\\tor\\tas\\tfast\\tas 80 mL/kg/h if necessary. 818    Rivaroxaban Regulatory Information Because of low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Rivaroxaban riv- a- rox\u2032a- ban Trade and other names: Xarelto","contraindications":"Contraindications and Precautions Do not exceed fluid rates of 80 mL/kg/h. Consider supplementing with potassium because this fluid will not meet maintenance potassium needs. Drug Interactions Ringer\u2019s solution contains calcium; do not mix with drugs that may bind to calcium.","indications":"Indications and Clinical Uses Ringer\u2019s solution is used as a fluid replacement and for maintenance. It has a balanced electrolyte concentration, but it does not contain any bases (see Lactated Ringer\u2019s Solution for solutions that contain bases). R Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ringer\u2019s solution is considered an acidifying solution because with prolonged administration, the chloride increases renal excretion of bicarbonate. Fluid overload occurs at high infusion rates.","notes":"Instructions for Use When administering IV fluid solution, monitor rate and electrolyte concentrations carefully. Add bicarbonate to fluids, if necessary, based on the calculation of the base deficit. Fluid\\tadministration\\trates\\tare\\tas\\tfollows:\\tnormal\\tmaintenance\\trates:\\t40\u201365\\tmL/ kg/24 h (\u22482\u20132.5\\tmL/kg/h).\\tFor\\treplacement\\tfluid,\\tuse\\tthe\\tfollowing\\tcalculation: Liters\xa0needed=%\xa0dehydration\xd7body\xa0weight (kg) or Milliliters\xa0needed=%\xa0dehydration\xd7body\xa0weight (kg) \xd7 1000 Patient Monitoring and Laboratory Tests Monitor pulmonary pressure when infusing high doses. Monitor electrolyte balance, especially potassium, during treatment. Formulations Ringer\u2019s solution is available in 250- , 500- , and 1000- mL bags for infusion. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Fluid replacement"},{"name":"Rivaroxaban","active_ingredient":"Rivaroxaban","species":["Canine","Feline"],"dosage":"warfarin. Rivaroxaban has been administered to dogs at an average dosage of 0.89 mg/kg once daily and was well tolerated, but the therapeutic benefits compared with traditional drugs are not known. In cats that received a range of doses from 1.25\u20135\\tmg\\tper\\tcat\\tq12h\\tPO,\\tall\\tdoses\\twere\\teffective\\twith\\ta\\tpeak\\teffect\\tat\\t3\\thours and a duration of 12 hours. R Precautionary Information  Dogs \u2022\\t\\t1\u20132\\tmg/kg\\tPO\\tq24h. \u2022\\t\\tHuman\\tdosage\\t(listed\\there\\tas\\ta\\tcomparison):\\t0.2\\tmg/kg\\tq12h\\tPO\\tinitially\\tfor\\t3 weeks;\\tthen\\t0.3\\tmg/kg\\tonce-\\tdaily\\tPO\\tthereafter.\\tFor\\tprophylaxis,\\tthe\\tdosage\\tis 0.14\\tmg/kg\\tPO\\tq24h. 820    Robenacoxib Cats \u2022\\t\\t0.5\u20131\\tmg/kg\\tq24h\\tPO.\\tCats\\tcan\\talso\\tbe\\tadministered\\ttablets\\tof\\t1.25-\\t,\\t2.5-\\t  ,\\tand 5 mg per cat, oral.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\tidentified. Regulatory Information No\\twithdrawal\\tinformation\\tor\\tregulatory\\trequirements\\tare\\tavailable.\\tAvoid\\tuse\\tin food- producing  animals. Robenacoxib Roe-ben-A-cocks-ib Trade and other names: Onsior (veterinary preparation)","contraindications":"Contraindications and Precautions The most important concern and precaution is any existing bleeding abnormality that exists in a patient prior to administration. Do not use in patients with hepatic impairment. Drug Interactions No specific drug interactions have been identified in animals, but the use has been\\tinfrequent\\tat\\tthis\\ttime\\tand\\trarely\\treported\\tto\\tunderstand\\tthe\\tfull\\tscope\\tof possible drug interactions. In people, rivaroxaban is a substrate for cytochrome P450\\tenzymes\\tand\\tP-\\tglycoprotein.\\tPotentially,\\tother\\tdrugs\\tthat\\tinhibit\\t(e.g., ketoconazole) or induce (e.g., rifampin, phenobarbital) these enzymes and the P-\\t glycoprotein\\ttransporter\\tcould\\taffect\\tresponse\\tto\\trivaroxaban.\\tAdministration with antiplatelet drugs (aspirin, clopidogrel) could increase the risk of bleeding.","indications":"Indications and Clinical Uses Rivaroxaban is approved in people for treatment of venous thrombosis and pulmonary embolism and prevention of venous thrombosis. It is also used in patients with atrial fibrillation. It is used in situations when the alternatives may\\tinclude\\tvitamin\\tK\\tantagonists\\t(warfarin)\\tor\\tlow-\\tmolecular\\tweight heparin (enoxaparin). The advantage of rivaroxaban is that it can be administered\\torally\\tand\\tdoes\\tnot\\trequire\\tthe\\tmonitoring\\t(international normalized ratio monitoring) that is needed to optimize the dose of warfarin. In animals, the uses identified at this time are based on small studies or anecdotal observations. Compared with warfarin, rivaroxaban is easier to use because the pharmacokinetics are more predictable, and a fixed dose may be administered\\tto\\tproduce\\tresults\\twithout\\troutine\\tmonitoring\\tas\\trequired\\tfor","side_effects":"Adverse Reactions and Side Effects Rivaroxaban has not been used to a large extent at this time in veterinary medicine to know all the possible adverse effects. Obviously, excessive bleeding is the major concern when administering any agents from this group. Adverse effects reported in people but not reported during animal use include abdominal pain, fatigue, muscle spasms, dizziness, anxiety, pruritus, and increased liver enzymes. If\\ta\\treversal\\tof\\tthe\\tantifactor\\tXa\\teffect\\tis\\trequired\\tbecause\\tof\\tan\\toverdose,\\tthere is a human product (Andexanet alfa), which is a genetically modified variant of human factor Xa (alanine is substituted for serine) that acts as a decoy, binding to factor Xa inhibitors and neutralizing their anticoagulant effect. This agent is very expensive and has not been tested in animals.","notes":"Instructions for Use Administration\\tof\\thuman\\trivaroxaban\\ttablets\\tmay\\trequire\\tmodification.\\tIf\\twhole tablets cannot be used, the tablets may be crushed and mixed with food (in people, applesauce is used) immediately prior to oral administration. Patient Monitoring and Laboratory Tests Monitor for signs of bleeding. Routine coagulation testing is not recommended or necessary for direct oral anticoagulants such as rivaroxaban. If antifactor Xa activity is measured, it must be specifically calibrated for rivaroxaban. If coagulation tests are performed, it will prolong the activated partial thromboplastin time. Formulations Oral\\ttablets:\\t2.5-\\t,\\t10-\\t  ,\\t15-\\t  ,\\tand\\t20\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticoagulant"},{"name":"Robenacoxib","active_ingredient":"Robenacoxib","species":["Canine","Feline"],"dosage":"dosage\\tin\\tdogs\\tand\\tcats\\tin\\tthe\\tUnited\\tStates\\tis\\tonce\\tper\\tday\\tPO\\tfor\\t3\\tdays\\tto\\ttreat pain associated with surgery and other conditions. The injectable formulation is intended to be administered prior to surgery (30 minutes) and continued for 2 more days to treat pain and inflammation associated with surgery. R It is also approved in Europe for dogs and cats to treat acute pain and inflammation associated with musculoskeletal disorders and has been administered for longer than 3 days. Outside the United States, tablets are approved for long- term treatment of pain and inflammation in dogs associated with chronic osteoarthritis. It has also been administered for long- term treatment in cats without safety problems. Robenacoxib has not been investigated for use in large animals. Precautionary Information  Dogs \u2022\\t\\tOral:\\t2\\tmg/kg\\tq24h\\tPO. \u2022\\t\\tInjection:\\t2\\tmg/kg\\tq24h\\tSQ. Cats \u2022\\t\\tOral:\\t1\\tmg/kg\\tPO\\tonce\\tper\\tday. \u2022\\t\\tInjection:\\t2\\tmg/kg\\tq24h\\tSQ\\tfor\\t3\\tdays.\\tAdminister\\t30\\tminutes\\tprior\\tto\\tsurgery\\tif used to decrease surgical pain.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\treported. Regulatory Information Withdrawal times or regulatory information for food- producing animals is not available. If administered to food- producing animals, contact FARAD at www.FARAD.org to identify the appropriate milk and meat slaughter withdrawal times. Romifidine Hydrochloride roe- mif\u2032ih- deen  hye- droe- klor\u2032ide Trade and other names: Sedivet","contraindications":"Contraindications and Precautions Dogs and cats with preexisting GI problems or kidney disease may be at a greater risk of adverse effects from NSAIDs. However, in cats with chronic kidney disease, robenacoxib did not cause any changes in kidney parameters during clinical studies. Safety in pregnant animals is not known, but adverse effects have not been reported. Do not use the dog tablets in cats because accurate dosing may be difficult. Administer the injection by the SQ route and avoid IM or IV injections. Drug Interactions Do not administer with other NSAIDs or with corticosteroids. Corticosteroids have been shown to exacerbate the GI adverse effects. Some NSAIDs may interfere with the action of diuretic drugs and ACE inhibitors. Robenacoxib has been administered prior to surgery with other agents such as sedatives, anesthetic agents, and antibiotics without producing any adverse reactions.","indications":"Indications and Clinical Uses Robenacoxib is used to decrease pain, inflammation, and fever. The FDA-approved","side_effects":"Adverse Reactions and Side Effects Major adverse effects are GI, including vomiting, diarrhea, and ulceration. In field trials, the most common adverse effects associated with robenacoxib administration in cats and dogs are GI adverse events (vomiting, soft feces). In dogs, after long- term oral treatment, an increase in liver enzyme activities may occur but is not necessarily associated with liver pathology. The solution for injection might cause pain on injection, apparently because of the excipient in the solution. Because robenacoxib appears to be relatively COX- 2 specific and has a short half- life, adverse effects are expected to be less than other NSAIDs that are not as selective. However, veterinarians should consider the potential for NSAID- induced\\tadverse\\teffects\\tas\\twith\\tany\\tother\\tdrug\\tin\\tthis\\tclass.\\tKidney\\tinjury, especially in dehydrated animals or animals with preexisting renal disease, has been shown for some NSAIDs, including those with COX- 2 selectivity. In safety studies in cats, robenacoxib was well tolerated even in cats with kidney disease and even when treatment was for longer and at higher doses than approved.","notes":"Instructions for Use The oral tablet may be administered once daily for up to 3 days in the United States and for 6 days in Europe. Studies in cats have shown that it is safe for cats for much longer periods for conditions such as osteoarthritis without adverse events. It was safe in cats for multiple doses even in animals with chronic kidney disease. Dogs also have been treated once daily chronically with safety. When used to decrease postoperative pain, it can be administered prior to surgery. The injection is administered subcutaneously to cats or dogs approximately 30\u201345 minutes before the start of surgery at 2 mg/kg. After surgery, it may be continued for an additional 2 days. 822    Romifidine Hydrochloride The oral absorption is greatly diminished with food in cats, and it is recommended to administer without food or with just one third of the daily ration (small meal). Patient Monitoring and Laboratory Tests Monitor GI signs for evidence of diarrhea, GI bleeding, or ulcers. Because of risk of kidney injury, monitor renal parameters (water consumption, blood urea nitrogen, creatinine, and urine- specific gravity) periodically during treatment. Safety has been evaluated in dogs and cats prior to approval in the respective countries. In safety studies,\\tyoung\\thealthy\\tcats\\thave\\ttolerated\\t10\\tmg/kg\\tq12h\\tfor\\t42\\tdays. Formulations \u2022\\t\\tTablets\\tfor\\tcats:\\t6\\tmg. \u2022\\t\\tTablets\\tfor\\tdogs:\\t10,\\t20,\\tand\\t40\\tmg. \u2022\\t\\tCats\\tand\\tdogs:\\t20-\\tmg/mL\\tinjectable\\tsolution\\tin\\ta\\t20-\\tmL\\tvial. Stability and Storage Store protected from excessive heat and in dry conditions. Stability of compounded formulations has not been evaluated.","original_category":"Anti- inflammatory"},{"name":"826    S-Adenosylmethionine","active_ingredient":"826    S-Adenosylmethionine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t20\\tmg/kg\\tper\\tday\\tPO\\tor\\t90\\tmg\\t(small\\tdogs),\\t225\\tmg\\t(medium\\tdogs),\\tand 425 mg (large dogs). \u2022\\t\\tFor\\tdogs\\twith\\tacetaminophen\\ttoxicity,\\tadminister\\t40\\tmg/kg\\tPO\\tfollowed\\tby 20 mg/kg q24h for 7 days. (Note: Acetylcysteine is a more reliable antidote.) Cats \u2022\\t\\t90\\tmg/cat/day\\tPO\\tup\\tto\\t5\\tkg\\tbody\\tweight. \u2022\\t\\tFor\\tcats\\texposed\\tto\\tacetaminophen,\\tadminister\\t180\\tmg\\tper\\tcat\\tSAMe\\tq12h\\tPO daily for 3 days and then 90 mg per cat q12h for 11 days. (Note: Acetylcysteine is a more reliable antidote.)  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Because of a low risk of harmful residues in food animals, no withdrawal time is suggested. Sarolaner sar\u2032 oh lan\u2032 er Trade and other names: Simparica","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions Reactions of SAMe with tricyclic antidepressants (TCAs) have been reported, although the mechanism is not known. In laboratory animals, administration with clomipramine has caused serotonin syndrome. S S Sarolaner 827","indications":"Indications and Clinical Uses SAMe has been used as a dietary supplement, primarily to support patients with hepatic disease. It may help restore hepatic GSH concentrations in deficient animals. It also has been administered to treat liver injury caused by intoxication of acetaminophen and other drugs that produce hepatotoxic oxidative drug injury. Another dietary supplement, silymarin (see Silymarin), also known as milk thistle and silybin, has hepatic antioxidant properties and has been combined with SAMe for treatment in dogs and cats (Denamarin). Via the effect on neurotransmitter synthesis, SAMe has been used to improve cognitive function in dogs. In dogs older than 8 years, SAMe (18 mg/kg/day) improved age- related mental impairment compared with placebo. It has been used to treat arthritis in dogs, but no studies have demonstrated effectiveness. Most of the benefits from SAMe in dogs and cats are based on small observational studies, clinical observations, and opinions from experts. There are no well- controlled studies that have supported therapeutic claims or confirmed the optimum dose through dose- ranging studies. Precautionary Information","side_effects":"Adverse Reactions and Side Effects As with most dietary supplements, there is a wide margin of safety. It may produce a self- limiting transient gastric upset. No other adverse effects are reported.","notes":"Instructions for Use SAMe is a dietary supplement widely available without a prescription (over the counter [OTC]). The potency of formulations may vary. Absorption is decreased when given with a meal. Administer 30 minutes to 1 hour before feeding. To ensure passage into the stomach of cats, administer with water. Coated tablets (e.g., Denosyl) protect the active ingredient from moisture during storage and destruction by stomach acid. Do not break tablets or disrupt coating. Patient Monitoring and Laboratory Tests Monitor liver enzymes in animals being treated for toxicity. Formulations \u2022\\t\\tSAMe\\tis\\twidely\\tavailable\\tOTC\\tin\\ttablets\\tand\\tpowder.\\tThe\\tbrand\\tDenosyl is available in 90- , 225- , and 425- mg tablets. Veterinary formulations (e.g., Denamarin) may also contain silymarin (silybin) and vitamin E. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Do not disrupt coating on tablet.","original_category":"Nutritional supplement"},{"name":"Selegiline Hydrochloride","active_ingredient":"Selegiline Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tBegin\\twith\\t1\\tmg/kg\\tq24h\\tPO.\\tIf\\tthere\\tis\\tno\\tresponse\\twithin\\t2\\tmonths,\\tincrease the dosage to a maximum of 2 mg/kg q24h PO. Cats \u2022\\t\\t0.25\u20130.5\\tmg/kg\\tq12h\\tPO.\\tIn\\tsome\\tcats,\\tonce-\\tdaily\\ttreatment\\tmay\\tbe\\tsufficient.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tIn\\tpreliminary\\tstudies\\tin\\twhich selegiline was administered at a dose of 30 mg/horse PO or IV, there were no observed effects on behavior or locomotor activity. Regulatory Information Do not administer to animals intended for food. Racing Commissioners International (RCI) Classification: 2 Senna sen\u2032na Trade and other names: Senokot","contraindications":"Contraindications and Precautions Selegiline is not indicated for adrenal tumors. Use cautiously with other drugs. (See the following list of interactions.) 832    Senna Drug Interactions Do not use with other MAOIs. Do not use with TCAs, such as clomipramine and amitriptyline, or with selective serotonin reuptake inhibitors, such as fluoxetine. Do not administer with meperidine, dobutamine, or amitraz. Use cautiously with sympathetic amines and other drugs that may produce interactions such as linezolid and tramadol. However, one clinical study showed that there were no adverse effects in dogs when selegiline was administered in combination with phenylpropanolamine.","indications":"Indications and Clinical Uses In dogs, selegiline is approved to control clinical signs of PDH (Cushing\u2019s disease) and to treat cognitive dysfunction in older dogs. However, the efficacy for Cushing\u2019s disease is not as high as for other drugs such as mitotane or trilostane. Selegiline effects may be limited to PDH caused by lesions of the pars intermedia and may not be effective for other forms of PDH. (Most cases of canine PDH have lesions of the pars distalis.) It may improve some clinical signs without lowering cortisol levels in dogs with PDH when administered at 1.0 mg/kg once daily. For\\tcanine\\tcognitive\\tdysfunction\\t(dementia)\\tin\\taged\\tdogs,\\ttreatment\\twith\\tselegiline inhibits MAO type B and increases dopamine concentrations in the brain, which restores dopamine balance and may improve cognitive ability. It has been administered to some older cats with age- related behavior problems, but clinical results in cats have not been reported, and doses are based on limited anecdotal experiences. It does not appear to produce any clinical effects in horses from oral administration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare in dogs but have included vomiting, diarrhea, and hyperactive and restless behavior. Amphetamine- like signs can be produced in experimental animals. At high doses in dogs, hyperactivity has been observed (doses greater than 3 mg/kg), which include salivation, panting, repetitive movements, decreased weight, and changes in activity level. At doses of 30 mg per horse IV or PO, there were no behavior effects. Two active metabolites are l- amphetamine  and l- methamphetamine.  Even though there were increases in amphetamine concentrations in dogs, they were not high enough to produce adverse effects at the approved label dose. However, at high doses (greater than 3 mg/kg), it may produce behavioral changes attributed to CNS stimulation. The l- isomer metabolites are not as active as their d forms, and studies have not supported a potential for amphetamine- like abuse or dependency from selegiline compared with other amphetamine- like drugs.","notes":"Instructions for Use Titrate the dose in each patient to achieve the desired effect without inducing excess CNS excitement. Start with low dose and increase gradually until clinical effect is observed. The transdermal patch for humans has not been evaluated for animals. Patient Monitoring and Laboratory Tests No specific monitoring is required. Serum cortisol testing is not valuable for evaluating efficacy. Formulations \u2022\\t\\tSelegiline\\tis\\tavailable\\tin\\t2-\\t,\\t5-\\t ,\\t10-\\t  ,\\t15-\\t  ,\\tand\\t30-\\tmg\\ttablets\\tfor\\tanimals;\\t5-\\tmg tablets or capsules for humans; and 20- , 30- , and 40- cm 2 transdermal patches (EmSam) for humans. Stability and Storage Stable if stored in manufacturer\u2019s original formulation.","original_category":"Dopamine agonist"},{"name":"Sevelamer Carbonate","active_ingredient":"Sevelamer Carbonate","species":["Not specified in source"],"dosage":"\u2022\\t\\t80\u2013100\\tmg/kg\\t(approximately)\\tper\\tday.\\tThis\\tdose\\tshould\\tbe\\tdivided\\tup\\tequally\\tfor each meal fed to the pet (e.g., 25\u201330 mg/kg PO three times daily).  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\tidentified. Regulatory Information No withdrawal times are established for animals intended for food. Because the effects are limited to the intestine, no withdrawal times are anticipated. Sevoflurane see- voe- floo\u2032rane Trade and other names: Ultane","contraindications":"Contraindications and Precautions There are no specific contraindications or precautions. Drug Interactions No drug interactions have been reported for animals. However, it may potentially interfere with oral absorption of other drugs. In people, it decreased oral absorption of fluoroquinolones by 50%.","indications":"Indications and Clinical Uses Sevelamer is used as an oral treatment to bind phosphate in patients with chronic kidney disease. There are two forms, sevelamer carbonate and sevelamer hydrochloride salt. The two forms react similarly and are interchangeable. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are not reported for animals. In people, it has had a good safety margin with constipation being the major adverse effect. There is no systemic absorption. Long- term administration can potentially decrease fat- soluble vitamins such as vitamins A, D, and K because of the effect on bile acids and normal fat absorption.","notes":"Instructions for Use Administer only by the oral route with food. When using the powder form, empty the entire contents of a 0.8-  or 2.4- g packet into a container and add 30 mL of water (for the 0.8- g packet) or 60 mL of water (for the 2.4- g packet). If switching from sevelamer hydrochloride to sevelamer carbonate, use the same dose and frequency. Phosphate levels in the blood are better controlled with frequent administration during the day with each meal rather than with one single dose. Patient Monitoring and Laboratory Tests Adjust dose based on measuring serum phosphorous. Formulations \u2022\\t\\tSevelamer\\tis\\tavailable\\tin\\ta\\tfilm-\\tcoated\\ttablet,\\t800\\tmg,\\tand\\tsevelamer\\tcarbonate powder (citrus flavor). Stability and Storage Sevelamer should be stored in a dry place in a tightly sealed container at room temperature.","original_category":"Phosphate binder"},{"name":"Silymarin","active_ingredient":"Silymarin","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t5\u201315\\tmg/kg\\tPO\\tonce\\tdaily.\\tSome\\tsources\\trecommend\\ta\\thigher\\tdosage\\twith\\ta minimum of 30 mg/kg PO per day. S Sodium Bicarbonate 839  Horses \u2022\\t \\tNo\\tclinically\\teffective\\tdosages\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals.\\tAt\\tdosages\\tof\\t6.5, 13, and 26 mg/kg q12h for 7 days, only minor antioxidant effects were observed. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sodium Bicarbonate Trade and other names: Baking soda, soda mint, Citrocarbonate, and Arm & Hammer pure baking soda","contraindications":"Contraindications and Precautions No contraindications have been reported for animals. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses As a dietary supplement, the manufacturer is not obligated to make therapeutic claims for marketing. Silymarin has been used to treat hepatic disease, including those caused by hepatotoxic reactions in people and animals. It has been administered to animals for the hepatoprotective effects after hepatotoxic drug injury caused by carbon tetrachloride, mushrooms, arsenic, and acetaminophen. It has also been recommended for dogs, cats, and horses with liver disease, but there are no well- controlled clinical studies documenting effectiveness for this use. In one observational study, the combination product with silymarin and SAMe reduced liver enzyme elevations associated with chemotherapy in tumor- bearing dogs. Studies in humans produced mixed results, and studies in dogs, cats, and horses are limited to small observational studies. Silymarin is used as a complementary treatment in canine and feline liver disease through antioxidant effects. However, there is no specific information on the optimum dose or evidence of efficacy of silymarin treatment based on well-controlled studies. Silymarin can be used with SAMe, and there are preparations that include both silymarin and SAMe (Denamarin). When administered to horses, it produced only minor changes in antioxidant capacity of blood. Precautionary Information","side_effects":"Adverse Reactions and Side Effects This is a natural chemical and no adverse reactions have been reported.","notes":"Instructions for Use SAMe, silymarin, and vitamin E are considered dietary supplements and, as such, are not\\tsubject\\tto\\tregulation\\tas\\tdrugs\\tby\\tthe\\tUS\\tFood\\tand\\tDrug\\tAdministration\\t(FDA). Products\\tavailable\\tOTC\\tand\\tthrough\\tvarious\\toutlets\\tare\\tnot\\tregulated\\tby\\tthe\\tFDA and may differ considerably in purity and potency. Patient Monitoring and Laboratory Tests Monitor liver enzymes in animals being treated for toxicity. Formulations \u2022\\t \\tSilymarin\\ttablets\\tare\\twidely\\tavailable\\tOTC.\\tCommercial\\tveterinary\\tformulations (Marin) also contain zinc and vitamin E in a phosphatidylcholine complex in tablets for dogs and cats. The combination of Denamarin contains both silymarin and SAMe. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Hepatic protectant"},{"name":"Sodium Bicarbonate","active_ingredient":"Sodium Bicarbonate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tMetabolic\\tacidosis:\\t0.5\u20131\\tmEq/kg\\tIV. \u2022\\t\\tAlkalinization\\tof\\turine:\\t50\\tmg/kg\\tq8\u201312h\\tPO. \u2022\\t\\tOral\\tantacid:\\t2\u20135\\tg\\tmixed\\twith\\twater\\tPO.\\t(Other\\tagents\\tare\\tmore\\teffective\\tto suppress gastric acid.) \u2022\\t\\tCardiopulmonary\\tresuscitation:\\t1\\tmEq/kg\\twith\\tadditional\\tdoses\\tof\\t0.5\\tmEq/kg\\tat 10- minute  intervals.  \u2022\\t \\tMetabolic\\tacidosis:\\t0.5\u20131\\tmEq/kg\\tIV\\tslowly.\\tOther\\tdoses\\tshould\\tbe\\tcalculated\\tbased on base deficits. Oral doses vary; 10\u201312 g of sodium bicarbonate may be given orally to adult large animals (horses and cattle) and 2\u20135 g to calves, foals, and pigs. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sodium Chloride 0.9% Trade and other names: Normal saline and generic brands","contraindications":"Contraindications and Precautions Do not administer to animals with hypocalcemia (may exacerbate tetany). Do not administer to animals with excessive chloride loss because of vomiting. Do not administer to animals with alkalosis. Administration of sodium bicarbonate may increase risk of hypernatremia, paradoxical CNS acidosis, and hyperosmolality. When used during cardiac resuscitation, caution is advised because of a risk of hyperosmolality, hypernatremia, and paradoxical CNS acidosis. Drug Interactions Sodium bicarbonate should not be mixed with drugs that require an acidic medium for stability and solubility. Such drugs may include solutions containing hydrochloride (HCl) salts. When mixing IV solutions, do not mix bicarbonate with solutions containing calcium. (Chelation may result.) When administered orally, interaction may occur to decrease absorption of other drugs. (A partial list includes anticholinergic drugs, ketoconazole, fluoroquinolones, and tetracyclines.) 840    Sodium Chloride 0.9%","indications":"Indications and Clinical Uses Sodium bicarbonate is an alkalinizing solution, once used commonly as a gastric antacid, but other agents are more commonly used for suppressing stomach acid. It is the most frequent alkalinizing solution used for IV therapy of systemic acidosis and to treat severe hyperkalemia. When adding to fluid therapy, the goal is to maintain PaCO 2 within 37\u201343 mm Hg. It also has been administered to alkalize urine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have been attributed to alkalizing activity. Hypokalemia may occur with excessive administration. Hyperosmolality, hypernatremia, paradoxical CNS, and intracellular acidosis may occur.","notes":"Instructions for Use When used for systemic acidosis, the dose should be adjusted on the basis of blood gas measurements or assessment of acidosis. The following equation may be used to estimate requirement: mEq Bicarbonate needed = body weight(kg)\xd7base deficit(mEq/L)\xd70.3 Initially, administer 25%\u201350% of this dose in IV fluids over 20\u201330 minutes. In calves or neonates, use a factor of 0.5 instead of 0.3 in the equation above because of higher water content in these animals. Patient Monitoring and Laboratory Tests Monitor acid\u2013base status. Formulations \u2022\\t\\tSodium\\tbicarbonate\\tis\\tavailable\\tin\\t325-\\t,\\t520-\\t   ,\\tand\\t650-\\tmg\\ttablets. \u2022\\t\\tIn\\teach\\tteaspoonful\\t(3.9\\tg)\\tof\\tcitrocarbonate,\\tthere\\tare\\t780\\tmg\\tof\\tsodium bicarbonate and 1.82 g of sodium citrate. \u2022\\t\\tInjection\\tsolutions:\\t4.2%\\tis\\t0.5\\tmEq/mL\\t(11.5\\tmg/mL\\tof\\tsodium),\\tand\\t8.4%\\tis 1 mEq/mL (23 mg/mL of sodium). Note on strength of formulations: \u2022\\t\\t1.4%\\tsolution\\t\\u001d\\t0.17\\tmEq/mL\\tand\\tprovides\\t13\\tg/L\\tof\\tbicarbonate. \u2022\\t\\t8.5%\\tsolution\\t\\u001d\\t1\\tmEq/mL\\tof\\tNaHCO 3 . \u2022\\t\\tOne\\tteaspoon\\tof\\tbaking\\tsoda\\tis\\tapproximately\\t2\\tg\\tof\\tNaHCO 3 . \u2022\\t\\t12\\tmEq\\tof\\tbicarbonate\\tis\\tequivalent\\tto\\t1\\tg\\tof\\tsodium\\tbicarbonate. Stability and Storage Store in a tightly sealed container at room temperature. Alkaline solution with pH of 7\u20138.5. Do not mix with acid solutions. Sodium bicarbonate is soluble in water. If exposed to air, it may decompose to sodium carbonate, which is more alkaline.","original_category":"Alkalinizing agent"},{"name":"Sodium Chloride 0.9%","active_ingredient":"Sodium Chloride 0.9%","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tMaintenance\\tadministration\\t(no\\tdeficits):\\t1.5\u20132.5\\tmL/kg/h.\\t(Caution:\\tthis\\tis\\tnot\\ta balanced maintenance solution.) \u2022\\t\\tModerate\\tdehydration:\\t15\u201330\\tmL/kg/h\\tIV. \u2022\\t\\tSevere\\tdehydration:\\t50\\tmL/kg/h\\tIV.  \u2022\\t\\t40\u201350\\tmL/kg\\tday\\tIV,\\tintraperitoneal,\\tor\\tSQ\\tmaintenance. \u2022\\t\\tModerate\\tdehydration:\\t15\u201330\\tmL/kg/h\\tIV. \u2022\\t\\tSevere\\tdehydration:\\t50\\tmL/kg/h\\tIV. 842    Sodium Chloride 7.2% and 7.5% Calves \u2022\\t\\tModerate\\tdehydration:\\t45\\tmL/kg\\tgiven\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h. \u2022\\t\\tSevere\\tdehydration:\\t80\u201390\\tmL/kg\\tgiven\\tat\\ta\\trate\\tof\\t30\u201340\\tmL/kg/h\\tor\\tas\\tfast\\tas 80 mL/kg/h if necessary. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sodium Chloride 7.2% and 7.5% Trade and other names: Hypertonic saline solution and HSS","contraindications":"Contraindications and Precautions Do not exceed the maximum dose rate of 80 mL/kg/h. This solution does not contain electrolyte balance for maintenance. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Sodium chloride is used for IV fluid supplementation. However, it is not a balanced electrolyte solution and should not be used for maintenance. It also is frequently used as a vehicle to deliver IV medications via constant- rate infusion. Precautionary Information","side_effects":"Adverse Reactions and Side Effects It is not a balanced electrolyte solution. Long- term infusion may cause electrolyte imbalance. Because saline solution is not balanced, it may cause acidemia because it increases renal elimination of bicarbonate. Prolonged use may cause hypokalemia.","notes":"Instructions for Use When administering IV fluid solution, monitor the rate and electrolyte concentrations carefully. Fluid\\tadministration\\trates\\tare\\tas\\tfollows: Replacement fluid: calculate\xa0as liters needed = % dehydration\xd7body weight(kg) or Milliliters\xa0needed = % dehydration\xd7body weight(kg)\xd71000 Add bicarbonate to fluids if necessary based on calculation of base deficit. Patient Monitoring and Laboratory Tests Monitor hydration status and serum electrolytes, particularly potassium. Formulations \u2022\\t\\tSodium\\tchloride\\t0.9%\\tis\\tavailable\\tin\\ta\\t500-\\t\\tand\\t1000-\\tmL\\tinfusion. Stability and Storage Store in a tightly sealed container at room temperature.","original_category":"Fluid replacement"},{"name":"Sodium Chloride 7.2% and 7.5%","active_ingredient":"Sodium Chloride 7.2% and 7.5%","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t3\u20138\\tmL/kg\\tIV\\tof\\t7.2%\\tsolution.\\t(The\\trate\\tof\\tadministration\\tshould\\tnot\\texceed\\t1 mL/kg/min.) \u2022\\t\\tHemorrhagic\\tshock:\\t4\u20135\\tmL/kg\\tIV\\tover\\t10\\tminutes.  \u2022\\t\\t4\u20138\\tmL/kg\\tof\\t7.2%\\tsolution\\tIV\\tat\\ta\\trate\\tof\\t1\\tmL/kg/min. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sodium Iodide (20%) Trade and other names: Iodopen and generic brands","contraindications":"Contraindications and Precautions Do not administer to hypernatremic animals. Do not administer solutions high in sodium to animals with renal insufficiency. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Hypertonic saline is used to treat hypovolemic shock in animals. The duration of its benefit is short lived because it quickly dissipates from the blood vessels. There may be benefits for combination with colloids such as Dextran 70 to maintain vascular pressure. It has been used at doses of 4 mL/kg IV to dogs during a 5- minute infusion to be effective for treatment of septic shock. Precautionary Information","side_effects":"Adverse Reactions and Side Effects This is not a balanced electrolyte solution. Long- term infusion may cause electrolyte imbalance.","notes":"Instructions for Use Hypertonic saline is used for short- term infusion for rapid replacement of vascular volume. Patient Monitoring and Laboratory Tests Monitor hematocrit and blood pressure in treated animals. Formulations \u2022\\t\\tSodium\\tchloride\\tis\\tavailable\\tin\\teither\\t7.2%\\tor\\t7.5%\\tconcentrated\\tsolution\\tas\\tan\\tIV infusion. S Sodium Iodide (20%) 843 Stability and Storage Store in a tightly sealed container at room temperature.","original_category":"Fluid replacement"},{"name":"Streptozocin","active_ingredient":"Streptozocin","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t500\\tmg/m 2 IV infused over 2 hours every 3 weeks (use with a saline diuresis). Cats \u2022\\t\\tA\\tsafe\\tdose\\thas\\tnot\\tbeen\\treported\\tfor\\tcats.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals that produce food. Succimer suks\u2032ih- mer Trade and other names: Chemet","contraindications":"Contraindications and Precautions Streptozocin may produce diabetes mellitus in treated animals. In addition, there may be a sudden release of insulin after IV administration, and IV dextrose should be available to treat acute hypoglycemia. Monitor animals for evidence of renal and hepatic injury. Do not administer to pregnant animals. Drug Interactions No specific drug interactions are reported for animals; however, use with any other nephrotoxic, hepatotoxic, or myelotoxic drug exacerbates toxicity. 854    Succimer","indications":"Indications and Clinical Uses In animals, streptozocin is used primarily for treating insulin- secreting tumors (insulinoma). It has been used in experimental animals to create models of diabetes mellitus. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Diabetes mellitus is anticipated in treated animals. In humans, the major adverse effect is kidney injury caused by tubular necrosis. Kidney injury has been reported in dogs at doses greater than 700 mg/m 2 . Other adverse effects include vomiting, nausea, and diarrhea. The GI toxicity occurs immediately or within 4 hours of administration but usually resolves within 24 hours. Increases in hepatic enzymes and hepatic injury have been reported in dogs; however, hepatotoxicity appears to be reversible. Bone marrow suppression is rare in animals. Local phlebitis may occur from IV administration.","notes":"Instructions for Use Risk of renal toxicosis caused by streptozocin may be decreased with administration of fluid diuresis. The diuresis should consist of administration of fluids (e.g., 0.9% saline) intravenously prior to drug administration. Antiemetics should be administered with each infusion because vomiting is common. Treatment with streptozocin is continued every 3 weeks until signs of tumor recurrence occur or until toxicosis limits the continuation of treatments. Reconstitute the injection vial prior to use by adding 9.5 mL of 5% dextrose or 0.9%\\tsaline\\tto\\tvial.\\tResulting\\tsolution\\tis\\t100\\tmg/mL.\\tFurther\\tdilute\\tthis\\tvial\\twith\\t5% dextrose or 0.9% saline for IV infusion. Patient Monitoring and Laboratory Tests Monitor serum glucose in treated animals. Monitor serum creatinine, urea nitrogen, and hepatic enzymes for evidence of hepatotoxicity and renal injury. Although myelotoxicity is unusual, monitor complete blood count before each treatment. Formulations \u2022\\t\\tStreptozocin\\tis\\tavailable\\tin\\t1-\\tg\\tvials\\tfor\\tinjection. Stability and Storage Store vial between 2\xb0C and 8\xb0C. After preparation, use the vial within 12 hours after reconstitution at room temperature. The approved formulation also contains citric acid. Do not use if color changes from pale yellow to a darker brown because this indicates degradation.","original_category":"Antihyperglycemic agent"},{"name":"Succimer","active_ingredient":"Succimer","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t10\\tmg/kg\\tq8h\\tPO\\tfor\\t5\\tdays;\\tthen\\t10\\tmg/kg\\tq12h\\tPO\\tfor\\t2\\tmore\\tweeks.\\tIt\\thas also been administered rectally in vomiting dogs. Cats \u2022\\t\\t10\\tmg/kg\\tq8h\\tPO\\tfor\\t2\\tweeks.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal\\ttimes\\tare\\tnot\\testablished\\tfor\\tanimals\\tthat\\tproduce\\tfood.\\tFor\\textralabel\\tuse withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Sucralfate soo- krahl\u2032fate Trade and other names: Carafate and Sulcrate (in Canada)","contraindications":"Contraindications and Precautions Do not use in cats with kidney disease. (See Adverse Effects and Side Effects.) Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Succimer is used for treatment of heavy metal toxicosis, primarily toxicosis caused by lead. Other chelators that have been used for lead toxicity include calcium- EDTA (ethylenediaminetetraacetic acid), BAL, and penicillamine. Calcium- EDTA is often S Sucralfate 855 the preferred drug for initial treatment. The advantages of succimer over other chelators are that it is better tolerated with fewer GI adverse effects, and it is not associated with nephrotoxicosis. It also does not bind other minerals such as copper, zinc, calcium, and iron. Precautionary Information","side_effects":"Adverse Reactions and Side Effects No adverse effects have been reported in dogs. However, kidney injury has been associated with succimer treatment in cats. Succimer should not be used as a phosphate binder in cats. When administered to cats, it did not decrease phosphorous, and caused vomiting and clinical decompensation.","notes":"Instructions for Use Doses cited are based on studies in dogs. In cats, succimer has been used at 10 mg/ kg q8h PO for 2 weeks. Treatment response and duration of treatment is monitored by measuring the blood levels of the toxin (e.g., lead). A poison control center may be contacted for specific protocols to treat toxicity in animals. Patient Monitoring and Laboratory Tests Monitor the patient\u2019s blood lead levels during treatment. Monitor renal function during treatment because renal failure has been associated with succimer administration in cats. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidote"},{"name":"Sucralfate","active_ingredient":"Sucralfate","species":["Equine","Canine","Feline"],"dosage":"dosages but have been examined in observational studies in small animals and horses. Precautionary Information  Dogs \u2022\\t\\t0.5\u20131\\tg\\tq8\u201312h\\tPO. \u2022\\t\\tIf\\ttablets\\tare\\tused\\tin\\tdogs,\\tit\\tis\\tadvised\\tto\\tcrush\\tup\\ttablets\\tto\\tform\\ta\\tliquid suspension prior to administration. Cats \u2022\\t\\t0.25\\tg\\t(one-\\tfourth\\ttablet)\\tq8\u201312h\\tPO.  Foals \u2022\\t\\t1\\tg\\tq8h\\tPO. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Sufentanil Citrate soo- fen\u2032tah- nil  sih\u2032trate Trade and other names: Sufenta","contraindications":"Contraindications and Precautions No contraindications have been listed for animals. Administration of intact tablets may not be effective (see Instructions for Use). Drug Interactions Sucralfate may decrease absorption of other drugs administered orally via chelation with aluminum (e.g., fluoroquinolones, digoxin, theophylline, and tetracyclines). Administer these other drugs at least 30 minutes to 2 hours before sucralfate.","indications":"Indications and Clinical Uses Sucralfate is used to prevent and treat gastric ulcers and prevent injury from gastroesophageal reflux. Sucralfate is administered orally and may protect ulcerated tissue and promote healing. There is little evidence that it prevents ulcers from NSAIDs in small animals, but experimental evidence demonstrates protective effects in horses. Prevention of esophageal injury from acid reflux is based on studies in people and laboratory animals. Dosage regimens for sucralfate have been extrapolated from human","side_effects":"Adverse Reactions and Side Effects Because sucralfate is not absorbed, it is virtually free of systemic adverse effects. The most common side effect associated with its use in people has been constipation.","notes":"Instructions for Use Dosing recommendations are based largely on empiricism and extrapolation from the human dose. There are no studies to demonstrate clinical efficacy of sucralfate in animals, but some evidence is available from studies in research animals. Sucralfate may be administered concurrently with histamine type 2 inhibitors (H 2 blockers) without causing an interaction, but this combination is rarely necessary. There is evidence that when intact sucralfate tablets are administered to animals, they may not undergo dissolution in the stomach and pass through the intestine intact. Therefore it is recommended to crush up tablets and prepare a liquid suspension prior to administration to small animals. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tSucralfate\\tis\\tavailable\\tin\\t1-\\tg\\ttablets\\tand\\ta\\t200-\\tmg/mL\\toral\\tsuspension. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Sucralfate is insoluble in water unless it is exposed to strong acid or alkaline conditions. S Sufentanil Citrate 857 The tablets may be crushed and suspended in water to a concentration of 200 mg/mL and stored in the refrigerator for 14 days. Shake this suspension before using.","original_category":"Antiulcer agent"},{"name":"Tacrolimus","active_ingredient":"Tacrolimus","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tApply\\ttopical\\tointment\\t(0.1%)\\tto\\tlocalized\\tlesions\\ton\\taffected\\tareas\\tof\\tskin.\\tIt\\thas been used in dogs twice daily. For perianal fistula, it has been applied twice daily.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Tadalafil tah- da\u2032la- fil Trade and other names: Cialis","contraindications":"Contraindications and Precautions Tacrolimus is a potent immunosuppressant. Use cautiously in animals prone to infection. Pet owners should be cautioned about skin contact when handling the medication for their pets. Safety from systemic treatment with tacrolimus has not been established in animals. Drug Interactions No drug interactions have been identified from topical administration.","indications":"Indications and Clinical Uses Tacrolimus is used as an immunosuppressive drug to treat autoimmune disease, prevent organ transplant rejection, and treat atopic dermatitis. Most use in animals is with a topical formulation. It has been applied topically (ointment) for localized areas of atopic dermatitis or on skin areas of dogs where local immunosuppressive treatment is needed (e.g., on the bridge of the nose). In some cases, after resolution of lesions with systemic treatment with cyclosporine, isolated skin lesions are managed topically with tacrolimus ointment. There has been limited use for preventing renal transplant rejection in cats because the pharmacokinetics have been highly variable. A related drug, pimecrolimus, also has been used topically. Precautionary Information","side_effects":"Adverse Reactions and Side Effects There may be a slight burning or pruritic sensation with initial topical application. These reactions are mild and decrease as the skin heals. With systemic administration, dogs may show gastrointestinal (GI) signs, which include diarrhea, intestinal discomfort, vomiting, intestinal intussusception, and intestinal injury. Tacrolimus is minimally absorbed systemically from topical application.","notes":"Instructions for Use There are no reports of safe systemic doses used in dogs. Most use is topical. It can be used topically for immune- mediated skin lesions where local treatment can be used T T Tadalafil 869 (e.g., on the bridge of the nose). It has also been applied topically for perianal fistula in addition to systemic prednisolone. Patient Monitoring and Laboratory Tests No specific monitoring is necessary with topical use. Formulations Available \u2022\\t\\tTacrolimus\\tis\\tavailable\\tin\\t0.1%\\tand\\t0.03%\\ttopical\\tointment\\tin\\t30-\\t,\\t60-\\t  ,\\tand\\t100-\\tg tubes. Stability and Storage Ointment is stable if stored in manufacturer\u2019s original formulation. Compounded formulations of tacrolimus have been available from pharmacists. It is practically insoluble in water and usually formulated in lipid-soluble bases (e.g., ointments). When prepared in a suspension, it was stable for several weeks, but the stability of other formulations has not been evaluated.","original_category":"Immunosuppressant"},{"name":"Tamsulosin Hydrochloride","active_ingredient":"Tamsulosin Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.4\\tmg\\tper\\tdog.\\tOften\\ta\\tfull\\tcapsule\\t(0.4\\tmg\\tper\\tdog)\\tis\\tadministered\\tq24h PO.\\tIt\\tis\\teffective\\tat\\t10\u201330\\tmcg/kg,\\tbut\\tsuch\\ta\\tprecise\\tdose\\tmay\\tbe\\tdifficult because of the capsule size. Cats \u2022\\t\\t0.1\u20130.4\\tmg\\tper\\tcat\\tq24h\\tPO.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. Tamoxifen Citrate tah- moks\u2032ih- fen  sih\u2032trate Trade and other names: Nolvadex","contraindications":"Contraindications and Precautions It may lower blood pressure and decrease cardiac output, but this likely would require high doses. Drug Interactions No drug interactions have been reported in animals, but the use has been rare, and a full range of potential drug interactions is not known. In people, it is highly metabolized by cytochrome P450 enzymes, and the metabolites undergo extensive conjugation to glucuronide or sulfate for elimination.","indications":"Indications and Clinical Uses The major use of tamsulosin in people is treatment of benign prostate enlargement that is responsible for interfering with urine flow. It is often used with other drugs, such as finasteride, that interfere with the action of testosterone on the prostate. It is highly effective in men and studied in multiple clinical trials. The use in dogs and cats has been anecdotal and based on extrapolation of the use and doses from human medicine. It has been used to improve the outcome posturethral blockage in male cats and to improve urine flow in dogs after surgery or calculi removal. It has improved urine flow in dogs with neurogenic bladders (0.4 mg per dog). In experimental dogs, it was more effective than prazosin for relaxing the urethral smooth muscle. The use in cats extends from the use of other alpha 1 antagonists such as phenoxybenzamine and prazosin in cats with urethral obstruction to improve urine flow. 872    Tamoxifen Citrate Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses cause vasodilation and hypotension, but this has been unusual. No other treatment-related effects have been reported.","notes":"Instructions for Use The dose form for people is a 0.4- mg capsule (approved dose is 0.8 mg per person), which is difficult to administer to some animals. A pharmacist may be able to divide up the capsule into smaller doses for animals. Patient Monitoring and Laboratory Tests Monitor urine flow and evidence for hypotension and reflex tachycardia. Formulations Tamsulosin is available as 0.4- mg capsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Smooth muscle relaxant"},{"name":"Tamoxifen Citrate","active_ingredient":"Tamoxifen Citrate","species":["Not specified in source"],"dosage":"\u2022\\t\\tVeterinary\\tdosage\\tnot\\testablished\\tbut\\thas\\tbeen\\textrapolated\\tfrom\\tthe\\thuman\\tdose. Human dosage is 10 mg q12h PO (\u22480.14 mg/kg q12h).  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. 874    Taurine Taurine tore\u2032een Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Do not use in pregnant animals. Drug Interactions Tamoxifen is a potent cytochrome P450 enzyme inhibitor. It may interact with other drugs that are cytochrome P450 substrates.","indications":"Indications and Clinical Uses Tamoxifen is used as adjunctive treatment for certain tumors, especially estrogen- responsive tumors. The most common use in animals is adjunctive treatment for mammary neoplasia. In women, the most common use is as an adjunct for the treatment of breast cancer. It also has been used to induce ovulation by stimulating release of GnRH from the hypothalamus. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been thoroughly documented in animals. However, in people, tamoxifen has been reported to cause increased tumor pain. There are several adverse effects reported in women because of the effect on estrogen blockade, but it is not known if these effects occur in animals.","notes":"Instructions for Use Tamoxifen is often used with other anticancer drug protocols. Consult specific protocols from oncology sources for optimum use and doses. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations Available \u2022\\t\\tTamoxifen\\tis\\tavailable\\tin\\t10-\\t\\tand\\t20-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antiestrogen"},{"name":"Taurine","active_ingredient":"Taurine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t500\\tmg/dog\\tq12h\\tPO. Cats \u2022\\t\\t250\\tmg/cat\\tq12h\\tPO. T Telmisartan 875  No doses have been reported for large animals. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Tegaserod Maleate teg- ah- ser\u2032odd mal\u2032ee- ate Trade and other names: Zelnorm","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Taurine is used in the prevention and treatment of ocular and cardiac disease (dilated cardiomyopathy) caused by taurine deficiency. Although current commercial diets have adequate amounts of taurine, it has been supplemented in dogs and cats with heart disease. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported. This is a naturally occurring amino acid.","notes":"Instructions for Use Routine supplementation with taurine may not be necessary in animals that are receiving a balanced diet. However, supplementation may be necessary in animals with diseases associated with taurine deficiency. Patient Monitoring and Laboratory Tests Taurine concentrations can be measured in some laboratories to detect deficiencies. Normal\\tlevels\\tin\\tplasma\\tare\\t60\u2013120\\tnmol/mL\\tin\\tdogs\\tand\\tcats\\tor\\t200\u2013350\\tnmol/ mL in whole blood. Levels below 40 nmol/mL in plasma and 150 nmol/mL in whole blood are considered deficient. Formulations Available \u2022\\t\\tTaurine\\tis\\tavailable\\tin\\tpowder\\tor\\tsupplemented\\tin\\tsome\\tdiets.\\tConsult\\ta compounding pharmacy for availability. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Nutritional supplement"},{"name":"Tepoxalin","active_ingredient":"Tepoxalin","species":["Not specified in source"],"dosage":"Not specified in source","contraindications":"Not specified in source","indications":"Not specified in source","side_effects":"Not specified in source","notes":"","original_category":"Anti- inflammatory"},{"name":"Terbutaline Sulfate","active_ingredient":"Terbutaline Sulfate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1.25\u20135\\tmg/dog\\tq8h\\tPO. \u2022\\t\\t3\u20135\\tmcg/kg\\t(0.003\u20130.005\\tmg/kg)\\tSQ,\\tusually\\tas\\ta\\tsingle\\tdose\\tin\\tan\\temergency.\\tIf necessary,\\trepeat\\tin\\t4\u20136\\th. Cats \u2022\\t\\t0.1\\tmg/kg\\tq8h\\tPO. \u2022\\t\\t0.625\\tmg/cat\\t(one\\tquarter\\tof\\ta\\t2.5-\\tmg\\ttablet)\\tq12h\\tPO. \u2022\\t\\t5\u201310\\tmcg/kg\\t(0.005\u20130.01\\tmg/kg)\\tq4h\\tSQ\\tor\\tIM.\\tThe\\tmost\\tcommon\\tdose\\tin\\tcats is 0.05 mg per cat (equivalent to 0.05 mL) injected SQ. 882    Testosterone  Horses \u2022\\t\\tNot\\tabsorbed\\torally.\\tUse\\tIV\\tfor\\ttreatment\\tof\\tchronic\\tRAO:\\t2\u20135\\tmcg/kg\\tq6\u20138h\\tIV or as needed. Regulatory Information Terbutaline has similar properties as clenbuterol and should not be administered to animals intended for food. RCI\\tClassification:\\t3 Testosterone tess- toss\u2032ter- one Trade and other names: Testosterone cypionate ester: Andro- Cyp, Andronate, Depo- Testosterone, and generic brands and testosterone propionate ester: Testex and Malogen (in Canada)","contraindications":"Contraindications and Precautions Administer cautiously to animals with cardiac disease, particularly animals that may be susceptible to tachyarrhythmias. Do not use late in gestation unless the intended effect is to delay uterine contractions. Drug Interactions Use cautiously with other drugs that may stimulate the heart and cause tachycardia.","indications":"Indications and Clinical Uses Terbutaline, like other beta 2 - agonists, is indicated in animals with reversible bronchoconstriction, such as cats with bronchial asthma. It also has been used in dogs to relieve bronchoconstriction and in animals with bronchitis and other airway diseases. Is has been useful as an injection to rapidly relieve bronchospasm in small animals associated with inflammatory airway disease or clinical procedures. It has been used in horses for short- term administration, by injection, to relieve bronchoconstriction associated with recurrent airway obstruction (RAO), which is a component of equine asthma syndrome. The use in animals has been primarily derived from empirical use, experience in humans, and recommendations from clinical experts. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness in animals. Albuterol injection may be used as an alternative for terbutaline injection (4 mcg/kg bolus up to 8 mcg/kg as needed). Terbutaline is not absorbed by the PO route in horses; therefore, it is not effective in horses for PO administration. Clenbuterol usually is the first drug of choice for oral administration in horses. (See Clenbuterol.) Terbutaline (and other beta 2 - agonists) have also been used during pregnancy to delay\\tlabor.\\t(The\\tdosage\\tin\\tpeople\\tis\\t2.5\\tmg\\tq6h\\tPO.) T Precautionary Information","side_effects":"Adverse Reactions and Side Effects Excessive beta- adrenergic stimulation from terbutaline at high doses can produce tachycardia and muscle tremors. Arrhythmias are possible with high doses. All beta 2 agonists inhibit uterine contractions at the end of gestation in pregnant animals. High doses of beta 2 agonists can lead to hypokalemia because they stimulate Na + - K + - ATPase and increase intracellular potassium while decreasing serum potassium and producing hyperglycemia. Treatment consists of potassium chloride (KCl) supplement at a rate of 0.5 mEq/kg/h.","notes":"Instructions for Use Terbutaline may be administered PO, IM, or SQ. Other beta 2 agonists used in animals for relief of bronchoconstriction include albuterol and salmeterol, and clenbuterol in horses. Animals with acute bronchoconstriction may also benefit from corticosteroid treatment and oxygen therapy. Caution should be used when administering repeated SQ doses. The maximum SQ dose in people is 500 mcg/ person (0.5 mg) within a 4- hour period. Patient Monitoring and Laboratory Tests Monitor heart rate in animals during treatment. Monitor potassium concentration if high doses are administered. Formulations \u2022\\t\\tTerbutaline\\tis\\tavailable\\tin\\t2.5-\\t\\tand\\t5-\\tmg\\ttablets\\tand\\t1-\\tmg\\tvials\\twith\\ta concentration of 1 mg/mL for injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Terbutaline sulfate is soluble in water and can be diluted in sterile water prior to administration. Solutions may be subject to degradation. Observe for color change and discard if solution turns a dark color. Suspensions have been prepared from tablets in syrup and remained stable for 55 days.","original_category":"Bronchodilator, beta agonist"},{"name":"Theophylline","active_ingredient":"Theophylline","species":["Canine","Feline","Equine","Bovine"],"dosage":"for\\tdogs\\tadministered\\tat\\ta\\tdosage\\tof\\t3\u20135\\tmg/kg\\tq12h\\tPO\\t(cat\\tdose:\\t5\\tmg/kg).\\tIt has been effective for feline bronchial disease. In dogs, it is approved for treatment of cognitive dysfunction in aged dogs (e.g., lethargy, apathy, stiff gait, poor appetite). Precautionary Information  Dogs \u2022\\t\\tTheophylline:\\t9\\tmg/kg\\tq8h\\tPO\\t(immediate-\\trelease\\tformulations). \u2022\\t\\tTheophylline\\tsustained\\trelease:\\t10\\tmg/kg\\tq12h\\tPO. Cats \u2022\\t\\t4\\tmg/kg\\tq8\u201312h\\tPO\\t(immediate-\\trelease\\tformulations). \u2022\\t\\tTheophylline\\tsustained\\trelease:\\t20\\tmg/kg\\tfor\\ttablets\\t(100\\tmg\\tper\\tcat)\\tq24h\\tPO\\tor 25 mg/kg for ER capsule (125 mg per cat) q24h PO. With long- term use in cats, this interval may be increased to q48h.  \u2022\\t\\tHorses,\\ttreatment\\tof\\tequine\\tasthma\\tsyndrome,\\twith\\tRAO:\\t5\\tmg/kg\\tq12h\\tPO. \u2022\\t\\tAlthough\\ttheophylline\\thas\\tbeen\\tadministered\\tto\\thorses\\tintravenously,\\tthis administration has caused transient excitement and restlessness. Give IV administration slowly. \u2022\\t\\tCattle\\tuse\\tas\\ta\\tbronchodilator:\\t20\\tmg/kg\\tq12h\\tPO.\\tWhen\\ttreating\\tdiseases secondary to virus infections, decrease frequency to once every 24 hours. Regulatory Information Withdrawal times are not established. However, for extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t3 Thiabendazole thye- ah- ben\u2032dah- zole Trade and other names: Omnizole, Equizole, TBZ, and Thibenzole","contraindications":"Contraindications and Precautions Administer with caution to patients with cardiovascular disease or patients with seizure disorders. Studies in people have concluded that administration of methylxanthines increases risk of seizures in susceptible patients. Drug Interactions Use cautiously with other PDE inhibitors such as pentoxifylline, sildenafil (Viagra), and pimobendan. Many drugs inhibit the metabolism of theophylline and potentially increase concentrations. Drugs responsible include cimetidine, erythromycin, fluoroquinolones, and propranolol. Some drugs decrease concentrations by increasing metabolism. Such drugs include phenobarbital and rifampin.","indications":"Indications and Clinical Uses Theophylline is administered for inflammatory airway disease in cats, dogs, and horses. Use in animals has been primarily derived from empirical use, some experimental models, and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. It has been used to control clinical signs of reversible airway constriction, such as seen with feline asthma. In dogs, the uses include collapsing trachea, bronchitis, and other airway diseases. In horses, it will relieves signs of RAO (heaves) associated with equine asthma syndrome, but the IV dose may cause adverse effects in horses. Other drugs (e.g., clenbuterol, albuterol, ciclesonide) are often used for this condition in horses. It has not been effective for respiratory diseases in cattle. T Other methylxanthine drugs have been examined for treatment of dogs and cats with airway disease, but these medications are not readily available in the United States and are not widely used. These drugs include propentofylline, which is an approved veterinary drug in some countries (Karsivan or Vivitonin), as 50- mg tablets","side_effects":"Adverse Reactions and Side Effects Adverse effects of theophylline include nausea, vomiting, and diarrhea. With high doses, tachycardia, excitement, tremors, and seizures are possible. Cardiovascular and central nervous system (CNS) adverse effects appear to be less frequent in dogs than people. Overdoses can cause hypokalemia.","notes":"Instructions for Use Adjust the dose of theophylline to maintain therapeutic blood levels. Older slow- release and extended- release (ER) formulations are no longer available. Some ER forms are sold through compounding pharmacies, but there is no evidence that they produce extended- duration treatment effects compared with conventional forms. The doses listed later were primarily established through pharmacokinetic studies using human- labeled tablets and capsules in dogs and cats. Some of these forms may no longer be available commercially. Patient Monitoring and Laboratory Tests Plasma concentrations of theophylline should be monitored in patients receiving chronic therapy to maintain plasma concentrations between 10 and 20 mcg/mL. Regularly monitor plasma concentrations in patients receiving chronic treatment. Formulations \u2022\\t\\tTheophylline\\thas\\tbeen\\tavailable\\tin\\t100-\\t,\\t125-\\t   ,\\t200-\\t   ,\\t250-\\t   ,\\tand\\t300-\\tmg\\ttablets; 27-\\t mg/5-\\t   mL\\t(5.3-\\tmg/mL)\\toral\\tsolution\\tor\\telixir;\\tand\\tinjection\\tin\\t5%\\tdextrose. \u2022\\t\\tTheophylline\\textended\\trelease\\twas\\tavailable\\tin\\t100-\\t,\\t200-\\t   ,\\t300-\\t   ,\\t400-\\t   ,\\t450-\\t   , and\\t600-\\tmg\\ttablets.\\tHowever,\\tavailability\\tof\\tvarious\\tsizes\\tof\\tER\\tformulations may vary, and most are no longer available. Some veterinarians have relied on compounded immediate- release tablets and capsules. But there is no evidence that the compounded versions are equivalent to the proprietary formulations. \u2022\\t\\tTransdermal\\ttheophylline\\tin\\tLipoderm\\tand\\tPLO\\tgel\\thas\\tbeen\\ttested\\tbut\\tproduced ineffective plasma concentrations. 888    Thiabendazole Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Theophylline is slightly soluble in water (8 mg/mL). It has been mixed with some oral liquids and found to be stable if administered shortly after mixing. When using the slow- release tablets or capsules in dogs and cats, do not disrupt coating on formulation.","original_category":"Bronchodilator"},{"name":"Thiamine Hydrochloride","active_ingredient":"Thiamine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t10\u2013100\\tmg/dog/day\\tPO. \u2022\\t\\t12.5\u201350\\tmg/dog/day\\tIM\\tor\\tSQ. Cats \u2022\\t\\t5\u201330\\tmg/cat/day\\tPO\\tup\\tto\\ta\\tmaximum\\tdosage\\tof\\t50\\tmg/cat/day. \u2022\\t\\t12.5\u201325\\tmg/cat/day\\tIM\\tor\\tSQ.  \u2022\\t\\tAll\\tdosages\\tare\\tlisted\\ton\\ta\\tper-\\tanimal\\tbasis. Lambs \u2022\\t\\t12.5\u201325\\tmg/day\\tIM. Sheep and Pigs \u2022\\t\\t65\u2013125\\tmg/day\\tIM. Calves and Foals \u2022\\t\\t37.5\u201365\\tmg/day\\tIM. Cattle and Horses \u2022\\t\\t125\u2013250\\tmg/day\\tIM. Regulatory Information Withdrawal time for animals intended for food: 0 days. Thioguanine thye- oh- gwah\u2032neen Trade and other names: Generic brands","contraindications":"Contraindications and Precautions Administer solutions of vitamin B 1 very slowly intravenously if at all. Rapid IV administration has caused anaphylactic reactions. Drug Interactions Thiamine hydrochloride is an acidic solution and may be susceptible in incompatibility when this hydrochloride is mixed with alkalinizing solutions.","indications":"Indications and Clinical Uses Thiamine is used to provide vitamin B 1 supplementation or to treat vitamin B 1 deficiency. It is often administered in combination with other vitamins (vitamin B complex). Vitamin B complex is often administered to patients, sometimes supplemented in IV fluids to help recovery from illness. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare because water- soluble vitamins are easily excreted.","notes":"Instructions for Use Vitamin B supplements are administered often in combination with other B vitamins as vitamin B complex solutions. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. 892    Thioguanine Formulations \u2022\\t\\tThiamine\\tis\\tavailable\\tin\\t250-\\tmcg/5-\\tmL\\telixir,\\t5-\\t\\tto\\t500-\\tmg\\ttablets,\\tand\\t100-\\t\\tand 500- mg/mL  injections. \u2022\\t\\tVitamin\\tB\\tcomplex\\taqueous\\tsolutions\\tfor\\tinjection\\tusually\\tcontain\\t12.5\\tmg/mL\\tof vitamin B 1 . Stability and Storage Store in a tightly sealed container, at room temperature, and protected from light. When mixed with other solutions (e.g., fluid solutions), incompatibility may result.","original_category":"Vitamin"},{"name":"Thioguanine","active_ingredient":"Thioguanine","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t40\\tmg/m 2 q24h PO. Cats \u2022\\t\\t25\\tmg/m 2 q24h\\tPO\\tfor\\t1\u20135\\tdays;\\tthen\\trepeat\\tevery\\t30\\tdays.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Thiopental Sodium thye- oh- pen\u2032tahl soe\u2032dee- um Trade and other names: Pentothal (previously used name was Thiopentone)","contraindications":"Contraindications and Precautions Do not administer to patients with depressed bone marrow. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Thioguanine is used in some anticancer protocols. It is not commonly used in animals. Use in animals has been primarily derived from empirical use and experience in humans. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. T Thiopental Sodium 893 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects, as with any anticancer drug, are expected. Adverse effects from thioguanine may be similar to those observed from mercaptopurine. Immunosuppression and leukopenia are common.","notes":"Instructions for Use Thioguanine may be combined with other agents for treatment of cancer. Patient Monitoring and Laboratory Tests Monitor the CBC to screen for evidence of bone marrow toxicity. Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Thiotepa","active_ingredient":"Thiotepa","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t0.2\u20130.5\\tmg/m 2 weekly or daily for 5\u201310 days IM, intracavitary, or injected directly into the tumor.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Thyroid- Releasing  Hormone Trade and other names: TRH, Protirelin, Thyrel","contraindications":"Contraindications and Precautions Avoid use in animals with depressed bone marrow. Drug Interactions No drug interactions have been reported in animals. 896     Thyroid- Releasing  Hormone","indications":"Indications and Clinical Uses Thiotepa has been used for various tumors, especially malignant effusions. The most common mode of administration is local infiltration of a lesion or local infusion (e.g., into\\tthe\\turinary\\tbladder).\\tFor\\tcancer\\tof\\tthe\\tbladder,\\t30\\tmg\\thas\\tbeen\\tdiluted\\tin\\t30\\tmL of distilled water and instilled directly in the bladder once per week. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are similar to other anticancer agents and alkylating drugs (many of which are unavoidable). Bone marrow suppression is the most common effect. When administered locally or by local infiltration, there is less systemic effect.","notes":"Instructions for Use One should consult the specific cancer chemotherapy protocol for guidance on administration. Thiotepa usually is administered directly in body cavities. Patient Monitoring and Laboratory Tests Monitor the CBC for evidence of bone marrow suppression. Formulations Thiotepa is available in 15- mg injections (usually in a solution of 10 mg/mL). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. When mixing solution, add 1.5 mL of sterile water to each vial. This solution is stable for 5 days if refrigerated. Solutions may be clear to slightly opaque, but if cloudiness or precipitate appears, discard the vial.","original_category":"Anticancer agent"},{"name":"Tiludronate Disodium","active_ingredient":"Tiludronate Disodium","species":["Canine","Feline","Equine"],"dosage":"\u2022\\t\\tNo\\tdoses\\thave\\tbeen\\testablished\\tfor\\tdogs\\tor\\tcats.  Horses \u2022\\t\\t1\\tmg/kg\\tadministered\\tas\\t0.1\\tmg/kg\\tper\\tday\\tfor\\t10\\tdays\\tintravenously\\tor administer as a single 1- mg/kg IV infusion for one dose. Administer an IV infusion in\\t1\\tL\\tof\\t0.9%\\tsaline\\tsolution\\tover\\t30\u201360\\tminutes. Regulatory Information In some racing jurisdictions, these drugs are prohibited in horses younger than 4 years of age. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Tinidazole tih- nih\u2032dah- zole Trade and other names: Tindamax","contraindications":"Contraindications and Precautions Do not use in horses with kidney disease because it is excreted by the kidney and could accumulate. After injection, monitor horses for signs of colic. The manufacturer warns that concurrent administration of nonsteroidal anti- inflammatory drugs (NSAIDs) with tiludronate may the increase risk of kidney injury. Use carefully in conditions associated with hypocalcemia. The manufacturer warns that horses with hyperkalemic periodic paralysis may be at an increased risk for adverse reactions, including colic signs, hyperkalemic episodes, and death. Do not use in pregnant mares because the safety in pregnancy has not been evaluated. Use in young horses: The manufacturer states that the safety of tiludronate in horses younger than 4 years of age has not been evaluated. The effect of bisphosphonates on the skeleton of growing horses has not been studied; however, bisphosphonates inhibit osteoclast activity, which impacts bone turnover and may affect bone growth. It is recommended not to administer bisphosphonates such as tiludronate in young performance horses because the change in bone metabolism may predispose young horses to fracture. In some racing jurisdictions, these drugs are prohibited in horses younger than 4 years of age. One study that examined clodronate and tiludronate in young horses concluded that tiludronate and clodronate did not appear to significantly impact bone tissue on a structural or cellular level using standard dose and administration schedules in young horses. Drug Interactions Do not mix with solutions containing calcium (e.g., lactated Ringer\u2019s solution). Do not administer with NSAIDs (see Contraindications and Precaution). If antacids are used concurrently, magnesium hydroxide and calcium carbonate may reduce effectiveness. T Tinidazole 909","indications":"Indications and Clinical Uses Tiludronate is licensed in countries in Europe and approved in the United States for treatment of palmar foot pain associated with navicular syndrome in horses. It also is used to treat distal tarsal osteoarthritis (bone spavin). Other bisphosphonate drugs are used in people to treat osteoporosis and hypercalcemia of malignancy. Like other drugs in this class, tiludronate is helpful for managing complications associated with pathologic bone resorption. It also may provide pain relief in patients with pathologic bone disease. Another bisphosphonate, clodronate (Osphos), also is approved for treating navicular disease in horses. Efficacy studies conducted in horses have shown that at a dosage of 0.1 mg/kg for 10 days (1.0 mg total dose), it is effective for treatment of navicular disease and distal tarsal osteoarthritis. Beneficial effects for treating chronic lameness are less certain. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Reaction to tiludronate has only been reported for horses. After IV infusion, increases in heart rate, restlessness, and transient hypocalcemia have been observed.\\tAbout\\t30%\u201345%\\tof\\thorses\\tadministered\\ttiludronate\\tdevelop\\tsigns\\tof colic after IV administration. However, colic signs that have been observed in horses resolved uneventfully. In people, there is some concern that it may result in excessive mineralization and hardening of the bone, which may result in a greater risk of fractures. However, this effect has not been reported for animals. No adverse effects on bone mineral density have been reported.","notes":"Instructions for Use Make sure horses are well hydrated prior to use to avoid kidney injury. For IV infusion, dilute in solvent and infuse slowly over 90 minutes. Observe horses for 4 hours after IV administration for signs of colic. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Monitor urea nitrogen, creatinine, urine- specific gravity, and food intake in treated animals. Formulations \u2022\\t\\tTiludronate\\tis\\tavailable\\tin\\t50-\\tmg\\tvials\\tfor\\tinjection\\tto\\tbe\\treconstituted\\twith\\t10\\tmL of diluent. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antihypercalcemic"},{"name":"Tinidazole","active_ingredient":"Tinidazole","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t15\\tmg/kg\\tq12h\\tPO.\\tDuration\\tof\\ttreatment\\tis\\tnot\\tknown\\tfor\\tall\\tconditions,\\tbut Giardia infections can be treated with 5 days of treatment or less. Cats \u2022\\t\\t15\\tmg/kg\\tq24h\\tPO.\\tThe\\tduration\\tof\\ttherapy\\tdepends\\ton\\twhether\\tone\\tis\\ttreating Giardia infection (5 days) or other anaerobic infections (longer than 5 days).  Horses \u2022\\t\\t10\u201315\\tmg/kg\\tq12h\\tPO. Regulatory Information Do not administer to animals that produce food. Administration of nitroimidazoles to animals intended for food is prohibited. T Tissue Plasminogen Activator 911 Tissue Plasminogen Activator Trade and other names: tPA and Retavase","contraindications":"Contraindications and Precautions Do not administer to animals that may be prone to seizures. Do not administer to animals already known to be sensitive to metronidazole. Do not administer to pregnant animals. Drug Interactions Like other nitroimidazoles, it can potentiate the effects of warfarin and cyclosporine via inhibition of drug metabolism.","indications":"Indications and Clinical Uses Tinidazole is indicated to treat diarrhea and other intestinal problems caused by intestinal protozoa such as Giardia, Trichomonas, and Entamoeba spp. In people, a single dose of tinidazole has been effective for treating infections caused by Giardia spp.; however, the single- dose protocol has not been tested in animals. Tinidazole also is active against many anaerobic bacteria and may be used as a substitute for metronidazole in small animals and horses for treatment of a variety of anaerobic infections. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tinidazole has similar action as metronidazole. With high doses, it can cause neurologic problems, including ataxia, tremors, nystagmus, and seizures. The CNS signs are related to inhibition of action of GABA and are responsive to benzodiazepines (diazepam). Like other nitroimidazoles, it has the potential to produce mutagenic changes in cells, but this has not been demonstrated in vivo. Nitroimidazoles such as tinidazole have a bitter taste and can cause vomiting and anorexia. However, the bitter taste is not as bad as that of metronidazole.","notes":"Instructions for Use Give oral dose with food to minimize the unpleasant taste and decrease nausea. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Most anaerobic bacteria have MIC values below 2 mcg/mL. Formulations \u2022\\t\\tTinidazole\\tis\\tavailable\\tin\\t250-\\t\\tand\\t500-\\tmg\\ttablets. Stability and Storage Tablets have been crushed and mixed with flavorings to improve palatability. These suspensions are stable for 7 days.","original_category":"Antiprotozoal"},{"name":"Tissue Plasminogen Activator","active_ingredient":"Tissue Plasminogen Activator","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t1\u20131.5\\tmg/kg\\tIV.\\tInfuse\\tthe\\tfirst\\thalf\\tof\\tthe\\tdose\\tover\\t1\\thour,\\twith\\t10%\u201320%\\tof\\tthis dose in the first 10 minutes and then the remaining dose over the next 2 hours.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\thave\\tbeen\\tinvestigated. Regulatory Information Do not administer to animals that produce food. Tobramycin Sulfate toe- brah- mye\u2032sin sul\u2032fate Trade and other names: Nebcin and Tobi (human nebulization product)","contraindications":"Contraindications and Precautions Do not administer to animals that have any ongoing bleeding problems. Do not administer unless the patient can be monitored carefully by clinical experts who are experienced with the use of tPA. If administered with other agents that impair clot formation, serious bleeding can result. Drug Interactions The use with any other drug that inhibits coagulation and clot formation exacerbates bleeding. 912    Tobramycin Sulfate","indications":"Indications and Clinical Uses Tissue plasminogen activator is used in people to treat acute stages of myocardial infarction. The other uses include pulmonary embolism, ischemic stroke, arterial thrombosis, to remove clots from occluded IV catheters, and occasionally for other disease in which thromboembolism occurs. In animals, the use is infrequent, but it is used in dogs and cats to dissolve blots associated with thromboembolism. In cats, this includes aortic thromboembolism, but there has been no convincing evidence that treatment with tPA is superior to other standard care protocols. In dogs, specific uses have not been defined, but it could potentially be used for diseases that are associated with thromboembolic episodes. The doses and protocols used in animals have not been rigorously tested. The cost is very high, which prevents more frequent use. The use in animals is based on limited clinical experience and observations from clinical experts. It is usually administered with antiplatelet drugs (e.g., clopidogrel) and anticoagulants (e.g., heparin). Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tissue plasminogen activator is very effective at dissolving blood clots and causes serious bleeding episodes with excessive use or if proper monitoring is not performed. In cats, there is a high frequency of adverse effects, some of which have been fatal. The problems identified in cats arise because of reperfusion injury, release of cytokines after blood flow is restored, and hyperkalemia.","notes":"Instructions for Use If tPA is selected for use, treatment should begin as promptly as possible. The vial should be reconstituted by mixing 50 mg of tPA with 50 mL of sterile water. Use water without preservatives. This provides a concentration of 1 mg/mL. If larger vials are used, reconstitute 100 mg of tPA with 100 mL of sterile water. There will be some slight foaming, which is expected during reconstitution. This solution can be\\tinjected\\tdirectly\\tIV\\tor\\tmay\\tbe\\tdiluted\\tfurther\\tto\\t0.5\\tmg/mL\\twith\\t0.9%\\tsodium chloride\\tsolution\\tor\\t5%\\tdextrose\\tsolution.\\tMix\\tthe\\tvials\\twith\\tgentle\\tswirling\\tbut\\tnot vigorous agitation. Use reconstituted or diluted solutions within 8 hours. Discard any unused solutions. Patient Monitoring and Laboratory Tests Monitor carefully for any signs of bleeding. Monitor any needle puncture sites for signs of bleeding. Formulations \u2022\\t\\ttPA\\tis\\tavailable\\tas\\tin\\tvials\\tcontaining\\t50\\tor\\t100\\tmg.\\t100\\tmg\\tis\\tequivalent\\tto\\t58 million units. Stability and Storage Store\\tthe\\tvials\\tcontaining\\tlyophilized\\tpowder\\tat\\tless\\tthan\\t30\xb0C\\tor\\trefrigerate\\tat 2\xb0C\u20138\xb0C","original_category":"Anticoagulant, fibrinolytic"},{"name":"Toceranib Phosphate","active_ingredient":"Toceranib Phosphate","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tThe\\tapproved\\tlabel\\tdosage\\tis\\t3.25\\tmg/kg\\tPO\\tevery\\tother\\tday.\\tHowever,\\tmedical oncologists recommend a lower dosage of 2.5\u20132.75 mg/kg per dose and treat on a\\tschedule\\tof\\t3\\tdays\\tper\\tweek\\t(e.g.,\\tMonday,\\tWednesday,\\tFriday).\\tThe\\tminimum effective dosage is 2.2 mg/kg every other day. If adverse reactions occur, discontinue the drug (for up to 2 weeks) and reinstate treatment at a lower dose. Cats \u2022\\t\\t2.5\u20132.75\\tmg/kg\\tgiven\\tthree\\ttimes\\tper\\tweek\\tor\\tonce\\tevery\\tother\\tday.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to food- producing animals. Toltrazuril tole- traz\u2032yoo\u2019ril Trade and other names: Baycox","contraindications":"Contraindications and Precautions Daily dosing should not be administered because of frequency of adverse events. Administration every other day is better tolerated. Toceranib should not be administered during pregnancy. People handling the drug, especially pregnant women, should receive proper instructions about the drug\u2019s adverse effects. Drug Interactions No drug interactions have been reported for animals. Metabolism is primarily via flavin monooxygenase, which is not typically involved in drug\u2013drug interactions. It is not known if toceranib may be responsible for drug\u2013drug interactions that involve the cytochrome P450 system.","indications":"Indications and Clinical Uses Toceranib is an approved anticancer agent for dogs. The use and safety has been established in clinical studies for grade II or III cutaneous mast cell tumors. Many dogs are also treated with corticosteroids (prednisolone). Alternative drugs also may be used for mast cell tumors, such as vinblastine plus prednisone. During treatment of mast cell tumors, antihistamines (e.g., cetirizine) can also be used to minimize the effects of histamine. Although toceranib is approved for mast cell tumors in dogs, some clinicians have used it to treat adenocarcinoma, melanoma, mammary carcinoma, soft tissue sarcoma, and anal gland adenocarcinoma; however, efficacy for these indications has not yet been established. Toceranib has been used in cats to treat epithelial tumors, squamous cell carcinoma, and mast cell tumors (in combination with corticosteroids). Dosage suggestions are listed later. There is not sufficient information available to document efficacy or safety in cats, but preliminary results were a low overall response rate. T Precautionary Information","side_effects":"Adverse Reactions and Side Effects Dogs with mast cell tumors often have GI problems associated with the tumor and treatment. Therefore many dogs are treated simultaneously with antihistamines and drugs to suppress stomach acid (e.g., H 2 blockers or proton pump inhibitors). The most common adverse effects are diarrhea, loss of appetite, lameness, musculoskeletal pain, weight loss, and blood in the feces. In people, tyrosine kinase inhibitors have been associated with proteinuria, thrombosis, hemorrhage, and systemic hypertension (discussed later). Tyrosine kinase inhibitors may cause systemic hypertension in some animals. The mechanism may be related to decreased NO availability. VEGF increases production of NO by endothelial cells, which helps to regulate blood pressure. Decreased NO caused by administration of tyrosine kinase inhibitors have a potential to cause systemic hypertension. This may occur in dogs, and they should be screened and monitored for this possibility during treatment. Toceranib can disrupt the hypothalamic\u2013pituitary\u2013thyroid axis in dogs by decreasing blood flow to the thyroid and altered iodine uptake. Therefore, as noted in the monitoring section, check the T 4 and free T 4 during treatment. Adverse effects in cats are similar as in dogs. These effects include vomiting, decreased appetite, and mild increase in alanine aminotransferase and alkaline phosphatase enzymes.","notes":"Instructions for Use Toceranib is approved for cutaneous mast cell tumor in dogs. There is clinical use for other tumors, but efficacy has not yet been established for other uses. Administer every other day to minimize the adverse effects. If adverse effects occur at the initial dose, a lower dose (e.g., 2.5 mg/kg) may be considered. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. If assays are available, the targeted plasma drug concentration is 40 ng/mL or greater for 48 hours. Because of potential effects on the thyroid, check the T 4 and free T 4 during treatment. Formulations Toceranib is available in 10- , 15- , and 50- mg tablets, which are film coated and should not be split. 918    Toltrazuril Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Toceranib\\tis\\tonly\\tsoluble\\tat\\tlow\\tpH\\tvalues\\t(pH\\tless\\tthan\\t3).\\tIf\\tmixed\\twith\\tother vehicles, it precipitates at higher pH values. Studies on compounded oral formulations of toceranib phosphate from compounding pharmacies found the strengths of formulations (capsules, tablets, suspensions) to be lower than the acceptable range.","original_category":"Anticancer agent"},{"name":"Toltrazuril","active_ingredient":"Toltrazuril","species":["Feline","Canine","Equine"],"dosage":"Cats \u2022\\t\\tTreatment\\tof\\ttoxoplasmosis:\\t5\u201310\\tmg/kg\\tq24h\\tPO\\tfor\\t2\\tdays. \u2022\\t\\tCoccidia\\tin\\tkittens:\\t30\\tmg/kg\\tonce\\tor\\t15\\tmg/kg\\tonce\\tdaily\\tfor\\t3\\tdays;\\tthen repeated again 10 days later. Dogs \u2022\\t\\tPuppies,\\ttreatment\\tof\\tintestinal\\tprotozoa:\\t10\u201330\\tmg/kg\\tq24h\\tPO\\tfor\\t3\\tdays.  Horses \u2022\\t\\tEPM\\tcaused\\tby\\tS. neurona: 5\u201310 mg/kg (7.5 mg/kg for most horses) q24h PO for\\ta\\tminimum\\tof\\t30\\tdays. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Torsemide tor\u2032sem- ide Trade and other names: Demadex","contraindications":"Contraindications and Precautions No contraindications are reported for animals. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Toltrazuril has been used as a treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona. However, it is recommended to use an approved drug, ponazuril (Marquis) for treatment of horses instead of administering toltrazuril. Toltrazuril has been used in puppies and kittens for treating intestinal protozoal infections. For treatment of coccidial infections in kittens, it has been administered at\\t30\\tmg/kg\\tonce\\tor\\t15\\tmg/kg\\tonce\\tdaily\\tfor\\t3\\tdays\\tand\\tthen\\trepeated\\tagain\\t10 days\\tlater.\\tIt\\thas\\tbeen\\tadministered\\tsuccessfully\\tto\\tpuppies\\tat\\t10,\\t20,\\tor\\t30\\tmg/kg\\tin 4- week- old  puppies. T Torsemide 919 Precautionary Information","side_effects":"Adverse Reactions and Side Effects Administration of 50 mg/kg to horses (5 and 10 times the recommended dose) produced minor adverse effects, according to the manufacturer. There were minimal changes in the serum analysis.","notes":"Instructions for Use Although toltrazuril has been used in horses, the approved drug ponazuril is preferred for use. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Fecal analysis should be performed to assess the effects for treating intestinal protozoa. Formulations \u2022\\t \\tToltrazuril\\tis\\tnot\\tcurrently\\tavailable\\tin\\tcommercial\\tformulations\\tin\\tthe\\tUnited\\tStates for horses. It is available in suspension for poultry and livestock in other countries. It has been imported to the United States after permission from the FDA. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antiprotozoal"},{"name":"Trazodone Hydrochloride","active_ingredient":"Trazodone Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"dogs safely for 28 days at dosages of 7\u201310 mg/kg q8\u201312h. It may have fewer anticholinergic effects than the TCAs. It has not produced adverse cardiac effects or seizure activity. When administered intravenously to dogs, adverse effects are more likely, which include aggression, behavior changes, and tachycardia. In cats, clinical studies with a dose of 100 mg per cat did not produce adverse effects. There were no instances of anorexia, vomiting, diarrhea, ataxia, tremor, paradoxical excitation, or behavioral disinhibition. No laboratory test abnormalities or physical exam changes were observed in any cat. It has been used in cats to facilitate echocardiographic examination without affecting the results. It may lower the blood pressure in treated cats. In horses, a dose of trazodone of 1.5 mg/kg caused ataxia and tremors. At high doses, trazodone caused tremors, aggression, and excitement. higher doses as needed. In dogs, the starting dosage is generally 25 or 50 mg per dog (depending on dog\u2019s size) once or twice per day; then increase the dose gradually if desired effects are not observed and there are no signs of adverse events. Compared with other behavior- modifying drugs such as SSRIs and TCAs, trazodone has a more rapid onset of effect. It may be administered 1 hour prior to an anticipated event that elicits anxiety in an animal, such as thunderstorms, loud noises, car ride, or visit to the veterinarian. It may be administered with benzodiazepine drugs. In cats, it may be administered up to doses of 100 mg per cat. When administered to cats, it may be mixed with food to facilitate dosing. After dosing to cats, it produces significant sedation and decreased activity. Peak sedation occurs between 2 and 2.5 hours.  Dogs \u2022\\t\\tA\\ttypical\\tstarting\\tdose\\tfor\\tdogs\\tis\\t5\u20138\\tmg/kg\\tq12h;\\tthen\\tincrease\\tthe\\tdose as needed to achieve desirable effects. Administer at least 1 hour prior to an anticipated event that may trigger anxiety. The frequency may vary from q8h to  \u2022\\t\\tTrazodone\\thas\\tbeen\\tstudied\\tin\\thorses,\\tbut\\tno\\tsafe\\tand\\teffective\\tdose\\thas\\tbeen established. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triamcinolone Diacetate trye\u2032 am sin\u2032 oh lone Trade and other names: Vetalog, TriamTabs, Aristocort, Kenalog (human injection), and generic brands","contraindications":"Contraindications and Precautions Use cautiously with other hypotensive drugs and diuretics. NSAIDs may decrease vasodilating effects. Discontinue ACE inhibitors in pregnant animals; they cross the placenta and have caused fetal malformations and death of the fetus. Drug Interactions Use cautiously with other hypotensive drugs and diuretics. NSAIDs may decrease vasodilating effects. T serotonin 2A (5- HT 2A ) and 2B (5- HT 2B ) receptor antagonist, a partial agonist for serotonin 1A (5- HT 1A ), and a (weak) SSRI, with little effect on dopamine. It has nonspecific sedating properties and is used as a sedative and hypnotic. It has an active metabolite that also may have effects on the serotonin- 1 receptor. The action as an antidepressant and antianxiety agent appears to be distinct from the tricyclic antidepressants (TCAs) and SSRIs. Pharmacokinetics: Trazodone is highly metabolized in people, but the metabolism and pharmacokinetics are not as well understood in animals. The half- life\\tis\\t6\u20139\\thours\\tin\\tpeople\\tbut\\tonly\\t2.8\\thours\\tin\\tdogs,\\twith\\t85%\\toral\\tabsorption. When administered with food to dogs, it has a peak at 7 hours, with high variation. There have been preliminary studies in cats in which it appears to be well absorbed orally and has a sufficiently long half- life for short- term treatment of anxiety and behavior problems. In horses, it has not been recommended for clinical\\tuse\\tbut\\thas\\tan\\toral\\tabsorption\\tof\\t63%\\tand\\ta\\thalf-\\tlife\\tof\\tapproximately 7 hours. Contraindications and Precautions Because of the effect of trazodone on serotonin metabolism, reuptake, and receptors, it should be used cautiously, if at all, with other drugs that affect serotonin. Serotonin syndrome effects have not been observed in dogs, but it should be used cautiously with drugs such as SSRIs (fluoxetine, paroxetine), TCAs (clomipramine), tramadol, and monoamine oxidase inhibitors (selegiline). Do not administer intravenously to dogs. Drug Interactions Trazodone is highly metabolized by cytochrome P450 enzymes. Such enzymes can be inhibited or induced by co- administration with other drugs. Although specific drug interactions have not been reported for dogs, there should be caution when administering to animals receiving other drugs known to affect cytochrome P450 enzymes. (See Appendixes H and I for a list of possible drugs.) Because of the effects of trazodone on serotonin receptors, there should be caution when administering trazodone with other drugs that may affect serotonin, such as tramadol and antidepressants (e.g., fluoxetine, clomipramine). However, based on reports available, excess serotonin effects have not been observed, and it has been administered with tramadol, TCAs, and other serotoninergic drugs safely. Thus far, there have been no adverse effects reported when trazodone was administered prior to anesthesia and surgery in dogs. T Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triamcinolone Diacetate 929 q24h, depending on the use. Alternatively, to avoid breaking tablets, give 25 or 50 mg per dog (depending on the dog\u2019s size) once daily and increase gradually to a maximum\\tof\\t300\\tmg\\tper\\tdose\\tor\\t900\\tmg\\tper\\tdog\\tper\\tday. Cats \u2022\\t\\t50\u2013100\\tmg\\tper\\tcat\\tPO\\t(peak\\teffect\\toccurs\\tin\\t2\u20132.5\\thours)\\tas\\tneeded\\tto\\tcontrol anxiety; 50 mg per cat is usually sufficient for most cats. Time to peak sedation in cats occurs in approximately 2 hours.","indications":"Indications and Clinical Uses Trazodone has been used in dogs for events that trigger anxiety and fear such as visits to the veterinarian, separation anxiety, thunderstorms, noise phobias, travel in a car, and other phobias and generalized anxiety events. It has been used to decrease stress in dogs and facilitate handling, confinement, and hospitalization. Although trazodone has been helpful to relieve anxiety in these situations, it has a delayed onset of activity and can be unpredictable. To optimize the effects, it should be administered approximately 1 hour prior to an anticipated anxiety- inducing event. It also has been used to calm anxious dogs to restrict activity after surgery in order to facilitate confinement tolerance. In cats, it has been used for temporary sedation and to facilitate events that may produce anxiety, such as to facilitate transportation of cats and visits to the veterinarian. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Although the experience has been mostly limited to small observational studies, there have not been serious adverse effects from oral trazodone in dogs. Uncommon but possible adverse effects in dogs have included soft feces, diarrhea, vomiting, paradoxical anxiety, agitation, vocalization, drowsiness, incontinence, and aggression. The most common effect is sedation at higher doses, which is not always an undesirable event for some of the suggested clinical uses. It has been used in some","notes":"Instructions for Use Start with a low dose in dogs (approximately 5 mg/kg) and work up gradually to Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Trazodone concentrations are usually not measured,\\tbut\\tin\\tpeople,\\tplasma\\tconcentrations\\tof\\t0.13\u20132\\tmcg/mL\\twere\\tresponsible for antidepression effects. Formulations \u2022\\t\\tIt\\tis\\tavailable\\tas\\t50-\\t,\\t75-\\t  ,\\t100-\\t   ,\\t150-\\t   ,\\tand\\t300-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Antianxiety agent, behavioral modification"},{"name":"Trientine Hydrochloride","active_ingredient":"Trientine Hydrochloride","species":["Canine"],"dosage":"Dogs \u2022\\t\\t10\u201315\\tmg/kg\\tq12h\\tPO\\t1\u20132\\thours\\tbefore\\tfeeding.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. 934    Trifluoperazine Hydrochloride Trifluoperazine Hydrochloride trye- floo- oh- pare\u2032ah- zeen  hye- droe- klor\u2032ide Trade and other names: Stelazine","contraindications":"Contraindications and Precautions Do not administer to pregnant animals; it may be teratogenic. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Trientine is used to chelate copper when penicillamine cannot be tolerated in a patient. In people, it is preferred over penicillamine. Use in animals has been primarily derived from empirical use and experience in humans. It is more potent than penicillamine and may produce fewer GI problems than penicillamine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects have not been reported in animals.","notes":"Instructions for Use Trientine is used for copper chelation, primarily in patients that cannot tolerate penicillamine. Patient Monitoring and Laboratory Tests Monitor copper levels in treated patients. Formulations \u2022\\t\\tTrientine\\tis\\tavailable\\tin\\t250-\\tmg\\tcapsules. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Antidote"},{"name":"Trilostane","active_ingredient":"Trilostane","species":["Canine","Feline","Equine"],"dosage":"Most\\tdogs\\tcan\\tbe\\tcontrolled\\twith\\ttreatment\\tat\\ta\\tstarting\\tdosage\\tof\\t2\u20133\\tmg/kg once\\tdaily.\\t(This\\tis\\tlower\\tthan\\tthe\\tmanufacturer\u2019s\\trange\\tof\\t3\u20136\\tmg/kg\\tonce\\ta day.) Within this range, larger dogs can be maintained on lower doses (mg/kg) than smaller dogs. In many dogs, 24- hour cortisol suppression does not occur; therefore, consider administration twice daily in patients that are not adequately controlled to improve clinical response. When using twice- daily treatment, a starting dosage of 0.5\u20131 mg/kg q12h PO can be used and gradually increased to 1.5\u20133\\tmg/kg\\tq12h\\tPO.\\tIn\\tsome\\tdogs,\\tadministration\\tthree\\ttimes\\tdaily\\tmay\\tbe needed. During treatment, especially in the initial phases, dogs may show adverse effects attributable to cortisol deficiency. In these cases, it is acceptable to instruct pet owners to administer a single dose of 0.5 mg/kg prednisone to relieve adverse clinical signs. In cats, once- daily dosing can be considered, but many cats are better controlled with twice- daily administration. If a cat is also receiving insulin twice daily, trilostane should also be given twice daily to coincide with the insulin treatment.  Dogs \u2022\\t\\tManufacturer\u2019s\\tlabel\\tdosage\\tis\\t2.2\u20136.7\\tmg/kg\\tonce\\tper\\tday\\tPO\\t(average,\\t5.9\\tmg/ kg). However, many dogs are controlled with a lower dosage starting at 0.5\u20131 mg/ kg\\tq12h\\tPO\\t(or\\t2\u20133\\tmg/kg\\tonce\\tdaily)\\tand\\tincreased\\tto\\t1.5\u20133.8\\tmg/kg\\tq12h\\tPO as needed based on testing. Refer to previous Instructions for Use section, for more complete dosing instructions. \u2022\\t\\tAdjust\\tdosage\\tbased\\ton\\tcortisol\\tmeasurements. \u2022\\t\\tLarge\\tdogs\\t(weighing\\tgreater\\tthan\\t25\u201330\\tkg)\\tmay\\trequire\\ta\\tlower\\tdosage\\tthan small dogs (weighing less than 15 kg), which can be verified through posttreatment testing. \u2022\\t\\tTreatment\\tof\\talopecia\\tX:\\t9\u201312\\tmg/kg/day\\tPO. Cats \u2022\\t\\tStart\\twith\\t1\u20132\\tmg/kg\\tper\\tday\\tPO.\\tGradually\\tincrease\\tas\\tneeded\\tto\\t3\u20136\\tmg/kg q24h\\tPO.\\tThe\\tdosage\\tfor\\tmost\\tcats\\tis\\tgenerally\\t10\u201330\\tmg\\tper\\tcat\\tq24h. \u2022\\t\\tSome\\tcats\\tare\\tbetter\\tcontrolled\\twith\\ttwice-\\tdaily\\tadministration.\\tIn\\tthese\\tcats,\\tstart with\\t3\\tmg/kg\\tq12h\\tPO;\\tthen\\treevaluate\\tand\\tincrease\\tthe\\tdosage\\tto\\t5\\tmg/kg\\tq12h PO as needed.  Horses \u2022\\t\\t0.4\u20131\\tmg/kg/day\\tPO\\t(added\\tto\\tfeed). Regulatory Information Trilostane should not be used in animals that produce food. Trimeprazine Tartrate and Trimeprazine\u2013Prednisolone trye- mep\u2032rah- zeen  tar\u2032trate Trade and other names: Temaril, Panectyl (in Canada), alimemazine, and Temaril- P (with prednisolone)","contraindications":"Contraindications and Precautions Trilostane may decrease synthesis of other adrenocortical hormones besides cortisol. Use cautiously in animals with low potassium concentrations. Do not administer to animals with kidney or liver disease and do not administer to animals intended for breeding. Drug Interactions Use cautiously, if at all, with aldosterone antagonists, such as spironolactone. If administered with ACE inhibitors, there is a risk of hyperkalemia.","indications":"Indications and Clinical Uses Trilostane is used to treat hypercortisolemia associated with pituitary- dependent hyperadrenocorticism (PDH) in dogs (Cushing\u2019s disease). Peak concentrations of trilostane occur at approximately 2\u20134 hours after an oral dose. Cortisol concentrations will decrease as early as 7\u201310 days after initiating treatment with trilostane. Trilostane T improves\\tpolyuria,\\tpolydipsia,\\tand\\tpolyphagia\\tin\\t70%\u201380%\\tof\\tdogs\\twith\\tPDH. Treatment with mitotane has been compared with trilostane, and it has been shown that each drug, although acting through different mechanisms, produces similar survival times in dogs with PDH. Other drugs used to treat canine PDH include mitotane (Lysodren), selegiline (Anipryl), and ketoconazole, all drugs acting through different\\tmechanisms.\\tTreatment\\tof\\talopecia\\tX\\tin\\tdogs\\t(Pomeranians\\tand\\tpoodles) has been effective in most animals (9\u201312 mg/kg/day PO). Surprisingly, some dogs do well despite high cortisol concentrations. Explanations for this observation is that it may affect glucocorticoid receptors or may convert cortisol to inactive cortisone in dogs by increasing 11- beta- hydroxysteroid dehydrogenase. Trilostane also has been used to manage clinical signs in dogs with adrenal tumors. Trilostane reduces clinical signs by reducing synthesis of cortisol but does not affect the tumor. The use of trilostane in these cases is palliative. Mitotane may be considered a more effective treatment in these cases. Trilostane also has been effective in cats with hyperadrenocorticism, with no reported adverse effects. Trilostane can decrease clinical signs of hyperadrenocorticism in cats but cannot produce resolution of clinical signs. It can also improve regulation of diabetes, which is often found concurrently in cats with hyperadrenocorticism. In horses, trilostane has been used to treat PPID (equine Cushing\u2019s disease), and there is preliminary evidence of some benefit (improved clinical signs, reduced laminitis, reduced cortisol) from trilostane at a dosage of 1 mg/kg per day PO. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In some dogs, transient lethargy, decreased appetite, or vomiting has been observed, which may be caused by excessive cortisol suppression. If excessive cortisol suppression has occurred, oral prednisolone or prednisone can be administered, and the dog should improve within 2 hours. When trilostane is again reintroduced in these cases, the dose should be reduced. Glucocorticoid or mineralocorticoid deficiency or development of adrenal gland necrosis has been associated with trilostane treatment. Trilostane may decrease aldosterone in some dogs; therefore, dehydration, weakness, hyponatremia, and hyperkalemia are possible and may be observed in some dogs that are sensitive to the mineralocorticoid inhibition. Although the effects of trilostane are ordinarily transient and reversible, some dogs have had irreversible adrenal gland necrosis from trilostane. These dogs must be managed for hypoadrenocorticism and treated with glucocorticoid and mineralocorticoid supplement. Adverse effects in cats are similar to dogs and include anorexia, lethargy, weight loss, and pancreatitis.","notes":"Instructions for Use Adjust dose as needed by monitoring cortisol concentrations. Trilostane is a short- acting drug with a peak effect at approximately 4 hours and duration of 8\u201310 hours. Administer with food if possible because food improves oral absorption. Patient Monitoring and Laboratory Tests Monitoring Dogs Monitor cortisol concentrations in treated animals approximately 10\u201314 days after starting\\ttreatment\\tand\\tthen\\tapproximately\\tevery\\t3\\tmonths.\\tClinical\\tsigns\\tsuch as the patient\u2019s thirst, urination habits, appetite, and skin condition also should be monitored during treatment. In most dogs, signs of successful treatment are observed within a few weeks, with improved activity and reduced polyuria, polydipsia, and polyphagia. Improvements in skin and hair coat may take longer. The\\tbaseline\\tserum\\tcortisol,\\tcollected\\tpreferably\\tat\\t4\u20136\\thours\\tafter\\ttrilostane administration, has been used to monitor initial effectiveness of trilostane therapy. The ideal\\ttarget\\trange\\tis\\t1.3\u20132.9\\tmcg/dL\\t(35\u201380\\tnmol/L),\\tor\\t\u226450%\\tof\\tthe\\tpretreatment baseline cortisol concentration. However, some endocrinologists have suggested that baseline measurements of cortisol are not valuable. If further evaluation is needed, use the ACTH stimulation test.\\tPerform\\ttesting\\tafter\\t2\\tweeks\\tof\\ttreatment\\tat\\t4\u20136\\thours\\tafter\\ttrilostane administration to coincide with peak effects. (Alternatively, some endocrinologists recommend 2\u20134 hours after trilostane administration.) Cortisol concentrations of 1.45\u20135.4 mcg/dL (40\u2013150 nmol/L) have been considered adequate after ACTH stimulation, in addition to monitoring clinical signs. Many endocrinologists round- off\\tthese\\tvalues\\tto\\ta\\tdesired\\trange\\tof\\tbetween\\t2\\tand\\t6\\tmcg/dL\\ttested\\tafter\\t2\\tweeks of treatment. If cortisol is too low, consider lowering the dose; if cortisol is too high, consider increasing the dose. Monitor sodium and potassium concentrations in treated dogs. If necessary, supplement with potassium because of aldosterone inhibition. Measurement of endogenous ACTH is not recommended for testing response to trilostane. The levels of ACTH do not correlate with clinical response. Monitoring Cats In cats, start with 1\u20132 mg/kg per day; then monitor with ACTH stimulation testing. The test should be performed 2\u20134 hours after trilostane administration. Formulations Veterinary formulations approved in the United States and Europe include capsules of 10,\\t30,\\t60,\\tand\\t120\\tmg. T Trimeprazine Tartrate and Trimeprazine\u2013Prednisolone 939 Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. The quality of compounded formulations has been highly variable. Tested products have\\tvaried\\tfrom\\t40%\\tto\\t150%\\tin\\tstrength\\tand\\tthe\\toral\\tabsorption\\tis\\tuncertain.","original_category":"Adrenal suppressant"},{"name":"Verapamil Hydrochloride","active_ingredient":"Verapamil Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\t0.05\\tmg/kg\\tevery\\t10\u201330\\tminutes\\tIV\\t(maximum\\tcumulative\\tdose\\tis\\t0.15\\tmg/kg). \u2022\\t\\tThe\\tPO\\tdose\\tis\\tnot\\testablished. Cats \u2022\\t\\tNot\\trecommended.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Do not administer to animals intended for food. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t4 Vinblastine Sulfate vin- blast\u2032een sul\u2032fate Trade and other names: Velban","contraindications":"Contraindications and Precautions Do not use in patients with decompensated congestive heart failure or advanced heart block. It is not well tolerated in cats. Drug Interactions Verapamil, like other calcium- channel- blocking drugs, is subject to interaction with\\tdrugs\\tthat\\tinterfere\\twith\\tthe\\tmultidrug\\tresistance\\t(MDR)\\tmembrane\\tpump (P-\\t glycoprotein)\\tand\\tthe\\tcytochrome\\tP450\\tenzymes.\\t(See\\tAppendixes\\tI\\tand J for a list of drugs that may cause interference.)","indications":"Indications and Clinical Uses Verapamil has been used to control supraventricular arrhythmias. However, the use of verapamil has greatly diminished because of adverse effects. It has practically become an outdated drug in veterinary medicine. The preferred drug from this class to use in animals is usually diltiazem. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects include hypotension, cardiac depression, bradycardia, and atrioventricular block. It may cause anorexia in some patients. Verapamil has caused sudden cardiac arrest in some patients with IV administration.","notes":"Instructions for Use The oral formulation of verapamil is not absorbed sufficiently (of the active stereoisomer) for adequate effects. Diltiazem is preferred over verapamil in patients with heart failure because of less myocardial depression. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during treatment. Formulations \u2022\\t\\tVerapamil\\tis\\tavailable\\tin\\t40-\\t,\\t80-\\t  ,\\tand\\t120-\\tmg\\timmediate-release\\ttablets;\\t120-, 180-, and 240-mg slow-release tablets and capsules; and a 2.5- mg/mL injection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Verapamil is soluble in water. Aqueous solutions are stable for 3 months. Maximum stability\\tis\\tat\\ta\\tpH\\tof\\t3\u20136.\\tIt\\tcan\\tbe\\tmixed\\twith\\tinfusion\\tsolutions\\tand\\tis\\tcompatible. Suspensions have been prepared for oral administration and found to be stable for 60 days. V Vinblastine Sulfate 965","original_category":"Calcium antagonist"},{"name":"Vinblastine Sulfate","active_ingredient":"Vinblastine Sulfate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\t2\\tmg/m 2 IV (slow infusion) once a week. (See Instructions for Use regarding higher doses.)  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Vincristine Sulfate vin- kriss\u2032teen sul\u2032fate Trade and other names: Oncovin, Vincasar, and generic brands","contraindications":"Not specified in source","indications":"Indications and Clinical Uses Vinblastine is used in cancer chemotherapy protocols for various tumors. One of the most\\tcommon\\tuses\\tis\\tfor\\tcanine\\tmast\\tcell\\ttumors\\t(MCTs).\\tThere\\tdoes\\tnot\\tappear to be cross- resistance from vincristine to vinblastine. Vinblastine has been used for lymphoreticular neoplasia and for canine transitional cell carcinoma and other tumors. Do not use vinblastine to increase platelet numbers as is done occasionally with vincristine. (Vinblastine may actually cause thrombocytopenia.) The doses and protocols for vinblastine are derived from small clinical studies and observational studies by oncologists. There is a lack of well- controlled studies to examine the effects of vinblastine in animals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most dose- limiting effect is bone marrow suppression, with the nadir of neutropenia occurring at 1 week after administration and recovery occurring at 2 weeks. Gastrointestinal toxicity is the second most important effect, but it is milder. Vinblastine does not produce neuropathy as vincristine does. It causes tissue necrosis if injected outside the vein. 966    Vincristine Sulfate","notes":"Instructions for Use Vinblastine may be used with other anticancer drugs or combined with prednisolone\\tfor\\tMCTs.\\tThe\\tmost\\tcommon\\tdosage\\thas\\tbeen\\t2\\tmg/m 2 every\\t7\u201314 days by slow IV infusion or rapid IV bolus. However, to increase the response rate for\\tMCTs,\\tevidence\\tsuggests\\tthat\\tdose\\tintensity\\tshould\\tbe\\tincreased\\tto\\ta\\tdosage of 3.5 mg/m 2 IV every 2 weeks. This dose produced more toxicity but higher efficacy. Patient Monitoring and Laboratory Tests Monitor complete blood count during treatment. Formulations \u2022\\t\\tVinblastine\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anticancer agent"},{"name":"Vincristine Sulfate","active_ingredient":"Vincristine Sulfate","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tAntitumor:\\t0.5\u20130.75\\tmg/m 2 IV\\t(or\\t0.025\u20130.05\\tmg/kg)\\tonce\\ta\\tweek. \u2022\\t\\tThrombocytopenia:\\t0.02\\tmg/kg\\tIV\\tonce\\ta\\tweek\\t(with\\tprednisolone).  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Withdrawal times are not established for animals that produce food. This drug should not be used in animals intended for food because it is an anticancer agent. Vitamin A Trade and other names: Retinol, Aquasol- A, vitamin AD, and vitamins A and D","contraindications":"Contraindications and Precautions If perivascular injection occurs, immediate flushing of area with fluids is recommended. Drug Interactions No drug interactions have been reported in animals. V chromosome migration during mitosis. Vinca alkaloids block polymerization of the cellular microtubules and therefore arrest mitosis in the metaphase (m- phase specific). Vincristine\\thas\\tan\\taffinity\\tfor\\tthe\\ttubulin\\tof\\tplatelets.\\tFor\\tthrombocytopenia, vincristine increases thrombopoiesis, increases fragmentation of megakaryocytes, and decreases platelet destruction. It may also decrease destruction of platelets by macrophages. Contraindications and Precautions If perivascular injection occurs, immediate flushing of the area with fluids is recommended to decrease tissue injury. When handling vincristine, pharmacy and hospital staff should take appropriate precautions to prevent exposure to people. Dogs with the ABCB1\\tmutation\\t(P-\\tglycoprotein\\tdeficient)\\tmay\\thave\\tan increased risk of toxicity. Drug Interactions There are no significant drug interactions reported in animals.","indications":"Indications and Clinical Uses Vincristine is used in combination chemotherapy protocols. It is included in several anticancer chemotherapy protocols, usually with corticosteroids, alkylating agents, and other drugs. It has been used in veterinary medicine for lymphoreticular tumors, transmissible venereal tumors, mammary neoplasia in cats, and other solid tumors. It is a component of several combination protocols and may also be useful as a single agent for some tumors. Vincristine is also administered to increase platelet counts in patients with immune-mediated\\tthrombocytopenia\\t(ITP).\\tThe\\tprotocol\\tfor\\ttreating\\tITP\\tis\\tlisted\\tlater. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Vincristine is generally well tolerated. It is less myelosuppressive than other anticancer\\tdrugs.\\tPeripheral\\tneuropathy\\thas\\tbeen\\treported,\\tbut\\tit\\tis\\trare. Constipation\\tcan\\toccur.\\tVincristine\\tis\\tirritating\\tto\\ttissues;\\tavoid\\textravasation outside the vein during administration. If accidental injection is made outside the vein, prompt action is needed to avoid severe tissue injury.","notes":"Instructions for Use Vincristine\\tis\\tused\\tin\\tcancer\\tchemotherapy\\tprotocols\\tfor\\tvarious\\ttumors.\\tFor\\texample, in\\tthe\\tCOAP\\tprotocol\\t(an\\tacronym\\tfor\\tcyclophosphamide,\\tOncovin,\\tasparaginase, and prednisolone), the Oncovin component is vincristine. Vincristine also increases numbers of functional circulating platelets and is used for thrombocytopenia. When used to treat immune- mediated thrombocytopenia, it may be administered with a corticosteroid (e.g., prednisone at 2 mg/kg) to produce a rapid increase in functional platelets. This regimen (compared with prednisone alone) has shortened the duration of hospitalization for dogs with immune- mediated thrombocytopenia. Patient Monitoring and Laboratory Tests Monitor platelets during therapy if used to increase platelet numbers. Formulations \u2022\\t\\tVincristine\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tinjection. Stability and Storage Maintain in the injectable vial. Do not mix with other drugs in vial. 968    Vitamin A","original_category":"Anticancer agent"},{"name":"Vitamin A","active_ingredient":"Vitamin A","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t625\u2013800\\tunits/kg\\tq24h\\tPO.  \u2022\\t\\tAll\\tdoses\\tare\\tlisted\\tas\\tper\\tanimal\\tand\\tmay\\tbe\\trepeated\\tin\\t2\u20133\\tmonths. Calves \u2022\\t\\t500,000\u20131\\tmillion\\tunits\\tIM. Sheep and swine \u2022\\t\\t500,000\u20131\\tmillion\\tunits\\tIM. Cattle \u2022\\t\\t1\u20132\\tmillion\\tunits\\tIM. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Vitamin E Trade and other names: Tocopherol, alpha- tocopherol, Aquasol E, and generic brands","contraindications":"Contraindications and Precautions Hypervitaminosis A can occur from high doses of vitamin A administered chronically. Doses needed to cause toxicity can be as high as 10,000 units/ kg/day. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Vitamin A is used as a supplement for animals with deficiency. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Excessive doses can cause bone or joint pain and dermatitis. Other signs of hypervitaminosis A can be excessive bleeding, confusion, diarrhea, and peeling of skin.","notes":"Instructions for Use Dosing\\tof\\tvitamin\\tA\\tmay\\tbe\\texpressed\\tas\\tunits,\\tretinol\\tequivalents\\t(REs),\\tor\\tmcg of\\tretinol.\\tOne\\tRE\\tequals\\t1\\tmcg\\tof\\tretinol.\\tOne\\tRE\\tof\\tvitamin\\tA\\tis\\tequal\\tto\\t3.33 units of retinol. To convert from units of vitamin A to mcg, multiply units by 0.3. To\\tconvert\\tfrom\\tmcg\\tvitamin\\tA\\tto\\tunits,\\tdivide\\tby\\t0.3.\\t(For\\texample,\\t5000\\tunits of vitamin A = 1500 mcg vitamin A.) One unit of vitamin A is equal to 0.6 mcg of beta- carotene. Patient Monitoring and Laboratory Tests Monitor for signs of toxicity if high doses are used. V Vitamin E 969 Formulations \u2022\\t\\tVitamin\\tA\\tis\\tavailable\\tin\\t5000\\tunits\\t(1500\\tRE)\\tper\\t0.1-\\tmL\\toral\\tsolution\\tand\\tin 10,000- , 25,000- , and 50,000- unit tablets. These tablets are listed as 3000, 7500, and\\t15,000\\tREs,\\trespectively.\\tInjectable\\tformulations\\tused\\tin\\tveterinary\\tmedicine usually are included with vitamin D. These combinations contain 100,000, 200,000, or 500,000 units/mL. Stability and Storage Store protected from light at room temperature. Vitamin A, like other fat- soluble vitamins, is insoluble in water but soluble in oils. It is subject to oxidation and should be kept in a tightly sealed container.","original_category":"Vitamin supplement"},{"name":"Vitamin E","active_ingredient":"Vitamin E","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\t100\u2013400\\tunits\\tq12h\\tPO\\t(as\\talpha-\\ttocopherol). \u2022\\t\\tImmune-\\tmediated\\tskin\\tdisease:\\t400\u2013600\\tunits\\tq12h\\tPO. \u2022\\t\\tDiscoid\\tlupus\\terythematosus\\t(dogs):\\t200\u2013400\\tunits\\tq12h\\tPO. \u2022\\t\\tLiver\\tdisease:\\t10\u201315\\tunits/kg/day,\\tPO.  All\\tdoses\\tare\\tlisted\\tas\\tper\\tanimal\\tand\\tmay\\tbe\\trepeated\\tin\\t2\u20133\\tmonths. Calves \u2022\\t\\t1200\u20131800\\tunits\\tIM. V Vitamin K 971 Cattle \u2022\\t\\t2400\u20133000\\tunits\\tIM. Sheep and Swine \u2022\\t\\t1200\u20131800\\tunits\\tIM. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Vitamin K Trade and other names: AquaMEPHYTON (injection), Mephyton (tablets), Veta- K1 (capsules), Veda- K1 (oral and injectable), vitamin K, phylloquinone, and phytomenadione","contraindications":"Contraindications and Precautions Use carefully in animals with coagulopathies. Drug Interactions Vitamin E may interact with anticoagulants. It may exacerbate the anticoagulant effect of warfarin.","indications":"Indications and Clinical Uses Vitamin E is used as supplement and as treatment of some immune- mediated dermatoses and hepatobiliary disorders. Vitamin E has been used as an oral treatment for discoid lupus in dogs; however, efficacy for many skin diseases has been questioned. Vitamin E is often included in a mixture with other dietary supplements (e.g., fish oils). Precautionary Information","side_effects":"Adverse Reactions and Side Effects At high doses, vitamin E can cause coagulopathies. Dosages known to cause coagulopathy\\tare\\t1000\\tunits/day\\t(15\\tunits/kg/day)\\tin\\thumans.\\tCoagulopathies are\\tcaused\\tby\\ta\\tdecrease\\tin\\tvitamin\\tK\u2013dependent\\tcoagulation\\tfactors.","notes":"Instructions for Use Vitamin E has been proposed as treatment for a wide range of human illnesses, but evidence for efficacy in animals is lacking. In animals, it is used as adjunctive antioxidant therapy for a variety of diseases. However, there are no well- controlled studies to document efficacy for these uses. \u2022\\t\\tTo\\tconvert\\tto\\tvitamin\\tE\\tfor\\ta\\tproduct\\tlabeled\\tas\\talpha-tocopherol:\\tmultiply\\tunits by 0.9 to determine mg. To convert from mg to units, divide by 0.9. \u2022\\t\\tTo\\tconvert\\tto\\tvitamin\\tE\\tfor\\ta\\tproduct\\tlabeled\\tas\\t\\talpha-\\t   tocopherol:\\tmultiply\\tunits by 0.67 to determine mg. \u2022\\t\\tTo\\tconvert\\tfrom\\tmg\\tto\\tunits,\\tdivide\\tby\\t0.67.\\tFor\\texample,\\t1\\tunit\\tof\\tvitamin\\tA\\tis equivalent to 0.67 mg  alpha-tocopherol or 0.9 mg  alpha-tocopherol. Patient Monitoring and Laboratory Tests Monitor for bleeding in animals treated with high doses. Formulations \u2022\\t\\tOral:\\tVitamin\\tE\\tis\\tavailable\\tin\\tcapsules,\\ttablets,\\tand\\tan\\toral\\tsolution\\t(e.g.,\\t1000 units/capsule). Injectable formulations for veterinary medicine may also contain vitamins A and D or selenium. \u2022\\t\\tInjection:\\tUsually\\tinjectable\\tcombinations\\tcontain\\t300\\tunits/mL. \u2022\\t \\tSolutions:\\tVitamin\\tE\\tis\\tfound\\tin\\tsolutions\\tas\\t\\talpha-\\t   tocopherol\\t(natural\\tsource of vitamin E). It is also often a component of omega fatty acid (fish oils) formulations. Stability and Storage Vitamin E, like other fat- soluble vitamins, is insoluble in water but soluble in oils. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vitamin"},{"name":"Vitamin K","active_ingredient":"Vitamin K","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tShort-\\t   acting\\trodenticides:\\t1\\tmg/kg/day\\tIM,\\tSQ,\\tor\\tPO\\tfor\\t10\u201314\\tdays. \u2022\\t\\tLong-\\t   acting\\trodenticides:\\t2.5\u20135\\tmg/kg/day\\tIM,\\tSQ,\\tor\\tPO\\tfor\\t3\u20134\\tweeks\\tand\\tup to 6 weeks. Birds \u2022\\t\\t2.5\u20135\\tmg/kg\\tq24h\\tSQ,\\tIM,\\tor\\tPO\\tfor\\t14\u201328\\tdays.  Cattle, Calves, Horses, Sheep, and Goats \u2022\\t\\t0.5\u20132.5\\tmg/kg\\tSQ\\tor\\tIM. Regulatory Information No meat or milk withdrawal time is necessary. Voriconazole vor- ih- kahn\u2032ah- zole Trade and other names: Vfend","contraindications":"Contraindications and Precautions Accurate diagnosis to rule out other causes of bleeding is suggested. Other forms of vitamin K may not be as rapidly acting as vitamin K 1 ; therefore consider using a specific preparation for the best outcome. To avoid anaphylactic reactions, do not administer intravenously. Drug Interactions Some\\tdrugs,\\tsuch\\tas\\tcephalosporins,\\tmay\\tdecrease\\tvitamin\\tK\u2013dependent\\tclotting factors. 972    Voriconazole","indications":"Indications and Clinical Uses 1 is a fat- soluble vitamin used to treat coagulopathies caused by anticoagulant toxicosis (warfarin or other rodenticides). Anticoagulants deplete vitamin K in the body, which is essential for synthesis of clotting factors. In large animals, it is used to treat sweet clover poisoning. Precautionary Information","side_effects":"Adverse Reactions and Side Effects In people, a rare hypersensitivity- like reaction has been observed after rapid IV injection. This reaction may be caused by histamine release from the drug vehicle, polysorbate 80. Signs resemble anaphylactic shock. These signs also have been observed in animals with IV administration. To avoid anaphylactic reactions, do not\\tadminister\\tintravenously.\\tReactions\\tfrom\\tIM\\tinjection,\\tsuch\\tas\\thematoma, may occur in animals with coagulopathies.","notes":"Instructions for Use Consult\\ta\\tpoison\\tcontrol\\tcenter\\tfor\\tspecific\\tprotocol\\tif\\tspecific\\trodenticide\\tis identified. Use vitamin K 1 for acute therapy because it is more highly bioavailable. Administer\\twith\\tfood\\tto\\tenhance\\tabsorption.\\tFoods\\twith\\tfat\\tare\\tbetter\\tbecause\\tthis\\tis a\\tfat-\\t  soluble\\tvitamin.\\tPhytonadione\\tand\\tphytomenadione\\tare\\tsynthetic\\tlipid-\\tsoluble forms of vitamin K 1 . Menadiol is vitamin K 4 , which is a water- soluble derivative converted in the body to vitamin K 3 (menadione). The injection can be diluted in 5% dextrose or 0.9% saline but not other solutions. Although vitamin K 1 veterinary labels have listed the IV route for administration, these\\tlabels\\thave\\tnot\\tbeen\\tapproved\\tby\\tthe\\tFDA.\\tTherefore\\tavoid\\tIV\\tadministration of vitamin K 1 . The preferred route is SQ, but IM also can be used. When treating for poisoning by second- generation rodenticides, which have long half- lives, 6 weeks of therapy may be necessary. Patient Monitoring and Laboratory Tests Monitoring bleeding times in patients is essential for accurate dosing of vitamin K 1 preparations. When treating long- acting rodenticide poisoning, periodic monitoring of the bleeding times is suggested. Formulations \u2022\\t\\tVitamin\\tK\\tis\\tavailable\\tin\\t2-\\t\\tor\\t10-\\tmg/mL\\tinjection.\\tMephyton\\tis\\ta\\t5-\\tmg\\ttablet. Veta-\\t  K1\\tis\\ta\\t25-\\tmg\\tcapsule.\\tPhytonadione\\t(aqueous\\tcolloidal\\tformulation)\\tis\\ta\\t2- or 10- mg/mL injection. Stability and Storage Vitamin K, like other fat- soluble vitamins, is insoluble in water but soluble in oils. Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Vitamin supplement"},{"name":"Warfarin Sodium","active_ingredient":"Warfarin Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tq24h\\tPO.\\tStart\\twith\\tthis\\tdose\\tq12h\\tfor\\tthe\\tfirst\\t2\u20134\\tdays\\tbecause of a lag time before maximum effect is observed. Cats \u2022\\t\\tStart\\twith\\t0.25\u20130.5\\tmg/cat/day\\t(\xbc\\tto\\t\xbd\\tof\\ta\\t1-\\tmg\\ttablet)\\tand\\tadjust\\tthe\\tdose based on bleeding time assessment. A dosage of 0.1 mg/kg per day generally prolongs the PT by 1.5\u20132 times.  Horses \u2022\\t\\t0.02\\tmg/kg\\tq24h\\tPO\\t(9\\tmg\\tper\\t450\\tkg\\tof\\tbody\\tweight\\t[1000\\tlb]).\\tIncrease this dosage gradually by increments of 20% until a 2-  to 4- second increase in PT bleeding\\ttime\\tis\\tachieved.\\tAllow\\t7\\tdays\\tbetween\\tchanges\\tin\\tdose. Regulatory Information Do not administer to animals intended for food. Racing Commissioners International Classification: 5 978    Xylazine Hydrochloride Xylazine Hydrochloride zye\u2032lah- zeen  hye- droe- klor\u2032ide Trade and other names: Rompun and generic brands","contraindications":"Contraindications and Precautions Do not administer to animals that may be prone to bleeding. Administer carefully with other drugs that are known to interfere with coagulation or with antiplatelet medications (e.g., aspirin or clopidogrel). Drug Interactions Multiple drugs and some foods may affect warfarin\u2019s action. Some of these that may potentiate warfarin\u2019s action include aspirin, chloramphenicol, phenylbutazone, ketoconazole, and cimetidine. Drug interactions are possible with administration with other highly protein- bound drugs, but such reactions are poorly documented in animals. Drug interactions are also possible with trimethoprim sulfonamides and metronidazole. Do not administer with some cephalosporin drugs (particularly those with N- methylthiotetrazole [NMTT]) because cephalosporins may induce bleeding through anti\u2013vitamin K\u2013dependent mechanisms.","indications":"Indications and Clinical Uses In small animals, it has been used to treat hypercoagulation disease and prevent thromboembolism. In horses, warfarin has been used to treat navicular disease, although it is no longer popular for this use. The use of warfarin has diminished in small animals because it requires monitoring to optimize the dose and because no clinical trials have shown efficacy for hypercoagulation states in animals. Instead, other anticoagulants and platelet- inhibiting drugs are used. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are attributable to decreased blood clotting. Spontaneous bleeding can result in blood loss, hemoperitoneum, hemarthrosis, gastrointestinal bleeding, epistaxis, and excessive bleeding from trauma or surgery. If excessive bleeding occurs, patients should be treated with vitamin K.","notes":"Instructions for Use Warfarin response can be highly variable among animals. Pharmacokinetic studies have attempted to correlate plasma pharmacokinetics with clinical response (prothrombin time [PT]). However, such a correlation has been difficult to W W demonstrate. A particular dose and plasma concentration that produces an effective prolongation of PT in one patient may not be effective in another individual. Because of the variation in response, adjust doses by monitoring bleeding times in treated animals. For a rapid effect, consider a loading dose of 6 mg per dog once daily for two treatments. Initial doses in cats have ranged from 0.06\u20130.09 mg/kg (0.25\u20130.5 mg/cat/day). When dividing tablets for treatment, it is best to crush up a whole tablet into a powder and divide the doses equally from the powder. When tablets are cut into halves or quarters, there may be uneven distribution of warfarin within the tablet. Some fractions of the tablet may contain a higher amount than others. Patient Monitoring and Laboratory Tests Adjust the dose by monitoring clotting times because the optimum dose is highly individualistic. The best method to monitor warfarin therapy is with the one- stage PT. PTs are reported in seconds and recorded as a ratio of the PT of the patient to the mean normal PT of the laboratory and as the international normalized ratio (INR). The INR is the most reliable way to monitor the PT, but it may not be available in all laboratories. In animals, the dose is adjusted to maintain PT at 1.5\u20132 times normal (or an INR of 2\u20133). Formulations \u2022\\t\\tWarfarin\\tsodium\\tis\\tavailable\\tin\\t1-\\t,\\t2-\\t ,\\t2.5-\\t  ,\\t4-\\t ,\\t5-\\t ,\\t7.5-\\t  ,\\tand\\t10-\\tmg\\ttablets. Stability and Storage Warfarin sodium is soluble in water. It is light sensitive and should be packaged in tight containers. Solutions should have a pH greater than 8 to maintain solubility. Some tablets do not have the drug distributed evenly; therefore uneven doses can result from splitting tablets.","original_category":"Anticoagulant"},{"name":"Xylazine Hydrochloride","active_ingredient":"Xylazine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t1.1\\tmg/kg\\tIV. \u2022\\t\\t2.2\\tmg/kg\\tIM. \u2022\\t\\tShort-\\t   term\\ttreatment\\tof\\tpain:\\t0.1\u20130.5\\tmg/kg\\tIM,\\tIV,\\tor\\tSQ. Cats \u2022\\t\\t1.1\\tmg/kg\\tIM. \u2022\\t\\tEmetic\\tdosage:\\t0.4\u20130.5\\tmg/kg\\tIM\\tor\\tIV. \u2022\\t\\tShort-\\t   term\\ttreatment\\tof\\tpain:\\t0.1\u20130.5\\tmg/kg\\tIM,\\tIV,\\tor\\tSQ.  Horses \u2022\\t\\t1\u20132\\tmg/kg\\tIM. \u2022\\t\\tStanding\\tchemical\\trestraint:\\t0.5\u20131.0\\tmg/kg\\tIV\\tbolus.\\t(The\\tIV\\tdose\\talso\\tcan\\tbe administered intraosseously with equal bioavailability.)","contraindications":"Contraindications and Precautions Ruminants are much more sensitive to xylazine than other species, and lower doses must be used compared with other animals. Use cautiously in animals that are pregnant. Xylazine impairs blood flow to the uterus during gestation in cows and may decrease oxygen delivery to the fetus, especially in late gestation. Use caution when using xylazine to sedate pregnant cows. It also may induce labor. Use cautiously, if at all, in patients with cardiac disease. Because of cardiac depression, it should not ordinarily be used with tranquilizers such as phenothiazines that can produce vasodilation. Drug Interactions Use with opioid analgesic drugs greatly enhances the central nervous system depression. Consider lowering doses if administered with opioids. Do not administer with other drugs that cause significant cardiac depression. \u2022\\t\\t0.5\u20131.1\\tmg/kg\\tIV\\tfollowed\\tby\\t(if\\tnecessary)\\ta\\t0.72\u20131\\tmg/kg/h\\tCRI. \u2022\\t\\tFor\\tcolic\\tpain:\\t0.3\u20130.5\\tmg/kg\\tIV\\t(150\u2013250\\tmg\\tIV\\tfor\\tan\\taverage-\\tsize\\thorse). \u2022\\t\\tFor\\tanesthesia\\tpurposes,\\tit\\tis\\tsometimes\\tcombined\\twith\\tother\\tagents\\tsuch as ketamine and guaifenesin in the equine \u201ctriple- drip\u201d combination. This combination\\tconsists\\tof\\t 500\\t  mg\\t  of\\t xylazine\\tand\\t  2\\t g\\t of\\t ketamine\\tadded\\t   to\\t 1\\t L\\t of\\t 5% of guaifenesin in dextrose. It is administered at a rate of 1.1 mL/kg for induction followed\\tby\\t2\u20134\\tmL/kg/h\\tfor\\tmaintenance.\\tRecovery\\tusually\\toccurs\\tin\\t25\u201330 minutes\\tor\\tadminister\\t0.125\\tmg/kg\\tyohimbine\\tto\\tspeed\\tup\\trecovery. Pigs \u2022\\t \\t0.5\u20133\\tmg/kg\\tIM.\\tXylazine\\tin\\tpigs\\tis\\tbest\\tused\\tin\\tcombination\\twith\\tother\\tdrugs (e.g., 2 mg/kg xylazine mixed in a syringe with 10 mg/kg of ketamine). It is unreliable used alone. Cattle \u2022\\t\\t0.1\u20130.2\\tmg/kg\\tIM. \u2022\\t\\t0.03\u20130.1\\tmg/kg\\tIV. Sheep \u2022\\t\\t0.1\u20130.3\\tmg/kg\\tIM. \u2022\\t\\t0.05\u20130.1\\tmg/kg\\tIV. Goats \u2022\\t\\t0.05\u20130.5\\tmg/kg\\tIM. \u2022\\t\\t0.01\u20130.5\\tmg/kg\\tIV. Regulatory Information Withdrawal\\ttime\\tfor\\tcattle:\\tAt\\ta\\tdosage\\tof\\t0.016\u20130.1\\tmg/kg,\\t5\\tdays\\tfor\\tmeat\\tand\\t72 hours\\tfor\\tmilk.\\tAt\\ta\\tdosage\\tof\\t0.05\u20130.3\\tmg/kg,\\t10\\tdays\\tfor\\tmeat\\tand\\t120\\thours\\tfor milk. Whereas in Canada, it is listed as 3 days for meat and 48 hours for milk, in the United Kingdom, it is listed as 14 days for meat and 48 hours for milk. If yohimbine is\\tused\\tas\\ta\\treversal\\tagent,\\tuse\\ta\\twithdrawal\\ttime\\tof\\t7\\tdays\\tfor\\tmeat\\tand\\t72\\thours\\tfor milk. Racing Commissioners International Classification: 3 Y Yohimbine 981 Yohimbine yoe- him\u2032been Trade and other names: Yobine","indications":"Indications and Clinical Uses Xylazine has been used for many years for short- term sedation, anesthesia, and analgesia in horses, dogs, cats, cattle, and exotic animals. Like other alpha 2 agonists, it is used as an anesthetic adjunct and analgesic. The duration of effect is approximately 30 minutes after a bolus injection, but it also may be administered by a CRI for up to 6 hours. Compared with xylazine, dexmedetomidine and medetomidine produce better sedation and analgesia in dogs. Xylazine is used more commonly in large animals for sedation and analgesia than in small animals. Usually, dexmedetomidine is preferred in dogs and cats. Romifidine produces the longest duration of sedative effects followed by detomidine, medetomidine (dexmedetomidine), and xylazine. X Precautionary Information","side_effects":"Adverse Reactions and Side Effects In small animals, vomiting is the most common acute effect, which is more prominent in cats than dogs. Xylazine produces sedation and ataxia, which is expected from all alpha 2 agonists. Xylazine, like other alpha 2 agonists, decreases sympathetic output. Cardiovascular depression may occur. Xylazine produces an initial hypertensive phase, followed by a hypotensive phase. Cardiac effects can include sinoatrial block, first-  and second- degree atrioventricular block, bradycardia, and sinus arrhythmia. Like other alpha 2 agonists, xylazine produces transient hyperglycemia, which may increase urine flow. In ruminants, use of xylazine may decrease gastrointestinal motility and cause bloating, salivation, and regurgitation. Note that cattle, sheep, and goats are much more sensitive to xylazine than other animals; therefore doses need to be lower than those in other animals. Among horses, draft horses are more sensitive to the effects than thoroughbred and Arab horses. X","notes":"Instructions for Use Xylazine is often used in combination with other drugs (e.g., ketamine, opioids, or butorphanol). It is combined with guaifenesin and ketamine in the equine \u201ctriple drip\u201d combination (see dosing section, below). Although low heart rates are anticipated with xylazine, it is not necessary to premedicate animals with atropine. For large animals, if sedation is needed without recumbency, use the lower end of the dose range. Reverse effects of xylazine with an alpha 2 antagonist (e.g., yohimbine, tolazoline, or atipamezole) if adverse effects are serious enough to warrant reversal. Xylazine also may be administered intraosseously to horses when it is not possible to give an IV injection. It is equally bioavailable from the intraosseous route as IV. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during anesthesia with xylazine. It may cause increased plasma glucose concentrations in animals. Formulations Available \u2022\\t\\tXylazine\\tis\\tavailable\\tin\\t20-\\t\\tand\\t100-\\tmg/mL\\tinjections. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Alpha"},{"name":"Yohimbine","active_ingredient":"Yohimbine","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t0.11\\tmg/kg\\tIV. \u2022\\t\\t0.25\u20130.5\\tmg/kg\\tSQ\\tor\\tIM.  Horses \u2022\\t\\t0.125\\tmg/kg\\tIV\\t(to\\treverse\\txylazine). \u2022\\t\\t0.2\\tmg/kg\\tIV\\t(to\\treverse\\tdetomidine). \u2022\\t\\tNote\\tabout\\treversal:\\tIt\\tmay\\tnot\\tbe\\tnecessary\\tto\\tgive\\tthe\\tfull\\tdose\\tinitially.\\tSee","contraindications":"Contraindications and Precautions When yohimbine is administered to reverse an alpha 2 agonist, monitor heart rate and rhythm carefully during treatment. There is no therapeutic justification to administer an alpha 2 antagonist such as yohimbine as a single agent to treat horses for any diseases. Drug Interactions Detomidine increases the plasma concentration and decreases clearance of yohimbine. No other interactions are reported, except the antagonism of alpha 2 agonists.","indications":"Indications and Clinical Uses Yohimbine is used primarily to reverse actions of xylazine or detomidine. Atipamezole is another alpha 2 antagonist that is more specific for the alpha 2 receptor and is preferred to use in small animals to reverse dexmedetomidine or medetomidine. Tolazoline has also been used to reverse effects of xylazine in horses. Y Precautionary Information","side_effects":"Adverse Reactions and Side Effects Yohimbine can produce a variety of responses in horses. Some horses show excitation rearing, striking, muscle tremors, and exaggerated response to stimuli. Yohimbine may cause more transient excitement than either atipamezole or tolazoline. It can produce cardiovascular events in horses such as increased heart rate. High doses can cause tremors and seizures. If used alone (not recommended), it can produce a variety of undesirable events.","notes":"Instructions for Use Yohimbine is used to reverse the signs of sedation and anesthesia caused by alpha 2 agonists. The drug concentrations of the alpha 2 agonist (e.g., xylazine, detomidine) may be diminished considerably by the time reversal becomes necessary in clinical practice; therefore, it may not be necessary to provide a full dose of yohimbine (or other alpha 2 antagonist) because a full dose may induce excitement and other undesirable events. Instead, one third of the recommended dose of yohimbine can be administered first followed by (if necessary) the same amount in 5-  to 10- minute increments. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during use of yohimbine. Formulations \u2022\\t\\tYohimbine\\tis\\tavailable\\tin\\ta\\t2-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Instructions for Use for more details. Cattle and Sheep \u2022\\t\\tTo\\treverse\\txylazine\\tor\\tmedetomidine:\\t0.125\u20130.2\\tmg/kg\\tIV. Regulatory Information Food\\tanimal\\twithdrawal\\ttime:\\tAt\\tleast\\t7\\tdays\\tfor\\tmeat\\tand\\t72\\thours\\tfor\\tmilk. Racing\\tCommissioners\\tInternational\\tClassification:\\t2 Z Zidovudine 983 Zidovudine zye- doe\u2032vyoo- deen Trade and other names: Retrovir and azidothymidine (AZT)","original_category":"Alpha"},{"name":"Zilpaterol Hydrochloride","active_ingredient":"Zilpaterol Hydrochloride","species":["Equine","Feline","Bovine"],"dosage":"\u2022\\t\\tNo\\tsmall\\tanimal\\tdose\\tis\\testablished.\\tNo\\testablished\\tuses\\tfor\\tsmall\\tanimals.  \u2022\\t\\tDo\\tnot\\tadminister\\tto\\thorses. \u2022\\t\\tCattle\\tdose:\\t6.8\\tg/ton\\tof\\tfeed\\tto\\tprovide\\t60\u201390\\tmg\\tof\\tzilpaterol\\thydrochloride\\tper head per day. Regulatory Information Cattle withdrawal time for slaughter: 3 days. Racing Commissioners International (RCI) Classification for horses: Class 3 Zinc Trade and other names: Zinc","contraindications":"Contraindications and Precautions Severe adverse effects such as tachycardia, tremors, and muscle fasciculations have been observed in horses. Zilpaterol should not be administered to horses, and precautions should be taken to ensure that horses are not accidentally exposed to zilpaterol- treated cattle feed. Because beta- adrenergic agonists such as clenbuterol are abused in humans for the purpose of promoting muscle gain and fat loss, there is a possibility that zilpaterol also could be abused in the same manner. Labeling should include the following information: (1) Do not allow horses or other equines access to feed containing zilpaterol. (2) Not for use in animals intended for breeding. (3) Do not use in veal calves. Drug Interactions Use caution when administering to animals receiving other adrenergic medications. Z Zinc 985","indications":"Indications and Clinical Uses Zilpaterol is fed to cattle (type A medicated feed) to improve weight gain and muscle mass. It has been approved in the United States and other countries for this use. It is not approved for other uses and should not be administered to horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other beta- adrenergic agonists, zilpaterol can produce cardiovascular problems associated with increased stimulation of receptors at high doses.","notes":"Instructions for Use Zilpaterol is used to increase rate of weight gain, improve feed efficiency, and increase carcass leanness in cattle fed in confinement for slaughter during the last 20\u201340 days on feed. It should be fed continuously as the sole ration during the last 20\u201340 days on feed. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tType\\tA\\tmedicated\\tarticles\\tcontaining\\t21.77\\tg\\tof\\tzilpaterol\\thydrochloride\\tper pound. There are several other feed additive formulations available that contain other ingredients, such as monensin, tylosin, and/or melengestrol acetate. Consult specific labeling for more details. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Beta- adrenergic agonist"},{"name":"Zinc","active_ingredient":"Zinc","species":["Canine","Feline"],"dosage":"Dogs and Cats Adjust\\tdose\\tbased\\ton\\tmeasuring\\tplasma\\tzinc\\tconcentrations. \u2022\\t\\tHepatic\\tdisease\\tin\\tdogs:\\t100\\tmg\\tof\\telemental\\tzinc\\tper\\tdog\\tq12h\\tPO,\\tequivalent to 3 mg/kg per day of zinc gluconate, or 2 mg/kg of zinc sulfate per day PO. (Consider including vitamin E with treatment.) \u2022\\t\\tZinc\\tsupplement:\\t1\\tmg/kg\\tof\\telemental\\tzinc\\tgluconate\\tor\\tsulfate\\tthree\\ttimes/day PO or 1.5\u20133 mg (of elemental zinc) of zinc acetate daily per animal PO. \u2022\\t\\tDermatologic\\tuse:\\t10\\tmg/kg\\tper\\tday\\t(zinc sulfate or zinc gluconate). \u2022\\t\\tIV\\tzinc\\ttreatment:\\t50\\tmcg\\tof\\telemental\\tzinc/kg\\tinfused\\tIV\\tslowly\\tper\\tday. Z Zoledronate 987  \u2022\\t\\tNo\\tspecific\\tdoses\\thave\\tbeen\\treported.\\tIf\\tzinc\\tsupplementation\\tis\\tneeded,\\textrapolate the dose from small animal use (approximately 1 mg/kg of elemental zinc three times per\\tday\\tPO)\\tand\\tadjust\\tthe\\tdose\\tby\\tmonitoring\\tzinc\\tconcentrations. Regulatory Information Because of a low risk of harmful residues in animals intended for food, no withdrawal time is suggested. Zoledronate zoe\u2032le- droe- nate Trade and other names: Zometa, Zoledronic acid, and Reclast","contraindications":"Contraindications and Precautions If IV forms are used (e.g., zinc sulfate), adverse effects may be more likely because it produces higher concentrations. The oral absorption is lower and more limited. Drug Interactions Oral absorption is impaired from tetracyclines, iron, copper, phytates (found in bran and grains), and penicillamine.","indications":"Indications and Clinical Uses Zinc supplementation has been used to treat zinc- deficient diseases such as those that cause dermatologic problems. It is also used as an antifibrotic agent in liver disease. Zinc administration also may be used as a chelating agent in animals. Most commonly, zinc has been used as a cupruretic to decrease copper concentrations in animals with liver disease, often in combination with other drugs (e.g., penicillamine or trientine). When used to treat copper liver disease, it is slow acting and may take as long as 3 months for the full effect. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common effect is gastrointestinal (GI) problems, including nausea and vomiting. Hemolysis and anemia can be observed with high doses.","notes":"Instructions for Use Administer without food to improve oral absorption, but a small meal often prevents some of the nausea associated with treatment. When considering various forms, the gluconate form may be better tolerated than the sulfate or acetate form. Patient Monitoring and Laboratory Tests Monitor blood zinc concentrations at least monthly to prevent high levels, which cause hemolysis. Blood zinc concentrations should ideally be 200\u2013500 mcg/dL. A concentration\\tabove\\t800\\tmcg/dL\\tis\\tconsidered\\ttoxic,\\tbut\\tlevels\\tabove\\t200\\tmcg/dL are needed to treat copper liver disease. Formulations \u2022\\t\\tZinc\\tis\\tavailable\\tin\\tseveral\\tforms,\\tincluding\\tzinc\\tsulfate\\t(23%\\tzinc),\\tzinc\\tgluconate (14%\\tzinc),\\tand\\tzinc\\tacetate\\t(35%\\tzinc). \u2022\\t\\tZinc\\tgluconate\\tis\\tavailable\\tin\\ttablets\\tranging\\tfrom\\t1.4\\tto\\t52\\tmg\\t(10\\tmg\\tzinc gluconate = 1.4 mg of elemental zinc). \u2022\\t\\tZinc\\tsulfate\\tis\\tavailable\\tin\\tcapsules\\tcontaining\\t25\\tand\\t50\\tmg\\tof\\telemental\\tzinc\\t(110 mg of zinc sulfate = 25 mg of elemental zinc). Zinc sulfate is also available in tablets containing\\t15,\\t25,\\t45,\\tand\\t50\\tmg\\tof\\telemental\\tzinc\\t(66\\tmg\\tof\\tzinc\\tsulfate\\t=\\t15\\tmg of elemental zinc). \u2022\\t\\tInjectable\\tzinc\\tsulfate\\tis\\tavailable\\tin\\ta\\t50-\\tmg/mL\\t(20.2\\tmg\\tof\\telemental\\tzinc\\tper milliliter) solution for IV use. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Nutritional supplement"},{"name":"Zoledronate","active_ingredient":"Zoledronate","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.2\u20130.25\\tmg/kg\\tIV\\tinfused\\tover\\t15\\tminutes,\\tdiluted\\tin\\t100\\tmL\\tof\\t0.9%\\tsaline (large\\tdogs)\\tor\\t50\\tmL\\tof\\t0.9%\\tsaline\\t(small\\tdogs).\\tThis\\tdose\\tcan\\tbe\\tadministered once\\tevery\\t28\\tdays. \u2022\\t\\tFor\\tosteoporosis:\\t5\\tmg\\t(per\\tdog)\\tevery\\t1\u20132\\tyears\\tIV. \u2022\\t\\tHypercalcemia\\tassociated\\twith\\tcancer:\\t4\\tmg\\t(per\\tdog)\\tinfusion\\tevery\\t7\\tdays. \u2022\\t\\tMultiple\\tmyeloma:\\t4\\tmg\\t(per\\tdog)\\tinfusion\\tevery\\t3\u20134\\tweeks. Cats \u2022\\t\\t0.2\\tmg/kg\\tIV\\tover\\t15\\tminutes\\tdiluted\\tin\\ta\\tvolume\\tof\\t25\\tmL\\tevery\\t21\u201328\\tdays. \u2022\\t\\tIdiopathic\\thypercalcemia:\\t1\u20133\\tmg/kg\\tper\\tweek. Z Zolpidem 989  Horses (Not recommended) \u2022\\t\\t0.075\\tmg/kg.\\tDissolve\\teach\\tdose\\tin\\t50\\tmL\\tof\\t11.3\\tmg/mL\\tcitrate\\tsolution;\\tthen mix with 500 mL (400 mL of saline and 100 mL of mannitol). Administer via IV infusion to horses over 15\u201330 minutes. Other bisphosphonates preferred for horses include tiludronate and clodronate. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at FARAD at www.FARAD.org. Zolpidem zolepi\u2032dem Trade and other names: Ambien, Edluar, Intermezzo, and Zolpimist","contraindications":"Contraindications and Precautions Do not administer during pregnancy. There are also concerns about using bisphosphonates in young animals when rapid development of bone is needed. Do not administer zoledronate to young horses. Drug Interactions Do not mix with calcium or other divalent cation- containing infusion solutions, such as lactated Ringer\u2019s solution. It should be administered as a single IV solution in a line separate from other drugs.","indications":"Indications and Clinical Uses Zoledronate, like other bisphosphonate drugs, is used to treat refractory hypercalcemia, osteoporosis, and treatment of hypercalcemia of malignancy. In animals, bisphosphonates are helpful for managing neoplastic complications and pain associated with pathologic bone resorption. They also may provide pain relief in patients with pathologic bone disease. Other uses include osteoporosis and skeletal metastasis. It has been used in similar protocols as for pamidronate but has the advantage of a 15- minute infusion IV rather than 2\u20134 hours for pamidronate. In horses, it has been administered via IV infusion for bone pain and conditions associated with bone fragility. However, other approved bisphosphonates are preferred in horses because of equine- specific labeling and experience. The agents approved for horses for treatment of navicular disease and other bone disorders include tiludronate and clodronate. See sections in this book for more information on these drugs for horses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Zoledronate\\tmay\\tbe\\tsafer\\tthan\\tpamidronate.\\tFever,\\tjoint\\tpain,\\tand\\tmyalgias\\thave been observed in people, but otherwise no serious adverse effects have been identified. The use in animals has not been common enough to identify a wider range of adverse effects. In people, there is some concern that the use of bisphosphonates produces excessive mineralization and hardening of the bone, which may result in a greater risk of fractures. However, this effect has not been reported for animals.","notes":"Instructions for Use Zoledronate\\tis\\tintended\\tfor\\tIV\\tinfusion.\\tDilute\\tthe\\tvial\\tin\\t0.9%\\tsaline\\tor\\t5%\\tdextrose solution for IV use. If not used immediately after dilution, the solution should be refrigerated, and the refrigerated solution then should be equilibrated to room temperature prior to administration. The total time between dilution, storage in the refrigerator, and end of administration must not exceed 24 hours. If administered to horses, which is not recommended, monitor creatinine, blood urea nitrogen (BUN), and calcium prior to administration to ensure that it is safe for the patient. However, as noted earlier, other agents are preferred for horses. Calcium supplementation in the diet is recommended. Patient Monitoring and Laboratory Tests Monitor serum calcium and phosphorus. Monitor BUN, creatinine, urine- specific gravity, and food intake in treated animals. Formulations \u2022\\t\\tZoledronate\\t(zoledronic\\tacid)\\tis\\tavailable\\tin\\ta\\t4-\\tmg/5\\tmL\\tvial\\tfor\\tinfusion\\tand 5-   mg/100 mL IV solution. Stability and Storage Store in a vial at room temperature. Vials may be diluted in fluid solutions. Storage and stability information is listed in the Instructions for Use section.","original_category":"Antihypercalcemic"}]},{"category":"Sedatives & Anesthetics","drugs":[{"name":"Acepromazine Maleate","active_ingredient":"Acepromazine Maleate","species":["Canine","Feline","Equine","Bovine"],"dosage":"Dogs \u2022\\t\\t0.025\u20130.1\\tmg/kg\\tIM,\\tIV,\\tor\\tSQ\\tin\\ta\\tsingle\\tdose\\t(most\\tcommon\\tis\\t0.025\\tmg/kg). Do not exceed 3 mg total in dogs. \u2022\\t\\tSedation:\\t0.5\u20132.2\\tmg/kg\\tq6\u20138h\\tPO. \u2022\\t\\tAnesthetic\\tprotocols:\\t0.01\u20130.05\\tmg/kg\\tIV,\\tadministered\\twith\\tother\\tagents. Cats \u2022\\t\\t0.025\u20130.1\\tmg/kg\\tIM,\\tIV,\\tor\\tSQ\\tin\\ta\\tsingle\\tdose. \u2022\\t\\tSedation:\\t1.1\u20132.2\\tmg/kg\\tq6\u20138h\\tPO. \u2022\\t\\tAnesthetic\\tprotocols:\\t0.01\u20130.05\\tmg/kg\\tIV,\\tadministered\\twith\\tother\\tagents.  Horses \u2022\\t\\t0.04\u20130.1\\tmg/kg\\tIM.\\tIt\\tcan\\tbe\\tadministered\\tq6\u201312h,\\tbut\\tsuch\\tfrequent\\tdosing\\tis not\\trecommended,\\tand\\tan\\tinterval\\tof\\t36\u201348\\thours\\tbetween\\tdoses\\tis\\tpreferred.\\tFor perioperative\\tuse,\\t0.01\u20130.05\\tmg/kg,\\tIM,\\tSQ,\\tor\\tIV. \u2022\\t\\tTreatment\\tof\\tlaminitis:\\t0.04\\tmg/kg,\\tIV. Cattle \u2022\\t\\t0.13\u20130.26\\tmg/kg\\tPO,\\t0.03\u20130.1\\tmg/kg\\tIM,\\tor\\t0.01\u20130.02\\tmg/kg\\tIV. Pigs \u2022\\t\\tAdult:\\t0.03\u20130.2\\tmg/kg\\tIV,\\tIM,\\tSQ\\t(single\\tdose). Regulatory Information Withdrawal\\ttimes:\\tThere\\tare\\tno\\twithdrawal\\ttimes\\testablished\\tin\\tthe\\tUnited\\tStates. It has been estimated that for extralabel use, establish a withdrawal time of at least 7 days\\tfor\\tmeat\\tand\\t48\\thours\\tfor\\tmilk. Canada:\\t7\\tdays\\tfor\\tmeat;\\t48\\thours\\tfor\\tmilk. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t3 Acetaminophen ah- seet- ah- mee \u0301noe- fen Trade and other names: Tylenol and generic brands. Known outside the United States as paracetamol.","contraindications":"Contraindications and Precautions It has been stated in some veterinary textbooks that acepromazine may increase the risk of seizures in animals, and it should be administered cautiously in animals that are prone to seizures. However, a risk of seizures in animals from administration of acepromazine has not been confirmed during clinical use. Seizures were not reported in retrospective studies in which animals prone to seizures were anesthetized and administered acepromazine as an anesthetic adjunct. Do not use in animals that have problems with dystonia or that have had previous extrapyramidal effects from use of phenothiazines. Dogs with a mutation in the ABCB1 gene (previously listed as MDR1), which is the gene that codes for the p- glycoprotein membrane transporter, are likely to have prolonged and increased sedation after administration of acepromazine. In these dogs, the dose should be decreased or another sedative selected for use. Phenothiazines can cause hypotension (via alpha- receptor blockade); therefore, use cautiously with other hypotensive drugs or in conditions that may exacerbate hypotension. When administered as a pre- anesthetic to dogs (0.05 mg/kg), it induces moderate hypotension but does not affect cardiac output significantly. In pregnancy, it produces only minor reduction in blood flow and oxygen delivery to the fetus when used in late pregnancy in cows. Drug Interactions Specific drug interactions have not been reported from the use of acepromazine in animals. However, it exacerbates the effects of other sedative drugs and may potentiate other drugs that cause vasodilation. Acepromazine has been used to sedate dogs for glucose tolerance testing (0.1 mg/kg), without adversely affecting the results. A Acetaminophen 3","indications":"Indications and Clinical Uses Acepromazine is used as a sedative, a tranquilizer, a pre- anesthetic, and an anesthetic adjunct. When used as an anesthetic pre- anesthetic, it induces muscle relaxation and lowers doses of anesthetic agents used concurrently. In pre- anesthetic protocols, it also may have some anti- arrhythmic effects. In small animals, duration of sedation can occur within 10 minutes and have a 4-  to 6- hour duration. In small animals, acepromazine can produce antiemetic effects via dopaminergic blockade. Acepromazine produces arterial smooth muscle relaxation by inhibiting alpha 1 receptor\u2013mediated constriction. This effect is used to increase blood flow to tissues, particularly in the metatarsal artery of horses, and produces increased blood flow to the palmar digital artery. This is used for the treatment of horses with laminitis. Acepromazine has been used as a behavior- modifying agent in animals (e.g., to treat anxiety). However, there are other agents that are preferred for long- term management of behavior disorders in animals that have fewer adverse effects. It should not be used as a first choice to decrease stress in hospitalized animals because there are other preferred agents available. Acepromazine does not provide analgesic activity. A Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation and ataxia are common side effects. Extrapyramidal effects (involuntary muscle movements), twitching, dystonia, or Parkinson- like effects are rare but are possible with the administration of phenothiazines to animals. Acepromazine may produce paradoxical excitation, disinhibition, and aggression in some dogs. Phenothiazines may produce excessive vagal tone in some animals. This may be especially prominent in brachycephalic breeds. Administration of atropine may be used to treat the signs of high vagal tone. Because of alpha- adrenergic antagonism, hypotension is possible in animals. Decreased vascular tone because of alpha 1 adrenergic blockade is a prominent effect of acepromazine. This may produce hypotension in susceptible animals.","notes":"Instructions for Use Acepromazine can be administered PO, IV, or IM. The doses used in anesthetic protocols are usually lower than the label dose. When used with general anesthetics, lower doses of general anesthetics can be used, especially when administering barbiturates and inhalant anesthetics. Clinical signs from acepromazine administration are most prominent during the first 3\u20134 hours after administration but may persist for 7 hours. Patient Monitoring and Laboratory Tests Monitor blood pressure in animals susceptible to hypotension. Acepromazine does not affect adrenal function testing in dogs. Dogs with a mutation in the ABCB1 gene may be deficient for the ABCB1 transporter (p- glycoprotein). These dogs may have increased sensitivity to the effects of acepromazine, resulting in greater sedation scores. Lower doses should be used in these dogs. In horses, persistent penile prolapse has been reported from use. This effect in horses is unpredictable. Some resources indicate that it is dose dependent with increased likelihood as the dose is increased from 0.01 to 0.1 mg/kg IV. The duration of penile prolapse in horses may be as long as 4 hours with high doses. In rare cases, penile prolapse can lead to permanent paraphimosis. The mechanism is unknown but may be caused by the alpha- adrenergic blockade induced by acepromazine. Formulations \u2022\\t\\tAcepromazine\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\tand\\t25-\\tmg\\ttablets\\tand\\tin\\ta\\t10-\\tmg/mL injection. \u2022\\t\\tAcepromazine\\toral\\tgranules\\tand\\tpowder\\tare\\tavailable\\tin\\tCanada. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been investigated.","original_category":"Tranquilizer, phenothiazine tranquilizer"},{"name":"Alfaxalone","active_ingredient":"Alfaxalone","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tInduction:\\t1.5\u20134.5 mg/kg IV if dogs did not receive a pre- anesthetic sedative. 0.2\u20133.5 mg/kg for dogs that received a pre- anesthetic. Always titrate the dose according to the patient response. Generally, the dose is 1\u20131.2 mg/kg (up to 2 mg/kg) for each 10 minutes of anesthesia. Deliver dose IV over 60 seconds. \u2022\\t\\tCRI:\\t6\u201310\\tmg/kg/h\\tIV\\t(suitable\\tto\\tuse\\twith\\tother\\tanesthetic\\tagents). Cats \u2022\\t\\t2.2\u201310\\tmg/kg\\t(average\\tdose\\tis\\t4\\tmg/kg)\\tIV\\tif\\tthe\\tcat\\tdid\\tnot\\treceive\\ta\\tpre- anesthetic sedative. If the cat received a pre- anesthetic sedative, the dose is 1\u20134 mg/kg IV or IM. Always consider the lower dose first and titrate the dose according to the patient\u2019s response. Generally, the dosage is 1\u20131.3 mg/kg IV (up to 5 mg/kg) delivered over 60 seconds followed by sequential doses of 2 mg/kg as needed. \u2022\\t\\tSedation\\tprotocols\\tfor\\tcats:\\tInject\\tIM\\tor\\tIV\\tat\\ta\\tdose\\tof\\t2\u20133\\tmg/kg\\tfor\\tmild sedation. It may be combined with other sedative agents in the same syringe (e.g., butorphanol at 0.2 mg/kg). \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t1.7\\tmg/kg\\tIV\\tfollowed\\tby\\tCRI\\tof\\t7\u201310\\tmg/kg/h\\tIV.  \u2022\\t\\tNo\\tlarge\\tanimal\\tdoses\\tare\\tavailable. Regulatory Information Do not administer to food- producing animals. Alfaxalone is a Schedule C- IV controlled substance. Allopurinol al- oh- pyoo \u0301rih- nole Trade and other names: Lopurin, Zyloprim, and Allopur (Europe)","contraindications":"Contraindications and Precautions Do\\tnot\\tadminister\\twith\\tfoods\\tor\\tmedications\\tcontaining\\tcalcium.\\tFood\\tdecreases absorption. Drug Interactions Do not mix with a solution containing calcium (e.g., lactated Ringer\u2019s solution). Do not give with foods containing calcium. oil formulation that induced mast cell degranulation and histamine release and produced swollen extremities, anaphylactic reactions, and other signs of histamine release. The new formulation (Alfaxan) available in 2012 overcomes the formulation issue by using a cyclodextrin- solubilizing vehicle, referred to chemically as alfaxalone- 2- hydroxypropyl- beta- cyclodextrin  (HPCD). The half- life is short in animals (less than 1 hour), but it exhibits nonlinear pharmacokinetics and may be eliminated more slowly with high doses.","indications":"Indications and Clinical Uses Alfaxalone is used as a general anesthetic agent. It can be injected directly into the cephalic vein or delivered via CRI. If injected directly, administer over 60 seconds to allow enough time to cross the blood\u2013brain barrier. It has been used successfully as an anesthetic induction agent. It has been used safely with other anesthetic agents (e.g., propofol) and in combination with premedications (e.g., opiates, atropine, phenothiazines, benzodiazepines, and NSAIDs). It can also be used as a maintenance anesthesia agent by administering an initial IV bolus and then repeating the boluses. Precautionary Information","side_effects":"Adverse Reactions and Side Effects As an anesthetic agent, CNS depression, respiratory depression, and some blood pressure decrease are expected after administration. At CRI doses greater than 0.1 mg/kg/min, it produces noticeable hypotension and hypoventilation. If injected IM,\\tit\\tcauses\\tpain\\tand\\tdiscomfort.\\tSQ\\tinjection\\tdoes\\tnot\\tproduce\\ta\\tgood\\tsurgical plane of anesthesia. If injected IM, animals may react to sound, and recovery can include excitement, incoordination, and hyper- reactivity. Drug Interactions No drug interactions are reported in animals. It may be used safely with other anesthetic agents and anesthetic adjuncts.","notes":"Instructions for Use For\\tinduction\\tof\\tanesthesia,\\tuse\\twith\\tappropriate\\tmonitoring\\tequipment\\tand ventilatory support. IV administration is recommended for alfaxalone for anesthetic purposes. However, for some sedative protocols, IM injection has been used and can be combined with other sedative agents. If administered IM, the peak effect does not occur until 10\u201315 minutes; therefore, the other agents may be administered at\\tdifferent\\ttimes.\\tFor\\texample,\\tit\\thas\\tbeen\\tadministered\\twith\\tbutorphanol\\t(0.4 mg/kg IM) followed by alfaxalone (2 mg/kg IM) 15 minutes later and used for short- term procedures. It has been used in cats IM in combination with ketamine, dexmedetomidine, or butorphanol for short- term surgical procedures of less than 1\\thour.\\tThere\\tmay\\tbe\\tpain\\tproduced\\tfrom\\tIM\\tinjection.\\tThe\\tSQ\\troute\\tof\\tinjection should be avoided. If used for anesthesia induction, it is recommended to include a pre- anesthetic sedative in the protocol. Agents that can be considered are acepromazine, benzodiazepines, opioids, and alpha 2 agonists (e.g., dexmedetomidine). If sedative drugs are included in the protocol, the dose listed can be decreased. Note that alfaxalone does not provide analgesia, and other agents can be added to the regimen to provide pain relief. Patient Monitoring and Laboratory Tests Monitor character and depth of anesthesia during use. Monitor blood pressure, heart rate, and body temperature during anesthesia. Apnea may occur after initial induction. Monitor character and rate of respiration. A Allopurinol 21 Formulations \u2022\\t\\tAlfaxalone\\twithout\\tpreservatives\\tis\\tavailable\\tas\\ta\\t10-\\tmg/mL\\tinjectable\\tformulation, 10- mL vial, with a shelf- life of 6 hours after initial puncture of the stopper. \u2022\\t\\tAlfaxalone\\twith\\tpreservatives\\tis\\tavailable\\tas\\ta\\tclear\\taqueous\\tsolution\\twith 2-   hydroxpropyl- beta- cyclodextrin. It has a pH of 6.5\u20137. The preservatives are ethanol, benzethonium chloride, and chlorocresol. It is available in 10-  and 20- mL vials\\twith\\ta\\tshelf-\\tlife\\tof\\t28\\tdays. Stability and Storage Microbial contamination can occur after opening the preservative- free vial. If the vial\\tdoes\\tnot\\tcontain\\tpreservatives,\\tthe\\tlabel\\tin\\tthe\\tUnited\\tStates\\tsays\\tthat\\tit\\tmust be discarded after 6 hours. However, the Australian label for the same product lists a 7- day duration when refrigerated after a single puncture of the stopper. Avoid multiple punctures and microbial contamination if preservative- free vials are used. If\\tthe\\tvial\\tcontains\\tpreservatives,\\tit\\tcan\\tbe\\tstored\\tfor\\t28\\tdays\\tafter\\tpuncturing\\tthe vial. Alfaxalone has been drawn up in the same syringe with other anesthetics and sedatives (e.g., opioids, alpha 2 agonists, midazolam) and injected immediately without observed interactions.","original_category":"Anesthetic agent"},{"name":"Alprazolam","active_ingredient":"Alprazolam","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.025\u20130.05\\tmg/kg\\tq8h\\tPO.\\tIncrease\\tto\\t0.1\\tmg/kg\\tif\\tneeded.\\tAdministration more frequently (q4\u20136h) has been used in some patients. Cats \u2022\\t\\t0.125\\tmg/cat\\tq12h\\tPO\\t(half\\tof\\t0.25-\\tmg\\ttablet)\\tor\\t0.0125\u20130.025\\tmg/kg\\tq12h PO\\tand\\tup\\tto\\tq8h.  Horses \u2022\\t\\tLoading\\tdose\\tof\\t0.1\\tmg/kg\\tinitially\\tfollowed\\tby\\t0.04\\tmg/kg\\tq12h\\tPO.","contraindications":"Contraindications and Precautions No serious contraindications. In rare individuals, benzodiazepines have caused\\tparadoxical\\texcitement.\\tUse\\tof\\tbenzodiazepines\\tin\\tearly\\tpregnancy has been associated with an increased risk of spontaneous abortions and fetal malformations in people. This incidence in animals is unknown. If an animal has been receiving alprazolam for an extended period, do not stop the medication abruptly but decrease the dose over a tapering period to minimize withdrawal signs. Drug Interactions Other drugs may decrease hepatic metabolism (e.g., ketoconazole, chloramphenicol, and itraconazole). A Altrenogest 25 Regulatory Information No\\tregulatory\\tinformation\\tis\\tavailable.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. RCI\\tClassification:\\t2 Altrenogest al- tren \u0301- oh- jest Trade and other names: Regu- Mate, Matrix","indications":"Indications and Clinical Uses Alprazolam is used to treat behavior problems in dogs and cats, particularly those associated with anxiety. Alprazolam has been used in dogs for the short- term treatment of anxiety states, such as noise phobias and thunderstorm phobia. For\\tthunderstorm\\tphobia,\\tit\\tmay\\tbe\\tmore\\teffective\\tif\\tcombined\\twith\\tlong-\\tterm clomipramine treatment. In horses, it has been administered orally to control some behavior problems. It has been used in horses is to decrease anxiety and facilitate a mare\u2013foal bonding and acceptance of a foal or orphan foal. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Sedation is the most common side effect, but alprazolam may also cause paradoxical excitement in dogs. It has been administered safely to horses without producing noticeable ataxia or sedation at a dose of 0.04 mg/kg. In cats, idiopathic fatal hepatic necrosis has been reported from diazepam, but this has not been reported from alprazolam, probably because of differences in metabolism. Alprazolam is not as extensively metabolized as diazepam. Chronic administration in any species may lead to dependence and a withdrawal syndrome if discontinued.","notes":"Instructions for Use Use\\tin\\tanimals\\thas\\tbeen\\tprimarily\\tderived\\tfrom\\tempirical\\tuse\\tand\\tclinical\\tobservation. There are no well- controlled clinical studies or efficacy trials to document clinical effectiveness. Duration of effect is only 2\u20133 hours in many dogs. Therefore, it is usually used for short- term problems, and if needed, more frequent administration may be required. When treating noise phobia (thunderstorm phobia), it is helpful in some dogs to administer 0.02 mg/kg of clomipramine 1 hour before a storm in addition to alprazolam. The\\tNiravam\\ttablets\\t(see\\tthe\\tFormulations\\tsection) are rapidly dissolving and may be easier to administer to animals that are difficult to medicate. Tablets easily dissolve on the tongue without requiring water and can be cut for accurate dosing. Patient Monitoring and Laboratory Tests Monitor hepatic enzymes in animals with chronic use. Although plasma drug concentrations are usually not measured in animals, 20\u201340 ng/mL has been associated with therapeutic effects in people. Formulations \u2022\\t\\tAlprazolam\\tis\\tavailable\\tin\\t0.25-\\t,\\t0.5-\\t  ,\\t1-\\t ,\\tand\\t2-\\t    mg\\ttablets\\tand\\t1-\\t\\tand\\t2-\\tmg\\tscored tablets. \u2022\\t\\tRapidly\\tdissolving\\ttablets\\t(Niravam)\\tare\\tavailable\\tin\\t0.25,\\t0.5,\\t1,\\tand\\t2\\tmg\\tthat\\tcan be cut for accurate dosing. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Drug is stable in some compounded formulations for 60 days.","original_category":"Tranquilizer, CNS depressant"},{"name":"Atipamezole Hydrochloride","active_ingredient":"Atipamezole Hydrochloride","species":["Equine"],"dosage":"\u2022\\t\\tInject\\tthe\\tsame\\tvolume\\tas\\tused\\tfor\\tdexmedetomidine\\tor\\tmedetomidine.\\tThe\\trange of\\tdoses\\t(IM\\tor\\tIV)\\tis\\t0.32\\tmg/kg\\tfor\\tsmall\\tanimals\\t(4\\tkg,\\tor\\t8.8\\tlb),\\t0.23\\tmg/kg for medium- sized animals (11 kg, or 24 lb), and up to 0.14 mg/kg for large- sized animals (45 kg or 100 lb).  \u2022\\t\\tHorses:\\tThe\\tdosage\\tused\\tin\\thorses\\tis\\t60\u201380\\tmcg/kg\\t(0.06\u20130.08\\tmg/kg)\\tIV\\tbut has ranged up to 150 mcg/kg (0.15 mg/kg). Typically, 100 mcg/kg (0.1 mg/kg) IV is used to reverse detomidine. Regulatory Information Do not administer to animals intended for food. Atovaquone a- toe \u0301- va- kwone \u0301 Trade and other names: Mepron","contraindications":"Contraindications and Precautions No contraindications reported for animals. Drug Interactions Atipamezole is an alpha 2 - antagonist. As such, it antagonizes other drugs that bind to the alpha- receptor and prevents their action. Such drugs that may be antagonized include xylazine, medetomidine, dexmedetomidine, romifidine, detomidine, and some alpha 1 - agonists.","indications":"Indications and Clinical Uses Atipamezole is used to reverse alpha 2 - agonists such as dexmedetomidine (Dexdomitor), medetomidine (Domitor), detomidine, and xylazine. Arousal from sedation should occur within 5\u201310 minutes of injection. It also can be used to reverse sedation caused by amitraz intoxication. In horses, it provides a satisfactory but incomplete reversal of detomidine. 66    Atovaquone Precautionary Information","side_effects":"Adverse Reactions and Side Effects Atipamezole can cause initial excitement in some animals shortly after reversal. There may be a transient decrease in blood pressure after injection. In horses, it can produce a dose- dependent increase in sweating and hyperexcitability that resolved after 10\u201315 minutes.","notes":"Instructions for Use When used to reverse dexmedetomidine or medetomidine, inject the same volume of atipamezole as the volume of dexmedetomidine or medetomidine that was administered. In horses, a wide range of doses has been used (see the dosing section). Typically, the higher dose is more effective for detomidine, but tolazoline antagonizes detomidine in horses more completely and hastens recovery better than atipamezole. Patient Monitoring and Laboratory Tests Monitor cardiovascular status when using alpha 2 - agonists. Providing oxygen during recovery may help recovery from alpha 2 - agonists. Formulations \u2022\\t\\tAtipamezole\\tis\\tavailable\\tin\\ta\\t5-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anesthetic"},{"name":"Bupivacaine Hydrochloride","active_ingredient":"Bupivacaine Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs and Cats \u2022\\t\\tEpidural\\tdose:\\t1\u20131.5\\tmg/kg;\\tfor\\tnerve\\tblocks,\\tusually\\t0.2\\tmL/kg\\tof\\t0.5%\\tsolution is used. \u2022\\t\\tMultivesicular\\tliposomes:\\tInfiltrate\\tsurgical\\tsite\\t  with\\t  100\u2013200\\tmg\\t  per\\t  site.\\t  Duration of\\teffect\\tis\\tusually\\t96\\thours. \u2022\\t\\tLiposomal\\tinjectable\\tsuspension\\t(13.3\\tmg/mL):\\t5.3\\tmg/kg\\t(0.4\\tmL/kg)\\tinjected by infiltration into the surgical tissues at the time of incisional closure. A single dose is designed to provide up to 72 hours of pain control. \u2022\\t\\tUse\\tin\\tcats\\tfor\\tonychectomy:\\t5.3\\tmg/kg\\tper\\tforelimb\\t(0.4\\tmL/kg\\tper\\tforelimb) to a total dose of 10.6 mg/kg per cat in a four- point nerve block. Inject volumes of\\t0.02\u20130.16\\tmL/kg\\tin\\tthe\\tregion\\tof\\tthe\\tnerves\\tsupplying\\tthe\\tdistal\\tlimb,\\tas instructed in the product insert.  \u2022\\t\\tLimited\\tto\\tlocal\\tinfiltration\\tfor\\tminor\\tsurgery. Regulatory Information No withdrawal times are established for animals intended for food (extralabel use). When used for local infiltration, clearance from the animal is expected to be rapid. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t2 100    Buprenorphine Hydrochloride Buprenorphine Hydrochloride byoo- preh- nor\u2032feen  hye- droe- klor\u2032ide Trade and other names: Buprenex (human form), Simbadol (veterinary form), and Vetergesic (UK veterinary form). Butrans is a human transdermal formulation.","contraindications":"Contraindications and Precautions When using for epidural anesthesia, respiratory support should be available. Some","indications":"Indications and Clinical Uses Bupivacaine is used for local anesthesia and epidural analgesia/anesthesia. It is administered by local infiltration or by epidural injection. There is also a liposomal injection as a suspension in multivesicular liposomes (Exparel and Nocita). The human preparation is contained in a foam delivery system (DepoFoam drug delivery), and a liposomal suspension for dogs and cats is administered by local infiltration. After injection of the liposomal formulation into soft tissue, bupivacaine is released from the multivesicular liposomes over a long period of time, providing pain\\trelieve\\tfor\\tat\\tleast\\t72\\thours\\tand\\tup\\tto\\t96\\thours.\\tThis\\tformulation\\tis\\tused to infiltrate around a surgical site or near a nerve for a local anesthetic effect. The bupivacaine liposomal suspension for dogs and cats (Nocita) is approved to relieve postoperative pain following cranial cruciate ligament surgery in dogs and onychectomy in cats for 72 hours. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare with local infiltration. High doses absorbed systemically can cause nervous system signs (tremors and convulsions). The toxic dose in cats is 5 mg/kg. In cats, signs of toxicity include bradycardia, arrhythmias, tremors, muscle twitching, and seizures. The dose necessary to stimulate seizures and produce cardiac arrhythmias in dogs is greater than 4 mg/kg, IV. After epidural administration, respiratory paralysis is possible with high doses. The liposomal formulation injected into surgical sites may produce occasional tissue irritation, but systemic absorption of the liposomal suspension is negligible and far below the concentrations necessary to induce CNS effects such as seizures. Therefore, the absorption of bupivacaine from the liposomal formulation is not expected to produce any systemic adverse effects.","notes":"formulations\\tcontain\\tepinephrine\\t(1:200,000)\\tand\\tshould\\tnot\\tbe\\tadministered\\tto animals that are prone to reactions from epinephrine. When using the liposomal suspension, do not administer IV or in a joint. Drug Interactions No drug interactions are reported in animals. Instructions for Use Used for local infiltration or infusion into epidural space. For epidural injection, the volume\\tof\\tinjection\\tis\\tapproximately\\t0.2\\tmL/kg,\\tor\\tnot\\tto\\texceed\\t6\\tmL\\tfor\\tlarge dogs.\\tOrdinarily,\\tthe\\tdose\\tfor\\ta\\tnerve\\tblock\\tin\\tsmall\\tanimals\\tdoes\\tnot\\texceed\\t1\\tmg/ kg.\\tOne\\tmay\\tmix\\t0.1\\tmEq\\tof\\tsodium\\tbicarbonate\\tper\\t10-\\tmL\\tsolution\\tto\\tincrease\\tpH, decrease pain from injection and produce a shorter onset of action. Use immediately after mixing with bicarbonate because of risk of precipitation. Increasing the pH accelerates the onset of anesthetic action. The liposomal formulation for dogs and cats (Nocita) is intended for single- dose use to infiltrate the surgical site and provide local postoperative analgesia for cranial cruciate ligament surgery in dogs and as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats. Use a 25- gauge needle for infiltration and inject slowly into the tissue site. It has also been used extralabel for B other surgical sites where pain management may be needed. The dose volume for the liposomal\\tformulation\\tis\\t0.4\\tmL/kg,\\tbut\\tif\\tthis\\tis\\tnot\\tsufficient\\tfor\\tthe\\tsurgical\\tsite, add\\tup\\tto\\tan\\tequal\\tvolume\\tof\\tfluid\\t(saline\\tor\\tlactated\\tRinger\u2019s\\tsolution)\\tto\\tincrease the volume. Do not use water or mix with other solutions because it could disrupt the liposomes. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations \u2022\\t\\tBupivacaine\\tis\\tavailable\\tin\\t0.25%,\\t0.5%,\\tand\\t0.75%\\t(2.5,\\t5,\\tand\\t7.5\\tmg/mL) solution for injection. \u2022\\t\\tExparel\\t(human\\tformulation)\\tlocal\\tmultivesicular\\tliposomes\\tare\\tavailable\\tin\\ta bupivacaine\\tconcentration\\tof\\t13.3\\tmg/mL\\tin\\t10-\\t\\tor\\t20-\\tmL\\tvials. \u2022\\t\\tNocita\\t(veterinary\\tformulation)\\tis\\ta\\tbupivacaine\\tliposome\\tinjectable\\tsuspension available\\tfor\\tdogs\\tand\\tcats\\tin\\ta\\tconcentration\\tof\\t13.3\\tmg/mL. Stability and Storage Store in a tightly sealed container at room temperature. Avoid mixing with strongly acidic or alkalinic solutions. If solutions change to a yellow, pink, or darker color, they should not be used. If pH is adjusted by mixing with alkalinizing solutions (e.g., bicarbonate), the drug is stable but must be used soon after mixing. When using the liposomal formulations, puncture the vial only once. Unopened vials should be stored in the refrigerator. After drawing the initial dose into the syringe, it may be stored at room temperature for up to 4 hours, but because it has no preservatives, the syringes should be discarded after 4 hours. Do not freeze the liposomal suspension. The liposomal suspension vials, if unopened, may be kept at room temperature for up to 30 days in sealed, intact (unopened) vials. Do not re- refrigerate.","original_category":"Local anesthetic"},{"name":"Enflurane","active_ingredient":"Enflurane","species":["Not specified in source"],"dosage":"\u2022\\t\\tInduction:\\t2%\u20133%. \u2022\\t\\tMaintenance:\\t1.5%\u20133%. 322    Enilconazole  \u2022\\t\\tMAC\\tvalue:\\t1.66%. Regulatory Information No withdrawal times are established for food animals. Clearance is rapid, and short withdrawal times are suggested. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Enilconazole en- il- kah \u0301nah- zole Trade and other names: Imazalil, Imaverol, and Clinafarm- EC","contraindications":"Contraindications and Precautions No specific contraindications are reported for animals. Drug Interactions Other sedatives and anesthetics (e.g., opiates, benzodiazepines, phenothiazines, alpha 2 agonists) will lower the requirement for inhalant gas anesthesia.","indications":"Indications and Clinical Uses Enflurane,\\tlike\\tother\\tinhalant\\tanesthetics,\\tis\\tused\\tfor\\tgeneral\\tanesthesia\\tin\\tanimals.\\tIt has\\ta\\tminimum\\talveolar\\tconcentration\\t(MAC)\\tvalue\\tof\\t2.37%,\\t2.06%,\\tand\\t2.12%\\tin cats, dogs, and horses, respectively. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like\\tother\\tinhalant\\tanesthetics,\\tenflurane\\tproduces\\tvasodilation\\tand\\tincreased blood\\tflow\\tto\\tcerebral\\tblood\\tvessels.\\tThis\\tmay\\tincrease\\tintracranial\\tpressure.\\tLike other\\tinhalant\\tanesthetics,\\tit\\tproduces\\ta\\tdose-\\tdependent\\tmyocardial\\tdepression with accompanying decrease in cardiac output. It also depresses respiratory rate and\\talveolar\\tventilation.\\tLike\\tother\\tinhalant\\tanesthetics,\\tit\\tincreases\\tthe\\trisk\\tof ventricular arrhythmias, especially in response to catecholamines.","notes":"Instructions for Use Titrate dose for each individual with anesthetic monitoring. Patient Monitoring and Laboratory Tests Monitor anesthesia parameters. During anesthesia, monitor heart rate and rhythm and respiratory rate. Formulations \u2022\\t\\tEnflurane\\tis\\tavailable\\tas\\ta\\tsolution\\tfor\\tinhalation. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Inhalant anesthetic"},{"name":"Halothane","active_ingredient":"Halothane","species":["Not specified in source"],"dosage":"\u2022\\t\\tInduction:\\t3% \u2022\\t\\tMaintenance:\\t0.5%\u20131.5%.  \u2022\\t\\tMAC\\tvalue:\\t1%. Regulatory Information No withdrawal times are established for food animals. Clearance is rapid, and short withdrawal times are suggested. For extralabel use withdrawal interval estimates, contact Food Animal Residue Avoidance Databank (FARAD) at www.FARAD.org. Hemoglobin Glutamer (Oxyglobin) hee\u2032moe- gloe- bin  gloot\u2032am- er Trade and other names: Oxyglobin","contraindications":"Contraindications and Precautions Administer with caution to patients with cardiovascular problems. Drug Interactions No specific drug interactions. Use of other anesthetics in conjunction with halothane lowers the requirement for the halothane dose.","indications":"Indications and Clinical Uses Halothane, like other inhalant anesthetics, is used for general anesthesia in animals. It has minimum alveolar concentration (MAC) values of 1.04%, 0.87%, and 0.88% in cats, dogs, and horses, respectively. However, it is rarely used today and has been replaced by newer inhalant anesthetics (e.g., isoflurane) in many veterinary practices. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other inhalant anesthetics, halothane produces vasodilation and increased blood flow to cerebral blood vessels. This may increase intracranial pressure. Also, like other inhalant anesthetics, it produces a dose- dependent myocardial depression, with an accompanying decrease in cardiac output. It also depresses respiratory rate and alveolar ventilation. In addition, like other inhalant anesthetics, it increases the risk of ventricular arrhythmias, especially in response to catecholamines. Hepatotoxicity has been reported in people.","notes":"Instructions for Use Use of inhalant anesthetics requires careful monitoring. Dose is determined by depth of anesthesia. Patient Monitoring and Laboratory Tests Monitor patient\u2019s heart rate and rhythm and respiration during anesthesia. Formulations Stability and Storage Halothane is highly volatile and should be stored in a tightly sealed container. H H Hemoglobin Glutamer (Oxyglobin) 427","original_category":"Inhalant anesthetic"},{"name":"Isoflurane","active_ingredient":"Isoflurane","species":["Not specified in source"],"dosage":"\u2022\\t\\tInduction:\\t5%;\\tmaintenance:\\t1.5%\u20132.5%.  \u2022\\t\\tMAC\\tvalue:\\t1.5%\u20132%. Regulatory Information Withdrawal times are not established for animals that produce food. Clearance is rapid, and short withdrawal times are suggested. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Isoniazid eye- soe- nye\u2032a- zid Trade and other names: INH and isonicotinic acid hydrazide","contraindications":"Contraindications and Precautions Do not administer unless it is possible to control ventilation and monitor heart rate and rhythm. Drug Interactions No drug interactions are reported. However, like other inhalant anesthetics, other anesthetic agents act synergistically and lower dose requirements.","indications":"Indications and Clinical Uses Isoflurane, like other inhalant anesthetics, is used for general anesthesia in animals. It is associated with rapid induction of anesthesia and rapid recovery rates. It is metabolized to only a small percentage (less than 1%) and has minimal effects on other organs. It has a minimum alveolar concentration (MAC) values of 1.63%, 1.3%, and 1.31% in cats, dogs, and horses, respectively. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to anesthetic effects (e.g., cardiovascular and respiratory depression).","notes":"Instructions for Use Use of inhalant anesthetics requires careful monitoring. Dose is determined by depth of anesthesia. Patient Monitoring and Laboratory Tests Monitor respiratory rate, heart rate, and rhythm during administration. I Isoniazid 475 Formulations Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anesthetic"},{"name":"Ketamine Hydrochloride","active_ingredient":"Ketamine Hydrochloride","species":["Canine","Feline","Equine","Bovine"],"dosage":"\u2022\\t\\tFor\\tall\\tanimals:\\tLower\\tdoses\\tlisted\\tfor\\tIV\\tuse;\\thigher\\tdoses\\tlisted\\tfor\\tIM\\tuse. Dogs \u2022\\t\\t5.5\u201322\\tmg/kg\\tIV\\tor\\tIM.\\t(Generally,\\tthe\\tlower\\tdose\\trange\\tis\\tgiven\\tIV\\tcompared with IM.) It is recommended to use adjunctive sedative or tranquilizer treatment. \u2022\\t\\tCRI\\tfor\\tperi-\\toperative\\tuse:\\tAdminister\\ta\\tloading\\tdose\\tof\\t0.3\u20130.5\\tmg/kg\\tIV followed\\tby\\t0.3\u20130.6\\tmg/kg/h\\t(5\u201310\\tmcg/kg/min)\\tduring\\tsurgery.\\tThe\\trate during surgery may be increased to 1 mg/kg/h if needed. After surgery, treatment can be continued to provide analgesia at a low rate of 0.12 mg/kg/h for up to 18 hours. To administer a rate of 0.3\u20130.6 mg/kg/h, mix 0.6 mL (60 mg) with 1 L of fluids\\tand\\tinfuse\\tat\\ta\\trate\\tof\\t5\u201310\\tmL/kg/h. \u2022\\t\\tCRI\\tfor\\tlight\\tsedation:\\t1\u20132\\tmg/kg/h,\\twhich\\tmay\\tbe\\tcombined\\twith\\tother sedatives. \u2022\\t\\tCombination\\tof\\tmorphine,\\tlidocaine,\\tand\\tketamine\\t(MLK):\\tMixed\\tas\\t100\\tmg/mL of\\tketamine\\t(1.6\\tmL/500\\tmL\\tfluids)\\t+\\t20\\tmg/mL\\tof\\tlidocaine\\t(30\\tmL/500\\tmL fluids)\\tand\\t15\\tmg/mL\\tof\\tmorphine\\t(1.6\\tmL/500\\tmL\\tfluids)\\tand\\tinfused\\tat\\ta\\trate of\\tmorphine,\\t0.24\\tmg/kg\\th;\\tlidocaine,\\t3\\tmg/kg/h;\\tand\\tketamine,\\t0.6\\tmg/kg/h, administered as CRI for perioperative analgesia. Cats \u2022\\t\\t2\u201325\\tmg/kg\\tIV\\tor\\tIM.\\t(Generally,\\tthe\\tlower\\tdose\\trange\\tis\\tgiven\\tIV\\tcompared with IM.) Note: When used in cats, a sedative such as acepromazine (0.1 mg/kg) or a benzodiazepine is recommended prior to or combined in same syringe with administration of ketamine. When combined in same syringe, inject immediately after mixing. (In cats, it also can be sprayed into the mouth and produces similar effect as IM 10 mg/kg.) \u2022\\t\\tShort-\\t   term\\tprocedures:\\t3\u20135\\tmg/kg\\tketamine\\t+\\t25\\tmcg/kg\\tdexmedetomidine, mixed together and administered IM (an opiate also may be included). \u2022\\t\\tMix\\twith\\tpropofol\\tcombined\\t1:1\\tin\\tthe\\tsame\\tsyringe\\tat\\ta\\tdose\\tof\\t2\\tmg/kg ketamine\\tand\\t2\\tmg/kg\\tpropofol\\tadministered\\tIV\\tfollowed\\tby\\tan\\tinfusion\\t(CRI)\\tof 10 mg/kg/h (both drugs combined). \u2022\\t\\tCRI:\\tLoading\\tdose\\tof\\t0.3\u20130.5\\tmg/kg\\tIV\\tfollowed\\tby\\t0.3\u20130.6\\tmg/kg/h\\t(5\u201310 mcg/kg/min).\\tThis\\trate\\tmay\\tbe\\tincreased\\tto\\t1\\tmg/kg/h\\t(15\\tmcg/kg/min)\\tif needed\\tor\\tlowered\\tto\\t2\u20135\\tmcg/kg/min\\twhen\\tcombined\\twith\\tother\\tdrugs\\t(e.g., opiates). 496    Ketoconazole  Horses, Cattle, Sheep, and Swine \u2022\\t\\t2\\tmg/kg\\tIV\\t(in\\thorses,\\tpretreat\\twith\\ta\\tsedative). \u2022\\t\\tKetamine\\tat\\t1.1\\tmg/kg\\tmixed\\twith\\txylazine\\tat\\t0.5\\tmg/kg\\tmay\\tbe\\tcombined\\tin\\tthe same\\tsyringe\\tand\\tadministered\\tIV. \u2022\\t\\tCRI\\tfor\\tanalgesia:\\tLoading\\tdose\\tof\\t0.6\\tmg/kg\\tIV\\tfollowed\\tby\\tCRI\\tof\\t0.4\u20130.8 mg/kg/h and increased to 1.2 mg/kg/h if needed. To prepare CRI solution for analgesia, add 30 mL of ketamine to a 1- L bag of fluids (3 mg/mL) and administer IV\\tover\\ta\\tduration\\tof\\t8\\thours\\tat\\ta\\trate\\tof\\t125\\tmL/h\\tfor\\taverage\\tsize\\thorse. \u2022\\t\\tTotal\\tIV\\tanesthesia:\\t2\\tmg/kg/h\\tup\\tto\\t6\\tmg/kg/h\\tdelivered\\tIV.\\tThis\\tmay\\tbe added to fluids in a concentration of 2 mg/mL of ketamine with other agents (e.g., guaifenesin,\\t100\\tmg/mL;\\tor\\tdetomidine,\\t0.02\\tmg/mL)\\tand\\tinfused\\tIV\\tat\\ta\\trate\\tof 1\u20133 mL/kg/h (to effect). \u2022\\t\\tEquine\\t\u201ctriple\\tdrip\u201d\\tconsists\\tof\\t500\\tmg\\txylazine\\tplus\\t2000\\tmg\\tof\\tketamine\\tadded to\\t1\\tL\\tof\\t5%\\tguaifenesin\\tin\\tdextrose.\\tInfused\\tat\\ta\\trate\\tof\\t1.1\\tmL/kg\\tfor\\tinduction; then\\t2.4\\tmL/kg/h\\tfor\\tmaintenance. \u2022\\t\\t10\\tmg/kg\\tIM.\\tOften\\tused\\tin\\tcombination\\twith\\tother\\tagents,\\tsuch\\tas\\txylazine. \u2022\\t\\tFoals,\\ttreatment\\tof\\tseizures:\\t0.02\\tmg/kg/min\\tCRI. Regulatory Information Extralabel\\tuse:\\tWithdrawal\\ttime\\tof\\tat\\tleast\\t3\\tdays\\tfor\\tmeat\\tand\\t48\\thours\\tfor\\tmilk. Schedule III controlled drug Racing Commissioners International (RCI) Classification: 2 Ketoconazole kee- toe- kah\u2032nah- zole Trade and other names: Nizoral","contraindications":"Contraindications and Precautions Do not use in animals with head injury because it may elevate cerebrospinal fluid pressure. Use cautiously, if at all, in animals with glaucoma (increases intraocular pressure). Do not use in animals prone to seizures (although some animals with seizures have been successfully treated with ketamine). Avoid use in animals with restrictive or hypertrophic cardiomyopathy. When used alone as a sole agent in horses, ketamine causes hyperexcitability and involuntary muscle movements. When used in horses, pretreat with a sedative (e.g., alpha 2 agonist). Drug Interactions Ketamine hydrochloride is maintained at an acidic pH for stability and solubility. If mixed with alkalinizing solutions, instability or precipitation can result. It can safely be mixed with other anesthetic agents in a syringe prior to injection as long as the pH of the solution remains low enough to prevent precipitation.","indications":"Indications and Clinical Uses Ketamine is commonly used for short- term anesthetic procedures in many animal species. Because of the short half- life, the duration of action is generally 30 minutes or\\tless.\\tFor\\tprocedures\\tthat\\trequire\\ta\\tlonger\\tduration\\t(e.g.,\\tsurgical\\tprocedures)\\tIV infusions have been used, often in combination with other anesthetic/sedative agents (referred to as total intravenous anesthesia). Ketamine is often combined in use with other anesthetics and sedatives such as benzodiazepines (diazepam, midazolam), propofol, lidocaine, opiates (hydromorphone, morphine), or alpha 2 agonists (medetomidine, dexmedetomidine, and xylazine). Such combinations have been synergistic and allowed lower doses of each individual component. One example of a combination is MLK, which is morphine (or fentanyl), lidocaine, and ketamine, or equine \u201ctriple- drip,\u201d also known as \u201cGKX,\u201d in which it is mixed with xylazine and guaifenesin (see dosing section for more details on these protocols). Another mixture, referred to as \u201cMKX,\u201d is a combination of midazolam, ketamine, and xylazine used for anesthesia in horses. Ketamine has also been added to protocols for cattle and horses using xylazine and butorphanol for standing restraint.\\tThe\\tdose\\tused\\tin\\tthese\\tprotocols\\tis\\tsubanesthetic\\t(e.g.,\\t0.05\u20130.1 mg/kg\\tIV). Although ordinarily contraindicated in patients with epilepsy, it has been used to treat cases of refractory status epilepticus through its NMDA receptor effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Ketamine\\tcauses\\tpain\\twith\\tIM\\tinjection\\t(pH\\tof\\tsolution\\tis\\t3.5).\\tTremors,\\tmuscle spasticity, and convulsive seizures have been reported. Spontaneous movements, salivation, and increased body temperature are more common in dogs when high doses are used. Ketamine increases sympathetic tone, heart rate, and blood pressure. It produces an increased cardiac output compared with other anesthetic agents. Salivation, mydriasis, and regurgitation are increased in animals that receive ketamine, which may be reduced by premedication within atropine. Apnea may develop in some animals, and oxygen supplementation should be available. Prolonged infusions in horses may delay GI transit times.","notes":"Instructions for Use Ketamine is often used in combination with other anesthetics and anesthetic adjuncts, such as xylazine, dexmedetomidine, medetomidine, acepromazine, opiates, propofol, lidocaine, and benzodiazepines (e.g., diazepam, midazolam). Because ketamine can cause behavior reactions and myoclonus, it is recommended to use with other agents such as alpha 2 agonists (e.g., dexmedetomidine) or benzodiazepines (e.g., midazolam). CRIs may be used to maintain a plane of anesthesia and analgesia. (See dosing section for\\tinfusion\\tdoses.)\\tIV\\tdoses\\tare generally less than IM doses. In cats, ketamine may be sprayed into the mouth (10 mg/kg) and produces similar effects as IM injection. Animals receiving ketamine have open eyelids, and artificial tears should be applied to prevent corneal injury. Patient Monitoring and Laboratory Tests Monitor heart rate and breathing in patients anesthetized with ketamine. Although plasma concentrations are not typically monitored, the concentration of 0.22\u20130.37 mcg/mL is associated with analgesic properties in cats and 0.1\u20130.2 mcg/mL in people. Formulations \u2022\\t\\tKetamine\\tis\\tavailable\\tin\\t100-\\tmg/mL\\tinjection\\tsolution. K \u2022\\t\\tEsketamine\\thydrochloride\\t(Spravato)\\tis\\tthe\\tS-\\tisomer\\tof\\tketamine\\t(the\\tactive\\tform). This product is used for intranasal delivery in people to treat depression. The use in animals has not been reported. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Ketamine is soluble in water and ethanol. Ketamine hydrochloride has been successfully administered when combined in a syringe immediately prior to injection with drugs such as alpha 2 agonists, opiates, lidocaine, propofol, guaifenesin, benzodiazepines, and acepromazine. Ketamine has been mixed with propofol at a ratio of 1:1 in the same syringe and administered intravenously. Ketamine hydrochloride\\tmixed\\twith\\tmidazolam\\tretained\\tpotency\\tfor\\t97\\thours.","original_category":"Anesthetic"},{"name":"Lidocaine Hydrochloride","active_ingredient":"Lidocaine Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\tAntiarrhythmic\\tIV\\tdose:\\t2\u20134\\tmg/kg\\tIV\\t(to\\ta\\tmaximum\\tdose\\tof\\t8\\tmg/kg\\tover\\ta 10- minute  period). \u2022\\t\\tAntiarrhythmic\\tCRI\\tdosage:\\t1\\tmg/kg\\tinitially\\tfollowed\\tby\\t50\u201375\\tmcg/kg/min\\tIV CRI. \u2022\\t\\tAntiarrhythmic\\tIM\\tdosage:\\t6\\tmg/kg\\tq1.5h\\tIM. \u2022\\t\\tEpidural:\\t4.4\\tmg/kg\\tof\\t2%\\tsolution. \u2022\\t\\tAdjunct\\tto\\tcontrol\\tpain\\tand\\tinflammation\\tassociated\\twith\\tsurgery:\\t2-\\tmg/kg\\tIV bolus followed by 0.05 mg/kg/min CRI for 24 hours (added to patient\u2019s fluids). \u2022\\t \\tMLK:\\tMixed\\tas\\t100\\tmg/mL\\tketamine\\t(1.6\\tmL\\tper\\t500\\tmL\\tof\\tfluids),\\t20\\tmg/mL lidocaine (30 mL per 500 mL of fluids), and 15 mg/mL morphine (1.6 mL per 500 mL of fluids) and infused at a rate of morphine, 0.24 mg/kg/h; lidocaine, 3 mg/ kg/h; and ketamine, 0.6 mg/kg/h, administered as CRI for peri- operative analgesia. Cats \u2022\\t\\tAntiarrhythmic\\tIV\\tdose:\\tStart\\twith\\t0.1\u20130.4\\tmg/kg\\tinitially\\tand\\tthen\\tincrease\\tto 0.25\u20130.75 mg/kg IV slowly if there has been no response. \u2022\\t\\tAntiarrhythmic\\tCRI\\tdose:\\tLoading\\tdose\\tof\\t0.5\u20131\\tmg/kg\\tIV\\tfollowed\\tby\\t10\u201320 mcg/kg/min (0.6\u20131.2 mg/kg/h) IV CRI. \u2022\\t\\tEpidural:\\t4.4\\tmg/kg\\tof\\t2%\\tsolution.  Horses \u2022\\t \\tVentricular\\ttachycardia:\\tStart\\twith\\t0.25\u20130.5\\tmg/kg\\tIV\\tinjection\\tover\\t5\u201310\\tminutes, up to 1.3\u20131.5 mg/kg for refractory cases. Follow with 0.03\u20130.05 mg/kg/min (30\u201350 mcg/kg/min) CRI. Consider adding magnesium sulfate to the infusion to enhance\\tthe\\tefficacy.\\tAdd\\t2.7\\tg\\tof\\tmagnesium\\tsulfate\\tto\\t1\\tL\\tof\\t0.9%\\tsodium\\tchloride solution and administer over 10 minutes IV for a dose of 2\u20136 mg/kg. \u2022\\t\\tPostoperative\\tileus:\\t1.3-\\tmg/kg\\tIV\\tbolus\\tadministered\\tover\\t15\\tmin\\tfollowed\\tby 0.05 mg/kg/min (50 mcg/kg/min) CRI. \u2022\\t\\tAnalgesia:\\t2\\tmg/kg\\tIV\\tfollowed\\tby\\t50\\tmcg/kg/min\\tCRI. Regulatory Information Extralabel\\tuse\\twithdrawal\\ttime:\\t1\\tday\\tfor\\tmeat\\tand\\t24\\thours\\tfor\\tmilk. Horses:\\tClearance\\tprior\\tto\\tracing:\\tapproximately\\t2.5\\tdays. Racing\\tCommissioners\\tInternational\\t(RCI)\\tClassification:\\t2 Lincomycin Hydrochloride, Lincomycin Hydrochloride Monohydrate lin- koe- mye\u2032sin  hye- droe- klor\u2032ide  and  lin- koe- mye\u2032sin  hye- droe- klor\u2032ide  mono- hye\u2032drate Trade and other names: Lincocin and Lincomix","contraindications":"Contraindications and Precautions Cats are more susceptible to adverse effects, and lower doses should be used. For example, the CRI in cats is lower than the rate in dogs. Absorption from lidocaine patches in cats is only 6.3% and is not expected to present a problem. In animals with decreased blood flow to the liver (e.g., animals under anesthesia), clearance may be reduced and the risk of adverse effects increased. Drug Interactions Lidocaine hydrochloride is maintained as an acidic solution for solubility. Although short- term mixing with alkaline solutions may not interfere with stability (i.e., immediately prior to administration), storage in alkalinizing solutions can cause precipitation. If mixed with alkalinizing solutions, it should be administered promptly.","indications":"Indications and Clinical Uses Lidocaine is used commonly as a local anesthetic and for treatment and conversion of ventricular arrhythmias. Lidocaine should be used cautiously for treating supraventricular arrhythmias because it may increase cardiac conduction. Lidocaine has been used on a limited basis to treat seizures that are refractory to other drugs. Lidocaine also is used for pain management. It has been administered as a CRI in animals, especially in postsurgical patients to improve recovery after intestinal or gastric surgery. Lidocaine has been combined with other analgesics, which may be synergistic and allow lower doses of each individual\\tcomponent.\\tOne\\texample\\tof\\ta\\tcombination\\tis\\tMLK,\\twhich\\tis\\tmorphine\\t(or fentanyl), lidocaine, and ketamine (see dosing section for formula). In horses, lidocaine infusions delivered by CRI may help to restore intestinal motility and are used to treat intestinal ileus. In dogs, when it was delivered as a CRI, there was no change in gastric emptying, and there were modest effects to increase intestinal motility. Lidocaine has been applied to animals as a transdermal patch. The patch (designed for people) is 5% strength and used primarily for neuropathic pain (postherpetic neuralgia). This patch also has been applied for some conditions in dogs and cats with anecdotal accounts of some success. Absorption from the patch is low (less than 5%), which is far below the threshold for toxic effects. Precautionary Information","side_effects":"Adverse Reactions and Side Effects High doses of lidocaine cause CNS effects (tremors, twitches, and seizures) and vomiting, but the risk of lidocaine- induced seizures is low. IV use and CRIs in horses have caused muscle fasciculations, rapid eye blinking, anxiety, ataxia, weakness, and seizures. Lidocaine can produce cardiac arrhythmias, but it has greater effect on abnormal cardiac tissue than normal tissue. Use lidocaine cautiously in cats. IV doses of lidocaine in cats have resulted in death. In cats under anesthesia, lidocaine administration has caused decreased cardiac output, cardiovascular depression, and decreased oxygen delivery to tissues. In cats, lidocaine has also produced methemoglobinemia and hemolysis.","notes":"Instructions for Use When used for local infiltration, many formulations contain epinephrine to prolong activity at the injection site. Avoid using formulations that contain epinephrine in patients with cardiac arrhythmias. Note that human formulations may contain epinephrine, but no veterinary formulations contain epinephrine. To increase pH, speed onset of action, and decrease pain from injection, one may add 1 mEq of sodium bicarbonate to 10 mL of lidocaine (use immediately after mixing). To prepare solutions for infusion in horses, mix 10 g of 2% lidocaine in 3 L of lactated Ringer\u2019s solution (0.33% solution). For treating ventricular arrhythmia in horses, consider adding magnesium sulfate to the infusion. See dosing instructions below for the magnesium sulfate dose. Patient Monitoring and Laboratory Tests Monitor for signs of neurotoxicity (e.g., depression, muscle twitching, and seizures). Monitor the electrocardiogram during treatment for cardiac rate and rhythm in treated animals. L Lincomycin Hydrochloride, Lincomycin Hydrochloride Monohydrate 521 Formulations \u2022\\t\\tLidocaine\\tis\\tavailable\\tin\\t5-\\t,\\t10-\\t  ,\\t15-\\t  ,\\tand\\t20-\\tmg/mL\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Topical preparations have been prepared and found to be stable for several weeks.","original_category":"Local anesthetic, antiarrhythmic"},{"name":"Mepivacaine","active_ingredient":"Mepivacaine","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\tLocal\\tinfiltration\\tdose\\tvaries\\tdepending\\ton\\tsite.\\tGenerally,\\t0.5\u20133\\tmL\\tof\\t2%\\tsolution is used. \u2022\\t\\tEpidural:\\t0.5\\tmL\\tof\\t2%\\tsolution\\tevery\\t30\\tseconds\\tuntil reflexes are absent.  Horses \u2022\\t\\tIntraarticular:\\t150\\tmg\\t(7.5\\tmL)\\tinjected\\tinto\\thorse\\tjoint.\\tOther\\tdoses\\tare\\tvariable doses used for local infiltration, depending on the need. Regulatory Information No regulatory information is available. Because of a low risk of residues when used for local infiltration, no withdrawal times are suggested. Horses:\\tClearance\\tprior\\tto\\tracing\\tis\\tapproximately\\t2\\tdays. RCI\\tClassification:\\t2 Mercaptopurine mer- kap- toe- pyoo\u2032reen Trade and other names: Purinethol","contraindications":"Contraindications and Precautions No contraindications have been reported for animals. Drug Interactions No drug interactions have been reported.","indications":"Indications and Clinical Uses Mepivacaine\\tis\\tused\\tas\\ta\\tlocal\\tanesthetic\\tfor\\tlocal\\tinfiltration\\tepidural\\tanalgesia/ anesthesia.\\tThe\\tuse\\tin\\tanimals\\tis\\tnot\\tas\\tcommon\\tas\\twith\\tlidocaine\\tor\\tbupivacaine. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are rare with local infiltration. High doses absorbed systemically can cause nervous system signs (tremors and convulsions), but this rarely occurs. After epidural administration, respiratory paralysis is possible with high doses. Mepivacaine may cause less irritation to tissues than lidocaine.","notes":"Instructions for Use For\\tepidural\\tuse,\\tdo\\tnot\\texceed\\t8\\tmg/kg\\ttotal\\tdose.\\tDuration\\tof\\tepidural\\tanalgesia\\tis 2.5\u20133\\thours. Patient Monitoring and Laboratory Tests No specific monitoring is necessary. Formulations Mepivacaine\\tis\\tavailable\\tin\\ta\\t2%\\t(20-\\tmg/mL)\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated. M Mercaptopurine 573","original_category":"Local anesthetic"},{"name":"Methohexital Sodium","active_ingredient":"Methohexital Sodium","species":["Canine","Feline","Equine"],"dosage":"Dogs and Cats \u2022\\t\\t3\u20136\\tmg/kg\\tIV\\t(give\\tslowly\\tto\\teffect).\\tDoses\\tas\\thigh\\tas\\t15\\tmg/kg\\tIV\\thave\\tbeen administered\\tto\\tdogs\\tover\\t30\\tseconds. \u2022\\t\\tCRI:\\t0.25\\tmg/kg/min\\tfor\\t30\\tminutes;\\tthen\\t0.125\\tmg/kg/min.  \u2022\\t\\tHorses:\\t5\\tmg/kg\\tIV\\t(to\\teffect). \u2022\\t\\tPigs:\\t5\u20138\\tmg/kg\\tIV\\t(to\\teffect). Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Schedule III controlled drug. RCI\\tClassification:\\t2 Methotrexate meth- oh- treks\u2032ate Trade and other names: MTX, Mexate, Folex, Rheumatrex, and generic brands","contraindications":"Contraindications and Precautions Overdoses can be caused by rapid or repeated injections. Avoid extravasation outside of the vein. Drug Interactions No drug interactions have been reported for animals. Drugs that affect cytochrome P450\\tenzymes\\t(see\\tAppendixes\\tH\\tand\\tI)\\tcan\\taffect\\tbarbiturate\\tmetabolism.","indications":"Indications and Clinical Uses Methohexital\\tis\\tused\\tas\\tan\\tIV\\tanesthetic\\tin\\tanimals,\\tgiven\\teither\\tas\\ta\\tbolus\\tor\\tCRI. It can be administered with other anesthetic adjuncts, such as tranquilizers, prior to methohexital\\tinfusion.\\tThe\\tuse\\tof\\tmethohexital\\thas\\tdeclined\\tbecause\\tof\\tavailability\\tof other\\tshort-\\tterm\\tanesthetics. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to the anesthetic effects of the drug. Severe adverse effects\\tare\\tcaused\\tby\\trespiratory\\tand\\tcardiovascular\\tdepression.\\tRespiratory\\tapnea is possible after an IV bolus.","notes":"Instructions for Use The\\ttherapeutic\\tindex\\tis\\tlow.\\tUse\\tthis\\tagent\\tonly\\twhen\\tit\\tis\\tpossible\\tto\\tmonitor cardiovascular and respiratory functions. Methohexital is often administered with other anesthetic adjuncts. 592    Methotrexate Patient Monitoring and Laboratory Tests Monitor heart rate and breathing in patients anesthetized with barbiturates. Formulations \u2022\\t\\tMethohexital\\tis\\tavailable\\tin\\t0.5-\\t,\\t2.5-\\t  ,\\tand\\t5-\\t    g\\tvials\\tfor\\tinjection. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Anesthetic, barbiturate"},{"name":"Methoxyflurane","active_ingredient":"Methoxyflurane","species":["Not specified in source"],"dosage":"\u2022\\t\\tInduction:\\t3%;\\tmaintenance:\\t0.5%\u20131.5%.  \u2022\\t\\tMinimum\\talveolar\\tconcentration\\tvalue\\tis\\t0.2%\u20130.3%. 596    Methylene Blue 0.1% Regulatory Information No withdrawal times are established for animals intended for food. Clearance is rapid, and short withdrawal times are suggested. For extralabel use withdrawal interval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Methylene Blue 0.1% meth\u2032ih- leen  bloo Trade and other names: New Methylene Blue and generic brands","contraindications":"Contraindications and Precautions Use\\tcautiously\\tin\\tanimals\\twith\\tcardiac\\tdisease. Drug Interactions Labeling\\trecommendations\\tin\\tsome\\tcountries\\tstate\\tthat\\tflunixin\\tshould\\tnot\\tbe administered to animals receiving methoxyflurane anesthesia.","indications":"Indications and Clinical Uses Methoxyflurane\\tis\\tnot\\tused\\toften\\tas\\tan\\tinhalant\\tanesthetic.\\tIn\\tthe\\tpast\\t20\\tyears,\\tuse has declined and been replaced by other agents. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to anesthetic effects (e.g., cardiovascular and respiratory depression). Methoxyflurane has been reported to cause hepatic injury in animals.","notes":"Instructions for Use Use\\tof\\tinhalant\\tanesthetics\\trequires\\tcareful\\tmonitoring.\\tDose\\tis\\tdetermined\\tby\\tdepth of anesthesia. Patient Monitoring and Laboratory Tests Monitor heart rate and breathing in patients undergoing anesthesia with inhalant anesthetics. Monitor hepatic enzymes. Formulations \u2022\\t\\tMethoxyflurane\\tis\\tcurrently\\tnot\\tavailable\\tthrough\\tcommercial\\tsources.\\tIt\\twas previously\\tavailable\\tas\\ta\\t4-\\toz\\tbottle\\tfor\\tinhalation. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anesthetic, inhalant"},{"name":"Midazolam Hydrochloride","active_ingredient":"Midazolam Hydrochloride","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.1\u20130.25\\tmg/kg\\tIV\\tor\\tIM. \u2022\\t\\t0.1\u20130.3\\tmg/kg/h\\tIV\\tinfusion. \u2022\\t\\tStatus\\tepilepticus:\\t0.1\u20130.2\\tmg/kg\\tIV\\tbolus\\tor\\t0.2\\tmg/kg\\tadministered\\tintranasal in\\ta\\t5-\\t   mg/mL\\tsolution. \u2022\\t\\tOral\\tadministration:\\tmidazolam\\tsyrup\\t(2\\tmg/mL),\\t0.5\u20130.75\\tmg/kg\\tfor\\tsedation (dose extrapolated from pediatric use). Cats \u2022\\t\\tSedation:\\t0.05\\tmg/kg\\tIV. \u2022\\t\\tInduction\\tof\\tanesthesia:\\t0.3\u20130.6\\tmg/kg\\tIV\\tcombined\\twith\\t3\\tmg/kg\\tof\\tketamine. (Additional\\tdoses\\tof\\tketamine\\tat\\t1\u20132\\tmg/kg\\tcan\\tbe\\tadministered\\tas\\tneeded.)  Pigs \u2022\\t\\tUp\\tto\\t0.5\\tmg/kg\\tIM,\\tusually\\tin\\tcombination\\twith\\tketamine. Horses \u2022\\t\\tNeonatal\\tseizures\\tin\\tfoals:\\t0.1\u20130.2\\tmg/kg\\t(5\u201310\\tmg\\tper\\tfoal)\\tIV\\tover\\t15\u201320 minutes\\tor\\tIM\\tfollowed\\tby\\t3\\tmg/h\\tIV\\t(range,\\t2\u20136\\tmL/h)\\tCRI\\tto\\tcontrol\\tseizures. The\\tinfusion\\tdose\\tis\\tprepared\\tby\\tadding\\t10\\tmL\\t(5\\tmg/mL)\\tto\\t100\\tmL\\tof\\tsaline\\tto make\\ta\\tsolution\\tof\\t0.5\\tmg/mL. \u2022\\t \\tAnesthetic\\tadjunct\\tin\\thorses:\\t0.1\\tmg/kg\\tIV\\tadministered\\twith\\tketamine\\t(2.2\\tmg/kg) or other anesthetics (e.g., xylazine). Sheep \u2022\\t\\t0.5\\tmg/kg\\tIV\\tor\\tIM\\tfor\\tshort-\\tterm\\tsedation. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal\\tinterval\\testimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. Schedule IV controlled drug. RCI\\tClassification:\\t2 Milbemycin Oxime mil- beh- mye\u2032sin ahk\u2032seem Trade and other names: Interceptor, Interceptor Flavor Tabs, and Safeheart Milbemycin also is an ingredient in Sentinel. It is combined with spinosad in Trifexis","contraindications":"Contraindications and Precautions Use\\tcautiously\\twhen\\tadministered\\tintravenously,\\tespecially\\twith\\topiates.\\tAdminister slowly if administered IV or administer IM or in fluids. Diazepam and midazolam can increase intraocular pressure, and use in patients with some forms of glaucoma should be avoided. Drug Interactions Compared with diazepam, it is water soluble and is more compatible with fluid solutions and IV anesthetics. It has been administered safely with several anesthetics, sedatives, preanesthetics, and anticonvulsants. However, midazolam is metabolized in\\tthe\\tliver\\tby\\tP450\\tenzymes,\\twhich\\tmay\\tbe\\tinhibited\\tby\\tsome\\tdrugs\\t(see\\tAppendix I). For example, ketoconazole inhibits clearance of midazolam in dogs.","indications":"Indications and Clinical Uses Midazolam has a variety of uses in veterinary medicine. Although it is not approved for any animal species, it is one of the most frequently used benzodiazepines used extralabel in animals. It is used as an anesthetic adjunct, frequently with other anesthetics. It is used for similar indications as diazepam, but because it is water soluble, midazolam can be administered in an aqueous vehicle and administered intramuscularly compared with other drugs of this class. (Drugs such as diazepam are not\\twater\\tsoluble.)\\tIt\\thas\\tbeen\\tmixed\\twith\\tother\\twater-\\tsoluble\\tanesthetic\\tagents\\tin the same syringe (e.g., ketamine and alpha 2 agonists) and administered intravenously. In horses, it has been administered in the same solution with ketamine and xylazine. In foals, it has been used to treat neonatal seizures (see dosing). In many animal species, it also has been administered as an anticonvulsant, muscle relaxant,\\tand\\tsedative.\\tThese\\tuses\\tand\\tdose\\tregimens\\tare\\tbased\\ton\\tobservational clinical studies, pharmacokinetic studies, or opinions from anesthesiologists and other clinical experts. Midazolam solution has been administered intranasal to dogs and shown\\tto\\tproduce\\teffective\\tlevels\\tfor\\tcontrol\\tof\\tseizures\\t(0.2\\tmg/kg).\\tThe\\tFDA- approved intranasal treatment for seizures in people is Nayzilam, and administered as a\\tsingle-dose\\t5-mg\\tspray.\\tMidazolam\\toral\\tsolution\\thas\\tbeen\\teffective\\tin\\tchildren\\tfor sedation\\tand\\thypnosis\\tat\\ta\\tdose\\tof\\t0.5\u20130.75\\tmg/kg\\twith\\tan\\tonset\\tof\\t10\u201330\\tminutes. The\\tuse\\tof\\tthe\\toral\\tmidazolam\\tsolution\\thas\\tnot\\tbeen\\treported\\tfor\\tanimals. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Side effects are consistent with effects of benzodiazepines and include sedation, ataxia, and lethargy. Midazolam administered intravenously can cause serious cardiorespiratory depression. Some animals may experience paradoxical excitement. Chronic administration may lead to dependence and a withdrawal syndrome if abruptly discontinued. In horses, it causes ataxia, swaying, agitation, and weakness shortly after IV administration. If severe adverse reactions occur, consider\\tadministering\\tan\\tantagonist\\t(flumazenil,\\tRomazicon).","notes":"Instructions for Use Well-\\t  controlled\\tclinical\\ttrials\\thave\\tnot\\tbeen\\treported,\\tbut\\tthe\\tuse\\tof\\tmidazolam\\tis reported in several anesthetic protocols for animals based on clinical experience. Unlike\\tother\\tbenzodiazepines,\\tmidazolam\\tcan\\tbe\\tadministered\\tintramuscularly. Patient Monitoring and Laboratory Tests Samples of plasma or serum may be analyzed for concentrations of benzodiazepines, but\\tthis\\tis\\tnot\\toften\\tperformed.\\tPlasma\\tconcentrations\\tin\\tthe\\trange\\tof\\t100\u2013250\\tng/ mL\\thave\\tbeen\\tcited\\tas\\tthe\\ttherapeutic\\trange\\tfor\\tpeople.\\tOther\\treferences\\thave\\tcited this\\trange\\tas\\t150\u2013300\\tng/mL.\\tHowever,\\tthere\\tare\\tno\\treadily\\tavailable\\ttests\\tfor monitoring\\tin\\tmany\\tveterinary\\tlaboratories.\\tLaboratories\\tthat\\tanalyze\\thuman\\tsamples may have nonspecific tests for benzodiazepines. M Milbemycin Oxime 613 Formulations \u2022\\t\\tMidazolam\\tis\\tavailable\\tin\\ta\\t5-\\tmg/mL\\tinjection. \u2022\\t \\tMidazolam\\tintranasal\\tspray\\t(Nayzilam)\\tis\\tavailable\\tas\\ta\\tsingle-dose\\t5\\tmg/0.1\\tmL\\tspray. \u2022\\t\\tMidazolam\\toral\\tsyrup\\tis\\tavailable\\tin\\ta\\tcherry-flavored\\tsyrup\\tfor\\tchildren\\tin\\ta concentration\\tof\\t2\\tmg/mL. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Solubility of midazolam in water is pH dependent. At lower pH values (pH less than 4),\\tit\\tbecomes\\tmore\\tsoluble.\\tIt\\tcan\\tbe\\tmixed\\tfor\\tshort-\\tterm\\tuse\\twith\\tother\\twater- soluble anesthetics if administered immediately after mixing. Midazolam and ketamine hydrochloride are compatible when mixed in the same syringe.","original_category":"Anticonvulsant, sedative"},{"name":"Pentobarbital Sodium","active_ingredient":"Pentobarbital Sodium","species":["Canine","Feline","Bovine"],"dosage":"Dogs and Cats \u2022\\t\\tGeneral\\tanesthesia:\\t25\u201330\\tmg/kg\\tIV\\tto\\teffect. \u2022\\t\\tCRI:\\t2\u201315\\tmg/kg\\tIV\\tto\\teffect\\tfollowed\\tby\\t0.2\u20131\\tmg/kg/h. \u2022\\t\\tStatus\\tepilepticus:\\t2\u20136\\tmg/kg\\tIV\\t(15\u201320\\tminutes\\tmay\\tbe\\tneeded\\tto\\ttake\\tfull effect). \u2022\\t\\tEuthanasia:\\tSee\\tInstructions\\tfor\\tUse.  Cattle \u2022\\t\\tStanding\\tsedation:\\t1\u20132\\tmg/kg\\tIV. Cattle, Sheep, and Goats \u2022\\t\\tGeneral\\tanesthesia:\\t20\u201330\\tmg/kg\\tIV\\tgiven\\tto\\teffect. Regulatory Information If used for a euthanasia agent, the carcass should not be fed to other animals or used for food. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Schedule II controlled drug. RCI\\tClassification:\\t2 Pentoxifylline pen- toks\u2032ih- fill- in Trade and other names: Trental, oxpentifylline, and generic brands","contraindications":"Contraindications and Precautions Rapid IV doses can be lethal. Every patient that receives IV pentobarbital should be carefully monitored. The IV dose should be carefully titrated to produce anesthesia but avoid a dose that could be fatal. Monitor respiration rate carefully after injection because respiratory depression may occur. Drug Interactions Pentobarbital potentiates the sedative and cardiorespiratory- depressing effects of other anesthetics. Pentobarbital is subject to effects from other drugs that may either induce or inhibit cytochrome P450 metabolizing enzymes. (See Appendixes H\\tand\\tI.)","indications":"Indications and Clinical Uses Pentobarbital is usually used as an IV anesthetic. It also is used to control severe seizures in animals for treatment during status epilepticus. In some instances, pentobarbital is included in mixtures used to induce euthanasia in animals. P Pentobarbital is not used regularly as a general anesthetic compared to many years ago. There are other agents that are safer, produce smoother recoveries, and are used more often. Another use of pentobarbital is for euthanasia at high doses IV, usually in combination with other agents, such as muscle relaxants. (See description below.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to anesthetic action. Cardiac depression and respiratory depression are common. Respiratory apnea can occur with rapid IV doses.","notes":"Instructions for Use Pentobarbital has a narrow therapeutic index. When administering intravenously, inject the first half of the dose initially and then the remainder of the calculated dose gradually until anesthetic effect is achieved. It should be used only by trained clinical personnel with experience using pentobarbital. Euthanasia use: Most euthanasia solutions contain pentobarbital as their active ingredient. Often other ingredients to facilitate euthanasia are included such as muscle relaxants and drugs with lethal cardiac effects (e.g., edetate disodium 0.05%). The concentration of pentobarbital in most euthanasia solutions is 390 mg/mL with a lethal dose of 1 mL per 10 lb, which is equivalent to 1 mL per 4.5 kg or 87 mg/kg IV. Patient Monitoring and Laboratory Tests Monitor vital signs, especially heart rate and rhythm and respiration, during anesthesia. Formulations \u2022\\t\\tPentobarbital\\thas\\tbeen\\tavailable\\tin\\ta\\t50-\\t\\tand\\t65-\\tmg/mL\\tsolution\\tfor\\tinjection (contains propylene glycol). It has been available in 50 or 20 mL multiple- dose vials. Other excipients in the vial include propylene glycol and alcohol. The availability has been inconsistent from some suppliers, but it may be available from some veterinary distributors. Some manufacturers discontinued production because of objection to its use for lethal injection in a human execution protocol. Stability and Storage Store\\tat\\t68\xb0F\u201377\xb0F\\tin\\ta\\ttightly\\tsealed\\tcontainer,\\tprotected\\tfrom\\tlight.\\tThe\\tpH of solution is 9\u201310.5 and may affect stability of other coadministered drugs. It precipitates\\tif\\tcombined\\twith\\tmost\\thydrochloride-\\tbased\\tdrugs\\tor\\tdrugs\\twith\\tlow\\tpH. If pentobarbital is used to euthanize animals, it remains stable even under rendering conditions used for disposal of the carcass. 716    Pentoxifylline","original_category":"Anesthetic, barbiturate"},{"name":"Propofol","active_ingredient":"Propofol","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\tThe\\tFDA-approved\\tlabel\\tdose\\tfor\\tinduction\\tranges\\tfrom\\t5.5\\tto\\t7.6\\tmg/kg IV\\tslowly\\tover\\t30\u201360\\tseconds.\\tIf\\tnecessary,\\tadditional\\tdoses\\tcan\\tbe\\tadministered in increments of 0.5\u20131 mg/kg for the desired effect. Most inductions can be performed with lower doses of approximately 4 mg/kg. If the patient has received a premedication with alpha 2 agonists, opioids, or benzodiazepines, lower the dose by at least 20%\u201330% (e.g., a lower dose of 3 mg/kg can be used). After initial induction, maintenance doses of 1\u20133 mg/kg IV can be used. \u2022\\t\\tCRI:\\t5\u20136\\tmg/kg\\tslowly\\tIV\\tfollowed\\tby\\t100\u2013450\\tmcg/kg/min\\t(or\\t6\u201325\\tmg/ kg/h).\\tIn\\tsome\\tanimals\\tthe\\trate\\tmay\\tbe\\tas\\thigh\\tas\\t600\\tmcg/kg/min\\t(36\\tmg/ kg/h) if they are not premedicated. If other agents are included in the protocol (e.g., ketamine), the dose can be decreased. \u2022\\t\\tStatus\\tepilepticus:\\t1\u20136\\tmg/kg\\tIV\\t(to\\teffect)\\tfollowed\\tby\\ta\\tCRI\\tof\\t0.1\u20130.6\\tmg/kg/ min. Cats \u2022\\t\\tAnesthesia\\tinduction:\\t4\u20138\\tmg/kg\\tIV\\tslowly.\\tThe\\tapproved\\tlabel\\tlists\\thigher\\tdoses, but\\tmost\\tcats\\tcan\\tbe\\tinduced\\twith\\tapproximately\\t6\\tmg/kg\\tIV.\\tAfter\\tthe\\tinitial dose, incremental doses of 1\u20133 mg/kg IV can be administered as needed. If other preanesthetics\\tand\\tsedatives\\tare\\tused,\\treduce\\tby\\t16%\u201324%.\\tIf\\tcombined\\twith midazolam, the propofol requirement listed can be reduced by as much as 25%. \u2022\\t\\tCRI:\\t6\\tmg/kg\\tslowly\\tIV\\tfollowed\\tby\\t200\u2013300\\tmcg/kg/min\\t(0.2\u20130.3\\tmg/ kg/h) IV. For short- term procedures, the total dose is 15 mg/kg for a 30- minute protocol. \u2022\\t\\tCRI\\tinfusion\\twith\\tketamine\\tin\\tcats:\\t0.025\\tmg/min/kg\\t+\\tketamine\\t23\u201346\\tmcg/ kg/min. \u2022\\t\\tShort-\\t   term\\tsurgery:\\t10-\\tmg/kg\\tIV\\tdose\\tdelivered\\tover\\t1\\tminute\\t(duration\\tof anesthesia, 10\u201320 minutes).  Horses \u2022\\t\\t2\\tmg/kg\\tIV\\tbolus.\\tGuaifenesin\\t(90\\tmg/kg\\tIV)\\tor\\tanother\\tsedative\\tshould\\tbe administered prior to propofol to prevent excitement and myotonus and other problems during recovery. Small Ruminants \u2022\\t\\t4\\tmg/kg\\tIV. Pigs \u2022\\t\\t2\u20135\\tmg/kg\\tIV. Regulatory Information Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. RCI\\tClassification:\\t2 P Propranolol Hydrochloride 789 Propranolol Hydrochloride proe- pran\u2032oh- lole  hye- droe- klor\u2032ide Trade and other names: Inderal and generic brands","contraindications":"Contraindications and Precautions Propofol can induce apnea, hypoxia, and cyanosis upon induction. Supplemental oxygen should be available to prevent adverse effects. Do not administer to hypotensive animals without providing fluids to correct hypotension. When propofol has been used to sedate animals for intradermal skin testing, it may produce a greater number of positive reactions. The use of propofol in pregnant and breeding animals has not been evaluated. Propofol crosses the placenta and can cause neonatal depression. Propofol has not been evaluated in dogs younger than 10 weeks of age. Propofol should not be used alone for anesthesia in horses\u2014combine with other sedatives or premedications. Drug Interactions Propofol can be used with several other anesthetics and adjuncts safely. It has been mixed\\t   with\\t  thiopental\\tsodium\\t(2.5%)\\t   in\\t a\\t 1:1\\t  mixture\\twithout\\tloss\\t  of\\t effectiveness. Propofol has been used with atropine, glycopyrrolate, acepromazine, xylazine, oxymorphone, halothane, and isoflurane without any interactions observed. without a preservative are used, there should be careful handling and injection technique to prevent microbial contamination of this formulation. The formulation with a benzyl alcohol preservative allows for a 28-day shelf-life after opening the vial (PropoFlo 28). Propofol\\thas\\tbeen\\tmixed\\twith\\tthiopental\\tsodium\\tin\\ta\\t1:1\\tmixture,\\tand\\tthey\\tare physically\\tand\\tchemically\\tcompatible.\\tHowever,\\tdo\\tnot\\tmix\\twith\\tother\\tdrugs\\tunless compatibility\\thas\\tbeen\\tverified.\\tPropofol\\thas\\ta\\tpH\\tof\\t7\u20138.5.\\tStore\\tat\\t40\xb0F\\tand\\t72\xb0F (4\xb0C\u201322\xb0C).\\tDo\\tnot\\tfreeze.\\tProtect\\tfrom\\tlight.\\tShake\\twell\\tbefore\\tuse.","indications":"Indications and Clinical Uses Propofol is used as a short- term injectable anesthetic. It is often used as an induction agent followed by inhalation with one of the inhalant anesthetics, or induction may be followed with maintenance doses. If repeated doses are administered for maintenance, it does not affect the recovery time. Thus, there is no cumulative effect. It has been used safely and effectively for short- term induction and surgical procedures. It is also appropriate for procedures that require repeated anesthetic episodes in dogs and cats without producing adverse effects. A significant advantage of propofol over other agents is smooth and rapid recovery. It is also highly compatible with other anesthetic agents. It can be used with acepromazine, diazepam, alpha 2 agonists (e.g., dexmedetomidine), butorphanol, ketamine, and inhalant anesthetics. The use of these other agents will lower the dose requirement for propofol. Propofol also can be used as a CRI to maintain an anesthetized state for surgical procedures. (See infusion dose rates later.) An additional use of propofol is treatment of status epilepticus. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Apnea and respiratory depression are the most common adverse effects, which are more likely at high doses. Propofol can induce a dose- dependent cardiovascular depression, but the severity of cardiac adverse events is generally low. Propofol can induce vasodilation, which can be minimized by providing sufficient IV fluids during the induction period and during anesthesia. Propofol can cause spontaneous muscle movements (paddling, tremors, muscle rigidity), panting, nystagmus, salivation, and retraction of tongue in some animals (incidence 3%\u20137%). Less frequent adverse reactions include vomiting during recovery and signs of pain. Pain upon injection occurs in people but is less common in dogs. The pain from injection is caused by the free propofol in the formulation and is decreased with newer formulations. Phenolic drugs such as propofol may potentially cause oxidative damage to hemoglobin in cats because of higher concentration of oxidizable\\tsulfhydryl\\tgroups\\tin\\tfeline\\tRBCs,\\tleading\\tto\\tHeinz-\\tbody\\tformation and\\tmethemoglobinemia.\\tHowever,\\tthis\\thas\\tnot\\tbeen\\ta\\tconsistent\\tproblem\\twith routine clinical use of propofol, and repeated anesthetic episodes have been performed safely in cats. Some formulations (PropoFlo 28) contain 2% benzyl alcohol added as a preservative (20 mg/mL), which can produce hematologic abnormalities\\tin\\tsome\\tanimals.\\tHowever,\\tthis\\tingredient\\tdid\\tnot\\tcause\\tadditional morbidity or problems in cats compared with other formulations. P","notes":"Instructions for Use Shake well before using. Use strict aseptic technique for administration. Propofol may be diluted in 5% dextrose, lactated Ringer\u2019s solution, and 0.9% saline but not to less than a 2- mg/mL concentration. There is a delay in penetration to brain after the\\tinitial\\tIV\\tinjection;\\ttherefore,\\texpect\\ta\\tdelayed\\tCNS\\teffect\\tduring\\tinjection\\tand re-\\t evaluate\\tthe\\tresponse\\tbefore\\tadministering\\tadditional\\tinjections.\\tA\\tmixture\\tof\\t1:1 thiopental (2.5%) and propofol can be used in dogs and results in a smooth induction. When using with other anesthetics and sedatives (acepromazine, barbiturates, opioids, benzodiazepines, alpha 2 agonists), lower doses should be administered because premedications and other sedatives greatly reduce the propofol dose requirements. The reduction in dose when used with premedications and other sedatives is approximately 16%\u201320%\\tin\\tcats\\tand\\t20%\u201330%\\tin\\tdogs\\tbut\\tmay\\tbe\\tas\\thigh\\tas\\t40%\u201350%\\tin\\tdogs. Patient Monitoring and Laboratory Tests Monitor respiration rate and character during anesthesia with propofol. Formulations \u2022\\t\\tThe\\thuman\\tformulation\\tof\\tpropofol\\tis\\tavailable\\tin\\t1%\\t(10-\\tmg/mL)\\tinjection\\tin\\t20- mL ampules. \u2022\\t\\tThe\\tveterinary\\tformulation\\tis\\tavailable\\tin\\tmultidose\\tvials\\tcontaining\\t10\\tmg\\tof propofol per milliliter. Propofol is only slightly soluble in water; therefore it is formulated in a white, oil- in- water emulsion. It also contains soybean oil (100 mg/ mL),\\tglycerol\\t(22.5\\tmg/mL),\\tegg\\tlecithin\\t(12\\tmg/mL),\\tand\\toleic\\tacid\\t(0.6\\tmg/ mL)\\twith\\tsodium\\thydroxide\\tto\\tadjust\\tthe\\tpH.\\tThe\\tpropofol\\temulsion\\tis\\tisotonic and\\thas\\ta\\tpH\\tof\\t6.0\u20139.0.\\tThe\\tformulation\\tPropoFlo\\t28\\thas\\tbenzyl\\talcohol\\tadded\\tas a preservative. \u2022\\t \\tNote:\\tThe\\tformulation\\tknown\\tas\\tPropoClear\\temulsion\\tfor\\tdogs\\tand\\tcats\\t(without lipids) was associated with adverse reactions and has been removed from the market. Stability and Storage The veterinary formulation (PropoFlo, Rapinovet, Rapanofal) has no preservatives and\\tshould\\tbe\\tdiscarded\\twithin\\t6\\thours\\tafter\\topening\\tthe\\tvial.\\tWhen\\tformulations When used alone in horses, it can cause excitement, myotonus, and problems during recovery. Therefore, when used in horses, other sedatives are recommended.","original_category":"Anesthetic"},{"name":"Remifentanil Hydrochloride","active_ingredient":"Remifentanil Hydrochloride","species":["Canine","Feline"],"dosage":"Dogs \u2022\\t\\tCRI:\\t0.2\\tmcg/kg/min,\\tup\\tto\\t1\\tmcg/kg/min.\\tThe\\tinfusion\\trate\\tcan\\tbe\\tadjusted to achieve the desired effect, but 0.30 mcg/kg/min is optimum to achieve desired effects in anesthetized dogs. Higher rates did not produce increased benefit. For CRI administration, it may be administered with propofol. Cats \u2022\\t\\tCRI:\\t2.5\\tmcg/kg\\tbolus\\tinjection\\tfollowed\\tby\\t0.2\u20130.4\\tmcg/kg/min\\tCRI.\\tIn\\ta dose- ranging study, the optimum dosage for cats undergoing ovariohysterectomy was a CRI of 0.4 mcg/kg/min IV.  \u2022\\t\\tNo\\tdoses\\thave\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information Remifentanil is a Schedule II controlled substance. Withdrawal times are not established for animals that produce food. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Riboflavin (Vitamin B 2 ) rye\u2032boe- flay- vin Trade and other names: Vitamin B 2","contraindications":"Contraindications and Precautions Remifentanil potentiates the effects of other anesthetics. Use cautiously in animals sensitive to opioids. It is intended for IV administration only. Do not administer via epidural, intrathecal, intradermal, IM, or SQ routes. Drug Interactions Other anesthetics are potentiated when used with remifentanil. Lower doses of other anesthetic agents may be used when combined with remifentanil.","indications":"Indications and Clinical Uses Remifentanil is used for induction and maintenance of anesthesia, often in combination with other agents. Because of its rapid metabolism and short half- life, it should be administered by CRI to maintain a balanced anesthetic effect. It can be administered with other drugs, including inhalant anesthetics, propofol, alpha 2 agonists,\\tsedatives,\\tand\\ttranquilizers.\\tBecause\\tit\\tdoes\\tnot\\trequire\\thepatic metabolism or renal elimination, it can be administered safely to patients that have liver or kidney disease. Experience with remifentanil use in dogs is limited to a few studies and case reports. Doses in animals have been extrapolated from humans (human starting dosage is 0.1 mcg/kg/min CRI). Remifentanil has been infused safely in cats, and over a wide range of doses (0.06\u201316 mcg/kg/min) IV, it did not affect isoflurane\u2019s minimum alveolar concentration. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Like other opioids and opiates, remifentanil has adverse effects that are attributed to the binding to opiate receptors. These effects include reduced heart rate and sedation. In people, at rates greater than 0.2 mcg/kg/min, respiratory depression occurs. In cats, remifentanil induced dysphoria at high infusion rates (greater than 8 mcg/kg/min).\\tAdverse\\teffects\\tquickly\\tdissipate\\twhen\\tthe\\tinfusion\\tis\\tdiscontinued because of the drug\u2019s rapid metabolism in the plasma and tissues. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.","notes":"Instructions for Use Administer intravenously as a CRI. A bolus dose may be administered prior to the start of the CRI. Patient Monitoring and Laboratory Tests Monitor patients during anesthetic protocol. Monitor electrocardiogram (ECG), heart rate, and breathing character. 812    Riboflavin (Vitamin B 2 ) Formulations \u2022\\t\\tRemifentanil\\tis\\tavailable\\tin\\ta\\t1-\\tmg/mL\\tsolution\\tand\\tin\\tvials\\tof\\t1,\\t2,\\tor\\t5\\tmg\\tof remifentanil base. Add 1 mL of diluent per milligram of remifentanil to produce a solution of 1 mg/mL. This solution can be further diluted for IV use to a concentration of 20, 25, 50, or 250 mcg/mL. Stability and Storage The vial is available in a lyophilized powder that must be reconstituted prior to use. Store powder for injection in refrigerator (36\xb0\u201346\xb0F) or at room temperature (less\\tthan\\t78\xb0F).\\tRemifentanil\\tHCl\\thas\\ta\\tpKa\\tof\\t7.07,\\tbut\\tthe\\tpH\\tof\\treconstituted solutions ranges from 2.5\u20133.5. The pH of solutions should be considered when combining with other drugs or fluid solutions. Remifentanil is compatible with sterile\\twater,\\tlactated\\tRinger\u2019s\\tsolution,\\t5%\\tdextrose,\\t0.9%\\tsodium\\tchloride,\\tand 0.45%\\tsodium\\tchloride.\\tAfter\\tbeing\\tmixed\\tin\\tsolution,\\tit\\tis\\tstable\\tfor\\t24\\thours\\tat room temperature. It can also be mixed in solution with propofol. Because of the presence of plasma esterases, it should not be mixed with blood products. Therefore administration with IV blood transfusions is not recommended.","original_category":"Anesthetic, analgesic, opioid"},{"name":"Sevoflurane","active_ingredient":"Sevoflurane","species":["Equine"],"dosage":"\u2022\\t\\tInduction:\\t8%;\\tmaintenance:\\t3%\u20136%.  Horses \u2022\\t\\tMAC\\tvalue:\\t2.31. Regulatory Information No withdrawal times are established for animals intended for food. Clearance is rapid, and\\tshort\\twithdrawal\\ttimes\\tare\\tsuggested.\\tFor\\textralabel\\tuse\\twithdrawal\\tinterval estimates,\\tcontact\\tFARAD\\tat\\twww.FARAD.org. 836    Sildenafil Citrate Sildenafil Citrate sill- den\u2032- ah- fil Trade and other names: Viagra and Revatio","contraindications":"Contraindications and Precautions Do not use unless there is an adequate facility to monitor patients. Use only with approved anesthetic vaporizer delivery systems. Drug Interactions No drug interactions have been reported for animals.","indications":"Indications and Clinical Uses Sevoflurane is used as an inhalant anesthetic. There are not any significant advantages over the use of isoflurane, and it is more expensive than isoflurane. It has minimum alveolar concentration (MAC) values of 2.58%, 2.36%, and 2.31% in cats, dogs, and horses, respectively. Sevoflurane, like other inhalant anesthetics, can be used with preanesthetics, opioids, alpha 2 - agonists, and tranquilizers. Precautionary Information","side_effects":"Adverse Reactions and Side Effects Adverse effects are related to anesthetic effects (e.g., cardiovascular and respiratory depression). Sevoflurane can produce byproducts of fluoride ions and compound A, which can be toxic to the kidneys, but this is a rare problem.","notes":"Instructions for Use Use of inhalant anesthetics requires careful monitoring. Dose is determined by depth of anesthesia. Patient Monitoring and Laboratory Tests Carefully monitor patient\u2019s heart rate and rhythm and respiratory rate during use. Formulations Stability and Storage Sevoflurane is highly volatile and should only be stored in approved containers.","original_category":"Anesthetic"},{"name":"Thiopental Sodium","active_ingredient":"Thiopental Sodium","species":["Canine","Feline","Bovine"],"dosage":"Dogs \u2022\\t\\t10\u201325\\tmg/kg\\tIV\\t(induction\\tdose;\\tadminister\\tto\\teffect). Cats \u2022\\t\\t5\u201310\\tmg/kg\\tIV\\t(induction\\tdose;\\tadminister\\tto\\teffect).  Cattle \u2022\\t\\tInduction:\\t6\u201312\\tmg/kg\\tIV\\t(to\\teffect). Pigs \u2022\\t\\t10\u201320\\tmg/kg\\tIV\\t(to\\teffect). Regulatory Information Extralabel use: Establish a withdrawal time of at least 1 day for meat and 24 hours for milk. Pig withdrawal time for meat: 0 days. Schedule III controlled drug. RCI Classification: 2 Thiotepa thye- oh- tep\u2032ah Trade and other names: Thioplex and generic brands","contraindications":"Contraindications and Precautions Use carefully in patients with respiratory or cardiac disease. Do not use unless there is an ability to monitor and maintain respiration. Because respiratory apnea can occur during induction, there should be a capability to ventilate the patient, if necessary. Drug Interactions Thiopental is compatible with other anesthetics. However, use of other sedatives and anesthetics lowers the dose of thiopental.","indications":"Indications and Clinical Uses Thiopental is the most commonly used injectable barbiturate in veterinary medicine. It is used primarily for induction of anesthesia or for short duration of anesthesia (10-  to 15- minute procedures). It induces a rapid, smooth, and generally excitement- free induction. It can be administered intravenously, with prior premedication of other anesthetic adjuncts such as tranquilizers and sedatives (e.g., alpha 2 agonists, phenothiazines, and opioids). Thiopental has been combined with propofol in a 1:1\\tmixture\\twithout\\tloss\\tof\\teffectiveness.\\tThis\\tmixture\\tof\\t1:1\\t2.5%\\tthiopental\\tand propofol has been used to induce anesthesia in dogs. Precautionary Information","side_effects":"Adverse Reactions and Side Effects The most common effect is transient apnea and respiratory depression. Other adverse effects are related to the anesthetic effects of the drug (CNS depression). Thiopental may cause cardiovascular depression with a slight decrease in stroke volume and little change in cardiac output or blood pressure. Premedication reduces the risk of cardiovascular events. Supplementation with oxygen during induction also decreases cardiovascular events. Overdoses are caused by rapid or repeated injections. Avoid extravasation outside of the vein.","notes":"Instructions for Use The therapeutic index is low. Administer to effect, by giving intermittent injections and observing the patient\u2019s response. Use only in patients in which it is possible to monitor cardiovascular and respiratory functions. Thiopental is often administered with other anesthetic adjuncts. Patient Monitoring and Laboratory Tests Monitor cardiovascular and respiratory function during anesthesia with thiopental. Formulations \u2022\\t\\tThiopental\\tis\\tavailable\\tin\\t250-\\tmg\\tto\\t10-\\tg\\tvials\\t(mix\\tto\\tdesired\\tconcentration\\twith sterile\\tdiluent).\\tThe\\tconcentration\\tcan\\tvary,\\tbut\\tgenerally,\\tthe\\t2.5%\\tsolution\\tis\\tused with\\tsmall\\tanimals,\\tand\\tthe\\t2.5%\\tor\\t5%\\tsolution\\tis\\tused\\twith\\tlarger\\tanimals. Stability and Storage Thiopental, when prepared properly, is chemically stable and resists bacterial growth for up to 4 weeks when refrigerated. Thiopental has a pH of 10\u201311 and should not be mixed with acidifying solutions. If mixed with other drugs, the alkalinity of the solution may affect their stability. Propofol has been mixed with thiopental sodium in a 1:1 mixture, and they are physically and chemically compatible if used promptly. T Thiotepa 895","original_category":"Anesthetic, barbiturate"},{"name":"Tiletamine and Zolazepam","active_ingredient":"Tiletamine and Zolazepam","species":["Canine","Feline"],"dosage":"(All doses listed are based on the combined milligrams of each component.) Dogs \u2022\\t\\tInitial\\tIM\\tdose\\tis\\t6.6\u201310\\tmg/kg\\tfor\\tminor\\tprocedures. \u2022\\t\\tShort-\\t   term\\tanesthesia:\\t10\u201313\\tmg/kg\\tIM. Cats \u2022\\t\\t10\u201312\\tmg/kg\\tIM\\tfor\\tminor\\tprocedures\\tand\\thigher\\tdoses\\tof\\t14\u201316\\tmg/kg\\tIM\\tfor surgery.  (All doses listed are based on the combined milligrams of each component.) Pigs \u2022\\t\\t3.5\u20136\\tmg/kg\\tIM.\\t(The\\taddition\\tof\\ta\\tmuscle\\trelaxant\\tand\\tsedative\\tis\\trecommended; see later.) \u2022\\t \\tThe\\tTXK\\tprotocol\\tfor\\tpigs:\\tTo\\tprepare\\tthis\\tsolution,\\tadd\\t2.5\\tmL\\tof\\tketamine\\t(100\\tmg/ mL) and 2.5 mL of xylazine (100 mg/mL) to one vial of tiletamine\u2013zolazepam powder. This solution contains 100 mg/mL of tiletamine and ketamine plus 50 mg/mL each of xylazine\\tand\\tzolazepam.\\tAdminister\\tthis\\tsolution\\tIM\\tat\\ta\\tdose\\tof\\t1\\tmL\\tper\\t35\u201375\\tkg. Regulatory Information No regulatory information is available. For extralabel use withdrawal interval estimates, contact FARAD at www.FARAD.org. Schedule III controlled drug T Tilmicosin Phosphate 905 Tilmicosin Phosphate til- mye\u2032koe- sin  foss\u2032fate Trade and other names: Micotil and Pulmotil AC (for water), Pulmotil tilmicosin premix","contraindications":"Contraindications and Precautions Low doses do not provide sufficient anesthesia for surgery. For surgical procedures, other anesthetic agents should be added. Do not use in patients with pancreatic disease. Avoid use in ferrets. Drug Interactions No drug interactions have been reported in animals.","indications":"Indications and Clinical Uses Tiletamine and zolazepam is used for short- term anesthesia in animals. For longer procedures, other drugs should be used. It is usually injected IM in animals for short- term procedures or occasionally for induction when other anesthetic agents are added. The approved uses and doses are based on the FDA- approved labeling for animals, clinical experience, and recommendations from anesthesiology experts. The use in large animals is extralabel but has been tested in small observational studies. (See protocol for pigs listed later.) Precautionary Information","side_effects":"Adverse Reactions and Side Effects Tiletamine and zolazepam has a wide margin of safety, which is greater in cats than in dogs. The use is also reported in pigs. Side effects include excessive salivation (may be antagonized with atropine), erratic recovery, and muscle twitching. Drying of the cornea may occur unless ophthalmic ointment is applied to the eyes. IM injection in animals can be painful. Adverse reactions have been observed when administered to ferrets.","notes":"Instructions for Use Administer by deep IM injection. Patient Monitoring and Laboratory Tests Monitor heart rate and rhythm during anesthesia. Monitor body temperature because of risk of hypothermia. Formulations \u2022\\t\\tTiletamine\\tand\\tzolazepam\\tis\\tavailable\\tin\\t50\\tmg\\tof\\teach\\tcomponent\\tper\\tmilliliter (100 mg total per milliliter). Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature.","original_category":"Anesthetic"},{"name":"Zolpidem","active_ingredient":"Zolpidem","species":["Canine","Feline","Equine"],"dosage":"Dogs \u2022\\t\\t0.5\\tmg\\tor\\t0.15\\tmg/kg\\tonce.\\t(Use\\tcautiously\\tbecause\\tof\\tadverse\\teffects.) Cats \u2022\\t\\tDose\\tregimens\\thave\\tnot\\tbeen\\tdefined\\tin\\tcats.  \u2022\\t\\tNo\\tdose\\thas\\tbeen\\treported\\tfor\\tlarge\\tanimals. Regulatory Information No regulatory information is available. Avoid use in food- producing animals. Do not use in racehorses. Schedule IV controlled substance Zonisamide zoe- nis\u2032a- mide Trade and other names: Zonegran","contraindications":"Contraindications and Precautions Because of the adverse reactions observed, it is not recommended for dogs. Drug Interactions Avoid use with other sedatives, behavior- modifying drugs, or drugs that decrease drug metabolism.","indications":"Indications and Clinical Uses Zolpidem is used as a sedative and sleep aid in people. However, this property has not been shown in animals. It is infrequently used in animals and may produce significant adverse effects. Precautionary Information Clinical uses have not been established for veterinary patients. 990    Zonisamide","side_effects":"Adverse Reactions and Side Effects In dogs, it produced adverse effects that included vocalization, restlessness, anxiety, dysphoria, rage reaction, excitement, muscle spasticity, and hyperreflexia.","notes":"Instructions for Use Patient Monitoring and Laboratory Tests No monitoring has been recommended for animals. Formulations \u2022\\t\\tAvailable\\tin\\t5-\\t\\tor\\t10-\\tmg\\ttablets. Stability and Storage Store in a tightly sealed container, protected from light, and at room temperature. Stability of compounded formulations has not been evaluated.","original_category":"Sedative"}]}]');function ru(){var t,e;const[a,n]=(0,i.useState)(null),[o,s]=(0,i.useState)(null),[r,l]=(0,i.useState)(!1),[d,c]=(0,i.useState)(!1),[m,u]=(0,i.useState)(!1),{siteData:h}=Kt()||{},f=(0,i.useMemo)(()=>su,[]);let g;if(r)g=(0,Gt.jsx)($m,{onBack:()=>l(!1)});else if(d)g=(0,Gt.jsx)(tu,{onBack:()=>c(!1)});else if(m)g=(0,Gt.jsx)(ou,{onBack:()=>u(!1)});else if(a){var p;const t=f.find(t=>t.category===a);g=(0,Gt.jsx)(Qm,{category:a,drugs:null!==(p=null===t||void 0===t?void 0:t.drugs)&&void 0!==p?p:[],onBack:()=>n(null),onSelectDrug:s,selectedDrug:o,onCloseDrug:()=>s(null),onOpenCalculator:()=>l(!0)})}else g=(0,Gt.jsx)(Gm,{categories:f,onSelectCategory:n,onSelectDrug:s,selectedDrug:o,onCloseDrug:()=>s(null),onOpenCalculator:()=>l(!0),onOpenFormulary:()=>c(!0),onOpenProtocols:()=>u(!0)});return(0,Gt.jsxs)("div",{className:"flex flex-col min-h-screen bg-slate-50 dark:bg-slate-900 font-sans selection:bg-teal-100 selection:text-teal-900",children:[(0,Gt.jsx)(Yt,{siteName:null===h||void 0===h||null===(t=h.site)||void 0===t?void 0:t.name,navigation:null===h||void 0===h?void 0:h.navigation}),(0,Gt.jsx)("div",{className:"flex-1",children:g}),(0,Gt.jsx)(Jt,{siteName:null===h||void 0===h||null===(e=h.site)||void 0===e?void 0:e.name,footer:null===h||void 0===h?void 0:h.footer})]})}function lu(){return(0,Gt.jsxs)(xt,{children:[(0,Gt.jsx)(vt,{path:"/",element:(0,Gt.jsx)(ee,{})}),(0,Gt.jsx)(vt,{path:"/articles",element:(0,Gt.jsx)(ae,{title:"Articles"})}),(0,Gt.jsx)(vt,{path:"/research-journals",element:(0,Gt.jsx)(cm,{})}),(0,Gt.jsx)(vt,{path:"/pet-health",element:(0,Gt.jsx)(ie,{title:"Pet Health",subCategoryNames:["Dogs","Cats","Small Mammals"]})}),(0,Gt.jsx)(vt,{path:"/poultry-health",element:(0,Gt.jsx)(ie,{title:"Poultry Health",subCategoryNames:["Chickens","Ducks","Turkeys","Disease Management"]})}),(0,Gt.jsx)(vt,{path:"/nutrition",element:(0,Gt.jsx)(ie,{title:"Nutrition",subCategoryNames:["Pet Nutrition","Poultry Nutrition"]})}),(0,Gt.jsx)(vt,{path:"/resources",element:(0,Gt.jsx)(ae,{title:"Resources"})}),(0,Gt.jsx)(vt,{path:"/nutrition-guides",element:(0,Gt.jsx)(ie,{title:"Nutrition Guides",subCategoryNames:["Pet Nutrition","Poultry Nutrition"]})}),(0,Gt.jsx)(vt,{path:"/drug-index/*",element:(0,Gt.jsx)(ru,{})}),(0,Gt.jsx)(vt,{path:"/about-us",element:(0,Gt.jsx)(om,{})}),(0,Gt.jsx)(vt,{path:"/contact-us",element:(0,Gt.jsx)(sm,{})}),(0,Gt.jsx)(vt,{path:"/medical-review-board",element:(0,Gt.jsx)(rm,{})}),(0,Gt.jsx)(vt,{path:"/careers",element:(0,Gt.jsx)(lm,{})}),(0,Gt.jsx)(vt,{path:"/editorial-policy",element:(0,Gt.jsx)(dm,{title:"Editorial Policy"})}),(0,Gt.jsx)(vt,{path:"/privacy-policy",element:(0,Gt.jsx)(dm,{title:"Privacy Policy"})}),(0,Gt.jsx)(vt,{path:"/terms-of-service",element:(0,Gt.jsx)(dm,{title:"Terms of Service"})}),(0,Gt.jsx)(vt,{path:"/cookie-policy",element:(0,Gt.jsx)(dm,{title:"Cookie Policy"})}),(0,Gt.jsx)(vt,{path:"/disclaimer",element:(0,Gt.jsx)(dm,{title:"Disclaimer"})}),(0,Gt.jsx)(vt,{path:"/admin/login",element:(0,Gt.jsx)(nm,{})}),(0,Gt.jsx)(vt,{path:"/admin/*",element:(0,Gt.jsx)(im,{})}),(0,Gt.jsx)(vt,{path:"/:slug",element:(0,Gt.jsx)(ae,{})})]})}const du=t=>{t&&t instanceof Function&&a.e(453).then(a.bind(a,453)).then(e=>{let{getCLS:a,getFID:i,getFCP:n,getLCP:o,getTTFB:s}=e;a(t),i(t),n(t),o(t),s(t)})};Ft.createRoot(document.getElementById("root")).render((0,Gt.jsx)(i.StrictMode,{children:(0,Gt.jsx)(Qt,{children:(0,Gt.jsx)(Xt,{children:(0,Gt.jsx)(Dt,{children:(0,Gt.jsx)(lu,{})})})})})),du()})()})();
//# sourceMappingURL=main.af6b048d.js.map